A1BG	19	58345178	58353499	N	.	N	N	-0.225611996	33.99317011	9.06E-05	72.2	.	.
A1CF	10	50799409	50885675	Y	Viable	N	Y	-0.881260137	9.93227991	0.003619701	59.5	.	.
A2M	12	9067664	9116229	N	Viable	N	Y	-0.311376616	28.82444869	0.000540115	66.8	DM	.
A2ML1	12	8822472	8887001	N	.	N	N	1.775537977	98.13046246	1.33E-22	99.1	.	.
A3GALT2	1	33306766	33321098	N	.	N	N	.	.	6.50E-07	83.3	.	.
A4GALT	22	42692121	42721298	N	.	N	Y	-0.332568014	27.61474793	0.111598718	42.5	DM	[Blood group, P1Pk system, p phenotype], 111400 (3); [Blood group, P1Pk system, P(2) phenotype], 111400 (3); NOR polyagglutination syndrome, 111400 (3)
A4GNT	3	138123718	138132387	N	.	N	Y	0.686086614	86.55437865	0.598408702	27.5	FTV	.
AAAS	12	53307456	53324864	N	.	N	Y	-0.197362146	35.68327835	4.54E-10	91.8	DM	Achalasia-addisonianism-alacrimia syndrome, 231550 (3)
AACS	12	125065379	125143333	N	.	N	N	0.947249024	91.97198588	4.25E-12	94.7	.	.
AADAC	3	151814037	151828488	N	.	N	N	0.385001656	75.16930023	0.000181834	70.1	DM?	.
AADACL2	3	151733916	151761339	N	.	N	N	0.416927285	76.69155525	1.78E-08	88.3	DM?	.
AADACL3	1	12716115	12728759	N	.	N	N	0.794959429	89.10690513	0.000156334	70.5	.	.
AADACL4	1	12644547	12667086	N	.	N	N	0.048322504	53.28471378	0.000547686	66.8	.	.
AADAT	4	170060222	170091699	N	.	N	Y	-0.53817717	18.67222319	0.250802295	37.1	.	.
AAED1	9	96639577	96655303	N	.	N	N	0.860434959	90.37448631	9.51E-08	86.2	.	.
AAGAB	15	67201033	67255195	N	.	N	N	-0.040907923	46.57058517	0.008102073	55.8	DM	Keratoderma, palmoplantar, punctate type IA, 148600 (3)
AAK1	2	69457997	69674349	N	.	N	N	-0.342789861	27.12855241	0.999320421	5.5	.	.
AAMDC	11	77821109	77918432	N	.	N	N	0.093995484	56.69387046	0.000474347	67.2	.	.
AAMP	2	218264123	218270257	N	.	N	N	0.01161301	50.38490479	0.531201269	29.1	.	.
AANAT	17	76453351	76470117	N	.	N	N	0.522779906	81.35092898	0.013038239	53.8	DP	{Delayed sleep phase syndrome, susceptibility to}, 614163 (3)
AAR2	20	36236459	36270918	N	.	N	N	0.430976902	77.46136482	0.000262136	69	.	.
AARD	8	116938199	116944487	N	Viable	N	Y	-0.246513473	32.65613243	0.328326488	34.9	.	.
AARS2	6	44299654	44313326	N	.	N	N	0.358321058	73.84383863	1.65E-07	85.5	DM	Combined oxidative phosphorylation deficiency 8, 614096 (3); Leukoencephalopathy, progressive, with ovarian failure, 615889 (3)
AARSD1	17	42950526	42964498	N	.	N	N	0.41788394	76.71470741	2.44E-07	84.9	.	.
AASDH	4	56338287	56387508	N	.	N	N	0.114392193	58.32031024	2.01E-05	76.2	.	.
AASDHPPT	11	106075501	106098710	N	.	N	N	-0.119765437	40.78833131	0.083941734	44.2	.	.
AASS	7	122075647	122144280	N	.	N	N	-0.641812633	15.62771314	1.36E-06	82.1	DM	Hyperlysinemia, 238700 (3); Saccharopinuria, 268700 (1)
AATK	17	81117295	81166077	N	.	N	Y	.	.	0.806763652	21.4	.	.
ABAT	16	8674565	8784575	N	.	N	N	-0.495721965	20.38548359	0.374368506	33.5	DM	GABA-transaminase deficiency, 613163 (3)
ABCA10	17	69147214	69244846	N	.	N	N	1.258481158	95.4969034	1.21E-27	99.5	DM?	.
ABCA13	7	48171458	48647496	N	Viable	N	Y	4.767707742	99.83214678	3.31E-78	100	DM	.
ABCA2	9	137007227	137028922	N	.	N	Y	-1.697556794	2.45991781	0.999999516	1.5	DM?	.
ABCA4	1	93992835	94121132	N	.	N	Y	2.090336531	98.7150547	1.27E-28	99.6	DM	Stargardt disease 1, 248200 (3); Retinitis pigmentosa 19, 601718 (3); Cone-rod dystrophy 3, 604116 (3); {Macular degeneration, age-related, 2}, 153800 (3); Fundus flavimaculatus, 248200 (3); Retinal dystrophy, early-onset severe, 248200 (3)
ABCA5	17	69244311	69327244	N	.	N	Y	0.345549227	73.16084968	2.53E-15	97	.	.
ABCA6	17	69078702	69141888	N	Viable	N	Y	0.810941833	89.35579094	1.83E-16	97.6	.	.
ABCA7	19	1040101	1065572	N	.	N	Y	2.403998151	99.09706546	1.89E-36	99.9	DP	.
ABCA8	17	68867292	68955392	N	Viable	N	Y	1.839438819	98.28095155	1.72E-33	99.8	FTV	.
ABCA9	17	68974488	69061064	N	.	N	N	-0.586004565	17.19048446	1.28E-26	99.5	.	.
ABCB1	7	87503633	87713323	N	.	N	Y	-0.161310924	37.88852231	0.734473812	23.6	DM	{Colchicine resistance}, 120080 (3); {Inflammatory bowel disease 13}, 612244 (3)
ABCB4	7	87401697	87480435	N	.	N	Y	-1.101313572	6.546275395	0.000203043	69.8	DM	Cholestasis, progressive familial intrahepatic 3, 602347 (3); Cholestasis, intrahepatic, of pregnancy, 3, 614972 (3); Gallbladder disease 1, 600803 (3)
ABCB5	7	20615207	20777038	N	.	N	N	2.92716117	99.47328819	1.17E-23	99.2	DM?	.
ABCB8	7	151028422	151047782	N	.	N	N	0.104018084	57.50419633	4.60E-06	79.7	.	.
ABCB9	12	122920951	122981649	N	Viable	N	Y	-1.100632192	6.569427563	0.002901108	60.5	.	.
ABCC1	16	15949577	16143074	N	.	N	Y	-1.459410983	3.577009898	0.01943576	51.8	FP	.
ABCC10	6	43427366	43450430	N	.	N	Y	-0.432925267	23.05955895	8.31E-21	98.8	.	.
ABCC11	16	48166910	48247568	N	.	N	N	1.80652302	98.20570701	5.70E-25	99.3	DFP	[Earwax, wet/dry], 117800 (3); [Axillary odor, variation in], 117800 (3); [Colostrum secretion, variation in], 117800 (3)
ABCC12	16	48082973	48156018	N	.	N	N	1.287536057	95.70527291	2.21E-26	99.4	DM?	.
ABCC2	10	99782732	99852192	N	Viable	N	Y	0.869231732	90.56549169	3.36E-29	99.6	DM	Dubin-Johnson syndrome, 237500 (3)
ABCC3	17	50634777	50692252	N	.	N	Y	-0.313815814	28.62765526	2.62E-14	96.5	DFP	.
ABCC4	13	95019829	95301446	N	.	N	Y	-0.443570983	22.5270591	0.001314683	63.7	FP	.
ABCC5	3	183919934	184018015	N	.	N	N	-3.147194401	0.538287897	0.896205135	17.9	.	.
ABCC6	16	16148928	16223522	N	.	N	Y	0.012674769	50.45436129	1.45E-06	82	DM	Pseudoxanthoma elasticum, 264800 (3); Pseudoxanthoma elasticum, forme fruste, 177850 (3); Arterial calcification, generalized, of infancy, 2, 614473 (3)
ABCC8	11	17392885	17476845	N	.	N	Y	-2.343482783	1.088151878	3.94E-15	96.9	DM	Hyperinsulinemic hypoglycemia, familial, 1, 256450 (3); Hypoglycemia of infancy, leucine-sensitive, 240800 (3); Diabetes mellitus, transient neonatal 2, 610374 (3); Diabetes mellitus, noninsulin-dependent, 125853 (3); Diabetes mellitus, permanent neonatal, 606176 (3)
ABCC9	12	21797401	21941402	N	.	N	Y	-2.053756819	1.522255021	0.000700543	66	DM	Cardiomyopathy, dilated, 1O, 608569 (3); Atrial fibrillation, familial, 12, 614050 (3); Hypertrichotic osteochondrodysplasia, 239850 (3)
ABCD1	X	153724868	153744762	N	.	N	Y	0.043538553	52.85061064	0.982118838	11.4	DM	Adrenoleukodystrophy, 300100 (3); Adrenomyeloneuropathy, adult, 300100 (3)
ABCD2	12	39550033	39619751	N	.	N	Y	-0.6936757	14.15176246	2.97E-06	80.6	.	.
ABCD3	1	94418455	94518666	N	.	N	N	-0.664619572	14.89263182	0.999695623	4.7	DM	?Bile acid synthesis defect, congenital, 5, 616278 (3)
ABCD4	14	74285423	74303056	N	.	N	Y	0.367428116	74.23742548	1.40E-08	88.5	DM	Methylmalonic aciduria and homocystinuria, cblJ type, 614857 (3)
ABCF1	6	30571376	30597179	N	.	N	N	-0.011549788	48.57324767	2.73E-06	80.7	.	.
ABCF2	7	151207837	151227230	N	.	N	N	-1.324134199	4.52624877	0.995417497	8.2	.	.
ABCF3	3	184186023	184194012	N	.	N	N	-0.294751724	29.72159518	0.004026166	59	.	.
ABCG1	21	42199689	42297244	N	.	N	Y	-1.286464315	4.792498698	0.358875895	33.9	DFP	.
ABCG2	4	88090264	88231322	N	Viable	N	Y	0.314906814	71.38392082	1.37E-18	98.3	DFP	[Junior blood group system], 614490 (3); [Uric acid concentration, serum, QTL1], 138900 (3)
ABCG4	11	119149012	119162653	N	.	N	Y	-0.790262178	11.74393703	0.000455417	67.3	.	.
ABCG5	2	43812472	43838865	N	.	N	Y	1.056929738	93.4537246	1.90E-15	97.2	DM	Sitosterolemia, 210250 (3)
ABCG8	2	43838964	43878466	N	.	N	Y	0.81793519	89.48312786	3.75E-16	97.5	DM	Sitosterolemia, 210250 (3); Gallbladder disease 4, 611465 (3)
ABHD1	2	27123789	27130812	N	.	N	N	-0.171177353	37.31550616	1.06E-21	99	.	.
ABHD10	3	111979010	111993363	N	.	N	N	0.352119595	73.52549632	0.000658971	66.2	.	.
ABHD11	7	73736094	73738867	N	.	N	N	-0.525887379	19.15841871	9.03E-06	78.3	.	.
ABHD12	20	25294743	25390983	N	.	N	Y	-0.031491274	47.21884586	1.98E-06	81.3	DM	Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3)
ABHD12B	14	50872160	50904970	N	.	N	N	0.897139902	91.05747526	3.28E-13	95.7	.	.
ABHD13	13	108218379	108234255	N	.	N	N	0.152256873	61.16223881	0.637356652	26.4	.	.
ABHD14A	3	51971426	51981199	N	.	N	N	0.910235282	91.27742085	0.000234514	69.3	.	.
ABHD14A-ACY1	3	51975050	51989183	N	.	N	N	.	.	2.25E-05	75.9	.	.
ABHD14B	3	51968510	51983409	N	.	N	N	0.38485322	75.1519361	0.116162846	42.3	.	.
ABHD15	17	29560547	29567137	N	.	N	N	0.288418427	69.82114951	0.001790126	62.3	.	.
ABHD16A	6	31686949	31703444	N	.	N	N	-0.08305528	43.36400996	0.988882578	10.2	.	.
ABHD16B	20	63861213	63863306	N	.	N	N	.	.	0.033092969	49.2	.	.
ABHD17A	19	1876810	1885547	N	.	N	N	1.066045452	93.57527348	0.050556875	46.9	.	.
ABHD17B	9	71862452	71910931	N	.	N	N	-0.214586899	34.6414308	0.961448199	13.8	.	.
ABHD17C	15	80679684	80755621	N	.	N	N	-0.239967611	33.04971928	0.84082863	20.2	.	.
ABHD2	15	89087459	89202360	N	.	N	N	-0.449899067	22.28396134	0.84946372	19.9	.	.
ABHD3	18	21650897	21704805	N	.	N	N	0.118568504	58.65022863	1.34E-06	82.2	.	.
ABHD4	14	22598237	22613215	N	.	N	N	-0.501463696	20.08450541	7.51E-05	72.8	.	.
ABHD6	3	58237506	58295693	N	.	N	N	-0.420843869	23.49366209	0.002559916	61	.	.
ABHD8	19	17292131	17310236	N	Viable	N	Y	-0.568991981	17.68825606	0.642340813	26.3	.	.
ABI2	2	203328219	203447723	N	.	N	Y	-0.603790891	16.62325635	0.953329216	14.4	.	.
ABI3	17	49210227	49223225	N	.	N	N	0.520058292	81.25832031	0.027711007	50.1	.	.
ABL2	1	179099327	179229684	N	.	N	Y	-1.005669692	7.779128321	0.009702577	55.1	.	Leukemia, acute myeloid, with eosinophilia (1)
ABLIM1	10	114431113	114685003	N	.	N	Y	-0.091212522	42.72732535	0.951991965	14.6	.	.
ABLIM2	4	7965310	8158832	N	.	N	N	-0.010592986	48.64849222	0.762415767	22.8	.	.
ABLIM3	5	149141483	149260542	N	.	N	N	0.164846502	62.1404179	0.016025349	52.8	.	.
ABO	9	133250401	133275214	N	Viable	N	Y	.	.	.	.	DM	[Blood group, ABO system], 616093 (3)
ABR	17	1003518	1229021	N	.	N	Y	-1.354001973	4.271574926	0.999949479	3.3	.	.
ABRA	8	106759483	106770245	N	.	N	Y	-0.468580168	21.49678764	4.06E-06	79.9	.	.
ABRACL	6	139028682	139043302	N	.	N	N	-0.044887353	46.22330266	0.267692922	36.6	.	.
ABT1	6	26596952	26600744	N	.	N	N	-0.647852776	15.44828385	0.027105567	50.2	.	.
ABTB1	3	127672935	127680920	N	.	N	N	0.111216702	58.0945766	0.001298307	63.7	.	.
ABTB2	11	34150988	34358008	N	.	N	Y	-0.496381337	20.3449673	0.12465044	41.9	.	.
AC002310.13	16	30534227	30558279	N	.	N	N	.	.	.	.	.	.
AC002398.9	19	35745678	35754519	N	.	N	N	.	.	.	.	.	.
AC002985.3	19	18907013	18934397	N	.	N	N	.	.	.	.	.	.
AC003002.4	19	57363566	57398584	N	.	N	N	.	.	.	.	.	.
AC003002.6	19	57389884	57419994	N	.	N	N	.	.	.	.	.	.
AC003005.4	19	57487718	57505381	N	.	N	N	.	.	.	.	.	.
AC003006.7	19	57682045	57753575	N	.	N	N	.	.	.	.	.	.
AC004076.7	19	57394183	57438457	N	.	N	N	.	.	.	.	.	.
AC004076.9	19	57437970	57477536	N	.	N	N	.	.	0.005605695	57.6	.	.
AC004158.1	16	72496967	72497341	N	.	N	N	.	.	.	.	.	.
AC004381.6	16	20806429	20849668	N	.	N	N	.	.	9.23E-07	82.6	.	.
AC004754.3	16	249547	269943	N	.	N	N	.	.	.	.	.	.
AC004813.1	12	119918001	119918375	N	.	N	N	.	.	.	.	.	.
AC004824.2	1	17329012	17331796	N	.	N	N	.	.	.	.	.	.
AC004853.1	7	143959971	143960924	N	.	N	N	.	.	.	.	.	.
AC004953.1	7	101635218	101638685	N	.	N	N	.	.	.	.	.	.
AC005477.1	14	71965306	71966899	N	.	N	N	.	.	.	.	.	.
AC005480.1	14	74003369	74003777	N	.	N	N	.	.	.	.	.	.
AC005779.2	19	45179822	45202444	N	.	N	N	.	.	.	.	.	.
AC005943.2	19	1578339	1605445	N	.	N	N	.	.	.	.	.	.
AC006328.4	Y	25463994	25473714	N	.	N	N	.	.	.	.	.	.
AC006386.1	Y	25307702	25308107	N	.	N	N	.	.	.	.	.	.
AC006449.2	17	38727833	38728198	N	.	N	N	.	.	.	.	.	.
AC006486.9	19	42234583	42255132	N	.	N	N	.	.	.	.	.	.
AC006538.4	19	2717769	2740048	N	.	N	N	.	.	.	.	.	.
AC006547.14	22	20148427	20151065	N	.	N	N	.	.	.	.	.	.
AC006994.3	2	210232692	210233976	N	.	N	N	.	.	.	.	.	.
AC007040.11	2	70939318	70995336	N	.	N	N	.	.	0.000106767	71.7	.	.
AC007163.2	2	200682822	200683196	N	.	N	N	.	.	.	.	.	.
AC007192.4	19	18153158	18178117	N	.	N	N	.	.	.	.	.	.
AC007326.1	22	18945123	18946971	N	.	N	N	.	.	.	.	.	.
AC007557.5	2	216863059	216865281	N	.	N	N	.	.	.	.	.	.
AC007906.1	16	53207941	53226385	N	.	N	N	.	.	.	.	.	.
AC008074.1	2	64552771	64592133	N	.	N	N	.	.	.	.	.	.
AC008622.1	19	46792971	46793189	N	.	N	N	.	.	.	.	.	.
AC008641.1	5	151016918	151017411	N	.	N	N	.	.	.	.	.	.
AC008686.1	19	13780070	13790158	N	.	N	N	.	.	.	.	.	.
AC008759.1	19	9615561	9616905	N	.	N	N	.	.	.	.	.	.
AC008810.1	5	40801222	40801596	N	.	N	N	.	.	.	.	.	.
AC008914.1	5	55928640	55928741	N	.	N	N	.	.	.	.	.	.
AC009022.1	16	70052395	70052769	N	.	N	N	.	.	.	.	.	.
AC009060.2	16	70205400	70205780	N	.	N	N	.	.	.	.	.	.
AC009065.4	16	2253737	2262342	N	.	N	N	.	.	.	.	.	.
AC009133.22	16	29663279	29695144	N	.	N	N	.	.	.	.	.	.
AC009336.19	2	176151085	176173097	N	.	N	N	.	.	.	.	.	.
AC009491.1	Y	8710885	8745985	N	.	N	N	.	.	.	.	.	.
AC009491.2	Y	8695281	8743495	N	.	N	N	.	.	.	.	.	.
AC009758.1	11	4367351	4368295	N	.	N	N	.	.	.	.	.	.
AC009977.1	Y	19576009	19576182	N	.	N	N	.	.	.	.	.	.
AC010287.1	16	58554337	58554935	N	.	N	N	.	.	.	.	.	.
AC010547.9	16	71447600	71489311	N	.	N	N	.	.	.	.	.	.
AC010642.1	19	58278966	58315197	N	.	N	N	.	.	.	.	.	.
AC010646.3	19	17235940	17255448	N	.	N	N	.	.	.	.	.	.
AC010655.1	7	128441694	128442726	N	.	N	N	.	.	.	.	.	.
AC011155.1	18	52409042	52409257	N	.	N	N	.	.	.	.	.	.
AC011513.3	19	41708612	41761282	N	.	N	N	.	.	.	.	.	.
AC011530.4	19	45779437	45785973	N	.	N	N	.	.	.	.	.	.
AC012005.3	Y	24362031	24362436	N	.	N	N	.	.	.	.	.	.
AC012005.4	Y	24196425	24206144	N	.	N	N	.	.	.	.	.	.
AC013269.5	2	130539095	130549883	N	.	N	N	.	.	.	.	.	.
AC015688.3	17	27623364	27640777	N	.	N	N	.	.	.	.	.	.
AC016142.1	3	150819598	150819972	N	.	N	N	.	.	.	.	.	.
AC016577.1	5	156658587	156660435	N	.	N	N	.	.	.	.	.	.
AC017028.10	2	239161797	239162357	N	.	N	N	.	.	.	.	.	.
AC017081.1	2	206355739	206356119	N	.	N	N	.	.	.	.	.	.
AC018512.1	15	43782843	43783033	N	.	N	N	.	.	.	.	.	.
AC018755.18	19	51612091	51646889	N	.	N	N	.	.	.	.	.	.
AC019206.1	2	69902350	69902709	N	.	N	N	.	.	.	.	.	.
AC022210.1	2	84895085	84895221	N	.	N	N	.	.	.	.	.	.
AC024592.12	19	5866171	5903787	N	.	N	N	.	.	.	.	.	.
AC025263.3	12	69801669	69855363	N	.	N	N	.	.	.	.	.	.
AC026449.1	5	115855994	115858468	N	.	N	N	.	.	.	.	.	.
AC037459.4	8	22589274	22602084	N	.	N	N	.	.	.	.	.	.
AC055733.1	3	130868872	130869246	N	.	N	N	.	.	.	.	.	.
AC063956.1	4	70020979	70021229	N	.	N	N	.	.	.	.	.	.
AC064829.1	Y	8549671	8748740	N	.	N	N	.	.	.	.	.	.
AC068533.7	7	66087761	66152277	N	.	N	N	.	.	.	.	.	.
AC069063.1	3	115113420	115114210	N	.	N	N	.	.	.	.	.	.
AC069063.2	3	115120172	115121489	N	.	N	N	.	.	.	.	.	.
AC069368.3	15	64841883	64930920	N	.	N	N	.	.	.	.	.	.
AC073333.1	7	16789242	16789622	N	.	N	N	.	.	.	.	.	.
AC073610.5	12	48921963	48939663	N	.	N	N	.	.	.	.	.	.
AC073657.1	15	41781148	41784031	N	.	N	N	.	.	.	.	.	.
AC079355.1	7	63762476	63765094	N	.	N	N	.	.	.	.	.	.
AC084219.2	19	44025354	44087318	N	.	N	N	.	.	.	.	.	.
AC087762.1	15	100783470	100785235	N	.	N	N	.	.	.	.	.	.
AC090154.1	8	66674499	66675916	N	.	N	N	.	.	.	.	.	.
AC092159.1	2	687799	688348	N	.	N	N	.	.	.	.	.	.
AC092718.1	16	81170740	81181213	N	.	N	N	.	.	.	.	.	.
AC092835.2	2	95207535	95259774	N	.	N	N	.	.	.	.	.	.
AC092881.1	12	70321677	70324274	N	.	N	N	.	.	.	.	.	.
AC104057.1	7	65554258	65555459	N	.	N	N	.	.	.	.	.	.
AC104073.2	7	65140528	65141723	N	.	N	N	.	.	.	.	.	.
AC104389.1	11	5253367	5254782	N	.	N	N	.	.	.	.	.	.
AC104389.2	11	5248449	5249858	N	.	N	N	.	.	.	.	.	.
AC104532.2	19	5904841	5914707	N	.	N	N	.	.	.	.	.	.
AC104534.3	19	38817471	38840178	N	.	N	N	.	.	.	.	.	.
AC104981.1	17	77777090	77777464	N	.	N	N	.	.	.	.	.	.
AC108925.1	8	127630283	127630657	N	.	N	N	.	.	.	.	.	.
AC108938.5	2	110402934	110473075	N	.	N	N	.	.	.	.	.	.
AC109829.1	2	27537386	27567144	N	.	N	N	.	.	.	.	.	.
AC109829.2	2	27556908	27557282	N	.	N	N	.	.	.	.	.	.
AC110615.1	4	75949920	75957413	N	.	N	N	.	.	0.006694544	56.8	.	.
AC113404.1	5	76170093	76174331	N	.	N	N	.	.	.	.	.	.
AC118758.1	7	56804059	56804689	N	.	N	N	.	.	.	.	.	.
AC124312.1	15	25091960	25092377	N	.	N	N	.	.	.	.	.	.
AC129492.1	17	8188933	8189688	N	.	N	N	.	.	.	.	.	.
AC138969.4	16	16317444	16350590	N	.	N	N	.	.	.	.	.	.
AC231657.1	X	49155242	49157351	N	.	N	N	.	.	.	.	.	.
AC234582.1	1	155190050	155191339	N	.	N	N	.	.	.	.	.	.
AC234582.2	1	155188587	155189452	N	.	N	N	.	.	.	.	.	.
AC242988.1	1	150302770	150303291	N	.	N	N	.	.	.	.	.	.
AC243756.1	1	146344006	146344790	N	.	N	N	.	.	.	.	.	.
AC243945.1	14	22638099	22638473	N	.	N	N	.	.	.	.	.	.
AC253572.1	1	120723923	120793877	N	.	N	N	.	.	.	.	.	.
ACAA1	3	38103129	38137242	N	.	N	Y	0.036035566	52.3065347	2.64E-05	75.5	.	.
ACAA2	18	49782167	49813960	N	.	N	N	-0.222893607	34.16102333	0.003508042	59.7	.	.
ACACB	12	109116595	109268226	N	.	N	Y	-2.323579519	1.099727962	5.12E-22	99	DM?	.
ACAD10	12	111686056	111757107	N	.	N	N	0.221505549	65.70585171	4.01E-20	98.7	FP	.
ACAD11	3	132558138	132660723	N	.	N	N	0.112325491	58.15824507	1.68E-07	85.5	.	.
ACAD8	11	134253495	134265855	N	.	N	N	-0.387960287	25.05064537	1.17E-05	77.7	DM	Isobutyryl-CoA dehydrogenase deficiency, 611283 (3)
ACAD9	3	128879596	128916067	N	.	N	N	-0.366105665	26.08670487	2.07E-05	76.1	DM	Mitochondrial complex I deficiency due to ACAD9 deficiency, 611126 (3)
ACADS	12	120725735	120740008	N	.	N	N	-0.127116299	40.27319558	0.00016291	70.4	DM	Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3)
ACADSB	10	123008979	123058311	N	.	N	N	0.157996972	61.60213	2.99E-08	87.6	DM	2-methylbutyrylglycinuria, 610006 (3)
ACADVL	17	7217125	7225273	N	.	N	Y	-0.837047289	10.84100249	1.31E-07	85.8	DM	VLCAD deficiency, 201475 (3)
ACAP1	17	7336529	7351478	N	Viable	N	Y	0.074658654	55.24685999	0.237755775	37.5	.	.
ACAP2	3	195274736	195443078	N	.	N	N	-0.628060421	15.93447937	0.999918185	3.6	.	.
ACAP3	1	1292376	1309609	N	.	N	Y	-0.752745356	12.53111073	0.03943093	48.4	.	.
ACAT1	11	108121516	108147776	N	.	N	N	-0.616882625	16.28176188	0.001599516	62.8	DM	Alpha-methylacetoacetic aciduria, 203750 (3)
ACBD4	17	45132600	45144181	N	.	N	N	0.665489359	86.0913353	1.83E-05	76.5	.	.
ACBD5	10	27195214	27242130	N	.	N	N	0.05486868	53.70724084	0.06164569	45.8	DM	.
ACBD6	1	180269653	180502954	N	.	N	N	-0.476237287	21.18423337	0.064959259	45.5	DM	.
ACBD7	10	15077523	15088776	N	.	N	N	0.290033479	69.90218209	0.086336608	44	.	.
ACCS	11	44065925	44084222	N	.	N	N	0.603699992	84.26231406	0.000171666	70.3	DP	.
ACCSL	11	44047981	44059977	N	.	N	N	-0.136381432	39.66545118	2.58E-11	93.7	.	.
ACE2	X	15561033	15602148	N	.	N	Y	0.150493969	61.02911385	0.999070361	5.8	.	.
ACER1	19	6306142	6333629	N	.	N	Y	0.084729555	56.09191411	0.335356707	34.7	.	.
ACER2	9	19409059	19452020	N	.	N	N	-0.059741353	45.11778665	0.146646887	40.7	.	.
ACER3	11	76860867	77026797	N	.	N	N	-0.042016662	46.43167217	0.831594949	20.6	.	.
ACIN1	14	23058564	23095614	N	.	N	N	-0.499917934	20.18290212	0.999998437	1.8	.	.
ACKR1	1	159203307	159206500	N	.	N	Y	.	.	.	.	.	.
ACKR2	3	42804752	42887974	N	.	N	Y	0.097973006	57.00063668	0.00037689	68	.	.
ACKR4	3	132597237	132618967	N	.	N	Y	0.480629485	79.77658158	0.007445108	56.3	.	.
ACMSD	2	134838547	134902034	N	.	N	N	0.384045085	75.10563176	1.99E-07	85.2	.	.
ACO2	22	41469125	41528989	N	.	N	N	-0.877433808	9.995948371	0.454377775	31.3	DM	Infantile cerebellar-retinal degeneration, 614559 (3); ?Optic atrophy 8, 616289 (3)
ACOT1	14	73537114	73543794	N	.	N	N	.	.	0.035999166	48.8	.	.
ACOT11	1	54542257	54639192	N	.	N	Y	0.584216026	83.65456966	1.33E-10	92.7	.	.
ACOT12	5	81330005	81394179	N	.	N	N	-0.183312917	36.54569659	1.29E-11	94.1	.	.
ACOT13	6	24667035	24705065	N	.	N	Y	0.268480327	68.6056607	3.43E-05	74.9	.	.
ACOT2	14	73567620	73575658	N	.	N	N	0.8382163	89.98089946	0.142294698	41	.	.
ACOT4	14	73591706	73596496	N	Viable	N	Y	0.141077527	60.28245644	4.21E-08	87.2	.	.
ACOT6	14	73610945	73619888	N	.	N	N	0.12592113	59.20588065	0.001523887	63	.	.
ACOT7	1	6264269	6394391	N	.	N	N	-0.902009032	9.53869306	0.381517902	33.3	.	.
ACOT8	20	45841721	45857406	N	.	N	N	0.976957029	92.43502923	3.57E-05	74.8	.	.
ACOT9	X	23702253	23766475	N	.	N	N	0.365212869	74.13902877	1.91E-05	76.4	.	.
ACOX1	17	75941507	75979363	N	.	N	Y	-0.441286593	22.67754819	0.094435306	43.5	DM	Peroxisomal acyl-CoA oxidase deficiency, 264470 (3)
ACOX2	3	58505136	58537319	N	.	N	N	-0.160653142	37.96376686	1.55E-09	90.8	.	.
ACOX3	4	8366282	8440723	N	.	N	N	0.374128395	74.64258841	3.03E-12	94.9	.	.
ACOXL	2	110732573	111118222	N	.	N	N	1.435803692	96.6024194	6.28E-10	91.5	.	.
ACP1	2	264140	278283	N	.	N	Y	-0.023183121	47.73398159	0.002207534	61.5	.	.
ACP2	11	47239302	47248906	N	.	N	Y	-0.362580181	26.22561787	0.000525977	66.9	.	?Lysosomal acid phosphatase deficiency, 200950 (1)
ACP5	19	11574660	11579008	N	.	N	Y	0.390591665	75.41239799	0.123568348	41.9	DM	Spondyloenchondrodysplasia with immune dysregulation, 607944 (3)
ACP6	1	147629652	147670496	N	.	N	N	0.854030858	90.2760896	3.14E-05	75.1	DM?	.
ACPP	3	132317367	132368298	N	.	N	Y	-0.431064706	23.12901545	1.76E-07	85.4	FTV	.
ACPT	19	50790415	50795224	N	.	N	N	-0.416058551	23.66730335	1.22E-13	96	.	.
ACR	22	50738196	50745334	N	.	N	Y	0.156083554	61.48058112	0.01545989	53	.	?Male infertility due to acrosin deficiency (2)
ACRBP	12	6638075	6647460	N	.	N	Y	0.003304686	49.75979626	1.88E-07	85.2	.	.
ACRC	X	71578411	71613583	N	.	N	N	0.085837372	56.15558257	0.982862106	11.3	.	.
ACRV1	11	125671522	125681123	N	.	N	N	0.242293684	67.01973722	0.000432843	67.5	.	.
ACSBG1	15	78167468	78245688	N	.	N	Y	-0.485199748	20.74434219	0.006700298	56.8	.	.
ACSBG2	19	6135247	6193094	N	.	N	Y	1.203331922	95.05122417	3.48E-07	84.3	.	.
ACSF2	17	50426158	50474845	N	Viable	N	Y	-0.6936757	14.15176246	0.08385164	44.2	.	.
ACSF3	16	89088375	89155846	N	.	N	N	0.062675124	54.32077328	1.37E-15	97.2	DM	Combined malonic and methylmalonic aciduria, 614265 (3)
ACSL1	4	184755595	184826818	N	.	N	N	-0.338006426	27.36007409	0.091837331	43.6	.	.
ACSL3	2	222860934	222944639	N	.	N	N	-0.158890404	38.10846791	0.530102681	29.1	.	.
ACSL5	10	112374018	112428380	N	Viable	N	Y	-0.535000983	18.79377207	0.016763711	52.6	DFP	.
ACSM1	16	20623237	20698890	N	.	N	N	0.91053248	91.28320889	4.37E-09	89.7	.	.
ACSM2A	16	20451461	20487667	N	Viable	N	Y	0.925696379	91.61891532	2.49E-06	80.9	.	.
ACSM2B	16	20536226	20576427	N	.	N	N	0.956668363	92.13405105	8.66E-06	78.4	FP	.
ACSM3	16	20610243	20797581	N	.	N	Y	0.635626645	85.2347051	4.98E-09	89.6	DFP	{?Hypertension, essential} (1)
ACSM4	12	7304284	7328724	N	.	N	N	0.777232305	88.74225849	4.67E-11	93.4	.	.
ACSM5	16	20409534	20441336	N	.	N	N	1.83386473	98.25779939	5.09E-08	86.9	.	.
ACSM6	10	95194200	95228928	N	.	N	N	.	.	.	.	.	.
ACSS1	20	25006230	25058980	N	.	N	Y	-0.408404087	24.00300978	0.001396696	63.4	.	.
ACSS2	20	34872146	34927962	N	.	N	N	-0.546330528	18.33651676	8.97E-11	93	.	.
ACSS3	12	80936414	81261205	N	.	N	N	-0.70294221	13.8392082	3.00E-11	93.7	.	.
ACTA2	10	88935074	88991390	N	.	N	Y	-0.267108277	31.41749146	0.734223241	23.6	DM	Aortic aneurysm, familial thoracic 6, 611788 (3); Multisystemic smooth muscle dysfunction syndrome, 613834 (3); Moyamoya disease 5, 614042 (3)
ACTBL2	5	57480016	57482809	N	.	N	N	0.827842702	89.72043758	6.02E-10	91.6	.	.
ACTG2	2	73892314	73919865	N	.	N	N	-0.525085865	19.18735892	0.692010864	24.8	DM	Visceral myopathy, 155310 (3)
ACTL10	20	33666498	33668525	N	.	N	N	0.316368397	71.5054697	0.001052601	64.5	.	.
ACTL7A	9	108862266	108863759	N	.	N	N	0.294159089	70.15106789	6.78E-06	79	.	.
ACTL7B	9	108854589	108856967	N	.	N	N	-0.822189382	11.12461654	6.60E-05	73.1	.	.
ACTL8	1	17755313	17827063	N	.	N	N	0.461946007	78.93152746	0.077144246	44.6	.	.
ACTL9	19	8697397	8698822	N	.	N	N	0.685278874	86.54280257	0.042627929	47.9	.	.
ACTN1	14	68874143	68979440	N	.	N	N	-1.654184846	2.650923193	0.999930574	3.5	.	Bleeding disorder, platelet-type, 15, 615193 (3)
ACTN2	1	236686454	236764631	N	.	N	N	-0.451361828	22.20871679	0.999811916	4.2	DM	Cardiomyopathy, dilated, 1AA, with or without LVNC, 612158 (3); Cardiomyopathy, hypertrophic, 23, with or without LVNC, 612158 (3)
ACTN3	11	66546395	66563329	N	.	N	Y	.	.	.	.	FP	[Alpha-actinin-3 deficiency] (3); [Sprinting performance] (3)
ACTR10	14	58200080	58235636	N	.	N	N	-0.154409651	38.42681021	0.004736237	58.4	.	.
ACTR1A	10	102479229	102502711	N	.	N	N	-0.402163571	24.28662384	0.941234074	15.5	.	.
ACTR1B	2	97655963	97664107	N	.	N	N	-0.608422187	16.49591943	0.031660126	49.4	.	.
ACTR2	2	65227753	65271253	N	.	N	N	-0.337507753	27.3890143	0.997096541	7.5	.	.
ACTR3B	7	152759749	152855378	N	.	N	N	-0.369279534	25.88991144	0.99754718	7.2	.	.
ACTR3C	7	150243916	150323725	N	.	N	N	1.01433189	92.92701279	0.001231511	63.9	DM?	.
ACTR5	20	38748442	38772520	N	.	N	N	-0.234877184	33.36806158	1.00E-12	95.3	.	.
ACTRT1	X	128050962	128052398	N	.	N	N	0.556617993	82.67639058	0.064112936	45.6	.	.
ACTRT2	1	3021483	3022903	N	.	N	N	-0.09614756	42.3337385	0.018722461	52	.	.
ACTRT3	3	169766921	169769895	N	.	N	N	0.125114793	59.14221219	0.000670124	66.1	.	.
ACVR1C	2	157526767	157629005	N	.	N	Y	-0.568991981	17.68825606	0.044891005	47.6	DM	.
ACY1	3	51983340	51989197	N	.	N	N	0.546393986	82.29437981	7.69E-05	72.7	DM	Aminoacylase 1 deficiency, 609924 (3)
ACY3	11	67642555	67650659	N	.	N	N	0.200145052	64.3919662	1.88E-07	85.2	.	.
ACYP1	14	75053221	75069483	N	.	N	N	0.047063497	53.15737686	0.223001664	37.9	.	.
ACYP2	2	53970838	54305300	N	.	N	N	0.366978017	74.20848527	0.000220645	69.5	.	.
AD000671.6	19	35739252	35745432	N	.	N	N	.	.	.	.	.	.
ADAD1	4	122378966	122429802	N	.	N	Y	-0.285636061	30.30618742	0.974992287	12.4	.	.
ADAD2	16	84191138	84197168	N	.	N	N	0.762537251	88.35445969	6.70E-05	73	.	.
ADAL	15	43330674	43354555	N	.	N	N	0.045300934	53.00688777	8.52E-09	89.1	.	.
ADAM11	17	44759031	44781846	N	.	N	Y	-0.585759916	17.21363663	0.024736381	50.5	.	.
ADAM15	1	155050566	155062775	N	.	N	Y	0.646156788	85.53568328	1.08E-11	94.2	.	.
ADAM18	8	39584489	39730064	N	.	N	Y	0.858165292	90.33397002	1.53E-19	98.6	.	.
ADAM2	8	39743735	39838289	N	.	N	Y	0.660205663	85.92927013	7.21E-14	96.2	.	.
ADAM20	14	70522358	70535015	N	.	N	N	-0.152193444	38.54257105	1.80E-09	90.6	.	.
ADAM21	14	70452157	70459899	N	.	N	Y	2.237413822	98.91184812	0.014672876	53.3	.	.
ADAM28	8	24294040	24359018	N	.	N	N	0.752160326	88.14030214	1.97E-17	98	.	.
ADAM29	4	174829668	174978180	N	.	N	N	-0.445771112	22.46917868	4.69E-07	83.8	.	.
ADAM30	1	119893533	119896495	N	.	N	N	-1.123143885	6.355270012	0.001938073	62	.	.
ADAM32	8	39106990	39284911	N	.	N	N	0.771642708	88.60334549	1.17E-08	88.7	.	.
ADAM33	20	3667965	3682246	N	.	N	Y	1.295138018	95.74000116	1.31E-11	94.1	DM?	.
ADAM7	8	24440930	24526970	N	.	N	N	1.388218809	96.33038143	1.74E-12	95.1	DP	.
ADAM8	10	133262403	133276868	N	Viable	N	Y	1.695900795	97.8873647	1.48E-07	85.6	.	.
ADAM9	8	38996869	39105144	N	.	N	Y	-0.613859382	16.36858251	0.828249261	20.7	DM	Cone-rod dystrophy 9, 612775 (3)
ADAMDEC1	8	24384285	24406013	N	.	N	N	0.397288115	75.70180008	1.76E-09	90.7	.	.
ADAMTS10	19	8580242	8610735	N	.	N	N	-0.35845456	26.37031892	0.98034624	11.7	DM	Weill-Marchesani syndrome 1, recessive, 277600 (3)
ADAMTS12	5	33523535	33892192	N	.	N	Y	-0.38326217	25.25322683	1.54E-11	94.1	.	.
ADAMTS13	9	133414358	133459402	N	Viable	N	Y	0.931784799	91.75204028	7.88E-11	93.1	DM	Thrombotic thrombocytopenic purpura, familial, 274150 (3)
ADAMTS14	10	70672803	70762441	N	.	N	N	1.062229429	93.52318111	2.33E-06	81	.	.
ADAMTS15	11	130448974	130476641	N	Viable	N	Y	0.134183897	59.75574463	0.679914358	25.2	.	.
ADAMTS16	5	5140330	5320304	N	.	N	N	0.96930333	92.31348035	0.001086503	64.4	DP	.
ADAMTS17	15	99971589	100342005	N	.	N	N	-0.378764424	25.50211264	3.83E-11	93.6	DM	Weill-Marchesani-like syndrome, 613195 (3)
ADAMTS18	16	77247813	77435114	N	Viable	N	Y	1.375858642	96.26671297	3.74E-15	96.9	DM	Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 (3)
ADAMTS19	5	129460265	129738683	N	.	N	N	-0.316304619	28.50610638	0.951958941	14.6	.	.
ADAMTS2	5	179110851	179345430	N	.	N	Y	-0.614382069	16.35121838	0.992213475	9.4	DM	Ehlers-Danlos syndrome, type VIIC, 225410 (3)
ADAMTS20	12	43353866	43551921	N	.	N	Y	-0.917977625	9.249290965	4.85E-26	99.4	.	.
ADAMTS3	4	72280969	72568799	N	.	N	N	-1.515974584	3.258667593	1.79E-06	81.5	.	.
ADAMTS4	1	161184308	161199056	N	.	N	Y	0.911647357	91.30636106	0.00546594	57.7	.	.
ADAMTS5	21	26917912	26966513	N	.	N	Y	-0.079882631	43.62447184	0.118850234	42.2	.	.
ADAMTS6	5	65148736	65481920	N	.	N	N	-0.431721062	23.10586329	0.998800473	6.1	.	.
ADAMTS7	15	78759203	78811431	N	.	N	N	4.441062911	99.81478266	2.99E-07	84.5	.	.
ADAMTS8	11	130404925	130428993	N	.	N	N	-0.049064732	45.89917231	1.06E-08	88.9	.	.
ADAMTSL1	9	18473894	18910950	N	.	N	N	1.429774462	96.55032702	8.83E-05	72.3	.	.
ADAMTSL2	9	133532164	133575519	N	.	N	N	.	.	0.071058667	45	DM	Geleophysic dysplasia 1, 231050 (3)
ADAMTSL3	15	83654086	84039842	N	.	N	N	0.257583618	67.87636742	9.55E-09	89	DM	.
ADAMTSL4	1	150549369	150560937	N	.	N	N	1.509780294	97.00758233	7.09E-16	97.4	DM	Ectopia lentis, isolated, autosomal recessive, 225100 (3); Ectopia lentis et pupillae, 225200 (3)
ADAMTSL5	19	1505018	1513604	N	.	N	N	0.258406299	67.95161197	3.22E-10	92.1	.	.
ADAP1	7	897901	955407	N	.	N	N	-0.388917343	25.00434103	0.657926854	25.8	.	.
ADAP2	17	30906344	30959322	N	.	N	N	-0.133814513	39.83909244	3.98E-05	74.5	.	.
ADARB2	10	1177318	1737476	N	.	N	N	0.192944613	64.01574347	0.738168861	23.5	.	.
ADAT1	16	75596981	75623300	N	.	N	N	0.116000912	58.43028304	6.80E-11	93.2	.	.
ADAT2	6	143422832	143450673	N	.	N	N	-0.153605457	38.49626671	2.09E-08	88.1	.	.
ADAT3	19	1905378	1913447	N	.	N	N	.	.	0.001179647	64.1	DM	Mental retardation, autosomal recessive 36, 615286 (3)
ADCK1	14	77800083	77935012	N	.	N	N	-0.126964929	40.27898362	4.23E-09	89.8	.	.
ADCK2	7	140673153	140696261	N	Viable	N	Y	0.551177708	82.49117324	0.000169238	70.3	.	.
ADCK3	1	226897536	226987545	N	.	N	N	0.350661874	73.39237136	1.24E-05	77.5	DM	Coenzyme Q10 deficiency, primary, 4, 612016 (3)
ADCK4	19	40691529	40718207	N	.	N	N	0.173154201	62.77710251	1.82E-07	85.3	.	Nephrotic syndrome, type 9, 615573 (3)
ADCK5	8	144373101	144393242	N	.	N	N	0.194555337	64.09677606	0.908275225	17.4	.	.
ADCY1	7	45574140	45723116	N	.	N	Y	-2.003251612	1.638015859	0.99990962	3.7	.	?Deafness, autosomal recessive 44, 610154 (3)
ADCY10	1	167809388	167914215	N	.	N	Y	0.08388323	56.0224576	5.85E-26	99.4	DM?	{Hypercalciuria, absorptive, susceptibility to}, 143870 (3)
ADCY2	5	7396208	7830081	N	.	N	N	-1.448691364	3.681194652	0.999995486	2.2	.	.
ADCY4	14	24318349	24335093	N	.	N	Y	-0.675506349	14.61480581	2.38E-13	95.8	.	.
ADCY5	3	123282296	123449758	N	.	N	Y	-2.016226141	1.597499566	0.989940592	10	DM	Dyskinesia, familial, with facial myokymia, 606703 (3)
ADCY6	12	48766194	48789037	N	.	N	Y	-1.476666571	3.490189269	0.596680215	27.5	DP	?Lethal congenital contracture syndrome 8, 616287 (3)
ADCY8	8	130780301	131042426	N	.	N	Y	-1.713138467	2.402037391	0.002985662	60.3	DM?	.
ADD2	2	70607618	70768225	N	.	N	Y	-0.84359461	10.71366557	0.999175207	5.7	.	.
ADD3	10	109996368	110135565	N	.	N	Y	-0.203908406	35.22023499	0.952357437	14.5	.	.
ADGB	6	146598965	146815462	N	.	N	N	.	.	.	.	.	.
ADGRA1	10	133070929	133131675	N	.	N	N	.	.	.	.	.	.
ADGRA3	4	22345071	22516054	N	.	N	Y	.	.	.	.	.	.
ADGRB2	1	31727117	31764893	N	.	N	Y	.	.	.	.	.	.
ADGRB3	6	68635367	69389511	N	.	N	N	.	.	.	.	.	.
ADGRD1	12	130953907	131141469	N	Viable	N	Y	.	.	.	.	.	.
ADGRD2	9	124451600	124478589	N	.	N	N	.	.	.	.	.	.
ADGRE1	19	6887566	6940459	N	.	N	Y	.	.	.	.	.	.
ADGRE2	19	14732393	14778541	N	.	N	N	.	.	.	.	.	.
ADGRE3	19	14619117	14690027	N	.	N	N	.	.	.	.	.	.
ADGRE5	19	14380501	14408725	N	.	N	Y	.	.	.	.	.	.
ADGRF1	6	46997703	47042363	N	.	N	N	.	.	.	.	.	.
ADGRF2	6	47656436	47697797	N	.	N	N	.	.	.	.	.	.
ADGRF3	2	26308173	26346817	N	.	N	N	.	.	.	.	.	.
ADGRF4	6	47685864	47722021	N	.	N	N	.	.	.	.	.	.
ADGRF5	6	46852512	46954943	N	Viable	N	Y	.	.	.	.	.	.
ADGRG1	16	57610652	57665580	N	.	N	Y	.	.	.	.	.	.
ADGRG2	X	18989309	19122637	N	.	N	Y	.	.	.	.	.	.
ADGRG3	16	57668187	57689378	N	.	N	N	.	.	.	.	.	.
ADGRG4	X	136300963	136416888	N	.	N	N	.	.	.	.	.	.
ADGRG5	16	57542421	57591681	N	.	N	N	.	.	.	.	.	.
ADGRG7	3	100609589	100695479	N	.	N	N	.	.	.	.	.	.
ADGRL1	19	14147743	14206187	N	.	N	Y	.	.	.	.	.	.
ADGRL3	4	61201258	62078335	N	Viable	N	Y	.	.	.	.	.	.
ADGRL4	1	78889764	79006718	N	.	N	Y	.	.	.	.	.	.
ADGRV1	5	90529344	91164221	N	Viable	N	Y	.	.	.	.	.	Febrile seizures, familial, 4, 604352 (3); Usher syndrome, type 2C, 605472 (3); Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 (3)
ADH1A	4	99276367	99291028	N	.	N	N	0.135487969	59.87729351	6.69E-08	86.6	.	.
ADH1B	4	99304964	99321401	N	.	N	N	0.718969098	87.40522081	0.193827609	38.9	DFP	{Alcohol dependence, protection against}, 103780 (3); {Aerodigestive tract cancer, squamous cell, alcohol-related, protection against} (3)
ADH1C	4	99336492	99353027	N	.	N	Y	.	.	.	.	DFP	{Alcohol dependence, protection against}, 103780 (3); {Parkinson disease, susceptibility to}, 168600 (3)
ADH4	4	99123657	99157792	N	.	N	N	0.551027573	82.47959715	7.01E-06	78.9	FP	.
ADH5	4	99070978	99088801	N	Viable	N	Y	-0.180746515	36.69039764	9.11E-07	82.7	FP	.
ADH6	4	99202638	99219537	N	.	N	N	0.23207049	66.37147653	0.002016524	61.9	.	.
ADH7	4	99412261	99435737	N	.	N	Y	0.17491644	62.86392313	7.33E-09	89.3	DP	.
ADHFE1	8	66430185	66471601	N	.	N	N	-0.482629449	20.86589107	3.88E-05	74.6	.	.
ADI1	2	3497361	3519736	N	.	N	N	0.642833002	85.44886265	0.006029451	57.2	.	.
ADIG	20	38581195	38588463	N	Viable	N	Y	0.471067589	79.34247844	.	.	.	.
ADIPOQ	3	186842690	186858463	N	.	N	Y	0.471213564	79.34826648	5.62E-07	83.6	DM	Adiponectin deficiency, 612556 (3)
ADIPOR1	1	202940823	202958572	N	Viable	N	Y	-0.500661427	20.13080975	0.592753906	27.6	DFP	.
ADIPOR2	12	1688574	1788678	N	.	N	Y	-0.303666373	29.26433987	0.810597984	21.3	.	.
ADIRF	10	86968192	86983934	N	.	N	N	0.143647524	60.46767379	0.033386817	49.2	.	.
ADM2	22	50481556	50486440	N	Viable	N	Y	0.479526897	79.73027725	0.015300038	53	.	.
ADM5	19	49688664	49690575	N	.	N	N	.	.	0.036214399	48.8	.	.
ADNP2	18	80109031	80147523	N	.	N	N	-1.116321995	6.401574347	0.346937921	34.3	.	.
ADO	10	62804857	62808483	N	.	N	N	0.163436574	62.02465706	0.745072785	23.3	.	.
ADORA1	1	203090654	203167405	N	.	N	Y	-0.232310623	33.58800718	0.021258038	51.3	DP	.
ADORA2A	22	24417879	24442360	N	.	N	Y	-0.471451247	21.36945071	0.331624356	34.8	DP	.
ADORA2B	17	15944917	15975746	N	Viable	N	Y	-0.534347745	18.81113619	2.01E-05	76.2	.	.
ADPGK	15	72751369	72785846	N	.	N	N	-0.33543894	27.48162297	0.022156295	51.1	.	.
ADPRH	3	119579268	119589945	N	.	N	Y	-0.009939149	48.69479655	8.59E-06	78.5	.	.
ADPRHL1	13	113421940	113453524	N	.	N	N	0.635476197	85.21734097	2.88E-07	84.6	.	.
ADPRHL2	1	36088875	36093932	N	.	N	N	-0.496832081	20.33339121	6.50E-05	73.1	.	.
ADPRM	17	10697594	10711233	N	.	N	N	0.122244706	58.89332639	0.065596775	45.5	.	.
ADRA1A	8	26748150	26867273	N	.	N	Y	-0.326827012	27.93309024	4.17E-07	84	DP	.
ADRA1B	5	159916783	159972544	N	.	N	Y	-0.359862201	26.32401459	0.182479135	39.2	.	.
ADRA1D	20	4220631	4249074	N	.	N	Y	-0.201341563	35.40545234	.	.	.	.
ADRA2A	10	111077163	111080907	N	Viable	N	Y	0.008742604	50.21705157	.	.	DP	.
ADRA2C	4	3766348	3768526	N	.	N	Y	-0.257690928	32.05996411	0.645951821	26.2	DFP	{Congestive heart failure and beta-blocker response, modifier of} (3)
ADRB2	5	148825245	148828687	N	.	N	Y	-0.297923775	29.57689414	0.476493104	30.7	DM	{Asthma, nocturnal, susceptibility to}, 600807 (3); {Obesity, susceptibility to}, 601665 (3); Beta-2-adrenoreceptor agonist, reduced response to (3)
ADRB3	8	37962991	37966965	N	.	N	Y	.	.	0.323569934	35	DFP	{Obesity, susceptibility to}, 601665 (3)
ADRBK2	22	25564849	25729294	N	.	N	Y	-0.750026799	12.61793135	0.793703983	21.9	DFP	.
ADSS	1	244408494	244452134	N	.	N	N	-0.378697035	25.5252648	0.822870228	20.9	.	.
ADSSL1	14	104724186	104747325	N	.	N	N	-0.557660845	17.99502228	0.000383323	67.9	.	.
ADTRP	6	11712054	11807046	N	.	N	N	-0.121679336	40.63205418	0.000702618	66	.	.
AEN	15	88621296	88632282	N	.	N	N	0.826886131	89.70886149	6.06E-08	86.7	.	.
AES	19	3052910	3063107	N	.	N	Y	0.139970692	60.17827169	0.650716677	26	.	.
AF131216.1	8	11283500	11285068	N	.	N	N	.	.	.	.	.	.
AF165138.7	21	14591930	14658821	N	.	N	N	.	.	.	.	.	.
AF196779.12	X	49071726	49079887	N	.	N	N	.	.	0.901680437	17.7	.	.
AFAP1	4	7758714	7939926	N	.	N	N	-0.713979515	13.56717023	0.37607178	33.5	.	.
AFAP1L1	5	149271871	149341802	N	.	N	N	0.087902717	56.29449557	4.07E-08	87.3	.	.
AFAP1L2	10	114294824	114404756	N	Viable	N	Y	0.410686531	76.37321294	0.446972664	31.5	.	.
AFF2	X	148500619	149000663	N	.	N	Y	-0.710299272	13.6192626	0.998760604	6.2	DM	Mental retardation, X-linked, FRAXE type, 309548 (3)
AFF3	2	99545419	100142739	N	.	N	Y	-1.500964494	3.362852347	0.998912591	6	DM	.
AFM	4	73481683	73504001	N	.	N	Y	0.706026988	87.04636222	2.51E-12	94.9	.	.
AFMID	17	78187317	78207701	N	Viable	N	Y	-0.086882719	43.06881982	0.002138128	61.6	.	.
AFP	4	73431138	73456174	N	.	N	Y	-0.047302484	46.03808532	4.90E-05	73.9	DM	[Hereditary persistence of alpha-fetoprotein], 615970 (3); Alpha-fetoprotein deficiency, 615969 (3)
AFTPH	2	64524305	64593005	N	.	N	N	0.090773389	56.50286508	0.996888388	7.6	.	.
AGA	4	177430770	177442503	N	.	N	Y	0.490045546	80.10071193	0.000640804	66.3	DM	Aspartylglucosaminuria, 208400 (3)
AGAP2	12	57723761	57742157	N	.	N	Y	-0.610989741	16.43225097	0.999218902	5.6	.	.
AGAP3	7	151085831	151144436	N	.	N	N	-1.08275718	6.754644904	0.991380425	9.6	.	.
AGAP4	10	45825594	45853875	N	.	N	N	.	.	.	.	.	.
AGAP5	10	73674285	73698159	N	.	N	N	.	.	.	.	.	.
AGAP6	10	49982190	50010499	N	.	N	N	1.797137322	98.1767668	.	.	.	.
AGAP9	10	47501854	47549750	N	.	N	N	.	.	.	.	.	.
AGBL1	15	86141996	87029052	N	.	N	N	1.489001704	96.91497366	3.60E-23	99.2	.	Corneal dystrophy, Fuchs endothelial, 8, 615523 (3)
AGBL2	11	47659591	47715389	N	.	N	N	-0.409211558	23.97985761	6.81E-12	94.4	.	.
AGBL3	7	134986508	135147963	N	.	N	N	.	.	.	.	.	.
AGBL4	1	48532855	50023913	N	.	N	N	.	.	3.58E-06	80.2	DP	.
AGBL5	2	27042364	27070622	N	.	N	N	-0.966377446	8.433177056	0.020694851	51.5	.	.
AGER	6	32180968	32184324	N	.	N	Y	0.42634373	77.18353881	1.46E-10	92.7	DFP	.
AGFG1	2	227472152	227561214	N	.	N	Y	-0.461077067	21.84985819	0.969265962	13.1	.	.
AGFG2	7	100539211	100568219	N	.	N	N	0.462902626	78.98361984	0.004764464	58.3	.	.
AGGF1	5	77029251	77065234	N	.	N	N	-0.142927664	39.19083174	6.10E-05	73.4	DM	.
AGK	7	141551189	141655244	N	.	N	N	0.353076131	73.59495283	2.47E-06	80.9	DM	Sengers syndrome, 212350 (3); Cataract 38, autosomal recessive, 614691 (3)
AGMAT	1	15572353	15585110	N	.	N	N	0.177635945	63.02598831	0.003672625	59.4	.	.
AGMO	7	15200318	15562015	N	.	N	N	1.146016972	94.48978411	3.26E-07	84.4	.	.
AGO1	1	35869808	35929610	N	.	N	Y	-1.195609276	5.625976732	0.999999463	1.5	.	.
AGO3	1	35930718	36072500	N	.	N	Y	-0.46953715	21.46205939	0.999998844	1.8	.	.
AGO4	1	35808172	35857890	N	.	N	Y	-1.012648026	7.692307692	0.990043812	9.9	.	.
AGPAT1	6	32168212	32178096	N	.	N	N	-0.08703502	43.03409157	0.984453681	11	.	.
AGPAT4	6	161129979	161274061	N	Viable	N	Y	-0.080336605	43.59553163	0.674499952	25.3	.	.
AGPAT5	8	6708357	6759666	N	.	N	N	-0.331611103	27.66105227	0.005794953	57.4	.	.
AGPAT6	8	41577187	41625001	N	.	N	Y	-0.543765506	18.41754934	0.446180355	31.5	.	.
AGPAT9	4	83535914	83605875	N	.	N	N	-0.074595468	44.09909128	3.04E-09	90.1	.	.
AGR2	7	16791811	16833433	N	.	N	Y	0.055523327	53.73618105	0.33545507	34.7	.	.
AGR3	7	16859405	16881987	N	.	N	N	0.013375229	50.50645367	3.85E-14	96.4	.	.
AGRP	16	67482571	67483813	N	.	N	Y	0.033970832	52.15025757	0.090387252	43.8	DFP	{Obesity, late-onset}, 601665 (3); {Leanness, inherited} (3)
AGTPBP1	9	85546539	85742029	N	.	N	N	-1.201865964	5.550732187	0.476341243	30.7	.	.
AGTR1	3	148697784	148743008	N	.	N	Y	-0.064373744	44.83996064	0.007276251	56.4	DM	{Hypertension, essential}, 145500 (3); Renal tubular dysgenesis, 267430 (3)
AGTR2	X	116170722	116174972	N	.	N	Y	0.516232886	81.10783122	0.012548958	54	DM	.
AGTRAP	1	11736084	11754802	N	.	N	N	0.598768956	84.07709672	0.041663403	48.1	.	.
AGXT	2	240868479	240880502	N	.	N	Y	0.551984057	82.50853736	0.003594369	59.6	DM	Hyperoxaluria, primary, type 1, 259900 (3)
AGXT2	5	34998101	35048135	N	.	N	Y	0.386109337	75.21560456	4.67E-15	96.9	DM	.
AHCYL1	1	109984686	110023741	N	.	N	Y	-0.521256062	19.41309255	0.99979528	4.3	.	.
AHCYL2	7	129225023	129430211	N	.	N	N	-0.557814484	17.98923424	0.949258836	14.8	.	.
AHDC1	1	27534035	27604431	N	.	N	N	-1.94085036	1.794292991	0.999431448	5.3	.	Xia-Gibbs syndrome, 615829 (3)
AHNAK2	14	104937244	104978357	N	.	N	N	51.16112747	100	.	.	DM?	.
AHRR	5	304176	438291	N	Viable	N	Y	-0.000219566	49.4067257	6.76E-05	73	DM?	.
AHSA1	14	77457870	77469474	N	.	N	N	-0.047605945	46.02072119	0.938521221	15.7	.	.
AHSA2	2	61177418	61191203	N	Viable	N	Y	0.535874184	81.906581	5.61E-06	79.3	.	.
AHSG	3	186612923	186621318	N	Viable	N	Y	0.31747395	71.6154425	2.86E-08	87.7	DFP	.
AHSP	16	31527864	31528803	N	.	N	Y	0.283486649	69.50859524	0.00985694	55	DM	.
AICDA	12	8602166	8612871	N	.	N	Y	-0.160151469	38.02743532	0.001255502	63.8	DM	Immunodeficiency with hyper-IgM, type 2, 605258 (3)
AIDA	1	222668013	222713210	N	.	N	N	-0.214586899	34.6414308	0.082372382	44.3	.	.
AIF1	6	31615184	31617021	N	Viable	N	Y	0.586485615	83.7298142	0.012798648	53.9	DP	.
AIF1L	9	131096476	131123152	N	Viable	N	Y	0.343512144	73.05666493	0.0330739	49.2	.	.
AIFM2	10	70098223	70132934	N	.	N	Y	0.441349938	77.95334838	1.41E-07	85.7	.	.
AIFM3	22	20965108	20981360	N	.	N	N	0.560594718	82.76899925	1.96E-10	92.5	.	.
AIG1	6	143060496	143340304	N	.	N	N	-0.206126746	35.13920241	1.90E-05	76.4	.	.
AIM1L	1	26321859	26354130	N	.	N	N	.	.	3.33E-07	84.4	.	.
AIM2	1	159062484	159147096	N	.	N	Y	-0.132857585	39.9027609	9.01E-08	86.2	.	.
AIMP1	4	106315544	106349226	N	.	N	N	-0.118808507	40.85199977	0.000209309	69.7	DM	Leukodystrophy, hypomyelinating, 3, 260600 (3)
AIPL1	17	6393693	6435199	N	.	N	Y	0.31284098	71.27973607	0.000113411	71.5	DM	Leber congenital amaurosis 4, 604393 (3); Retinitis pigmentosa, juvenile, 604393 (3); Cone-rod dystrophy, 604393 (3)
AIRE	21	44285838	44298648	N	.	N	Y	1.491204948	96.92076171	1.55E-06	81.9	DM	Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 (3)
AJ239318.1	21	13305171	13314664	N	.	N	N	.	.	.	.	.	.
AJAP1	1	4654732	4792534	N	Viable	N	Y	0.255536257	67.80112288	0.977592767	12.1	.	.
AJUBA	14	22971174	22982642	N	.	N	Y	0.206691474	64.80870522	0.833400048	20.5	.	.
AK1	9	127866480	127877743	N	.	N	Y	0.141883914	60.31139665	0.654809128	25.9	DM	Hemolytic anemia due to adenylate kinase deficiency, 612631 (3)
AK2	1	33007940	33080996	N	.	N	N	1.412189772	96.44614227	0.005565586	57.6	DM	Reticular dysgenesis, 267500 (3)
AK3	9	4709559	4742043	N	.	N	N	-0.285788866	30.29461133	5.63E-05	73.6	.	.
AK4	1	65147549	65232145	N	.	N	N	-0.08703502	43.03409157	0.236133361	37.5	.	.
AK5	1	77282051	77559969	N	.	N	N	-0.923562311	9.156682294	0.139499449	41.1	.	.
AK6	5	69350984	69370013	N	.	N	N	0.149386991	60.95386931	.	.	.	.
AK7	14	96392111	96489427	N	.	N	N	-0.018095978	48.04653586	9.79E-09	88.9	.	.
AK8	9	132725578	132878777	N	.	N	N	0.173959705	62.80604272	1.51E-07	85.6	.	.
AK9	6	109492856	109691217	N	.	N	N	0.072091972	55.04427852	7.10E-12	94.4	.	.
AKAP1	17	57085092	57121349	N	.	N	Y	0.225024168	65.93158534	0.561768713	28.4	.	.
AKAP11	13	42272153	42323267	N	Viable	N	Y	-0.11393393	41.21085837	0.896372712	17.9	.	.
AKAP12	6	151239999	151358557	N	.	N	Y	1.074724744	93.69682236	0.372501822	33.5	.	.
AKAP14	X	119895837	119920716	N	.	N	N	0.206542259	64.76240088	0.633383828	26.5	.	.
AKAP17A	X	1591593	1602514	N	.	N	N	1.491361519	96.92654975	0.713632078	24.2	.	.
AKAP2	9	110048598	110172512	N	.	N	N	0.787921628	88.93326388	0.066516441	45.4	DM?	.
AKAP3	12	4615508	4649047	N	.	N	N	0.660205663	85.92927013	0.026332979	50.3	.	.
AKAP4	X	50190768	50201013	N	.	N	Y	0.882280274	90.76807316	0.98437775	11	.	.
AKAP5	14	64465499	64474503	N	.	N	Y	0.35116309	73.45025178	0.84112954	20.2	DP	.
AKAP7	6	131135666	131283535	N	.	N	Y	0.771492772	88.59755745	0.001598773	62.8	.	.
AKAP8	19	15353385	15379798	N	.	N	N	0.307557959	70.8977253	0.982554657	11.4	.	.
AKAP8L	19	15380048	15419141	N	.	N	N	-0.156171384	38.30526133	0.542386261	28.8	.	.
AKAP9	7	91940867	92110673	N	.	N	Y	-0.105270668	41.75493431	2.29E-05	75.9	DM	?Long QT syndrome-11, 611820 (3)
AKIP1	11	8911139	8920084	N	Viable	N	Y	0.309821667	71.05979047	1.86E-05	76.4	.	.
AKIRIN1	1	38991223	39006059	N	.	N	Y	-0.096452026	42.31637437	0.67201582	25.5	.	.
AKNA	9	114334156	114394405	N	.	N	N	0.994876835	92.7070672	0.02852574	50	.	.
AKNAD1	1	108815898	108858228	N	.	N	N	0.80659943	89.26897031	8.21E-19	98.4	.	.
AKR1A1	1	45550543	45570049	N	.	N	Y	0.300554575	70.56201887	0.000107486	71.6	.	.
AKR1B1	7	134442350	134459284	N	.	N	Y	-0.511838334	19.74301094	1.07E-05	77.9	DM	.
AKR1B10	7	134527592	134541408	N	Viable	N	Y	0.437523469	77.762343	1.22E-05	77.6	.	.
AKR1B15	7	134549136	134579875	N	.	N	N	0.64393597	85.47780286	4.53E-15	96.9	.	.
AKR1C1	10	4963253	5107522	N	.	N	N	1.112980726	94.08462117	8.40E-06	78.5	.	.
AKR1C2	10	4922564	5135226	N	.	N	N	0.549114755	82.41014065	0.004103172	59	DM	Obesity, hyperphagia, and developmental delay (3); 46XY sex reversal 8, 614279 (3)
AKR1C3	10	5035354	5107686	N	.	N	Y	1.28093688	95.65896857	1.07E-11	94.2	DFP	.
AKR1C4	10	5195462	5218949	N	.	N	N	0.742435639	87.92614459	1.68E-10	92.6	DM	{46XY sex reversal 8, modifier of}, 614279 (3)
AKR1D1	7	138002324	138117986	N	.	N	N	-0.352359149	26.65972102	5.69E-08	86.8	DM	Bile acid synthesis defect, congenital, 2, 235555 (3)
AKR1E2	10	4786629	4848062	N	.	N	N	1.361570754	96.18568038	6.35E-06	79.1	DM	.
AKR7A2	1	19303965	19312146	N	.	N	N	0.795915884	89.11848122	3.56E-06	80.2	FP	.
AKR7A3	1	19282558	19289250	N	.	N	N	1.184341243	94.90652312	6.14E-10	91.6	DP	.
AKT1S1	19	49869033	49878459	N	.	N	N	.	.	0.476648977	30.6	.	.
AKT2	19	40230317	40285536	N	.	N	Y	-1.017434179	7.663367483	0.997816207	7.1	DM	Diabetes mellitus, type II, 125853 (3); Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 (3)
AKT3	1	243488233	243851079	N	.	N	Y	-0.554140994	18.08184291	0.999585399	5	DM	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3)
AKTIP	16	53491040	53504411	N	Viable	N	Y	-0.304623579	29.21803554	0.788012646	22	.	.
AL008723.1	22	32191094	32191452	N	.	N	N	.	.	.	.	.	.
AL021546.6	12	120438198	120460006	N	.	N	N	.	.	.	.	.	.
AL022578.1	X	47835953	47836793	N	.	N	N	.	.	.	.	.	.
AL023806.1	6	145789760	145791832	N	.	N	N	.	.	.	.	.	.
AL049794.1	20	16551149	16553012	N	.	N	N	.	.	.	.	.	.
AL049872.1	14	92070230	92071042	N	.	N	N	.	.	.	.	.	.
AL109927.1	1	27850574	27850744	N	.	N	N	.	.	.	.	.	.
AL133335.1	20	54249953	54250327	N	.	N	N	.	.	.	.	.	.
AL135745.1	14	64894339	64894713	N	.	N	N	.	.	.	.	.	.
AL135842.1	1	152511791	152512783	N	.	N	N	.	.	.	.	.	.
AL138706.2	13	37020528	37020772	N	.	N	N	.	.	.	.	.	.
AL158801.1	14	55229217	55229681	N	.	N	N	.	.	.	.	.	.
AL158839.1	1	70363780	70366135	N	.	N	N	.	.	.	.	.	.
AL162426.1	9	127742855	127743407	N	.	N	N	.	.	.	.	.	.
AL354828.1	13	22663953	22679652	N	.	N	N	.	.	.	.	.	.
AL354828.2	13	22664217	22675253	N	.	N	N	.	.	.	.	.	.
AL356135.1	6	61585946	61587035	N	.	N	N	.	.	.	.	.	.
AL356289.1	1	48102068	48104707	N	.	N	N	.	.	.	.	.	.
AL356585.2	13	18206570	18207469	N	.	N	N	.	.	.	.	.	.
AL357140.1	1	9827610	9828258	N	.	N	N	.	.	.	.	.	.
AL358852.1	6	149717621	149718888	N	.	N	N	.	.	.	.	.	.
AL365181.2	1	156597173	156599410	N	.	N	N	.	.	.	.	.	.
AL365202.1	9	3452305	3453987	N	.	N	N	.	.	.	.	.	.
AL445183.1	1	53053624	53054949	N	.	N	N	.	.	.	.	.	.
AL513523.2	1	153772371	153774079	N	.	N	N	.	.	.	.	.	.
AL589743.1	14	19300177	19302924	N	.	N	N	.	.	.	.	.	.
AL591806.1	1	161065865	161066153	N	.	N	N	.	.	.	.	.	.
AL596220.1	1	186394991	186396776	N	.	N	N	.	.	.	.	.	.
AL645728.1	1	1579756	1580046	N	.	N	N	.	.	.	.	.	.
AL645922.1	6	32006168	32007104	N	.	N	N	.	.	.	.	.	.
ALAD	9	113386317	113401333	N	.	N	N	0.065090757	54.56387104	0.06295026	45.7	DM	Porphyria, acute hepatic, 612740 (3); {Lead poisoning, susceptibility to}, 612740 (3)
ALB	4	73397114	73421412	N	.	N	Y	-0.738695505	12.9420617	0.985726825	10.8	DM	Analbuminemia, 616000 (3); [Dysalbuminemic hyperthyroxinemia], 615999 (3)
ALCAM	3	105366909	105576900	N	.	N	Y	0.17778674	63.04335243	0.988336238	10.3	DFP	.
ALDH16A1	19	49453169	49471048	N	.	N	Y	1.29258323	95.72263703	1.35E-07	85.8	DP	.
ALDH1A1	9	72900662	73080442	N	.	N	Y	-0.320432866	28.29194883	0.993850729	8.9	FP	.
ALDH1B1	9	38392664	38398661	N	.	N	N	0.070026176	54.89378943	0.000426749	67.6	.	.
ALDH1L1	3	126103562	126197994	N	Viable	N	Y	0.464323039	79.03571222	9.62E-06	78.2	.	.
ALDH1L2	12	105019784	105084577	N	.	N	N	-0.475783963	21.19580946	3.50E-11	93.6	.	.
ALDH2	12	111766887	111817529	N	.	N	Y	-0.430107764	23.15216762	1.73E-06	81.6	DFP	Alcohol sensitivity, acute, 610251 (3); {Hangover, susceptibility to}, 610251 (3); {Sublingual nitroglycerin, susceptibility to poor response to} (3); {Esophageal cancer, alcohol-related, susceptibility to} (3)
ALDH3A1	17	19737984	19748943	N	Viable	N	Y	0.954596424	92.08774672	1.33E-12	95.2	.	.
ALDH3A2	17	19648136	19677598	N	.	N	Y	-0.410469485	23.93355328	0.011288384	54.4	DM	Sjogren-Larsson syndrome, 270200 (3)
ALDH3B2	11	67662162	67681200	N	.	N	N	2.841653393	99.41540777	0.000359299	68.1	.	.
ALDH4A1	1	18871430	18902781	N	.	N	N	0.479017244	79.71291312	0.000434044	67.5	DM	Hyperprolinemia, type II, 239510 (3)
ALDH6A1	14	74056850	74084493	N	.	N	N	-0.415101607	23.69045552	1.62E-05	76.8	DM	Methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3)
ALDH7A1	5	126541841	126595418	N	.	N	N	0.131812033	59.53579904	1.95E-12	95	DM	Epilepsy, pyridoxine-dependent, 266100 (3)
ALDH8A1	6	134917390	134950122	N	.	N	N	-0.093277119	42.60577647	9.46E-06	78.2	.	.
ALDH9A1	1	165662216	165698863	N	Viable	N	Y	0.369189464	74.35318632	1.29E-05	77.4	.	.
ALDOA	16	30053090	30070457	N	.	N	N	-0.363537126	26.20825375	0.024834403	50.5	DM	Glycogen storage disease XII, 611881 (3)
ALDOB	9	101420578	101435823	N	.	N	N	-0.044583575	46.25803091	0.000813754	65.5	DM	Fructose intolerance, 229600 (3)
ALDOC	17	28573115	28577264	N	Viable	N	Y	-0.201341563	35.40545234	0.790720532	22	.	.
ALG1	16	5033960	5087379	N	.	N	N	1.374008436	96.2435608	9.22E-10	91.2	DM	Congenital disorder of glycosylation, type Ik, 608540 (3)
ALG10B	12	38316578	38329728	N	.	N	N	0.715292071	87.27788389	0.000152772	70.6	DM	.
ALG11	13	52012398	52029664	N	.	N	N	-0.477040255	21.14950512	0.000122135	71.3	DM	Congenital disorder of glycosylation, type Ip, 613661 (3)
ALG12	22	49900229	49918458	N	.	N	N	0.252968646	67.60432946	0.007881983	56	DM	Congenital disorder of glycosylation, type Ig, 607143 (3)
ALG14	1	94974407	95072945	N	.	N	N	0.272306077	68.81981826	0.000832661	65.4	DM	?Myasthenic syndrome, congenital, 15, without tubular aggregates, 616227 (3)
ALG1L	3	125929275	125937039	N	.	N	N	1.057585586	93.45951265	3.26E-09	90	.	.
ALG1L2	3	130081831	130113227	N	.	N	N	.	.	.	.	.	.
ALG3	3	184242301	184249548	N	.	N	N	-0.118656486	40.85778781	4.18E-06	79.9	DM	Congenital disorder of glycosylation, type Id, 601110 (3)
ALG6	1	63367590	63438562	N	.	N	N	0.369995468	74.38791457	0.055367626	46.4	DM	Congenital disorder of glycosylation, type Ic, 603147 (3)
ALG8	11	78100936	78139660	N	.	N	N	0.507921503	80.78370087	1.01E-05	78	DM	Congenital disorder of glycosylation, type Ih, 608104 (3)
ALG9	11	111782195	111871581	N	.	N	N	-0.109391694	41.51183655	0.001225309	63.9	DM	Congenital disorder of glycosylation, type Il, 608776 (3)
ALK	2	29192774	29921566	N	.	N	N	-0.992073901	7.970133704	0.522362517	29.4	DM	{Neuroblastoma, susceptibility to, 3}, 613014 (3)
ALKBH1	14	77672404	77708020	N	.	N	Y	0.370952088	74.45158303	2.13E-05	76.1	.	.
ALKBH2	12	109088188	109093631	N	.	N	Y	0.562208663	82.80951554	0.000816686	65.5	.	.
ALKBH3	11	43880811	43920266	N	.	N	Y	0.110108772	57.98460381	2.56E-09	90.3	.	.
ALKBH5	17	18183078	18209954	N	.	N	Y	-0.794245158	11.66869248	0.803934846	21.5	.	.
ALKBH6	19	36009120	36014239	N	.	N	N	0.603404191	84.22179777	0.46893419	30.9	.	.
ALKBH7	19	6372433	6375251	N	.	N	N	0.309821667	71.05979047	2.76E-06	80.7	.	.
ALKBH8	11	107502726	107565746	N	.	N	Y	.	.	0.00282935	60.6	.	.
ALLC	2	3658195	3702671	N	.	N	N	1.168376904	94.72130578	4.61E-11	93.4	.	.
ALMS1	2	73385758	73610793	N	.	N	Y	-1.184605549	5.730161486	3.04E-39	99.9	DM	Alstrom syndrome, 203800 (3)
ALOX12	17	6996065	7010736	N	.	N	Y	0.249141007	67.41332407	6.34E-10	91.5	DFP	.
ALOX15	17	4630902	4642294	N	.	N	Y	1.122706235	94.21774614	3.60E-19	98.5	DFP	.
ALOX15B	17	8039017	8049134	N	.	N	N	1.480983252	96.87445737	1.92E-12	95	.	.
ALOX5	10	45374176	45446119	N	.	N	Y	-1.059433781	7.07877525	0.001644393	62.7	DFP	{Atherosclerosis, susceptibility to} (3); {Asthma, diminished response to antileukotriene treatment in}, 600807 (3)
ALOX5AP	13	30713478	30764426	N	.	N	Y	0.071486219	54.9863981	0.846184682	20	DP	{Stroke, susceptibility to}, 601367 (3)
ALPI	2	232456123	232460032	N	.	N	Y	0.713530267	87.24315564	4.03E-16	97.5	.	.
ALPK1	4	112285509	112442620	N	.	N	N	0.983350829	92.57394224	1.00E-07	86.1	.	.
ALPK2	18	58481247	58628957	N	.	N	N	2.025851938	98.61086994	3.56E-13	95.7	.	.
ALPK3	15	84816680	84873482	N	.	N	Y	0.211762956	65.19071598	3.54E-09	89.9	.	.
ALPPL2	2	232406843	232410714	N	.	N	N	0.998660862	92.73021937	6.22E-06	79.2	.	.
ALS2	2	201700554	201781189	N	.	N	Y	-1.60592502	2.812988366	0.000769641	65.6	DM	Amyotrophic lateral sclerosis 2, juvenile, 205100 (3); Primary lateral sclerosis, juvenile, 606353 (3); Spastic paralysis, infantile onset ascending, 607225 (3)
ALS2CL	3	46668997	46693704	N	.	N	N	0.853700044	90.26451352	2.73E-18	98.3	FTV	.
ALS2CR11	2	201487425	201619178	N	.	N	N	.	.	7.66E-11	93.1	.	.
ALS2CR12	2	201288271	201357398	N	.	N	N	0.37190874	74.50946345	1.66E-10	92.6	.	.
ALYREF	17	81887844	81891586	N	.	N	N	-0.109544183	41.48289634	0.8318655	20.6	.	.
AMACR	5	33986178	34008108	N	.	N	Y	0.248033216	67.35544365	0.125255655	41.8	DM	Alpha-methylacyl-CoA racemase deficiency, 614307 (3); Bile acid synthesis defect, congenital, 4, 214950 (3)
AMBN	4	70592256	70607288	N	.	N	Y	0.81474924	89.43103548	1.86E-05	76.4	.	Amelogenesis imperfecta, type IF, 616270 (3)
AMBP	9	114060127	114078472	N	.	N	Y	0.183376188	63.43115124	4.48E-10	91.8	.	.
AMDHD1	12	95943293	95968716	N	.	N	N	0.113935742	58.3145222	2.47E-06	80.9	.	.
AMDHD2	16	2520357	2531422	N	.	N	N	-0.502118866	20.07292933	2.64E-07	84.7	.	.
AMELX	X	11293413	11300761	N	.	N	Y	0.057436789	53.89824622	0.187525655	39.1	DM	Amelogenesis imperfecta, type 1E, 301200 (3)
AMELY	Y	6865918	6874027	N	.	N	N	.	.	0.002055054	61.8	DM	.
AMER2	13	25161684	25172288	N	.	N	N	0.21721532	65.4974822	.	.	.	.
AMER3	2	130755435	130768134	N	.	N	N	0.425849461	77.12565839	0.000112023	71.5	.	.
AMFR	16	56361452	56425538	N	.	N	N	-0.688086328	14.26173525	0.001425759	63.2	.	.
AMH	19	2249309	2252073	N	.	N	Y	.	.	4.90E-05	74	DM	Persistent Mullerian duct syndrome, type I, 261550 (3)
AMHR2	12	53423855	53431534	N	.	N	Y	-0.723688873	13.31249638	5.93E-07	83.5	DM	Persistent Mullerian duct syndrome, type II, 261550 (3)
AMICA1	11	118193740	118225094	N	.	N	N	0.809966306	89.33263877	0.004059094	59	.	.
AMIGO1	1	109504175	109509738	N	.	N	N	-0.208844572	35.00607744	0.888492589	18.3	.	.
AMIGO2	12	47075707	47079951	N	.	N	N	-0.628060421	15.93447937	0.545241647	28.8	.	.
AMIGO3	3	49716834	49719695	N	Viable	N	Y	-0.530367513	18.99635353	7.51E-06	78.8	.	.
AMMECR1	X	110194186	110440233	N	.	N	N	0.047063497	53.15737686	0.910792997	17.2	.	.
AMMECR1L	2	127861630	127885922	N	.	N	N	0.127834418	59.29270128	0.995586602	8.2	.	.
AMN1	12	31671137	31729174	N	.	N	N	-0.26151962	31.75319789	0.020102656	51.7	.	.
AMOTL1	11	94706431	94876753	N	.	N	Y	-0.452318052	22.1682005	0.311228186	35.4	.	.
AMOTL2	3	134355874	134375479	N	.	N	N	1.043040569	93.30323552	0.207914897	38.5	.	.
AMPD2	1	109616104	109632051	N	.	N	Y	-1.577225576	2.928749204	0.008542497	55.5	.	?Spastic paraplegia 63, 615686 (3); Pontocerebellar hypoplasia, type 9, 615809 (3)
AMPD3	11	10308313	10507579	N	.	N	Y	-0.217807755	34.4330613	1.33E-08	88.6	DM	[AMP deaminase deficiency, erythrocytic], 612874 (3)
AMPH	7	38383704	38631567	N	.	N	Y	-0.256429528	32.11205649	0.032266566	49.3	.	.
AMTN	4	70518540	70532742	N	.	N	N	0.50027016	80.45378249	1.12E-06	82.4	.	.
AMY1A	1	103655290	103664554	N	.	N	N	.	.	0.365183317	33.8	.	.
AMY1B	1	103687415	103696680	N	.	N	N	.	.	.	.	.	.
AMY1C	1	103750406	103758690	N	.	N	N	.	.	0.844157662	20.1	.	.
AMY2A	1	103616811	103625780	N	.	N	N	.	.	0.005603917	57.6	.	.
AMY2B	1	103553815	103579534	N	.	N	N	0.307403782	70.88614922	7.65E-09	89.2	.	.
AMZ1	7	2679522	2775500	N	.	N	N	2.664510789	99.2822828	5.12E-18	98.1	.	.
AMZ2	17	68247574	68257164	N	.	N	N	0.269585727	68.68669329	1.55E-08	88.4	.	.
ANAPC1	2	111766271	111884690	N	.	N	N	-0.104962094	41.77229843	.	.	FTV	.
ANAPC10	4	144967112	145098541	N	.	N	N	0.063983137	54.4886265	0.057568239	46.2	.	.
ANAPC11	17	81890790	81900991	N	.	N	N	0.171896242	62.66134167	0.192592194	38.9	.	.
ANAPC13	3	134477706	134486716	N	.	N	N	0.031100532	51.89558372	0.001349795	63.6	.	.
ANAPC16	10	72216000	72235860	N	.	N	N	0.290033479	69.90218209	0.072586498	44.9	.	.
ANAPC5	12	121308245	121399896	N	.	N	N	-0.835282644	10.8699427	4.18E-05	74.3	.	.
ANAPC7	12	110372900	110403730	N	.	N	N	-0.822343474	11.1188285	0.99925787	5.6	.	.
ANG	14	20684177	20698971	N	Viable	N	Y	0.269436731	68.66354112	0.224577463	37.9	DM	Amyotrophic lateral sclerosis 9, 611895 (3)
ANGEL1	14	76786178	76826246	N	.	N	N	0.09253511	56.58389767	3.06E-10	92.1	.	.
ANGEL2	1	212992182	213015826	N	.	N	N	-0.113067189	41.2571627	0.121064259	42	FTV	.
ANGPT4	20	869899	916317	N	.	N	N	0.15623458	61.48636916	2.06E-09	90.5	.	.
ANGPTL1	1	178849705	178871052	N	.	N	Y	0.191835947	63.9231348	1.53E-08	88.4	.	.
ANGPTL2	9	127087332	127122883	N	.	N	Y	-0.861620382	10.35480697	0.182258217	39.2	.	.
ANGPTL3	1	62597487	62606159	N	.	N	Y	0.047365707	53.22683336	2.12E-07	85.1	DM	Hypobetalipoproteinemia, familial, 2, 605019 (3)
ANGPTL4	19	8363289	8374373	Y	Viable	N	Y	0.248033216	67.35544365	9.46E-09	89	DM	Plasma triglyceride level QTL, low, 615881 (3)
ANGPTL5	11	101890674	101916522	N	.	N	N	1.16742048	94.7097297	1.75E-11	94	DM?	.
ANGPTL7	1	11189341	11195981	N	.	N	N	0.029489373	51.73930659	8.44E-09	89.2	.	.
ANHX	12	133218312	133236095	N	.	N	N	.	.	.	.	.	.
ANKAR	2	189674290	189761193	N	.	N	N	0.89601281	91.04011113	6.61E-24	99.2	.	.
ANKDD1A	15	64911902	64958700	N	.	N	N	1.11408732	94.10777334	1.16E-15	97.3	.	.
ANKDD1B	5	75611459	75671846	N	.	N	N	.	.	.	.	.	.
ANKEF1	20	9986126	10058303	N	.	N	N	0.149840497	60.9943856	2.75E-09	90.2	.	.
ANKFN1	17	56110958	56511659	N	.	N	N	-0.351099457	26.71181339	4.03E-06	80	.	.
ANKFY1	17	4163907	4263977	N	.	N	N	-1.127644115	6.320541761	0.994632888	8.5	.	.
ANKH	5	14704804	14871778	N	.	N	Y	-0.332568014	27.61474793	0.167376866	39.8	DM	Craniometaphyseal dysplasia, 123000 (3); Chondrocalcinosis 2, 118600 (3)
ANKHD1	5	140401814	140539856	N	.	N	N	-2.263665138	1.203912716	1	0.4	.	.
ANKHD1-EIF4EBP3	5	140401908	140549569	N	.	N	N	-2.200760416	1.273369219	1	0.4	.	.
ANKIB1	7	92246234	92401384	N	.	N	N	0.250097881	67.46541645	0.999885675	3.9	.	.
ANKK1	11	113387791	113400418	N	.	N	N	2.521702301	99.20125022	2.51E-08	87.9	DFP	Dopamine receptor D2, reduced brain density of (3)
ANKLE1	19	17281645	17287646	N	.	N	N	2.392969988	99.0739133	8.12E-14	96.2	DP	.
ANKLE2	12	132725503	132761888	N	.	N	N	-0.160503316	37.97534294	7.47E-07	83.1	.	.
ANKMY1	2	240479422	240569209	N	.	N	N	0.817310968	89.46576373	7.81E-14	96.2	.	.
ANKMY2	7	16599776	16645817	N	.	N	N	0.152407451	61.18539098	0.000223758	69.4	.	.
ANKRA2	5	73552335	73565686	N	.	N	N	-0.53817717	18.67222319	0.003505038	59.7	.	.
ANKRD1	10	90912096	90921276	N	Viable	N	Y	0.192642013	63.98680326	0.000250276	69.1	DM	.
ANKRD10	13	110878540	110915069	N	.	N	N	-0.465862421	21.6299126	0.127073152	41.7	.	.
ANKRD12	18	9136228	9285985	N	.	N	Y	-1.855347252	2.031602709	0.999985244	2.7	.	.
ANKRD13A	12	109999186	110039763	N	.	N	N	-0.368169446	25.94779186	0.350624809	34.2	.	.
ANKRD13B	17	29589769	29614761	N	.	N	N	-0.84389619	10.70208948	0.970860716	12.9	.	.
ANKRD13C	1	70260588	70354734	N	.	N	N	-0.691914915	14.19227875	0.999095558	5.8	.	.
ANKRD13D	11	67288547	67302485	N	.	N	N	-0.712510304	13.59032239	0.984538264	11	.	.
ANKRD16	10	5861617	5889906	N	.	N	N	0.513511574	81.03837472	2.58E-06	80.8	.	.
ANKRD18A	9	38543253	38620660	N	.	N	N	.	.	0.000945591	65	.	.
ANKRD18B	9	33524394	33573009	N	.	N	N	.	.	0.007480147	56.3	.	.
ANKRD2	10	97572499	97583884	N	.	N	Y	0.091275867	56.54338137	1.01E-06	82.5	.	.
ANKRD20A1	9	67859147	67902094	N	.	N	N	.	.	0.864283492	19.3	.	.
ANKRD20A2	9	40223285	40266392	N	.	N	N	.	.	0.118527454	42.2	.	.
ANKRD20A3	9	66106815	66153135	N	.	N	N	.	.	.	.	.	.
ANKRD20A4	9	64369394	64413142	N	.	N	N	.	.	0.31960399	35.2	.	.
ANKRD22	10	88822132	88851818	N	.	N	N	0.961805403	92.22087168	2.03E-05	76.2	.	.
ANKRD23	2	96824526	96857934	N	.	N	Y	-0.066287483	44.66631938	8.66E-16	97.3	.	.
ANKRD24	19	4183354	4224814	N	.	N	N	.	.	1.87E-06	81.4	.	.
ANKRD26	10	26991914	27100498	N	.	N	N	0.576407999	83.3014991	7.09E-15	96.8	DM	Thrombocytopenia 2, 188000 (3)
ANKRD27	19	32597007	32676597	N	Viable	N	Y	-0.824486802	11.06094808	7.79E-16	97.3	.	.
ANKRD28	3	15667236	15859771	N	.	N	N	-0.223547372	34.11471899	0.99992881	3.5	.	.
ANKRD29	18	23598926	23662885	N	.	N	N	-0.119765437	40.78833131	2.60E-05	75.6	.	.
ANKRD30A	10	37125788	37384111	N	.	N	N	2.012814151	98.58771778	1.26E-23	99.2	.	.
ANKRD30B	18	14728272	14852738	N	.	N	N	.	.	1.49E-09	90.8	.	.
ANKRD30BL	2	132147591	132257969	N	.	N	N	.	.	.	.	.	.
ANKRD31	5	75068275	75236878	N	.	N	N	.	.	.	.	.	.
ANKRD33	12	51887960	51891664	N	.	N	N	0.886107801	90.86068183	1.96E-14	96.5	.	.
ANKRD33B	5	10564330	10657816	N	.	N	N	.	.	.	.	.	.
ANKRD34A	1	145959442	145964582	N	.	N	N	-0.918930637	9.231926839	0.974591387	12.5	.	.
ANKRD34B	5	80556755	80570488	N	.	N	N	0.153364212	61.26642357	2.53E-09	90.3	.	.
ANKRD34C	15	79293285	79298235	N	.	N	N	.	.	.	.	.	.
ANKRD35	1	145866560	145885866	N	.	N	N	1.207331238	95.07437634	4.68E-13	95.6	.	.
ANKRD36	2	97113496	97264521	N	.	N	N	.	.	2.12E-19	98.5	.	.
ANKRD36B	2	97492663	97589965	N	.	N	N	.	.	.	.	.	.
ANKRD36C	2	95836919	95991831	N	.	N	N	.	.	.	.	.	.
ANKRD37	4	185396021	185400628	N	.	N	N	0.467388591	79.20356543	0.005704852	57.5	.	.
ANKRD39	2	96836611	96858095	N	.	N	N	0.208455225	64.9591943	0.057308291	46.3	.	.
ANKRD40	17	50693190	50707924	N	.	N	N	-0.142274465	39.26028824	0.313648022	35.3	.	.
ANKRD42	11	83193739	83260694	N	.	N	N	0.179549296	63.17068936	2.60E-08	87.8	.	.
ANKRD44	2	196967017	197311173	N	.	N	N	-0.5962877	16.80268565	0.775902812	22.4	.	.
ANKRD45	1	173609561	173669862	N	.	N	N	0.469300995	79.2961741	0.019887275	51.7	.	.
ANKRD46	8	100509752	100559784	N	.	N	N	-0.072985841	44.23221624	0.918715846	16.8	.	.
ANKRD49	11	94493629	94499583	N	.	N	N	-0.093581117	42.57683626	0.173264896	39.6	.	.
ANKRD50	4	124664052	124712732	N	.	N	N	-1.660479685	2.610406899	0.918119609	16.8	.	.
ANKRD52	12	56237807	56258391	N	.	N	N	-0.195448671	35.80482723	0.999987967	2.6	.	.
ANKRD53	2	70978380	70985499	N	.	N	N	0.165499977	62.20408636	0.000455608	67.3	.	.
ANKRD54	22	37830855	37849327	N	.	N	N	0.316368397	71.5054697	0.015308473	53	.	.
ANKRD55	5	56099678	56233359	N	.	N	N	-0.234877184	33.36806158	2.44E-07	84.9	.	.
ANKRD6	6	89433170	89633834	N	Viable	N	Y	0.273563809	68.87191063	3.49E-07	84.3	DP	.
ANKRD60	20	58218495	58228653	N	.	N	N	.	.	.	.	.	.
ANKRD61	7	6031376	6036386	N	.	N	N	.	.	.	.	.	.
ANKRD62	18	12093853	12129749	N	.	N	N	.	.	0.458132581	31.2	.	.
ANKRD63	15	40281444	40282586	N	.	N	N	.	.	.	.	.	.
ANKRD65	1	1418420	1421769	N	.	N	N	.	.	.	.	.	.
ANKRD66	6	46746917	46759506	N	.	N	N	.	.	.	.	.	.
ANKRD7	7	118214673	118242731	N	.	N	N	0.423325465	77.03304972	0.007524569	56.3	.	.
ANKRD9	14	102501760	102509799	N	.	N	Y	.	.	0.180354468	39.3	.	.
ANKS1A	6	34889265	35091413	N	.	N	N	-0.478506547	21.06268449	0.846859678	20	DM	.
ANKS1B	12	98726457	99984654	N	.	N	Y	-1.624030749	2.760895989	0.992771668	9.2	DM	.
ANKS3	16	4696510	4734378	N	.	N	N	0.740985255	87.86826417	0.01235561	54.1	DM?	.
ANKS4B	16	21233665	21253845	N	.	N	N	-0.070919872	44.37691729	3.41E-06	80.3	.	.
ANKUB1	3	149761105	149968385	N	.	N	N	.	.	.	.	.	.
ANKZF1	2	219229757	219236669	N	.	N	N	0.563621518	82.85581988	4.83E-14	96.3	.	.
ANLN	7	36389806	36453791	N	.	N	N	0.571283847	83.1220698	0.923521452	16.5	.	Focal segmental glomerulosclerosis 8, 616032 (3)
ANO10	3	43354859	43691594	N	.	N	N	0.629080409	85.03791167	1.92E-06	81.4	DM	Spinocerebellar ataxia, autosomal recessive 10, 613728 (3)
ANO2	12	5531869	5946232	N	.	N	Y	.	.	2.85E-18	98.2	.	.
ANO3	11	26309599	26663288	N	.	N	N	-1.54816213	3.102390461	4.09E-13	95.6	DM	Dystonia 24, 615034 (3)
ANO4	12	100717526	101128641	N	.	N	N	-1.196415872	5.614400648	0.844044637	20.1	.	.
ANO5	11	22193176	22283357	N	.	N	N	-0.548904416	18.24969613	9.89E-16	97.3	DM	Gnathodiaphyseal dysplasia, 166260 (3); Muscular dystrophy, limb-girdle, type 2L, 611307 (3); Miyoshi muscular dystrophy 3, 613319 (3)
ANO7	2	241188509	241225377	N	.	N	N	1.311601149	95.86733808	1.87E-30	99.7	DM	.
ANO8	19	17323223	17334829	N	.	N	N	-1.048105347	7.240840424	0.992936317	9.2	.	.
ANO9	11	417933	442011	N	.	N	N	-0.444814836	22.49811889	4.59E-11	93.4	.	.
ANOS1	X	8528874	8732187	N	.	N	N	.	.	.	.	.	.
ANP32A	15	68778535	68820897	N	.	N	N	-0.0579797	45.26827574	0.973870036	12.5	.	.
ANP32D	12	48472665	48473624	N	.	N	N	0.368890551	74.33003415	0.147937099	40.7	.	.
ANP32E	1	150218417	150236156	N	.	N	Y	-0.170525669	37.3618105	0.976918663	12.2	.	.
ANPEP	15	89784889	89815401	N	.	N	Y	-0.350805407	26.72338948	0.000244242	69.2	.	.
ANTXR1	2	69013178	69249327	N	.	N	Y	-0.135576128	39.70596747	0.985283203	10.9	DM	{Hemangioma, capillary infantile, susceptibility to}, 602089 (3); GAPO syndrome, 230740 (3)
ANTXR2	4	79901149	80125454	N	.	N	Y	0.009699407	50.29229612	0.405188748	32.6	DM	Hyaline fibromatosis syndrome, 228600 (3)
ANTXRL	10	46286345	46330207	N	.	N	N	.	.	0.317924027	35.2	.	.
ANXA1	9	73151757	73170393	N	.	N	Y	-0.109391694	41.51183655	0.00044237	67.4	.	.
ANXA10	4	168092515	168187690	N	.	N	N	0.754573317	88.21554668	1.28E-08	88.6	.	.
ANXA11	10	80150889	80205572	N	.	N	N	0.317625038	71.63280662	3.46E-06	80.3	DP	.
ANXA13	8	123680794	123737407	N	.	N	N	1.129901083	94.33350697	0.007256523	56.4	.	.
ANXA2	15	60347134	60402883	N	.	N	Y	-0.306383832	29.09069862	0.009843463	55	.	.
ANXA2R	5	43039081	43043170	N	.	N	N	0.285399426	69.6822365	3.08E-06	80.5	.	.
ANXA3	4	78551519	78610451	N	Viable	N	Y	0.656073283	85.80772125	2.04E-09	90.5	.	.
ANXA4	2	69644425	69826464	N	.	N	N	0.086643016	56.19609886	0.000342407	68.3	.	.
ANXA5	4	121667955	121697113	N	.	N	Y	-0.051281473	45.6908028	3.82E-06	80.1	DFP	{Pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3)
ANXA6	5	151100712	151157882	N	.	N	Y	0.147926643	60.87862476	0.000183002	70.1	.	.
ANXA8	10	47460162	47484158	N	.	N	N	.	.	.	.	.	.
ANXA8L1	10	46375627	46537864	N	.	N	N	.	.	.	.	.	.
ANXA9	1	150982017	150995634	N	Viable	N	Y	1.530492306	97.09440296	3.36E-14	96.4	.	.
AOAH	7	36512949	36724549	N	.	N	Y	0.999617879	92.75915958	6.15E-11	93.2	DP	.
AOC1	7	150824627	150861504	N	Viable	N	Y	0.437025457	77.73919083	1.24E-08	88.6	.	.
AOC2	17	42844600	42850707	N	.	N	N	-0.410020958	23.9509174	5.14E-10	91.7	.	.
AOC3	17	42851184	42858130	N	.	N	Y	0.497050585	80.34959773	6.47E-09	89.4	.	.
AOX1	2	200585868	200677064	N	.	N	N	-0.908809864	9.428720264	2.68E-22	99.1	FP	.
AP000275.65	21	32578822	32612281	N	.	N	N	.	.	.	.	.	.
AP000295.9	21	33246774	33283212	N	.	N	N	.	.	.	.	.	.
AP000304.12	21	33584687	33931607	N	.	N	N	.	.	.	.	.	.
AP000322.53	21	34418715	34423966	N	.	N	N	.	.	.	.	.	.
AP000349.2	22	23782283	23783958	N	.	N	N	.	.	.	.	.	.
AP000350.10	22	23862188	23895223	N	.	N	N	.	.	.	.	.	.
AP000721.4	11	63974620	63988346	N	.	N	N	.	.	0.136411776	41.3	.	.
AP000866.1	11	124789244	124790069	N	.	N	N	.	.	.	.	.	.
AP002884.2	11	112086903	112193805	N	.	N	N	.	.	.	.	.	.
AP003419.11	11	67351572	67373584	N	.	N	N	.	.	.	.	.	.
AP005242.1	18	15057125	15066579	N	.	N	N	.	.	.	.	.	.
AP006285.2	11	1580492	1585989	N	.	N	N	.	.	.	.	.	.
AP1AR	4	112231737	112270047	N	.	N	N	-0.061655126	44.98466169	0.511166929	29.7	.	.
AP1B1	22	29327680	29423179	N	.	N	N	-1.28918889	4.763558488	0.991583129	9.6	.	.
AP1G2	14	23559565	23568070	N	.	N	N	0.056128986	53.78827343	8.94E-14	96.1	.	.
AP1M2	19	10572671	10587315	N	.	N	N	-0.175004808	37.08977253	0.001345952	63.6	.	.
AP1S1	7	101154397	101161596	N	.	N	N	-0.074899744	44.03542282	0.520227034	29.4	DM	MEDNIK syndrome, 609313 (3)
AP1S2	X	15825806	15855014	N	.	N	N	0.082665704	55.90669676	0.79261117	21.9	DM	Mental retardation, X-linked syndromic 5, 304340 (3)
AP1S3	2	223751686	223838027	N	.	N	N	0.609951659	84.47647161	0.167450177	39.8	.	{Psoriasis 15, pustular, susceptibility to}, 616106 (3)
AP2A1	19	49766968	49807113	N	.	N	N	-0.76870886	12.24170863	0.99984728	4.1	.	.
AP2A2	11	924894	1012245	N	Viable	N	Y	-1.364375071	4.207906465	0.999932215	3.4	.	.
AP2B1	17	35578046	35726409	N	.	N	Y	-1.431107245	3.773803322	0.999667233	4.8	.	.
AP2S1	19	46838136	46850992	N	.	N	N	-0.014874933	48.27805753	0.919495985	16.7	DM	Hypocalciuric hypercalcemia, familial, type III, 600740 (3)
AP3B2	15	82659281	82709914	N	.	N	Y	-0.810712359	11.35035018	0.99006557	9.9	DM?	.
AP3M1	10	74120255	74151063	N	.	N	N	-0.595330347	16.85477803	0.76861788	22.6	.	.
AP3M2	8	42152946	42171673	N	.	N	Y	-0.359862201	26.32401459	4.40E-05	74.3	.	.
AP3S1	5	115841481	115914081	N	Viable	N	Y	0.254430455	67.72009029	0.001853724	62.2	.	.
AP3S2	15	89830599	89894638	N	Viable	N	Y	0.278852726	69.23076923	0.00023091	69.4	.	.
AP4B1	1	113894748	113905201	N	.	N	Y	-0.206628003	35.11605024	2.69E-08	87.8	DM	Spastic paraplegia 47, autosomal recessive, 614066 (3)
AP4E1	15	50908672	51005900	N	Viable	N	Y	-0.252453844	32.27990971	0.979862099	11.8	DM	Spastic paraplegia 51, autosomal recessive, 613744 (3)
AP4M1	7	100101549	100110345	N	Viable	N	Y	-0.666382202	14.85211553	2.36E-11	93.8	DM	Spastic paraplegia 50, autosomal recessive, 612936 (3)
AP4S1	14	31025106	31096450	N	.	N	N	0.261933591	68.13682931	1.34E-07	85.8	DM	Spastic paraplegia 52, autosomal recessive, 614067 (3)
AP5B1	11	65775893	65780802	N	.	N	N	-0.060243695	45.07148232	6.97E-06	78.9	.	.
AP5M1	14	57268909	57298742	N	.	N	N	0.040819533	52.64802917	0.000108637	71.6	.	.
AP5S1	20	3820524	3828837	N	.	N	N	0.039711445	52.54384442	0.000277046	68.9	.	.
AP5Z1	7	4775622	4794312	N	Viable	N	Y	0.640729605	85.35046594	.	.	.	Spastic paraplegia 48, autosomal recessive, 613647 (3)
APBA1	9	69427530	69672306	N	.	N	Y	-1.583775091	2.899808995	0.865841339	19.2	.	.
APBA2	15	28884483	29118315	N	.	N	Y	-0.507709403	19.89928807	0.073526972	44.8	DM	.
APBA3	19	3750819	3761699	N	.	N	Y	0.68991226	86.66435145	2.12E-11	93.9	.	.
APBB1	11	6395124	6419414	N	.	N	Y	-0.043475309	46.35642762	0.986993652	10.6	DP	.
APBB1IP	10	26438203	26567803	N	.	N	N	-0.406641629	24.08404237	0.594392028	27.6	.	.
APBB2	4	40810027	41216714	N	.	N	Y	0.124460775	59.08433177	0.039888866	48.3	.	{Alzheimer disease, late-onset}, 104300 (3)
APBB3	5	140558268	140593752	N	.	N	N	-0.102693711	41.95172773	1.54E-05	76.9	DP	.
APC2	19	1446302	1473244	N	.	N	Y	.	.	0.999980518	2.8	.	.
APCDD1	18	10454628	10489948	N	.	N	N	-0.274305776	31.04126874	0.000654608	66.2	DM	Hypotrichosis 1, 605389 (3)
APCDD1L	20	58459101	58515131	N	.	N	N	0.433846831	77.56554957	0.017559216	52.3	.	.
APCS	1	159587825	159588865	N	.	N	Y	0.166306355	62.25039069	0.038637544	48.5	.	{?Amyloidosis, secondary, susceptibility to} (1)
APEH	3	49674002	49683963	N	.	N	N	-0.871843314	10.13486138	0.013215707	53.8	.	.
APELA	4	164877004	164898965	N	.	N	N	.	.	.	.	.	.
APEX2	X	55000357	55009057	N	.	N	Y	0.748026206	88.05926955	0.889124801	18.2	.	.
APH1B	15	63276018	63309126	N	.	N	Y	0.412144579	76.45424553	0.000234972	69.3	DFP	.
API5	11	43311963	43344529	N	.	N	N	-0.581281335	17.35833767	0.999555019	5.1	.	.
APIP	11	34853094	34916499	N	Viable	N	Y	0.486219979	79.93864676	4.20E-10	91.9	.	.
APITD1	1	10430443	10442809	N	.	N	N	0.124007879	59.04381548	0.008520901	55.6	.	.
APITD1-CORT	1	10430102	10452153	N	.	N	N	-0.207083847	35.09289807	0.008520901	55.6	.	.
APLF	2	68467561	68655862	N	.	N	N	0.525797823	81.46668982	1.14E-17	98.1	.	.
APLN	X	129645259	129654937	N	Viable	N	Y	.	.	0.377456159	33.4	.	.
APLP1	19	35867899	35879791	N	.	N	Y	-0.55192045	18.15708746	0.525926956	29.3	.	.
APLP2	11	130069837	130144811	Y	Viable	N	Y	0.121742358	58.84123401	0.521618003	29.4	.	.
APMAP	20	24962925	24992979	N	.	N	N	0.159910445	61.75261909	2.36E-07	84.9	.	.
APOA1	11	116835751	116837950	N	.	N	Y	-0.143231429	39.15031545	0.048738376	47.2	DM	ApoA-I and apoC-III deficiency, combined (3); Hypoalphalipoproteinemia, 604091 (3); Corneal clouding, autosomal recessive (3); Amyloidosis, 3 or more types, 105200 (3)
APOA1BP	1	156591762	156594299	N	.	N	N	0.905599564	91.18481218	1.73E-06	81.6	.	.
APOA2	1	161222292	161223631	N	.	N	Y	-0.073942787	44.13960757	0.009437055	55.2	DM	Apolipoprotein A-II deficiency (3); {Hypercholesterolemia, familial, modifier of}, 143890 (3)
APOA4	11	116820700	116823306	N	.	N	Y	0.641216095	85.39677027	3.58E-05	74.8	DM	.
APOA5	11	116789367	116792420	N	.	N	Y	0.224567453	65.92000926	1.38E-06	82.1	DM	{Hypertriglyceridemia, susceptibility to}, 145750 (3); Hyperchylomicronemia, late-onset, 144650 (3)
APOBEC1	12	7649400	7665903	N	.	N	Y	0.696312802	86.81484054	0.000144862	70.8	.	.
APOBEC2	6	41053304	41064511	N	.	N	Y	0.099735608	57.19164207	0.132007273	41.5	.	.
APOBEC3A	22	38952741	38992778	N	.	N	N	0.902731639	91.12693176	0.226347919	37.8	.	.
APOBEC3B	22	38982347	38992804	N	.	N	Y	2.597574415	99.23597847	2.51E-05	75.7	DFP	.
APOBEC3C	22	39014083	39020352	N	.	N	N	0.362343698	74.02326793	0.092624561	43.6	.	.
APOBEC3D	22	39014363	39033276	N	.	N	N	0.867273314	90.49024715	2.36E-05	75.8	.	.
APOBEC3F	22	39040604	39053910	N	.	N	N	0.906704344	91.21954043	0.013960193	53.5	.	.
APOBEC3G	22	39040961	39087743	N	.	N	N	-0.075552304	44.00069457	1.47E-06	82	DP	.
APOBEC3H	22	39097224	39104067	N	.	N	N	0.917738936	91.46263819	0.637623187	26.4	FP	.
APOBEC4	1	183646404	183653316	N	.	N	N	0.670123656	86.20709614	0.000618475	66.3	.	.
APOBR	16	28494649	28498970	N	.	N	N	1.296253244	95.75736528	6.30E-06	79.1	.	.
APOC1	19	44914247	44919349	N	.	N	Y	0.153063769	61.21433119	0.050738273	46.9	DP	.
APOC2	19	44946035	44949565	N	.	N	N	0.630550326	85.07263993	0.022796132	51	DM	Hyperlipoproteinemia, type Ib, 207750 (3)
APOC3	11	116829706	116833072	N	.	N	Y	0.245014457	67.16443827	0.000678026	66.1	DM	Apolipoprotein C-III deficiency, 614028 (3)
APOC4	19	44942238	44945496	N	Viable	N	Y	0.496445565	80.32644556	0.000150692	70.6	DP	.
APOC4-APOC2	19	44942238	44949565	N	.	N	N	.	.	.	.	.	.
APOD	3	195568702	195584205	N	.	N	Y	0.324827936	72.00902935	0.000853904	65.3	FP	.
APOE	19	44905754	44909393	N	.	N	Y	0.110914976	58.05984835	0.034533583	49	DM	Hyperlipoproteinemia, type III (3); {Myocardial infarction susceptibility} (3); Sea-blue histiocyte disease, 269600 (3); Alzheimer disease-2, 104310 (3); {?Macular degeneration, age-related}, 603075 (3); Lipoprotein glomerulopathy, 611771 (3)
APOF	12	56360569	56362823	N	Viable	N	Y	0.473126302	79.46402732	0.019338008	51.9	.	.
APOL1	22	36253010	36267530	N	.	N	N	0.77531884	88.67859003	3.75E-08	87.4	DM?	{Glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 (3); {End-stage renal disease, nondiabetic, susceptibility to}, 612551 (3)
APOL2	22	36226203	36239954	N	.	N	N	0.566990485	82.96000463	0.000139187	70.9	.	{Schizophrenia}, 181500 (1)
APOL3	22	36140330	36166177	N	.	N	N	0.432890148	77.54818545	2.87E-05	75.3	FTV	.
APOL4	22	36189124	36204840	N	.	N	N	.	.	9.93E-05	71.9	.	{Schizophrenia}, 181500 (1)
APOL5	22	35717872	35729483	N	.	N	N	0.674905651	86.29391677	1.01E-08	88.9	.	.
APOL6	22	35648395	35668409	N	.	N	N	1.166464164	94.69815361	0.000704108	65.9	.	.
APOLD1	12	12725917	12829975	N	.	N	N	0.034927599	52.21971407	0.000507905	67	.	.
APOM	6	31652416	31658210	N	.	N	Y	-0.306538083	29.06754645	0.008543076	55.5	DFP	.
APOO	X	23833353	23907934	N	Viable	N	Y	0.496445565	80.32644556	0.754113198	23	.	.
APOOL	X	85003826	85093316	N	.	N	N	0.502992837	80.54639116	0.866312702	19.2	.	.
APOPT1	14	103562962	103607523	N	.	N	N	0.269436731	68.66354112	0.000361376	68.1	.	Mitochondrial complex IV deficiency, 220110 (3)
APP	21	25880550	26171128	N	.	N	Y	-1.193547275	5.643340858	0.331710617	34.8	DM	Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 (3); Alzheimer disease 1, familial, 104300 (3)
APPBP2	17	60443149	60526219	N	.	N	N	-0.405837712	24.10719454	0.999071283	5.8	.	.
APPL1	3	57227737	57273468	N	.	N	Y	-0.548244002	18.2728483	0.18416101	39.2	.	{Maturity-onset diabetes of the young, type 14}, 616511 (3)
APPL2	12	105173296	105236238	N	.	N	N	0.405900506	76.14747931	3.53E-09	90	.	.
APTX	9	32972606	33025168	N	.	N	Y	-0.008982334	48.74110089	7.73E-06	78.7	DM	Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3)
AQP10	1	154321090	154325325	N	.	N	N	-0.015680094	48.2317532	0.015278293	53	.	.
AQP12A	2	240691845	240698483	N	.	N	Y	.	.	0.046266364	47.4	.	.
AQP12B	2	240676418	240682906	N	.	N	N	.	.	0.004358648	58.7	.	.
AQP3	9	33441154	33447611	N	Viable	N	Y	-0.666689105	14.82317532	0.504827505	29.8	DM	[Blood group GIL], 607457 (3)
AQP4	18	26852038	26865818	N	.	N	Y	-0.374868313	25.69311802	0.018149042	52.2	DM	.
AQP6	12	49967194	49977139	N	Viable	N	Y	0.739566505	87.83932396	0.211427985	38.4	.	.
AQP7	9	33383179	33402682	N	.	N	Y	4.420370447	99.80899462	1.86E-09	90.6	DFP	[Glycerol quantitative trait locus], 614411 (3)
AQP8	16	25215731	25228940	N	.	N	Y	0.094146026	56.71123459	0.003848216	59.2	.	.
AQP9	15	58138169	58185911	N	.	N	Y	0.057587761	53.92139839	0.446614671	31.5	.	.
AQR	15	34851782	34969839	N	.	N	N	-1.697174078	2.465705852	0.99999882	1.8	.	.
AR	X	67544032	67730619	N	.	N	Y	0.326890353	72.17109452	0.99490981	8.5	DM	Androgen insensitivity, 300068 (3); Spinal and bulbar muscular atrophy of Kennedy, 313200 (3); Androgen insensitivity, partial, with or without breast cancer, 312300 (3); {Prostate cancer, susceptibility to}, 176807 (3); Hypospadias 1, X-linked, 300633 (3)
ARAP1	11	72685069	72793599	N	Viable	N	Y	-0.381631428	25.32268334	1.50E-05	77	.	.
ARAP2	4	35948221	36244509	N	.	N	N	-0.52202128	19.36100017	7.56E-13	95.4	.	.
ARCN1	11	118572390	118603033	N	.	N	Y	-0.337353053	27.42374255	0.999850871	4.1	.	.
AREG	4	74445134	74455009	N	Viable	N	Y	.	.	0.652354961	26	.	.
AREL1	14	74653437	74713115	N	.	N	N	-0.638133811	15.7318979	0.011802084	54.3	.	.
ARF1	1	228082660	228099212	N	.	N	N	-0.134924458	39.72911964	0.819433491	21	.	.
ARF3	12	48935723	48957551	N	Viable	N	Y	0.024554204	51.41517625	0.622731324	26.8	.	.
ARF5	7	127588345	127591705	N	.	N	N	-0.127421372	40.23267928	0.234001127	37.6	.	.
ARFGAP1	20	63272785	63289793	N	.	N	N	0.905747523	91.19060022	0.016682107	52.6	.	.
ARFGAP2	11	47164299	47177125	N	.	N	N	0.262233352	68.20049777	0.562990971	28.4	.	.
ARFGAP3	22	42796502	42858106	N	.	N	N	1.020214838	93.01962146	2.28E-06	81.1	.	.
ARFGEF1	8	67173511	67343677	N	.	N	N	-2.096888699	1.470162644	0.999999909	1.1	.	.
ARFGEF3	6	138161921	138344663	N	.	N	Y	.	.	.	.	.	.
ARFIP1	4	152687727	152918463	N	.	N	N	-0.172286507	37.23447358	0.003729023	59.3	.	.
ARFIP2	11	6474683	6481479	N	Viable	N	Y	-0.719211967	13.43404526	0.94293271	15.4	.	.
ARG2	14	67619798	67651720	N	.	N	Y	0.297684879	70.38258957	0.542999038	28.8	.	.
ARGFX	3	121570704	121586634	N	.	N	N	0.236703709	66.62615037	1.03E-05	78	.	.
ARGLU1	13	106541673	106568164	N	.	N	N	-0.108587205	41.55814088	0.992267193	9.4	.	.
ARHGAP10	4	147732063	148072780	N	.	N	N	0.267171024	68.47832378	1.22E-10	92.8	.	.
ARHGAP11A	15	32615144	32639949	N	.	N	N	-0.540445085	18.55067431	0.124921594	41.8	.	.
ARHGAP11B	15	30624494	30772993	N	.	N	N	0.312691067	71.2565839	0.072132343	44.9	.	.
ARHGAP12	10	31805404	31928876	N	.	N	N	-1.390567441	3.987960873	0.002317772	61.4	.	.
ARHGAP15	2	143091362	143768352	N	.	N	Y	-0.922605213	9.179834462	5.25E-06	79.4	.	.
ARHGAP17	16	24919385	25015666	N	.	N	N	-0.848230086	10.59790473	0.990465511	9.9	.	.
ARHGAP19	10	97222173	97292673	N	Viable	N	Y	-0.180594035	36.70776176	1.63E-07	85.5	.	.
ARHGAP19-SLIT1	10	97153045	97292637	N	.	N	N	.	.	2.95E-07	84.6	.	.
ARHGAP20	11	110577042	110713189	N	.	N	N	-0.506607982	19.92822828	0.009020047	55.3	.	.
ARHGAP21	10	24583609	24723668	N	.	N	N	-2.348085481	1.076575794	0.999946673	3.3	.	.
ARHGAP22	10	48446034	48656265	N	.	N	Y	0.558680874	82.74005904	0.000724652	65.8	.	.
ARHGAP23	17	38419280	38512392	N	Viable	N	Y	.	.	.	.	.	.
ARHGAP24	4	85475114	86002670	N	.	N	N	0.30836083	70.9671818	0.004696081	58.4	DM	.
ARHGAP25	2	68679601	68826833	N	.	N	Y	0.545588402	82.25965156	0.438207321	31.7	.	.
ARHGAP26	5	142770384	143229011	N	.	N	N	-1.387844318	4.022689124	0.9988598	6.1	.	Leukemia, juvenile myelomonocytic, somatic, 607785 (3)
ARHGAP27	17	45393902	45434421	N	.	N	N	-0.267759536	31.40012734	0.001255844	63.8	.	.
ARHGAP28	18	6729718	6915716	N	.	N	N	-0.48167256	20.94692366	0.002958419	60.3	.	.
ARHGAP29	1	94148988	94275068	N	.	N	N	-0.32461675	28.04306303	0.999986514	2.7	DM	.
ARHGAP30	1	161046946	161069970	N	.	N	N	0.217675986	65.50327024	0.968957888	13.1	.	.
ARHGAP31	3	119294373	119420714	N	.	N	N	-0.359120884	26.32980263	0.999634466	4.9	DM	Adams-Oliver syndrome 1, 100300 (3)
ARHGAP32	11	128965060	129279324	N	.	N	Y	-1.682692814	2.494646061	0.98708852	10.6	.	.
ARHGAP36	X	131058242	131089883	N	.	N	N	-0.231353608	33.64009955	0.989879514	10	.	.
ARHGAP39	8	144529179	144605816	N	.	N	N	-1.485125489	3.438096892	0.001681796	62.6	.	.
ARHGAP4	X	153907367	153934999	N	.	N	N	0.2520117	67.56381316	0.98366194	11.1	.	.
ARHGAP40	20	38601934	38651035	N	.	N	N	.	.	.	.	.	.
ARHGAP42	11	100687653	100991937	N	.	N	N	.	.	.	.	.	.
ARHGAP44	17	12789539	12991643	N	.	N	N	-1.539845527	3.148694797	0.999299004	5.5	.	.
ARHGAP6	X	11137543	11665701	N	.	N	Y	-0.101736898	42.02697228	0.991844365	9.5	DM	.
ARHGAP8	22	44752558	44862788	N	.	N	N	3.441951701	99.66429357	.	.	.	.
ARHGAP9	12	57472255	57488814	N	.	N	N	0.695806891	86.8090525	2.89E-09	90.2	DFP	.
ARHGDIA	17	81867721	81871406	N	.	N	Y	-0.025096816	47.5834925	0.727995864	23.8	DM	Nephrotic syndrome, type 8, 615244 (3)
ARHGDIB	12	14942017	14961728	N	.	N	Y	-0.410624002	23.91618915	0.000280474	68.9	.	.
ARHGDIG	16	268727	283010	N	.	N	Y	0.426194468	77.17775077	0.486229755	30.4	.	.
ARHGEF1	19	41883161	41930150	N	.	N	Y	-0.578107514	17.41043005	0.909497464	17.3	.	.
ARHGEF10	8	1823976	1958641	N	Viable	N	Y	0.218308904	65.57272675	1.11E-13	96	DM	?Slowed nerve conduction velocity, AD, 608236 (3)
ARHGEF10L	1	17539835	17697874	N	.	N	N	-0.549576654	18.21496788	0.038306294	48.5	.	.
ARHGEF11	1	156934840	157045370	N	Viable	N	Y	-1.193980979	5.637552816	0.999945339	3.3	DP	.
ARHGEF16	1	3454426	3481113	N	.	N	N	0.5127051	80.99785842	9.37E-08	86.2	.	.
ARHGEF17	11	73308289	73369091	N	.	N	N	-1.951878761	1.765352781	0.995257099	8.3	DP	.
ARHGEF19	1	16197854	16212609	N	.	N	N	0.267974672	68.57093245	7.64E-09	89.3	.	.
ARHGEF2	1	155946851	156007070	N	.	N	Y	-1.315524797	4.613069399	0.999993235	2.3	.	.
ARHGEF25	12	57610180	57619379	N	.	N	N	0.076572313	55.40892516	5.18E-06	79.5	.	.
ARHGEF26	3	154121003	154257827	N	.	N	Y	0.392964189	75.49921861	5.99E-06	79.2	.	.
ARHGEF28	5	73626158	73941993	N	Viable	N	Y	0.087404089	56.21925103	1.83E-10	92.5	DM	.
ARHGEF3	3	56727418	57079329	N	.	N	N	0.303424512	70.72408404	0.991271358	9.7	.	.
ARHGEF33	2	38889880	38975449	N	.	N	N	.	.	.	.	.	.
ARHGEF35	7	144186083	144195655	N	.	N	N	.	.	0.127616617	41.7	.	.
ARHGEF37	5	149551947	149634968	N	.	N	N	0.946291251	91.93725763	1.08E-13	96.1	.	.
ARHGEF38	4	105552620	105708093	N	.	N	N	.	.	0.005631717	57.6	.	.
ARHGEF39	9	35658875	35675866	N	.	N	N	0.654160748	85.75562887	2.22E-08	88	.	.
ARHGEF4	2	130836916	131047263	N	.	N	Y	-0.306080941	29.11963883	0.068594877	45.1	DM?	.
ARHGEF40	14	21070270	21090240	N	.	N	N	-0.808393656	11.38507843	7.19E-05	72.8	.	.
ARHGEF5	7	144355288	144380632	N	Viable	N	Y	.	.	.	.	.	.
ARHGEF6	X	136665547	136782088	N	.	N	Y	-0.174047919	37.14186491	0.998212123	6.8	DM	Mental retardation, X-linked 46, 300436 (3)
ARHGEF9	X	63634967	63809274	N	.	N	Y	0.308865253	70.99612201	0.983065394	11.3	DM	Epileptic encephalopathy, early infantile, 8, 300607 (3)
ARID1B	6	156777374	157210779	N	.	N	N	-1.876999975	1.97372229	0.99994993	3.3	DM	Mental retardation, autosomal dominant 12, 614562 (3)
ARID3C	9	34621379	34628107	N	.	N	N	0.248033216	67.35544365	6.79E-07	83.2	.	.
ARID5A	2	96536743	96552638	N	.	N	Y	0.434803554	77.64079412	0.971125744	12.9	DM?	.
ARIH1	15	72474326	72602985	N	.	N	N	-0.531631495	18.90953291	0.999665082	4.8	DM?	.
ARIH2OS	3	48917788	48919385	N	.	N	N	0.152256873	61.16223881	0.437613435	31.7	.	.
ARL1	12	101393120	101407820	N	.	N	N	0.007634404	50.08971465	0.480262743	30.6	.	.
ARL10	5	176365468	176401865	N	Viable	N	Y	-0.198623704	35.57909359	4.90E-05	73.9	.	.
ARL11	13	49628299	49633872	N	.	N	N	0.621278951	84.78323783	8.09E-06	78.6	DP	.
ARL13A	X	100969708	100990829	N	.	N	N	0.223461474	65.83897667	0.007531879	56.3	.	.
ARL14	3	160677159	160678452	N	.	N	N	0.59126564	83.85715113	2.57E-06	80.8	.	.
ARL14EP	11	30323051	30338227	N	.	N	N	-0.283071606	30.49140476	0.151697478	40.5	.	.
ARL14EPL	5	116051466	116060118	N	.	N	N	.	.	.	.	.	.
ARL15	5	53883945	54310582	N	.	N	N	0.230008154	66.23835157	0.008866422	55.4	.	.
ARL16	17	81681174	81683924	N	.	N	N	-0.219218665	34.36360479	0.021572054	51.3	.	.
ARL17A	17	46516702	46579722	N	.	N	N	.	.	.	.	.	.
ARL17B	17	46274784	46361797	N	.	N	N	.	.	.	.	.	.
ARL2	11	65014113	65022184	N	.	N	N	0.043387416	52.82745847	0.00739854	56.4	.	.
ARL2BP	16	57245098	57253635	N	.	N	N	0.207498734	64.86658563	0.000774156	65.6	DM	Retinitis pigmentosa with or without situs inversus, 615434 (3)
ARL2-SNX15	11	65014182	65040570	N	.	N	N	.	.	.	.	.	.
ARL4A	7	12686856	12690934	N	.	N	Y	-0.034513598	46.96996006	0.6402994	26.3	.	.
ARL4C	2	234493041	234497053	N	.	N	N	-0.095495045	42.38583087	0.607389355	27.3	.	.
ARL4D	17	43398959	43401137	N	.	N	Y	-0.247470694	32.59246397	0.132429776	41.5	.	.
ARL5A	2	151788984	151828492	N	.	N	N	-0.064525847	44.79365631	0.017364843	52.3	.	.
ARL5B	10	18659405	18681639	N	.	N	N	-0.125507302	40.39474446	0.463976138	31	.	.
ARL5C	17	39156894	39167484	N	Viable	N	Y	.	.	.	.	.	.
ARL6	3	97764521	97801242	N	.	N	Y	-0.041059779	46.53585692	0.004270868	58.8	DM	Bardet-Biedl syndrome 3, 600151 (3); {Bardet-Biedl syndrome 1, modifier of}, 209900 (3); ?Retinitis pigmentosa 55, 613575 (3)
ARL6IP1	16	18791667	18801678	N	.	N	N	-0.192077745	36.04213695	0.006675689	56.8	.	?Spastic paraplegia 61, autosomal recessive, 615685 (3)
ARL6IP4	12	122980060	122982913	N	.	N	N	.	.	0.011234201	54.4	.	.
ARL6IP5	3	69084944	69106066	N	.	N	Y	0.096865517	56.89645193	0.313164924	35.4	DFP	.
ARL6IP6	2	152717893	152761253	N	.	N	N	0.063177242	54.40180587	0.170955561	39.7	DM?	.
ARL8A	1	202133404	202144743	N	.	N	N	-0.202452202	35.31863171	0.630040288	26.6	.	.
ARL9	4	56505343	56524448	N	Viable	N	Y	0.403538004	75.98541413	0.397380994	32.8	.	.
ARMC1	8	65602456	65634217	N	.	N	N	0.021835061	51.22417086	0.876351937	18.8	.	.
ARMC10	7	103074881	103099764	N	.	N	N	0.458119953	78.71158187	0.031202217	49.5	.	.
ARMC12	6	35737032	35749079	N	.	N	N	0.372865427	74.57313191	0.000270202	69	.	.
ARMC2	6	108848416	108974472	N	.	N	N	-0.046194419	46.1191179	2.20E-08	88	.	.
ARMC3	10	22928024	23038523	N	.	N	N	0.596350229	84.00185217	4.53E-08	87.1	.	.
ARMC4	10	27812164	27999048	N	.	N	N	-0.022577373	47.75134572	3.96E-15	96.9	DM	Ciliary dyskinesia, primary, 23, 615451 (3)
ARMC5	16	31458080	31467166	N	.	N	N	0.062827436	54.32656132	0.046292475	47.4	.	ACTH-independent macronodular adrenal hyperplasia 2, 615954 (3)
ARMC6	19	19033575	19060311	N	.	N	N	-0.068854605	44.475314	7.24E-07	83.1	.	.
ARMC8	3	138187248	138298389	N	.	N	N	-0.645938225	15.50037622	0.99988377	3.9	.	.
ARMC9	2	231198546	231374837	N	.	N	N	-0.026555762	47.50245992	1.03E-08	88.9	.	.
ARMCX1	X	101550531	101554700	N	.	N	N	-0.387157394	25.09116166	0.395796527	32.9	.	.
ARMCX2	X	101655281	101659891	N	.	N	N	0.112022239	58.14666898	0.730479736	23.7	.	.
ARMCX3	X	101622797	101627843	N	.	N	N	0.109958322	57.97881577	0.249589239	37.1	.	.
ARMCX4	X	101418287	101533459	N	.	N	N	.	.	.	.	.	.
ARMCX5	X	102599168	102604159	N	.	N	N	0.398094787	75.74231637	0.550666214	28.6	.	.
ARMCX6	X	101615118	101618001	N	.	N	N	0.140927298	60.26509232	0.259563478	36.8	.	.
ARMS2	10	122454653	122457352	N	.	N	N	0.281573966	69.3928344	0.039182646	48.4	DFP	.
ARMT1	6	151452258	151470101	N	.	N	N	.	.	.	.	.	.
ARNTL	11	13276652	13387266	N	.	N	Y	-0.720970763	13.3703768	0.987642967	10.5	.	.
ARNTL2	12	27332854	27425289	N	.	N	N	-0.375672502	25.64681368	2.37E-06	81	.	.
ARPC1A	7	99325898	99388164	N	.	N	N	-0.060698235	45.04254211	0.734759683	23.6	.	.
ARPC1B	7	99374249	99394801	N	.	N	Y	0.141077527	60.28245644	0.156070499	40.3	.	.
ARPC4-TTLL3	3	9793082	9835401	N	.	N	N	0.238919593	66.78821555	1.37E-12	95.1	.	.
ARPC5	1	183620846	183635757	N	.	N	N	-0.0579797	45.26827574	0.772685975	22.5	.	.
ARPC5L	9	124862130	124877733	N	.	N	N	-0.043930449	46.31591133	0.775599153	22.4	.	.
ARPIN	15	89895006	89912956	N	.	N	N	.	.	.	.	.	.
ARPP19	15	52547045	52569883	N	.	N	N	-0.03642736	46.82525901	0.269804298	36.5	.	.
ARPP21	3	35638945	35794496	N	.	N	Y	-0.364192698	26.16773745	0.003676931	59.4	.	.
ARR3	X	70268305	70281840	N	.	N	N	0.129747743	59.39109799	0.137242313	41.2	.	.
ARRB1	11	75264182	75351705	N	Viable	N	Y	-0.201341563	35.40545234	0.986801821	10.7	.	.
ARRB2	17	4710489	4721499	N	Viable	N	Y	-0.14882052	38.83197314	0.769282968	22.6	.	.
ARRDC1	9	137605654	137615360	N	Viable	N	Y	-0.594219906	16.88950628	0.000232263	69.3	.	.
ARRDC2	19	18001132	18014102	N	.	N	N	0.072745024	55.10794698	5.13E-05	73.8	.	.
ARRDC4	15	97960698	97973838	N	.	N	N	0.336156875	72.63992591	0.000815443	65.5	.	.
ARRDC5	19	4890437	4902867	N	.	N	N	0.18146271	63.30960236	1.98E-06	81.3	.	.
ARSA	22	50622754	50628173	N	.	N	Y	0.826886131	89.70886149	8.51E-08	86.3	DM	Metachromatic leukodystrophy, 250100 (3)
ARSB	5	78777209	78986087	N	.	N	Y	-0.400095467	24.4197488	0.001261753	63.8	DM	Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 (3)
ARSD	X	2903970	2929351	N	.	N	N	0.711616165	87.19106326	0.292872844	35.9	.	.
ARSE	X	2934632	2968310	N	.	N	N	0.636432699	85.26364531	0.120625325	42.1	DM	Chondrodysplasia punctata, X-linked recessive, 302950 (3)
ARSF	X	3041471	3112726	N	.	N	N	1.204133238	95.05701221	4.08E-07	84	DM?	.
ARSG	17	68259182	68422731	N	.	N	Y	-0.094233924	42.51895584	1.55E-05	76.9	.	.
ARSH	X	3006613	3033571	N	.	N	N	1.654392583	97.7484517	0.001600231	62.8	DM?	.
ARSI	5	150296343	150339307	N	.	N	N	-0.164479923	37.75539735	1.05E-09	91.1	.	.
ARSJ	4	113900284	113979727	N	.	N	N	-0.065178849	44.7647161	0.003455799	59.8	.	.
ARSK	5	95555074	95605064	N	Viable	N	Y	0.398244896	75.74810442	0.00461421	58.5	.	.
ART1	11	3645128	3664416	N	.	N	N	0.199338946	64.3514499	1.54E-09	90.8	.	.
ART3	4	76011184	76112802	N	.	N	N	0.118568504	58.65022863	2.27E-08	88	.	.
ART4	12	14825569	14843495	N	.	N	N	0.65702964	85.81929733	0.001451809	63.2	FP	[Blood group, Dombrock], 616060 (3)
ART5	11	3638503	3642316	N	.	N	N	0.868081708	90.53076344	0.017226475	52.4	.	.
ARTN	1	43933320	43937241	N	.	N	Y	.	.	0.293100342	35.9	.	.
ARV1	1	230978981	231000595	N	.	N	N	-0.233267662	33.50118655	1.55E-06	81.9	.	.
ARVCF	22	19969896	20016808	N	.	N	Y	1.134211654	94.37981131	8.22E-07	82.9	DP	.
AS3MT	10	102869516	102901899	N	.	N	Y	0.427150878	77.22984314	5.09E-07	83.7	FP	.
ASAH2	10	50182778	50248610	N	.	N	Y	.	.	0.015900691	52.9	FTV	.
ASAH2B	10	50739318	50816495	N	.	N	N	.	.	0.15486755	40.4	.	.
ASAP1	8	130052104	130443660	N	.	N	N	-1.55184575	3.06766221	0.999983091	2.8	.	.
ASAP2	2	9206765	9405683	N	.	N	N	-1.678475031	2.523586271	0.999986043	2.7	.	.
ASAP3	1	23428563	23484568	N	.	N	N	-0.157783196	38.16634832	2.36E-10	92.3	.	.
ASB1	2	238426742	238452250	N	.	N	Y	-0.314843927	28.5639868	0.350835779	34.2	DM?	.
ASB10	7	151175698	151187832	N	Viable	N	Y	1.613191661	97.56323436	0.000421836	67.6	DM	Glaucoma 1, open angle, F, 603383 (3)
ASB11	X	15281697	15315656	N	.	N	N	0.640110346	85.33310181	0.155409013	40.3	.	.
ASB12	X	64224196	64230631	N	.	N	N	1.062221793	93.51739307	1.62E-05	76.8	.	.
ASB13	10	5638867	5666595	N	.	N	N	0.139164133	60.1377554	0.257156363	36.9	.	.
ASB14	3	57268347	57292682	N	.	N	N	.	.	6.08E-10	91.6	.	.
ASB15	7	123567010	123639481	N	Viable	N	Y	0.938632293	91.84464896	6.01E-08	86.7	.	.
ASB16	17	44170447	44179083	N	.	N	N	1.945327354	98.47774498	2.42E-10	92.3	.	.
ASB17	1	75918873	75932431	N	.	N	N	-0.051281473	45.6908028	0.006158696	57.1	.	.
ASB18	2	236194872	236264409	N	.	N	N	.	.	0.004573374	58.6	.	.
ASB2	14	93934153	93976791	N	.	N	N	1.306471588	95.83260983	4.59E-05	74.1	.	.
ASB3	2	53532672	53787610	N	.	N	N	-0.063265228	44.90941714	0.247642059	37.2	.	.
ASB4	7	95478444	95540232	N	.	N	N	0.31284098	71.27973607	0.011019713	54.5	.	.
ASB5	4	176213673	176277571	N	.	N	N	-0.161912646	37.86537015	1.83E-11	94	.	.
ASB6	9	129634604	129642169	N	.	N	N	-0.354120223	26.60762864	0.004646337	58.5	.	.
ASB7	15	100602534	100651705	N	.	N	N	-0.471606334	21.36366267	0.9932441	9.1	.	.
ASB8	12	48147788	48181213	N	.	N	N	0.082816117	55.93563697	0.01802853	52.2	.	.
ASB9	X	15235288	15270467	N	.	N	N	0.165349748	62.17514615	0.887238949	18.3	.	.
ASCC1	10	72096032	72217134	N	.	N	N	0.169176254	62.44718412	1.30E-05	77.3	DM	Barrett esophagus/esophageal adenocarcinoma, 614266 (3)
ASCC3	6	100508194	100881372	N	.	N	Y	-2.862513623	0.659836777	1.43E-10	92.7	DM	.
ASCL3	11	8937579	8938211	N	.	N	N	0.241337169	66.9618568	0.008283971	55.7	.	.
ASCL4	12	107774385	107776644	N	.	N	N	.	.	0.247411889	37.2	.	.
ASCL5	1	201113953	201127184	N	.	N	N	.	.	.	.	.	.
ASF1B	19	14119509	14136956	N	.	N	N	-0.250187888	32.45355096	0.565696011	28.3	.	.
ASGR1	17	7173431	7179564	N	.	N	Y	-0.459316521	21.9193147	0.000452324	67.3	.	.
ASGR2	17	7101322	7115700	N	.	N	Y	-0.070919872	44.37691729	6.64E-06	79	.	.
ASH1L	1	155335268	155562807	N	.	N	Y	-3.784757315	0.300978179	1	0.2	DM?	.
ASIC1	12	50057548	50083611	N	.	N	Y	-1.060541298	7.061411125	0.988325492	10.3	.	.
ASIC2	17	33013087	34174964	N	.	N	Y	-0.69271885	14.1575505	0.989195649	10.1	.	.
ASIC3	7	151048292	151052756	N	.	N	Y	0.398397436	75.75389246	7.96E-07	82.9	.	.
ASIC4	2	219514170	219538772	N	Viable	N	Y	-0.097909737	42.2237657	0.728514783	23.8	.	.
ASIC5	4	155829729	155866273	N	.	N	N	0.058695894	54.00821902	2.26E-07	85	.	.
ASMT	X	1615001	1643081	N	.	N	N	1.201262418	95.02228396	2.58E-13	95.8	DM	.
ASMTL	X	1403139	1453762	N	.	N	N	1.091897158	93.87625166	1.22E-05	77.6	FTV	.
ASNS	7	97852118	97872542	N	.	N	Y	-0.719056482	13.4398333	0.001665928	62.6	FP	Asparagine synthetase deficiency, 615574 (3)
ASNSD1	2	189661385	189670831	N	.	N	N	-0.516317865	19.57515772	1.64E-08	88.4	.	.
ASPDH	19	50511600	50514690	N	.	N	N	0.26384649	68.31047057	0.001111334	64.3	.	.
ASPG	14	104085679	104115581	N	.	N	N	0.550220861	82.45065694	1.18E-06	82.3	.	.
ASPH	8	61500556	61714640	N	.	N	Y	-0.561999192	17.86768536	1.02E-08	88.9	DM?	Traboulsi syndrome, 601552 (3)
ASPHD1	16	29900375	29919864	N	.	N	N	-0.769819997	12.19540429	0.120035613	42.1	.	.
ASPHD2	22	26429273	26445015	N	.	N	N	-0.728474054	13.19673554	0.526013416	29.3	.	.
ASPM	1	197084128	197146694	N	.	N	Y	-0.00656315	48.92631823	6.16E-26	99.4	DM	Microcephaly 5, primary, autosomal recessive, 608716 (3)
ASPN	9	92456205	92482506	N	Viable	N	Y	.	.	0.023321537	50.9	DP	{Osteoarthritis susceptibility 3}, 607850 (3); {Lumbar disc degeneration}, 603932 (3)
ASPRV1	2	69960089	69962265	N	.	N	Y	0.157040256	61.54424958	0.091805263	43.7	DM?	.
ASPSCR1	17	81976807	82017406	N	.	N	N	-0.403621272	24.19401516	6.07E-08	86.7	.	Alveolar soft-part sarcoma, 606243 (3)
ASRGL1	11	62337448	62393412	N	.	N	N	-0.154409651	38.42681021	0.000386788	67.9	.	.
ASTE1	3	131013875	131027649	N	.	N	Y	0.257600888	6.79E+01	3.39E-12	94.8	.	.
ASTL	2	96123850	96138436	N	.	N	Y	0.633712862	85.17103664	3.67E-05	74.7	.	.
ASTN1	1	176857302	177164973	N	.	N	Y	-1.09368195	6.656248191	0.999415997	5.4	.	.
ASTN2	9	116425225	117415070	N	.	N	N	-1.513115903	3.276031718	0.989172284	10.1	DM	.
ASUN	12	26905181	26938326	N	.	N	N	-0.992051392	7.993285871	0.998587604	6.4	.	.
ASXL3	18	33578615	33751192	N	.	N	N	-1.466822179	3.52491752	0.999977048	2.9	DM	Bainbridge-Ropers syndrome, 615485 (3)
ASZ1	7	117363222	117428123	N	.	N	Y	0.145861223	60.69919546	1.72E-06	81.6	.	.
ATAD1	10	87751512	87841343	N	.	N	N	-0.332721412	27.59738381	0.536354315	29	.	.
ATAD2	8	123319850	123416350	N	.	N	N	-1.966424754	1.73062453	0.999997953	2	.	.
ATAD2B	2	23748664	23927114	N	Viable	N	Y	-0.761056448	12.37483359	0.999998682	1.8	.	.
ATAD3B	1	1471769	1497848	N	.	N	N	3.065512133	99.56010882	1.92E-13	95.9	.	.
ATAD3C	1	1449689	1470158	N	.	N	N	2.844527514	99.42119581	4.91E-05	73.9	.	.
ATAT1	6	30626842	30646823	N	.	N	Y	0.224567453	65.92000926	0.014373925	53.4	.	.
ATCAY	19	3879864	3928079	N	.	N	N	-0.647852776	15.44828385	0.087473326	43.9	DM	Ataxia, cerebellar, Cayman type, 601238 (3)
ATF1	12	50763710	50821122	N	.	N	Y	0.067810037	54.72014817	0.663831054	25.7	DP	.
ATF3	1	212565334	212620777	N	Viable	N	Y	0.155933478	61.44006483	0.276113481	36.3	DM	.
ATF6	1	161766294	161964070	N	.	N	Y	-0.773342052	12.10858367	3.11E-05	75.1	DP	Achromatopsia 7, 616517 (3)
ATF7	12	53507856	53626410	N	.	N	Y	-0.072833607	44.24958037	0.983314715	11.2	.	.
ATF7IP	12	14365632	14502935	N	.	N	N	-0.672639528	14.70162644	0.999741038	4.5	.	.
ATF7IP2	16	10326434	10483638	N	.	N	N	0.511901029	80.95734213	0.797518042	21.8	.	.
ATG10	5	81972025	82276857	N	.	N	N	0.734785964	87.69462291	0.001685054	62.6	.	.
ATG101	12	52069246	52077494	N	.	N	N	.	.	.	.	.	.
ATG12	5	115828200	115841858	N	.	N	N	0.278852726	69.23076923	0.001658071	62.6	.	.
ATG13	11	46617527	46674818	N	.	N	N	0.160867203	61.83943972	0.984296607	11.1	.	.
ATG14	14	55366392	55411858	N	.	N	N	-0.568034909	17.71140823	0.326846074	35	.	.
ATG16L2	11	72814308	72843674	N	.	N	Y	-0.088644586	42.93569485	8.94E-09	89	.	.
ATG2A	11	64894546	64917248	N	.	N	N	-0.43470076	22.97852636	0.99992273	3.6	.	.
ATG2B	14	96279202	96363870	N	.	N	N	-0.524754243	19.23366325	8.13E-05	72.5	.	.
ATG4A	X	108091668	108154671	N	.	N	N	0.080902701	55.81408809	0.988883247	10.2	.	.
ATG4C	1	62784135	62865513	N	.	N	Y	0.456356165	78.6189732	3.33E-09	90	.	.
ATG4D	19	10543895	10553418	N	.	N	N	0.061414866	54.25131678	0.000323904	68.4	.	.
ATG9B	7	151012209	151024499	N	Viable	N	Y	.	.	1.85E-11	94	.	.
ATHL1	11	289135	296107	N	.	N	N	-0.154106795	38.46153846	3.53E-09	89.9	.	.
ATIC	2	215311817	215349773	N	.	N	N	0.02692196	51.57724142	2.49E-13	95.8	DM	AICA-ribosiduria due to ATIC deficiency, 608688 (3)
ATL1	14	50532509	50633068	N	.	N	Y	-0.768862541	12.2243445	0.992118036	9.4	DM	Spastic paraplegia 3A, autosomal dominant, 182600 (3); Neuropathy, hereditary sensory, type ID, 613708 (3)
ATL2	2	38294880	38377285	N	.	N	N	0.110259893	58.00196793	0.980197371	11.7	.	.
ATL3	11	63624087	63671921	N	.	N	N	0.122395494	58.93963072	0.000317252	68.5	.	Neuropathy, hereditary sensory, type IF, 615632 (3)
ATN1	12	6924463	6942321	Y	Viable	N	Y	-0.676462075	14.59744169	0.998533107	6.5	DM	Dentatorubro-pallidoluysian atrophy, 125370 (3)
ATOH7	10	68230624	68232103	N	.	N	Y	0.003001751	49.6961278	0.043020032	47.8	DM	Persistent hyperplastic primary vitreous, autosomal recessive, 221900 (3)
ATP10A	15	25677273	25865172	N	.	N	N	0.159076164	61.67737454	0.611013499	27.2	DM	.
ATP10B	5	160563120	160852214	N	.	N	N	1.323327674	95.93679458	1.34E-23	99.2	.	.
ATP10D	4	47485288	47593486	N	.	N	N	-0.123645981	40.5105053	2.24E-11	93.8	DM?	.
ATP11B	3	182793500	182921635	N	.	N	N	-0.187795448	36.27365862	0.992834851	9.2	.	.
ATP11C	X	139726346	139945276	N	.	N	N	0.065242053	54.58123517	0.999724526	4.6	.	.
ATP12A	13	24680411	24712493	N	.	N	Y	0.269240739	68.64038896	9.71E-10	91.2	.	.
ATP13A1	19	19645198	19663693	N	.	N	N	-2.049111231	1.545407189	0.994473889	8.6	.	.
ATP13A2	1	16985958	17011928	N	.	N	Y	-1.134064911	6.210568965	0.001204951	64	DM	Kufor-Rakeb syndrome, 606693 (3); ?Ceroid lipofuscinosis, neuronal, 12, 606693 (3)
ATP13A3	3	194402672	194498364	N	.	N	N	-0.62393804	16.04445216	0.999967445	3.1	.	.
ATP13A4	3	193402077	193593111	N	.	N	N	-0.476451835	21.16108121	6.08E-10	91.6	DM	.
ATP13A5	3	193274790	193378843	N	.	N	N	0.57990836	83.43462407	6.23E-28	99.6	DM?	.
ATP1A4	1	160151570	160186977	N	Viable	N	Y	1.158642234	94.61712103	1.90E-11	94	.	.
ATP1B1	1	169105697	169132722	N	.	N	N	0.180355903	63.21120565	0.995564605	8.2	DM?	[Blood pressure regulation QTL], 145500 (2)
ATP1B3	3	141876124	141926514	N	.	N	N	-0.214586899	34.6414308	0.641391597	26.3	.	.
ATP1B4	X	120362085	120383249	N	.	N	N	0.554705396	82.60114603	0.002780625	60.7	DM?	.
ATP2A3	17	3923870	3964464	N	.	N	Y	-1.282372433	4.827226949	0.06445003	45.6	DM	.
ATP2B2	3	10324023	10708031	N	.	N	Y	-2.802705495	0.711929154	0.999921506	3.6	DM	{Deafness, autosomal recessive 12, modifier of}, 601386 (3)
ATP2B3	X	153517676	153582939	N	.	N	N	-0.487921954	20.6633096	0.998768934	6.2	DM	?Spinocerebellar ataxia, X-linked 1, 302500 (3)
ATP2B4	1	203626561	203744081	N	.	N	Y	-0.449305125	22.31868959	0.521756389	29.4	DM?	.
ATP2C2	16	84368527	84464187	N	.	N	N	0.526931574	81.50141807	.	.	.	.
ATP4A	19	35550043	35563658	N	.	N	Y	-1.476666571	3.490189269	6.99E-08	86.6	.	.
ATP4B	13	113648804	113658186	N	.	N	Y	0.262082672	68.1773456	1.84E-05	76.5	.	.
ATP5C1	10	7788129	7807815	N	.	N	N	-0.265193969	31.55061643	0.425803631	32.1	.	.
ATP5D	19	1241746	1244826	N	.	N	N	.	.	0.001183238	64.1	.	.
ATP5EP2	13	27945206	27945590	N	.	N	N	.	.	0.022481607	51.1	.	.
ATP5F1	1	111448864	111462773	N	.	N	N	-0.438721742	22.81646119	0.012867526	53.9	.	.
ATP5G1	17	48892765	48895871	N	.	N	N	0.002044933	49.63824738	0.327525829	34.9	.	.
ATP5G3	2	175176258	175184607	N	.	N	N	0.06302642	54.36707762	0.538092564	28.9	.	.
ATP5H	17	75038863	75046985	N	.	N	N	0.101498578	57.33634312	0.010871565	54.5	.	.
ATP5I	4	672436	674338	N	.	N	N	0.144604076	60.5660705	0.207299098	38.5	.	.
ATP5J	21	25716503	25735673	N	.	N	N	0.145560638	60.65289113	0.100188832	43.1	.	.
ATP5J2	7	99448475	99466331	N	.	N	N	0.169983117	62.51085258	0.34850304	34.2	.	.
ATP5J2-PTCD1	7	99419749	99466197	N	.	N	N	0.72039146	87.45152515	1.78E-09	90.6	.	.
ATP5L2	22	42639803	42640601	N	.	N	N	0.116504775	58.48816345	0.166948561	39.9	.	.
ATP5O	21	33903453	33915980	N	.	N	N	0.285399426	69.6822365	0.434076663	31.8	.	.
ATP5S	14	50312326	50335558	N	.	N	N	0.567799588	82.98894484	6.30E-05	73.3	.	.
ATP5SL	19	41431318	41440717	N	.	N	N	0.959081062	92.17456734	5.83E-05	73.5	FP	.
ATP6AP1L	5	82279462	82386977	N	.	N	N	0.309821667	71.05979047	0.139629451	41.1	.	.
ATP6AP2	X	40580908	40606637	N	.	N	N	0.049933723	53.40047462	0.785047268	22.1	DM	?Mental retardation, X-linked, syndromic, Hedera type, 300423 (3); ?Parkinsonism with spasticity, X-linked, 300911 (3)
ATP6V0A2	12	123712318	123761755	N	.	N	N	-0.194341948	35.87428373	4.74E-06	79.6	DM	Cutis laxa, autosomal recessive, type IIA, 219200 (3); Wrinkly skin syndrome, 278250 (3)
ATP6V0B	1	43974487	43978295	N	.	N	N	-0.277483031	30.77501881	0.927635231	16.2	.	.
ATP6V0D1	16	67438014	67481237	N	.	N	N	-0.438721742	22.81646119	0.988131751	10.4	.	.
ATP6V0D2	8	85987323	86154228	N	.	N	Y	0.492915188	80.18174452	2.37E-08	88	.	.
ATP6V0E1	5	172983757	173035445	N	.	N	N	-0.059893552	45.10042253	0.277597261	36.3	.	.
ATP6V0E2	7	149872968	149880698	N	.	N	N	0.331374701	72.39104011	2.06E-05	76.1	.	.
ATP6V1A	3	113747019	113812056	N	.	N	N	0.120481978	58.76598947	0.986543792	10.7	.	.
ATP6V1B1	2	70935882	70965406	N	.	N	Y	-0.432826756	23.07113504	0.00024405	69.2	DM	.
ATP6V1C1	8	103021063	103073051	N	.	N	N	-0.188249534	36.2562945	0.142543168	40.9	.	.
ATP6V1C2	2	10721649	10785110	N	.	N	N	0.395374663	75.60919141	2.26E-06	81.1	.	.
ATP6V1E1	22	17592136	17628818	N	.	N	N	0.140927298	60.26509232	0.882471623	18.5	.	.
ATP6V1E2	2	46490750	46542557	N	.	N	N	0.44774765	78.23696244	9.71E-05	72	.	.
ATP6V1F	7	128862826	128865844	N	.	N	N	0.086492393	56.17873473	0.56300253	28.4	.	.
ATP6V1G1	9	114587746	114598373	N	.	N	N	.	.	0.045173671	47.6	.	.
ATP6V1G2	6	31544462	31548427	N	.	N	N	-0.005458152	49.05944319	0.224789736	37.8	.	.
ATP6V1G2-DDX39B	6	31530219	31546608	N	.	N	N	.	.	.	.	.	.
ATP6V1G3	1	198523222	198540945	N	.	N	N	0.472979635	79.42351103	0.030501779	49.5	.	.
ATP6V1H	8	53715557	53843558	N	.	N	N	-0.659987499	15.04312091	3.86E-05	74.6	.	.
ATP8A1	4	42408373	42657105	N	.	N	Y	-1.552800803	3.061874168	0.999804446	4.3	.	.
ATP8B1	18	57646426	57803101	N	.	N	N	-0.103198421	41.9054234	3.67E-07	84.2	DM	Cholestasis, progressive familial intrahepatic 1, 211600 (3); Cholestasis, benign recurrent intrahepatic, 243300 (3); Cholestasis, intrahepatic, of pregnancy, 1, 147480 (3)
ATP8B2	1	154325553	154351307	N	.	N	Y	-0.776734806	12.07964346	0.999564592	5	.	.
ATP8B3	19	1782075	1812276	N	.	N	Y	0.527550356	81.53614632	9.19E-22	99	.	.
ATP8B4	15	49858238	50182817	N	.	N	N	0.040470343	52.57857267	2.42E-27	99.5	.	.
ATP9A	20	51596514	51768634	N	.	N	N	-1.883982735	1.950570122	0.999980637	2.8	.	.
ATP9B	18	79069285	79378283	N	.	N	N	-1.626647731	2.737743821	7.02E-12	94.4	.	.
ATPAF1	1	46632737	46673867	N	.	N	N	-0.025096816	47.5834925	0.236382638	37.5	.	.
ATPIF1	1	28236109	28246906	N	.	N	Y	-0.125507302	40.39474446	0.059353504	46.1	.	.
ATRAID	2	27212027	27217178	N	.	N	N	0.113784984	58.30294611	0.007913949	56	.	.
ATRN	20	3471040	3651122	N	.	N	Y	-0.771141629	12.16067604	0.999999976	0.9	DM?	.
ATRNL1	10	115093365	115948992	N	.	N	N	-1.777826596	2.257336343	0.995631864	8.1	DM?	.
ATXN1	6	16299112	16761491	N	.	N	Y	-0.168962986	37.46599525	0.398661149	32.8	DM	Spinocerebellar ataxia 1, 164400 (3)
ATXN2L	16	28823035	28837237	N	.	N	N	-1.982389608	1.695896278	0.999950396	3.2	.	.
ATXN3	14	92038652	92106621	N	.	N	Y	-0.217304588	34.45621346	0.176363908	39.5	DM	Machado-Joseph disease, 109150 (3)
ATXN3L	X	13318236	13319952	N	.	N	N	1.183240604	94.88337096	4.32E-09	89.7	FTV	.
ATXN7	3	63864557	64003462	N	.	N	N	-0.752452811	12.54268681	0.928556028	16.2	DM	Spinocerebellar ataxia 7, 164500 (3)
ATXN7L1	7	105605067	105876604	N	.	N	N	.	.	0.111091575	42.6	.	.
ATXN7L2	1	109483479	109492804	N	.	N	N	-0.935549769	8.936736702	0.718954812	24.1	.	.
ATXN7L3B	12	74537827	74545430	N	.	N	N	.	.	0.097960612	43.3	.	.
AUH	9	91213815	91361913	N	.	N	N	0.17380942	62.79446663	0.00725254	56.4	DM	3-methylglutaconic aciduria, type I, 250950 (3)
AUNIP	1	25831913	25859458	N	.	N	N	0.396181853	75.63234358	5.49E-08	86.8	.	.
AUP1	2	74526645	74529939	N	.	N	N	-0.169415642	37.44284309	0.024155048	50.7	.	.
AURKAIP1	1	1373730	1375495	N	.	N	N	0.280765669	69.35810615	0.002475388	61.2	.	.
AURKC	19	57230802	57235548	N	.	N	Y	-0.552226052	18.13393529	0.151759586	40.5	DM	.
AUTS2	7	69598919	70793068	N	.	N	N	-1.87909671	1.956358164	0.996187482	7.9	DM	.
AVEN	15	33866227	34039176	N	.	N	Y	0.406554426	76.19378364	5.70E-08	86.8	.	.
AVL9	7	32495426	32588721	N	.	N	N	-0.161760738	37.87694623	0.000325495	68.4	.	.
AVPI1	10	97677424	97687323	N	Viable	N	Y	1.028384116	93.12959426	1.07E-05	77.8	.	.
AVPR1A	12	63142759	63150942	N	.	N	Y	0.029489373	51.73930659	1.29E-05	77.4	DFP	.
AVPR1B	1	206109692	206117699	N	.	N	Y	0.338220438	72.790415	2.82E-05	75.3	DP	.
AWAT1	X	70234655	70240627	N	.	N	N	0.264802972	68.36835099	0.015095904	53.1	.	.
AWAT2	X	70040542	70049938	N	.	N	N	0.101498578	57.33634312	0.603147994	27.4	.	.
AXDND1	1	179365720	179554735	N	.	N	N	0.116306296	58.43607108	1.80E-15	97.2	.	.
AXL	19	41219203	41261766	N	.	N	Y	-0.3499951	26.79284598	0.766301151	22.7	FTV	.
AZGP1	7	99966720	99976157	N	.	N	Y	0.223610811	65.85055276	0.017597583	52.3	.	.
AZI2	3	28315003	28349127	N	.	N	Y	-0.03627546	46.84841118	0.185308909	39.1	.	.
AZIN2	1	33081104	33120530	N	.	N	N	.	.	.	.	.	.
AZU1	19	825097	832018	N	.	N	N	0.504095467	80.61584766	8.74E-05	72.3	.	.
B2M	15	44711477	44718877	N	.	N	Y	-0.044887353	46.22330266	0.856561948	19.7	DM	Hypoproteinemia, hypercatabolic, 241600 (3)
B3GALNT2	1	235449923	235504481	N	.	N	N	-0.068049328	44.53319442	4.87E-06	79.6	DM	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 (3)
B3GALT1	2	167868948	167874041	N	.	N	N	-0.211715637	34.80928402	0.329724364	34.9	.	.
B3GALT2	1	193179045	193186654	N	.	N	Y	-0.5962877	16.80268565	0.491100476	30.2	.	.
B3GALT4	6	33277132	33284832	N	.	N	N	-0.663816607	14.92736007	0.236708748	37.5	.	.
B3GALT5	21	39556442	39673137	N	.	N	Y	-0.314843927	28.5639868	0.003583967	59.6	.	.
B3GALT6	1	1232265	1235041	N	.	N	N	.	.	0.048104466	47.2	DM	Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3); Ehlers-Danlos syndrome, progeroid type, 2, 615349 (3)
B3GAT1	11	134378504	134411918	N	.	N	Y	-0.474322733	21.23632575	0.789152807	22	DM?	.
B3GAT2	6	70856679	70957038	N	.	N	N	-0.195752553	35.7874631	7.04E-07	83.1	.	.
B3GAT3	11	62615296	62622175	N	.	N	N	-0.502420818	20.06714129	0.000286975	68.8	DM	Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects, 245600 (3)
B3GLCT	13	31199936	31332276	N	.	N	N	.	.	.	.	.	Peters-plus syndrome, 261540 (3)
B3GNT2	2	62196113	62224731	N	.	N	Y	-0.224807605	34.0336864	0.696953714	24.7	.	.
B3GNT3	19	17794828	17813082	N	.	N	Y	0.0200728	51.09683394	0.20097195	38.7	DP	.
B3GNT4	12	122203543	122208952	N	.	N	N	-0.2423802	32.90501823	3.94E-06	80	.	.
B3GNT6	11	77034398	77041973	N	.	N	Y	1.162639977	94.65763732	2.42E-06	80.9	.	.
B3GNT7	2	231395543	231401164	N	Viable	N	Y	-0.21156288	34.83822423	0.62084526	26.9	.	.
B3GNT8	19	41425359	41428730	N	.	N	N	0.209712323	65.05759102	3.49E-07	84.3	.	.
B3GNT9	16	67148105	67151214	N	.	N	N	-0.240770687	32.9976269	0.022824654	51	.	.
B3GNTL1	17	82942155	83051810	N	.	N	N	0.751852095	88.12872605	2.14E-11	93.9	.	.
B4GALNT1	12	57623410	57633355	N	.	N	Y	-0.543611442	18.44070151	0.056073773	46.4	DM	Spastic paraplegia 26, autosomal recessive, 609195 (3)
B4GALNT2	17	49132460	49176840	N	.	N	Y	0.090621427	56.49707704	9.64E-07	82.6	.	.
B4GALNT3	12	460364	563509	N	.	N	Y	0.809638013	89.32106268	1.06E-07	86.1	.	.
B4GALNT4	11	369796	382116	N	.	N	N	0.080399727	55.73884355	0.816930491	21.1	.	.
B4GALT2	1	43978943	43991170	N	.	N	Y	-0.334481932	27.51635122	0.295417381	35.8	.	.
B4GALT3	1	161171310	161177968	N	.	N	N	-0.403923475	24.17665104	0.020822874	51.4	.	.
B4GALT4	3	119211732	119241103	N	.	N	N	-0.134771456	39.75805985	2.33E-06	81	.	.
B4GALT6	18	31622247	31685836	N	.	N	N	-0.255776741	32.13520866	0.995466888	8.2	.	.
B4GALT7	5	177600100	177610347	N	.	N	N	-0.477997281	21.09741275	0.003197496	60	DM	Ehlers-Danlos syndrome, progeroid type, 1, 130070 (3)
BAALC	8	103140710	103230305	N	.	N	N	0.57802637	83.37095561	5.02E-05	73.9	FP	.
BAAT	9	101360417	101383519	N	.	N	N	-0.059589522	45.15830295	7.96E-06	78.6	DM	Hypercholanemia, familial, 607748 (3)
BABAM1	19	17267350	17281249	N	.	N	N	0.052803966	53.57411588	0.729375765	23.8	DP	.
BACE2	21	41167801	41282518	N	.	N	Y	-0.841981514	10.74839382	0.952644809	14.5	.	.
BACH2	6	89926529	90296908	N	.	N	Y	-0.351099457	26.71181339	0.874039851	18.9	.	.
BAD	11	64269830	64284704	N	.	N	Y	0.253474025	67.62169358	0.000414579	67.6	.	.
BAG2	6	57172326	57189833	N	.	N	N	-0.186488904	36.36626729	0.088336138	43.9	.	.
BAG4	8	38176533	38213301	N	.	N	Y	0.362492381	74.04063205	0.023740903	50.7	.	.
BAG5	14	103556544	103562831	N	.	N	N	-0.462034049	21.80355386	0.043218188	47.8	.	.
BAGE5	22	11066501	11068089	N	.	N	N	.	.	.	.	.	.
BAHD1	15	40439721	40468242	N	.	N	Y	0.363753561	74.08114835	0.991930032	9.5	.	.
BAIAP2L1	7	98291651	98401068	N	.	N	N	0.119676499	58.71968513	0.042773726	47.9	.	.
BAIAP2L2	22	38084889	38110670	N	Viable	N	Y	0.335350119	72.61677375	0.000100358	71.9	.	.
BAIAP3	16	1333601	1349441	N	.	N	Y	-0.366482921	26.05197662	2.21E-19	98.5	.	.
BAK1	6	33572547	33580293	N	.	N	Y	0.240380673	66.89818834	0.003486548	59.7	.	.
BAMBI	10	28677342	28682939	N	Viable	N	Y	-0.150734446	38.66411993	0.002176656	61.6	.	.
BANF1	11	66002079	66004149	N	.	N	N	0.000131289	49.44145396	0.739287243	23.5	DM	Nestor-Guillermo progeria syndrome, 614008 (3)
BANF2	20	17693672	17735871	N	.	N	N	0.145560638	60.65289113	0.048123609	47.2	.	.
BANK1	4	101411286	102074812	N	.	N	Y	0.551331208	82.49696128	1.76E-10	92.6	DFP	.
BANP	16	87949244	88118422	N	.	N	N	-0.518231377	19.52306535	0.958647668	14.1	.	.
BARHL1	9	132582185	132590266	N	.	N	Y	-0.400249026	24.39659663	0.038438589	48.5	.	.
BATF	14	75522425	75547015	N	.	N	Y	-0.133967403	39.81015223	0.74490492	23.3	.	.
BATF2	11	64987943	64997045	N	.	N	Y	0.652248451	85.69774845	0.029531877	49.7	.	.
BATF3	1	212686418	212699985	N	.	N	Y	0.129597795	59.37952191	0.030761382	49.5	.	.
BAX	19	48954815	48961798	N	.	N	Y	-0.249230788	32.49406726	0.167938541	39.8	DFP	Colorectal cancer, somatic, 114500 (3); T-cell acute lymphoblastic leukemia, somatic, 613065 (3)
BAZ1A	14	34752731	34875647	N	Viable	N	Y	-1.899823947	1.857961452	0.999999774	1.3	.	.
BAZ2A	12	56595596	56636816	N	.	N	N	-1.700646911	2.442553684	0.999999726	1.3	.	.
BAZ2B	2	159318979	159616692	N	.	N	N	-1.315754322	4.607281357	0.99992144	3.6	.	.
BBC3	19	47220822	47232766	N	.	N	Y	.	.	0.071243538	45	.	.
BBS12	4	122732702	122744943	N	.	N	Y	0.350507982	73.38658332	3.93E-07	84.1	DM	Bardet-Biedl syndrome 12, 615989 (3)
BBS2	16	56466836	56520283	N	.	N	Y	-0.050978291	45.70816693	1.85E-10	92.5	DM	Bardet-Biedl syndrome 2, 615981 (3); Retinitis pigmentosa 74, 616562 (3)
BBS5	2	169479178	169506655	N	Viable	N	Y	-0.097256408	42.28164612	0.002599365	61	DM	Bardet-Biedl syndrome 5, 615983 (3)
BBS9	7	33129244	33606068	N	.	N	N	-0.231857415	33.61115934	6.38E-10	91.5	DM	Bardet-Biedl syndrome 9, 615986 (3)
BBX	3	107522936	107811324	N	.	N	Y	-0.233770467	33.44909417	0.958097849	14.1	.	.
BCAM	19	44809059	44821420	N	.	N	Y	1.43978974	96.65451178	0.036851184	48.7	FP	[Blood group, Lutheran system], 111200 (3); [Blood group, Auberger system], 111200 (3); [Blood group, Lutheran null], 247420 (3)
BCAN	1	156641390	156659532	N	.	N	Y	-0.871555489	10.14643746	0.003612125	59.5	.	.
BCAP29	7	107579977	107629170	N	.	N	N	0.117611782	58.55761996	0.220058296	38	.	.
BCAP31	X	153700497	153724697	N	.	N	N	0.23846774	66.7534873	0.869367471	19.1	DM	Deafness, dystonia, and cerebral hypomyelination, 300475 (3)
BCAR3	1	93561786	93847150	N	.	N	Y	0.876046181	90.68704057	0.916779855	16.9	.	.
BCAS1	20	53936777	54070594	N	.	N	N	0.925539471	91.61312728	0.013656996	53.6	.	.
BCAS2	1	114567557	114581639	N	.	N	N	-0.410624002	23.91618915	6.53E-05	73.1	.	.
BCAS3	17	60677453	61392838	N	.	N	N	-1.061201249	7.044046999	0.998848202	6.1	.	.
BCAS4	20	50794894	50882676	N	.	N	N	0.437375642	77.75655496	0.046639324	47.4	.	.
BCAT1	12	24810022	24949459	N	.	N	Y	-0.099974947	42.10800486	7.05E-06	78.9	.	?Hyperleucinemia-isoleucinemia or hypervalinemia (1)
BCCIP	10	125823546	125853695	N	.	N	N	0.142034241	60.34033686	0.001654858	62.7	.	.
BCDIN3D	12	49836039	49843129	N	.	N	N	-0.201341563	35.40545234	0.005039148	58.1	.	.
BCHE	3	165772904	165837472	N	.	N	Y	0.666596561	86.12027551	4.44E-11	93.4	DM	Apnea, postanesthetic (3)
BCKDHA	19	41397460	41431345	N	.	N	N	-0.444157039	22.51548301	7.66E-08	86.4	DM	Maple syrup urine disease, type Ia, 248600 (3)
BCKDHB	6	80106647	80346270	N	.	N	N	-0.466819625	21.58360827	2.91E-06	80.6	DM	Maple syrup urine disease, type Ib, 248600 (3)
BCL2A1	15	79960889	79971446	N	.	N	Y	0.079946001	55.69832726	0.481233411	30.5	DP	.
BCL2L10	15	52109263	52112775	N	.	N	Y	0.321958851	71.87011634	0.000387595	67.9	.	.
BCL2L12	19	49665142	49673916	N	.	N	Y	0.731106858	87.60780228	1.56E-05	76.9	.	.
BCL2L13	22	17628855	17730855	N	.	N	N	0.35035623	73.38079528	0.070274402	45.1	.	.
BCL2L14	12	12049844	12211084	N	.	N	N	0.473126302	79.46402732	0.143123586	40.9	.	.
BCL2L15	1	113878168	113887547	N	.	N	N	0.109958322	57.97881577	0.003614688	59.5	.	.
BCL2L2	14	23298790	23311759	N	.	N	Y	-0.078575026	43.76338485	0.312495748	35.4	DP	.
BCL2L2-PABPN1	14	23306835	23325369	N	.	N	N	-0.256733821	32.08311628	0.42596845	32.1	.	.
BCL3	19	44747705	44760044	N	.	N	Y	0.297684879	70.38258957	0.862172685	19.4	.	Leukemia/lymphoma, B-cell, 3 (2)
BCL6B	17	7023020	7030290	N	.	N	Y	-0.746198832	12.73948023	0.151089912	40.5	.	.
BCL7A	12	122019422	122062044	N	.	N	N	-0.228635876	33.80216473	0.215729268	38.2	.	B-cell non-Hodgkin lymphoma, high-grade (3)
BCL7B	7	73536356	73558002	N	.	N	N	-0.306538083	29.06754645	0.706637384	24.5	.	.
BCL7C	16	30833626	30894960	N	.	N	N	0.043387416	52.82745847	0.150443663	40.6	.	.
BCL9	1	147541412	147626216	N	.	N	N	-0.62066116	16.17178908	0.831846217	20.6	DM	.
BCL9L	11	118893875	118925608	N	.	N	N	-1.644303192	2.714591654	0.998124599	6.8	DM	.
BCO1	16	81238448	81291142	N	.	N	Y	.	.	.	.	.	Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 (3)
BCO2	11	112175467	112224699	N	.	N	Y	1.546607822	97.22752793	1.83E-13	95.9	.	.
BCORL1	X	129981107	130058083	N	.	N	N	-0.394869643	24.65705852	0.981790312	11.5	DM?	.
BCR	22	23179704	23318037	N	.	N	Y	-1.399587635	3.91850437	0.999967225	3.1	DP	Leukemia, chronic myeloid, somatic, 608232 (3); Leukemia, acute lymphocytic, somatic, 613065 (3)
BCS1L	2	218658764	218663443	N	.	N	Y	0.278045399	69.20761706	2.28E-08	88	DM	Mitochondrial complex III deficiency, nuclear type 1, 124000 (3); Leigh syndrome, 256000 (3); Bjornstad syndrome, 262000 (3); GRACILE syndrome, 603358 (3)
BDH1	3	197509783	197573323	N	.	N	N	0.052955103	53.58569196	0.000383113	67.9	.	.
BDH2	4	103079435	103099883	N	.	N	N	0.60627228	84.34334665	4.05E-06	79.9	.	.
BDKRB1	14	96255824	96268967	N	.	N	Y	1.136448576	94.40296348	0.070104692	45.1	.	.
BDP1	5	71455615	71567820	N	.	N	N	1.334592926	96.01203913	4.37E-11	93.5	.	.
BEAN1	16	66427297	66493529	N	.	N	Y	.	.	.	.	DM	.
BEGAIN	14	100537149	100587413	N	.	N	N	-0.240617998	33.02077907	0.890710075	18.2	.	.
BEND2	X	18162931	18220883	N	.	N	N	0.35226973	73.53707241	0.34821659	34.2	DM?	.
BEND3	6	107065182	107115269	N	.	N	N	-1.814524443	2.170515715	0.498328913	30	.	.
BEND4	4	42110938	42152878	N	.	N	N	0.153213524	61.2432714	0.986764686	10.7	.	.
BEND5	1	48727523	48776969	N	.	N	N	-0.545680331	18.36545697	0.114990689	42.4	.	.
BEND6	6	56955126	57027342	N	.	N	N	0.211324798	65.16756381	0.135146273	41.3	.	.
BEND7	10	13438484	13528974	N	.	N	N	0.335350119	72.61677375	0.011190322	54.5	.	.
BEST1	11	61949821	61965515	N	.	N	Y	0.285699223	69.69381258	4.89E-08	87	DM	Macular dystrophy, vitelliform, 2, 153700 (3); Bestrophinopathy, autosomal recessive, 611809 (3); Vitreoretinochoroidopathy, 193220 (3); Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 (3); Retinitis pigmentosa-50, 613194 (3); Retinitis pigmentosa, concentric, 613194 (3)
BEST2	19	12751702	12758458	N	.	N	Y	-0.539936486	18.57961452	9.02E-11	93	.	.
BEST3	12	69643360	69699476	N	.	N	N	0.079442861	55.64623488	3.69E-17	97.9	.	.
BEST4	1	44783585	44787705	N	.	N	N	-0.175157533	37.05504428	0.003095114	60.2	.	.
BET1	7	93962762	94004382	N	.	N	N	0.099585278	57.16270186	0.0020112	61.9	.	.
BET1L	11	167784	207428	N	.	N	N	-0.055108985	45.45349308	0.378367597	33.4	.	.
BEX1	X	103062651	103064240	N	.	N	Y	0.13805751	60.04514673	0.572647843	28.2	.	.
BEX2	X	103309346	103311046	N	.	N	N	0.524546884	81.42038548	0.592514905	27.7	.	.
BEX4	X	103215092	103217246	N	.	N	N	0.092082157	56.56653354	0.673985987	25.4	FTV	.
BEX5	X	102153708	102156057	N	.	N	N	0.053609874	53.60305609	0.016338883	52.7	.	.
BFAR	16	14632815	14669236	N	.	N	N	-0.181550908	36.64988135	0.002309748	61.4	.	.
BFSP1	20	17493905	17569220	N	.	N	Y	0.027727205	51.63512184	0.000105944	71.7	DM	Cataract 33, 611391 (3)
BFSP2	3	133399995	133475222	N	.	N	Y	0.447896377	78.26590265	6.66E-05	73.1	DM	Cataract 12, multiple types, 611597 (3)
BGLAP	1	156241962	156243321	N	.	N	Y	0.495489526	80.30908144	1.76E-05	76.6	DM?	.
BGN	X	153494939	153509554	N	.	N	Y	-0.293291902	29.80841581	0.916364713	16.9	FP	.
BHLHA15	7	98211427	98212979	N	.	N	Y	.	.	0.142841396	40.9	.	.
BHLHA9	17	1270559	1271460	N	.	N	Y	.	.	.	.	DM	Syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 (3)
BHLHB9	X	102720688	102753540	N	.	N	N	0.428107326	77.30508769	0.37049796	33.6	.	.
BHLHE22	8	64580367	64583628	N	.	N	Y	.	.	0.677980337	25.2	.	.
BHLHE23	20	63005927	63007035	N	.	N	Y	.	.	0.060122917	46	.	.
BHLHE40	3	4979116	4985323	N	.	N	Y	-0.282917726	30.50876888	0.941607018	15.5	.	.
BHLHE41	12	26120026	26125127	N	.	N	Y	.	.	.	.	DM	[Short sleeper], 612975 (3)
BHMG1	19	45733251	45764534	N	.	N	N	.	.	.	.	.	.
BHMT	5	79111779	79132290	N	Viable	N	Y	-0.076509147	43.9370261	0.000316952	68.5	DP	.
BHMT2	5	79069717	79089466	N	.	N	N	0.300554575	70.56201887	2.74E-12	94.9	.	.
BICD1	12	32106835	32383633	N	.	N	N	-1.388655886	3.993748915	0.144785241	40.8	DFP	.
BICD2	9	92711363	92764812	N	.	N	N	-1.029274527	7.495514268	0.332593897	34.8	DM	Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 (3)
BID	22	17734138	17774770	N	.	N	Y	0.723603463	87.49782948	2.68E-07	84.7	.	.
BIK	22	43110748	43129712	N	.	N	Y	0.307908866	70.93824159	2.54E-05	75.6	.	.
BIN2	12	51281038	51324668	N	.	N	N	-0.133662442	39.85066852	0.000209938	69.7	.	.
BIN3	8	22620418	22669148	N	.	N	Y	0.58104049	83.5214447	5.99E-06	79.2	.	.
BIRC2	11	102347211	102378670	N	.	N	Y	-0.555747173	18.05869074	0.404455648	32.6	.	.
BIRC3	11	102317450	102339403	N	.	N	Y	-0.09614756	42.3337385	0.886667093	18.3	.	.
BIRC7	20	63235883	63240507	N	.	N	N	0.922519097	91.57839903	0.003802906	59.3	.	.
BIRC8	19	53289601	53291626	N	.	N	N	0.978724315	92.4581814	6.54E-07	83.2	.	.
BIVM	13	102799049	102841535	N	.	N	N	-0.508966819	19.83561961	6.43E-06	79.1	.	.
BIVM-ERCC5	13	102807354	102872398	N	.	N	N	.	.	.	.	.	.
BLACE	7	155356985	155367934	N	.	N	N	.	.	.	.	.	.
BLCAP	20	37492472	37527931	N	.	N	N	-0.067396649	44.56792267	0.468529446	30.9	.	.
BLID	11	122115354	122116215	N	.	N	N	0.631506073	85.09579209	0.590165692	27.7	.	.
BLK	8	11494001	11564604	N	Viable	N	Y	-0.047151187	46.04387336	2.86E-07	84.6	DM	Maturity-onset diabetes of the young, type 11, 613375 (3)
BLNK	10	96191702	96271587	N	.	N	Y	0.31747395	71.6154425	0.990011102	9.9	DM	Agammaglobulinemia 4, 613502 (3)
BLOC1S1	12	55716037	55720087	N	.	N	Y	0.087449076	56.25976732	0.205801576	38.6	.	.
BLOC1S3	19	45178745	45181801	N	.	N	N	.	.	0.01842977	52.1	DM	Hermansky-Pudlak syndrome 8, 614077 (3)
BLOC1S4	4	6716055	6717671	N	.	N	N	.	.	0.15897212	40.2	.	.
BLOC1S5	6	8013567	8064414	N	.	N	N	0.86984981	90.57706778	1.60E-05	76.8	.	.
BLOC1S5-TXNDC5	6	7881250	8064364	N	.	N	N	.	.	.	.	.	.
BLOC1S6	15	45587123	45615999	N	.	N	N	0.327549473	72.20003473	9.82E-06	78.1	DM	Hermansky-pudlak syndrome 9, 614171 (3)
BLVRA	7	43758680	43807342	N	.	N	N	0.593178019	83.91503154	0.08322203	44.2	DM	Hyperbiliverdinemia, 614156 (3)
BLVRB	19	40447789	40465840	N	Viable	N	Y	0.849250529	90.19505701	4.13E-05	74.4	.	.
BLZF1	1	169367970	169396540	N	.	N	Y	0.1035625	57.4868322	7.05E-06	78.9	.	.
BMF	15	40087890	40108892	N	.	N	Y	0.231921074	66.33674828	0.354021066	34.1	.	.
BMP15	X	50910784	50916607	N	.	N	Y	0.607228418	84.37228686	0.053543924	46.6	DM	Ovarian dysgenesis 2, 300510 (3); Premature ovarian failure 4, 300510 (3)
BMP2K	4	78776342	78916372	N	.	N	N	0.092839903	56.58968571	0.001916525	62	DP	.
BMP3	4	81030965	81057531	N	.	N	Y	0.230307728	66.27307982	0.110241118	42.6	DM?	.
BMP6	6	7726797	7881422	N	.	N	Y	0.407661641	76.23429994	0.895081718	17.9	.	.
BMP8A	1	39491646	39525935	N	.	N	Y	.	.	0.456963119	31.2	.	.
BMPR1B	4	94757968	95158448	N	.	N	Y	-0.098061234	42.21218962	0.991704371	9.5	DM	Brachydactyly, type A2, 112600 (3); Chrondrodysplasia, acromesomelic, with genital anomalies, 609441 (3)
BMX	X	15464246	15556529	N	Viable	N	Y	-0.077465999	43.85599352	0.583862245	27.8	.	.
BNC1	15	83255903	83284716	N	.	N	Y	-1.278818335	4.850379117	0.886168665	18.4	.	.
BNIP1	5	173144442	173164387	N	.	N	N	0.016245619	50.75533947	0.001436928	63.2	.	.
BNIP2	15	59659146	59689534	N	Viable	N	Y	-0.292334822	29.87208427	1.69E-05	76.7	.	.
BNIP3	10	131966455	131982013	N	.	N	Y	0.04243066	52.74063784	0.048726846	47.2	.	.
BNIP3L	8	26382898	26505636	N	.	N	Y	-0.298077744	29.55953001	0.330817931	34.8	.	.
BNIPL	1	151036570	151047600	N	.	N	N	0.663576603	86.05081901	1.03E-09	91.1	.	.
BOC	3	113211003	113287459	N	Viable	N	Y	0.040470343	52.57857267	0.004727486	58.4	.	.
BOD1	5	173607514	173616660	N	.	N	N	0.078032613	55.54205012	0.031829615	49.4	.	.
BOD1L1	4	13568738	13627723	N	.	N	N	0.526689032	81.49563003	0.999528154	5.1	.	.
BOD1L2	18	57147062	57150300	N	.	N	N	0.624002642	84.88163454	0.510146461	29.7	.	.
BOK	2	241558721	241574138	N	Viable	N	Y	0.133424212	59.69786421	0.318891848	35.2	.	.
BOLA1	1	149887890	149900798	N	.	N	N	0.421412982	76.87677259	0.634184001	26.5	.	.
BOLA2	16	29453593	29454964	N	Viable	N	Y	.	.	.	.	.	.
BOLA2B	16	30192934	30194306	N	.	N	N	.	.	.	.	.	.
BOLA3	2	74135398	74147994	N	.	N	N	0.31158679	71.14082306	0.418296316	32.3	DM	Multiple mitochondrial dysfunctions syndrome 2, 614299 (3)
BOLL	2	197726879	197786762	N	.	N	Y	0.180355903	63.21120565	0.007902184	56	.	.
BOP1	8	144262102	144291370	N	.	N	N	.	.	0.526839489	29.2	.	.
BORA	13	72727749	72756198	N	.	N	N	0.122395494	58.93963072	0.000692705	66	.	.
BPGM	7	134646808	134679813	N	.	N	N	-0.031643	47.17832957	0.126322244	41.7	DM	Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 (3)
BPHL	6	3118374	3153578	N	.	N	Y	0.510642281	80.89946171	0.000194971	69.9	.	.
BPI	20	38260149	38337505	N	.	N	N	1.464059313	96.79342478	8.86E-09	89.1	DP	.
BPIFA1	20	33235995	33243311	N	.	N	Y	-0.2707828	31.23227412	3.60E-05	74.7	DFP	.
BPIFA2	20	33161768	33181412	N	.	N	N	0.577215218	83.32465127	0.002664863	60.8	.	.
BPIFA3	20	33217310	33227758	N	.	N	N	0.928110403	91.68837182	0.00040926	67.7	DM?	.
BPIFB1	20	33273480	33309878	N	Viable	N	Y	1.111216243	94.07304509	5.77E-07	83.5	.	.
BPIFB2	20	33007600	33023709	N	.	N	N	0.239724325	66.86346009	7.69E-08	86.4	.	.
BPIFB3	20	33055424	33073628	N	Viable	N	Y	1.028675391	93.14695838	1.27E-05	77.4	.	.
BPIFB4	20	33079644	33111751	N	.	N	N	0.105779404	57.64889738	3.47E-17	97.9	.	.
BPIFB6	20	33031648	33044047	N	.	N	N	0.467686361	79.23250564	1.20E-11	94.2	.	.
BPIFC	22	32413847	32464484	N	.	N	N	0.891697353	90.98801875	3.13E-06	80.5	.	.
BPNT1	1	220057482	220090462	N	.	N	Y	0.083772833	56.01666956	0.000218975	69.6	.	.
BPY2	Y	22973819	23005465	N	.	N	N	.	.	.	.	.	.
BPY2B	Y	24607560	24639207	N	.	N	N	.	.	.	.	.	.
BPY2C	Y	25030901	25062548	N	.	N	N	.	.	.	.	.	.
BRAT1	7	2537877	2555727	N	.	N	N	0.865830993	90.46130694	3.86E-09	89.8	DM	Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3)
BRCC3	X	155071420	155123074	N	.	N	N	0.273114451	68.84297042	0.033967074	49.1	DM	.
BRD3	9	134030305	134068535	N	.	N	N	-1.030375296	7.4723621	0.766979379	22.7	.	.
BRD9	5	850291	892824	N	.	N	N	-0.837196214	10.83521445	0.249187874	37.1	.	.
BRDT	1	91949371	92014426	N	.	N	Y	0.305643473	70.8282688	2.47E-06	80.9	.	.
BRE	2	27889941	28338901	N	.	N	Y	-0.549354042	18.22075592	0.279976283	36.2	.	.
BRF1	14	105209286	105315589	N	.	N	N	-1.225333658	5.353938763	0.634632788	26.5	.	Cerebellofaciodental syndrome, 616202 (3)
BRF2	8	37843268	37849904	N	.	N	N	-0.087687764	42.98199919	1.88E-09	90.6	.	.
BRI3	7	98252379	98310441	N	.	N	N	0.032057299	51.99976848	0.015258414	53.1	.	.
BRI3BP	12	124993700	125031231	N	.	N	N	0.013375229	50.50645367	0.125132505	41.8	.	.
BRICD5	16	2209253	2211950	N	.	N	N	0.946942523	91.94304567	1.62E-10	92.6	.	.
BRINP1	9	119153458	119369467	N	.	N	N	-0.751640611	12.56005093	0.995424258	8.2	.	.
BRINP2	1	177171497	177282422	N	.	N	N	0.263342657	68.24101406	0.999086308	5.8	.	.
BRINP3	1	190097662	190478404	N	.	N	N	-0.722583176	13.34722463	0.003759093	59.3	.	.
BRIP1	17	61681266	61863521	N	.	N	N	-1.34622475	4.341031429	5.38E-13	95.5	DM	Breast cancer, early-onset, 114480 (3); Fanconi anemia, complementation group J, 609054 (3)
BRIX1	5	34915376	34925996	N	.	N	N	0.241337169	66.9618568	0.981126894	11.6	.	.
BRMS1L	14	35826318	35932325	N	.	N	N	0.035884366	52.28917057	0.368282761	33.7	.	.
BROX	1	222712553	222735196	N	.	N	N	-0.684411658	14.4064363	2.48E-05	75.7	.	.
BRPF1	3	9731729	9748018	N	.	N	Y	-2.128819974	1.406494183	0.999626031	4.9	.	.
BRS3	X	136487887	136493780	N	.	N	Y	0.181312488	63.27487411	0.888203115	18.3	.	.
BRSK1	19	55282072	55312533	N	.	N	Y	-1.302579215	4.699890027	0.993996393	8.8	.	.
BRSK2	11	1389899	1462689	N	.	N	Y	-1.397115963	3.941656538	0.779570081	22.3	DM?	.
BRWD1	21	39184176	39321559	N	.	N	N	-1.738951772	2.326792846	0.999999462	1.5	DM?	.
BRWD3	X	80670854	80809688	N	.	N	Y	-1.564127144	2.975053539	0.999999996	0.7	DM	Mental retardation, X-linked 93, 300659 (3)
BSDC1	1	32365103	32394731	N	.	N	N	-0.266954701	31.4637958	0.482345221	30.5	.	.
BSN	3	49554489	49671545	N	.	N	Y	-3.238120662	0.491983562	0.999999992	0.8	.	.
BSPH1	19	47968046	47992170	N	.	N	N	.	.	.	.	.	.
BSPRY	9	113349541	113371233	N	.	N	Y	0.233983822	66.4640852	9.79E-05	72	.	.
BST1	4	15702950	15738313	N	.	N	Y	0.479673105	79.74185333	2.81E-08	87.7	DP	.
BST2	19	17402939	17405648	N	.	N	Y	0.087449076	56.25976732	0.000608699	66.4	.	.
BSX	11	122977570	122981720	N	.	N	Y	0.346381025	73.21294206	0.136321314	41.3	.	.
BTAF1	10	91923769	92030325	N	.	N	N	-2.485355169	0.978179082	1	0.4	DM	.
BTBD1	15	83016422	83067354	N	.	N	N	-0.41429797	23.70781964	0.014946424	53.2	.	.
BTBD10	11	13388001	13463297	N	.	N	N	-0.391788739	24.87121607	0.477320145	30.6	.	.
BTBD11	12	107318413	107659642	N	.	N	N	-0.945777407	8.792035654	0.993432981	9	.	.
BTBD16	10	122271306	122338162	N	Viable	N	Y	0.545588402	82.25965156	3.41E-12	94.8	.	.
BTBD17	17	74356416	74361946	N	.	N	N	.	.	0.010834936	54.6	.	.
BTBD18	11	57743514	57751781	N	.	N	N	.	.	.	.	.	.
BTBD19	1	44808482	44815585	N	.	N	N	.	.	.	.	.	.
BTBD2	19	1985438	2034881	N	.	N	N	-1.134621455	6.198992881	0.987678942	10.5	.	.
BTBD3	20	11890723	11926609	N	.	N	N	-0.093428832	42.59420038	0.061421577	45.8	.	.
BTBD6	14	105248490	105251093	N	.	N	N	-0.696546643	14.05336575	0.000422096	67.6	.	.
BTBD7	14	93237550	93333092	N	.	N	N	-0.891201395	9.770214736	0.682366257	25.1	.	.
BTBD8	1	92080305	92147836	N	.	N	N	-0.345813209	26.95491115	1.30E-06	82.2	.	.
BTBD9	6	38168451	38640148	N	Viable	N	Y	-1.32126329	4.55518898	0.005732994	57.5	DP	.
BTC	4	74744759	74794686	N	.	N	Y	0.914871845	91.3816056	0.116138687	42.3	DFP	.
BTD	3	15601341	15645822	N	.	N	Y	0.280109924	69.32916594	1.29E-06	82.2	DM	.
BTF3L4	1	52056125	52090716	N	.	N	N	0.091125502	56.52022921	0.451300212	31.3	.	.
BTG1	12	92140278	92145897	N	.	N	N	-0.170525669	37.3618105	0.483157589	30.5	.	.
BTG2	1	203305491	203309602	N	Viable	N	Y	0.04051715	52.61908896	0.048978487	47.1	.	.
BTG3	21	17593653	17612947	N	.	N	Y	-0.132053341	39.94906523	0.696545555	24.7	.	.
BTG4	11	111467526	111512354	N	.	N	N	-0.161108498	37.92903861	0.256389241	36.9	.	.
BTK	X	101349447	101390796	N	.	N	Y	-0.01663693	48.16808474	0.99956322	5	DM	Agammaglobulinemia, X-linked 1, 300755 (3); Agammaglobulinemia and isolated hormone deficiency, 307200 (3)
BTLA	3	112463968	112499561	N	.	N	Y	-0.063568931	44.88047693	0.430977023	31.9	DFP	.
BTN1A1	6	26501221	26510422	N	.	N	Y	1.184341243	94.90652312	1.14E-09	91	DM?	.
BTN2A1	6	26457904	26476621	N	.	N	N	0.95842552	92.1687793	1.07E-18	98.4	DFP	.
BTN2A2	6	26383096	26394874	N	.	N	N	1.239738972	95.37535452	0.000150288	70.6	.	.
BTN3A1	6	26402237	26415216	N	.	N	N	0.608332922	84.41280315	8.65E-07	82.8	.	.
BTN3A2	6	26365159	26378320	N	.	N	N	0.376541981	74.76413729	0.000124519	71.2	.	.
BTN3A3	6	26440472	26453415	N	.	N	N	1.064433402	93.55212132	7.19E-10	91.4	.	.
BTNL2	6	32393963	32407128	N	.	N	N	.	.	2.03E-07	85.1	DFP	{Sarcoidosis, susceptibility to, 2}, 612387 (3)
BTNL3	5	180988845	181006727	N	.	N	N	0.915971805	91.40475777	0.039637148	48.4	.	.
BTNL8	5	180899077	180950906	N	.	N	N	1.607601722	97.52850611	0.000235088	69.3	FP	.
BTNL9	5	181040225	181061523	N	.	N	N	0.035230174	52.24286624	6.53E-10	91.5	.	.
BTRC	10	101354033	101557321	N	Viable	N	Y	0.082967032	55.94721306	0.863167824	19.4	DM?	.
BUD13	11	116748170	116772988	N	.	N	N	0.060609534	54.16449615	0.002295428	61.5	.	.
BUD31	7	99408641	99419616	N	.	N	N	-0.209955284	34.90768073	0.417010233	32.3	.	.
BVES	6	105096822	105137174	N	Viable	N	Y	-0.102845596	41.94593969	0.000308543	68.5	DM	.
BZRAP1	17	58301228	58328760	N	.	N	N	1.98033341	98.55298952	0.056626408	46.3	.	.
BZW1	2	200810594	200827338	N	.	N	N	-0.396575171	24.57602593	0.744805847	23.3	.	.
BZW2	7	16646131	16706523	N	Viable	N	Y	-0.656313373	15.18203392	0.995822418	8.1	.	.
C10orf10	10	44970981	44978810	N	.	N	N	0.46275405	78.96625572	3.87E-05	74.6	.	.
C10orf105	10	71711701	71737824	N	.	N	N	.	.	.	.	.	.
C10orf107	10	61662961	61766766	N	.	N	N	0.022791848	51.2704752	0.00079093	65.5	.	.
C10orf11	10	75431453	76560167	N	.	N	Y	-0.091667236	42.70417318	0.041056618	48.2	DM	Albinism, oculocutaneous, type VII, 615179 (3)
C10orf113	10	21125763	21146559	N	.	N	N	0.809821032	89.32685073	0.007537782	56.3	.	.
C10orf12	10	96981284	96986212	N	.	N	N	-0.23825608	33.15969208	0.979876887	11.7	.	.
C10orf120	10	122697709	122699822	N	.	N	Y	0.414057549	76.56421832	1.30E-06	82.2	.	.
C10orf128	10	49154725	49188585	N	.	N	N	0.572434794	83.18573826	0.045128478	47.6	.	.
C10orf131	10	95907603	95938723	N	.	N	N	.	.	.	.	.	.
C10orf142	10	44292569	44294649	N	.	N	N	.	.	.	.	.	.
C10orf32	10	102854223	102864961	N	.	N	N	-0.021421177	47.83816635	0.031637861	49.4	.	.
C10orf32-ASMT	10	102854272	102901899	N	.	N	N	.	.	.	.	.	.
C10orf35	10	69630251	69633599	N	.	N	N	0.207498734	64.86658563	0.068371581	45.2	.	.
C10orf53	10	49679651	49710261	N	.	N	N	0.443922687	78.05174509	0.00106877	64.5	.	.
C10orf54	10	71747559	71773498	N	.	N	N	0.58199694	83.58511316	0.385978708	33.1	.	.
C10orf55	10	73909969	73922777	N	.	N	N	.	.	0.005065636	58	.	.
C10orf62	10	97589727	97590934	N	.	N	N	0.766711782	88.47600857	9.87E-05	71.9	.	.
C10orf67	10	23267195	23344845	N	.	N	N	.	.	1.97E-06	81.3	.	.
C10orf71	10	49299193	49327487	N	.	N	N	1.773824872	98.12467442	9.35E-05	72.1	.	.
C10orf82	10	116663696	116670264	N	.	N	N	0.513364317	81.01522255	0.003878381	59.2	.	.
C10orf88	10	122930903	122954403	N	.	N	N	0.460989431	78.87943509	0.038585003	48.5	.	.
C10orf90	10	126424997	126670446	N	.	N	N	0.81873272	89.4889159	6.06E-11	93.2	.	.
C10orf99	10	84173738	84185294	N	.	N	N	0.184032836	63.46009145	0.08244671	44.3	.	.
C11orf1	11	111878935	111885975	N	.	N	N	0.306952505	70.86878509	7.81E-07	83	.	.
C11orf16	11	8920076	8933006	N	.	N	N	0.382281971	75.03617526	4.79E-06	79.6	.	.
C11orf21	11	2295645	2303049	N	.	N	N	.	.	.	.	.	.
C11orf24	11	68261335	68272001	N	.	N	N	0.096210753	56.84435955	0.030766321	49.5	.	.
C11orf30	11	76444923	76553025	N	.	N	N	-1.793790937	2.211032008	0.999997097	2	.	.
C11orf31	11	57741250	57743554	N	.	N	N	0.055523327	53.73618105	0.000781712	65.6	.	.
C11orf40	11	4571423	4577820	N	.	N	N	0.532195638	81.73293975	4.85E-08	87	DM	.
C11orf42	11	6205566	6211132	N	.	N	N	0.233983822	66.4640852	3.05E-06	80.5	.	.
C11orf45	11	128899565	128906035	N	.	N	N	0.307908866	70.93824159	0.013711288	53.6	.	.
C11orf49	11	46936689	47164385	N	.	N	N	0.077377607	55.48416971	5.45E-07	83.6	.	.
C11orf52	11	111918032	111926872	N	.	N	N	0.351015356	73.42131157	0.023724378	50.7	.	.
C11orf53	11	111255982	111286401	N	.	N	N	0.381175578	74.97829484	7.53E-05	72.8	.	.
C11orf54	11	93741591	93764749	N	.	N	N	0.075313076	55.32210453	0.007358555	56.4	.	.
C11orf57	11	112074086	112085150	N	.	N	N	-0.31116943	28.88232911	0.913210186	17.1	.	.
C11orf58	11	16613132	16756881	N	.	N	N	-0.11145818	41.38449962	0.709037216	24.4	.	.
C11orf63	11	122882528	122959798	N	.	N	N	0.076724269	55.4147132	1.16E-11	94.2	.	.
C11orf65	11	108308519	108467531	N	.	N	N	0.418691306	76.76679979	8.78E-17	97.7	DP	.
C11orf68	11	65916808	65919117	N	.	N	N	-0.23518181	33.35069746	0.409498865	32.5	.	.
C11orf70	11	102047443	102084560	N	.	N	N	-0.455642657	22.04665162	8.93E-06	78.3	.	.
C11orf71	11	114391443	114400550	N	.	N	N	0.427960039	77.28193552	0.008424815	55.6	.	.
C11orf74	11	36594493	36659290	N	.	N	N	0.672846598	86.25918852	0.007620751	56.2	.	.
C11orf80	11	66744451	66843328	N	.	N	N	-0.389874437	24.9580367	0.008462596	55.6	.	.
C11orf84	11	63813388	63827718	N	.	N	N	0.908468236	91.25426868	0.471418765	30.8	.	.
C11orf85	11	64937517	64972085	N	.	N	N	-0.061655126	44.98466169	0.007357188	56.4	.	.
C11orf86	11	66975277	66977004	N	.	N	N	.	.	.	.	.	.
C11orf87	11	109422120	109429114	N	.	N	N	-0.008177066	48.7989813	0.245098741	37.2	.	.
C11orf88	11	111514785	111537031	N	.	N	N	0.778851069	88.76541066	0.098613658	43.2	.	.
C11orf91	11	33698261	33700801	N	.	N	N	.	.	.	.	.	.
C11orf94	11	45906513	45907282	N	.	N	N	0.5630196	82.82687967	0.000289638	68.8	.	.
C11orf95	11	63759892	63768775	N	.	N	N	.	.	.	.	.	.
C11orf96	11	43925342	43944338	N	.	N	N	.	.	.	.	.	.
C11orf98	11	62662816	62665217	N	.	N	N	.	.	.	.	.	.
C12orf10	12	53299686	53307177	N	.	N	Y	0.229350964	66.18625919	2.44E-06	80.9	DFP	.
C12orf29	12	88033846	88050160	N	.	N	N	-0.401206279	24.32714013	2.46E-05	75.7	.	.
C12orf4	12	4487728	4538508	N	Viable	N	Y	-0.927391577	9.098801875	9.83E-05	71.9	.	.
C12orf40	12	39626167	39908300	N	.	N	N	0.455550929	78.57845691	1.15E-19	98.6	.	.
C12orf42	12	103237591	103496010	N	.	N	N	0.471362413	79.35984257	2.29E-07	85	.	.
C12orf43	12	121000486	121016502	N	.	N	Y	0.008742604	50.21705157	2.56E-07	84.8	.	.
C12orf45	12	104986310	105049737	N	.	N	N	0.271349605	68.75614979	0.389486545	33	.	.
C12orf49	12	116710185	116738070	N	.	N	N	0.18881556	63.69161313	0.045210317	47.6	.	.
C12orf50	12	87980035	88034037	N	.	N	N	0.461946007	78.93152746	0.000154448	70.6	.	.
C12orf54	12	48482503	48496512	N	.	N	N	0.533962119	81.81976038	0.004167354	58.9	.	.
C12orf56	12	64264762	64391192	N	.	N	N	0.308057642	70.95560572	2.91E-11	93.7	.	.
C12orf57	12	6942978	6946003	N	.	N	N	0.028381319	51.66985009	0.060336064	46	DM	Temtamy syndrome, 218340 (3)
C12orf60	12	14803572	14906586	N	Viable	N	Y	0.780762778	88.79435087	0.006292168	57	.	.
C12orf65	12	123232916	123257959	N	.	N	N	-0.040102903	46.61110146	0.17232859	39.7	DM	Combined oxidative phosphorylation deficiency 7, 613559 (3); Spastic paraplegia 55, autosomal recessive, 615035 (3)
C12orf66	12	64186316	64222296	N	.	N	N	-0.367365256	26.00567228	0.7577885	22.9	DM?	.
C12orf71	12	27081058	27082514	N	.	N	N	0.295771879	70.24367656	0.36033075	33.9	.	.
C12orf73	12	103950202	103965708	N	.	N	N	.	.	.	.	.	.
C12orf74	12	92702843	92708549	N	.	N	N	0.416778578	76.67419112	0.000522237	66.9	DM?	.
C12orf75	12	105235290	105396097	N	.	N	N	.	.	.	.	.	.
C12orf76	12	110027028	110073686	N	.	N	N	0.167113525	62.29669503	0.000101301	71.8	.	.
C12orf79	12	91984976	92142914	N	.	N	N	.	.	.	.	.	.
C14orf1	14	75649791	75661189	N	.	N	N	0.093038818	56.61283788	0.891783234	18.1	.	.
C14orf105	14	57469301	57493867	N	.	N	N	0.829607924	89.778318	0.000136147	71	DM?	.
C14orf119	14	23094765	23100462	N	.	N	N	0.374481231	74.6541645	0.002761662	60.7	.	.
C14orf142	14	93202894	93207094	N	.	N	N	0.426047805	77.14302252	0.190974081	39	.	.
C14orf159	14	91060333	91225632	N	.	N	N	0.630192747	85.0552758	2.07E-14	96.5	.	.
C14orf166	14	51989475	52010691	N	.	N	N	-0.01663693	48.16808474	0.666285716	25.6	.	.
C14orf169	14	73490964	73493392	N	.	N	N	.	.	.	.	.	.
C14orf177	14	98711613	98717761	N	.	N	N	0.406406543	76.17063148	0.006747015	56.8	.	.
C14orf178	14	77760830	77769742	N	.	N	N	0.289077164	69.85587776	0.008523424	55.6	.	.
C14orf180	14	104579684	104590515	N	.	N	N	.	.	0.01343143	53.7	.	.
C14orf2	14	103912288	103928269	N	.	N	N	0.242145304	67.0023731	0.65863463	25.8	.	.
C14orf28	14	44897295	44907257	N	.	N	N	0.130704421	59.46634254	2.08E-10	92.4	.	.
C14orf37	14	57999735	58298139	N	.	N	N	0.690218668	86.67013949	8.27E-05	72.4	.	.
C14orf39	14	60396469	60515543	N	.	N	N	0.264147024	68.34519882	0.00852079	55.6	.	.
C14orf79	14	104985775	105010482	N	.	N	N	0.40846756	76.27481623	5.13E-08	86.9	.	.
C14orf80	14	105489855	105499575	N	.	N	N	.	.	0.001222281	63.9	.	.
C14orf93	14	22985908	23010166	N	.	N	N	0.167413441	62.33142328	0.032127772	49.3	.	.
C15orf26	15	81007033	81149175	N	.	N	N	-0.317715301	28.40770967	0.835174204	20.5	.	.
C15orf27	15	76059837	76229121	N	.	N	N	-0.031339741	47.22463391	1.48E-08	88.5	.	.
C15orf38-AP3S2	15	89834308	89912882	N	.	N	N	0.33630686	72.651502	1.04E-09	91.1	.	.
C15orf39	15	75195643	75212169	N	.	N	N	0.820810314	89.53522023	0.919030415	16.7	.	.
C15orf40	15	82988441	83011641	N	.	N	N	0.674758577	86.28812873	0.268492643	36.5	.	.
C15orf41	15	36579611	36810248	N	.	N	N	0.218827885	65.61903108	0.015552565	53	.	Dyserythropoietic anemia, congenital, type Ib, 615631 (3)
C15orf43	15	44956702	44979229	N	.	N	N	0.172852824	62.72501013	0.000137585	70.9	.	.
C15orf48	15	45430529	45448761	N	.	N	N	0.214045409	65.29490074	0.000404125	67.7	.	.
C15orf52	15	40331452	40340967	N	.	N	N	0.947092883	91.96619784	0.002576941	61	.	.
C15orf53	15	38696598	38700038	N	.	N	N	0.194405525	64.08519998	0.093609809	43.5	.	.
C15orf57	15	40528683	40565057	N	.	N	N	0.132467594	59.58789142	0.611394297	27.2	.	.
C15orf59	15	73735431	73752747	N	.	N	N	0.042581773	52.76957805	0.244691482	37.3	.	.
C15orf61	15	67521068	67530143	N	.	N	N	.	.	.	.	.	.
C15orf62	15	40770080	40772449	N	.	N	N	.	.	.	.	FTV	.
C15orf65	15	55408548	55418764	N	.	N	N	.	.	0.360932048	33.9	.	.
C16orf13	16	634427	636366	N	.	N	N	.	.	0.004537254	58.6	.	.
C16orf45	16	15434295	15625028	N	.	N	N	0.097822207	56.98327256	0.214680178	38.3	.	.
C16orf46	16	81053497	81077267	N	.	N	N	0.934804937	91.79255658	5.35E-06	79.4	.	.
C16orf52	16	22007638	22087534	N	.	N	N	.	.	.	.	.	.
C16orf54	16	29742463	29746006	N	.	N	N	.	.	0.668080508	25.6	.	.
C16orf58	16	31489471	31509309	N	.	N	N	0.105475995	57.64310934	1.18E-10	92.9	.	.
C16orf59	16	2460080	2464963	N	.	N	N	-0.407598535	24.04931412	1.92E-08	88.2	.	.
C16orf62	16	19555240	19706793	N	.	N	N	0.13131254	59.48370666	1.29E-05	77.4	.	.
C16orf70	16	67109958	67148539	N	.	N	N	-0.398334639	24.51814551	0.803545517	21.5	.	.
C16orf71	16	4734272	4749396	N	.	N	N	0.405900506	76.14747931	1.38E-13	96	.	.
C16orf72	16	9091648	9121640	N	.	N	N	0.087449076	56.25976732	0.986081397	10.8	.	.
C16orf74	16	85690084	85751129	N	.	N	N	.	.	0.024048646	50.7	.	.
C16orf78	16	49373823	49399431	N	.	N	N	0.427150878	77.22984314	4.19E-06	79.9	.	.
C16orf86	16	67666816	67668758	N	.	N	N	0.122244706	58.89332639	0.652428951	26	.	.
C16orf87	16	46796607	46831411	N	.	N	N	-0.112415198	41.29189095	0.097478782	43.3	.	.
C16orf90	16	3493484	3495480	N	.	N	N	1.045302804	93.3148116	0.002406448	61.2	.	.
C16orf91	16	1419744	1420800	N	.	N	N	0.215958347	65.40487353	3.85E-07	84.1	.	.
C16orf92	16	30023334	30027736	N	.	N	N	0.260977174	68.09052498	0.01892544	52	.	.
C16orf93	16	30757423	30762710	N	.	N	N	0.305187971	70.79932859	8.00E-05	72.6	.	.
C16orf95	16	87083562	87317420	N	.	N	N	.	.	.	.	.	.
C16orf96	16	4556490	4600714	N	.	N	N	.	.	0.070287805	45	.	.
C17orf100	17	6651914	6652270	N	.	N	N	.	.	0.003778342	59.3	.	.
C17orf104	17	44656404	44690308	N	.	N	N	0.130855251	59.47791862	0.978536145	12	.	.
C17orf105	17	43780435	43787612	N	Viable	N	Y	.	.	.	.	.	.
C17orf107	17	4899418	4902932	N	.	N	N	.	.	.	.	.	.
C17orf47	17	58541587	58544368	N	.	N	N	0.064285248	5.45E+01	1.30E-05	77.3	.	.
C17orf49	17	7014495	7017525	N	.	N	N	-0.22208995	34.19575158	0.007622931	56.2	.	.
C17orf50	17	35760897	35765079	N	.	N	N	.	.	0.007952764	56	.	.
C17orf51	17	21524790	21574458	N	.	N	N	.	.	.	.	.	.
C17orf53	17	44141906	44162476	N	.	N	N	0.743543456	87.94929675	5.99E-08	86.7	DP	.
C17orf58	17	67991101	67993649	N	.	N	N	-0.079531963	43.66498813	0.082156416	44.3	.	.
C17orf59	17	8188333	8190907	N	.	N	N	0.1249645	59.10748394	.	.	.	.
C17orf62	17	82442589	82450829	N	.	N	Y	0.626870269	84.96845517	0.000955064	64.9	.	.
C17orf64	17	60392429	60431421	N	Viable	N	Y	0.102455237	57.40579962	0.013804092	53.6	.	.
C17orf67	17	56791913	56838773	N	.	N	N	.	.	2.48E-05	75.7	.	.
C17orf74	17	7425615	7427568	N	.	N	N	0.676013937	86.32285698	2.15E-06	81.2	.	.
C17orf75	17	32324565	32350023	N	.	N	N	0.138207453	60.05093477	0.980996283	11.6	.	.
C17orf78	17	37375986	37392708	N	.	N	N	0.157846676	61.58476587	0.004075283	59	.	.
C17orf80	17	73232233	73248947	N	.	N	N	0.843958731	90.09087226	2.54E-07	84.8	.	.
C17orf85	17	3802165	3846251	N	.	N	N	0.025662211	51.48463275	0.992974565	9.2	.	.
C17orf89	17	81239239	81241281	N	.	N	N	.	.	0.372022649	33.6	.	.
C17orf96	17	38671703	38675421	N	.	N	N	.	.	.	.	.	.
C17orf97	17	410327	431062	N	.	N	N	1.018301315	92.98489321	2.03E-05	76.2	.	.
C17orf98	17	38835088	38841455	N	.	N	N	0.194405525	64.08519998	0.457750608	31.2	.	.
C17orf99	17	78146353	78166177	N	.	N	N	.	.	.	.	.	.
C18orf21	18	35972083	35979286	N	.	N	N	0.202865163	64.54245529	0.002771518	60.7	.	.
C18orf25	18	46173553	46266991	N	.	N	N	-0.27637172	30.86762748	0.90199634	17.7	.	.
C18orf32	18	49477250	49492565	N	.	N	N	0.244058053	67.12392198	0.182752689	39.2	.	.
C18orf42	18	5145285	5197503	N	.	N	N	.	.	.	.	.	.
C18orf54	18	54357917	54385218	N	.	N	N	0.697415576	86.86114487	6.01E-06	79.2	.	.
C18orf63	18	74315813	74359187	N	.	N	N	.	.	.	.	.	.
C18orf8	18	23503470	23531807	N	.	N	N	0.210669154	65.1386236	0.999882357	3.9	.	.
C19orf12	19	29698886	29715789	N	.	N	N	0.13438084	59.79626092	0.667745724	25.6	DM	Neurodegeneration with brain iron accumulation 4, 614298 (3); ?Spastic paraplegia 43, autosomal recessive, 615043 (3)
C19orf18	19	57958437	57974534	N	.	N	N	0.461797774	78.90258725	6.22E-05	73.3	.	.
C19orf24	19	1275438	1279249	N	.	N	N	.	.	.	.	.	.
C19orf25	19	1461143	1479556	N	.	N	N	.	.	0.034363222	49	.	.
C19orf33	19	38304161	38305009	N	.	N	N	-0.037384251	46.76159055	0.269214272	36.5	.	.
C19orf35	19	2274622	2282176	N	.	N	N	.	.	0.006354567	57	.	.
C19orf38	19	10836575	10869790	N	Viable	N	Y	.	.	.	.	.	.
C19orf43	19	12730640	12734775	N	.	N	N	.	.	0.310238874	35.5	.	.
C19orf44	19	16496311	16521352	N	.	N	N	-0.313584016	28.64501939	4.22E-07	84	.	.
C19orf45	19	7492976	7508450	N	Viable	N	Y	0.751852095	88.12872605	2.71E-15	97	.	.
C19orf47	19	40319536	40348527	N	.	N	N	-0.562445944	17.85610928	0.802242559	21.6	.	.
C19orf48	19	50797704	50804929	N	.	N	N	0.799450376	89.14742143	0.55106013	28.6	DP	.
C19orf52	19	10928733	10933535	N	.	N	N	.	.	0.001989919	61.9	.	.
C19orf53	19	13774168	13778462	N	.	N	N	0.740377707	87.845112	0.236661552	37.5	.	.
C19orf54	19	40740856	40751553	N	.	N	N	0.89331644	91.01695896	0.001265945	63.8	.	.
C19orf57	19	13882348	13906452	N	.	N	N	0.982851246	92.56236615	7.18E-05	72.9	.	.
C19orf60	19	18588685	18592336	N	.	N	N	.	.	0.249879078	37.1	.	.
C19orf66	19	10086122	10093252	N	.	N	N	0.13438084	59.79626092	0.930534705	16.1	.	.
C19orf68	19	48170692	48197620	N	.	N	N	.	.	.	.	.	.
C19orf70	19	5678421	5680896	N	.	N	N	-0.051433536	45.65607455	0.015922184	52.9	.	.
C19orf71	19	3539154	3544030	N	.	N	N	.	.	.	.	.	.
C19orf73	19	49118397	49119140	N	.	N	N	0.422369205	76.96359322	0.484013121	30.4	.	.
C19orf80	19	11237450	11241943	N	.	N	Y	.	.	2.61E-06	80.8	DP	.
C19orf81	19	50649445	50659310	N	.	N	N	.	.	.	.	.	.
C19orf84	19	51388289	51390574	N	.	N	N	.	.	.	.	.	.
C1D	2	68041130	68110948	N	.	N	N	0.169983117	62.51085258	0.365972887	33.8	.	.
C1orf100	1	244352635	244389663	N	.	N	N	0.353884195	73.67019737	3.54E-08	87.4	.	.
C1orf101	1	244454377	244641177	N	.	N	N	0.093491966	56.65914221	5.89E-07	83.5	.	.
C1orf105	1	172420688	172468831	N	.	N	N	0.732874214	87.64253053	0.000319848	68.5	.	.
C1orf106	1	200891048	200915735	N	.	N	N	0.623339387	84.85848238	0.555282613	28.5	.	.
C1orf109	1	37681570	37692249	N	.	N	N	0.26384649	68.31047057	6.27E-08	86.7	.	.
C1orf110	1	162824458	162868815	N	.	N	N	0.525648717	81.46090178	1.06E-05	77.9	.	.
C1orf111	1	162373203	162376870	N	.	N	N	0.412144579	76.45424553	2.10E-05	76.1	.	.
C1orf115	1	220689845	220699157	N	.	N	N	.	.	0.283640867	36.1	.	.
C1orf116	1	207018521	207032756	N	.	N	N	1.085986995	93.8125832	0.371958032	33.6	.	.
C1orf122	1	37806979	37809454	N	.	N	N	.	.	0.1232465	42	.	.
C1orf123	1	53214099	53220617	N	.	N	N	-0.161108498	37.92903861	1.26E-07	85.9	.	.
C1orf127	1	10946471	10982037	N	.	N	Y	1.332815197	95.994675	1.33E-05	77.3	DM?	.
C1orf131	1	231223763	231241187	N	.	N	N	0.299597983	70.48098628	1.77E-07	85.3	.	.
C1orf141	1	67092165	67231853	N	.	N	N	-0.024945118	47.60085663	2.70E-05	75.5	.	.
C1orf145	1	228203506	228213664	N	.	N	N	.	.	0.097680709	43.3	.	.
C1orf146	1	92217940	92245813	N	.	N	N	0.24597088	67.24547086	0.02404793	50.7	.	.
C1orf158	1	12746215	12763699	N	.	N	N	0.598768956	84.07709672	1.57E-08	88.4	.	.
C1orf159	1	1081818	1116361	N	.	N	N	.	.	0.090877636	43.7	.	.
C1orf162	1	111473792	111478512	N	.	N	N	0.366978017	74.20848527	0.006131316	57.1	.	.
C1orf167	1	11761787	11789585	N	.	N	N	.	.	0.155526802	40.3	.	.
C1orf168	1	56718804	56819696	N	.	N	N	0.14329444	60.44452162	2.36E-30	99.7	DM?	.
C1orf174	1	3889125	3900293	N	.	N	Y	0.805185239	89.25160618	0.018742502	52	.	.
C1orf177	1	54806063	54842252	N	.	N	N	0.841893045	90.05035596	2.53E-11	93.7	.	.
C1orf185	1	51102234	51148086	N	.	N	N	.	.	.	.	.	.
C1orf186	1	206037231	206102459	N	.	N	N	0.073399639	55.17740348	0.001895127	62.1	.	.
C1orf189	1	154199372	154206333	N	.	N	N	0.320046263	71.77750767	0.000114765	71.4	.	.
C1orf194	1	109105951	109113857	N	.	N	N	0.837924022	89.95195925	2.50E-07	84.8	.	.
C1orf198	1	230837119	230869589	N	.	N	Y	0.183225703	63.41957516	0.027375276	50.2	.	.
C1orf204	1	159834474	159855347	N	.	N	N	.	.	0.093368149	43.6	.	.
C1orf21	1	184387058	184629020	N	.	N	N	0.099585278	57.16270186	0.819116614	21	.	.
C1orf210	1	43281883	43285617	N	.	N	N	0.268480327	68.6056607	0.001219636	63.9	.	.
C1orf216	1	35713875	35719472	N	.	N	N	0.530283168	81.66927129	0.128378758	41.6	.	.
C1orf226	1	162366908	162386818	N	.	N	N	0.141883914	60.31139665	0.723357169	24	.	.
C1orf228	1	44674692	44725591	N	.	N	N	.	.	.	.	.	.
C1orf233	1	1598012	1600096	N	.	N	N	.	.	.	.	.	.
C1orf234	1	23010834	23015850	N	.	N	N	.	.	.	.	.	.
C1orf27	1	186375758	186421378	N	.	N	N	0.176679292	62.95653181	1.38E-06	82.1	.	.
C1orf35	1	228100726	228105411	N	.	N	N	0.307908866	70.93824159	0.074007037	44.8	.	.
C1orf43	1	154206706	154220628	N	.	N	N	-0.31116943	28.88232911	0.173985957	39.6	.	.
C1orf50	1	42767269	42794493	N	.	N	N	0.200952107	64.44405857	0.007015926	56.6	.	.
C1orf52	1	85249953	85259672	N	.	N	N	0.073399639	55.17740348	0.359076552	33.9	.	.
C1orf53	1	197902647	197907367	N	.	N	N	0.509540192	80.83000521	0.104698727	42.8	.	.
C1orf54	1	150268200	150280916	N	.	N	N	-0.245556279	32.71401285	0.178651547	39.4	FTV	.
C1orf56	1	151047740	151051986	N	.	N	Y	-0.064373744	44.83996064	0.001317284	63.7	.	.
C1orf61	1	156404250	156430701	N	.	N	N	-0.072985841	44.23221624	0.10442249	42.9	.	.
C1orf64	1	16004236	16008807	N	.	N	N	0.621278951	84.78323783	0.010559209	54.7	.	.
C1orf68	1	152719522	152720470	N	.	N	N	.	.	.	.	.	.
C1orf74	1	209779208	209784559	N	.	N	N	-0.161108498	37.92903861	0.489345231	30.3	.	.
C1orf87	1	59987269	60073770	N	.	N	N	1.037136038	93.22799097	1.58E-17	98	.	.
C1orf94	1	34166883	34219131	N	.	N	N	0.430170878	77.43821265	0.00437226	58.7	.	.
C1orf95	1	226548800	226609214	N	.	N	N	-0.09740902	42.25270591	0.092054081	43.6	.	.
C1QA	1	22636506	22639608	N	Viable	N	Y	0.149386991	60.95386931	0.049789979	47	DM	C1q deficiency, 613652 (3)
C1QB	1	22652762	22661538	N	Viable	N	Y	-0.181703531	36.63251722	0.085881049	44	DM	C1q deficiency, 613652 (3)
C1QC	1	22643630	22648110	N	.	N	N	-0.357145068	26.46871563	0.017381903	52.3	DM	C1q deficiency, 613652 (3)
C1QL1	17	44959693	44968071	N	.	N	N	-0.03259986	47.11466111	.	.	.	.
C1QL2	2	119156243	119158889	N	.	N	N	-0.005458152	49.05944319	0.396068457	32.9	.	.
C1QL3	10	16513743	16522005	N	.	N	N	-0.148973548	38.82039706	0.718803252	24.1	.	.
C1QL4	12	49332411	49337188	N	.	N	N	0.079946001	55.69832726	0.621177258	26.9	.	.
C1QTNF1	17	79022814	79049788	N	.	N	N	-0.200384589	35.4691208	7.24E-05	72.8	.	.
C1QTNF2	5	160347751	160370641	N	Viable	N	Y	0.127984973	59.3100654	0.001358535	63.5	.	.
C1QTNF3	5	34019448	34043832	N	.	N	Y	-0.339267298	27.29640563	0.000296344	68.7	.	.
C1QTNF3-AMACR	5	33987174	34124528	N	.	N	N	.	.	.	.	.	.
C1QTNF4	11	47589664	47594659	N	.	N	N	.	.	0.679081391	25.2	.	.
C1QTNF5	11	119338942	119340883	N	Viable	N	Y	-0.103955104	41.8649071	0.830646789	20.6	DM	Retinal degeneration, late-onset, autosomal dominant, 605670 (3)
C1QTNF6	22	37180167	37199385	N	.	N	N	0.505051907	80.64478787	0.023789385	50.7	.	.
C1QTNF7	4	15339818	15446166	N	Viable	N	Y	-0.088796495	42.91254269	0.019910131	51.7	.	.
C1QTNF8	16	1090005	1096244	N	.	N	N	0.448703989	78.31799502	8.98E-11	93	.	.
C1QTNF9	13	24307166	24322535	N	.	N	N	1.018154755	92.97910517	0.169231076	39.8	.	.
C1QTNF9B	13	23891099	23902655	N	.	N	N	1.18338473	94.889159	0.040010474	48.3	.	.
C1R	12	7080209	7092607	N	.	N	N	.	.	.	.	DM	C1r/C1s deficiency, combined, 216950 (1)
C1RL	12	7089587	7109273	N	Viable	N	Y	0.306294697	70.83984488	0.000277417	68.9	.	.
C1S	12	6988259	7071032	N	.	N	N	-0.2423802	32.90501823	0.863410048	19.4	DM	C1s deficiency, 613783 (3)
C2	6	31897785	31945672	N	.	N	N	0.02692196	51.57724142	1.38E-06	82.1	DM	C2 deficiency, 217000 (3); {Macular degeneration, age-related, 14, reduced risk of}, 615489 (3)
C20orf141	20	2814987	2815833	N	.	N	N	0.112828307	58.21033744	0.000122911	71.3	.	.
C20orf173	20	35523186	35529652	N	.	N	N	.	.	.	.	.	.
C20orf194	20	3249305	3407625	N	Viable	N	Y	-0.778645282	12.05070325	0.006004692	57.2	.	.
C20orf195	20	63547891	63556708	N	.	N	N	-0.52956212	19.03686983	0.000298557	68.7	.	.
C20orf196	20	5750393	5863912	N	.	N	N	0.187858986	63.66846096	0.333004444	34.8	.	.
C20orf202	20	1203454	1208274	N	.	N	N	.	.	.	.	.	.
C20orf24	20	36605734	36612557	N	.	N	N	0.063983137	54.4886265	0.856745481	19.6	.	.
C20orf27	20	3753508	3768387	N	.	N	N	0.045300934	53.00688777	0.027098916	50.2	.	.
C20orf62	20	44451984	44465344	N	.	N	N	.	.	.	.	.	.
C20orf85	20	58150904	58161150	N	.	N	N	1.104378711	93.98622446	1.38E-05	77.2	.	.
C20orf96	20	270863	290778	N	.	N	N	0.47695229	79.62609249	7.45E-13	95.4	.	.
C21orf140	21	34400317	34401072	N	.	N	N	.	.	.	.	.	.
C21orf2	21	44328944	44339402	N	.	N	N	1.412189772	96.44614227	0.013530383	53.6	DM?	.
C21orf33	21	44133605	44145723	N	.	N	N	0.330566867	72.36788794	0.001172128	64.1	.	.
C21orf58	21	46300181	46323875	N	.	N	N	0.167262974	62.32563524	3.74E-09	89.9	.	.
C21orf59	21	32592079	32612866	N	.	N	N	0.252666418	67.59275337	0.000141358	70.8	.	.
C21orf62	21	32790674	32813743	N	.	N	Y	0.218827885	65.61903108	0.057627844	46.2	.	.
C21orf91	21	17788967	17819386	N	.	N	N	0.440244459	77.90125601	0.00484582	58.3	DP	.
C22orf15	22	23763021	23765861	N	.	N	N	.	.	0.081346646	44.4	.	.
C22orf23	22	37943050	37953669	N	.	N	N	0.400815894	75.88122938	2.51E-06	80.8	.	.
C22orf29	22	19846138	19854896	N	.	N	N	0.846527348	90.14296464	5.81E-06	79.2	.	.
C22orf31	22	29058672	29061844	N	.	N	N	0.170132915	62.53400475	2.32E-05	75.8	.	.
C22orf39	22	19351368	19448232	N	.	N	N	.	.	3.69E-07	84.2	.	.
C22orf42	22	32149006	32159322	N	.	N	N	1.298669382	95.78630549	1.42E-06	82	.	.
C22orf46	22	41688939	41698136	N	.	N	N	.	.	.	.	.	.
C2CD2	21	41885112	41953890	N	.	N	N	-0.423410291	23.40684147	0.060028248	46	.	.
C2CD2L	11	119102198	119118544	N	.	N	N	-0.023836771	47.69925334	0.99815174	6.8	.	.
C2CD4A	15	62066977	62070917	N	.	N	N	.	.	0.088805803	43.8	.	.
C2CD4B	15	62163535	62165283	N	.	N	N	.	.	0.496545387	30.1	.	.
C2CD4C	19	405438	409170	N	.	N	N	.	.	.	.	.	.
C2CD4D	1	151837819	151840557	N	.	N	N	.	.	.	.	.	.
C2CD5	12	22448583	22544546	N	.	N	N	-0.487112477	20.69224981	8.69E-07	82.8	.	.
C2orf15	2	99141485	99151487	N	.	N	N	0.236554885	66.60299821	0.543252453	28.8	.	.
C2orf16	2	27576522	27582720	N	.	N	N	0.340290591	72.88881171	3.92E-17	97.9	.	.
C2orf40	2	106063246	106078159	N	.	N	N	0.830420398	89.79568212	0.001678641	62.6	.	.
C2orf42	2	70149880	70248615	N	.	N	N	-0.369126321	25.91885165	0.134381994	41.4	DM?	.
C2orf44	2	24029340	24049575	N	.	N	N	-0.091363535	42.7215373	0.001441348	63.2	.	.
C2orf47	2	199955317	200008540	N	.	N	N	-0.195752553	35.7874631	0.00977968	55	.	.
C2orf49	2	105337359	105349211	N	.	N	N	0.273262571	68.86033455	0.192673532	38.9	.	.
C2orf50	2	11133053	11146790	N	.	N	N	0.619366893	84.74272154	0.003602248	59.5	.	.
C2orf54	2	240886048	240896889	N	.	N	Y	0.586779993	83.75296637	6.77E-06	79	.	.
C2orf57	2	231592901	231594283	N	.	N	N	0.864403486	90.43236673	0.002295965	61.4	.	.
C2orf61	2	47045538	47155378	N	.	N	N	0.939294228	91.85622504	0.014100347	53.5	.	.
C2orf66	2	196805002	196810276	N	.	N	N	0.069572814	54.86484922	0.004547084	58.6	.	.
C2orf68	2	85606654	85612066	N	.	N	N	0.118418051	58.60971233	0.012486499	54	.	.
C2orf69	2	199911256	199955935	N	.	N	N	0.33887786	72.80777913	0.432171539	31.9	.	.
C2orf70	2	26562582	26579532	N	.	N	N	1.280794407	95.65318053	0.000944694	65	.	.
C2orf71	2	29060976	29074261	N	.	N	N	1.358924118	96.16831626	5.65E-10	91.6	DM	Retinitis pigmentosa 54, 613428 (3)
C2orf72	2	231037490	231049719	N	.	N	N	.	.	.	.	.	.
C2orf73	2	54330034	54383742	N	Viable	N	Y	0.460841539	78.85628292	0.000860168	65.3	.	.
C2orf74	2	61145068	61164829	N	.	N	N	.	.	.	.	.	.
C2orf76	2	119302225	119366828	N	.	N	N	0.275983486	69.05712797	0.003332056	59.9	.	.
C2orf78	2	73784189	73817147	N	.	N	N	-0.151236787	38.62360363	6.92E-05	72.9	.	.
C2orf81	2	74414176	74421591	N	.	N	N	.	.	.	.	.	.
C2orf82	2	232857270	232878708	N	.	N	N	.	.	0.466831049	30.9	.	.
C2orf83	2	227610090	227633320	N	.	N	N	0.578982235	83.39989582	0.050110607	47	.	.
C2orf88	2	189879609	190203484	N	.	N	N	0.30503986	70.79354055	0.023588527	50.8	.	.
C2orf91	2	41935368	41954266	N	.	N	N	.	.	.	.	.	.
C3	19	6677704	6730562	N	Viable	N	Y	-3.093538981	0.567228107	0.999590151	4.9	DM	C3 deficiency, 613779 (3); {Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3); {Macular degeneration, age-related, 9}, 611378 (3)
C3AR1	12	8058302	8066471	N	.	N	Y	0.025813593	51.49042079	4.69E-05	74	DM?	.
C3orf14	3	62318973	62336213	N	Viable	N	Y	0.230008154	66.23835157	1.60E-06	81.8	.	.
C3orf18	3	50558025	50571027	N	.	N	N	0.193448992	64.03889564	0.014308008	53.4	.	.
C3orf20	3	14675099	14773034	N	.	N	N	0.744817967	87.97244892	2.36E-14	96.5	.	.
C3orf22	3	126526999	126558965	N	.	N	N	-0.071071979	44.35376512	0.127310951	41.7	.	.
C3orf30	3	119146150	119160042	N	.	N	N	1.6272439	97.60375065	1.65E-06	81.7	.	.
C3orf33	3	155762617	155806351	N	.	N	N	0.657839783	85.8424495	1.52E-07	85.6	.	.
C3orf36	3	133928145	133929812	N	.	N	N	0.399859596	75.829137	0.003672537	59.4	.	.
C3orf38	3	88149743	88168729	N	.	N	N	0.162629888	61.97256468	0.006998783	56.6	.	.
C3orf49	3	63819362	63848636	N	.	N	N	.	.	.	.	.	.
C3orf52	3	112086335	112131004	N	.	N	N	.	.	1.27E-08	88.6	.	.
C3orf58	3	143971798	144048719	N	.	N	N	-0.522213436	19.34942409	0.162503916	40.1	.	.
C3orf62	3	49268602	49277909	N	.	N	N	0.159759922	61.72946692	0.007124659	56.5	.	.
C3orf67	3	58717365	59050084	N	.	N	N	-0.093277119	42.60577647	1.51E-05	77	.	.
C3orf70	3	185078050	185153014	N	.	N	N	0.16167322	61.90310818	0.002390948	61.3	.	.
C3orf80	3	160225636	160228213	N	.	N	N	.	.	.	.	.	.
C3orf84	3	49177632	49191858	N	.	N	N	0.171896242	62.66134167	0.000221292	69.5	.	.
C4A	6	31982024	32002681	N	.	N	N	.	.	.	.	DM	C4a deficiency, 614380 (3); [Blood group, Rodgers], 614374 (3)
C4B	6	32014762	32035418	N	.	N	Y	.	.	.	.	DM	C4B deficiency, 614379 (3)
C4BPA	1	207104262	207144972	N	.	N	N	-0.07268182	44.25536841	0.012739358	54	DM?	.
C4BPB	1	207088842	207099993	N	.	N	N	-0.015680094	48.2317532	2.58E-06	80.8	.	.
C4orf17	4	99511004	99542303	N	.	N	N	0.838067604	89.96932338	5.65E-09	89.5	.	.
C4orf19	4	37453941	37623495	N	.	N	N	0.669167441	86.18394397	0.00416046	58.9	.	.
C4orf22	4	80335720	80963756	N	Viable	N	Y	0.477760474	79.6550327	1.12E-05	77.8	.	.
C4orf26	4	75556048	75565885	N	.	N	N	0.687853448	86.58910691	0.124857081	41.8	DM	Amelogenesis imperfecta, type IIA4, 614832 (3)
C4orf27	4	169729465	169757953	N	.	N	N	0.100692319	57.27267465	0.000423307	67.6	.	.
C4orf29	4	127965306	128039711	N	.	N	N	-0.013766433	48.44591075	7.67E-07	83	.	.
C4orf3	4	119296419	119304445	N	.	N	N	.	.	0.868030874	19.1	.	.
C4orf32	4	112145397	112195256	N	.	N	N	0.227138911	66.07628639	0.285815912	36.1	.	.
C4orf33	4	129093317	129116640	N	.	N	N	0.535874184	81.906581	0.000824304	65.4	.	.
C4orf36	4	86876205	86936202	N	.	N	N	0.556472142	82.66481449	0.001484865	63.1	.	.
C4orf45	4	158893134	159038760	N	Viable	N	Y	0.89331644	91.01695896	1.28E-05	77.4	.	.
C4orf46	4	158666679	158672255	N	.	N	N	0.274070774	68.90085084	0.259003018	36.8	.	.
C4orf47	4	185426249	185449826	N	.	N	N	.	.	.	.	.	.
C4orf48	4	2041993	2043970	N	.	N	N	.	.	.	.	.	.
C4orf50	4	5897591	5989818	N	.	N	N	.	.	6.34E-10	91.5	.	.
C4orf51	4	145680204	145771032	N	.	N	N	0.272306077	68.81981826	0.01518088	53.1	.	.
C5	9	120952335	121050276	N	.	N	Y	-0.982899275	8.184291254	5.61E-11	93.3	DM	C5 deficiency, 609536 (3); [Eculizumab, poor response to], 615749 (3)
C5AR1	19	47290023	47322066	N	.	N	Y	-0.104607368	41.83596689	0.000416366	67.6	.	.
C5AR2	19	47332147	47347327	N	.	N	Y	0.599873048	84.11761301	0.023140977	50.9	.	.
C5orf15	5	133955502	133968787	N	.	N	N	0.9252426	91.60733924	0.015999938	52.8	.	.
C5orf22	5	31532266	31555058	N	.	N	N	-0.281960735	30.55507322	0.169565363	39.7	.	.
C5orf24	5	134845680	134859737	N	.	N	N	-0.170525669	37.3618105	0.640813736	26.3	.	.
C5orf28	5	43444252	43483893	N	.	N	N	-0.258648061	31.95577936	1.49E-05	77.1	.	.
C5orf34	5	43486701	43515145	N	.	N	N	-0.211411415	34.85558835	9.91E-11	92.9	.	.
C5orf38	5	2752131	2755397	N	.	N	N	0.078032613	55.54205012	0.162071502	40.1	.	.
C5orf42	5	37106228	37249428	N	.	N	N	0.315861112	71.47074145	6.32E-19	98.4	DM	Joubert syndrome 17, 614615 (3); Orofaciodigital syndrome VI, 277170 (3)
C5orf45	5	179835133	179862173	N	.	N	Y	0.70396241	86.97690571	3.29E-06	80.4	.	.
C5orf46	5	147880726	147906538	N	.	N	N	0.160566904	61.79892342	0.299424892	35.7	.	.
C5orf47	5	173973779	174006140	N	.	N	N	.	.	.	.	.	.
C5orf49	5	7830378	7851490	N	.	N	N	0.814457585	89.41367135	0.346800141	34.3	.	.
C5orf51	5	41904188	41921636	N	.	N	N	0.045300934	53.00688777	0.0038889	59.2	.	.
C5orf52	5	157671553	157680143	N	.	N	Y	.	.	.	.	.	.
C5orf56	5	132410636	132476044	N	.	N	N	.	.	0.107649238	42.7	.	.
C5orf63	5	127042558	127073492	N	.	N	N	.	.	.	.	.	.
C5orf67	5	56511567	56606232	N	.	N	N	.	.	.	.	.	.
C6	5	41142234	41261438	N	.	N	N	0.973756605	92.36557273	1.20E-14	96.6	DM	C6 deficiency, 612446 (3); Combined C6/C7 deficiency (3)
C6orf1	6	34246380	34249470	N	.	N	N	0.369846866	74.37633848	0.298718643	35.8	.	.
C6orf10	6	32288526	32371912	N	.	N	N	1.487377846	96.90339758	1.23E-13	96	.	.
C6orf106	6	34587288	34696859	N	.	N	N	-0.153605457	38.49626671	0.454029671	31.3	.	.
C6orf118	6	165279664	165309607	N	Viable	N	Y	0.947092883	91.96619784	1.46E-17	98	.	.
C6orf120	6	169702190	169704856	N	.	N	N	0.151300234	61.07541819	0.046340118	47.4	.	.
C6orf132	6	42101118	42142619	N	.	N	N	.	.	.	.	.	.
C6orf136	6	30647039	30653210	N	.	N	N	-0.005306604	49.07680732	0.873894203	18.9	.	.
C6orf141	6	49550646	49561907	N	.	N	N	.	.	.	.	.	.
C6orf15	6	31111223	31112559	N	.	N	N	0.541611524	82.1265266	0.001427697	63.2	DP	.
C6orf163	6	87344849	87365463	N	.	N	N	.	.	.	.	.	.
C6orf165	6	87408012	87511634	N	.	N	N	1.38614466	96.31301731	.	.	.	.
C6orf201	6	4079209	4130951	N	.	N	N	0.852931302	90.24136135	0.092248285	43.6	.	.
C6orf203	6	107028213	107051342	N	.	N	N	0.279809186	69.29443769	0.001786923	62.3	.	.
C6orf222	6	36315757	36336885	N	.	N	N	0.995144162	92.71285524	1.39E-13	96	.	.
C6orf223	6	44000580	44005958	N	.	N	N	1.644835133	97.69635932	0.020490674	51.5	.	.
C6orf226	6	42890265	42890816	N	.	N	N	0.580894119	83.51565665	0.494949272	30.1	.	.
C6orf229	6	24797321	24798889	N	.	N	N	.	.	.	.	.	.
C6orf25	6	31718594	31726714	N	Viable	N	Y	0.472169912	79.41193494	0.004037692	59	.	.
C6orf47	6	31658298	31660772	N	.	N	N	0.577215218	83.32465127	0.169847833	39.7	.	.
C6orf48	6	31834608	31839766	N	.	N	N	0.100541925	57.24952249	5.82E-05	73.5	.	.
C6orf49	6	41783474	41787129	N	.	N	N	.	.	.	.	.	.
C6orf52	6	10671418	10694797	N	.	N	N	.	.	.	.	.	.
C6orf58	6	127519455	127591817	N	.	N	N	0.224567453	65.92000926	1.61E-10	92.6	.	.
C6orf62	6	24704861	24720836	N	.	N	N	-0.139556392	39.44550559	0.946557424	15.1	.	.
C6orf89	6	36871870	36928964	N	.	N	N	-0.222893607	34.16102333	8.22E-05	72.5	.	.
C7	5	40909252	40982939	N	.	N	N	0.132116298	59.54158708	1.26E-11	94.1	DM	C7 deficiency, 610102 (3)
C7orf25	7	42908726	42912305	N	.	N	N	-0.512795604	19.70249465	0.352368933	34.1	.	.
C7orf26	7	6590017	6608726	N	.	N	N	-0.717142473	13.46877351	0.82656656	20.8	.	.
C7orf31	7	25134697	25180356	N	.	N	N	1.539103335	97.16385947	7.44E-08	86.5	.	.
C7orf33	7	148590565	148615860	N	.	N	N	0.414865996	76.60473462	0.000634926	66.3	.	.
C7orf34	7	142939343	142940868	N	Viable	N	Y	0.929879279	91.71731203	0.000149478	70.6	.	.
C7orf43	7	100154420	100158715	N	.	N	N	-0.593415811	16.91265845	0.300413007	35.7	DM?	.
C7orf49	7	135092363	135170795	N	.	N	N	0.315412023	71.43022515	0.335421676	34.7	.	.
C7orf50	7	996986	1138260	N	.	N	N	0.60627228	84.34334665	0.001396208	63.4	.	.
C7orf55-LUC7L2	7	139340359	139423457	N	.	N	N	-0.321389901	28.22828037	0.995965818	8	.	.
C7orf57	7	48035511	48061304	N	.	N	N	1.002191365	92.79388783	4.29E-05	74.3	.	.
C7orf60	7	112819147	112939916	N	.	N	N	-0.455642657	22.04665162	0.99081084	9.8	.	.
C7orf61	7	100456615	100464271	N	.	N	N	-0.10763024	41.63338543	0.012081249	54.2	.	.
C7orf62	7	88794106	88795721	N	.	N	N	0.326740798	72.14794235	0.023507222	50.8	.	.
C7orf72	7	50096036	50159830	N	.	N	N	.	.	.	.	.	.
C7orf73	7	135662496	135693418	N	.	N	N	.	.	.	.	.	.
C7orf77	7	124777292	124790689	N	.	N	N	.	.	.	.	.	.
C8A	1	56854806	56918221	N	Viable	N	Y	0.814902524	89.44261156	5.36E-11	93.3	DM	C8 deficiency, type I, 613790 (3)
C8B	1	56929210	56966140	N	Viable	N	Y	0.821448548	89.56416044	1.49E-09	90.8	DM	C8 deficiency, type II, 613789 (3)
C8G	9	136945246	136946974	N	.	N	N	0.956213162	92.11668692	1.63E-09	90.7	.	.
C8orf22	8	49054311	49076090	N	.	N	N	0.403538004	75.98541413	0.375401959	33.5	.	.
C8orf33	8	145052378	145056030	N	.	N	N	-0.080336605	43.59553163	6.35E-05	73.2	.	.
C8orf34	8	68330722	68819022	N	.	N	N	-0.266954701	31.4637958	9.85E-06	78.1	.	.
C8orf37	8	95244919	95269201	N	.	N	N	0.202865163	64.54245529	0.00218443	61.6	DM	Retinitis pigmentosa 64, 614500 (3); Cone-rod dystrophy 16, 614500 (3)
C8orf4	8	40153455	40155308	N	.	N	N	0.063983137	54.4886265	0.0652715	45.5	.	.
C8orf44	8	66667615	66685564	N	.	N	N	0.390443887	75.38924582	0.016940286	52.5	.	.
C8orf44-SGK3	8	66667596	66860472	N	.	N	N	.	.	0.136791141	41.3	.	.
C8orf46	8	66460003	66518524	N	Viable	N	Y	0.170939673	62.57452104	0.639231508	26.3	.	.
C8orf48	8	13566843	13568287	N	.	N	N	.	.	.	.	.	.
C8orf58	8	22599601	22604150	N	Viable	N	Y	0.696459078	86.83220467	7.26E-07	83.1	.	.
C8orf59	8	85214076	85220421	N	.	N	N	0.274070774	68.90085084	0.042725949	47.9	.	.
C8orf74	8	10672637	10700593	N	.	N	N	1.015431742	92.94437692	1.01E-11	94.3	.	.
C8orf76	8	123219957	123241398	N	.	N	N	0.080096755	55.71569138	1.72E-05	76.7	.	.
C8orf82	8	144525733	144529132	N	.	N	N	.	.	0.006667633	56.8	.	.
C8orf86	8	38510834	38528662	N	.	N	N	0.44679135	78.19644614	6.35E-05	73.2	.	.
C8orf88	8	90958637	90985257	N	.	N	N	.	.	.	.	.	.
C8orf89	8	73241329	73259502	N	.	N	N	.	.	.	.	.	.
C9	5	39284262	39424868	N	Viable	N	Y	1.062518565	93.53475719	6.82E-17	97.8	DM	C9 deficiency, 613825 (3); {Macular degeneration, age-related, 15, susceptibility to}, 615591 (3)
C9orf116	9	135495181	135501734	N	.	N	N	0.133424212	59.69786421	0.010032602	54.9	.	.
C9orf117	9	127706989	127716002	N	.	N	N	0.599873048	84.11761301	6.01E-06	79.2	.	.
C9orf129	9	93318199	93346414	N	.	N	N	0.718823127	87.39364473	0.375838564	33.5	.	.
C9orf131	9	35041095	35045991	N	.	N	N	0.590122987	83.839787	3.48E-13	95.7	.	.
C9orf135	9	69820793	69906232	N	.	N	N	0.259212925	68.00370435	1.84E-05	76.5	.	.
C9orf142	9	136992418	136993984	N	.	N	N	-0.033556726	47.03941657	0.569785721	28.2	.	.
C9orf152	9	110190048	110208189	N	.	N	N	-0.028772452	47.38091104	0.004747681	58.3	.	.
C9orf153	9	86220265	86259657	N	.	N	N	0.129597795	59.37952191	0.233307325	37.6	.	.
C9orf156	9	97904489	97922570	N	.	N	N	-0.084968981	43.20194478	4.08E-05	74.5	.	.
C9orf16	9	128160260	128163928	N	.	N	N	0.151150685	61.04647798	0.01649363	52.7	.	.
C9orf171	9	132410043	132573317	N	.	N	N	0.819382688	89.51785611	5.91E-07	83.5	.	.
C9orf172	9	136844415	136848801	N	.	N	N	.	.	.	.	.	.
C9orf173	9	137251261	137253483	N	.	N	N	0.563164925	82.83845575	3.94E-11	93.5	.	.
C9orf24	9	34379019	34397832	N	.	N	N	0.602593883	84.18706951	1.69E-05	76.7	.	.
C9orf3	9	94726701	95087218	N	.	N	N	-0.277025306	30.8155351	5.20E-12	94.6	.	.
C9orf40	9	74946581	74952886	N	.	N	N	0.099585278	57.16270186	0.2639862	36.7	.	.
C9orf43	9	113410054	113429684	N	Viable	N	Y	0.427300457	77.23563119	3.00E-08	87.6	.	.
C9orf47	9	88990863	88996140	N	.	N	N	0.556472142	82.66481449	0.08509201	44.1	.	.
C9orf50	9	129612225	129620776	N	.	N	N	0.838067604	89.96932338	7.28E-10	91.3	.	.
C9orf57	9	72051376	72072721	N	.	N	N	.	.	.	.	.	.
C9orf64	9	83938311	83956986	N	.	N	N	0.071637002	55.02112635	0.001138203	64.2	.	.
C9orf66	9	212824	215741	N	.	N	N	1.026614462	93.11223013	0.000775174	65.6	.	.
C9orf69	9	136114581	136118863	N	.	N	N	0.549924771	82.42171673	0.496755436	30	.	.
C9orf72	9	27546545	27573866	N	Viable	N	Y	-0.538022286	18.68379927	0.000715132	65.9	DM	Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3)
C9orf78	9	129827290	129835863	N	.	N	N	-0.402163571	24.28662384	0.117679602	42.3	.	.
C9orf84	9	111686173	111795008	N	.	N	N	0.608004798	84.38965098	4.97E-16	97.5	.	.
C9orf85	9	71911510	71986054	N	.	N	N	0.148430386	60.90756497	0.006921051	56.6	.	.
C9orf89	9	93096218	93113283	N	.	N	N	0.324827936	72.00902935	5.83E-05	73.5	.	.
C9orf9	9	132878027	132890201	N	.	N	N	0.249796776	67.44226428	0.212814053	38.3	.	.
C9orf91	9	114611206	114646422	N	.	N	N	0.253623009	67.679574	0.000442176	67.4	.	.
C9orf92	9	16203935	16276313	N	.	N	N	.	.	.	.	.	.
CA1	8	85327608	85379014	N	.	N	N	0.660707924	85.93505817	3.77E-05	74.6	DM	.
CA10	17	51630313	52160017	N	.	N	N	-0.294249011	29.74474735	0.973117502	12.7	.	.
CA11	19	48637942	48646312	N	.	N	N	-0.221132832	34.27099612	0.976097038	12.2	.	.
CA12	15	63321378	63382161	N	.	N	Y	0.135487969	59.87729351	9.91E-09	88.9	DM	Hyperchlorhidrosis, isolated, 143860 (3)
CA13	8	85220587	85284073	N	.	N	N	-0.103802501	41.88805927	0.000339444	68.3	.	.
CA14	1	150257159	150265078	N	.	N	Y	0.208604733	64.97655843	1.43E-09	90.8	.	.
CA2	8	85463852	85481493	N	.	N	Y	-0.303666373	29.26433987	0.100369923	43.1	DM	Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 (3)
CA3	8	85373436	85449040	N	.	N	Y	-0.158237463	38.14319616	4.69E-05	74	.	.
CA5A	16	87881546	87936529	N	.	N	Y	0.40846756	76.27481623	0.010723138	54.7	.	Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 (3)
CA5B	X	15688830	15788409	N	.	N	N	0.037797903	52.3759912	0.00331243	59.9	.	.
CA6	1	8945867	8975092	N	.	N	Y	0.09510276	56.80384326	0.008023621	55.9	DP	.
CA7	16	66844379	66854153	N	Viable	N	Y	-0.449096955	22.33605371	0.775375974	22.4	.	.
CA8	8	60187347	60281412	N	.	N	N	-0.031643	47.17832957	0.783927467	22.2	DM	Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 (3)
CA9	9	35673856	35681159	N	.	N	Y	-0.223698301	34.10893095	4.39E-07	83.9	.	.
CAAP1	9	26840685	26892804	N	.	N	N	-0.057827611	45.27406378	0.708931875	24.4	.	.
CAB39	2	230712845	230821075	N	.	N	N	-0.304623579	29.21803554	0.062179596	45.8	.	.
CAB39L	13	49308650	49444126	N	Viable	N	Y	-0.081293491	43.49713492	0.016420554	52.7	.	.
CABLES1	18	23134564	23260467	N	.	N	Y	0.271498993	68.77351392	0.445044394	31.6	.	.
CABLES2	20	62388632	62407285	N	.	N	N	0.18146271	63.30960236	0.000167847	70.3	.	.
CABP1	12	120640552	120667324	N	Viable	N	Y	-0.10204113	42.00382011	0.994401234	8.7	.	.
CABP2	11	67518912	67523428	N	.	N	N	0.021835061	51.22417086	0.021209537	51.3	DM	Deafness, autosomal recessive 93, 614899 (3)
CABP4	11	67452406	67460313	N	Viable	N	Y	0.611053519	84.5169879	1.84E-05	76.5	DM	Cone-rod synaptic disorder, congenital nonprogressive, 610427 (3)
CABP5	19	48029953	48044053	N	.	N	N	0.57434681	83.2320426	0.004220803	58.9	.	.
CABP7	22	29720084	29731839	N	.	N	N	-0.349641992	26.83336227	0.899633392	17.8	.	.
CABS1	4	70334966	70337116	N	.	N	N	0.294008138	70.13370377	0.054137713	46.5	.	.
CABYR	18	24138956	24161603	N	.	N	N	-0.245402639	32.7487411	0.000210501	69.7	.	.
CACFD1	9	133459965	133470848	N	.	N	Y	.	.	0.005746769	57.5	.	.
CACHD1	1	64470792	64693058	N	.	N	N	-0.393913783	24.68599873	0.838036969	20.3	DM?	.
CACNA1B	9	137877789	138124624	Y	Viable	N	Y	-2.640989538	0.839266076	0.982603443	11.3	DM?	?Dystonia 23, 614860 (3)
CACNA1D	3	53494656	53813733	N	.	N	Y	-3.180841713	0.526711813	1	0.3	DM	Sinoatrial node dysfunction and deafness, 614896 (3); Primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3)
CACNA1E	1	181413102	181808084	N	.	N	Y	-1.816946992	2.153151589	1	0.2	DM?	.
CACNA1F	X	49205063	49233371	N	.	N	Y	-0.258044198	32.0020837	0.873703604	18.9	DM	Night blindness, congenital stationary (incomplete), 2A, X-linked, 300071 (3); Cone-rod dystropy, X-linked, 3, 300476 (3); Aland Island eye disease, 300600 (3)
CACNA1G	17	50561068	50627474	N	.	N	Y	-2.660683447	0.833478034	0.999996517	2.1	DM	.
CACNA1H	16	1153241	1221771	N	.	N	Y	-0.723239071	13.32407247	0.755916976	23	DM	{Epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3); {Epilepsy, childhood absence, susceptibility to, 6}, 611942 (3)
CACNA1I	22	39570753	39689737	N	Viable	N	Y	-1.263548734	5.018232332	0.999998894	1.7	.	.
CACNA2D1	7	81946444	82443798	N	.	N	Y	-0.72449582	13.27776813	0.999995804	2.2	DM	.
CACNA2D3	3	54122547	55074557	N	Viable	N	Y	-1.36982546	4.150026046	0.998032255	6.9	DM?	.
CACNA2D4	12	1791957	1918836	N	.	N	N	-0.478363114	21.06847254	4.57E-22	99	DM	Retinal cone dystrophy 4, 610478 (3)
CACNB3	12	48813794	48828941	N	.	N	Y	-0.462034049	21.80355386	0.049583653	47.1	.	.
CACNB4	2	151832776	152099079	N	.	N	Y	-0.731345989	13.12727904	0.011363582	54.4	DM	{Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3); {Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3); Episodic ataxia, type 5, 613855 (3)
CACNG1	17	67044590	67056797	N	.	N	Y	-0.103802501	41.88805927	4.78E-07	83.8	.	.
CACNG2	22	36563921	36703558	N	.	N	Y	-0.000674037	49.38936158	0.958056003	14.1	DM	Mental retardation, autosomal dominant 10, 614256 (3)
CACNG3	16	24255553	24362801	N	.	N	Y	-0.6076209	16.52485964	0.987801232	10.4	.	.
CACNG4	17	66964910	67033398	N	.	N	Y	0.160716564	61.81628755	0.215774473	38.2	.	.
CACNG5	17	66835117	66885486	N	.	N	N	0.162629888	61.97256468	0.053560444	46.6	.	.
CACNG6	19	53992288	54012669	N	.	N	N	0.475848013	79.55084795	0.180522903	39.3	.	.
CACNG7	19	53909335	53943941	N	.	N	Y	-0.234224724	33.42015396	0.712700867	24.3	.	.
CACNG8	19	53963040	53990215	N	.	N	Y	0.049933723	53.40047462	.	.	.	.
CACTIN	19	3610641	3626815	N	.	N	N	-0.94783526	8.745731319	0.999345096	5.5	.	.
CACUL1	10	118674167	118755249	N	.	N	N	-0.459316521	21.9193147	0.846686967	20	.	.
CACYBP	1	174999163	175011715	N	.	N	Y	-0.026053671	47.51982404	0.943386849	15.4	.	.
CAD	2	27217390	27243943	N	.	N	N	-5.109961657	0.086820629	0.999999702	1.4	.	?Congenital disorder of glycosylation, type Iz, 616457 (3)
CADM1	11	115169218	115504957	N	.	N	Y	-0.443353128	22.55021126	0.994386404	8.7	DM	.
CADM2	3	84958981	86074429	N	.	N	N	-0.623428585	16.06181629	0.98466891	10.9	.	.
CADM3	1	159171609	159203313	N	.	N	Y	-0.79887591	11.61081206	0.975630651	12.4	.	.
CADM4	19	43622368	43639839	N	.	N	N	-0.301752054	29.35694854	0.979491545	11.8	.	.
CADPS2	7	122318425	122886759	N	.	N	Y	-1.496448015	3.380216473	0.997778954	7.1	.	.
CAGE1	6	7326656	7389743	N	.	N	N	0.539847451	82.05707009	2.62E-06	80.7	.	.
CALB1	8	90058608	90095475	N	.	N	Y	-0.411581382	23.84673265	0.898924669	17.8	.	.
CALB2	16	71358713	71390438	N	.	N	Y	-0.338310159	27.33692192	0.001238901	63.8	.	.
CALCA	11	14966668	14972354	N	.	N	Y	0.416778578	76.67419112	0.001395557	63.4	DM	.
CALCB	11	14904997	15082342	N	Viable	N	Y	-0.147059443	38.92458181	0.057876195	46.2	.	.
CALCOCO1	12	53708517	53727745	N	.	N	N	-0.172939654	37.1823812	0.171891881	39.7	.	.
CALCOCO2	17	48830988	48866522	N	.	N	N	0.140120824	60.21878798	0.031762453	49.4	.	.
CALHM1	10	103453387	103458888	N	.	N	Y	0.959229114	92.18035539	9.36E-05	72.1	DFP	.
CALHM2	10	103446786	103452402	N	.	N	N	0.014483413	50.59906234	5.29E-07	83.6	.	.
CALHM3	10	103472804	103479240	N	.	N	N	.	.	.	.	.	.
CALM1	14	90396502	90408261	N	.	N	N	0.075162561	55.29316432	0.894820173	18	DM	Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3); Long QT syndrome 14, 616247 (3)
CALM2	2	47160082	47176601	N	.	N	N	0.075162561	55.29316432	0.856387219	19.7	DM	Long QT syndrome 15, 616249 (3)
CALM3	19	46601074	46610793	N	.	N	N	0.038603643	52.45123575	0.580172432	28	DFP	.
CALML3	10	5524009	5526771	N	.	N	N	0.073399639	55.17740348	0.03792497	48.6	.	.
CALML4	15	68190705	68206110	N	.	N	N	0.182269088	63.36169474	0.010209058	54.8	.	.
CALML5	10	5498697	5499555	N	.	N	N	0.42987242	77.39769636	0.536579599	29	.	.
CALML6	1	1914827	1917296	N	.	N	N	0.44583509	78.14435377	0.000127437	71.2	.	.
CALN1	7	71779491	72447151	N	.	N	N	-0.38156897	25.32847138	0.15365029	40.4	.	.
CALR3	19	16479057	16496192	N	.	N	Y	-0.13094377	40.00115761	8.79E-08	86.3	DM	?Cardiomyopathy, hypertrophic, 19, 613875 (3)
CALU	7	128739292	128771807	N	.	N	N	-0.408709366	23.99722174	0.447140101	31.5	.	.
CALY	10	133324072	133336935	N	.	N	Y	.	.	0.706613402	24.5	.	.
CAMK1	3	9757342	9769992	N	Viable	N	Y	-0.266954701	31.4637958	0.004746546	58.4	.	.
CAMK1D	10	12349482	12835545	N	.	N	N	-0.450856222	22.22608092	0.993807052	8.9	.	.
CAMK1G	1	209583717	209613938	N	.	N	Y	-0.044583575	46.25803091	0.101614387	43	.	.
CAMK2A	5	150219491	150290291	N	.	N	Y	-0.545680331	18.36545697	0.998004221	6.9	.	.
CAMK2B	7	44217150	44334577	N	.	N	Y	-0.350445024	26.76390577	0.468620194	30.9	.	.
CAMK2D	4	113451032	113761927	N	.	N	Y	-0.687283786	14.28488742	0.016661669	52.6	DM?	.
CAMK2G	10	73812501	73874591	N	.	N	Y	-0.556857198	18.01238641	0.994506146	8.6	DM?	.
CAMK2N1	1	20482391	20486220	N	.	N	N	0.090168851	56.43919662	0.138563182	41.2	.	.
CAMK2N2	3	184259213	184261463	N	.	N	N	0.015137522	50.6627308	0.320487801	35.1	.	.
CAMK4	5	111223653	111494886	N	.	N	Y	-0.282917726	30.50876888	0.01582967	52.9	DM?	.
CAMKK1	17	3860315	3894891	N	.	N	Y	-0.914144691	9.312959426	0.06323909	45.7	DP	.
CAMKK2	12	121237691	121298308	N	.	N	Y	-0.310864193	28.90548128	0.503475917	29.8	DP	.
CAMKMT	2	44361950	44772592	N	Viable	N	Y	-0.460273767	21.90195057	5.15E-13	95.5	.	.
CAMKV	3	49857988	49870222	N	.	N	N	0.222654188	65.80424842	0.996846171	7.6	.	.
CAMP	3	48223347	48225491	N	.	N	Y	0.498357775	80.40169011	0.089655702	43.8	DP	.
CAMSAP1	9	135808487	135907228	N	.	N	N	-1.581505322	2.905597037	0.753664482	23.1	.	.
CAMSAP2	1	200739558	200860704	N	.	N	N	-0.869645063	10.1927418	0.999973882	3	.	.
CAMSAP3	19	7595902	7618304	N	.	N	N	-1.243208268	5.168721422	0.999943969	3.3	.	.
CAMTA1	1	6785324	7769706	N	.	N	N	-1.54017246	3.142906755	0.999999955	1	DM	Cerebellar ataxia, nonprogressive, with mental retardation, 614756 (3)
CAMTA2	17	4967992	4987652	N	.	N	Y	-0.614382069	16.35121838	0.999991614	2.5	DM?	.
CAND1	12	67269281	67319951	N	.	N	N	-1.534108474	3.183423048	0.999927001	3.5	.	.
CAND2	3	12796472	12871916	N	.	N	Y	0.783459827	88.85801933	4.53E-09	89.7	.	.
CAP1	1	40040233	40072649	N	.	N	N	0.432890148	77.54818545	0.585940926	27.8	.	{?Herpes simplex encephalitis, susceptibility to, 3}, 614849 (3)
CAPG	2	85394748	85418432	N	.	N	Y	0.286505086	69.72275279	5.33E-09	89.5	.	.
CAPN1	11	65180566	65212006	N	.	N	Y	0.016548514	50.77849164	5.00E-05	73.9	.	.
CAPN10	2	240586716	240617705	N	.	N	Y	-0.442093457	22.63703189	2.38E-08	88	DM?	{Diabetes mellitus, noninsulin-dependent 1}, 601283 (3)
CAPN11	6	44158811	44184402	N	.	N	N	0.716401928	87.31840019	2.97E-10	92.2	.	.
CAPN12	19	38730187	38769904	N	Viable	N	Y	0.835655068	89.89986688	7.48E-20	98.6	.	.
CAPN13	2	30722771	30820542	N	.	N	N	1.467890428	96.82236499	1.83E-09	90.6	DP	.
CAPN14	2	31173056	31233858	N	.	N	N	.	.	.	.	.	.
CAPN15	16	527717	554636	N	.	N	N	0.051496629	53.46414308	0.965209511	13.5	.	.
CAPN3	15	42359500	42412318	N	.	N	Y	-0.691469023	14.20385484	9.74E-09	88.9	DM	Muscular dystrophy, limb-girdle, type 2A, 253600 (3)
CAPN6	X	111245103	111270523	N	.	N	Y	-0.373911225	25.72784627	0.984532251	11	.	.
CAPN8	1	223538007	223665734	N	Viable	N	Y	.	.	0.015180936	53.1	.	.
CAPN9	1	230747384	230802003	N	.	N	Y	1.374169102	96.24934885	1.73E-11	94	.	.
CAPNS2	16	55566672	55567687	N	.	N	N	0.218827885	65.61903108	0.131736738	41.5	.	.
CAPRIN2	12	30709552	30754951	N	.	N	N	-1.212099669	5.458123517	0.012089127	54.2	.	.
CAPS	19	5911707	5916208	N	.	N	N	0.731106858	87.60780228	5.18E-07	83.7	.	.
CAPS2	12	75275979	75390928	N	.	N	N	0.626060077	84.945303	2.65E-09	90.3	.	.
CAPSL	5	35904295	35938779	N	.	N	N	0.199188423	64.32250969	0.000440615	67.4	.	.
CAPZA1	1	112619173	112671619	N	.	N	N	0.364256447	74.10430052	0.983027525	11.3	.	.
CAPZA2	7	116811070	116922049	N	.	N	N	0.261933591	68.13682931	0.986605821	10.7	.	.
CAPZA3	12	18738101	18739187	N	.	N	N	0.389635172	75.36030561	0.000212652	69.6	.	.
CARD11	7	2906141	3043945	N	.	N	Y	-0.746720095	12.71632807	0.999939282	3.4	DM	B-cell expansion with NFKB and T-cell anergy, 616452 (3); Immunodeficiency 11, 615206 (3)
CARD14	17	80169992	80209331	N	.	N	N	1.481316925	96.88024541	3.15E-14	96.4	DM	Psoriasis 2, 602723 (3); Pityriasis rubra pilaris, 173200 (3)
CARD16	11	105041326	105101431	N	.	N	N	0.848294696	90.1661168	0.040164332	48.3	.	.
CARD17	11	105092469	105101431	N	.	N	N	0.756340519	88.25027493	0.000301792	68.6	.	.
CARD18	11	105137721	105139726	N	.	N	N	0.501080921	80.47693465	0.048753747	47.2	.	.
CARD6	5	40841184	40860175	N	.	N	N	1.636990561	97.6789952	1.46E-16	97.7	.	.
CARD8	19	48180770	48255946	N	.	N	N	1.26879824	95.54899577	0.016289375	52.7	DFP	.
CARD9	9	136361903	136373681	N	.	N	Y	0.849547686	90.20084505	2.29E-11	93.8	DM	Candidiasis, familial, 2, autosomal recessive, 212050 (3)
CARF	2	202912214	202987063	N	Viable	N	Y	-0.380305159	25.44423222	0.004541037	58.6	.	.
CARHSP1	16	8852942	8869012	N	.	N	N	1.125120265	94.25826243	.	.	.	.
CARKD	13	110615460	110639993	N	.	N	N	0.516381288	81.11361926	0.00650288	56.9	.	.
CARNMT1	9	74981020	75028423	N	.	N	N	.	.	.	.	.	.
CARNS1	11	67414968	67425607	N	.	N	N	.	.	0.022129	51.2	.	.
CARS	11	3000922	3057613	N	.	N	N	0.056128986	53.78827343	2.96E-06	80.6	.	.
CARS2	13	110641412	110713603	N	.	N	N	0.793195884	89.0606008	0.040465118	48.2	.	.
CARTPT	5	71719163	71721048	N	.	N	Y	0.123051266	58.96278289	0.420347163	32.2	DM	{?Obesity, susceptibility to}, 601665 (3)
CASC1	12	25108420	25195162	N	.	N	N	-0.101585715	42.03276032	8.06E-12	94.3	.	.
CASC10	10	21492658	21497262	N	.	N	N	0.510496156	80.89367367	0.020054862	51.7	.	.
CASC4	15	44288729	44415758	N	Viable	N	Y	0.233027146	66.41199282	0.00096773	64.9	.	.
CASD1	7	94509219	94557019	N	.	N	N	-0.306231452	29.11385078	0.036794338	48.7	.	.
CASKIN2	17	75500261	75515583	N	Viable	N	Y	0.208413927	64.92446605	0.999986555	2.7	.	.
CASP1	11	105025443	105035250	N	.	N	N	0.454442874	78.52057649	0.136798331	41.3	DM?	.
CASP10	2	201182881	201229406	N	.	N	N	0.090621427	56.49707704	8.54E-12	94.3	DM	Autoimmune lymphoproliferative syndrome, type II, 603909 (3); Lymphoma, non-Hodgkin, somatic, 605027 (3); Gastric cancer, somatic, 613659 (3)
CASP14	19	15049384	15058293	N	.	N	Y	0.746113675	88.00138913	0.001233881	63.9	.	.
CASP16P	16	3144219	3149963	N	.	N	N	.	.	.	.	.	.
CASP2	7	143288215	143307696	N	.	N	Y	-0.423561627	23.40105342	0.423101054	32.2	DM	.
CASP4	11	104942866	104969436	N	Viable	N	Y	0.279958701	69.3233779	8.21E-07	82.9	.	.
CASP5	11	104994235	105023168	N	.	N	N	0.737802049	87.79301962	8.11E-09	89.2	DP	.
CASP6	4	109688622	109703583	N	.	N	Y	0.266716005	68.46095966	0.000855158	65.3	.	.
CASP7	10	113679162	113730907	N	.	N	Y	0.361535788	73.98853968	0.000373926	68	.	.
CASQ1	1	160190556	160201886	N	Viable	N	Y	0.598916451	84.09446084	1.04E-09	91.1	.	Myopathy, vacuolar, with CASQ1 aggregates, 616231 (3)
CASS4	20	56412112	56460387	N	.	N	N	0.303729111	70.73566013	0.296175209	35.8	.	.
CAST	5	96525267	96779595	N	Viable	N	Y	0.628277759	84.99739538	1.56E-06	81.8	FP	Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 (3)
CAT	11	34438925	34472062	N	.	N	Y	-0.381261924	25.37477571	1.48E-06	81.9	DM	.
CATIP	2	218356856	218368099	N	Viable	N	Y	.	.	.	.	.	.
CATSPER1	11	66016752	66026517	N	.	N	Y	0.404140759	76.01435434	1.14E-08	88.8	DM	Spermatogenic failure 7, 612997 (3)
CATSPER2	15	43628503	43668118	N	.	N	Y	0.720076471	87.43994907	3.04E-05	75.2	DM	.
CATSPER3	5	134967906	135011707	N	.	N	Y	0.856899996	90.31660589	0.000487202	67.1	DM?	.
CATSPER4	1	26190561	26202968	N	.	N	Y	1.141231441	94.44926781	3.16E-05	75.1	DM?	.
CATSPERB	14	91580696	91780707	N	.	N	N	-1.375419813	4.109509753	4.26E-13	95.6	.	.
CATSPERD	19	5720677	5778734	N	.	N	Y	1.325476072	95.95415871	1.07E-08	88.8	.	.
CATSPERG	19	38335775	38370943	N	.	N	N	-0.458865063	21.93089078	1.31E-11	94.1	FTV	.
CAV1	7	116524785	116561184	N	.	N	Y	0.261933591	68.13682931	0.018707972	52	DM	?Lipodystrophy, congenital generalized, type 3, 612526 (3); Pulmonary hypertension, primary, 3, 615343 (3); ?Partial lipodystrophy, congenital cataracts, and neurodegeneration syndrome, 606721 (3)
CAV2	7	116287380	116508541	N	.	N	Y	0.23846774	66.7534873	0.004116385	59	.	.
CAV3	3	8733800	8841808	N	.	N	Y	0.291946181	70.03530706	0.339836386	34.5	DM	Muscular dystrophy, limb-girdle, type IC, 607801 (3); Rippling muscle disease, 606072 (3); Creatine phosphokinase, elevated serum, 123320 (3); Myopathy, distal, Tateyama type, 614321 (3); Cardiomyopathy, familial hypertrophic, 192600 (3); Long QT syndrome 9, 611818 (3)
CBARP	19	1228287	1238027	N	.	N	N	.	.	.	.	.	.
CBFA2T3	16	88874858	88977204	N	.	N	Y	0.797981156	89.14163339	0.454440082	31.3	.	.
CBLB	3	105655461	105869552	N	.	N	Y	-1.180308971	5.805406031	0.913125167	17.1	DM	.
CBLC	19	44777869	44800634	N	.	N	Y	0.200295721	64.41511837	0.00018299	70.1	.	.
CBLL1	7	107743697	107761667	N	.	N	N	-1.16846588	5.909590785	0.997784848	7.1	.	.
CBLN1	16	49277917	49281831	N	.	N	Y	0.06302642	54.36707762	0.814123267	21.1	.	.
CBLN2	18	72536680	72638521	N	.	N	N	-0.155519548	38.35156567	0.318302604	35.2	.	.
CBLN3	14	24426532	24430954	N	Viable	N	Y	0.126877769	59.25218499	0.000188311	70	.	.
CBLN4	20	55997440	56005472	N	.	N	Y	-0.277483031	30.77501881	0.348291543	34.2	.	.
CBR1	21	36069941	36073166	N	.	N	N	0.413101046	76.51212595	0.006462202	56.9	FP	.
CBR3	21	36134912	36146566	N	.	N	N	0.60818461	84.40701511	8.03E-06	78.6	FP	.
CBR4	4	168863770	169010275	N	.	N	N	-0.166697481	37.63384847	8.22E-06	78.6	.	.
CBSL	21	6444869	6468040	N	.	N	N	.	.	.	.	.	.
CBWD1	9	121038	179147	N	.	N	N	.	.	0.642141452	26.3	.	.
CBWD2	2	113437691	113496189	N	.	N	N	0.399859596	75.829137	0.967070796	13.3	.	.
CBWD3	9	68232003	68300015	N	.	N	N	.	.	0.358916975	33.9	.	.
CBWD5	9	65668805	65734041	N	.	N	N	.	.	0.534115236	29	.	.
CBWD7	9	41131306	41199261	N	.	N	N	.	.	.	.	.	.
CBX6	22	38861450	38872314	N	.	N	Y	-0.065330609	44.75314001	0.610925096	27.2	.	.
CBX7	22	39120167	39152674	N	.	N	Y	-0.093581117	42.57683626	0.83745538	20.4	.	.
CBX8	17	79792132	79801683	N	.	N	Y	0.066047521	54.62175146	0.994625905	8.6	.	.
CBY3	5	179678583	179680974	N	.	N	N	.	.	.	.	.	.
CC2D1B	1	52345723	52366193	N	.	N	N	0.850824075	90.21242114	4.76E-10	91.8	.	.
CC2D2B	10	96000091	96032684	N	.	N	N	0.493723196	80.22226081	2.52E-05	75.6	.	.
CCAR1	10	68721012	68792377	N	.	N	N	-1.020002522	7.628639231	0.99874622	6.2	.	.
CCAR2	8	22604632	22621514	N	.	N	Y	-1.337897694	4.422064016	0.960454889	13.9	.	.
CCBL1	9	128832942	128882494	N	.	N	N	0.700285457	86.90166117	6.51E-08	86.6	.	.
CCBL2	1	88935773	88992953	N	.	N	N	0.037949145	52.39335533	3.05E-08	87.6	.	.
CCDC101	16	28553915	28591790	N	.	N	Y	-0.116090248	41.04300515	0.867208408	19.2	.	.
CCDC102A	16	57512178	57536599	N	.	N	N	-0.043626754	46.35063958	9.22E-05	72.1	.	.
CCDC102B	18	68715209	69055189	N	.	N	N	1.066193793	93.58106153	3.31E-09	90	.	.
CCDC103	17	44899142	44905390	N	.	N	N	-0.008177066	48.7989813	0.002185523	61.6	DM	Ciliary dyskinesia, primary, 17, 614679 (3)
CCDC105	19	15010744	15023269	N	.	N	N	0.809009944	89.29791052	2.34E-10	92.3	.	.
CCDC106	19	55641062	55653161	N	.	N	N	0.009699407	50.29229612	0.010803208	54.6	.	.
CCDC107	9	35658290	35661511	N	.	N	N	0.539698884	82.04549401	1.70E-07	85.4	.	.
CCDC108	2	219002846	219041527	N	.	N	N	1.660729856	97.76581582	2.33E-18	98.3	.	.
CCDC109B	4	109560205	109688726	N	Viable	N	Y	0.667255193	86.13763964	0.006149257	57.1	DM?	.
CCDC110	4	185445182	185471759	N	.	N	N	1.36937762	96.21462059	1.35E-08	88.6	.	.
CCDC112	5	115267188	115296831	N	.	N	N	-0.364494105	26.16194941	0.821147626	20.9	.	.
CCDC113	16	58231157	58283836	N	.	N	N	0.40846756	76.27481623	3.95E-13	95.6	.	.
CCDC114	19	48296457	48321894	N	.	N	N	0.812030693	89.37315506	0.002706897	60.8	DM	Ciliary dyskinesia, primary, 20, 615067 (3)
CCDC115	2	130338241	130342349	N	.	N	N	-0.10763024	41.63338543	1.51E-05	77	.	.
CCDC116	22	21632716	21637327	N	Viable	N	Y	1.837536138	98.26937547	3.98E-05	74.5	.	.
CCDC117	22	28772674	28789301	N	.	N	N	-0.106673287	41.69126584	0.619564485	26.9	.	.
CCDC12	3	46921726	46982010	N	.	N	N	-0.070115062	44.4058575	0.77413072	22.5	.	.
CCDC120	X	49053572	49069857	N	Viable	N	Y	0.549114755	82.41014065	0.691311336	24.8	.	.
CCDC121	2	27625639	27629012	N	.	N	N	-0.066287483	44.66631938	9.73E-05	72	.	.
CCDC122	13	43823909	43879727	N	.	N	Y	-0.002587674	49.23887249	8.65E-08	86.3	.	.
CCDC124	19	17933016	17943991	N	.	N	N	0.276939876	69.10922035	0.316957011	35.2	.	.
CCDC125	5	69280175	69332809	N	.	N	N	0.198382189	64.28778144	8.05E-06	78.6	.	.
CCDC126	7	23597379	23644708	N	.	N	N	-0.148973548	38.82039706	0.351142327	34.1	.	.
CCDC127	5	196871	218215	N	Viable	N	Y	0.321150679	71.84696417	0.020957492	51.4	.	.
CCDC129	7	31514071	31658720	N	.	N	N	1.874441992	98.34462002	2.61E-17	97.9	.	.
CCDC13	3	42692663	42773253	N	.	N	N	0.680800377	86.4501939	1.16E-07	86	.	.
CCDC130	19	13731760	13763296	N	.	N	N	0.290331873	69.95427447	0.025049031	50.5	.	.
CCDC136	7	128790757	128822132	N	.	N	N	0.341244376	72.95248018	4.89E-08	87	.	.
CCDC138	2	108786757	108885477	N	.	N	N	-0.515361182	19.6272501	1.08E-05	77.8	.	.
CCDC14	3	123897305	123961408	N	.	N	N	-0.251796722	32.34936621	3.41E-07	84.4	DM?	.
CCDC140	2	222298147	222305217	N	.	N	N	0.118418051	58.60971233	0.063085752	45.7	.	.
CCDC141	2	178829757	179050086	N	.	N	N	.	.	1.43E-09	90.8	.	.
CCDC142	2	74471986	74483408	N	.	N	N	0.37397413	74.63680037	0.000167048	70.3	.	.
CCDC144A	17	16689537	16777881	N	.	N	N	.	.	.	.	.	.
CCDC144NL	17	20836447	20896140	N	.	N	N	1.73599018	98.01470163	8.14E-06	78.6	FTV	.
CCDC146	7	77122434	77329533	N	.	N	N	-0.39692684	24.5586618	3.02E-18	98.2	.	.
CCDC148	2	158171081	158456753	N	.	N	N	0.949007258	92.00092609	7.95E-19	98.4	DM?	.
CCDC149	4	24806117	24980204	N	.	N	N	-0.083207293	43.33506975	0.002049284	61.8	.	.
CCDC15	11	124954121	125041489	N	.	N	N	0.919950548	91.49736644	3.21E-16	97.5	.	.
CCDC150	2	196639554	196763490	N	.	N	N	1.000894538	92.77073566	3.80E-24	99.3	.	.
CCDC151	19	11420604	11435782	N	.	N	Y	0.097167572	56.91381606	8.77E-07	82.7	.	Ciliary dyskinesia, primary, 30, 616037 (3)
CCDC152	5	42756801	42802360	N	.	N	N	.	.	.	.	.	.
CCDC153	11	119189638	119196769	N	.	N	N	0.77693964	88.71331828	0.154452993	40.4	.	.
CCDC154	16	1434383	1444556	N	.	N	N	.	.	0.311572586	35.4	.	.
CCDC155	19	49388218	49417994	N	.	N	N	0.430976902	77.46136482	7.22E-07	83.1	.	.
CCDC157	22	30356635	30378658	N	.	N	N	0.941661328	91.87937721	2.42E-15	97.1	.	.
CCDC158	4	76312997	76421868	N	.	N	N	0.364067005	74.08693639	2.99E-13	95.7	.	.
CCDC159	19	11344684	11354944	N	.	N	Y	0.186902427	63.61058054	9.21E-05	72.1	FP	.
CCDC160	X	134237047	134246207	N	.	N	Y	.	.	0.029462881	49.7	.	.
CCDC166	8	143706694	143708109	N	.	N	N	.	.	.	.	.	.
CCDC167	6	37482920	37499922	N	.	N	N	-0.019507464	47.94813914	0.002089879	61.7	.	.
CCDC168	13	102729369	102759070	N	.	N	N	.	.	.	.	.	.
CCDC169	13	36222008	36297840	N	.	N	N	.	.	.	.	.	.
CCDC169-SOHLH2	13	36168794	36297842	N	.	N	N	0.142034241	60.34033686	0.429898601	32	.	.
CCDC17	1	45620044	45624057	N	.	N	N	0.771492772	88.59755745	3.59E-13	95.7	.	.
CCDC170	6	151494030	151621193	N	.	N	N	2.094636594	98.72663078	1.02E-19	98.6	.	.
CCDC171	9	15552897	16061663	N	.	N	N	-0.537984272	18.68958731	.	.	.	.
CCDC172	10	116324428	116380029	N	.	N	N	-0.008177066	48.7989813	0.008329616	55.7	.	.
CCDC173	2	169645425	169694433	N	.	N	N	1.214357007	95.18434913	1.08E-15	97.3	.	.
CCDC175	14	59504539	59576831	N	.	N	N	.	.	.	.	.	.
CCDC176	14	74019353	74082863	N	.	N	N	0.787456004	88.92747583	0.000124143	71.2	.	.
CCDC177	14	69569816	69574837	N	.	N	N	.	.	.	.	.	.
CCDC178	18	32937402	33441101	N	.	N	N	0.767166977	88.48758465	4.11E-29	99.6	.	.
CCDC179	11	22846931	22860426	N	.	N	N	.	.	.	.	.	.
CCDC18	1	93179919	93278730	N	.	N	N	.	.	.	.	DM?	.
CCDC180	9	97307304	97378524	N	.	N	N	-0.224724976	34.03947445	5.35E-22	99	.	.
CCDC181	1	169394870	169460669	N	Viable	N	Y	0.076420824	55.39156103	3.80E-07	84.2	.	.
CCDC182	17	57744481	57745312	N	.	N	N	.	.	.	.	.	.
CCDC183	9	136796350	136807741	N	.	N	N	1.133727624	94.37402327	.	.	.	.
CCDC184	12	48183584	48185926	N	.	N	N	.	.	.	.	.	.
CCDC185	1	223393417	223395470	N	.	N	N	.	.	.	.	.	.
CCDC186	10	114120862	114174220	N	.	N	N	.	.	.	.	.	.
CCDC22	X	49235467	49250526	N	.	N	N	0.836155347	89.91144296	0.995198908	8.3	DM	.
CCDC24	1	43991359	43996528	N	.	N	N	0.147623843	60.84968455	2.01E-08	88.1	.	.
CCDC25	8	27733311	27772653	N	.	N	N	-0.125507302	40.39474446	0.051834011	46.8	.	.
CCDC27	1	3752398	3771645	N	.	N	N	1.436915322	96.61399549	1.61E-19	98.5	.	.
CCDC28A	6	138773509	138793319	N	.	N	N	0.502182723	80.52902703	1.50E-05	77.1	.	.
CCDC28B	1	32200386	32205387	N	.	N	N	0.172852824	62.72501013	9.97E-08	86.1	DFP	{Bardet-Biedl syndrome 1, modifier of}, 209900 (3)
CCDC3	10	12896625	13099652	N	.	N	N	-0.029729296	47.29987845	0.000821908	65.4	.	.
CCDC30	1	42463330	42654664	N	.	N	N	-0.137338205	39.61914684	6.07E-12	94.5	.	.
CCDC33	15	74236289	74336472	N	Viable	N	Y	0.373171102	74.58470799	8.63E-09	89.1	DM?	.
CCDC34	11	27330827	27363868	N	.	N	N	-0.191924635	36.05950107	4.91E-07	83.8	.	.
CCDC36	3	49198428	49258104	N	.	N	N	-0.136532991	39.65966314	0.509348612	29.7	.	.
CCDC37	3	126394939	126436556	N	.	N	N	0.518447004	81.21201597	4.73E-14	96.3	.	.
CCDC38	12	95867048	95942974	N	.	N	N	0.748175766	88.07084563	1.57E-08	88.4	.	.
CCDC39	3	180602858	180871005	N	.	N	Y	0.712573182	87.22000347	5.10E-05	73.8	DM	Ciliary dyskinesia, primary, 14, 613807 (3)
CCDC42	17	8729934	8745219	N	.	N	N	0.710509334	87.14475893	1.69E-05	76.7	FTV	.
CCDC42B	12	113149858	113159276	N	.	N	N	.	.	.	.	.	.
CCDC43	17	44673069	44689779	N	.	N	N	-0.071071979	44.35376512	0.000257178	69.1	.	.
CCDC50	3	191329077	191398670	N	.	N	N	-0.051129725	45.70237889	9.33E-06	78.2	DM	?Deafness, autosomal dominant 44, 607453 (3)
CCDC51	3	48432164	48440456	N	.	N	N	0.468492577	79.26144585	1.46E-06	82	.	.
CCDC53	12	102012927	102062149	N	.	N	N	0.093995484	56.69387046	0.035125929	48.9	.	.
CCDC54	3	107377194	107378637	N	.	N	N	0.935614038	91.8099207	8.55E-08	86.3	.	.
CCDC57	17	82101460	82212830	N	.	N	Y	.	.	2.64E-13	95.8	.	.
CCDC58	3	122359591	122383231	N	.	N	N	-0.141470476	39.31238062	0.080276122	44.4	.	.
CCDC59	12	82223681	82358805	N	.	N	N	0.398094787	75.74231637	0.000680495	66	.	.
CCDC6	10	59788763	59906656	N	.	N	N	-0.344856099	27.00700353	0.967799856	13.2	.	.
CCDC60	12	119334712	119541047	N	.	N	N	1.833705251	98.25201134	8.62E-06	78.5	.	.
CCDC61	19	45995461	46021318	N	.	N	N	0.837111437	89.94617121	2.17E-05	76	.	.
CCDC62	12	122774327	122827528	N	.	N	N	0.417078537	76.69734329	1.44E-12	95.1	.	.
CCDC63	12	110846769	110907535	N	.	N	N	1.419033617	96.47508248	4.48E-10	91.8	.	.
CCDC64	12	119989869	120094494	N	Viable	N	Y	-0.593415811	16.91265845	0.549254949	28.7	.	.
CCDC64B	16	3027682	3036926	N	.	N	N	.	.	5.73E-06	79.3	.	.
CCDC65	12	48904110	48931840	N	.	N	N	0.949812072	92.00671413	9.60E-07	82.6	.	Ciliary dyskinesia, primary, 27, 615504 (3)
CCDC66	3	56557161	56621818	N	.	N	N	0.764453356	88.44706836	8.99E-28	99.6	.	.
CCDC67	11	93329971	93438487	N	.	N	N	0.190879187	63.84789026	2.60E-11	93.7	.	.
CCDC68	18	54901509	54959508	N	.	N	N	0.171089591	62.59767321	6.41E-07	83.3	.	.
CCDC69	5	151181052	151224145	N	Viable	N	Y	0.566034018	82.93685246	3.79E-08	87.3	.	.
CCDC7	10	32567723	32882874	N	.	N	Y	1.434847045	96.59663136	3.52E-09	90	.	.
CCDC70	13	51861981	51866232	N	.	N	N	0.578171457	83.38831973	0.053153462	46.7	.	.
CCDC71	3	49162535	49166321	N	.	N	N	0.085837372	56.15558257	0.016989639	52.5	.	.
CCDC71L	7	106656765	106660996	N	.	N	N	.	.	0.482182658	30.5	.	.
CCDC73	11	32602246	32794658	N	.	N	N	0.161171425	61.8510158	1.19E-13	96	.	.
CCDC74A	2	131527675	131533666	N	.	N	N	2.839738644	99.40961973	1.17E-05	77.7	.	.
CCDC74B	2	130139287	130145134	N	.	N	N	1.754826223	98.07837009	1.19E-06	82.3	.	.
CCDC77	12	389273	442645	N	.	N	Y	-0.01265806	48.49800313	9.40E-15	96.7	.	.
CCDC78	16	722582	726954	N	.	N	N	2.104860104	98.73820686	1.71E-19	98.5	DM	Myopathy, centronuclear, 4, 614807 (3)
CCDC79	16	66754976	66801620	N	Viable	N	Y	.	.	.	.	.	.
CCDC8	19	46410372	46413584	N	.	N	N	0.682560097	86.50807432	0.167397003	39.8	DM	3-M syndrome 3, 614205 (3)
CCDC80	3	112596794	112649530	N	.	N	Y	0.296381077	70.27261677	0.005843099	57.4	.	.
CCDC81	11	86374736	86423109	N	.	N	N	0.430170878	77.43821265	2.79E-09	90.2	.	.
CCDC82	11	96352769	96389923	N	.	N	N	0.238767519	66.77663946	1.73E-07	85.4	.	.
CCDC83	11	85855101	85920021	N	.	N	N	0.326890353	72.17109452	6.83E-07	83.2	.	.
CCDC84	11	118998142	119015791	N	.	N	N	0.404641438	76.06644672	4.70E-06	79.7	.	.
CCDC85A	2	56184123	56386173	N	.	N	N	-0.414144703	23.73097181	0.001735205	62.4	.	.
CCDC85B	11	65890112	65891635	N	.	N	N	.	.	0.491379558	30.2	.	.
CCDC85C	14	99500180	99604026	N	.	N	N	.	.	.	.	.	.
CCDC87	11	66590176	66593083	N	.	N	N	0.936073992	91.81570875	3.06E-06	80.5	.	.
CCDC88A	2	55287842	55419921	N	.	N	Y	-2.124905547	1.412282225	0.999999956	1	.	.
CCDC88B	11	64340223	64357534	N	.	N	N	1.636208397	97.67320715	0.000929045	65	.	.
CCDC88C	14	91271323	91417844	N	Viable	N	Y	2.162651248	98.79608728	2.17E-06	81.2	DM	Hydrocephalus, nonsyndromic, autosomal recessive, 236600 (3); ?Spinocerebellar ataxia 40, 616053 (3)
CCDC89	11	85684866	85686277	N	.	N	N	0.324977012	72.03796955	0.005821824	57.4	.	.
CCDC9	19	47255980	47271953	N	.	N	N	0.743543456	87.94929675	1.57E-06	81.8	.	.
CCDC90B	11	83259097	83286407	N	.	N	N	0.615687917	84.61538462	0.009063821	55.3	DM?	.
CCDC91	12	28133249	28581511	N	.	N	N	0.090470018	56.47392487	3.15E-05	75.1	.	.
CCDC92	12	123918660	123972831	N	.	N	N	-0.038994253	46.68055797	0.368849606	33.7	.	.
CCDC93	2	117915478	118014133	N	.	N	N	0.103713727	57.49262025	0.064375261	45.6	.	.
CCDC96	4	7040849	7042939	N	.	N	N	-0.391635495	24.88858019	2.71E-06	80.7	.	.
CCDC97	19	41310189	41324883	N	.	N	N	0.153364212	61.26642357	2.84E-08	87.7	.	.
CCER1	12	90905622	90955176	N	.	N	N	0.082010267	55.87196851	4.85E-07	83.8	.	.
CCER2	19	38908980	38912158	N	.	N	N	.	.	.	.	.	.
CCHCR1	6	31142439	31158238	N	.	N	N	1.432285506	96.58505528	6.50E-08	86.6	DP	.
CCIN	9	36169394	36171334	N	.	N	N	0.166608064	62.25617873	0.010492041	54.7	.	.
CCK	3	42257825	42266207	N	Viable	N	Y	0.078032613	55.54205012	0.023105402	50.9	DP	.
CCKAR	4	26481400	26490462	N	.	N	Y	0.450766518	78.38166348	0.017408483	52.3	DP	.
CCKBR	11	6259736	6272127	N	.	N	Y	0.141228615	60.28824449	9.67E-05	72	DP	.
CCL1	17	34360328	34363231	N	.	N	Y	0.206542259	64.76240088	0.063040841	45.7	.	.
CCL11	17	34285668	34288334	N	.	N	Y	-0.004501323	49.10574753	0.083041004	44.2	FP	{HIV1, resistance to}, 609423 (3); {Asthma, susceptibility to}, 600807 (3)
CCL13	17	34356452	34358610	N	.	N	N	0.502036857	80.5116629	0.051133284	46.9	FP	.
CCL14	17	35983291	35987004	N	.	N	N	0.381984452	75.00723505	0.000121912	71.3	.	.
CCL15	17	35996440	36002038	N	.	N	N	0.768480455	88.5223129	0.076707705	44.6	.	.
CCL15-CCL14	17	35983656	36001621	N	.	N	N	.	.	.	.	.	.
CCL16	17	35976493	35981496	N	.	N	N	0.70749651	87.0579383	0.09206146	43.6	.	.
CCL17	16	57404767	57416062	N	.	N	Y	0.304083576	70.74144817	0.077124722	44.6	FP	.
CCL18	17	36064280	36072032	N	.	N	N	0.266567586	68.44359553	0.010306615	54.8	.	.
CCL19	9	34689567	34691277	N	.	N	Y	0.152107222	61.13329861	0.317197583	35.2	.	.
CCL2	17	34255218	34257203	N	.	N	Y	0.228095308	66.11101464	0.667686005	25.6	DFP	{HIV-1, resistance to}, 609423 (3); {Spina bifida, susceptibility to}, 182940 (3); {Coronary artery disease, modifier of} (3); {Mycobacterium tuberculosis, susceptibility to}, 607948 (3)
CCL20	2	227813842	227817564	N	.	N	N	0.244058053	67.12392198	0.087740002	43.9	.	.
CCL21	9	34709005	34710124	N	.	N	N	0.018007904	50.90004052	0.110386514	42.6	.	.
CCL22	16	57358772	57366190	N	.	N	Y	0.184989352	63.48903166	0.279053455	36.2	DP	.
CCL23	17	36013056	36017968	N	.	N	N	0.284443026	69.58383979	0.042812014	47.9	.	.
CCL24	7	75811665	75823356	N	.	N	Y	0.230008154	66.23835157	0.01718922	52.4	.	.
CCL25	19	8052767	8062650	N	.	N	Y	0.540509506	82.06864618	0.169939684	39.7	.	.
CCL26	7	75769533	75789896	N	Viable	N	Y	0.281573966	69.3928344	0.019786154	51.8	DM?	.
CCL27	9	34661880	34664048	N	.	N	N	0.230008154	66.23835157	0.016889411	52.5	.	.
CCL28	5	43376645	43412391	N	.	N	N	0.268480327	68.6056607	0.281065701	36.2	.	.
CCL3	17	36088256	36090169	N	.	N	Y	0.411041265	76.39636511	0.145338664	40.8	.	{HIV infection, resistance to}, 609423 (2)
CCL3L3	17	36194869	36196758	N	.	N	N	.	.	.	.	.	.
CCL4	17	36103590	36105621	N	.	N	N	0.487986222	79.98495109	0.264898889	36.7	.	.
CCL4L2	17	36210924	36212878	N	.	N	N	.	.	0.48993731	30.2	.	.
CCL5	17	35871491	35880793	N	.	N	Y	0.312543059	71.22764369	0.012909422	53.9	DFP	{HIV-1 disease, delayed progression of} (3); {HIV-1 disease, rapid progression of} (3)
CCL7	17	34270221	34272242	N	.	N	Y	0.374481231	74.6541645	0.009262338	55.2	DFP	.
CCL8	17	34319036	34321402	N	Viable	N	Y	0.510496156	80.89367367	0.052901134	46.7	.	.
CCM2L	20	32010450	32032180	N	.	N	Y	0.039711445	52.54384442	0.000537998	66.8	.	.
CCNA1	13	36431520	36442882	N	.	N	Y	-0.099974947	42.10800486	0.009906296	55	.	.
CCNB1IP1	14	20311368	20333312	N	.	N	N	0.310778106	71.09451872	0.183416412	39.2	.	.
CCNB3	X	50202713	50351910	N	.	N	N	0.347790268	73.27661052	0.570886943	28.2	.	.
CCNC	6	99542380	99568973	N	.	N	N	-0.171482763	37.26341379	0.990104534	9.9	.	.
CCND2	12	4273772	4305350	N	.	N	Y	-0.297120516	29.6000463	0.949000818	14.8	.	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938 (3)
CCND3	6	41934933	42050357	N	.	N	Y	0.098778904	57.07588123	0.946445162	15.1	.	.
CCNDBP1	15	43185118	43197176	N	.	N	Y	-0.497789345	20.304451	0.037272546	48.6	.	.
CCNE1	19	29811898	29824308	N	.	N	Y	-0.33080711	27.69578052	0.268926805	36.5	DFP	.
CCNE2	8	94879770	94896678	N	.	N	Y	-0.241727755	32.9281704	0.338179976	34.6	.	.
CCNG1	5	163437569	163446151	N	.	N	Y	0.212281357	65.20808011	0.359162745	33.9	.	.
CCNG2	4	77157151	77433388	N	.	N	N	-0.240770687	32.9976269	0.89320436	18	.	.
CCNH	5	87391494	87413019	N	.	N	N	0.822104421	89.58152457	0.004729763	58.4	.	.
CCNI	4	77047158	77076005	N	.	N	Y	-0.331764245	27.65526422	0.789094043	22	.	.
CCNI2	5	132747445	132754403	N	.	N	N	0.194405525	64.08519998	4.53E-05	74.2	.	.
CCNJ	10	96043394	96060870	N	.	N	N	-0.340224471	27.22116108	0.983940396	11.1	.	.
CCNJL	5	160251652	160345396	N	.	N	N	-0.120570168	40.6899346	1.95E-05	76.3	.	.
CCNL1	3	157146508	157160760	N	.	N	N	-0.293291902	29.80841581	0.942872593	15.4	.	.
CCNL2	1	1385711	1399328	N	.	N	N	0.097167572	5.69E+01	0.104548195	42.8	.	.
CCNO	5	55231152	55233680	N	.	N	N	0.538742637	81.99918967	0.040710125	48.2	.	Ciliary dyskinesia, primary, 29, 615872 (3)
CCNT1	12	48688458	48716998	N	.	N	N	0.167564929	62.36036349	0.995809373	8.1	.	.
CCNY	10	35247025	35572669	N	.	N	Y	-0.135728413	39.6828153	0.384469091	33.2	.	.
CCNYL1	2	207711540	207761839	N	.	N	Y	-0.047605945	46.02072119	0.977770144	12.1	.	.
CCP110	16	19523811	19553408	N	.	N	N	-0.591201517	17.01105516	0.015731918	52.9	.	.
CCPG1	15	55340032	55408510	N	.	N	N	-0.310864193	28.90548128	0.962563039	13.7	.	.
CCR1	3	46201709	46208396	N	.	N	Y	0.002196401	49.64982346	0.891828752	18.1	DP	.
CCR2	3	46353734	46360928	N	.	N	Y	-0.607465004	16.53643572	0.011463318	54.3	DP	{HIV infection, susceptibility/resistance to} (3)
CCR3	3	46163604	46266706	N	.	N	Y	1.021979115	93.07171384	0.031893053	49.4	DFP	.
CCR4	3	32951574	32956349	N	.	N	Y	-0.610336728	16.45540314	0.760806753	22.8	.	.
CCR5	3	46370854	46376206	N	.	N	Y	0.553897176	82.57799386	3.51E-08	87.4	DFP	{HIV infection, susceptibility/resistance to} (3); {West nile virus, susceptibility to}, 610379 (3); {Hepatitis C virus, resistance to}, 609532 (3); {Diabetes mellitus, insulin-dependent, 22}, 612522 (3)
CCR6	6	167111807	167139696	N	Viable	N	Y	-0.421801054	23.46472188	0.066481499	45.4	DFP	.
CCR7	17	40553769	40565472	N	.	N	Y	-0.496832081	20.33339121	0.647008605	26.1	FP	.
CCR8	3	39329706	39333511	N	.	N	Y	0.322107219	71.89326851	0.017625819	52.3	.	.
CCR9	3	45886504	45903177	N	.	N	Y	0.57162449	83.15679806	0.004640309	58.5	.	.
CCRL2	3	46407163	46412997	N	.	N	Y	0.210518064	65.10968339	0.002163778	61.6	DP	.
CCS	11	66592821	66606019	N	.	N	Y	-0.042821613	46.39115587	3.77E-06	80.1	DM	.
CCSAP	1	229321005	229343294	N	.	N	N	0.367934269	74.27215373	0.111783071	42.5	.	.
CCSER1	4	90127535	91601913	N	.	N	N	0.065242053	54.58123517	0.211350847	38.4	.	.
CCSER2	10	84328586	84518521	N	.	N	N	-0.630630498	15.85923482	0.475105131	30.7	.	.
CCT2	12	69585334	69601570	N	.	N	N	-0.780997286	11.9754587	0.999501007	5.2	.	.
CCT4	2	61868089	61888804	N	.	N	N	-0.301598985	29.37431267	0.99918405	5.7	.	.
CCT5	5	10249921	10266412	N	.	N	N	-0.688086328	14.26173525	0.998786782	6.1	DM	Neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3)
CCT6A	7	56051630	56063989	N	.	N	N	-0.167501818	37.55860392	0.998661755	6.3	.	.
CCT6B	17	34927859	34981078	N	.	N	N	0.503288375	80.58111941	8.86E-05	72.3	.	.
CCT7	2	73233420	73253021	N	.	N	N	-0.591501503	16.99369103	0.989844502	10	.	.
CCT8	21	29055805	29073797	N	.	N	N	-0.628060421	15.93447937	0.98279276	11.3	.	.
CCT8L2	22	16590751	16592810	N	.	N	N	1.046553959	93.33217572	0.001833343	62.2	.	.
CCZ1	7	5898725	5926550	N	.	N	N	0.48445544	79.89234242	0.994694688	8.5	.	.
CCZ1B	7	6794134	6826770	N	.	N	N	0.610097161	84.49383574	.	.	.	.
CD101	1	117001750	117036476	N	.	N	Y	0.951245864	92.02407825	5.54E-10	91.6	.	.
CD109	6	73695785	73828316	N	Viable	N	Y	1.033174539	93.18168664	2.29E-32	99.8	FP	.
CD14	5	140631728	140633701	N	.	N	Y	-0.371997156	25.78572669	6.69E-05	73.1	DFP	.
CD151	11	832843	839831	N	.	N	Y	-0.080336605	43.59553163	0.001643112	62.7	DM?	Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3); [Blood group, Raph], 179620 (3)
CD160	1	145719471	145739288	N	.	N	N	0.178442775	63.08386873	1.91E-05	76.4	.	.
CD163	12	7470813	7503893	N	Viable	N	Y	-0.413845749	23.73675985	0.015136904	53.1	.	.
CD163L1	12	7346685	7479897	N	.	N	N	0.258221817	67.93424784	2.22E-17	97.9	.	.
CD164	6	109366514	109382559	N	.	N	N	-0.041059779	46.53585692	0.401084248	32.7	.	.
CD164L2	1	27379176	27383380	N	.	N	N	0.079946001	55.69832726	0.033744866	49.1	.	.
CD177	19	43353659	43363172	N	.	N	N	-0.340071051	27.25010129	.	.	DM	.
CD180	5	67179613	67196799	N	.	N	Y	0.426495593	77.18932685	1.35E-05	77.3	.	.
CD19	16	28931939	28939346	N	.	N	Y	-0.521102007	19.43624472	0.853622377	19.7	DM	Immunodeficiency, common variable, 3, 613493 (3)
CD1A	1	158254137	158258269	N	.	N	N	0.318430612	71.66753487	5.01E-17	97.8	DP	.
CD1B	1	158327951	158331531	N	.	N	N	0.515424669	81.09625514	1.15E-07	86	.	.
CD1C	1	158289786	158293630	N	.	N	N	-0.221936642	34.22469179	6.44E-07	83.3	.	.
CD1D	1	158179947	158184896	N	.	N	Y	0.703005985	86.95375355	0.000899329	65.1	.	.
CD1E	1	158353696	158357553	N	.	N	N	0.517337954	81.13677143	8.78E-13	95.3	DP	.
CD2	1	116754385	116769228	N	.	N	Y	-0.123440781	40.55680963	0.768323769	22.7	DP	.
CD200	3	112332347	112362812	N	.	N	Y	0.038754674	52.485964	0.16023863	40.2	.	.
CD200R1	3	112921209	112975122	N	.	N	Y	0.450616788	78.37587544	7.04E-09	89.3	.	.
CD200R1L	3	112815709	112846856	N	Viable	N	Y	0.427150878	77.22984314	0.003062273	60.3	.	.
CD207	2	70830214	70835822	N	.	N	Y	.	.	1.65E-06	81.7	DM	?[Birbeck granule deficiency], 613393 (3)
CD209	19	7739994	7747564	N	.	N	Y	0.447896377	78.26590265	2.96E-08	87.6	DFP	{Dengue fever, protection against}, 614371 (3); {HIV type 1, susceptibility to}, 609423 (3); {Mycobacterium tuberculosis, susceptibility to}, 607948 (3)
CD22	19	35319261	35347355	N	.	N	Y	-0.107981578	41.58708109	0.030849875	49.5	DP	.
CD226	18	69831158	69961803	N	.	N	Y	0.610097161	84.49383574	0.505154015	29.8	DFP	.
CD24	6	106969831	106975627	N	.	N	Y	.	.	.	.	DFP	.
CD244	1	160830160	160862855	N	.	N	Y	0.066047521	54.62175146	0.001747172	62.4	DFP	{Rheumatoid arthritis, susceptibility to}, 180300 (3)
CD248	11	66314487	66317044	N	Viable	N	Y	0.982851246	92.56236615	0.541815275	28.8	.	.
CD27	12	6444867	6451718	N	.	N	Y	-0.226721694	33.94107773	0.266793353	36.6	DM	Lymphoproliferative syndrome 2, 615122 (3)
CD276	15	73683966	73714518	N	.	N	Y	0.960340612	92.2092956	2.02E-05	76.2	.	.
CD28	2	203706475	203738912	N	.	N	Y	0.241337169	66.9618568	0.511989197	29.6	.	.
CD2AP	6	47477789	47627263	N	.	N	Y	0.059652711	54.08346356	0.813221347	21.2	DM	Glomerulosclerosis, focal segmental, 3, 607832 (3)
CD2BP2	16	30350766	30355361	N	.	N	N	-0.181550908	36.64988135	0.000336174	68.3	.	.
CD300A	17	74466416	74484796	N	.	N	Y	0.124158088	59.0611796	8.94E-07	82.7	.	.
CD300C	17	74541108	74546143	N	.	N	Y	0.084729555	56.09191411	0.000578296	66.6	.	.
CD300E	17	74609887	74623738	N	.	N	N	.	.	0.080460666	44.4	.	.
CD300LB	17	74521174	74531474	N	.	N	Y	.	.	0.000639118	66.3	.	.
CD300LD	17	74579365	74592283	N	.	N	N	0.833287532	89.86513862	0.046219391	47.4	.	.
CD300LF	17	74694311	74712978	N	.	N	Y	0.489089088	80.05440759	4.97E-06	79.6	.	.
CD300LG	17	43847148	43863629	N	.	N	Y	0.589500178	83.82242287	0.029935109	49.6	DP	.
CD302	2	159768630	159798255	N	.	N	N	-0.116090248	41.04300515	0.009385287	55.2	.	.
CD320	19	8302127	8308356	N	.	N	N	0.621278951	84.78323783	0.05992656	46	DM	Methylmalonic aciduria due to transcobalamin receptor defect, 613646 (3)
CD33	19	51225064	51243860	N	Viable	N	Y	1.539909426	97.16964751	2.31E-05	75.9	DP	.
CD34	1	207880972	207911402	N	.	N	Y	0.479673105	79.74185333	0.003449569	59.8	.	.
CD36	7	80369575	80679277	N	.	N	Y	0.910689415	91.28899693	8.31E-46	100	DM	[Macrothrombocytopenia] (1); Platelet glycoprotein IV deficiency, 608404 (3); {Malaria, cerebral, susceptibility to}, 611162 (3); {Malaria, cerebral, reduced risk of}, 611162 (3); {Coronary heart disease, susceptibility to, 7}, 610938 (3)
CD37	19	49335171	49343335	N	.	N	Y	-0.133814513	39.83909244	0.006401814	56.9	.	.
CD38	4	15778275	15853230	N	.	N	Y	0.502182723	80.52902703	7.66E-05	72.7	DP	.
CD3D	11	118338954	118342744	N	.	N	Y	0.012418429	50.43120912	0.006627946	56.8	DM	Immunodeficiency 19, 615617 (3)
CD3E	11	118304545	118316175	N	.	N	Y	0.247883787	67.32650344	0.302672925	35.7	DM	Immunodeficiency 18, 615615 (3); Immunodeficiency 18, SCID variant, 615615 (3)
CD3EAP	19	45406209	45410766	N	.	N	N	0.413251052	76.53527812	5.69E-05	73.5	DP	.
CD3G	11	118344344	118355161	N	.	N	Y	0.344468409	73.11454535	0.025030528	50.5	DM	Immunodeficiency 17, CD3 gamma deficient, 615607 (3)
CD4	12	6786858	6820808	N	.	N	Y	0.886914013	90.88962204	0.001506887	63	FP	OKT4 epitope deficiency, 613949 (3)
CD40	20	46118272	46129863	N	.	N	Y	0.250753302	67.48856862	0.658237504	25.8	DM	Immunodeficiency with hyper-IgM, type 3, 606843 (3)
CD40LG	X	136648193	136660390	N	.	N	Y	0.131510986	59.50685883	0.864433713	19.3	DM	Immunodeficiency, X-linked, with hyper-IgM, 308230 (3)
CD44	11	35138870	35232402	N	.	N	Y	0.70139538	86.92481334	0.008269385	55.7	DFP	[Blood group, Indian system], 609027 (3)
CD46	1	207752057	207795513	N	.	N	Y	-0.289463756	30.10939399	0.000191603	69.9	DM	{Hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3)
CD47	3	108043298	108091025	N	.	N	Y	-0.350599275	26.7407536	0.886113811	18.4	.	.
CD48	1	160678746	160711851	N	.	N	Y	0.296728366	70.30734503	0.000152359	70.6	.	.
CD5	11	61102395	61127852	N	Viable	N	Y	-0.07363864	44.1569717	2.73E-05	75.4	DM?	.
CD52	1	26317957	26320523	N	.	N	Y	0.546101147	82.2654396	0.530686212	29.1	.	.
CD53	1	110873154	110899928	N	.	N	N	-0.076661182	43.91387394	0.024019828	50.7	.	.
CD55	1	207321508	207360966	N	.	N	Y	-0.093428832	42.59420038	2.49E-07	84.8	DFP	[Blood group Cromer], 613793 (3)
CD58	1	116514535	116571039	N	.	N	N	0.315412023	71.43022515	0.299199171	35.7	DFP	.
CD59	11	33698261	33736445	N	.	N	Y	-0.027010532	47.48509579	0.068380919	45.2	DM	Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 (3)
CD5L	1	157830914	157898256	N	Viable	N	Y	-0.114980914	41.14140186	7.10E-07	83.1	.	.
CD6	11	60971680	61020377	N	.	N	N	-0.512641945	19.71985877	0.004304658	58.8	DFP	.
CD63	12	55725323	55729707	N	.	N	Y	-0.015680094	48.2317532	0.007160776	56.5	.	.
CD68	17	7579467	7582113	N	.	N	Y	-0.076509147	43.9370261	0.000599774	66.5	.	.
CD69	12	9752486	9760901	N	.	N	Y	0.080902701	55.81408809	0.018883358	52	.	.
CD7	17	82314868	82317602	N	.	N	Y	0.657839783	85.8424495	0.445277574	31.6	.	.
CD70	19	6583183	6604103	N	.	N	Y	-0.237096056	33.23493662	0.045752208	47.5	.	.
CD72	9	35609533	35646810	N	.	N	Y	0.108195341	57.87463101	0.956612026	14.2	FP	.
CD74	5	150401637	150412929	N	.	N	Y	0.507773402	80.77212479	0.050058058	47	.	.
CD79A	19	41877120	41881372	N	.	N	Y	0.528370887	81.58245066	0.94856776	14.9	DM	Agammaglobulinemia 3, 613501 (3)
CD79B	17	63928740	63932354	N	.	N	Y	-0.001630854	49.29675291	0.950002657	14.8	DM	Agammaglobulinemia 6, 612692 (3)
CD80	3	119524293	119559602	N	.	N	Y	0.213237933	65.26017248	0.255224581	36.9	.	.
CD81	11	2376177	2397419	N	.	N	Y	-0.561644168	17.8734734	0.950521598	14.7	DM	Immunodeficiency, common variable, 6, 613496 (3)
CD82	11	44564427	44620363	N	.	N	N	0.238616903	66.76506338	0.004961833	58.1	.	{Prostate cancer, susceptibility to}, 176807 (2)
CD83	6	14117256	14136918	N	Viable	N	Y	0.332331078	72.43734445	0.017780686	52.2	.	.
CD84	1	160541095	160579516	N	Viable	N	Y	0.33806995	72.74989871	0.000390057	67.8	.	.
CD86	3	122055366	122121139	N	.	N	Y	0.583762331	83.63720553	0.962700436	13.7	DFP	.
CD8A	2	86784610	86808396	N	.	N	Y	0.021835061	51.22417086	0.024181099	50.6	DM	CD8 deficiency, familial, 608957 (3)
CD8B	2	86815339	86861924	N	.	N	Y	0.224417956	65.88528101	0.412381163	32.5	.	.
CD9	12	6199715	6238271	N	.	N	Y	0.014332026	50.57012213	0.147688595	40.7	.	.
CD93	20	23079349	23086340	N	.	N	Y	1.281245278	95.67054465	7.82E-10	91.3	.	.
CD96	3	111292719	111665750	N	.	N	N	-0.362428915	26.23719396	1.00E-05	78	DM	C syndrome, 211750 (3)
CD99	X	2691179	2741309	N	.	N	N	0.370803213	74.41685478	0.217612898	38.1	.	.
CD99L2	X	150766337	150898816	N	.	N	N	0.673802557	86.26497656	0.003341338	59.9	.	.
CDA	1	20588948	20618908	N	.	N	N	0.321958851	71.87011634	0.787227682	22.1	DM?	.
CDADC1	13	49247925	49293485	N	.	N	N	-0.245402639	32.7487411	6.89E-08	86.6	.	.
CDC14A	1	100351734	100520277	N	.	N	N	-0.552877054	18.12814725	0.015618479	52.9	.	.
CDC14B	9	96490241	96619830	N	.	N	Y	-0.243488712	32.84134977	0.576306679	28.1	.	.
CDC16	13	114234887	114272723	N	.	N	N	-0.400095467	24.4197488	0.95225535	14.5	.	.
CDC20B	5	55112995	55173175	N	.	N	N	0.368232636	74.30688198	1.44E-11	94.1	.	.
CDC23	5	138187648	138213343	N	.	N	N	-0.676908408	14.57428952	0.999307693	5.5	.	.
CDC25B	20	3786772	3806121	N	.	N	Y	0.179700355	63.18226544	0.590733232	27.7	.	.
CDC25C	5	138285265	138338355	N	.	N	Y	-0.059589522	45.15830295	3.01E-08	87.6	.	.
CDC27	17	47117703	47189422	N	.	N	N	4.646981931	99.82635874	0.486673202	30.3	FTV	.
CDC37	19	10391134	10420121	N	.	N	N	-0.002436163	49.25623662	0.962357896	13.7	.	.
CDC37L1	9	4679559	4708398	N	.	N	N	-0.285788866	30.29461133	0.935601046	15.8	.	.
CDC40	6	110180141	110254275	N	.	N	N	-0.306383832	29.09069862	0.973128081	12.6	.	.
CDC42BPA	1	226989865	227318474	N	.	N	N	-1.783314704	2.239972217	0.999920148	3.6	.	.
CDC42BPB	14	102932379	103057462	N	.	N	N	-2.63077268	0.856630202	1	0.5	DM	.
CDC42BPG	11	64823387	64844569	N	.	N	N	-0.560628611	17.90241361	1.41E-17	98	.	.
CDC42EP1	22	37560447	37569405	N	.	N	N	0.8382163	89.98089946	1.06E-05	77.9	.	.
CDC42EP2	11	65314818	65322429	N	.	N	N	0.272306077	68.81981826	0.150921493	40.5	.	.
CDC42EP3	2	37641882	37738468	N	.	N	N	-0.27924293	30.68241014	0.275699033	36.3	.	.
CDC42EP4	17	73283624	73312175	N	.	N	N	0.341896466	72.98142039	0.097590183	43.3	.	.
CDC42EP5	19	54465026	54473264	N	.	N	N	.	.	0.359353006	33.9	.	.
CDC42SE1	1	151050971	151070325	N	.	N	N	0.08362237	55.98772935	0.013519491	53.7	.	.
CDC42SE2	5	131245493	131398447	N	.	N	N	0.076119241	55.36840887	0.753728627	23	.	.
CDC5L	6	44387525	44450426	N	.	N	N	-0.973216156	8.317416218	0.999992549	2.4	.	.
CDCA2	8	25458997	25507920	N	.	N	N	-0.043173207	46.36221566	1.61E-05	76.8	.	.
CDCA3	12	6844793	6852066	N	.	N	N	0.060307001	54.1297679	0.913578465	17.1	.	.
CDCA4	14	105009573	105021148	N	.	N	N	0.245163355	67.1818024	0.499553163	30	.	.
CDCA7	2	173354820	173368997	N	.	N	N	-0.646895469	15.48880014	0.141954503	41	.	.
CDCA7L	7	21900900	21946084	N	.	N	N	0.01926743	51.03895352	0.120661405	42	DM?	.
CDCP1	3	45082278	45146422	N	.	N	Y	-0.007722577	48.82213347	0.021152526	51.3	.	.
CDCP2	1	54133074	54153770	N	.	N	N	0.793195884	89.0606008	6.92E-10	91.4	FTV	.
CDH10	5	24487100	24644978	N	Viable	N	Y	-1.410357166	3.872200035	0.309152977	35.5	.	.
CDH11	16	64943753	65126112	N	.	N	N	-0.745093372	12.7626324	0.999267145	5.6	.	.
CDH12	5	21750673	22853622	N	.	N	N	-0.782610543	11.92915437	0.001451194	63.2	DP	.
CDH13	16	82626803	83800640	N	Viable	N	Y	-0.186838866	36.34311512	0.217594377	38.1	DM?	.
CDH15	16	89171767	89195492	N	.	N	Y	-0.019707016	47.91341089	5.96E-12	94.5	DM	Mental retardation, autosomal dominant 3, 612580 (3)
CDH16	16	66908122	66918984	N	.	N	N	-0.652995945	15.28621867	6.80E-13	95.4	.	.
CDH17	8	94127171	94217303	N	.	N	Y	-0.421348952	23.48208601	2.81E-06	80.6	.	.
CDH18	5	19472951	20575873	N	.	N	N	-1.291100353	4.734618279	0.46392646	31	DM?	.
CDH19	18	66501083	66604138	N	.	N	N	0.123656278	59.02645135	1.92E-09	90.5	DM?	.
CDH20	18	61333582	61555773	N	.	N	N	-0.834178931	10.89888291	0.980513136	11.7	.	.
CDH22	20	46173733	46308498	N	.	N	N	-0.575386652	17.49725068	.	.	.	.
CDH23	10	71396934	71815947	N	.	N	Y	-1.302644029	4.688313943	0.050692959	46.9	DM	Usher syndrome, type 1D, 601067 (3); Deafness, autosomal recessive 12, 601386 (3); Usher syndrome, type 1D/F digenic, 601067 (3)
CDH24	14	23047062	23057538	N	.	N	N	-0.150430658	38.69884818	6.70E-05	73	.	.
CDH26	20	59958427	60034011	N	Viable	N	Y	1.521544591	97.0712508	5.56E-23	99.1	.	.
CDH3	16	68636189	68722616	N	.	N	Y	-0.374417221	25.7046941	1.81E-08	88.3	DM	Mental retardation, autosomal dominant 3, 612580 (3)
CDH4	20	61252426	61940617	N	Viable	N	Y	-0.314244952	28.58713897	0.966988414	13.4	FP	.
CDH6	5	31193750	31329146	N	.	N	Y	-1.076354181	6.847253574	0.980834799	11.6	.	.
CDH7	18	65750252	65890341	N	.	N	N	-1.452514503	3.640678359	0.763007123	22.8	.	.
CDH8	16	61647242	62037035	N	.	N	Y	-0.984396794	8.143774961	0.997463771	7.3	DM	.
CDH9	5	26880600	27121150	N	.	N	N	-1.020958787	7.611275106	0.99248359	9.3	.	.
CDHR1	10	84194635	84219621	N	.	N	Y	1.432452422	96.59084332	5.15E-10	91.7	DM	Cone-rod dystrophy 15, 613660 (3); Retinitis pigmentosa 65, 613660 (3)
CDHR2	5	176542511	176595974	N	.	N	N	-0.922741915	9.17404642	6.37E-10	91.5	.	.
CDHR3	7	105876796	106033773	N	.	N	N	0.270999829	68.74457371	6.99E-13	95.4	.	.
CDHR4	3	49790732	49799835	N	.	N	N	.	.	0.013473949	53.7	.	.
CDHR5	11	616565	626078	N	.	N	N	1.232898551	95.32905018	1.31E-10	92.8	.	.
CDIP1	16	4510675	4538828	N	.	N	N	0.018007904	50.90004052	0.734505012	23.6	.	.
CDK10	16	89680737	89696364	N	.	N	N	0.107389526	57.79938647	2.34E-10	92.3	.	.
CDK11A	1	1702730	1724324	N	.	N	N	0.926496713	91.63627945	5.24E-05	73.7	DM?	.
CDK12	17	39461511	39564907	N	.	N	N	-1.820954607	2.135787463	0.999991813	2.5	.	.
CDK13	7	39950037	40097134	N	.	N	N	-0.950414433	8.705215026	0.751250538	23.1	.	.
CDK14	7	90466424	91210590	N	.	N	Y	-0.237899627	33.20599641	0.476260128	30.7	FTV	.
CDK15	2	201790461	201895550	N	Viable	N	Y	0.366319083	74.16796898	5.06E-13	95.5	.	.
CDK16	X	47217860	47229997	N	.	N	Y	-0.327132777	27.8867859	0.995702616	8.1	.	.
CDK17	12	96278261	96400560	N	.	N	N	-0.662859235	14.96208833	0.988843485	10.2	.	.
CDK18	1	205504595	205532793	N	.	N	N	0.326890353	72.17109452	7.16E-08	86.5	.	.
CDK19	6	110609978	110815958	N	.	N	N	-0.431218644	23.11743937	0.998017091	6.9	.	.
CDK20	9	87966441	87974753	N	.	N	N	0.068917845	54.82433293	7.19E-12	94.4	.	.
CDK2AP2	11	67506497	67508649	N	.	N	N	0.167113525	62.29669503	0.256474774	36.9	.	.
CDK3	17	76000906	76005999	N	.	N	N	0.185138978	63.52375991	0.000751723	65.7	.	.
CDK5R1	17	32486619	32491256	N	.	N	Y	-0.469691512	21.4504833	0.738441122	23.5	DM	.
CDK5R2	2	218959655	218962162	N	.	N	Y	0.025510984	51.4499045	.	.	.	.
CDK5RAP1	20	33358839	33401561	N	.	N	N	0.506158829	80.71424437	1.08E-14	96.7	.	.
CDK5RAP3	17	47967810	47981774	N	.	N	N	0.695652645	86.80326446	2.87E-12	94.9	DFP	.
CDK6	7	92604921	92836594	N	.	N	Y	-0.283071606	30.49140476	0.923677276	16.5	.	?Microcephaly 12, primary, autosomal recessive, 616080 (3)
CDKAL1	6	20534457	21232404	N	Viable	N	Y	-0.278133044	30.72292643	0.577650481	28.1	DM?	{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)
CDKL1	14	50329404	50416461	N	.	N	N	0.389635172	75.36030561	3.60E-05	74.7	.	.
CDKL2	4	75578005	75630716	N	Viable	N	Y	-0.071725006	44.30746079	1.87E-09	90.6	.	.
CDKL3	5	134286350	134371047	N	.	N	N	0.376541981	74.76413729	4.33E-07	83.9	DM?	.
CDKL4	2	39175646	39229588	N	.	N	N	0.434654036	77.61764195	3.69E-08	87.4	.	.
CDKL5	X	18425583	18653629	N	.	N	Y	-1.019194721	7.640215315	0.997790055	7.1	DM	Epileptic encephalopathy, early infantile, 2, 300672 (3)
CDKN1A	6	36676460	36687339	N	Viable	N	Y	0.248840271	67.3901719	0.027202551	50.2	DM	.
CDKN1B	12	12715058	12722371	N	.	N	Y	0.465623125	79.12832089	0.847005306	20	DM	Multiple endocrine neoplasia, type IV, 610755 (3)
CDKN2A	9	21967753	21995301	N	.	N	Y	1.161684198	94.6402732	0.357648776	34	DM	{Melanoma, cutaneous malignant, 2}, 155601 (3); Melanoma and neural system tumor syndrome, 155755 (3); Pancreatic cancer/melanoma syndrome, 606719 (3); Orolaryngeal cancer, multiple, (3)
CDKN2AIP	4	183444591	183448198	N	.	N	N	-0.785629384	11.82496961	0.987251416	10.5	.	.
CDKN2AIPNL	5	134402087	134411898	N	Viable	N	Y	0.108045035	57.83990276	0.058245191	46.2	.	.
CDKN2B	9	22002903	22009363	N	.	N	Y	-0.076661182	43.91387394	0.281057557	36.2	DM	.
CDKN2C	1	50960745	50974633	N	.	N	Y	-0.027010532	47.48509579	0.315707026	35.3	DM	.
CDKN2D	19	10566462	10569059	N	.	N	Y	0.085535714	56.11506627	0.147286959	40.7	.	.
CDKN3	14	54396849	54420218	N	.	N	N	0.366978017	74.20848527	0.066297457	45.4	.	.
CDNF	10	14819250	14838575	N	.	N	N	0.194405525	64.08519998	0.000111034	71.5	.	.
CDPF1	22	46244011	46250679	N	.	N	N	0.132467594	59.58789142	0.001138931	64.2	.	.
CDR1	X	140782405	140784871	N	.	N	N	0.021835061	51.22417086	0.05956161	46.1	FTV	.
CDR2	16	22345936	22437165	N	.	N	Y	-0.855073997	10.47056781	5.61E-06	79.3	.	.
CDR2L	17	74987632	75005800	N	.	N	N	.	.	0.001327179	63.6	.	.
CDRT1	17	15565483	15619704	N	.	N	N	1.384385903	96.30722926	.	.	.	.
CDRT15	17	14235673	14236862	N	.	N	N	1.461855466	96.77606066	0.007506438	56.3	.	.
CDRT15L2	17	20579724	20580911	N	.	N	N	.	.	0.321628092	35.1	.	.
CDRT4	17	15436015	15503608	N	.	N	N	.	.	0.244291014	37.3	.	.
CDS1	4	84582979	84651338	N	.	N	N	0.147623843	60.84968455	0.005325533	57.8	.	Li-Fraumeni syndrome, 609265 (3); Osteosarcoma, somatic, 259500 (3); {Breast cancer, susceptibility to}, 114480 (3); {Prostate cancer, familial, susceptibility to}, 176807 (3); {Breast and colorectal cancer, susceptibility to} (3)
CDT1	16	88803213	88809258	N	.	N	N	1.169645334	94.74445795	7.76E-09	89.2	DM	Meier-Gorlin syndrome 4, 613804 (3)
CDV3	3	133573730	133590261	N	.	N	N	0.223461474	65.83897667	0.201907144	38.7	.	.
CDX1	5	150166795	150184558	N	.	N	Y	.	.	0.702597063	24.6	DM	.
CDX4	X	73447254	73455245	N	.	N	Y	0.23383407	66.45250912	0.013558448	53.6	.	.
CDY1	Y	25622162	25624902	N	.	N	N	.	.	.	.	.	.
CDY1B	Y	24045229	24048019	N	.	N	N	.	.	.	.	.	.
CDY2A	Y	18025787	18028597	N	.	N	N	.	.	.	.	.	.
CDY2B	Y	17877410	17880220	N	.	N	N	.	.	.	.	.	.
CDYL	6	4706159	4955551	N	.	N	N	-0.908555319	9.434508306	0.946570708	15.1	.	.
CDYL2	16	80597906	80804329	N	.	N	N	-1.038835532	7.402905597	0.624960005	26.8	.	.
CEACAM1	19	42507304	42561234	N	.	N	Y	0.716248817	87.31261214	0.658400055	25.8	.	.
CEACAM16	19	44699151	44710714	N	Viable	N	Y	0.037949145	52.39335533	0.029580258	49.7	DM	?Deafness, autosomal dominant 4B, 614614 (3)
CEACAM18	19	51478622	51490952	N	.	N	N	.	.	4.11E-10	91.9	.	.
CEACAM19	19	44662278	44684359	N	.	N	N	0.805185239	89.25160618	5.78E-07	83.5	.	.
CEACAM20	19	44501677	44529788	N	.	N	N	.	.	.	.	.	.
CEACAM21	19	41549518	41586844	N	.	N	N	0.807097444	89.28054639	2.38E-10	92.3	.	.
CEACAM3	19	41796437	41811553	N	.	N	N	0.358666204	73.88435492	1.50E-07	85.6	.	.
CEACAM4	19	41618971	41627074	N	.	N	N	0.700137096	86.89008508	1.68E-06	81.6	.	.
CEACAM5	19	41576273	41729798	N	.	N	N	0.932242013	91.76940441	3.67E-05	74.7	.	.
CEACAM6	19	41750977	41772208	N	.	N	N	0.567947004	82.99473288	0.191109811	39	.	.
CEACAM7	19	41673307	41706976	N	.	N	N	0.693589967	86.75117208	9.14E-07	82.7	.	.
CEACAM8	19	42580241	42740384	N	.	N	N	0.159910445	61.75261909	1.25E-07	85.9	.	.
CEBPD	8	47736909	47739086	N	.	N	Y	.	.	0.540717582	28.9	.	.
CEBPE	14	23117304	23119616	N	.	N	Y	-0.145949748	39.0056144	0.002392376	61.3	DM	Specific granule deficiency, 245480 (3)
CEBPZ	2	37201612	37231713	N	.	N	N	-0.508377015	19.86455982	1.78E-05	76.6	.	.
CEBPZOS	2	37196488	37216193	N	.	N	N	.	.	.	.	.	.
CECR1	22	17178790	17221989	N	.	N	N	0.302618984	70.67777971	5.25E-05	73.7	DM?	Polyarteritis nodosa, childhood-onset, 615688 (3); ?Sneddon syndrome, 182410 (3)
CECR5	22	17137511	17165287	N	.	N	N	-0.673079812	14.68426231	2.11E-08	88.1	DM?	.
CECR6	22	17116299	17121367	N	.	N	N	.	.	.	.	.	.
CEL	9	133061978	133087355	N	.	N	Y	0.771797354	88.60913353	6.34E-05	73.3	DM	Maturity-onset diabetes of the young, type VIII, 609812 (3)
CELA1	12	51328443	51346679	N	.	N	N	0.623191232	84.85269433	0.129951932	41.6	FTV	.
CELA2A	1	15456728	15472091	N	.	N	N	0.527561494	81.54772241	1.98E-06	81.3	.	.
CELA2B	1	15465909	15491400	N	.	N	N	-0.260408668	31.84580656	0.000617209	66.4	.	.
CELA3A	1	22001656	22012539	N	.	N	N	1.052950347	93.40163223	9.82E-08	86.1	.	.
CELA3B	1	21977021	21998642	N	.	N	N	1.667489557	97.79475603	2.12E-10	92.4	.	.
CELF2	10	11005321	11336675	N	.	N	N	-0.686326345	14.33119176	0.998785801	6.2	.	.
CELF3	1	151702404	151716814	N	.	N	Y	-0.426587603	23.26214042	0.293142911	35.9	.	.
CELF5	19	3224703	3297076	N	.	N	N	-0.891789373	9.747062569	0.996405707	7.8	.	.
CELF6	15	72284727	72320129	N	Viable	N	Y	.	.	0.376807001	33.4	DM?	.
CELSR2	1	109250019	109275750	N	.	N	Y	-3.087169748	0.573016149	0.9999992	1.6	.	.
CEMIP	15	80779343	80951776	N	.	N	N	.	.	.	.	.	.
CEMP1	16	2530035	2531417	N	.	N	N	0.361535788	73.98853968	4.84E-09	89.6	.	.
CEND1	11	787104	790123	N	.	N	Y	0.050890469	53.42941483	0.584353271	27.8	.	.
CENPB	20	3783851	3786690	N	.	N	Y	-0.811010727	11.34456213	0.973451328	12.6	.	.
CENPBD1	16	89969791	89972534	N	.	N	N	.	.	0.020072095	51.7	.	.
CENPF	1	214603195	214664588	N	.	N	N	1.179378975	94.82549054	2.13E-25	99.4	.	Ciliary dyskinesia, primary, 31, 616369 (3)
CENPI	X	101098218	101163681	N	.	N	N	0.521971277	81.33356486	0.996692511	7.7	.	.
CENPK	5	65517766	65563171	N	.	N	N	0.349250172	73.35185507	1.66E-08	88.4	.	.
CENPL	1	173799550	173824720	N	.	N	N	0.304231467	70.75881229	0.513926394	29.6	.	.
CENPM	22	41938721	41947164	N	.	N	N	0.13438084	59.79626092	0.21398356	38.3	.	.
CENPN	16	81006498	81033114	N	.	N	N	0.101800117	57.35949528	3.16E-05	75.1	.	.
CENPP	9	92325484	92620533	N	.	N	N	0.46275405	78.96625572	0.023928461	50.7	.	.
CENPQ	6	49463378	49493107	N	.	N	N	0.30327499	70.71250796	6.27E-07	83.3	.	.
CENPT	16	67828157	67847811	N	.	N	N	-0.089449983	42.83729814	0.055362352	46.4	.	.
CENPV	17	16342534	16353656	N	.	N	N	-0.0579797	45.26827574	0.313327865	35.4	.	.
CENPW	6	126340174	126348875	N	.	N	N	0.432595039	77.50766916	0.500136307	30	.	.
CEP104	1	3812081	3857214	N	.	N	N	0.991473777	92.64918678	2.63E-08	87.8	.	.
CEP112	17	65635538	66192084	N	.	N	N	0.348902918	73.33449094	3.06E-18	98.2	.	.
CEP120	5	123344885	123423592	N	.	N	N	-0.312479128	28.74920414	4.34E-11	93.5	.	Short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3)
CEP126	11	101915015	102001058	N	.	N	N	.	.	.	.	.	.
CEP128	14	80476983	80959517	N	.	N	N	-0.269225353	31.30173062	4.09E-18	98.2	.	.
CEP131	17	81189593	81222999	N	.	N	N	.	.	.	.	.	.
CEP135	4	55948871	56033363	N	.	N	N	-0.226118711	33.95844186	4.85E-17	97.8	DM	?Microcephaly 8, primary, autosomal recessive, 614673 (3)
CEP152	15	48712928	48811146	N	.	N	Y	0.409410873	76.30954448	4.42E-21	98.9	DM	Microcephaly 9, primary, autosomal recessive, 614852 (3); Seckel syndrome 5, 613823 (3)
CEP162	6	84124241	84227635	N	.	N	N	.	.	.	.	.	.
CEP170	1	243124428	243255348	N	.	N	N	-0.286292138	30.26567112	.	.	.	.
CEP170B	14	104865280	104896770	N	.	N	N	0.692459389	86.72223187	0.87050986	19	DM?	.
CEP19	3	196706277	196712293	N	.	N	Y	0.133424212	59.69786421	0.052618933	46.7	.	Morbid obesity and spermatogenic failure, 615703 (3)
CEP192	18	12991362	13125052	N	.	N	N	0.539234729	82.02234184	7.44E-10	91.3	.	.
CEP250	20	35455164	35519280	N	.	N	N	0.015850152	50.67430688	8.25E-17	97.7	.	.
CEP290	12	88049014	88142216	N	.	N	Y	0.127792229	59.26954911	1.04E-34	99.8	DM	Joubert syndrome 5, 610188 (3); Senior-Loken syndrome 6, 610189 (3); Leber congenital amaurosis 10, 611755 (3); Meckel syndrome 4, 611134 (3); ?Bardet-Biedl syndrome 14, 615991 (3)
CEP295	11	93661639	93730358	N	.	N	N	.	.	.	.	.	.
CEP295NL	17	78870910	78903217	N	Viable	N	Y	.	.	.	.	.	.
CEP350	1	179954738	180114880	N	.	N	N	-0.073248487	44.18012386	0.99999639	2.1	.	.
CEP44	4	174283677	174333380	N	.	N	N	0.300554575	70.56201887	0.000569745	66.6	.	.
CEP55	10	93496632	93529092	N	.	N	N	1.174924397	94.78497424	1.30E-07	85.8	.	.
CEP57	11	95789965	95832693	N	.	N	N	-0.34661718	26.92597094	0.565432341	28.3	DM	Mosaic variegated aneuploidy syndrome 2, 614114 (3)
CEP57L1	6	109095110	109163932	N	.	N	N	0.455399499	78.56688082	4.26E-09	89.7	.	.
CEP63	3	134485743	134575017	N	.	N	N	0.420906656	76.84783238	8.50E-21	98.8	DM	?Seckel syndrome 6, 614728 (3)
CEP68	2	65056366	65087004	N	.	N	N	0.769082647	88.54546507	0.371622602	33.6	DP	.
CEP70	3	138494344	138594538	N	.	N	N	0.224718319	65.9257973	5.95E-11	93.2	.	.
CEP72	5	612272	667168	N	.	N	N	0.258710853	67.9689761	1.06E-09	91.1	.	.
CEP76	18	12661833	12702777	N	Viable	N	Y	-0.263127019	31.65480118	0.018822651	52	.	.
CEP78	9	78236062	78279690	N	.	N	N	0.219129001	65.63060717	5.36E-06	79.4	.	.
CEP83	12	94306449	94459988	N	.	N	N	.	.	.	.	.	Nephronophthisis 18, 615862 (3)
CEP85	1	26234153	26279038	N	.	N	N	-0.033101966	47.07414482	0.005851269	57.4	.	.
CEP85L	6	118460772	118710075	N	.	N	N	-0.018095978	48.04653586	0.004963907	58.1	.	.
CEP89	19	32875925	32971991	N	.	N	N	1.927762929	98.43722869	4.17E-20	98.7	DM	.
CEP95	17	64506588	64542461	N	.	N	N	-0.320130544	28.29773688	9.44E-12	94.3	.	.
CEP97	3	101723925	101770562	N	.	N	N	0.10482249	57.59101696	1.33E-06	82.2	.	.
CEPT1	1	111139627	111185102	N	.	N	N	-0.302709198	29.29906813	0.94656469	15.1	.	.
CER1	9	14719724	14722717	N	.	N	Y	-0.412383648	23.80042832	2.58E-05	75.6	DP	.
CERCAM	9	128411751	128437351	N	.	N	N	0.731408503	87.61359032	0.018254249	52.1	.	.
CERK	22	46684411	46738261	N	.	N	Y	0.467686361	79.23250564	1.60E-05	76.8	.	.
CERKL	2	181536676	181680665	N	.	N	N	0.947092883	91.96619784	5.40E-11	93.3	DM	Retinitis pigmentosa 26, 608380 (3)
CERS1	19	18868545	18896727	N	.	N	Y	-0.190163599	36.15789778	0.045457044	47.5	.	?Epilepsy, progressive myoclonic, 8, 616230 (3)
CERS2	1	150960583	150975004	N	.	N	N	-0.595330347	16.85477803	0.910163043	17.3	.	.
CERS4	19	8206736	8262421	N	.	N	Y	-0.192729499	36.01898478	2.04E-13	95.8	.	.
CERS5	12	50129306	50167533	N	Viable	N	Y	0.018159209	50.92319268	1.31E-05	77.3	.	.
CERS6	2	168455862	168775137	N	.	N	Y	-0.237899627	33.20599641	0.684541332	25	.	.
CES1	16	55802851	55833337	N	.	N	N	1.892947107	98.38513631	6.77E-14	96.2	DM	Carboxylesterase 1 deficiency (3)
CES2	16	66934444	66945096	N	.	N	N	-0.648506122	15.42513168	1.08E-10	92.9	FP	.
CES3	16	66961237	66975148	N	.	N	Y	1.040964966	93.28008335	2.06E-08	88.1	.	.
CES4A	16	66988589	67009758	N	Viable	N	Y	0.173002985	62.75973838	0.000495399	67.1	.	.
CES5A	16	55846154	55956031	N	.	N	N	1.438831465	96.63135961	5.95E-19	98.4	.	.
CETN1	18	580357	582114	N	.	N	N	-0.071071979	44.35376512	0.531422797	29.1	.	.
CETN2	X	152826973	152830777	N	.	N	Y	0.289077164	69.85587776	0.451744392	31.3	.	.
CETN3	5	90392261	90409786	N	.	N	N	-0.224004258	34.09156682	0.01132078	54.4	.	.
CETP	16	56961850	56983845	N	.	N	N	-0.061351631	45.00781386	5.18E-12	94.6	DM	Hyperalphalipoproteinemia, 143470 (3); [High density lipoprotein cholesterol level QTL 10], 143470 (3)
CFAP126	1	161364731	161367874	N	.	N	Y	.	.	.	.	.	.
CFAP20	16	58113588	58129450	N	.	N	N	.	.	.	.	.	.
CFAP221	2	119544432	119662251	N	.	N	N	.	.	.	.	.	.
CFAP36	2	55519604	55545879	N	.	N	Y	.	.	.	.	.	.
CFAP43	10	104129888	104232362	N	.	N	N	.	.	.	.	.	.
CFAP44	3	113286930	113441610	N	.	N	N	.	.	.	.	.	.
CFAP45	1	159872364	159900163	N	.	N	N	.	.	.	.	.	.
CFAP46	10	132808392	132942823	N	.	N	N	.	.	.	.	.	.
CFAP47	X	35919734	36385319	N	.	N	N	.	.	.	.	.	.
CFAP52	17	9576627	9643459	N	.	N	N	.	.	.	.	.	.
CFAP53	18	50227193	50266522	N	.	N	N	.	.	.	.	.	.
CFAP54	12	96489571	96875555	N	.	N	N	.	.	.	.	.	.
CFAP57	1	43172149	43254358	N	.	N	N	.	.	.	.	.	.
CFAP58	10	104353764	104455090	N	.	N	N	.	.	.	.	.	.
CFAP61	20	20052514	20360702	N	.	N	N	.	.	.	.	.	.
CFAP69	7	90245174	90311063	N	Viable	N	Y	.	.	.	.	.	.
CFAP70	10	73253759	73358859	N	.	N	N	.	.	.	.	.	.
CFAP74	1	1921951	2003837	N	.	N	N	.	.	.	.	.	.
CFAP97	4	185159665	185209504	N	.	N	N	.	.	.	.	.	.
CFAP99	4	2418974	2462963	N	.	N	N	.	.	.	.	.	.
CFB	6	31945650	31952084	N	Viable	N	Y	-0.287398361	30.21936679	0.000978859	64.8	DM	{Macular degeneration, age-related, 14, reduced risk of}, 615489 (3); {Hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3); ?Complement factor B deficiency, 615561 (3)
CFC1B	2	130521197	130528604	N	.	N	N	.	.	.	.	.	.
CFD	19	859643	863630	N	.	N	Y	.	.	0.019566874	51.8	DM	Complement factor D deficiency, 613912 (3)
CFDP1	16	75293698	75433485	N	.	N	N	0.132617807	59.62261967	0.084939582	44.1	.	.
CFH	1	196651878	196747504	N	.	N	Y	-0.289822764	30.07466574	0.999630968	4.9	DM	{Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3); Complement factor H deficiency, 609814 (3); {Macular degeneration, age-related, 4}, 610698 (3); Basal laminar drusen, 126700 (3)
CFHR1	1	196819757	196832189	N	.	N	N	0.739566505	87.83932396	0.000909322	65.1	DM	{Macular degeneration, age-related, reduced risk of}, 603075 (3); {Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3)
CFHR2	1	196943772	196959226	N	.	N	N	0.541611524	82.1265266	8.62E-09	89.1	DM	.
CFHR3	1	196774795	196795406	N	.	N	N	1.430065809	96.55611507	1.22E-05	77.6	DM	{Macular degeneration, age-related, reduced risk of}, 603075 (3); {Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3)
CFHR4	1	196850241	196918972	N	.	N	N	1.611432942	97.55744632	1.90E-13	95.9	.	.
CFHR5	1	196977556	197009674	N	.	N	N	0.761421735	88.33709556	9.57E-22	99	DM	Nephropathy due to CFHR5 deficiency, 614809 (3)
CFI	4	109740694	109802179	N	Viable	N	Y	0.55404856	82.58378191	2.24E-05	75.9	DM	Complement factor I deficiency, 610984 (3); {Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3); {Macular degeneration, age-related, 13, susceptibility to}, 615439 (3)
CFP	X	47624213	47630305	N	.	N	Y	0.277896289	69.16131273	0.944168669	15.3	DM	.
CGA	6	87085498	87095406	N	.	N	Y	-0.082402837	43.40452625	0.251018987	37.1	DFP	.
CGB	19	49022869	49024333	N	.	N	N	.	.	0.57407227	28.1	DM?	.
CGB1	19	49035610	49036895	N	.	N	N	0.991820467	92.66655091	0.267464648	36.6	.	.
CGB2	19	49031912	49033238	N	.	N	N	.	.	0.069421978	45.1	.	.
CGB5	19	49043884	49045311	N	.	N	N	.	.	.	.	.	.
CGB7	19	49054275	49058860	N	.	N	N	0.868894179	90.55391561	0.013101838	53.8	.	.
CGB8	19	49047638	49049106	N	.	N	N	.	.	0.091777955	43.7	.	.
CGGBP1	3	88051944	88149885	N	.	N	N	-0.149930626	38.75094056	0.777631518	22.4	.	.
CGNL1	15	57375967	57550727	N	.	N	N	0.992954836	92.68391503	9.05E-14	96.1	.	.
CGREF1	2	27098889	27119115	N	.	N	N	0.070680254	54.93430572	5.50E-08	86.8	.	.
CGRRF1	14	54509812	54539309	N	.	N	N	0.032208434	52.02870869	0.005226927	57.9	.	.
CH17-140K24.5	5	141182409	141188582	N	.	N	N	.	.	.	.	.	.
CH17-140K24.8	5	141223372	141245861	N	.	N	N	.	.	.	.	.	.
CH25H	10	89205629	89207314	N	Viable	N	Y	-0.310212249	28.91705736	0.342292546	34.4	.	.
CH507-152C13.3	21	6560714	6564489	N	.	N	N	.	.	.	.	.	.
CH507-396I9.6	21	7816675	7829926	N	.	N	N	.	.	.	.	.	.
CH507-42P11.8	21	6111134	6123739	N	.	N	N	.	.	.	.	.	.
CH507-9B2.2	21	5011799	5017145	N	.	N	N	.	.	.	.	.	.
CH507-9B2.3	21	5079294	5128425	N	.	N	N	.	.	.	.	.	.
CH507-9B2.4	21	5116343	5133805	N	.	N	N	.	.	.	.	.	.
CH507-9B2.5	21	5130871	5154734	N	.	N	N	.	.	.	.	.	.
CH507-9B2.9	21	5155499	5165472	N	.	N	N	.	.	.	.	.	.
CHAC1	15	40952962	40956519	N	.	N	N	0.395225439	75.60340337	0.000276506	68.9	.	.
CHAC2	2	53767792	53775196	N	.	N	N	0.121288029	58.8122938	0.00282189	60.6	.	.
CHAD	17	50464496	50468966	N	.	N	Y	0.142034241	60.34033686	0.033702414	49.1	.	.
CHADL	22	41229510	41240934	N	.	N	N	.	.	0.080813456	44.4	.	.
CHAF1B	21	36385378	36419015	N	.	N	N	-0.398181691	24.52393355	0.536697059	29	.	.
CHAMP1	13	114314513	114327328	N	.	N	N	-1.078120613	6.829889448	0.985193951	10.9	FTV	Mental retardation, autosomal dominant 40, 616579 (3)
CHCHD1	10	73782047	73783652	N	.	N	N	0.017051112	50.83058401	0.103831181	42.9	.	.
CHCHD10	22	23765834	23768443	N	.	N	N	0.456060966	78.59003299	0.000132412	71.1	.	Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3); ?Myopathy, isolated mitochondrial, autosomal dominant, 616209 (3); Spinal muscular atrophy, Jokela type, 615048 (3)
CHCHD2	7	56101569	56106576	N	.	N	N	0.209411733	65.03443885	0.00022132	69.5	.	.
CHCHD4	3	14112077	14124870	N	.	N	N	-0.133010364	39.8622446	0.144674863	40.8	.	.
CHCHD5	2	112584240	112589275	N	.	N	N	0.315412023	71.43022515	0.033641013	49.1	.	.
CHCHD6	3	126704220	126960406	N	.	N	N	0.720735065	87.46310123	1.08E-08	88.8	.	.
CHCHD7	8	56211686	56218798	N	.	N	N	0.117461409	58.54604387	0.387975837	33.1	.	.
CHD1L	1	147242641	147295766	N	.	N	N	-0.100478486	42.07327661	1.05E-20	98.8	DM?	.
CHD2	15	92900189	93028005	Y	Viable	N	Y	-2.580205025	0.902934537	0.999999999	0.6	DM	Epileptic encephalopathy, childhood-onset, 615369 (3)
CHD3	17	7884806	7912760	N	.	N	N	-1.78236329	2.251548301	0.999999996	0.7	DM?	.
CHD5	1	6101793	6180123	N	.	N	Y	-2.525577091	0.955026914	0.999999995	0.7	.	.
CHD6	20	41402101	41618494	N	.	N	Y	-2.600540075	0.87978237	1	0.3	DM	.
CHD9	16	53055033	53329150	N	.	N	N	-3.181756997	0.520923771	0.999999929	1.1	.	.
CHDH	3	53812335	53846390	N	.	N	Y	-0.826017495	11.02621983	0.00530866	57.8	DFP	.
CHEK2	22	28687743	28742422	N	Viable	N	Y	0.356097127	73.757018	1.18E-15	97.2	DM	Li-Fraumeni syndrome, 609265 (3); Osteosarcoma, somatic, 259500 (3); {Breast cancer, susceptibility to}, 114480 (3); {Prostate cancer, familial, susceptibility to}, 176807 (3); {Breast and colorectal cancer, susceptibility to} (3)
CHERP	19	16517889	16542530	N	.	N	N	-1.086727969	6.696764485	0.999988396	2.6	.	.
CHFR	12	132822187	132956304	N	.	N	Y	-0.59613365	16.80847369	0.636712517	26.4	DP	.
CHGB	20	5911430	5925361	N	.	N	Y	0.245465636	67.19916652	3.82E-07	84.1	DFP	.
CHI3L1	1	203178931	203186749	N	.	N	Y	1.199349099	95.00491984	0.001125812	64.2	DFP	{Schizophrenia, susceptibility to}, 181500 (3); {Asthma-related traits, susceptibility to, 7}, 611960 (3)
CHI3L2	1	111200771	111243440	N	.	N	N	0.964819248	92.2382358	6.54E-07	83.2	FP	.
CHIA	1	111290862	111320566	N	.	N	N	1.161982	94.64606124	2.26E-15	97.1	DFP	.
CHIC1	X	73563200	73687102	N	.	N	N	.	.	0.684233596	25.1	.	.
CHID1	11	867860	915058	N	.	N	N	-0.347574091	26.90281878	0.000725517	65.8	.	.
CHIT1	1	203212827	203273641	N	.	N	Y	1.476196155	96.8513052	1.39E-09	90.9	DM	.
CHKB	22	50578949	50601455	N	.	N	N	-0.39546335	24.64548243	0.000644971	66.2	DM	Muscular dystrophy, congenital, megaconial type, 602541 (3)
CHKB-CPT1B	22	50568869	50582965	N	.	N	N	.	.	.	.	.	.
CHL1	3	196596	409417	N	.	N	Y	-0.656404047	15.16466979	2.05E-06	81.3	DM	.
CHML	1	241628853	241635930	N	.	N	N	-0.377435075	25.60629739	0.00115778	64.2	.	.
CHMP1A	16	89644431	89657845	N	.	N	N	0.521823729	81.30462465	0.252036809	37	DM	Pontocerebellar hypoplasia, type 8, 614961 (3)
CHMP1B	18	11851396	11854449	N	.	N	N	0.028381319	51.66985009	0.682019463	25.1	.	.
CHMP2A	19	58551566	58555124	N	.	N	N	-0.296163317	29.65792672	0.906239123	17.5	.	.
CHMP2B	3	87227271	87255548	N	.	N	N	-0.03259986	47.11466111	0.013080315	53.8	DM	Dementia, familial, nonspecific, 600795 (3); Amyotrophic lateral sclerosis 17, 614696 (3)
CHMP4A	14	24209583	24213869	N	.	N	N	0.637241741	85.28100943	1.26E-06	82.3	.	.
CHMP4C	8	81732434	81759515	N	Viable	N	Y	0.332331078	72.43734445	0.00183041	62.2	.	.
CHMP7	8	23243637	23262000	N	.	N	N	-0.112262427	41.3266192	0.980739997	11.6	.	.
CHN1	2	174799363	175005369	N	Viable	N	Y	-0.399291813	24.48341726	0.83742443	20.4	DM	Duane retraction syndrome 2, 604356 (3)
CHN2	7	29122274	29514328	N	.	N	Y	-0.870080871	10.18116571	0.025502324	50.4	.	.
CHODL	21	17901263	18267373	N	.	N	N	-0.211715637	34.80928402	0.001285078	63.7	.	.
CHP1	15	41230839	41281890	N	.	N	N	-0.277483031	30.77501881	0.228123192	37.7	.	.
CHP2	16	23754627	23758951	N	Viable	N	Y	0.750748847	88.09978584	0.006591256	56.9	.	.
CHPF	2	219538947	219543787	N	.	N	Y	-0.425174275	23.33159692	0.231251266	37.6	.	.
CHPF2	7	151232489	151238827	N	.	N	N	0.932403889	91.77519245	7.24E-17	97.7	.	.
CHPT1	12	101696947	101744140	N	.	N	N	-0.035318613	46.92365573	0.003570477	59.6	.	.
CHRAC1	8	140511298	140517137	N	.	N	N	0.298492991	70.40574174	0.658094861	25.8	.	.
CHRDL1	X	110673856	110795819	N	.	N	N	0.457163544	78.66527754	0.053628494	46.6	DM	Megalocornea 1, X-linked 309300 (3)
CHRDL2	11	74696429	74731385	N	.	N	N	-0.248121003	32.57509984	2.14E-05	76	.	.
CHRFAM7A	15	30357766	30393849	N	.	N	N	.	.	.	.	DFP	.
CHRM1	11	62908679	62921807	N	.	N	Y	-0.670362473	14.74214273	0.931378497	16.1	FP	.
CHRM2	7	136868669	137020255	N	.	N	Y	-0.171329534	37.29814204	0.005870594	57.3	DM	.
CHRM3	1	239386565	239915452	N	.	N	Y	-0.216195302	34.51409388	0.937026128	15.8	DM	?Prune belly syndrome, 100100 (3)
CHRM4	11	46385098	46386608	N	.	N	Y	-0.55398566	18.10499508	0.916843942	16.9	.	.
CHRM5	15	33968720	34067457	N	.	N	Y	-0.378543229	25.54262893	0.003831972	59.2	.	.
CHRNA10	11	3665587	3671384	N	.	N	Y	1.096208714	93.89940383	1.04E-05	78	.	.
CHRNA2	8	27459762	27479883	N	.	N	Y	-1.015367919	7.680731608	0.001766479	62.4	DM	Epilepsy, nocturnal frontal lobe, type 4, 610353 (3)
CHRNA5	15	78565520	78595269	N	.	N	Y	0.165499977	62.20408636	2.41E-06	80.9	DFP	{Lung cancer susceptibility 2}, 612052 (3); {Nicotine dependence, susceptibility to}, 612052 (3)
CHRNA6	8	42752620	42796392	N	.	N	Y	-0.392592402	24.83069977	2.04E-06	81.3	.	.
CHRNA7	15	32030488	32172521	Y	Viable	N	Y	0.390591665	75.41239799	.	.	DM	Schizophrenia, neurophysiologic defect in (2)
CHRNA9	4	40335329	40355217	N	.	N	Y	0.952682416	92.05880651	0.000411144	67.6	FP	.
CHRNB1	17	7445061	7457707	N	.	N	N	-0.026707188	47.49667188	4.34E-06	79.8	DM	Myasthenic syndrome, congenital, 2A, slow-channel, 616313 (3); ?Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency, 616314 (3)
CHRNB3	8	42697376	42737407	N	.	N	Y	0.212431469	65.21965619	0.000131863	71.1	DM?	.
CHRNB4	15	78624119	78727754	N	.	N	Y	0.706026988	87.04636222	0.018626609	52	DFP	.
CHRND	2	232525993	232536667	N	.	N	N	0.574644112	83.23783064	7.26E-07	83.1	DM	?Myasthenic syndrome, congenital, 3A, slow-channel, 616321 (3); Myasthenic syndrome, congenital, 3B, fast-channel, 616322 (3); ?Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency, 616323 (3); Multiple pterygium syndrome, lethal type, 253290 (3)
CHRNE	17	4897774	4903074	N	.	N	Y	-0.856836351	10.44741564	0.0003479	68.2	DM	Myasthenic syndrome, congenital, 4A, slow-channel, 605809 (3); Myasthenic syndrome, congenital, 4B, fast-channel, 616324 (3); Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931 (3)
CHST1	11	45648877	45665622	N	.	N	Y	-0.662859235	14.96208833	0.820990319	21	.	.
CHST10	2	100391860	100417656	N	.	N	Y	0.239573531	66.85188401	0.003303063	59.9	.	.
CHST12	7	2403560	2448483	N	.	N	N	-0.0163338	48.1912369	0.000240663	69.2	.	.
CHST13	3	126524283	126543291	N	.	N	N	.	.	0.000159792	70.5	.	.
CHST15	10	124007666	124093607	N	.	N	Y	-0.120418693	40.70151068	0.17782212	39.4	.	.
CHST2	3	143119331	143124014	N	.	N	Y	0.056630995	53.83457776	0.123805841	41.9	.	.
CHST3	10	71964365	72013564	N	.	N	Y	-0.240770687	32.9976269	0.165928594	39.9	DM	Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3)
CHST4	16	71525233	71538746	N	.	N	Y	0.060458083	54.14713203	5.59E-09	89.5	.	.
CHST5	16	75528535	75535247	N	.	N	Y	-0.155214561	38.38050587	0.005380225	57.8	.	.
CHST7	X	46573784	46598408	N	.	N	N	.	.	0.098519353	43.2	.	.
CHST8	19	33621955	33773509	N	Viable	N	Y	-0.467623231	21.54888001	0.004222016	58.9	DM	?Peeling skin syndrome 3, 616265 (3)
CHST9	18	26906481	27185317	N	.	N	N	0.097016249	56.90223997	5.84E-07	83.5	.	.
CHSY1	15	101175723	101251932	N	.	N	Y	-0.723539465	13.31828442	0.913667234	17.1	DM	Temtamy preaxial brachydactyly syndrome, 605282 (3)
CHSY3	5	129904472	130186634	N	.	N	N	-0.672928946	14.6958384	0.011861287	54.2	.	.
CHTF8	16	69118010	69132584	N	.	N	N	-0.0579797	45.26827574	0.275816999	36.3	.	.
CHURC1	14	64914361	64944591	N	.	N	N	0.080902701	55.81408809	3.13E-05	75.1	.	.
CHURC1-FNTB	14	64914485	65061803	N	.	N	N	.	.	.	.	.	.
CIAO1	2	96266132	96273349	N	.	N	N	0.328653775	72.25212711	0.01471613	53.2	DM?	.
CIART	1	150282543	150287093	N	.	N	Y	.	.	.	.	.	.
CIB1	15	90229975	90234047	N	.	N	Y	0.217871355	65.53221045	0.016102965	52.8	.	.
CIB2	15	78104606	78131544	N	Viable	N	Y	0.006828994	50.02025815	0.000468493	67.2	DM	Deafness, autosomal recessive 48, 609439 (3); Usher syndrome, type IJ, 614869 (3)
CIB3	19	16161368	16173525	N	.	N	N	-0.008177066	48.7989813	4.43E-07	83.9	.	.
CIB4	2	26581202	26641368	N	.	N	N	0.179399332	63.14753719	2.30E-06	81	.	.
CIDEA	18	12254319	12277595	N	.	N	Y	0.389635172	75.36030561	0.014628439	53.3	DP	.
CIDEB	14	24305096	24311430	N	.	N	Y	0.363300057	74.07536031	1.52E-11	94.1	.	.
CIDEC	3	9866711	9880254	N	.	N	Y	0.561252451	82.78636337	0.001416632	63.3	DM	?Lipodystrophy, familial partial, type 5, 615238 (3)
CIITA	16	10877198	10932281	N	.	N	Y	-0.565402387	17.76350061	5.54E-05	73.6	DM	.
CILP	15	65194758	65211488	N	.	N	N	-0.328151058	27.79996527	1.40E-19	98.6	DP	{Lumbar disc disease, susceptibility to}, 603932 (3)
CILP2	19	19538248	19546659	N	.	N	N	-0.80102047	11.55293164	0.000278936	68.9	.	.
CIPC	14	77098097	77117287	N	.	N	N	.	.	.	.	.	.
CIRBP	19	1259384	1274880	N	.	N	Y	-0.199580796	35.52700122	0.622585655	26.9	.	.
CIRH1A	16	69131291	69231130	N	.	N	N	-0.72449582	13.27776813	0.094027705	43.5	DM	Cirrhosis, North American Indian childhood type, 604901 (3)
CISD1	10	58269058	58289586	N	.	N	N	0.053609874	53.60305609	0.464700956	31	.	.
CISD2	4	102868978	102889242	N	.	N	Y	-0.09740902	42.25270591	0.649111069	26	DM	Wolfram syndrome 2, 604928 (3)
CISD3	17	38730235	38735044	N	.	N	N	.	.	.	.	.	.
CISH	3	50606490	50611831	N	.	N	Y	0.054717474	53.7014528	0.001444258	63.2	DFP	{Tuberculosis, susceptibility to}, 607948 (3); {Malaria, susceptibility to}, 611162 (3); {Bacteremia, susceptibility to}, 614383 (3)
CITED4	1	40861051	40862366	N	Viable	N	Y	.	.	0.358265029	34	.	.
CIZ1	9	128166064	128204383	N	.	N	N	0.079442861	55.64623488	0.993095776	9.1	DM	.
CKAP2	13	52455429	52476628	N	.	N	N	0.427452644	77.24720727	3.96E-08	87.3	.	.
CKAP2L	2	112736607	112764677	N	.	N	N	0.761421735	88.33709556	0.218393604	38.1	.	Filippi syndrome, 272440 (3)
CKB	14	103519659	103523111	N	.	N	Y	0.038754674	52.485964	0.850845461	19.9	FP	.
CKLF	16	66552563	66566251	N	.	N	N	-0.10204113	42.00382011	0.027093108	50.2	.	.
CKLF-CMTM1	16	66552563	66579135	N	.	N	N	0.208455225	64.9591943	0.008028449	55.9	.	.
CKM	19	45306414	45322977	N	.	N	Y	-0.25849473	31.97314349	0.005050586	58.1	DM	.
CKMT1A	15	43692886	43699222	N	.	N	N	.	.	0.014121793	53.5	.	.
CKMT1B	15	43593054	43604901	N	.	N	Y	.	.	0.073210647	44.8	.	.
CKMT2	5	81233285	81266397	N	.	N	Y	-1.05208042	7.182960005	7.87E-10	91.3	.	.
CKS1B	1	154974653	154979249	N	.	N	Y	0.030143764	51.8087631	0.723280936	24	.	.
CKS2	9	89311198	89316703	N	.	N	Y	0.030143764	51.8087631	0.383050487	33.2	.	.
CLASP1	2	121337776	121649587	N	.	N	N	.	.	0.999999989	0.8	.	.
CLASP2	3	33496245	33718356	N	.	N	Y	.	.	0.99994836	3.3	.	.
CLASRP	19	45039040	45070956	N	.	N	N	-0.650570088	15.3730393	0.964966482	13.5	.	.
CLC	19	39731250	39738028	N	.	N	N	0.594944888	83.97870001	3.42E-05	74.9	.	.
CLCA1	1	86468368	86500289	N	.	N	Y	-0.547948419	18.29600046	6.08E-06	79.2	DP	.
CLCA2	1	86424086	86456558	N	.	N	Y	-0.167049899	37.59333218	1.91E-20	98.8	DP	.
CLCA4	1	86547078	86580754	N	.	N	N	-0.687788994	14.27331134	3.19E-09	90.1	.	.
CLCC1	1	108929508	108963457	N	.	N	N	0.153364212	61.26642357	0.026710088	50.3	.	.
CLCN1	7	143316126	143352083	N	.	N	N	-0.015074272	48.25490537	6.82E-13	95.4	DM	Myotonia congenita, recessive, 255700 (3); Myotonia congenita, dominant, 160800 (3); Myotonia levior, recessive (3)
CLCN2	3	184346185	184361651	N	.	N	Y	-0.378095669	25.54841697	2.27E-07	85	DM	{Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3); {Epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3); {Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3); Leukoencephalopathy with ataxia, 615651 (3)
CLCN4	X	10156945	10237660	N	.	N	N	-0.562445944	17.85610928	0.98878792	10.2	DM	.
CLCN5	X	49922615	50099235	N	.	N	Y	-0.016485314	48.17966082	0.994241666	8.8	DM	Dent disease, 300009 (3); Nephrolithiasis, type I, 310468 (3); Hypophosphatemic rickets, 300554 (3); Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3)
CLCN6	1	11806096	11843144	N	.	N	Y	-1.572450602	2.951901372	0.163974191	40	DM?	.
CLCNKA	1	16018875	16034050	N	.	N	Y	0.774670312	88.64964982	2.75E-14	96.5	DM	Bartter syndrome, type 4b, digenic, 613090 (3)
CLCNKB	1	16043736	16057308	N	.	N	N	0.886424446	90.86646987	7.81E-12	94.4	DM	Bartter syndrome, type 3, 607364 (3); Bartter syndrome, type 4b, digenic, 613090 (3)
CLDN10	13	95433604	95579759	N	.	N	N	-0.029729296	47.29987845	0.045930413	47.5	.	.
CLDN11	3	170418865	170860380	N	.	N	Y	-0.140513426	39.38183712	0.328912245	34.9	.	.
CLDN12	7	90383721	90513402	N	.	N	N	-0.328090038	27.8173294	0.100921397	43.1	.	.
CLDN14	21	36460621	36576569	N	.	N	Y	-0.240770687	32.9976269	0.000330687	68.4	DM	Deafness, autosomal recessive 29, 614035 (3)
CLDN15	7	101232092	101238820	N	.	N	Y	-0.01663693	48.16808474	0.889708635	18.2	.	.
CLDN16	3	190322541	190412143	N	.	N	Y	0.133574517	59.72680442	0.033386903	49.2	DM	Hypomagnesemia 3, renal, 248250 (3)
CLDN17	21	30165564	30166756	N	.	N	N	0.820192266	89.52364415	0.000147442	70.7	.	.
CLDN18	3	137998735	138033655	N	Viable	N	Y	-0.337353053	27.42374255	0.012644934	54	.	.
CLDN19	1	42733093	42740254	N	Viable	N	Y	0.162480005	61.94941251	0.175565901	39.5	DM	Hypomagnesemia 5, renal, with ocular involvement, 248190 (3)
CLDN2	X	106900164	106930861	N	.	N	Y	0.321002544	71.81802396	0.605106672	27.3	.	.
CLDN20	6	155264013	155276548	N	.	N	N	0.470257259	79.32511431	0.000765369	65.6	.	.
CLDN22	4	183318194	183320774	N	.	N	N	0.257299872	67.86479134	0.000437371	67.4	.	.
CLDN23	8	8701938	8704106	N	.	N	N	-0.088796495	42.91254269	2.47E-05	75.7	.	.
CLDN24	4	183321764	183322426	N	.	N	N	0.473935719	79.48717949	0.000259988	69.1	.	.
CLDN25	11	113779747	113780500	N	.	N	N	-0.257690928	32.05996411	2.36E-09	90.4	.	.
CLDN3	7	73768997	73770270	N	.	N	N	0.26384649	68.31047057	0.67853732	25.2	.	.
CLDN34	X	9967358	9968352	N	.	N	N	.	.	.	.	.	.
CLDN4	7	73799542	73832693	N	.	N	Y	-0.013766433	48.44591075	0.000137158	70.9	.	.
CLDN6	16	3014712	3020071	N	.	N	Y	0.146667159	60.78022805	0.010429515	54.8	.	.
CLDN8	21	30214006	30216073	N	.	N	N	0.311734573	71.17555131	0.057634377	46.2	.	.
CLDN9	16	3012456	3014505	N	.	N	N	-0.221936642	34.22469179	0.059927003	46	.	.
CLDND1	3	98497912	98523066	N	.	N	N	-0.12072238	40.65520634	0.590515429	27.7	.	.
CLDND2	19	51367098	51369003	N	.	N	N	0.938338578	91.83886091	3.87E-05	74.6	.	.
CLEC10A	17	7074537	7080307	N	Viable	N	Y	1.06508939	93.5636974	4.25E-08	87.2	.	.
CLEC11A	19	50723329	50725718	N	.	N	N	0.30327499	70.71250796	0.002266726	61.5	DP	.
CLEC12A	12	9951316	9995694	N	.	N	N	0.46275405	78.96625572	6.28E-06	79.1	.	.
CLEC12B	12	10010627	10018619	N	.	N	N	0.521823729	81.30462465	0.000124716	71.2	.	.
CLEC14A	14	38254103	38256369	N	.	N	N	0.022943191	51.29941541	0.000668541	66.2	.	.
CLEC17A	19	14583084	14611157	N	.	N	N	0.494679511	80.27435319	0.002618856	60.9	.	.
CLEC18A	16	69950705	69964452	N	.	N	N	.	.	0.144113695	40.8	.	.
CLEC18B	16	74408270	74421953	N	.	N	N	2.890383758	99.45592406	.	.	.	.
CLEC18C	16	70173322	70187361	N	.	N	N	.	.	0.876992462	18.8	.	.
CLEC19A	16	19285739	19322145	N	.	N	N	.	.	.	.	.	.
CLEC1A	12	10069554	10111627	N	.	N	N	-0.065330609	44.75314001	2.08E-10	92.4	.	.
CLEC2A	12	9898673	9932381	N	.	N	N	.	.	.	.	.	.
CLEC2B	12	9852984	9870136	N	.	N	N	0.237511303	66.66087862	0.002731955	60.8	.	.
CLEC2D	12	9664969	9699555	N	.	N	N	0.505861042	80.68530416	0.767944822	22.7	DP	.
CLEC2L	7	139523856	139544984	N	.	N	N	0.457973076	78.70579383	0.01759438	52.3	.	.
CLEC3A	16	78022515	78066761	N	.	N	N	-0.018398956	48.03495977	5.32E-07	83.6	.	.
CLEC3B	3	45001548	45036071	N	.	N	Y	-0.139556392	39.44550559	0.00038011	67.9	.	.
CLEC4A	12	8123632	8138607	N	.	N	Y	0.400815894	75.88122938	7.44E-07	83.1	.	.
CLEC4C	12	7729415	7751605	N	.	N	N	0.247883787	67.32650344	0.000999349	64.7	.	.
CLEC4D	12	8509475	8522366	N	.	N	Y	0.288268772	69.80378538	0.000109415	71.6	.	.
CLEC4E	12	8533305	8540963	N	.	N	Y	0.218827885	65.61903108	0.003558028	59.6	.	.
CLEC4F	2	70808643	70820600	N	.	N	Y	1.99418963	98.56456561	4.19E-12	94.7	.	.
CLEC4G	19	7728957	7733906	N	.	N	Y	-0.044735327	46.24066678	0.001122767	64.3	.	.
CLEC4M	19	7763149	7769605	N	.	N	N	0.72838545	87.5557099	3.09E-05	75.2	DFP	SARS infection, protection against (2)
CLEC5A	7	141927357	141947007	N	.	N	Y	0.163436574	62.02465706	0.238602268	37.4	.	.
CLEC6A	12	8455926	8478330	N	.	N	Y	0.362343698	74.02326793	1.79E-06	81.5	.	.
CLEC7A	12	10116777	10130258	N	.	N	N	0.386765898	75.22718064	7.99E-08	86.4	DFP	Candidiasis, familial, 4, autosomal recessive, 613108 (3); {Aspergillosis, susceptibility to}, 614079 (3)
CLEC9A	12	10030677	10066027	N	.	N	Y	0.075313076	55.32210453	2.45E-05	75.7	.	.
CLECL1	12	9715860	9733299	N	.	N	N	0.633417736	85.14788447	1.65E-06	81.7	.	.
CLGN	4	140388455	140427968	N	.	N	Y	-0.110196686	41.44816808	2.85E-07	84.6	.	.
CLHC1	2	55174791	55232563	N	.	N	N	0.531539113	81.72136366	4.15E-15	96.9	FTV	.
CLIC1	6	31730581	31739763	N	.	N	Y	0.300405715	70.5388667	0.012456213	54	.	.
CLIC2	X	155276211	155334657	N	.	N	N	0.487986222	79.98495109	0.493262624	30.2	DM	?Mental retardation, X-linked, syndromic 32, 300886 (3)
CLIC3	9	136994635	136996803	N	.	N	N	0.466432451	79.14568501	0.000387773	67.9	.	.
CLIC4	1	24745357	24844324	N	.	N	Y	-0.38061162	25.41529201	0.009462004	55.2	.	.
CLIC5	6	45898451	46080395	N	.	N	N	0.828651821	89.73201366	0.001876851	62.1	.	?Deafness, autosomal recessive 103, 616042 (3)
CLIC6	21	34669389	34718227	N	.	N	N	.	.	0.000535224	66.8	.	.
CLINT1	5	157785743	157859175	N	.	N	N	-0.368169446	25.94779186	0.800888476	21.6	.	.
CLIP1	12	122271432	122422632	N	.	N	Y	-0.64998985	15.38461538	0.968496014	13.2	.	.
CLIP2	7	74289475	74405943	N	.	N	Y	-0.338667074	27.31376975	0.999881647	3.9	.	.
CLIP4	2	29097705	29189643	N	.	N	N	-0.710445546	13.61347456	0.000288888	68.8	.	.
CLK1	2	200853009	200864744	N	.	N	Y	-1.069002279	6.922498119	0.095347455	43.5	.	.
CLK2	1	155262868	155278491	N	.	N	N	-0.23502878	33.3564855	0.999952949	3.2	DM	.
CLK3	15	74598500	74645414	N	.	N	N	-0.742523485	12.81472478	0.928146533	16.2	.	.
CLK4	5	178602664	178630615	N	.	N	N	-0.071876736	44.2958847	0.449835921	31.4	.	.
CLLU1	12	92421531	92431002	N	.	N	N	.	.	0.041368284	48.1	.	.
CLLU1OS	12	92420094	92428148	N	.	N	N	0.229051722	66.16310702	0.05273188	46.7	.	.
CLMN	14	95181940	95319906	N	Viable	N	Y	0.390248931	75.37766973	2.06E-07	85.1	.	.
CLMP	11	123069865	123195281	N	.	N	N	-0.419886724	23.51681426	3.02E-05	75.2	DM	Congenital short bowel syndrome, 615237 (3)
CLN3	16	28477279	28495575	N	.	N	Y	-0.526691349	19.14105458	9.99E-07	82.5	DM	Ceroid lipofuscinosis, neuronal, 3, 204200 (3)
CLN5	13	76990660	77002517	N	.	N	Y	0.406554426	76.19378364	5.08E-06	79.5	DM	Ceroid lipofuscinosis, neuronal, 5, 256731 (3)
CLN6	15	68206992	68257211	N	Viable	N	Y	0.352119595	73.52549632	0.381706051	33.3	DM	Ceroid lipofuscinosis, neuronal, 6, 601780 (3); Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 (3)
CLN8	8	1755778	1786572	N	.	N	N	0.445983156	78.16171789	0.000747073	65.7	DM	Ceroid lipofuscinosis, neuronal, 8, 600143 (3); Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3)
CLNK	4	10486395	10684865	N	.	N	Y	0.340939791	72.94090409	1.35E-20	98.8	DP	.
CLOCK	4	55427903	55547138	N	.	N	Y	-0.60635615	16.57695202	0.998479651	6.6	DM?	.
CLPB	11	72292425	72434680	N	.	N	N	0.845873512	90.12560051	9.13E-06	78.3	.	3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia, 616271 (3)
CLPSL1	6	35781017	35793675	N	.	N	N	0.542421446	82.15546681	0.001648465	62.7	.	.
CLPSL2	6	35776594	35779552	N	.	N	N	.	.	0.146625367	40.7	.	.
CLPTM1	19	44954585	44993341	N	.	N	N	-0.272392294	31.15124153	0.980483077	11.7	DM	.
CLPTM1L	5	1317744	1345099	N	.	N	N	-0.381261924	25.37477571	0.311319339	35.4	DM	.
CLPX	15	65148219	65185342	N	.	N	N	-0.371997156	25.78572669	0.766826744	22.7	.	.
CLRN1	3	150926163	150972999	N	Viable	N	Y	-0.407752108	24.03194999	0.000915822	65.1	DM	Usher syndrome, type 3A, 276902 (3); Retinitis pigmentosa 61, 614180 (3)
CLRN2	4	17515165	17527104	N	.	N	N	0.449660369	78.35272327	0.00028945	68.8	.	.
CLRN3	10	127877841	127892947	N	.	N	N	0.410231756	76.34427273	0.140040446	41.1	.	.
CLSTN1	1	9729026	9824526	N	Viable	N	Y	-1.358372311	4.231058633	0.84421445	20.1	.	.
CLSTN2	3	139935185	140577397	N	.	N	N	-0.142627384	39.20819587	4.54E-05	74.2	DP	.
CLSTN3	12	7129698	7158945	N	Viable	N	Y	-0.882880944	9.909127742	0.997857932	7	.	.
CLTA	9	36190856	36304781	N	.	N	N	-0.237096056	33.23493662	0.961296504	13.8	.	.
CLTB	5	176392455	176416569	N	.	N	N	-0.304623579	29.21803554	0.11549246	42.3	.	.
CLTC	17	59619689	59696956	N	.	N	N	-2.059614657	1.516466979	0.999999993	0.7	.	.
CLTCL1	22	19179473	19291716	N	.	N	N	2.655912858	99.26491868	1.24E-26	99.5	DM	.
CLU	8	27596917	27615031	N	Viable	N	Y	0.21434495	65.31226486	0.453463613	31.3	DM	.
CLUH	17	2689386	2712663	N	.	N	N	-1.655717436	2.639347109	0.99970183	4.6	.	.
CLUL1	18	596988	650334	N	.	N	N	-0.032448102	47.13781328	3.21E-06	80.4	DP	.
CLVS1	8	61057158	61501645	N	Viable	N	Y	-0.566274989	17.74613648	0.853643445	19.7	.	.
CLVS2	6	122995971	123072927	N	.	N	N	-0.257690928	32.05996411	0.125512834	41.8	.	.
CLYBL	13	99606669	99897134	N	.	N	N	0.132617807	59.62261967	8.32E-06	78.5	DP	.
CMA1	14	24505353	24508265	N	.	N	Y	0.968497077	92.30190427	4.11E-08	87.3	DP	.
CMAS	12	22046174	22065674	N	.	N	N	-0.144188409	39.10979915	0.472364311	30.8	.	.
CMBL	5	10275875	10308026	N	.	N	N	0.274219089	68.94136714	0.007765304	56.1	.	.
CMC1	3	28241584	28325142	N	.	N	N	0.236554885	66.60299821	0.001441886	63.2	.	Sturge-Weber syndrome, somatic, mosaic, 185300 (3); Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3)
CMC2	16	80966448	81020270	N	.	N	N	0.275027119	68.98767147	0.00149211	63	.	.
CMC4	X	155061622	155071362	N	.	N	N	0.394122531	75.52815882	0.164577984	40	.	.
CMKLR1	12	108288044	108339341	N	.	N	Y	0.21706442	65.48590612	0.068526963	45.2	.	.
CMPK1	1	47333797	47378839	N	.	N	N	0.266567586	68.44359553	0.31927351	35.2	FP	.
CMPK2	2	6840570	6866635	N	.	N	N	.	.	0.001807965	62.3	.	.
CMSS1	3	99817834	100178603	N	.	N	N	0.600681311	84.1291891	0.000665485	66.2	.	.
CMTM1	16	66566393	66579137	N	.	N	N	-0.086882719	43.06881982	0.001297531	63.7	.	.
CMTM2	16	66579448	66588275	N	.	N	N	0.083772833	56.01666956	2.07E-05	76.1	.	.
CMTM3	16	66603874	66613892	N	.	N	N	0.025510984	51.4499045	0.107243309	42.7	.	.
CMTM4	16	66614750	66696707	N	.	N	N	0.169983117	62.51085258	0.039383463	48.4	.	.
CMTM5	14	23376808	23379772	N	.	N	N	0.225374457	65.97210164	0.060087642	46	.	.
CMTM6	3	32481312	32503408	N	.	N	Y	0.153063769	61.21433119	0.822756767	20.9	.	.
CMTM7	3	32391671	32483067	N	.	N	N	0.139014096	60.0972391	0.426220205	32.1	.	.
CMTM8	3	32238679	32370325	N	.	N	N	0.193448992	64.03889564	0.847881588	20	.	.
CMTR1	6	37433219	37482827	N	.	N	N	-1.357827396	4.236846675	0.999294924	5.5	.	.
CMTR2	16	71281389	71289715	N	.	N	N	-0.221634091	34.24205591	1.42E-07	85.7	.	.
CMYA5	5	79689877	79800240	N	.	N	N	6.15294775	99.90160329	3.81E-43	100	.	.
CNBD1	8	86866442	87615219	N	Viable	N	Y	1.149543986	94.51293627	2.82E-10	92.2	.	.
CNBD2	20	35954564	36030700	N	.	N	Y	1.227602136	95.28274585	2.29E-07	85	.	.
CNDP1	18	74534440	74587212	N	.	N	N	0.257600888	67.89373155	1.91E-05	76.4	DP	.
CNDP2	18	74495816	74523454	N	.	N	N	-0.214281688	34.66458297	0.001191008	64	DM?	.
CNEP1R1	16	50024410	50037088	N	.	N	N	0.197126183	64.20674886	0.291176145	35.9	.	.
CNFN	19	42387019	42390287	N	.	N	N	0.395078624	75.58603924	0.347229317	34.3	.	.
CNGA1	4	47935977	48016672	N	.	N	N	-0.28085205	30.59558951	5.71E-10	91.6	DM	Retinitis pigmentosa 49, 613756 (3)
CNGA3	2	98346155	98398601	N	.	N	Y	0.796222621	89.1300573	1.18E-08	88.7	DM	Achromatopsia-2, 216900 (3)
CNGA4	11	6234765	6244429	N	.	N	Y	0.736040148	87.76986745	9.86E-05	71.9	.	.
CNGB3	8	86553977	86743675	N	.	N	Y	0.769082647	88.54546507	8.86E-11	93	DM	Achromatopsia-3, 262300 (3); Macular degeneration, juvenile, 248200 (3)
CNIH1	14	54423560	54441431	N	.	N	N	0.097672002	56.94854431	0.84399372	20.1	.	.
CNIH2	11	66278190	66285301	N	.	N	Y	-0.007371823	48.85686172	0.894540207	18	.	.
CNIH3	1	224434660	224740549	N	.	N	N	0.115548149	58.40713087	0.381818439	33.3	.	.
CNIH4	1	224356850	224379459	N	.	N	N	0.563975498	82.86739596	0.08472499	44.1	.	.
CNKSR1	1	26177403	26189886	N	.	N	N	0.602896139	84.20443364	3.79E-16	97.5	DM	.
CNKSR2	X	21374418	21654695	N	.	N	N	-0.606507878	16.56537593	0.999748049	4.5	DM	.
CNKSR3	6	154159828	154510659	N	.	N	N	-0.654245712	15.2341263	0.211063418	38.4	.	.
CNN2	19	1026581	1039068	N	.	N	Y	0.235897236	66.56248191	0.212309401	38.4	DM?	.
CNN3	1	94896949	94927278	N	.	N	N	-0.10204113	42.00382011	0.864370513	19.3	.	.
CNNM1	10	99329099	99394330	N	.	N	N	-0.458206381	21.95404295	0.906070593	17.5	.	.
CNNM2	10	102918293	103090221	N	.	N	N	-0.830649701	10.97412745	0.994106431	8.8	DM	Hypomagnesemia 6, renal, 613882 (3); Hypomagnesemia, seizures, and mental retardation, 616418 (3)
CNNM3	2	96816245	96833911	N	.	N	N	-0.156171384	38.30526133	.	.	.	.
CNNM4	2	96760902	96811891	N	.	N	Y	-1.432870149	3.76801528	0.000338909	68.3	DM	Jalili syndrome, 217080 (3)
CNOT1	16	58519951	58629886	N	.	N	N	-3.380915515	0.434103143	1	0.3	.	.
CNOT10	3	32685145	32773875	N	.	N	N	-1.109239253	6.447878683	0.999834446	4.2	.	.
CNOT11	2	101252802	101270316	N	.	N	N	0.183225703	63.41957516	0.993507645	9	.	.
CNOT2	12	70242994	70354993	N	.	N	N	-0.477194633	21.11477687	0.999868597	4	.	.
CNOT4	7	135361795	135510127	N	.	N	N	-0.527648223	19.09475025	0.996013725	8	DM?	.
CNOT6L	4	77713387	77819615	N	.	N	N	-0.12631151	40.31371187	0.954497484	14.4	.	.
CNOT7	8	17224964	17246878	N	.	N	Y	-0.169568594	37.41390288	0.986495484	10.7	.	.
CNOT8	5	154857553	154876793	N	.	N	N	-0.109544183	41.48289634	0.675125645	25.3	.	.
CNP	17	41966741	41977731	N	.	N	Y	-0.320432866	28.29194883	0.890888252	18.2	.	.
CNPPD1	2	219171897	219178106	N	.	N	N	0.493871825	80.23962493	1.63E-05	76.8	.	.
CNPY1	7	155474206	155533862	N	.	N	N	0.259064403	67.99212826	0.008745655	55.4	.	.
CNPY2	12	56309842	56316336	N	.	N	N	0.003958565	49.8061006	0.030095347	49.6	.	.
CNPY4	7	100119613	100125511	N	.	N	Y	0.17476603	62.85234705	3.68E-09	89.9	.	.
CNR2	1	23870526	23913362	N	.	N	Y	-0.138446759	39.5439023	0.000110726	71.5	DFP	.
CNRIP1	2	68284171	68320051	N	.	N	N	0.206542259	64.76240088	0.299559965	35.7	.	.
CNST	1	246566444	246668584	N	.	N	N	0.072896737	55.12531111	0.925062822	16.4	.	.
CNTD1	17	42798792	42811587	N	.	N	N	0.404641438	76.06644672	0.021834511	51.2	.	.
CNTD2	19	40222208	40226690	N	.	N	N	.	.	0.114056189	42.4	.	.
CNTF	11	58622673	58625733	N	.	N	Y	0.644745092	85.49516699	0.000349252	68.2	DFP	.
CNTLN	9	17134982	17503923	N	.	N	N	0.565237919	82.88476009	.	.	.	.
CNTN2	1	205043197	205078499	N	.	N	Y	0.144404569	60.54291833	0.129621135	41.6	DM	?Epilepsy, myoclonic, familial adult, 5, 615400 (3)
CNTN3	3	74262568	74521140	N	.	N	N	0.346030702	73.18978989	0.014141786	53.5	.	.
CNTN4	3	2098813	3057956	N	.	N	Y	-0.589145487	17.09208775	0.996606388	7.7	DM	.
CNTN5	11	99020953	100358885	N	.	N	Y	0.182074686	63.33854257	0.001354061	63.5	.	.
CNTN6	3	1092576	1404217	N	.	N	Y	-0.874151312	10.09434508	3.59E-22	99	.	.
CNTNAP1	17	42682613	42699814	Y	Viable	N	Y	-2.855175346	0.665624819	0.004108758	59	.	Lethal congenital contracture syndrome 7, 616286 (3)
CNTNAP2	7	146116002	148420998	N	.	N	Y	-0.07847643	43.76917289	3.83E-05	74.6	DM	Cortical dysplasia-focal epilepsy syndrome, 610042 (3); {Autism susceptibility 15}, 612100 (3); Pitt-Hopkins like syndrome 1, 610042 (3)
CNTNAP3	9	39072767	39288315	N	.	N	N	.	.	0.072566366	44.9	.	.
CNTNAP3B	9	41890314	42129510	N	.	N	N	.	.	.	.	.	.
CNTNAP4	16	76277278	76559238	N	.	N	Y	-0.03169225	47.14938936	2.34E-05	75.8	DM?	.
CNTNAP5	2	124025287	124915287	N	.	N	N	-1.178138133	5.828558199	0.097272924	43.3	DM?	.
CNTRL	9	121074863	121177610	N	.	N	N	-0.999367083	7.871736991	4.17E-35	99.8	.	.
CNTROB	17	7932101	7949918	N	.	N	N	0.470868486	79.3366904	1.24E-11	94.1	DM	.
COA1	7	43608456	43729717	N	.	N	N	0.427960039	77.28193552	0.038462532	48.5	.	.
COA3	17	42795147	42798704	N	.	N	N	-0.050476626	45.73710714	0.004708378	58.4	.	.
COA4	11	73872667	73876988	N	.	N	N	0.449513717	78.32957111	0.000586606	66.5	.	.
COA6	1	234373456	234384049	N	.	N	N	0.154020328	61.30693986	0.08854731	43.9	.	Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4, 616501 (3)
COA7	1	52684451	52698366	N	.	N	N	.	.	.	.	.	.
COASY	17	42561467	42566277	N	.	N	N	-0.664469158	14.90420791	1.05E-07	86.1	.	Neurodegeneration with brain iron accumulation 6, 615643 (3)
COBL	7	51016212	51316818	N	.	N	N	0.846540302	90.14875268	0.982698637	11.3	.	.
COBLL1	2	164653624	164843679	N	.	N	N	-0.284231863	30.38722	0.012197364	54.1	DP	.
COCH	14	30874514	30895065	N	.	N	Y	0.282828845	69.49123112	0.000262849	69	DM	Deafness, autosomal dominant 9, 601369 (3)
COG1	17	73192632	73208507	N	.	N	N	0.01589496	50.68009492	0.102527996	42.9	DM	Congenital disorder of glycosylation, type IIg, 611209 (3)
COG4	16	70480568	70523565	N	.	N	N	-0.339770436	27.26167737	4.39E-06	79.8	DM	Congenital disorder of glycosylation, type IIj, 613489 (3)
COG5	7	107201555	107564514	N	.	N	N	-0.019858235	47.90762285	1.14E-11	94.2	DM	Congenital disorder of glycosylation, type IIi, 613612 (3)
COG6	13	39655627	39791665	N	.	N	N	-0.483435313	20.83695086	6.72E-10	91.4	DM	Congenital disorder of glycosylation, type IIl, 614576 (3); Shaheen syndrome, 615328 (3)
COG7	16	23388493	23453180	N	.	N	N	-0.350142939	26.7812699	1.29E-06	82.2	DM	Congenital disorder of glycosylation, type IIe, 608779 (3)
COG8	16	69320140	69339667	N	.	N	N	-0.543460696	18.45806564	1.87E-05	76.4	DM	Congenital disorder of glycosylation, type IIh, 611182 (3)
COIL	17	56938187	56961054	N	.	N	Y	-0.092320323	42.68102101	0.015600234	53	.	.
COL11A2	6	33162681	33192499	N	.	N	Y	-0.636756378	15.74926202	0.999999325	1.6	DM	Stickler syndrome, type III, 184840 (3); Otospondylomegaepiphyseal dysplasia, 215150 (3); Weissenbacher-Zweymuller syndrome, 277610 (3); Deafness, autosomal dominant 13, 601868 (3); Deafness, autosomal recessive 53, 609706 (3); Fibrochondrogenesis 2, 614524 (3)
COL13A1	10	69801931	69964275	N	.	N	Y	-0.165436653	37.69172889	0.003928968	59.1	.	.
COL14A1	8	120059780	120372036	N	Viable	N	Y	-0.479859725	20.99322799	0.001367918	63.5	DM	.
COL15A1	9	98943179	99070792	N	.	N	Y	1.420885533	96.49244661	3.68E-06	80.1	.	.
COL16A1	1	31652247	31704319	N	.	N	N	-0.200301498	35.47490884	3.38E-15	97	.	.
COL18A1	21	45405137	45513720	N	Viable	N	Y	0.570035795	83.05840134	1.24E-05	77.5	DM	Knobloch syndrome, type 1, 267750 (3)
COL1A2	7	94394561	94431232	Y	Viable	N	Y	-0.356396786	26.49765584	0.999754944	4.5	DM	Ehlers-Danlos syndrome, type VIIB, 130060 (3); Osteogenesis imperfecta, type IV, 166220 (3); Osteogenesis imperfecta, type III, 259420 (3); Osteogenesis imperfecta, type II, 166210 (3); {Osteoporosis, postmenopausal}, 166710 (3); Ehlers-Danlos syndrome, cardiac valvular form, 225320 (3)
COL20A1	20	63293186	63334851	N	.	N	N	1.124962592	94.2408983	1.27E-24	99.3	.	.
COL21A1	6	56056590	56394094	N	.	N	N	-0.098715546	42.17746136	1.15E-20	98.8	.	.
COL22A1	8	138588235	138914006	N	.	N	N	1.511147515	97.01915842	8.26E-32	99.7	.	.
COL23A1	5	178237618	178590555	N	.	N	N	0.311884256	71.19291544	9.57E-10	91.2	.	.
COL24A1	1	85729233	86156943	N	Viable	N	Y	-0.379441387	25.49053655	1.06E-25	99.4	.	.
COL25A1	4	108810721	109302657	N	.	N	N	-0.953425857	8.682062858	7.12E-08	86.5	FTV	Fibrosis of extraocular muscles, congenital, 5, 616219 (3)
COL26A1	7	101362820	101559024	N	.	N	N	0.590456673	83.84557504	0.000191086	70	.	.
COL28A1	7	7356203	7535853	N	.	N	N	0.680329144	86.40967761	1.89E-20	98.8	.	.
COL4A3	2	227164565	227314792	N	Viable	N	Y	-0.181760636	36.59200093	7.58E-05	72.7	DM	Alport syndrome, autosomal recessive, 203780 (3); Hematuria, benign familial, 141200 (3); Alport syndrome, autosomal dominant, 104200 (3)
COL4A4	2	227002711	227164113	N	.	N	N	-1.19196533	5.666493025	1.69E-08	88.3	DM	Alport syndrome, autosomal recessive, 203780 (3); Hematuria, familial benign (3)
COL4A5	X	108439844	108697545	N	.	N	Y	0.315061037	71.38970886	0.999918348	3.6	DM	Alport syndrome, 301050 (3)
COL4A6	X	108155607	108439497	N	.	N	Y	1.081685319	93.76049083	0.990988266	9.7	DM	?Deafness, X-linked 6, 300914 (3)
COL5A3	19	9959561	10010471	N	.	N	Y	-0.231130271	33.66325172	7.12E-07	83.1	.	.
COL6A1	21	45981737	46005050	N	.	N	Y	0.782500809	88.84065521	0.999994535	2.3	DM	Bethlem myopathy 1, 158810 (3); Ullrich congenital muscular dystrophy 1, 254090 (3)
COL6A2	21	46098097	46132849	N	Viable	N	Y	0.696821712	86.84378075	0.002133757	61.6	DM	Bethlem myopathy 1, 158810 (3); Ullrich congenital muscular dystrophy 1, 254090 (3); ?Myosclerosis, congenital, 255600 (3)
COL6A3	2	237324003	237414375	N	.	N	N	0.927038847	91.64206749	7.79E-11	93.1	DM	Bethlem myopathy 1, 158810 (3); Ullrich congenital muscular dystrophy 1, 254090 (3); Dystonia 27, 616411 (3)
COL6A5	3	130345516	130484844	N	.	N	N	.	.	9.56E-12	94.3	DP	.
COL6A6	3	130560334	130678155	N	.	N	N	1.611094495	97.54587023	3.59E-45	100	.	.
COL8A1	3	99638475	99799226	N	.	N	Y	-0.856836351	10.44741564	0.038167365	48.6	.	.
COL8A2	1	36095236	36125220	N	.	N	Y	-0.233114996	33.52433872	0.699343493	24.6	DM	Corneal dystrophy, Fuchs endothelial, 1, 136800 (3); Corneal dystrophy, posterior polymorphous 2, 609140 (3)
COL9A1	6	70215061	70303083	N	.	N	Y	-0.460631969	21.8787984	4.77E-15	96.9	DM	?Epiphyseal dysplasia, multiple, 6, 614135 (3); Stickler syndrome, type IV, 614134 (3)
COL9A2	1	40300487	40317816	N	Viable	N	Y	1.118720025	94.16565376	0.182801206	39.2	DM	Epiphyseal dysplasia, multiple, 2, 600204 (3); {Intervertebral disc disease, susceptibility to}, 603932 (3); ?Stickler syndrome, type V, 614284 (3)
COL9A3	20	62816244	62841159	N	.	N	N	1.198702313	94.99913179	3.25E-05	75	DM	Epiphyseal dysplasia, multiple, 3, 600969 (3); Epiphyseal dysplasia, multiple, with myopathy (3); {Intervertebral disc disease, susceptibility to}, 603932 (3)
COLCA2	11	111298546	111308735	N	Viable	N	Y	.	.	.	.	.	.
COLEC10	8	118995452	119106582	N	.	N	N	0.145710487	60.67604329	0.098536735	43.2	.	.
COLEC11	2	3594832	3644644	N	.	N	N	0.239573531	66.85188401	0.072034475	44.9	DM	3MC syndrome 2, 265050 (3)
COLEC12	18	316740	500722	N	.	N	N	0.37397413	74.63680037	0.991466233	9.6	.	.
COLGALT1	19	17555594	17583162	N	.	N	N	-0.205821909	35.15077849	0.003730356	59.3	.	.
COLGALT2	1	183929854	184037729	N	.	N	N	0.332631104	72.45470857	5.02E-07	83.7	.	.
COMMD2	3	149738470	149752499	N	.	N	N	-0.062612024	44.95572148	3.65E-07	84.2	.	.
COMMD3	10	22315974	22320308	N	.	N	N	-0.20804097	35.04659374	0.007420115	56.3	.	.
COMMD3-BMI1	10	22316388	22329542	N	.	N	N	-0.824258627	11.07831221	0.022599348	51	.	.
COMMD4	15	75335891	75343224	N	.	N	N	0.317324799	71.58071424	0.23775819	37.4	.	.
COMMD5	8	144841042	144853736	N	.	N	N	0.455250847	78.5495167	0.000302003	68.6	.	.
COMMD6	13	75525219	75549439	N	.	N	N	-0.081445868	43.46240667	0.131043403	41.5	.	.
COMMD7	20	32702691	32743997	N	.	N	N	0.072442927	55.09058286	6.05E-06	79.2	.	.
COMMD8	4	47450796	47463719	N	.	N	N	0.284443026	69.58383979	9.08E-07	82.7	.	.
COMP	19	18782773	18791314	N	.	N	Y	-0.675798769	14.60322973	.	.	DM	Pseudoachondroplasia, 177170 (3); Epiphyseal dysplasia, multiple 1, 132400 (3)
COMT	22	19941607	19969975	N	Viable	N	Y	0.943117683	91.90252937	0.000846658	65.4	DM	{Schizophrenia, susceptibility to}, 181500 (3); {Panic disorder, susceptibility to}, 167870 (3)
COMTD1	10	75233969	75236030	N	.	N	N	.	.	5.22E-06	79.5	.	.
COPA	1	160289273	160343400	N	.	N	N	-0.940185321	8.855704115	0.999999998	0.7	.	{Autoimmune interstitial lung, joint, and kidney disease}, 616414 (3)
COPB1	11	14443440	14500027	N	.	N	N	-0.40744745	24.05510216	0.99976344	4.4	.	.
COPB2	3	139355600	139389732	N	.	N	N	-0.751788615	12.55426289	0.999998457	1.8	.	.
COPE	19	18899514	18919397	N	.	N	N	0.071637002	55.02112635	0.616647941	27	.	.
COPG2	7	130506238	130668748	N	.	N	N	.	.	0.056037357	46.4	.	.
COPRS	17	31851864	31859337	N	.	N	N	0.04897698	53.33680616	0.832459193	20.5	.	.
COPS4	4	83034447	83075818	N	.	N	Y	-0.174200506	37.13028882	0.997696128	7.2	.	.
COPS7A	12	6723741	6731875	N	.	N	N	-0.054152096	45.51716154	0.922072581	16.6	.	.
COPS7B	2	231781671	231809254	N	.	N	N	0.08936246	56.39289228	0.207502332	38.5	.	.
COPZ1	12	54301202	54351849	N	.	N	N	0.24597088	67.24547086	0.890701153	18.2	.	.
COPZ2	17	48026167	48038030	N	.	N	N	.	.	0.001709489	62.5	.	.
COQ10A	12	56266858	56270966	N	.	N	N	-0.151691433	38.58887538	0.121096484	42	.	.
COQ10B	2	197453423	197475308	N	.	N	N	-0.055108985	45.45349308	0.140032717	41.1	.	.
COQ3	6	99369400	99394204	N	.	N	N	0.582953443	83.61405337	7.06E-10	91.4	.	.
COQ5	12	120503274	120534434	N	.	N	N	0.474082735	79.50454361	7.95E-05	72.6	DM	.
COQ9	16	57447425	57461275	N	.	N	Y	0.678583269	86.3807374	0.000172325	70.3	DM	Coenzyme Q10 deficiency, primary, 5, 614654 (3)
CORIN	4	47593998	47838106	N	.	N	Y	-0.013966238	48.32436187	6.35E-20	98.7	DM	Preeclampsia/eclampsia 5, 614595 (3)
CORO1A	16	30182827	30189076	N	Viable	N	Y	-0.80542189	11.43717081	0.954491479	14.4	DM	Immunodeficiency 8, 615401 (3)
CORO1B	11	67435510	67443821	N	.	N	N	-0.200232492	35.49227296	0.260249265	36.7	.	.
CORO1C	12	108645109	108731596	N	.	N	Y	-0.488371748	20.65173352	0.997273678	7.4	.	.
CORO2A	9	98120975	98192640	N	.	N	N	-0.14484119	39.0750709	2.57E-06	80.8	.	.
CORO2B	15	68578969	68727806	N	.	N	N	-0.736934592	12.97100191	0.779053737	22.3	.	.
CORO6	17	29614756	29622907	N	.	N	N	0.030446167	51.85506743	3.14E-05	75.1	.	.
CORO7	16	4354542	4425705	N	.	N	N	1.158642234	94.61712103	7.31E-12	94.4	.	.
CORO7-PAM16	16	4340251	4420494	N	.	N	N	0.770371059	88.56861724	1.63E-12	95.1	.	.
CORT	1	10449719	10451902	N	.	N	Y	0.018964694	50.97528506	0.009837791	55	.	.
COTL1	16	84565594	84618077	N	Viable	N	Y	-0.155519548	38.35156567	0.066759152	45.4	.	.
COX10	17	14069496	14208677	N	.	N	N	0.445177058	78.10962551	0.646572546	26.1	DM	Mitochondrial complex IV deficiency, 220110 (3); Leigh syndrome due to mitochondrial COX4 deficiency, 256000 (3)
COX11	17	54951902	54968785	N	.	N	N	-0.182660566	36.56884876	0.402262801	32.7	.	.
COX14	12	50111979	50120457	N	.	N	N	0.152107222	61.13329861	0.193248417	38.9	.	?Mitochondrial complex IV deficiency, 220110 (3)
COX16	14	70325081	70359731	N	.	N	N	0.078032613	55.54205012	0.030459984	49.5	.	.
COX18	4	73052362	73069755	N	.	N	N	-0.054152096	45.51716154	3.71E-05	74.7	.	.
COX20	1	244835322	244845057	N	.	N	N	0.131510986	59.50685883	0.011885436	54.2	DM	Mitochondrial complex IV deficiency, 220110 (3)
COX4I2	20	31637888	31645006	N	.	N	Y	0.490854514	80.1238641	0.001475715	63.1	DM	Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3)
COX5A	15	74919791	74938168	N	.	N	N	-0.202452202	35.31863171	0.324238693	35	.	.
COX6A1	12	120438090	120440742	N	.	N	Y	-0.184574695	36.47624009	0.060957562	45.9	.	Charcot-Marie-Tooth disease, recessive intermediate D, 616039 (3)
COX6A2	16	31427731	31428428	N	.	N	Y	0.190579485	63.80158592	0.549091486	28.7	.	.
COX6B1	19	35648223	35658861	N	.	N	N	0.046106757	53.06476819	0.081622093	44.3	DM	?Mitochondrial complex IV deficiency, 220110 (3)
COX6B2	19	55349306	55354814	N	.	N	N	0.25810805	67.9284598	0.048710576	47.2	.	.
COX6C	8	99873200	99894062	N	.	N	N	0.153063769	61.21433119	0.230650731	37.7	.	.
COX7A1	19	36150922	36152869	N	Viable	N	Y	0.061112993	54.1992244	0.003562518	59.6	FP	.
COX7A2	6	75237675	75250323	N	.	N	N	0.102455237	57.40579962	0.375561255	33.5	DP	.
COX7A2L	2	42333546	42425088	N	.	N	N	0.064939857	54.54650692	0.000410249	67.7	.	.
COX7B	X	77899438	77907373	N	.	N	N	0.197126183	64.20674886	0.656619052	25.9	DM	Linear skin defects with multiple congenital anomalies, 300887 (3)
COX7B2	4	46734827	46909235	N	.	N	N	0.009548021	50.25756786	0.474554621	30.7	.	.
COX8A	11	63974607	63976543	N	.	N	N	0.152107222	61.13329861	0.49140758	30.2	.	.
COX8C	14	93347191	93348356	N	.	N	N	0.296580367	70.28419286	0.144098451	40.9	.	.
CP	3	149162410	149222055	N	Viable	N	Y	0.592835591	83.89187938	0.000168752	70.3	DM	[Hypoceruloplasminemia, hereditary], 604290 (3); Cerebellar ataxia, 604290 (3); Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3)
CPA1	7	130380339	130388114	N	.	N	Y	0.508878128	80.81264108	1.10E-05	77.8	.	.
CPA2	7	130266827	130289798	N	Viable	N	Y	0.152407451	61.18539098	1.74E-08	88.3	.	.
CPA3	3	148865256	148897196	N	.	N	Y	1.292267138	95.71684899	1.28E-12	95.2	.	.
CPA4	7	130293134	130324180	N	.	N	N	0.563313685	82.85003183	3.55E-07	84.3	DP	.
CPA5	7	130344816	130368730	N	.	N	N	0.878454064	90.71598078	0.047488738	47.3	.	.
CPA6	8	67422125	67746345	N	.	N	N	0.138358236	60.06251085	1.70E-09	90.7	DM	Epilepsy, familial temporal lobe, 5, 614417 (3); Febrile seizures, familial, 11, 614418 (3)
CPAMD8	19	16892947	17026815	N	.	N	N	1.503858881	96.97285408	2.02E-14	96.5	.	.
CPB1	3	148791102	148860187	N	Viable	N	Y	0.122395494	58.93963072	2.27E-14	96.5	.	.
CPD	17	30378905	30469989	N	.	N	N	-0.783422682	11.90021416	0.247131561	37.2	.	.
CPE	4	165361194	165498320	N	Viable	N	Y	0.466579567	79.16883718	0.997846906	7	DFP	.
CPEB1	15	82543201	82648861	N	.	N	Y	-0.228482701	33.83110494	0.999591314	4.9	.	.
CPEB2	4	15002674	15070153	N	.	N	N	-0.799833369	11.59923598	0.992723049	9.2	.	.
CPEB3	10	92046692	92291087	N	.	N	Y	-0.207887594	35.06395786	0.994664052	8.5	.	.
CPEB4	5	173888280	173961976	N	.	N	Y	-1.045533968	7.252416507	0.996854728	7.6	.	.
CPED1	7	120988677	121297444	N	.	N	N	0.139772777	60.16090756	8.35E-17	97.7	.	.
CPLX1	4	784957	826198	N	.	N	Y	-0.223047092	34.13208312	0.795789957	21.8	.	.
CPLX2	5	175796310	175884020	N	.	N	Y	0.069572814	54.86484922	0.717836321	24.1	DFP	.
CPLX3	15	74826547	74831802	N	.	N	Y	0.04897698	53.33680616	0.385406551	33.2	.	.
CPLX4	18	59275156	59318649	N	.	N	Y	0.071486219	54.9863981	0.002189416	61.6	.	.
CPM	12	68842197	68971570	N	.	N	N	-0.086882719	43.06881982	8.07E-07	82.9	.	.
CPN1	10	100042193	100081877	N	.	N	Y	-0.800636123	11.57608381	1.33E-06	82.2	DM	.
CPN2	3	194339765	194351328	N	.	N	N	0.167564929	62.36036349	0.000231795	69.3	.	.
CPNE1	20	35626031	35664956	N	.	N	N	1.675143936	97.82369624	3.87E-07	84.1	.	.
CPNE2	16	57092537	57148367	N	.	N	N	-0.657116328	15.15309371	0.54400307	28.8	.	.
CPNE3	8	86484830	86561498	N	.	N	N	0.424581613	77.07935405	5.16E-13	95.5	.	.
CPNE4	3	131533555	132285410	N	.	N	N	-1.099017094	6.586791688	0.775139285	22.4	.	.
CPNE5	6	36740775	36840002	N	Viable	N	Y	-0.269673173	31.29015454	0.07788975	44.6	.	.
CPNE6	14	24070837	24078100	N	.	N	N	-0.989180225	8.05116629	0.918263626	16.8	.	.
CPNE7	16	89575768	89597246	N	.	N	N	-0.322043675	28.14724779	1.63E-13	95.9	.	.
CPNE8	12	38646822	38907430	N	.	N	N	-1.008973152	7.750188111	0.078004273	44.6	.	.
CPNE9	3	9703807	9729908	N	.	N	N	-0.70963918	13.64820281	0.001032103	64.6	.	.
CPO	2	206939554	206969474	N	.	N	N	0.316517317	71.52862187	1.83E-13	95.9	.	.
CPOX	3	98521132	98593723	N	.	N	N	0.278045399	69.20761706	0.023227347	50.9	DM	Coproporphyria, 121300 (3); Harderoporphyria, 121300 (3)
CPPED1	16	12659799	12804017	N	.	N	N	1.109302711	94.06146901	3.26E-10	92.1	.	.
CPQ	8	96645227	97149654	N	.	N	N	0.903834133	91.15587197	7.30E-10	91.3	.	.
CPSF1	8	144393229	144409349	N	.	N	N	-2.449623969	1.012907333	0.001104454	64.3	.	.
CPSF2	14	92121937	92172145	N	.	N	N	-0.869123828	10.20431788	7.81E-05	72.6	.	.
CPSF3L	1	1311585	1324691	N	.	N	N	-1.204876245	5.52758002	5.79E-09	89.5	.	.
CPSF4	7	99438922	99457371	N	.	N	N	-0.207083847	35.09289807	0.629613784	26.7	.	.
CPSF4L	17	73248449	73262352	N	.	N	N	.	.	.	.	.	.
CPSF6	12	69239537	69274358	N	.	N	N	-0.490286222	20.58227702	0.99911368	5.8	.	.
CPSF7	11	61402641	61430031	N	.	N	N	-0.814840098	11.29246976	0.991330175	9.7	.	.
CPT1C	19	49690898	49713731	N	.	N	Y	-1.256305676	5.099264919	0.000284628	68.8	.	?Spastic paraplegia 73, autosomal dominant, 616282 (3)
CPTP	1	1324756	1328897	N	.	N	N	.	.	.	.	.	.
CPXCR1	X	88747225	88754785	N	.	N	N	0.567799588	82.98894484	0.077471847	44.6	.	.
CPXM1	20	2794069	2800637	N	.	N	N	-0.525584879	19.16999479	2.34E-11	93.8	.	.
CPXM2	10	123706207	123940267	N	.	N	N	0.324323993	71.99166522	1.83E-10	92.5	FTV	.
CPZ	4	8592660	8619759	N	.	N	N	1.442053718	96.6718759	4.51E-21	98.9	DM?	.
CR1	1	207496147	207640647	N	.	N	N	1.294272966	95.73421312	9.34E-08	86.2	DM?	CR1 deficiency (1); {?SLE susceptibility} (1); [Blood group, Knops system], 607486 (3); {Malaria, severe, resistance to}, 611162 (3)
CR2	1	207454230	207489895	N	.	N	Y	1.577914105	97.37222897	2.17E-11	93.8	DM	{Systemic lupus erythematosus, susceptibility to, 9}, 610927 (3); Immunodeficiency, common variable, 7, 614699 (3)
CR392000.1	9	136249978	136251205	N	.	N	N	.	.	.	.	.	.
CRABP1	15	78340324	78348230	N	.	N	Y	-0.095495045	42.38583087	0.125504894	41.8	.	.
CRABP2	1	156699606	156705816	N	.	N	Y	-0.193034849	35.95531632	0.008166869	55.8	.	.
CRACR2A	12	3606633	3764819	N	.	N	N	.	.	.	.	.	.
CRACR2B	11	826144	831991	N	.	N	N	.	.	.	.	.	.
CRAMP1L	16	1612325	1677908	N	.	N	Y	-0.647404139	15.47722406	0.954541936	14.3	.	.
CRAT	9	129094810	129111189	N	.	N	N	0.382434228	75.04775135	3.46E-07	84.3	.	?Carnitine acetyltransferase deficiency (1)
CRBN	3	3148992	3179710	N	Viable	N	Y	-0.212519778	34.79191989	0.038494438	48.5	DM	Mental retardation, autosomal recessive 2, 607417 (3)
CRCP	7	66114604	66154568	N	.	N	N	-0.38061162	25.41529201	0.001398927	63.3	.	.
CRCT1	1	152514502	152516010	N	.	N	N	0.145560638	60.65289113	0.00367304	59.4	.	.
CREB3L1	11	46277661	46321422	N	.	N	Y	0.309014254	71.0076981	0.39937941	32.8	.	.
CREB3L3	19	4153601	4173054	N	.	N	Y	0.568097884	83.00052092	1.59E-09	90.7	DM	.
CREB3L4	1	153967534	153974363	N	.	N	Y	0.522927841	81.36829311	8.06E-05	72.5	FP	.
CREBL2	12	12611827	12645108	N	.	N	N	0.113634918	58.26821786	0.623023672	26.8	.	.
CREBRF	5	173056352	173139284	N	.	N	N	-0.607465004	16.53643572	0.998406138	6.6	.	.
CREBZF	11	85659708	85682908	N	.	N	N	-0.493960577	20.43757597	0.036661649	48.7	.	.
CREG1	1	167529677	167553767	N	.	N	N	.	.	0.017079445	52.4	.	.
CREG2	2	101345551	101387595	N	.	N	N	.	.	0.005611307	57.6	.	.
CRELD1	3	9933822	9945413	N	.	N	N	-0.231201301	33.65746368	1.41E-06	82	DM	{Atrioventricular septal defect, susceptibility to, 2}, 606217 (3); Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3)
CRELD2	22	49918167	49927540	N	Viable	N	Y	1.82141532	98.22885918	4.96E-08	87	DM	.
CREM	10	35126791	35212958	N	.	N	Y	-0.023988294	47.67610117	0.644423493	26.2	.	.
CRH	8	66176382	66178725	N	.	N	Y	.	.	0.527789353	29.2	DM	.
CRHBP	5	76952713	76981158	N	.	N	Y	0.470257259	79.32511431	0.98959447	10	.	.
CRHR1	17	45784280	45835828	N	.	N	Y	-0.745395207	12.75684436	0.792134286	21.9	DM	.
CRHR2	7	30651943	30700129	N	.	N	Y	0.885957592	90.84910575	6.66E-07	83.2	.	.
CRIP1	14	105487199	105492267	N	.	N	N	0.403538004	75.98541413	0.00135796	63.5	.	.
CRIP2	14	105472962	105480170	N	.	N	N	.	.	0.005070278	58	.	.
CRIP3	6	43299710	43308797	N	.	N	Y	0.051847216	53.50465937	0.033902639	49.1	.	.
CRIPAK	4	1391552	1395989	N	.	N	N	5.975155692	99.89581525	2.43E-12	94.9	.	.
CRISP1	6	49834257	49877096	N	.	N	Y	0.866169548	90.46709498	0.000219402	69.5	.	.
CRISP2	6	49692358	49713590	N	.	N	N	1.002191365	92.79388783	7.55E-10	91.3	FP	.
CRISP3	6	49727384	49744437	N	.	N	Y	0.335200382	72.59362158	0.000109838	71.6	.	.
CRISPLD1	8	74984515	75034558	N	.	N	N	-0.175004808	37.08977253	0.000148412	70.7	.	.
CRLF2	X	1187549	1212750	N	.	N	Y	.	.	0.002780207	60.7	.	.
CRLF3	17	30769388	30824776	N	Viable	N	Y	0.126071509	59.22903282	0.975928566	12.3	.	.
CRLS1	20	6006090	6040053	N	.	N	N	0.148430386	60.90756497	0.03350806	49.2	.	.
CRMP1	4	5748084	5893058	N	.	N	Y	-1.100778721	6.563639521	0.953273235	14.5	DM?	.
CRNKL1	20	20034368	20056046	N	.	N	N	-0.682197707	14.45852868	0.881981247	18.5	.	.
CRNN	1	152409243	152414263	N	.	N	N	-0.049216095	45.88759623	0.000495361	67.1	.	.
CROCC	1	16740273	16972979	N	.	N	Y	4.828947821	99.83793483	4.71E-20	98.7	.	.
CROCC2	2	240906330	240993311	N	.	N	N	.	.	.	.	.	.
CROT	7	87345681	87399795	N	.	N	N	0.4799743	79.7650055	6.75E-21	98.9	.	.
CRP	1	159712289	159714589	N	.	N	Y	0.016245619	50.75533947	3.06E-05	75.2	DFP	.
CRTAC1	10	97865000	98030828	N	.	N	Y	0.222956617	65.82161255	0.000140635	70.9	.	.
CRTAM	11	122838500	122872639	N	.	N	Y	-0.106521065	41.70862997	1.15E-06	82.4	.	.
CRTAP	3	33113979	33147773	N	.	N	Y	0.47503921	79.52769578	5.34E-05	73.7	DM	Osteogenesis imperfecta, type VII, 610682 (3)
CRTC1	19	18683677	18782333	N	.	N	Y	-0.994770199	7.935405452	0.980548236	11.7	.	Mucoepidermoid salivary gland carcinoma (3)
CRTC2	1	153947669	153958625	N	.	N	Y	-0.513447957	19.68513052	0.996361791	7.8	.	.
CRX	19	47819779	47843330	N	.	N	Y	0.111065501	58.08300052	0.623714816	26.8	DM	Cone-rod retinal dystrophy-2, 120970 (3); Leber congenital amaurosis 7, 613829 (3)
CRY1	12	106991364	107093829	N	.	N	Y	-0.968583512	8.404236847	4.24E-07	84	.	.
CRY2	11	45847118	45883248	N	.	N	Y	-0.724645773	13.26040401	0.993283036	9.1	.	.
CRYAA	21	43169008	43172805	N	.	N	Y	-0.226721694	33.94107773	0.521020324	29.4	DM	Cataract 9, multiple types, 604219 (3)
CRYAB	11	111908565	111923722	N	.	N	N	0.132467594	59.58789142	0.00909092	55.3	DM	Myopathy, myofibrillar, 2, 608810 (3); Cataract 16, multiple types, 613763 (3); Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related, 613869 (3); Cardiomyopathy, dilated, 1II, 615184 (3)
CRYBA1	17	29246863	29254494	N	.	N	N	0.006828994	50.02025815	0.000721666	65.9	DM	Cataract 10, multiple types, 600881 (3)
CRYBA2	2	218990189	218993421	N	.	N	N	0.227287513	66.09365052	0.000626082	66.3	DM	?Cataract 42, 115900 (3)
CRYBA4	22	26621964	26630672	N	.	N	N	0.44774765	78.23696244	6.69E-08	86.6	DM	Cataract 23, 610425 (3)
CRYBB1	22	26599278	26618088	N	.	N	N	0.23015724	66.25571569	0.00038865	67.8	DM	Cataract 17, multiple types, 611544 (3)
CRYBB2	22	25219522	25231869	N	.	N	Y	0.05935026	54.0603114	0.583885171	27.8	DM	Cataract 3, multiple types, 601547 (3)
CRYBB3	22	25199850	25207363	N	Viable	N	Y	1.019110704	93.00225734	4.07E-10	91.9	DM	Cataract 22, autosomal recessive, 609741 (3)
CRYBG3	3	97822040	97944963	N	.	N	N	.	.	0.000473718	67.2	.	.
CRYGA	2	208160740	208163576	N	.	N	N	0.622235063	84.81217804	0.000127117	71.2	FTV	.
CRYGB	2	208142573	208146168	N	.	N	N	0.030294875	51.83191526	2.06E-09	90.5	DM	Cataract 39, multiple types, autosomal dominant, 615188 (3)
CRYGC	2	208128137	208129830	N	Viable	N	Y	0.30327499	70.71250796	0.043609846	47.8	DM	Cataract 2, multiple types, 604307 (3)
CRYGD	2	208121607	208124501	N	.	N	N	0.38485322	75.1519361	0.008226481	55.8	DM	Cataract 4, multiple types, 115700 (3)
CRYGN	7	151428835	151440813	N	.	N	N	0.567799588	82.98894484	4.64E-05	74.1	.	.
CRYGS	3	186538441	186546702	N	.	N	Y	-0.116090248	41.04300515	0.182730047	39.2	DM	Cataract 20, multiple types, 116100 (3)
CRYL1	13	20403667	20525857	N	.	N	N	0.131661109	59.52422296	1.87E-05	76.4	.	.
CRYM	16	21238874	21303083	N	Viable	N	Y	0.066853307	54.65069167	0.027148784	50.2	DM	Deafness, autosomal dominant 40, 616357 (3)
CRYZ	1	74705482	74733408	N	.	N	N	0.33806995	72.74989871	1.14E-14	96.7	.	.
CRYZL1	21	33589341	33643926	N	.	N	N	-0.194795544	35.85113156	0.090615676	43.7	DM?	.
CSAD	12	53157663	53180909	N	.	N	N	0.309165138	71.01927418	2.48E-06	80.9	.	.
CSAG1	X	152727484	152733735	N	.	N	N	0.661519885	85.95821034	0.000227012	69.4	FTV	.
CSDC2	22	41560763	41577741	N	.	N	N	0.032057299	51.99976848	0.079803516	44.5	.	.
CSDE1	1	114716913	114758676	N	.	N	N	-1.058626991	7.084563292	0.999951564	3.2	DM?	.
CSF2RA	X	1268800	1310381	N	.	N	N	1.077525936	93.70839845	0.001866576	62.1	DM	Surfactant metabolism dysfunction, pulmonary, 4, 300770 (3)
CSF2RB	22	36913628	36940449	N	.	N	Y	0.096515022	56.85593564	0.001866652	62.1	DM	Surfactant metabolism dysfunction, pulmonary, 5, 614370 (3)
CSF3	17	40015361	40017813	N	.	N	Y	0.467388591	79.20356543	0.480555586	30.6	.	.
CSGALNACT1	8	19404161	19758029	N	.	N	Y	0.332784162	72.46628466	6.88E-05	72.9	DM?	.
CSGALNACT2	10	43138486	43185308	N	.	N	N	-0.11115351	41.40186375	0.451240635	31.3	.	.
CSH1	17	63894909	63896661	N	.	N	N	0.398903333	75.78283267	0.741138849	23.4	DM	[Placental lactogen deficiency] (1)
CSH2	17	63872012	63881863	N	.	N	N	0.579127749	83.41725994	0.458223921	31.2	.	.
CSHL1	17	63909597	63918838	N	Viable	N	Y	1.953643795	98.50089715	0.000458793	67.3	.	.
CSMD1	8	2935353	4994972	N	.	N	Y	-5.289547213	0.075244545	.	.	DM?	.
CSMD2	1	33513999	34165842	N	.	N	N	-3.281807087	0.457255311	.	.	.	.
CSMD3	8	112222928	113437099	N	.	N	N	-5.164125256	0.081032587	0.999999996	0.7	DM?	.
CSN1S1	4	69931081	69946574	N	.	N	Y	0.77693964	88.71331828	8.30E-06	78.5	.	.
CSN2	4	69955256	69961007	N	.	N	Y	0.154170188	61.31851595	0.058878796	46.1	.	.
CSN3	4	70242588	70251428	N	.	N	Y	0.476804223	79.61451641	0.000194175	69.9	.	.
CSNK1A1L	13	37103259	37105664	N	.	N	N	0.724559727	87.51519361	0.000361794	68.1	FTV	.
CSNK1E	22	38290691	38398522	N	.	N	Y	-0.53817717	18.67222319	0.967319235	13.3	DP	.
CSNK1G1	15	64165517	64356187	N	.	N	N	-0.490286222	20.58227702	0.999715379	4.6	.	.
CSNK1G2	19	1941149	1981338	N	.	N	N	-0.351402069	26.69444927	0.923449277	16.5	.	.
CSNK1G3	5	123512099	123617045	N	.	N	N	-0.809251878	11.37929039	0.996751666	7.7	FTV	.
CSNK2A2	16	58157907	58197920	N	.	N	Y	-0.012004394	48.53851942	0.999154189	5.7	DM	.
CSNK2A3	11	11351942	11353357	N	.	N	N	1.275345668	95.59530011	1.32E-11	94.1	.	.
CSPG4	15	75674322	75712848	N	Viable	N	Y	2.363228224	99.04497309	8.90E-05	72.2	.	.
CSPG5	3	47562239	47580792	N	.	N	Y	-0.119613321	40.80569543	0.414829723	32.4	.	.
CSPP1	8	67062426	67196263	N	.	N	N	-0.061855873	44.96729756	3.28E-13	95.7	.	Joubert syndrome 21, 615636 (3)
CSRNP2	12	51061205	51083664	N	.	N	N	-0.145949748	39.0056144	0.950516344	14.7	.	.
CSRNP3	2	165469647	165689407	N	.	N	N	-0.293139081	29.82577994	0.83245293	20.5	.	.
CSRP1	1	201483530	201509456	N	.	N	Y	-0.086078072	43.11512415	0.003422034	59.8	.	.
CSRP2	12	76858715	76879060	N	.	N	Y	-0.199580796	35.52700122	0.000305232	68.6	.	.
CST1	20	23747553	23751268	N	.	N	N	0.9186948	91.47421427	2.87E-08	87.7	.	.
CST11	20	23450403	23452857	N	.	N	N	0.315412023	71.43022515	0.004833312	58.3	.	.
CST2	20	23823769	23826731	N	.	N	N	1.29771377	95.77472941	2.19E-06	81.1	.	.
CST3	20	23626706	23638473	N	.	N	Y	.	.	0.069035214	45.1	DM	Cerebral amyloid angiopathy, 105150 (3); Macular degeneration, age-related, 11, 611953 (3)
CST4	20	23685640	23689040	N	.	N	N	0.836155347	89.91144296	7.30E-06	78.8	.	.
CST5	20	23875935	23879750	N	.	N	Y	0.741333534	87.88562829	0.021648392	51.2	.	.
CST7	20	24949230	24959928	N	.	N	Y	0.437375642	77.75655496	9.92E-07	82.5	.	.
CST8	20	23491101	23496018	N	.	N	N	0.468344773	79.24408173	0.085629146	44.1	.	.
CST9	20	23602410	23605876	N	.	N	N	0.498357775	80.40169011	0.095109295	43.5	DM?	.
CST9L	20	23564732	23568749	N	.	N	Y	0.671890699	86.22446027	2.08E-10	92.4	.	.
CSTA	3	122325244	122341972	N	.	N	N	0.388531503	75.30242519	0.000533614	66.9	DM	Exfoliative ichthyosis, autosomal recessive, ichthyosis bullosa of Siemens-like, 607936 (3)
CSTB	21	43772512	43776445	N	.	N	Y	-0.043930449	46.31591133	0.000132259	71.1	DM	Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 (3)
CSTF1	20	56392371	56406369	N	.	N	N	-0.891789373	9.747062569	0.93789587	15.7	.	.
CSTF2	X	100820359	100840932	N	.	N	N	-0.266151109	31.49273601	0.30579834	35.6	.	.
CSTF2T	10	51695487	51699591	N	.	N	Y	-0.245250499	32.76031718	0.229519704	37.7	DM?	.
CSTF3	11	33077188	33162371	N	.	N	N	-0.556857198	18.01238641	0.9964343	7.8	.	.
CSTL1	20	23439685	23444930	N	.	N	N	0.929879279	91.71731203	0.000159598	70.5	.	.
CT45A1	X	135713453	135723539	N	.	N	N	.	.	.	.	.	.
CT45A10	X	135881063	135889086	N	.	N	N	.	.	.	.	.	.
CT45A2	X	135811668	135820012	N	.	N	N	.	.	.	.	.	.
CT45A3	X	135759846	135768191	N	.	N	N	.	.	.	.	.	.
CT45A5	X	135777130	135785298	N	.	N	N	.	.	9.39E-06	78.2	DM?	.
CT45A6	X	135794706	135802656	N	.	N	N	.	.	.	.	.	.
CT45A7	X	135829247	135837268	N	.	N	N	.	.	.	.	.	.
CT45A8	X	135846499	135854538	N	.	N	N	.	.	.	.	.	.
CT45A9	X	135863776	135871812	N	.	N	N	.	.	.	.	.	.
CT47A1	X	120982466	120985788	N	.	N	N	.	.	.	.	.	.
CT47A10	X	120938701	120942023	N	.	N	N	.	.	.	.	.	.
CT47A11	X	120933840	120937158	N	.	N	N	.	.	.	.	.	.
CT47A12	X	120930250	120932301	N	.	N	N	.	.	.	.	.	.
CT47A2	X	120977606	120980928	N	.	N	N	.	.	.	.	.	.
CT47A3	X	120972746	120976068	N	.	N	N	.	.	.	.	.	.
CT47A4	X	120967886	120971208	N	.	N	N	.	.	.	.	.	.
CT47A5	X	120958165	120966348	N	.	N	N	.	.	.	.	.	.
CT47A6	X	120953282	120961487	N	.	N	N	.	.	.	.	.	.
CT47A7	X	120953288	120956600	N	.	N	N	.	.	.	.	.	.
CT47A8	X	120877490	120951744	N	.	N	N	.	.	.	.	.	.
CT47A9	X	120943561	120946883	N	.	N	N	.	.	.	.	.	.
CT47B1	X	120872603	120875929	N	.	N	N	1.284763074	95.69948486	0.351018055	34.1	.	.
CT55	X	135156536	135171398	N	.	N	N	0.267523946	68.51884008	.	.	.	.
CT62	15	71110244	71115494	N	.	N	N	0.109001675	57.91514731	0.033198161	49.2	.	.
CT83	X	116461682	116463003	N	.	N	N	0.205585801	64.70452046	.	.	.	.
CTAG1A	X	154585143	154586821	N	.	N	N	.	.	.	.	.	.
CTAG1B	X	154617604	154619282	N	.	N	N	.	.	.	.	.	.
CTAG2	X	154651972	154653579	N	.	N	N	1.137260955	94.40875152	0.005954387	57.3	.	.
CTAGE1	18	22413601	22417915	N	.	N	N	0.185594633	63.55848816	2.10E-06	81.2	.	.
CTAGE15	7	143571801	143574387	N	.	N	N	.	.	0.784298474	22.2	.	.
CTAGE4	7	144183466	144186053	N	.	N	N	.	.	.	.	.	.
CTAGE5	14	39265284	39388513	N	.	N	N	0.147122374	60.79180413	0.001876368	62.1	.	.
CTAGE6	7	143755089	143757696	N	.	N	N	.	.	0.366836245	33.7	.	.
CTAGE8	7	144266701	144269288	N	.	N	N	.	.	.	.	.	.
CTAGE9	6	131708684	131711017	N	.	N	N	.	.	.	.	.	.
CTB-102L5.4	19	38289151	38304910	N	.	N	N	.	.	.	.	.	.
CTB-133G6.1	19	7348943	7383385	N	.	N	N	.	.	.	.	.	.
CTB-50L17.14	19	4528427	4540067	N	.	N	N	.	.	.	.	.	.
CTB-54O9.9	19	5784005	5785619	N	.	N	N	.	.	.	.	.	.
CTB-55O6.8	19	14072536	14075062	N	.	N	N	.	.	.	.	.	.
CTB-60B18.6	19	49022953	49036895	N	.	N	N	.	.	.	.	.	.
CTB-96E2.2	17	28364288	28368012	N	.	N	N	.	.	.	.	.	.
CTBS	1	84549606	84574480	N	.	N	Y	0.957169041	92.14562713	2.01E-07	85.2	.	.
CTC1	17	8224821	8248044	N	.	N	N	0.116460058	58.44185912	3.51E-07	84.3	DM	Cerebroretinal microangiopathy with calcifications and cysts, 612199 (3)
CTC-260F20.3	19	19516227	19536076	N	.	N	N	.	.	9.13E-08	86.2	.	.
CTC-273B12.7	19	48465837	48472431	N	.	N	N	.	.	.	.	.	.
CTC-326K19.6	19	49909501	49958391	N	.	N	N	.	.	.	.	.	.
CTC-360G5.8	19	38915404	38949855	N	.	N	N	.	.	.	.	.	.
CTC-398G3.6	19	11466240	11505698	N	.	N	N	.	.	.	.	.	.
CTC-429P9.4	19	16577642	16660115	N	.	N	N	.	.	.	.	.	.
CTC-432M15.3	5	131425891	131796983	N	.	N	N	.	.	0.996763358	7.7	.	.
CTC-435M10.3	19	41350853	41425004	N	.	N	N	.	.	1.23E-08	88.7	.	.
CTC-454I21.3	19	37093019	37210512	N	.	N	N	.	.	.	.	.	.
CTC-479C5.12	16	67929614	67936017	N	.	N	N	.	.	.	.	.	.
CTC-487M23.8	5	112861188	112893079	N	.	N	N	.	.	.	.	.	.
CTC-490E21.12	19	40801297	40898282	N	.	N	N	.	.	.	.	.	.
CTC-512J12.6	19	44329695	44401608	N	.	N	N	.	.	.	.	.	.
CTC-534A2.2	5	65624765	65630891	N	.	N	N	.	.	.	.	.	.
CTC-554D6.1	5	112827213	112867582	N	.	N	N	.	.	.	.	.	.
CTCFL	20	57495966	57525652	N	.	N	Y	-0.079076712	43.71129247	0.783031842	22.2	.	.
CTD-2006C1.10	19	12017888	12052967	N	.	N	N	.	.	.	.	.	.
CTD-2006C1.13	19	11925075	11979290	N	.	N	N	.	.	.	.	.	.
CTD-2105E13.6	19	55352301	55359516	N	.	N	N	.	.	.	.	.	.
CTD-2116N17.1	15	64180348	64373781	N	.	N	N	.	.	0.993204961	9.1	.	.
CTD-2132N18.3	17	42119674	42154916	N	.	N	N	.	.	.	.	.	.
CTD-2135J3.4	8	10725399	10839847	N	.	N	N	.	.	.	.	.	.
CTD-2140B24.4	12	133130984	133202369	N	.	N	N	.	.	0.000562248	66.7	.	.
CTD-2192J16.20	19	12525720	12580975	N	.	N	N	.	.	.	.	.	.
CTD-2192J16.22	19	12643831	12648397	N	.	N	N	.	.	.	.	.	.
CTD-2192J16.24	19	12664828	12669397	N	.	N	N	.	.	.	.	.	.
CTD-2207O23.10	19	7533595	7540059	N	.	N	N	.	.	.	.	.	.
CTD-2207O23.12	19	7507052	7519622	N	.	N	N	.	.	.	.	.	.
CTD-2207O23.3	19	7380964	7472477	N	.	N	N	.	.	.	.	.	.
CTD-2278I10.6	19	17267418	17282966	N	.	N	N	.	.	.	.	.	.
CTD-2287O16.3	5	116022391	116058928	N	.	N	N	.	.	.	.	.	.
CTD-2313N18.7	11	71878453	71884561	N	.	N	N	.	.	.	.	.	.
CTD-2349B8.1	16	19114002	19173578	N	.	N	N	.	.	.	.	.	.
CTD-2369P2.10	19	10305427	10316009	N	.	N	N	.	.	.	.	.	.
CTD-2369P2.12	19	10315471	10320678	N	.	N	N	.	.	.	.	.	.
CTD-2370N5.3	17	31305213	31318831	N	.	N	N	.	.	.	.	.	.
CTD-2410N18.5	5	134167170	134226071	N	.	N	N	.	.	.	.	.	.
CTD-2501B8.1	17	63484817	63521848	N	.	N	N	.	.	.	.	.	.
CTD-2510F5.6	17	59197566	59215226	N	.	N	N	.	.	.	.	.	.
CTD-2521M24.10	19	17436611	17460804	N	.	N	N	.	.	.	.	.	.
CTD-2528L19.4	19	37689865	37719188	N	.	N	N	.	.	.	.	.	.
CTD-2535L24.2	17	65538102	65641033	N	.	N	N	.	.	.	.	.	.
CTD-2545G14.7	17	7240427	7244635	N	.	N	N	.	.	.	.	.	.
CTD-2545M3.6	19	50415799	50428409	N	.	N	N	.	.	.	.	.	.
CTD-2550O8.5	19	8308283	8321379	N	.	N	N	.	.	.	.	.	.
CTD-2561J22.3	19	21405159	21491266	N	.	N	N	.	.	.	.	.	.
CTD-2583A14.10	19	57819719	57858941	N	.	N	N	.	.	.	.	.	.
CTD-2583A14.9	19	57876765	57916591	N	.	N	N	.	.	.	.	.	.
CTD-2587H24.4	19	55154757	55160671	N	.	N	N	.	.	.	.	.	.
CTD-2616J11.11	19	51350373	51368099	N	.	N	N	.	.	.	.	.	.
CTD-3074O7.11	11	66509079	66533613	N	.	N	N	.	.	2.03E-07	85.1	.	.
CTD-3088G3.8	16	11359845	11523588	N	.	N	N	.	.	.	.	.	.
CTD-3105H18.14	19	12379189	12401274	N	.	N	N	.	.	.	.	.	.
CTD-3105H18.16	19	12391949	12441082	N	.	N	N	.	.	.	.	.	.
CTD-3105H18.18	19	12433103	12484816	N	.	N	N	.	.	.	.	.	.
CTD-3138B18.4	19	58229465	58286807	N	.	N	N	.	.	.	.	.	.
CTD-3148I10.9	19	49462752	49486231	N	.	N	N	.	.	.	.	.	.
CTD-3214H19.16	19	7678501	7682854	N	.	N	N	.	.	.	.	.	.
CTD-3214H19.4	19	7629796	7643048	N	.	N	N	.	.	.	.	.	.
CTD-3222D19.2	19	16479067	16628204	N	.	N	N	.	.	.	.	.	.
CTDP1	18	79679801	79756623	N	.	N	N	-0.424217888	23.37790126	0.924155319	16.4	DM	Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3)
CTDSP1	2	218398256	218405941	N	.	N	N	-0.143231429	39.15031545	0.902026976	17.7	.	.
CTDSP2	12	57819927	57846739	N	.	N	N	-0.38061162	25.41529201	0.397665011	32.8	.	.
CTDSPL	3	37861960	37984469	N	Viable	N	Y	0.096865517	56.89645193	0.088848186	43.8	.	.
CTF1	16	30896607	30903560	N	.	N	Y	.	.	0.138254694	41.2	DM	.
CTGLF11P	10	46337224	46358714	N	.	N	N	.	.	.	.	.	.
CTH	1	70411218	70439851	N	.	N	Y	0.164543267	62.12884181	4.09E-05	74.4	DM	Cystathioninuria, 219500 (3); Homocysteine, total plasma, elevated (3)
CTHRC1	8	103371515	103382997	N	.	N	Y	0.369846866	74.37633848	0.008180662	55.8	DM	Barrett esophagus/esophageal adenocarcinoma, 614266 (3)
CTIF	18	48539046	48863217	N	.	N	N	-0.46092589	21.86143428	0.98275458	11.3	.	.
CTLA4	2	203867786	203873960	N	.	N	Y	-0.064525847	44.79365631	0.577322419	28.1	DFP	{Hashimoto thyroiditis}, 140300 (3); {Systemic lupus erythematosus, susceptibility to}, 152700 (3); {Diabetes mellitus, insulin-dependent, 12}, 601388 (3); {Celiac disease, susceptibility to, 3}, 609755 (3); Autoimmune lymphoproliferative syndrome, type V, 616100 (3)
CTNNA3	10	65912518	67696169	N	.	N	Y	-0.271137911	31.19175783	6.54E-08	86.6	DM	Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3)
CTNNAL1	9	108942569	109013529	N	.	N	N	0.210669154	65.1386236	2.31E-06	81	.	.
CTNNBL1	20	37693955	37872129	N	.	N	N	-0.688086328	14.26173525	0.285800479	36.1	.	.
CTNND1	11	57753243	57819546	N	.	N	N	-0.417671117	23.59205881	0.995312685	8.3	DM?	.
CTNND2	5	10971840	11904043	N	.	N	Y	-2.704142359	0.792961741	0.999999952	1	DM?	.
CTNS	17	3636468	3661542	N	.	N	Y	0.436717121	77.73340279	0.034122009	49	DM	Cystinosis, nephropathic, 219800 (3); Cystinosis, ocular nonnephropathic, 219750 (3); Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3); Cystinosis, atypical nephropathic, 219800 (3)
CTPS1	1	40979335	41012565	N	.	N	N	-0.594373051	16.88371824	0.932192404	16	.	Immunodeficiency 24, 615897 (3)
CTPS2	X	16588003	16712936	N	.	N	Y	-0.158237463	38.14319616	0.433684611	31.9	.	.
CTRB1	16	75219000	75224924	N	.	N	N	.	.	0.001796672	62.3	.	.
CTRB2	16	75204096	75207185	N	.	N	N	.	.	0.283515253	36.1	.	.
CTRC	1	15438439	15449242	N	.	N	N	0.541611524	82.1265266	5.22E-06	79.5	DM	{Pancreatitis, chronic, susceptibility to}, 167800 (3)
CTRL	16	67927640	67932414	N	.	N	N	0.708596698	87.08109047	7.87E-06	78.7	DP	.
CTSA	20	45890144	45898820	N	.	N	Y	-0.695589597	14.07651791	4.23E-05	74.3	DM	Galactosialidosis, 256540 (3)
CTSB	8	11842524	11869448	N	.	N	Y	-0.15697692	38.23580483	.	.	DP	.
CTSC	11	88293592	88337787	N	.	N	Y	-0.423561627	23.40105342	0.000816868	65.5	DM	Papillon-Lefevre syndrome, 245000 (3); Haim-Munk syndrome, 245010 (3); Periodontitis 1, juvenile, 170650 (3)
CTSE	1	206009264	206023909	N	.	N	Y	0.419797365	76.81889217	4.87E-07	83.8	.	.
CTSF	11	66563463	66568841	N	.	N	Y	-0.173091047	37.17659316	1.33E-13	96	DM	Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3)
CTSG	14	24573522	24576260	N	.	N	Y	0.075313076	55.32210453	0.202072536	38.7	FP	.
CTSH	15	78921058	78949574	N	.	N	Y	-0.004349788	49.11153557	3.17E-06	80.4	DM	.
CTSK	1	150796208	150808323	N	Viable	N	Y	-0.129182361	40.14585866	0.000135211	71	DM	Pycnodysostosis, 265800 (3)
CTSO	4	155924118	155953917	N	Viable	N	Y	-0.044735327	46.24066678	6.35E-06	79.1	.	.
CTSS	1	150730196	150765957	N	.	N	Y	-0.190163599	36.15789778	0.628282929	26.7	.	.
CTSV	9	97029679	97039643	N	.	N	N	0.284591847	69.63014412	9.73E-06	78.1	.	.
CTSW	11	65879809	65883741	N	.	N	Y	0.455399499	78.56688082	2.63E-07	84.7	.	.
CTSZ	20	58995185	59007247	N	.	N	Y	-0.041864765	46.45482433	1.32E-09	90.9	DP	.
CTTN	11	70398404	70436584	Y	Viable	N	Y	-0.543460696	18.45806564	0.215776883	38.2	.	.
CTTNBP2	7	117710651	117874139	N	Viable	N	Y	-1.068188972	6.945650287	2.60E-06	80.8	DM?	.
CTTNBP2NL	1	112396181	112463456	N	.	N	N	-0.062308427	44.96150952	0.141381252	41	.	.
CTU1	19	51097606	51108370	N	.	N	N	.	.	0.134628145	41.4	.	.
CTU2	16	88706463	88715386	N	.	N	N	1.333939312	96.00046304	3.22E-14	96.4	.	.
CTXN1	19	7924485	7926166	N	.	N	N	0.007634404	50.08971465	0.105057381	42.8	.	.
CTXN2	15	48191539	48203756	N	.	N	N	.	.	.	.	.	.
CTXN3	5	127649044	127658630	N	.	N	N	0.160566904	61.79892342	0.544481268	28.8	.	.
CU104787.1	22	11065974	11067346	N	.	N	N	.	.	.	.	.	.
CUEDC1	17	57861243	57955323	N	.	N	N	-0.387003268	25.10852579	6.38E-05	73.2	.	.
CUEDC2	10	102423245	102432661	N	.	N	N	-0.242684848	32.87607802	0.071907438	44.9	.	.
CUL2	10	35008551	35090642	N	.	N	N	-0.848527708	10.5805406	0.99999841	1.9	.	.
CUL4A	13	113208193	113267108	N	.	N	Y	-0.868166866	10.23904613	0.999412877	5.4	.	.
CUL5	11	108008733	108107776	N	.	N	N	-0.964909164	8.462117266	0.999964792	3.1	DM?	.
CUL9	6	43182175	43224587	N	.	N	Y	-1.155957785	6.025351624	0.967475855	13.3	.	.
CUTA	6	33416442	33418317	N	.	N	N	0.507773402	80.77212479	1.14E-05	77.7	FTV	.
CUTC	10	99702558	99756134	N	.	N	N	-0.008177066	48.7989813	0.020486565	51.5	.	.
CUZD1	10	122832149	122850793	N	.	N	Y	1.11313019	94.09040921	5.28E-06	79.4	.	.
CWC15	11	94962622	94973612	N	.	N	N	.	.	0.900277212	17.8	.	.
CWC22	2	179944876	180007113	N	.	N	N	0.104670547	57.58522892	0.018189074	52.2	.	.
CWC25	17	38800434	38825481	N	.	N	N	0.785543295	88.88695954	0.008010166	55.9	.	.
CWF19L1	10	100232298	100267680	N	.	N	N	-0.158085076	38.15477224	5.69E-09	89.5	.	?Spinocerebellar ataxia, autosomal recessive 17, 616127 (3)
CWF19L2	11	107326345	107457844	N	.	N	N	-0.037885915	46.7268623	9.65E-09	88.9	.	.
CWH43	4	48986247	49062081	N	.	N	N	-1.268587893	4.942987787	5.77E-15	96.8	.	.
CX3CL1	16	57372458	57385048	N	.	N	Y	0.039862734	52.54963246	0.963378217	13.6	.	.
CX3CR1	3	39263494	39281735	N	.	N	Y	0.930022697	91.72888812	0.107291641	42.7	DP	{Rapid progression to AIDS from HIV1 infection}, 609423 (3); {Coronary artery disease, resistance to}, 607339 (3); {Macular degeneration, age-related, 12}, 613784 (3)
CXCL1	4	73869393	73871242	N	.	N	N	0.22250501	65.75794409	0.092410293	43.6	.	.
CXCL10	4	76021117	76023497	N	.	N	Y	0.456060966	78.59003299	0.73102593	23.7	DP	.
CXCL11	4	76033682	76041415	N	.	N	N	0.039560397	52.53226833	0.12608338	41.7	DFP	.
CXCL13	4	77511753	77611834	N	.	N	Y	0.251561226	67.52329687	0.461397955	31.1	.	.
CXCL16	17	4733526	4739922	N	.	N	Y	0.442157199	77.99386468	0.04321106	47.8	DP	.
CXCL17	19	42428288	42443048	N	Viable	N	Y	-0.088948948	42.87202639	0.028588373	49.9	.	.
CXCL2	4	74097035	74099293	N	.	N	N	0.145560638	60.65289113	0.00141255	63.3	.	.
CXCL3	4	74036589	74038807	N	.	N	N	-0.035470476	46.91207964	0.010000245	54.9	.	.
CXCL5	4	73995642	73998779	N	.	N	N	0.017051112	50.83058401	0.000222602	69.5	FP	.
CXCL6	4	73836497	73849064	N	.	N	Y	-0.08703502	43.03409157	0.000196265	69.8	.	.
CXCL8	4	73740506	73743716	N	.	N	Y	.	.	.	.	.	.
CXCL9	4	76001275	76007488	N	Viable	N	Y	0.154020328	61.30693986	0.005333952	57.8	.	.
CXCR1	2	218162845	218166995	N	.	N	Y	0.659899072	85.911906	0.000374556	68	DM	{AIDS, slow progression to}, 609423 (3)
CXCR2	2	218125289	218137253	N	.	N	Y	-0.410469485	23.93355328	0.405284397	32.6	.	.
CXCR3	X	71615916	71618517	N	.	N	Y	0.066853307	54.65069167	0.257493403	36.8	FP	.
CXCR5	11	118883766	118897799	N	.	N	Y	-0.208844572	35.00607744	0.16025379	40.2	.	.
CXCR6	3	45940933	45948353	N	.	N	Y	-0.559729217	17.94292991	6.15E-05	73.3	.	.
CXorf21	X	30558824	30577844	N	.	N	N	0.306952505	70.86878509	0.255813631	36.9	.	.
CXorf23	X	19912860	19970298	N	.	N	N	-0.532433342	18.88638074	0.803897864	21.5	.	.
CXorf36	X	45148374	45200901	N	.	N	N	0.92619845	91.62470336	0.007603593	56.2	.	.
CXorf38	X	40626921	40647554	N	.	N	N	0.156890071	61.50952133	0.005163584	58	.	.
CXorf40A	X	149540355	149550510	N	.	N	N	0.502036857	80.5116629	0.610741242	27.2	.	.
CXorf40B	X	149929527	149938811	N	.	N	N	0.672846598	86.25918852	0.642796581	26.3	.	.
CXorf49	X	71714371	71718151	N	.	N	N	.	.	.	.	.	.
CXorf49B	X	71763424	71767204	N	.	N	N	.	.	.	.	.	.
CXorf56	X	119538149	119565408	N	.	N	N	0.076119241	55.36840887	0.925801506	16.3	.	.
CXorf57	X	106611930	106679442	N	.	N	N	-0.621514277	16.14863692	0.1871725	39.1	.	.
CXorf58	X	23907801	23939507	N	.	N	N	0.9252426	91.60733924	0.000356507	68.1	.	.
CXorf65	X	71103889	71106788	N	.	N	N	0.814457585	89.41367135	0.905102153	17.6	.	.
CXorf66	X	139955725	139965520	N	.	N	N	0.432741275	77.53082132	0.018393036	52.1	.	.
CXorf67	X	51406915	51408843	N	.	N	N	.	.	0.868926866	19.1	.	.
CXXC4	4	104468312	104494901	N	.	N	N	-0.349641992	26.83336227	.	.	.	.
CXXC5	5	139647299	139683882	N	.	N	N	-0.315801021	28.52347051	0.795355279	21.8	.	.
CYB561	17	63432304	63446378	N	Viable	N	Y	0.335200382	72.59362158	0.698896027	24.6	.	.
CYB561A3	11	61348745	61362299	N	.	N	N	0.006828994	50.02025815	0.058731723	46.1	.	.
CYB561D1	1	109494052	109502932	N	.	N	N	0.073399639	55.17740348	0.015830419	52.9	.	.
CYB561D2	3	50350695	50358460	N	.	N	N	0.294815417	70.1800081	0.014710475	53.3	.	.
CYB5A	18	74250847	74292016	N	.	N	N	0.026467762	51.52514904	0.033739316	49.1	DM	Methemoglobinemia, type IV, 250790 (3)
CYB5B	16	69424525	69466266	N	.	N	N	0.291946181	70.03530706	0.25957799	36.8	.	.
CYB5D1	17	7857746	7862282	N	Viable	N	Y	0.097822207	56.98327256	4.58E-05	74.1	.	.
CYB5D2	17	4143168	4187310	N	Viable	N	Y	0.642979476	85.46622678	4.57E-05	74.1	.	.
CYB5R1	1	202961869	202967280	N	.	N	N	-0.367365256	26.00567228	9.33E-09	89	.	.
CYB5R2	11	7665100	7677222	N	Viable	N	Y	0.203971741	64.62927592	2.71E-05	75.5	.	.
CYB5R3	22	42617840	42649568	N	.	N	N	-0.049367758	45.85286797	0.210867104	38.4	DM	Methemoglobinemia, type I, 250800 (3); Methemoglobinemia, type II, 250800 (3)
CYB5R4	6	83859643	83967424	N	.	N	Y	-0.14307911	39.17346762	0.00034348	68.3	FP	.
CYB5RL	1	54172336	54200036	N	.	N	N	0.792090504	89.02008451	4.23E-05	74.3	.	.
CYBA	16	88643283	88651152	N	.	N	Y	.	.	0.003572983	59.6	DM	Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 (3)
CYBB	X	37780011	37813461	N	Viable	N	Y	-0.081293491	43.49713492	0.997697898	7.2	DM	Chronic granulomatous disease, X-linked, 306400 (3); Immunodeficiency 34, mycobacteriosis, X-linked, 300645 (3)
CYBRD1	2	171522247	171558133	N	Viable	N	Y	0.629738398	85.04369972	0.351788246	34.1	DM	.
CYC1	8	144095027	144097525	N	.	N	N	-0.09438571	42.50159171	0.979014368	11.9	DM	Mitochondrial complex III deficiency, nuclear type 6, 615453 (3)
CYGB	17	76527356	76551175	N	.	N	Y	-0.321544247	28.21670429	0.23461677	37.6	.	.
CYHR1	8	144449582	144465677	N	.	N	N	.	.	0.053830788	46.6	.	.
CYLC1	X	83861126	83886699	N	.	N	N	1.219948174	95.23065347	0.606280836	27.3	.	.
CYLC2	9	102995311	103018488	N	.	N	N	1.053906726	93.41320831	5.14E-07	83.7	.	.
CYP11B1	8	142872356	142879846	N	.	N	Y	0.058847615	54.0197951	0.001433932	63.2	DM	Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3); Aldosteronism, glucocorticoid-remediable, 103900 (3)
CYP17A1	10	102830531	102837533	Y	Viable	N	Y	-0.568991981	17.68825606	0.035030608	48.9	DM	17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3); 17,20-lyase deficiency, isolated, 202110 (3)
CYP19A1	15	51208057	51338610	N	.	N	Y	-0.48167256	20.94692366	0.00055961	66.7	DM	Aromatase deficiency, 613546 (3); Aromatase excess syndrome, 139300 (3)
CYP1A1	15	74719542	74725610	N	.	N	Y	1.585087949	97.40695723	1.97E-07	85.2	DFP	.
CYP1B1	2	38066973	38109902	N	.	N	Y	0.238767519	66.77663946	0.000296476	68.7	DM	Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 (3); Peters anomaly, 604229 (3)
CYP20A1	2	203238449	203305840	N	.	N	Y	0.461946007	78.93152746	7.41E-10	91.3	.	.
CYP21A2	6	32038265	32041670	N	.	N	N	1.323093579	95.93100654	0.672306731	25.4	DM	Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3); Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3)
CYP26C1	10	93060808	93069536	N	.	N	Y	0.647613662	85.55883545	0.022954901	51	DM	Focal facial dermal dysplasia 4, 614974 (3)
CYP27A1	2	218781749	218815293	N	.	N	Y	0.64967619	85.60513978	3.90E-11	93.5	DM	Cerebrotendinous xanthomatosis, 213700 (3)
CYP27B1	12	57762334	57768986	N	Viable	N	Y	-0.474169447	21.24790183	3.60E-06	80.2	DM	Vitamin D-dependent rickets, type I, 264700 (3)
CYP27C1	2	127184120	127220078	N	.	N	N	-0.766947849	12.27064884	0.000184567	70.1	.	.
CYP2A13	19	41088472	41096195	N	.	N	Y	1.186408634	94.93546333	0.001434457	63.2	DFP	.
CYP2A6	19	40843538	40882210	N	.	N	N	2.176406349	98.82502749	2.18E-06	81.2	DP	Coumarin resistance, 122700 (3); {Nicotine addiction, protection from}, 188890 (3); {Lung cancer, resistance to}, 211980 (3)
CYP2A7	19	40875439	40882752	N	.	N	N	2.928246229	99.47907623	3.01E-10	92.1	.	.
CYP2B6	19	40991299	41018398	N	.	N	N	2.747882579	99.33437518	2.29E-05	75.9	DM	Efavirenz, poor metabolism of, 614546 (3); {Efavirenz central nervous system toxicity, susceptibility to}, 614546 (3)
CYP2C18	10	94683621	94736190	N	.	N	N	-0.008830831	48.74688893	5.27E-08	86.9	DFP	.
CYP2C19	10	94762624	94853260	N	.	N	N	1.262405321	95.51426752	2.54E-10	92.2	DFP	Mephenytoin poor metabolizer, 609535 (3); Opremazole poor metabolizer, 609535 (3); Proguanil poor metabolizer, 609535 (3); Clopidogrel, impaired responsiveness to, 609535 (3)
CYP2C8	10	95036772	95069497	N	.	N	N	1.088704967	93.83573537	5.35E-12	94.6	DM	Rhabdomyolysis, cerivastatin-induced (3)
CYP2C9	10	94938658	94989390	N	.	N	N	0.698523715	86.86693292	2.54E-08	87.9	DM	Tolbutamide poor metabolizer (3); Warfarin sensitivity, 122700 (3)
CYP2D6	22	42126499	42130906	N	.	N	N	2.761148347	99.34595126	9.23E-10	91.2	DM	{Debrisoquine sensitivity}, 608902 (3); {Codeine sensitivity}, 608902 (3)
CYP2E1	10	133520406	133561220	N	Viable	N	Y	0.125265848	59.15378827	0.265925587	36.6	DP	.
CYP2F1	19	41114432	41128366	N	.	N	Y	1.54101848	97.18122359	2.76E-05	75.4	DP	.
CYP2J2	1	59893308	59926790	N	.	N	N	0.503288375	80.58111941	4.51E-12	94.7	DFP	.
CYP2R1	11	14877440	14892252	N	Viable	N	Y	-0.483586384	20.81958673	3.05E-09	90.1	DM	Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3)
CYP2S1	19	41193049	41207539	N	.	N	Y	0.267822797	68.56514441	0.000914984	65.1	.	.
CYP2U1	4	107931369	107953457	N	.	N	N	-0.079379727	43.6881403	0.081783015	44.3	DM	Spastic paraplegia 56, autosomal recessive, 615030 (3)
CYP2W1	7	983199	989640	N	.	N	N	.	.	0.000980916	64.8	DP	.
CYP39A1	6	46549580	46652830	N	.	N	N	0.139315016	60.15511952	2.01E-12	95	.	.
CYP3A4	7	99756960	99784265	N	.	N	N	0.207798719	64.91288997	2.82E-07	84.7	DFP	.
CYP3A43	7	99828013	99866102	N	.	N	N	0.313797733	71.32025236	1.47E-10	92.7	FP	.
CYP3A5	7	99648194	99679998	N	.	N	N	0.031402963	51.9476761	5.21E-11	93.3	DFP	{Hypertension, salt-sensitive essential, susceptibility to}, 145500 (3)
CYP3A7	7	99705037	99735196	N	.	N	Y	-0.142122259	39.27186433	2.93E-07	84.6	DM	.
CYP46A1	14	99684304	99727301	N	.	N	Y	-0.875824863	10.04225271	0.754693331	23	DFP	.
CYP4A11	1	46929177	46941484	N	.	N	Y	0.888979319	90.91277421	1.57E-15	97.2	DFP	.
CYP4A22	1	47137435	47149741	N	.	N	N	2.271107925	98.9639405	1.42E-08	88.5	FP	.
CYP4B1	1	46757838	46819413	N	Viable	N	Y	1.89566188	98.39092435	5.37E-10	91.7	FP	.
CYP4F11	19	15912367	15934867	N	.	N	N	0.809314096	89.3094866	8.08E-15	96.7	.	.
CYP4F12	19	15672757	15697174	N	Viable	N	Y	2.432579527	99.13179371	1.18E-09	91	FP	.
CYP4F2	19	15878023	15898120	N	.	N	N	1.400352262	96.38247381	3.52E-11	93.6	DFP	.
CYP4F22	19	15508493	15552317	N	.	N	N	0.347637183	73.26503444	0.000303611	68.6	DM	Ichthyosis, congenital, autosomal recessive 5, 604777 (3)
CYP4F3	19	15615617	15662825	N	.	N	N	0.735238353	87.74671529	6.83E-14	96.2	DM?	.
CYP4F8	19	15615218	15630638	N	.	N	N	.	.	.	.	.	.
CYP4V2	4	186191520	186213456	N	.	N	N	0.200295721	64.41511837	0.000200713	69.8	DM	Bietti crystalline corneoretinal dystrophy, 210370 (3)
CYP4X1	1	47023568	47050751	N	.	N	N	0.031402963	51.9476761	1.72E-06	81.6	.	.
CYP4Z1	1	47067488	47118319	N	.	N	N	0.882280274	90.76807316	5.28E-06	79.4	.	.
CYP7B1	8	64587763	64798761	N	Viable	N	Y	-0.909512511	9.411356138	2.14E-06	81.2	DM	Bile acid synthesis defect, congenital, 3, 613812 (3); Spastic paraplegia 5A, autosomal recessive, 270800 (3)
CYP8B1	3	42856005	42876165	N	.	N	Y	0.292245427	70.07003531	0.000512932	67	.	.
CYSLTR1	X	78271464	78327691	N	.	N	Y	-0.27924293	30.68241014	0.004320462	58.8	DP	.
CYSLTR2	13	48653711	48711226	N	.	N	Y	1.307129319	95.83839787	0.001554021	62.9	DFP	.
CYSRT1	9	137224635	137226311	N	.	N	N	.	.	.	.	.	.
CYSTM1	5	140174642	140282052	N	Viable	N	Y	0.024554204	51.41517625	0.28430926	36.1	.	.
CYTH1	17	78674048	78782297	N	.	N	N	-0.535305023	18.7706199	0.994541234	8.6	.	.
CYTH2	19	48469032	48482314	N	.	N	N	-1.040902558	7.35081322	0.863501033	19.4	.	.
CYTH3	7	6161776	6272644	N	.	N	N	-0.648810144	15.40776755	0.356369423	34	.	.
CYTH4	22	37282027	37315345	N	.	N	N	-0.53897936	18.62591885	0.572494882	28.2	.	.
CYTIP	2	157414619	157488961	N	Viable	N	Y	-0.040907923	46.57058517	0.048798672	47.1	.	.
CYTL1	4	5014586	5019472	N	.	N	Y	0.336965217	72.66886612	0.000652771	66.2	.	.
CYYR1	21	26466209	26573284	N	.	N	N	0.302318539	70.64305146	0.034426589	49	.	.
D2HGDH	2	241734579	241768816	N	.	N	N	0.241638002	66.97922093	0.000752024	65.7	DM	D-2-hydroxyglutaric aciduria, 600721 (3)
D4S234E	4	4348140	4419058	N	.	N	N	-0.23518181	33.35069746	.	.	.	.
DAAM2	6	39792298	39904877	N	Viable	N	Y	0.572082303	83.16837414	0.998285962	6.7	.	.
DAB2IP	9	121567057	121785530	N	.	N	Y	-0.67072861	14.73056665	0.999652088	4.8	DM?	.
DACH2	X	86148458	86832604	N	.	N	Y	0.47503921	79.52769578	0.859033207	19.6	.	.
DACT2	6	168292830	168319754	N	Viable	N	Y	.	.	.	.	.	.
DACT3	19	46647612	46661138	N	Viable	N	Y	.	.	.	.	.	.
DAGLA	11	61680433	61747001	N	.	N	Y	-1.941166528	1.788504949	0.953148342	14.5	.	.
DAGLB	7	6409126	6484190	N	.	N	Y	0.019570635	51.05631765	1.65E-06	81.7	.	.
DALRD3	3	49015488	49022293	N	.	N	N	-0.645938225	15.50037622	1.85E-05	76.5	.	.
DAO	12	108858932	108901043	N	.	N	N	0.29496479	70.19737223	9.26E-15	96.7	DM	{Schizophrenia}, 181500 (2)
DAOA	13	105465867	105491034	N	.	N	N	0.181312488	63.27487411	0.008045246	55.9	DP	{Schizophrenia}, 181500 (2)
DAP	5	10679230	10761272	N	.	N	Y	0.213088965	65.23702032	0.000324904	68.4	.	.
DAPK1	9	87497228	87708633	N	Viable	N	Y	-1.864930071	2.002662499	0.999700496	4.6	DM	.
DAPK2	15	63907036	64072033	N	.	N	N	0.456356165	78.6189732	0.000134613	71	.	.
DAPL1	2	158795317	158862958	N	.	N	N	0.661519885	85.95821034	0.000268263	69	.	.
DAPP1	4	99816833	99870154	N	.	N	Y	-0.154562494	38.40365804	0.18349368	39.2	DM?	.
DARS	2	135906677	135986100	N	.	N	N	-0.33911414	27.30219367	0.000611999	66.4	DM	Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3)
DAW1	2	227871054	227924344	N	.	N	Y	0.682408952	86.50228628	0.000785948	65.6	.	.
DAZ1	Y	23129355	23199094	N	.	N	N	.	.	.	.	DM	.
DAZ2	Y	23219434	23291356	N	.	N	N	.	.	.	.	DM	.
DAZ3	Y	24763069	24813492	N	.	N	N	.	.	.	.	.	.
DAZ4	Y	24833820	24907040	N	.	N	N	.	.	.	.	.	.
DAZAP2	12	51238292	51271362	N	.	N	N	0.340790619	72.91775192	0.52754374	29.2	.	.
DAZL	3	16586792	16670306	N	.	N	Y	-0.068201255	44.52161834	0.961607976	13.8	DM	{Spermatogenic failure, susceptibility to} (3)
DBF4	7	87876216	87909541	N	.	N	N	0.277239383	69.12658448	0.998167682	6.8	.	.
DBF4B	17	44708608	44752264	N	.	N	N	0.181614038	63.32696649	4.43E-08	87.1	DM?	.
DBNDD1	16	90004865	90020128	N	.	N	N	-0.243641967	32.83556173	0.000234996	69.3	.	.
DBNDD2	20	45406057	45410610	N	Viable	N	Y	.	.	0.050608864	46.9	.	.
DBP	19	48630030	48637438	N	.	N	Y	0.132467594	59.58789142	0.820194275	21	.	.
DBR1	3	138161012	138174949	N	.	N	N	-0.248121003	32.57509984	8.71E-05	72.3	.	.
DBX2	12	45014672	45051099	N	.	N	N	-0.000674037	49.38936158	4.42E-08	87.2	.	.
DCAF10	9	37800502	37867666	N	Viable	N	Y	-0.159194457	38.09110378	0.967142661	13.3	.	.
DCAF11	14	24114195	24125242	N	.	N	N	0.34476668	73.13769752	0.071451319	45	.	.
DCAF12	9	34086387	34127399	N	.	N	N	-0.055913898	45.41297679	0.003485564	59.7	.	.
DCAF12L1	X	126549383	126552851	N	.	N	N	-0.383328502	25.24743879	0.80516316	21.4	.	.
DCAF12L2	X	126164531	126165951	N	.	N	N	0.263039301	68.2178619	0.162975822	40.1	.	.
DCAF13	8	103414714	103443453	N	.	N	N	0.277391673	69.1439486	6.93E-05	72.9	DM?	.
DCAF15	19	13952492	13961449	N	.	N	N	-0.71986195	13.41668114	0.995060212	8.4	.	.
DCAF16	4	17800655	17810758	N	.	N	N	-0.076661182	43.91387394	0.00409866	59	.	.
DCAF17	2	171434217	171485052	N	.	N	N	-0.524930204	19.22208717	0.000284985	68.8	DM	Woodhouse-Sakati syndrome, 241080 (3)
DCAF4	14	72926332	72959703	N	.	N	N	1.074654463	93.69103432	0.003645184	59.5	DM?	.
DCAF4L1	4	41981696	41986467	N	.	N	N	-0.359862201	26.32401459	0.851426397	19.9	.	.
DCAF4L2	8	87870743	87874068	N	.	N	N	-0.256580891	32.10626845	0.001649444	62.7	.	.
DCAF5	14	69050881	69153150	N	.	N	N	-1.049061373	7.223476298	0.999968932	3	.	.
DCAF6	1	167935783	168075843	N	.	N	N	-0.564057396	17.79822886	0.996908923	7.6	.	.
DCAF7	17	63550461	63594266	N	.	N	N	.	.	0.875048579	18.9	.	.
DCAF8	1	160215715	160262531	N	.	N	N	-0.29042075	30.03993749	0.999730107	4.5	.	?Giant axonal neuropathy 2, autosomal dominant, 610100 (3)
DCAF8L1	X	27977993	27981355	N	.	N	N	0.557724031	82.72269491	0.119165931	42.2	.	.
DCAF8L2	X	27590382	27748821	N	.	N	N	0.408319078	76.25166406	0.575393469	28.1	.	.
DCAKD	17	45023340	45061109	N	.	N	N	0.57162449	83.15679806	0.029386085	49.8	DM?	.
DCANP1	5	135444214	135447348	N	.	N	N	.	.	.	.	.	.
DCBLD1	6	117453817	117569858	N	.	N	N	-0.369126321	25.91885165	8.21E-05	72.5	.	.
DCBLD2	3	98795941	98901689	N	.	N	Y	0.438630851	77.81443538	0.000553237	66.7	DM?	.
DCD	12	54644591	54648493	N	.	N	N	0.230008154	66.23835157	0.003610671	59.5	.	.
DCDC1	11	30830369	31369810	N	.	N	N	-0.237899627	33.20599641	9.13E-05	72.2	.	.
DCDC2	6	24171756	24358052	N	.	N	Y	0.160867203	61.83943972	1.05E-05	77.9	DP	Nephronophthisis 19, 616217 (3); ?Deafness, autosomal recessive 66, 610212 (3)
DCDC2B	1	32209094	32216196	N	Viable	N	Y	0.58199694	83.58511316	8.88E-08	86.2	.	.
DCDC2C	2	3703592	3847408	N	.	N	Y	.	.	.	.	.	.
DCHS2	4	154232037	154491716	N	.	N	N	2.405299251	99.1028535	7.25E-28	99.6	.	.
DCK	4	70992538	71030914	N	.	N	Y	0.196318636	64.16623256	0.390659945	33	FP	.
DCLK1	13	35768652	36131306	N	.	N	Y	-1.159047258	5.996411414	0.961271824	13.8	DFP	.
DCLK2	4	150078274	150257457	N	.	N	N	-0.123289027	40.56838572	0.966310095	13.4	.	.
DCLK3	3	36712422	36739861	N	.	N	N	-0.029426144	47.35197083	0.439315818	31.7	.	.
DCLRE1A	10	113834725	113854383	N	.	N	Y	0.353533797	73.61231695	4.68E-08	87.1	DM?	.
DCLRE1C	10	14897359	14954432	N	.	N	Y	-0.548094539	18.29021242	0.002869357	60.6	DM	Severe combined immunodeficiency, Athabascan type, 602450 (3); Omenn syndrome, 603554 (3)
DCN	12	91140484	91183123	N	.	N	Y	-0.384285668	25.21271054	0.457565653	31.2	DM	Corneal dystrophy, congenital stromal, 610048 (3)
DCP1A	3	53283428	53347610	N	.	N	N	.	.	0.943913888	15.3	.	.
DCP1B	12	1946054	2004535	N	.	N	N	0.455550929	78.57845691	5.32E-07	83.6	DP	.
DCST1	1	155033824	155050930	N	.	N	N	-0.244143247	32.8181976	3.89E-15	96.9	.	.
DCST2	1	155018520	155033781	N	.	N	N	1.544057783	97.20437576	1.46E-09	90.8	.	.
DCSTAMP	8	104339087	104356689	N	.	N	Y	0.518294668	81.20622793	0.001345266	63.6	.	.
DCT	13	94436808	94479682	N	Viable	N	Y	-0.106369495	41.71441801	6.55E-12	94.5	.	.
DCTD	4	182890060	182917936	N	.	N	N	-0.252102165	32.32621404	1.64E-05	76.8	FP	.
DCTN2	12	57530102	57547331	N	.	N	N	0.17476603	62.85234705	0.996367311	7.8	.	.
DCTN3	9	34613545	34620523	N	.	N	N	0.240380673	66.89818834	0.020223962	51.6	.	.
DCTN4	5	150708440	150759109	N	.	N	N	-0.651527147	15.34409909	0.953389998	14.4	DP	.
DCTN6	8	30156297	30183640	N	.	N	N	0.004915377	49.86976906	0.026238399	50.3	.	.
DCTPP1	16	30423619	30430075	N	.	N	N	0.453338311	78.48584824	0.184698214	39.1	.	.
DCUN1D1	3	182938074	182985953	N	.	N	N	-0.065482771	44.7241998	0.990513001	9.8	.	.
DCUN1D2	13	113455819	113490952	N	.	N	N	-0.27924293	30.68241014	9.91E-05	71.9	.	.
DCUN1D3	16	20854925	20900384	N	.	N	N	-0.288660263	30.16727441	0.898154103	17.8	.	.
DCUN1D4	4	51843000	51916837	N	.	N	N	-0.136685385	39.64229901	0.160650286	40.1	.	.
DCUN1D5	11	103062076	103092215	N	.	N	N	0.003001751	49.6961278	0.97199487	12.8	.	.
DCXR	17	82035136	82037732	N	Viable	N	Y	0.414865996	76.60473462	3.47E-05	74.8	DM	[Pentosuria], 260800 (3)
DDA1	19	17309518	17323301	N	.	N	N	0.015137522	50.6627308	0.893417442	18	.	.
DDAH2	6	31727038	31730617	N	.	N	N	-0.130139339	40.0821902	0.842139471	20.2	DFP	.
DDB2	11	47214465	47239240	N	.	N	Y	-0.442395976	22.60809168	0.005117907	58	DM	Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3)
DDHD1	14	53036745	53153282	N	.	N	Y	-0.912082792	9.353475719	0.968458214	13.2	DM	Spastic paraplegia 28, autosomal recessive, 609340 (3)
DDHD2	8	38225218	38275558	N	.	N	Y	-0.613859382	16.36858251	3.10E-08	87.6	DM	Spastic paraplegia 54, autosomal recessive, 615033 (3)
DDI1	11	104036580	104039188	N	.	N	N	0.522927841	81.36829311	5.48E-06	79.4	.	.
DDI2	1	15617500	15669044	N	.	N	N	-0.332721412	27.59738381	0.941088127	15.5	.	.
DDIAS	11	82899975	82958277	N	.	N	N	.	.	.	.	.	.
DDIT3	12	57516588	57520517	N	Viable	N	Y	-0.077618099	43.83284135	0.515502017	29.5	.	Myxoid liposarcoma, 613488 (1)
DDIT4	10	72273920	72276036	N	.	N	Y	-0.181703531	36.63251722	0.019495468	51.8	.	.
DDIT4L	4	100185870	100190782	N	.	N	N	0.150343606	61.02332581	0.000548864	66.8	.	.
DDN	12	48995149	48999309	N	.	N	N	-0.539784071	18.5911906	0.986679784	10.7	.	.
DDO	6	110391771	110415562	N	.	N	Y	1.53336136	97.12913121	3.15E-11	93.7	.	.
DDR1	6	30876421	30900156	N	.	N	Y	-1.050830532	7.206112172	0.026477857	50.3	DP	.
DDR2	1	162631373	162787400	N	.	N	Y	-0.193535266	35.90901198	0.990992372	9.7	DM	Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3)
DDRGK1	20	3190350	3204685	N	.	N	N	0.365212869	74.13902877	0.000149759	70.6	FTV	.
DDT	22	23971365	23980469	N	.	N	N	.	.	0.412925624	32.4	.	.
DDTL	22	23966901	23972532	N	.	N	N	.	.	0.416727572	32.3	.	.
DDX1	2	15591178	15631111	N	.	N	N	-0.700222136	13.91445274	0.998606607	6.4	.	.
DDX10	11	108665025	108940930	N	.	N	N	-0.049870415	45.77183539	5.42E-11	93.3	.	.
DDX18	2	117814650	117832379	N	.	N	N	0.440544747	77.91283209	0.839996435	20.3	.	.
DDX19A	16	70299224	70373383	N	.	N	N	-0.624385828	16.01551195	0.923061309	16.5	.	.
DDX19B	16	70289663	70335283	N	.	N	N	-0.27637172	30.86762748	0.03571178	48.9	.	.
DDX23	12	48829764	48852842	N	.	N	N	-1.664704402	2.587254732	0.999558303	5	.	.
DDX24	14	94048291	94081245	N	.	N	N	0.564579113	82.87897204	0.221392665	38	.	.
DDX25	11	125903376	125928829	N	.	N	Y	-0.480868635	20.95849974	4.23E-09	89.8	DP	.
DDX26B	X	135520659	135582510	N	.	N	N	-0.08305528	43.36400996	0.999847761	4.1	.	.
DDX28	16	68021274	68023442	N	.	N	N	-0.003241475	49.17520403	0.034893731	49	.	.
DDX31	9	132592997	132670401	N	.	N	N	0.405098119	76.10117497	2.76E-06	80.7	.	.
DDX39A	19	14408819	14419383	N	.	N	N	-0.389874437	24.9580367	0.843485807	20.1	.	.
DDX39B	6	31530219	31542448	N	.	N	N	-0.048562831	45.92232448	0.997728044	7.1	DFP	.
DDX3X	X	41333348	41364472	N	.	N	N	-0.318672489	28.34982925	0.998930065	6	FTV	Mental retardation, X-linked 102, 300958 (3)
DDX3Y	Y	12904108	12920478	N	.	N	N	.	.	0.77309953	22.5	DM	.
DDX4	5	55738017	55817157	N	.	N	Y	-0.450703279	22.237657	0.998516038	6.5	.	.
DDX42	17	63773603	63819317	N	.	N	N	-1.506958138	3.316548012	0.999995784	2.2	.	.
DDX43	6	73394748	73417569	N	.	N	N	-0.229287694	33.77322452	6.82E-05	73	.	.
DDX46	5	134758771	134855133	N	.	N	N	-1.089598905	6.673612317	0.999997754	2	.	.
DDX47	12	12813316	12829981	N	.	N	N	0.001391072	49.59773109	1.14E-08	88.8	DM?	.
DDX49	19	18919675	18928633	N	.	N	N	0.099886544	57.20321815	3.24E-10	92.1	.	.
DDX50	10	68901278	68946847	N	.	N	N	-0.769665733	12.20698038	0.000758121	65.7	.	.
DDX52	17	37609739	37643464	N	.	N	Y	0.296072862	70.26682873	1.44E-10	92.7	.	.
DDX53	X	22999961	23003589	N	.	N	N	0.478865545	79.695549	0.825398953	20.8	DM	.
DDX54	12	113157174	113185479	N	.	N	N	0.704426716	86.9884818	1.04E-06	82.5	.	.
DDX56	7	44565417	44575051	N	.	N	N	-0.289311826	30.11518203	3.52E-06	80.2	.	.
DDX59	1	200623896	200669969	N	.	N	N	0.21625851	65.43381374	0.001077915	64.4	.	Orofaciodigital syndrome V, 174300 (3)
DDX6	11	118747766	118791149	N	.	N	N	-0.393703195	24.72072698	0.998985996	5.9	.	.
DDX60	4	168216293	168318807	N	.	N	N	-1.657513418	2.627771025	3.67E-10	92	.	.
DDX60L	4	168356735	168537786	N	.	N	N	0.352094546	73.49076807	8.17E-30	99.7	.	.
DEC1	9	115141818	115402644	N	.	N	N	0.372568852	74.5441917	0.000209449	69.7	DFP	Esophageal squamous cell carcinoma, 133239 (1)
DECR1	8	90001405	90052092	N	.	N	Y	-0.049367758	45.85286797	1.67E-05	76.8	.	.
DECR2	16	401826	412487	N	.	N	N	0.825929637	89.67413324	3.47E-09	90	.	.
DEDD	1	161120974	161132688	N	.	N	Y	-0.242684848	32.87607802	0.86950321	19.1	.	.
DEDD2	19	42198598	42220140	N	.	N	N	0.334243918	72.52995312	0.284523204	36.1	.	.
DEF6	6	35297852	35321771	N	.	N	Y	0.452529749	78.4395439	0.976824149	12.2	.	.
DEF8	16	89947925	89968060	N	.	N	N	-0.4732126	21.32314638	0.389991488	33	.	.
DEFA1	8	6977649	6980080	N	.	N	N	.	.	.	.	.	.
DEFA1B	8	6996766	7018289	N	.	N	N	.	.	.	.	.	.
DEFA3	8	6996837	7018301	N	.	N	N	.	.	0.489152997	30.3	.	.
DEFA4	8	6935822	6938338	N	.	N	N	0.596856816	84.01342826	0.271968353	36.4	.	.
DEFA5	8	7055304	7056734	N	.	N	N	0.505861042	80.68530416	0.000100681	71.8	.	.
DEFA6	8	6924693	6926076	N	.	N	N	-0.078575026	43.76338485	0.00438946	58.7	.	.
DEFB103A	8	7881204	7882664	N	.	N	N	.	.	.	.	.	.
DEFB103B	8	7428888	7430348	N	.	N	N	.	.	.	.	.	.
DEFB104A	8	7836471	7841242	N	.	N	N	0.872576171	90.6349482	0.519473453	29.5	.	.
DEFB104B	8	7470308	7475082	N	.	N	N	.	.	.	.	.	.
DEFB105A	8	7821966	7823889	N	.	N	N	.	.	0.436248235	31.8	.	.
DEFB105B	8	7487669	7489593	N	.	N	N	.	.	.	.	.	.
DEFB106A	8	7825172	7829053	N	.	N	N	0.401625817	75.89859351	0.409307652	32.5	.	.
DEFB106B	8	7482504	7486400	N	.	N	N	0.462608295	78.94310355	.	.	.	.
DEFB107A	8	7811720	7815716	N	.	N	N	.	.	.	.	.	.
DEFB107B	8	7495846	7509311	N	.	N	N	.	.	.	.	.	.
DEFB108B	11	71833200	71837710	N	.	N	N	0.601492401	84.14076518	0.02354854	50.8	.	.
DEFB110	6	50009138	50021981	N	.	N	N	0.299449341	70.47519824	0.033222191	49.2	.	.
DEFB112	6	50043575	50048651	N	.	N	N	0.352927885	73.57180066	4.67E-05	74.1	.	.
DEFB113	6	49968677	49969625	N	.	N	N	0.183076334	63.39063495	0.000538841	66.8	.	.
DEFB114	6	49960249	49964105	N	.	N	N	0.190579485	63.80158592	0.162703129	40.1	.	.
DEFB115	20	31257664	31259632	N	.	N	N	0.139014096	60.0972391	0.033715286	49.1	.	.
DEFB116	20	31303212	31308585	N	.	N	N	0.284443026	69.58383979	0.001628841	62.7	.	.
DEFB118	20	31368618	31373923	N	.	N	N	0.404494149	76.04329455	0.089118876	43.8	.	.
DEFB119	20	31377164	31390603	N	.	N	N	0.922375556	91.54945882	0.058626512	46.1	.	.
DEFB121	20	31404845	31412838	N	.	N	N	0.001088113	49.55142675	0.031538297	49.5	.	.
DEFB123	20	31440519	31450257	N	.	N	N	0.076119241	55.36840887	0.006369854	57	.	.
DEFB124	20	31465506	31476757	N	.	N	N	0.356606194	73.78595821	0.187335649	39.1	.	.
DEFB125	20	87250	97094	N	.	N	N	0.102455237	57.40579962	0.000941817	65	.	.
DEFB126	20	142369	145751	N	.	N	Y	0.685941771	86.54859061	0.00072303	65.9	FP	.
DEFB127	20	157470	159163	N	.	N	N	0.48703021	79.96758697	7.42E-06	78.8	.	.
DEFB128	20	187853	189681	N	.	N	N	0.555516228	82.64166233	0.560121292	28.4	.	.
DEFB129	20	227258	229886	N	.	N	N	0.580894119	83.51565665	0.008710345	55.5	.	.
DEFB130	8	12310962	12318316	N	.	N	N	.	.	.	.	.	.
DEFB131	4	9444534	9450514	N	.	N	N	0.23846774	66.7534873	0.157398012	40.3	.	.
DEFB132	20	257736	261096	N	.	N	N	1.04148133	93.28587139	0.006474774	56.9	.	.
DEFB133	6	49946101	49949444	N	.	N	N	.	.	.	.	.	.
DEFB134	8	11993174	11996312	N	.	N	N	0.100541925	57.24952249	0.032237341	49.3	.	.
DEFB135	8	11982321	11984590	N	.	N	N	0.154020328	61.30693986	1.32E-06	82.2	.	.
DEFB136	8	11973937	11974599	N	.	N	N	0.009548021	50.25756786	0.034000099	49.1	.	.
DEFB4A	8	7894629	7896711	N	.	N	N	.	.	0.399812614	32.8	DP	.
DEFB4B	8	7414860	7416863	N	.	N	N	.	.	.	.	.	.
DEGS2	14	100143957	100160163	N	.	N	N	0.156083554	61.48058112	0.005864274	57.3	.	.
DEK	6	18223868	18264823	N	.	N	Y	-0.610336728	16.45540314	0.102359187	43	.	Leukemia, acute nonlymphocytic (2)
DENND1A	9	123379654	123930152	N	.	N	N	-0.858458862	10.4011113	0.904475401	17.6	.	.
DENND1B	1	197504748	197775696	N	.	N	N	-0.564360358	17.79244082	0.636578248	26.4	.	.
DENND1C	19	6467207	6482557	N	Viable	N	Y	1.427495467	96.5329629	0.036005999	48.8	.	.
DENND2A	7	140518420	140673993	N	.	N	N	-0.1801432	36.71354981	0.97223128	12.8	.	.
DENND2C	1	114582848	114670422	N	.	N	N	0.571124702	83.11628176	1.70E-07	85.4	.	.
DENND2D	1	111187174	111204535	N	.	N	N	-0.302555896	29.33379638	1.03E-05	78	.	.
DENND3	8	141117278	141195808	N	.	N	N	-1.004583993	7.796492447	0.017173033	52.4	.	.
DENND4A	15	65658046	65792293	N	.	N	N	-1.066656595	6.980378538	0.001354621	63.5	.	.
DENND4B	1	153929501	153946696	N	.	N	N	-1.856578873	2.020026625	0.999987069	2.7	.	.
DENND5A	11	9138825	9265390	N	.	N	N	-2.166352473	1.33703768	0.991775356	9.5	DM?	.
DENND5B	12	31382223	31591097	N	.	N	N	-1.020958787	7.611275106	0.999945504	3.3	.	.
DENND6A	3	57625457	57693089	N	.	N	N	-0.486457463	20.70961394	0.852272523	19.8	.	.
DENND6B	22	50309030	50327060	N	.	N	N	-0.326978896	27.91572611	0.031020348	49.5	.	.
DEPDC1	1	68474152	68497221	N	.	N	N	-0.898988059	9.608149563	3.30E-07	84.4	.	.
DEPDC1B	5	60596912	60700190	N	.	N	N	-0.892591249	9.729698443	2.29E-05	75.9	.	.
DEPDC4	12	100203669	100267079	N	.	N	N	-0.087839602	42.97621115	4.10E-09	89.8	.	.
DEPDC7	11	33015864	33033582	N	.	N	N	0.097973006	57.00063668	1.25E-05	77.5	.	.
DEPTOR	8	119873717	120050913	N	.	N	N	1.063323503	93.54054523	0.000777356	65.6	.	.
DERA	12	15911172	16037282	N	.	N	N	-0.091667236	42.70417318	0.03407648	49	.	.
DERL3	22	23834503	23839128	N	.	N	Y	0.840791109	90.0272038	0.000238218	69.2	.	.
DES	2	219418377	219426739	N	.	N	Y	0.323063788	71.95114893	0.003082434	60.2	DM	Myopathy, myofibrillar, 1, 601419 (3); Cardiomyopathy, dilated, 1I, 604765 (3); Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 (3); ?Muscular dystrophy, limb-girdle, type 2R, 615325 (3)
DESI1	22	41598028	41621096	N	.	N	N	0.010504826	50.32702437	0.093722478	43.5	.	.
DESI2	1	244652935	244709033	N	.	N	Y	-0.005458152	49.05944319	0.915084441	17	DM?	.
DET1	15	88511559	88546675	N	.	N	N	-1.115786296	6.407362389	0.542030762	28.8	.	.
DEXI	16	10928891	10942460	N	.	N	N	-0.043930449	46.31591133	0.453687572	31.3	.	.
DFFA	1	10456522	10472526	N	.	N	Y	0.202058361	64.50772704	0.000218371	69.6	.	.
DFFB	1	3857267	3885429	N	.	N	Y	0.051041541	53.45835504	5.09E-05	73.8	.	.
DFNA5	7	24698353	24758113	N	.	N	Y	0.296072862	70.26682873	1.22E-05	77.6	DM	Deafness, autosomal dominant 5, 600994 (3)
DFNB31	9	114402080	114505450	N	.	N	Y	1.63524758	97.66163107	0.011088497	54.5	DM	Deafness, autosomal recessive 31, 607084 (3); Usher syndrome, type 2D, 611383 (3)
DFNB59	2	178451436	178461390	N	.	N	N	-0.027815612	47.43879146	1.07E-05	77.9	DM	Deafness, autosomal recessive 59, 610220 (3)
DGAT1	8	144314584	144326910	N	.	N	Y	-0.170220531	37.39653875	2.90E-10	92.2	DM	?Diarrhea 7, 615863 (3)
DGAT2L6	X	70177483	70205545	N	.	N	N	0.030294875	51.83191526	3.37E-08	87.5	DM?	.
DGCR14	22	19130279	19144684	N	.	N	N	-0.380305159	25.44423222	9.98E-06	78.1	DM?	.
DGCR2	22	19036282	19122454	N	Viable	N	Y	-0.514404546	19.65619031	0.001095938	64.3	DM?	.
DGCR6	22	18906028	18914238	N	.	N	N	0.472169912	79.41193494	7.62E-07	83	DM?	.
DGCR6L	22	20314276	20320080	N	.	N	N	0.037797903	52.3759912	0.128574001	41.6	.	.
DGKA	12	55927319	55954027	N	.	N	Y	-0.898180758	9.631301731	0.999250949	5.6	.	.
DGKB	7	14145049	14974777	N	.	N	N	-0.837196214	10.83521445	0.669214094	25.5	.	.
DGKE	17	56834099	56869567	N	.	N	Y	-0.738695505	12.9420617	0.000684088	66	DM	Nephrotic syndrome, type 7, 615008 (3); {Hemolytic uremic syndrome, atypical, susceptibility to, 7}, 615008 (3)
DGKG	3	186105668	186362237	N	.	N	N	-0.040453851	46.5879493	5.44E-06	79.4	.	.
DGKH	13	42040036	42256578	N	.	N	N	0.286963286	69.72854083	0.8181238	21	.	.
DGKI	7	137381037	137847092	N	.	N	N	-1.337081488	4.427852058	0.738016172	23.5	.	.
DGKK	X	50365409	50470738	N	.	N	N	.	.	.	.	.	.
DGKQ	4	958887	986895	N	Viable	N	Y	-1.010445004	7.71545986	0.001194024	64	.	.
DGKZ	11	46332905	46380554	N	.	N	Y	0.377802509	74.81622967	0.998142634	6.8	.	.
DGUOK	2	73926826	73958961	N	.	N	N	0.130704421	59.46634254	0.368434605	33.7	DM	Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 (3)
DHDDS	1	26432282	26471294	N	.	N	N	0.123201392	58.99751114	0.704700923	24.5	DM	Retinitis pigmentosa 59, 613861 (3)
DHDH	19	48933682	48944969	N	.	N	N	0.886914013	90.88962204	3.49E-06	80.3	FTV	.
DHFRL1	3	94047836	94063389	N	.	N	N	-0.039146033	46.66319384	0.102597563	42.9	.	.
DHH	12	49089421	49094819	N	.	N	Y	-0.206126746	35.13920241	0.259714235	36.8	DM	46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 (3); 46XY sex reversal 7, 233420 (3)
DHPS	19	12675717	12681902	N	.	N	N	-0.718099444	13.46298547	0.003452152	59.8	.	.
DHRS1	14	24290598	24299833	N	.	N	N	-0.389874437	24.9580367	2.41E-10	92.3	.	.
DHRS11	17	36591798	36600806	N	.	N	N	-0.166697481	37.63384847	0.031561334	49.4	.	.
DHRS12	13	51767993	51804157	N	.	N	N	0.872717176	90.64652428	0.007257764	56.4	.	.
DHRS13	17	28897781	28903071	N	.	N	N	0.21706442	65.48590612	0.00023405	69.3	.	.
DHRS2	14	23630115	23645639	N	.	N	Y	1.465821154	96.80500087	4.75E-06	79.6	.	.
DHRS4	14	23953586	23969279	N	.	N	Y	1.849523581	98.30410372	0.121200513	42	.	.
DHRS4L2	14	23969874	24006408	N	.	N	N	1.455447332	96.73554437	0.357376762	34	.	.
DHRS7	14	60144120	60169856	N	.	N	N	0.163586571	62.05938531	1.22E-05	77.5	.	.
DHRS7C	17	9771434	9791297	N	.	N	N	0.966584727	92.26717601	1.12E-06	82.4	.	.
DHRS9	2	169064789	169096167	N	.	N	N	0.459076404	78.76946229	2.61E-07	84.7	.	.
DHRSX	X	2219516	2502805	N	.	N	N	0.763033015	88.39497598	0.00645955	56.9	.	.
DHTKD1	10	12068972	12123225	N	.	N	N	-0.746720095	12.71632807	1.98E-16	97.6	DM	2-aminoadipic 2-oxoadipic aciduria, 204750 (3); ?Charcot-Marie-Tooth disease, axonal, type 2Q, 615025 (3)
DHX15	4	24517441	24584550	N	.	N	N	-0.957405629	8.612606355	0.999997156	2	.	.
DHX16	6	30653119	30673037	N	.	N	N	-0.533897786	18.8400764	2.01E-07	85.2	DP	.
DHX32	10	125836337	125896436	N	.	N	N	-0.029426144	47.35197083	6.97E-07	83.1	.	.
DHX34	19	47349281	47382704	N	.	N	N	-0.08884967	42.87781444	2.88E-08	87.7	.	.
DHX35	20	38962299	39039723	N	.	N	N	-0.425174275	23.33159692	9.69E-11	93	.	.
DHX37	12	124946825	124989122	N	.	N	N	1.210386576	95.12646872	0.978475418	12	FTV	.
DHX38	16	72093562	72112912	N	.	N	N	-1.978580097	1.707472362	1.04E-06	82.5	.	.
DHX40	17	59565525	59608345	N	Viable	N	Y	-1.213489004	5.446547433	0.996354247	7.8	.	.
DHX57	2	38797729	38875934	N	.	N	N	-0.697611045	13.98969729	4.42E-08	87.2	.	.
DHX8	17	43483865	43544463	N	.	N	N	-1.661689773	2.604618857	0.934509015	15.9	.	.
DIABLO	12	122207662	122227534	N	.	N	Y	0.229200645	66.1746831	0.000889965	65.2	DM	Deafness, autosomal dominant 64, 614152 (3)
DIAPH1	5	141515016	141619055	N	.	N	Y	-0.703751826	13.82184407	0.267109674	36.6	DM	Deafness, autosomal dominant 1, 124900 (3)
DIAPH2	X	96684663	97604997	N	.	N	Y	-0.68521557	14.38328413	0.9991191	5.7	DM	Premature ovarian failure, 300511 (3)
DIEXF	1	209828007	209857565	N	.	N	N	0.391851489	75.4702784	0.04923486	47.1	.	.
DIMT1	5	62387254	62403939	N	.	N	N	-0.187292531	36.30259883	1.47E-05	77.1	.	.
DIO1	1	53891239	53911086	N	.	N	Y	0.143797178	60.51397812	0.271104149	36.4	FP	.
DIO2	14	80197527	80387757	N	.	N	Y	-0.024139966	47.63558488	0.217796807	38.1	DFP	.
DIP2A	21	46458899	46569852	N	Viable	N	Y	-1.92402988	1.829021242	0.726099074	23.9	DM?	.
DIP2B	12	50504985	50748667	N	.	N	Y	-2.505978539	0.960814956	0.999668382	4.7	DM	Mental retardation, FRA12A type, 136630 (3)
DIP2C	10	274190	689743	N	.	N	N	-4.044009001	0.196793425	0.999999838	1.2	DM?	.
DIRAS1	19	2714567	2721418	N	.	N	N	-0.078575026	43.76338485	0.623341671	26.8	.	.
DIRAS2	9	90609832	90643104	N	.	N	N	-0.291531924	29.91838861	0.327172252	34.9	.	.
DIRAS3	1	68045962	68051631	N	.	N	N	-0.357145068	26.46871563	0.037239176	48.6	.	.
DIRC1	2	188734155	188790104	N	.	N	N	0.365065607	74.12745268	0.022258844	51.1	.	.
DIRC2	3	122794795	122881139	N	.	N	N	-0.426432699	23.27950454	6.80E-06	79	DM	Renal cell carcinoma, 144700 (2)
DIRC3	2	217284019	217756593	N	.	N	N	.	.	.	.	DM	.
DIS3L	15	66293217	66333898	N	.	N	N	0.444528588	78.0806853	1.29E-10	92.8	.	.
DIS3L2	2	231961245	232344350	N	.	N	N	-0.617390553	16.25860971	0.863517182	19.4	DM	Perlman syndrome, 267000 (3)
DISC1	1	231626815	232041272	N	.	N	Y	0.832781819	89.85356254	0.019709884	51.8	DM	{Schizophrenia, susceptibility to}, 604906 (3); {Schizoaffective disorder, susceptibility to}, 181500 (3)
DISP2	15	40358235	40378639	N	.	N	N	0.016198627	50.72061122	0.016251164	52.7	.	.
DIXDC1	11	111927144	112022584	N	Viable	N	Y	0.027424541	51.61775771	4.27E-06	79.8	.	.
DKC1	X	154762742	154777689	N	.	N	Y	-0.304623579	29.21803554	0.998900173	6	DM	Dyskeratosis congenita, X-linked, 305000 (3)
DKFZp313A047	11	118025369	118029863	N	.	N	N	.	.	.	.	.	.
DKFZp434P228	5	98792863	98795766	N	.	N	N	.	.	.	.	.	.
DKK2	4	106921802	107283806	N	.	N	Y	0.280765669	69.35810615	0.864037652	19.3	DP	.
DKK3	11	11963106	12009769	N	.	N	Y	-0.009939149	48.69479655	1.89E-05	76.4	DP	.
DKK4	8	42374068	42377232	N	Viable	N	Y	0.106281943	57.6662615	0.02137976	51.3	DM?	.
DKKL1	19	49361783	49375116	N	.	N	Y	1.20766407	95.09174046	0.000105208	71.7	.	.
DLAT	11	112024814	112064390	N	.	N	N	-0.083860557	43.30034149	6.68E-06	79	DM	Pyruvate dehydrogenase E2 deficiency, 245348 (3)
DLEC1	3	38039205	38124025	N	Viable	N	Y	0.588100985	83.78190658	6.45E-18	98.1	.	Lung cancer, 211980 (1); Esophageal cancer, 133239 (1)
DLEU1	13	50082171	50723236	N	.	N	N	.	.	.	.	.	.
DLEU7	13	50711008	50843939	N	.	N	N	.	.	0.031020475	49.5	DM	.
DLG2	11	83455012	85627922	N	.	N	Y	-1.801422445	2.193667882	0.67354537	25.4	DM?	.
DLG3	X	70444861	70505490	N	.	N	Y	-0.587827164	17.15575621	0.999544465	5.1	DM	Mental retardation, X-linked 90, 300850 (3)
DLG5	10	77790791	77926526	N	.	N	Y	-0.881290679	9.920703826	0.999998542	1.8	DP	.
DLGAP1	18	3496032	4455335	N	.	N	N	-2.164566437	1.354401806	0.993045514	9.1	DM?	.
DLGAP2	8	1501366	1708476	N	.	N	N	-0.768275956	12.25328471	0.950397326	14.7	DM	.
DLGAP3	1	34865436	34929585	N	.	N	Y	-1.170079336	5.89222666	0.999638516	4.8	DM	.
DLGAP4	20	36306336	36528637	N	.	N	N	-1.006624573	7.773340279	0.991952626	9.5	.	.
DLGAP5	14	55148112	55191678	N	.	N	Y	0.497851981	80.3727499	1.74E-05	76.6	.	.
DLK2	6	43450352	43456632	N	.	N	N	0.193598667	64.04468368	0.685774158	25	.	.
DLST	14	74881891	74903745	N	.	N	N	-0.780997286	11.9754587	0.950393652	14.7	.	.
DLX1	2	172084740	172089677	N	.	N	Y	-0.116090248	41.04300515	0.926719408	16.3	.	.
DLX4	17	49968970	49974959	N	.	N	N	0.017202414	50.84794814	0.00519723	57.9	.	.
DMC1	22	38518949	38570286	N	.	N	Y	-0.347727532	26.88545465	0.180759801	39.3	DM	.
DMGDH	5	78997606	79236038	N	.	N	N	0.052301478	53.53359958	8.90E-17	97.7	DM	Dimethylglycine dehydrogenase deficiency, 605850 (3)
DMKN	19	35497220	35513658	N	.	N	N	0.687192474	86.58331886	3.47E-09	90	.	.
DMP1	4	87650307	87664361	N	.	N	Y	1.071783895	93.66209411	0.000223014	69.5	DM	.
DMPK	19	45769717	45782552	N	.	N	Y	-0.272392294	31.15124153	0.033081179	49.2	DM	Myotonic dystrophy 1, 160900 (3)
DMRT1	9	841690	969090	N	.	N	Y	-0.213476698	34.71088731	0.68359281	25.1	DM	.
DMRT3	9	976964	991731	N	.	N	Y	0.32608497	72.09584997	0.001373452	63.5	.	.
DMRTA1	9	22446841	22455740	N	.	N	Y	0.022943191	51.29941541	8.39E-05	72.4	.	.
DMRTB1	1	53459399	53467488	N	.	N	N	0.234790597	66.51038954	0.589036511	27.7	.	.
DMRTC1	X	72872025	72943814	N	.	N	N	.	.	0.43895356	31.7	.	.
DMRTC1B	X	72777009	72848802	N	.	N	N	.	.	.	.	.	.
DMRTC2	19	41844743	41852333	N	.	N	Y	0.292094913	70.04688314	0.726527694	23.8	.	.
DMTN	8	22048995	22082527	N	.	N	Y	-0.63939225	15.70295769	0.96176259	13.8	.	.
DMWD	19	45782947	45792802	N	.	N	N	-0.465709488	21.64727673	0.007902113	56	.	.
DMXL1	5	119037772	119249138	N	.	N	N	-1.267482717	4.960351913	0.999998843	1.8	DM?	.
DNAAF1	16	84145287	84178767	N	.	N	N	2.355768452	99.03918504	5.41E-06	79.4	DM	.
DNAAF3	19	55158661	55166722	N	.	N	N	0.633712862	85.17103664	3.22E-06	80.4	DM	Ciliary dyskinesia, primary, 2, 606763 (3)
DNAAF5	7	726701	786475	N	.	N	N	.	.	.	.	.	.
DNAH1	3	52316319	52400491	N	.	N	Y	2.478570418	99.16652197	4.42E-20	98.7	.	.
DNAH10	12	123762188	123936206	N	.	N	N	1.158038772	94.5997569	4.14E-37	99.9	FTV	.
DNAH10OS	12	123926424	123934984	N	.	N	N	.	.	0.013366389	53.7	.	.
DNAH11	7	21543215	21901839	N	.	N	Y	3.267873792	99.6411414	.	.	DM	Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3)
DNAH12	3	57293699	57544344	N	.	N	N	0.848440048	90.17769289	0.000394166	67.8	.	.
DNAH14	1	224896262	225399292	N	.	N	N	.	.	8.77E-06	78.4	FTV	.
DNAH17	17	78423697	78577394	N	.	N	N	.	.	.	.	.	.
DNAH2	17	7717354	7833744	N	.	N	N	-2.372351484	1.070787753	2.49E-21	98.9	.	.
DNAH3	16	20933111	21159441	N	.	N	N	1.467343992	96.81657695	9.63E-51	100	.	.
DNAH6	2	84516455	84819589	N	.	N	N	.	.	0.000223495	69.4	.	.
DNAH7	2	195737703	196068812	N	.	N	N	0.593194259	83.92081959	1.04E-47	100	DM?	.
DNAH8	6	38715341	39030529	N	.	N	N	.	.	2.09E-37	99.9	.	.
DNAH9	17	11598431	11969748	N	.	N	N	0.719664039	87.42258494	1.37E-35	99.8	DM?	.
DNAI2	17	74274247	74314884	N	.	N	N	0.238919593	66.78821555	4.57E-11	93.4	DM	Ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3)
DNAJA2	16	46955362	46973788	N	.	N	N	-0.446224844	22.44602651	0.985455361	10.9	.	.
DNAJA4	15	78264086	78282196	N	Viable	N	Y	-0.166544931	37.66857672	3.57E-05	74.8	FTV	.
DNAJB1	19	14514770	14529770	N	.	N	Y	-1.179644424	5.816982115	0.37215695	33.6	.	.
DNAJB11	3	186567403	186597203	N	.	N	N	0.052803966	53.57411588	0.909930974	17.3	.	.
DNAJB13	11	73950319	73970366	N	.	N	N	0.488132675	80.00231522	0.121954827	42	.	.
DNAJB14	4	99896248	99946726	N	.	N	N	-0.461231059	21.83249407	0.95625497	14.2	.	.
DNAJB2	2	219279267	219286900	N	.	N	N	0.239573531	66.85188401	5.20E-06	79.5	DM	Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 (3); ?Charcot-Marie-Tooth disease, axonal, type 2T, 616233 (3)
DNAJB4	1	77979175	78017964	N	.	N	N	-0.234224724	33.42015396	0.840407621	20.3	.	.
DNAJB5	9	34989641	34998900	N	.	N	N	-0.159194457	38.09110378	0.491267707	30.2	.	.
DNAJB7	22	40859549	40862126	N	Viable	N	Y	0.413101046	76.51212595	2.09E-11	93.9	.	.
DNAJB8	3	128462439	128467248	N	.	N	N	0.231113855	66.29623198	0.047540687	47.3	.	.
DNAJB9	7	108569568	108574850	N	.	N	N	0.17380942	62.79446663	0.224582946	37.8	.	.
DNAJC1	10	21756537	22003769	N	.	N	N	-0.461077067	21.84985819	1.42E-08	88.5	.	.
DNAJC10	2	182716041	182794464	N	.	N	N	-0.442093457	22.63703189	8.95E-05	72.2	.	.
DNAJC11	1	6634168	6701924	N	.	N	N	-0.58863046	17.126816	0.99997079	3	.	.
DNAJC12	10	67796665	67838166	N	.	N	N	0.104368575	57.54471262	0.000104074	71.7	.	.
DNAJC13	3	132417526	132539032	N	.	N	N	-2.009281512	1.60907565	1	0.5	.	Parkinson disease 21, 616361 (3)
DNAJC14	12	55820960	55830824	N	Viable	N	Y	-0.371845358	25.79151473	0.999707755	4.6	.	.
DNAJC15	13	43023203	43114224	N	Viable	N	Y	0.156890071	61.50952133	2.92E-07	84.6	.	.
DNAJC18	5	139408588	139444491	N	.	N	N	0.26862913	68.62881287	0.005469335	57.7	.	.
DNAJC19	3	180983709	180989774	N	.	N	Y	0.123051266	58.96278289	0.01440369	53.4	DM	3-methylglutaconic aciduria, type V, 610198 (3)
DNAJC2	7	103312474	103344873	N	.	N	N	-0.500506623	20.165538	0.984694418	10.9	.	.
DNAJC22	12	49346917	49357546	N	.	N	N	0.104519243	57.57365283	1.11E-05	77.8	.	.
DNAJC25	9	111631352	111654351	N	.	N	N	-0.099170261	42.1543092	0.005620635	57.6	.	.
DNAJC25-GNG10	9	111631386	111670229	N	.	N	N	.	.	0.002778174	60.7	.	.
DNAJC27	2	24943636	24972094	N	.	N	N	-0.075704275	43.9775424	0.048258233	47.2	.	.
DNAJC28	21	33485530	33491720	N	Viable	N	Y	0.1035625	57.4868322	2.51E-07	84.8	.	.
DNAJC3	13	95677139	95794989	N	.	N	Y	-0.305426803	29.16015512	0.951080562	14.6	.	?Ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus, 616192 (3)
DNAJC30	7	73680969	73683453	N	.	N	N	0.087599756	56.28870753	0.004798278	58.3	.	.
DNAJC4	11	64230278	64234286	N	.	N	N	0.183225703	63.41957516	6.44E-06	79.1	.	.
DNAJC5	20	63895182	63936031	N	.	N	Y	-0.375023253	25.68154193	0.858492459	19.6	DM	Ceroid lipofuscinosis, neuronal, 4, Parry type, 162350 (3)
DNAJC5B	8	66021560	66100526	N	Viable	N	Y	0.37735004	74.78150142	0.009677585	55.1	.	.
DNAJC5G	2	27275421	27281499	N	Viable	N	Y	0.414865996	76.60473462	0.003974789	59.1	.	.
DNAJC7	17	41976433	42021376	N	Viable	N	Y	-0.391788739	24.87121607	0.999727953	4.5	.	.
DNAL1	14	73644875	73703732	N	.	N	N	0.113634918	58.26821786	0.006401469	57	DM	Ciliary dyskinesia, primary, 16, 614017 (3)
DNALI1	1	37556919	37566857	N	.	N	N	-0.442395976	22.60809168	6.82E-08	86.6	.	.
DNASE1	16	3611728	3680143	N	.	N	Y	1.785803208	98.15361463	1.01E-11	94.3	DM	{Systemic lupus erythematosus, susceptibility to}, 152700 (3)
DNASE1L1	X	154401238	154412112	N	.	N	Y	0.319237683	71.71383921	0.061265801	45.9	.	.
DNASE1L2	16	2235816	2238711	N	Viable	N	Y	0.339834225	72.85987151	2.28E-07	85	.	.
DNASE1L3	3	58192257	58214697	N	.	N	Y	0.473126302	79.46402732	0.155489629	40.3	DM	Systemic lupus erythematosus 16, 614420 (3)
DNASE2B	1	84398532	84415018	N	.	N	Y	0.133574517	59.72680442	3.79E-14	96.4	.	.
DND1	5	140670794	140673586	N	.	N	Y	.	.	0.709666236	24.4	DM	.
DNER	2	229357629	229714558	N	Viable	N	Y	0.126374573	59.23482086	0.78550209	22.1	.	.
DNHD1	11	6497260	6593758	N	.	N	N	.	.	1.33E-18	98.4	.	.
DNLZ	9	136359480	136363789	N	.	N	N	1.157862148	94.59396886	0.008941565	55.4	.	.
DNM3	1	171841498	172418466	N	.	N	Y	-0.805268966	11.44874689	0.028276991	50	FP	.
DNMBP	10	99875577	100009919	N	.	N	N	-0.740728535	12.85524107	1.15E-09	91	FTV	.
DNPEP	2	219373546	219400022	N	.	N	N	-0.23966114	33.10181166	0.000202596	69.8	.	.
DNPH1	6	43225629	43229484	N	.	N	N	0.102455237	57.40579962	0.00071657	65.9	.	.
DNTT	10	96304396	96338564	N	.	N	Y	0.361686411	74.00011576	8.54E-05	72.4	.	.
DNTTIP1	20	45791937	45811427	N	.	N	N	-0.190163599	36.15789778	0.431436688	31.9	.	.
DNTTIP2	1	93866283	93879918	N	.	N	N	-0.061351631	45.00781386	0.000217904	69.6	.	.
DOC2A	16	30005509	30023270	N	.	N	Y	0.348442859	73.32291486	0.018553646	52.1	DM?	.
DOC2B	17	142789	181636	N	.	N	Y	.	.	0.382719812	33.2	.	.
DOCK10	2	224765090	225042445	N	.	N	N	-0.770745886	12.17225213	0.02919253	49.8	.	.
DOCK11	X	118495898	118686163	N	.	N	Y	0.293665186	70.09897552	0.998084519	6.9	.	.
DOCK2	5	169637247	170083382	N	.	N	Y	-1.064495486	7.009318747	0.999999893	1.1	.	Immunodeficiency 40, 616433 (3)
DOCK3	3	50675241	51384198	N	.	N	Y	-2.756529648	0.746657406	0.999999699	1.4	DM	.
DOCK4	7	111726110	112206411	N	.	N	N	-1.505498726	3.339700179	0.998535733	6.5	.	.
DOCK5	8	25184723	25418082	N	.	N	N	-0.588606514	17.13260404	0.001342686	63.6	DP	.
DOCK6	19	11199295	11262481	N	.	N	N	0.725100733	87.52098165	2.83E-19	98.5	DM	Adams-Oliver syndrome 2, 614219 (3)
DOCK7	1	62454728	62688368	N	.	N	Y	-3.198696115	0.509347688	0.771361086	22.6	.	Epileptic encephalopathy, early infantile, 23, 615859 (3)
DOCK8	9	214854	465259	N	.	N	Y	-0.696068023	14.05915379	0.000135434	71	DM	Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 (3)
DOCK9	13	98793487	99086625	N	.	N	N	-1.960612155	1.753776697	0.999999307	1.6	DM?	.
DOK1	2	74549026	74557554	N	.	N	Y	0.003304686	49.75979626	0.016992884	52.5	.	[Blood group, Dombrock], 616060 (3)
DOK2	8	21908873	21913860	N	.	N	Y	0.751852095	88.12872605	2.34E-06	81	.	.
DOK3	5	177501907	177511274	N	.	N	Y	0.892654271	91.00538288	7.28E-05	72.8	.	.
DOK4	16	57471922	57487327	N	.	N	N	-0.236942655	33.25230075	0.19760291	38.8	.	.
DOK5	20	54475597	54651171	N	.	N	N	0.123201392	58.99751114	0.043981192	47.7	.	.
DOK6	18	69401055	69849087	N	.	N	N	-0.41429797	23.70781964	0.458839967	31.1	.	.
DOLK	9	128945530	128947619	N	.	N	N	-0.429150862	23.17531979	0.057602442	46.2	DM	.
DOLPP1	9	129081100	129090438	N	.	N	N	-0.206126746	35.13920241	0.604058624	27.3	.	.
DOPEY1	6	83067666	83171350	N	.	N	N	-2.146311726	1.383342015	0.999995778	2.2	.	.
DOPEY2	21	36156782	36294274	N	.	N	Y	-0.092747243	42.61156451	9.61E-08	86.1	.	.
DPCD	10	101570560	101609668	N	.	N	N	0.157846676	61.58476587	0.002703404	60.8	.	.
DPCR1	6	30940972	30954221	N	.	N	N	.	.	0.140380581	41.1	.	.
DPEP1	16	89613308	89638456	N	.	N	Y	0.001542562	49.60351913	0.000136493	71	.	.
DPEP2	16	67987394	68000586	N	.	N	N	0.554853813	82.61272212	4.01E-05	74.5	.	.
DPEP3	16	67975663	67980829	N	.	N	N	0.275325819	69.02818776	9.14E-07	82.7	.	.
DPF1	19	38211006	38229714	N	.	N	N	-0.566274989	17.74613648	0.98898605	10.1	.	.
DPF2	11	65333754	65353249	N	.	N	Y	-0.528759206	19.07738612	0.999787288	4.3	.	.
DPF3	14	72619296	72894116	N	.	N	Y	0.042581773	52.76957805	0.828481786	20.7	.	.
DPH5	1	100989623	101026088	N	.	N	N	-0.05223834	45.61555826	0.001899435	62	.	.
DPH6	15	35217345	35546193	N	.	N	N	0.524692399	81.42617353	0.002468628	61.2	.	.
DPH7	9	137554904	137578935	N	.	N	N	0.335350119	72.61677375	4.38E-05	74.3	.	.
DPM3	1	155139891	155140595	N	.	N	N	-0.072985841	44.23221624	0.23347017	37.6	DM	Congenital disorder of glycosylation, type Io, 612937 (3)
DPP10	2	114442299	115845752	N	Viable	N	Y	0.389937289	75.36609365	0.999989286	2.6	DM?	.
DPP3	11	66480013	66509657	N	.	N	N	-0.141820446	39.27765237	4.36E-09	89.7	DM?	.
DPP4	2	161992241	162074542	N	.	N	Y	-0.617536576	16.25282167	4.06E-10	91.9	DM?	.
DPP6	7	153887097	154894285	N	.	N	Y	.	.	0.967691107	13.3	DM	{Ventricular fibrillation, paroxysmal familial, 2}, 612956 (3); Mental retardation, autosomal dominant 33, 616311 (3)
DPP7	9	137110542	137115177	N	.	N	N	1.03441881	93.19326272	2.02E-15	97.1	.	.
DPP8	15	65442463	65517704	N	.	N	N	-0.520951132	19.44203276	0.999271313	5.6	.	.
DPPA2	3	109293788	109316517	N	.	N	N	-0.337353053	27.42374255	7.76E-08	86.4	.	.
DPPA3	12	7711454	7717559	N	.	N	Y	0.111871637	58.12930486	0.165194336	39.9	.	.
DPPA5	6	73353062	73354295	N	.	N	Y	-0.035470476	46.91207964	0.000949315	64.9	.	.
DPRX	19	53632056	53637009	N	.	N	N	-0.01663693	48.16808474	1.14E-06	82.4	.	.
DPT	1	168695459	168729264	N	.	N	Y	1.11474907	94.11934942	9.11E-05	72.2	.	.
DPY19L1	7	34928876	35038271	N	.	N	N	-0.521102007	19.43624472	0.142871737	40.9	.	.
DPY19L2	12	63558913	63668939	N	.	N	Y	0.107541068	57.80517451	7.03E-05	72.9	DM	Spermatogenic failure 9, 613958 (3)
DPY19L3	19	32405543	32485895	N	.	N	Y	-0.780845438	11.99282283	0.080040472	44.5	.	.
DPY19L4	8	94719703	94793836	N	.	N	N	0.728536848	87.56149795	1.51E-15	97.2	.	.
DPYD	1	97077743	97921049	N	Viable	N	Y	0.533767637	81.80818429	4.19E-09	89.8	DM	Dihydropyrimidine dehydrogenase deficiency, 274270 (3); 5-fluorouracil toxicity, 274270 (3)
DPYS	8	104330324	104467053	N	.	N	N	-0.393549347	24.76703131	9.90E-08	86.1	DM	Dihydropyrimidinuria, 222748 (3)
DPYSL2	8	26514275	26658178	N	.	N	Y	-0.743480655	12.77999653	0.995558289	8.2	DP	.
DPYSL3	5	147390811	147510056	N	.	N	N	-0.765033447	12.30537709	0.996483174	7.7	DFP	.
DPYSL4	10	132186900	132205776	N	.	N	Y	-1.245119683	5.151357296	5.86E-06	79.2	.	.
DPYSL5	2	26847747	26950351	N	.	N	Y	-0.946072869	8.786247612	0.998332101	6.7	.	.
DQX1	2	74518131	74526336	N	.	N	N	-0.349336167	26.8507264	7.47E-15	96.8	.	.
DR1	1	93345888	93369498	N	.	N	N	0.221548563	65.71742779	0.835491729	20.4	.	.
DRAM1	12	101877351	102012130	N	Viable	N	Y	-0.367520149	25.97673207	0.080700077	44.4	.	.
DRAM2	1	111117333	111140216	N	.	N	N	-0.000674037	49.38936158	0.001395866	63.4	.	Cone-rod dystrophy 21, 616502 (3)
DRAXIN	1	11691729	11725857	N	.	N	Y	0.854987159	90.29345372	6.64E-10	91.4	.	.
DRC1	2	26401916	26456711	N	.	N	N	1.253146233	95.46217515	1.30E-10	92.8	DM	Ciliary dyskinesia, primary, 21, 615294 (3)
DRC7	16	57694793	57731805	N	.	N	N	.	.	.	.	.	.
DRD2	11	113409615	113475691	N	.	N	Y	-0.577452276	17.42779418	0.733263889	23.6	DM	Dystonia, myoclonic, 159900 (3)
DRD3	3	114128652	114199407	N	.	N	Y	0.058544531	53.99664294	0.010295343	54.8	DFP	{Schizophrenia, susceptibility to}, 181500 (3); {Essential tremor, susceptibility to}, 190300 (3)
DRD4	11	637293	640706	N	.	N	Y	.	.	7.58E-06	78.8	DM	Autonomic nervous system dysfunction (3); [Novelty seeking personality], 601696 (1); {Attention deficit-hyperactivity disorder}, 143465 (3)
DRG1	22	31399523	31528740	N	.	N	N	-0.297120516	29.6000463	0.953443603	14.4	.	.
DRG2	17	18087886	18107971	N	.	N	Y	-0.465862421	21.6299126	0.148077282	40.7	.	.
DRICH1	22	23608452	23632321	N	.	N	N	.	.	.	.	.	.
DRP2	X	101219769	101264497	N	.	N	N	-0.503225097	20.03820108	0.009400215	55.2	DM?	.
DSC1	18	31129236	31162856	N	.	N	Y	0.598422958	84.05973259	4.39E-08	87.2	.	.
DSC2	18	31058840	31102415	N	.	N	N	-0.603339807	16.62904439	0.000683302	66	DM	Arrhythmogenic right ventricular dysplasia 11, 610476 (3); Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3)
DSCR3	21	37223420	37267919	N	.	N	N	-0.195752553	35.7874631	0.505918972	29.8	.	.
DSCR4	21	37951425	38121360	N	.	N	N	0.101498578	57.33634312	0.001317005	63.7	.	.
DSCR8	21	38121451	38188016	N	.	N	N	.	.	.	.	FTV	.
DSE	6	116254173	116444860	N	.	N	Y	-0.291074804	29.95311686	0.385415297	33.1	.	?Ehlers-Danlos syndrome, musculocontractural type 2, 615539 (3)
DSEL	18	67506582	67516980	N	.	N	Y	-0.195149556	35.81061527	5.16E-06	79.5	.	.
DSG1	18	31318089	31357029	N	.	N	Y	0.6332263	85.13630839	0.97910346	11.9	DM	Keratosis palmoplantaris striata I, AD, 148700 (3); Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE, 615508 (3)
DSN1	20	36751791	36773818	N	.	N	N	-0.104759418	41.81281472	1.72E-06	81.6	.	.
DSPP	4	87608529	87616910	N	Viable	N	Y	.	.	0.000618023	66.4	DM	Dentinogenesis imperfecta, Shields type II, 125490 (3); Deafness, autosomal dominant 39, with dentinogenesis, 605594 (3); Dentinogenesis imperfecta, Shields type III, 125500 (3); Dentin dysplasia, type II, 125420 (3)
DSTN	20	17569863	17609919	N	.	N	Y	-0.179942957	36.73091393	0.759201435	22.9	.	.
DSTYK	1	205142505	205211566	N	.	N	N	-0.341683338	27.17485675	0.147285746	40.7	.	{Congenital anomalies of kidney and urinary tract, susceptibility to}, 610805 (3)
DTD1	20	18567453	18763917	N	.	N	N	-0.08703502	43.03409157	0.290212859	36	.	.
DTD2	14	31446036	31457510	N	.	N	N	-0.050476626	45.73710714	0.001708149	62.5	.	.
DTHD1	4	36281622	36345756	N	.	N	N	.	.	.	.	DM?	.
DTNA	18	34493290	34891844	N	.	N	Y	-0.467472441	21.55466806	0.921398185	16.6	DM	Left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3)
DTNB	2	25377198	25673647	N	.	N	Y	-0.266802755	31.46958384	0.000530412	66.9	DM	.
DTNBP1	6	15522801	15663058	N	Viable	N	Y	-0.265040808	31.57376859	1.34E-06	82.2	DM	{Schizophrenia}, 181500 (2); Hermansky-Pudlak syndrome 7, 614076 (3)
DTWD1	15	49620980	49656232	N	.	N	N	-0.233267662	33.50118655	1.41E-05	77.2	.	.
DTWD2	5	118837322	118988545	N	.	N	N	0.360579228	73.94802338	2.16E-05	76	.	.
DTX1	12	113056709	113098028	N	.	N	Y	-1.18155876	5.782253864	0.001255918	63.8	.	.
DTX2	7	76461676	76505995	N	.	N	N	0.240833594	66.92134051	0.106757916	42.8	.	.
DTX3	12	57604622	57609804	N	.	N	N	-0.197666633	35.6485501	0.921137255	16.7	.	.
DTX3L	3	122564238	122575203	N	.	N	N	-0.073487243	44.16854778	2.44E-05	75.7	.	.
DTX4	11	59171430	59208587	N	.	N	N	-0.707725431	13.70608323	0.594144205	27.6	.	.
DTYMK	2	241675742	241686991	N	.	N	N	-0.108587205	41.55814088	0.546091427	28.7	.	.
DUOX1	15	45129933	45165576	N	.	N	N	-0.540847573	18.53909822	1.97E-13	95.9	.	.
DUOX2	15	45092650	45114344	N	.	N	N	2.812851526	99.38646756	1.90E-37	99.9	DM	Thryoid dyshormonogenesis 6, 607200 (3)
DUOXA1	15	45117367	45129938	N	.	N	N	-0.049216095	45.88759623	0.00010972	71.6	.	.
DUOXA2	15	45114321	45118421	N	Viable	N	Y	-0.105564211	41.74335822	1.50E-07	85.6	DM	Thyroid dyshormonogenesis 5, 274900 (3)
DUPD1	10	75037836	75058514	N	.	N	N	0.927154384	91.64785553	1.18E-07	85.9	.	.
DUS1L	17	82057506	82065887	N	.	N	N	-0.433783493	23.03061874	1.53E-06	81.9	.	.
DUS2	16	67987746	68079320	N	.	N	N	0.047365707	53.22683336	0.000272032	68.9	.	.
DUS3L	19	5784832	5791238	N	.	N	N	-0.641002831	15.65665335	2.45E-09	90.3	.	.
DUS4L	7	107563484	107578464	N	.	N	N	0.061263744	54.22237657	0.000141354	70.9	.	.
DUSP1	5	172768090	172771195	N	.	N	Y	-0.151691433	38.58887538	0.020500202	51.5	.	.
DUSP10	1	221701424	221742176	N	.	N	Y	-0.347574091	26.90281878	0.49952147	30	.	.
DUSP11	2	73762184	73780157	N	Viable	N	Y	-0.443353128	22.55021126	9.06E-05	72.2	.	.
DUSP12	1	161749758	161757238	N	.	N	N	0.23015724	66.25571569	0.003535337	59.7	.	.
DUSP13	10	75094432	75109221	N	Viable	N	Y	1.234956206	95.35799039	9.99E-08	86.1	.	.
DUSP14	17	37489831	37513501	N	.	N	N	-0.185531789	36.42414771	0.773652009	22.5	.	.
DUSP15	20	31847637	31870747	N	.	N	N	.	.	0.000219668	69.5	DM?	.
DUSP18	22	30652051	30667890	N	.	N	N	0.325784353	72.08427389	0.061803728	45.8	.	.
DUSP19	2	183078559	183100005	N	.	N	N	0.688809378	86.60647103	0.004394	58.7	.	.
DUSP2	2	96143166	96145440	N	.	N	Y	.	.	0.791321032	21.9	.	.
DUSP21	X	44844004	44844888	N	.	N	N	0.375437469	74.69468079	0.003586501	59.6	FTV	.
DUSP22	6	291630	351355	N	.	N	N	0.391548194	75.45291428	0.004307071	58.8	.	.
DUSP23	1	159780932	159782543	N	.	N	N	.	.	0.041146827	48.1	DP	.
DUSP26	8	33591332	33600106	N	.	N	Y	-0.288660263	30.16727441	0.003914765	59.2	.	.
DUSP27	1	167094045	167129165	N	.	N	N	2.209685164	98.87133183	2.05E-15	97.1	.	.
DUSP28	2	240560054	240564014	N	.	N	N	.	.	0.232216945	37.6	.	.
DUSP3	17	43766121	43778988	N	Viable	N	Y	-0.049519725	45.82392777	0.736744916	23.5	DM?	.
DUSP4	8	29333064	29350668	N	.	N	Y	0.089513257	56.41025641	0.539069242	28.9	.	.
DUSP5	10	110497838	110511544	N	.	N	N	0.254579622	67.73166638	0.025593878	50.4	.	.
DUSP7	3	52048919	52056550	N	Viable	N	Y	-0.385242872	25.15483012	0.228528647	37.7	.	.
DUSP8	11	1554044	1571920	N	.	N	N	.	.	0.684472965	25	.	.
DUT	15	48331011	48343373	N	.	N	N	-0.125507302	40.39474446	0.339206865	34.6	.	.
DUX4	4	190173774	190185942	N	.	N	N	.	.	.	.	DM	.
DUXA	19	57154021	57167443	N	.	N	N	0.111871637	58.12930486	3.06E-05	75.2	.	.
DVL1	1	1335276	1349350	N	.	N	Y	-0.71684682	13.47456156	0.157164972	40.3	.	.
DXO	6	31969810	31972292	N	.	N	N	0.48445544	79.89234242	4.98E-10	91.8	.	.
DYDC1	10	80336105	80356755	N	.	N	N	-0.011047557	48.60797592	0.002065792	61.8	.	.
DYDC2	10	80344745	80368073	N	.	N	N	0.428916211	77.3340279	0.02331224	50.9	.	.
DYM	18	49041474	49461347	N	.	N	N	-0.816449514	11.27510563	5.18E-09	89.6	DM	Dyggve-Melchior-Clausen disease, 223800 (3); Smith-McCort dysplasia, 607326 (3)
DYNAP	18	54587757	54599493	N	.	N	N	0.18881556	63.69161313	0.40940293	32.5	.	.
DYNC1I1	7	95772506	96110322	N	.	N	N	-0.861620382	10.35480697	0.011637704	54.3	.	.
DYNC1LI1	3	32525971	32570874	N	.	N	N	0.470405758	79.33090236	0.97791889	12.1	.	.
DYNC1LI2	16	66720893	66751798	N	.	N	N	-0.698460933	13.95496903	0.798419344	21.7	.	.
DYNLL2	17	58083415	58095536	N	.	N	N	0.03764689	52.34705099	0.687802227	24.9	.	.
DYNLRB2	16	80540734	80550760	N	.	N	Y	0.404494149	76.04329455	0.390767289	33	DM?	.
DYNLT1	6	158636474	158644739	N	.	N	N	-0.10299811	41.92278752	0.039210973	48.4	.	.
DYNLT3	X	37836757	37847637	N	.	N	N	0.341599703	72.95826822	0.650718442	26	.	.
DYRK1B	19	39825350	39834201	N	.	N	N	-0.68521557	14.38328413	0.915927122	17	.	Abdominal obesity-metabolic syndrome 3, 615812 (3)
DYRK2	12	67648338	67665406	N	.	N	N	-0.959165893	8.572090062	0.979337329	11.9	.	.
DYRK3	1	206635536	206684419	N	.	N	Y	-0.253710318	32.23939341	0.000220922	69.5	.	.
DYRK4	12	4562204	4615302	N	.	N	N	0.133725635	5.97E+01	3.80E-10	92	.	.
DYSF	2	71453722	71686768	N	.	N	Y	0.423355685	77.03883776	1.00E-15	97.3	DM	Muscular dystrophy, limb-girdle, type 2B, 253601 (3); Myopathy, distal, with anterior tibial onset, 606768 (3); Miyoshi muscular dystrophy 1, 254130 (3)
DYTN	2	206651621	206718396	N	.	N	N	1.183536078	94.89494704	2.80E-15	97	.	.
DZANK1	20	18383367	18467281	N	Viable	N	Y	1.042880019	93.29744747	4.60E-15	96.9	.	.
DZIP1L	3	138061990	138115818	N	.	N	N	0.649029949	85.57041153	6.93E-20	98.6	.	.
E2F1	20	33675683	33686404	N	.	N	Y	0.235747143	66.55090583	0.955530545	14.3	.	.
E2F2	1	23506430	23531220	N	.	N	Y	-0.493003504	20.4838803	0.914702778	17	.	.
E2F5	8	85177225	85217158	N	.	N	Y	-0.396575171	24.57602593	0.026329098	50.3	.	.
E2F6	2	11444375	11466177	N	.	N	Y	0.021835061	51.22417086	0.554509012	28.5	.	.
E2F7	12	77021247	77065580	N	.	N	Y	0.014786452	50.61063842	0.423130676	32.2	.	.
E2F8	11	19224063	19241620	N	.	N	Y	-0.848230086	10.59790473	0.995041279	8.4	.	.
EAF2	3	121835183	121886526	N	.	N	Y	0.190728755	63.83052613	0.000680758	66	.	.
EAPP	14	34515929	34539711	N	.	N	N	-0.239813643	33.09023557	2.72E-05	75.5	.	.
EBAG9	8	109539711	109565996	N	.	N	Y	-0.072028905	44.27852058	0.717057363	24.2	DM?	.
EBF1	5	158695916	159099761	N	.	N	Y	-1.130946928	6.239509174	0.996264497	7.9	.	.
EBF4	20	2692878	2760108	N	.	N	N	.	.	0.078056999	44.6	.	.
EBI3	19	4229498	4237531	N	.	N	Y	0.018159209	50.92319268	0.01959965	51.8	.	.
EBLN1	10	22208814	22210021	N	.	N	N	.	.	6.91E-05	72.9	.	.
EBLN2	3	73061659	73063337	N	.	N	N	0.525648717	81.46090178	0.086523004	44	.	.
EBNA1BP2	1	43164175	43270936	N	.	N	N	-0.081293491	43.49713492	2.38E-06	81	.	.
EBPL	13	49660723	49691475	N	.	N	N	0.231921074	66.33674828	0.038853333	48.5	.	.
ECE2	3	184249650	184293031	N	.	N	N	-0.240978099	32.95132257	1.65E-17	98	.	.
ECH1	19	38815422	38832005	N	.	N	N	-0.092471964	42.67523297	0.004166427	58.9	.	.
ECHDC1	6	127288710	127343609	N	.	N	N	0.046257695	53.10528448	6.03E-05	73.4	.	.
ECHDC2	1	52895910	52927212	N	.	N	N	0.444070097	78.05753314	1.18E-07	85.9	.	.
ECHDC3	10	11742366	11764070	N	.	N	N	0.33806995	72.74989871	0.000536786	66.8	.	.
ECHS1	10	133362480	133373689	N	.	N	N	-0.220175737	34.30572437	0.51980084	29.5	.	Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 (3)
ECI1	16	2239395	2252300	N	.	N	Y	0.239573531	66.85188401	4.20E-10	91.9	DM	.
ECI2	6	4115689	4135597	N	.	N	N	0.416927285	76.69155525	3.84E-09	89.9	.	.
ECM2	9	92493554	92536655	N	.	N	N	0.070983022	54.94588181	1.56E-06	81.8	DM?	.
ECSCR	5	139442316	139462707	N	Viable	N	Y	.	.	.	.	.	.
ECT2L	6	138795926	138904070	N	.	N	N	2.169076825	98.81345141	7.34E-32	99.7	.	.
EDA	X	69616067	70039469	Y	.	N	Y	0.058393523	53.97927881	0.922511723	16.6	DM	Ectodermal dysplasia 1, hypohidrotic, X-linked, 305100 (3); Tooth agenesis, selective, X-linked 1, 313500 (3)
EDA2R	X	66595637	66639298	N	.	N	Y	0.459885344	78.80419054	0.136305949	41.3	DM	.
EDC3	15	74630558	74696292	N	.	N	N	-0.43393578	23.0248307	0.635930663	26.5	.	?Mental retardation, autosomal recessive 50, 616460 (3)
EDDM3A	14	20731699	20748380	N	.	N	N	0.528370887	81.58245066	2.79E-09	90.2	.	.
EDDM3B	14	20768427	20770948	N	.	N	N	0.034927599	52.21971407	0.018512767	52.1	.	.
EDEM1	3	5187646	5219957	N	.	N	N	-0.593263118	16.91844649	5.60E-11	93.3	.	.
EDEM2	20	35115357	35147364	N	.	N	N	-0.169263725	37.45441917	0.000137533	70.9	.	.
EDEM3	1	184690231	184754913	N	.	N	N	-0.654096722	15.24570238	0.122702493	42	.	.
EDF1	9	136862119	136866286	N	.	N	N	-0.041059779	46.53585692	0.908576776	17.4	.	.
EDIL3	5	83940554	84384793	N	.	N	Y	-0.265997742	31.51588818	4.09E-05	74.5	DM?	.
EDRF1	10	125719515	125764143	N	.	N	N	.	.	.	.	.	.
EEA1	12	92770637	92929331	N	.	N	N	-0.89966024	9.590785437	0.697358815	24.7	DM?	.
EED	11	86244544	86278813	N	.	N	Y	-0.477194633	21.11477687	0.997671033	7.2	DFP	.
EEF1A1	6	73515750	73523797	N	.	N	N	-0.716339415	13.49192568	0.984461027	11	.	.
EEF1A2	20	63488013	63499315	N	.	N	N	-0.394660481	24.6686346	0.964131454	13.6	DM?	Mental retardation, autosomal dominant 38, 616393 (3); Epileptic encephalopathy, early infantile, 33, 616409 (3)
EEF1B2	2	206159585	206162928	N	.	N	N	-0.272697012	31.12808937	0.333347472	34.8	DM	.
EEF1D	8	143579697	143599541	N	.	N	N	1.203331922	95.05122417	0.394239744	32.9	.	.
EEF1E1-BLOC1S5	6	8015726	8102530	N	.	N	N	.	.	.	.	.	.
EEF1G	11	62559601	62574086	N	.	N	N	-0.498746657	20.24078254	0.998058441	6.9	.	.
EEF2K	16	22206282	22288732	N	.	N	Y	0.012067581	50.413845	8.34E-11	93.1	FTV	.
EEF2KMT	16	5084304	5097808	N	Viable	N	Y	.	.	.	.	.	.
EEFSEC	3	128153454	128408646	N	.	N	N	-0.083860557	43.30034149	0.013115288	53.8	.	.
EEPD1	7	36153149	36301543	N	.	N	N	-0.584803178	17.23678879	0.002657198	60.8	.	.
EFCAB1	8	48710789	48735311	N	.	N	N	-0.161108498	37.92903861	0.000635898	66.3	.	.
EFCAB10	7	105565120	105600875	N	.	N	N	.	.	0.100686561	43.1	.	.
EFCAB11	14	89794669	89954777	N	Viable	N	Y	0.467388591	79.20356543	0.020262273	51.6	.	.
EFCAB12	3	129401321	129428651	N	.	N	N	1.617825458	97.57481044	2.18E-06	81.2	.	.
EFCAB13	17	47323290	47441312	N	.	N	N	1.540221645	97.17543555	8.22E-19	98.4	DM?	.
EFCAB14	1	46675159	46719064	N	.	N	N	-0.059589522	45.15830295	0.000132863	71.1	.	.
EFCAB2	1	244969705	245127164	N	.	N	N	0.026467762	51.52514904	7.51E-05	72.8	.	.
EFCAB3	17	62370218	62416476	N	.	N	N	0.362492381	74.04063205	0.000159092	70.5	.	.
EFCAB5	17	29929200	30108452	N	.	N	N	0.947578659	91.97777392	7.42E-16	97.4	DM?	.
EFCAB6	22	43528744	43812337	N	.	N	N	0.834594619	89.88829079	4.57E-19	98.5	.	.
EFCAB7	1	63523372	63572693	N	.	N	N	1.216270287	95.2075013	1.67E-12	95.1	.	.
EFCAB8	20	32858923	32961609	N	.	N	N	.	.	.	.	.	.
EFCAB9	5	172194172	172203452	N	.	N	N	.	.	.	.	.	.
EFCC1	3	129001629	129040742	N	.	N	N	.	.	0.00046692	67.2	.	.
EFEMP1	2	55865967	55924139	N	Viable	N	Y	-0.615925383	16.32227817	0.999786493	4.3	DM	Doyne honeycomb degeneration of retina, 126600 (3)
EFHB	3	19879472	19947025	N	.	N	N	1.114244424	94.11356138	6.03E-17	97.8	.	.
EFHC1	6	52420308	52495785	N	.	N	Y	0.769882418	88.56282919	5.06E-12	94.7	DM	{Myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3); {Epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3)
EFHC2	X	44147882	44343672	N	.	N	N	0.903687532	91.15008393	0.941723124	15.5	DM	.
EFHD1	2	232606057	232682781	N	.	N	N	0.38485322	75.1519361	0.770005564	22.6	.	.
EFHD2	1	15409895	15430343	N	.	N	N	-0.025096816	47.5834925	0.378995544	33.4	.	.
EFNA1	1	155127460	155134857	N	.	N	Y	0.285399426	69.6822365	0.872063428	19	.	.
EFNA2	19	1286154	1300237	N	.	N	Y	-0.283071606	30.49140476	0.376749731	33.4	.	.
EFNA3	1	155078872	155087538	N	.	N	Y	0.064939857	54.54650692	0.180564105	39.3	.	.
EFNA4	1	155063731	155069553	N	.	N	N	0.363300057	74.07536031	0.000252891	69.1	.	.
EFNA5	5	107376889	107670895	Y	Viable	N	Y	-0.148016487	38.85512531	0.889436552	18.2	.	.
EFR3A	8	131904088	132013642	N	.	N	N	-0.443049941	22.55599931	0.009266191	55.2	DM?	.
EFR3B	2	25042130	25159137	N	.	N	N	.	.	.	.	.	.
EFS	14	23356402	23365752	N	.	N	Y	0.721033554	87.46888927	2.45E-06	80.9	.	.
EFTUD1	15	82130230	82262763	N	.	N	N	0.255993667	67.82427505	0.033655675	49.1	.	.
EFTUD2	17	44849943	44899662	N	.	N	N	-1.802515406	2.18787984	0.999991435	2.5	DM	Mandibulofacial dysostosis, Guion-Almeida type, 610536 (3)
EGF	4	109912884	110012266	N	.	N	Y	-0.321748239	28.15882387	7.01E-12	94.4	DM	Hypomagnesemia 4, renal, 611718 (3)
EGFL6	X	13569605	13633575	N	.	N	Y	1.016388172	92.96752908	2.66E-08	87.8	.	.
EGFL8	6	32164583	32168281	N	Viable	N	Y	0.125114793	59.14221219	3.52E-06	80.2	.	.
EGFLAM	5	38258409	38465021	N	.	N	Y	0.667073187	86.12606355	9.38E-10	91.2	.	.
EGLN2	19	40798996	40808433	N	.	N	Y	-0.901051837	9.56763327	0.286988739	36	DFP	.
EGLN3	14	33924231	34462774	N	.	N	Y	-0.313083888	28.69711177	0.002641336	60.9	.	.
EGR4	2	73290929	73293705	N	.	N	Y	-0.116894686	40.97933669	0.006266778	57	.	.
EHBP1	2	62673851	63046487	N	.	N	N	-1.068566293	6.939862245	0.999748962	4.5	.	{Prostate cancer, hereditary, 12}, 611868 (3)
EHD2	19	47713343	47743134	N	.	N	N	-0.686172425	14.3369798	0.531641412	29.1	DM?	.
EHD3	2	31234337	31269447	N	.	N	Y	-0.572667189	17.57828327	0.088534396	43.9	.	.
EHD4	15	41895939	41972578	N	.	N	Y	-1.019194721	7.640215315	0.001496806	63	.	.
EHF	11	34621093	34661057	N	.	N	N	0.015288823	50.66851884	0.978731449	12	.	.
EHHADH	3	185190624	185281990	N	.	N	Y	1.879854198	98.36777218	8.50E-11	93	.	?Fanconi renotubular syndrome 3, 615605 (3)
EID1	15	48877886	48880183	N	.	N	N	-0.343096194	27.10540024	0.64535521	26.2	.	.
EID2	19	39538250	39540230	N	.	N	N	0.178442775	63.08386873	0.750053235	23.2	.	.
EID2B	19	39530990	39532854	N	.	N	N	0.164393154	62.10568965	0.126192495	41.7	.	.
EID3	12	104303739	104305202	N	.	N	N	0.004110017	49.83504081	0.237610982	37.5	.	.
EIF1	17	41688885	41692668	N	.	N	N	-0.007371823	48.85686172	0.764131765	22.8	.	.
EIF1AD	11	65996545	66002176	N	.	N	N	0.057436789	53.89824622	0.181571134	39.3	.	.
EIF1AX	X	20124518	20141844	N	.	N	N	0.105175156	57.60838108	0.88157217	18.5	.	.
EIF1AY	Y	20575725	20593154	N	.	N	N	.	.	0.424064593	32.2	.	.
EIF1B	3	40309684	40312424	N	.	N	N	0.082665704	55.90669676	0.394740519	32.9	.	.
EIF2A	3	150546678	150584242	N	.	N	N	-0.282917726	30.50876888	0.000158939	70.5	.	.
EIF2AK1	7	6022244	6059230	N	.	N	Y	-0.355882518	26.53817214	0.000121058	71.3	.	.
EIF2AK2	2	37099210	37157065	N	.	N	Y	-1.143082398	6.117960294	0.051553423	46.9	.	.
EIF2B1	12	123620406	123633766	N	.	N	N	-0.112262427	41.3266192	0.104796388	42.8	DM	Leukoencephalopathy with vanishing white matter, 603896 (3)
EIF2B5	3	184135038	184684758	N	.	N	Y	-0.699265356	13.93181687	0.996711861	7.7	DM	Leukoencephalopathy with vanishing white matter, 603896 (3); Ovarioleukodystrophy, 603896 (3)
EIF2D	1	206571292	206612463	N	.	N	N	-0.558617759	17.96608207	6.60E-06	79.1	.	.
EIF2S3	X	24054716	24077971	N	.	N	N	0.437375642	77.75655496	0.916323958	16.9	DM	.
EIF2S3L	12	10505602	10523135	N	.	N	N	.	.	0.147907105	40.7	.	.
EIF3A	10	119033670	119080823	N	.	N	N	-1.22424493	5.359726804	1	0.5	.	.
EIF3C	16	28688558	28735730	N	.	N	N	.	.	0.343303109	34.4	DM?	.
EIF3CL	16	28379579	28403879	N	.	N	N	.	.	.	.	.	.
EIF3D	22	36510850	36529436	N	.	N	N	-1.002426984	7.825432656	0.994221961	8.8	.	.
EIF3E	8	108201216	108435333	N	.	N	N	-0.49315829	20.47809226	0.734231962	23.6	.	.
EIF3F	11	7970251	8001862	N	.	N	N	0.128941721	59.34479366	0.669067338	25.5	.	.
EIF3G	19	10115017	10119920	N	.	N	N	-0.45181342	22.19714071	0.983422492	11.2	.	.
EIF3H	8	116642130	116766925	N	.	N	N	-0.474322733	21.23632575	0.46505125	31	DFP	.
EIF3I	1	32221928	32231604	N	.	N	N	-0.500661427	20.13080975	0.417329825	32.3	.	.
EIF3J	15	44537057	44563029	N	.	N	N	0.118418051	58.60971233	0.85908426	19.5	.	.
EIF3K	19	38619082	38636955	N	.	N	N	0.484307457	79.86340221	0.002331635	61.4	.	.
EIF3L	22	37848868	37889407	N	.	N	N	-1.258512563	5.070324709	0.938813614	15.7	.	.
EIF4A1	17	7572706	7579005	N	.	N	N	-0.673234787	14.6553221	0.999614421	4.9	.	.
EIF4A2	3	186783205	186789900	N	.	N	N	-0.494115743	20.42599988	0.997112605	7.5	.	.
EIF4A3	17	80135214	80147183	N	.	N	N	-0.507207153	19.92244024	0.998989655	5.9	.	Robin sequence with cleft mandible and limb anomalies, 268305 (3)
EIF4B	12	53006158	53042209	N	.	N	N	-0.526691349	19.14105458	0.999986524	2.7	.	.
EIF4E	4	98871684	98930637	N	.	N	Y	-0.058936621	45.1930312	0.983573342	11.2	DM	{Autism, susceptibility to, 19}, 615091 (3)
EIF4E1B	5	176630682	176646641	N	.	N	N	0.762888245	88.37182381	0.111053692	42.6	.	.
EIF4E3	3	71675416	71754773	N	.	N	Y	-0.051433536	45.65607455	0.004232503	58.9	.	.
EIF4EBP1	8	38030341	38060365	N	.	N	Y	0.038603643	52.45123575	0.184082877	39.2	.	.
EIF4EBP2	10	70404379	70428618	N	.	N	Y	0.13805751	60.04514673	0.694677116	24.8	.	.
EIF4EBP3	5	140547666	140549578	N	Viable	N	Y	0.174616683	62.82340684	0.054243025	46.5	.	.
EIF4ENIF1	22	31436977	31496108	N	.	N	N	-1.265720737	4.983504081	0.999689054	4.7	.	.
EIF4G1	3	184314495	184335358	N	.	N	Y	-1.665970387	2.575678648	1	0.4	DM	{Parkinson disease 18}, 614251 (3)
EIF4G3	1	20806292	21176888	N	.	N	N	-1.181952709	5.776465822	0.999999907	1.1	.	.
EIF4H	7	74174245	74197101	N	.	N	Y	-0.169568594	37.41390288	0.92254488	16.6	.	.
EIF5	14	103333544	103345025	N	.	N	N	-0.80542189	11.43717081	0.90785981	17.4	.	.
EIF5A	17	7306999	7312463	N	.	N	N	0.018007904	50.90004052	0.890876904	18.2	.	.
EIF5A2	3	170888415	170908693	N	.	N	N	0.06302642	54.36707762	0.167390172	39.8	.	.
EIF5AL1	10	79512601	79516440	N	.	N	N	0.161523449	61.87995601	.	.	.	.
EIF5B	2	99337353	99401326	N	.	N	N	-0.771282946	12.154888	0.895387513	17.9	.	.
ELAC1	18	50967991	50988121	N	.	N	N	-0.095342599	42.403195	0.895039746	17.9	.	.
ELAC2	17	12992391	13018187	N	.	N	N	-1.049875098	7.217688256	4.06E-11	93.5	DM	{Prostate cancer, hereditary, 2, susceptibility to}, 614731 (3); Combined oxidative phosphorylation deficiency 17, 615440 (3)
ELANE	19	851014	856247	N	.	N	Y	0.253623009	67.679574	0.767207228	22.7	DM	Neutropenia, cyclic, 162800 (3); Neutropenia, severe congenital 1, autosomal dominant, 202700 (3)
ELAVL2	9	23690104	23826337	N	.	N	N	-0.733260961	13.05782254	0.972927704	12.7	DP	.
ELAVL4	1	50048014	50203786	N	.	N	Y	-0.27924293	30.68241014	0.976912762	12.2	.	Neuropathy, paraneoplastic sensory (1)
ELF1	13	40931920	41061440	N	.	N	Y	0.507115742	80.74897262	0.547779993	28.7	.	.
ELF2	4	139028112	139177218	N	.	N	N	-0.21156288	34.83822423	0.985385387	10.9	.	.
ELF4	X	130064874	130110716	N	.	N	Y	-0.105564211	41.74335822	0.611464084	27.1	DM?	.
ELFN1	7	1688119	1747954	N	Viable	N	Y	.	.	0.699066032	24.6	.	.
ELFN2	22	37367960	37427470	N	Viable	N	Y	-0.125857678	40.34265208	0.849015287	19.9	.	.
ELK1	X	47635521	47650604	N	.	N	Y	0.283486649	69.50859524	0.756057874	22.9	DM	.
ELK4	1	205597556	205631962	N	.	N	Y	-0.281003772	30.58401343	0.084588675	44.1	.	.
ELL2	5	95885098	95962071	N	Viable	N	Y	-0.526691349	19.14105458	0.998288545	6.7	.	.
ELL3	15	43772600	43777543	N	.	N	N	0.0200728	51.09683394	3.17E-06	80.4	.	.
ELMO1	7	36854361	37449249	N	.	N	Y	-0.805268966	11.44874689	0.993000632	9.2	.	.
ELMO2	20	46366049	46432985	N	.	N	N	-0.784672448	11.84812178	0.000350882	68.2	.	.
ELMO3	16	67199111	67204029	N	Viable	N	Y	0.438940537	77.82601146	1.20E-07	85.9	.	.
ELMOD1	11	107591091	107666779	N	Viable	N	Y	0.179399332	63.14753719	0.536337679	29	.	.
ELMOD2	4	140524158	140553770	N	.	N	N	-0.007220243	48.88580193	0.804445978	21.5	.	.
ELMOD3	2	85354394	85391752	N	.	N	N	0.544480852	82.23071135	4.56E-11	93.4	.	?Deafness, autosomal recessive 88, 615429 (3)
ELMSAN1	14	73715122	73790285	N	.	N	N	0.113435163	58.22770157	0.99977278	4.4	.	.
ELOVL2	6	10980759	11044314	N	.	N	N	-0.156323524	38.27632112	0.000198697	69.8	.	.
ELOVL3	10	102226328	102229589	N	.	N	Y	-0.31116943	28.88232911	0.010089351	54.9	.	.
ELOVL5	6	53267398	53349179	N	.	N	N	-0.228635876	33.80216473	0.924260372	16.4	.	Spinocerebellar ataxia 38, 615957 (3)
ELOVL6	4	110045846	110199199	N	.	N	Y	-0.126464329	40.30213579	0.971074457	12.9	.	.
ELOVL7	5	60751791	60844389	N	.	N	N	-0.089753398	42.80835793	0.001560922	62.9	.	.
ELP2	18	36129444	36180556	N	.	N	N	-0.158739832	38.11425595	1.31E-07	85.8	DM	.
ELP3	8	28089673	28191156	N	.	N	N	-0.839110097	10.78312207	3.93E-07	84.1	.	.
ELP4	11	31509750	31783998	N	.	N	N	0.02389999	51.36308387	0.012558281	54	DM?	?Aniridia, 106210 (3)
ELP5	17	7251416	7259940	N	.	N	N	0.370952088	74.45158303	6.48E-06	79.1	.	.
ELP6	3	47495640	47513761	N	.	N	N	0.333287484	72.48364878	0.003507899	59.7	.	.
ELSPBP1	19	47994651	48025153	N	.	N	N	1.175736565	94.79655033	0.00018142	70.1	.	.
EMB	5	50396192	50443248	N	.	N	N	-0.179789518	36.75985414	6.39E-05	73.2	.	.
EMC1	1	19215664	19251552	N	.	N	N	-0.399649431	24.44290097	6.04E-14	96.3	DM?	.
EMC10	19	50476400	50490870	N	Viable	N	Y	0.457163544	78.66527754	1.56E-07	85.6	.	.
EMC2	8	108443601	108486918	N	.	N	N	-0.144188409	39.10979915	8.61E-05	72.3	.	.
EMC3	3	9962537	10011116	N	.	N	N	-0.229593003	33.74428431	0.801934562	21.6	.	.
EMC4	15	34224999	34230156	N	.	N	N	-0.148973548	38.82039706	0.9124682	17.2	.	.
EMC6	17	3668815	3669668	N	.	N	N	-0.043930449	46.31591133	0.491983958	30.2	.	.
EMC7	15	34084017	34101948	N	.	N	N	-0.275568538	30.94287203	0.93565156	15.8	.	.
EMC8	16	85771758	85799608	N	.	N	N	-0.182660566	36.56884876	0.259008428	36.8	.	.
EMC9	14	24138959	24141588	N	.	N	N	0.44679135	78.19644614	0.000353828	68.2	.	.
EMCN	4	100395341	100880126	N	.	N	N	0.190728755	63.83052613	1.65E-05	76.8	.	.
EMD	X	154379197	154381523	N	.	N	Y	0.218827885	65.61903108	0.84440846	20.1	DM	Emery-Dreifuss muscular dystrophy 1, X-linked, 310300 (3)
EME1	17	50373220	50381483	N	Viable	N	Y	1.196629346	94.98176767	7.07E-11	93.2	DP	.
EME2	16	1773207	1781708	N	.	N	N	0.836302786	89.917231	9.50E-14	96.1	.	.
EMID1	22	29205851	29259597	N	.	N	Y	0.452529749	78.4395439	0.039707727	48.4	.	.
EMILIN1	2	27078567	27086408	N	.	N	Y	0.790634811	88.99693234	0.005216561	57.9	.	.
EMILIN2	18	2847030	2915993	N	.	N	N	0.304841601	70.77038838	1.60E-09	90.7	DM	.
EMILIN3	20	41359966	41366827	N	.	N	N	0.867584647	90.50182323	0.001398097	63.4	.	.
EML1	14	99737693	99942060	N	.	N	N	-1.089448899	6.679400359	0.99944646	5.3	.	.
EML2	19	45606994	45645629	N	Viable	N	Y	-0.176615867	36.95664757	7.58E-10	91.3	.	.
EML3	11	62602218	62612765	N	.	N	N	-1.153159657	6.054291833	0.394340909	32.9	.	.
EML4	2	42169350	42332548	N	.	N	N	-0.666091563	14.85790357	0.391138665	33	.	.
EML5	14	88612431	88792752	N	.	N	N	-2.438407461	1.024483417	0.158418535	40.2	.	.
EML6	2	54723499	54972025	N	.	N	N	.	.	0.443032449	31.6	.	.
EMP1	12	13196716	13219939	N	.	N	Y	0.527414817	81.53035828	0.411003666	32.5	.	.
EMP2	16	10528422	10580698	N	.	N	N	-0.053195214	45.56346588	5.90E-05	73.5	.	Nephrotic syndrome, type 10, 615861 (3)
EMP3	19	48321509	48330553	N	.	N	N	0.367934269	74.27215373	0.000573648	66.6	.	.
EMX1	2	72916260	72936071	N	Viable	N	Y	.	.	0.710215197	24.3	.	.
EN2	7	155458129	155464831	N	.	N	Y	.	.	0.433107379	31.9	DFP	.
ENAH	1	225486835	225653142	N	.	N	Y	-0.175004808	37.08977253	0.995700037	8.1	.	.
ENAM	4	70628744	70686816	N	.	N	Y	-0.296369944	29.6405626	5.67E-07	83.5	DM	Amelogenesis imperfecta, type IB, 104500 (3); Amelogenesis imperfecta, type IC, 204650 (3)
ENC1	5	74627406	74641424	N	.	N	Y	-1.054952342	7.142443711	0.879896897	18.6	.	.
ENDOD1	11	95089810	95132645	N	.	N	N	0.083923805	56.03403369	1.42E-06	82	.	.
ENDOG	9	128818474	128822677	Y	Viable	N	Y	.	.	0.006243353	57	.	.
ENDOU	12	47709734	47725567	N	.	N	N	0.687999311	86.60068299	6.22E-12	94.5	.	.
ENDOV	17	80415165	80438086	N	.	N	N	1.041622011	93.29165943	2.63E-06	80.7	DM?	.
ENGASE	17	79074939	79088599	N	.	N	N	1.220420634	95.23644151	8.06E-21	98.8	.	.
ENHO	9	34521040	34523041	N	.	N	Y	-0.074899744	44.03542282	0.113449546	42.4	.	.
ENKD1	16	67662945	67667265	N	.	N	N	0.535064702	81.88342884	2.15E-05	76	.	.
ENKUR	10	24981979	25062279	N	.	N	N	0.463710367	79.01834809	9.61E-06	78.2	.	.
ENO2	12	6913745	6923698	N	.	N	N	-0.601876237	16.64640852	0.01857771	52.1	.	.
ENO3	17	4948092	4957131	N	.	N	N	-0.260256521	31.86317069	6.91E-11	93.2	DM	?Glycogen storage disease XIII, 612932 (3)
ENO4	10	116849512	116911788	N	.	N	N	.	.	.	.	.	.
ENOPH1	4	82430562	82461091	N	.	N	N	-0.320586962	28.25722058	0.001757841	62.4	.	.
ENOSF1	18	670324	712676	N	.	N	N	0.208755511	64.98813451	1.26E-10	92.8	.	.
ENOX1	13	43213518	43786908	N	.	N	N	-0.868166866	10.23904613	0.036401417	48.8	DM?	.
ENOX2	X	130623369	130903317	N	.	N	N	-0.303512836	29.281704	0.003145551	60.1	.	.
ENPEP	4	110365733	110565285	N	.	N	N	-0.113571418	41.22822249	3.58E-19	98.5	.	.
ENPP1	6	131808016	131895155	N	.	N	Y	-0.609076927	16.4785553	2.31E-05	75.9	DM	{Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3); {Obesity, susceptibility to}, 601665 (3); Arterial calcification, generalized, of infancy, 1, 208000 (3); Hypophosphatemic rickets, autosomal recessive, 2, 613312 (3); Cole disease, 615522 (3)
ENPP3	6	131628442	131747418	N	.	N	N	0.579585496	83.42883602	6.44E-17	97.8	.	.
ENPP4	6	46129993	46146699	N	.	N	N	0.127028236	59.25797303	0.414683931	32.4	.	.
ENPP5	6	46159187	46170971	N	.	N	N	0.242443541	67.04288939	1.92E-05	76.3	.	.
ENPP6	4	184088706	184221230	N	.	N	N	-0.024793574	47.60664467	6.11E-07	83.4	.	.
ENPP7	17	79730919	79742222	N	.	N	Y	1.602970324	97.51114198	2.21E-10	92.4	.	.
ENSA	1	150600851	150629612	N	.	N	N	0.018964694	50.97528506	0.162369766	40.1	DP	.
ENTHD1	22	39743044	39893864	N	.	N	N	0.185289731	63.54112404	3.67E-06	80.1	.	.
ENTHD2	17	81228277	81239091	N	Viable	N	Y	0.434803554	77.64079412	0.000515476	67	.	.
ENTPD1	10	95711779	95877266	N	Viable	N	Y	-0.296009812	29.68107889	0.519393999	29.5	DM	Spastic paraplegia 64, 615683 (3)
ENTPD2	9	137048098	137054045	N	.	N	Y	0.741629376	87.90299242	9.49E-07	82.6	.	.
ENTPD3	3	40387156	40428619	N	.	N	N	0.589650479	83.82821092	2.56E-19	98.5	.	.
ENTPD4	8	23385783	23457695	N	.	N	N	0.346833134	73.23609423	2.07E-11	93.9	.	.
ENTPD5	14	73958010	74019399	N	.	N	Y	-0.720013589	13.41089309	0.000105198	71.7	.	.
ENTPD6	20	25195693	25226729	N	.	N	Y	0.815706054	89.44839961	4.99E-05	73.9	.	.
ENTPD7	10	99659506	99706240	N	.	N	Y	-0.599809597	16.72744111	2.57E-08	87.9	.	.
ENTPD8	9	137434364	137441816	N	Viable	N	Y	0.388023238	75.29084911	1.72E-07	85.4	.	.
ENY2	8	109334324	109345953	N	.	N	N	-0.007371823	48.85686172	0.797810082	21.8	.	.
EOGT	3	68975214	69013961	N	.	N	N	-0.255624009	32.14678474	9.79E-06	78.1	DM	Adams-Oliver syndrome 4, 615297 (3)
EP400NL	12	132084283	132131639	N	.	N	N	.	.	0.091220759	43.7	.	.
EPB41L1	20	36091504	36232799	N	.	N	Y	-0.910170724	9.405568096	0.645386133	26.2	DM	?Mental retardation, autosomal dominant 11, 614257 (3)
EPB41L2	6	130839347	131063322	N	.	N	Y	0.340442364	72.89459976	0.993883458	8.9	.	.
EPB41L3	18	5392381	5630700	N	.	N	Y	-0.358308745	26.37610696	0.029278388	49.8	.	.
EPB41L4A	5	112142441	112419316	N	Viable	N	Y	1.274699624	95.57793598	1.99E-11	93.9	.	.
EPB41L4B	9	109171975	109320964	N	Viable	N	Y	-0.448640177	22.35920588	0.999700027	4.6	.	.
EPB42	15	43106225	43221283	N	.	N	Y	0.20140456	64.46721074	1.56E-07	85.6	DM	Spherocytosis, hereditary, type 5, 612690 (3)
EPDR1	7	37683843	37951941	N	Viable	N	Y	0.196318636	64.16623256	0.029388014	49.8	.	.
EPG5	18	45847609	45967274	N	.	N	N	0.885016194	90.82595358	6.94E-07	83.2	DM	Vici syndrome, 242840 (3)
EPGN	4	74308473	74315307	N	Viable	N	Y	-0.072028905	44.27852058	0.003492546	59.7	.	.
EPHA1	7	143390289	143408892	N	.	N	Y	0.049735058	53.37153441	5.30E-11	93.3	.	.
EPHA10	1	37713880	37765133	N	Viable	N	Y	1.207331238	95.07437634	3.16E-18	98.2	.	.
EPHA2	1	16124337	16156087	N	.	N	Y	-0.046849448	46.06123748	0.738294173	23.5	DM	Cataract 6, multiple types, 116600 (3)
EPHA4	2	221418027	221574202	N	.	N	Y	-1.571631855	2.957689414	0.999891325	3.8	DM	.
EPHA5	4	65319563	65670495	N	.	N	Y	-0.932540882	8.988829079	0.00039007	67.8	DM	.
EPHA6	3	96814581	97752460	N	Viable	N	Y	-0.746860747	12.70475198	0.954513147	14.4	DM?	.
EPHA7	6	93240020	93419547	N	.	N	Y	-0.805120956	11.45453493	0.987759367	10.5	DM	.
EPHA8	1	22563564	22603594	N	.	N	Y	-0.307552508	29.00387799	1.14E-08	88.8	.	.
EPHB1	3	134597801	135260467	N	.	N	Y	-1.184947408	5.724373444	0.998398641	6.6	.	.
EPHB2	1	22710839	22921500	N	.	N	Y	-1.11359062	6.424726515	0.999948635	3.3	DM	{Prostate cancer/brain cancer susceptibility, somatic}, 603688 (3)
EPHB3	3	184561784	184582409	N	.	N	Y	-1.326574189	4.508884644	0.956539592	14.2	.	.
EPHB6	7	142855061	142871094	N	.	N	Y	-0.005657548	49.03629102	0.253348704	37	DM?	.
EPHX1	1	225810092	225845563	N	.	N	Y	0.717205629	87.34155235	1.62E-07	85.5	DFP	?Fetal hydantoin syndrome (1); Diphenylhydantoin toxicity (1); Hypercholanemia, familial, 607748 (3); {Preeclampsia, susceptibility to}, 189800 (3)
EPHX2	8	27490779	27545564	N	.	N	Y	1.57758339	97.36644093	4.92E-13	95.5	DFP	{Hypercholesterolemia, familial, due to LDLR defect, modifier of}, 143890 (3)
EPHX3	19	15226919	15233435	N	.	N	N	0.482542375	79.82867396	5.05E-07	83.7	.	.
EPHX4	1	92029982	92063536	N	.	N	N	-0.150734446	38.66411993	0.033543927	49.2	.	.
EPM2A	6	145501583	145736024	N	.	N	Y	-0.105716346	41.73178214	3.59E-05	74.8	DM	Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3)
EPM2AIP1	3	36985043	36993168	N	.	N	Y	-0.856031129	10.45899172	0.164415268	40	.	.
EPN1	19	55675226	55709858	N	.	N	Y	-0.748112675	12.68738786	0.430317763	32	.	.
EPN2	17	19215615	19336715	N	.	N	Y	-0.759291969	12.41534989	0.177426617	39.4	.	.
EPN3	17	50532543	50543750	N	Viable	N	Y	1.252187802	95.44481102	1.33E-09	90.9	.	.
EPPIN	20	45540626	45547752	N	.	N	N	0.427003903	77.20669098	0.000111214	71.5	.	.
EPPIN-WFDC6	20	45536986	45547426	N	.	N	N	0.421412982	76.87677259	0.000111214	71.5	.	.
EPPK1	8	143857324	143878464	N	.	N	Y	.	.	4.95E-21	98.9	FTV	.
EPS15	1	51354263	51519328	N	.	N	Y	-0.175659207	37.02610407	0.241707066	37.3	.	.
EPS15L1	19	16355239	16472085	N	.	N	N	-1.150292794	6.071655959	0.970002535	13	.	.
EPS8	12	15620158	15882329	N	.	N	Y	-0.128727668	40.18637495	0.947393284	15	.	?Deafness, autosomal recessive 102, 615974 (3)
EPS8L1	19	55072020	55087923	N	Viable	N	Y	0.388980245	7.53E+01	2.75E-08	87.8	.	.
EPS8L2	11	694438	727727	N	.	N	Y	-1.380340066	4.051629334	0.001827008	62.2	.	.
EPS8L3	1	109750080	109764027	N	.	N	N	0.637540668	85.28679748	0.000100217	71.9	DM	.
EPSTI1	13	42886388	42992271	N	.	N	N	0.919797841	91.4915784	1.35E-18	98.3	.	.
EPT1	2	26308547	26395891	N	.	N	N	-0.060698235	45.04254211	0.34746175	34.3	.	.
EPX	17	58192737	58205174	N	.	N	Y	1.371459735	96.23777276	6.21E-10	91.6	DM	[Eosinophil peroxidase deficiency], 261500 (3)
EPYC	12	90963679	91005026	N	.	N	N	0.02757579	51.6293338	5.05E-05	73.8	.	.
EQTN	9	27284659	27297139	N	.	N	N	0.564121238	82.873184	1.33E-07	85.8	.	.
ERAL1	17	28854938	28861067	N	.	N	N	-0.03053445	47.25357412	1.04E-06	82.5	.	.
ERAP1	5	96760810	96808100	N	.	N	Y	0.485874847	79.92707067	9.99E-18	98.1	DM?	.
ERAP2	5	96875939	96919716	N	.	N	N	0.811390077	89.36157898	3.18E-22	99.1	FP	.
ERAS	X	48828873	48830138	N	.	N	N	-0.005458152	49.05944319	0.519995648	29.5	.	.
ERBB2IP	5	65926475	66082549	N	.	N	Y	0.289034669	69.82693755	0.993356912	9	.	.
ERC2	3	55508308	56468363	N	.	N	Y	-1.577225576	2.928749204	0.996856462	7.6	.	.
ERCC6	10	49455368	49539538	N	.	N	Y	2.220295662	98.87711987	5.01E-13	95.5	DM	Cockayne syndrome, type B, 133540 (3); Cerebrooculofacioskeletal syndrome 1, 214150 (3); De Sanctis-Cacchione syndrome, 278800 (3); {Macular degeneration, age-related, susceptibility to 5}, 613761 (3); UV-sensitive syndrome 1, 600630 (3); {Lung cancer, susceptibility to}, 211980 (3)
ERCC6L	X	72204657	72239047	N	.	N	N	0.079291193	55.62887075	0.986827394	10.7	FTV	.
ERCC6L2	9	95875701	96014571	N	.	N	N	-0.023836771	47.69925334	0.001555907	62.9	.	Bone marrow failure syndrome 2, 615715 (3)
ERCC6-PGBD3	10	49515201	49539538	N	.	N	N	0.121895288	58.84702205	2.07E-06	81.3	.	.
ERCC8	5	60873831	60945073	N	.	N	Y	0.05199832	53.51623546	8.57E-09	89.1	DM	Cockayne syndrome, type A, 216400 (3); UV-sensitive syndrome 2, 614621 (3)
EREG	4	74365143	74388751	N	.	N	Y	-0.138599374	39.52075013	0.000400111	67.7	.	.
ERGIC1	5	172834275	172952685	N	.	N	N	-0.696702134	14.03600162	0.714836766	24.2	.	.
ERGIC2	12	29337352	29381189	N	.	N	N	-0.391788739	24.87121607	0.320357206	35.1	.	.
ERGIC3	20	35542021	35557634	N	.	N	N	-0.875824863	10.04225271	0.003859077	59.2	.	.
ERH	14	69380123	69398627	N	.	N	N	0.18116337	63.25172194	0.846059924	20	.	.
ERI2	16	20780193	20900349	N	.	N	N	.	.	6.39E-05	73.2	.	.
ERI3	1	44221070	44355260	N	.	N	N	-0.484697758	20.7732824	0.129756091	41.6	.	.
ERICH1	8	614746	738106	N	.	N	N	0.30836083	70.9671818	1.39E-10	92.7	.	.
ERICH2	2	170783786	170798971	N	.	N	N	.	.	.	.	.	.
ERICH3	1	74568111	74673738	N	.	N	N	.	.	.	.	.	.
ERICH4	19	41443158	41444765	N	.	N	N	.	.	.	.	.	.
ERICH5	8	98064311	98093610	N	.	N	N	.	.	.	.	.	.
ERICH6	3	150659885	150703971	N	.	N	N	.	.	.	.	.	.
ERICH6B	13	45534522	45615739	N	.	N	N	.	.	.	.	.	.
ERLEC1	2	53787044	53818819	N	.	N	N	-0.015528497	48.24911732	0.000679063	66.1	.	.
ERLIN1	10	100150094	100188334	N	.	N	N	0.006828994	50.02025815	0.931709474	16	.	.
ERLIN2	8	37736599	37759101	N	.	N	N	-0.545680331	18.36545697	0.111582005	42.5	DM	Spastic paraplegia 18, autosomal recessive, 611225 (3)
ERMAP	1	42817124	42844989	N	.	N	N	1.176837334	94.81391445	5.81E-05	73.5	FP	[Blood group, Scianna system], 111750 (3); [Blood group, Radin], 111620 (3)
ERMARD	6	169751622	169781584	N	.	N	N	0.574798023	83.24361868	5.17E-10	91.7	.	?Periventricular nodular heterotopia 6, 615544 (3)
ERMN	2	157318625	157327713	N	.	N	N	0.244206777	67.1412861	0.003101525	60.2	.	.
ERMP1	9	5765076	5833117	N	Viable	N	Y	-1.022726395	7.570758812	4.55E-05	74.2	DM?	.
ERN2	16	23690326	23713500	N	.	N	Y	0.267325961	68.48411182	1.79E-15	97.2	.	.
ERO1A	14	52639916	52695900	N	.	N	N	.	.	.	.	.	.
ERO1B	1	236215555	236281985	N	.	N	N	.	.	.	.	.	.
ERP27	12	14914035	14939082	N	.	N	N	0.413101046	76.51212595	1.11E-07	86	.	.
ERP29	12	112013316	112023451	N	.	N	N	0.289225269	69.8616658	0.470649236	30.8	.	.
ERV3-1	7	64990809	65006743	N	.	N	N	0.793195884	89.0606008	4.31E-07	83.9	.	.
ERVMER34-1	4	52722618	52751640	N	.	N	N	.	.	.	.	.	.
ERVV-1	19	53013921	53016122	N	.	N	N	.	.	.	.	.	.
ERVV-2	19	53044738	53051076	N	.	N	N	.	.	.	.	.	.
ERVW-1	7	92468380	92477986	N	.	N	N	1.252833539	95.4563871	0.013567172	53.6	.	.
ESAM	11	124752583	124762290	N	.	N	Y	0.12989848	59.41425016	0.191978714	38.9	DM?	.
ESCO1	18	21529281	21600884	N	.	N	Y	-0.237596807	33.2175725	0.998809461	6.1	.	.
ESD	13	46771256	46797232	N	.	N	N	0.151300234	61.07541819	0.000611692	66.4	.	.
ESF1	20	13714322	13784886	N	.	N	N	-0.60061732	16.68692481	0.084445279	44.1	.	.
ESM1	5	54977864	55022671	N	.	N	N	0.208455225	64.9591943	0.026176218	50.3	.	.
ESPN	1	6424788	6461370	N	.	N	Y	-0.030382941	47.27093824	0.002553841	61.1	DM	Deafness, autosomal recessive 36, 609006 (3); Deafness, neurosensory, without vestibular involvement, autosomal dominant (3)
ESPNL	2	238100157	238133287	N	Viable	N	Y	2.426032376	99.12600567	3.88E-10	91.9	.	.
ESR1	6	151656691	152129619	N	.	N	Y	-0.673079812	14.68426231	0.987167021	10.5	DM	Estrogen resistance, 615363 (3); {HDL response to hormone replacement, augmented} (3); {Migraine, susceptibility to}, 157300 (3); {Atherosclerosis, susceptibility to} (3); {Myocardial infarction, susceptibility to}, 608446 (3); {Breast cancer}, 114480 (1)
ESR2	14	64084232	64338112	N	.	N	Y	-0.041561741	46.46640042	5.15E-08	86.9	DM?	.
ESRP1	8	94641074	94707466	N	.	N	N	-0.112110344	41.35555941	0.999134057	5.7	.	.
ESRP2	16	68229111	68238102	N	.	N	N	-0.89707561	9.654453898	0.731424519	23.7	.	.
ESRRA	11	64305572	64316743	N	.	N	Y	0.005066824	49.89292122	0.527244157	29.2	.	.
ESX1	X	104250038	104254933	N	.	N	Y	0.375585437	74.723621	0.635809622	26.5	.	.
ESYT1	12	56118250	56144671	N	.	N	N	-1.37719724	4.080569543	2.14E-07	85.1	.	.
ESYT2	7	158730995	158830253	N	Viable	N	Y	-0.874564914	10.08855704	0.008440951	55.6	.	.
ESYT3	3	138434586	138481686	N	Viable	N	Y	1.608720829	97.53429415	2.43E-11	93.8	.	.
ETAA1	2	67397319	67410545	N	.	N	N	0.61231395	84.53435203	0.975314596	12.4	.	.
ETF1	5	138506095	138543300	N	.	N	N	-0.472563815	21.34629855	0.998925127	6	.	.
ETFA	15	76215355	76311472	N	.	N	N	0.17476603	62.85234705	0.012927273	53.9	DM	Glutaric acidemia IIA, 231680 (3)
ETFB	19	51345169	51366418	N	.	N	N	-0.115937794	41.07194536	0.003716163	59.3	DM	Glutaric acidemia IIB, 231680 (3)
ETFDH	4	158672125	158709623	N	.	N	N	-0.592306384	16.9473867	1.63E-07	85.5	DM	Glutaric acidemia IIC, 231680 (3)
ETNK1	12	22625075	22690665	N	Viable	N	Y	0.382132046	75.02459918	0.865130479	19.3	.	.
ETNK2	1	204131062	204152003	N	.	N	Y	0.060307001	54.1297679	0.007118854	56.5	.	.
ETNPPL	4	108742040	108763054	N	.	N	N	-0.720013589	13.41089309	0.000225469	69.4	.	.
ETV1	7	13891228	13991425	N	.	N	Y	-0.863534559	10.30271459	0.996674203	7.7	.	.
ETV3	1	157121191	157138474	N	.	N	N	.	.	0.783799556	22.2	.	.
ETV3L	1	157092044	157099808	N	.	N	N	1.477004488	96.85709325	1.21E-05	77.6	.	.
ETV4	17	43527844	43579620	N	.	N	Y	0.138358236	60.06251085	0.00270291	60.8	.	.
ETV7	6	36354091	36387800	N	.	N	N	0.513511574	81.03837472	2.01E-08	88.1	.	.
EVA1A	2	75469302	75569722	N	.	N	N	0.353884195	73.67019737	0.061811031	45.8	.	.
EVA1B	1	36322031	36324154	N	.	N	N	0.547056981	82.31174394	0.656674968	25.9	.	.
EVA1C	21	32412006	32515397	N	.	N	N	0.460989431	78.87943509	0.325814898	35	.	.
EVI2A	17	31317560	31321884	N	.	N	N	0.282678709	69.47965503	8.69E-06	78.4	.	.
EVI2B	17	31303766	31314112	N	.	N	N	0.445983156	78.16171789	0.177043581	39.5	.	.
EVI5	1	92508696	92792404	N	.	N	N	0.708898651	87.08687851	2.33E-06	81	DM?	.
EVI5L	19	7830233	7864976	N	.	N	N	-0.708836138	13.66556694	0.989107013	10.1	.	.
EVL	14	99971449	100144236	N	Viable	N	Y	-0.479911471	20.98743995	0.99261527	9.3	.	.
EVPL	17	76004502	76027452	N	.	N	Y	0.712397123	87.20842739	6.49E-14	96.3	FTV	.
EVPLL	17	18377662	18389647	N	.	N	N	.	.	2.73E-08	87.8	.	.
EVX2	2	176077472	176083913	N	.	N	Y	0.086643016	56.19609886	.	.	.	.
EXD1	15	41182725	41230743	N	.	N	N	-0.343746643	27.07067199	2.03E-13	95.8	.	.
EXD2	14	69191511	69244020	N	.	N	N	-0.461077067	21.84985819	1.11E-08	88.8	.	.
EXD3	9	137306896	137423262	N	.	N	N	2.093842613	98.72084274	1.19E-08	88.7	.	.
EXO1	1	241847967	241895148	N	.	N	Y	0.809473582	89.31527464	9.25E-09	89	DM	.
EXO5	1	40508741	40516556	N	.	N	N	0.055674233	53.76512126	0.000872651	65.2	.	.
EXOC1	4	55853616	55905034	N	.	N	N	-1.288376997	4.76934653	0.096664204	43.4	.	.
EXOC2	6	485133	693111	N	.	N	N	-1.448691364	3.681194652	0.000114966	71.4	.	.
EXOC3	5	443158	471937	N	.	N	N	-0.435697089	22.93222203	0.755230038	23	.	.
EXOC3L1	16	67184366	67190204	N	.	N	N	0.998816062	92.73600741	7.64E-10	91.3	.	.
EXOC3L4	14	103100144	103110559	N	.	N	N	.	.	3.13E-07	84.4	.	.
EXOC5	14	57200507	57269008	N	.	N	N	0.087599756	56.28870753	0.996683025	7.7	.	.
EXOC6B	2	72175984	72826041	N	.	N	N	0.026770398	51.55987729	0.666298052	25.6	DM	.
EXOC7	17	76081017	76121576	N	.	N	N	-0.354925841	26.57868843	0.000651393	66.2	.	.
EXOG	3	38496127	38542161	N	.	N	N	0.225524115	65.99525381	2.86E-08	87.7	.	.
EXOSC1	10	97436142	97446017	N	.	N	N	0.226330975	66.02998206	1.88E-07	85.2	.	.
EXOSC10	1	11066618	11099881	N	.	N	N	-0.168962986	37.46599525	1.66E-07	85.5	.	.
EXOSC2	9	130693721	130704894	N	.	N	N	-0.172286507	37.23447358	0.004089806	59	.	.
EXOSC4	8	144078626	144080647	N	.	N	N	0.136294125	59.95253806	0.099450175	43.1	.	.
EXOSC5	19	41386374	41397479	N	.	N	N	0.237660296	66.68403079	0.001192557	64	.	.
EXOSC6	16	70246778	70251930	N	.	N	N	.	.	0.494173934	30.1	.	.
EXOSC7	3	44975241	45036066	N	.	N	N	-0.179789518	36.75985414	0.014139529	53.5	.	.
EXPH5	11	108505431	108593738	N	.	N	N	1.628547649	97.61532673	5.76E-21	98.9	DM	Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 (3)
EXTL1	1	26019884	26036464	N	.	N	N	0.912447063	91.3121491	1.18E-12	95.2	.	.
EXTL2	1	100872372	100895998	N	.	N	Y	0.183225703	63.41957516	3.16E-05	75.1	.	.
EYA2	20	46894624	47188844	N	.	N	N	0.072745024	55.10794698	0.335504422	34.7	.	.
EYA3	1	27970344	28088696	N	.	N	N	-0.510881113	19.77773919	0.995035731	8.4	.	.
EYS	6	63719980	65707225	N	.	N	N	.	.	8.21E-09	89.2	DM	Retinitis pigmentosa 25, 602772 (3)
EZH1	17	42700275	42745049	N	Viable	N	Y	-0.85044222	10.54002431	0.000641438	66.3	.	.
F11	4	186265945	186288806	N	.	N	Y	-0.664469158	14.90420791	1.91E-22	99.1	DM	Factor XI deficiency, autosomal recessive, 612416 (3); Factor XI deficiency, autosomal dominant, 612416 (3)
F12	5	177402140	177409576	N	.	N	Y	0.270693188	68.73299763	3.46E-06	80.3	DM	Factor XII deficiency, 234000 (3); Angioedema, hereditary, type III, 610618 (3)
F13A1	6	6144085	6321013	N	Viable	N	Y	-0.185075564	36.45308792	0.001027361	64.6	DM	Factor XIIIA deficiency, 613225 (3); {Myocardial infarction, protection against}, 608446 (3); {Venous thrombosis, protection against}, 188050 (3)
F13B	1	197039191	197067267	N	.	N	Y	-0.33433006	27.52213926	2.13E-05	76	DM	Factor XIIIB deficiency, 613235 (3)
F2RL1	5	76818933	76835315	Y	Viable	N	Y	0.124158088	59.0611796	0.002022517	61.8	DP	.
F2RL2	5	76615482	76623434	N	.	N	Y	0.203015042	64.55981941	7.37E-07	83.1	.	.
F2RL3	19	16888860	16892606	N	.	N	Y	1.067001612	93.59842565	0.003022354	60.3	.	.
F8	X	154835788	155026940	N	.	N	Y	-0.051482541	45.63292238	0.999999812	1.2	DM	Hemophilia A, 306700 (3)
F8A1	X	154886349	154888061	N	.	N	N	.	.	.	.	.	.
F8A2	X	155382115	155383230	N	.	N	N	.	.	.	.	.	.
F8A3	X	155456914	155458672	N	.	N	N	.	.	.	.	.	.
FA2H	16	74712955	74774831	N	.	N	Y	-0.066287483	44.66631938	0.726409724	23.8	DM	Spastic paraplegia 35, autosomal recessive, 612319 (3)
FAAH	1	46394265	46413848	N	.	N	Y	-0.497635687	20.31602709	5.93E-07	83.5	DM	Spastic paraplegia 35, autosomal recessive, 612319 (3)
FAAH2	X	57286706	57489196	N	.	N	N	1.015582212	92.95016496	2.46E-17	97.9	DM	.
FAAP100	17	81539885	81553961	N	.	N	N	.	.	.	.	.	.
FAAP20	1	2184461	2212720	N	.	N	N	.	.	.	.	.	.
FAAP24	19	32972209	32978222	N	.	N	N	.	.	.	.	.	.
FABP1	2	88122982	88128116	N	Viable	N	Y	-0.072985841	44.23221624	0.01606198	52.8	FP	.
FABP12	8	81524981	81531378	N	.	N	N	0.632461877	85.11894426	0.00294557	60.4	.	.
FABP2	4	119317250	119322390	N	.	N	Y	0.192492475	63.9636511	0.001177905	64.1	DFP	.
FABP3	1	31365625	31376850	N	.	N	Y	0.071486219	54.9863981	0.354913337	34	DP	.
FABP4	8	81478419	81483263	N	.	N	Y	0.109001675	57.91514731	0.004925642	58.2	DFP	.
FABP5	8	81280363	81284777	N	.	N	Y	0.06302642	54.36707762	0.095838201	43.4	.	.
FABP6	5	160187367	160238735	N	.	N	Y	0.44679135	78.19644614	0.000205946	69.7	DP	.
FABP7	6	122779475	122784074	N	.	N	Y	0.236554885	66.60299821	0.090713461	43.7	DP	.
FABP9	8	81458341	81461579	N	.	N	Y	.	.	0.000340177	68.3	.	.
FADS1	11	61799625	61829318	N	Viable	N	Y	-0.146102415	38.98246223	0.383801127	33.2	.	.
FADS2	11	61792980	61867354	N	.	N	Y	-0.663816607	14.92736007	0.990052486	9.9	DFP	.
FADS3	11	61873519	61892051	N	.	N	N	-0.460273767	21.90195057	0.048872245	47.1	.	.
FADS6	17	74877299	74893781	N	.	N	N	1.012563014	92.90964867	2.48E-07	84.8	.	.
FAF2	5	176447628	176510074	N	.	N	N	-0.119765437	40.78833131	0.998046615	6.9	.	.
FAHD1	16	1826941	1840207	N	.	N	N	0.065090757	54.56387104	1.19E-08	88.7	.	.
FAHD2A	2	95402721	95416616	N	.	N	Y	0.247076574	67.28019911	0.054072034	46.5	.	.
FAHD2B	2	97083583	97094882	N	.	N	N	0.29113834	69.98900272	0.027911384	50	.	.
FAIM	3	138608606	138633376	N	.	N	Y	0.226330975	66.02998206	0.068117194	45.2	.	.
FAIM2	12	49866896	49904217	N	.	N	Y	0.00123959	49.58036696	0.619353001	27	.	.
FAM101A	12	123973215	124316024	N	.	N	N	0.316368397	71.5054697	0.212634236	38.4	.	.
FAM101B	17	439978	445939	N	.	N	Y	.	.	.	.	.	.
FAM102A	9	127940579	127980513	N	.	N	N	-0.627257916	15.94605545	0.430347065	31.9	.	.
FAM102B	1	108560089	108644900	N	.	N	N	0.084729555	56.09191411	0.047930772	47.2	.	.
FAM103A1	15	82986207	82991057	N	.	N	N	0.291946181	70.03530706	0.828445215	20.7	.	.
FAM104A	17	73207353	73236753	N	.	N	Y	0.215958347	65.40487353	0.612044065	27.1	.	.
FAM104B	X	55143102	55161310	N	.	N	N	0.881990556	90.74492099	0.008709939	55.5	.	.
FAM105A	5	14581775	14615007	N	.	N	N	0.806141305	89.25739422	2.33E-07	84.9	.	.
FAM106A	17	18524566	18526846	N	.	N	N	.	.	.	.	.	.
FAM107A	3	58564117	58627610	N	.	N	N	0.111871637	58.12930486	0.001645089	62.7	.	.
FAM107B	10	14518557	14774897	N	.	N	Y	-0.434892888	22.97273832	0.000196116	69.9	.	.
FAM109A	12	111360651	111369121	N	.	N	N	0.423325465	77.03304972	0.005149827	58	.	.
FAM109B	22	42074251	42079441	N	.	N	N	0.387722289	75.27927302	0.000109677	71.6	.	.
FAM110A	20	833715	857463	N	.	N	N	.	.	0.747790603	23.2	.	.
FAM110B	8	57994509	58204279	N	.	N	N	-0.26232271	31.69531747	0.172625631	39.6	.	.
FAM110C	2	38814	46870	N	.	N	N	-0.145145404	39.04034265	8.71E-08	86.3	.	.
FAM110D	1	26159020	26162628	N	.	N	N	.	.	0.550404227	28.6	.	.
FAM111A	11	59142748	59155039	N	.	N	N	-0.577299978	17.43937026	3.22E-09	90	DM	Kenny-Caffey syndrome, type 2, 127000 (3); Gracile bone dysplasia, 602361 (3)
FAM111B	11	59107185	59127410	N	.	N	N	-0.709489106	13.6597789	7.17E-11	93.2	DM?	Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3)
FAM114A1	4	38867677	38945739	N	.	N	N	0.250097881	67.46541645	2.38E-08	87.9	.	.
FAM114A2	5	153990128	154038936	N	.	N	N	-0.519188205	19.50570122	3.08E-07	84.5	.	.
FAM117A	17	49710332	49789180	N	.	N	N	-0.594373051	16.88371824	1.22E-05	77.6	.	.
FAM117B	2	202635188	202769757	N	.	N	Y	-0.383328502	25.24743879	0.067387015	45.3	.	.
FAM118A	22	45308968	45341955	N	.	N	N	-0.583998323	17.25415292	0.591868565	27.7	.	.
FAM118B	11	126211414	126262986	N	.	N	N	-0.316758145	28.47137813	0.390427139	33	.	.
FAM120A	9	93451722	93566107	N	.	N	N	-1.702899586	2.436765642	0.99990705	3.7	DM	.
FAM120AOS	9	93446494	93453592	N	.	N	N	0.414865996	76.60473462	0.514390707	29.6	.	.
FAM120B	6	170290703	170407065	N	.	N	N	0.533608827	81.80239625	2.34E-08	88	DM?	.
FAM120C	X	54068324	54183281	N	.	N	N	-0.638435006	15.72032182	0.973037035	12.7	.	.
FAM122A	9	68780055	68784608	N	.	N	N	-0.250187888	32.45355096	0.800532188	21.6	.	.
FAM122B	X	134769566	134797232	N	.	N	N	0.260977174	68.09052498	0.757591089	22.9	.	.
FAM122C	X	134796789	134854610	N	.	N	N	0.428916211	77.3340279	0.174595944	39.6	.	.
FAM124A	13	51222334	51284241	N	.	N	N	0.267822797	68.56514441	5.43E-07	83.6	.	.
FAM124B	2	224378698	224402085	N	.	N	N	0.243250221	67.10655785	0.002299402	61.4	.	.
FAM126A	7	22889371	23014130	N	.	N	N	0.206841947	64.8202813	0.803307845	21.5	DM	Leukodystrophy, hypomyelinating, 5, 610532 (3)
FAM126B	2	200973718	201071671	N	.	N	N	-1.100931968	6.552063437	0.979818816	11.8	.	.
FAM127A	X	135032366	135033546	N	.	N	N	0.030143764	51.8087631	0.599977363	27.5	.	.
FAM127B	X	135050932	135052196	N	.	N	N	0.245014457	67.16443827	0.027908298	50	.	.
FAM127C	X	135020504	135022529	N	.	N	N	0.131510986	59.50685883	0.025598157	50.4	.	.
FAM129A	1	184790724	184974550	N	.	N	Y	0.394879236	75.56288708	1.40E-13	96	.	.
FAM129B	9	127505339	127578989	N	.	N	N	-0.089299094	42.84308618	0.096703214	43.4	.	.
FAM129C	19	17523301	17553839	N	.	N	N	1.382470236	96.30144122	1.34E-10	92.7	.	.
FAM131A	3	184335926	184346275	N	.	N	N	-0.240770687	32.9976269	0.031328424	49.5	.	.
FAM131B	7	143353400	143362770	N	.	N	N	-0.277328762	30.80974706	0.921928278	16.6	.	.
FAM131C	1	16057769	16073632	N	.	N	N	1.245184528	95.39850669	0.276924373	36.3	.	.
FAM132A	1	1242446	1246722	N	.	N	N	.	.	4.68E-05	74.1	.	.
FAM132B	2	238158982	238168900	N	.	N	Y	.	.	.	.	.	.
FAM133A	X	93674013	93712274	N	.	N	N	0.274070774	68.90085084	0.659793341	25.8	.	.
FAM133B	7	92560793	92590394	N	.	N	N	-0.149930626	38.75094056	0.000297399	68.7	.	.
FAM134A	2	219176225	219185479	N	.	N	N	-0.269673173	31.29015454	0.758589563	22.9	.	.
FAM134B	5	16473038	16617058	N	.	N	N	-0.247316664	32.6098281	0.005651396	57.5	DM	Neuropathy, hereditary sensory and autonomic, type IIB, 613115 (3)
FAM134C	17	42579513	42610623	N	Viable	N	Y	-0.465709488	21.64727673	0.145899134	40.8	.	.
FAM135A	6	70412941	70561174	N	.	N	N	-0.606878479	16.54801181	0.78712561	22.1	.	.
FAM135B	8	138130023	138496822	N	.	N	N	-1.591865586	2.859292701	0.999998682	1.8	.	.
FAM136A	2	70295975	70302090	N	.	N	N	0.983361131	92.57973028	0.001478617	63.1	.	.
FAM13A	4	88725955	89111398	N	.	N	N	-0.249584647	32.47091509	2.45E-14	96.5	.	.
FAM13C	10	59246129	59363181	N	.	N	N	-0.081141613	43.508711	0.000441696	67.4	.	.
FAM149A	4	186104419	186172667	N	.	N	N	2.063655672	98.66875036	0.00644453	56.9	.	.
FAM149B1	10	73168166	73244504	N	.	N	N	.	.	.	.	.	.
FAM150A	8	52534037	52565507	N	.	N	N	-0.014874933	48.27805753	0.001845521	62.2	.	.
FAM150B	2	279558	288851	N	.	N	N	.	.	0.384937771	33.2	.	.
FAM151A	1	54609182	54623556	N	Viable	N	Y	1.422864858	96.50981073	3.92E-13	95.6	.	.
FAM151B	5	80487969	80542563	N	Viable	N	Y	0.643789018	85.47201482	8.21E-07	82.9	.	.
FAM153A	5	177707981	177783398	N	.	N	N	.	.	0.276667825	36.3	.	.
FAM153B	5	176060689	176132258	N	.	N	N	1.663666097	97.78317995	0.647490029	26.1	.	.
FAM153C	5	178006405	178055559	N	.	N	N	.	.	0.848853442	19.9	.	.
FAM155A	13	107163510	107866735	N	.	N	N	-0.394506329	24.68021068	0.800415326	21.7	.	.
FAM155B	X	69505241	69532508	N	.	N	N	0.252666418	67.59275337	0.870611038	19	.	.
FAM156A	X	52926402	52995472	N	.	N	N	.	.	.	.	.	.
FAM156B	X	52891306	52908560	N	.	N	N	.	.	.	.	.	.
FAM159A	1	52633344	52669683	N	.	N	N	0.34829376	73.28818661	0.000284218	68.8	.	.
FAM159B	5	64690308	64718090	N	.	N	N	.	.	0.101184302	43	.	.
FAM160A1	4	151409216	151663632	N	.	N	N	.	.	.	.	.	.
FAM160A2	11	6211335	6234711	N	.	N	N	0.002802409	49.67876367	0.999881559	3.9	.	.
FAM160B1	10	114821744	114899832	N	.	N	N	-1.129837298	6.274237425	0.999984985	2.7	.	.
FAM160B2	8	22089159	22104898	N	.	N	N	-0.214131045	34.67037101	2.05E-05	76.2	.	.
FAM161A	2	61824854	61854143	N	Viable	N	Y	0.868383761	90.54812757	3.03E-09	90.1	DM	Retinitis pigmentosa 28, 606068 (3)
FAM161B	14	73931501	73950414	N	.	N	N	0.660205663	85.92927013	9.86E-11	92.9	.	.
FAM162A	3	122384176	122412334	N	.	N	N	0.404494149	76.04329455	0.000629842	66.3	.	.
FAM162B	6	116752197	116765723	N	.	N	N	0.533006157	81.75030387	0.000825835	65.4	.	.
FAM163A	1	179743163	179816198	N	Viable	N	Y	0.41390976	76.54106616	0.579850964	28	.	.
FAM163B	9	133578415	133586197	N	.	N	N	.	.	0.428150995	32	.	.
FAM166A	9	137243584	137247770	N	.	N	N	0.992114278	92.67812699	1.70E-11	94	DM?	.
FAM166B	9	35561831	35563899	N	.	N	N	0.718823127	87.39364473	3.85E-06	80.1	.	.
FAM167A	8	11421463	11474715	N	.	N	N	0.588543737	83.79927071	0.000192998	69.9	.	.
FAM167B	1	32247233	32248856	N	.	N	N	0.411041265	76.39636511	0.002691153	60.8	.	.
FAM168A	11	73400487	73598189	N	.	N	N	-0.449096955	22.33605371	0.951667905	14.6	.	.
FAM168B	2	131047876	131093460	N	.	N	N	-0.224004258	34.09156682	0.043771494	47.7	.	.
FAM169A	5	74777574	74866951	N	.	N	N	-0.383175561	25.25901488	0.998576225	6.4	.	.
FAM169B	15	98437162	98514382	N	.	N	N	1.440296905	96.66029982	0.001356899	63.5	.	.
FAM170A	5	119629559	119635822	N	.	N	N	0.982548198	92.53921398	.	.	.	.
FAM170B	10	49131154	49134008	N	.	N	N	.	.	.	.	.	.
FAM171A1	10	15211643	15371062	N	.	N	N	-0.857503418	10.42426347	0.987016298	10.6	.	.
FAM171A2	17	44353215	44363875	N	.	N	N	.	.	.	.	.	.
FAM171B	2	186693971	186765965	N	.	N	N	-1.103500292	6.511547144	0.057421357	46.2	.	.
FAM172A	5	93618069	94111699	N	.	N	N	-0.426432699	23.27950454	0.018287109	52.1	.	.
FAM173A	16	720581	722601	N	.	N	N	.	.	0.00048241	67.1	.	.
FAM173B	5	10226330	10249897	N	.	N	N	0.336156875	72.63992591	2.44E-07	84.9	.	.
FAM174A	5	100535305	100586741	N	.	N	N	0.005872186	49.93922556	0.000618294	66.4	.	.
FAM174B	15	92617443	92809884	N	.	N	N	0.329462031	72.26949123	0.00994225	54.9	.	.
FAM175A	4	83459517	83523348	N	.	N	N	-0.048410911	45.9396886	0.314878215	35.3	DM	.
FAM175B	10	124801785	124836670	N	.	N	Y	-0.146906657	38.94194594	0.086852197	44	.	.
FAM177A1	14	35044907	35113130	N	.	N	N	-0.045692193	46.15384615	0.002067883	61.7	.	.
FAM177B	1	222737207	222750805	N	.	N	N	0.427960039	77.28193552	9.21E-06	78.3	.	.
FAM178B	2	96875882	97018438	N	.	N	N	.	.	8.70E-05	72.3	.	.
FAM179A	2	28956611	29061373	N	.	N	N	3.261713327	99.63535336	2.53E-20	98.8	.	.
FAM179B	14	44962208	45074431	N	.	N	N	-1.36754803	4.16160213	2.89E-06	80.6	.	.
FAM180A	7	135728348	135748846	N	.	N	N	0.711319676	87.16212305	0.33707826	34.7	.	.
FAM180B	11	47586693	47589194	N	.	N	N	.	.	0.315838165	35.3	.	.
FAM181A	14	93918894	93929608	N	.	N	N	0.296878173	70.31892111	0.024983863	50.5	.	.
FAM181B	11	82729941	82733864	N	.	N	N	.	.	0.216567008	38.2	.	.
FAM182B	20	25763466	25868225	N	.	N	N	.	.	.	.	.	.
FAM183A	1	43145153	43156396	N	.	N	N	0.602448269	84.17549343	0.029326736	49.8	.	.
FAM184A	6	118959763	119149387	N	.	N	N	-0.329398138	27.76523702	2.04E-13	95.8	.	.
FAM184B	4	17629306	17781512	N	.	N	Y	.	.	.	.	.	.
FAM185A	7	102748971	102809225	N	.	N	N	.	.	.	.	.	.
FAM186A	12	50326230	50396622	N	.	N	N	.	.	.	.	.	.
FAM186B	12	49582885	49605639	N	Viable	N	Y	0.860081217	90.36869827	2.40E-12	94.9	.	.
FAM187A	17	44899712	44905390	N	.	N	N	.	.	.	.	.	.
FAM187B	19	35224800	35228729	N	.	N	N	1.08951302	93.84152341	3.67E-06	80.2	FTV	.
FAM188A	10	15778170	15860520	N	.	N	N	-0.411426546	23.88724894	0.629692868	26.7	DFP	.
FAM188B	7	30771417	30892387	N	.	N	N	1.604093597	97.51693002	2.25E-15	97.1	.	.
FAM189A1	15	29120254	29570723	N	.	N	N	.	.	.	.	.	.
FAM189A2	9	69324572	69392455	N	.	N	N	0.523884453	81.41459744	8.92E-06	78.3	.	.
FAM189B	1	155247205	155255483	N	.	N	N	0.185289731	63.54112404	0.000482815	67.1	.	.
FAM192A	16	57152466	57186116	N	.	N	N	-0.236138921	33.29860508	0.944099351	15.3	.	.
FAM193A	4	2625261	2732565	N	.	N	N	-0.482044269	20.89483128	0.997818289	7.1	.	.
FAM193B	5	177519788	177554541	N	.	N	N	0.176829957	62.97389593	0.923710453	16.5	.	.
FAM195A	16	636817	648474	N	.	N	N	.	.	0.053361787	46.6	.	.
FAM195B	17	81822361	81833302	N	.	N	N	.	.	0.317596824	35.2	.	.
FAM196A	10	127135426	127196158	N	.	N	N	-0.138294989	39.54969034	0.849026865	19.9	.	.
FAM196B	5	169864264	169980740	N	.	N	N	.	.	.	.	.	.
FAM198A	3	42979267	43060211	N	.	N	N	.	.	.	.	.	.
FAM198B	4	158124474	158173318	N	.	N	N	0.361686411	74.00011576	2.50E-06	80.8	.	.
FAM199X	X	104166620	104195902	N	.	N	N	-0.08048891	43.56080338	0.926151028	16.3	.	.
FAM19A1	3	68004216	68545625	N	.	N	N	-0.239967611	33.04971928	0.861963101	19.4	.	.
FAM19A2	12	61708259	62279150	N	.	N	N	0.266567586	68.44359553	0.54745717	28.7	.	.
FAM19A3	1	112720419	112727235	N	.	N	N	0.423325465	77.03304972	0.027147378	50.2	.	.
FAM19A4	3	68731766	68932610	N	.	N	N	0.398903333	75.78283267	0.19814882	38.8	.	.
FAM19A5	22	48489460	48850912	N	.	N	N	0.056480057	53.81721364	0.310031382	35.5	.	.
FAM200A	7	99546308	99558536	N	.	N	N	.	.	6.01E-05	73.4	.	.
FAM200B	4	15681662	15705565	N	.	N	N	.	.	.	.	.	.
FAM204A	10	118297930	118342328	N	.	N	N	-0.132053341	39.94906523	0.050712422	46.9	.	.
FAM205A	9	34723055	34729467	N	.	N	N	.	.	.	.	.	.
FAM206A	9	108934181	108950744	N	.	N	N	0.36138737	73.96538751	0.003362344	59.9	.	.
FAM207A	21	44940010	44976989	N	.	N	N	0.005872186	49.93922556	0.039581765	48.4	.	.
FAM208B	10	5684838	5763740	N	.	N	N	0.534009862	81.82554842	0.965063265	13.5	.	.
FAM209A	20	56517187	56526142	N	.	N	N	0.786354605	88.89274758	0.031677045	49.4	.	.
FAM209B	20	56533246	56536520	N	Viable	N	Y	0.376393738	74.74098512	0.02972064	49.7	.	.
FAM20A	17	68535113	68601389	Y	Viable	N	Y	0.721838716	87.4862534	0.002501122	61.1	DM	Amelogenesis imperfecta, type IG (enamel-renal syndrome), 204690 (3)
FAM210B	20	56358915	56368663	N	Viable	N	Y	-0.058936621	45.1930312	0.072330494	44.9	.	.
FAM212B	1	111680630	111755824	N	.	N	N	0.033165214	52.10395323	0.003590517	59.6	.	.
FAM213A	10	80407829	80437115	N	.	N	N	0.165349748	62.17514615	0.000157315	70.5	.	.
FAM213B	1	2586491	2591469	N	.	N	N	.	.	0.0001667	70.3	.	.
FAM214A	15	52581317	52709817	N	.	N	N	0.16212845	61.93204839	0.966998569	13.4	.	.
FAM214B	9	35104112	35116341	N	.	N	N	0.319387303	71.73699138	0.387716111	33.1	.	.
FAM216A	12	110468364	110490385	N	Viable	N	Y	0.309821667	71.05979047	0.001116299	64.3	.	.
FAM216B	13	42781550	42791549	N	.	N	N	-0.079531963	43.66498813	9.42E-05	72.1	.	.
FAM217A	6	4049434	4087344	N	.	N	N	0.760312099	88.31973143	1.67E-06	81.7	.	.
FAM217B	20	59933764	59948680	N	.	N	N	-0.13094377	40.00115761	0.001081324	64.4	.	.
FAM218A	4	164956948	164959122	N	.	N	N	0.579938151	83.45198819	0.001826325	62.3	.	.
FAM219A	9	34398184	34458570	N	.	N	N	0.215958347	65.40487353	0.272603036	36.4	.	.
FAM219B	15	74899987	74907121	N	.	N	N	0.322915185	71.92799676	0.001227651	63.9	.	.
FAM21A	10	50067888	50133506	N	.	N	N	.	.	.	.	.	.
FAM21C	10	45727200	45792961	N	.	N	N	.	.	.	.	.	.
FAM220A	7	6329409	6348981	N	.	N	N	0.391548194	75.45291428	1.23E-05	77.5	.	.
FAM221A	7	23680130	23703249	N	.	N	N	0.752660945	88.14609018	5.10E-09	89.6	.	.
FAM221B	9	35816391	35828747	N	.	N	N	0.736697979	87.7756555	4.05E-06	79.9	.	.
FAM222A	12	109714228	109770507	N	.	N	N	0.54352436	82.19019506	0.400389072	32.8	.	.
FAM222B	17	28755978	28855232	N	.	N	N	-0.08673095	43.07460786	0.549446554	28.6	.	.
FAM227A	22	38578120	38656629	N	.	N	N	.	.	.	.	.	.
FAM227B	15	49326962	49620931	N	.	N	N	0.518294668	81.20622793	2.74E-16	97.6	.	.
FAM228A	2	24175069	24200849	N	.	N	N	0.656883854	85.81350929	0.00040974	67.7	.	.
FAM228B	2	24076526	24169640	N	.	N	N	.	.	.	.	.	.
FAM229A	1	32361270	32364278	N	.	N	N	.	.	.	.	.	.
FAM229B	6	112087599	112102790	N	.	N	N	0.395078624	75.58603924	0.549545407	28.6	.	.
FAM231A	1	16673003	16673512	N	.	N	N	.	.	.	.	.	.
FAM231C	1	16733951	16734461	N	.	N	N	.	.	.	.	.	.
FAM231D	1	149702328	149705721	N	.	N	N	.	.	.	.	.	.
FAM24A	10	122910701	122913111	N	.	N	N	0.199039114	64.30514557	0.167839102	39.8	.	.
FAM24B	10	122849078	122879641	N	.	N	N	0.547056981	82.31174394	0.033649941	49.1	.	.
FAM25A	10	87020306	87024730	N	.	N	N	.	.	.	.	.	.
FAM25C	10	47995355	47999791	N	.	N	N	.	.	.	.	.	.
FAM25G	10	47487219	47491693	N	.	N	N	.	.	.	.	.	.
FAM26D	6	116529013	116558868	N	.	N	N	0.450469806	78.36429936	0.033838822	49.1	.	.
FAM26E	6	116511646	116524792	N	.	N	N	0.222654188	65.80424842	0.001108388	64.3	.	.
FAM26F	6	116461370	116463779	N	.	N	N	.	.	1.80E-05	76.5	.	.
FAM32A	19	16185380	16192046	N	.	N	N	.	.	0.009052868	55.3	.	.
FAM35A	10	87094161	87191468	N	.	N	N	0.658136345	85.85981363	0.156586369	40.3	.	.
FAM3A	X	154506159	154516242	N	.	N	N	0.003958565	49.8061006	0.844646764	20.1	.	.
FAM3B	21	41304212	41357431	N	.	N	Y	0.410231756	76.34427273	1.18E-06	82.3	.	.
FAM3C	7	121348851	121396364	N	.	N	N	-0.314041164	28.6045031	0.001081075	64.4	DM	.
FAM3D	3	58633946	58666848	N	.	N	Y	-0.134771456	39.75805985	0.004030909	59	.	.
FAM43A	3	194686544	194689037	N	.	N	N	.	.	.	.	.	.
FAM43B	1	20552439	20555010	N	.	N	N	.	.	.	.	.	.
FAM45A	10	119104086	119137984	N	.	N	N	-0.30079494	29.40904092	0.000243199	69.2	.	.
FAM46A	6	81491439	81752774	N	.	N	N	-0.284831791	30.36985588	0.347457969	34.3	.	.
FAM46B	1	27005020	27012836	N	.	N	N	-0.393549347	24.76703131	0.051189875	46.9	.	.
FAM46D	X	80335504	80445311	N	.	N	N	0.090319161	56.46813683	0.674763512	25.3	.	.
FAM47A	X	34129756	34132314	N	.	N	N	0.602896139	84.20443364	0.748400418	23.2	.	.
FAM47B	X	34942796	34944915	N	.	N	N	1.1685284	94.72709382	0.000117993	71.4	FTV	.
FAM47C	X	37008397	37011666	N	.	N	N	1.790926265	98.15940267	0.057797311	46.2	.	.
FAM47E	4	76214040	76283780	N	.	N	N	.	.	0.341134282	34.5	.	.
FAM47E-STBD1	4	76306026	76311599	N	.	N	N	.	.	1.58E-07	85.6	.	.
FAM49A	2	16549459	16666331	N	.	N	N	-0.375023253	25.68154193	0.805360676	21.4	.	.
FAM50A	X	154444126	154450654	N	.	N	N	-0.049519725	45.82392777	0.945400813	15.2	.	.
FAM50B	6	3849386	3851317	N	.	N	N	-0.314843927	28.5639868	0.195542493	38.8	.	.
FAM53A	4	1617915	1684302	N	.	N	N	1.410421111	96.4229901	3.01E-05	75.2	.	.
FAM53B	10	124619292	124744269	N	Viable	N	Y	0.188965718	63.72634138	0.400479602	32.7	.	.
FAM53C	5	138331935	138349729	N	.	N	N	-0.129986883	40.1111304	0.639249208	26.3	.	.
FAM57A	17	732412	742972	N	.	N	N	0.379262743	74.89726226	0.020765198	51.4	.	.
FAM57B	16	30024427	30052978	N	.	N	N	-0.312126643	28.79550848	0.285736246	36.1	.	.
FAM58A	X	153587919	153600045	N	.	N	N	.	.	0.840139168	20.3	DM	STAR syndrome, 300707 (3)
FAM60A	12	31280584	31327058	N	.	N	N	0.048020238	53.25577357	0.93695984	15.8	.	.
FAM63A	1	150996086	151008375	N	Viable	N	Y	0.327847069	72.2231869	8.24E-06	78.6	.	.
FAM63B	15	58771192	58861900	N	.	N	N	0.025008309	51.42096429	0.189061306	39	DM?	.
FAM64A	17	6444415	6451469	N	.	N	N	-0.058784478	45.21039532	0.239012864	37.4	DM?	.
FAM65A	16	67518418	67546788	N	.	N	N	-1.129422189	6.280025467	0.895578366	17.9	.	.
FAM65B	6	24804282	25042168	N	.	N	N	0.46481599	79.08201655	0.971310089	12.9	.	?Deafness, autosomal recessive 104, 616515 (3)
FAM65C	20	50586108	50691528	N	.	N	N	1.356625739	96.15095213	1.45E-12	95.1	.	.
FAM69A	1	92832737	92961522	N	.	N	N	.	.	0.090865226	43.7	.	.
FAM69B	9	136712570	136724050	N	.	N	N	-0.442243367	22.62545581	0.003577159	59.6	.	.
FAM69C	18	74434099	74457944	N	.	N	N	.	.	0.016640101	52.6	.	.
FAM71A	1	212624474	212626778	N	.	N	N	0.754875774	88.23291081	2.16E-10	92.4	DM?	.
FAM71B	5	157161846	157166264	N	.	N	N	1.313975629	95.89049025	0.002329674	61.4	.	.
FAM71C	12	99647753	99650046	N	.	N	N	0.675714658	86.31128089	0.029997997	49.6	FTV	.
FAM71D	14	67189393	67228550	N	.	N	N	-0.496832081	20.33339121	.	.	.	.
FAM71E1	19	50466785	50476753	N	.	N	N	0.509685942	80.85894542	0.006132393	57.1	.	.
FAM71E2	19	55354908	55363260	N	.	N	N	.	.	.	.	.	.
FAM71F1	7	128709061	128731743	N	.	N	N	0.518145495	81.19465185	8.95E-06	78.3	.	.
FAM71F2	7	128672288	128687872	N	.	N	N	0.691677544	86.71065579	0.062473892	45.7	.	.
FAM72A	1	206186179	206204414	N	.	N	N	.	.	.	.	.	.
FAM72B	1	121167646	121185539	N	.	N	N	.	.	0.251829881	37	.	.
FAM72C	1	143955364	143971965	N	.	N	N	.	.	.	.	.	.
FAM72D	1	145096000	145112696	N	.	N	N	.	.	0.5808181	27.9	.	.
FAM73A	1	77779624	77879539	N	Viable	N	Y	-0.68521557	14.38328413	0.000750459	65.7	.	.
FAM73B	9	129036621	129072082	N	.	N	Y	0.175067916	62.86971118	0.003518966	59.7	.	.
FAM76A	1	27725979	27763122	N	.	N	N	0.119374702	58.69074492	0.000561029	66.7	.	.
FAM76B	11	95768942	95790409	N	.	N	N	-0.355230595	26.57290039	0.022449199	51.1	.	.
FAM78A	9	131258076	131276547	N	.	N	N	-0.234224724	33.42015396	0.480800491	30.6	.	.
FAM78B	1	166057426	166166969	N	.	N	N	-0.002587674	49.23887249	0.770974374	22.6	.	.
FAM81A	15	59372693	59523549	N	.	N	N	-0.316758145	28.47137813	0.48707232	30.3	.	.
FAM81B	5	95391344	95450454	N	.	N	N	0.651439248	85.66880824	5.12E-06	79.5	DM?	.
FAM83A	8	123178960	123210079	N	.	N	N	1.16742048	94.7097297	0.002865746	60.6	.	.
FAM83B	6	54846771	54942022	N	.	N	N	-0.825577938	11.04358396	7.60E-08	86.5	.	.
FAM83C	20	35285731	35292401	N	.	N	N	0.591719213	83.86872721	3.49E-05	74.8	.	.
FAM83D	20	38926312	38953106	N	.	N	N	0.056782277	53.85194189	2.58E-05	75.6	.	.
FAM83E	19	48600810	48614854	N	.	N	N	1.228408518	95.29432193	6.62E-06	79.1	.	.
FAM83F	22	39994949	40043529	N	.	N	N	1.007928055	92.86913237	0.000400741	67.7	.	.
FAM83G	17	18968789	19004804	N	.	N	Y	-0.535809982	18.74746773	0.015726782	52.9	.	.
FAM83H	8	143723933	143733801	N	.	N	N	0.246731277	67.26283498	0.88482471	18.4	DM	Amelogenesis imperfecta, type III, 130900 (3)
FAM84A	2	14632686	14650814	N	.	N	N	0.014332026	50.57012213	0.087816303	43.9	.	.
FAM84B	8	126552442	126558393	N	.	N	N	-0.135728413	39.6828153	0.015691006	52.9	.	.
FAM86B1	8	12182096	12194133	N	.	N	N	.	.	0.744460341	23.3	.	.
FAM86B2	8	12425614	12436343	N	.	N	N	.	.	0.674121349	25.4	.	.
FAM86C1	11	71787510	71801236	N	.	N	N	1.283660986	95.69369682	1.48E-08	88.5	.	.
FAM89A	1	231018958	231040246	N	.	N	N	.	.	0.009640542	55.1	.	.
FAM89B	11	65572349	65574198	N	.	N	N	.	.	0.029138465	49.8	.	.
FAM8A1	6	17600355	17611719	N	.	N	N	-0.188249534	36.2562945	0.170367796	39.7	DM?	.
FAM90A1	12	8221260	8227618	N	.	N	N	2.226070996	98.88290791	6.49E-12	94.5	.	.
FAM90A26	4	9170409	9176730	N	.	N	N	.	.	.	.	.	.
FAM91A1	8	123768456	123815452	N	.	N	N	-0.69830864	13.97233316	0.515693527	29.5	DM?	.
FAM92A1	8	93698561	93731527	N	.	N	N	-0.031643	47.17832957	3.69E-05	74.7	.	.
FAM92B	16	85098358	85112508	N	.	N	N	0.622382754	84.82375412	3.59E-11	93.6	.	.
FAM96A	15	64072559	64094018	N	.	N	Y	-0.20053791	35.44596863	0.013450896	53.7	.	.
FAM96B	16	66932055	66934423	N	.	N	N	-0.072985841	44.23221624	0.002103752	61.7	.	.
FAM98A	2	33583658	33599382	N	.	N	N	0.171240551	62.60924929	0.689414914	24.9	.	.
FAM98B	15	38454127	38487710	N	.	N	N	-0.083207293	43.33506975	0.394827183	32.9	.	.
FAM98C	19	38403135	38409088	N	.	N	N	0.988139789	92.62024657	3.57E-10	92.1	.	.
FAM9A	X	8790795	8801383	N	.	N	N	0.681305964	86.45598194	2.86E-05	75.3	.	.
FAM9B	X	9024232	9164639	N	.	N	N	0.351971606	73.48498003	9.50E-05	72.1	.	.
FAM9C	X	13035618	13044682	N	.	N	N	0.381984452	75.00723505	5.54E-05	73.6	DM?	.
FAN1	15	30903852	30943108	N	Viable	N	Y	0.520677151	81.26989639	1.47E-15	97.2	DM	Interstitial nephritis, karyomegalic, 614817 (3)
FANCA	16	89737549	89816657	N	.	N	Y	-0.291025439	29.9589049	2.08E-34	99.8	DM	Fanconi anemia, complementation group A, 227650 (3)
FANCB	X	14843407	14873069	N	.	N	Y	-0.126159463	40.331076	0.988393525	10.3	DM	Fanconi anemia, complementation group B, 300514 (3)
FANCC	9	95099054	95317709	N	.	N	Y	-0.356839227	26.4918678	5.88E-10	91.6	DM	Fanconi anemia, complementation group C, 227645 (3)
FANCD2OS	3	10081317	10108231	N	.	N	N	0.907368144	91.23111651	0.048454315	47.2	.	.
FANCE	6	35452361	35467103	N	.	N	N	0.593326484	83.93239567	0.003138899	60.1	DM	Fanconi anemia, complementation group E, 600901 (3)
FANCF	11	22622519	22626787	N	.	N	N	0.115849285	58.42449499	0.003814534	59.3	DM	Fanconi anemia, complementation group F, 603467 (3)
FANCG	9	35073835	35080016	N	.	N	Y	0.924582316	91.59576315	9.75E-09	88.9	DM	Fanconi anemia, complementation group G, 614082 (3)
FANCI	15	89243949	89317261	N	.	N	Y	-0.720253809	13.39352897	5.17E-19	98.4	DM	Fanconi anemia, complementation group I, 609053 (3)
FANCL	2	58159243	58241372	Y	Viable	N	Y	0.599873048	84.11761301	2.10E-08	88.1	DM	Fanconi anemia, complementation group L, 614083 (3)
FANCM	14	45135940	45200890	N	.	N	Y	0.961391665	92.21508364	6.24E-12	94.5	DM	.
FANK1	10	125896539	126009592	N	.	N	N	0.361535788	73.98853968	0.000115654	71.4	.	.
FAP	2	162170684	162245151	N	.	N	Y	-1.026550089	7.524454477	3.27E-11	93.6	.	.
FAR1	11	13668670	13732346	N	.	N	N	-0.28674597	30.23094287	0.879567462	18.6	.	Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 (3)
FAR2	12	29149103	29340980	N	Viable	N	Y	-0.144992854	39.06349482	0.922173888	16.6	.	.
FARP1	13	98142562	98455176	N	Viable	N	Y	-0.548621403	18.25548417	0.045263074	47.5	.	.
FARP2	2	241356243	241494841	N	.	N	Y	1.55576962	97.25068009	1.98E-20	98.8	DP	.
FARS2	6	5261044	5771580	N	.	N	N	0.21530172	65.35278115	4.54E-06	79.7	DM	Combined oxidative phosphorylation deficiency 14, 614946 (3)
FARSB	2	222570536	222656337	N	.	N	N	-0.307188276	29.02703016	0.900979754	17.7	.	.
FAS	10	88990531	89015785	N	.	N	Y	0.243250221	67.10655785	0.726173344	23.9	DM	{Autoimmune lymphoproliferative syndrome}, 601859 (3); Squamous cell carcinoma, burn scar-related, somatic (3); Autoimmune lymphoproliferative syndrome, type IA, 601859 (3)
FASLG	1	172659018	172666874	N	.	N	Y	0.000282778	49.45881808	0.611670214	27.1	DM	Autoimmune lymphoproliferative syndrome, type IB, 601859 (3); {Lung cancer, susceptibility to}, 211980 (3)
FASTK	7	151076593	151080866	N	Viable	N	Y	-0.060546352	45.05411819	0.030531352	49.5	.	.
FASTKD1	2	169529749	169573875	N	.	N	N	1.135797669	94.39717544	1.65E-12	95.1	FTV	.
FASTKD2	2	206765357	206792509	N	.	N	N	0.160061943	61.76419517	4.03E-06	80	DM	?Mitochondrial complex IV deficiency, 220110 (3)
FASTKD3	5	7859159	7869037	N	.	N	N	-0.191772697	36.06528911	2.49E-10	92.3	.	.
FASTKD5	20	3146519	3159897	N	.	N	N	0.270845681	68.73878567	3.43E-06	80.3	.	.
FAT2	5	151504093	151568944	N	.	N	Y	0.710937291	87.15633501	7.35E-11	93.1	DM?	.
FAT3	11	92352096	92896470	N	.	N	Y	.	.	0.999999814	1.2	DM?	.
FATE1	X	151716035	151723194	N	.	N	N	-0.018550615	48.01759565	0.03446373	49	.	.
FAU	11	65120628	65122473	N	.	N	N	0.130554386	59.44897841	0.768145175	22.7	.	.
FAXC	6	99271169	99350062	N	.	N	N	-0.337353053	27.42374255	0.872413322	19	.	.
FAXDC2	5	154818491	154859252	N	.	N	N	0.883088819	90.78543729	1.48E-06	81.9	.	.
FBF1	17	75909574	75941140	N	.	N	N	1.280452044	95.64739249	1.14E-19	98.6	.	.
FBLIM1	1	15756607	15786594	N	.	N	Y	-0.166544931	37.66857672	0.00078906	65.5	DP	.
FBLL1	5	168529116	168530634	N	.	N	N	.	.	.	.	.	.
FBLN2	3	13549131	13638422	N	.	N	N	0.367739397	74.24321352	0.629825153	26.7	DM	.
FBLN5	14	91869412	91947987	N	.	N	Y	-0.25849473	31.97314349	0.995790693	8.1	DM	Cutis laxa, autosomal recessive, type IA, 219100 (3); Cutis laxa, autosomal dominant 2, 614434 (3); Macular degeneration, age-related, 3, 608895 (3)
FBLN7	2	112138385	112188216	N	Viable	N	Y	0.17587319	62.9275916	1.58E-05	76.9	.	.
FBN2	5	128257909	128659185	N	.	N	Y	-1.415813552	3.831683741	0.999999992	0.8	DM	Contractural arachnodactyly, congenital, 121050 (3); Macular degeneration, early-onset, 616118 (3)
FBN3	19	8065402	8149846	N	.	N	N	5.419240442	99.86108699	1.35E-27	99.5	DP	.
FBP1	9	94603133	94640249	N	.	N	N	0.050084766	53.41783875	0.098590793	43.2	DM	Fructose-1,6-bisphosphatase deficiency, 229700 (3)
FBRS	16	30658431	30670814	N	.	N	N	.	.	0.981524682	11.5	.	.
FBRSL1	12	132489551	132585188	N	.	N	N	.	.	.	.	.	.
FBXL12	19	9810267	9827816	N	.	N	N	0.352119595	73.52549632	0.014518338	53.3	.	.
FBXL13	7	102813230	103074843	N	.	N	N	0.086945846	56.21346299	1.66E-11	94	.	.
FBXL14	12	1565993	1594165	N	.	N	N	-0.823301011	11.09567633	0.405270086	32.6	.	.
FBXL15	10	102419189	102423136	N	.	N	N	0.063983137	54.4886265	0.002101117	61.7	.	.
FBXL17	5	107859035	108382098	N	.	N	N	.	.	0.977900472	12.1	.	.
FBXL18	7	5431335	5513798	N	.	N	N	-0.375521858	25.65838977	2.57E-07	84.8	.	.
FBXL19	16	30923055	30948783	N	.	N	N	-0.30734089	29.00966603	0.982522203	11.4	.	.
FBXL2	3	33277025	33403662	N	.	N	N	-0.506249788	19.96874457	0.216479061	38.2	.	.
FBXL22	15	63597353	63602428	N	Viable	N	Y	0.145710487	60.67604329	0.000439659	67.4	.	.
FBXL3	13	76992598	77027195	N	.	N	Y	-0.469691512	21.4504833	0.251434579	37.1	.	.
FBXL4	6	98868538	98948006	N	.	N	N	-0.350292913	26.77548185	0.007908799	56	.	Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 (3)
FBXL6	8	144355431	144359376	N	.	N	N	0.189117027	63.73212942	3.70E-06	80.1	DM?	.
FBXL7	5	15500196	15939795	N	.	N	N	-0.907598212	9.440296348	0.200106852	38.7	.	.
FBXL8	16	67159931	67164570	N	.	N	N	.	.	0.014439075	53.4	.	.
FBXO10	9	37510892	37576349	N	.	N	N	-0.898843902	9.613937605	0.001492532	63	DM?	.
FBXO15	18	74073353	74147865	N	.	N	Y	0.348442859	73.32291486	0.027470177	50.1	.	.
FBXO17	19	38941401	38975910	N	.	N	N	0.324827936	72.00902935	1.23E-07	85.9	.	.
FBXO18	10	5890203	5937594	N	.	N	N	-1.001985877	7.842796782	0.755821848	23	DM?	.
FBXO2	1	11648367	11655785	N	Viable	N	Y	0.027424541	51.61775771	0.273382986	36.4	.	.
FBXO21	12	117141988	117190531	N	.	N	N	-0.963951725	8.491057475	0.990625619	9.8	.	.
FBXO22	15	75903859	75942510	N	.	N	N	-0.520298739	19.46518493	0.893814403	18	.	.
FBXO24	7	100583982	100601117	N	.	N	N	0.445177058	78.10962551	0.141279968	41	.	.
FBXO25	8	406428	477967	N	.	N	N	-0.286592944	30.25409504	0.310315222	35.4	.	.
FBXO27	19	38990714	39032785	N	.	N	N	0.038754674	52.485964	2.08E-10	92.4	.	.
FBXO28	1	224114087	224162047	N	.	N	N	0.080902701	55.81408809	0.930139055	16.1	.	.
FBXO3	11	33740939	33774543	N	.	N	N	-0.110348593	41.44238004	0.969760026	13	.	.
FBXO30	6	145793502	145814753	N	.	N	N	-0.515361182	19.6272501	0.987340441	10.5	.	.
FBXO31	16	87326987	87392142	N	Viable	N	Y	-0.923562311	9.156682294	0.911167117	17.2	.	?Mental retardation, autosomal recessive 45, 615979 (3)
FBXO32	8	123497889	123541206	N	.	N	Y	-0.234224724	33.42015396	0.972568188	12.8	.	.
FBXO33	14	39397669	39432500	N	Viable	N	Y	-0.36545112	26.11564508	0.986077142	10.8	.	.
FBXO34	14	55271303	55361918	N	.	N	N	-0.445919635	22.46339063	0.004598477	58.6	.	.
FBXO36	2	229922302	230013109	N	Viable	N	Y	0.908323774	91.24848064	3.23E-06	80.4	.	.
FBXO38	5	148383935	148442836	N	.	N	N	-0.894207554	9.694970192	0.99996218	3.1	.	Neuronopathy, distal hereditary motor, type IID, 615575 (3)
FBXO39	17	6776223	6797101	N	.	N	N	0.546393986	82.29437981	0.025018434	50.5	.	.
FBXO4	5	41925254	41941743	N	.	N	Y	-0.2707828	31.23227412	7.11E-05	72.9	.	.
FBXO40	3	121593119	121630295	N	.	N	N	0.588847047	83.80505875	3.64E-08	87.4	.	.
FBXO41	2	73254682	73284431	N	Viable	N	Y	.	.	0.951773201	14.6	.	.
FBXO42	1	16246839	16352454	N	.	N	N	-1.154262141	6.048503791	0.975946027	12.3	.	.
FBXO43	8	100133360	100145800	N	.	N	N	-0.265845998	31.52167622	0.000150255	70.6	.	.
FBXO44	1	11654375	11663327	N	Viable	N	Y	0.906555705	91.21375239	3.60E-05	74.7	.	.
FBXO46	19	45710629	45730904	N	.	N	N	-0.982633595	8.195867338	0.876437042	18.8	.	.
FBXO47	17	38936432	38967402	N	.	N	Y	1.090469244	93.85888754	0.014052557	53.5	.	.
FBXO48	2	68459419	68467258	N	.	N	N	0.048020238	53.25577357	0.016665308	52.6	.	.
FBXO6	1	11664124	11674354	N	.	N	N	0.330566867	72.36788794	0.000485731	67.1	.	.
FBXO7	22	32474676	32498829	N	.	N	Y	0.231264514	66.30780807	0.098722423	43.2	DM	Parkinson disease 15, autosomal recessive, 260300 (3)
FBXO8	4	174236658	174284264	N	Viable	N	Y	-0.046649065	46.09017769	0.836833762	20.4	.	.
FBXO9	6	53051991	53100873	N	Viable	N	Y	-0.151691433	38.58887538	0.734879395	23.6	.	.
FBXW10	17	18744024	18779349	N	.	N	N	1.428787046	96.54453898	.	.	.	.
FBXW11	5	171861549	172006873	N	.	N	N	-0.612251503	16.42067489	0.997161484	7.4	DM?	.
FBXW12	3	48372219	48401259	N	.	N	N	0.047365707	53.22683336	1.97E-07	85.2	.	.
FBXW2	9	120751978	120793412	N	Viable	N	Y	-0.132857585	39.9027609	0.976204028	12.2	.	.
FBXW4	10	101610664	101695295	N	.	N	N	-0.490286222	20.58227702	0.00069101	66	DM	.
FBXW5	9	136940435	136944696	N	.	N	N	-0.289161662	30.12675812	1.16E-08	88.8	.	.
FBXW9	19	12688053	12696643	N	Viable	N	Y	0.099886544	57.20321815	2.00E-09	90.5	.	.
FCAMR	1	206957965	206970625	N	.	N	Y	0.541611524	82.1265266	8.00E-06	78.6	.	.
FCAR	19	54874248	54890472	N	.	N	N	1.19456775	94.96440354	0.000228787	69.4	DFP	.
FCER1A	1	159289714	159308224	N	.	N	Y	0.274219089	68.94136714	0.002558028	61	DFP	.
FCER2	19	7688758	7702146	N	.	N	Y	1.598034205	97.48798981	1.50E-09	90.8	FP	.
FCF1	14	74713144	74738620	N	.	N	N	0.209411733	65.03443885	0.934256695	15.9	.	.
FCGBP	19	39863323	39934626	N	Viable	N	Y	7.697810369	99.92475546	.	.	.	.
FCGR1A	1	149782671	149792518	N	.	N	Y	0.780762778	88.79435087	0.971633432	12.8	DM	[IgG receptor I, phagocytic, familial deficiency of] (3)
FCGR1B	1	121087345	121096310	N	.	N	N	0.779806888	88.78277479	0.676508623	25.3	.	.
FCGR2A	1	161505430	161524013	N	.	N	Y	0.589500178	83.82242287	0.000150862	70.6	DFP	{Lupus nephritis, susceptibility to}, 152700 (3); {Malaria, severe, susceptibility to}, 611162 (3); {Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3)
FCGR2B	1	161581311	161678654	N	.	N	Y	0.440244459	77.90125601	0.047402608	47.3	DFP	{Systemic lupus erythematosus, susceptibility to}, 152700 (3); {Malaria, resistance to}, 611162 (3)
FCGR3A	1	161541759	161550737	N	.	N	Y	0.688955753	86.6296232	1.22E-05	77.6	DFP	Immunodeficiency 20, 615707 (3)
FCGR3B	1	161623196	161631963	N	.	N	N	1.082009205	93.76627887	3.30E-05	75	DFP	Neutropenia, alloimmune neonatal (3)
FCGRT	19	49506816	49526333	N	.	N	Y	0.111065501	58.08300052	0.82558718	20.8	FP	.
FCHO1	19	17747718	17788568	N	.	N	N	0.040166042	52.56699659	0.998992548	5.9	.	.
FCHO2	5	72955981	73090522	N	.	N	N	-0.221936642	34.22469179	0.999038489	5.9	.	.
FCHSD1	5	141639302	141651419	N	.	N	N	1.713625442	97.94524512	1.92E-16	97.6	.	.
FCHSD2	11	72836745	73142261	N	.	N	N	-0.657116328	15.15309371	0.994752587	8.5	.	.
FCMR	1	206904386	206923247	N	Viable	N	Y	.	.	.	.	.	.
FCN1	9	134905890	134917963	N	.	N	Y	0.319387303	71.73699138	1.26E-11	94.1	.	.
FCN2	9	134880812	134887520	N	.	N	N	0.592369826	83.88609134	1.93E-09	90.5	DM	.
FCN3	1	27369112	27374824	N	.	N	N	1.254600192	95.47375123	0.017251338	52.4	DFP	Immunodeficiency due to ficolin 3 deficiency, 613860 (3)
FCRL1	1	157794403	157820105	N	.	N	N	0.283785611	69.53174741	0.001595267	62.8	.	.
FCRL2	1	157745733	157777132	N	.	N	N	0.080247996	55.73305551	0.00016004	70.4	.	.
FCRL3	1	157674321	157700857	N	.	N	N	1.013984552	92.92122475	4.56E-18	98.2	DP	.
FCRL4	1	157573749	157598080	N	.	N	N	0.90766125	91.23690456	1.60E-07	85.5	.	.
FCRL5	1	157513377	157552520	N	.	N	N	0.591877629	83.87451525	7.49E-14	96.2	.	.
FCRL6	1	159800511	159816251	N	.	N	N	0.826080348	89.67992128	5.08E-14	96.3	DM?	.
FCRLA	1	161706972	161714352	N	Viable	N	Y	0.719925571	87.43416102	0.000166358	70.4	.	.
FCRLB	1	161721563	161728143	N	.	N	Y	0.902877564	91.13850784	1.20E-08	88.7	.	.
FDCSP	4	70226071	70235252	N	.	N	N	0.175573187	62.89865139	0.358744942	34	.	.
FDPS	1	155308748	155320666	N	.	N	N	-0.352359149	26.65972102	0.001751278	62.4	.	.
FDX1L	19	10310045	10316015	N	.	N	N	0.06589658	54.61017538	0.003189351	60.1	.	.
FDXACB1	11	111874056	111881243	N	Viable	N	Y	0.479017244	79.71291312	3.15E-07	84.4	.	.
FDXR	17	74862497	74873031	N	.	N	N	1.378640464	96.27828905	0.000894955	65.2	.	.
FEM1A	19	4791681	4801273	N	.	N	N	-0.465709488	21.64727673	.	.	DM?	.
FEM1B	15	68277803	68295865	N	.	N	Y	-0.84389619	10.70208948	0.540948667	28.9	.	.
FEM1C	5	115520908	115544894	N	.	N	N	-0.841981514	10.74839382	0.624676085	26.8	.	.
FER	5	108747822	109196841	N	.	N	N	-1.323985091	4.532036812	0.968420467	13.2	.	.
FER1L5	2	96642737	96704887	N	.	N	N	.	.	.	.	.	.
FER1L6	8	123851987	124120061	N	.	N	N	2.408426772	99.11442959	8.00E-30	99.7	.	.
FERD3L	7	19144782	19145421	N	.	N	Y	-0.410624002	23.91618915	0.258156359	36.8	.	.
FETUB	3	186635969	186653141	N	.	N	Y	0.894417541	91.02853505	6.88E-05	72.9	.	.
FEZ1	11	125445745	125496317	N	.	N	Y	-0.291377772	29.93575273	0.540112166	28.9	.	.
FEZ2	2	36531805	36646087	N	.	N	N	-0.391788739	24.87121607	3.59E-05	74.7	.	.
FEZF2	3	62369681	62374324	N	.	N	Y	-0.272697012	31.12808937	0.902033504	17.7	DM?	.
FFAR1	19	35351552	35353862	N	Viable	N	Y	.	.	0.001370255	63.5	DM	.
FFAR2	19	35443907	35451767	N	.	N	Y	0.119525236	58.70810905	0.000643947	66.2	.	.
FFAR3	19	35358460	35360485	N	.	N	Y	1.534317997	97.13491926	.	.	.	.
FFAR4	10	93566665	93604480	N	.	N	Y	-0.244445663	32.81240956	0.005572493	57.6	.	{Obesity, susceptibility to}, 607514 (3)
FGA	4	154583126	154590766	N	.	N	Y	-0.793793488	11.68605661	6.35E-10	91.5	DM	Dysfibrinogenemia, congenital, 616004 (3); Hypodysfibrinogenemia, congenital, 616004 (3); Amyloidosis, familial visceral, 105200 (3); Afibrinogenemia, congenital, 202400 (3)
FGB	4	154562956	154571086	N	.	N	N	0.340939791	72.94090409	0.195390176	38.8	DM	Dysfibrinogenemia, congenital, 616004 (3); Afibrinogenemia, congenital, 202400 (3); Hypofibrinogenemia, congenital, 202400 (3)
FGD1	X	54445454	54496166	N	.	N	N	-0.487414582	20.68067373	0.972835312	12.7	DM	Aarskog-Scott syndrome, 305400 (3); Mental retardation, X-linked syndromic 16, 305400 (3)
FGD2	6	37005646	37029070	N	.	N	N	0.539197001	82.0165538	4.71E-05	74	.	Glucocorticoid deficiency 2, 607398 (3)
FGD3	9	92947451	93036236	N	.	N	N	-0.380155411	25.4558083	8.70E-06	78.4	DM?	Glucocorticoid deficiency 3 (2)
FGD4	12	32399529	32646050	N	.	N	Y	0.01926743	51.03895352	0.335778542	34.7	DM	Charcot-Marie-Tooth disease, type 4H, 609311 (3)
FGD6	12	95076749	95217482	N	.	N	N	0.22054812	65.65954738	0.995227689	8.3	.	.
FGF1	5	142592178	142698070	N	.	N	Y	0.019921484	51.06789373	0.320471736	35.1	DP	.
FGF11	17	7438273	7444937	N	.	N	Y	-0.025096816	47.5834925	0.068195836	45.2	.	.
FGF12	3	192139395	192767764	N	.	N	N	-0.275568538	30.94287203	0.114210585	42.4	.	.
FGF13	X	138614731	139222777	N	.	N	N	0.185945882	63.57006425	0.96422364	13.5	DM?	.
FGF14	13	101710804	102402457	N	.	N	Y	-0.053195214	45.56346588	0.724525963	23.9	DM	Spinocerebellar ataxia 27, 609307 (3)
FGF17	8	22042398	22048809	N	.	N	Y	-0.071071979	44.35376512	0.86533156	19.3	DM	Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3)
FGF2	4	122826708	122898236	N	Viable	N	Y	-0.095495045	42.38583087	.	.	DP	.
FGF20	8	16992169	17002181	N	.	N	Y	0.276939876	69.10922035	0.702854984	24.5	DFP	?Renal hypodysplasia/aplasia 2, 615721 (3)
FGF21	19	48755559	48758330	N	.	N	Y	0.509685942	80.85894542	0.21300202	38.3	.	.
FGF22	19	639879	644371	N	Viable	N	Y	.	.	0.000103154	71.8	DM?	.
FGF23	12	4368227	4379728	N	.	N	Y	-0.150734446	38.66411993	0.027989665	50	DM	Hypophosphatemic rickets, autosomal dominant, 193100 (3); Osteomalacia, tumor-induced (1); Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3)
FGF5	4	80266599	80336680	N	.	N	Y	0.140120824	60.21878798	4.32E-05	74.3	.	Trichomegaly, 190330 (3)
FGF6	12	4428155	4445614	N	.	N	Y	0.139164133	60.1377554	0.000705758	65.9	.	.
FGF7	15	49423096	49488775	N	Viable	N	Y	0.464520293	79.05307634	0.874992688	18.9	.	.
FGFBP1	4	15935569	15938740	N	.	N	N	0.44120081	77.9417723	0.001037031	64.6	DFP	.
FGFBP2	4	15960243	15969309	N	.	N	N	0.562208663	82.80951554	1.14E-07	86	.	.
FGFBP3	10	91906589	91909483	N	Viable	N	Y	.	.	0.001712168	62.5	.	.
FGFR1OP2	12	26938383	26966650	N	.	N	N	-0.372151226	25.76836256	0.429728003	32	.	.
FGFR4	5	177086886	177098144	N	Viable	N	Y	0.190380285	63.75528159	1.30E-06	82.2	DFP	{Cancer progression/metastasis} (3)
FGGY	1	59296638	59767675	N	.	N	N	0.69948087	86.878509	1.21E-11	94.2	.	.
FGL1	8	17864380	17910365	N	.	N	Y	1.133727624	94.37402327	1.87E-16	97.6	.	.
FGR	1	27612064	27635277	N	.	N	Y	-0.729431296	13.17937142	0.177174439	39.5	.	.
FHAD1	1	15247272	15400283	N	.	N	N	.	.	.	.	.	.
FHDC1	4	152936352	152979696	N	.	N	N	1.556541607	97.25646814	0.024454127	50.6	.	.
FHIT	3	59749310	61251459	N	.	N	Y	-0.000674037	49.38936158	0.001391839	63.4	.	.
FHL1	X	136146702	136211359	N	.	N	Y	0.051847216	53.50465937	0.918480756	16.8	DM	Scapuloperoneal myopathy, X-linked dominant, 300695 (3); Myopathy, X-linked, with postural muscle atrophy, 300696 (3); Myopathy, reducing body, X-linked, severe early-onset, 300717 (3); Myopathy, reducing body, X-linked, childhood-onset, 300718 (3); Emery-Dreifuss muscular dystrophy 6, X-linked, 300696 (3)
FHL2	2	105357712	105438513	N	.	N	Y	-0.218261615	34.41569717	0.002880602	60.5	DP	.
FHL3	1	37996770	38005606	N	.	N	N	0.237660296	66.68403079	0.534417266	29	.	Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3)
FHL5	6	96562548	96616636	N	.	N	Y	0.276132196	69.08028014	1.68E-08	88.3	.	Hemophagocytic lymphohistiocytosis, familial, 5, 613101 (3)
FHOD1	16	67229387	67247658	N	.	N	N	-0.363900171	26.1735255	9.46E-11	93	.	.
FIBCD1	9	130902438	130939286	N	.	N	N	0.774362215	88.6322857	7.56E-06	78.8	.	.
FIBIN	11	26994184	26996121	N	.	N	N	0.317324799	71.58071424	0.308532919	35.5	.	.
FIBP	11	65883741	65888539	N	.	N	N	-0.011852785	48.56745963	0.014722785	53.2	.	.
FICD	12	108515185	108525837	N	.	N	N	-0.305274657	29.1717312	0.006385822	57	.	.
FIG4	6	109691312	109825428	N	.	N	N	-1.130647808	6.251085258	6.59E-27	99.5	DM	Charcot-Marie-Tooth disease, type 4J, 611228 (3); Amyotrophic lateral sclerosis 11, 612577 (3); Yunis-Varon syndrome, 216340 (3); ?Polymicrogyria, bilateral temporooccipital, 612691 (3)
FIGF	X	15345591	15384376	N	.	N	Y	0.235747143	66.55090583	0.010906328	54.5	.	.
FIGLA	2	70777310	70790643	N	.	N	Y	0.177486232	63.00862418	0.731738228	23.7	DM	Premature ovarian failure 6, 612310 (3)
FIGNL1	7	50444128	50542535	N	.	N	N	-0.353012585	26.62499276	0.000108679	71.6	.	.
FILIP1	6	75291859	75493738	N	.	N	N	-0.632255374	15.83608265	1.85E-07	85.3	.	.
FILIP1L	3	99830141	100114513	N	.	N	N	-0.127621085	40.2211032	0.000245912	69.2	.	.
FIP1L1	4	53377643	53460861	N	.	N	N	-0.972412709	8.334780344	0.600789667	27.4	DM	.
FIS1	7	101239458	101252316	N	.	N	N	0.391400129	75.43555015	0.040178577	48.3	.	.
FITM1	14	24131275	24132849	N	.	N	N	0.459076404	78.76946229	0.072113819	44.9	.	.
FITM2	20	44302838	44311169	N	.	N	N	-0.060698235	45.04254211	0.000110417	71.5	.	.
FIZ1	19	55591371	55601970	N	.	N	N	.	.	0.450714684	31.4	.	.
FJX1	11	35618419	35620868	N	Viable	N	Y	.	.	0.823951147	20.8	.	.
FKBP10	17	41812680	41823217	N	.	N	Y	-0.976893157	8.29426405	0.000807425	65.5	DM	Osteogenesis imperfecta, type XI, 610968 (3); Bruck syndrome 1, 259450 (3)
FKBP11	12	48921518	48926474	N	.	N	N	-0.24459911	32.77768131	2.23E-05	76	.	.
FKBP14	7	30010587	30026684	N	.	N	N	-0.252102165	32.32621404	4.19E-05	74.3	DM	Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss, 614557 (3)
FKBP15	9	113161006	113221361	N	.	N	N	1.157513327	94.58818082	1.85E-07	85.3	.	.
FKBP1B	2	24049701	24063681	N	.	N	Y	-0.067396649	44.56792267	0.008885327	55.4	.	.
FKBP1C	6	63211446	63213024	N	.	N	N	.	.	0.000605467	66.4	.	.
FKBP2	11	64241003	64244132	N	.	N	N	0.093995484	56.69387046	0.307159556	35.6	.	.
FKBP3	14	45115600	45135319	N	.	N	N	-0.077618099	43.83284135	0.812901762	21.2	.	.
FKBP6	7	73328164	73358637	N	.	N	Y	0.426194468	77.17775077	0.130600639	41.5	DM	.
FKBP7	2	178463664	178478600	N	.	N	N	-0.402163571	24.28662384	3.16E-05	75.1	.	.
FKBP9	7	32957404	33006931	N	.	N	Y	0.717205629	87.34155235	0.072366214	44.9	.	.
FKBPL	6	32128707	32130291	N	.	N	N	-0.271739892	31.18018174	5.35E-05	73.7	DM	.
FKSG51	4	3538044	3538418	N	.	N	N	.	.	.	.	.	.
FKSG52	5	60430738	60431112	N	.	N	N	.	.	.	.	.	.
FKSG54	7	23638162	23638536	N	.	N	N	.	.	.	.	.	.
FKSG56	9	92227001	92227375	N	.	N	N	.	.	.	.	.	.
FKSG59	8	128118011	128118385	N	.	N	N	.	.	.	.	.	.
FKSG61	14	77416398	77416772	N	.	N	N	.	.	.	.	.	.
FKSG62	15	47133652	47134026	N	.	N	N	.	.	.	.	.	.
FKSG63	16	70224358	70224738	N	.	N	N	.	.	.	.	.	.
FKSG66	15	40683694	40684068	N	.	N	N	.	.	.	.	.	.
FKSG68	21	35898055	35898429	N	.	N	N	.	.	.	.	.	.
FKSG70	X	42285229	42285603	N	.	N	N	.	.	.	.	.	.
FLAD1	1	154983338	154993111	N	.	N	N	-0.083860557	43.30034149	0.091793511	43.7	.	.
FLG2	1	152348735	152360006	N	.	N	N	0.142948115	60.40400532	4.65E-41	99.9	.	.
FLJ20019	2	109344229	109344918	N	.	N	N	.	.	.	.	.	.
FLOT1	6	30727709	30742733	N	.	N	Y	-0.073790488	44.15118365	0.015273438	53	.	.
FLOT2	17	28879335	28897679	N	.	N	Y	-0.190967704	36.11159345	0.017234347	52.4	.	.
FLRT1	11	64103188	64119173	N	.	N	N	0.025159982	51.43254037	0.546319767	28.7	.	.
FLT3	13	28003274	28100592	N	.	N	Y	-0.048913667	45.90496035	0.609047701	27.2	DP	Leukemia, acute myeloid, reduced survival in, somatic, 601626 (3); Leukemia, acute myeloid, somatic, 601626 (3); Leukemia, acute lymphoblastic, somatic, 613065 (3)
FLT3LG	19	49474207	49486231	N	.	N	Y	-0.03259986	47.11466111	0.950828698	14.7	.	.
FLVCR2	14	75578617	75663214	N	.	N	N	0.003304686	49.75979626	0.000368276	68	DM	Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 (3)
FLYWCH1	16	2911937	2951208	N	.	N	N	3.187583265	99.60062511	.	.	.	.
FLYWCH2	16	2883186	2899382	N	.	N	N	-0.101084162	42.05591248	0.58053708	28	.	.
FMN2	1	240014348	240475189	N	.	N	Y	0.253751309	67.68536204	0.994502609	8.6	DM	Mental retardation, autosomal recessive 47, 616193 (3)
FMNL1	17	45221444	45247320	N	.	N	N	-0.708532731	13.67714302	0.999687036	4.7	.	.
FMNL2	2	152335237	152649834	N	.	N	N	-0.662556357	14.97366441	0.996999397	7.6	.	.
FMNL3	12	49636499	49708165	N	Viable	N	Y	-1.048919759	7.235052382	0.356499504	34	.	.
FMO1	1	171248471	171285978	N	.	N	N	0.602743172	84.19285756	5.10E-07	83.7	DP	.
FMO2	1	171185208	171211230	N	.	N	N	1.625330166	97.59217457	0.00129018	63.7	FP	.
FMO3	1	171090877	171117819	N	.	N	N	0.899200844	91.07483938	2.83E-09	90.2	DM	Trimethylaminuria, 602079 (3)
FMO4	1	171314208	171342084	N	.	N	N	0.458269625	78.73473404	2.41E-09	90.3	FP	.
FMO5	1	147175351	147243050	N	.	N	N	0.558680874	82.74005904	3.69E-15	96.9	FP	.
FMOD	1	203340628	203351489	N	.	N	Y	0.251860006	67.55802512	0.049581381	47.1	.	.
FMR1	X	147911951	147951125	N	.	N	Y	0.767667839	88.51073682	0.127197887	41.7	DM	Fragile X syndrome, 300624 (3); Fragile X tremor/ataxia syndrome, 300623 (3); Premature ovarian failure 1, 311360 (3)
FMR1NB	X	147981329	148026667	N	.	N	N	-0.091667236	42.70417318	0.18015421	39.3	.	.
FN3K	17	82735575	82751197	N	.	N	Y	-0.14882052	38.83197314	1.64E-05	76.8	DM?	.
FN3KRP	17	82716683	82730328	N	.	N	N	0.605463152	84.30861839	3.66E-07	84.2	.	.
FNBP1	9	129887187	130043194	N	.	N	N	-0.452617031	22.15662441	0.846297746	20	DM?	.
FNBP1L	1	93448131	93554661	N	Viable	N	Y	-0.174200506	37.13028882	0.965504529	13.5	.	.
FNBP4	11	47716517	47767443	N	.	N	N	-0.427087162	23.23320021	0.999993423	2.3	DM?	.
FNDC1	6	159169397	159272109	N	.	N	N	1.586196123	97.41274527	3.07E-07	84.5	.	.
FNDC3A	13	48975912	49209779	N	.	N	N	-1.237476756	5.226601841	0.999884368	3.9	.	.
FNDC4	2	27491883	27495245	N	.	N	N	-0.138599374	39.52075013	0.759219016	22.9	.	.
FNDC5	1	32862268	32872482	N	.	N	N	.	.	0.406509132	32.6	.	.
FNDC7	1	108712657	108742740	N	.	N	N	0.950768765	92.01829021	0.000318365	68.5	.	.
FNDC8	17	35121579	35130732	N	.	N	N	0.163586571	62.05938531	1.90E-05	76.4	.	.
FNDC9	5	157341600	157345721	N	.	N	N	1.153224527	94.53608844	0.003993824	59.1	.	.
FNIP1	5	131641714	131797063	N	.	N	Y	-0.831311259	10.95676333	0.999819445	4.2	DM	.
FNIP2	4	158769138	158908049	N	.	N	N	-0.735534504	13.0115182	0.997777002	7.1	.	.
FNTA	8	43034194	43085788	N	.	N	N	-0.45372795	22.13347225	0.988212602	10.3	.	.
FO082796.1	9	138281751	138294550	N	.	N	N	.	.	.	.	.	.
FO538757.2	1	184923	200322	N	.	N	N	.	.	.	.	.	.
FO538757.3	1	182393	184158	N	.	N	N	.	.	.	.	.	.
FOCAD	9	20658309	20995955	N	.	N	N	-0.036681894	46.79631881	5.37E-16	97.4	.	.
FOLH1	11	49146635	49208670	N	.	N	Y	-0.424366955	23.37211321	0.253396885	37	FP	.
FOLR2	11	72216601	72221950	N	.	N	Y	0.744201416	87.96666088	6.17E-07	83.4	.	.
FOLR3	11	72114869	72139892	N	.	N	N	.	.	0.01086744	54.6	.	.
FOPNL	16	15865720	15888625	N	.	N	N	0.86984981	90.57706778	9.47E-06	78.2	.	.
FOSB	19	45467995	45475179	N	Viable	N	Y	-0.339267298	27.29640563	0.852916177	19.8	.	.
FOXA3	19	45863989	45873797	N	.	N	Y	-0.206930636	35.10447416	0.395510308	32.9	DM?	.
FOXB2	9	77019655	77020953	N	.	N	N	-0.064373744	44.83996064	2.39E-06	80.9	.	.
FOXD2	1	47436017	47440691	N	.	N	Y	.	.	.	.	.	.
FOXD4	9	116231	118204	N	.	N	N	1.79171188	98.16519072	.	.	DM	.
FOXD4L1	2	113498665	113501155	N	.	N	N	1.723849598	97.97997338	.	.	.	.
FOXD4L3	9	68302867	68304905	N	.	N	N	.	.	.	.	.	.
FOXD4L4	9	65736555	65738784	N	.	N	N	.	.	.	.	.	.
FOXD4L5	9	65282101	65285209	N	.	N	N	.	.	.	.	.	.
FOXD4L6	9	41126430	41128463	N	.	N	N	.	.	.	.	.	.
FOXE3	1	47416072	47418052	N	.	N	Y	.	.	.	.	DM	Anterior segment mesenchymal dysgenesis, 107250 (3); Aphakia, congenital primary, 610256 (3)
FOXI2	10	127737235	127741186	N	Viable	N	Y	0.406406543	76.17063148	1.60E-05	76.9	.	.
FOXJ2	12	8032703	8055503	N	.	N	N	-0.328740556	27.78838919	0.998394612	6.6	.	.
FOXK1	7	4682309	4771443	N	.	N	Y	-1.170226657	5.886438618	0.962670921	13.7	.	.
FOXK2	17	82519713	82644662	N	.	N	N	-0.282615149	30.51455693	0.918748433	16.8	.	.
FOXL2NB	3	138947234	138953451	N	.	N	N	.	.	.	.	.	.
FOXN2	2	48314637	48379294	N	.	N	N	-0.788500635	11.77866528	0.392770621	32.9	.	.
FOXN3	14	89124871	89619149	N	.	N	N	-0.234071877	33.43751809	0.90779936	17.4	.	.
FOXO3	6	108559835	108684774	N	Viable	N	Y	-0.340071051	27.25010129	.	.	.	.
FOXO4	X	71096197	71103535	N	.	N	Y	-0.013766433	48.44591075	0.861869127	19.4	.	.
FOXO6	1	41361922	41383590	N	.	N	Y	.	.	0.437580051	31.8	.	.
FOXR1	11	118971707	118981291	N	.	N	N	0.425238096	77.10250622	0.002926578	60.4	.	.
FOXR2	X	55623400	55625325	N	.	N	N	0.196318636	64.16623256	0.002566244	61	.	.
FOXRED1	11	126269055	126278131	N	.	N	N	0.393612399	75.52237078	4.09E-11	93.5	DM	Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3); Mitochondrial complex I deficiency, 252010 (3)
FOXRED2	22	36487190	36507101	N	.	N	N	0.106736329	57.67204955	0.006915467	56.7	.	.
FOXS1	20	31844301	31845619	N	.	N	Y	1.128944711	94.31035481	0.09963315	43.1	.	.
FP325317.1	9	43109628	43127172	N	.	N	N	.	.	.	.	.	.
FP325331.1	22	47115838	47117217	N	.	N	N	.	.	.	.	.	.
FPGS	9	127794597	127814327	N	.	N	Y	0.190879187	63.84789026	0.000112878	71.5	FP	.
FPGT	1	74198212	74234086	N	.	N	N	.	.	5.97E-08	86.8	.	.
FPGT-TNNI3K	1	74198235	74543982	N	.	N	N	.	.	1.84E-38	99.9	.	.
FPR1	19	51745172	51804110	N	Viable	N	Y	0.475995728	79.57978816	0.063805813	45.6	DFP	.
FPR2	19	51752026	51770526	N	.	N	Y	-0.171329534	37.29814204	0.01917529	51.9	DM?	.
FPR3	19	51795163	51826189	N	Viable	N	Y	-0.202298558	35.34178387	0.113913458	42.4	.	.
FRA10AC1	10	93667883	93702572	N	.	N	N	0.44774765	78.23696244	9.72E-10	91.2	.	.
FRAT1	10	97319267	97321915	N	.	N	Y	.	.	0.271480885	36.4	.	.
FRAT2	10	97332497	97334709	N	.	N	Y	.	.	0.630848044	26.6	.	.
FREM3	4	143577302	143700675	N	.	N	N	.	.	.	.	DM?	.
FRG1	4	189940788	189963204	N	.	N	N	2.688480138	99.30543497	3.67E-06	80.1	.	.
FRG1BP	20	30377181	30399334	N	.	N	N	.	.	.	.	.	.
FRG2	4	190024351	190027257	N	.	N	N	.	.	0.431237853	31.9	.	.
FRG2B	10	133623895	133626795	N	.	N	N	2.305477064	98.98709267	0.152494212	40.5	.	.
FRG2C	3	75664330	75667220	N	.	N	N	.	.	.	.	.	.
FRK	6	115931149	116060758	N	.	N	Y	0.116806072	58.51131562	6.59E-10	91.4	FTV	.
FRMD1	6	168055745	168081557	N	.	N	N	1.389016774	96.33616947	5.15E-13	95.5	.	.
FRMD3	9	83242990	83538546	N	.	N	N	-0.632692809	15.83029461	0.195215062	38.8	.	.
FRMD4A	10	13643706	14462142	N	.	N	N	-0.988888838	8.056954332	0.999986541	2.7	.	.
FRMD4B	3	69169990	69542583	N	.	N	N	1.228883655	95.30010997	0.807013708	21.4	.	.
FRMD5	15	43870761	44195252	N	Viable	N	Y	-0.674036865	14.64953406	0.991843164	9.5	.	.
FRMD6	14	51489100	51730727	N	.	N	N	-0.302404441	29.33958442	0.438403935	31.7	DP	.
FRMD7	X	132076993	132128020	N	.	N	Y	0.462902626	78.98361984	0.910660049	17.3	DM	Nystagmus 1, congenital, X-linked, 310700 (3); Nystagmus, infantile periodic alternating, X-linked, 310700 (3)
FRMD8	11	65386599	65413525	N	.	N	N	0.251860006	67.55802512	0.084290943	44.1	.	.
FRMPD1	9	37651000	37746904	N	.	N	N	1.026815315	93.11801817	3.53E-10	92.1	.	.
FRMPD2	10	48156558	48274870	N	.	N	N	-0.068402422	44.49846617	1.17E-15	97.2	.	.
FRMPD3	X	107522450	107605251	N	.	N	N	.	.	0.91076789	17.2	.	.
FRMPD4	X	12138466	12724523	N	.	N	Y	-0.67087028	14.72477861	0.997190829	7.4	DM	.
FRS3	6	41770176	41786542	N	.	N	N	0.519251431	81.23516814	0.808550861	21.3	.	.
FRY	13	32031300	32299122	N	.	N	N	-5.00579119	0.09260867	1	0.4	DM	.
FRZB	2	182833275	182867162	N	.	N	Y	-0.164783496	37.74382127	0.125665908	41.8	DM	{Osteoarthritis susceptibility 1}, 165720 (3)
FSBP	8	94378377	94436952	N	.	N	N	.	.	.	.	.	.
FSCB	14	44504342	44507279	N	.	N	N	0.016700113	50.79585576	4.81E-13	95.6	DM?	.
FSCN1	7	5592823	5606655	N	.	N	Y	-0.326978896	27.91572611	0.776273596	22.4	.	.
FSCN2	17	81528396	81537130	N	Viable	N	Y	.	.	9.46E-09	89	DM	Retinitis pigmentosa 30, 607921 (3)
FSCN3	7	127591409	127602144	N	.	N	N	0.301662112	70.59095908	7.76E-12	94.4	.	.
FSD1	19	4304600	4323843	N	.	N	N	-0.38972179	24.96961278	0.732578211	23.7	.	.
FSD1L	9	105447796	105552433	N	.	N	N	.	.	.	.	.	.
FSD2	15	82755362	82806070	N	.	N	N	0.81394517	89.40209527	2.36E-12	94.9	.	.
FSHB	11	30231016	30235261	N	.	N	Y	0.055523327	53.73618105	0.012899169	53.9	DM	Hypogonadotropic hypogonadism 24 without anosmia, 229070 (3)
FSIP1	15	39600031	39782830	N	.	N	N	0.786649421	88.91011171	4.51E-07	83.9	.	.
FSIP2	2	185738628	185833290	N	.	N	N	.	.	3.22E-08	87.5	.	.
FSTL1	3	120392293	120451253	Y	Viable	N	Y	0.214194527	65.30647682	0.959341929	14	.	.
FSTL3	19	676365	683399	N	Viable	N	Y	.	.	0.418831973	32.3	.	.
FSTL4	5	133196455	133612564	N	.	N	Y	0.776585991	88.69595416	0.981626121	11.5	DM?	.
FSTL5	4	161383897	162164035	N	.	N	N	0.235244663	66.5335417	0.002562607	61	DM?	.
FTCD	21	46136262	46155567	N	.	N	N	1.339205502	96.04097934	4.30E-08	87.2	DM	Glutamate formiminotransferase deficiency, 229100 (3)
FTCDNL1	2	199760544	199851173	N	.	N	N	.	.	.	.	.	.
FTHL17	X	31071241	31072053	N	.	N	N	0.528370887	81.58245066	0.000467383	67.2	FTV	.
FTL	19	48965301	48966878	N	.	N	N	-0.434090717	23.00746657	0.000458653	67.3	DM	Hyperferritinemia-cataract syndrome, 600886 (3); Neurodegeneration with brain iron accumulation 3, 606159 (3); L-ferritin deficiency, dominant and recessive, 615604 (3)
FTMT	5	121851955	121852833	N	.	N	Y	0.563164925	82.83845575	0.081623987	44.3	DM	.
FTSJ1	X	48476021	48486364	N	Viable	N	Y	0.231921074	66.33674828	0.96163278	13.8	DM	Mental retardation, X-linked 9, 309549 (3)
FTSJ2	7	2234231	2242198	N	.	N	N	0.290181792	69.94269839	1.97E-05	76.3	.	.
FTSJ3	17	63819433	63830012	N	.	N	N	-0.600471978	16.69271286	0.484157752	30.4	FTV	.
FUBP1	1	77944055	77979110	N	.	N	N	-0.743480655	12.77999653	0.999972831	3	.	.
FUBP3	9	130578965	130638352	N	.	N	N	-0.468580168	21.49678764	0.862679425	19.4	.	.
FUCA1	1	23845077	23868294	N	.	N	N	0.134531237	59.82520113	3.39E-08	87.5	DM	Fucosidosis, 230000 (3)
FUCA2	6	143494811	143511690	N	.	N	N	0.226480797	66.06471031	0.000365584	68	.	.
FUK	16	70454421	70480274	N	.	N	N	1.688741044	97.86421254	8.48E-16	97.3	.	.
FUNDC1	X	44523639	44543001	N	.	N	N	0.289077164	69.85587776	0.44069234	31.7	.	.
FUNDC2	X	155025980	155060303	N	.	N	N	0.046106757	53.06476819	0.841264939	20.2	.	.
FUOM	10	133355154	133358035	N	.	N	N	0.13805751	60.04514673	0.001601072	62.8	.	.
FUT1	19	48748011	48755390	N	.	N	Y	-0.099974947	42.10800486	0.000508775	67	DM	[Bombay phenotype] (3)
FUT10	8	33370824	33473422	N	.	N	N	-0.002284668	49.2678127	3.08E-07	84.5	.	.
FUT11	10	73772291	73780251	N	.	N	N	-0.390678624	24.91173236	1.26E-05	77.5	.	.
FUT2	19	48695971	48705950	N	.	N	Y	2.39105608	99.06233721	5.47E-12	94.6	DM	{Norwalk virus infection, resistance to} (3); [Bombay phenotype] (3); {Vitamin B12 plasma level QTL1}, 612542 (3)
FUT3	19	5842888	5851474	N	.	N	N	1.6272439	97.60375065	0.373828733	33.5	FP	[Blood group, Lewis] (3)
FUT4	11	94543840	94549898	N	.	N	Y	0.147623843	60.84968455	0.055379992	46.4	.	.
FUT5	19	5865826	5870540	N	.	N	N	1.361717971	96.19725647	0.002357884	61.3	.	.
FUT6	19	5830610	5839731	N	.	N	N	0.914207853	91.36424148	0.022129953	51.1	DM	Fucosyltransferase 6 deficiency, 613852 (3)
FUT7	9	137030174	137033010	N	.	N	Y	1.095104727	93.89361579	0.905391612	17.6	DM	.
FUT9	6	96015984	96215612	N	.	N	Y	-0.424672857	23.343173	0.081371162	44.4	.	.
FXR2	17	7591230	7614871	N	.	N	Y	-0.029577629	47.32881866	0.999770109	4.4	.	.
FXYD1	19	35138808	35143109	N	.	N	Y	0.160566904	61.79892342	0.233039912	37.6	.	.
FXYD2	11	117800844	117828698	N	.	N	Y	0.402581894	75.95068588	0.698943754	24.6	DM	Hypomagnesemia 2, renal, 154020 (3)
FXYD3	19	35115879	35124324	N	.	N	N	0.650336389	85.63407999	0.003432336	59.8	.	.
FXYD4	10	43371642	43376335	N	.	N	Y	0.123051266	58.96278289	0.052450321	46.7	.	.
FXYD5	19	35154730	35169883	N	.	N	N	0.241337169	66.9618568	0.464175278	31	.	.
FXYD6	11	117820075	117877486	N	.	N	N	0.243101669	67.0718296	0.829814384	20.6	.	.
FXYD6-FXYD2	11	117820163	117876667	N	.	N	N	0.48703021	79.96758697	0.637758563	26.4	.	.
FXYD7	19	35143250	35154301	N	.	N	N	0.280617659	69.33495399	0.122293437	42	.	.
FYB	5	39105236	39274528	N	Viable	N	Y	-0.094082712	42.53631996	0.792005859	21.9	.	.
FYCO1	3	45917899	45995824	N	.	N	N	1.692982792	97.88157666	9.67E-13	95.3	DM	Cataract 18, autosomal recessive, 610019 (3)
FYTTD1	3	197737179	197787596	N	.	N	N	-0.232310623	33.58800718	0.829001567	20.7	.	.
FZD1	7	91264364	91271326	N	.	N	Y	-1.042662624	7.333449094	0.344486648	34.4	DFP	.
FZD10	12	130162459	130165740	N	.	N	Y	0.029640828	51.75088268	.	.	.	.
FZD6	8	103298433	103332866	N	.	N	Y	-0.561336896	17.87926145	8.03E-08	86.4	DM	Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 (3)
FZD7	2	202034587	202038445	N	.	N	Y	-1.525793161	3.223939341	0.73019873	23.8	.	.
FZD8	10	35638249	35642278	N	.	N	Y	-1.084009665	6.725704694	.	.	.	.
FZD9	7	73433783	73436120	N	.	N	Y	-1.210617064	5.469699601	.	.	DM	.
G0S2	1	209675420	209676388	N	.	N	Y	0.259064403	67.99212826	0.153689954	40.4	.	.
G6PC	17	42900797	42913369	N	.	N	Y	-0.086882719	43.06881982	0.001811356	62.3	DM	Glycogen storage disease Ia, 232200 (3)
G6PC2	2	168901240	168910000	N	.	N	Y	0.636432699	85.26364531	1.91E-09	90.5	DM?	.
G6PC3	17	44070735	44076344	N	.	N	Y	-0.405837712	24.10719454	1.07E-05	77.8	DM	Neutropenia, severe congenital 4, autosomal recessive, 612541 (3); Dursun syndrome, 612541 (3)
GAA	17	80101556	80119879	N	.	N	Y	0.155890926	61.41691266	4.62E-11	93.4	DM	Glycogen storage disease II, 232300 (3)
GAB2	11	78215297	78418348	N	.	N	Y	-0.351099457	26.71181339	0.998921871	6	DP	.
GAB3	X	154675249	154751583	N	.	N	Y	-0.025901946	47.53140013	0.990602403	9.8	.	.
GAB4	22	16961936	17008222	N	.	N	N	0.071939875	55.03849048	6.04E-06	79.2	.	.
GABARAP	17	7240014	7242770	N	.	N	N	0.007634404	50.08971465	0.67018621	25.5	.	.
GABARAPL1	12	10212458	10223130	N	.	N	N	-0.052390454	45.59819413	0.782335275	22.2	.	.
GABBR2	9	98288109	98709197	N	.	N	Y	-1.304341715	4.670949818	0.999790263	4.3	.	{Nicotine dependence, susceptibility to}, 188890 (3); {Nicotine dependence, protection against}, 188890 (3)
GABPB2	1	151070578	151125542	N	.	N	N	0.415970669	76.65103895	0.002629052	60.9	.	.
GABRA3	X	152166234	152451358	N	.	N	Y	-0.440636427	22.72385252	0.273213946	36.4	.	.
GABRA4	4	46918900	46994407	N	.	N	Y	-0.818514107	11.21143717	0.981416569	11.5	.	.
GABRA5	15	26866363	26949207	N	.	N	Y	-0.467776875	21.53730393	0.951529195	14.6	.	.
GABRA6	5	161547063	161702593	N	.	N	Y	-0.126159463	40.331076	9.42E-08	86.2	DM?	.
GABRB1	4	46993723	47426444	N	.	N	N	-0.640349555	15.66822944	0.977782833	12.1	.	.
GABRB2	5	161288429	161549044	N	.	N	Y	-0.988377353	8.062742374	0.94029923	15.5	.	.
GABRE	X	151953124	151974680	N	.	N	N	0.976957029	92.43502923	0.000183719	70.1	.	.
GABRG1	4	46035769	46124081	N	.	N	N	-0.652484268	15.30937084	0.008474484	55.6	.	.
GABRG3	15	26971282	27541991	N	.	N	N	-0.419886724	23.51681426	0.993679844	8.9	FTV	.
GABRP	5	170763350	170814047	N	.	N	Y	0.473275854	79.46981536	9.63E-06	78.2	.	.
GABRQ	X	152638183	152657534	N	.	N	Y	-0.233114996	33.52433872	0.01008834	54.9	.	.
GABRR1	6	89177501	89231278	N	.	N	Y	-0.232158138	33.59958326	2.12E-07	85.1	.	.
GABRR2	6	89257208	89315299	N	Viable	N	Y	0.793195884	89.0606008	4.52E-07	83.9	DP	.
GABRR3	3	97986673	98035304	N	.	N	N	.	.	.	.	.	.
GAD2	10	26216307	26304558	N	Viable	N	Y	-0.534194499	18.82271228	0.898626708	17.8	DP	.
GADD45A	1	67685061	67688338	N	.	N	Y	-0.163022609	37.81906581	0.109847669	42.6	.	.
GADD45B	19	2476122	2478259	N	.	N	Y	-0.109544183	41.48289634	0.185427442	39.1	DFP	.
GADD45G	9	89605013	89606555	N	.	N	Y	0.259064403	67.99212826	0.720982248	24	.	.
GADL1	3	30726200	30894765	N	.	N	N	0.803419309	89.21108989	5.39E-09	89.5	.	.
GAFA3	4	37866561	37867091	N	.	N	N	.	.	.	.	.	.
GAGE1	X	49589496	49608536	N	.	N	N	.	.	0.438832811	31.7	.	.
GAGE10	X	49303669	49319844	N	.	N	N	0.555516228	82.64166233	0.001119948	64.3	.	.
GAGE12B	X	49529869	49529985	N	.	N	N	.	.	.	.	.	.
GAGE12C	X	49532211	49539538	N	.	N	N	.	.	.	.	.	.
GAGE12D	X	49541767	49549094	N	.	N	N	.	.	.	.	.	.
GAGE12E	X	49551333	49558649	N	.	N	N	.	.	.	.	.	.
GAGE12F	X	49560876	49568205	N	.	N	N	.	.	.	.	.	.
GAGE12G	X	49570434	49577754	N	.	N	N	.	.	.	.	.	.
GAGE12H	X	49579983	49587301	N	.	N	N	.	.	.	.	.	.
GAGE12J	X	49322057	49329384	N	.	N	N	.	.	0.023588906	50.8	.	.
GAGE13	X	49331616	49338952	N	.	N	N	.	.	.	.	.	.
GAGE2A	X	49589529	49596827	N	.	N	N	.	.	.	.	.	.
GAGE2E	X	49341192	49345922	N	.	N	N	.	.	.	.	.	.
GAL	11	68683779	68691175	N	.	N	Y	0.330418352	72.31579557	0.000289003	68.8	FP	?Epilepsy, familial temporal lobe, 8, 616461 (3)
GAL3ST1	22	30554635	30574587	N	.	N	Y	0.753765456	88.16924235	0.379107293	33.3	.	.
GAL3ST2	2	241776825	241804208	N	.	N	N	0.805185239	89.25160618	4.42E-05	74.2	.	.
GAL3ST3	11	66041952	66049180	N	.	N	N	-0.463948146	21.72830931	1.25E-06	82.3	DM	.
GAL3ST4	7	100159244	100168750	N	.	N	N	0.25473034	67.7490305	3.82E-10	91.9	DM	.
GALC	14	87837820	87993665	Y	Viable	N	Y	0.439587779	77.86652775	6.28E-07	83.3	DM	Krabbe disease, 245200 (3)
GALE	1	23795599	23800804	N	.	N	N	-0.265997742	31.51588818	3.27E-08	87.5	DM	Galactose epimerase deficiency, 230350 (3)
GALK1	17	75751594	75765711	N	.	N	Y	-0.032448102	47.13781328	0.000940521	65	DM	Galactokinase deficiency with cataracts, 230200 (3)
GALK2	15	49155656	49367869	N	.	N	N	-0.317561949	28.41928576	8.74E-06	78.4	.	.
GALM	2	38665910	38741237	N	.	N	N	-0.008982334	48.74110089	8.93E-09	89.1	.	.
GALNS	16	88813734	88856970	N	.	N	Y	0.369189464	74.35318632	0.00086204	65.3	DM	Mucopolysaccharidosis IVA, 253000 (3)
GALNT10	5	154190730	154420984	N	.	N	N	-0.313734483	28.63923135	0.00044926	67.3	.	.
GALNT11	7	152025674	152122347	N	.	N	N	0.266060797	68.42623141	0.004047419	59	.	.
GALNT12	9	98807699	98850081	N	.	N	N	-0.369126321	25.91885165	0.002825659	60.6	DM	{Colorectal cancer, susceptibility to, 1}, 608812 (3)
GALNT13	2	153871913	154453849	N	.	N	N	-0.477997281	21.09741275	0.853952804	19.7	.	.
GALNT14	2	30910467	31155202	N	.	N	N	0.108497929	57.89199514	3.03E-09	90.1	.	.
GALNT15	3	16174649	16231992	N	.	N	N	-0.662556357	14.97366441	5.52E-10	91.6	.	.
GALNT16	14	69259277	69357033	N	.	N	N	-0.175809925	37.02031603	0.016827717	52.5	.	.
GALNT18	11	11270876	11622005	N	Viable	N	Y	-0.687935562	14.2675233	0.047685176	47.3	.	.
GALNT2	1	230057990	230282124	N	.	N	N	-0.511685065	19.76037507	0.881985613	18.5	DM	.
GALNT3	2	165747591	165794682	N	.	N	Y	-0.676755502	14.5858656	2.01E-05	76.2	DM	Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3)
GALNT4	12	89519408	89524806	N	.	N	Y	-0.327783769	27.85784569	0.112929757	42.5	.	.
GALNT5	2	157257598	157314211	N	.	N	N	-0.39692684	24.5586618	1.34E-12	95.2	.	.
GALNT6	12	51351247	51392867	N	.	N	N	-0.421497081	23.47629797	1.66E-06	81.7	.	.
GALNT7	4	173168753	173323967	N	.	N	N	-0.14962524	38.77409272	0.000181549	70.1	.	.
GALNT8	12	4720341	4851927	N	.	N	N	0.891851594	90.9938068	1.87E-10	92.5	.	.
GALNT9	12	132196372	132329349	N	.	N	N	0.207648094	64.90710193	0.594228593	27.6	DM	.
GALNTL5	7	151956379	152019934	N	Viable	N	Y	1.232235001	95.31168606	6.05E-13	95.5	DM	.
GALNTL6	4	171812254	173041559	N	.	N	N	-0.718099444	13.46298547	0.001655681	62.7	.	.
GALP	19	56176020	56185775	N	Viable	N	Y	0.215958347	65.40487353	0.001215115	64	DP	.
GALR1	18	77250549	77277896	N	.	N	Y	-0.102845596	41.94593969	0.000193369	69.9	DM	.
GALR2	17	76074794	76077541	N	.	N	Y	0.308057642	70.95560572	0.007970937	55.9	.	.
GALR3	22	37823382	37825495	N	.	N	Y	.	.	0.023153423	50.9	.	.
GALT	9	34638133	34651035	N	.	N	Y	-0.488371748	20.65173352	0.001190739	64.1	DM	Galactosemia, 230400 (3)
GAN	16	81314952	81390884	N	.	N	Y	-1.317437138	4.595705273	0.036349934	48.8	DM	Giant axonal neuropathy-1, 256850 (3)
GANAB	11	62624826	62646726	N	.	N	N	-0.260913414	31.79371419	0.99994841	3.3	.	.
GANC	15	42273233	42356935	N	.	N	N	1.002812104	92.79967587	2.38E-21	98.9	.	.
GAPDHS	19	35533412	35545316	N	.	N	Y	0.144904459	60.59501071	0.135772126	41.3	.	.
GAPT	5	58491435	58497090	N	.	N	Y	0.641877044	85.40834636	0.001630933	62.7	.	.
GAPVD1	9	125261794	125367207	N	.	N	N	-2.01050931	1.603287608	0.999999872	1.2	.	.
GAR1	4	109815510	109824740	N	.	N	Y	0.247883787	67.32650344	0.81256498	21.2	.	.
GAREM	18	32124877	32470484	N	.	N	N	-0.582742031	17.31782138	0.827971734	20.7	.	.
GAREML	2	26173091	26189663	N	.	N	N	.	.	.	.	.	.
GARNL3	9	127224265	127393660	N	.	N	N	-1.07429771	6.870405742	0.021086841	51.3	.	.
GAS2	11	22625642	22813055	N	.	N	N	-0.119765437	40.78833131	0.026289766	50.3	.	.
GAS2L1	22	29306582	29312785	N	Viable	N	Y	0.016397017	50.77270359	0.700430404	24.6	.	.
GAS2L2	17	35744511	35752878	N	.	N	N	1.02724099	93.12380622	0.000457989	67.3	FTV	.
GAS2L3	12	100573683	100628286	N	.	N	N	-0.292988049	29.83735602	0.000258593	69.1	.	.
GAS6	13	113820549	113864067	N	.	N	Y	0.37493117	74.67152862	0.333438602	34.8	DP	.
GAS7	17	9910609	10198551	N	.	N	N	-0.597090606	16.7679574	0.025529644	50.4	.	.
GAS8	16	90019629	90044975	N	.	N	N	1.276455552	95.60687619	8.04E-08	86.4	.	.
GAST	17	41712326	41715969	N	.	N	Y	0.078032613	55.54205012	0.003173784	60.1	.	.
GATA5	20	62463497	62475970	N	Viable	N	Y	.	.	0.250742909	37.1	DM	.
GATAD1	7	92447453	92458836	N	.	N	N	0.078989305	55.61150663	0.507483499	29.7	DM	?Cardiomyopathy, dilated, 2B, 614672 (3)
GATAD2B	1	153804725	153922975	N	.	N	N	-0.65344145	15.2630665	0.998594716	6.4	DM?	Mental retardation, autosomal dominant 18, 615074 (3)
GATB	4	151670504	151761023	N	.	N	N	.	.	.	.	.	.
GATM	15	45361124	45402327	N	Viable	N	Y	-0.537219736	18.72431556	0.866491077	19.2	DM	Cerebral creatine deficiency syndrome 3, 612718 (3)
GATS	7	100200653	100272218	N	.	N	N	-0.145145404	39.04034265	0.000965025	64.9	.	.
GATSL2	7	74964818	75024798	N	.	N	N	.	.	.	.	.	.
GATSL3	22	30285117	30289627	N	.	N	N	0.175722654	62.91601551	0.453126498	31.3	.	.
GBA2	9	35736866	35749228	N	.	N	Y	-0.543313266	18.46964172	4.79E-09	89.6	DM	Spastic paraplegia 46, autosomal recessive, 614409 (3)
GBAS	7	55951793	56000181	N	.	N	N	-0.251145013	32.40145859	4.15E-05	74.4	.	.
GBP1	1	89052319	89065360	N	.	N	Y	0.109454802	57.9556636	1.81E-12	95	.	.
GBP2	1	89106132	89150456	N	Viable	N	Y	-0.084817347	43.21352087	1.97E-05	76.3	.	.
GBP3	1	89006666	89022894	N	.	N	N	1.213551575	95.16698501	5.83E-18	98.1	.	.
GBP4	1	89181148	89198932	N	.	N	N	1.381512598	96.29565318	1.42E-09	90.9	.	.
GBP5	1	89258950	89272804	N	.	N	Y	0.05214974	53.52781154	7.95E-06	78.6	.	.
GBP6	1	89364058	89386461	N	.	N	N	0.850504873	90.2066331	2.45E-10	92.3	.	.
GBP7	1	89131751	89176040	N	.	N	N	0.806441799	89.26318227	5.51E-11	93.3	.	.
GBX1	7	151148589	151174745	N	Viable	N	Y	0.424281762	77.06777797	0.269607761	36.5	.	.
GC	4	71741693	71804041	N	Viable	N	Y	0.631799315	85.10158014	5.78E-06	79.3	DP	.
GCA	2	162318840	162371595	N	.	N	Y	0.143797178	60.51397812	0.000445655	67.4	.	.
GCAT	22	37807905	37817176	N	.	N	N	0.250903275	67.50593274	7.76E-06	78.7	.	.
GCC1	7	127580618	127593611	N	.	N	N	-0.571560634	17.60722348	6.69E-08	86.6	.	.
GCC2	2	108448561	108509415	N	.	N	N	-1.215543029	5.429183307	0.013465761	53.7	.	.
GCDH	19	12891026	12914207	N	.	N	Y	-0.285636061	30.30618742	0.335283401	34.7	DM	Glutaricaciduria, type I, 231670 (3)
GCFC2	2	75652000	75710989	N	.	N	N	1.815020927	98.21728309	6.27E-12	94.5	.	.
GCG	2	162142873	162152404	N	.	N	Y	0.096865517	56.89645193	0.077203462	44.6	.	[?Hyperproglucagonemia] (1)
GCGR	17	81804132	81814013	Y	Viable	N	Y	.	.	0.452713871	31.3	DM	{Diabetes mellitus, noninsulin-dependent}, 125853 (3)
GCH1	14	54842008	54902852	N	.	N	N	-0.063568931	44.88047693	0.942485933	15.4	DM	Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 (3); Hyperphenylalaninemia, BH4-deficient, B, 233910 (3)
GCHFR	15	40764020	40767710	N	.	N	N	-0.09740902	42.25270591	0.041896885	48	.	.
GCKR	2	27496842	27523684	N	.	N	Y	0.088859598	56.34658795	3.58E-16	97.5	DM	[Fasting plasma glucose level QTL 5], 613463 (3)
GCLM	1	93885205	93909456	N	.	N	Y	-0.154562494	38.40365804	0.414918212	32.4	DFP	{Myocardial infarction, susceptibility to}, 608446 (3)
GCN1	12	120127203	120194710	N	.	N	N	.	.	.	.	.	.
GCNT1	9	76419850	76507416	N	.	N	Y	-0.502420818	20.06714129	0.066576637	45.4	.	.
GCNT2	6	10492223	10629368	N	.	N	Y	-0.706336147	13.73502344	0.019397722	51.8	DM	[Blood group, Ii], 110800 (3); Cataract 13 with adult i phenotype, 116700 (3); Adult i phenotype without cataract, 110800 (3)
GCNT3	15	59594875	59640239	N	.	N	Y	0.270693188	68.73299763	4.04E-09	89.8	.	.
GCNT4	5	75025346	75030899	N	.	N	Y	-0.691914915	14.19227875	0.021235042	51.3	.	.
GCNT7	20	56491492	56525925	N	.	N	N	.	.	.	.	.	.
GCOM1	15	57591908	57714745	N	.	N	N	0.735083071	87.7351392	3.95E-09	89.8	.	.
GCSAM	3	112120841	112133305	N	.	N	Y	0.543377487	82.18440702	0.098501307	43.2	.	.
GCSAML	1	247507058	247577690	N	.	N	N	0.22250501	65.75794409	0.03579586	48.9	.	.
GCSH	16	81081961	81096403	N	.	N	N	-0.012961236	48.47485096	0.019728343	51.8	DM	Glycine encephalopathy, 605899 (3)
GDA	9	72114595	72257193	N	.	N	N	0.24898988	67.40753603	0.998845433	6.1	.	.
GDAP1	8	74321130	74488872	N	Viable	N	Y	-0.399291813	24.48341726	0.000184529	70.1	DM	Charcot-Marie-Tooth disease, type 4A, 214400 (3); Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 (3); Charcot-Marie-Tooth disease, axonal, type 2K, 607831 (3); Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 (3)
GDAP1L1	20	44247099	44280917	N	.	N	N	-0.019355782	47.95971523	0.353968502	34.1	.	.
GDAP2	1	117863485	117929630	N	.	N	N	-0.674993982	14.6263819	8.51E-05	72.4	.	.
GDE1	16	19501689	19522145	N	.	N	Y	0.0931893	56.64756613	4.09E-05	74.4	.	.
GDF10	10	47300386	47313547	N	Viable	N	Y	-0.413187838	23.76570006	0.308234425	35.5	.	.
GDF15	19	18374731	18389176	N	Viable	N	Y	-0.298880801	29.53637784	0.000282487	68.8	DFP	.
GDF2	10	47322490	47326270	N	Viable	N	Y	-0.056719065	45.36088441	0.086007141	44	.	Telangiectasia, hereditary hemorrhagic, type 5, 615506 (3)
GDF5	20	35433347	35454746	N	.	N	N	-0.026707188	47.49667188	0.923194899	16.5	DM	?Acromesomelic dysplasia, Hunter-Thompson type, 201250 (3); Brachydactyly, type C, 113100 (3); Chondrodysplasia, Grebe type, 200700 (3); Du Pan syndrome, 228900 (3); Brachydactyly, type A2, 112600 (3); Symphalangism, proximal, 1B, 615298 (3); Multiple synostoses syndrome 2, 610017 (3); {Osteoarthritis-5}, 612400 (3); Brachydactyly, type A1, C, 615072 (3)
GDF5OS	20	35433029	35435450	N	.	N	N	.	.	0.042362392	48	.	.
GDF7	2	20666664	20679245	N	.	N	Y	.	.	0.778067352	22.3	.	.
GDF9	5	132861181	132866884	N	.	N	Y	-0.006111899	49.02471494	1.19E-05	77.6	DM	.
GDI1	X	154436913	154443467	N	.	N	Y	-0.644179392	15.54668056	0.987884009	10.4	DM	Mental retardation, X-linked 41, 300849 (3)
GDPD1	17	59220467	59275967	N	.	N	N	-0.439679063	22.75279273	0.00337917	59.9	.	.
GDPD2	X	70423031	70433390	N	.	N	N	0.540655179	82.08022226	0.116236324	42.3	.	.
GDPD3	16	30104810	30113856	N	.	N	N	0.436566952	77.72182671	1.05E-07	86.1	.	.
GDPD4	11	77216558	77301687	N	.	N	N	0.32976059	72.2926434	9.33E-09	89	.	.
GDPGP1	15	90233808	90245811	N	.	N	N	0.531387625	81.71557562	8.69E-06	78.4	.	.
GEM	8	94249253	94262350	N	.	N	Y	0.0200728	51.09683394	6.13E-06	79.2	.	.
GEMIN4	17	744414	753999	N	.	N	N	1.869047686	98.33883197	1.89E-07	85.2	DP	.
GEMIN5	5	154887416	154938209	N	.	N	N	0.603544851	84.22758581	3.13E-14	96.4	.	.
GEMIN6	2	38751534	38785000	N	.	N	N	-0.236138921	33.29860508	0.002595146	61	.	.
GEMIN7	19	45079195	45091524	N	.	N	N	0.435463288	77.66394629	0.347103991	34.3	.	.
GEMIN8	X	14008279	14029893	N	.	N	N	0.247883787	67.32650344	0.906251195	17.5	.	.
GEN1	2	17753858	17788941	N	.	N	N	0.108650217	57.89778318	2.86E-10	92.2	DP	.
GET4	7	876552	896436	N	.	N	N	-1.031483997	7.449209932	0.972149419	12.8	.	.
GFAP	17	44905008	44916937	N	.	N	Y	0.124309052	59.07275569	2.23E-05	75.9	DM	Alexander disease, 203450 (3)
GFER	16	1984207	1987749	N	.	N	N	0.466432451	79.14568501	1.85E-06	81.5	DM	Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 (3)
GFI1	1	92474762	92486876	N	.	N	Y	-0.097256408	42.28164612	0.029628557	49.7	DM	Neutropenia, severe congenital 2, autosomal dominant, 613107 (3); Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3)
GFM2	5	74721204	74767371	N	.	N	N	1.488487602	96.90918562	1.23E-08	88.7	DM	.
GFOD1	6	13357830	13487662	N	.	N	N	-0.723842698	13.29513226	0.04961907	47	.	.
GFOD2	16	67674531	67719421	N	Viable	N	Y	-0.591501503	16.99369103	0.060537434	45.9	.	.
GFPT2	5	180300690	180353387	N	Viable	N	Y	-1.619527857	2.766684031	6.63E-07	83.2	DP	.
GFRA2	8	21690403	21812357	N	.	N	Y	0.079140008	55.61729467	0.337127995	34.7	.	.
GFRA3	5	138252379	138274671	N	.	N	Y	-0.186335547	36.37784338	0.029060962	49.8	.	.
GFRA4	20	3659292	3663399	N	.	N	Y	.	.	0.00834572	55.7	.	.
GFRAL	6	55327469	55402493	N	.	N	N	0.454442874	78.52057649	0.00011482	71.4	.	.
GFY	19	49423749	49428818	N	.	N	Y	.	.	.	.	.	.
GGA1	22	37608475	37633564	Y	Viable	N	Y	-1.408444368	3.88956416	0.999441827	5.3	.	.
GGACT	13	100530164	100589528	N	.	N	N	.	.	.	.	.	.
GGCT	7	30496621	30504844	N	.	N	N	0.117461409	58.54604387	0.000385991	67.9	.	.
GGH	8	63015079	63039171	N	.	N	N	0.206691474	64.80870522	0.578462955	28	DFP	.
GGT1	22	24583750	24629005	N	.	N	Y	0.868230085	90.53655148	0.676974717	25.3	.	.
GGT2	22	21207973	21227637	N	.	N	N	.	.	0.80481651	21.4	.	[Gamma-glutamyltransferase, familial high serum] (2)
GGT5	22	24219654	24245142	N	.	N	Y	-0.220827915	34.28836025	1.39E-05	77.2	DP	.
GGT6	17	4556927	4560818	N	.	N	N	0.613922929	84.57486832	2.46E-06	80.9	.	.
GGT7	20	34844720	34872860	N	.	N	N	-0.274305776	31.04126874	0.998200259	6.8	.	.
GGTLC1	20	23985050	23988779	N	.	N	N	0.382132046	75.02459918	0.000145547	70.7	.	.
GGTLC2	22	22644475	22647903	N	.	N	N	0.915827458	91.39896973	0.000421522	67.6	.	.
GGTLC3	22	18516344	18518161	N	.	N	N	.	.	.	.	.	.
GH1	17	63917200	63918838	N	.	N	Y	0.617600446	84.70220524	0.017431562	52.3	DM	Growth hormone deficiency, isolated, type IA, 262400 (3); Growth hormone deficiency, isolated, type IB, 612781 (3); Growth hormone deficiency, isolated, type II, 173100 (3); Kowarski syndrome, 262650 (3)
GH2	17	63880215	63881935	N	.	N	N	0.18146271	63.30960236	3.39E-05	74.9	DM	.
GHDC	17	42188799	42194532	N	.	N	N	0.386914904	75.23875673	2.12E-05	76.1	.	.
GHITM	10	84139440	84153555	N	.	N	N	-0.322346967	28.12409562	0.129493358	41.6	.	.
GHR	5	42423777	42721878	Y	Viable	N	Y	0.31012201	71.07136656	0.000232177	69.3	DM	Laron dwarfism, 262500 (3); {Hypercholesterolemia, familial, modifier of}, 143890 (3); Increased responsiveness to growth hormone (3); Growth hormone insensitivity, partial, 604271 (3)
GHRH	20	37251082	37261835	N	.	N	Y	0.191535973	63.89419459	0.455312664	31.2	DP	?Isolated growth hormone deficiency due to defect in GHRF (1); Gigantism due to GHRF hypersecretion (1)
GHRHR	7	30938669	30993254	N	Viable	N	Y	0.255536257	67.80112288	0.002679459	60.8	DM	Growth hormone deficiency, isolated, type IB, 612781 (3)
GHRL	3	10285675	10292947	N	.	N	Y	0.534918128	81.86027667	8.37E-05	72.4	DFP	{Obesity, susceptibility to}, 601665 (3)
GHSR	3	172445133	172448456	N	Viable	N	Y	0.00793724	50.1244429	0.043345347	47.8	DM	Growth hormone deficiency, isolated partial, 615925 (3)
GID4	17	18039292	18068404	N	.	N	N	-0.081445868	43.46240667	0.937456357	15.8	.	.
GID8	20	62938119	62948475	N	.	N	N	-0.330004658	27.72472073	0.961707186	13.8	.	.
GIF	11	59829268	59845501	N	.	N	Y	0.445983156	78.16171789	0.43420207	31.8	DM	Intrinsic factor deficiency, 261000 (3)
GIGYF1	7	100679507	100689448	N	.	N	N	-2.26573636	1.198124674	0.978704812	12	.	.
GIMAP1	7	150716557	150724284	N	.	N	N	0.448703989	78.31799502	0.8393214	20.3	.	.
GIMAP2	7	150685697	150693641	N	.	N	N	0.464666725	79.07044047	0.001228334	63.9	.	.
GIMAP4	7	150567277	150573955	N	.	N	Y	0.278045399	69.20761706	7.69E-05	72.7	.	.
GIMAP5	7	150722253	150750033	N	.	N	Y	0.248033216	67.35544365	0.189192166	39	.	.
GIMAP6	7	150625375	150632648	N	Viable	N	Y	1.552050096	97.24489205	0.09734362	43.3	.	.
GIMAP7	7	150514830	150521073	N	.	N	N	-0.005306604	49.07680732	0.001844893	62.2	.	.
GIMAP8	7	150450630	150479392	N	.	N	N	0.352422016	73.54864849	6.85E-06	79	DM?	.
GIN1	5	103086000	103120151	N	.	N	N	-0.310058921	28.94020953	0.006677682	56.8	.	.
GINM1	6	149566294	149591748	N	.	N	N	0.158803293	61.65422238	7.71E-05	72.7	.	.
GINS2	16	85676198	85690073	N	.	N	N	-0.059741353	45.11778665	6.08E-09	89.4	.	.
GINS3	16	58295080	58406144	N	.	N	N	0.14284054	60.39821728	0.236040219	37.5	.	.
GIP	17	48958554	48968596	N	.	N	Y	0.079946001	55.69832726	0.162839345	40.1	FP	.
GIPC1	19	14477760	14496149	N	.	N	Y	-0.730388607	13.14464317	0.020370586	51.6	.	.
GIPC2	1	77979542	78138449	N	.	N	N	0.426194468	77.17775077	3.42E-08	87.5	.	.
GIPC3	19	3585553	3593541	N	Viable	N	Y	0.108195341	57.87463101	0.054252131	46.5	DM	Deafness, autosomal recessive 15, 601869 (3)
GIPR	19	45668244	45683724	N	.	N	Y	0.965775925	92.24981189	2.54E-22	99.1	DM?	[Plasma glucose, 2-hour, QTL 2] (2)
GIT2	12	109929792	109996389	N	.	N	Y	-0.976893157	8.29426405	0.970632701	12.9	.	.
GJA10	6	89894469	89896120	N	.	N	Y	0.0052183	49.89870927	4.55E-13	95.6	.	.
GJA3	13	20138255	20161049	N	.	N	N	.	.	0.000279889	68.9	DM	Cataract 14, multiple types, 601885 (3)
GJA4	1	34792998	34795747	N	.	N	Y	0.284591847	69.63014412	0.239138209	37.4	DFP	.
GJA8	1	147907956	147909257	N	Viable	N	Y	-0.360666394	26.29507438	2.68E-05	75.5	DM	Cataract 1, multiple types, 116200 (3)
GJA9	1	38874451	38881587	N	.	N	N	-0.007068709	48.91474214	3.07E-06	80.5	.	.
GJB1	X	71215194	71225516	N	.	N	Y	0.23846774	66.7534873	0.659801724	25.8	DM	Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 (3)
GJB4	1	34759741	34763724	N	Viable	N	Y	1.910522619	98.41407652	1.96E-06	81.3	DM	Erythrokeratodermia variabilis with erythema gyratum repens, 133200 (3)
GJB6	13	20221971	20232395	N	.	N	Y	0.048171225	53.26734966	0.00018982	70	DM	Deafness, autosomal dominant 3B, 612643 (3); Deafness, autosomal recessive 1B, 612645 (3); Deafness, digenic GJB2/GJB6, 220290 (3); Ectodermal dysplasia 2, Clouston type, 129500 (3)
GJB7	6	87282978	87329278	N	.	N	N	1.05376226	93.40742027	1.50E-06	81.9	.	.
GJC2	1	228149852	228159826	N	.	N	Y	-0.152648436	38.52520692	0.483282479	30.5	DM	Leukodystrophy, hypomyelinating, 2, 608804 (3); Spastic paraplegia 44, autosomal recessive, 613206 (3); Lymphedema, hereditary, IC, 613480 (3)
GJC3	7	99923269	99929620	N	.	N	Y	0.312691067	71.2565839	0.005788822	57.4	DM	.
GJD2	15	34751032	34754965	N	.	N	Y	-0.349641992	26.83336227	0.1177216	42.2	DP	.
GJD3	17	40362931	40363815	N	.	N	Y	.	.	0.004901368	58.2	.	.
GJD4	10	35605410	35608935	N	Viable	N	Y	0.140120824	60.21878798	2.78E-05	75.4	.	.
GJE1	6	142133090	142135151	N	.	N	Y	.	.	.	.	.	.
GK2	4	79406352	79408293	N	.	N	N	0.390741825	75.41818603	2.90E-08	87.7	.	.
GK5	3	142157527	142225607	N	.	N	N	-0.542808172	18.4812178	0.519887601	29.5	.	.
GKAP1	9	83739421	83829516	N	.	N	N	-0.218261615	34.41569717	0.12282841	42	.	.
GKN1	2	68974573	68980974	N	Viable	N	Y	-0.077618099	43.83284135	0.000264878	69	.	.
GKN2	2	68945232	68952970	N	Viable	N	Y	0.044344174	52.90849106	0.00014306	70.8	.	.
GLA	X	101397803	101407925	N	.	N	Y	0.459885344	78.80419054	0.985045991	10.9	DM	Fabry disease, 301500 (3); Fabry disease, cardiac variant, 301500 (3)
GLB1	3	32996608	33097230	N	.	N	Y	-0.181399394	36.65566939	4.86E-08	87	DM	GM1-gangliosidosis, type I, 230500 (3); GM1-gangliosidosis, type II, 230600 (3); GM1-gangliosidosis, type III, 230650 (3); Mucopolysaccharidosis type IVB (Morquio), 253010 (3)
GLB1L	2	219236606	219245478	N	.	N	N	0.010959166	50.34438849	2.52E-10	92.2	.	.
GLB1L2	11	134331874	134378341	N	.	N	N	0.406857631	76.20535973	1.45E-16	97.7	.	.
GLB1L3	11	134274245	134319564	N	.	N	N	0.164846502	62.1404179	1.89E-13	95.9	.	.
GLCCI1	7	7968794	8094272	N	.	N	N	-0.63939225	15.70295769	0.24528208	37.2	DFP	{Glucocorticoid therapy, response to}, 614400 (3)
GLDN	15	51341629	51408013	N	.	N	Y	0.557724031	82.72269491	1.79E-11	94	.	.
GLI1	12	57460135	57472262	N	.	N	Y	-0.890246442	9.787578862	1.95E-06	81.3	DFP	.
GLI4	8	143267433	143276931	N	.	N	N	-0.201341563	35.40545234	0.001021287	64.6	.	.
GLIPR1	12	75480680	75503853	N	.	N	Y	0.342703496	73.00457255	1.05E-09	91.1	.	.
GLIPR1L1	12	75334639	75370560	N	.	N	N	0.288268772	69.80378538	0.003663385	59.4	.	.
GLIPR1L2	12	75391070	75432688	N	.	N	N	0.34365998	73.06824101	0.003108624	60.2	.	.
GLIPR2	9	36136536	36163913	N	.	N	N	0.148430386	60.90756497	0.000501677	67	.	.
GLIS1	1	53506237	53738106	N	.	N	Y	0.346833134	73.23609423	0.099980948	43.1	.	.
GLIS2	16	4314761	4339597	N	.	N	Y	-0.084968981	43.20194478	0.953068391	14.5	DM	Nephronophthisis 7, 611498 (3)
GLMP	1	156290089	156295689	N	.	N	Y	.	.	.	.	.	.
GLO1	6	38675925	38703141	N	.	N	N	-0.351556594	26.68287318	0.000220689	69.5	DM?	.
GLOD4	17	757097	783390	N	.	N	N	0.277088785	69.12079643	8.11E-05	72.5	.	.
GLOD5	X	48761750	48773648	N	.	N	N	0.881990556	90.74492099	0.046077731	47.5	.	.
GLP1R	6	39048798	39087743	N	Viable	N	Y	0.234940518	66.52775366	0.064078049	45.6	DP	.
GLP2R	17	9822206	9892102	N	.	N	Y	0.01926743	51.03895352	1.04E-07	86.1	.	.
GLRA2	X	14529298	14731812	N	.	N	Y	-0.062612024	44.95572148	0.908587632	17.4	.	.
GLRA3	4	174636914	174829314	N	.	N	Y	-0.500506623	20.165538	0.043752559	47.7	.	.
GLRA4	X	103707224	103728655	N	.	N	N	0.64856997	85.56462349	4.17E-05	74.4	DM?	.
GLRX	5	95751319	95823005	N	.	N	Y	0.13805751	60.04514673	0.000187399	70	.	.
GLRX2	1	193096468	193106114	N	.	N	Y	0.390443887	75.38924582	6.51E-05	73.1	.	.
GLRX5	14	95533503	95544724	N	.	N	N	.	.	0.626214087	26.7	DM	?Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3)
GLS2	12	56470944	56488414	N	.	N	N	-0.763119335	12.3343173	0.000987122	64.8	.	.
GLT1D1	12	128853427	128984968	N	.	N	N	0.251709849	67.54644904	9.15E-05	72.1	.	.
GLT6D1	9	135623656	135639540	N	.	N	N	1.211487933	95.1380448	0.003188288	60.1	.	.
GLT8D1	3	52694485	52706083	N	.	N	Y	-0.41429797	23.70781964	0.003489775	59.7	.	.
GLTP	12	109850943	109880488	N	.	N	N	-0.236138921	33.29860508	0.227088706	37.8	.	.
GLTPD2	17	4788959	4790390	N	.	N	N	0.382940675	75.05932743	0.025977798	50.4	.	.
GLTSCR1	19	47608196	47703277	N	.	N	N	.	.	0.997123314	7.5	DP	.
GLTSCR2	19	47745522	47757058	N	.	N	N	0.651439248	85.66880824	0.253946324	37	.	.
GLUD1	10	87050486	87094866	N	.	N	N	-0.770777527	12.16646409	0.013935465	53.5	DM	Hyperinsulinism-hyperammonemia syndrome, 606762 (3)
GLUD2	X	121047588	121050080	N	.	N	N	0.208604733	64.97655843	0.071307892	45	DFP	.
GLYAT	11	58640426	58731974	N	.	N	N	0.700137096	86.89008508	8.04E-05	72.6	FP	.
GLYATL1	11	58905398	59043527	N	.	N	N	0.203971741	64.62927592	6.27E-05	73.3	.	.
GLYATL2	11	58834065	58904215	N	.	N	N	1.298669382	95.78630549	9.10E-11	93	.	.
GLYATL3	6	49499958	49527047	N	.	N	N	.	.	.	.	.	.
GLYCTK	3	52287089	52293476	N	.	N	N	-0.06039484	45.06569428	1.36E-06	82.1	DM	D-glyceric aciduria, 220120 (3)
GLYR1	16	4803203	4847342	N	.	N	N	-1.338185338	4.416275974	0.999877719	3.9	.	.
GM2A	5	151212150	151270440	N	.	N	Y	0.378306375	74.85095792	0.111186455	42.5	DM	GM2-gangliosidosis, AB variant, 272750 (3)
GMCL1	2	69829642	69881396	N	.	N	Y	-0.2153906	34.56618626	9.62E-06	78.2	.	.
GMDS	6	1623806	2245692	N	.	N	N	-0.530674014	18.96162528	0.997690129	7.2	DM?	.
GMEB1	1	28668732	28719353	N	.	N	N	-0.80542189	11.43717081	0.960593932	13.9	.	.
GMEB2	20	63587602	63627041	N	.	N	N	-0.770622677	12.17804017	0.990659131	9.8	.	.
GMFB	14	54474484	54489196	N	.	N	Y	0.017051112	50.83058401	0.323144112	35.1	.	.
GMFG	19	39328353	39342372	N	.	N	N	0.178442775	63.08386873	1.91E-05	76.3	.	.
GMIP	19	19629476	19643667	N	.	N	N	-0.073336293	44.17433582	7.29E-05	72.8	DFP	.
GML	8	142834247	142916506	N	.	N	N	0.761932533	88.3428836	0.439134842	31.7	FTV	.
GMNC	3	190852877	190892429	N	Viable	N	Y	.	.	.	.	.	.
GMPPA	2	219498867	219506988	N	.	N	N	0.133574517	59.72680442	2.35E-06	81	.	Alacrima, achalasia, and mental retardation syndrome, 615510 (3)
GMPPB	3	49716844	49723951	N	.	N	N	-0.608422187	16.49591943	8.25E-05	72.5	DM	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 (3); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 (3); Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 (3)
GMPR	6	16238580	16295549	N	.	N	N	0.058544531	53.99664294	0.002525686	61.1	.	.
GMPR2	14	24232422	24239242	N	.	N	N	0.224567453	65.92000926	0.000987613	64.8	.	.
GMPS	3	155870536	155944026	N	.	N	N	-0.750026799	12.61793135	0.993904306	8.9	.	.
GNA11	19	3094410	3124004	N	.	N	Y	-0.399291813	24.48341726	0.966183014	13.4	DM	Hypocalciuric hypercalcemia, type II, 145981 (3); Hypocalcemia, autosomal dominant 2, 615361 (3)
GNA12	7	2728112	2844324	N	.	N	Y	0.059501305	54.07188748	0.908269982	17.4	.	.
GNA14	9	77423079	77648307	N	.	N	N	0.28091539	69.36968224	6.82E-10	91.4	.	.
GNA15	19	3136193	3163769	N	.	N	Y	0.00315321	49.71927997	0.306963812	35.6	.	.
GNAI1	7	80133955	80219402	N	Viable	N	Y	-0.484697758	20.7732824	0.917528244	16.8	.	.
GNAI3	1	109548611	109618321	N	.	N	Y	-0.31116943	28.88232911	0.038811278	48.5	DM	Auriculocondylar syndrome 1, 602483 (3)
GNAT1	3	50191612	50196516	N	.	N	Y	-0.418929621	23.54575447	2.51E-06	80.8	DM	Night blindness, congenital stationary, autosomal dominant 3, 610444 (3); ?Night blindness, congenital stationary, type 1G, 616389 (3)
GNAT2	1	109603267	109619929	N	.	N	N	-0.02031261	47.87868264	0.008158652	55.8	DM	Achromatopsia-4, 613856 (3)
GNAT3	7	80458671	80512020	N	.	N	Y	0.107238638	57.76465822	0.000297548	68.7	.	.
GNAZ	22	23070361	23125037	N	.	N	Y	-0.658228302	15.08363721	0.886293664	18.4	.	.
GNB2	7	100673531	100679174	N	.	N	N	-0.725757668	13.23725184	0.989239435	10.1	.	.
GNB2L1	5	181236909	181248096	N	.	N	N	-0.230550154	33.7153441	0.994631521	8.5	.	.
GNB4	3	179396089	179451590	N	.	N	N	0.098778904	57.07588123	0.629775083	26.7	DM	Charcot-Marie-Tooth disease, dominant intermediate F, 615185 (3)
GNG10	9	111661335	111670246	N	.	N	N	0.075162561	55.29316432	0.00031015	68.5	.	.
GNG11	7	93921699	93928610	N	.	N	N	0.288120873	69.75748104	0.163792462	40	.	.
GNG12	1	67701466	67833467	N	.	N	N	0.295624092	70.22631244	0.553351818	28.6	.	.
GNG2	14	51826195	51979342	N	.	N	N	0.166157019	62.22723853	0.523770491	29.3	.	.
GNG3	11	62707658	62709201	N	.	N	Y	0.000131289	49.44145396	0.52722723	29.2	.	.
GNG4	1	235547687	235650754	N	.	N	N	0.159610371	61.7121028	0.158455672	40.2	.	.
GNG5	1	84498325	84506565	N	.	N	N	0.15865385	61.61949413	0.524989345	29.3	.	.
GNG7	19	2511219	2702709	N	.	N	Y	0.052653149	53.55096371	0.47555714	30.7	.	.
GNG8	19	46634076	46634685	N	.	N	Y	0.319090009	71.70805117	0.147000774	40.7	.	.
GNGT1	7	93591573	93911265	N	.	N	Y	0.145560638	60.65289113	0.276892737	36.3	.	.
GNGT2	17	49202791	49210574	N	.	N	N	0.25810805	67.9284598	0.173047626	39.6	.	.
GNL1	6	30541377	30557174	N	.	N	N	-0.386046286	25.13167795	0.999930615	3.5	FTV	.
GNL2	1	37566816	37595935	N	.	N	N	-0.731042844	13.13306708	0.45303247	31.3	.	.
GNL3L	X	54530211	54561071	N	.	N	N	0.036992354	52.33547491	0.991954332	9.4	.	.
GNLY	2	85685175	85698854	N	.	N	N	1.00682807	92.85176825	0.001549957	62.9	.	.
GNMT	6	42960758	42963880	N	.	N	Y	0.083772833	56.01666956	0.667933556	25.6	DM	Glycine N-methyltransferase deficiency, 606664 (3)
GNPAT	1	231241207	231277973	N	.	N	Y	-0.229287694	33.77322452	0.291272733	35.9	DM	Chondrodysplasia punctata, rhizomelic, type 2, 222765 (3)
GNPDA2	4	44682200	44726595	N	Viable	N	Y	-0.161108498	37.92903861	0.012646181	54	.	.
GNPTAB	12	101745497	101830938	N	.	N	N	-0.648217925	15.43091972	4.23E-06	79.9	DM	Mucolipidosis III alpha/beta, 252600 (3); Mucolipidosis II alpha/beta, 252500 (3)
GNPTG	16	1351923	1364113	N	.	N	Y	-0.710596154	13.60768652	6.00E-08	86.7	DM	.
GNRH1	8	25419260	25424654	N	.	N	N	0.608040007	84.39543902	0.098691606	43.2	DM	?Hypogonadotropic hypogonadism 12 with or without anosmia, 614841 (3)
GNRH2	20	3043622	3045747	N	.	N	N	0.427960039	77.28193552	0.000228749	69.4	.	.
GNRHR	4	67739328	67754360	N	.	N	N	0.101649038	57.35370724	0.013968045	53.5	DM	Hypogonadotropic hypogonadism 7 without anosmia, 146110 (3)
GNS	12	64713445	64759447	N	.	N	N	-0.993965971	7.95855762	0.082905296	44.2	DM	Mucopolysaccharidosis type IIID, 252940 (3)
GOLGA1	9	124878357	124948492	N	.	N	N	-0.295858114	29.68686693	0.006107394	57.1	.	.
GOLGA2	9	128255829	128275995	N	.	N	N	0.030901164	51.86664351	0.994925569	8.4	.	.
GOLGA3	12	132768909	132828858	N	Viable	N	Y	-0.367161705	26.02303641	0.991564256	9.6	DM?	.
GOLGA4	3	37243177	37366751	N	.	N	N	-0.589434358	17.0862997	2.26E-09	90.4	.	.
GOLGA5	14	92794231	92839963	N	.	N	N	0.002499372	49.67297563	0.363133885	33.8	DP	.
GOLGA6A	15	74069857	74082550	N	.	N	N	.	.	0.224411354	37.9	.	.
GOLGA6B	15	72654738	72666394	N	.	N	N	.	.	0.302338864	35.7	.	.
GOLGA6C	15	75258599	75270199	N	.	N	N	.	.	0.04005143	48.3	.	.
GOLGA6D	15	75258558	75295530	N	.	N	N	.	.	0.318585416	35.2	.	.
GOLGA6L1	15	23128268	23136822	N	.	N	N	.	.	.	.	.	.
GOLGA6L10	15	82339998	82349475	N	.	N	N	.	.	0.36895894	33.6	.	.
GOLGA6L2	15	23439498	23447234	N	.	N	N	.	.	8.97E-06	78.3	.	.
GOLGA6L22	15	22458903	22469230	N	.	N	N	.	.	.	.	.	.
GOLGA6L4	15	84235773	84245368	N	.	N	N	.	.	0.389324704	33	.	.
GOLGA6L6	15	20531856	20541800	N	.	N	N	.	.	0.086864302	44	FTV	.
GOLGA6L9	15	82430018	82439153	N	.	N	N	.	.	.	.	.	.
GOLGA7	8	41490396	41510980	N	.	N	N	0.122094661	58.87017422	0.691723361	24.8	.	.
GOLGA7B	10	97850239	97871580	N	.	N	N	-0.193034849	35.95531632	0.010488375	54.7	.	.
GOLGA8A	15	34379068	34437466	N	.	N	N	.	.	0.693302517	24.8	.	.
GOLGA8B	15	34525207	34588503	N	.	N	N	.	.	0.280132445	36.2	.	.
GOLGA8F	15	28378621	28392018	N	.	N	N	.	.	0.559396883	28.4	.	.
GOLGA8G	15	28519611	28533014	N	.	N	N	.	.	0.447085283	31.5	.	.
GOLGA8H	15	30604126	30614561	N	.	N	N	.	.	3.20E-05	75.1	.	.
GOLGA8J	15	30083053	30093499	N	.	N	N	.	.	0.35505685	34	.	.
GOLGA8K	15	32392782	32403292	N	.	N	N	.	.	0.33764279	34.6	.	.
GOLGA8M	15	28701954	28738384	N	.	N	N	.	.	0.920983506	16.7	.	.
GOLGA8N	15	32593456	32607310	N	.	N	N	.	.	.	.	.	.
GOLGA8O	15	32445106	32455634	N	.	N	N	.	.	.	.	.	.
GOLGA8Q	15	30552078	30562501	N	.	N	N	.	.	0.480898387	30.5	.	.
GOLGA8R	15	30403740	30414162	N	.	N	N	.	.	0.175047824	39.5	.	.
GOLGA8S	15	23354748	23367231	N	.	N	N	.	.	0.004662616	58.5	.	.
GOLGA8T	15	30135149	30145567	N	.	N	N	.	.	0.761434671	22.8	.	.
GOLGB1	3	121663199	121749767	N	.	N	N	-0.271922988	31.15702958	4.23E-06	79.8	DP	.
GOLIM4	3	168008677	168095975	N	.	N	N	-0.527497788	19.10053829	5.54E-11	93.3	.	.
GOLM1	9	86026146	86100173	N	.	N	N	0.926344755	91.6304914	0.002612536	60.9	.	.
GOLPH3	5	32124704	32174350	N	.	N	N	-0.130139339	40.0821902	0.014365491	53.4	.	.
GOLPH3L	1	150646225	150697144	N	.	N	N	0.401772227	75.92174567	0.022106746	51.2	.	.
GOLT1A	1	204198160	204214092	N	.	N	N	0.23846774	66.7534873	0.038757883	48.5	.	.
GOLT1B	12	21501781	21518408	N	.	N	N	0.13805751	60.04514673	0.79838372	21.7	.	.
GON4L	1	155749662	155859400	N	.	N	N	-1.446203587	3.704346819	0.999998892	1.7	DM	.
GOPC	6	117560269	117602542	N	.	N	Y	-0.321389901	28.22828037	0.02198408	51.2	.	.
GORAB	1	170532129	170553446	N	.	N	N	-0.196556891	35.70643051	6.83E-06	79	DM	Geroderma osteodysplasticum, 231070 (3)
GORASP1	3	39096659	39108363	N	.	N	N	0.279958701	69.3233779	0.69837775	24.7	.	.
GORASP2	2	170928464	170967129	N	.	N	N	-0.388917343	25.00434103	0.89106444	18.2	.	.
GOSR1	17	30477362	30527592	N	.	N	N	-0.417169759	23.60942293	0.450937721	31.4	.	.
GOT1	10	99396870	99430624	N	.	N	N	-0.292334822	29.87208427	0.129221467	41.6	DM	Aspartate aminotransferase, serum level of, QTL1, 614419 (3)
GOT1L1	8	37934281	37940129	N	.	N	N	0.447896377	78.26590265	2.12E-10	92.4	.	.
GOT2	16	58707131	58734357	N	.	N	N	0.271498993	68.77351392	0.89649116	17.9	.	.
GP1BA	17	4932297	4935030	N	.	N	Y	-0.368018762	25.9535799	0.013157716	53.8	DM	Bernard-Soulier syndrome, type A1 (recessive), 231200 (3); {Nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3); Bernard-Soulier syndrome, type A2 (dominant), 153670 (3); von Willebrand disease, platelet-type, 177820 (3)
GP1BB	22	19722945	19724771	N	Viable	N	Y	.	.	0.101120792	43	DM	Bernard-Soulier syndrome, type B, 231200 (3); Giant platelet disorder, isolated, 231200 (3)
GP2	16	20309572	20327808	N	.	N	Y	0.058695894	54.00821902	1.13E-12	95.2	DFP	.
GP5	3	194394821	194398354	N	.	N	Y	-0.01265806	48.49800313	4.01E-06	80	.	.
GP6	19	55013705	55038264	N	.	N	Y	0.745457818	87.97823696	1.20E-14	96.7	DM	Bleeding disorder, platelet-type, 11, 614201 (3)
GP9	3	129060767	129062406	N	Viable	N	Y	0.557428105	82.71111883	0.570607601	28.2	DM	Bernard-Soulier syndrome, type C, 231200 (3)
GPA33	1	167052836	167166479	N	.	N	N	0.545437394	82.24807548	1.50E-06	81.9	.	.
GPAA1	8	144082590	144086216	N	.	N	N	-0.05002151	45.76604735	2.89E-07	84.6	.	.
GPALPP1	13	44989529	45037669	N	.	N	N	0.328653775	72.25212711	0.000396088	67.7	.	.
GPAM	10	112149864	112215377	N	.	N	Y	-0.048107958	45.96284077	0.000580579	66.6	DM	.
GPANK1	6	31661229	31666283	N	Viable	N	Y	0.383088549	75.0824796	0.000931901	65	DP	.
GPAT2	2	96021946	96039451	N	.	N	N	0.572730387	83.19152631	0.0016123	62.8	.	.
GPATCH1	19	33080880	33130542	N	.	N	N	-0.086428999	43.0803959	3.44E-05	74.9	.	.
GPATCH11	2	37084451	37099244	N	.	N	N	0.313499354	71.29131215	1.27E-05	77.4	.	.
GPATCH2	1	217426992	217631082	N	.	N	N	0.067004291	54.66226775	9.66E-05	72	.	.
GPATCH2L	14	76151916	76254342	N	.	N	N	-0.726559776	13.22567575	0.539068808	28.9	.	.
GPATCH3	1	26890488	26900466	N	.	N	N	-0.029426144	47.35197083	6.05E-07	83.4	.	.
GPATCH4	1	156594487	156601496	N	.	N	N	0.443113628	78.02859293	1.69E-07	85.4	FTV	.
GPATCH8	17	44395284	44503430	N	.	N	N	-0.759682553	12.39798576	0.99949549	5.2	DM	.
GPBAR1	2	218259496	218263859	N	Viable	N	Y	0.386914904	75.23875673	1.86E-06	81.4	DM?	.
GPBP1	5	57173948	57264679	N	.	N	N	-0.175004808	37.08977253	0.975851112	12.3	.	.
GPBP1L1	1	45627304	45688113	N	.	N	N	-0.172134192	37.24026162	0.43532405	31.8	.	.
GPC1	2	240435671	240468078	N	.	N	N	0.873972423	90.65810036	0.109569938	42.6	DM	.
GPC4	X	133300103	133415490	N	.	N	Y	0.065090757	54.56387104	0.948476975	14.9	DM?	.
GPC5	13	91398675	92873682	N	.	N	Y	0.100038089	57.21479424	1.99E-05	76.2	DM	.
GPC6	13	93226842	94407401	N	.	N	N	-0.321237518	28.23406841	0.338854613	34.6	DM	Omodysplasia 1, 258315 (3)
GPCPD1	20	5544404	5611026	N	.	N	N	-0.194643158	35.86849569	0.125571599	41.8	.	.
GPD1	12	50103819	50111319	N	.	N	N	0.400007863	75.84071309	0.147319093	40.7	DM	Hypertriglyceridemia, transient infantile, 614480 (3)
GPD1L	3	32105689	32168713	N	.	N	N	-0.526844603	19.11790241	0.009537828	55.1	DM	Brugada syndrome 2, 611777 (3)
GPER1	7	1082208	1093815	N	.	N	Y	-0.490132566	20.5938531	0.725420979	23.9	.	.
GPHA2	11	64934471	64935888	N	.	N	N	0.268480327	68.6056607	2.07E-05	76.1	.	.
GPHB5	14	63312835	63318879	N	.	N	Y	.	.	.	.	.	.
GPIHBP1	8	143213193	143217170	N	.	N	Y	0.640921144	85.36783006	0.023780963	50.7	DM	Hyperlipoproteinemia, type 1D, 615947 (3)
GPKOW	X	49113389	49123801	N	.	N	N	0.382132046	75.02459918	0.979573127	11.8	.	.
GPLD1	6	24424565	24495205	N	Viable	N	Y	0.325436142	72.05533368	5.64E-09	89.5	.	.
GPM6A	4	175632934	176002664	N	.	N	Y	-0.464103204	21.6993691	0.952961852	14.5	DFP	.
GPM6B	X	13771031	13938638	N	.	N	Y	-0.221132832	34.27099612	0.494053307	30.1	.	.
GPN1	2	27628247	27651508	N	.	N	N	0.135487969	59.87729351	0.004903592	58.2	.	.
GPN2	1	26876133	26890297	N	.	N	N	-0.200384589	35.4691208	0.036923454	48.7	.	.
GPN3	12	110452484	110469268	N	.	N	N	-0.316758145	28.47137813	0.000100472	71.8	.	.
GPNMB	7	23235967	23275108	N	Viable	N	Y	0.729493997	87.56728599	1.12E-12	95.2	.	.
GPR1	2	206175316	206218047	N	Viable	N	Y	0.23207049	66.37147653	1.84E-05	76.5	FTV	.
GPR101	X	137030148	137031674	N	.	N	N	0.921562896	91.52630665	0.403512442	32.7	.	Pituitary adenoma, growth hormone-secreting 2, 300943 (3)
GPR108	19	6729914	6737603	N	.	N	N	0.932085829	91.76361637	1.69E-08	88.3	.	.
GPR119	X	130384440	130385447	N	.	N	N	-0.039146033	46.66319384	0.097255905	43.4	.	.
GPR12	13	26755200	26760785	N	.	N	Y	-0.45372795	22.13347225	0.852043162	19.8	DM	.
GPR132	14	105049389	105065445	N	.	N	Y	-0.310058921	28.94020953	0.03471241	49	.	.
GPR135	14	59429022	59465342	N	.	N	N	0.724559727	87.51519361	0.003932041	59.1	.	.
GPR137	11	64270062	64289500	N	.	N	N	-0.203103007	35.27811541	0.48439827	30.4	.	.
GPR137B	1	236142505	236221865	N	.	N	N	-0.048410911	45.9396886	0.00025303	69.1	.	.
GPR137C	14	52553148	52637713	N	.	N	N	-0.481825845	20.92377149	0.695444477	24.8	.	.
GPR139	16	20031485	20073917	N	Viable	N	Y	-0.186335547	36.37784338	0.144423629	40.8	DM?	.
GPR141	7	37683796	37833788	N	.	N	N	-0.010895966	48.63112809	1.53E-05	77	.	.
GPR142	17	74367407	74372622	N	.	N	N	1.361717971	96.19725647	5.60E-05	73.6	.	.
GPR143	X	9725346	9786297	N	.	N	Y	0.368890551	74.33003415	0.672222024	25.5	DM	Ocular albinism, type I, Nettleship-Falls type, 300500 (3); Nystagmus 6, congenital, X-linked, 300814 (3)
GPR146	7	1044576	1059261	N	.	N	N	-0.020161029	47.89604677	0.002794126	60.6	.	.
GPR148	2	130729070	130730336	N	.	N	N	0.862490667	90.4150026	0.004809517	58.3	.	.
GPR149	3	154337672	154429715	N	.	N	Y	-0.879200336	9.955432077	2.65E-05	75.5	.	.
GPR15	3	98531899	98533150	N	.	N	Y	-0.275414705	30.96023615	0.003264999	60	.	.
GPR150	5	95620078	95622142	N	.	N	N	.	.	0.002247162	61.5	.	.
GPR151	5	146513103	146516190	N	.	N	Y	1.220904521	95.24222955	1.06E-05	77.9	.	.
GPR152	11	67451301	67452729	N	Viable	N	Y	0.067155682	54.6680558	1.01E-05	78	DM?	.
GPR153	1	6247346	6260975	N	.	N	N	0.078334396	55.57677838	0.000377954	68	.	.
GPR155	2	174431571	174487094	N	.	N	N	-0.898988059	9.608149563	8.13E-11	93.1	.	.
GPR156	3	120164645	120285094	N	.	N	N	0.657333237	85.83087342	3.68E-07	84.2	.	.
GPR157	1	9100305	9129170	N	.	N	N	0.383088549	75.0824796	2.63E-05	75.5	.	.
GPR158	10	25175062	25602226	N	Viable	N	Y	-0.523384016	19.28575563	0.678504825	25.2	.	.
GPR160	3	170037929	170085403	N	.	N	N	0.675714658	86.31128089	0.00375672	59.3	.	.
GPR162	12	6821545	6829972	N	.	N	N	-0.574430068	17.52040285	0.017134388	52.4	.	.
GPR17	2	127645864	127652639	N	Viable	N	Y	0.77531884	88.67859003	1.07E-05	77.9	.	.
GPR171	3	151197832	151203201	N	.	N	N	-0.461231059	21.83249407	0.001675121	62.6	.	.
GPR173	X	53049091	53080615	N	.	N	N	-0.290574674	29.99363315	0.678239842	25.2	.	.
GPR174	X	79170972	79172229	N	.	N	Y	0.225374457	65.97210164	0.888101966	18.3	DM?	.
GPR176	15	39799023	39920892	N	.	N	N	-0.524930204	19.22208717	0.413262635	32.4	.	.
GPR179	17	38325530	38343847	N	.	N	N	3.00533003	99.54274469	2.68E-20	98.8	DM	Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 (3)
GPR18	13	99254714	99261744	N	.	N	N	-0.29042075	30.03993749	9.92E-07	82.5	.	.
GPR180	13	94601903	94634645	N	.	N	Y	-0.511838334	19.74301094	6.59E-11	93.2	.	.
GPR182	12	56994446	56998441	N	Viable	N	Y	-0.46953715	21.46205939	0.000859696	65.3	.	.
GPR183	13	99294530	99307405	N	.	N	Y	0.0931893	56.64756613	0.025545632	50.4	.	.
GPR19	12	12660891	12696207	N	.	N	Y	-0.283874745	30.4277363	0.348589814	34.2	.	.
GPR20	8	141356500	141367267	N	Viable	N	Y	0.83998017	90.00405163	0.3150686	35.3	.	.
GPR21	9	123034527	123035696	N	.	N	Y	-0.535305023	18.7706199	0.024651114	50.6	.	.
GPR22	7	107470018	107475659	N	Viable	N	Y	-0.363690885	26.19088962	0.427181285	32.1	.	.
GPR25	1	200873038	200874123	N	.	N	N	0.127834418	59.29270128	0.005635451	57.5	.	.
GPR26	10	123666355	123694607	N	.	N	Y	-0.296163317	29.65792672	0.627337377	26.7	.	.
GPR27	3	71754050	71756496	N	.	N	N	.	.	0.598851196	27.5	.	.
GPR3	1	27392644	27395814	N	.	N	Y	-0.17883254	36.80037043	0.020935797	51.4	.	.
GPR31	6	167156271	167158329	N	.	N	N	0.802462863	89.1995138	0.000351018	68.2	.	.
GPR32	19	50770464	50771732	N	.	N	N	-0.075552304	44.00069457	7.91E-05	72.6	.	.
GPR33	14	31482964	31487945	N	Viable	N	Y	.	.	.	.	FP	.
GPR34	X	41688973	41697277	N	.	N	Y	-0.025096816	47.5834925	0.457038661	31.2	.	.
GPR35	2	240605431	240631259	N	.	N	N	0.932891782	91.78676854	0.003635581	59.5	.	.
GPR37	7	124745997	124765627	N	.	N	Y	-0.319323968	28.32088904	0.799390711	21.7	DM?	.
GPR37L1	1	202122858	202133592	N	.	N	Y	-0.655202523	15.19939804	2.88E-07	84.6	.	.
GPR39	2	132416574	132646559	N	.	N	Y	-0.000371054	49.40093766	1.55E-12	95.1	.	.
GPR42	19	35370929	35372962	N	.	N	N	.	.	0.659177796	25.8	.	.
GPR45	2	105241743	105243049	N	.	N	N	-0.752898517	12.51953464	0.864764501	19.3	.	.
GPR50	X	151176653	151181465	N	Viable	N	Y	0.686235642	86.56595474	0.445210115	31.6	.	.
GPR52	1	174448111	174449198	N	.	N	Y	0.047214459	53.18052903	0.065458592	45.5	.	.
GPR55	2	230907318	230961066	N	.	N	Y	-0.071876736	44.2958847	0.000388569	67.8	DFP	.
GPR6	6	109978256	109980718	N	.	N	Y	-0.146906657	38.94194594	0.746040035	23.2	.	.
GPR61	1	109539872	109548406	N	.	N	N	-0.920845623	9.20298663	0.801488898	21.6	.	.
GPR62	3	51955314	51957504	N	.	N	N	.	.	0.229621631	37.7	.	.
GPR63	6	96794126	96837463	N	Viable	N	Y	-0.259451686	31.91526307	0.64635908	26.1	.	.
GPR65	14	88005124	88014811	N	Viable	N	Y	-0.013766433	48.44591075	0.505440551	29.8	.	.
GPR68	14	91232532	91253925	N	.	N	Y	-0.599160107	16.73322915	0.000219037	69.5	DP	.
GPR75	2	53852913	53859989	N	.	N	N	-0.375672502	25.64681368	0.003194802	60.1	DM?	.
GPR75-ASB3	2	53670293	53860160	N	.	N	N	0.012721269	50.46593737	0.247642059	37.2	.	.
GPR78	4	8558725	8619761	N	.	N	N	0.240681152	66.90976443	1.28E-05	77.4	.	.
GPR82	X	41724155	41730135	N	.	N	Y	-0.001630854	49.29675291	0.001018511	64.6	.	.
GPR83	11	94377311	94401419	N	.	N	Y	0.262233352	68.20049777	0.032467713	49.3	.	.
GPR84	12	54362445	54364487	N	Viable	N	Y	1.113937017	94.1019853	2.72E-07	84.7	.	.
GPR85	7	113078331	113087778	N	.	N	Y	-0.606663309	16.55379985	0.8104471	21.3	.	.
GPR87	3	151294086	151316952	N	.	N	Y	0.324977012	72.03796955	0.290536849	36	.	.
GPR88	1	100538137	100542018	N	.	N	N	.	.	0.754055177	23	.	.
GPR89A	1	145607990	145670648	N	.	N	N	.	.	0.847988631	20	.	.
GPR89B	1	147928393	147993521	N	.	N	N	.	.	0.791699862	21.9	.	.
GPRASP1	X	102651366	102659083	N	.	N	Y	0.916277267	91.4221219	0.501518109	29.9	.	.
GPRASP2	X	102712176	102717733	N	.	N	N	0.752808741	88.15187822	0.498014765	30	.	.
GPRC5A	12	12890782	12917937	N	.	N	Y	0.599873048	84.11761301	8.03E-06	78.6	.	.
GPRC5B	16	19856691	19886167	Y	Viable	N	Y	-0.006111899	49.02471494	0.527206906	29.2	.	.
GPRC5C	17	74424851	74451653	N	.	N	Y	0.242594876	67.05446547	0.005513607	57.7	.	.
GPRC5D	12	12940775	12952147	N	Viable	N	Y	-0.214433638	34.65879493	2.97E-05	75.2	.	.
GPRC6A	6	116792085	116829037	N	.	N	Y	1.430533819	96.56190311	4.64E-14	96.4	DP	.
GPRIN1	5	176595802	176610133	N	.	N	N	-0.214938193	34.59512647	0.787287342	22.1	.	.
GPRIN2	10	46549044	46555530	N	.	N	N	2.932091438	99.48486427	0.000296291	68.7	.	.
GPRIN3	4	89236386	89308010	N	.	N	N	1.650080493	97.73108757	0.000266284	69	DM?	.
GPS2	17	7311324	7315564	N	.	N	N	-0.587827164	17.15575621	0.590137502	27.7	.	.
GPSM1	9	136327476	136359605	N	Viable	N	Y	-0.50977145	19.81246744	0.002149527	61.6	.	.
GPSM3	6	32190766	32195523	N	Viable	N	Y	0.343512144	73.05666493	0.609591628	27.2	.	.
GPT	8	144502973	144507174	N	.	N	N	0.043689954	52.85639868	2.84E-15	97	DM	.
GPT2	16	46884378	46931297	N	.	N	N	-0.72751688	13.20252359	0.00368564	59.4	.	?Mental retardation, autosomal recessive 49, 616281 (3)
GPX1	3	49357176	49358600	N	Viable	N	Y	0.097822207	56.98327256	0.006931651	56.6	DFP	Hemolytic anemia due to glutathione peroxidase deficiency, 614164 (1)
GPX2	14	64939152	64942905	N	.	N	N	-0.031643	47.17832957	0.002317034	61.4	.	.
GPX5	6	28525925	28534952	N	.	N	Y	0.612819541	84.5575042	0.008884677	55.4	.	.
GPX6	6	28503296	28528215	N	.	N	N	0.991820467	92.66655091	3.14E-05	75.1	.	.
GPX7	1	52602372	52609051	N	.	N	Y	0.330418352	72.31579557	0.000179755	70.1	.	.
GPX8	5	55160118	55167071	N	.	N	N	0.056480057	53.81721364	0.019066229	51.9	.	.
GRAMD1A	19	34994784	35026471	N	.	N	N	-0.531175395	18.9500492	0.568380699	28.3	.	.
GRAMD1B	11	123454398	123627774	N	.	N	N	-0.182507799	36.58042484	0.984850768	10.9	.	.
GRAMD1C	3	113828182	113947174	N	.	N	N	-0.038842712	46.68634601	8.13E-10	91.3	.	.
GRAMD2	15	72159807	72197785	N	.	N	N	0.662620317	85.99872663	2.96E-08	87.6	.	.
GRAMD3	5	126360132	126496494	N	.	N	N	-0.160955729	37.95219077	1.54E-07	85.6	.	.
GRAMD4	22	46576012	46679790	N	.	N	N	-0.852203082	10.52266018	0.999791413	4.3	.	.
GRAP	17	19020673	19047637	N	.	N	Y	.	.	0.217063635	38.1	.	.
GRAP2	22	39901082	39973721	N	.	N	Y	-0.102845596	41.94593969	0.101871595	43	.	.
GRAPL	17	19127469	19159176	N	.	N	N	.	.	.	.	.	.
GRASP	12	52006940	52015889	N	.	N	Y	-0.071071979	44.35376512	0.930936502	16.1	.	.
GRB14	2	164492812	164621848	N	.	N	Y	0.003304686	49.75979626	0.096601217	43.4	.	.
GRB7	17	39737927	39747291	N	Viable	N	Y	-0.110045452	41.45395613	0.000820006	65.4	.	.
GREB1	2	11482341	11642788	N	Viable	N	Y	0.093768091	56.66493025	0.025485538	50.4	.	.
GREB1L	18	21242242	21525417	N	.	N	N	.	.	.	.	FTV	.
GREM2	1	240489573	240612149	N	.	N	N	-0.049519725	45.82392777	0.081742843	44.3	.	.
GRHL1	2	9951693	10002277	N	.	N	Y	-0.671165896	14.71899057	0.983150779	11.2	.	.
GRHPR	9	37422666	37436990	N	.	N	N	-0.063416885	44.9036291	0.00013344	71	DM	Hyperoxaluria, primary, type II, 260000 (3)
GRIA1	5	153489615	153813869	N	.	N	Y	-1.278004027	4.856167159	0.999436341	5.3	DM?	.
GRIA3	X	123184153	123490915	N	.	N	Y	-0.865449062	10.26798634	0.998653778	6.3	DM	Mental retardation, X-linked 94, 300699 (3)
GRIA4	11	105609994	105982092	N	.	N	Y	-1.530428038	3.194999132	0.98874921	10.2	.	.
GRID1	10	85599555	86366493	N	.	N	Y	-1.939259633	1.800081033	0.950796126	14.7	DP	.
GRID2IP	7	6497462	6551436	N	.	N	Y	.	.	0.314734428	35.3	.	.
GRIFIN	7	2474844	2476894	N	.	N	N	.	.	.	.	.	.
GRIK1	21	29536933	29940033	N	.	N	Y	-0.843451541	10.71945361	3.21E-05	75	DP	.
GRIK2	6	101398788	102070083	N	.	N	Y	-1.171991482	5.880650576	0.994567954	8.6	DM	Mental retardation, autosomal recessive, 6, 611092 (3)
GRIK3	1	36795527	37034129	N	.	N	Y	-1.725415058	2.361521097	0.99998017	2.8	DM	.
GRIK4	11	120511759	120988904	N	.	N	Y	-0.856689587	10.45320368	0.630846158	26.6	DFP	.
GRIK5	19	41998321	42069498	N	.	N	Y	-0.903623108	9.509752851	0.917779688	16.8	.	.
GRIN2A	16	9753404	10182754	N	.	N	Y	-2.3464153	1.082363836	0.998044808	6.9	DM	Epilepsy, focal, with speech disorder and with or without mental retardation, 245570 (3)
GRIN2C	17	74842023	74861504	N	.	N	Y	0.418189625	76.72049546	0.003937648	59.1	FTV	.
GRIN2D	19	48394875	48444931	N	.	N	Y	-1.163679704	5.961683163	0.998648757	6.3	.	.
GRIN3A	9	101569353	101738580	N	.	N	Y	-0.167049899	37.59333218	0.123333065	41.9	DM?	.
GRIN3B	19	1000419	1009732	N	.	N	Y	.	.	0.001113712	64.3	.	.
GRINA	8	143990058	143993415	N	.	N	Y	-0.124397678	40.48156509	0.757342473	22.9	.	.
GRIP2	3	14489111	14542081	N	.	N	N	.	.	.	.	.	.
GRIPAP1	X	48973720	49002264	N	.	N	N	-0.427389804	23.21583608	0.996933311	7.6	.	.
GRK1	13	113667155	113737735	N	.	N	Y	.	.	0.009154212	55.3	DM	Oguchi disease-2, 613411 (3)
GRK4	4	2963608	3040747	N	.	N	Y	0.927454043	91.66521966	5.69E-07	83.5	DP	.
GRK5	10	119207589	119459742	N	Viable	N	Y	-0.185226508	36.44151184	0.984107718	11.1	DFP	.
GRK6	5	177403204	177442901	N	.	N	Y	-0.486305293	20.71540198	0.248841091	37.1	.	.
GRK7	3	141778148	141818490	N	.	N	N	0.976150073	92.41187706	1.19E-07	85.9	.	.
GRM1	6	146027646	146437598	N	.	N	Y	-1.410078509	3.883776119	0.989964592	9.9	DM	Spinocerebellar ataxia, autosomal recessive 13, 614831 (3)
GRM2	3	51707070	51718613	N	.	N	Y	-0.165286254	37.70330497	0.983083426	11.2	.	.
GRM3	7	86643914	86864884	N	Viable	N	Y	-1.278960202	4.844591075	0.984710457	10.9	DP	.
GRM4	6	34018645	34155622	N	.	N	Y	-1.867063133	1.996874457	0.979350085	11.9	.	.
GRM5	11	88504576	89065945	N	.	N	Y	-1.775221198	2.263124385	0.985984068	10.8	DM	.
GRM6	5	178978327	178996206	N	Viable	N	Y	1.122871013	94.22353418	2.42E-09	90.3	DM	Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 (3)
GRM7	3	6770001	7741533	N	.	N	Y	-1.045237847	7.269780633	0.999169069	5.7	DM	.
GRM8	7	126438598	127253294	N	.	N	Y	-0.972925806	8.32320426	0.004038623	59	DM	.
GRN	17	44345086	44353102	N	.	N	Y	-0.39148464	24.90015628	0.060278429	46	DM	Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3); Aphasia, primary progressive, 607485 (3); Ceroid lipofuscinosis, neuronal, 11, 614706 (3)
GRP	18	59220168	59230774	N	.	N	N	0.448557666	78.28905481	2.14E-06	81.2	.	.
GRPEL1	4	7058906	7068197	N	.	N	N	-0.01663693	48.16808474	0.896268186	17.9	.	.
GRPEL2	5	149345430	149354583	N	.	N	N	-0.01663693	48.16808474	0.005754672	57.4	.	.
GRPR	X	16123556	16153021	N	.	N	Y	0.000282778	49.45881808	0.138137202	41.2	DM	.
GRSF1	4	70815782	70839945	N	.	N	N	-0.380457228	25.42686809	7.98E-07	82.9	.	.
GRTP1	13	113324164	113364148	N	Viable	N	Y	0.455399499	78.56688082	4.79E-06	79.6	.	.
GRWD1	19	48445773	48457022	N	.	N	N	0.236853976	66.63772646	0.337778594	34.6	.	.
GRXCR1	4	42893267	43030658	N	.	N	N	-0.382371374	25.31110725	1.27E-07	85.9	DM	Deafness, autosomal recessive 25, 613285 (3)
GRXCR2	5	145859733	145872968	N	.	N	Y	0.071637002	55.02112635	1.75E-05	76.6	.	?Deafness, autosomal recessive 101, 615837 (3)
GS1-259H13.11	7	99558668	99607810	N	.	N	N	.	.	.	.	.	.
GS1-393G12.13	8	144353228	144355609	N	.	N	N	.	.	.	.	.	.
GSAP	7	77310751	77416400	N	.	N	N	-0.176615867	36.95664757	3.60E-16	97.5	.	.
GSC2	22	19148576	19150283	N	.	N	Y	.	.	0.037186207	48.6	.	.
GSDMA	17	39962973	39977766	N	.	N	N	0.528517954	81.59981478	7.61E-13	95.4	DP	.
GSDMB	17	39904595	39919854	N	.	N	N	0.320344023	71.78908375	1.73E-07	85.4	DP	.
GSDMC	8	129748196	129786888	N	.	N	N	0.976150073	92.41187706	9.35E-12	94.3	.	.
GSDMD	8	143553207	143563062	N	.	N	Y	0.72838545	87.5557099	4.81E-07	83.8	.	.
GSE1	16	85611409	85676204	N	.	N	Y	-0.542498177	18.49858193	.	.	.	.
GSG1	12	13083560	13103683	N	.	N	N	0.642023041	85.42571048	0.001349334	63.6	.	.
GSG1L	16	27787535	28063509	N	.	N	N	-0.198623704	35.57909359	0.541032305	28.9	.	.
GSG1L2	17	9802386	9822071	N	.	N	N	.	.	.	.	.	.
GSG2	17	3723903	3726699	N	.	N	N	0.430324044	77.44400069	0.051131763	46.9	.	.
GSK3A	19	42230186	42242625	N	.	N	Y	-0.395617806	24.63390635	0.997436756	7.3	.	.
GSKIP	14	96363452	96387288	N	.	N	N	-0.066439705	44.63737917	0.718816129	24.1	.	.
GSPT1	16	11868128	11916082	N	.	N	N	0.035884366	52.28917057	0.951655492	14.6	DP	.
GSPT2	X	51743431	51746232	N	.	N	N	-0.499704018	20.18869017	0.90474887	17.6	DM	.
GSR	8	30678061	30727926	N	.	N	N	0.31747395	71.6154425	0.012481214	54	DM	Hemolytic anemia due to glutathione reductase deficiency (1)
GSTA1	6	52791664	52803910	N	.	N	N	-0.399291813	24.48341726	0.059010542	46.1	FP	.
GSTA2	6	52750089	52763569	N	.	N	N	0.434654036	77.61764195	4.24E-08	87.2	FP	.
GSTA3	6	52847910	52909685	N	.	N	Y	0.576259031	83.29571106	0.086863157	44	FP	.
GSTA4	6	52977948	52995378	N	Viable	N	Y	0.081859407	55.83724026	0.021302254	51.3	.	.
GSTA5	6	52831655	52870329	N	.	N	N	0.509685942	80.85894542	3.98E-09	89.8	.	.
GSTCD	4	105708778	105847728	N	Viable	N	Y	-0.859706529	10.38374718	1.33E-07	85.8	.	.
GSTK1	7	143244093	143270854	N	.	N	Y	-0.203255573	35.26075129	1.10E-09	91.1	DFP	.
GSTM1	1	109687814	109709039	N	.	N	Y	.	.	0.34571372	34.4	DFP	.
GSTM2	1	109668022	109709551	N	.	N	N	-0.008177066	48.7989813	0.008902004	55.4	.	.
GSTM3	1	109733932	109741038	N	.	N	N	0.165349748	62.17514615	0.000572589	66.6	DFP	.
GSTM4	1	109656081	109674836	N	Viable	N	Y	0.705728228	87.03478613	0.000917345	65	FP	.
GSTM5	1	109712255	109775428	N	.	N	N	0.65320457	85.72668866	0.000214167	69.6	.	.
GSTO1	10	104235356	104267459	N	.	N	N	0.477760474	79.6550327	0.015037843	53.1	DP	.
GSTO2	10	104268873	104304945	N	.	N	Y	0.478716768	79.67818487	1.67E-07	85.5	DP	.
GSTP1	11	67583595	67586660	N	.	N	Y	0.151300234	61.07541819	0.115024063	42.4	DM?	.
GSTT2B	22	23957414	23961186	N	.	N	N	.	.	0.520153497	29.4	FP	.
GSTZ1	14	77320884	77331597	N	.	N	Y	0.683218038	86.51386236	1.07E-05	77.9	FP	Tyrosinemia, type Ib (1)
GTDC1	2	143938068	144332568	N	.	N	N	0.911337664	91.30057302	2.41E-10	92.3	.	.
GTF2A1L	2	48617798	48733148	N	.	N	N	-0.312777691	28.73184002	5.65E-07	83.6	.	.
GTF2A2	15	59638062	59657541	N	.	N	N	0.038603643	52.45123575	0.386341515	33.1	.	.
GTF2E1	3	120742637	120783069	N	.	N	N	0.355945931	73.73965388	0.902579886	17.7	DP	.
GTF2E2	8	30578318	30658251	N	.	N	N	-0.341181678	27.18643283	0.008668552	55.5	.	.
GTF2F1	19	6379569	6393981	N	.	N	N	-0.582889864	17.31203334	0.028735271	49.9	.	.
GTF2F2	13	45120515	45284909	N	.	N	N	-0.01759377	48.06389998	0.025230232	50.5	.	.
GTF2H1	11	18322295	18367044	N	.	N	N	-0.477997281	21.09741275	0.995912256	8	DFP	.
GTF2H2	5	71032670	71067689	N	.	N	N	.	.	0.724561789	23.9	.	.
GTF2H2C	5	69560208	69594723	N	.	N	N	.	.	0.891905532	18.1	.	.
GTF2H3	12	123633739	123662606	N	.	N	N	-0.271739892	31.18018174	1.59E-05	76.9	.	.
GTF2H4	6	30908184	30914106	N	.	N	N	-0.393549347	24.76703131	0.258034887	36.8	.	.
GTF2IRD2	7	74796144	74851551	N	.	N	N	.	.	.	.	DM	.
GTF2IRD2B	7	75092573	75149817	N	.	N	N	.	.	.	.	.	.
GTF3A	13	27424544	27435823	N	.	N	N	0.107238638	57.76465822	.	.	.	.
GTF3C2	2	27325849	27357034	N	.	N	N	-1.217971526	5.417607223	0.999786436	4.4	.	.
GTF3C3	2	196763032	196799725	N	.	N	N	-1.099822064	6.581003646	5.36E-06	79.4	.	.
GTF3C4	9	132670035	132694955	N	.	N	N	-0.648656154	15.41355559	0.014976256	53.2	.	.
GTF3C6	6	110958560	110967890	N	.	N	N	-0.185531789	36.42414771	0.01171949	54.3	.	.
GTPBP1	22	38705723	38738299	N	.	N	Y	-0.803507355	11.4776871	0.996188562	7.9	.	.
GTPBP10	7	90335223	90391455	N	.	N	N	0.407510974	76.22851189	0.130731485	41.5	.	.
GTPBP3	19	17334920	17342735	N	.	N	N	-0.1964054	35.71221856	0.044752092	47.6	.	Combined oxidative phosphorylation deficiency 23, 616198 (3)
GTPBP4	10	988019	1019936	N	.	N	N	0.123503895	59.02066331	0.999865567	4	FTV	.
GTPBP6	X	304529	318819	N	.	N	N	.	.	.	.	.	.
GTPBP8	3	112990918	113015060	N	.	N	N	0.087599756	56.28870753	2.88E-06	80.6	.	.
GTSE1	22	46296741	46330810	N	.	N	N	1.247559531	95.41008277	6.90E-06	79	.	.
GTSF1	12	54455950	54473602	N	.	N	Y	0.056480057	53.81721364	0.513379498	29.6	.	.
GTSF1L	20	43726164	43726998	N	.	N	N	0.732874214	87.64253053	0.0573625	46.3	.	.
GUCA1A	6	42155406	42180056	N	.	N	Y	0.272306077	68.81981826	0.009918328	54.9	DM	Cone dystrophy-3, 602093 (3); Cone-rod dystrophy 14, 602093 (3)
GUCA1B	6	42184401	42194916	N	.	N	Y	-0.076661182	43.91387394	0.001995062	61.9	DM	Retinitis pigmentosa 48, 613827 (3)
GUCA1C	3	108907792	108953895	N	.	N	N	0.369846866	74.37633848	0.000632586	66.3	.	.
GUCA2A	1	42162691	42164718	N	.	N	Y	0.654972172	85.79035712	0.006072258	57.2	.	.
GUCA2B	1	42153421	42155824	N	.	N	Y	0.147473793	60.82653238	0.707935696	24.4	.	.
GUCD1	22	24540423	24555935	N	.	N	N	-0.440636427	22.72385252	0.016687865	52.6	.	.
GUCY1A2	11	106674012	107018524	N	.	N	N	-0.307188276	29.02703016	0.377257493	33.4	.	.
GUCY1A3	4	155666711	155732349	N	.	N	Y	-0.558467104	17.97187012	1.41E-06	82.1	.	Moyamoya 6 with achalasia, 615750 (3)
GUCY2C	12	14612632	14696585	N	.	N	Y	-0.713979515	13.56717023	1.78E-18	98.3	DM	Diarrhea 6, 614616 (3); Meconium ileus, 614665 (3)
GUCY2D	17	8002594	8020339	N	.	N	Y	-1.372555661	4.126873879	0.000772457	65.6	DM	Leber congenital amaurosis 1, 204000 (3); Cone-rod dystrophy 6, 601777(3)
GUCY2F	X	109372906	109482072	N	.	N	Y	1.573116317	97.33750072	1.52E-05	77	.	.
GUF1	4	44678427	44700926	N	.	N	N	1.152563454	94.5303004	2.37E-11	93.8	.	.
GUK1	1	228139962	228148984	N	.	N	N	0.055674233	53.76512126	0.00010002	71.9	.	.
GULP1	2	188291669	188595931	N	.	N	N	-0.257690928	32.05996411	0.67755775	25.3	.	.
GVQW1	9	32566789	32568621	N	.	N	N	.	.	.	.	.	.
GXYLT1	12	42081845	42144879	N	.	N	N	0.535064702	81.88342884	0.987483161	10.5	.	.
GXYLT2	3	72888073	72998138	N	.	N	N	0.080096755	55.71569138	1.76E-06	81.6	.	.
GYG2	X	2828788	2882818	N	.	N	N	0.718012692	87.37049256	1.71E-05	76.7	DM?	.
GYLTL1B	11	45921621	45929096	N	.	N	N	0.361839242	74.0059038	8.27E-12	94.3	FTV	.
GYPA	4	144109303	144140751	N	.	N	N	0.255386906	67.77218267	0.015312982	53	DM	[Blood group, MN] (3); {Malaria, resistance to}, 611162 (3)
GYPB	4	143996104	144019345	N	.	N	N	1.004917158	92.81704	0.442245535	31.7	FP	[Blood group, Ss] (3); {Malaria, resistance to}, 611162 (3)
GYPC	2	126655933	126696675	N	.	N	N	0.612819541	84.5575042	0.013869769	53.6	DM	{Malaria, resistance to}, 611162 (3); [Blood group, Gerbich], 616089 (3)
GYPE	4	143870867	143905563	N	.	N	N	0.457017001	78.64212537	0.001639097	62.7	DP	.
GYS2	12	21536189	21604847	N	.	N	Y	-0.623127192	16.07918041	1.22E-14	96.6	DM	Glycogen storage disease 0, liver, 240600 (3)
GZF1	20	23362182	23373063	N	.	N	N	-0.65887892	15.06048504	0.007885723	56	.	.
GZMA	5	55102648	55110252	N	.	N	Y	0.65320457	85.72668866	3.24E-07	84.4	.	.
GZMB	14	24630954	24634267	N	.	N	Y	0.032208434	52.02870869	1.79E-06	81.5	DFP	.
GZMH	14	24606480	24609699	N	.	N	N	0.578171457	83.38831973	0.000213178	69.6	.	.
GZMK	5	55024253	55034570	N	Viable	N	Y	0.282678709	69.47965503	0.000569041	66.6	.	.
GZMM	19	544034	549924	N	.	N	N	1.071637256	93.65051803	0.001210033	64	.	.
H1F0	22	37805093	37807436	N	.	N	Y	-0.24459911	32.77768131	0.154802582	40.4	.	.
H1FNT	12	48328980	48330279	N	.	N	Y	0.258256388	67.94003589	0.005066233	58	.	.
H1FOO	3	129543214	129551467	N	Viable	N	Y	0.301362114	70.58517104	0.398598146	32.8	.	.
H1FX	3	129314771	129316277	N	Viable	N	Y	.	.	0.496856075	30	.	.
H2AFB1	X	154884972	154885558	N	.	N	N	.	.	.	.	.	.
H2AFB2	X	155380787	155381134	N	.	N	N	.	.	.	.	.	.
H2AFB3	X	155459415	155460005	N	.	N	N	.	.	.	.	.	.
H2AFJ	12	14774383	14778002	N	.	N	N	-0.042973552	46.37957979	0.765927442	22.7	.	.
H2AFV	7	44826791	44848083	N	.	N	N	0.159610371	61.7121028	0.41211435	32.5	.	.
H2AFX	11	119093854	119095467	N	.	N	Y	-0.149930626	38.75094056	0.6204105	26.9	.	.
H2AFY	5	135333900	135399914	N	.	N	Y	-0.620712187	16.16600104	0.79508957	21.8	.	.
H2AFY2	10	70052796	70112280	N	.	N	N	-0.164783496	37.74382127	0.97564111	12.3	.	.
H2BFM	X	104039949	104042454	N	.	N	N	.	.	0.186492117	39.1	.	.
H2BFS	21	43565189	43565648	N	.	N	N	.	.	.	.	.	.
H2BFWT	X	104011147	104013687	N	.	N	N	1.461855466	96.77606066	0.000863658	65.3	DM	.
H3F3C	12	31791185	31792241	N	.	N	N	0.626870269	84.96845517	0.297369302	35.8	.	.
H6PD	1	9234775	9271337	N	.	N	Y	1.514215072	97.0307345	0.000111404	71.5	DM	Cortisone reductase deficiency 1, 604931 (3)
HAAO	2	42767089	42792593	N	.	N	N	0.767667839	88.51073682	7.80E-06	78.7	.	.
HABP2	10	113550837	113589602	N	.	N	Y	0.809314096	89.3094866	1.17E-14	96.7	DFP	{?Thyroid cancer, nonmedullary, 5}, 616535 (3); {Venous thromboembolism, susceptibility to}, 188050 (3)
HABP4	9	96450201	96491336	N	.	N	N	0.078183267	55.57099033	0.004932505	58.2	.	.
HACD1	10	17589032	17617377	N	.	N	N	.	.	.	.	.	.
HACD2	3	123490820	123585185	N	.	N	N	.	.	.	.	.	.
HACD3	15	65530418	65578352	N	.	N	N	.	.	.	.	.	.
HACD4	9	20999515	21031636	N	.	N	N	.	.	.	.	.	.
HACL1	3	15560704	15601852	N	Viable	N	Y	-0.046345684	46.11332986	4.18E-10	91.9	.	.
HADH	4	107989714	108035175	N	.	N	Y	0.231113855	66.29623198	0.00061369	66.4	DM	.
HADHB	2	26243170	26290468	N	.	N	N	-0.86257743	10.33744284	1.05E-07	86.1	DM	Trifunctional protein deficiency, 609015 (3)
HAGH	16	1795620	1827194	N	.	N	N	-0.074595468	44.09909128	0.000143398	70.8	.	[Glyoxalase II deficiency], 614033 (1)
HAGHL	16	726936	735525	N	.	N	N	.	.	0.00014893	70.7	.	.
HAL	12	95972662	95996365	N	.	N	N	0.477257157	79.63188053	5.91E-17	97.8	DM	[Histidinemia], 235800 (3)
HAMP	19	35280716	35285143	N	.	N	Y	0.130554386	59.44897841	0.042505134	47.9	DM	Hemochromatosis, type 2B, 613313 (3)
HAO1	20	7882981	7940474	N	.	N	N	0.233027146	66.41199282	0.000672389	66.1	.	.
HAO2	1	119368779	119394130	N	.	N	N	-0.197513786	35.67170226	4.48E-08	87.1	.	.
HAPLN2	1	156619294	156625725	N	.	N	Y	-0.077618099	43.83284135	1.05E-05	77.9	.	.
HAPLN3	15	88877288	88895626	N	.	N	N	0.883237032	90.79122533	3.92E-06	80	FTV	.
HAPLN4	19	19255641	19262796	N	.	N	N	-0.30079494	29.40904092	0.032684785	49.3	.	.
HARBI1	11	46602861	46617909	N	.	N	N	0.117611782	58.55761996	0.005701341	57.5	.	.
HARS	5	140673173	140692024	N	.	N	N	-0.097104392	42.28743416	0.000736051	65.8	DM	Usher syndrome type 3B, 614504 (3)
HARS2	5	140691426	140699291	N	.	N	N	-0.431064706	23.12901545	8.13E-05	72.5	DM	?Perrault syndrome 2, 614926 (3)
HAS1	19	51713112	51723994	N	Viable	N	Y	0.830712876	89.8072582	6.04E-11	93.2	DFP	.
HAS3	16	69105564	69118719	N	.	N	Y	-0.291225399	29.94154078	0.269387112	36.5	.	.
HAUS1	18	46104332	46128333	N	.	N	N	0.054717474	53.7014528	0.000296743	68.7	.	.
HAUS2	15	42548810	42569994	N	.	N	N	0.29385898	70.12212768	0.001400432	63.3	.	.
HAUS4	14	22946228	22957161	N	.	N	N	0.109152052	57.94408752	0.03680988	48.7	.	.
HAUS5	19	35612744	35625349	N	.	N	N	1.069064982	93.61000174	0.000826137	65.4	.	.
HAUS6	9	19053143	19103119	N	.	N	N	0.853700044	90.26451352	6.61E-10	91.4	.	.
HAUS7	X	153447666	153495516	N	.	N	N	0.788266285	88.93905192	0.95945396	14	.	.
HAUS8	19	17049729	17075625	N	.	N	N	0.199338946	64.3514499	0.000726405	65.8	.	.
HAVCR1	5	157029413	157059119	N	.	N	Y	0.826886131	89.70886149	0.003054336	60.3	DFP	{Atopy, resistance to}, 147050 (3)
HAVCR2	5	157085832	157142869	N	.	N	Y	0.609140858	84.45331944	0.111384119	42.5	.	.
HAX1	1	154272511	154275875	N	.	N	Y	0.107238638	57.76465822	1.11E-05	77.8	DM	Neutropenia, severe congenital 3, autosomal recessive, 610738 (3)
HBA1	16	176680	177522	N	.	N	N	.	.	0.511601563	29.6	DM	Thalassemias, alpha-, 604131 (3); Methemoglobinemias, alpha- (3); Erythremias, alpha- (3); Heinz body anemias, alpha-, 140700 (3); Hemoglobin H disease, nondeletional, 613978 (3)
HBA2	16	172847	173710	N	.	N	Y	.	.	0.448693557	31.4	DM	Thalassemia, alpha-, 604131 (3); Heinz body anemia, 140700 (3); Erythrocytosis (3); Hypochromic microcytic anemia (3); Hemoglobin H disease, nondeletional, 613978 (3)
HBD	11	5232678	5235370	N	.	N	N	0.285399426	69.6822365	0.000155108	70.6	DM	Thalassemia, delta- (3); Thalassemia due to Hb Lepore (3)
HBE1	11	5268345	5505617	N	.	N	N	-0.094538075	42.4726515	0.010814424	54.6	DM	.
HBG1	11	5248083	5249892	N	.	N	N	.	.	0.02977947	49.6	DM	Fetal hemoglobin quantitative trait locus 1, 141749 (3)
HBG2	11	5248274	5645789	N	.	N	N	-0.013918082	48.39381837	0.24130351	37.3	DM	Fetal hemoglobin quantitative trait locus 1, 141749 (3); Cyanosis, transient neonatal, 613977 (3)
HBM	16	153892	166768	N	.	N	N	0.556472142	82.66481449	0.006846745	56.7	DM	.
HBP1	7	107168961	107202529	N	.	N	N	-0.341984971	27.1690687	0.770302412	22.6	.	.
HBQ1	16	180453	181181	N	.	N	N	.	.	0.005828393	57.4	.	.
HBS1L	6	134960378	135103056	N	.	N	Y	0.575601056	83.28413498	0.924522221	16.4	DP	.
HCAR1	12	122726076	122730843	N	.	N	Y	-0.327935902	27.84048157	0.14099939	41	DM?	.
HCAR2	12	122701293	122703343	N	.	N	Y	0.288418427	69.82114951	0.020109273	51.7	.	.
HCAR3	12	122714756	122716892	N	.	N	N	1.66094097	97.77160387	6.93E-06	79	.	.
HCCS	X	11111301	11123078	N	.	N	N	0.50490493	80.62742374	0.950550391	14.7	DM	Linear skin defects with multiple congenital anomalies 1, 309801 (3)
HCFC1	X	153947553	153971807	N	.	N	N	-1.258080084	5.081900793	0.999995934	2.2	DM	Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cblX type ), 309541 (3)
HCFC1R1	16	3022620	3024286	N	.	N	N	0.77693964	88.71331828	0.000463237	67.2	.	.
HCFC2	12	104064457	104106524	N	.	N	N	-0.470494176	21.42154309	0.994468276	8.6	.	.
HCG27	6	31197760	31203968	N	.	N	N	.	.	.	.	.	.
HCK	20	32052188	32101856	N	.	N	Y	0.410380843	76.3674249	.	.	FP	.
HCLS1	3	121631399	121660927	N	.	N	Y	1.544693273	97.2101638	5.09E-05	73.8	DFP	.
HCN1	5	45259247	45696151	N	.	N	Y	-1.10173548	6.534699311	0.953138503	14.5	DM?	Epileptic encephalopathy, early infantile, 24, 615871 (3)
HCN3	1	155277583	155289848	N	.	N	Y	0.132920659	59.63419575	0.015093383	53.1	.	.
HCRT	17	42184060	42185452	N	Viable	N	Y	.	.	0.502440434	29.9	DM	?Narcolepsy 1, 161400 (3)
HCRTR1	1	31617686	31632518	N	.	N	Y	0.122395494	58.93963072	0.261800018	36.7	DP	.
HCRTR2	6	55106460	55282620	N	.	N	Y	0.142990968	60.43294553	0.063644036	45.6	DM	.
HCST	19	35902480	35904377	N	.	N	Y	0.236554885	66.60299821	0.011933598	54.2	.	.
HDAC10	22	50245183	50251405	N	Viable	N	Y	-0.377286168	25.61208543	3.28E-12	94.8	.	.
HDAC11	3	13479724	13506424	N	.	N	N	-0.412383648	23.80042832	0.044780208	47.6	.	.
HDAC5	17	44076746	44123702	N	.	N	Y	-1.368870346	4.155814088	0.999808248	4.3	.	.
HDAC6	X	48801377	48824982	N	.	N	Y	0.271650036	68.78509	0.999920798	3.6	DM?	?Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863 (3)
HDAC9	7	18086949	19002416	N	.	N	Y	-0.851098137	10.53423627	0.998375125	6.6	DM?	.
HDC	15	50241947	50266026	N	.	N	Y	-0.750831944	12.57741506	0.514822964	29.6	DM	{Gilles de la Tourette syndrome, susceptibility to}, 137580 (3)
HDDC2	6	125219962	125302078	N	.	N	N	0.353884195	73.67019737	0.001273362	63.7	.	.
HDDC3	15	90929964	90932569	N	Viable	N	Y	0.418544532	76.73785958	0.071830628	45	.	.
HDGF	1	156742107	156766925	N	.	N	Y	-0.122636306	40.5799618	0.269699274	36.5	.	.
HDGFL1	6	22569493	22571666	N	.	N	N	.	.	0.313343421	35.4	.	.
HDGFRP2	19	4472287	4502211	N	.	N	Y	-0.288506791	30.17306245	0.89285412	18.1	.	.
HDGFRP3	15	83112738	83208018	N	.	N	N	0.183076334	63.39063495	0.939816244	15.6	.	.
HDHD1	X	7048920	7148190	N	.	N	N	0.148430386	60.90756497	0.259847002	36.7	.	.
HDHD3	9	113373419	113376999	N	.	N	N	0.35116309	73.45025178	0.005551021	57.6	.	.
HDLBP	2	241227264	241317061	N	.	N	N	-1.461657023	3.571221856	0.999998383	1.9	DM?	.
HDX	X	84317874	84502479	N	.	N	Y	0.135487969	59.87729351	0.517074459	29.5	DM	.
HEATR1	1	236549005	236604504	N	.	N	N	1.263701825	95.52584361	0.999999993	0.8	.	.
HEATR3	16	50065941	50106387	N	.	N	N	0.026770398	51.55987729	0.000127665	71.2	DP	.
HEATR4	14	73478484	73558947	N	.	N	N	0.754238147	88.18081843	6.23E-17	97.8	.	.
HEATR5A	14	31291791	31420582	N	.	N	N	.	.	.	.	.	.
HEATR5B	2	36968383	37084342	N	.	N	N	-2.742347867	0.769809573	8.10E-10	91.3	.	.
HEATR6	17	60043194	60078931	N	.	N	N	-0.619159379	16.20072929	4.94E-10	91.8	.	.
HEATR9	17	35854946	35868891	N	.	N	N	.	.	.	.	.	.
HEBP1	12	12974864	13000273	N	.	N	N	0.257299872	67.86479134	8.07E-05	72.5	.	.
HEBP2	6	138403531	138422197	N	.	N	N	0.680350018	86.42704173	0.000947406	64.9	.	.
HECA	6	139135112	139180802	N	.	N	N	-1.084967057	6.71412861	0.347342389	34.3	.	.
HECTD2	10	91409280	91514829	N	Viable	N	Y	-0.289463756	30.10939399	0.99441649	8.7	.	.
HECTD3	1	45002540	45011329	N	Viable	N	Y	-0.964608267	8.47369335	0.01704278	52.5	.	.
HECTD4	12	112160188	112382439	N	.	N	N	.	.	1	0.2	.	.
HECW1	7	43112599	43566001	N	.	N	N	-2.664524996	0.816113909	0.999999894	1.1	.	.
HECW2	2	196194370	196593692	N	.	N	Y	-1.405186821	3.901140244	0.999995852	2.2	.	.
HELB	12	66302545	66347645	N	.	N	N	0.721349648	87.47467732	2.02E-13	95.8	FTV	.
HELQ	4	83407343	83455856	N	.	N	N	0.115349237	58.37240262	4.80E-11	93.4	DM?	.
HELZ	17	67070438	67245989	N	.	N	N	-1.392919556	3.976384789	1	0.4	.	.
HELZ2	20	63558086	63574239	N	.	N	N	3.985443847	99.76847832	1.26E-09	91	.	.
HEMGN	9	97926791	97944856	N	.	N	N	-0.197513786	35.67170226	3.19E-07	84.4	.	.
HEMK1	3	50569152	50596168	N	.	N	N	0.03507878	52.23129015	8.23E-05	72.5	.	.
HENMT1	1	108648290	108661526	N	.	N	N	-0.10747793	41.66232564	1.42E-06	82	.	.
HEPACAM	11	124919193	124936412	N	.	N	Y	0.245163355	67.1818024	0.630644861	26.6	DM	Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 (3); Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 (3)
HEPACAM2	7	93188586	93226524	N	.	N	N	-0.08305528	43.36400996	8.71E-09	89.1	.	.
HEPH	X	66162549	66268867	N	.	N	Y	-0.023685392	47.70504138	0.009589268	55.1	.	.
HEPHL1	11	94021361	94113751	N	.	N	N	1.154978029	94.54766453	7.16E-28	99.6	.	.
HEPN1	11	124919244	124920677	N	.	N	N	0.145560638	60.65289113	0.026229492	50.3	.	.
HERC1	15	63608618	63833942	N	.	N	N	-6.402280028	0.040516293	1	0.3	.	.
HERC3	4	88521048	88708542	N	.	N	Y	-0.929002374	9.064073624	0.719742123	24.1	.	.
HERC4	10	67921899	68075348	N	.	N	Y	-1.018237878	7.657579441	0.992707096	9.2	.	.
HERC5	4	88457117	88506163	N	.	N	N	-0.743181062	12.78578457	5.21E-05	73.7	.	.
HERC6	4	88378739	88443111	N	Viable	N	Y	1.164854921	94.69236557	3.19E-09	90.1	.	.
HERPUD1	16	56932048	56944863	N	.	N	Y	-0.434892888	22.97273832	0.821042866	21	.	.
HERPUD2	7	35632659	35695571	N	.	N	N	-0.041864765	46.45482433	0.906200798	17.5	.	.
HES2	1	6412418	6424670	N	.	N	N	.	.	0.067046655	45.3	.	.
HES3	1	6244192	6245578	N	.	N	Y	.	.	0.268868568	36.5	.	.
HES4	1	998962	1000172	N	.	N	N	.	.	0.000147943	70.7	.	.
HES5	1	2528745	2530245	N	.	N	Y	.	.	0.532717162	29.1	.	.
HES6	2	238238267	238240662	N	.	N	N	.	.	0.008861564	55.4	FP	.
HEXA	15	72340919	72376476	N	.	N	Y	0.208755511	64.98813451	5.05E-07	83.7	DM	Tay-Sachs disease, 272800 (3); GM2-gangliosidosis, several forms, 272800 (3); [Hex A pseudodeficiency], 272800 (3)
HEXB	5	74640023	74722647	N	.	N	Y	-0.104607368	41.83596689	1.49E-05	77.1	DM	Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3)
HEXDC	17	82418318	82442645	N	.	N	N	1.598340338	97.49377785	1.59E-06	81.8	.	.
HEXIM2	17	45160700	45170040	N	.	N	N	-0.508164568	19.87034786	0.368236513	33.7	.	.
HEY1	8	79764010	79767863	N	.	N	Y	-0.090710311	42.74468947	0.91610473	17	DM	.
HEYL	1	39624153	39639945	N	Viable	N	Y	0.523736129	81.40302136	6.81E-07	83.2	.	.
HFE	6	26087281	26098343	N	.	N	Y	0.549114755	82.41014065	8.50E-07	82.8	DM	Hemochromatosis, 235200 (3); {Microvascular complications of diabetes 7}, 612635 (3); {Porphyria variegata, susceptibility to}, 176200 (3); {Porphyria cutanea tarda, susceptibility to}, 176100 (3); {Alzheimer disease, susceptibility to}, 104300 (3); [Transferrin serum level QTL2], 614193 (3)
HFE2	1	146017468	146021918	N	Viable	N	Y	-0.205016781	35.17393066	0.012330397	54.1	DM	.
HFM1	1	91260766	91404869	N	.	N	N	-1.377073005	4.086357585	1.45E-23	99.2	.	Premature ovarian failure 9, 615724 (3)
HGD	3	120628173	120682571	N	.	N	N	-0.468580168	21.49678764	6.42E-05	73.2	DM	Alkaptonuria, 203500 (3)
HGFAC	4	3441887	3449495	N	.	N	Y	1.020529703	93.03119755	5.21E-07	83.7	.	.
HGH1	8	144137769	144140843	N	.	N	N	.	.	.	.	.	.
HGSNAT	8	43140455	43202855	N	.	N	N	0.264147024	68.34519882	1.44E-06	82	DM	Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 (3); Retinitis pigmentosa 73, 616544 (3)
HHATL	3	42692663	42702827	N	.	N	N	0.823209461	89.61046478	1.49E-05	77.1	.	.
HHIPL1	14	99645110	99680569	N	Viable	N	Y	-0.891634218	9.764426694	0.00214437	61.6	.	.
HHIPL2	1	222522258	222548103	N	.	N	N	0.696764379	86.83799271	1.14E-17	98.1	FTV	.
HHLA1	8	132061486	132111159	N	.	N	N	.	.	.	.	.	.
HHLA2	3	108296490	108378285	N	.	N	N	0.906555705	91.21375239	8.09E-05	72.5	.	.
HHLA3	1	70354805	70385339	N	.	N	N	0.14651721	60.7454998	0.00618097	57.1	.	.
HIAT1	1	100038097	100083377	N	.	N	N	-0.719211967	13.43404526	0.983243231	11.2	.	.
HIATL1	9	94374551	94461042	N	.	N	N	-0.051129725	45.70237889	0.023950186	50.7	.	.
HIATL2	9	96898066	97013580	N	.	N	N	.	.	0.663791002	25.7	.	.
HIBADH	7	27525442	27662995	N	Viable	N	Y	-0.240770687	32.9976269	0.250720099	37.1	.	.
HIBCH	2	190189735	190344193	N	.	N	N	-0.039951086	46.61688951	4.18E-08	87.2	DM	3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3)
HIC2	22	21417404	21451463	N	.	N	N	-0.498441623	20.26393471	0.947187316	15	.	.
HID1	17	74950743	74973166	N	.	N	N	0.32608497	72.09584997	0.46550532	31	DM?	.
HIF1AN	10	100529072	100559998	N	.	N	Y	-0.086078072	43.11512415	0.867690855	19.2	DP	.
HIF3A	19	46297046	46343433	N	.	N	Y	0.597307564	84.0192163	0.21811305	38.1	.	.
HIGD1A	3	42784298	42804531	N	.	N	N	0.267523946	68.51884008	0.450480882	31.4	.	.
HIGD1B	17	44846353	44850480	N	.	N	N	0.163436574	62.02465706	0.002345584	61.3	.	.
HIGD1C	12	50953922	50970506	N	.	N	N	0.37161271	74.48052324	2.42E-05	75.7	.	.
HIGD2A	5	176388747	176389771	N	.	N	N	-0.172439875	37.20553337	0.238671224	37.4	DM?	.
HIGD2B	15	72675783	72686149	N	.	N	N	.	.	0.094380787	43.5	.	.
HILPDA	7	128455849	128458418	N	.	N	N	0.356606194	73.78595821	0.422104597	32.2	.	.
HINT1	5	131159027	131171735	N	.	N	Y	0.039560397	52.53226833	0.084264497	44.2	DM	Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 (3)
HINT2	9	35812960	35815354	N	.	N	N	0.169983117	62.51085258	0.000235168	69.3	.	.
HINT3	6	125956781	125980244	N	.	N	N	0.115548149	58.40713087	0.096712748	43.4	.	.
HIP1R	12	122834453	122862960	N	Viable	N	Y	-1.294647487	4.728830237	1.44E-06	82	.	.
HIPK1	1	113929192	113977869	N	.	N	Y	-1.342537681	4.381547722	0.999942915	3.4	.	.
HIPK3	11	33256672	33357023	N	.	N	Y	-0.741127124	12.84366499	0.893187377	18	.	.
HIPK4	19	40379271	40390187	N	.	N	N	0.34491897	73.14348556	0.003924876	59.2	.	.
HIRIP3	16	29992321	29996436	N	Viable	N	Y	-0.00691722	48.92053018	0.019002782	52	.	.
HIST1H1A	6	26017085	26017732	N	.	N	Y	0.032359762	52.04607281	0.003530799	59.7	.	.
HIST1H1B	6	27866849	27867529	N	.	N	N	-0.119613321	40.80569543	0.509138756	29.7	.	.
HIST1H1C	6	26055787	26056428	N	.	N	Y	0.868383761	90.54812757	.	.	.	.
HIST1H1D	6	26234268	26234933	N	.	N	Y	0.312035841	71.21027956	.	.	.	.
HIST1H1E	6	26156391	26157050	N	.	N	Y	-0.686979096	14.30225155	.	.	.	.
HIST1H1T	6	26107419	26108136	N	.	N	Y	1.035222159	93.19905076	.	.	.	.
HIST1H2AA	6	25726132	25726527	N	.	N	N	-0.590699388	17.02263124	0.000860979	65.3	.	.
HIST1H2AB	6	26033176	26033568	N	.	N	N	-0.325218356	28.00833478	0.005319443	57.8	.	.
HIST1H2AC	6	26124145	26139116	N	.	N	N	-0.450054414	22.26080917	0.599175549	27.5	.	.
HIST1H2AD	6	26198851	26199243	N	.	N	N	-0.498746657	20.24078254	4.00E-05	74.5	.	.
HIST1H2AE	6	26216975	26217367	N	.	N	N	-0.351556594	26.68287318	0.624123654	26.8	DM?	.
HIST1H2AG	6	27133042	27135291	N	.	N	N	-0.416212455	23.64993923	0.000610464	66.4	.	.
HIST1H2AH	6	27147129	27147515	N	.	N	N	0.229200645	66.1746831	6.30E-05	73.3	.	.
HIST1H2AI	6	27808199	27808701	N	.	N	N	-0.313083888	28.69711177	0.581587114	27.9	.	.
HIST1H2AJ	6	27814354	27814740	N	.	N	N	-0.555098546	18.06447879	0.191197681	38.9	.	.
HIST1H2AK	6	27837947	27838339	N	.	N	N	0.166306355	62.25039069	0.068428502	45.2	.	.
HIST1H2AL	6	27865355	27865747	N	.	N	N	0.043387416	52.82745847	0.062486916	45.7	.	.
HIST1H2AM	6	27892757	27893149	N	.	N	N	-0.297120516	29.6000463	0.000856482	65.3	.	.
HIST1H2BA	6	25726909	25727292	N	.	N	N	0.000282778	49.45881808	0.132823726	41.4	.	.
HIST1H2BB	6	26043227	26123904	N	.	N	N	-0.078575026	43.76338485	0.130327871	41.6	.	.
HIST1H2BC	6	26114873	26123926	N	.	N	N	-0.510079547	19.80089136	0.002878012	60.5	.	.
HIST1H2BD	6	26158146	26171349	N	.	N	N	-0.365605444	26.09828095	0.000277979	68.9	.	.
HIST1H2BE	6	26183795	26184180	N	.	N	N	0.035884366	52.28917057	0.000307872	68.6	.	.
HIST1H2BF	6	26199559	26199939	N	.	N	N	-0.394660481	24.6686346	0.00030002	68.7	.	.
HIST1H2BG	6	26216066	26216692	N	.	N	N	-0.160151469	38.02743532	2.94E-06	80.6	.	.
HIST1H2BH	6	26251651	26252031	N	.	N	N	-0.402163571	24.28662384	0.00029573	68.7	.	.
HIST1H2BI	6	26272976	26273356	N	.	N	N	-0.123593291	40.51629334	0.138012142	41.2	.	.
HIST1H2BJ	6	27125897	27132750	N	.	N	N	-0.402163571	24.28662384	0.478842114	30.6	.	.
HIST1H2BK	6	27146418	27146798	N	.	N	N	-0.037232312	46.79053076	0.490754148	30.2	.	.
HIST1H2BL	6	27807444	27807931	N	.	N	N	-0.274611335	31.00075245	0.002867554	60.6	.	.
HIST1H2BM	6	27815044	27815424	N	.	N	N	-0.151691433	38.58887538	0.002753464	60.7	.	.
HIST1H2BN	6	27837760	27865798	N	.	N	N	-0.292489205	29.84314406	0.139774615	41.1	.	.
HIST1H2BO	6	27893463	27893843	N	.	N	N	-0.192077745	36.04213695	3.07E-05	75.2	.	.
HIST1H3A	6	26020490	26020900	N	.	N	N	-0.458359319	21.93667882	3.98E-05	74.5	.	.
HIST1H3B	6	26031650	26032060	N	.	N	N	-0.540092197	18.56225039	0.307282993	35.6	.	.
HIST1H3C	6	26045411	26045821	N	.	N	N	-0.478152026	21.08004862	0.215540519	38.2	.	.
HIST1H3D	6	26196840	26197250	N	.	N	N	-0.344053504	27.04173178	0.011195071	54.4	.	.
HIST1H3E	6	26225155	26225565	N	.	N	N	-0.416212455	23.64993923	0.000813429	65.5	.	.
HIST1H3F	6	26250195	26250605	N	.	N	N	-0.299035003	29.50743763	0.042215362	48	.	.
HIST1H3G	6	26269405	26271815	N	.	N	N	-0.440636427	22.72385252	1.71E-05	76.7	.	.
HIST1H3H	6	27810064	27811300	N	.	N	N	-0.375023253	25.68154193	0.024939156	50.5	.	.
HIST1H3I	6	27871905	27872315	N	.	N	N	-0.321544247	28.21670429	0.360879945	33.9	.	.
HIST1H3J	6	27890382	27893106	N	.	N	N	-0.179942957	36.73091393	0.695883937	24.7	.	.
HIST1H4A	6	26021679	26021990	N	.	N	N	0.275027119	68.98767147	0.002285403	61.5	.	.
HIST1H4B	6	26026815	26027252	N	.	N	N	-0.141317516	39.35289691	0.008541827	55.5	.	.
HIST1H4C	6	26103876	26104310	N	.	N	N	-0.426587603	23.26214042	8.86E-05	72.3	.	.
HIST1H4D	6	26188765	26189076	N	.	N	N	-0.31116943	28.88232911	0.0022643	61.5	.	.
HIST1H4E	6	26204645	26204956	N	.	N	N	-0.350599275	26.7407536	0.000642251	66.2	.	.
HIST1H4F	6	26240426	26240737	N	.	N	N	-0.395617806	24.63390635	0.181985151	39.2	.	.
HIST1H4G	6	26246681	26246977	N	.	N	N	-0.072985841	44.23221624	0.002629997	60.9	.	.
HIST1H4H	6	26285113	26285509	N	.	N	N	-0.600117693	16.70428894	0.008790329	55.4	.	.
HIST1H4I	6	27138588	27139881	N	.	N	N	-0.20804097	35.04659374	0.446296013	31.5	.	.
HIST1H4J	6	27824108	27824480	N	.	N	N	-0.344053504	27.04173178	0.42375383	32.2	.	.
HIST1H4K	6	27831216	27831527	N	.	N	N	-0.540092197	18.56225039	0.429118935	32	.	.
HIST1H4L	6	27873199	27873510	N	.	N	N	0.072442927	55.09058286	0.191234624	38.9	.	.
HIST2H2AA3	1	149842188	149842736	N	.	N	N	.	.	.	.	.	.
HIST2H2AA4	1	149851061	149851624	N	.	N	N	.	.	.	.	.	.
HIST2H2AB	1	149887524	149887916	N	.	N	N	-0.178028729	36.84667477	0.216215034	38.2	.	.
HIST2H2AC	1	149886975	149887364	N	.	N	N	-0.450054414	22.26080917	0.209670055	38.5	.	.
HIST2H2BE	1	149842204	149886652	N	.	N	Y	-0.15647662	38.26474504	0.487682589	30.3	.	.
HIST2H2BF	1	149782689	149812373	N	.	N	N	-0.018550615	48.01759565	0.025999981	50.4	.	.
HIST2H3A	1	149852619	149854274	N	.	N	N	.	.	.	.	.	.
HIST2H3C	1	149839538	149841193	N	.	N	N	.	.	.	.	.	.
HIST2H3D	1	149813271	149813681	N	.	N	N	-0.212672702	34.75719164	0.49893728	30	.	.
HIST2H3PS2	1	143905556	143905966	N	.	N	N	.	.	0.13598352	41.3	.	.
HIST2H4A	1	149832659	149839767	N	.	N	N	.	.	.	.	.	.
HIST2H4B	1	149854045	149861210	N	.	N	N	.	.	.	.	.	.
HIST3H2A	1	228456979	228457873	N	.	N	N	-0.223047092	34.13208312	0.484381729	30.4	.	.
HIST3H2BB	1	228458107	228460470	N	.	N	N	-0.59261449	16.93002257	0.022826387	51	.	.
HIST3H3	1	228424845	228425325	N	.	N	N	0.222654188	65.80424842	0.000822081	65.4	DM	.
HIST4H4	12	14767999	14771131	N	.	N	N	-0.230550154	33.7153441	0.260791363	36.7	.	.
HIVEP1	6	12008762	12164999	N	.	N	N	-0.90340038	9.515540893	0.999986917	2.7	.	.
HIVEP2	6	142751467	142945201	N	.	N	Y	-2.554537125	0.937662789	0.999999664	1.4	DM?	.
HIVEP3	1	41506365	42035925	N	.	N	Y	0.429900454	77.4034844	0.030810602	49.5	.	.
HJURP	2	233833416	233854566	N	.	N	N	0.408772001	76.28639231	1.26E-05	77.5	.	.
HK1	10	69269984	69401882	N	.	N	N	-1.534108474	3.183423048	0.55573331	28.5	DM	.
HK3	5	176880869	176899332	N	.	N	N	0.425050837	77.0851421	1.16E-14	96.7	.	.
HKDC1	10	69220303	69267559	N	.	N	N	-0.252306318	32.28569775	1.85E-12	95	.	.
HKR1	19	37312837	37369365	N	.	N	N	0.770839849	88.58019332	2.72E-10	92.2	.	.
HLA-A	6	29941260	29945884	N	.	N	Y	8.683577596	99.94790762	0.132779665	41.4	FP	{Hypersensitivity syndrome, carbamazepine-induced, susceptibility to}, 608579 (3)
HLA-B	6	31353872	31357188	N	.	N	N	6.678780804	99.90739133	0.002664635	60.8	DP	{Spondyloarthropathy, susceptibility to, 1}, 106300 (3); {Abacavir hypersensitivity, susceptibility to} (3); {Synovitis, chronic, susceptibility to} (3); {Drug-induced liver injury due to flucloxacillin} (3); {Toxic epidermal necrolysis, susceptibility to}, 608579 (3); {Stevens-Johnson syndrome, susceptibility to}, 608579 (3)
HLA-C	6	31268749	31357158	N	.	N	Y	8.184183119	99.93633154	9.95E-10	91.1	DM	{Psoriasis susceptibility 1}, 177900 (3); {HIV-1 viremia, susceptibility to}, 609423 (3)
HLA-DMA	6	32948613	32969094	N	.	N	Y	0.491810698	80.14701626	0.687977633	24.9	.	.
HLA-DMB	6	32934629	32941070	N	.	N	N	0.378306375	74.85095792	0.004905106	58.2	FP	.
HLA-DOB	6	32812763	32817048	N	.	N	N	0.106281943	57.6662615	9.09E-05	72.2	.	.
HLA-DPA1	6	33064569	33080775	N	.	N	N	1.352154859	96.12779997	0.000185717	70	.	.
HLA-DPB1	6	33075926	33087201	N	.	N	N	2.854615681	99.43277189	7.18E-09	89.3	DP	{Beryllium disease, chronic, susceptibility to} (3)
HLA-DQA1	6	32628179	32647062	N	.	N	Y	3.886575016	99.73953811	0.16662533	39.9	DM?	{Celiac disease, susceptibility to}, 212750 (3)
HLA-DQA2	6	32741342	32747215	N	.	N	N	3.668710906	99.69902182	0.005044064	58.1	.	.
HLA-DQB1	6	32659467	32668383	N	.	N	Y	4.017167969	99.78005441	0.353015152	34.1	DP	{Creutzfeldt-Jakob disease, variant, resistance to}, 123400 (3); {Multiple sclerosis, susceptibility to, 1}, 126200 (3); {Celiac disease, susceptibility to}, 212750 (3)
HLA-DQB2	6	32756098	32763534	N	.	N	N	0.975857343	92.39451294	0.009355929	55.2	.	.
HLA-DRA	6	32439842	32445046	N	.	N	N	0.346381025	73.21294206	0.70016489	24.6	DP	.
HLA-DRB1	6	32552990	32589848	N	.	N	N	6.957514208	99.91317937	5.62E-05	73.6	DM	{Pemphigoid, susceptibility to} (2); {Sarcoidosis, susceptibility to, 1}, 181000 (3); {Multiple sclerosis, susceptibility to, 1}, 126200 (3); {Rheumatoid arthritis, susceptibility to}, 180300 (3)
HLA-DRB5	6	32517343	32530287	N	.	N	N	.	.	0.003227266	60	FP	.
HLA-E	6	30489467	30494205	N	.	N	Y	0.206691474	64.80870522	0.347084032	34.3	DP	.
HLA-F	6	29722775	29738528	N	.	N	Y	0.500418343	80.45957053	4.40E-05	74.3	.	.
HLA-G	6	29826967	29831125	N	.	N	N	0.477908896	79.66082074	9.55E-08	86.2	DFP	{Asthma, susceptibility to}, 600807 (2)
HLCS	21	36750888	36990236	N	.	N	N	-0.370739403	25.83781907	0.486548324	30.4	DM	Holocarboxylase synthetase deficiency, 253270 (3)
HLF	17	55265012	55325065	N	.	N	N	-0.59261449	16.93002257	0.877861798	18.7	.	.
HM13	20	31514428	31577923	N	.	N	N	-0.445267562	22.48075476	0.882288325	18.5	.	.
HMBOX1	8	28890394	29064764	N	.	N	N	-0.468734171	21.47363547	0.997096381	7.5	.	.
HMCES	3	129278828	129306186	N	.	N	N	-0.192881585	36.00162065	4.52E-05	74.2	.	.
HMCN1	1	185734551	186190949	N	.	N	N	-1.640677262	2.720379696	2.19E-18	98.3	DM	{Macular degeneration, age-related, 1}, 603075 (3)
HMCN2	9	130265882	130434123	N	.	N	N	.	.	.	.	.	.
HMG20A	15	77420412	77485607	N	.	N	N	-0.195752553	35.7874631	0.932476251	15.9	.	.
HMG20B	19	3572777	3579088	N	.	N	N	0.322915185	71.92799676	0.342236181	34.5	.	.
HMGA2	12	65824131	65966295	N	.	N	Y	0.190579485	63.80158592	0.733852104	23.6	DM	Leiomyoma, uterine, somatic, 150699 (2)
HMGB2	4	173331695	173335125	N	.	N	Y	-0.079531963	43.66498813	0.907849743	17.4	.	.
HMGB3	X	150980509	150990775	N	.	N	Y	-0.10491211	41.78387452	0.770459764	22.6	.	?Microphthalmia, syndromic 13, 300915 (3)
HMGB4	1	33860475	33864791	N	.	N	N	0.409275399	76.30375644	9.96E-06	78.1	.	.
HMGCLL1	6	55434369	55579214	N	.	N	N	0.180505995	63.22856977	8.77E-07	82.7	.	.
HMGCS1	5	43289395	43313512	N	.	N	N	-0.112262427	41.3266192	0.972848684	12.7	.	.
HMGCS2	1	119747996	119768905	N	.	N	N	-0.539784071	18.5911906	1.06E-08	88.9	DM	HMG-CoA synthase-2 deficiency, 605911 (3)
HMGN2	1	26472450	26475972	N	.	N	N	-0.044887353	46.22330266	0.796674559	21.8	.	.
HMGN3	6	79201245	79234738	N	.	N	Y	0.334096466	72.51837703	0.175434355	39.5	.	.
HMGN4	6	26538405	26546254	N	.	N	N	0.334096466	72.51837703	0.557082342	28.5	.	.
HMGN5	X	81113701	81201942	N	.	N	Y	.	.	0.32671565	35	.	.
HMGXB3	5	150000046	150053142	N	.	N	N	.	.	.	.	.	.
HMGXB4	22	35257452	35295807	N	.	N	N	-0.771579694	12.14909996	0.218813415	38.1	.	.
HMHA1	19	1065923	1086628	N	.	N	N	-1.01412853	7.68651965	0.453633762	31.3	DM?	.
HMHB1	5	143812161	143820719	N	.	N	N	0.431639031	77.47872895	.	.	.	.
HMMR	5	163460203	163491945	N	.	N	Y	0.955553563	92.0993228	1.04E-14	96.7	.	{Breast cancer, susceptibility to}, 114480 (3)
HMOX2	16	4474690	4510347	N	.	N	Y	0.253623009	67.679574	0.001100656	64.3	DP	.
HMP19	5	174045604	174243501	N	.	N	N	-0.313083888	28.69711177	.	.	.	.
HMSD	18	63949301	63981774	N	.	N	N	0.176529703	62.94495572	0.002323952	61.4	FP	.
HN1	17	75135248	75168281	N	.	N	N	0.132467594	59.58789142	0.019313451	51.9	.	.
HN1L	16	1678256	1702280	N	.	N	N	0.003958565	49.8061006	0.516099964	29.5	.	.
HNF4G	8	75407914	75566843	N	.	N	Y	-0.470494176	21.42154309	0.54463419	28.8	.	.
HNMT	2	137964020	138016364	N	.	N	N	0.049127994	53.35995833	0.096729383	43.4	DFP	{Asthma, susceptibility to}, 600807 (3)
HNRNPA0	5	137745651	137754376	N	.	N	N	-0.041059779	46.53585692	0.863701458	19.3	.	.
HNRNPA1	12	54280193	54287088	N	.	N	N	-0.10763024	41.63338543	0.966614388	13.4	DM	?Inclusion body myopathy wtih early-onset Paget disease without frontotemporal dementia 3, 615424 (3); Amyotrophic lateral sclerosis 20, 615426 (3)
HNRNPA1L2	13	52640786	52643796	N	.	N	N	0.875585258	90.67546449	6.70E-05	73	.	.
HNRNPA2B1	7	26189927	26201529	N	.	N	N	-0.402163571	24.28662384	0.970043353	13	DM	.
HNRNPA3	2	177212563	177223958	N	.	N	N	-0.426587603	23.26214042	0.99264494	9.3	.	.
HNRNPAB	5	178204507	178211180	N	.	N	N	-0.196709583	35.69485443	0.960162612	13.9	.	.
HNRNPCL1	1	12847377	12947578	N	.	N	N	3.533647902	99.67586965	0.010723266	54.6	.	.
HNRNPCL2	1	13115496	13116854	N	.	N	N	.	.	.	.	.	.
HNRNPCL3	1	13060869	13062229	N	.	N	N	.	.	.	.	.	.
HNRNPCL4	1	13164586	13165467	N	.	N	N	.	.	.	.	.	.
HNRNPD	4	82352498	82374503	N	.	N	Y	-0.15743371	38.19528853	0.957344185	14.2	.	.
HNRNPDL	4	82422564	82430408	N	.	N	N	-0.238856623	33.14811599	0.916051063	17	.	Limb-girdle muscular dystrophy, type 1G, 609115 (3)
HNRNPF	10	43385617	43409166	N	.	N	N	-0.443353128	22.55021126	0.864039577	19.3	.	.
HNRNPH1	5	179614178	179634784	N	.	N	N	-0.319629709	28.30352492	0.999148294	5.7	.	.
HNRNPH2	X	101408295	101414133	N	.	N	N	-0.216501186	34.48515367	0.86828424	19.1	.	.
HNRNPH3	10	68331174	68343191	N	.	N	N	-0.062612024	44.95572148	0.996456324	7.8	FP	.
HNRNPK	9	83968083	83980616	N	.	N	N	-0.787699492	11.80181745	0.999782389	4.4	.	Au-Kline syndrome, 616580 (3)
HNRNPLL	2	38561978	38603586	N	.	N	N	-0.89083175	9.776002778	0.005394388	57.8	.	.
HNRNPM	19	8444767	8489114	N	.	N	N	-1.379383555	4.063205418	0.999948049	3.3	.	.
HNRNPR	1	23303771	23344336	N	.	N	N	-0.820428635	11.15934479	0.999079074	5.8	.	.
HNRNPUL1	19	41262496	41307598	N	.	N	N	-1.24335267	5.16293338	0.999847512	4.1	.	.
HNRNPUL2	11	62712630	62727349	N	.	N	N	-0.455336082	22.06980379	0.999925395	3.5	.	.
HNRNPUL2-BSCL2	11	62690275	62727384	N	.	N	N	.	.	.	.	.	.
HOGA1	10	97584323	97612802	N	.	N	N	0.204928458	64.67558025	7.33E-06	78.8	DM	Hyperoxaluria, primary, type III, 613616 (3)
HOMER1	5	79372636	79514217	N	.	N	Y	-0.465060678	21.67042889	0.995922024	8	.	.
HOMER2	15	82836946	82986153	N	.	N	Y	-0.374868313	25.69311802	0.054546879	46.5	DP	.
HOMER3	19	18929201	18941261	N	.	N	N	0.023748636	51.34571974	0.222332288	37.9	.	.
HOMEZ	14	23272422	23299447	N	.	N	N	0.206841947	64.8202813	0.342229012	34.5	DM	.
HOOK1	1	59814786	59876378	N	.	N	N	-0.943201879	8.820975864	4.16E-05	74.4	.	.
HOOK2	19	12763003	12872740	N	.	N	N	0.256796681	67.83585113	6.32E-09	89.4	.	.
HOOK3	8	42896932	43030539	N	.	N	N	-1.067087781	6.963014412	0.999998005	1.9	.	.
HORMAD1	1	150698060	150720888	N	.	N	Y	0.372716004	74.56155583	0.003126913	60.1	DM?	.
HORMAD2	22	30080174	30177075	N	.	N	Y	0.439288148	77.85495167	3.45E-05	74.9	.	.
HOXA10	7	27170591	27180261	N	.	N	Y	0.288268772	69.80378538	0.678435261	25.2	DM	.
HOXA10-HOXA9	7	27163535	27180013	N	.	N	N	.	.	.	.	.	.
HOXA11	7	27181510	27185223	N	.	N	Y	0.227287513	66.09365052	0.863825169	19.3	DM	Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432 (3)
HOXA4	7	27128507	27130799	N	.	N	Y	0.399859596	75.829137	0.00942667	55.2	DM	.
HOXA6	7	27145396	27150603	N	.	N	Y	-0.294249011	29.74474735	1.80E-05	76.5	.	.
HOXA7	7	27153716	27157936	N	.	N	Y	0.146667159	60.78022805	0.00316907	60.1	.	.
HOXA9	7	27162435	27175180	N	.	N	Y	0.152256873	61.16223881	0.000100013	71.9	.	.
HOXB13	17	48724763	48729178	N	.	N	Y	-0.239813643	33.09023557	0.009874751	55	DM	.
HOXB5	17	48591257	48593961	N	.	N	Y	-0.098213329	42.19482549	0.481440388	30.5	DP	.
HOXB6	17	48595751	48604992	N	.	N	Y	-0.079531963	43.66498813	0.009583407	55.1	DM	.
HOXB7	17	48607227	48633572	N	.	N	Y	0.467388591	79.20356543	0.007596391	56.2	.	.
HOXB8	17	48611377	48614939	N	.	N	Y	-0.130139339	40.0821902	0.444768418	31.6	.	.
HOXB9	17	48621159	48626356	N	.	N	Y	0.180355903	63.21120565	0.101637476	43	.	.
HOXC10	12	53985065	53990279	N	.	N	Y	0.042581773	52.76957805	0.648346218	26.1	.	.
HOXC11	12	53973126	53977643	N	.	N	N	0.152256873	61.16223881	0.078695281	44.5	.	.
HOXC12	12	53954834	53958956	N	.	N	N	-0.227678773	33.88319731	1.89E-09	90.6	.	.
HOXC5	12	54032853	54035358	N	.	N	N	0.097822207	56.98327256	0.039073776	48.4	.	.
HOXC6	12	53990624	54030823	N	.	N	Y	0.005872186	49.93922556	0.907689925	17.5	.	.
HOXC9	12	53994895	54003337	N	.	N	Y	-0.031643	47.17832957	0.128099662	41.6	.	.
HOXD1	2	176188579	176190907	N	.	N	Y	0.098778904	57.07588123	0.01058846	54.7	.	.
HOXD10	2	176108790	176119942	N	.	N	Y	-0.010895966	48.63112809	0.132556118	41.4	DM	Vertical talus, congenital, 192950 (3); Charcot-Marie-Tooth disease, foot deformity of, 192950 (3)
HOXD11	2	176104216	176109754	N	.	N	Y	.	.	0.013189848	53.8	.	.
HOXD12	2	176099730	176101193	N	.	N	Y	0.709552984	87.11003068	0.003345917	59.9	.	.
HOXD13	2	176092891	176095938	N	.	N	Y	0.387722289	75.27927302	0.332069485	34.8	DM	Synpolydactyly, type II, 186000 (3); Brachydactyly, type E, 113300 (3); Brachydactyly, type D, 113200 (3); Synpolydactyly with foot anomalies, 186000 (3); Syndactyly, type V, 186300 (3); ?Brachydactyly-syndactyly syndrome, 610713 (3)
HOXD4	2	176151222	176153226	N	.	N	Y	-0.127268446	40.25583145	0.167399011	39.8	DM	.
HOXD8	2	176129694	176132695	N	.	N	Y	0.317324799	71.58071424	0.617630962	27	.	.
HOXD9	2	176122720	176124937	N	.	N	Y	0.104368575	57.54471262	0.422099308	32.2	.	.
HPCA	1	32885994	32898441	N	.	N	Y	-0.254973777	32.16414887	0.433846186	31.8	.	Dystonia 2, torsion, autosomal recessive, 224500 (3)
HPCAL1	2	10302889	10427617	N	.	N	N	-0.254016546	32.19887712	0.779954229	22.3	.	.
HPCAL4	1	39678648	39691689	N	Viable	N	Y	-0.10204113	42.00382011	0.018422751	52.1	.	.
HPD	12	121839527	121863596	N	.	N	N	-0.060546352	45.05411819	0.007765206	56.1	DM	Tyrosinemia, type III, 276710 (3); Hawkinsinuria, 140350 (3)
HPDL	1	45326905	45328533	N	.	N	N	-0.139403663	39.45708167	0.013964827	53.5	.	.
HPGDS	4	94298535	94342876	N	.	N	Y	0.401772227	75.92174567	8.22E-07	82.9	.	.
HPN	19	35040506	35066571	N	.	N	Y	-0.110348593	41.44238004	0.997916182	7	.	.
HPR	16	72063224	72077246	N	.	N	N	1.509891283	97.01337038	2.95E-07	84.6	.	.
HPRT1	X	134460153	134520513	N	.	N	Y	0.06765942	54.67384384	0.916893576	16.9	DM	Lesch-Nyhan syndrome, 300322 (3); HPRT-related gout, 300323 (3)
HPS3	3	149129584	149173732	N	.	N	N	0.036490487	52.31232274	3.52E-15	97	DM	Hermansky-Pudlak syndrome 3, 614072 (3)
HPS4	22	26443423	26483837	N	.	N	Y	0.384503612	75.11141981	1.40E-05	77.2	DM	Hermansky-Pudlak syndrome 4, 614073 (3)
HPS5	11	18278668	18322198	N	.	N	N	0.366781783	74.17375702	9.08E-06	78.3	DM	Hermansky-Pudlak syndrome 5, 614074 (3)
HPS6	10	102065390	102068038	N	.	N	N	-0.581933287	17.32939746	0.301742442	35.7	DM	Hermansky-Pudlak syndrome 6, 614075 (3)
HPSE	4	83292461	83335153	N	Viable	N	Y	-0.043626754	46.35063958	1.81E-08	88.3	.	.
HPSE2	10	98457077	99235862	N	.	N	N	-0.22178469	34.23626787	1.85E-06	81.5	DM	Urofacial syndrome 1, 236730 (3)
HPX	11	6431049	6442617	N	.	N	Y	0.434803554	77.64079412	0.004121447	58.9	.	.
HRAS	11	532242	537287	N	.	N	Y	-0.379654309	25.47317243	0.007941049	56	DM	{Bladder cancer, somatic}, 109800 (3); Costello syndrome, 218040 (3); {Thyroid carcinoma, follicular, somatic}, 188470 (3); Congenital myopathy with excess of muscle spindles, 218040 (3); {Nevus sebaceous or woolly hair nevus, somatic}, 162900 (3); Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3); {Spitz nevus or nevus spilus, somatic}, 137550 (3)
HRASLS	3	193241125	193277738	N	.	N	N	0.353884195	73.67019737	0.000717831	65.9	.	.
HRASLS2	11	63552770	63563383	N	.	N	N	0.170939673	62.57452104	0.018273804	52.1	.	.
HRASLS5	11	63461404	63491194	N	.	N	N	1.427198658	96.52717486	0.00012337	71.3	.	.
HRC	19	49151198	49155424	N	.	N	Y	2.87664955	99.45013602	3.14E-05	75.1	DFP	.
HRCT1	9	35906192	35907141	N	.	N	N	1.30139682	95.80945766	0.15829062	40.3	.	.
HRG	3	186660216	186678240	N	.	N	Y	1.271668837	95.5663599	1.70E-12	95.1	DM	Thrombophilia due to HRG deficiency, 613116 (3); Thrombophilia due to elevated HRG, 613116 (1)
HRH1	3	11137093	11263557	N	.	N	Y	0.260319777	68.05579672	0.001561168	62.9	.	.
HRH2	5	175658030	175686242	N	.	N	Y	-0.61320898	16.38015859	0.835273259	20.4	DFP	.
HRH3	20	62214970	62220267	N	.	N	Y	-0.079379727	43.6881403	0.366881478	33.7	DFP	.
HRH4	18	24460629	24479957	N	.	N	Y	0.036035566	52.3065347	1.67E-07	85.5	DFP	.
HRK	12	116856144	116881441	N	.	N	Y	.	.	.	.	.	.
HRNR	1	152212082	152224193	N	.	N	N	13.3972395	99.96527175	5.01E-29	99.6	.	.
HRSP12	8	98102344	98117241	N	.	N	N	-0.125507302	40.39474446	0.281991269	36.2	.	.
HS1BP3	2	20560448	20651089	N	.	N	N	0.660855672	85.94663425	0.000353325	68.2	DP	.
HS3ST2	16	22814177	22916338	N	.	N	N	-0.265193969	31.55061643	0.212162588	38.4	.	.
HS3ST3A1	17	13495689	13601927	N	.	N	N	.	.	.	.	.	.
HS3ST3B1	17	14301083	14349404	N	.	N	N	0.100692319	57.27267465	0.085454927	44.1	.	.
HS3ST4	16	25692026	26137688	N	.	N	N	0.136294125	59.95253806	0.581015605	27.9	.	.
HS3ST5	6	114055586	114343045	N	.	N	N	0.00315321	49.71927997	0.569245913	28.2	.	.
HS3ST6	16	1911463	1918440	N	.	N	N	1.202071758	95.03386005	0.003223754	60	.	.
HS6ST2	X	132626016	132961395	N	.	N	Y	0.455250847	78.5495167	0.119199983	42.1	.	.
HS6ST3	13	96090839	96839562	N	.	N	N	0.262082672	68.1773456	0.747377573	23.2	.	.
HSBP1L1	18	79964561	79970822	N	.	N	N	.	.	.	.	.	.
HSCB	22	28742031	28757515	N	.	N	N	0.037797903	52.3759912	0.00014192	70.8	.	.
HSD11B1	1	209686178	209734950	N	.	N	Y	-0.478152026	21.08004862	0.691555251	24.8	DM	Cortisone reductase deficiency 2, 614662 (3)
HSD11B1L	19	5680604	5688523	N	.	N	N	.	.	0.001696306	62.5	.	.
HSD17B1	17	42549214	42555213	N	Viable	N	Y	-0.410469485	23.93355328	0.056017513	46.4	DP	.
HSD17B10	X	53431258	53434373	N	.	N	N	0.062069705	54.29762111	0.886870268	18.3	DM	17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 (3); ?Mental retardation, X-linked syndromic 10, 300220 (3)
HSD17B11	4	87336610	87391386	N	Viable	N	Y	-0.273654159	31.05284482	0.000142446	70.8	.	.
HSD17B13	4	87303789	87322906	N	.	N	N	0.518145495	81.19465185	0.001957426	61.9	.	.
HSD17B14	19	48813017	48836678	N	.	N	N	1.132624181	94.35665914	0.001372525	63.5	.	.
HSD17B3	9	96235306	96302152	N	.	N	N	-0.338310159	27.33692192	2.49E-05	75.7	DM	Pseudohermaphroditism, male, with gynecomastia, 264300 (3)
HSD17B6	12	56752161	56787790	N	.	N	N	0.480629485	79.77658158	0.381986471	33.3	.	.
HSD17B8	6	33204642	33206831	N	.	N	N	0.14284054	60.39821728	0.744497984	23.3	.	.
HSD3B1	1	119507198	119515054	N	.	N	N	0.510791519	80.90524975	8.51E-05	72.4	DP	.
HSD3B2	1	119414931	119423035	N	.	N	N	0.165499977	62.20408636	1.21E-06	82.3	DM	3-beta-hydroxysteroid dehydrogenase, type II, deficiency, 201810 (3)
HSDL1	16	84122146	84145192	N	.	N	N	-0.826017495	11.02621983	0.000929031	65	.	.
HSDL2	9	112379937	112472410	N	.	N	N	-0.109391694	41.51183655	3.95E-05	74.5	.	.
HSF2	6	122399546	122433119	Y	Viable	N	Y	-0.707878759	13.69450715	0.919340111	16.7	DM	.
HSF2BP	21	43529192	43659493	N	Viable	N	Y	0.1035625	57.4868322	6.37E-10	91.5	.	.
HSF4	16	67163385	67169945	N	Viable	N	Y	0.327847069	72.2231869	2.50E-10	92.2	DM	Cataract 5, multiple types, 116800 (3)
HSF5	17	58420167	58488384	N	.	N	N	0.022943191	51.29941541	0.741540032	23.4	.	.
HSFX1	X	149774068	149776867	N	.	N	N	.	.	.	.	.	.
HSFX2	X	149592515	149594716	N	.	N	N	.	.	.	.	.	.
HSFY1	Y	18546671	18588963	N	.	N	N	.	.	.	.	DM?	.
HSFY2	Y	18731440	18828662	N	.	N	N	.	.	.	.	.	.
HSH2D	19	16134028	16158575	N	.	N	Y	.	.	.	.	.	.
HSPA12A	10	116671192	116742574	N	.	N	N	-0.535957502	18.74167969	0.980307172	11.7	.	.
HSPA12B	20	3732667	3753111	N	.	N	N	0.17587319	62.9275916	0.010508204	54.7	.	.
HSPA13	21	14371115	14383484	N	.	N	N	-0.274457717	31.01811657	0.00188637	62.1	.	.
HSPA14	10	14838164	14871741	N	.	N	N	-0.379500211	25.48474851	0.991685162	9.5	.	.
HSPA1A	6	31815464	31817946	N	.	N	Y	.	.	.	.	DFP	.
HSPA1B	6	31827735	31830255	N	.	N	Y	.	.	.	.	DFP	.
HSPA1L	6	31809619	31815065	N	.	N	N	-0.186988947	36.33732708	2.19E-06	81.1	DP	.
HSPA2	14	64535905	64546173	N	.	N	Y	-0.701178982	13.88551253	.	.	.	.
HSPA4	5	133051962	133106449	N	.	N	Y	-0.507858025	19.88771199	0.999958226	3.2	.	.
HSPA4L	4	127781821	127840733	N	.	N	Y	-0.466515898	21.58939631	0.030011121	49.6	.	.
HSPA6	1	161524540	161526910	N	.	N	N	1.2323896	95.32326214	0.461296069	31.1	.	.
HSPA8	11	123057489	123063230	N	.	N	N	-1.333552846	4.456792267	0.997882601	7	DFP	.
HSPA9	5	138554882	138575444	N	.	N	N	-0.888763627	9.822307114	0.981119322	11.6	DM?	.
HSPB1	7	76302544	76304295	N	Viable	N	Y	-0.396575171	24.57602593	6.92E-06	79	DM	Neuropathy, distal hereditary motor, type IIB, 608634 (3); Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3)
HSPB2	11	111912242	111914093	N	Viable	N	Y	0.180355903	63.21120565	0.211781189	38.4	.	.
HSPB2-C11orf52	11	111912736	111926871	N	.	N	N	.	.	.	.	.	.
HSPB3	5	54455601	54456384	N	Viable	N	Y	0.482395106	79.81709788	0.000440374	67.4	DM	?Neuronopathy, distal hereditary motor, type IIC, 613376 (3)
HSPB6	19	35754568	35758079	N	.	N	N	.	.	0.391248531	33	DM	.
HSPB7	1	16014028	16019594	N	.	N	N	0.196318636	64.16623256	0.013149237	53.8	DP	.
HSPB8	12	119178642	119221131	N	.	N	Y	0.13438084	59.79626092	0.02775547	50.1	DM	Neuropathy, distal hereditary motor, type IIA, 158590 (3); Charcot-Marie-Tooth disease, axonal, type 2L, 608673 (3)
HSPB9	17	42121431	42123352	N	.	N	N	0.353884195	73.67019737	5.41E-05	73.7	.	.
HSPBAP1	3	122740003	122793824	N	.	N	N	0.19742545	64.22990102	9.98E-07	82.5	.	.
HSPBP1	19	55262231	55280381	N	.	N	Y	0.064133998	54.51756671	0.009480862	55.2	.	.
HSPC047	7	102672879	102678856	N	.	N	N	.	.	.	.	.	.
HSPE1	2	197499994	197503457	N	.	N	N	0.174616683	62.82340684	0.787528048	22.1	.	.
HSPE1-MOB4	2	197500413	197550726	N	.	N	N	-0.020464318	47.86710656	0.889798358	18.2	.	.
HSPH1	13	31134974	31162388	N	.	N	Y	-0.338963051	27.30798171	0.983009121	11.3	.	.
HTATIP2	11	20363685	20383783	N	.	N	Y	-0.202298558	35.34178387	3.64E-12	94.8	.	.
HTATSF1	X	136497079	136512346	N	.	N	N	-0.168458721	37.48335938	0.973206628	12.6	.	.
HTN1	4	70050402	70058845	N	.	N	N	0.653060723	85.71511258	0.00180852	62.3	.	.
HTN3	4	70028413	70036538	N	.	N	N	0.319090009	71.70805117	0.000271793	68.9	FP	.
HTR1A	5	63960356	63962507	N	Viable	N	Y	-0.038037426	46.71528622	0.926694463	16.3	DM	Periodic fever, menstrual cycle dependent, 614674 (3)
HTR1D	1	23191895	23194729	N	Viable	N	Y	0.226480797	66.06471031	0.813006425	21.2	.	.
HTR1E	6	86937306	87016683	N	.	N	N	-0.421801054	23.46472188	0.023709766	50.8	.	.
HTR1F	3	87990696	87993835	N	Viable	N	Y	-0.557814484	17.98923424	0.001614775	62.8	.	.
HTR2A	13	46831550	46897076	N	.	N	Y	-0.714424723	13.54401806	0.77277361	22.5	DFP	{Schizophrenia, susceptibility to}, 181500 (3); {Obsessive-compulsive disorder, susceptibility to}, 164230 (3); {Seasonal affective disorder, susceptibility to}, 608516 (3); {Alcohol dependence, susceptibility to}, 103780 (3); {Anorexia nervosa, susceptibility to}, 606788 (3); {Major depressive disorder, response to citalopram therapy in}, 608516 (3)
HTR3A	11	113974881	113990313	N	.	N	Y	-0.468429026	21.50257568	1.03E-09	91.1	DM?	.
HTR3B	11	113904677	113946565	N	Viable	N	Y	0.978869896	92.46975748	6.15E-07	83.4	DFP	.
HTR3C	3	184053047	184060671	N	.	N	N	0.413251052	76.53527812	2.34E-08	88	DP	.
HTR3D	3	184031544	184039369	N	.	N	N	1.173011897	94.76761012	2.59E-06	80.8	.	.
HTR3E	3	184097064	184106995	N	.	N	N	1.150649146	94.52451236	0.001336466	63.6	DFP	.
HTR5A	7	155070324	155085749	N	.	N	Y	-0.166544931	37.66857672	0.005788634	57.4	DP	.
HTR6	1	19665287	19679562	N	.	N	Y	-0.300642103	29.41482896	0.001067254	64.5	DP	.
HTR7	10	90740823	90857698	N	Viable	N	Y	-0.796961222	11.64554031	0.034017699	49.1	FP	.
HTRA1	10	122461525	122514908	N	.	N	Y	-0.738849285	12.91312149	0.016947547	52.5	DM	{Macular degeneration, age-related, 7}, 610149 (3); {Macular degeneration, age-related, neovascular type}, 610149 (3); CARASIL syndrome, 600142 (3)
HTRA2	2	74529377	74533348	N	Viable	N	Y	-0.253862657	32.21624125	0.002301276	61.4	DM	{Parkinson disease 13}, 610297 (3)
HTRA3	4	8269765	8307111	N	.	N	N	0.190879187	63.84789026	1.72E-05	76.7	.	Vitreoretinopathy, neovascular inflammatory, 193235 (3)
HTRA4	8	38974164	38988662	N	Viable	N	Y	0.209561389	65.04601493	2.53E-07	84.8	.	.
HUNK	21	31873315	32044633	N	.	N	Y	0.123503895	59.02066331	0.997271075	7.4	.	.
HUS1B	6	655939	656963	N	.	N	N	0.688955753	86.6296232	0.008313233	55.7	DP	.
HVCN1	12	110627841	110704950	N	.	N	Y	0.302318539	70.64305146	0.750490678	23.1	FP	.
HYAL1	3	50299889	50312381	N	.	N	Y	-0.156171384	38.30526133	0.005536706	57.7	DM	?Mucopolysaccharidosis type IX, 601492 (3)
HYAL3	3	50292828	50299468	N	.	N	N	-0.090558257	42.75047751	1.52E-05	77	.	.
HYAL4	7	123828983	123877478	N	Viable	N	Y	0.655265795	85.79614516	2.05E-15	97.1	.	.
HYI	1	43451003	43453989	N	.	N	N	0.363300057	74.07536031	3.16E-08	87.6	.	.
HYKK	15	78507564	78537372	N	.	N	N	0.504095467	80.61584766	0.000214856	69.6	.	.
HYLS1	11	125883614	125900648	N	.	N	N	0.054717474	53.7014528	5.82E-05	73.5	DM	Hydrolethalus syndrome, 236680 (3)
HYPK	15	43796142	43803043	N	.	N	N	0.147473793	60.82653238	0.02103075	51.4	.	.
HYPM	X	37990817	37991317	N	.	N	N	.	.	.	.	.	.
HZGJ	2	68130149	68261230	N	.	N	N	.	.	.	.	.	.
IAH1	2	9473658	9496543	N	Viable	N	Y	-0.045692193	46.15384615	0.000119135	71.3	.	.
IAPP	12	21354959	21379978	N	.	N	Y	0.342555909	72.99878451	0.166030146	39.9	DM	.
IARS	9	92210207	92293756	N	.	N	N	-1.173494473	5.86328645	4.35E-09	89.7	.	.
IARS2	1	220094102	220148041	N	.	N	N	-0.382876691	25.276379	0.472741795	30.8	.	?Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007 (3)
IBA57	1	228165815	228182257	N	.	N	N	0.123201392	58.99751114	0.083021015	44.2	DM	?Multiple mitochondrial dysfunctions syndrome 3, 615330 (3); ?Spastic paraplegia 74, autosomal recessive, 616451 (3)
IBSP	4	87799581	87812435	N	.	N	Y	0.428107326	77.30508769	7.13E-08	86.5	DP	.
IBTK	6	82169983	82247754	N	.	N	N	-0.683965545	14.41801239	0.901146102	17.7	.	.
ICA1	7	8113184	8262687	N	.	N	Y	-0.294095963	29.76211148	0.004950368	58.2	.	.
ICA1L	2	202773150	202871985	N	.	N	N	0.013526612	50.54118192	0.442027586	31.7	.	.
ICAM1	19	10270835	10286615	N	.	N	Y	0.494023468	80.24541298	0.117797321	42.2	DFP	{Malaria, cerebral, susceptibility to}, 611162 (3)
ICAM2	17	64002594	64020634	N	.	N	Y	0.593178019	83.91503154	0.023266939	50.9	.	.
ICAM3	19	10333776	10339823	N	.	N	N	0.38052018	74.94356659	2.08E-22	99.1	.	.
ICAM4	19	10286967	10288522	N	.	N	Y	0.366169324	74.15639289	1.53E-05	77	FP	[Blood group, Landsteiner-Wiener], 111250 (3)
ICAM5	19	10289981	10296778	N	.	N	N	-0.590393082	17.04578341	.	.	DP	.
ICE1	5	5420664	5490234	N	.	N	N	.	.	.	.	.	.
ICE2	15	60419609	60479160	N	.	N	N	.	.	.	.	.	.
ICK	6	53001279	53061802	N	Viable	N	Y	-0.730235358	13.15043121	0.107449829	42.7	DM	Endocrine-cerebroosteodysplasia, 612651 (3)
ICOS	2	203936748	203961577	N	.	N	Y	0.072442927	55.09058286	0.052009229	46.8	DM	Immunodeficiency, common variable, 1, 607594 (3)
ICOSLG	21	44222991	44240966	N	.	N	Y	0.16167322	61.90310818	0.042548452	47.9	.	.
ICT1	17	75012670	75021261	N	.	N	N	0.407362793	76.21114777	0.019342733	51.9	.	.
ID1	20	31605283	31606515	N	.	N	Y	0.44679135	78.19644614	0.007655575	56.2	.	.
ID3	1	23557918	23559794	N	.	N	Y	0.157846676	61.58476587	0.688794338	24.9	DFP	.
IDE	10	92451684	92574076	N	.	N	Y	-1.328621411	4.491520519	0.426771018	32.1	DFP	.
IDH1	2	208236227	208266074	N	Viable	N	Y	-0.190967704	36.11159345	0.001453708	63.1	DM	{Glioma, susceptibility to, somatic}, 137800 (3)
IDH2	15	90083045	90102504	N	Viable	N	Y	-0.609379428	16.47276726	0.376558105	33.4	DM	D-2-hydroxyglutaric aciduria 2, 613657 (3)
IDH3A	15	78131498	78171949	N	.	N	N	-0.151691433	38.58887538	0.23094836	37.7	.	.
IDH3B	20	2658395	2664219	N	.	N	N	-0.387003268	25.10852579	3.06E-05	75.2	DM	Retinitis pigmentosa 46, 612572 (3)
IDH3G	X	153785766	153794523	N	.	N	N	0.107238638	57.76465822	0.968084889	13.2	.	.
IDI1	10	1039908	1049170	N	.	N	N	-0.10763024	41.63338543	0.002050009	61.8	.	.
IDI2	10	1018907	1025859	N	.	N	N	-0.193838554	35.89164786	6.34E-09	89.4	FTV	.
IDNK	9	83623049	83644130	N	.	N	Y	0.640921144	85.36783006	0.484632918	30.4	.	.
IDO1	8	39902275	39928444	N	.	N	Y	0.21706442	65.48590612	1.42E-05	77.2	DM?	.
IDO2	8	39934614	40016391	N	.	N	Y	.	.	9.40E-06	78.2	.	.
IDS	X	149476990	149521096	N	.	N	Y	0.375585437	74.723621	0.979259919	11.9	DM	Mucopolysaccharidosis II, 309900 (3)
IDUA	4	986997	1004506	N	.	N	Y	0.610246384	84.49962378	2.64E-08	87.8	DM	Mucopolysaccharidosis Ih, 607014 (3); Mucopolysaccharidosis Is, 607016 (3); Mucopolysaccharidosis Ih/s, 607015 (3)
IER2	19	13150415	13154908	N	.	N	N	-0.033556726	47.03941657	0.681051567	25.1	.	.
IER3	6	30743199	30744554	N	.	N	Y	0.168070043	62.3893037	0.671461599	25.5	.	.
IER3IP1	18	47152998	47176374	N	.	N	N	0.001088113	49.55142675	0.018434689	52.1	DM	Microcephaly, epilepsy, and diabetes syndrome, 614231 (3)
IER5	1	181088712	181092899	N	.	N	N	0.17476603	62.85234705	0.666267931	25.6	.	.
IER5L	9	129175552	129178262	N	.	N	N	.	.	0.829266816	20.7	.	.
IFFO1	12	6538375	6556083	N	.	N	N	-0.48167256	20.94692366	0.020732349	51.4	.	.
IFFO2	1	18904281	18956686	N	.	N	N	.	.	0.382583916	33.2	.	.
IFI16	1	158999968	159055155	N	.	N	N	0.268931648	68.63460091	0.002956041	60.4	.	.
IFI27	14	94104836	94116698	N	.	N	N	0.442966544	78.02280489	0.056185609	46.3	.	.
IFI27L1	14	94081282	94103846	N	.	N	N	0.745969788	87.98981305	0.076473378	44.7	.	.
IFI27L2	14	94127779	94130253	N	.	N	N	0.026467762	51.52514904	0.001507401	63	.	.
IFI30	19	18173162	18178117	N	.	N	Y	.	.	2.60E-05	75.6	DP	.
IFI35	17	43006725	43014456	N	.	N	N	0.852118493	90.23557331	5.70E-08	86.8	.	.
IFI44	1	78649796	78664078	N	Viable	N	Y	-0.048259287	45.95126469	4.72E-14	96.4	.	.
IFI44L	1	78619922	78646145	N	.	N	N	1.102755647	93.96886033	2.22E-10	92.4	FP	.
IFI6	1	27666061	27672218	N	.	N	N	.	.	0.230931225	37.7	.	.
IFIT1	10	89392546	89406486	N	.	N	Y	0.485412039	79.91549459	0.0053482	57.8	.	.
IFIT1B	10	89378056	89385205	N	.	N	N	0.980783127	92.51606182	7.26E-09	89.3	.	.
IFIT2	10	89301955	89309276	N	.	N	Y	-0.363537126	26.20825375	0.001482201	63.1	.	.
IFIT3	10	89327894	89340971	N	.	N	N	0.051041541	53.45835504	0.004426533	58.7	.	.
IFIT5	10	89414586	89421001	N	.	N	N	0.392504758	75.48764253	0.05814235	46.2	.	.
IFITM1	11	313506	315272	N	.	N	Y	-0.018550615	48.01759565	0.221686063	37.9	.	.
IFITM10	11	1732410	1750591	N	.	N	N	.	.	.	.	.	.
IFITM2	11	307631	315272	N	.	N	N	0.642833002	85.44886265	0.2993759	35.7	.	.
IFITM3	11	319669	327537	N	.	N	Y	0.307908866	70.93824159	0.199202473	38.8	DFP	{Influenza, severe, susceptibility to}, 614680 (3)
IFNA1	9	21409169	21441316	N	.	N	N	0.299449341	70.47519824	0.711485384	24.3	.	Interferon, alpha, deficiency (1)
IFNA10	9	21206181	21207143	N	.	N	N	1.163595862	94.66342536	0.001872534	62.1	DP	.
IFNA13	9	21367424	21368962	N	.	N	N	0.72537073	87.52676969	0.711459503	24.3	.	.
IFNA14	9	21239002	21239991	N	.	N	N	0.171089591	62.59767321	.	.	.	.
IFNA16	9	21216373	21217311	N	.	N	N	0.837111437	89.94617121	0.006569869	56.9	.	.
IFNA17	9	21206528	21228222	N	.	N	N	1.351199238	96.12201192	0.007025822	56.6	DP	.
IFNA2	9	21384254	21385388	N	.	N	N	0.369846866	74.37633848	0.044589404	47.6	DFP	.
IFNA21	9	21165637	21166660	N	.	N	N	0.395225439	75.60340337	8.63E-08	86.3	.	.
IFNA4	9	21186694	21187671	N	.	N	Y	1.380261207	96.28986514	0.240444347	37.4	.	.
IFNA5	9	21304326	21305312	N	.	N	N	0.417734923	76.70313133	0.006836061	56.7	.	.
IFNA6	9	21349835	21351378	N	.	N	N	0.44583509	78.14435377	0.000913991	65.1	.	.
IFNA7	9	21201469	21202205	N	.	N	N	0.972176436	92.35399664	9.02E-05	72.2	.	.
IFNA8	9	21409147	21410185	N	.	N	N	0.013375229	50.50645367	2.12E-06	81.2	.	.
IFNAR1	21	33324477	33359862	N	.	N	Y	-0.140208598	39.40498929	0.00062033	66.3	DP	.
IFNAR2	21	33229901	33265675	N	.	N	Y	-0.017290605	48.08126411	0.005066026	58	DP	{Hepatitis B virus, susceptibility to}, 610424 (3)
IFNB1	9	21077105	21077963	N	.	N	Y	0.604360167	84.27967818	0.013694438	53.6	DM?	.
IFNE	9	21480839	21482313	N	.	N	Y	0.302318539	70.64305146	8.79E-07	82.7	.	.
IFNG	12	68154768	68159747	N	.	N	Y	-0.081445868	43.46240667	0.020446566	51.5	DFP	{TSC2 angiomyolipomas, renal, modifier of}, 613254 (3); {Aplastic anemia}, 609135 (3); {Tuberculosis, protection against}, 607948 (3); {AIDS, rapid progression to}, 609423 (3);{Hepatitis C virus, response to therapy of}, 609532 (3)
IFNGR1	6	137197484	137219449	N	.	N	Y	0.183376188	63.43115124	0.327969027	34.9	DM	Immunodeficiency 27A, mycobacteriosis, AR, 209950 (3); {H. pylori infection, susceptibility to}, 600263 (3); {Tuberculosis, susceptibility to}, 607948 (3); Immunodeficiency 27B, mycobacteriosis, AD, 615978 (3); {Tuberculosis infection, protection against}, 607948 (3); {Hepatitis B virus infection, susceptibility to}, 610424 (3)
IFNGR2	21	33402896	33479348	N	.	N	Y	0.00123959	49.58036696	0.881281109	18.6	DM	Immunodeficiency 28, mycobacteriosis, 614889 (3)
IFNK	9	27524314	27526498	N	.	N	N	0.840791109	90.0272038	9.61E-09	88.9	.	.
IFNL1	19	39296325	39298673	N	.	N	N	0.607228418	84.37228686	2.82E-05	75.3	.	.
IFNL2	19	39268514	39270092	N	.	N	N	1.532262713	97.11176709	1.95E-05	76.3	FTV	.
IFNL3	19	39243553	39245129	N	Viable	N	Y	2.262347004	98.95236442	1.16E-05	77.7	.	{Hepatitis C virus infection, response to therapy of}, 609532 (3)
IFNLR1	1	24154157	24187959	N	.	N	Y	-0.302555896	29.33379638	0.308615222	35.5	FTV	.
IFNW1	9	21140214	21142145	N	.	N	N	0.689765371	86.64698732	0.006165915	57.1	.	.
IFRD1	7	112422968	112481017	N	.	N	Y	-0.412383648	23.80042832	0.105462457	42.8	DM?	.
IFRD2	3	50287732	50292918	N	.	N	N	-0.075552304	44.00069457	5.53E-06	79.4	.	.
IFT22	7	101313367	101321823	N	Viable	N	Y	.	.	.	.	.	.
IFT43	14	75902136	76084585	N	.	N	N	0.352119595	73.52549632	4.38E-07	83.9	DM	Cranioectodermal dysplasia 3, 614099 (3)
IFT46	11	118544528	118572970	N	.	N	N	0.29113834	69.98900272	0.950870755	14.7	.	.
IFT74	9	26947039	27062930	N	.	N	Y	0.076572313	55.40892516	9.27E-06	78.3	.	.
IFT81	12	110124335	110218797	N	.	N	N	-0.584803178	17.23678879	5.76E-07	83.5	.	.
IGBP1	X	70133449	70166324	N	.	N	N	0.453338311	78.48584824	0.933825158	15.9	DM	Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 (3)
IGDCC3	15	65327127	65378040	N	.	N	Y	-0.330354499	27.71893269	0.00023306	69.3	.	.
IGDCC4	15	65381464	65423072	N	.	N	N	0.710176367	87.13318284	0.014885498	53.2	.	.
IGF2BP2	3	185643739	185825056	N	.	N	N	-0.673079812	14.68426231	0.942124149	15.4	.	{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)
IGF2BP3	7	23310209	23470467	N	.	N	N	-0.705964203	13.78132778	0.999726189	4.6	.	.
IGFALS	16	1790413	1794971	N	.	N	Y	0.934957546	91.80413266	2.80E-05	75.4	DM	Acid-labile subunit, deficiency of, 615961 (3)
IGFBP1	7	45888357	45893668	N	.	N	Y	0.119374702	58.69074492	0.00178328	62.4	DP	.
IGFBP2	2	216632828	216664436	N	.	N	Y	-0.154562494	38.40365804	0.844353785	20.1	.	.
IGFBP3	7	45912245	45921874	N	Viable	N	Y	0.034927599	52.21971407	0.362251902	33.9	DFP	.
IGFBP4	17	40443461	40457731	N	.	N	Y	-0.033556726	47.03941657	0.23666901	37.5	.	.
IGFBP5	2	216672105	216695525	N	.	N	N	0.314455675	71.33761648	0.85997835	19.5	DFP	.
IGFBP6	12	53097436	53102345	N	.	N	N	0.337921524	72.70938242	0.092331337	43.6	.	.
IGFBP7	4	57030773	57110385	N	Viable	N	Y	.	.	0.005963209	57.3	DM	Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3)
IGFBPL1	9	38408994	38424447	N	.	N	N	.	.	0.008503933	55.6	.	.
IGFL1	19	46229752	46231243	N	.	N	N	0.890449695	90.94171442	5.93E-06	79.2	.	.
IGFL2	19	46143106	46161299	N	.	N	N	0.299449341	70.47519824	0.000244161	69.2	.	.
IGFL3	19	46120071	46124674	N	.	N	N	0.177486232	63.00862418	0.001093786	64.4	.	.
IGFL4	19	46039748	46077118	N	.	N	N	0.419500646	76.80152804	0.003129503	60.1	.	.
IGFLR1	19	35738801	35742453	N	.	N	N	0.54080415	82.10337443	0.000164884	70.4	.	.
IGFN1	1	201190825	201228952	N	.	N	N	.	.	2.50E-18	98.3	.	.
IGHMBP2	11	68903842	68940602	N	.	N	N	0.931612255	91.74625224	1.51E-08	88.4	DM	Neuronopathy, distal hereditary motor, type VI, 604320 (3); Charcot-Marie-Tooth disease, axonal, type 2S, 616155 (3)
IGIP	5	140125935	140129392	N	.	N	N	0.379115977	74.87411009	0.419918844	32.3	.	.
IGLL1	22	23573125	23580308	N	.	N	Y	1.752771321	98.07258205	0.017167742	52.4	DM	Agammaglobulinemia 2, 613500 (3)
IGLL5	22	22734620	22896107	N	.	N	N	0.88117671	90.72176883	.	.	.	.
IGLON5	19	51311848	51330354	N	.	N	N	-0.076661182	43.91387394	0.822062298	20.9	.	.
IGSF1	X	131273506	131399703	N	.	N	Y	-0.162416454	37.83064189	0.996859546	7.6	DM	Hypothyroidism, central, and testicular enlargement, 300888 (3)
IGSF10	3	151425384	151458709	N	.	N	N	0.884471867	90.8143775	2.99E-36	99.9	.	.
IGSF11	3	118900557	119146068	N	Viable	N	Y	-0.235985706	33.32175725	0.175167238	39.5	.	.
IGSF21	1	18107746	18378483	N	.	N	N	-0.30431789	29.24697575	0.547298803	28.7	.	.
IGSF22	11	18704305	18726230	N	.	N	N	1.699908	97.89894079	1.20E-20	98.8	.	.
IGSF23	19	44613630	44636781	N	.	N	N	.	.	.	.	.	.
IGSF3	1	116574399	116667755	N	.	N	N	0.248803099	67.37280778	0.987084919	10.6	.	?Lacrimal duct defect, 149700 (3)
IGSF5	21	39745407	39802096	N	.	N	Y	1.563379651	97.28540835	2.32E-11	93.8	.	.
IGSF6	16	21639537	21652660	N	.	N	N	0.561252451	82.78636337	0.072554781	44.9	.	.
IGSF8	1	160091340	160098943	N	.	N	N	-0.253559528	32.24518146	2.28E-06	81.1	.	.
IGSF9	1	159927039	159945604	N	.	N	Y	-0.966240282	8.438965098	0.56891088	28.2	.	.
IGSF9B	11	133908564	133956985	N	.	N	N	-1.949401103	1.771140823	0.999873394	4	.	.
IK	5	140647058	140662479	N	.	N	N	-0.331764245	27.65526422	3.47E-06	80.3	.	.
IKBIP	12	98613405	98645113	N	.	N	N	0.422667795	76.98674538	9.59E-05	72	DM?	.
IKBKE	1	206470476	206496889	N	.	N	Y	-0.400900992	24.36186838	0.804391777	21.5	DFP	.
IKZF3	17	39757715	39864188	N	Viable	N	Y	-0.756573024	12.45586618	0.994921788	8.5	.	.
IKZF4	12	56007659	56038435	N	.	N	N	0.425387042	77.11408231	0.953608121	14.4	.	.
IKZF5	10	122990806	123008817	N	Viable	N	Y	-0.438721742	22.81646119	0.42273684	32.2	.	.
IL10	1	206767602	206772494	N	.	N	Y	0.284443026	69.58383979	0.029162226	49.8	DM	{HIV-1, susceptibility to}, 609423 (3); {Graft-versus-host disease, protection against}, 614395 (3); {Rheumatoid arthritis, progression of}, 180300 (3)
IL10RA	11	117986348	118001483	N	.	N	Y	0.953639376	92.07038259	0.968345856	13.2	DM	Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 (3)
IL10RB	21	33266358	33297234	N	.	N	Y	0.311734573	71.17555131	0.000334787	68.4	DM	.
IL11	19	55364389	55370463	N	.	N	N	.	.	0.427157856	32.1	.	.
IL12A	3	159988750	159996019	N	.	N	Y	0.08936246	56.39289228	0.299096926	35.7	DP	.
IL12B	5	159314783	159330887	N	.	N	Y	0.412144579	76.45424553	0.000223246	69.4	DM	Immunodeficiency 29, mycobacteriosis, 614890 (3)
IL12RB1	19	18058995	18098944	N	Viable	N	Y	0.530736432	81.68084737	1.18E-07	85.9	DM	Immunodeficiency 30, 614891 (3)
IL12RB2	1	67307364	67396900	N	Viable	N	Y	0.439741618	77.8723158	4.51E-06	79.8	DM	.
IL13	5	132656263	132661110	N	Viable	N	Y	0.291946181	70.03530706	0.025714691	50.4	DFP	{Asthma, susceptibility to}, 600807 (3); {Allergic rhinitis, susceptibility to}, 607154 (3)
IL13RA1	X	118727572	118794539	N	.	N	Y	0.302318539	70.64305146	0.979171606	11.9	.	.
IL13RA2	X	115003975	115019977	N	.	N	Y	-0.190163599	36.15789778	7.64E-05	72.7	.	.
IL15	4	141636599	141733987	N	Viable	N	Y	-0.125507302	40.39474446	0.917197527	16.9	.	.
IL15RA	10	5937569	5978187	N	.	N	Y	0.397138302	75.69601204	3.17E-08	87.6	.	.
IL16	15	81159575	81314058	N	.	N	Y	-0.292401762	29.84893211	3.12E-05	75.1	DFP	.
IL17A	6	52186387	52190638	N	.	N	Y	0.209411733	65.03443885	0.167208391	39.8	DFP	.
IL17B	5	149371324	149404202	N	.	N	N	0.302318539	70.64305146	0.002074284	61.7	.	.
IL17C	16	88638591	88640473	N	.	N	Y	0.154170188	61.31851595	0.000566477	66.6	.	.
IL17D	13	20702127	20723098	N	.	N	N	0.571478862	83.14522197	0.158810135	40.2	.	.
IL17F	6	52236681	52244537	N	.	N	Y	0.317324799	71.58071424	0.030273925	49.6	DM	?Candidiasis, familial, 6, autosomal dominant, 613956 (3)
IL17RA	22	17084954	17115694	N	.	N	Y	1.139630217	94.42611565	0.11941793	42.1	DM	?Candidiasis, familial, 5, autosomal recessive, 613953 (3)
IL17RB	3	53846580	53865800	N	.	N	Y	0.663725837	86.05660705	3.51E-08	87.4	DFP	.
IL17RC	3	9917074	9933630	N	.	N	Y	0.171545609	62.62082537	4.25E-10	91.8	.	Candidiasis, familial, 9, 616445 (3)
IL17RD	3	57089982	57170306	N	Viable	N	Y	-0.372652286	25.7452104	2.64E-05	75.5	DM	Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3)
IL17RE	3	9902612	9916402	N	.	N	Y	0.542717698	82.16125485	0.008619878	55.5	.	.
IL17REL	22	49994513	50012659	N	.	N	N	0.738610262	87.81038375	0.327459012	34.9	DP	.
IL18	11	112143251	112164117	N	Viable	N	Y	0.289077164	69.85587776	0.102774109	42.9	DFP	.
IL18BP	11	71998541	72005715	N	Viable	N	Y	0.55566167	82.64745037	3.33E-06	80.3	.	.
IL18R1	2	102311529	102398775	N	.	N	Y	-0.635563637	15.77820223	5.02E-07	83.7	FP	.
IL18RAP	2	102418689	102452565	N	.	N	Y	-0.010744443	48.64270417	0.366507425	33.7	DFP	.
IL19	1	206798870	206842981	N	.	N	N	0.261933591	68.13682931	0.020320233	51.6	DP	.
IL1A	2	112773915	112784590	N	.	N	Y	0.916783155	91.42790994	1.12E-05	77.8	DFP	.
IL1B	2	112829751	112836903	N	.	N	Y	-0.312126643	28.79550848	0.925868312	16.3	DFP	{Gastric cancer risk after H. pylori infection}, 137215 (3)
IL1F10	2	113067970	113075850	N	.	N	N	0.619366893	84.74272154	0.003960243	59.1	.	.
IL1R1	2	102064544	102179874	N	.	N	Y	-0.521102007	19.43624472	0.362921431	33.8	DFP	.
IL1R2	2	101991844	102028544	N	Viable	N	Y	0.02389999	51.36308387	1.95E-07	85.2	.	.
IL1RAP	3	190514051	190659750	N	.	N	Y	-0.286592944	30.25409504	0.506746749	29.8	.	.
IL1RAPL1	X	28587399	29956723	N	.	N	Y	-0.626300493	15.98657174	0.996893678	7.6	DM	Mental retardation, X-linked 21/34, 300143 (3)
IL1RAPL2	X	104566315	105767829	N	.	N	N	0.26862913	68.62881287	0.973379476	12.6	.	.
IL1RL1	2	102311502	102352037	N	.	N	Y	1.093490704	93.88203971	1.28E-07	85.9	.	.
IL1RL2	2	102186973	102240002	N	.	N	Y	0.409575464	76.31533252	1.97E-07	85.2	.	.
IL1RN	2	113107214	113134016	N	.	N	Y	-0.341181678	27.18643283	0.340218949	34.5	DM	{Gastric cancer risk after H. pylori infection}, 137215 (3); {Microvascular complications of diabetes 4}, 612628 (3); Interleukin 1 receptor antagonist deficiency, 612852 (3)
IL2	4	122451470	122456725	N	.	N	Y	-0.051433536	45.65607455	0.784777637	22.2	DFP	Severe combined immunodeficiency due to IL2 deficiency (1)
IL20	1	206865354	206869223	N	.	N	N	0.565887443	82.91948834	0.002539178	61.1	DP	.
IL20RA	6	136999971	137045180	N	Viable	N	Y	0.418840633	76.77837588	0.007575317	56.2	DP	.
IL20RB	3	136946230	137011085	N	.	N	Y	-0.073790488	44.15118365	0.000354183	68.1	DM?	.
IL21	4	122612628	122621069	N	.	N	Y	0.001088113	49.55142675	0.50219058	29.9	DFP	.
IL21R	16	27402162	27452042	N	.	N	Y	-0.057675878	45.29142791	0.846367844	20	DM	[IgE, elevated level of], 147050 (3); Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 (3)
IL22	12	68248242	68253607	N	.	N	Y	0.322915185	71.92799676	0.490718396	30.2	DP	.
IL22RA1	1	24119771	24143121	N	.	N	Y	0.062523198	54.31498524	0.064400851	45.6	.	.
IL22RA2	6	137143820	137173648	N	.	N	Y	0.449660369	78.35272327	1.21E-09	91	.	.
IL23A	12	56334174	56340410	N	.	N	Y	-0.269022695	31.31330671	0.842438306	20.2	.	.
IL23R	1	67166400	67259979	N	.	N	Y	0.094297141	56.72281067	0.006495296	56.9	DFP	{Inflammatory bowel disease 17, protection against}, 612261 (3); {Psoriasis, protection against}, 605606 (3)
IL24	1	206897443	206904139	N	Viable	N	Y	-0.001630854	49.29675291	0.002715888	60.8	.	.
IL25	14	23372809	23376403	N	.	N	Y	0.431784952	77.48451699	3.63E-06	80.2	.	.
IL26	12	68201351	68225821	N	.	N	N	0.094952155	56.76911501	0.052761762	46.7	.	.
IL27	16	28499362	28512051	N	.	N	Y	0.080902701	55.81408809	0.927792678	16.2	.	.
IL27RA	19	14031748	14053216	N	.	N	Y	-0.333373338	27.57423164	8.97E-07	82.7	.	.
IL2RA	10	6010689	6062325	N	.	N	Y	-0.013766433	48.44591075	0.88128872	18.6	DM	Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3); {Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3)
IL2RB	22	37125838	37175054	N	.	N	Y	0.118719679	58.66180471	0.986756576	10.7	FTV	.
IL2RG	X	71107404	71112108	N	.	N	Y	0.368890551	74.33003415	0.957764471	14.1	DM	Severe combined immunodeficiency, X-linked, 300400 (3); Combined immunodeficiency, X-linked, moderate, 312863 (3)
IL3	5	132060529	132063204	N	.	N	Y	0.399859596	75.829137	3.72E-09	89.9	DFP	.
IL31	12	122172030	122174199	N	.	N	N	-0.260562407	31.82844244	0.150887238	40.5	.	.
IL31RA	5	55851379	55922853	N	Viable	N	Y	-0.524628496	19.24523934	2.13E-15	97.1	DM	Amyloidosis, primary localized cutaneous, 2, 613955 (3)
IL32	16	3065297	3082192	N	.	N	N	0.754573317	88.21554668	3.77E-07	84.2	.	.
IL33	9	6215786	6257983	N	Viable	N	Y	0.00315321	49.71927997	1.05E-08	88.9	.	.
IL34	16	70579895	70660682	N	.	N	Y	0.389635172	75.36030561	0.114215553	42.4	DM?	.
IL36A	2	113005461	113008044	N	.	N	N	0.679394134	86.39231348	0.00012331	71.3	.	.
IL36B	2	113022091	113052867	N	.	N	N	0.454294559	78.50321236	0.003517297	59.7	.	.
IL36G	2	112973203	112985665	N	.	N	N	0.285399426	69.6822365	2.50E-05	75.7	.	.
IL36RN	2	113058638	113065382	N	.	N	Y	0.604360167	84.27967818	0.00097234	64.8	DM	Psoriasis 14, pustular, 614204 (3)
IL37	2	112912971	112918882	N	.	N	N	0.714187722	87.25473172	0.007836058	56.1	.	.
IL3RA	X	1336616	1382689	N	.	N	N	0.397440353	75.71337616	1.10E-12	95.2	.	.
IL4	5	132673986	132682676	N	.	N	Y	0.094952155	56.76911501	0.168021415	39.8	DFP	.
IL4I1	19	49889654	49929539	N	.	N	Y	-0.157128223	38.22422874	0.262058045	36.7	.	.
IL4R	16	27313668	27364778	N	.	N	Y	0.231570067	66.31359611	0.031743833	49.4	DFP	{Atopy, susceptibility to}, 147050 (3); {AIDS, slow progression to}, 609423 (3)
IL5	5	132541444	132556838	N	.	N	Y	0.154976897	61.35903224	0.028374415	50	DP	.
IL5RA	3	3066326	3126613	N	.	N	Y	0.159910445	61.75261909	0.000332265	68.4	.	.
IL6	7	22725884	22732002	N	.	N	Y	-0.130139339	40.0821902	0.289669117	36	DFP	{Rheumatoid arthritis, systemic juvenile}, 604302 (3); {Kaposi sarcoma, susceptibility to}, 148000 (3); {Diabetes, susceptibility to}, 222100, 125853 (3); {Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3); {Crohn disease-associated growth failure}, 266600 (3)
IL6R	1	154405193	154469450	N	Viable	N	Y	-0.020161029	47.89604677	0.047869037	47.2	DFP	[Interleukin-6 receptor, soluble, serum level of, QTL], 614689 (3); [Interleukin 6, serum level of, QTL], 614752 (3)
IL6ST	5	55935095	55994993	Y	Viable	N	Y	-0.250689729	32.4303988	0.997842778	7.1	.	.
IL7	8	78675743	78805523	N	.	N	Y	0.23846774	66.7534873	0.879873742	18.6	FP	.
IL7R	5	35852695	35879603	N	.	N	Y	1.071783895	93.66209411	3.72E-06	80.1	DM	Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 (3)
IL9	5	135892246	135895827	N	.	N	Y	0.632461877	85.11894426	0.00054088	66.8	DFP	.
IL9R	X	155997581	156010817	N	.	N	Y	0.938787742	91.850437	1.92E-06	81.4	FTV	.
ILDR1	3	121987323	122022204	N	.	N	Y	0.621577198	84.79481391	7.94E-07	83	DM	Deafness, autosomal recessive 42, 609646 (3)
ILDR2	1	166895711	166975482	N	.	N	N	0.030446167	51.85506743	0.398939847	32.8	.	.
ILKAP	2	238170401	238203729	N	.	N	N	-0.384285668	25.21271054	0.992507797	9.3	.	.
ILVBL	19	15114984	15125785	N	.	N	N	0.116957788	58.52289171	1.14E-05	77.7	.	.
IMMP1L	11	31432401	31509645	N	.	N	N	-0.071071979	44.35376512	0.020713165	51.5	.	.
IMMP2L	7	110663051	111562517	N	.	N	N	-0.055108985	45.45349308	0.040760918	48.2	DM	.
IMMT	2	86143932	86195770	N	.	N	N	-0.491895074	20.51860855	0.000945647	64.9	DM?	.
IMP3	15	75639085	75648706	N	.	N	N	0.038754674	52.485964	5.33E-05	73.7	.	.
IMP4	2	130342225	130347810	N	.	N	N	-0.103802501	41.88805927	0.000968218	64.8	.	.
IMPA2	18	11981025	12030883	N	.	N	Y	0.069723511	54.87642531	0.237822649	37.4	DP	.
IMPACT	18	24426616	24453535	N	.	N	N	0.617600446	84.70220524	3.32E-05	75	.	.
IMPDH1	7	128392277	128410252	N	.	N	Y	-0.429150862	23.17531979	0.005811859	57.4	DM	Retinitis pigmentosa 10, 180105 (3); Leber congenital amaurosis 11, 613837 (3)
IMPG1	6	75921115	76072678	N	.	N	N	0.663078664	86.01609076	6.13E-13	95.5	.	Macular dystrophy, vitelliform, 4, 616151 (3)
IMPG2	3	101222546	101320560	N	.	N	N	-1.04032596	7.379753429	1.47E-08	88.5	DM	Retinitis pigmentosa 56, 613581 (3); Macular dystrophy, vitelliform, 5, 616152 (3)
INA	10	103277163	103290351	N	.	N	Y	0.032208434	52.02870869	0.292917015	35.9	.	.
INADL	1	61742477	62163920	N	.	N	N	1.251172472	95.43323494	6.18E-26	99.4	DP	.
INAFM1	19	47274453	47275707	N	.	N	N	.	.	.	.	.	.
INCA1	17	4988130	4997610	N	.	N	Y	0.264802972	68.36835099	8.26E-09	89.2	.	.
INF2	14	104689606	104722535	N	Viable	N	Y	0.598422958	84.05973259	0.999083288	5.8	DM	Glomerulosclerosis, focal segmental, 5, 613237 (3); Charcot-Marie-Tooth disease, dominant intermediate E, 614455 (3)
ING1	13	110712736	110723339	N	.	N	Y	-0.322194338	28.12988366	0.011435702	54.3	.	Squamous cell carcinoma, head and neck, somatic, 275355 (3)
ING2	4	183504994	183511096	N	.	N	Y	-0.124550289	40.46420096	0.283379994	36.1	.	.
ING3	7	120950749	120977216	N	.	N	N	-0.64226435	15.61034902	0.993602955	9	.	.
ING4	12	6650280	6663148	N	.	N	N	-0.283071606	30.49140476	0.052101924	46.8	.	.
ING5	2	241702035	241729478	N	.	N	N	-0.358102358	26.39347109	0.445393628	31.6	.	.
INHA	2	219569162	219575713	N	.	N	Y	0.179549296	63.17068936	0.199710682	38.8	DM	.
INHBC	12	57434760	57450828	N	.	N	Y	0.374628926	74.65995254	0.083686117	44.2	.	.
INHBE	12	57452323	57459280	N	.	N	Y	-0.010895966	48.63112809	7.68E-06	78.7	.	.
INIP	9	112683926	112718236	N	.	N	N	0.091125502	56.52022921	0.017451553	52.3	.	.
INMT	7	30697985	30757602	N	.	N	N	1.058541661	93.47108873	0.000120278	71.3	FP	.
INMT-FAM188B	7	30752137	30892081	N	.	N	N	.	.	.	.	.	.
INO80B-WBP1	2	74455088	74460884	N	.	N	N	.	.	.	.	.	.
INO80C	18	35452230	35497991	N	.	N	N	0.022791848	51.2704752	0.000502409	67	.	.
INO80D	2	205993721	206086303	N	.	N	N	-0.820127946	11.18249696	0.998179514	6.8	.	.
INO80E	16	29995294	30005793	N	.	N	N	0.36138737	73.96538751	0.017414685	52.3	.	.
INPP1	2	190343470	190371665	N	Viable	N	Y	-0.383328502	25.24743879	0.000237352	69.2	.	.
INPP4B	4	142023160	142847432	N	.	N	Y	-0.978659686	8.259535799	0.99861101	6.4	.	.
INPP5B	1	37860697	37947057	N	.	N	Y	-0.802252896	11.51241535	7.43E-09	89.3	.	.
INPP5D	2	233059967	233207903	N	.	N	Y	.	.	0.167430841	39.8	.	.
INPP5F	10	119726097	119829278	N	.	N	N	0.14344749	60.45030966	0.001468831	63.1	.	.
INPP5J	22	31122731	31134696	N	.	N	N	0.059652711	54.08346356	6.43E-12	94.5	.	.
INSC	11	15112424	15247208	N	.	N	N	1.390932169	96.34195752	1.34E-09	90.9	.	.
INSIG1	7	155297776	155310235	N	.	N	Y	0.147473793	60.82653238	0.124543666	41.9	DFP	.
INSIG2	2	118088452	118110997	N	.	N	N	0.011461629	50.36754066	0.023277147	50.9	DFP	.
INS-IGF2	11	2132538	2161209	N	.	N	N	0.337921524	72.70938242	0.036441413	48.7	.	.
INSL3	19	17816512	17821574	N	.	N	Y	.	.	0.034126507	49	DM	Cryptorchidism, 219050 (3)
INSL4	9	5231419	5235304	N	.	N	N	0.415822269	76.63946287	2.06E-05	76.1	.	.
INSL5	1	66797741	66801256	N	.	N	Y	0.663431417	86.02766684	1.52E-05	77	.	.
INSL6	9	5131979	5185668	N	.	N	Y	0.430020338	77.42084853	4.57E-05	74.1	DM?	.
INSM2	14	35534042	35537054	N	.	N	N	0.152407451	61.18539098	.	.	.	.
INSRR	1	156840063	156859018	N	.	N	Y	-0.603876577	16.61746831	4.92E-07	83.8	.	.
INTS10	8	19817140	19852083	N	.	N	N	-0.901857354	9.544481102	0.984216595	11.1	.	.
INTS3	1	153728067	153774808	N	.	N	N	-1.810020592	2.182091798	0.999997023	2.1	.	.
INTS4	11	77878720	77994678	N	.	N	N	-1.139107606	6.158476587	0.653071264	25.9	.	.
INTS5	11	62646848	62653302	N	.	N	N	-1.890534102	1.910053829	0.999284368	5.6	.	.
INTS7	1	211940399	212035542	N	.	N	N	-1.200095311	5.585460439	0.860980155	19.5	.	.
INTS8	8	94813311	94881746	N	.	N	N	-1.148523552	6.094808126	0.989948635	10	.	.
INTS9	8	28767661	28890242	N	.	N	N	-1.47694018	3.478613185	2.00E-06	81.3	.	.
IP6K1	3	49724294	49786542	N	.	N	Y	-0.298880801	29.53637784	0.235179981	37.5	.	.
IP6K2	3	48688003	48740353	N	.	N	Y	-0.533390518	18.85165249	0.989457703	10.1	.	.
IP6K3	6	33721667	33746985	N	.	N	N	1.322283531	95.9252185	0.048533853	47.2	.	.
IPCEF1	6	154154496	154356792	N	.	N	N	-0.222893607	34.16102333	0.39994059	32.8	.	.
IPO11	5	62403972	62628582	N	.	N	N	-1.335169968	4.451004225	0.996456955	7.8	.	.
IPO13	1	43946939	43968022	N	.	N	N	-0.923411499	9.168258378	0.972444338	12.8	.	.
IPO4	14	24180219	24188964	N	.	N	N	-0.654766065	15.21676217	3.22E-06	80.4	.	.
IPO5	13	97953658	98024297	N	.	N	N	-1.371736065	4.138449962	0.999998737	1.8	.	.
IPO7	11	9384622	9448126	N	.	N	N	-1.363418664	4.213694507	0.999998375	1.9	.	.
IPO8	12	30628988	30695986	N	.	N	N	-0.940185321	8.855704115	0.979783803	11.8	.	.
IPP	1	45694324	45750650	N	Viable	N	Y	-0.403771142	24.18822712	0.00253171	61.1	.	.
IQCA1	2	236324147	236507542	N	.	N	N	0.709856007	87.1273948	0.001381171	63.5	.	.
IQCA1L	7	151190873	151205496	N	.	N	N	.	.	.	.	.	.
IQCB1	3	121769763	121835079	N	.	N	N	0.193749521	64.05047173	1.20E-07	85.9	DM	Senior-Loken syndrome 5, 609254 (3)
IQCC	1	32205661	32208687	N	.	N	N	0.406704787	7.62E+01	2.26E-07	85	.	.
IQCD	12	113195441	113221094	N	.	N	N	0.057587761	53.92139839	7.66E-06	78.7	.	.
IQCE	7	2558972	2614734	N	Viable	N	Y	0.91739686	91.45685015	1.34E-25	99.4	DM?	.
IQCF1	3	51894876	51903335	N	.	N	N	0.68226197	86.49071019	0.0468541	47.4	.	.
IQCF2	3	51861629	51863424	N	.	N	N	0.443922687	78.05174509	0.000296978	68.7	.	.
IQCF3	3	51817604	51830856	N	.	N	N	0.694401032	86.77432425	0.127529597	41.7	.	.
IQCF5	3	51873721	51875584	N	.	N	N	.	.	0.433199986	31.9	.	.
IQCF6	3	51778561	51779187	N	.	N	N	.	.	.	.	.	.
IQCG	3	197889075	197960142	N	.	N	Y	0.68991226	86.66435145	3.61E-15	96.9	.	.
IQCH	15	67254800	67502260	N	.	N	N	-0.834992399	10.88151878	2.69E-12	94.9	.	.
IQCJ	3	158962928	159266307	N	.	N	N	0.337921524	72.70938242	0.098429365	43.2	.	.
IQCJ-SCHIP1	3	158962235	159897366	N	.	N	N	-0.058784478	45.21039532	0.66050206	25.7	.	.
IQCK	16	19716456	19858467	N	.	N	N	0.35116309	73.45025178	0.053932626	46.5	.	.
IQGAP1	15	90388218	90502243	N	.	N	Y	-1.985982759	1.684320194	0.999976585	2.9	DP	.
IQGAP2	5	76403249	76708132	N	Viable	N	Y	-0.481905319	20.90061932	4.10E-15	96.9	FTV	.
IQGAP3	1	156525405	156572604	N	.	N	N	0.500581919	80.46535857	6.47E-16	97.4	DM?	.
IQSEC1	3	12897220	13073117	N	.	N	N	-1.376243171	4.092145627	0.998506227	6.5	.	.
IQSEC2	X	53232876	53321324	N	.	N	N	-0.357948071	26.40504717	0.975390479	12.4	DM	Mental retardation, X-linked 1, 309530 (3)
IQSEC3	12	66765	178460	N	Viable	N	Y	-0.331310888	27.67262835	0.925104239	16.4	.	.
IQUB	7	123452400	123535077	N	Viable	N	Y	-0.569647938	17.64773977	3.24E-13	95.7	.	.
IRAK1	X	154010500	154019980	N	.	N	Y	1.000424379	92.76494762	0.994301924	8.7	DFP	.
IRAK1BP1	6	78867472	78946440	N	.	N	N	0.373672448	74.62522429	0.000864774	65.2	.	.
IRAK2	3	10164865	10243743	N	Viable	N	Y	1.210835784	95.13225676	2.90E-08	87.7	.	.
IRAK3	12	66188879	66254622	N	.	N	Y	0.999617879	92.75915958	3.58E-15	97	DM	{Asthma susceptibility 5}, 611064 (3)
IRAK4	12	43758944	43789543	N	.	N	Y	-0.212519778	34.79191989	0.000576872	66.6	DM	IRAK4 deficiency, 607676 (3); Invasive pneumococcal disease, recurrent isolated, 1, 610799 (3)
IREB2	15	78437431	78501456	N	.	N	Y	-0.525584879	19.16999479	0.99999973	1.3	.	.
IRF1	5	132481609	132490798	N	.	N	Y	-0.440636427	22.72385252	0.867788618	19.2	FP	Myelodysplastic syndrome, preleukemic (3); Myelogenous leukemia, acute (3); Gastric cancer, somatic, 613659 (3); Nonsmall cell lung cancer, somatic, 211980 (3)
IRF2	4	184387713	184474580	N	.	N	Y	-0.210758594	34.87295248	0.382047181	33.3	DP	.
IRF2BP1	19	45883607	45886170	N	.	N	N	-0.835435412	10.86415466	0.974430422	12.5	.	.
IRF2BP2	1	234604269	234609525	N	.	N	N	-0.531476218	18.93268507	0.470291319	30.8	.	.
IRF2BPL	14	77024543	77028699	N	.	N	N	-0.984396794	8.143774961	0.968935346	13.1	.	.
IRF3	19	49659569	49665875	N	.	N	Y	0.499461757	80.4422064	0.003217418	60	.	{?Herpes simplex encephalitis, susceptibility to, 7}, 616532 (3)
IRF4	6	391739	411447	N	.	N	Y	-0.641306922	15.65086531	0.92222069	16.6	DM?	[Skin/hair/eye pigmentation, variation in, 8], 611724 (3)
IRF5	7	128937612	128950035	N	.	N	Y	-0.273500756	31.08178503	0.288476016	36	DFP	{Inflammatory bowel disease 14}, 612245 (3); {Systemic lupus erythematosus, susceptibility to, 10}, 612251 (3)
IRF7	11	612553	615999	N	.	N	Y	-0.009787637	48.71216068	3.31E-07	84.4	DFP	?Immunodeficiency 39, 616345 (3)
IRF8	16	85898803	85922609	N	Viable	N	Y	0.813792502	89.39630723	0.926540238	16.3	DM	Immunodeficiency 32A, mycobacteriosis, autosomal dominant, 614893 (3); Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive, 614894 (3)
IRF9	14	24161053	24166565	N	.	N	Y	-0.389874437	24.9580367	0.631965598	26.6	.	.
IRG1	13	76948497	76958642	N	.	N	N	.	.	.	.	.	.
IRGC	19	43716010	43720021	N	.	N	N	-0.083860557	43.30034149	0.043735507	47.7	.	.
IRGM	5	150846523	150900736	N	.	N	Y	.	.	.	.	DFP	{Mycobacterium tuberculosis, protection against}, 607948 (3); Inflammatory bowel disease 19, 612278 (3)
IRGQ	19	43584369	43596135	N	.	N	N	-0.413187838	23.76570006	0.001197228	64	.	.
IRS2	13	109752698	109786568	N	.	N	Y	.	.	.	.	DM?	{Diabetes mellitus, noninsulin-dependent}, 125853 (3)
IRS4	X	108732482	108736409	N	.	N	Y	-0.027361277	47.46194362	0.609434374	27.2	DM?	.
IRX1	5	3596054	3601403	N	.	N	N	-0.281003772	30.58401343	0.002310654	61.4	.	.
IRX2	5	2745845	2751662	N	.	N	Y	-0.508966819	19.83561961	0.648697597	26.1	.	.
IRX3	16	54283304	54286763	N	.	N	Y	0.031251654	51.92452393	.	.	.	.
IRX4	5	1877413	1887236	N	.	N	Y	.	.	0.253769011	37	DM?	.
IRX5	16	54930862	54934485	N	.	N	Y	-0.746352589	12.73369219	.	.	DM	Hamamy syndrome, 611174 (3)
IRX6	16	55323760	55330760	N	.	N	Y	0.371103225	74.46315911	2.82E-08	87.7	.	.
ISCA1	9	86264546	86282538	N	.	N	N	0.045150018	52.96637148	0.778973883	22.3	.	.
ISCA2	14	74493720	74497106	N	.	N	N	-0.013918082	48.39381837	6.27E-05	73.3	.	Multiple mitochondrial dysfunctions syndrome 4, 616370 (3)
ISCU	12	108562582	108569384	N	.	N	N	-0.028924269	47.36354691	0.135947771	41.3	DM	Myopathy with lactic acidosis, hereditary, 255125 (3)
ISG15	1	1001138	1014541	N	.	N	Y	0.39426906	75.53973491	0.009847813	55	DM	Immunodeficiency 38, 616126 (3)
ISG20	15	88636153	88656483	N	.	N	N	-0.181703531	36.63251722	0.006091387	57.1	.	.
ISG20L2	1	156721891	156728799	N	.	N	N	-0.088796495	42.91254269	0.821397244	20.9	.	.
ISLR	15	74173671	74176872	N	.	N	N	0.048322504	53.28471378	0.000436482	67.5	.	.
ISM1	20	13221771	13300651	N	.	N	N	0.302467839	70.66620362	0.05422219	46.5	.	.
ISM2	14	77474394	77498850	N	.	N	N	1.326111482	95.96573479	1.26E-05	77.5	.	.
ISOC1	5	129094751	129114028	N	.	N	N	-0.567232387	17.72298431	0.005293034	57.9	.	.
ISOC2	19	55452985	55462343	N	.	N	N	0.273262571	68.86033455	0.043319434	47.8	.	.
IST1	16	71845996	71931199	N	.	N	N	-0.189053899	36.22156624	0.023110672	50.9	.	.
ISX	22	35066136	35087387	N	.	N	Y	1.283660986	95.69369682	0.000189151	70	.	.
ISY1	3	129127415	129161293	N	.	N	N	-0.313083888	28.69711177	0.998290706	6.7	.	.
ISY1-RAB43	3	129087575	129161036	N	.	N	N	-0.266151109	31.49273601	0.998894935	6	.	.
ISYNA1	19	18434388	18438301	N	.	N	N	-0.73214908	13.11570296	0.0026393	60.9	DP	.
ITCH	20	34363235	34511393	N	.	N	N	-1.32126329	4.55518898	0.999990177	2.5	DM	Autoimmune disease, multisystem, with facial dysmorphism, 613385 (3)
ITFG1	16	47154387	47464149	N	.	N	N	-0.25003479	32.45933901	0.962023993	13.8	.	.
ITFG2	12	2812622	2859791	N	.	N	N	-0.765990612	12.28222492	1.39E-06	82.1	.	.
ITFG3	16	234546	268971	N	.	N	N	0.40031172	75.85228917	2.74E-05	75.4	.	.
ITGA1	5	52787896	52959210	N	.	N	Y	-0.832126352	10.9393992	0.002375685	61.3	.	.
ITGA10	1	145891208	145910189	N	.	N	Y	0.072244512	55.05006656	8.55E-11	93	.	.
ITGA11	15	68296533	68432162	N	.	N	Y	0.517964696	81.1599236	0.000116169	71.4	DP	.
ITGA2	5	52989326	53094779	N	Viable	N	Y	-0.625707325	16.00972391	9.23E-09	89	DM	?Glycoprotein Ia deficiency, 614200 (1)
ITGA2B	17	44372180	44389505	N	.	N	Y	-1.354816673	4.259998842	4.07E-05	74.5	DM	Glanzmann thrombasthenia, 273800 (3); Thrombocytopenia, neonatal alloimmune, BAK antigen related (3); Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3)
ITGAD	16	31393312	31426505	N	.	N	Y	1.460906828	96.76448457	6.33E-12	94.5	FTV	.
ITGAE	17	3714628	3801243	N	Viable	N	Y	0.070483395	54.91115356	7.99E-13	95.3	DP	.
ITGAL	16	30472658	30523185	N	.	N	Y	-1.560174255	3.021357875	0.430339544	32	.	.
ITGAM	16	31259990	31332892	N	.	N	Y	-0.428706734	23.18110783	1.34E-08	88.6	DFP	{Systemic lupus erythematous, association with susceptibility to, 6}, 609939 (3)
ITGAX	16	31355134	31382997	N	.	N	Y	-0.708110035	13.68871911	6.11E-05	73.3	.	.
ITGB1BP2	X	71301734	71305371	N	.	N	Y	0.240380673	66.89818834	0.000383159	67.9	.	.
ITGB3BP	1	63440770	63593721	N	.	N	N	0.063983137	54.4886265	1.47E-05	77.1	.	.
ITGB5	3	124761948	124901418	N	.	N	Y	0.297183223	70.32470915	0.000480019	67.1	.	.
ITGB6	2	160099666	160271888	N	.	N	Y	0.034576738	52.17340974	1.91E-15	97.1	.	Amelogenesis imperfecta, type IH, 616221 (3)
ITGB7	12	53191318	53207307	N	.	N	Y	-1.246075562	5.145569254	0.002654239	60.9	.	.
ITGBL1	13	101452593	101720856	N	.	N	N	-0.530519144	18.97898941	0.170877824	39.7	.	.
ITIH1	3	52777592	52792068	N	.	N	N	0.638813246	85.31573769	4.79E-18	98.2	FP	.
ITIH2	10	7703269	7749520	N	.	N	N	-0.042216466	46.40273196	7.07E-10	91.4	.	.
ITIH3	3	52794768	52809009	N	.	N	N	0.968004654	92.28454014	6.67E-12	94.4	DP	.
ITIH4	3	52812975	52831479	N	.	N	Y	0.908934892	91.26005672	4.63E-05	74.1	DP	{Hypercholesterolemia, susceptibility to}, 143890 (3)
ITIH5	10	7559270	7666998	N	.	N	N	.	.	5.64E-13	95.5	.	.
ITIH6	X	54748899	54798240	N	.	N	N	2.327856338	99.01603288	9.89E-11	92.9	DM?	.
ITK	5	157142933	157255191	N	.	N	Y	-0.927237968	9.104589917	1.50E-05	77.1	DM	Lymphoproliferative syndrome 1, 613011 (3)
ITLN1	1	160876539	160885170	N	.	N	Y	0.173002985	62.75973838	0.004891194	58.2	.	.
ITLN2	1	160945025	160954799	N	.	N	N	0.733019432	87.65410662	1.15E-05	77.7	.	.
ITM2A	X	79360384	79367667	N	.	N	Y	0.209411733	65.03443885	0.842718352	20.2	.	.
ITM2B	13	48233158	48270357	N	.	N	Y	-0.08703502	43.03409157	0.715126636	24.2	DM	Dementia, familial British, 176500 (3); Dementia, familial Danish, 117300 (3); ?Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, 616079 (3)
ITPKA	15	41493393	41503551	N	.	N	Y	-0.129182361	40.14585866	0.821022369	21	.	.
ITPKB	1	226631690	226739323	N	.	N	Y	0.259822834	68.02106847	0.998850076	6.1	.	.
ITPKC	19	40717103	40740860	N	.	N	Y	0.21817215	65.5669387	0.164215304	40	DP	{Kawasaki disease, susceptibility to}, 611775 (3)
ITPR2	12	26336515	26833198	N	.	N	Y	-2.963895081	0.619320484	5.74E-11	93.3	.	?Anhidrosis, isolated, with normal sweat glands, 106190 (3)
ITPR3	6	33620365	33696574	N	.	N	Y	-3.57163418	0.358858598	4.98E-12	94.7	DP	{Diabetes, type 1, susceptibility to}, 222100 (2)
ITPRIP	10	104309698	104338404	N	.	N	Y	-0.556554166	18.01817445	1.35E-05	77.3	.	.
ITPRIPL1	2	96325331	96330517	N	.	N	N	0.346680316	73.22451815	1.11E-07	86	.	.
ITPRIPL2	16	19113932	19121629	N	.	N	N	0.259363026	68.00949239	0.018503394	52.1	.	.
ITSN2	2	24202864	24360714	N	Viable	N	Y	-0.612202673	16.42646293	0.024433691	50.6	DM?	.
IVL	1	152908545	152911886	N	Viable	N	Y	.	.	3.43E-09	90	.	.
IWS1	2	127436207	127526886	N	.	N	N	-0.645785708	15.51195231	0.98644488	10.7	.	.
IYD	6	150368892	150405969	N	.	N	N	0.464666725	79.07044047	0.088309192	43.9	DM	Thyroid dyshormonogenesis 4, 274800 (3)
IZUMO1	19	48740852	48746909	N	.	N	Y	0.040668219	52.64224113	0.002416263	61.2	.	.
IZUMO1R	11	94305593	94307721	N	Viable	N	Y	.	.	.	.	.	.
IZUMO2	19	50152548	50163195	N	.	N	N	0.265759477	68.41465532	1.07E-05	77.9	.	.
IZUMO3	9	24542952	24545946	N	.	N	N	.	.	.	.	.	.
IZUMO4	19	2096429	2099593	N	.	N	N	0.414057549	76.56421832	4.70E-08	87.1	.	.
JADE2	5	134524312	134583230	N	.	N	N	0.247379597	67.29756323	.	.	.	.
JADE3	X	46912276	47061242	N	.	N	N	-0.318518891	28.37876946	.	.	.	.
JAGN1	3	9890554	9894349	N	.	N	N	0.126877769	59.25218499	0.023062733	50.9	.	Neutropenia, severe congenital, 6, autosomal recessive, 616022 (3)
JAK3	19	17824780	17848071	N	.	N	Y	-0.29011822	30.06308966	0.9958638	8	DM	SCID, autosomal recessive, T-negative/B-positive type, 600802 (3)
JAKMIP1	4	6026199	6200591	N	.	N	N	-1.120420525	6.372634138	0.993166784	9.1	.	.
JAKMIP2	5	147585439	147782848	N	.	N	N	-0.92915172	9.05249754	0.999936528	3.4	.	.
JAKMIP3	10	132104671	132184809	N	.	N	N	-0.510578472	19.78352723	0.053931825	46.6	.	.
JAM2	21	25639272	25717562	N	Viable	N	Y	0.218827885	65.61903108	0.148660697	40.7	.	.
JAZF1	7	27830573	28180743	N	Viable	N	Y	-0.041059779	46.53585692	0.958302382	14.1	.	.
JCHAIN	4	70655541	70681817	N	.	N	Y	.	.	.	.	.	.
JDP2	14	75427716	75474111	N	.	N	Y	-0.033556726	47.03941657	0.85610611	19.7	.	.
JKAMP	14	59484443	59505410	N	.	N	N	-0.342138919	27.14591654	0.059897686	46	.	.
JMJD1C	10	63167221	63521850	N	.	N	Y	-2.22506306	1.250217052	1	0.4	DM	.
JMJD4	1	227730425	227735411	N	.	N	N	0.314754515	71.37813278	1.87E-07	85.3	.	.
JMJD7	15	41828085	41837581	N	.	N	N	0.780909061	88.81750304	0.234310957	37.6	.	.
JMJD7-PLA2G4B	15	41828095	41848155	N	.	N	N	0.980647789	92.51027377	9.16E-25	99.3	.	.
JMJD8	16	681671	684528	N	.	N	N	.	.	3.80E-10	91.9	.	.
JMY	5	79236189	79327215	N	.	N	N	-0.197362146	35.68327835	0.999722637	4.6	.	.
JOSD1	22	38685543	38701556	N	.	N	N	-0.268065472	31.35961104	0.319904565	35.1	.	.
JOSD2	19	50505998	50511353	N	.	N	N	0.049933723	53.40047462	0.428022034	32.1	.	.
JPH3	16	87601835	87698156	N	.	N	Y	0.084227285	56.03982173	0.986177997	10.7	DM	Huntington disease-like 2, 606438 (3)
JPH4	14	23568035	23578800	N	.	N	N	.	.	0.987347573	10.5	.	.
JRK	8	142657460	142681968	N	.	N	N	.	.	.	.	DM	.
JRKL	11	96389989	96507574	N	.	N	N	-0.384285668	25.21271054	0.000583511	66.6	.	.
JSRP1	19	2252252	2269759	N	.	N	Y	0.284591847	69.63014412	8.90E-10	91.2	FP	.
JTB	1	153974269	153977688	N	.	N	N	0.063983137	54.4886265	0.645223905	26.2	.	.
JUNB	19	12791496	12793315	N	.	N	N	.	.	0.585014693	27.8	.	.
JUND	19	18279760	18281622	N	.	N	Y	.	.	0.560887374	28.4	.	.
KAAG1	6	24356903	24358284	N	.	N	N	0.372568852	74.5441917	0.019191239	51.9	.	.
KANK1	9	470291	746106	N	.	N	N	-0.408236857	24.02037391	.	.	DM	Cerebral palsy, spastic quadriplegic, 2, 612900 (3)
KANK2	19	11164267	11197791	N	.	N	N	0.40158319	75.89280546	0.981511999	11.5	.	Palmoplantar keratoderma and woolly hair, 616099 (3)
KANK3	19	8322584	8343262	N	.	N	N	.	.	8.53E-06	78.5	.	.
KANK4	1	62236979	62319414	N	.	N	N	0.890258742	90.93592638	5.40E-08	86.9	.	.
KANSL1	17	46029916	46225374	N	.	N	Y	0.393122134	75.50500666	0.999733506	4.5	DM	Koolen-De Vries syndrome, 610443 (3)
KANSL1L	2	210021423	210171383	N	.	N	N	-0.11739796	40.93303236	0.476930027	30.6	.	.
KANSL2	12	48653401	48682238	N	.	N	N	-0.247316664	32.6098281	0.404028497	32.6	DM?	.
KANSL3	2	96593170	96642787	N	.	N	N	-0.522058982	19.35521213	0.994530637	8.6	.	.
KAT2B	3	20040023	20154404	N	.	N	Y	-0.122332238	40.60890201	0.998926901	6	.	.
KATNA1	6	149594873	149648972	N	.	N	N	-0.789457867	11.75551311	0.001925875	62	.	.
KATNAL1	13	30202630	30307484	N	.	N	N	-0.43393578	23.0248307	0.946326583	15.1	.	.
KATNAL2	18	46917492	47102243	N	.	N	N	0.35226973	73.53707241	0.000125862	71.2	DM?	.
KATNBL1	15	34140674	34210096	N	.	N	N	-0.054152096	45.51716154	0.014154739	53.5	.	.
KAZALD1	10	101061841	101068131	N	.	N	N	0.266716005	68.46095966	0.000335811	68.4	.	.
KAZN	1	14598704	15118043	N	.	N	Y	0.076572313	55.40892516	0.144589791	40.8	.	.
KBTBD11	8	1973878	2006936	N	.	N	N	.	.	0.273543145	36.4	.	.
KBTBD12	3	127915232	127987671	N	.	N	N	0.287612942	69.74590496	9.96E-13	95.3	.	.
KBTBD13	15	65076816	65078192	N	.	N	N	.	.	3.34E-05	75	DM	Nemaline myopathy 6, autosomal dominant, 609273 (3)
KBTBD2	7	32868172	32894131	N	.	N	N	-0.962994377	8.508421601	0.991275949	9.7	.	.
KBTBD3	11	106051098	106077765	N	.	N	N	-0.740609356	12.8726052	2.60E-05	75.6	.	.
KBTBD4	11	47572197	47579015	N	.	N	N	-0.643066859	15.59298489	0.018074364	52.2	.	.
KBTBD6	13	41127569	41132746	N	.	N	N	-0.747155718	12.69896394	0.93481936	15.8	.	.
KBTBD7	13	41189833	41194566	N	.	N	N	-1.162722796	5.973259246	0.223860925	37.9	.	.
KBTBD8	3	66998307	67011210	N	.	N	N	-0.93761225	8.902008451	0.00167057	62.6	.	.
KCNA1	12	4909905	4931361	Y	Viable	N	Y	-0.821386015	11.14198067	0.051801456	46.8	DM	Episodic ataxia/myokymia syndrome, 160120 (3)
KCNA10	1	110517251	110518838	N	.	N	Y	0.735083071	87.7351392	0.003059489	60.3	.	.
KCNA3	1	110672465	110675033	N	.	N	Y	-0.404880574	24.14192279	.	.	DP	.
KCNA4	11	30009741	30017023	N	.	N	Y	-1.057669987	7.113503502	0.946234021	15.2	.	.
KCNA5	12	5043989	5046788	N	.	N	Y	-0.459969298	21.90773861	0.000687392	66	DM	Atrial fibrillation, familial, 7, 612240 (3)
KCNA6	12	4809176	4813412	N	.	N	Y	-0.917973275	9.260867049	0.961132595	13.8	.	.
KCNA7	19	49067418	49072941	N	.	N	N	-0.635563637	15.77820223	0.008250223	55.7	.	.
KCNAB1	3	156037701	156539138	N	.	N	Y	-0.103650534	41.89963535	0.066550343	45.4	.	.
KCNAB2	1	5991466	6101193	N	.	N	Y	-0.257690928	32.05996411	0.839972632	20.3	DM	.
KCNAB3	17	7921859	7929803	N	Viable	N	Y	-0.29042075	30.03993749	6.03E-12	94.5	.	.
KCNB1	20	49363877	49482647	N	Viable	N	Y	-0.42723718	23.22162412	0.98258787	11.3	.	Epileptic encephalopathy, early infantile, 26, 616056 (3)
KCNB2	8	72537391	72938349	N	.	N	Y	-1.132559664	6.22793309	0.954615847	14.3	DM?	.
KCNC1	11	17734812	17783055	N	.	N	N	-0.687283786	14.28488742	0.709972136	24.4	.	Epilepsy, progressive myoclonic 7, 616187 (3)
KCNC2	12	75040077	75209868	N	Viable	N	Y	-0.14962524	38.77409272	0.003596818	59.6	.	.
KCNC3	19	50311937	50333515	N	.	N	Y	-1.024937791	7.536030561	0.850943335	19.9	DM	Spinocerebellar ataxia 13, 605259 (3)
KCNC4	1	110211343	110283100	N	.	N	N	0.039057439	52.49754008	0.000534225	66.9	.	.
KCND1	X	48961378	48971569	N	.	N	N	-0.076509147	43.9370261	0.447025941	31.5	.	.
KCND2	7	120273668	120750331	N	.	N	Y	-0.697503755	14.01863749	0.980460832	11.7	DM	.
KCND3	1	111770662	111989155	N	.	N	N	-0.741566385	12.83787695	0.803752595	21.5	DM	Spinocerebellar ataxia 19, 607346 (3); Brugada syndrome 9, 616399 (3)
KCNE1	21	34446688	34512275	N	.	N	Y	0.38485322	75.1519361	0.004186135	58.9	DM	Jervell and Lange-Nielsen syndrome 2, 612347 (3); Long QT syndrome 5, 613695 (3)
KCNE2	21	34364024	34371389	N	.	N	Y	0.276939876	69.10922035	0.001018406	64.7	DM	Long QT syndrome 6, 613693 (3); Atrial fibrillation, familial, 4, 611493 (3)
KCNE3	11	74454841	74467729	N	.	N	Y	0.04051715	52.61908896	0.444435272	31.6	DM	Brugada syndrome 6, 613119 (3)
KCNE4	2	223051814	223198399	N	.	N	N	-0.078575026	43.76338485	0.560426843	28.4	DM?	.
KCNE5	X	109623700	109625172	N	.	N	N	.	.	.	.	.	.
KCNF1	2	10911937	10914225	N	.	N	N	-0.858903013	10.38953522	0.49836903	30	.	.
KCNG1	20	51003656	51023129	N	.	N	N	-0.753855899	12.49059443	0.274579646	36.4	.	.
KCNG2	18	79863668	79900184	N	.	N	N	-0.260408668	31.84580656	0.00583162	57.4	.	.
KCNG3	2	42442017	42494097	N	.	N	N	-0.651682625	15.33831105	0.04059744	48.2	.	.
KCNG4	16	84218667	84239750	N	.	N	N	0.905101911	91.16166001	3.97E-17	97.8	.	.
KCNH1	1	210678315	211134115	N	.	N	Y	-1.768671446	2.286276553	0.33301456	34.8	.	Temple-Baraitser syndrome, 611816 (3); Zimmermann-Laband syndrome 1, 135500 (3)
KCNH3	12	49539157	49558308	N	Viable	N	Y	-1.043326658	7.32187301	0.999889995	3.8	.	.
KCNH4	17	42156891	42181278	N	Viable	N	Y	-1.574360157	2.934537246	0.999978751	2.8	.	.
KCNH5	14	62699454	63102037	N	.	N	Y	-1.464655946	3.548069688	0.769049292	22.6	.	.
KCNH6	17	63523334	63548977	N	Viable	N	Y	0.580866935	83.49829253	3.94E-17	97.9	DM?	.
KCNH7	2	162371407	162838730	N	.	N	N	-1.540522108	3.137118713	0.984445949	11	.	.
KCNH8	3	19148454	19535646	N	.	N	N	-0.500060532	20.17711408	0.000102484	71.8	.	.
KCNIP1	5	170353487	170736632	N	.	N	N	-0.023183121	47.73398159	0.020231957	51.6	.	.
KCNIP2	10	101825974	101843920	N	.	N	Y	0.151300234	61.07541819	0.018688178	52	.	.
KCNIP3	2	95297304	95386083	N	.	N	Y	0.123201392	58.99751114	0.852600761	19.8	.	.
KCNIP4	4	20728616	21948799	N	.	N	Y	-0.448139541	22.37657001	0.967714667	13.3	DM?	.
KCNJ11	11	17385859	17389331	N	.	N	Y	-0.252905653	32.27412166	0.31472413	35.3	DM	Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3); Diabetes, permanent neonatal, 606176 (3); Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3); {Diabetes mellitus, type 2, susceptibility to}, 125853 (3); Diabetes mellitus, transient neonatal, 3, 610582 (3); Maturity-onset diabetes of the young, type 13, 616329 (3)
KCNJ12	17	21376197	21419872	N	.	N	Y	5.775631456	99.87266308	1.43E-05	77.2	.	.
KCNJ13	2	232766464	232776568	N	.	N	N	-0.159194457	38.09110378	0.758052442	22.9	DM	Snowflake vitreoretinal degeneration, 193230 (3); Leber congenital amaurosis 16, 614186 (3)
KCNJ14	19	48455509	48466980	N	Viable	N	Y	-0.056870751	45.35509637	8.51E-05	72.4	.	.
KCNJ15	21	38157034	38307357	N	.	N	Y	-0.049367758	45.85286797	0.150462039	40.6	DFP	.
KCNJ16	17	70053429	70135608	N	.	N	Y	0.471362413	79.35984257	5.42E-06	79.4	.	.
KCNJ18	17	21692523	21704612	N	.	N	N	.	.	.	.	DM	{Thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3)
KCNJ3	2	154698299	154858352	N	Viable	N	Y	-0.340224471	27.22116108	0.989708243	10	DP	.
KCNJ4	22	38426327	38455199	N	.	N	N	-1.124400756	6.343693928	0.825953321	20.8	.	.
KCNJ5	11	128891356	128921035	N	.	N	Y	-0.842938812	10.72524165	0.309232169	35.5	DM	Long QT syndrome 13, 613485 (3); Hyperaldosteronism, familial, type III, 613677 (3)
KCNJ8	12	21764955	21775581	N	.	N	Y	-0.417169759	23.60942293	0.256769968	36.9	DM	.
KCNJ9	1	160081570	160090563	N	Viable	N	Y	0.093995484	56.69387046	0.583029242	27.9	DP	.
KCNK1	1	233614004	233672512	N	.	N	Y	-0.238856623	33.14811599	0.580150979	28	.	.
KCNK10	14	88180103	88326907	N	.	N	N	-1.259317288	5.064536667	0.007579692	56.2	.	.
KCNK12	2	47516581	47570939	N	.	N	N	.	.	0.671633264	25.5	.	.
KCNK13	14	90061765	90185857	N	.	N	N	0.594134289	83.9497598	0.25800786	36.8	.	.
KCNK15	20	44745780	44752313	N	.	N	N	0.213237933	65.26017248	0.106847942	42.8	.	.
KCNK16	6	39314698	39322968	N	.	N	N	0.566990485	82.96000463	0.011361865	54.4	.	.
KCNK17	6	39299001	39314553	N	.	N	N	0.525648717	81.46090178	3.39E-06	80.3	.	.
KCNK18	10	117197489	117210299	N	Viable	N	Y	0.075464048	55.32789257	0.000349561	68.2	DM	{Migraine, with or without aura, susceptibility to, 13}, 613656 (3)
KCNK2	1	215005775	215237093	N	.	N	Y	-0.292334822	29.87208427	0.339842885	34.5	.	.
KCNK3	2	26692690	26733420	N	.	N	Y	-0.018550615	48.01759565	.	.	DM	Pulmonary hypertension, primary, 4, 615344 (3)
KCNK4	11	64291302	64300031	N	.	N	N	-0.079379727	43.6881403	0.0424812	48	.	.
KCNK6	19	38319844	38332076	N	.	N	Y	0.718012692	87.37049256	0.199609234	38.8	FP	.
KCNK7	11	65592855	65595996	N	.	N	Y	-0.160955729	37.95219077	6.43E-06	79.1	.	.
KCNK9	8	139600838	139703056	N	.	N	Y	-0.846768806	10.63263298	0.126993746	41.7	DM	Birk-Barel mental retardation dysmorphism syndrome, 612292 (3)
KCNMA1	10	76869601	77638595	N	.	N	Y	-1.965723023	1.736412572	0.999216603	5.6	DM	Generalized epilepsy and paroxysmal dyskinesia, 609446 (3)
KCNMB1	5	170374671	170389677	N	.	N	Y	0.523736129	81.40302136	2.07E-05	76.1	DFP	{Hypertension, diastolic, resistance to}, 608622 (3)
KCNMB2	3	178272932	178844429	N	.	N	N	-0.17611458	36.99137582	0.65245963	26	.	.
KCNMB3	3	179236691	179267002	N	.	N	N	0.463710367	79.01834809	2.58E-08	87.9	DFP	.
KCNMB4	12	70366276	70434292	N	.	N	Y	-0.049519725	45.82392777	0.829402296	20.7	.	.
KCNN1	19	17951293	18000080	N	.	N	N	.	.	0.931699633	16	.	.
KCNN3	1	154697455	154870280	N	.	N	Y	-0.860663415	10.36638305	0.864940881	19.3	DM?	.
KCNN4	19	43766533	43781257	N	.	N	Y	-0.69095767	14.20964288	8.36E-06	78.5	.	.
KCNQ1	11	2444684	2849109	N	.	N	Y	-0.926281221	9.127742085	2.45E-05	75.7	DM	Long QT syndrome 1, 192500 (3); Jervell and Lange-Nielsen syndrome, 220400 (3); Atrial fibrillation, familial, 3, 607554 (3); Short QT syndrome 2, 609621 (3); {Long QT syndrome 1, acquired, susceptibility to}, 192500 (3)
KCNQ4	1	40784012	40840452	N	.	N	Y	0.080247996	55.73305551	0.985178282	10.9	DM	Deafness, autosomal dominant 2A, 600101 (3)
KCNRG	13	50015254	50020922	N	.	N	N	0.084729555	56.09191411	0.000520289	67	.	.
KCNS1	20	45092310	45101112	N	.	N	N	-0.058784478	45.21039532	0.362998541	33.8	DM?	.
KCNS2	8	98427022	98432848	N	.	N	Y	-0.531476218	18.93268507	0.528896631	29.2	.	.
KCNS3	2	17877847	18361616	N	.	N	N	-0.135576128	39.70596747	0.016090126	52.8	DP	.
KCNT1	9	135702185	135795508	N	.	N	N	-1.793675731	2.21682005	0.005348738	57.8	DM	Epileptic encephalopathy, early infantile, 14, 614959 (3); Epilepsy, nocturnal frontal lobe, 5, 615005 (3)
KCNT2	1	196225779	196609225	N	.	N	N	-2.026724347	1.574347398	0.666802214	25.6	.	.
KCNU1	8	36784324	36936128	N	.	N	Y	-0.508377015	19.86455982	3.91E-12	94.7	.	.
KCNV1	8	109963645	109975847	N	.	N	Y	-0.417169759	23.60942293	0.778125704	22.3	.	.
KCNV2	9	2717502	2730037	N	.	N	Y	-0.17727383	36.89876715	6.27E-17	97.8	DM	Retinal cone dystrophy 3B, 610356 (3)
KCP	7	128862451	128910719	N	.	N	Y	.	.	.	.	.	.
KCTD1	18	26454910	26657401	N	.	N	N	-0.282114394	30.53770909	0.934855731	15.8	DM	Scalp-ear-nipple syndrome, 181270 (3)
KCTD11	17	7351889	7354944	N	.	N	N	0.196318636	64.16623256	0.447451322	31.5	DP	.
KCTD12	13	76880166	76886390	N	.	N	N	0.05935026	54.0603114	0.353531089	34.1	.	.
KCTD13	16	29905012	29927035	N	.	N	N	-0.506249788	19.96874457	0.791960934	21.9	DM	.
KCTD14	11	78015715	78080219	N	.	N	N	1.20766407	95.09174046	0.002892993	60.5	.	.
KCTD16	5	144170832	144485686	N	.	N	N	-0.266954701	31.4637958	0.959972608	13.9	.	.
KCTD17	22	37051736	37063390	N	.	N	N	0.210368257	65.09231927	0.051116993	46.9	.	Dystonia 26, myoclonic, 616398 (3)
KCTD18	2	200488952	200519784	N	.	N	N	0.503288375	80.58111941	0.000526111	66.9	.	.
KCTD19	16	67289428	67326763	N	.	N	N	0.404140759	76.01435434	3.34E-08	87.5	.	.
KCTD2	17	75032575	75065889	N	.	N	N	-0.283071606	30.49140476	0.061899988	45.8	.	.
KCTD20	6	36442767	36491143	N	.	N	N	-0.116894686	40.97933669	0.399321758	32.8	.	.
KCTD21	11	78171249	78188822	N	.	N	N	-0.082250388	43.42189037	0.291108596	35.9	.	.
KCTD3	1	215567392	215621807	N	.	N	N	-1.035158958	7.414481681	0.986866111	10.6	.	.
KCTD4	13	45192853	45194717	N	.	N	N	-0.410624002	23.91618915	0.040704502	48.2	.	.
KCTD5	16	2682475	2709030	N	.	N	N	-0.009133893	48.72373676	0.544871004	28.8	.	.
KCTD6	3	58492114	58502360	N	.	N	N	-0.277483031	30.77501881	0.206951627	38.5	.	.
KCTD7	7	66628881	66811187	N	.	N	N	-0.378697035	25.5252648	0.496529666	30.1	DM	Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3)
KCTD8	4	44173909	44448807	N	.	N	N	-0.555899965	18.03553858	0.291159282	35.9	.	.
KCTD9	8	25427847	25458476	N	.	N	N	-0.282114394	30.53770909	0.073396831	44.8	.	.
KDELC1	13	102784281	102799007	N	.	N	N	-0.512641945	19.71985877	6.42E-06	79.1	.	.
KDELC2	11	108472105	108498432	N	.	N	N	0.013526612	50.54118192	1.57E-08	88.4	.	.
KDELR1	19	48382570	48391553	N	.	N	N	0.109001675	57.91514731	0.895487512	17.9	.	.
KDELR2	7	6445953	6484242	N	.	N	N	-0.316758145	28.47137813	0.268728641	36.5	.	.
KDELR3	22	38468062	38483447	N	.	N	N	0.349250172	73.35185507	2.26E-06	81.1	.	.
KDM1B	6	18155329	18223853	N	.	N	Y	-0.496678803	2.03E+01	0.815087937	21.1	.	.
KDM2A	11	67119269	67258087	N	.	N	N	-1.512550516	3.28181976	0.999999955	1	.	.
KDM3A	2	86440647	86492716	N	.	N	Y	-1.591979062	2.853504659	0.98175684	11.5	.	.
KDM3B	5	138352596	138437028	N	.	N	N	-1.988943098	1.672744111	0.999999999	0.6	.	.
KDM4A	1	43650158	43705515	N	.	N	N	-0.29011822	30.06308966	0.999993865	2.3	.	.
KDM4C	9	6757641	7175648	N	.	N	Y	-1.141569323	6.13532442	0.000758735	65.7	DP	.
KDM4D	11	94973681	94999518	N	.	N	Y	0.121438731	58.82965793	0.149201647	40.6	.	.
KDM4E	11	95025258	95027596	N	.	N	N	.	.	0.764772098	22.8	.	.
KDM5D	Y	19703865	19744939	N	.	N	N	.	.	0.015134044	53.1	.	.
KDSR	18	63327726	63367510	N	.	N	N	-0.589741923	17.07472362	0.472000395	30.8	.	.
KEL	7	142941114	142962681	N	.	N	Y	0.752160326	88.14030214	2.01E-16	97.6	FP	[Blood group, Kell], 110900 (3)
KERA	12	91050491	91057983	N	.	N	Y	-0.191924635	36.05950107	0.00041437	67.6	DM	Cornea plana congenita, recessive, 217300 (3)
KHDC1	6	73241314	73310365	N	.	N	N	0.454294559	78.50321236	6.80E-05	73	.	.
KHDC1L	6	73223544	73225770	N	.	N	N	0.190579485	63.80158592	0.013352848	53.7	.	.
KHDC3L	6	73362677	73364171	N	.	N	Y	0.204778284	64.66400417	0.241204609	37.3	DM	Hydatidiform mole, recurrent, 2, 614293 (3)
KHDRBS2	6	61679960	62286227	N	.	N	Y	-0.038994253	46.68055797	0.142878302	40.9	.	.
KHDRBS3	8	135457457	135656722	N	Viable	N	Y	-0.369279534	25.88991144	0.868289437	19.1	.	.
KHK	2	27086747	27100772	N	.	N	N	0.523884453	81.41459744	5.36E-05	73.7	DM	[Fructosuria], 229800 (3)
KHNYN	14	24429286	24441834	N	.	N	N	-0.801442629	11.54135556	1.39E-05	77.2	.	.
KHSRP	19	6413348	6424794	N	.	N	Y	-0.980873791	8.219019506	0.999711222	4.6	.	.
KIAA0020	9	2720469	2844241	N	.	N	N	1.547726072	97.23331597	1.66E-14	96.6	.	.
KIAA0040	1	175156987	175192999	N	.	N	N	.	.	.	.	.	.
KIAA0100	17	28614440	28645454	N	.	N	N	-2.275782148	1.180760549	0.265243746	36.6	DM?	.
KIAA0101	15	64364311	64387687	N	.	N	Y	0.047063497	53.15737686	0.129504562	41.6	.	.
KIAA0141	5	141923808	141942047	N	.	N	N	0.12063333	58.77177751	3.06E-10	92.1	.	.
KIAA0195	17	75441159	75500090	N	.	N	Y	-1.494295704	3.40336864	1.59E-07	85.5	.	.
KIAA0196	8	125024260	125091840	N	.	N	N	-2.1973317	1.279157261	4.81E-13	95.6	DM	Spastic paraplegia 8, autosomal dominant, 603563 (3); Ritscher-Schinzel syndrome, 220210 (3)
KIAA0226	3	197671393	197749727	N	.	N	N	-0.047956921	45.97441685	4.77E-06	79.6	DM	?Spinocerebellar ataxia, autosomal recessive 15, 615705 (3)
KIAA0226L	13	46342000	46438190	N	.	N	N	0.861683483	90.40342652	2.02E-11	93.9	.	.
KIAA0232	4	6781375	6884170	N	.	N	N	-1.465346464	3.542281646	0.994720896	8.5	DM?	.
KIAA0319	6	24544104	24646155	N	.	N	N	0.398709818	75.7596805	7.96E-12	94.3	DFP	{Dyslexia, susceptibility to, 2}, 600202 (3)
KIAA0319L	1	35433490	35557950	N	.	N	N	-1.197228081	5.608612606	0.188543869	39	.	.
KIAA0355	19	34254537	34355586	N	.	N	N	-0.740171751	12.88418128	0.877125217	18.7	.	.
KIAA0368	9	111360692	111484745	N	.	N	N	-0.146965037	38.93036986	0.999999936	1	.	.
KIAA0391	14	35121846	35277614	N	.	N	N	-0.369126321	25.91885165	1.78E-05	76.6	.	.
KIAA0408	6	127440343	127459391	N	.	N	N	-0.322043675	28.14724779	1.96E-06	81.3	.	.
KIAA0430	16	15594386	15643166	N	.	N	N	-2.482421466	0.983967124	0.999999566	1.5	.	.
KIAA0513	16	85027751	85094230	N	.	N	N	-0.216195302	34.51409388	0.075830642	44.7	FP	.
KIAA0556	16	27550133	27780369	N	.	N	N	0.264291444	68.35098686	1.31E-17	98	.	.
KIAA0825	5	94152966	94618604	N	.	N	N	0.243250221	67.10655785	4.26E-07	84	.	.
KIAA0895	7	36324221	36390125	N	.	N	N	0.211474757	65.18492794	0.00114572	64.2	.	.
KIAA0895L	16	67175602	67184040	N	.	N	N	0.03507878	52.23129015	0.018433058	52.1	.	.
KIAA0907	1	155913043	155934400	N	.	N	N	-0.962037121	8.514209643	0.997113618	7.5	.	.
KIAA0922	4	153466346	153636711	N	.	N	N	-0.723940186	13.28934421	0.999390133	5.4	.	.
KIAA0930	22	45190338	45240769	N	.	N	N	-0.764076355	12.32852926	0.815289887	21.1	.	.
KIAA1024	15	79432516	79472290	N	.	N	N	0.292707678	70.07582335	0.000865676	65.2	.	.
KIAA1024L	5	129748079	129766732	N	Viable	N	Y	.	.	.	.	.	.
KIAA1033	12	105107324	105169134	N	.	N	N	-0.092018727	42.68680905	0.155503529	40.3	DM	?Mental retardation, autosomal recessive 43, 615817 (3)
KIAA1107	1	92167052	92184723	N	.	N	N	.	.	.	.	.	.
KIAA1109	4	122152333	122362758	N	.	N	N	-7.487976255	0.023152168	3.91E-08	87.3	.	.
KIAA1143	3	44737661	44761662	N	.	N	Y	0.580894119	83.51565665	0.02510247	50.5	.	.
KIAA1147	7	141656728	141702153	N	.	N	N	-0.133814513	39.83909244	0.00204302	61.8	.	.
KIAA1161	9	34366670	34376853	N	Viable	N	Y	.	.	5.13E-10	91.7	.	.
KIAA1191	5	176346061	176361968	N	.	N	N	0.085686282	56.13821844	0.001560873	62.9	.	.
KIAA1210	X	119078635	119150579	N	.	N	N	1.667187968	97.78896799	0.090793121	43.7	DM?	.
KIAA1211	4	56049073	56328625	N	.	N	N	0.104171219	57.50998437	0.130364633	41.5	.	.
KIAA1211L	2	98793846	98936259	N	Viable	N	Y	-0.448789697	22.35341784	.	.	.	.
KIAA1217	10	23694746	24547848	N	.	N	N	-1.455437124	3.605950107	0.014167894	53.4	DM?	.
KIAA1257	3	128909866	129002690	N	.	N	N	0.688955753	86.6296232	1.75E-08	88.3	.	.
KIAA1324L	7	86876906	87059699	N	.	N	N	0.009045538	50.2344157	0.000166955	70.3	.	.
KIAA1328	18	36829106	37232172	N	.	N	N	0.416927285	76.69155525	6.07E-05	73.4	.	.
KIAA1407	3	113964137	114056613	N	.	N	N	1.859257012	98.32725589	3.29E-23	99.2	.	.
KIAA1456	8	12945642	13031503	N	.	N	N	0.952837085	92.06459455	.	.	.	.
KIAA1462	10	30012800	30115494	N	.	N	N	1.060490273	93.48845286	0.104293752	42.9	DM?	.
KIAA1467	12	13044284	13142521	N	.	N	N	-0.353969197	26.61341668	0.221017048	38	.	.
KIAA1468	18	62187258	62307829	N	.	N	N	-0.450553088	22.24344504	0.99999956	1.5	.	.
KIAA1522	1	32741885	32774970	N	.	N	N	-0.158441584	38.12004399	0.802365147	21.6	.	.
KIAA1524	3	108549869	108589644	N	.	N	N	0.023246295	51.30520345	5.75E-08	86.8	.	.
KIAA1549	7	138831381	138981318	N	Viable	N	Y	1.991949146	98.55877757	0.99864579	6.3	DM?	.
KIAA1549L	11	33542072	33674102	N	.	N	Y	-1.309199063	4.642009608	0.003708229	59.4	.	.
KIAA1551	12	31959370	31993107	N	.	N	N	2.07427233	98.68611449	0.036491109	48.7	.	.
KIAA1586	6	57046532	57055239	N	.	N	N	-0.030382941	47.27093824	1.78E-06	81.5	DM?	.
KIAA1614	1	180913154	180951614	N	.	N	N	0.913898289	91.32372518	2.19E-13	95.8	.	.
KIAA1644	22	44243667	44312851	N	.	N	N	-0.363690885	26.19088962	0.676861238	25.3	.	.
KIAA1671	22	24952730	25197448	N	.	N	N	.	.	.	.	.	.
KIAA1683	19	18257097	18274509	N	.	N	N	2.768525459	99.35173931	8.28E-06	78.5	.	.
KIAA1755	20	38210488	38260772	N	.	N	N	1.650443233	97.73687561	2.32E-15	97.1	FTV	.
KIAA1841	2	61065871	61138034	N	.	N	N	-0.203908406	35.22023499	3.33E-06	80.3	.	.
KIAA1875	8	144107726	144118315	N	.	N	N	.	.	.	.	.	.
KIAA1919	6	111259348	111271167	N	.	N	N	-0.368169446	25.94779186	4.16E-05	74.4	DM?	.
KIAA1958	9	112486847	112669397	N	.	N	N	-0.869930295	10.18695375	0.04900214	47.1	.	.
KIAA2012	2	202073255	202197862	N	.	N	N	.	.	.	.	.	.
KIAA2013	1	11919591	11926428	N	.	N	N	-0.317561949	28.41928576	.	.	.	.
KIAA2022	X	74732849	74925485	N	.	N	N	-0.846318438	10.64999711	0.950542379	14.7	DM	Mental retardation, X-linked 98, 300912 (3)
KIAA2026	9	5881596	6007901	N	.	N	N	.	.	.	.	.	.
KIF12	9	114086126	114099227	N	.	N	N	0.086794166	56.20767494	1.78E-05	76.6	.	.
KIF13A	6	17759183	17987623	N	.	N	Y	-0.216409728	34.49094171	0.999958506	3.2	.	.
KIF13B	8	29067279	29263124	N	.	N	Y	-1.878991742	1.962146206	0.000199447	69.8	.	.
KIF15	3	44761717	44873376	N	.	N	N	0.544145033	82.20755918	7.47E-13	95.4	.	.
KIF17	1	20664014	20718017	N	.	N	Y	1.2760016	95.60108815	3.34E-13	95.7	DM	.
KIF18A	11	28020620	28108308	N	.	N	Y	-0.531175395	18.9500492	0.149441083	40.6	DP	.
KIF18B	17	44924709	44947711	N	.	N	N	0.057890757	53.94455056	8.31E-05	72.4	.	.
KIF1C	17	4997948	5028401	N	.	N	Y	-0.89966024	9.590785437	0.470778561	30.8	.	Spastic ataxia 2, autosomal recessive, 611302 (3)
KIF21A	12	39293228	39443390	N	.	N	N	-1.284156203	4.815650865	6.18E-05	73.3	DM	Fibrosis of extraocular muscles, congenital, 1, 135700 (3); Fibrosis of extraocular muscles, congenital, 3B, 135700 (3)
KIF21B	1	200969390	201023700	N	.	N	Y	-2.556559016	0.931874747	0.99941409	5.4	.	.
KIF23	15	69414246	69448427	N	.	N	N	-0.222590721	34.17838745	0.999999791	1.3	DM	.
KIF24	9	34252381	34329200	N	Viable	N	Y	0.067765378	54.67963188	7.56E-14	96.2	.	.
KIF25	6	167996241	168045089	N	.	N	N	1.069870684	93.62157782	3.75E-09	89.9	.	.
KIF27	9	83836698	83921465	N	.	N	N	0.322878573	71.90484459	1.35E-09	90.9	.	.
KIF2B	17	53822901	53825213	N	.	N	N	1.622771174	97.58638653	3.73E-15	96.9	.	.
KIF2C	1	44739818	44767767	N	.	N	N	-0.694482425	14.12861029	0.017194072	52.4	.	.
KIF3C	2	25926596	25982749	N	.	N	Y	-0.549050942	18.24390809	0.909864326	17.3	.	.
KIF4A	X	70290090	70420832	N	.	N	N	0.467686361	79.23250564	0.999968445	3	.	?Mental retardation, X-linked 100, 300923 (3)
KIF4B	5	155013755	155018132	N	.	N	N	0.645521627	85.51831915	3.11E-19	98.5	.	.
KIF5C	2	148875250	149026759	N	.	N	Y	.	.	0.999515597	5.2	DM	Cortical dysplasia, complex, with other brain malformations 2, 615282 (3)
KIF6	6	39329990	39725405	N	.	N	N	0.509184403	80.81842913	1.04E-16	97.7	DP	.
KIF9	3	47228026	47283451	N	.	N	N	0.568252232	83.00630897	2.17E-11	93.8	.	.
KIFC1	6	33391536	33409924	N	.	N	N	-0.029426144	47.35197083	0.015578034	53	.	.
KIFC2	8	144466043	144474202	N	.	N	N	-0.139907192	39.41656538	0.001340579	63.6	.	.
KIFC3	16	57758217	57863053	N	.	N	N	-1.262039736	5.029808416	0.46789312	30.9	.	.
KIN	10	7750962	7787981	N	.	N	N	-0.261365676	31.77635006	0.003221987	60	.	.
KIR2DL1	19	54769811	54784322	N	.	N	N	2.154531528	98.79029924	0.184502117	39.1	FP	.
KIR2DL3	19	54724459	54767884	N	.	N	N	2.191105909	98.8539677	0.038026499	48.6	FTV	.
KIR2DL4	19	54803535	54814517	N	.	N	N	.	.	0.875263421	18.9	FP	.
KIR3DL1	19	54724497	54867215	N	.	N	N	2.399519659	99.08548938	9.78E-06	78.1	DP	{AIDS, delayed/rapid progression to}, 609423 (3)
KIR3DL2	19	54850443	54867207	N	.	N	N	.	.	0.221236755	38	DP	.
KIR3DL3	19	54724479	54736536	N	.	N	N	.	.	0.532094899	29.1	.	.
KIR3DX1	19	54532692	54545771	N	.	N	N	.	.	.	.	.	.
KIRREL2	19	35855861	35867109	N	.	N	N	0.830866718	89.81304625	8.95E-06	78.3	.	.
KIRREL3	11	126423359	127003460	N	.	N	Y	-0.46092589	21.86143428	0.977505781	12.1	DM	Mental retardation, autosomal dominant 4, 612581 (3)
KISS1	1	204190341	204196486	N	.	N	Y	0.706540877	87.05215026	0.524779455	29.3	DM	?Hypogonadotropic hypogonadism 13 with or without anosmia, 614842 (3)
KISS1R	19	917287	921015	Y	Viable	N	Y	.	.	0.003971074	59.1	DM	Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3); ?Precocious puberty, central, 1, 176400 (3)
KIZ	20	21125983	21246622	N	.	N	Y	.	.	.	.	.	Retinitis pigmentosa 69, 615780 (3)
KL	13	33016433	33066145	N	.	N	Y	-0.064876519	44.77050414	1.95E-05	76.3	DM	{Coronary artery disease, susceptibility to} (3); Tumoral calcinosis, hyperphosphatemic, 211900 (3)
KLB	4	39406853	39451536	N	.	N	Y	0.475498699	79.53348382	0.094473079	43.5	DFP	.
KLC1	14	103561896	103714249	N	.	N	Y	-0.93856934	8.878856283	0.514955332	29.6	.	.
KLC2	11	66257294	66267860	N	.	N	Y	-0.820275787	11.17092088	0.997255173	7.4	.	.
KLC3	19	45333434	45351520	N	.	N	N	0.63834588	85.3041616	3.16E-06	80.4	.	.
KLC4	6	43040777	43075099	N	.	N	N	-0.415907187	23.67309139	0.236002385	37.5	.	.
KLF10	8	102648779	102655902	N	.	N	Y	-0.059589522	45.15830295	0.003421767	59.8	DM	.
KLF11	2	10042849	10054836	N	.	N	Y	-0.498441623	20.26393471	0.00111669	64.3	DM	Maturity-onset diabetes of the young, type VII, 610508 (3)
KLF12	13	73686089	74133905	N	.	N	N	-0.123440781	40.55680963	0.982233162	11.4	.	.
KLF13	15	31326855	31435665	N	.	N	Y	.	.	0.62911365	26.7	.	.
KLF14	7	130731235	130734061	N	Viable	N	Y	.	.	0.218113823	38.1	.	.
KLF15	3	126342635	126357442	N	.	N	Y	0.108195341	57.87463101	0.435175999	31.8	.	.
KLF16	19	1852399	1863568	N	.	N	N	.	.	0.473218601	30.8	.	.
KLF17	1	44118850	44135140	N	Viable	N	Y	0.2133882	65.27174857	4.25E-09	89.7	.	.
KLF8	X	56232421	56287889	N	.	N	N	0.317324799	71.58071424	0.027862422	50.1	DM	.
KLF9	9	70384597	70414624	N	.	N	Y	-0.002587674	49.23887249	0.882452241	18.5	.	.
KLHDC1	14	49693105	49753152	N	.	N	N	-0.608422187	16.49591943	0.000148223	70.7	.	.
KLHDC10	7	130070510	130135720	N	.	N	N	-0.440636427	22.72385252	0.99668379	7.7	.	.
KLHDC3	6	43014103	43021298	N	.	N	N	-0.545680331	18.36545697	0.993829271	8.9	.	.
KLHDC4	16	87696485	87765992	N	.	N	N	1.574075574	97.34328877	3.71E-19	98.5	.	.
KLHDC7A	1	18480982	18486126	N	.	N	N	0.649987795	85.61671587	2.58E-10	92.2	.	.
KLHDC7B	22	50548033	50551023	N	.	N	N	.	.	0.000573067	66.6	.	.
KLHDC8A	1	205336065	205357090	N	.	N	N	-0.508966819	19.83561961	1.59E-05	76.9	.	.
KLHDC8B	3	49171611	49176486	N	.	N	N	-0.588784515	17.09787579	0.01042142	54.8	DM	{Hodgkin lymphoma, susceptibility to}, 236000 (3)
KLHDC9	1	161098361	161100346	N	.	N	N	0.403684998	75.99699022	5.37E-06	79.4	.	.
KLHL1	13	69700594	70108493	N	.	N	Y	-0.161609816	37.88273427	0.008083442	55.9	DM?	.
KLHL10	17	41835685	41848384	N	.	N	Y	0.061414866	54.25131678	0.931027664	16.1	DM	Spermatogenic failure 11, 615081 (3)
KLHL11	17	41853545	41865431	N	.	N	N	-0.800636123	11.57608381	0.053467776	46.6	.	.
KLHL12	1	202891100	202928636	N	.	N	N	-0.888916757	9.804942988	0.008086988	55.8	.	.
KLHL13	X	117897813	118117340	N	.	N	N	-0.352359149	26.65972102	0.731977363	23.7	.	.
KLHL14	18	32672671	32773062	N	.	N	N	-1.258360725	5.076112751	0.082722189	44.2	.	.
KLHL15	X	23983720	24027186	N	.	N	N	-0.750182833	12.58899114	0.954395214	14.4	.	.
KLHL17	1	960587	965715	N	.	N	N	-1.192451557	5.660704984	2.52E-07	84.8	.	.
KLHL18	3	47282917	47346816	N	.	N	Y	-0.846613517	10.63842102	0.984175217	11.1	.	.
KLHL2	4	165207618	165323156	N	.	N	N	-0.398334639	24.51814551	0.998554857	6.5	.	.
KLHL20	1	173714941	173786702	N	.	N	Y	-0.705964203	13.78132778	0.061677082	45.8	.	.
KLHL22	22	20441519	20495883	N	.	N	N	-1.160809308	5.979047288	0.702611047	24.5	.	.
KLHL23	2	169694488	169776989	N	.	N	N	-0.876627282	10.0133125	0.020660798	51.5	.	.
KLHL24	3	183635568	183684477	N	.	N	N	-0.6149682	16.3396423	0.25241443	37	.	.
KLHL25	15	85759323	85795030	N	.	N	N	-1.178398399	5.822770157	2.20E-10	92.4	.	.
KLHL26	19	18636965	18671714	N	.	N	N	-1.70017013	2.448341726	6.67E-05	73.1	.	.
KLHL28	14	44924319	45042322	N	.	N	N	0.037949145	52.39335533	0.188871209	39	.	.
KLHL3	5	137617500	137736090	N	Viable	N	Y	-0.422604684	23.42999363	0.924154761	16.4	DM	Pseudohypoaldosteronism, type IID, 614495 (3)
KLHL30	2	238138722	238152947	N	.	N	N	2.068288359	98.6745384	8.30E-11	93.1	.	.
KLHL31	6	53647901	53665708	N	.	N	N	0.317625038	71.63280662	0.019083264	51.9	.	.
KLHL32	6	96924620	97140754	N	.	N	N	-0.587673557	17.16733229	0.509586629	29.7	.	.
KLHL33	14	20428811	20435642	N	.	N	N	.	.	.	.	.	.
KLHL34	X	21654690	21658330	N	.	N	N	0.310778106	71.09451872	4.42E-05	74.2	FTV	.
KLHL35	11	75422394	75430629	N	.	N	N	.	.	1.35E-12	95.1	.	.
KLHL36	16	84648525	84667686	N	.	N	N	-1.644769255	2.708803612	0.939925902	15.6	.	.
KLHL38	8	123645527	123652950	N	.	N	N	1.296253244	95.75736528	3.94E-06	80	.	.
KLHL4	X	87517749	87670050	N	.	N	N	-0.394506329	24.68021068	0.872766937	18.9	.	.
KLHL40	3	42685519	42692544	N	.	N	N	0.339330085	72.82514325	0.078102706	44.6	DM	Nemaline myopathy 8, autosomal recessive, 615348 (3)
KLHL41	2	169509702	169526262	N	.	N	N	-0.036123783	46.87156335	0.01881204	52	.	Nemaline myopathy 9, 615731 (3)
KLHL42	12	27780020	27803040	N	.	N	N	-0.396420408	24.5991781	0.438781824	31.7	.	.
KLHL5	4	39045039	39126857	N	.	N	N	-0.236790701	33.25808879	0.00136508	63.5	.	.
KLHL6	3	183487531	183555689	N	.	N	Y	-0.543460696	18.45806564	3.43E-06	80.3	.	.
KLHL7	7	23105758	23177914	N	.	N	N	-0.883328302	9.9033397	0.000319112	68.5	DM	Retinitis pigmentosa 42, 612943 (3)
KLHL8	4	87160103	87240314	N	Viable	N	Y	-0.310058921	28.94020953	0.001208351	64	.	.
KLHL9	9	21329671	21335380	N	.	N	N	-0.824103283	11.08410025	0.988339535	10.3	DM	.
KLK1	19	50819148	50823787	N	.	N	N	0.404641438	76.06644672	0.000319897	68.5	DM?	[Kallikrein, decreased urinary activity of], 615953 (3)
KLK10	19	51012739	51020175	N	.	N	N	0.029338097	51.71036638	4.41E-05	74.2	.	.
KLK11	19	51022216	51028039	N	.	N	N	1.050081795	93.36111593	0.057475122	46.2	.	.
KLK12	19	51029092	51035230	N	.	N	N	0.412144579	76.45424553	0.001824117	62.3	DM	.
KLK13	19	51056206	51065114	N	.	N	N	0.244206777	67.1412861	0.755462838	23	.	.
KLK14	19	51077495	51084245	N	Viable	N	Y	1.061266122	93.50581698	1.10E-09	91.1	FTV	.
KLK15	19	50825289	50837213	N	.	N	N	0.464666725	79.07044047	0.046580258	47.4	DP	.
KLK2	19	50861568	50880567	N	.	N	N	0.312691067	71.2565839	0.000292492	68.8	.	.
KLK3	19	50854915	50860764	N	.	N	Y	0.741479193	87.89141633	0.003472671	59.7	DM	.
KLK4	19	50906352	50910738	N	Viable	N	Y	0.168219607	62.41824391	0.020194729	51.6	DM	Amelogenesis imperfecta, type IIA1, 204700 (3)
KLK5	19	50943303	50953093	N	.	N	N	0.390591665	75.41239799	0.072760721	44.8	.	.
KLK6	19	50958631	50969673	N	.	N	Y	0.128791076	59.33321757	0.497244484	30	.	.
KLK7	19	50976482	50984099	N	.	N	N	-0.028772452	47.38091104	0.006882965	56.7	DP	.
KLK8	19	50996007	51002711	N	.	N	Y	-0.399291813	24.48341726	0.003383666	59.9	.	.
KLK9	19	50996018	51009581	N	.	N	Y	0.008742604	50.21705157	0.003938943	59.1	.	.
KLKB1	4	186208979	186258471	N	Viable	N	Y	0.918035971	91.46842623	4.76E-11	93.4	DM	Fletcher factor (prekallikrein) deficiency, 612423 (3)
KLLN	10	87859161	87863437	N	.	N	N	.	.	.	.	DM?	Cowden syndrome 4, 615107 (3)
KLRB1	12	9594551	9607886	N	.	N	N	0.423325465	77.03304972	4.43E-06	79.8	.	.
KLRC1	12	10442264	10454685	N	.	N	N	0.136294125	59.95253806	0.001175461	64.1	.	.
KLRC2	12	10426854	10442300	N	.	N	N	0.222654188	65.80424842	0.004278232	58.8	DFP	.
KLRC3	12	10412312	10420595	N	.	N	N	0.947753661	91.98356196	0.204478936	38.6	.	.
KLRC4	12	10407382	10409757	N	.	N	N	0.442966544	78.02280489	0.001087349	64.4	.	.
KLRC4-KLRK1	12	10372353	10410146	N	.	N	N	.	.	.	.	.	.
KLRD1	12	10226058	10329600	N	.	N	N	0.474891845	79.5161197	0.015657763	52.9	.	.
KLRF1	12	9827481	9845007	N	.	N	N	-0.01663693	48.16808474	0.00436476	58.7	.	.
KLRF2	12	9881489	9895833	N	.	N	N	.	.	.	.	.	.
KLRG1	12	8950044	9010760	N	.	N	Y	0.178442775	63.08386873	0.058025611	46.2	.	.
KLRG2	7	139452690	139483712	N	.	N	N	.	.	4.21E-07	84	.	.
KLRK1	12	10372353	10391874	N	.	N	Y	0.150343606	61.02332581	9.75E-10	91.1	DP	.
KMO	1	241532134	241595642	N	Viable	N	Y	0.067961065	54.72593622	0.000261679	69	DP	.
KNCN	1	46545644	46551527	N	.	N	N	0.373525026	74.60207212	0.029530671	49.7	.	.
KNDC1	10	133160447	133226412	N	.	N	Y	0.66182694	85.97557446	4.44E-05	74.2	.	.
KNG1	3	186717276	186743954	N	.	N	Y	-0.519038112	19.51148926	4.17E-08	87.2	DM	[Kininogen deficiency], 228960 (3); [High molecular weight kininogen deficiency], 228960 (3)
KNOP1	16	19701934	19718235	N	Viable	N	Y	0.34380991	73.08560514	3.17E-05	75.1	.	.
KNSTRN	15	40382721	40394246	N	Viable	N	Y	0.778996188	88.7711987	3.16E-07	84.4	.	.
KNTC1	12	122527246	122626396	N	.	N	Y	0.373016467	74.57891995	4.78E-32	99.8	.	.
KPNA1	3	122421949	122514945	N	.	N	Y	-0.522213436	19.34942409	0.99300095	9.2	FTV	.
KPNA2	17	68035519	68046842	N	.	N	N	-0.117699662	40.92724431	0.728640007	23.8	.	.
KPNA3	13	49699307	49792921	N	.	N	N	-0.355230595	26.57290039	0.809823934	21.3	.	.
KPNA4	3	160494995	160565588	N	.	N	Y	-0.32617555	27.96781849	0.998180756	6.8	.	.
KPNA5	6	116681187	116741866	N	.	N	N	-0.432978714	23.05377091	0.001223215	63.9	.	.
KPNA6	1	32108038	32176568	N	.	N	Y	-0.43680723	22.88591769	0.988827606	10.2	.	.
KPNA7	7	99173574	99207506	N	.	N	N	.	.	.	.	.	.
KPRP	1	152759561	152762052	N	.	N	N	1.450965995	96.71818024	7.83E-14	96.2	FTV	.
KPTN	19	47475144	47484268	N	.	N	Y	-0.154409651	38.42681021	0.000791095	65.5	.	Mental retardation, autosomal recessive 41, 615637 (3)
KRBA1	7	149714781	149734575	N	.	N	N	.	.	1.47E-12	95.1	.	.
KRBA2	17	8368637	8376711	N	.	N	N	0.758398892	88.27921514	3.93E-07	84.1	.	.
KRBOX1	3	42809483	42942792	N	.	N	N	.	.	0.4168236	32.3	.	.
KRBOX4	X	46446857	46497422	N	.	N	N	0.191535973	63.89419459	0.377824216	33.4	.	.
KRCC1	2	88027205	88055729	N	.	N	N	0.234790597	66.51038954	0.187811675	39	.	.
KREMEN1	22	29073078	29168333	N	.	N	Y	0.21530172	65.35278115	0.372971656	33.5	.	.
KREMEN2	16	2963944	2968383	N	.	N	Y	.	.	0.414292182	32.4	.	.
KRI1	19	10553078	10566037	N	.	N	N	.	.	8.40E-09	89.2	.	.
KRR1	12	75490861	75511636	N	.	N	N	-0.442395976	22.60809168	0.019350581	51.9	.	.
KRT12	17	40861303	40867210	N	.	N	Y	0.230307728	66.27307982	9.44E-11	93	DM	Meesmann corneal dystrophy, 122100 (3)
KRT13	17	41500981	41505705	N	.	N	N	0.459226419	78.77525033	0.001667541	62.6	DM	White sponge nevus 2, 615785 (3)
KRT15	17	41513743	41522529	N	.	N	N	1.120633958	94.20617005	3.51E-15	97	.	.
KRT17	17	41619437	41624842	N	Viable	N	Y	-0.131748807	39.96064132	7.07E-06	78.9	DM	Pachyonychia congenita 2, 167210 (3); Steatocystoma multiplex, 184500 (3)
KRT18	12	52948871	52952901	N	.	N	Y	-0.251948674	32.33200208	0.624782588	26.8	DM	Cirrhosis, cryptogenic, 215600 (3); {Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3)
KRT20	17	40875941	40885227	N	.	N	N	-0.173091047	37.17659316	5.58E-06	79.3	.	.
KRT222	17	40628797	40665141	N	.	N	N	-0.159194457	38.09110378	0.002126682	61.6	.	.
KRT23	17	40922696	40937634	N	.	N	N	0.441349938	77.95334838	2.83E-08	87.7	.	.
KRT24	17	40697991	40703750	N	.	N	N	0.379563212	74.9030503	5.09E-13	95.5	.	.
KRT25	17	40748021	40755332	N	.	N	N	0.275325819	69.02818776	1.85E-06	81.5	.	.
KRT26	17	40766238	40772162	N	.	N	N	1.079287635	93.73155062	7.23E-10	91.4	.	.
KRT27	17	40776808	40782534	N	.	N	N	0.086794166	56.20767494	8.01E-14	96.2	.	.
KRT28	17	40792203	40799959	N	.	N	N	0.421710946	76.92307692	2.07E-07	85.1	.	.
KRT3	12	52789685	52796117	N	.	N	N	0.947092883	91.96619784	1.93E-06	81.4	DM	Meesmann corneal dystrophy, 122100 (3)
KRT31	17	41393724	41397592	N	.	N	N	-0.154257752	38.43838629	0.928538286	16.2	DFP	.
KRT32	17	41459811	41467429	N	.	N	N	1.667639178	97.80054408	1.21E-15	97.2	.	.
KRT33A	17	41346092	41350812	N	.	N	Y	0.431127766	77.4729409	2.04E-11	93.9	.	.
KRT33B	17	41363494	41397592	N	.	N	N	1.234148932	95.34062627	2.40E-06	80.9	.	.
KRT34	17	41377650	41382403	N	.	N	N	1.11695934	94.15407768	2.61E-06	80.8	.	.
KRT35	17	41476689	41481140	N	.	N	N	1.129094856	94.31614285	0.017032338	52.5	.	.
KRT36	17	41486136	41492546	N	.	N	N	1.431170141	96.57347919	3.98E-09	89.8	.	.
KRT37	17	41420753	41424523	N	.	N	N	1.108498153	94.0325288	0.000453721	67.3	FTV	.
KRT38	17	41436446	41440921	N	.	N	N	0.448047836	78.27747873	2.17E-05	76	FTV	.
KRT39	17	40958417	40966892	N	.	N	N	0.511748286	80.94576605	8.46E-09	89.1	.	.
KRT40	17	40977716	40987135	N	.	N	N	1.648801149	97.71951149	0.000203217	69.8	.	.
KRT6C	12	52468516	52473785	N	.	N	N	0.838370111	89.9866875	4.11E-12	94.7	DM	Palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 (3)
KRT7	12	52232520	52252186	N	Viable	N	Y	0.331674235	72.41419228	2.79E-09	90.2	.	.
KRT71	12	52543909	52553147	N	.	N	N	1.03441881	93.19326272	3.13E-08	87.6	DM	?Hypotrichosis 13, 615896 (3)
KRT72	12	52585589	52601538	N	.	N	N	1.65167234	97.74266366	3.07E-05	75.2	.	.
KRT73	12	52607570	52618559	N	.	N	N	0.677928319	86.36337327	2.01E-11	93.9	.	.
KRT74	12	52565782	52573825	N	Viable	N	Y	1.460386131	96.75869653	8.40E-09	89.2	DM	Woolly hair, autosomal dominant, 194300 (3); ?Hypotrichosis 3, 613981 (3); ?Ectodermal dysplasia 7, hair/nail type, 614929 (3)
KRT75	12	52424070	52434525	N	.	N	N	2.037466694	98.62823407	5.14E-07	83.7	DM?	{Pseudofolliculitis barbae, susceptibility to}, 612318 (3)
KRT76	12	52768155	52777345	N	.	N	Y	1.763444293	98.10152226	6.27E-07	83.3	.	.
KRT77	12	52689626	52703463	N	.	N	N	0.814902524	89.44261156	1.05E-06	82.5	.	.
KRT78	12	52837804	52849092	N	.	N	N	1.44250399	96.68345199	2.06E-08	88.1	.	.
KRT79	12	52821410	52834295	N	.	N	N	1.215466464	95.20171326	2.99E-10	92.2	.	.
KRT80	12	52168996	52192000	N	.	N	N	1.278215881	95.62424032	5.43E-05	73.7	.	.
KRT81	12	52285913	52291534	N	.	N	N	.	.	2.16E-07	85	DM	Monilethrix, 158000 (3)
KRT82	12	52393931	52406355	N	.	N	N	1.574868409	97.36065289	2.61E-16	97.6	.	.
KRT83	12	52314301	52321398	N	.	N	N	1.391890064	96.35932164	1.70E-10	92.6	DM	?Monilethrix, 158000 (3)
KRT84	12	52377812	52385652	N	.	N	N	1.965125549	98.5356254	9.43E-07	82.6	.	.
KRT85	12	52360006	52367481	N	.	N	N	0.462097059	78.93731551	0.001109146	64.3	DM	Ectodermal dysplasia 4, hair/nail type, 602032 (3)
KRT86	12	52249300	52309163	N	.	N	N	0.292245427	70.07003531	3.64E-05	74.7	DM	Monilethrix, 158000 (3)
KRT9	17	41565841	41572058	N	Viable	N	Y	0.179700355	63.18226544	0.001318731	63.7	DM	Palmoplantar keratoderma, epidermolytic, 144200 (3)
KRTAP10-1	21	44538981	44540195	N	.	N	N	2.248432447	98.92342421	0.106027011	42.8	.	.
KRTAP10-10	21	44637356	44638455	N	.	N	N	1.919940748	98.43144064	2.64E-05	75.5	.	.
KRTAP10-11	21	44646414	44697984	N	.	N	N	1.648801149	97.71951149	0.000395208	67.8	.	.
KRTAP10-12	21	44697172	44698044	N	.	N	N	0.566034018	82.93685246	0.114715058	42.4	.	.
KRTAP10-2	21	44550357	44551505	N	.	N	N	0.794959429	89.10690513	0.017072106	52.4	.	.
KRTAP10-3	21	44557790	44558760	N	.	N	N	1.63747025	97.68478324	0.065246072	45.5	.	.
KRTAP10-4	21	44573729	44575371	N	.	N	N	2.518826268	99.19546218	0.001830723	62.2	.	.
KRTAP10-5	21	44579455	44580604	N	.	N	N	1.108346101	94.02674075	8.25E-05	72.4	.	.
KRTAP10-6	21	44579737	44592505	N	.	N	N	2.664339778	99.27070672	1.55E-05	76.9	.	.
KRTAP10-7	21	44600597	44612906	N	.	N	N	.	.	0.007594055	56.2	.	.
KRTAP10-8	21	44612079	44612954	N	.	N	N	0.884044995	90.80858945	5.21E-06	79.5	.	.
KRTAP10-9	21	44627123	44628293	N	.	N	N	1.719215563	97.95682121	0.442793927	31.6	.	.
KRTAP1-1	17	41040559	41041461	N	.	N	N	1.462810562	96.7818487	0.008442977	55.6	FTV	.
KRTAP11-1	21	30880644	30881555	N	.	N	N	0.285399426	69.6822365	0.00426873	58.8	.	.
KRTAP12-1	21	44681576	44682163	N	.	N	N	0.578982235	83.39989582	0.025197119	50.5	.	.
KRTAP12-2	21	44666189	44666927	N	.	N	N	1.18132968	94.85443075	5.58E-05	73.6	.	.
KRTAP12-3	21	44646657	44658341	N	.	N	N	0.517999482	81.17149968	0.146058957	40.8	.	.
KRTAP12-4	21	44654213	44654659	N	.	N	N	0.154020328	61.30693986	0.002790687	60.6	.	.
KRTAP1-3	17	41033884	41034855	N	.	N	N	1.09783013	93.922556	0.653995931	25.9	.	.
KRTAP13-1	21	30396074	30396822	N	.	N	N	0.475848013	79.55084795	0.007112706	56.5	.	.
KRTAP13-2	21	30348075	30425912	N	.	N	N	0.507773402	80.77212479	0.000843088	65.4	FTV	.
KRTAP13-3	21	30425265	30425968	N	.	N	N	0.020878273	51.13735023	0.000682837	66	.	.
KRTAP13-4	21	30430230	30431026	N	.	N	N	0.597812859	84.04236847	0.007741209	56.1	.	.
KRTAP1-4	17	41029697	41030104	N	.	N	N	0.557428105	82.71111883	0.141056283	41	.	.
KRTAP1-5	17	41026026	41027202	N	.	N	N	1.592300831	97.44168548	0.001046463	64.6	.	.
KRTAP15-1	21	30440275	30440945	N	.	N	N	0.193448992	64.03889564	0.00443717	58.6	.	.
KRTAP16-1	17	41307700	41309253	N	.	N	N	.	.	.	.	.	.
KRTAP17-1	17	41314917	41315695	N	.	N	N	0.229051722	66.16310702	0.540107765	28.9	.	.
KRTAP19-1	21	30479699	30480344	N	.	N	N	0.048020238	53.25577357	0.041048079	48.2	.	.
KRTAP19-2	21	30487057	30487436	N	.	N	N	0.310630546	71.0771546	0.126076455	41.7	.	.
KRTAP19-3	21	30480048	30491985	N	.	N	N	0.108045035	57.83990276	0.004405843	58.7	.	.
KRTAP19-4	21	30496824	30497133	N	.	N	N	0.418544532	76.73785958	0.023888003	50.7	.	.
KRTAP19-5	21	30501657	30502117	N	.	N	N	0.427003903	77.20669098	0.005182713	57.9	.	.
KRTAP19-6	21	30541535	30541864	N	.	N	N	0.508584272	80.78948892	0.020360822	51.6	.	.
KRTAP19-7	21	30541660	30561314	N	.	N	N	0.630550326	85.07263993	0.141234959	41	.	.
KRTAP19-8	21	31038159	31038476	N	.	N	N	0.289077164	69.85587776	0.007486123	56.3	.	.
KRTAP20-1	21	30616425	30616699	N	.	N	N	0.326593235	72.13057823	0.023274211	50.9	.	.
KRTAP20-2	21	30635236	30635619	N	.	N	N	0.250604857	67.47120449	0.137405133	41.2	.	.
KRTAP20-3	21	30642864	30643136	N	.	N	N	.	.	.	.	.	.
KRTAP20-4	21	30620627	30620850	N	.	N	N	.	.	.	.	.	.
KRTAP2-1	17	41046541	41047316	N	.	N	N	.	.	.	.	.	.
KRTAP21-1	21	30754830	30755428	N	.	N	N	0.335052688	72.57046941	0.485522902	30.4	.	.
KRTAP21-2	21	30746794	30747233	N	.	N	N	0.380072103	74.92620247	0.250319145	37.1	.	.
KRTAP21-3	21	30718525	30718777	N	.	N	N	.	.	.	.	.	.
KRTAP2-2	17	41054498	41055230	N	.	N	N	.	.	.	.	.	.
KRTAP22-1	21	30601087	30601382	N	.	N	N	0.355650049	73.72807779	0.124017871	41.9	.	.
KRTAP22-2	21	30590105	30590397	N	.	N	N	.	.	.	.	.	.
KRTAP2-3	17	41059240	41060114	N	.	N	N	.	.	0.0777172	44.6	.	.
KRTAP23-1	21	30348399	30348609	N	.	N	N	0.501080921	80.47693465	0.454990924	31.2	.	.
KRTAP2-4	17	41065116	41065879	N	.	N	N	.	.	0.086348363	44	.	.
KRTAP24-1	21	30281309	30282958	N	.	N	N	0.411188149	76.40794119	9.17E-06	78.3	.	.
KRTAP25-1	21	30289145	30289514	N	.	N	N	.	.	.	.	.	.
KRTAP26-1	21	30319124	30320316	N	.	N	N	0.50027016	80.45378249	0.001006633	64.7	.	.
KRTAP27-1	21	30337013	30337694	N	.	N	N	0.537786438	81.96446142	1.09E-05	77.8	.	.
KRTAP29-1	17	41301826	41302851	N	.	N	N	.	.	.	.	.	.
KRTAP3-1	17	41008521	41019324	N	.	N	N	0.434507168	77.58870174	0.473819461	30.7	.	.
KRTAP3-2	17	40999193	40999894	N	.	N	N	0.473935719	79.48717949	0.474662317	30.7	.	.
KRTAP3-3	17	40993430	40994133	N	.	N	N	0.412953559	76.48897378	0.004787667	58.3	.	.
KRTAP4-1	17	41184102	41185342	N	.	N	N	.	.	0.179915849	39.3	.	.
KRTAP4-11	17	41117181	41118360	N	.	N	N	1.868216586	98.33304393	0.09863984	43.2	.	.
KRTAP4-12	17	41123091	41124167	N	.	N	N	0.60818461	84.40701511	0.741776469	23.4	.	.
KRTAP4-16P	17	41101502	41102209	N	.	N	N	.	.	0.005496296	57.7	.	.
KRTAP4-2	17	41177446	41178208	N	.	N	N	0.406406543	76.17063148	0.005024741	58.1	.	.
KRTAP4-3	17	41167231	41168194	N	.	N	N	1.628870292	97.62111478	0.000536885	66.8	.	.
KRTAP4-4	17	41159651	41160731	N	.	N	N	0.819236301	89.50049198	0.001041594	64.6	.	.
KRTAP4-5	17	41148924	41149802	N	.	N	N	1.614815421	97.5690224	0.010387961	54.8	.	.
KRTAP4-6	17	41139433	41140487	N	.	N	N	1.951732722	98.48932106	0.014500199	53.3	.	.
KRTAP4-7	17	41084150	41106067	N	.	N	N	1.431837213	96.57926723	1.11E-05	77.8	.	.
KRTAP4-8	17	41096981	41098141	N	.	N	N	1.05839969	93.46530069	0.009770819	55	DM?	.
KRTAP4-9	17	41105332	41106488	N	.	N	N	1.760276505	98.08415813	0.001503782	63	.	.
KRTAP5-1	11	1584342	1585283	N	.	N	N	0.763989364	88.43549227	0.000129616	71.1	.	.
KRTAP5-10	11	71527263	71568934	N	.	N	N	0.814600928	89.4194594	0.191708884	38.9	.	.
KRTAP5-11	11	71579714	71603353	N	.	N	N	0.126877769	59.25218499	0.033567492	49.1	.	.
KRTAP5-2	11	1597177	1598294	N	.	N	N	0.354840535	73.70492562	0.000625083	66.3	.	.
KRTAP5-3	11	1607565	1608463	N	.	N	N	0.236703709	66.62615037	0.262910457	36.7	.	.
KRTAP5-4	11	1620958	1622138	N	.	N	N	.	.	0.006793706	56.7	.	.
KRTAP5-5	11	1629775	1630707	N	.	N	N	0.890592391	90.9532905	1.15E-05	77.7	.	.
KRTAP5-6	11	1697195	1697755	N	.	N	N	0.109958322	57.97881577	0.00039398	67.8	.	.
KRTAP5-7	11	71527267	71528674	N	.	N	N	0.56029629	82.76321121	0.581964461	27.9	.	.
KRTAP5-8	11	71527301	71549167	N	.	N	N	1.212301453	95.14383284	0.006907479	56.7	.	.
KRTAP5-9	11	71548418	71549553	N	.	N	N	1.233858592	95.33483822	0.000861771	65.3	.	.
KRTAP6-1	21	30613431	30613930	N	.	N	N	0.653060723	85.71511258	0.000321176	68.4	.	.
KRTAP6-2	21	30598590	30598902	N	.	N	N	0.479526897	79.73027725	0.165055211	39.9	.	.
KRTAP6-3	21	30592440	30593075	N	.	N	N	.	.	0.532856912	29.1	.	.
KRTAP7-1	21	30829039	30829759	N	.	N	N	.	.	.	.	.	.
KRTAP8-1	21	30812697	30813252	N	.	N	N	0.319090009	71.70805117	0.020512482	51.5	.	.
KRTAP9-1	17	41189887	41190639	N	.	N	N	0.971220586	92.33663252	0.001398091	63.4	.	.
KRTAP9-2	17	41189853	41227652	N	.	N	N	0.782674771	88.85223129	0.238025346	37.4	.	.
KRTAP9-3	17	41232463	41233454	N	.	N	N	-0.136685385	39.64229901	0.044712944	47.6	DM?	.
KRTAP9-4	17	41249687	41250653	N	.	N	N	0.249796776	67.44226428	0.000785607	65.6	.	.
KRTAP9-6	17	41265339	41266641	N	.	N	N	0.419500646	76.80152804	0.194495478	38.8	.	.
KRTAP9-7	17	41275659	41276697	N	.	N	N	1.036843424	93.21641489	0.00547083	57.7	.	.
KRTAP9-8	17	41232475	41239004	N	.	N	N	0.789222232	88.97378017	0.043754126	47.7	.	.
KRTAP9-9	17	41226653	41256364	N	.	N	N	1.24422892	95.39271864	0.007298706	56.4	.	.
KRTCAP2	1	155169408	155173475	N	.	N	N	-0.155519548	38.35156567	0.02997049	49.6	.	.
KRTCAP3	2	27442366	27446481	N	.	N	N	-0.219218665	34.36360479	0.044523534	47.6	.	.
KRTDAP	19	35487324	35495558	N	.	N	N	0.085535714	56.11506627	0.075330919	44.7	.	.
KSR1	17	27456714	27626438	N	.	N	Y	0.072896737	55.12531111	0.609182271	27.2	.	.
KSR2	12	117453012	117968983	N	.	N	Y	-1.274180508	4.91983562	0.999946625	3.3	.	.
KTI12	1	52032103	52033816	N	.	N	N	0.242443541	67.04288939	0.034293834	49	.	.
KTN1	14	55559072	55701526	N	.	N	Y	-0.000873422	49.33148116	0.639772921	26.3	.	.
KXD1	19	18557762	18569387	N	.	N	Y	0.33887786	72.80777913	0.140915882	41	.	.
KY	3	134603138	134651636	N	.	N	N	0.024051489	51.38044799	1.07E-08	88.8	.	.
KYNU	2	142877498	143055832	N	.	N	N	-0.209649144	34.96556115	1.83E-09	90.6	DM	?Hydroxykynureninuria, 236800 (3)
L1TD1	1	62194831	62212328	N	.	N	Y	.	.	0.000340201	68.3	.	.
L2HGDH	14	50237563	50312548	N	.	N	N	0.211474757	65.18492794	0.309969498	35.5	DM	L-2-hydroxyglutaric aciduria, 236792 (3)
L34079.2	19	43554692	43593036	N	.	N	N	.	.	.	.	.	.
L3HYPDH	14	59460363	59484430	N	.	N	N	0.263995952	68.32783469	1.52E-07	85.6	.	.
L3MBTL1	20	43507680	43550950	N	.	N	N	0.277391673	69.1439486	2.08E-07	85.1	DM?	.
L3MBTL4	18	5954706	6415237	N	.	N	N	-0.013463392	48.46327487	4.20E-08	87.2	.	.
LA16c-306E5.2	16	3365099	3479550	N	.	N	N	.	.	.	.	.	.
LA16c-380H5.3	16	2988256	3002016	N	.	N	N	.	.	.	.	.	.
LA16c-431H6.6	16	1632259	1686715	N	.	N	N	.	.	.	.	.	.
LACC1	13	43879284	43893932	N	.	N	N	-0.329850009	27.74208485	4.64E-06	79.7	DP	.
LACE1	6	108294894	108526796	N	.	N	N	0.199338946	64.3514499	2.79E-06	80.7	.	.
LACRT	12	54630811	54634895	N	.	N	N	-0.078575026	43.76338485	8.88E-05	72.3	.	.
LACTB	15	63121800	63142061	N	.	N	N	-0.252905653	32.27412166	0.002659612	60.8	.	.
LACTB2	8	70635318	70669174	N	.	N	N	-0.316758145	28.47137813	0.000281761	68.8	.	.
LACTBL1	1	22953043	22965338	N	.	N	N	.	.	.	.	.	.
LAD1	1	201373244	201399915	N	.	N	N	1.317650215	95.90785437	4.13E-08	87.3	FTV	.
LAG3	12	6772512	6778455	N	.	N	Y	0.585823275	83.70087399	0.109617011	42.6	.	.
LAGE3	X	154477769	154479257	N	.	N	N	0.447601653	78.21381027	0.227379901	37.8	.	.
LAIR1	19	54351384	54370558	N	.	N	Y	0.385001656	75.16930023	2.06E-05	76.1	.	.
LAIR2	19	54497879	54510687	N	.	N	N	0.597812859	84.04236847	0.000138974	70.9	FTV	.
LALBA	12	48567684	48570066	N	.	N	Y	0.259064403	67.99212826	0.395945445	32.9	.	.
LAMA4	6	112108760	112254939	Y	Viable	N	Y	-0.92917749	9.046709498	9.75E-09	88.9	DM	Cardiomyopathy, dilated, 1JJ, 615235 (3)
LAMB3	1	209614870	209652466	Y	Viable	N	Y	1.951806343	98.4951091	1.36E-09	90.9	DM	Epidermolysis bullosa, junctional, Herlitz type, 226700 (3); Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3); Amelogenesis imperfecta, type IA, 104530 (3)
LAMB4	7	108023548	108130356	N	.	N	N	-0.274244383	31.04705678	3.21E-30	99.7	DM?	.
LAMC3	9	131009082	131094473	N	.	N	Y	1.91278304	98.4256526	9.82E-11	92.9	DM	Cortical malformations, occipital, 614115 (3)
LAMP1	13	113297241	113323672	N	.	N	Y	-0.445113938	22.4865428	0.978974559	12	.	.
LAMP2	X	120427827	120469365	N	.	N	Y	0.183225703	63.41957516	0.949783835	14.8	DM	Danon disease, 300257 (3)
LAMP3	3	183122213	183163839	N	.	N	N	0.628929435	85.03212363	0.833342527	20.5	.	.
LAMP5	20	9514358	9530524	N	.	N	N	-0.382371374	25.31110725	3.84E-08	87.3	.	.
LAMTOR3	4	99878336	99894490	N	.	N	N	-0.082402837	43.40452625	0.680579445	25.1	.	.
LAMTOR4	7	100148907	100155944	N	.	N	N	0.198082641	64.25305319	0.025687025	50.4	.	.
LANCL1	2	210431249	210477652	N	.	N	Y	0.533300984	81.79660821	9.92E-06	78.1	.	.
LANCL2	7	55365448	55433742	N	Viable	N	Y	-0.093428832	42.59420038	0.786760146	22.1	.	.
LANCL3	X	37571569	37684463	N	.	N	N	.	.	0.522828102	29.4	.	.
LAP3	4	17577192	17607972	N	.	N	N	-0.127116299	40.27319558	0.001220134	63.9	.	.
LAPTM4A	2	20032650	20052028	N	Viable	N	Y	0.097822207	56.98327256	0.50380241	29.8	.	.
LAPTM4B	8	97775057	97853013	N	.	N	N	0.737654087	87.78144354	3.43E-05	74.9	DM?	.
LAPTM5	1	30732469	30757820	N	.	N	Y	0.387722289	75.27927302	0.735702166	23.6	.	.
LARP1	5	154712902	154817607	N	.	N	N	-0.781654413	11.94651849	0.999952189	3.2	.	.
LARP1B	4	128061268	128222931	N	.	N	N	-0.213174425	34.71667535	2.24E-06	81.1	.	.
LARP4	12	50392383	50480004	N	.	N	N	-0.700222136	13.91445274	0.994628856	8.6	.	.
LARP4B	10	806914	931705	N	.	N	N	-0.210454696	34.89610465	0.999885804	3.9	.	.
LARP6	15	70829130	70854159	N	.	N	N	-0.591501503	16.99369103	0.882216412	18.5	.	.
LARS	5	146113038	146182660	N	.	N	N	-0.590101185	17.0573595	2.27E-05	75.9	DM	?Infantile liver failure syndrome 1, 615438 (3)
LARS2	3	45388506	45549421	N	.	N	N	-0.482330978	20.88325519	2.61E-07	84.7	DM	Perrault syndrome 4, 615300 (3)
LAS1L	X	65512582	65534775	N	.	N	N	-0.339267298	27.29640563	0.892095595	18.1	.	.
LASP1	17	38869859	38921770	N	.	N	Y	-0.182660566	36.56884876	0.866739435	19.2	.	.
LAT	16	28984826	28990783	N	.	N	Y	0.078183267	55.57099033	0.097433294	43.3	.	.
LAT2	7	74199652	74229834	N	.	N	Y	0.077226532	55.46680558	0.000691063	66	.	.
LAX1	1	203765176	203776233	N	.	N	Y	0.825929637	89.67413324	4.68E-07	83.9	.	.
LAYN	11	111540280	111561745	N	.	N	N	0.353076131	73.59495283	2.18E-06	81.2	.	.
LBH	2	30231531	30323730	N	.	N	Y	-0.042973552	46.37957979	0.300590032	35.7	DM?	.
LBHD1	11	62662817	62672255	N	.	N	N	.	.	.	.	.	.
LBP	20	38346356	38377023	N	Viable	N	Y	2.334832157	99.02760896	5.69E-14	96.3	DFP	.
LBX2	2	74497517	74503316	N	.	N	N	0.439288148	77.85495167	0.617324062	27	.	.
LCA5	6	79484991	79537458	N	.	N	N	-0.535000983	18.79377207	0.004282174	58.8	DM	Leber congenital amaurosis 5, 604537 (3)
LCA5L	21	39405844	39445805	N	.	N	N	0.614073992	84.58644441	1.91E-06	81.4	.	.
LCAT	16	67939750	67944131	N	.	N	Y	0.136444713	59.97569022	0.496435716	30.1	DM	Norum disease, 245900 (3); Fish-eye disease, 136120 (3)
LCE1A	1	152827473	152827894	N	.	N	N	0.542421446	82.15546681	0.000409834	67.7	.	.
LCE1B	1	152737518	152813109	N	.	N	N	0.102455237	57.40579962	0.027267491	50.2	.	.
LCE1C	1	152804835	152806628	N	.	N	N	0.043387416	52.82745847	0.02751645	50.1	.	.
LCE1D	1	152796751	152798181	N	.	N	N	0.716911447	87.32418823	0.003567547	59.6	.	.
LCE1E	1	152786214	152788426	N	.	N	N	0.817324593	89.47733982	0.0003997	67.7	.	.
LCE1F	1	152776372	152776728	N	Viable	N	Y	0.557428105	82.71111883	0.029498772	49.7	.	.
LCE2A	1	152698364	152699442	N	.	N	N	0.299449341	70.47519824	0.006193801	57.1	.	.
LCE2B	1	152686123	152687401	N	.	N	N	0.28635585	69.71117671	0.137251509	41.2	.	.
LCE2C	1	152675295	152676574	N	.	N	N	0.187858986	63.66846096	0.022606204	51	.	.
LCE2D	1	152663396	152664659	N	.	N	N	0.330418352	72.31579557	0.139231288	41.1	.	.
LCE3A	1	152622834	152623103	N	.	N	N	0.130554386	59.44897841	0.496361201	30.1	.	.
LCE3B	1	152613811	152614098	N	.	N	N	.	.	0.039623989	48.4	DM?	.
LCE3C	1	152511535	152601086	N	.	N	N	.	.	0.496169125	30.1	DFP	.
LCE3D	1	152579381	152580504	N	.	N	N	0.867938626	90.50761128	7.91E-05	72.6	.	.
LCE3E	1	152565654	152566772	N	.	N	N	0.396990911	75.66707183	0.039000927	48.5	.	.
LCE4A	1	152708160	152709491	N	.	N	N	0.783487616	88.86380737	0.003280182	60	.	.
LCE5A	1	152510844	152512177	N	.	N	N	0.571478862	83.14522197	0.076726019	44.6	FTV	.
LCE6A	1	152842868	152843983	N	.	N	N	.	.	.	.	.	.
LCK	1	32251239	32286165	N	.	N	Y	0.050084766	53.41783875	0.999425041	5.3	DM	?Immunodeficiency 22, 615758 (3)
LCLAT1	2	30447226	30644225	N	.	N	Y	-0.115937794	41.07194536	0.00017561	70.2	.	.
LCMT2	15	43323649	43330605	N	.	N	N	-0.201845034	35.34757192	7.27E-08	86.5	.	.
LCN1	9	135521438	135526532	N	.	N	N	0.34829376	73.28818661	1.91E-07	85.2	.	.
LCN10	9	136738167	136743356	N	.	N	N	0.401772227	75.92174567	0.002128013	61.6	DM?	.
LCN12	9	136949551	136955497	N	.	N	N	0.79481394	89.07217688	0.001532037	62.9	.	.
LCN15	9	136759634	136766255	N	.	N	N	0.119374702	58.69074492	0.006880598	56.7	.	.
LCN2	9	128149071	128153455	N	.	N	Y	0.803273327	89.20530185	0.000596069	66.5	.	.
LCN6	9	136744011	136748528	N	.	N	N	0.416778578	76.67419112	2.55E-05	75.6	.	.
LCN8	9	136754386	136758543	N	.	N	N	0.453338311	78.48584824	0.042675812	47.9	.	.
LCN9	9	135663322	135666422	N	.	N	N	0.817324593	89.47733982	0.014871729	53.2	.	.
LCNL1	9	136981904	136986410	N	.	N	N	.	.	0.003015951	60.3	.	.
LCOR	10	96832260	96981043	N	.	N	N	-0.17787558	36.8640389	0.913200262	17.1	.	.
LCORL	4	17841199	18021876	N	.	N	N	.	.	0.96311457	13.7	.	.
LCP1	13	46125920	46211871	N	.	N	Y	0.122395494	58.93963072	0.973076021	12.7	.	.
LCT	2	135787840	135837180	N	.	N	N	-1.134780252	6.193204839	0.064255017	45.6	DM	Lactase deficiency, congenital, 223000 (3)
LCTL	15	66547179	66565979	N	.	N	N	-0.083860557	43.30034149	4.65E-08	87.1	.	.
LDAH	2	20684014	20823130	N	Viable	N	Y	.	.	.	.	.	.
LDB2	4	16501541	16898809	N	.	N	Y	-0.597245112	16.75638132	0.976067857	12.3	.	.
LDHAL6A	11	18455824	18479600	N	.	N	N	0.868081708	90.53076344	0.000200256	69.8	.	.
LDHAL6B	15	59206823	59208515	N	.	N	N	0.458269625	78.73473404	7.95E-07	83	.	.
LDHB	12	21635342	21757857	N	Viable	N	Y	-0.400249026	24.39659663	2.03E-05	76.2	DM	[Lactate dehydrogenase-B deficiency], 614128 (3)
LDHC	11	18412307	18452058	N	.	N	Y	0.290181792	69.94269839	0.000944178	65	.	.
LDHD	16	75111860	75116771	N	.	N	N	-0.812772372	11.32719801	4.49E-06	79.8	.	.
LDLR	19	11089362	11133816	N	.	N	Y	-0.563768197	17.8040169	2.59E-16	97.6	DM	Hypercholesterolemia, familial, 143890 (3); LDL cholesterol level QTL2, 143890 (3)
LDLRAD1	1	54007299	54018186	N	.	N	N	0.932746276	91.78098049	0.000101665	71.8	DP	.
LDLRAD2	1	21812265	21825221	N	.	N	N	0.296728366	70.30734503	0.000195123	69.9	.	.
LDLRAD3	11	35943981	36232136	N	.	N	N	0.37749856	74.80465359	0.02508931	50.5	.	.
LDLRAD4	18	13217498	13652755	N	Viable	N	Y	-0.224807605	34.0336864	0.377306395	33.4	.	.
LDLRAP1	1	25543580	25568886	N	.	N	Y	0.034121997	52.16762169	2.90E-05	75.3	DM	Hypercholesterolemia, familial, autosomal recessive, 603813 (3)
LDOC1	X	141175745	141177125	N	.	N	N	0.007634404	50.08971465	0.575480326	28.1	.	.
LDOC1L	22	44492572	44498298	N	.	N	N	-0.388114712	25.02170516	0.142833061	40.9	.	.
LEAP2	5	132872322	132875046	N	.	N	N	0.290033479	69.90218209	0.007898378	56	.	.
LECT1	13	52703264	52739812	N	.	N	Y	0.186095639	63.59900446	6.68E-06	79	.	.
LECT2	5	135922279	135955034	N	.	N	Y	0.095908833	56.83278347	0.005802494	57.4	.	.
LEKR1	3	156825481	157046129	N	.	N	N	.	.	.	.	.	.
LELP1	1	153203443	153205120	N	.	N	N	0.206542259	64.76240088	0.000473718	67.2	.	.
LEMD1	1	205381378	205457091	N	.	N	N	0.133424212	59.69786421	0.004572606	58.6	.	.
LENEP	1	154993586	154994315	N	.	N	N	0.220592134	65.68848758	0.032282623	49.3	.	.
LENG1	19	54155161	54159882	N	.	N	N	0.62046966	84.76008566	2.63E-09	90.3	.	.
LENG8	19	54448887	54462037	N	.	N	N	-0.662410983	14.97945245	0.998395296	6.6	.	.
LENG9	19	54461796	54463711	N	.	N	N	1.196629346	94.98176767	4.99E-10	91.8	.	.
LEO1	15	51938025	51971806	N	.	N	N	-0.658073323	15.10678937	0.99960597	4.9	.	.
LEPR	1	65420652	65641559	N	.	N	Y	-1.0845293	6.719916652	0.999805342	4.3	DM	Obesity, morbid, due to leptin receptor deficiency, 614963 (3)
LEPROT	1	65420587	65436007	N	Viable	N	Y	0.070529515	54.92272964	0.094789357	43.5	.	.
LEPROTL1	8	30095398	30177208	N	Viable	N	Y	-0.112415198	41.29189095	0.622320079	26.9	.	.
LETM1	4	1811479	1856247	N	.	N	N	-0.577151203	17.4451583	0.081054726	44.4	DM	.
LETM2	8	38386207	38409527	N	.	N	N	0.370952088	74.45158303	1.34E-10	92.7	.	.
LETMD1	12	51047962	51060424	N	.	N	N	0.1035625	57.4868322	0.793860582	21.9	.	.
LEUTX	19	39776595	39786135	N	.	N	N	.	.	.	.	.	.
LGALS1	22	37675608	37679806	N	.	N	Y	-0.230550154	33.7153441	0.004636898	58.5	.	.
LGALS12	11	63506084	63516774	N	.	N	Y	0.369995468	74.38791457	2.69E-09	90.3	.	.
LGALS13	19	39602501	39607476	N	.	N	N	0.543377487	82.18440702	6.78E-05	73	DM	.
LGALS14	19	39704306	39709444	N	.	N	N	0.748837022	88.07663367	0.010012279	54.9	.	.
LGALS16	19	39655894	39660647	N	.	N	N	0.525502816	81.44353765	4.37E-05	74.3	.	.
LGALS2	22	37570246	37582616	N	.	N	Y	0.618410947	84.71956937	0.014689032	53.3	DFP	{Myocardial infarction, susceptibility to}, 608446 (3)
LGALS3	14	55124110	55145413	N	Viable	N	Y	0.274219089	68.94136714	0.000175114	70.2	DFP	.
LGALS3BP	17	78971238	78980109	N	.	N	Y	0.570969045	83.11049372	3.93E-07	84.1	.	.
LGALS4	19	38801671	38813364	N	.	N	N	-0.86449177	10.29113851	6.57E-06	79.1	.	.
LGALS7	19	38770971	38773492	N	.	N	Y	.	.	0.433767043	31.9	.	.
LGALS7B	19	38789211	38791749	N	Viable	N	Y	.	.	0.478395552	30.6	.	.
LGALS8	1	236518000	236552981	N	.	N	Y	-0.136532991	39.65966314	0.000188797	70	FTV	.
LGALS9	17	27629798	27649560	N	.	N	Y	0.763989364	88.43549227	0.00139054	63.4	.	.
LGALS9B	17	20449395	20467539	N	.	N	N	0.341747043	72.9698443	.	.	DM?	.
LGALS9C	17	18476737	18494945	N	.	N	N	0.861534378	90.39763848	0.940115541	15.6	.	.
LGALSL	2	64453969	64461381	N	.	N	N	0.457973076	78.70579383	0.670765299	25.5	.	.
LGI2	4	24998847	25030879	N	.	N	N	-0.878541444	9.972796203	4.42E-05	74.2	.	.
LGI3	8	22146825	22157084	N	.	N	N	-0.167350159	37.57018001	1.95E-05	76.3	.	.
LGMN	14	92703807	92748702	N	Viable	N	Y	0.289375137	69.87324188	0.000974895	64.8	.	.
LGR6	1	202193901	202319781	N	.	N	Y	0.003759245	49.7655843	4.09E-05	74.4	.	.
LGSN	6	63275951	63319977	N	.	N	N	0.347637183	73.26503444	2.59E-07	84.8	.	.
LHB	19	49015980	49017090	N	.	N	Y	0.955257371	92.09353476	0.065600109	45.5	DM	Hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3)
LHCGR	2	48686775	48755730	N	.	N	Y	-0.258342977	31.98471957	2.80E-08	87.7	DM	Precocious puberty, male, 176410 (3); Leydig cell hypoplasia with pseudohermaphroditism, 238320 (3); Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3); Luteinizing hormone resistance, female, 238320 (3); Leydig cell adenoma, somatic, with precocious puberty, 176410 (3)
LHFP	13	39342892	39603528	N	.	N	N	0.06589658	54.61017538	0.463787542	31	.	.
LHFPL1	X	112630648	112680054	N	.	N	N	0.375437469	74.69468079	0.070647458	45	.	.
LHFPL2	5	78485215	78770021	N	.	N	Y	0.187858986	63.66846096	0.015014468	53.1	.	.
LHFPL3	7	104328656	104907232	N	.	N	N	.	.	0.795069316	21.8	.	.
LHFPL4	3	9498361	9553802	N	.	N	N	-0.22208995	34.19575158	0.178387581	39.4	.	.
LHFPL5	6	35805293	35833874	N	.	N	Y	0.090319161	56.46813683	0.494778073	30.1	DM	Deafness, autosomal recessive 67, 610265 (3)
LHPP	10	124461834	124617888	N	.	N	N	0.23015724	66.25571569	1.60E-06	81.8	.	.
LHX9	1	197911902	197935478	N	.	N	Y	-0.184421636	36.49360421	0.941757643	15.5	.	.
LILRA1	19	54573879	54602090	N	.	N	N	2.618506266	99.24755455	1.54E-16	97.7	.	.
LILRA2	19	54572920	54590287	N	.	N	N	5.709631942	99.86687504	6.89E-12	94.4	.	.
LILRA4	19	54333185	54339150	N	.	N	N	1.724003605	97.98576142	2.41E-12	94.9	.	.
LILRA5	19	54307070	54313139	N	.	N	N	-0.023988294	47.67610117	4.63E-08	87.1	.	.
LILRA6	19	54216868	54242800	N	.	N	N	3.673825906	99.70480986	0.000155086	70.6	.	.
LILRB1	19	54617158	54700954	N	.	N	N	4.062947602	99.79741853	9.91E-06	78.1	.	.
LILRB2	19	54238904	54281184	N	.	N	N	3.545174008	99.6816577	7.83E-06	78.7	.	.
LILRB3	19	54216278	54223506	N	.	N	Y	2.752514881	99.34016322	0.027760685	50.1	.	.
LILRB4	19	54643889	54670359	N	.	N	Y	2.276697185	98.96972854	4.67E-08	87.1	.	.
LILRB5	19	54249431	54257301	N	.	N	N	1.508286872	96.99600625	7.17E-12	94.4	.	.
LIM2	19	51379909	51387960	N	.	N	N	-0.361776472	26.25455808	0.000989157	64.7	DM	Cataract 19, 615277 (3)
LIMCH1	4	41359607	41700044	N	.	N	N	0.03281494	52.05186086	0.999638379	4.8	.	.
LIMD1	3	45555394	45686338	N	.	N	Y	0.019418972	51.05052961	0.127770681	41.6	.	.
LIMD2	17	63695902	63701172	N	.	N	N	0.101498578	57.33634312	0.017630169	52.3	.	.
LIME1	20	63736283	63739103	N	.	N	N	.	.	0.000332935	68.4	.	.
LIMK1	7	74082933	74122525	N	.	N	Y	-0.660792224	15.00839266	0.990896287	9.7	DM?	.
LIMK2	22	31212239	31280080	N	.	N	Y	-0.858601673	10.39532326	0.008440401	55.6	.	.
LIMS2	2	127638381	127681786	N	.	N	Y	-0.077465999	43.85599352	1.14E-05	77.7	.	.
LIMS3	2	109898428	109924868	N	.	N	N	.	.	.	.	.	.
LIMS3L	2	110446640	110473075	N	.	N	N	.	.	.	.	.	.
LIN28B	6	104957048	105083332	N	.	N	Y	-0.214586899	34.6414308	0.721962207	24	DFP	.
LIN37	19	35748361	35754519	N	.	N	N	0.271349605	68.75614979	0.356935099	34	.	.
LIN52	14	74084796	74201235	N	.	N	N	0.342555909	72.99878451	0.891966387	18.1	.	.
LIN54	4	82909973	83012926	N	.	N	N	-0.72560274	13.24303988	0.999433599	5.3	.	.
LIN7A	12	80792520	80937925	N	.	N	Y	-0.161108498	37.92903861	0.041148496	48.1	.	.
LIN7B	19	49114324	49118460	N	.	N	Y	-0.018550615	48.01759565	0.83883725	20.3	.	.
LIN7C	11	27494576	27506773	N	.	N	Y	-0.026053671	47.51982404	0.03006523	49.6	.	.
LINC00116	2	110211529	110245420	N	.	N	N	.	.	.	.	.	.
LINC00493	20	18567347	18569563	N	.	N	N	.	.	.	.	.	.
LINGO1	15	77613027	77820900	N	.	N	Y	-0.98071975	8.23059559	0.952116231	14.5	.	.
LINGO2	9	27948078	28670286	N	.	N	N	-1.319349969	4.572553105	0.807167304	21.4	DM?	.
LINGO3	19	2289784	2292024	N	.	N	N	-0.313886865	28.62186722	.	.	.	.
LINGO4	1	151800264	151806154	N	.	N	N	-0.235833932	33.32754529	0.002854097	60.6	.	.
LINS	15	100559369	100603230	N	.	N	N	0.483802987	79.84603809	3.26E-05	75	DM	.
LIPA	10	89213569	89414557	N	.	N	Y	0.012569811	50.44857325	0.011277804	54.4	DM	Wolman disease, 278000 (3); Cholesteryl ester storage disease, 278000 (3)
LIPC	15	58410569	58569843	N	.	N	Y	0.457464994	78.67685362	0.000171127	70.3	DM	[High density lipoprotein cholesterol level QTL 12], 612797 (3); {Diabetes mellitus, noninsulin-dependent}, 125853 (3); Hepatic lipase deficiency, 614025 (3)
LIPE	19	42401507	42427426	N	Viable	N	Y	0.777706884	88.74804654	5.73E-09	89.5	DFP	Lipodystrophy, familial partial, type 6, 615980 (3)
LIPF	10	88664441	88678814	N	.	N	N	-0.344856099	27.00700353	0.000753525	65.7	.	.
LIPG	18	49560699	49599182	N	.	N	Y	0.292245427	70.07003531	8.36E-05	72.4	DM	.
LIPH	3	185506262	185552613	N	.	N	Y	-0.303512836	29.281704	2.13E-06	81.2	DM	[High density lipoprotein cholesterol level QTL 12], 612797 (3); {Diabetes mellitus, noninsulin-dependent}, 125853 (3); Hepatic lipase deficiency, 614025 (3)
LIPJ	10	88586753	88606976	N	.	N	N	0.634519753	85.18261272	2.64E-07	84.7	FTV	.
LIPK	10	88724544	88752786	N	.	N	N	0.822104421	89.58152457	1.19E-08	88.7	.	.
LIPM	10	88802730	88820546	N	.	N	N	.	.	0.169253545	39.7	.	.
LIPN	10	88761406	88778242	N	Viable	N	Y	0.511598665	80.93418996	1.71E-07	85.4	DM	Ichthyosis, congenital, autosomal recessive 8, 613943 (3)
LIPT1	2	99154955	99163157	N	.	N	N	-0.202298558	35.34178387	6.17E-05	73.3	.	Lipoyltransferase 1 deficiency, 616299 (3)
LIPT2	11	74491712	74493733	N	.	N	N	.	.	.	.	.	.
LITAF	16	11547722	11636381	N	.	N	Y	0.035884366	52.28917057	0.313932119	35.3	DM	Charcot-Marie-Tooth disease, type 1C, 601098 (3)
LIX1	5	97091867	97142872	N	.	N	N	0.052803966	53.57411588	0.016674688	52.6	.	.
LIX1L	1	145933423	145958001	N	.	N	Y	-0.260562407	31.82844244	0.116630314	42.3	.	.
LKAAEAR1	20	64083380	64084359	N	.	N	N	.	.	.	.	.	.
LL0XNC01-16G2.1	X	153317681	153321822	N	.	N	N	.	.	.	.	.	.
LLfos-48D6.2	19	2269525	2341172	N	.	N	N	.	.	.	.	.	.
LLPH	12	66116555	66130768	N	.	N	N	-0.08048891	43.56080338	0.341447375	34.5	.	.
LMAN1L	15	74812716	74825758	N	Viable	N	Y	0.443263415	78.03438097	1.88E-09	90.6	.	.
LMAN2	5	177331562	177351852	N	.	N	N	-0.657116328	15.15309371	0.0500443	47	.	.
LMAN2L	2	96705929	96740064	N	.	N	N	-0.927391577	9.098801875	1.29E-07	85.8	.	.
LMBR1	7	156668946	156893230	N	.	N	Y	-0.644981042	15.53510447	0.000687936	66	DM	Acheiropody, 200500 (3); Polydactyly, preaxial type II, 174500 (3); Triphalangeal thumb, type I, 174500 (3); Triphalangeal thumb-polysyndactyly syndrome, 174500 (3); Syndactyly, type IV, 186200 (3); Hypoplastic or aplastic tibia with polydactyly, 188740 (3); Laurin-Sandrow syndrome, 135750 (3)
LMBR1L	12	49096551	49110900	N	.	N	Y	-0.187140168	36.325751	2.18E-06	81.1	.	.
LMBRD2	5	36098412	36151961	N	.	N	N	-0.73214908	13.11570296	0.014565218	53.3	.	.
LMCD1	3	8501707	8574673	N	.	N	N	0.582953443	83.61405337	0.376043791	33.5	.	.
LMF2	22	50502949	50507691	N	.	N	N	0.205386487	64.68715634	.	.	.	.
LMLN	3	197960200	198043720	N	.	N	N	-0.73678193	12.99415408	7.36E-06	78.8	.	.
LMNTD1	12	25409307	25648579	N	.	N	N	.	.	.	.	.	.
LMNTD2	11	554855	560779	N	.	N	N	.	.	.	.	.	.
LMO1	11	8224304	8268716	N	.	N	Y	-0.117047237	40.96776061	0.477078993	30.6	.	Leukemia, T-cell acute lymphoblastic (2)
LMO3	12	16548373	16610594	N	.	N	Y	-0.006414986	48.96104648	0.434209084	31.8	.	.
LMO7DN	13	75871038	75883811	N	.	N	N	.	.	.	.	.	.
LMOD1	1	201896452	201946588	N	.	N	N	0.716248817	87.31261214	0.790872727	22	.	.
LMOD2	7	123655807	123664290	N	.	N	N	0.126071509	59.22903282	0.004996303	58.1	.	.
LMOD3	3	69106872	69123032	N	.	N	N	0.553091557	82.5548417	0.008058416	55.9	.	Nemaline myopathy 10, 616165 (3)
LMTK3	19	48485271	48513189	N	.	N	N	.	.	.	.	DM?	.
LNP1	3	100401193	100456319	N	.	N	N	0.81636885	89.45997569	0.001885176	62.1	.	.
LNPEP	5	96935394	97037515	N	.	N	Y	-0.938273701	8.890432367	0.998308426	6.7	.	.
LNX1	4	53459301	53701405	N	.	N	Y	-0.021771814	47.80922614	0.007243627	56.5	.	.
LNX2	13	27545911	27620404	N	.	N	N	-0.211411415	34.85558835	0.215281596	38.3	DP	.
LOH12CR1	12	12357079	12469694	N	.	N	N	0.302318539	70.64305146	0.021632085	51.3	.	.
LONP1	19	5691834	5720572	N	.	N	N	-0.080539029	43.52607513	0.999697933	4.6	.	CODAS syndrome, 600373 (3)
LONP2	16	48244296	48363122	N	.	N	N	-0.816449514	11.27510563	2.91E-16	97.6	.	.
LONRF1	8	12721894	12756073	N	.	N	N	-0.825060351	11.049372	0.919751764	16.7	.	.
LONRF2	2	100273291	100322733	N	.	N	N	-0.558617759	17.96608207	0.851045049	19.9	.	.
LONRF3	X	118974614	119018355	N	Viable	N	Y	-0.231353608	33.64009955	0.153377588	40.4	.	.
LOXHD1	18	46476972	46657033	N	.	N	Y	.	.	.	.	DM	Deafness, autosomal recessive 77, 613079 (3)
LOXL1	15	73925989	73952137	N	Viable	N	Y	0.472169912	79.41193494	.	.	DP	{Exfoliation syndrome, susceptibility to}, 177650 (3)
LOXL2	8	23297189	23425328	N	.	N	N	-0.068552734	44.48689009	3.00E-07	84.5	DP	.
LOXL3	2	74532414	74555690	N	.	N	N	-0.474019054	21.27684204	5.65E-08	86.8	.	.
LOXL4	10	98247690	98268250	N	.	N	N	1.065551516	93.56948544	2.14E-09	90.4	.	.
LPA	6	160531483	160664259	N	.	N	N	1.941103126	98.46038085	2.44E-32	99.8	DM	{Coronary artery disease, susceptibility to} (1); [LPA deficiency, congenital] (3)
LPAR2	19	19623668	19628930	N	.	N	Y	0.223610811	65.85055276	0.337269897	34.6	.	.
LPAR3	1	84811602	84893213	N	.	N	Y	0.005066824	49.89292122	0.786363329	22.1	.	.
LPAR5	12	6618835	6636447	N	.	N	Y	0.021835061	51.22417086	0.029642921	49.7	.	.
LPAR6	13	48389567	48444704	N	Viable	N	Y	-0.164783496	37.74382127	0.030436524	49.6	DM	Hypotrichosis 8, 278150 (3); Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 (3)
LPCAT2	16	55508998	55586670	N	.	N	N	0.008894044	50.22283961	1.13E-06	82.4	.	.
LPCAT3	12	6976186	7018510	N	.	N	N	-0.086882719	43.06881982	0.980678849	11.6	.	.
LPCAT4	15	34358618	34367278	N	.	N	N	-0.245402639	32.7487411	0.996222992	7.9	.	.
LPGAT1	1	211743457	211830772	N	.	N	N	-0.009133893	48.72373676	0.967547481	13.3	.	.
LPIN2	18	2916994	3013315	N	Viable	N	Y	-0.770327084	12.18961625	0.673512975	25.4	DM	Majeed syndrome, 609628 (3)
LPIN3	20	41340920	41360582	N	Viable	N	Y	1.477477965	96.86288129	4.44E-11	93.5	DM	.
LPO	17	58218548	58268518	N	Viable	N	Y	-0.601573654	16.66377265	2.91E-11	93.7	.	.
LPPR2	19	11355386	11365698	N	.	N	N	-0.403923475	24.17665104	.	.	.	.
LPPR3	19	812488	821977	N	.	N	N	.	.	0.056279308	46.3	.	.
LPPR5	1	98890245	99005032	N	.	N	N	-0.528759206	19.07738612	0.959898117	13.9	.	.
LPXN	11	58526871	58578220	N	.	N	N	0.233027146	66.41199282	0.017200443	52.4	.	.
LRAT	4	154626945	154753118	N	.	N	Y	0.120331361	58.7428373	0.096962506	43.4	DM	Retinal dystrophy, early-onset severe, 613341 (3); Leber congenital amaurosis 14, 613341 (3); Retinitis pigmentosa, juvenile, 613341 (3)
LRBA	4	150264531	151015727	N	.	N	N	-0.716581471	13.4803496	0.044229437	47.7	DM	Immunodeficiency, common variable, 8, with autoimmunity, 614700 (3)
LRCH1	13	46553168	46753040	N	.	N	N	-0.068854605	44.475314	0.982396864	11.4	DP	.
LRCH2	X	115110616	115234072	N	.	N	N	.	.	0.915538079	17	.	.
LRCH3	3	197791226	197888436	N	.	N	N	0.253925617	67.70272617	1.20E-08	88.7	.	.
LRCH4	7	100574011	100586153	N	.	N	N	-1.002126797	7.83700874	0.000176443	70.2	.	.
LRCOL1	12	132603150	132610543	N	.	N	N	.	.	.	.	.	.
LRFN1	19	39306568	39315336	N	.	N	N	-0.854116945	10.49371997	0.830755525	20.6	.	.
LRFN2	6	40391586	40587465	N	Viable	N	Y	-0.918630336	9.243502923	0.117460637	42.3	.	.
LRFN3	19	35935358	35945767	N	Viable	N	Y	-0.778932369	12.04491521	0.860302996	19.5	.	.
LRFN4	11	66856647	66860475	N	.	N	N	-0.401052411	24.3502923	0.942092245	15.4	.	.
LRFN5	14	41607570	41904549	N	.	N	N	-0.76870886	12.24170863	0.712324783	24.3	DM?	.
LRG1	19	4536409	4540474	N	.	N	N	0.66835895	86.17236789	3.42E-05	74.9	.	.
LRGUK	7	134127299	134264591	N	.	N	N	1.278534082	95.63002836	1.92E-08	88.2	DM?	.
LRIF1	1	110947185	110964079	N	.	N	N	-0.74891881	12.67581177	0.000245001	69.2	.	.
LRIG1	3	66378797	66501263	N	.	N	Y	1.253672672	95.46796319	0.835793558	20.4	.	.
LRIG2	1	113073209	113132260	N	.	N	Y	-0.302107062	29.34537246	3.29E-12	94.8	DM	Urofacial syndrome 2, 615112 (3)
LRIG3	12	58872149	58920522	N	.	N	Y	-0.486965882	20.69803785	0.426287753	32.1	.	.
LRIT1	10	84231593	84241461	N	.	N	N	0.493066458	80.1933206	2.92E-08	87.7	.	.
LRIT2	10	84220495	84225589	N	.	N	N	0.411489443	76.41372924	1.83E-09	90.6	.	.
LRIT3	4	109848202	109872315	N	.	N	N	0.456356165	78.6189732	2.23E-08	88	DM	Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 (3)
LRMP	12	25021002	25108334	N	.	N	N	0.228394221	66.13995485	0.020912707	51.4	.	.
LRP10	14	22871613	22881580	N	.	N	N	-0.698160609	13.98390924	0.000211411	69.7	.	.
LRP11	6	149818798	149864026	N	.	N	N	0.155126864	61.40533657	0.100969715	43.1	.	.
LRP12	8	104489231	104589024	N	.	N	N	-1.155071428	6.036927707	0.969751549	13	.	.
LRP2BP	4	185363879	185395899	N	.	N	N	0.049127994	53.35995833	1.10E-06	82.4	.	.
LRP3	19	33177603	33208867	N	.	N	N	-0.323000284	28.07779128	0.039236654	48.4	.	.
LRP5L	22	25351418	25405377	N	.	N	N	1.159916575	94.63448515	3.87E-11	93.5	.	.
LRP8	1	53242364	53328070	N	.	N	Y	-0.314540604	28.57556289	0.99998576	2.7	DP	{Myocardial infarction, susceptibility to}, 608446 (3)
LRR1	14	49598697	49614672	N	.	N	N	0.05199832	53.51623546	8.61E-07	82.8	.	.
LRRC1	6	53794497	53924121	N	.	N	N	0.016397017	50.77270359	0.573184205	28.2	.	.
LRRC10	12	69608564	69611162	N	.	N	Y	0.086643016	56.19609886	0.009191766	55.3	.	.
LRRC10B	11	61508800	61511018	N	.	N	N	.	.	.	.	.	.
LRRC14	8	144517992	144525178	N	.	N	N	-1.055756275	7.130867627	0.006652734	56.8	.	.
LRRC14B	5	191511	195353	N	.	N	N	0.952533561	92.05301846	3.31E-09	90	.	.
LRRC15	3	194355247	194369743	N	Viable	N	Y	0.921865474	91.53788273	1.36E-06	82.1	.	.
LRRC16A	6	25279078	25620530	N	.	N	N	-0.184925748	36.45887596	0.502318842	29.9	.	.
LRRC16B	14	24052000	24069728	N	.	N	N	-1.224118901	5.365514846	4.87E-05	74	.	.
LRRC17	7	102912991	102944949	N	.	N	N	-0.08305528	43.36400996	6.64E-08	86.6	.	.
LRRC18	10	48909483	48935190	N	.	N	N	0.422517211	76.9751693	0.000124173	71.2	.	.
LRRC19	9	26993136	27005693	N	.	N	N	0.649526336	85.59935174	5.17E-05	73.8	.	.
LRRC2	3	46515423	46580099	N	Viable	N	Y	1.239591998	95.36956648	4.77E-05	74	.	.
LRRC20	10	70298970	70382650	N	.	N	N	-0.023183121	47.73398159	0.136831661	41.2	.	.
LRRC23	12	6873569	6914243	N	.	N	N	0.264952627	68.37992707	0.000915909	65.1	.	.
LRRC24	8	144522377	144527032	N	.	N	N	-0.200384589	35.4691208	0.775315502	22.4	.	.
LRRC25	19	18391144	18397617	N	.	N	N	0.7751713	88.66701395	0.943472206	15.4	.	.
LRRC26	9	137168758	137170051	N	.	N	N	.	.	0.028439438	50	.	.
LRRC27	10	132332154	132379918	N	.	N	N	1.040964966	93.28008335	9.75E-14	96.1	.	.
LRRC28	15	99251362	99390729	N	.	N	N	-0.356034079	26.53238409	8.60E-05	72.3	.	.
LRRC29	16	67207139	67227048	N	.	N	N	0.626870269	84.96845517	0.007203759	56.5	DM?	.
LRRC3	21	44455486	44462196	N	.	N	N	-0.192881585	36.00162065	0.006456948	56.9	.	.
LRRC30	18	7231125	7232047	N	.	N	N	-0.228482701	33.83110494	2.19E-08	88	.	.
LRRC31	3	169839179	169869930	N	.	N	N	0.70970233	87.11581872	5.24E-06	79.5	.	.
LRRC32	11	76657524	76670747	N	.	N	N	0.379716921	74.90883834	0.021575526	51.3	.	.
LRRC34	3	169793428	169812986	N	.	N	N	0.225524115	65.99525381	5.89E-07	83.5	FTV	.
LRRC36	16	67326798	67385203	N	.	N	N	-0.128878445	40.18058691	3.63E-10	92	.	.
LRRC37A	17	46292733	46337794	N	.	N	N	.	.	0.890487356	18.2	.	.
LRRC37A2	17	46511511	46555650	N	.	N	N	.	.	.	.	.	.
LRRC37A3	17	64854312	64919480	N	.	N	N	1.290833903	95.71106095	.	.	.	.
LRRC37B	17	32007872	32053504	N	.	N	N	0.125570254	59.15957632	0.948665375	14.9	.	.
LRRC38	1	13474977	13514048	N	.	N	N	.	.	.	.	.	.
LRRC39	1	100148449	100178273	N	.	N	N	0.352119595	73.52549632	0.039707461	48.4	.	.
LRRC3B	3	26622806	26710776	N	.	N	N	-0.163022609	37.81906581	0.228541146	37.7	.	.
LRRC3C	17	39941474	39944747	N	.	N	N	.	.	.	.	.	.
LRRC4	7	128027071	128032107	N	.	N	Y	-0.802399101	11.50662731	0.877360672	18.7	DM	.
LRRC40	1	70144805	70205620	N	.	N	N	0.840130127	90.01562771	2.65E-19	98.5	.	.
LRRC41	1	46261196	46303608	N	.	N	N	-0.864339828	10.29692655	0.999804641	4.3	DM?	.
LRRC42	1	53946077	53968168	N	.	N	N	-0.241574879	32.93395844	1.67E-06	81.7	.	.
LRRC43	12	122167738	122203471	N	.	N	N	0.808356587	89.29212247	6.70E-14	96.3	.	.
LRRC45	17	82023302	82031151	N	.	N	N	-0.64402392	15.57562077	3.15E-06	80.5	.	.
LRRC46	17	47831627	47837713	N	.	N	N	0.199188423	64.32250969	0.000135433	71	.	.
LRRC47	1	3778558	3796504	N	.	N	N	-0.506095743	19.97453262	0.603832188	27.4	.	.
LRRC48	17	17972813	18016889	N	.	N	N	0.415164716	76.6163107	6.09E-06	79.2	.	.
LRRC49	15	70853239	71053657	N	.	N	N	-0.267759536	31.40012734	0.446510312	31.5	.	.
LRRC4B	19	50516892	50568045	N	.	N	N	-1.07922423	6.800949239	0.297156811	35.8	.	.
LRRC4C	11	40114203	41459773	N	.	N	Y	-0.613054008	16.39173468	0.953730869	14.4	.	.
LRRC52	1	165544007	165563961	N	.	N	N	0.202058361	64.50772704	0.001329071	63.6	.	.
LRRC53	1	74469878	74512614	N	.	N	N	.	.	.	.	.	.
LRRC55	11	57181747	57191717	N	.	N	N	-0.659987499	15.04312091	0.677224186	25.3	.	.
LRRC56	11	537527	554916	N	.	N	N	1.080398324	93.75470278	0.000110646	71.5	.	.
LRRC57	15	42537820	42548802	N	.	N	N	-0.002587674	49.23887249	0.00068689	66	.	.
LRRC58	3	120324509	120349339	N	.	N	N	0.064939857	54.54650692	0.019132693	51.9	.	.
LRRC59	17	50375059	50397553	N	.	N	N	-0.015680094	48.2317532	0.482144865	30.5	.	.
LRRC6	8	132571953	132675617	N	.	N	N	0.394417992	75.55131099	8.30E-08	86.3	DM	Ciliary dyskinesia, primary, 19, 614935 (3)
LRRC61	7	150322639	150338150	N	.	N	N	0.21610777	65.42223766	0.005195551	57.9	.	.
LRRC63	13	46211943	46277366	N	.	N	N	.	.	.	.	.	.
LRRC66	4	51993702	52017620	N	.	N	N	-0.28901326	30.1383342	9.28E-14	96.1	.	.
LRRC69	8	91101832	91219236	N	.	N	N	.	.	.	.	DM?	.
LRRC7	1	69568398	70151945	N	.	N	Y	-2.13156432	1.400706141	0.999998533	1.8	.	.
LRRC70	5	62578735	62581448	N	.	N	N	.	.	.	.	.	.
LRRC71	1	156920650	156933094	N	.	N	N	.	.	0.009049218	55.3	.	.
LRRC72	7	16526880	16581568	N	.	N	N	.	.	.	.	.	.
LRRC73	6	43506969	43510686	N	.	N	N	-0.227678773	33.88319731	0.635116133	26.5	.	.
LRRC74A	14	76826372	76870302	N	.	N	N	.	.	.	.	.	.
LRRC74B	22	21045960	21064168	N	.	N	N	.	.	.	.	.	.
LRRC75A	17	16441577	16492153	N	.	N	N	.	.	.	.	.	.
LRRC75B	22	24585620	24593208	N	.	N	N	.	.	.	.	.	.
LRRC8A	9	128882112	128918039	N	.	N	N	-1.342674255	4.375759681	0.916104676	17	DM	Agammaglobulinemia 5, 613506 (3)
LRRC8B	1	89524836	89597864	N	.	N	N	-1.109239253	6.447878683	0.806424943	21.4	.	.
LRRC8C	1	89633072	89769903	N	.	N	N	0.021181046	51.1605024	0.016527923	52.7	.	.
LRRC8D	1	89821014	89936611	N	.	N	N	-0.958208997	8.606818313	0.868441355	19.1	.	.
LRRC8E	19	7888505	7902021	N	.	N	N	0.346030702	73.18978989	0.000781502	65.6	.	.
LRRC9	14	59919713	60063559	N	.	N	N	.	.	.	.	.	.
LRRCC1	8	85107147	85146076	N	.	N	N	1.127498258	94.2814146	5.40E-19	98.4	.	.
LRRD1	7	92112159	92179531	N	.	N	N	.	.	.	.	.	.
LRRFIP1	2	237627576	237813682	N	.	N	N	-0.054352659	45.48822133	0.36551249	33.8	.	.
LRRFIP2	3	37052656	37183689	N	.	N	N	0.054063388	53.63778434	4.80E-08	87	.	.
LRRIQ1	12	85036314	85263224	N	.	N	N	0.332621519	72.44892053	6.85E-19	98.4	.	.
LRRIQ3	1	74026015	74198187	N	.	N	N	1.343034388	96.0641315	3.22E-15	97	.	.
LRRIQ4	3	169821922	169837775	N	.	N	N	0.482692587	79.834462	0.001685548	62.5	.	.
LRRK1	15	100919215	101078254	Y	Viable	N	Y	-0.819233031	11.19986109	1.59E-05	76.9	.	.
LRRN1	3	3799437	3847703	N	.	N	Y	-0.732955602	13.06939862	0.876589037	18.8	.	.
LRRN2	1	204617170	204685733	N	.	N	Y	-0.216044341	34.51988192	0.22078125	38	.	.
LRRN3	7	111091006	111125454	N	.	N	Y	-0.624232756	16.02708804	0.68645235	25	.	.
LRRN4	20	6040778	6054049	N	.	N	Y	0.241638002	66.97922093	1.45E-08	88.5	.	.
LRRN4CL	11	62686402	62689899	N	.	N	N	0.0077858	50.10707878	5.44E-05	73.7	.	.
LRRTM1	2	80288351	80304749	N	.	N	Y	-0.393549347	24.76703131	0.951075573	14.6	.	.
LRRTM2	5	138868923	138875368	N	.	N	N	-0.442395976	22.60809168	0.923558762	16.5	.	.
LRRTM3	10	66926006	67099830	N	Viable	N	Y	-0.478954353	21.04532037	0.852645121	19.8	.	.
LRRTM4	2	76747719	77593319	N	.	N	Y	-0.780040126	12.00439891	0.748069164	23.2	.	.
LRSAM1	9	127451486	127503501	N	.	N	N	0.303729111	70.73566013	2.93E-05	75.3	DM	Charcot-Marie-Toothe disease, axonal, type 2P, 614436 (3)
LRTM1	3	54918237	54967088	N	.	N	N	0.348442859	73.32291486	5.25E-09	89.5	.	.
LRTM2	12	1820267	1836752	N	.	N	N	-0.235985706	33.32175725	0.739704571	23.5	.	.
LRTOMT	11	72080331	72110782	N	.	N	N	.	.	0.014564264	53.3	DM	Deafness, autosomal recessive 63, 611451 (3)
LRWD1	7	102464929	102473168	N	.	N	N	-0.178529231	36.81194652	2.02E-07	85.1	.	.
LSAMP	3	115802363	117139389	N	.	N	Y	-0.219218665	34.36360479	0.946283747	15.1	.	.
LSG1	3	194640788	194672477	N	.	N	N	0.927454043	91.66521966	6.59E-07	83.2	.	.
LSM12	17	44034635	44067619	N	.	N	N	0.032057299	51.99976848	0.931681763	16	.	.
LSM14B	20	62122461	62135378	N	.	N	N	-0.253862657	32.21624125	0.96722748	13.3	.	.
LSM2	6	31797396	31806984	N	.	N	N	0.015137522	50.6627308	0.005962817	57.3	.	.
LSM3	3	14178358	14201119	N	.	N	N	-0.15743371	38.19528853	2.77E-05	75.4	.	.
LSM5	7	32485332	32495283	N	.	N	N	0.129597795	59.37952191	0.018231933	52.1	.	.
LSM6	4	146175685	146200000	N	.	N	N	0.151150685	61.04647798	0.868075946	19.1	.	.
LSM7	19	2321517	2328620	N	.	N	N	.	.	0.281731307	36.2	.	.
LSM8	7	118184032	118192824	N	.	N	N	.	.	.	.	.	.
LSMEM1	7	112480853	112491062	N	.	N	N	-0.027010532	47.48509579	0.005194861	57.9	.	.
LSMEM2	3	50279027	50288114	N	.	N	N	0.339834225	72.85987151	2.89E-05	75.3	.	.
LSP1	11	1852970	1892267	N	.	N	Y	0.09510276	56.80384326	0.259641696	36.8	.	.
LST1	6	31586124	31588909	N	Viable	N	Y	0.548012863	82.36383631	0.002537915	61.1	.	Hyperbilirubinemia, Rotor type, digenic, 237450 (3)
LTA	6	31572054	31574324	N	Viable	N	Y	0.442966544	78.02280489	0.743246562	23.3	DFP	{Myocardial infarction, susceptibility to}, 608446 (3); {Psoriatic arthritis, susceptibility to}, 607507 (3); {Leprosy, susceptibility to, 4}, 610988 (3)
LTA4H	12	96000828	96043520	N	Viable	N	Y	-0.961079954	8.531573769	0.049421819	47.1	.	.
LTB	6	31580525	31582522	N	.	N	Y	0.014332026	50.57012213	1.01E-05	78	.	.
LTB4R	14	24311450	24318036	N	.	N	Y	-0.272697012	31.12808937	0.677367973	25.3	.	.
LTB4R2	14	24305734	24312053	N	.	N	Y	0.856899996	90.31660589	0.000267453	69	.	.
LTBP3	11	65538560	65558930	N	.	N	Y	-0.8801563	9.943855994	0.996034359	7.9	DM	Glaucoma 3, primary congenital, D, 613086 (3); Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3); Weill-Marchesani syndrome 3, recessive, 614819 (3)
LTBR	12	6375045	6391571	N	.	N	Y	-0.101888702	42.01539619	0.42868315	32	.	.
LTC4S	5	179793980	179796647	N	.	N	Y	0.002044933	49.63824738	0.002169106	61.6	DM	Leukotriene C4 synthase deficiency, 614037 (1)
LTF	3	46435645	46485234	N	.	N	Y	1.37512779	96.25513689	1.76E-13	95.9	DFP	.
LTK	15	41503638	41513887	N	.	N	N	0.920108871	91.50315448	4.12E-21	98.9	DP	.
LTV1	6	143843344	143863812	N	.	N	N	-0.068049328	44.53319442	2.05E-05	76.2	.	.
LUC7L	16	188969	229463	N	.	N	N	0.004110017	49.83504081	0.164212797	40	DM?	.
LUC7L2	7	139341360	139422599	N	.	N	N	-0.242684848	32.87607802	0.590287986	27.7	.	.
LUC7L3	17	50719544	50756213	N	.	N	N	0.107238638	57.76465822	0.999974251	3	.	.
LUM	12	91102629	91111831	N	.	N	Y	-0.219218665	34.36360479	0.101924741	43	DM?	.
LURAP1	1	46203334	46221261	N	.	N	N	0.022791848	51.2704752	0.220934119	38	.	.
LURAP1L	9	12775021	12822131	N	.	N	N	0.326740798	72.14794235	0.076624269	44.7	.	.
LUZP2	11	24496970	25082631	N	.	N	Y	0.057587761	53.92139839	8.71E-05	72.3	DM?	.
LUZP4	X	115289727	115307556	N	.	N	N	0.425238096	77.10250622	0.000221317	69.5	DM?	.
LUZP6	7	135927274	135927450	N	.	N	N	.	.	.	.	.	.
LVRN	5	115962454	116027619	N	.	N	N	.	.	.	.	.	.
LXN	3	158645822	158672693	N	.	N	Y	0.999324262	92.74758349	0.003620445	59.5	.	.
LY6D	8	142784880	142786592	N	.	N	N	0.30599617	70.83405684	0.000620135	66.3	.	.
LY6G5B	6	31670167	31673776	N	.	N	N	0.438331876	77.80285929	0.000871194	65.2	.	.
LY6G5C	6	31676684	31684040	N	.	N	N	0.267523946	68.51884008	0.614670423	27.1	.	.
LY6G6C	6	31718648	31721845	N	.	N	N	0.328505738	72.23476298	0.001652695	62.7	.	.
LY6G6D	6	31715356	31717804	N	.	N	N	0.715955704	87.28945998	0.542857604	28.8	.	.
LY6G6E	6	31711771	31714065	N	.	N	N	.	.	.	.	.	.
LY6G6F	6	31706885	31710595	N	.	N	N	1.14012811	94.43769173	2.56E-06	80.8	DM?	.
LY6H	8	143157914	143160711	N	.	N	N	-0.065482771	44.7241998	0.460605569	31.1	.	.
LY6K	8	142700111	142705127	N	.	N	N	0.187858986	63.66846096	0.000583632	66.5	.	.
LY75	2	159803355	159904749	N	.	N	Y	-0.720951317	13.37616484	3.63E-27	99.5	.	.
LY75-CD302	2	159771851	159904710	N	.	N	N	-0.913215259	9.32453551	3.63E-27	99.5	.	.
LY86	6	6588108	6654983	N	.	N	Y	0.605316196	84.29125427	9.98E-06	78.1	.	.
LY9	1	160796074	160828261	N	.	N	Y	1.021326834	93.05434971	4.14E-10	91.9	.	.
LY96	8	73991352	74029087	N	.	N	Y	-0.064525847	44.79365631	2.41E-06	80.9	DM	.
LYAR	4	4267701	4290169	N	.	N	N	0.499461757	80.4422064	0.000132449	71.1	.	.
LYG1	2	99284238	99304742	N	.	N	N	0.28635585	69.71117671	0.000104428	71.7	.	.
LYG2	2	99242246	99255282	N	.	N	N	0.090319161	56.46813683	5.77E-06	79.3	.	.
LYL1	19	13099033	13103161	N	.	N	Y	.	.	0.672721211	25.4	.	Leukemia, T-cell acute lymphoblastoid (2)
LYN	8	55879813	56014168	N	.	N	Y	-0.989334973	8.028014123	0.995480464	8.2	FTV	.
LYNX1	8	142764334	142778224	N	.	N	Y	0.288268772	69.80378538	0.110678246	42.6	.	.
LYPD1	2	132644853	132671579	N	.	N	Y	0.026467762	51.52514904	0.000238591	69.2	.	.
LYPD2	8	142750150	142752534	N	.	N	N	.	.	0.063302205	45.7	.	.
LYPD4	19	41837074	41844697	N	.	N	N	0.099735608	57.19164207	3.41E-05	74.9	.	.
LYPD5	19	43795929	43827206	N	.	N	N	0.066853307	54.65069167	9.45E-05	72.1	.	.
LYPD6B	2	149038107	149215262	N	Viable	N	Y	0.096865517	56.89645193	0.001033508	64.6	.	.
LYPD8	1	248718649	248755739	N	.	N	N	.	.	.	.	.	.
LYPLA1	8	54046367	54102017	N	.	N	N	0.307908866	70.93824159	0.008494426	55.6	.	.
LYPLA2	1	23790970	23795539	N	.	N	N	-0.320586962	28.25722058	0.979519145	11.8	.	.
LYPLAL1	1	219173844	219212865	N	Viable	N	Y	0.449660369	78.35272327	3.45E-08	87.4	.	.
LYRM1	16	20899868	20925006	N	.	N	N	0.079946001	55.69832726	1.79E-05	76.5	.	.
LYRM2	6	89568144	89638753	N	.	N	N	0.184032836	63.46009145	0.059681335	46	.	.
LYRM4	6	5102593	5260939	N	.	N	N	.	.	0.04025804	48.3	DFP	?Combined oxidative phosphorylation deficiency 19, 615595 (3)
LYRM5	12	25195216	25209645	N	.	N	N	0.319090009	71.70805117	0.00088717	65.2	.	.
LYRM7	5	131170810	131205426	N	.	N	N	0.007634404	50.08971465	0.013501999	53.7	.	?Mitochondrial complex III deficiency, nuclear type 8, 615838 (3)
LYRM9	17	27878314	27894752	N	.	N	N	0.622091168	84.80060196	0.045000307	47.6	.	.
LYSMD1	1	151159748	151165948	N	.	N	N	0.05935026	54.0603114	0.181950236	39.2	.	.
LYSMD2	15	51723011	51751585	N	.	N	N	0.548012863	82.36383631	0.256648624	36.9	.	.
LYSMD3	5	90515611	90529584	N	.	N	N	1.002191365	92.79388783	0.77181509	22.6	.	.
LYSMD4	15	99715697	99733561	N	.	N	N	0.966584727	92.26717601	1.73E-05	76.7	.	.
LYST	1	235661041	235883640	N	Viable	N	Y	-1.030808084	7.460786016	0.999978423	2.9	DM	Chediak-Higashi syndrome, 214500 (3)
LYVE1	11	10556966	10611689	N	.	N	Y	0.595090612	83.99027609	4.22E-07	84	.	.
LYZ	12	69348341	69354234	N	.	N	Y	0.594944888	83.97870001	0.001375517	63.5	DM	Amyloidosis, renal, 105200 (3)
LYZL1	10	29289061	29318328	N	.	N	N	0.562208663	82.80951554	0.048695746	47.2	.	.
LYZL2	10	30611779	30629762	N	.	N	N	1.14012811	94.43769173	3.26E-06	80.4	.	.
LYZL4	3	42397078	42410600	N	.	N	N	0.162480005	61.94941251	0.112282902	42.5	.	.
LYZL6	17	35934518	35943699	N	.	N	N	0.367934269	74.27215373	7.45E-05	72.8	.	.
LZIC	1	9922113	9943407	N	.	N	N	-0.049519725	45.82392777	0.001979247	61.9	.	.
LZTFL1	3	45823316	45916042	N	.	N	N	0.216914842	65.45696591	0.19410281	38.9	DM	Bardet-Biedl syndrome 17, 615994 (3)
LZTS1	8	20246165	20303963	N	.	N	Y	-0.005960414	49.03050298	0.525971473	29.3	DP	Esophageal squamous cell carcinoma, 133239 (3)
LZTS2	10	100996618	101007836	N	.	N	Y	0.51653284	81.12519535	0.875482096	18.8	.	.
LZTS3	20	3162617	3173592	N	.	N	N	-0.499549597	20.20605429	0.875742311	18.8	.	.
M1AP	2	74557883	74648338	N	.	N	N	-0.458206381	21.95404295	5.83E-12	94.6	.	.
MAATS1	3	119703022	119767102	N	.	N	N	0.985724572	92.60867049	9.78E-10	91.1	.	.
MAB21L1	13	35474182	35477209	N	.	N	Y	-0.702290312	13.85078428	0.367416502	33.7	.	.
MAB21L3	1	116111755	116135240	N	.	N	N	0.857856534	90.32818198	0.000490219	67.1	.	.
MACC1	7	20134655	20217404	N	.	N	N	1.565611848	97.29698443	7.56E-17	97.7	DM?	.
MACROD1	11	63998558	64166106	N	.	N	N	-0.195752553	35.7874631	0.006624769	56.8	.	.
MACROD2	20	13995369	16053197	N	Viable	N	Y	0.582953443	83.61405337	0.011356747	54.4	DM	.
MAD2L1BP	6	43629540	43640952	N	.	N	N	0.334243918	72.52995312	0.00824444	55.7	.	.
MADCAM1	19	489176	505342	N	.	N	Y	.	.	0.428374924	32	.	.
MAEL	1	166975582	167022214	N	.	N	N	-0.511838334	19.74301094	0.021254638	51.3	.	.
MAF1	8	144104499	144107611	N	.	N	N	-0.25960522	31.89789894	0.79402458	21.9	.	.
MAFA	8	143419182	143430406	N	.	N	Y	.	.	.	.	.	.
MAFF	22	38200767	38216511	N	.	N	Y	.	.	0.042201122	48	.	.
MAFK	7	1530714	1543043	N	.	N	N	.	.	0.557286406	28.5	.	.
MAG	19	35292125	35313804	N	Viable	N	Y	-0.377435075	25.60629739	0.540766817	28.9	.	.
MAGEA1	X	153179285	153183880	N	.	N	N	0.536830287	81.94130926	0.369816631	33.6	.	.
MAGEA10	X	152133310	152138578	N	.	N	N	1.08568913	93.79521908	0.305621879	35.6	.	.
MAGEA11	X	149688228	149717266	N	.	N	N	0.684174168	86.52543844	0.594544547	27.6	.	.
MAGEA12	X	152733779	152737669	N	.	N	N	0.883088819	90.78543729	0.700103439	24.6	.	.
MAGEA2	X	152749863	152753884	N	.	N	N	.	.	.	.	.	.
MAGEA2B	X	152714586	152718607	N	.	N	N	.	.	.	.	.	.
MAGEA3	X	152698752	152702347	N	.	N	N	1.25555613	95.47953927	0.373340459	33.5	.	.
MAGEA4	X	151912509	151925170	N	.	N	N	0.975044523	92.37136077	0.744658643	23.3	.	.
MAGEA6	X	152766136	152769747	N	.	N	N	0.967540858	92.27296406	0.094196105	43.5	.	.
MAGEA8	X	149881141	149885835	N	.	N	N	0.779806888	88.78277479	0.238209592	37.4	.	.
MAGEA9	X	149781930	149787737	N	.	N	N	.	.	.	.	.	.
MAGEA9B	X	149581653	149587453	N	.	N	N	.	.	.	.	.	.
MAGEB1	X	30243730	30252038	N	.	N	N	-0.05223834	45.61555826	0.070133898	45.1	.	.
MAGEB10	X	27807990	27823014	N	.	N	N	0.718823127	87.39364473	0.710701864	24.3	.	.
MAGEB16	X	35798342	35803735	N	.	N	N	0.672846598	86.25918852	0.001663682	62.6	.	.
MAGEB17	X	16167481	16171464	N	.	N	N	.	.	0.028436273	50	.	.
MAGEB18	X	26138343	26140735	N	.	N	N	0.240380673	66.89818834	0.040371281	48.3	.	.
MAGEB2	X	30215560	30220089	N	.	N	N	0.370803213	74.41685478	0.006479817	56.9	.	.
MAGEB3	X	30230436	30237492	N	.	N	N	0.544333577	82.21334722	0.661352679	25.7	.	.
MAGEB4	X	30242052	30244193	N	.	N	N	0.310778106	71.09451872	0.255054608	36.9	.	.
MAGEB5	X	26216169	26218270	N	.	N	N	.	.	0.114589766	42.4	.	.
MAGEB6	X	26192440	26195646	N	.	N	N	0.826886131	89.70886149	0.386744087	33.1	.	.
MAGEB6P1	X	26160601	26161824	N	.	N	N	.	.	.	.	.	.
MAGEC1	X	141903894	141909388	N	.	N	N	8.18631223	99.94211958	.	.	DP	.
MAGEC2	X	142202345	142205290	N	.	N	N	-0.550311326	18.19760375	0.659070497	25.8	.	.
MAGEC3	X	141838316	141897832	N	.	N	N	0.173154201	62.77710251	3.25E-08	87.5	DM?	.
MAGED1	X	51803007	51902357	N	.	N	Y	-0.152495841	38.53678301	0.982074597	11.4	.	.
MAGED2	X	54807599	54816012	N	.	N	N	0.172852824	62.72501013	0.989729719	10	.	.
MAGED4	X	52184823	52192268	N	.	N	N	.	.	.	.	.	.
MAGED4B	X	52061827	52069248	N	.	N	N	.	.	.	.	.	.
MAGEE1	X	76427724	76431353	N	.	N	N	0.167564929	62.36036349	0.699601223	24.6	.	.
MAGEE2	X	75782988	75785236	N	.	N	N	0.843806232	90.08508422	1.53E-08	88.4	FTV	.
MAGEF1	3	184710367	184712002	N	.	N	N	0.837111437	89.94617121	0.034031466	49.1	.	.
MAGEH1	X	55452105	55453566	N	.	N	N	-0.269022695	31.31330671	0.338067799	34.6	.	.
MAGI1	3	65353525	66038834	N	.	N	N	-1.923938495	1.834809284	0.999615675	4.9	DM	.
MAGI3	1	113390749	113685923	N	.	N	N	-1.937353449	1.811657116	0.570580157	28.2	.	.
MAGIX	X	49162564	49168483	N	.	N	N	0.663431417	86.02766684	0.003592186	59.6	.	.
MAGOHB	12	10604190	10613623	N	.	N	N	-0.119918286	40.73045089	0.041782997	48.1	.	.
MAGT1	X	77826364	77895593	N	.	N	N	0.217871355	65.53221045	0.887373876	18.3	DM	Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 (3)
MAK	6	10762723	10838555	N	.	N	Y	-0.168306934	37.48914742	9.63E-11	93	DM	Retinitis pigmentosa 62, 614181 (3)
MAK16	8	33484750	33501260	N	.	N	N	-0.164783496	37.74382127	0.993980456	8.9	.	.
MAL	2	95025677	95053996	N	.	N	Y	0.033970832	52.15025757	0.786079025	22.1	.	Megakaryoblastic leukemia, acute (3)
MAL2	8	119165034	119245673	N	.	N	N	.	.	0.458862108	31.1	.	.
MALAT1	11	65502034	65503622	N	.	N	Y	.	.	.	.	.	.
MALL	2	110083870	110116566	N	.	N	N	.	.	0.201463447	38.7	.	.
MALRD1	10	19048771	19790401	N	.	N	N	.	.	.	.	.	.
MALSU1	7	23298739	23311729	N	.	N	N	0.146667159	60.78022805	1.78E-08	88.3	.	.
MALT1	18	58671386	58754477	N	.	N	Y	-0.180594035	36.70776176	0.994144578	8.8	DM	Immunodeficiency 12, 615468 (3)
MAMDC2	9	70043581	70226970	N	.	N	N	0.485563343	79.92128263	0.004171475	58.9	.	.
MAMDC4	9	136850943	136860799	N	.	N	N	2.833190656	99.39804364	2.60E-35	99.8	.	.
MAML2	11	95976598	96343180	N	.	N	N	0.489547433	80.07755976	0.998525114	6.5	.	Mucoepidermoid salivary gland carcinoma (3)
MAML3	4	139716753	140154184	N	.	N	Y	0.665952246	86.10291139	0.329895048	34.9	.	.
MAMLD1	X	150361422	150514178	N	.	N	N	0.187203344	63.63952075	0.840109495	20.3	DM	Hypospadias 2, X-linked, 300758 (3)
MAMSTR	19	48712742	48719721	N	Viable	N	Y	-0.212672702	34.75719164	0.001233258	63.9	.	.
MAN1A1	6	119177209	119349761	N	.	N	N	-0.292182226	29.87787232	0.803866877	21.5	.	.
MAN1B1	9	137086927	137109187	N	.	N	N	0.040166042	52.56699659	2.63E-06	80.7	DM	Mental retardation, autosomal recessive 15, 614202 (3)
MAN1C1	1	25617468	25786207	N	.	N	N	-0.623275987	16.07339237	0.04904804	47.1	.	.
MAN2A1	5	109689366	109869625	N	.	N	Y	-0.971834916	8.357932511	0.018644433	52	.	.
MAN2A2	15	90902218	90922584	N	.	N	Y	-0.912625941	9.341899635	3.61E-09	89.9	FTV	.
MAN2B1	19	12646511	12666742	N	.	N	Y	0.644400409	85.48937894	1.56E-12	95.1	DM	Mannosidosis, alpha-, types I and II, 248500 (3)
MAN2B2	4	6575175	6623362	N	Viable	N	Y	2.710165779	99.3227991	4.36E-18	98.2	.	.
MAN2C1	15	75355207	75368630	N	.	N	Y	-0.180951479	36.67303351	2.94E-25	99.4	.	.
MANBA	4	102631488	102760994	N	.	N	Y	0.07017815	54.90536551	1.15E-11	94.2	DM	Mannosidosis, beta, 248510 (3)
MANBAL	20	37289638	37317260	N	.	N	N	0.290033479	69.90218209	0.16924055	39.7	.	.
MANEA	6	95577543	95609457	N	.	N	N	0.622382754	84.82375412	0.000414997	67.6	.	.
MANEAL	1	37793802	37801137	N	.	N	N	0.430976902	77.46136482	0.004389044	58.7	.	.
MANF	3	51385047	51389397	N	.	N	N	0.207498734	64.86658563	0.327002524	35	.	.
MANSC1	12	12326056	12350541	N	.	N	N	0.524841114	81.43196157	0.000352736	68.2	DM?	.
MANSC4	12	27762738	27771276	N	.	N	N	.	.	.	.	.	.
MAOA	X	43654907	43746824	N	.	N	N	-0.121679336	40.63205418	0.993222491	9.1	DM	Brunner syndrome, 300615 (3)
MAOB	X	43766611	43882447	N	.	N	Y	0.169176254	62.44718412	0.970339617	13	DFP	.
MAP10	1	232804892	232808407	N	.	N	N	0.701714561	86.93060138	1.29E-14	96.6	.	.
MAP1A	15	43510958	43531620	N	.	N	N	-0.003641254	49.12311165	0.999688998	4.7	.	.
MAP1LC3A	20	34546854	34560345	N	.	N	N	-0.013918082	48.39381837	0.739731535	23.5	.	.
MAP1LC3B	16	87383995	87404779	N	.	N	Y	0.442010439	77.98228859	0.061760877	45.8	DM	.
MAP1LC3B2	12	116548105	116576448	N	.	N	N	0.534918128	81.86027667	0.023705685	50.8	.	.
MAP1LC3C	1	241995490	241999073	N	.	N	N	0.011461629	50.36754066	0.000381762	67.9	.	.
MAP1S	19	17719242	17734516	N	.	N	Y	-0.408255186	24.01458587	0.637852411	26.4	.	.
MAP2	2	209424058	209734118	N	.	N	Y	-2.0336989	1.568559356	0.999983365	2.7	DM	.
MAP2K2	19	4090321	4124129	N	.	N	Y	-0.209801572	34.94819702	0.863261159	19.4	DM	Cardiofaciocutaneous syndrome 4, 615280 (3)
MAP2K3	17	21284672	21315240	N	.	N	Y	1.682648711	97.85263645	0.000496053	67.1	DM	.
MAP2K6	17	69414698	69543331	N	.	N	Y	-0.214586899	34.6414308	0.951049684	14.6	.	.
MAP3K10	19	40191744	40215575	N	Viable	N	Y	-0.986309891	8.109046709	0.792721034	21.9	.	.
MAP3K13	3	185282941	185489097	N	.	N	N	-0.581785888	17.33518551	0.966849138	13.4	.	.
MAP3K14	17	45263121	45317040	N	.	N	Y	.	.	.	.	.	.
MAP3K15	X	19360056	19515261	N	.	N	N	.	.	1.01E-28	99.6	DM?	.
MAP3K19	2	134964491	135047468	N	.	N	N	0.88659089	90.87225792	3.70E-14	96.4	.	.
MAP3K2	2	127298730	127388465	N	.	N	Y	-0.616882625	16.28176188	0.999560917	5	.	.
MAP3K5	6	136557047	136792518	N	.	N	Y	-1.85860355	2.014238583	0.995107743	8.4	.	.
MAP3K6	1	27355184	27366892	N	.	N	Y	0.049887589	53.37732245	4.91E-15	96.9	.	.
MAP3K7CL	21	29077471	29175889	N	.	N	N	0.307908866	70.93824159	0.002265389	61.5	.	.
MAP3K8	10	30433937	30461833	Y	Viable	N	Y	-0.683454413	14.42958847	0.870951295	19	.	Lung cancer, somatic, 211980 (3)
MAP3K9	14	70722526	70809534	N	.	N	Y	-0.762682675	12.34589338	0.923395179	16.5	.	.
MAP4	3	47850690	48089272	N	.	N	N	-0.321748239	28.15882387	0.998848724	6.1	DM?	.
MAP4K1	19	38587641	38618882	N	.	N	Y	-0.274305776	31.04126874	0.991409179	9.6	.	.
MAP4K2	11	64784914	64803241	N	.	N	N	-0.15697692	38.23580483	6.48E-05	73.2	.	.
MAP4K3	2	39249266	39437312	N	.	N	N	-0.828587586	10.99149158	0.804701046	21.5	.	.
MAP4K5	14	50418501	50561126	N	.	N	Y	.	.	0.944269982	15.3	DP	.
MAP6D1	3	183815876	183825594	N	.	N	N	.	.	0.051828003	46.8	.	.
MAP7	6	136342281	136550819	N	.	N	N	0.490348861	80.10649997	0.929880602	16.1	.	.
MAP7D1	1	36155579	36180849	N	.	N	N	0.20412301	64.63506396	0.973584104	12.6	.	.
MAP7D2	X	20006713	20116917	N	.	N	N	0.313797733	71.32025236	0.555948305	28.5	.	.
MAP7D3	X	136213220	136256482	N	.	N	N	0.867426333	90.49603519	1.13E-07	86	DM?	.
MAP9	4	155342658	155376970	N	.	N	N	1.158152973	94.60554494	5.17E-12	94.6	.	.
MAPK10	4	86015123	86594131	N	.	N	Y	-0.392745948	24.81333565	0.834149756	20.5	DM	.
MAPK11	22	50263713	50270767	N	Viable	N	Y	-0.226721694	33.94107773	0.472036682	30.8	.	.
MAPK12	22	50245450	50261825	N	.	N	Y	0.734932275	87.72356312	0.013620058	53.6	.	.
MAPK13	6	36127809	36144524	N	.	N	Y	0.242443541	67.04288939	5.48E-07	83.6	.	.
MAPK15	8	143716259	143722458	N	.	N	N	1.735341783	98.00891358	1.29E-16	97.7	.	.
MAPK1IP1L	14	55051631	55070192	N	.	N	N	-0.379654309	25.47317243	0.389494276	33	.	.
MAPK3	16	30114105	30123506	N	.	N	Y	-0.678823093	14.52219714	0.409692328	32.5	DM?	.
MAPK4	18	50560078	50731824	N	.	N	Y	-0.634606635	15.80714244	0.319051501	35.2	.	.
MAPK8	10	48306639	48439360	N	.	N	Y	-0.537219736	18.72431556	0.983602118	11.2	.	.
MAPK8IP2	22	50600685	50613981	N	.	N	Y	.	.	0.99752478	7.2	.	.
MAPK9	5	180233143	180292099	N	.	N	Y	-0.322346967	28.12409562	0.009564338	55.1	.	.
MAPKAPK2	1	206684944	206734283	N	Viable	N	Y	0.146667159	60.78022805	0.996185445	7.9	DFP	.
MAPKAPK3	3	50611520	50649297	N	.	N	N	-0.505292472	19.99768478	2.71E-06	80.7	.	.
MAPKAPK5	12	111841978	111902238	N	.	N	Y	-0.037232312	46.79053076	0.023422603	50.9	.	.
MAPKBP1	15	41774434	41827855	N	Viable	N	Y	0.047169294	53.1631649	0.99902489	5.9	.	.
MAPRE1	20	32819893	32850405	N	.	N	N	-0.175157533	37.05504428	0.968087389	13.2	.	.
MAPRE2	18	34976928	35143470	N	.	N	N	-0.071071979	44.35376512	0.969644737	13	.	.
MAPRE3	2	26970612	27027196	N	.	N	Y	-0.435048161	22.94958616	0.799864407	21.7	.	.
MAPT	17	45894382	46028334	N	Viable	N	Y	0.355293324	73.71650171	4.68E-05	74.1	DM	Dementia, frontotemporal, with or without parkinsonism, 600274 (3); Pick disease, 172700 (3); Supranuclear palsy, progressive, 601104 (3); Supranuclear palsy, progressive atypical, 260540 (3); {Parkinson disease, susceptibility to}, 168600 (3)
MARC1	1	220786759	220819657	N	.	N	N	1.002191365	92.79388783	8.20E-05	72.5	.	.
MARC2	1	220748225	220784815	N	.	N	Y	0.675714658	86.31128089	0.032600703	49.3	.	.
MARCH1	4	163524298	164384050	N	.	N	Y	-0.205169667	35.16235458	0.218777255	38.1	.	.
MARCH10	17	62701314	62808344	N	.	N	N	1.02228461	93.07750188	3.45E-16	97.5	.	.
MARCH11	5	16067139	16180762	N	.	N	N	-0.025096816	47.5834925	0.002466243	61.2	.	.
MARCH2	19	8413270	8439017	N	.	N	N	-0.202298558	35.34178387	0.246993249	37.2	.	.
MARCH3	5	126867714	127030808	N	.	N	N	-0.476237287	21.18423337	0.636727871	26.4	.	.
MARCH4	2	216257865	216372027	N	.	N	N	-0.064373744	44.83996064	0.01625841	52.7	.	.
MARCH6	5	10353703	10440388	N	.	N	N	-1.343775714	4.369971639	0.999995976	2.1	.	.
MARCH7	2	159712457	159771027	N	.	N	N	-0.224504041	34.05105053	0.977026371	12.2	.	.
MARCH8	10	45454585	45594906	N	.	N	N	0.016245619	50.75533947	1.37E-05	77.2	DP	.
MARCH9	12	57755098	57760407	N	.	N	Y	0.110914976	58.05984835	0.350280136	34.2	.	.
MARCO	2	118942166	118994660	N	.	N	Y	1.054057623	93.41899635	6.42E-08	86.7	.	.
MARK1	1	220528183	220664461	N	.	N	N	-0.601723109	16.6579846	0.990825676	9.8	.	.
MARK4	19	45079288	45305283	N	.	N	N	-0.714271963	13.55559414	0.999932136	3.5	.	.
MARS	12	57475445	57517569	N	.	N	N	-0.269372985	31.29594258	2.74E-12	94.9	DM	Interstitial lung and liver disease, 615486 (3); Charcot-Marie-Tooth disease, axonal, type 2U, 616280 (3)
MARS2	2	197705369	197708387	N	.	N	N	-0.326827012	27.93309024	1.42E-06	82	DM	Spastic ataxia 3, autosomal recessive, 611390 (3); ?Combined oxidative phosphorylation deficiency 25, 616430 (3)
MARVELD1	10	97713173	97718152	N	.	N	N	.	.	.	.	.	.
MARVELD2	5	69415112	69444330	N	Viable	N	Y	0.492109495	80.16438039	4.23E-11	93.5	DM	Deafness, autosomal recessive 49, 610153 (3)
MARVELD3	16	71626161	71642114	N	.	N	N	-0.677712298	14.56850148	0.000303794	68.6	.	.
MAS1	6	159906690	159916530	N	Viable	N	Y	-0.032448102	47.13781328	0.000870823	65.2	.	.
MAS1L	6	29486697	29487956	N	.	N	N	0.278045399	69.20761706	0.000466206	67.2	.	.
MASP2	1	11026523	11047233	N	.	N	Y	0.855292023	90.29924177	1.58E-14	96.6	DFP	MASP2 deficiency, 613791 (3)
MAST1	19	12833951	12874951	N	.	N	N	-2.279906232	1.169184465	0.999999024	1.7	.	.
MAST2	1	45786987	46036124	N	.	N	Y	-0.651503821	15.34988713	5.44E-11	93.3	.	.
MAST3	19	18097793	18151692	N	.	N	N	-1.313474725	4.636221566	0.998925261	6	.	.
MAST4	5	66596361	67169595	N	.	N	N	-1.233954275	5.267118134	0.008130239	55.8	FTV	.
MAT1A	10	80271820	80289684	N	.	N	Y	-0.617839926	16.24124559	0.754129518	23	DM	Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 (3); Methionine adenosyltransferase deficiency, autosomal recessive, 250850 (3)
MAT2B	5	163503114	163519336	N	.	N	N	-0.189206557	36.19841408	0.252497397	37	.	.
MATK	19	3777970	3802129	N	.	N	Y	-1.215250083	5.434971349	0.000234673	69.3	.	.
MATN1	1	30711277	30723587	N	.	N	Y	0.199338946	64.3514499	0.005273986	57.9	.	.
MATN2	8	97868840	98036716	N	.	N	Y	1.438997274	96.63714765	7.29E-09	89.3	.	.
MATN3	2	19992111	20012694	N	.	N	Y	0.513511574	81.03837472	1.61E-06	81.7	DM	Epiphyseal dysplasia, multiple, 5, 607078 (3); {Osteoarthritis susceptibility 2}, 140600 (3); Spondyloepimetaphyseal dysplasia, 608728 (3)
MATN4	20	45293445	45308529	N	.	N	N	0.655418603	85.80193321	9.70E-05	72	.	.
MATR3	5	139273752	139331677	N	.	N	N	-1.466714554	3.530705562	0.999818898	4.2	DM	Amyotrophic lateral sclerosis 21, 606070 (3)
MAU2	19	19320681	19358755	N	.	N	N	-1.145954475	6.100596168	0.999717755	4.6	.	.
MAVS	20	3846799	3876123	N	.	N	Y	0.35705406	73.80911038	1.77E-07	85.3	DFP	.
MAZ	16	29806106	29811164	N	.	N	N	-0.69830864	13.97233316	0.953969622	14.4	.	.
MB21D1	6	73413515	73452276	N	.	N	Y	0.407510974	76.22851189	2.61E-05	75.5	.	.
MB21D2	3	192796815	192918161	N	.	N	N	0.068917845	54.82433293	0.385737571	33.1	.	.
MBD1	18	50266882	50281774	N	.	N	Y	-1.134471937	6.204780923	0.959615951	14	DM	.
MBD2	18	54151601	54224788	N	.	N	Y	-0.402163571	24.28662384	0.989310018	10.1	.	.
MBD3L1	19	8832398	8843340	N	.	N	Y	0.308865253	70.99612201	1.30E-05	77.3	.	.
MBD3L2	19	7049321	7051735	N	.	N	Y	.	.	.	.	.	.
MBD3L3	19	7056209	7058640	N	.	N	N	.	.	0.208438986	38.5	.	.
MBD3L4	19	7037748	7040179	N	.	N	N	.	.	.	.	.	.
MBD3L5	19	7030577	7033011	N	.	N	N	.	.	.	.	.	.
MBIP	14	36298558	36320676	N	.	N	N	-0.344856099	27.00700353	2.40E-05	75.8	.	.
MBL2	10	52765380	52771700	N	.	N	N	0.811732769	89.36736702	0.000741512	65.8	DFP	{Chronic infections, due to MBL deficiency}, 614372 (3)
MBLAC1	7	100126694	100128498	N	.	N	N	.	.	0.313958463	35.3	.	.
MBLAC2	5	90458203	90474768	N	.	N	N	-0.085121135	43.16142849	0.0002801	68.9	.	.
MBNL1	3	152243828	152465780	N	.	N	Y	-0.384285668	25.21271054	0.981577652	11.5	DP	.
MBNL3	X	132369317	132489968	N	.	N	N	0.029338097	51.71036638	0.833044766	20.5	.	.
MBOAT1	6	20102145	20212399	N	.	N	N	0.095253943	5.68E+01	8.84E-07	82.7	.	.
MBOAT2	2	8852690	9003813	N	.	N	N	0.156083554	61.48058112	0.71697038	24.2	.	.
MBOAT4	8	30131824	30144686	N	.	N	Y	.	.	.	.	.	.
MBP	18	76978827	77133683	N	.	N	Y	0.406554426	76.19378364	0.568470954	28.3	.	.
MBTPS2	X	21839636	21885424	N	.	N	N	-0.03818917	46.70949818	0.940199322	15.6	DM	IFAP syndrome with or without BRESHECK syndrome, 308205 (3); Keratosis follicularis spinulosa decalvans, X-linked, 308800 (3); ?Olmsted syndrome, X-linked, 300918 (3)
MC1R	16	89912119	89920977	N	.	N	Y	1.448093241	96.69502807	3.25E-07	84.4	DM	[Skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3); [Skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3); [Analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3); {UV-induced skin damage}, 266300 (3); {Albinism, oculocutaneous, type II, modifier of}, 203200 (3); {Melanoma, cutaneous malignant, 5}, 613099 (3)
MC3R	20	56248732	56249815	N	.	N	Y	-0.213476698	34.71088731	0.00136038	63.5	DM	{Obesity, severe, susceptibility to, BMIQ9}, 602025 (3); {Mycobacterium tuberculosis, protection against}, 607948 (3)
MC4R	18	60371110	60372775	N	.	N	Y	-0.205016781	35.17393066	1.54E-05	77	DM	Obesity, autosomal dominant, 601665 (3)
MC5R	18	13824155	13826743	N	.	N	Y	-0.343899023	27.05330787	0.001088314	64.4	.	.
MCAM	11	119308529	119321521	N	Viable	N	Y	-0.404577762	24.14771083	0.054753129	46.4	.	.
MCAT	22	43132206	43143394	N	.	N	N	-0.092471964	42.67523297	0.000123488	71.3	.	.
MCC	5	113022099	113488830	N	.	N	N	0.42233778	76.92886496	2.26E-08	88	.	Colorectal cancer, somatic, 114500 (3)
MCCC1	3	183015218	183116075	N	.	N	N	0.261428632	68.11367714	2.51E-05	75.6	DM	3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3)
MCCC2	5	71587288	71658704	N	.	N	N	-0.185226508	36.44151184	4.09E-08	87.3	DM	3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3)
MCCD1	6	31528717	31530232	N	.	N	N	0.714044409	87.24894368	0.008963094	55.3	.	.
MCEE	2	71109684	71130239	N	.	N	N	0.398903333	75.78283267	0.00211926	61.7	DM	Methylmalonyl-CoA epimerase deficiency, 251120 (3)
MCEMP1	19	7676628	7679826	N	.	N	N	.	.	.	.	.	.
MCF2	X	139581770	139708227	N	.	N	Y	0.32321436	71.96272501	0.943290929	15.4	DM?	.
MCF2L	13	112894378	113099739	N	.	N	Y	-0.51779174	19.52885339	0.795541404	21.8	.	.
MCF2L2	3	183178043	183428778	N	.	N	N	-0.892156428	9.735486485	1.61E-12	95.1	DP	.
MCFD2	2	46901870	46941855	N	.	N	N	-0.20053791	35.44596863	0.069991235	45.1	DM	Factor V and factor VIII, combined deficiency of, 613625 (3)
MCHR1	22	40678750	40682814	N	.	N	Y	-0.479758918	21.01638016	0.001148393	64.2	DM	.
MCHR2	6	99919910	99994247	N	.	N	N	-0.617839926	16.24124559	3.50E-05	74.8	.	.
MCIDAS	5	55219614	55227315	N	.	N	N	.	.	.	.	.	.
MCM8	20	5950652	5998977	N	.	N	Y	1.192156784	94.9586155	1.93E-10	92.5	DP	?Premature ovarian failure 10, 612885 (3)
MCMBP	10	119829404	119892556	N	.	N	N	-1.263144718	5.024020374	0.998215055	6.8	.	.
MCMDC2	8	66870749	66922048	N	.	N	N	0.108346305	57.8862071	5.69E-06	79.3	.	.
MCOLN1	19	7522626	7534009	N	.	N	Y	-0.097909737	42.2237657	0.037055973	48.7	DM	Mucolipidosis IV, 252650 (3)
MCOLN2	1	84925583	84997113	N	.	N	N	0.05214974	53.52781154	1.32E-10	92.8	.	.
MCTP1	5	94703741	95284575	N	.	N	N	-1.261083769	5.0413845	0.009889118	55	.	.
MCTP2	15	94231538	94483952	N	.	N	N	0.627639564	84.9858193	7.93E-41	99.9	.	.
MCTS1	X	120594010	120621074	N	.	N	N	0.340643524	72.9003878	0.825030346	20.8	.	.
MCUR1	6	13786557	13814568	N	.	N	N	-0.151691433	38.58887538	0.001563031	62.9	.	.
MDC1	6	30699807	30717889	N	.	N	N	2.164344673	98.80187533	0.000941847	65	.	.
MDFIC	7	114922154	115019916	N	.	N	N	0.584718507	83.67193378	.	.	.	.
MDGA1	6	37630679	37699306	N	.	N	Y	-0.661600048	14.99102854	0.995236957	8.3	.	.
MDGA2	14	46839629	47674954	N	.	N	N	-0.370888658	25.82624298	0.993216871	9.1	.	.
MDH1B	2	206737763	206765547	N	.	N	N	0.32321436	71.96272501	5.81E-12	94.6	.	.
MDH2	7	76048051	76067508	N	.	N	N	-0.001479352	49.31411703	0.177605136	39.4	.	.
MDM1	12	68272443	68332381	N	.	N	N	0.065393747	54.58702321	5.78E-08	86.8	.	.
MDP1	14	24213937	24216070	N	Viable	N	Y	-0.01663693	48.16808474	0.001526159	62.9	.	.
MDS2	1	23581495	23640568	N	.	N	N	.	.	0.042965573	47.9	.	.
ME1	6	83210389	83431071	N	.	N	N	-0.076357581	43.94860219	2.22E-10	92.3	.	.
ME2	18	50879049	50954257	N	.	N	N	-0.006111899	49.02471494	1.17E-07	86	.	.
ME3	11	86441108	86672636	N	.	N	N	-0.766795331	12.27643688	1.14E-05	77.7	.	.
MEA1	6	43012094	43013968	N	.	N	N	0.194405525	64.08519998	0.043401233	47.8	.	.
MEAF6	1	37492575	37514774	N	.	N	N	0.078989305	55.61150663	0.730388139	23.8	.	.
MED10	5	6371881	6378594	N	.	N	N	0.009548021	50.25756786	0.039721058	48.3	.	.
MED12L	3	151085697	151437072	N	.	N	N	-3.418409083	0.416739017	0.999999276	1.6	.	.
MED13	17	61942605	62065282	N	.	N	N	-2.754578727	0.752445448	1	0.4	DM	.
MED13L	12	115953872	116277338	N	.	N	N	-1.695895722	2.471493894	0.999999999	0.6	DM	Transposition of the great arteries, dextro-looped 1, 608808 (3)
MED14	X	40648306	40735858	N	.	N	N	-0.247164145	32.62140418	0.999999382	1.6	.	.
MED15	22	20495913	20587632	N	.	N	N	-0.618493002	16.2296695	0.960808623	13.9	.	.
MED16	19	867630	893218	N	.	N	N	-2.245968758	1.221276842	0.018766118	52	.	.
MED17	11	93784227	93814695	N	.	N	N	-0.906641191	9.463448515	3.89E-06	80.1	DM	Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3)
MED18	1	28329002	28335967	N	.	N	Y	-0.117047237	40.96776061	0.000448334	67.3	.	.
MED19	11	57703714	57712221	N	.	N	N	-0.142427542	39.22555999	0.683790051	25.1	.	.
MED20	6	41905354	41921139	N	.	N	N	-0.199580796	35.52700122	0.488942721	30.3	DM	.
MED26	19	16574907	16629062	N	.	N	N	-0.904579196	9.492388725	0.948549942	14.9	.	.
MED27	9	131860107	132079908	N	.	N	N	-0.219218665	34.36360479	0.003604247	59.5	.	.
MED29	19	39391303	39400637	N	.	N	N	0.295771879	70.24367656	0.001012258	64.7	.	.
MED4	13	48053323	48095131	N	.	N	N	-0.03818917	46.70949818	0.061620028	45.8	.	.
MED6	14	70581257	70600690	N	.	N	N	-0.335593115	27.47004688	0.01496795	53.2	.	.
MED7	5	157137412	157159019	N	.	N	N	0.118418051	58.60971233	0.215739811	38.2	.	.
MED8	1	43383917	43389808	N	.	N	N	0.006828994	50.02025815	8.16E-06	78.6	.	.
MED9	17	17476986	17493226	N	.	N	N	-0.027967398	47.43300341	0.315748749	35.3	.	.
MEDAG	13	30906191	30925572	N	Viable	N	Y	0.121288029	58.8122938	0.000667054	66.2	.	.
MEF2B	19	19145568	19170289	N	.	N	N	-0.377739799	25.58314522	0.590447263	27.7	.	.
MEF2BNB	19	19176903	19192591	N	.	N	N	.	.	.	.	.	.
MEF2BNB-MEF2B	19	19145567	19192158	N	.	N	N	-0.377739799	25.58314522	0.247287511	37.2	.	.
MEF2D	1	156463727	156500828	N	.	N	N	-0.697503755	14.01863749	0.998547093	6.5	.	.
MEGF10	5	127290831	127465737	N	.	N	Y	-1.440924885	3.727498987	0.994324945	8.7	DM	Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 (3); Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 (3)
MEGF11	15	65895079	66253747	N	.	N	Y	0.649830009	85.61092782	2.52E-24	99.3	DM?	.
MEGF6	1	3489920	3611495	N	.	N	N	3.235020455	99.62377728	4.42E-15	96.9	.	.
MEGF9	9	120600813	120714470	N	.	N	N	0.157040256	61.54424958	0.921919105	16.6	.	.
MEI1	22	41699499	41799456	N	.	N	N	-0.902389918	9.527116976	1.22E-08	88.7	.	.
MEI4	6	77690658	77926974	N	.	N	Y	.	.	.	.	.	.
MEIG1	10	14959439	14988050	N	.	N	Y	0.388531503	75.30242519	0.053173799	46.7	.	.
MEIKIN	5	131806993	131945698	N	.	N	N	.	.	.	.	.	.
MEIOB	16	1833983	1884294	N	.	N	Y	.	.	9.45E-07	82.6	.	.
MEIS2	15	36889204	37101299	N	.	N	N	-0.434892888	22.97273832	0.994254955	8.7	DM?	.
MEIS3	19	47403124	47419523	N	.	N	N	0.499461757	80.4422064	0.000113443	71.4	.	.
MELK	9	36572862	36677683	N	.	N	N	-0.392441253	24.83648782	1.87E-08	88.2	.	.
MEOX1	17	43640388	43661954	N	.	N	N	1.169188195	94.73288187	0.065397404	45.5	DM	Klippel-Feil syndrome 2, 214300 (3)
MEP1A	6	46793390	46839782	N	.	N	Y	-0.234727022	33.37963767	5.77E-07	83.5	.	.
MEPCE	7	100428790	100434126	N	.	N	N	-0.626146471	15.99814783	0.996809252	7.6	.	.
MEPE	4	87821411	87846817	N	.	N	Y	0.828799349	89.74937779	0.362907709	33.8	.	.
MERTK	2	111898479	112029561	N	.	N	Y	-0.248628289	32.52879551	9.66E-08	86.1	DM	Retinitis pigmentosa 38, 613862 (3)
MESDC1	15	81000944	81005788	N	.	N	N	-0.252102165	32.32621404	0.683511246	25.1	.	.
MESDC2	15	80946289	80989878	N	.	N	Y	-0.014723262	48.28963362	0.846200196	20	DM?	.
METAP1	4	98995620	99062813	N	.	N	N	-0.177071645	36.92770736	0.043547683	47.8	.	.
METAP1D	2	171999583	172082430	N	.	N	N	0.170132915	62.53400475	1.56E-06	81.9	.	.
METRN	16	715115	719655	N	.	N	N	.	.	0.081804436	44.3	.	.
METRNL	17	83079691	83095119	N	.	N	N	0.025662211	51.48463275	0.860216826	19.5	.	.
METTL1	12	57768471	57772793	N	.	N	N	-0.618797287	16.21230538	0.005915617	57.3	DFP	.
METTL10	10	124748149	124791870	N	.	N	N	0.367934269	74.27215373	0.371286245	33.6	.	.
METTL11B	1	170146001	170167790	N	.	N	N	.	.	.	.	.	.
METTL12	11	62665309	62668496	N	.	N	N	0.654160748	85.75562887	0.009460264	55.2	.	.
METTL13	1	171781664	171814023	N	.	N	N	-0.868973906	10.21010592	0.00133198	63.6	.	.
METTL14	4	118685368	118715433	N	.	N	N	-0.103802501	41.88805927	0.847165775	20	DM?	.
METTL15	11	28108248	28333507	N	.	N	N	0.185138978	63.52375991	0.000155431	70.5	.	.
METTL17	14	20989770	20997035	N	.	N	N	0.21625851	65.43381374	5.78E-08	86.8	.	.
METTL18	1	169792529	169794966	N	.	N	N	0.185138978	63.52375991	0.028935054	49.9	.	.
METTL20	12	31647160	31673114	N	Viable	N	Y	0.689765371	86.64698732	5.20E-05	73.8	.	.
METTL21A	2	207580631	207625928	N	.	N	N	0.461797774	78.90258725	0.052177654	46.8	.	.
METTL21B	12	57771492	57782798	N	.	N	N	0.045300934	53.00688777	0.00509294	58	.	.
METTL21C	13	102685744	102694504	N	.	N	N	0.533151945	81.77345604	3.55E-06	80.2	.	.
METTL22	16	8621683	8649654	N	.	N	N	0.797023952	89.13584534	3.96E-08	87.3	.	.
METTL23	17	76726830	76733936	N	.	N	N	0.195362073	64.12571627	0.113237609	42.5	.	Mental retardation, autosomal recessive 44, 615942 (3)
METTL24	6	110245928	110358272	N	.	N	Y	0.364256447	74.10430052	0.012714482	54	.	.
METTL25	12	82358497	82479236	N	.	N	N	-0.338006426	27.36007409	1.65E-07	85.5	.	.
METTL2A	17	62423867	62450822	N	.	N	N	0.375585437	74.723621	1.77E-05	76.6	.	.
METTL2B	7	128476729	128506602	N	.	N	N	0.644892524	85.51253111	0.082709098	44.2	.	.
METTL3	14	21498133	21511375	N	.	N	N	-0.031491274	47.21884586	0.001004965	64.7	.	.
METTL4	18	2537525	2571509	N	.	N	N	-0.059589522	45.15830295	2.55E-05	75.6	.	.
METTL5	2	169810081	169824931	N	.	N	N	-0.001630854	49.29675291	0.003672715	59.4	.	.
METTL6	3	15381275	15440566	N	.	N	N	-0.31116943	28.88232911	0.000603418	66.5	.	.
METTL7A	12	50923472	50932517	N	.	N	N	-0.150734446	38.66411993	0.005518765	57.7	.	.
METTL7B	12	55681546	55684611	N	Viable	N	Y	0.530283168	81.66927129	0.522330681	29.4	.	.
METTL8	2	171317405	171434802	N	.	N	N	.	.	1.44E-09	90.8	FTV	.
METTL9	16	21597218	21657473	N	.	N	N	-0.26151962	31.75319789	0.377292455	33.4	.	.
MEX3A	1	156072013	156081998	N	.	N	N	-0.523170861	19.29733171	0.881462711	18.5	.	.
MEX3B	15	82041778	82046141	N	.	N	N	-1.200242224	5.573884355	0.201034761	38.7	.	.
MEX3D	19	1554669	1568058	N	.	N	N	.	.	.	.	.	.
MFAP1	15	43804492	43824802	N	.	N	N	-0.512795604	19.70249465	0.986958817	10.6	.	.
MFAP2	1	16974502	16980835	N	.	N	Y	0.163436574	62.02465706	0.000124328	71.2	.	.
MFAP3	5	154038906	154220478	N	.	N	N	0.209561389	65.04601493	0.008444779	55.6	.	.
MFAP3L	4	169986597	170033031	N	.	N	N	0.013526612	50.54118192	0.910529966	17.3	.	.
MFAP4	17	19383442	19387240	N	Viable	N	Y	-0.251145013	32.40145859	0.559557122	28.4	.	.
MFAP5	12	8637346	8662888	N	.	N	Y	0.058393523	53.97927881	0.348683723	34.2	.	Aortic aneurysm, familial thoracic 9, 616166 (3)
MFF	2	227325151	227357836	N	.	N	N	0.284591847	69.63014412	0.375813389	33.5	DM	.
MFGE8	15	88898683	88913411	N	.	N	Y	0.002347879	49.66139955	0.000594282	66.5	DM	.
MFHAS1	8	8783354	8893645	N	.	N	N	-2.045185428	1.551195231	2.23E-05	75.9	.	Malignant fibrous histiocytoma (2)
MFI2	3	196988621	197029816	N	.	N	N	1.350866236	96.11622388	7.71E-12	94.4	DP	.
MFNG	22	37469063	37486401	N	.	N	Y	0.112978986	58.22191353	1.32E-07	85.8	.	.
MFRP	11	119341168	119346673	N	.	N	Y	-0.539634949	18.59697864	5.34E-08	86.9	DM	Microphthalmia, isolated 5, 611040 (3); Nanophthalmos 2, 609549 (3)
MFSD1	3	158732198	158829719	N	.	N	N	-0.694632616	14.11703421	1.02E-09	91.1	.	.
MFSD10	4	2930561	2934859	N	.	N	N	0.042733143	52.78694218	3.02E-07	84.5	.	.
MFSD11	17	76735865	76781449	N	.	N	N	-0.52397308	19.2683915	0.004532282	58.6	.	.
MFSD12	19	3538261	3574290	N	.	N	N	0.343158802	73.0393008	1.07E-09	91.1	.	.
MFSD2B	2	24010081	24063321	N	.	N	N	0.633712862	85.17103664	1.76E-07	85.3	.	.
MFSD3	8	144509074	144511213	N	.	N	N	0.330566867	72.36788794	2.02E-08	88.1	.	.
MFSD4	1	205568885	205602918	N	.	N	N	-0.462034049	21.80355386	0.009988657	54.9	.	.
MFSD5	12	53251251	53254405	N	.	N	N	-0.513598872	19.67934248	0.102466255	42.9	.	.
MFSD6	2	190408355	190509205	N	.	N	N	-0.277981954	30.72871448	0.001846694	62.2	.	.
MFSD6L	17	8797162	8799349	N	.	N	N	1.035376388	93.2048388	2.40E-08	87.9	DM	.
MFSD7	4	681829	689441	N	.	N	N	0.146012849	60.7049835	2.76E-12	94.9	.	.
MFSD8	4	127917805	127965995	N	Viable	N	Y	-0.194643158	35.86849569	4.67E-06	79.7	DM	Ceroid lipofuscinosis, neuronal, 7, 610951 (3); Macular dystrophy with central cone involvement, 616170 (3)
MFSD9	2	102715840	102736888	N	.	N	N	1.062518565	93.53475719	7.72E-06	78.7	.	.
MGA	15	41621224	41773081	N	.	N	N	-2.280382886	1.163396423	1	0.5	.	.
MGAM	7	141907813	142106747	N	.	N	Y	1.583741836	97.40116918	1.55E-23	99.2	.	.
MGAM2	7	142111749	142222324	N	.	N	N	.	.	.	.	.	.
MGARP	4	139266163	139280338	N	.	N	N	0.304231467	70.75881229	0.023824158	50.7	.	.
MGAT3	22	39457344	39492194	N	.	N	Y	0.061414866	54.25131678	0.460179519	31.1	.	.
MGAT4A	2	98619106	98731126	N	.	N	Y	0.051041541	53.45835504	0.059816175	46	.	.
MGAT4B	5	179797597	179806952	N	.	N	Y	0.433998674	77.57133762	0.813383751	21.2	.	.
MGAT4C	12	85955666	86838904	N	.	N	N	0.185138978	63.52375991	0.011169053	54.5	DM	.
MGAT4D	4	140442262	140498377	N	Viable	N	Y	.	.	.	.	.	.
MGAT5	2	134119983	134454621	N	.	N	Y	-0.753702167	12.50217052	0.999925017	3.5	.	.
MGAT5B	17	76868456	76950393	N	.	N	Y	-0.876332924	10.01910054	0.126104149	41.7	.	.
MGLL	3	127689062	127823250	N	.	N	Y	-0.104759418	41.81281472	0.00459891	58.5	DM	.
MGME1	20	17968913	17991122	N	.	N	N	0.222654188	65.80424842	0.003614328	59.5	DM	Mitochondrial DNA depletion syndrome 11, 615084 (3)
MGMT	10	129467184	129768007	N	.	N	Y	0.054717474	53.7014528	9.21E-09	89	DFP	.
MGP	12	14881181	14885926	N	.	N	Y	0.617455056	84.68484112	0.006728334	56.8	DM	Keutel syndrome, 245150 (3)
MGST1	12	16347142	16609259	N	.	N	N	0.12592113	59.20588065	0.014028944	53.5	.	.
MGST2	4	139665768	139740745	N	.	N	N	0.254430455	67.72009029	0.055150566	46.4	DM	.
MGST3	1	165630861	165661796	N	Viable	N	Y	0.063983137	54.4886265	0.007153041	56.5	DM	.
MIA	19	40771648	40777490	N	.	N	Y	0.169983117	62.51085258	0.00695373	56.6	.	.
MIA2	14	39230231	39253655	N	.	N	N	0.825123308	89.64519303	0.00020882	69.7	.	.
MIA-RAB4B	19	40771648	40786685	N	.	N	N	.	.	.	.	.	.
MICA	6	31399784	31415315	N	.	N	N	1.881317108	98.37356022	0.00037802	68	DM	.
MICAL1	6	109444062	109465968	N	.	N	N	0.385779118	75.18087631	2.55E-12	94.9	.	.
MICAL2	11	12094008	12263789	N	.	N	N	0.754404924	88.18660647	0.132223746	41.5	.	.
MICAL3	22	17787649	18024559	N	.	N	N	0.149015084	60.9249291	0.999997948	2	DM?	.
MICALCL	11	12276080	12359144	N	.	N	N	2.046890196	98.63981015	5.42E-16	97.4	DM?	.
MICALL1	22	37905657	37942822	N	.	N	N	-0.336093267	27.44110667	0.000381389	67.9	.	.
MICALL2	7	1428465	1459502	N	.	N	N	2.439489764	99.13758176	7.76E-17	97.7	.	.
MICB	6	31494881	31511124	N	.	N	N	0.521971277	81.33356486	0.000284377	68.8	DFP	.
MICU1	10	72367327	72626191	N	.	N	N	0.019116005	51.00422527	1.68E-10	92.6	.	Myopathy with extrapyramidal signs, 615673 (3)
MICU2	13	21492691	21604214	N	.	N	N	0.28091539	69.36968224	2.60E-13	95.8	.	.
MICU3	8	17027238	17122644	N	.	N	N	0.12989848	59.41425016	3.12E-06	80.5	.	.
MID1	X	10445310	10833654	N	.	N	Y	-0.577452276	17.42779418	0.500724578	29.9	DM	Opitz GBBB syndrome, type I, 300000 (3)
MID1IP1	X	38801432	38806537	N	Viable	N	Y	-0.026053671	47.51982404	0.489439187	30.3	.	.
MID2	X	107825755	107927193	N	.	N	Y	-0.228482701	33.83110494	0.985076414	10.9	.	?Mental retardation, X-linked 101, 300928 (3)
MIDN	19	1248553	1259140	N	.	N	N	-0.312777691	28.73184002	0.049062651	47.1	.	.
MIEF1	22	39499432	39518132	N	.	N	N	-0.066135668	44.67789547	0.062893833	45.7	.	.
MIEF2	17	18260534	18266552	N	.	N	N	0.489238883	80.06598368	0.077014522	44.6	.	.
MIEN1	17	39728496	39730787	N	.	N	N	0.061112993	54.1992244	0.773016773	22.5	.	.
MIER1	1	66924895	66988619	N	.	N	Y	0.031402963	51.9476761	0.966295466	13.4	.	.
MIER2	19	301444	344807	N	.	N	N	0.425538583	77.11987035	0.977262863	12.1	.	.
MIER3	5	56919602	56971675	N	.	N	N	-0.706921447	13.72344736	0.99921643	5.6	.	.
MIF	22	23894004	23895227	N	.	N	Y	.	.	0.032484223	49.3	DFP	{Rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3)
MIF4GD	17	75266228	75271227	N	.	N	N	-0.627257916	15.94605545	3.58E-05	74.8	.	.
MIIP	1	12019466	12032045	N	.	N	N	1.209723165	95.11489263	1.96E-15	97.1	DFP	.
MILR1	17	64449037	64468643	N	.	N	Y	.	.	.	.	.	.
MINA	3	97941818	97972457	N	.	N	Y	0.700285457	8.69E+01	1.58E-05	76.9	.	.
MINK1	17	4833388	4898061	N	.	N	N	-1.48430348	3.443884934	0.999984022	2.7	.	.
MINOS1	1	19596977	19629821	N	.	N	N	0.069572814	54.86484922	0.348880395	34.2	.	.
MINOS1-NBL1	1	19596979	19658056	N	.	N	N	.	.	0.068107983	45.2	.	.
MINPP1	10	87504875	87553460	N	.	N	Y	-0.742523485	12.81472478	0.454406267	31.3	DM	Thyroid carcinoma, follicular, 188470 (3)
MIOS	7	7566872	7608929	N	.	N	N	-1.336125667	4.439428141	0.001435669	63.2	.	.
MIOX	22	50486784	50490648	N	.	N	N	0.956359059	92.12247497	4.60E-12	94.7	.	.
MIP	12	56449502	56469166	N	.	N	N	-0.039146033	46.66319384	0.677914765	25.2	DM	Cataract 15, multiple types, 615274 (3)
MIPEP	13	23730189	23889419	N	.	N	N	0.934957546	91.80413266	8.49E-07	82.8	.	.
MIPOL1	14	37197913	37552361	N	Viable	N	Y	-0.803507355	11.4776871	6.82E-06	79	DM	.
MIS12	17	5486285	5490814	N	.	N	N	-0.055108985	45.45349308	0.020597647	51.5	.	.
MIS18BP1	14	45203190	45253540	N	.	N	N	-0.400605488	24.37344446	2.30E-05	75.9	.	.
MISP	19	751126	764318	N	.	N	N	1.417444011	96.46929444	1.95E-10	92.5	.	.
MITD1	2	99161427	99181058	N	.	N	N	-0.100127206	42.09064074	0.00170794	62.5	.	.
MKI67	10	128096659	128126385	N	.	N	N	2.95700911	99.50801644	4.17E-16	97.5	.	.
MKLN1	7	131110096	131496636	N	.	N	N	-0.179637179	36.77143023	0.999577505	5	.	.
MKNK1	1	46557408	46616843	N	.	N	Y	-0.160955729	37.95219077	0.000222399	69.5	.	.
MKNK2	19	2037465	2051244	N	.	N	Y	0.00602363	49.96237773	9.34E-06	78.2	.	.
MKRN1	7	140453040	140479569	N	.	N	N	-0.199427635	35.53278926	0.979423651	11.8	.	.
MKRN2	3	12557014	12583713	N	Viable	N	Y	-0.212519778	34.79191989	0.407628906	32.6	.	.
MKRN2OS	3	12514934	12561059	N	.	N	N	.	.	.	.	.	.
MKRN3	15	23565678	23630075	N	.	N	N	-0.827779211	10.99727962	0.023577506	50.8	DM	Precocious puberty, central, 2, 615346 (3)
MKX	10	27672875	27746060	N	.	N	Y	0.626060077	84.945303	0.882320086	18.5	.	.
MLANA	9	5890802	5910606	N	.	N	Y	0.321002544	71.81802396	1.08E-08	88.8	.	.
MLC1	22	50059391	50085902	N	Viable	N	Y	0.356902595	73.80332234	5.03E-05	73.9	DM	Megalencephalic leukoencephalopathy with subcortical cysts, 604004 (3)
MLEC	12	120686869	120701864	N	.	N	Y	-0.184574695	36.47624009	0.470920638	30.8	.	.
MLF1	3	158571163	158607252	N	.	N	N	0.44774765	78.23696244	1.28E-06	82.2	.	Leukemia, acute myeloid, 601626 (1)
MLF2	12	6747996	6767475	N	.	N	N	0.013375229	50.50645367	0.921484672	16.6	.	.
MLH1	3	36993332	37050918	Y	Viable	N	Y	-0.228180536	33.84846906	0.739578311	23.5	DM	Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3); Mismatch repair cancer syndrome, 276300 (3); Muir-Torre syndrome, 158320 (3)
MLH3	14	75013764	75051532	N	.	N	Y	0.862332525	90.40921456	0.000425002	67.6	DM	Colorectal cancer, somatic, 114500 (3); Colorectal cancer, hereditary nonpolyposis, type 7, 614385 (3); {Endometrial cancer, susceptibility to}, 608089 (3)
MLIP	6	53929982	54266280	N	.	N	N	.	.	1.02E-11	94.3	.	.
MLK4	1	233327768	233385148	N	.	N	N	.	.	0.000607299	66.4	.	.
MLKL	16	74671855	74700960	N	.	N	Y	1.046553959	93.33217572	7.48E-14	96.2	.	.
MLLT10	10	21524675	21743630	N	.	N	N	-1.447601781	3.686982694	0.999583699	5	.	.
MLLT11	1	151057758	151068497	N	.	N	N	0.001088113	49.55142675	0.473311552	30.7	.	Leukemia, acute myelomonocytic, somatic, somatic 607785 (3)
MLLT6	17	38705542	38729803	N	.	N	N	-0.833222965	10.92782312	0.998762157	6.2	.	.
MLN	6	33794673	33804011	N	.	N	N	0.297536667	70.34207328	0.001658574	62.6	.	.
MLNR	13	49220338	49222377	N	.	N	N	0.175722654	62.91601551	0.046587675	47.4	.	.
MLX	17	42567068	42573239	N	.	N	N	-0.4706489	21.39260288	0.469292432	30.9	.	.
MLXIP	12	122078722	122147347	N	.	N	N	.	.	0.975747589	12.3	.	.
MLXIPL	7	73593194	73624543	N	.	N	Y	-0.175809925	37.02031603	0.676823094	25.3	DM	.
MLYCD	16	83899126	83927026	N	.	N	Y	0.065242053	54.58123517	0.000280848	68.8	DM	Malonyl-CoA decarboxylase deficiency, 248360 (3)
MMAA	4	145618263	145660035	N	.	N	N	-0.63939225	15.70295769	0.003181808	60.1	DM	Methylmalonic aciduria, vitamin B12-responsive, 251100 (3)
MMAB	12	109553737	109573874	N	.	N	N	0.274219089	68.94136714	0.00387716	59.2	DM	Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3)
MMACHC	1	45500053	45513382	N	.	N	N	1.03889927	93.2453551	5.26E-14	96.3	DM	Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3)
MMADHC	2	149569634	149587816	N	.	N	N	0.297684879	70.38258957	0.020776843	51.4	DM	Homocystinuria, cblD type, variant 1, 277410 (3); Methylmalonic aciduria, cblD type, variant 2, 277410 (3); Methylmalonic aciduria and homocystinuria, cblD type, 277410 (3)
MMD	17	55392613	55421992	N	.	N	N	-0.411581382	23.84673265	0.013644655	53.6	.	.
MMD2	7	4905989	4959213	N	.	N	N	-0.310212249	28.91705736	0.000916863	65.1	.	Miyoshi muscular dystrophy 2 (2)
MME	3	155024124	155183729	N	.	N	Y	-0.722583176	13.34722463	2.19E-08	88	DM	[Neutral endopeptidase deficiency], 614692 (1); Membranous glomerulonephritis, antenatal, 614692 (1)
MMEL1	1	2590639	2632990	N	.	N	Y	0.835655068	89.89986688	8.88E-13	95.3	DP	.
MMGT1	X	135962070	135974063	N	.	N	N	0.113634918	58.26821786	0.408287058	32.6	FTV	.
MMP1	11	102789920	102798160	N	.	N	Y	0.695652645	86.80326446	2.49E-15	97	DFP	COPD, rate of decline of lung function in, 606963 (3); {Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 (3)
MMP10	11	102770503	102780628	N	.	N	Y	0.476146347	79.59715228	1.98E-13	95.9	DP	.
MMP11	22	23768226	23784316	N	.	N	Y	0.640259297	85.3446779	6.59E-05	73.1	.	.
MMP12	11	102862736	102875034	N	.	N	Y	.	.	.	.	DFP	.
MMP13	11	102942995	102955734	N	.	N	Y	0.366319083	74.16796898	2.17E-05	76	DM	Spondyloepimetaphyseal dysplasia, Missouri type, 602111 (3); Metaphyseal anadysplasia 1, 602111 (3)
MMP15	16	58025566	58046901	N	Viable	N	Y	0.509986769	80.8705215	0.651305092	26	.	.
MMP16	8	88032009	88328025	N	Viable	N	Y	-0.706921447	13.72344736	0.916974084	16.9	.	.
MMP17	12	131828393	131851783	N	.	N	Y	0.215453614	65.36435724	1.15E-06	82.4	.	.
MMP19	12	55835433	55842966	N	.	N	Y	0.750089699	88.0939978	1.45E-13	96	DM?	Cavitary optic disc anomalies, 611543 (3)
MMP2	16	55389700	55506691	N	.	N	Y	-0.95997312	8.554725936	0.791258492	22	DM	Multicentric osteolysis, nodulosis, and arthropathy, 259600 (3)
MMP20	11	102576835	102625332	N	.	N	Y	0.432084694	77.49609307	1.63E-08	88.4	DM	Amelogenesis imperfecta, type IIA2, 612529 (3)
MMP21	10	125766453	125775821	N	.	N	N	0.02389999	51.36308387	3.21E-07	84.4	.	.
MMP23B	1	1632095	1701810	N	Viable	N	Y	.	.	.	.	.	.
MMP24	20	35226654	35277000	N	.	N	Y	-0.204059885	35.20865891	0.028762329	49.9	.	.
MMP25	16	3046681	3060726	N	.	N	N	0.038100617	52.39914337	1.65E-06	81.7	.	.
MMP26	11	4704927	4992429	N	.	N	N	0.410231756	76.34427273	0.022171884	51.1	.	.
MMP27	11	102691487	102705806	N	.	N	N	1.030589476	93.16432251	2.35E-10	92.3	.	.
MMP28	17	35756249	35795707	N	.	N	Y	0.260020778	68.03264456	0.00013926	70.9	.	.
MMP3	11	102835801	102843803	N	.	N	Y	0.429214031	77.35718007	3.50E-08	87.4	DFP	{Coronary heart disease, susceptibility to, 6}, 614466 (3)
MMP7	11	102520508	102530753	N	.	N	Y	0.345573038	73.16663773	1.66E-09	90.7	DFP	.
MMP8	11	102711795	102727050	N	Viable	N	Y	0.922668267	91.58418707	1.18E-19	98.6	DM?	.
MMP9	20	46008908	46016561	N	Viable	N	Y	0.191987689	63.94049893	2.79E-08	87.7	DM	Metaphyseal anadysplasia 2, 613073 (3)
MMRN1	4	89879532	89954629	N	Viable	N	Y	-0.453800883	22.11032008	9.35E-17	97.7	.	.
MMRN2	10	86935540	86969481	N	.	N	N	-0.725306169	13.24882792	2.49E-10	92.3	DM?	.
MMS19	10	97458324	97498794	N	.	N	N	-0.417671117	23.59205881	0.831821999	20.6	.	.
MMS22L	6	97142161	97283217	N	.	N	N	0.649191201	85.57619957	0.671142491	25.5	.	.
MND1	4	153344649	153415118	N	.	N	N	0.36138737	73.96538751	1.28E-05	77.4	.	.
MNDA	1	158831317	158849506	N	.	N	N	0.434803554	77.64079412	7.23E-11	93.2	.	.
MOAP1	14	93182196	93184928	N	.	N	N	0.511598665	80.93418996	0.001403636	63.3	.	.
MOB1A	2	74152528	74178898	N	.	N	N	-0.088948948	42.87202639	0.853010255	19.8	.	.
MOB1B	4	70902326	71022449	N	.	N	N	-0.131096333	39.98379348	0.007973715	55.9	.	.
MOB2	11	1469457	1501247	N	.	N	N	0.060307001	54.1297679	0.641498729	26.3	.	.
MOB3A	19	2071038	2096673	N	.	N	N	-0.033404934	47.05678069	0.002927403	60.4	.	.
MOB3B	9	27325209	27529781	N	.	N	N	-0.25960522	31.89789894	0.030377777	49.6	.	.
MOB3C	1	46607715	46616891	N	.	N	N	0.033165214	52.10395323	0.034004954	49.1	FTV	.
MOB4	2	197515571	197553699	N	.	N	N	-0.164936793	37.70909301	0.77783291	22.4	DM?	.
MOBP	3	39467198	39529479	N	.	N	Y	.	.	0.592010033	27.7	.	.
MOCOS	18	36187519	36272157	N	.	N	N	0.461449991	78.89101117	6.10E-07	83.4	DM	.
MOCS3	20	50958826	50963931	N	.	N	N	-0.324108069	28.06042716	1.14E-05	77.7	.	.
MOG	6	29656981	29672372	N	.	N	Y	0.105325255	57.63153325	0.103680313	42.9	DM	?Narcolepsy 7, 614250 (3)
MOGAT1	2	222671786	222709930	N	.	N	N	0.626060077	84.945303	2.13E-06	81.2	.	.
MOGAT2	11	75717819	75732958	N	.	N	Y	0.499461757	80.4422064	0.218649113	38.1	.	.
MOGAT3	7	101195007	101201021	N	.	N	N	0.71146575	87.17948718	2.40E-10	92.3	FTV	.
MOK	14	102224500	102305200	N	.	N	N	0.298791665	70.43468195	5.96E-17	97.8	FTV	.
MON1A	3	49908862	49930173	N	.	N	N	-0.958208997	8.606818313	0.00636811	57	.	.
MON1B	16	77190835	77202405	N	.	N	N	-1.332445495	4.462580309	0.229740475	37.7	.	.
MON2	12	62466817	62600479	N	.	N	N	-1.044013138	7.292932801	0.982708263	11.3	.	.
MORC1	3	108958239	109118142	N	.	N	N	-0.050827166	45.71395497	0.000240876	69.2	.	.
MORC2	22	30925130	30968298	N	.	N	N	-1.509683337	3.293395844	0.99996748	3.1	.	.
MORC4	X	106813871	107000244	N	.	N	N	-0.360666394	26.29507438	0.993467674	9	.	.
MORF4L2	X	103675496	103688158	N	.	N	Y	-0.072985841	44.23221624	0.63639472	26.4	.	.
MORN1	1	2321253	2391707	N	.	N	N	1.157195988	94.58239278	7.88E-07	83	.	.
MORN2	2	38875962	38929072	N	.	N	N	.	.	.	.	.	.
MORN3	12	121648742	121672631	N	.	N	N	0.395225439	75.60340337	1.83E-06	81.5	.	.
MORN4	10	97614553	97633500	N	.	N	N	0.056480057	53.81721364	0.182745761	39.2	.	.
MORN5	9	122159908	122200088	N	.	N	N	0.119374702	58.69074492	0.001663335	62.6	.	.
MOS	8	56112942	56113982	N	.	N	Y	-0.231353608	33.64009955	0.149307838	40.6	.	.
MOSPD1	X	134887626	134915267	N	.	N	N	-0.073942787	44.13960757	0.871382679	19	.	.
MOSPD2	X	14873441	14922327	N	.	N	N	-0.130139339	40.0821902	0.99271393	9.2	.	.
MOV10	1	112673141	112700746	N	.	N	N	-1.08275718	6.754644904	0.998090428	6.9	DM?	.
MOV10L1	22	50089879	50161690	N	.	N	Y	-0.867601561	10.25062221	5.75E-10	91.6	.	.
MOXD1	6	132296055	132401545	N	Viable	N	Y	-0.445919635	22.46339063	8.99E-11	93	.	.
MPC1	6	166364919	166383013	N	.	N	N	0.093038818	56.61283788	0.145968077	40.8	.	Mitochondrial pyruvate carrier deficiency, 614741 (3)
MPC2	1	167916729	167937040	N	.	N	N	0.007634404	50.08971465	0.449429467	31.4	.	.
MPDU1	17	7583529	7592789	N	.	N	N	0.561252451	82.78636337	0.144211428	40.8	DM	Congenital disorder of glycosylation, type If, 609180 (3)
MPDZ	9	13105704	13279590	N	.	N	N	0.781671857	88.82329108	.	.	DM	Hydrocephalus, nonsyndromic, autosomal recessive 2, 615219 (3)
MPEG1	11	59208510	59212951	N	.	N	N	-0.264739339	31.59113272	3.46E-12	94.8	.	.
MPG	16	77007	85853	N	.	N	Y	0.568903575	83.02367309	4.24E-09	89.8	FP	.
MPHOSPH10	2	71130314	71150101	N	.	N	N	1.311103324	95.86155004	0.585921553	27.8	.	.
MPHOSPH6	16	82147798	82170226	N	.	N	N	0.400815894	75.88122938	0.001208434	64	.	.
MPHOSPH8	13	19633681	19673459	N	.	N	N	-0.669103383	14.78844707	0.930242309	16.1	DM?	.
MPHOSPH9	12	123152320	123244014	N	.	N	N	-0.533897786	18.8400764	0.000759987	65.7	.	.
MPL	1	43337807	43352772	N	.	N	Y	0.368232636	74.30688198	1.44E-06	82	DM	Thrombocytopenia, congenital amegakaryocytic, 604498 (3); Thrombocythemia 2, 601977 (3); Myelofibrosis with myeloid metaplasia, somatic, 254450 (3)
MPLKIP	7	40126023	40134659	N	Viable	N	Y	.	.	0.002058352	61.8	.	Trichothiodystrophy 4, nonphotosensitive, 234050 (3)
MPND	19	4343527	4360086	N	.	N	N	0.71146575	87.17948718	0.015724967	52.9	.	.
MPO	17	58269856	58280935	N	Viable	N	Y	-0.120267952	40.70729872	1.75E-09	90.7	DM	Myeloperoxidase deficiency, 254600 (3); {Alzheimer disease, susceptibility to}, 104300 (3); {Lung cancer, protection against, in smokers} (3)
MPP1	X	154778684	154821007	N	.	N	Y	-0.006263422	49.00156277	0.940116718	15.6	.	.
MPP2	17	43875357	43909711	N	.	N	N	-0.760248704	12.39219772	0.002580507	61	.	.
MPP3	17	43800799	43833170	N	.	N	N	-0.267759536	31.40012734	2.00E-05	76.2	DP	.
MPP4	2	201644870	201698694	N	.	N	Y	-0.269673173	31.29015454	5.88E-09	89.4	.	.
MPP5	14	67241109	67335819	N	.	N	N	-0.517274597	19.5577936	0.660477587	25.8	.	.
MPP6	7	24573268	24694193	N	.	N	N	-0.244445663	32.81240956	0.930676771	16.1	DM?	.
MPP7	10	28050993	28334486	N	.	N	N	-0.130792007	40.01852173	8.58E-07	82.8	DP	.
MPPE1	18	11882622	11909223	N	.	N	N	0.295921468	70.25525265	8.34E-06	78.5	.	.
MPPED1	22	43411196	43507848	N	.	N	N	-0.347727532	26.88545465	0.283449525	36.1	.	.
MPPED2	11	30384493	30586872	N	.	N	N	-0.441593835	22.64281993	0.970565202	12.9	.	.
MPRIP	17	17042545	17217679	N	.	N	N	-1.897918178	1.863749494	0.870658012	19	.	.
MPST	22	37019635	37029822	N	.	N	Y	-0.024139966	47.63558488	0.006776468	56.7	DP	.
MPV17	2	27309492	27325680	N	.	N	N	0.513364317	81.01522255	1.10E-08	88.8	DM	Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 (3)
MPV17L	16	15395754	15413268	N	.	N	N	.	.	0.000500982	67	.	.
MPV17L2	19	18193182	18196948	N	.	N	N	0.633417736	85.14788447	1.67E-07	85.5	.	.
MPZ	1	161304735	161309972	N	.	N	Y	-0.146102415	38.98246223	0.691715781	24.8	DM	Charcot-Marie-Tooth disease, type 1B, 118200 (3); Dejerine-Sottas disease, 145900 (3); Neuropathy, congenital hypomyelinating, 605253 (3); Charcot-Marie-Tooth disease, type 2J, 607736 (3); Roussy-Levy syndrome, 180800 (3); Charcot-Marie-Tooth disease, type 2I, 607677 (3); Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3)
MPZL1	1	167721192	167791919	N	Viable	N	Y	-0.426587603	23.26214042	0.327816834	34.9	.	.
MPZL2	11	118253403	118264536	N	.	N	Y	0.759208317	88.28500318	1.22E-11	94.1	.	.
MPZL3	11	118226690	118252350	N	.	N	N	0.108195341	57.87463101	6.52E-09	89.4	.	.
MR1	1	181033425	181061938	N	.	N	Y	0.461946007	78.93152746	5.61E-09	89.5	DM?	Paroxysmal nonkinesigenic dyskinesia, 118800 (3)
MRAP	21	32291813	32314784	N	.	N	N	0.432741275	77.53082132	0.010638416	54.7	DM	Glucocorticoid deficiency 2, 607398 (3)
MRAP2	6	84033756	84090881	N	.	N	Y	-0.152648436	38.52520692	0.000348739	68.2	DM	{Obesity, susceptibility to, BMIQ18}, 615457 (3)
MRAS	3	138347648	138405534	N	.	N	N	-0.148016487	38.85512531	0.859946833	19.5	.	.
MRC2	17	62627401	62693597	N	.	N	Y	-0.937046659	8.913584534	0.985888158	10.8	.	.
MREG	2	215942805	216034096	N	.	N	N	-0.116090248	41.04300515	5.96E-06	79.2	.	.
MRFAP1	4	6640091	6642745	N	.	N	Y	-0.079531963	43.66498813	0.17706447	39.5	.	.
MRFAP1L1	4	6707701	6709880	N	.	N	N	0.095908833	56.83278347	0.008908008	55.4	.	.
MRGBP	20	62796453	62801738	N	.	N	N	-0.11145818	41.38449962	0.905748428	17.5	.	.
MRGPRD	11	68980021	68980986	N	.	N	Y	1.028526616	93.14117034	0.000404523	67.7	.	.
MRGPRE	11	3227698	3232386	N	.	N	Y	1.04816991	93.33796377	4.76E-05	74	.	.
MRGPRF	11	69004395	69013409	N	.	N	N	.	.	0.370675551	33.6	.	.
MRGPRG	11	3217944	3218813	N	.	N	N	.	.	.	.	.	.
MRGPRX1	11	18933813	18939507	N	.	N	N	-0.019204219	47.96550327	0.083147317	44.2	.	.
MRGPRX2	11	19054455	19060681	N	.	N	N	0.915015508	91.38739364	0.002490612	61.1	.	.
MRGPRX3	11	18120955	18138480	N	.	N	N	1.011754378	92.90386062	2.86E-08	87.7	.	.
MRGPRX4	11	18172837	18197348	N	.	N	N	0.675862236	86.31706894	0.001818565	62.3	.	.
MRI1	19	13764532	13774282	N	.	N	N	0.906555705	91.21375239	0.000533201	66.9	.	.
MRLN	10	59736692	59756041	N	.	N	N	.	.	.	.	.	.
MRO	18	50795120	50825402	N	.	N	Y	0.358666204	73.88435492	0.000178042	70.2	.	.
MROH1	8	144148016	144261940	N	.	N	N	.	.	0.587142255	27.8	.	.
MROH2A	2	233775679	233833423	N	.	N	N	.	.	0.314233042	35.3	.	.
MROH2B	5	40998017	41071342	N	.	N	N	2.249354331	98.92921225	1.29E-26	99.5	.	.
MROH6	8	143566187	143572971	N	.	N	N	0.338220438	72.790415	1.27E-10	92.8	.	.
MROH7	1	54641754	54710266	N	.	N	N	3.868118543	99.72796203	6.65E-19	98.4	.	.
MROH7-TTC4	1	54641786	54742308	N	.	N	N	.	.	.	.	.	.
MROH8	20	37101226	37179588	N	.	N	N	.	.	.	.	.	.
MROH9	1	170935471	171064765	N	.	N	N	0.833583749	89.88250275	2.47E-06	80.9	.	.
MRPL1	4	77862520	77952790	N	.	N	N	-0.141317516	39.35289691	3.21E-05	75	.	.
MRPL10	17	47823272	47831534	N	.	N	Y	-0.013766433	48.44591075	0.288891351	36	.	.
MRPL11	11	66435075	66466738	N	.	N	N	-0.393703195	24.72072698	2.04E-05	76.2	.	.
MRPL12	17	81703357	81707526	N	.	N	N	-0.327132777	27.8867859	0.050197139	47	DM	.
MRPL13	8	120380761	120445402	N	.	N	N	0.04243066	52.74063784	7.02E-07	83.1	.	.
MRPL14	6	44113454	44127457	N	.	N	N	-0.20804097	35.04659374	0.036998987	48.7	.	.
MRPL15	8	54135210	54147901	N	.	N	N	0.575302895	83.26677085	1.34E-05	77.3	.	.
MRPL16	11	59806135	59810872	N	.	N	N	0.472169912	79.41193494	0.003108656	60.2	.	.
MRPL17	11	6680782	6683401	N	.	N	N	-0.251145013	32.40145859	0.464121316	31	.	.
MRPL18	6	159789812	159798436	N	.	N	N	-0.100127206	42.09064074	0.000794103	65.5	.	.
MRPL19	2	75646783	75690851	N	.	N	N	-0.030686146	47.24199803	0.001318591	63.7	.	.
MRPL2	6	43054029	43059806	N	.	N	N	0.125114793	59.14221219	0.001593721	62.8	.	.
MRPL20	1	1401908	1407313	N	.	N	N	-0.130139339	40.0821902	0.000171803	70.3	.	.
MRPL21	11	68891276	68903835	N	.	N	N	0.463710367	79.01834809	5.46E-08	86.8	.	.
MRPL22	5	154941070	154969411	N	.	N	N	0.349250172	73.35185507	3.44E-07	84.3	.	.
MRPL23	11	1947278	1984522	N	.	N	N	0.742289427	87.92035654	1.46E-06	82	.	.
MRPL24	1	156737303	156741590	N	.	N	N	0.020878273	51.13735023	0.001491227	63	.	.
MRPL27	17	50367857	50373214	N	.	N	N	0.438331876	77.80285929	0.385344633	33.2	.	.
MRPL28	16	367384	370527	N	.	N	N	0.31284098	71.27973607	2.42E-08	87.9	.	.
MRPL3	3	131462212	131502983	N	.	N	N	0.309014254	71.0076981	2.81E-08	87.7	DM	Combined oxidative phosphorylation deficiency 9, 614582 (3)
MRPL30	2	99181079	99197626	N	.	N	N	0.291946181	70.03530706	0.543252453	28.8	.	.
MRPL32	7	42932200	42948958	N	.	N	N	0.44679135	78.19644614	0.00129078	63.7	.	.
MRPL33	2	27771717	27988087	N	.	N	N	0.08457904	56.06876194	0.749164757	23.2	.	.
MRPL34	19	17292609	17306843	N	.	N	N	0.274070774	68.90085084	0.040128443	48.3	.	.
MRPL35	2	86199355	86213794	N	.	N	N	0.202865163	64.54245529	0.02093701	51.4	.	.
MRPL36	5	1798386	1801366	N	.	N	N	0.254430455	67.72009029	0.254818113	36.9	.	.
MRPL37	1	54184041	54225464	N	.	N	N	-0.658073323	15.10678937	0.000268371	69	.	.
MRPL38	17	75898643	75905413	N	.	N	N	1.008884495	92.87492041	4.09E-06	79.9	.	.
MRPL39	21	25585656	25607517	N	.	N	N	0.341896466	72.98142039	0.000718692	65.9	.	.
MRPL4	19	10251901	10260045	N	.	N	N	1.077374442	93.70261041	1.13E-07	86	.	.
MRPL40	22	19431902	19436075	N	.	N	N	0.225374457	65.97210164	0.020081691	51.7	.	.
MRPL41	9	137551199	137552555	N	.	N	N	0.04897698	53.33680616	0.213388425	38.3	.	.
MRPL42	12	93467488	93516213	N	.	N	N	0.003958565	49.8061006	0.027881567	50.1	.	.
MRPL43	10	100969458	100987515	N	.	N	N	0.586631015	83.74139029	0.000110896	71.5	.	.
MRPL44	2	223957404	223967714	N	.	N	N	0.140120824	60.21878798	9.28E-06	78.2	DM	?Combined oxidative phosphorylation deficiency 16, 615395 (3)
MRPL45	17	38297023	38323218	N	.	N	N	0.709552984	87.11003068	0.00150597	63	.	.
MRPL46	15	88459476	88467419	N	.	N	N	0.201101698	64.45563466	8.03E-07	82.9	.	.
MRPL47	3	179588285	179604654	N	.	N	N	0.409275399	76.30375644	0.000142436	70.8	.	.
MRPL48	11	73787316	73865133	N	.	N	N	-0.179942957	36.73091393	0.138891985	41.2	FTV	.
MRPL49	11	65122183	65127371	N	.	N	N	0.232877563	66.3946287	0.042302919	48	.	.
MRPL50	9	101387633	101398614	N	.	N	N	0.550880798	82.46802107	0.00031841	68.5	.	.
MRPL52	14	22829879	22835037	N	.	N	N	0.351971606	73.48498003	0.000108205	71.6	.	.
MRPL53	2	74471958	74473322	N	.	N	N	0.118418051	58.60971233	0.22224943	37.9	.	.
MRPL54	19	3762664	3768575	N	.	N	Y	0.323871546	71.97430109	0.085695868	44.1	.	.
MRPL55	1	228106679	228109312	N	.	N	N	0.490854514	80.1238641	0.000411108	67.7	.	.
MRPL57	13	21176645	21179084	N	.	N	N	.	.	.	.	.	.
MRPL9	1	151759643	151763564	N	.	N	N	0.658795771	85.87717775	0.05130785	46.9	.	.
MRPS10	6	42206801	42217865	N	.	N	N	0.42987242	77.39769636	0.028212146	50	.	.
MRPS11	15	88467453	88480773	N	.	N	N	0.030294875	51.83191526	0.000434482	67.5	.	.
MRPS12	19	38930548	38933162	N	.	N	N	0.080902701	55.81408809	0.010426267	54.8	.	.
MRPS14	1	175010789	175023425	N	.	N	N	0.018964694	50.97528506	0.001658745	62.6	.	.
MRPS15	1	36455718	36464437	N	.	N	N	0.198231811	64.27620536	0.000342016	68.3	.	.
MRPS16	10	73248843	73252693	N	.	N	N	0.080902701	55.81408809	0.082765903	44.2	DM	Combined oxidative phosphorylation deficiency 2, 610498 (3)
MRPS17	7	55951819	55956501	N	.	N	N	0.624958462	84.90478671	0.742813785	23.4	.	.
MRPS18A	6	43671303	43687791	N	.	N	N	0.217871355	65.53221045	0.001126108	64.2	.	.
MRPS18B	6	30617709	30626395	N	.	N	N	0.428107326	77.30508769	0.000565209	66.7	.	.
MRPS18C	4	83455932	83469735	N	.	N	N	0.094952155	56.76911501	0.008973186	55.3	.	.
MRPS2	9	135499984	135504673	N	.	N	N	0.286505086	69.72275279	0.037223405	48.6	.	.
MRPS21	1	150293720	150308979	N	.	N	N	0.442010439	77.98228859	0.353450051	34.1	.	.
MRPS22	3	139005806	139357223	N	.	N	N	-0.108434806	41.56971696	6.39E-05	73.2	DM	Combined oxidative phosphorylation deficiency 5, 611719 (3)
MRPS23	17	57834781	57850056	N	.	N	N	0.074356355	55.24107195	0.049486058	47.1	.	.
MRPS24	7	43866558	43869893	N	.	N	N	0.428916211	77.3340279	0.001657669	62.7	.	.
MRPS26	20	3045945	3048254	N	.	N	N	0.033014066	52.06922498	0.187857588	39	.	.
MRPS27	5	72219409	72320646	N	.	N	N	0.203971741	64.62927592	0.028586687	50	.	.
MRPS28	8	79918717	80030289	N	.	N	N	0.492766925	80.17595647	0.00035548	68.1	.	.
MRPS30	5	44808925	44820428	N	.	N	N	0.505201964	80.65057591	5.58E-05	73.6	.	.
MRPS31	13	40729135	40771173	N	.	N	N	-0.517427071	19.54042947	4.09E-05	74.4	.	.
MRPS33	7	141002610	141015228	N	.	N	N	-0.148973548	38.82039706	0.003395718	59.8	.	.
MRPS34	16	1771890	1773155	N	.	N	N	0.140927298	60.26509232	5.52E-05	73.7	.	.
MRPS35	12	27710773	27756295	N	.	N	Y	0.071637002	55.02112635	0.040928275	48.2	.	.
MRPS36	5	69217760	69230129	N	.	N	N	-0.051433536	45.65607455	0.746558797	23.2	.	.
MRPS6	21	34073224	34143034	N	.	N	N	0.488942276	80.04283151	0.136243673	41.3	.	.
MRPS7	17	75261674	75266373	N	.	N	N	-0.065330609	44.75314001	0.002491618	61.1	.	.
MRPS9	2	105037983	105099960	N	.	N	N	0.021986393	51.23574695	3.36E-06	80.3	.	.
MRRF	9	122264603	122331343	N	.	N	N	0.168219607	62.41824391	3.58E-05	74.8	DM	.
MRS2	6	24402908	24426194	N	.	N	N	-0.25099172	32.42461075	8.85E-05	72.3	.	.
MRTO4	1	19251539	19260128	N	.	N	N	-0.127268446	40.25583145	0.86997792	19	.	.
MRVI1	11	10573091	10693988	N	.	N	Y	1.185611377	94.91809921	0.001841215	62.2	.	.
MS4A1	11	60455752	60470760	N	.	N	Y	0.046257695	53.10528448	0.015388169	53	DM	Immunodeficiency, common variable, 5, 613495 (3)
MS4A10	11	60785348	60801305	N	.	N	N	0.716100076	87.30103606	1.79E-08	88.3	DM?	.
MS4A12	11	60492778	60507430	N	.	N	N	0.789222232	88.97378017	4.96E-05	73.9	FTV	.
MS4A13	11	60515413	60542721	N	.	N	N	0.24597088	67.24547086	0.053865836	46.6	.	.
MS4A14	11	60378530	60417756	N	.	N	N	0.95842552	92.1687793	2.19E-16	97.6	.	.
MS4A15	11	60756953	60776732	N	.	N	N	0.531239379	81.69242345	0.038468197	48.5	.	.
MS4A18	11	60729304	60744212	N	.	N	N	.	.	.	.	.	.
MS4A2	11	60088261	60098466	N	.	N	Y	0.659751818	85.90032992	6.50E-05	73.1	DM	{Atopy, susceptibility to}, 147050 (3)
MS4A3	11	60056587	60071128	N	Viable	N	Y	0.522779906	81.35092898	4.21E-05	74.3	DP	.
MS4A4A	11	60280541	60308972	N	.	N	N	0.469300995	79.2961741	0.000743082	65.7	.	.
MS4A4E	11	60201253	60243088	N	.	N	N	.	.	0.515839924	29.5	.	.
MS4A5	11	60429589	60455214	N	.	N	N	0.460841539	78.85628292	0.009204538	55.3	.	.
MS4A6A	11	60172014	60184666	N	.	N	N	0.372716004	74.56155583	1.49E-09	90.8	DP	.
MS4A6E	11	60334831	60396596	N	.	N	N	0.489898374	80.08913585	0.720551081	24	DP	.
MS4A7	11	60378482	60395951	N	.	N	N	0.554705396	82.60114603	9.27E-06	78.3	.	.
MS4A8	11	60699574	60715811	N	.	N	N	0.143797178	60.51397812	0.002609212	61	.	.
MSANTD1	4	3244369	3271738	N	Viable	N	Y	-0.063568931	44.88047693	0.322172214	35.1	.	.
MSANTD2	11	124766498	124800673	N	.	N	N	-0.64226435	15.61034902	0.709971707	24.4	.	.
MSANTD3	9	100427156	100451711	N	.	N	N	-0.007220243	48.88580193	0.063002986	45.7	.	.
MSANTD3-TMEFF1	9	100442271	100577636	N	.	N	N	.	.	.	.	.	.
MSANTD4	11	105995623	106022403	N	.	N	N	-0.476237287	21.18423337	0.005461954	57.7	.	.
MSC	8	71841549	71844468	N	.	N	Y	-0.011047557	48.60797592	0.673682721	25.4	.	.
MSH2	2	47402969	47562311	N	.	N	Y	-1.181128061	5.793829947	0.867725631	19.2	DM	Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3); Muir-Torre syndrome, 158320 (3); Mismatch repair cancer syndrome, 276300 (3)
MSH3	5	80654648	80876460	N	.	N	Y	-0.491458858	20.53597268	4.57E-23	99.1	DM?	Endometrial carcinoma, somatic, 608089 (3)
MSH4	1	75796882	75913238	N	.	N	Y	-0.832267074	10.93361116	3.70E-15	96.9	DP	.
MSH5	6	31739948	31762834	N	.	N	Y	-0.573473538	17.54934306	6.14E-08	86.7	DFP	.
MSH5-SAPCD1	6	31740020	31764851	N	.	N	N	.	.	.	.	.	.
MSH6	2	47695530	47810101	N	.	N	Y	-2.188587383	1.302309429	.	.	DM	Colorectal cancer, hereditary nonpolyposis, type 5, 614350 (3); Endometrial cancer, familial, 608089 (3); Mismatch repair cancer syndrome, 276300 (3)
MSI1	12	120341330	120369180	N	.	N	Y	-0.17611458	36.99137582	0.997146451	7.4	.	.
MSL1	17	40122298	40136916	N	.	N	N	-0.456600078	21.99455924	0.984496891	11	.	.
MSL2	3	136148922	136197241	N	.	N	N	-0.6365207	15.76083811	0.889663742	18.2	.	.
MSL3	X	11758159	11775753	N	.	N	N	-0.340224471	27.22116108	0.945646874	15.2	.	.
MSLN	16	643262	768865	N	.	N	Y	2.610222309	99.24176651	2.48E-15	97	.	.
MSLNL	16	769428	783370	N	.	N	N	.	.	3.46E-16	97.5	.	.
MSMB	10	46033307	46046269	N	.	N	N	0.107088402	57.71835388	0.098703187	43.2	DFP	{Prostate cancer, hereditary, 13}, 611928 (3)
MSMP	9	35752990	35756613	N	.	N	N	0.579938151	83.45198819	0.443121281	31.6	.	.
MSN	X	65588377	65741931	N	.	N	Y	-0.257690928	32.05996411	0.993557146	9	.	.
MSR1	8	16107878	16567490	N	.	N	Y	0.63849777	85.30994964	8.21E-16	97.3	DM	Prostate cancer, hereditary, 176807 (3); Barrett esophagus/esophageal adenocarcinoma, 614266 (3)
MSRA	8	10054268	10428891	N	.	N	Y	-0.167501818	37.55860392	1.70E-06	81.6	.	.
MSRB1	16	1938210	1943326	N	.	N	Y	0.253474025	67.62169358	0.003104711	60.2	.	.
MSRB2	10	23095506	23122013	N	.	N	N	0.913916314	91.33530127	0.004247611	58.9	.	.
MSRB3	12	65278643	65488244	N	.	N	Y	-0.193034849	35.95531632	0.007026796	56.6	DM	Deafness, autosomal recessive 74, 613718 (3)
MSS51	10	73423579	73433561	N	.	N	N	1.101798925	93.94570817	4.16E-05	74.4	.	.
MST1	3	49683947	49689501	N	.	N	Y	1.636030838	97.66741911	1.73E-10	92.6	DFP	T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3)
MSTN	2	190055697	190062729	N	.	N	Y	0.36808233	74.28951786	0.812914736	21.2	DM	Muscle hypertrophy, 614160 (3)
MSTO1	1	155610205	155614967	N	.	N	N	0.754573317	88.21554668	0.041804485	48.1	.	.
MSX2	5	174724533	174730893	N	.	N	Y	-0.366562778	26.04618857	0.421492416	32.2	DM	Craniosynostosis, type 2, 604757 (3); Parietal foramina 1, 168500 (3); Parietal foramina with cleidocranial dysplasia, 168550 (3)
MT1A	16	56638666	56750276	N	.	N	N	0.174616683	62.82340684	0.007776186	56.1	DFP	.
MT1B	16	56651899	56653204	N	.	N	N	0.751562215	88.10557388	0.248269442	37.1	.	.
MT1E	16	56625475	56627112	N	.	N	N	0.584573969	83.6603577	0.659212996	25.8	.	.
MT1F	16	56657694	56660698	N	.	N	N	0.380072103	74.92620247	0.053849699	46.6	.	.
MT1G	16	56666731	56668065	N	.	N	N	0.502036857	80.5116629	0.008119484	55.8	.	.
MT1H	16	56669814	56671129	N	.	N	N	0.623046877	84.84111825	0.054841215	46.4	.	.
MT1HL1	1	237004103	237004418	N	.	N	N	.	.	0.020062126	51.7	.	.
MT1M	16	56632233	56633986	N	.	N	N	0.403538004	75.98541413	9.84E-05	71.9	.	.
MT1X	16	56682424	56684196	N	.	N	N	0.265611248	68.3972912	0.049611192	47	.	.
MT2A	16	56608199	56609497	N	.	N	N	0.212132538	65.20229206	0.053869187	46.6	DFP	.
MT3	16	56589074	56591088	N	.	N	Y	0.243101669	67.0718296	0.25413347	37	.	.
MT4	16	56565049	56568957	N	.	N	N	0.38757536	75.25033281	0.007994585	55.9	.	.
MTA1	14	105419820	105470729	N	.	N	Y	-1.060390185	7.067199167	0.999747857	4.5	.	.
MTA3	2	42494569	42756947	N	.	N	Y	-0.569949107	17.64195173	0.855163472	19.7	.	.
MT-ATP6	MT	8527	9207	N	.	N	N	.	.	.	.	.	.
MT-ATP8	MT	8366	8572	N	.	N	N	.	.	.	.	.	.
MTCH1	6	36968141	36986298	N	.	N	N	-0.321544247	28.21670429	0.964878856	13.5	.	.
MTCL1	18	8705661	8832778	N	.	N	N	.	.	.	.	.	.
MT-CO1	MT	5904	7445	N	.	N	N	.	.	.	.	.	.
MT-CO2	MT	7586	8269	N	.	N	N	.	.	.	.	.	.
MT-CO3	MT	9207	9990	N	.	N	N	.	.	.	.	.	.
MTCP1	X	155061622	155147937	N	.	N	N	0.075162561	55.29316432	0.342313099	34.4	.	.
MT-CYB	MT	14747	15887	N	.	N	N	.	.	.	.	.	.
MTDH	8	97644179	97728770	N	.	N	Y	-0.279089927	30.68819818	0.721809341	24	.	.
MTERF1	7	91692008	91880720	N	.	N	N	.	.	.	.	.	.
MTERF2	12	106977291	106987166	N	.	N	N	.	.	.	.	.	.
MTFP1	22	30425530	30429053	N	.	N	N	0.333287484	72.48364878	0.316869739	35.2	.	.
MTFR1	8	65644734	65771261	N	.	N	N	0.078183267	55.57099033	2.18E-05	76	.	.
MTFR1L	1	25818640	25832942	N	.	N	N	0.266716005	68.46095966	0.431750878	31.9	.	.
MTFR2	6	136231024	136250335	N	.	N	N	0.187052315	63.62794467	0.000151538	70.6	.	.
MTG1	10	133394094	133421307	N	.	N	N	0.127984973	59.3100654	0.062671961	45.7	.	.
MTG2	20	62183029	62203568	N	.	N	N	1.29609522	95.7457892	0.000608857	66.4	.	.
MTHFD2L	4	74114174	74303099	N	Viable	N	Y	0.267672556	68.5362042	0.000263185	69	.	.
MTHFR	1	11785723	11806920	N	.	N	Y	0.097319489	56.92539214	2.46E-07	84.9	DM	Homocystinuria due to MTHFR deficiency, 236250 (3); {Schizophrenia, susceptibility to}, 181500 (3); {Vascular disease, susceptibility to} (3); {Neural tube defects, susceptibility to}, 601634 (3); {Thromboembolism, susceptibility to}, 188050 (3)
MTHFS	15	79833585	79897379	Y	Viable	N	Y	0.481438994	79.79973375	0.04065105	48.2	DM?	.
MTHFSD	16	86530176	86555235	N	.	N	N	0.496742012	80.34380969	3.76E-09	89.9	.	.
MTIF2	2	55236595	55269347	N	.	N	N	-0.641959288	15.6219251	9.07E-08	86.2	.	.
MTIF3	13	27435643	27450591	N	.	N	N	0.181312488	63.27487411	0.029635307	49.7	.	.
MTL5	11	68707440	68751564	N	.	N	N	0.40846756	76.27481623	0.033221402	49.2	.	.
MTMR1	X	150692971	150765103	N	.	N	Y	0.132617807	59.62261967	0.982418902	11.4	.	.
MTMR10	15	30938941	30991607	N	.	N	N	0.612160073	84.52856399	0.035049797	48.9	.	.
MTMR11	1	149928651	149936898	N	.	N	N	-0.322043675	28.14724779	7.33E-13	95.4	.	.
MTMR12	5	32226994	32313009	N	Viable	N	Y	0.253773539	67.69115008	0.997884435	7	DM?	.
MTMR14	3	9649433	9702394	N	.	N	Y	-0.885893782	9.868611449	0.002939821	60.4	DM	{Centronuclear myopathy, autosomal, modifier of}, 160150 (3)
MTMR3	22	29883155	30030866	N	.	N	Y	-1.082619493	6.760432946	0.994951612	8.4	.	.
MTMR4	17	58489529	58517905	N	.	N	N	-0.472915409	21.34051051	0.997305474	7.3	.	.
MTMR6	13	25246201	25288009	N	.	N	N	-0.177723518	36.87561498	3.01E-06	80.6	.	.
MTMR7	8	17298030	17413528	N	.	N	N	-1.552800803	3.061874168	1.64E-09	90.7	.	.
MTMR8	X	64268081	64395431	N	.	N	N	0.872057982	90.62916016	1.34E-11	94.1	DM?	.
MTMR9	8	11284416	11328146	N	.	N	N	-0.381111893	25.38056376	0.210866149	38.4	DM?	.
MT-ND1	MT	3307	4262	N	.	N	N	.	.	.	.	.	.
MT-ND2	MT	4470	5511	N	.	N	Y	.	.	.	.	.	.
MT-ND3	MT	10059	10404	N	.	N	N	.	.	.	.	.	.
MT-ND4	MT	10760	12137	N	.	N	N	.	.	.	.	.	.
MT-ND4L	MT	10470	10766	N	.	N	N	.	.	.	.	.	.
MT-ND5	MT	12337	14148	N	.	N	N	.	.	.	.	.	.
MT-ND6	MT	14149	14673	N	.	N	Y	.	.	.	.	.	.
MTNR1A	4	186533655	186555567	N	.	N	Y	0.23207049	66.37147653	0.003032392	60.3	DM	.
MTNR1B	11	92969720	92985066	N	Viable	N	Y	0.205885193	64.72188459	0.00870273	55.5	DM	{Diabetes mellitus, type 2, susceptiblity to}, 125853 (3)
MTO1	6	73461578	73509236	N	.	N	Y	-1.058477476	7.090351334	9.82E-05	72	DM	Combined oxidative phosphorylation deficiency 10, 614702 (3)
MTPAP	10	30309801	30374448	N	.	N	N	-0.740609356	12.8726052	0.910575497	17.3	DM	Ataxia, spastic, 4, 613672 (3)
MTPN	7	135926761	135977353	N	.	N	N	0.030143764	51.8087631	0.754654167	23	.	.
MTRF1	13	41216369	41263577	N	.	N	Y	0.628929435	85.03212363	1.54E-07	85.6	.	.
MTRNR2L1	17	22523111	22524663	N	.	N	N	.	.	.	.	.	.
MTRNR2L10	X	55181391	55182920	N	.	N	N	.	.	.	.	.	.
MTRNR2L11	1	237943724	237945275	N	.	N	N	.	.	.	.	.	.
MTRNR2L12	3	96617188	96618236	N	.	N	N	.	.	.	.	.	.
MTRNR2L13	4	116298876	116300320	N	.	N	N	.	.	.	.	.	.
MTRNR2L3	20	57358442	57359980	N	.	N	N	.	.	.	.	.	.
MTRNR2L4	16	3370979	3372740	N	.	N	N	.	.	.	.	.	.
MTRNR2L5	10	55599303	55600041	N	.	N	N	.	.	.	.	.	.
MTRNR2L6	7	142666272	142667718	N	.	N	N	.	.	.	.	.	.
MTRNR2L7	10	37601440	37602974	N	.	N	N	.	.	.	.	.	.
MTRNR2L8	11	10507887	10509189	N	.	N	N	.	.	.	.	.	.
MTRR	5	7851186	7906025	N	.	N	N	-0.074293017	44.10487932	4.11E-07	84	DM	Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3); {Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3)
MTSS1	8	124550790	124728429	N	.	N	Y	-0.270478912	31.25542629	0.999823848	4.2	.	.
MTSS1L	16	70661204	70686066	N	.	N	Y	-0.230093763	33.72692018	0.86986055	19.1	.	.
MTURN	7	30134810	30162762	N	Viable	N	Y	0.137100934	59.98726631	.	.	.	.
MTUS1	8	17643795	17800917	N	.	N	Y	2.262173949	98.94657637	1.14E-05	77.7	DP	.
MTUS2	13	28820348	29505947	N	.	N	N	0.705716972	87.02321005	0.330673094	34.8	.	.
MTX1	1	155208699	155213824	N	.	N	N	.	.	0.19822129	38.8	DP	.
MTX2	2	176269395	176338025	N	.	N	N	-0.045692193	46.15384615	0.081371808	44.3	.	.
MTX3	5	79976731	79991262	N	.	N	N	0.378306375	74.85095792	0.100351117	43.1	.	.
MUC1	1	155185824	155192916	N	.	N	Y	0.204928458	64.67558025	0.730964975	23.7	DM	Medullary cystic kidney disease 1, 174000 (3)
MUC12	7	100969623	101018949	N	.	N	N	.	.	.	.	.	.
MUC13	3	124905442	124953819	N	.	N	N	.	.	0.025133916	50.5	DP	.
MUC15	11	26559033	26572233	N	.	N	N	0.149537247	60.98280952	3.93E-05	74.6	.	.
MUC16	19	8848844	8981342	N	.	N	N	15.60105068	99.97105979	.	.	.	.
MUC17	7	101020072	101058745	N	.	N	N	16.89936876	99.97684783	.	.	.	.
MUC20	3	195720882	195741123	N	.	N	N	.	.	.	.	.	.
MUC21	6	30983718	30989903	N	.	N	N	4.849172727	99.84372287	0.331419151	34.8	.	.
MUC22	6	31010474	31035402	N	.	N	N	.	.	.	.	.	.
MUC3A	7	100949555	100968346	N	.	N	N	.	.	.	.	DP	.
MUC4	3	195746765	195812277	N	.	N	N	.	.	.	.	DP	.
MUC5AC	11	1157953	1201138	N	.	N	Y	.	.	.	.	.	.
MUC5B	11	1223066	1262172	N	.	N	Y	21.745047	99.98263587	0.999999706	1.3	DP	{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3)
MUC6	11	1012821	1036706	N	.	N	N	21.91064912	99.98842392	1.09E-32	99.8	DFP	.
MUC7	4	70430492	70482997	N	.	N	N	1.349430616	96.1046478	9.14E-05	72.2	DP	{Asthma, protection against}, 600807 (3)
MUCL1	12	54830519	54858393	N	.	N	N	0.572434794	83.18573826	1.15E-05	77.7	.	.
MUL1	1	20499448	20508161	N	.	N	N	-0.110348593	41.44238004	3.49E-06	80.2	.	.
MUM1	19	1285893	1378431	N	.	N	N	0.173154201	62.77710251	0.032092633	49.4	.	.
MUM1L1	X	106168305	106208956	N	.	N	N	-0.123440781	40.55680963	0.635560374	26.5	.	.
MURC	9	100578079	100587906	N	.	N	Y	0.218977775	65.62481912	3.73E-07	84.2	DM	.
MUSTN1	3	52833114	52835219	N	.	N	N	0.615543438	84.60380853	0.001752188	62.4	.	.
MUTYH	1	45329163	45340470	N	.	N	Y	-0.073487243	44.16854778	8.57E-11	93	DM	Adenomas, multiple colorectal, 608456 (3); Gastric cancer, somatic, 613659 (3); Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3)
MVB12A	19	17405722	17433724	N	.	N	N	0.358666204	73.88435492	0.000679169	66.1	.	.
MVB12B	9	126326849	126507041	N	.	N	N	-0.515667713	19.60409793	0.622016654	26.9	.	.
MVD	16	88651935	88663161	N	.	N	N	0.54080415	82.10337443	2.16E-12	95	.	.
MVK	12	109573255	109598117	N	.	N	N	-0.342941981	27.12276437	0.042161397	48	DM	Mevalonic aciduria, 610377 (3); Hyper-IgD syndrome, 260920 (3); Porokeratosis 3, disseminated superficial actinic, 175900 (3)
MVP	16	29820394	29848039	N	.	N	Y	-0.814392652	11.30404584	0.007448525	56.3	.	Mitral valve prolapse, myxomatous 1 (2)
MX1	21	41420304	41459214	N	.	N	N	-0.440180607	22.72964056	4.50E-09	89.7	DFP	.
MX2	21	41361943	41409390	N	.	N	Y	-0.35764605	26.43398738	7.01E-08	86.6	.	.
MXD1	2	69897688	69942945	N	.	N	Y	-0.274611335	31.00075245	0.388108481	33.1	.	.
MXD3	5	177301461	177312757	N	.	N	Y	0.234790597	66.51038954	0.001569929	62.9	.	.
MXD4	4	2247432	2262294	N	.	N	N	0.270393157	68.7156335	0.896936709	17.9	.	.
MXI1	10	110207605	110287365	N	.	N	Y	-0.076661182	43.91387394	0.707739926	24.4	.	Neurofibrosarcoma (3); {Prostate cancer, susceptibility to}, 176807 (3)
MXRA5	X	3308565	3346641	N	.	N	N	2.849287423	99.42698385	0.37648408	33.4	DM?	.
MXRA7	17	76672551	76711016	N	Viable	N	Y	.	.	0.013741642	53.6	.	.
MXRA8	1	1352689	1361777	N	.	N	N	-0.236942655	33.25230075	0.004712972	58.4	.	.
MYADM	19	53866223	53876437	N	.	N	N	-0.304469805	29.22961162	0.148243112	40.7	.	.
MYADML2	17	81939645	81947233	N	.	N	N	.	.	.	.	.	.
MYBL1	8	66562175	66614247	N	.	N	Y	-0.1984707	35.58488163	0.998332687	6.7	.	.
MYBPC1	12	101568353	101686018	N	.	N	N	-1.349087618	4.31209122	0.657926418	25.8	DM	Arthrogryposis, distal, type 1B, 614335 (3); Lethal congenital contracture syndrome 4, 614915 (3)
MYBPC2	19	50432903	50466321	N	.	N	N	1.520759045	97.05967471	4.01E-17	97.8	FTV	.
MYBPC3	11	47331397	47352702	N	.	N	Y	0.128595019	59.31585345	1.35E-06	82.1	DM	Cardiomyopathy, hypertrophic, 4, 115197 (3); Cardiomyopathy, dilated, 1MM, 615396 (3); Left ventricular noncompaction 10, 615396 (3)
MYBPH	1	203167811	203175813	N	.	N	N	0.414207864	76.57000637	3.22E-11	93.6	.	.
MYCBP	1	38862964	38874105	N	.	N	N	0.325637024	72.06690976	0.739328409	23.5	.	.
MYCBPAP	17	50508384	50531501	N	.	N	N	2.060154188	98.65717428	0.001733006	62.4	.	.
MYCL	1	39895426	39902256	N	.	N	Y	-0.346770353	26.9201829	0.358812473	33.9	.	.
MYCT1	6	152697895	152724567	N	.	N	N	0.805185239	89.25160618	6.34E-05	73.2	.	.
MYD88	3	38138478	38143022	N	.	N	Y	-0.209801572	34.94819702	0.711854614	24.3	DM	Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 (3); Macroglobulinemia, Waldenstrom, somatic, 153600 (3)
MYDGF	19	4641374	4670370	N	.	N	Y	.	.	.	.	.	.
MYEF2	15	48134631	48178517	N	.	N	N	-0.342941981	27.12276437	0.999492304	5.2	.	.
MYEOV	11	69294138	69367726	N	.	N	N	0.681452437	86.46755803	0.001192906	64	.	.
MYEOV2	2	240126563	240136807	N	.	N	N	0.206691474	64.80870522	0.000104799	71.7	.	.
MYH1	17	10492307	10518543	N	.	N	Y	0.451103974	78.39323957	1.29E-29	99.7	.	.
MYH13	17	10298084	10373130	N	.	N	N	1.1736446	94.7791862	1.89E-29	99.6	DP	.
MYH14	19	50188186	50310545	N	.	N	Y	1.468602717	96.82815304	0.999847921	4.1	DM	.
MYH15	3	108380369	108529322	N	.	N	N	-0.312721275	28.73762806	4.74E-39	99.9	DP	.
MYH2	17	10521148	10549957	N	.	N	N	-1.709008901	2.413613475	1.37E-08	88.5	DM	Proximal myopathy and ophthalmoplegia, 605637 (3)
MYH3	17	10628526	10657309	N	.	N	N	-1.895726289	1.875325577	3.60E-13	95.7	DM	Arthrogryposis, distal, type 2A, 193700 (3); Arthrogryposis, distal, type 2B, 601680 (3); Arthrogryposis, distal, type 8, 178110 (3)
MYH4	17	10443290	10469559	N	.	N	Y	1.145348053	94.47820802	8.81E-35	99.8	DM?	.
MYH7	14	23412738	23435718	N	.	N	N	-4.368176026	0.144701048	0.000145766	70.7	DM	Cardiomyopathy, hypertrophic, 1, 192600 (3); Cardiomyopathy, dilated, 1S, 613426 (3); Myopathy, myosin storage, autosomal dominant, 608358 (3); Liang distal myopathy, 160500 (3); Scapuloperoneal syndrome, myopathic type, 181430 (3); Left ventricular noncompaction 5, 613426 (3); Myopathy, myosin storage, autosomal recessive, 255160 (3)
MYH7B	20	34975403	35002437	N	.	N	N	-0.086198386	43.08618394	1.33E-23	99.2	DM	.
MYH8	17	10390322	10421950	N	.	N	N	-0.52380009	19.27417955	1.61E-34	99.8	DM	Carney complex variant, 608837 (3); Trismus-pseudocamptodactyly syndrome, 158300 (3)
MYL10	7	101613325	101629296	N	.	N	N	0.120331361	58.7428373	0.00804655	55.9	.	.
MYL12A	18	3247481	3256236	N	.	N	N	-0.088948948	42.87202639	0.001501508	63	.	.
MYL12B	18	3261909	3278284	N	.	N	Y	-0.021421177	47.83816635	0.290511999	36	.	.
MYL3	3	46857872	46882169	N	.	N	N	-0.275568538	30.94287203	0.888080621	18.3	DM	Cardiomyopathy, hypertrophic, 8, 608751 (3)
MYL4	17	47200446	47223679	N	.	N	N	0.210368257	65.09231927	0.000175625	70.2	.	.
MYL5	4	673580	682033	N	.	N	N	0.615687917	84.61538462	4.43E-08	87.1	.	.
MYL6	12	56158161	56163496	N	.	N	N	0.086492393	56.17873473	0.25661637	36.9	.	.
MYL6B	12	56152256	56159647	N	.	N	N	-0.304623579	29.21803554	0.003733811	59.3	.	.
MYL9	20	36541484	36551447	N	.	N	N	-0.275568538	30.94287203	0.066042135	45.4	.	.
MYLIP	6	16129125	16148248	N	Viable	N	Y	-0.326021923	27.98518261	0.020226887	51.6	DM	.
MYLK	3	123610049	123884331	N	.	N	Y	-0.318315109	28.3845575	9.38E-06	78.2	DM	Aortic aneurysm, familial thoracic 7, 613780 (3)
MYLK2	20	31819308	31834689	N	.	N	Y	-0.030382941	47.27093824	0.220320912	38	DM	Cardiomyopathy, hypertrophic, 1, digenic, 192600 (3)
MYLK3	16	46703369	46790407	N	.	N	Y	0.08055195	55.74463159	0.140967535	41	.	.
MYLK4	6	2663629	2750966	N	.	N	N	-0.084012126	43.26561324	1.66E-11	94.1	.	.
MYNN	3	169772831	169789716	N	.	N	N	-0.318518891	28.37876946	0.650144394	26	.	.
MYO10	5	16661914	16936276	N	.	N	Y	-0.435523428	22.93801007	0.00396952	59.1	.	.
MYO15A	17	18108706	18179802	N	.	N	Y	-0.769812224	12.20119234	.	.	DM	Deafness, autosomal recessive 3, 600316 (3)
MYO15B	17	75588058	75626501	N	.	N	N	.	.	.	.	.	.
MYO16	13	108596152	109208007	N	.	N	N	-0.913331324	9.318747468	0.998667246	6.3	.	.
MYO19	17	36495633	36543435	N	.	N	N	0.517803265	81.14834751	2.43E-18	98.3	.	.
MYO1A	12	57028517	57051198	N	.	N	Y	1.412036667	96.43456619	1.95E-35	99.8	DM	Deafness, autosomal dominant 48, 607841 (3)
MYO1B	2	191245185	191425389	N	.	N	N	-1.792008176	2.222608092	0.878004108	18.7	.	.
MYO1C	17	1464098	1492812	N	.	N	N	-0.530748449	18.95583724	3.89E-08	87.3	DM?	.
MYO1D	17	32492522	32877177	N	.	N	N	-0.676462075	14.59744169	3.30E-09	90	.	.
MYO1F	19	8520790	8577577	N	.	N	Y	-1.145384873	6.10638421	0.158022191	40.3	DM?	.
MYO1G	7	44962662	44979098	N	.	N	Y	0.308515249	70.97296984	7.64E-07	83	.	.
MYO1H	12	109347903	109455523	N	.	N	N	0.574955444	83.24940673	2.92E-17	97.9	.	.
MYO3A	10	25934267	26212527	N	.	N	Y	1.019311288	93.00804538	6.59E-30	99.7	DM	Deafness, autosomal recessive 30, 607101 (3)
MYO3B	2	170178145	170655171	N	.	N	N	0.950632634	92.01250217	4.47E-20	98.7	.	.
MYO5B	18	49822813	50195093	N	.	N	N	0.095527005	56.81541934	5.42E-10	91.7	DM	Microvillus inclusion disease, 251850 (3)
MYO5C	15	52192322	52295798	N	.	N	N	-0.5839644	17.265729	4.35E-18	98.2	.	.
MYO6	6	75749192	75919537	N	.	N	N	-1.506685884	3.322336054	0.017788399	52.2	DM	Deafness, autosomal dominant 22, 606346 (3); Deafness, autosomal recessive 37, 607821 (3); Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 (3)
MYO7A	11	77128264	77215239	N	.	N	Y	0.977362481	92.44081727	5.38E-25	99.3	DM	Usher syndrome, type 1B, 276900 (3); Deafness, autosomal recessive 2, 600060 (3); Deafness, autosomal dominant 11, 601317 (3)
MYO7B	2	127535802	127637729	N	Viable	N	Y	0.952157323	92.03565434	6.38E-16	97.4	DM?	.
MYO9A	15	71822289	72118577	N	Viable	N	Y	-0.284338968	30.38143196	0.999991726	2.5	.	.
MYO9B	19	17075781	17214537	N	.	N	Y	-0.782894194	11.91757828	0.999998877	1.7	DP	{Celiac disease, susceptibility to, 4}, 609753 (3)
MYOC	1	171635417	171652683	N	.	N	Y	0.981739879	92.5276379	5.02E-08	87	DM	Glaucoma 1A, primary open angle, 137750 (3)
MYOD1	11	17719568	17722131	N	.	N	Y	-0.382371374	25.31110725	2.68E-05	75.5	.	.
MYOF	10	93306429	93482317	N	.	N	Y	0.517859049	81.15413556	2.08E-36	99.9	DM?	.
MYOM1	18	3066807	3220108	N	.	N	N	1.578691216	97.37801702	1.08E-21	99	DM	.
MYOM2	8	2045040	2165552	N	.	N	N	3.640857875	99.68744574	1.49E-55	100	.	.
MYOM3	1	24056035	24112175	N	.	N	N	2.989425543	99.53695665	9.28E-28	99.5	.	.
MYOT	5	137867791	137887851	N	.	N	Y	-0.173091047	37.17659316	2.64E-05	75.5	DM	Muscular dystrophy, limb-girdle, type 1A, 159000 (3); Myopathy, myofibrillar, 3, 609200 (3); Myopathy, spheroid body, 182920 (3)
MYOZ1	10	73631654	73641757	N	Viable	N	Y	-0.080336605	43.59553163	0.004592103	58.6	.	.
MYOZ2	4	119135784	119187789	N	.	N	N	0.439288148	77.85495167	0.016734638	52.6	DM	Cardiomyopathy, hypertrophic, 16, 613838 (3)
MYOZ3	5	150660874	150679365	N	.	N	N	0.478716768	79.67818487	0.346673296	34.3	.	.
MYPN	10	68106117	68212017	N	.	N	N	-0.251204251	32.35515425	0.065221397	45.5	DM	Cardiomyopathy, dilated, 1KK, 615248 (3); Cardiomyopathy, hypertrophic, 22, 615248 (3); Cardiomyopathy, familial restrictive, 4, 615248 (3)
MYPOP	19	45890020	45902604	N	.	N	N	.	.	0.810391051	21.3	.	Proximal myopathy and ophthalmoplegia, 605637 (3)
MYRF	11	61752642	61788518	N	.	N	N	-0.901711179	9.550269144	0.999847803	4.1	.	.
MYRFL	12	69825304	69959097	N	.	N	N	.	.	.	.	.	.
MYRIP	3	39808914	40260321	N	.	N	N	0.543027199	82.16704289	0.000902541	65.1	.	.
MYT1L	2	1789113	2331260	N	.	N	Y	-1.664556841	2.593042774	0.999963989	3.1	DM	Mental retardation, autosomal dominant 39, 616521 (3)
MYZAP	15	57591941	57685364	N	.	N	N	0.579276796	83.42304798	2.21E-09	90.4	.	.
MZB1	5	139387480	139390081	N	.	N	N	.	.	0.003811455	59.3	.	.
MZF1	19	58561931	58573575	N	.	N	Y	1.264321101	95.53741969	1.81E-06	81.5	.	.
MZT1	13	72708357	72727687	N	.	N	N	0.023597424	51.32256758	0.611862318	27.1	.	.
MZT2A	2	131464900	131492743	N	.	N	N	.	.	0.005567677	57.6	.	.
MZT2B	2	130181737	130190729	N	.	N	N	.	.	0.575112152	28.1	.	.
N4BP1	16	48538726	48620148	N	.	N	N	-1.158896251	6.002199456	0.361226868	33.9	.	.
N4BP2	4	40056826	40158252	N	.	N	N	0.310906049	71.10030677	0.000473118	67.2	.	.
N4BP2L1	13	32400723	32428178	N	.	N	N	-0.299035003	29.50743763	0.945268895	15.2	.	.
N4BP2L2	13	32432417	32538885	N	.	N	N	0.4981674	80.38432598	3.06E-06	80.5	.	.
N4BP3	5	178113443	178126087	N	Viable	N	Y	-0.094082712	42.53631996	0.276863142	36.3	.	.
N6AMT2	13	20728731	20773958	N	.	N	N	-0.160151469	38.02743532	0.00099088	64.7	.	.
NAA10	X	153929242	153935223	N	.	N	N	-0.149930626	38.75094056	0.1884278	39	DM	N-terminal acetyltransferase deficiency, 300855 (3); ?Microphthalmia, syndromic 1, 309800 (3)
NAA11	4	79225694	79326050	N	.	N	N	-0.045692193	46.15384615	0.002822275	60.6	.	.
NAA15	4	139301455	139420033	N	.	N	N	-0.91605881	9.284019216	0.99857684	6.4	DM	.
NAA16	13	41311205	41377030	N	.	N	N	-1.066793815	6.974590496	1.71E-10	92.6	.	.
NAA20	20	20017116	20033655	N	.	N	N	-0.08703502	43.03409157	0.013606364	53.6	.	.
NAA25	12	112026689	112109022	N	.	N	N	-0.652332274	15.32094692	0.999989964	2.5	.	.
NAA30	14	57390544	57415917	N	.	N	N	0.033165214	52.10395323	0.973715071	12.6	.	.
NAA35	9	85941146	86022298	N	.	N	N	-0.197513786	35.67170226	0.999995237	2.2	.	.
NAA38	17	7856685	7885238	N	.	N	N	-0.022378042	47.78028593	0.008272463	55.7	.	.
NAA40	11	63938959	63957328	N	.	N	N	-0.203255573	35.26075129	0.005446684	57.8	.	.
NAA50	3	113716460	113746300	N	.	N	N	-0.066439705	44.63737917	0.876848813	18.8	.	.
NAA60	16	3443611	3486963	N	.	N	N	0.012418429	50.43120912	0.908883492	17.4	.	.
NAAA	4	75913657	75941051	N	.	N	Y	0.376541981	74.76413729	3.31E-06	80.3	.	.
NAALAD2	11	90131515	90192894	N	.	N	N	0.124460775	59.08433177	7.02E-15	96.8	.	.
NAALADL1	11	65044818	65058549	N	.	N	N	0.339330085	72.82514325	3.83E-12	94.7	.	.
NAALADL2	3	174438573	175810552	N	.	N	N	0.981095185	92.52184986	3.04E-06	80.5	.	.
NAB1	2	190646746	190692766	N	.	N	Y	-0.93393763	8.95988887	0.848508408	20	.	.
NAB2	12	57088894	57095476	N	Viable	N	Y	-0.343899023	27.05330787	0.987535198	10.5	.	.
NABP1	2	191678068	191696659	N	.	N	N	-0.138599374	39.52075013	0.014256968	53.4	.	.
NACA2	17	61590426	61591202	N	.	N	N	0.546245901	82.28280373	0.098926282	43.2	.	.
NACAD	7	45080438	45088914	N	.	N	Y	.	.	0.365728808	33.8	.	.
NACC2	9	136006537	136095285	N	Viable	N	Y	.	.	0.134607341	41.4	.	.
NADK	1	1751232	1780457	N	.	N	N	0.013678077	50.54696996	0.00126769	63.8	.	.
NADK2	5	36192592	36242279	N	.	N	N	0.143797178	60.51397812	0.907647887	17.5	.	?2,4-dienoyl-CoA reductase deficiency, 616034 (3)
NADSYN1	11	71453109	71524107	N	Viable	N	Y	-0.034864321	46.94101985	2.45E-09	90.3	.	.
NAF1	4	163110073	163166921	N	.	N	N	-0.219065877	34.38675696	0.959542887	14	.	.
NAGA	22	42058354	42070842	N	.	N	Y	-0.25849473	31.97314349	2.02E-06	81.3	DM	Schindler disease, type I, 609241 (3); Kanzaki disease, 609242 (3); Schindler disease, type III, 609241 (3)
NAGK	2	71064344	71079805	N	Viable	N	Y	0.370952088	74.45158303	8.58E-09	89.1	.	.
NAGLU	17	42536172	42544449	N	.	N	Y	-0.765838674	12.29380101	0.000404074	67.7	DM	Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 (3); ?Charcot-Marie-Tooth disease, axonal, type 2V, 616491 (3)
NAGPA	16	5024844	5034141	N	.	N	Y	0.157191398	61.55582566	2.86E-07	84.6	DM	.
NAIF1	9	128061233	128068206	N	.	N	N	-0.141317516	39.35289691	0.022545578	51.1	.	.
NAIP	5	70968483	71025114	N	.	N	Y	.	.	0.000869318	65.2	DM	.
NANOGNB	12	7765216	7774121	N	.	N	N	.	.	.	.	.	.
NANOGP8	15	35084193	35085110	N	.	N	N	.	.	.	.	.	.
NANOS1	10	119029716	119033732	N	.	N	Y	.	.	0.180809141	39.3	DM	Spermatogenic failure 12, 615413 (3)
NANOS2	19	45913214	45914870	N	.	N	Y	-0.094538075	42.4726515	0.575905924	28.1	.	.
NANOS3	19	13862063	13880757	N	.	N	Y	-0.192077745	36.04213695	0.007905076	56	.	.
NANP	20	25612935	25624175	N	.	N	N	-0.454685281	22.09295595	0.026541647	50.3	.	.
NANS	9	98056739	98083075	N	.	N	N	-0.396420408	24.5991781	0.000176879	70.2	.	.
NAP1L1	12	76036587	76085033	N	.	N	N	-0.539134657	18.60276668	0.993880985	8.9	.	.
NAP1L2	X	73212299	73214848	N	.	N	N	-0.239813643	33.09023557	0.791659154	21.9	.	.
NAP1L3	X	93670930	93673568	N	.	N	N	0.767667839	88.51073682	0.411770226	32.5	.	.
NAP1L4	11	2944431	2992377	N	.	N	N	-0.087839602	42.97621115	0.99573103	8.1	.	.
NAP1L5	4	88695915	88698235	N	.	N	N	-0.151691433	38.58887538	0.78862439	22	.	.
NAP1L6	X	73126037	73128080	N	.	N	N	.	.	.	.	.	.
NAPB	20	23374519	23421519	N	.	N	Y	-0.064525847	44.79365631	0.989108778	10.1	.	.
NAPEPLD	7	103099776	103149560	N	.	N	Y	-0.101888702	42.01539619	0.062721499	45.7	.	.
NAPG	18	10525905	10552761	N	.	N	N	-0.10763024	41.63338543	0.086131935	44	.	.
NAPRT	8	143574785	143578649	N	.	N	N	.	.	.	.	.	.
NAPSA	19	50358477	50365830	N	.	N	N	0.503288375	80.58111941	7.96E-07	83	.	.
NARF	17	82458180	82490537	N	.	N	N	-0.549200816	18.232332	0.001224919	63.9	.	.
NARS	18	57600656	57622213	N	.	N	N	-0.936655249	8.925160618	3.48E-07	84.3	.	.
NARS2	11	78435961	78574874	N	.	N	N	-0.010744443	48.64270417	0.000838256	65.4	FTV	Combined oxidative phosphorylation deficiency 24, 616239 (3)
NAT1	8	18170477	18223689	N	.	N	Y	0.049127994	53.35995833	2.85E-10	92.2	DFP	Orthostatic intolerance, 604715 (3)
NAT14	19	55485004	55487568	N	.	N	N	.	.	0.143168129	40.9	.	.
NAT16	7	101170493	101180276	N	.	N	N	-0.654398695	15.22255021	5.91E-05	73.4	.	.
NAT2	8	18391245	18401218	N	Viable	N	Y	1.270564352	95.56057186	0.022607866	51	DFP	[Acetylation, slow], 243400 (3)
NAT6	3	50296402	50299421	N	.	N	N	0.397138302	75.69601204	0.402945153	32.7	.	.
NAT8	2	73640832	73642393	N	.	N	N	0.914059295	91.35266539	0.075651692	44.7	.	.
NAT8L	4	2059512	2069089	N	.	N	Y	-0.177071645	36.92770736	0.324677884	35	DM	?N-acetylaspartate deficiency, 614063 (3)
NAT9	17	74770547	74776367	N	.	N	N	-0.083207293	43.33506975	0.080661177	44.4	.	.
NATD1	17	21238870	21253410	N	Viable	N	Y	.	.	.	.	.	.
NAV1	1	201622885	201826969	N	.	N	N	-2.225256472	1.24442901	0.999999985	0.8	DM?	.
NAV2	11	19350724	20121598	N	.	N	N	-1.979027737	1.70168432	0.997517125	7.3	DM?	.
NAV3	12	77830905	78213008	N	.	N	N	-3.790405915	0.295190137	0.999999399	1.6	.	.
NBAS	2	15166909	15561330	N	.	N	N	-0.357220576	26.43977542	1.89E-25	99.4	DM?	Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 (3); Infantile liver failure syndrome 2, 616483 (3)
NBEAL1	2	203014879	203226378	N	.	N	N	-0.491458858	20.53597268	1.09E-10	92.9	.	.
NBEAL2	3	46979683	47009703	N	.	N	Y	-1.347422713	4.317879261	0.862533062	19.4	DM	Gray platelet syndrome, 139090 (3)
NBL1	1	19640554	19658456	N	.	N	Y	-0.003544497	49.14626382	0.108864873	42.7	.	.
NBPF1	1	16562319	16613562	N	.	N	N	.	.	.	.	DM	.
NBPF10	1	146064699	146144942	N	.	N	N	.	.	2.81E-13	95.7	.	.
NBPF11	1	148102046	148152322	N	.	N	N	.	.	.	.	.	.
NBPF12	1	146938744	146996202	N	.	N	N	.	.	0.210636207	38.4	.	.
NBPF14	1	148531385	148679751	N	.	N	N	.	.	.	.	.	.
NBPF15	1	144421386	144461674	N	.	N	N	.	.	0.123939064	41.9	.	.
NBPF19	1	149390623	149556361	N	.	N	N	.	.	.	.	.	.
NBPF20	1	145289900	145405778	N	.	N	N	.	.	0.000445919	67.4	.	.
NBPF26	1	120805418	120841481	N	.	N	N	.	.	.	.	.	.
NBPF3	1	21440128	21485005	N	.	N	N	1.53447182	97.1407073	1.98E-11	93.9	.	.
NBPF4	1	108223341	108244081	N	.	N	N	.	.	0.346635144	34.3	.	.
NBPF6	1	108375799	108471002	N	.	N	N	.	.	0.087453851	44	.	.
NBPF9	1	149054027	149103561	N	.	N	N	.	.	.	.	.	.
NBR1	17	43170481	43211689	N	Viable	N	Y	0.061566363	54.27446895	0.000436707	67.5	.	.
NCALD	8	101686543	102124907	Y	Viable	N	Y	-0.193034849	35.95531632	0.817423495	21.1	DFP	.
NCAM2	21	20998315	21543329	N	.	N	Y	-0.505944787	19.98032066	0.922157338	16.6	.	.
NCAN	19	19211973	19252233	N	.	N	Y	-1.154671147	6.042715749	0.154546738	40.4	DP	.
NCAPD2	12	6493356	6531955	N	.	N	N	-0.006311647	48.96683452	5.93E-08	86.8	DM?	.
NCAPD3	11	134150119	134225454	N	.	N	N	-0.781940841	11.94073045	0.073152087	44.8	.	.
NCAPG	4	17810902	17844862	N	.	N	N	-0.669103383	14.78844707	0.618144197	27	.	.
NCBP1	9	97633626	97673748	N	.	N	N	-1.119613893	6.37842218	0.999956109	3.2	.	.
NCBP2	3	196935402	196942597	N	.	N	N	-0.095495045	42.38583087	0.266930249	36.6	.	.
NCBP2-AS2	3	196942623	196943540	N	.	N	N	.	.	.	.	.	.
NCBP2L	X	107777733	107794682	N	.	N	N	.	.	0.12966993	41.6	.	.
NCCRP1	19	39196961	39201884	N	.	N	N	0.567799588	82.98894484	0.000145564	70.7	.	.
NCEH1	3	172630249	172711218	N	.	N	Y	-0.576495149	17.46252243	0.001074511	64.4	.	.
NCF1	7	74773962	74789315	N	.	N	N	.	.	0.923359561	16.5	DM	Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3)
NCF2	1	183555563	183590876	N	.	N	N	0.342853172	73.02193668	8.51E-05	72.4	DM	Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3)
NCF4	22	36860988	36878015	Y	Viable	N	Y	0.041776336	52.69433351	7.90E-06	78.7	DM	Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 (3)
NCK1	3	136862208	136949823	N	.	N	Y	-0.308297979	28.9923019	0.001035026	64.6	DFP	.
NCK2	2	105744897	105894274	N	.	N	Y	-0.834478112	10.89309487	0.702843118	24.5	.	.
NCKAP1L	12	54497711	54548238	N	.	N	N	-1.093943487	6.650460149	0.990439664	9.9	.	.
NCKAP5	2	132671799	133568463	N	.	N	N	0.984866801	92.59130636	0.524874192	29.3	DM?	.
NCKAP5L	12	49791146	49828750	N	.	N	N	-0.674411145	14.63216994	0.565619252	28.3	.	.
NCKIPSD	3	48673844	48686364	N	.	N	Y	0.154472727	61.33588007	0.007131362	56.5	.	.
NCL	2	231453531	231483641	N	.	N	N	-0.65696586	15.15888175	0.999106738	5.8	.	.
NCLN	19	3185563	3209575	N	.	N	N	-0.723688873	13.31249638	0.509474338	29.7	.	.
NCMAP	1	24556111	24609328	N	.	N	N	0.464520293	79.05307634	0.067267034	45.3	.	.
NCOA1	2	24491914	24770702	N	.	N	Y	-2.471290201	0.995543208	0.999077343	5.8	FP	.
NCOA2	8	70109762	70403805	N	.	N	Y	-1.29083085	4.740406321	0.999997382	2	.	.
NCOA4	10	46005088	46030714	N	.	N	Y	0.044646769	52.94321931	0.008565806	55.5	.	.
NCOA5	20	46060985	46089952	N	.	N	Y	-1.230257993	5.313422469	0.996800144	7.7	.	.
NCOA7	6	125781161	125932030	N	Viable	N	Y	-0.635265313	15.78977832	0.960907672	13.9	.	.
NCR1	19	54906150	54916140	N	.	N	Y	0.278045399	69.20761706	7.82E-05	72.6	.	.
NCR2	6	41335655	41350887	N	.	N	N	0.474082735	79.50454361	0.000163783	70.4	.	.
NCR3	6	31588895	31592985	N	.	N	N	0.363300057	74.07536031	0.001461307	63.1	DFP	{Malaria, mild, susceptibility to}, 609148 (3)
NCR3LG1	11	17351726	17377341	N	.	N	N	.	.	.	.	.	.
NDC1	1	53765460	53838860	N	.	N	N	-0.578256721	17.40464201	0.937525026	15.7	.	.
NDC80	18	2571511	2616635	N	.	N	N	-0.823146294	11.10725242	0.001486174	63.1	.	.
NDE1	16	15643267	15726353	N	.	N	Y	-0.401052411	24.3502923	0.047109548	47.3	DM	Lissencephaly 4 (with microcephaly), 614019 (3); ?Microhydranencephaly, 605013 (3)
NDFIP1	5	142108505	142154443	N	.	N	Y	-0.148973548	38.82039706	0.920196503	16.7	.	.
NDFIP2	13	79481124	79556075	N	Viable	N	Y	-0.002587674	49.23887249	0.80187873	21.6	.	.
NDNF	4	121035613	121073021	N	.	N	N	0.125265848	59.15378827	0.152719665	40.5	.	.
NDNL2	15	29268149	29269829	N	.	N	N	0.101649038	57.35370724	0.195522567	38.8	.	.
NDOR1	9	137205670	137217009	N	.	N	N	0.515730143	81.10204318	2.61E-05	75.6	FP	.
NDP	X	43948776	43973504	N	.	N	Y	0.182119845	63.34433061	0.643828841	26.2	DM	Norrie disease, 310600 (3); Exudative vitreoretinopathy 2, X-linked, 305390 (3)
NDRG1	8	133237171	133302022	N	.	N	Y	-0.29042075	30.03993749	0.053823241	46.6	DM	Charcot-Marie-Tooth disease, type 4D, 601455 (3)
NDRG2	14	21016763	21070872	N	.	N	Y	0.050084766	53.41783875	0.126597034	41.7	.	.
NDRG4	16	58462846	58513628	N	Viable	N	Y	-0.327935902	27.84048157	0.019809072	51.8	.	.
NDST2	10	73801911	73811798	N	.	N	Y	-0.400752019	24.36765642	0.052949614	46.7	.	.
NDST3	4	118033618	118258648	N	.	N	Y	-1.10636931	6.482606934	0.020116746	51.6	.	.
NDST4	4	114827763	115113876	N	.	N	N	-0.048107958	45.96284077	0.082339173	44.3	.	.
NDUFA1	X	119871487	119876662	N	.	N	N	0.27215815	68.79087805	0.580718048	28	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFA10	2	239892450	240025402	N	.	N	N	0.163586571	62.05938531	0.00138794	63.4	DM	?Leigh syndrome, 256000 (3)
NDUFA11	19	5891276	5904006	N	.	N	N	.	.	0.538189295	28.9	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFA12	12	94897055	95003770	N	.	N	N	0.102455237	57.40579962	0.002015993	61.9	DM	Leigh syndrome due to mitochondrial complex 1 deficiency, 256000 (3)
NDUFA2	5	140638740	140647785	N	.	N	N	0.268480327	68.6056607	0.339536516	34.6	DM	Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)
NDUFA3	19	54102728	54109257	N	.	N	N	0.631506073	85.09579209	0.001385562	63.4	.	.
NDUFA4	7	10931951	10940256	N	.	N	N	0.008591214	50.15917115	0.480021717	30.6	DM	.
NDUFA4L2	12	57234903	57240715	N	.	N	N	0.168070043	62.3893037	0.014252375	53.4	.	.
NDUFA6	22	42085525	42090955	N	.	N	N	0.112828307	58.21033744	0.003259494	60	DM	.
NDUFA7	19	8308768	8321396	N	.	N	N	0.617455056	84.68484112	0.004021957	59.1	.	.
NDUFA9	12	4649095	4694317	N	.	N	N	0.491958596	80.15280431	0.542744184	28.8	DM	Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)
NDUFAB1	16	23581002	23596356	N	.	N	N	0.033970832	52.15025757	0.755255332	23	.	.
NDUFAF1	15	41387349	41402519	N	.	N	N	0.922519097	91.57839903	0.00389629	59.2	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFAF2	5	60945129	61153037	N	.	N	Y	0.057436789	53.89824622	3.86E-07	84.1	DM	Mitochondrial complex I deficiency, 252010 (3); Leigh syndrome, 256000 (3)
NDUFAF3	3	49020459	49023495	N	.	N	N	-0.221132832	34.27099612	4.86E-05	74	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFAF4	6	96889313	96897881	N	.	N	N	0.034927599	52.21971407	0.382015185	33.3	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFAF5	20	13784950	13821582	N	.	N	N	-0.054957051	45.47085721	1.00E-05	78	.	Mitochondrial complex 1 deficiency, 252010 (3)
NDUFAF6	8	94895767	95116455	N	.	N	N	-0.008177066	48.7989813	2.91E-05	75.3	.	Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)
NDUFB1	14	92116122	92121917	N	.	N	N	0.06302642	54.36707762	0.311678003	35.4	DM	.
NDUFB10	16	1959508	1961975	N	.	N	N	-0.275568538	30.94287203	0.046629914	47.4	.	.
NDUFB11	X	47142216	47145504	N	.	N	N	0.252517615	67.5696012	0.750858556	23.1	.	Linear skin defects with multiple congenital anomalies 3, 300952 (3)
NDUFB2	7	140690777	140722790	N	.	N	N	0.024554204	51.41517625	0.011815067	54.2	.	.
NDUFB3	2	201071433	201085750	N	.	N	N	0.175573187	62.89865139	0.042565284	47.9	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFB4	3	120596309	120602500	N	.	N	N	0.018964694	50.97528506	0.002266066	61.5	.	.
NDUFB5	3	179604690	179627647	N	.	N	N	0.301362114	70.58517104	0.003441089	59.8	.	.
NDUFB6	9	32552999	32573184	N	.	N	N	0.260977174	68.09052498	0.047218448	47.3	DP	.
NDUFB7	19	14566078	14572062	N	.	N	N	0.669023361	86.17815593	0.045465922	47.5	.	.
NDUFB9	8	124539103	124568510	N	.	N	N	0.422369205	76.96359322	0.042889447	47.9	DM	?Mitochondrial complex I deficiency, 252010 (3)
NDUFC1	4	139266880	139302551	N	.	N	N	0.204629358	64.65242808	0.459572169	31.1	.	.
NDUFC2	11	78068304	78080219	N	.	N	N	0.017051112	50.83058401	0.625235914	26.8	DP	.
NDUFC2-KCTD14	11	78016971	78079865	N	.	N	N	0.069572814	54.86484922	0.626507874	26.7	.	.
NDUFS2	1	161197104	161214395	N	.	N	N	-0.183464709	36.53990855	0.997735395	7.1	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFS4	5	53560633	53683340	N	.	N	Y	0.196318636	64.16623256	0.004164996	58.9	DM	Leigh syndrome, 256000 (3); Mitochondrial complex I deficiency, 252010 (3)
NDUFS5	1	39026318	39034636	N	.	N	N	-0.0579797	45.26827574	0.098217332	43.3	DM	.
NDUFS6	5	1801400	1816605	N	.	N	N	0.073399639	55.17740348	0.000262201	69	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFS8	11	68030617	68036644	N	.	N	N	-0.166697481	37.63384847	0.014174502	53.4	DM	Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3)
NDUFV1	11	67606852	67612535	N	.	N	N	-0.267759536	31.40012734	9.83E-05	71.9	DM	Mitochondrial complex I deficiency, 252010 (3)
NDUFV3	21	42879644	42913304	N	.	N	N	-0.080184792	43.61289576	4.33E-09	89.7	DM?	.
NEBL	10	20779973	21174187	N	.	N	N	0.285362033	69.64172021	5.77E-24	99.2	DM	.
NECAB1	8	90791550	90959408	N	.	N	N	-0.125507302	40.39474446	0.377811814	33.4	.	.
NECAB2	16	83968632	84002776	N	.	N	N	-0.292988049	29.83735602	.	.	.	.
NECAB3	20	33657087	33674463	N	.	N	N	0.46275405	78.96625572	0.797631145	21.8	.	.
NECAP1	12	8082211	8097771	N	.	N	N	0.181312488	63.27487411	0.040911439	48.2	.	?Epileptic encephalopathy, early infantile, 21, 615833 (3)
NECAP2	1	16440672	16460078	N	.	N	N	0.253623009	67.679574	6.87E-05	72.9	.	.
NEDD1	12	96907223	96953777	N	.	N	N	-0.401857672	24.31556404	0.221564199	38	.	.
NEDD8	14	24216852	24232454	N	.	N	N	0.097672002	56.94854431	0.429440681	32	.	.
NEDD8-MDP1	14	24213955	24232352	N	.	N	N	.	.	.	.	.	.
NEDD9	6	11183298	11382348	N	.	N	Y	0.077681175	55.50153383	0.534981125	29	DP	.
NEFH	22	29480230	29491390	N	Viable	N	Y	0.162932629	61.98414077	0.001261041	63.8	DM	?{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)
NEFL	8	24950955	24957110	N	.	N	Y	.	.	.	.	DM	Charcot-Marie-Tooth disease, type 2E, 607684 (3); Charcot-Marie-Tooth disease, type 1F, 607734 (3)
NEFM	8	24913012	24919098	N	.	N	Y	-0.200081618	35.49806101	0.035956328	48.8	DM	.
NEGR1	1	71395940	72282734	N	Viable	N	Y	-0.308297979	28.9923019	0.951349395	14.6	DM	.
NEIL1	15	75346955	75357114	N	.	N	Y	0.223761511	65.86212884	0.000108858	71.6	FP	.
NEIL2	8	11769639	11787346	N	.	N	N	1.102755647	93.96886033	2.11E-09	90.4	DM?	.
NEIL3	4	177309836	177362943	N	.	N	Y	0.7745139	88.64386178	3.55E-07	84.3	.	.
NEK10	3	27110085	27369460	N	.	N	N	-0.602679949	16.63483244	0.000236569	69.3	.	.
NEK11	3	131026850	131350465	N	Viable	N	Y	0.261428632	68.11367714	3.82E-17	97.9	.	.
NEK2	1	211658657	211675630	N	.	N	N	0.014483413	50.59906234	8.72E-07	82.8	.	?Retinitis pigmentosa 67, 615565 (3)
NEK3	13	52132639	52159861	N	.	N	N	0.945986183	91.92568154	5.06E-10	91.7	FTV	.
NEK4	3	52708449	52770949	N	.	N	N	-0.383024958	25.26480292	1.22E-12	95.2	.	.
NEK5	13	52033611	52129078	N	.	N	N	0.176981701	62.98547201	5.03E-20	98.7	.	.
NEK6	9	124257606	124353307	N	.	N	Y	-0.339267298	27.29640563	0.644137661	26.2	.	.
NELFA	4	1982714	2041903	N	.	N	N	-1.505193607	3.345488221	0.16688872	39.9	.	.
NELFCD	20	58981208	58995133	N	.	N	N	-0.993965971	7.95855762	0.20597781	38.6	.	.
NELFE	6	31952087	31959110	N	.	N	N	-0.139403663	39.45708167	0.756273167	22.9	.	.
NELL2	12	44508275	44921848	N	.	N	Y	-0.532131719	18.89216878	0.999853572	4.1	.	.
NEMP1	12	57055643	57088063	N	.	N	N	.	.	.	.	.	.
NEMP2	2	190504342	190534722	N	.	N	N	.	.	.	.	.	.
NENF	1	212432887	212446379	N	.	N	Y	0.078989305	55.61150663	0.002991004	60.3	.	.
NES	1	156668763	156677397	Y	Viable	N	Y	0.242257395	67.00816114	2.07E-05	76.1	.	.
NET1	10	5412551	5458463	N	.	N	N	-0.760248704	12.39219772	0.066854195	45.3	.	Orthostatic intolerance, 604715 (3)
NETO1	18	72742314	72868146	N	.	N	Y	-0.182507799	36.58042484	0.949402709	14.8	.	.
NETO2	16	47077703	47143997	N	.	N	N	-0.758487286	12.43271401	0.158399551	40.2	.	.
NEU1	6	31857659	31862906	N	.	N	Y	-0.411426546	23.88724894	1.93E-05	76.3	DM	Sialidosis, type I, 256550 (3); Sialidosis, type II, 256550 (3)
NEU2	2	233032672	233035057	N	.	N	N	0.616792848	84.65590091	3.09E-12	94.8	FP	.
NEU3	11	74988134	75018893	N	.	N	Y	1.085834749	93.80100712	1.64E-06	81.7	.	.
NEU4	2	241808825	241817413	N	.	N	Y	1.629158242	97.6384789	0.000277583	68.9	.	.
NEURL1	10	103493979	103592552	N	.	N	Y	-0.281960735	30.55507322	.	.	.	.
NEURL1B	5	172641266	172691540	N	.	N	N	.	.	0.370536573	33.6	.	.
NEURL2	20	45888625	45891287	N	Viable	N	Y	-0.280200056	30.62452972	0.002620214	60.9	.	.
NEURL3	2	96497643	96508109	N	.	N	N	.	.	.	.	.	.
NEURL4	17	7315628	7329393	N	.	N	N	-1.941799743	1.782716907	0.999976734	2.9	.	.
NEUROD2	17	39603536	39609777	N	.	N	Y	-0.321544247	28.21670429	0.729792595	23.8	.	.
NEUROD6	7	31337461	31340894	N	.	N	N	-0.212672702	34.75719164	0.681645767	25.1	.	.
NEXN	1	77888513	77943895	N	.	N	N	-0.895310436	9.677606066	3.66E-06	80.2	DM	Cardiomyopathy, dilated, 1CC, 613122 (3); Cardiomyopathy, hypertrophic, 20, 613876 (3)
NFAM1	22	42380410	42432395	N	.	N	N	-0.255776741	32.13520866	0.026079622	50.3	.	.
NFATC2	20	51386957	51562831	N	.	N	Y	-0.868689967	10.22747005	0.999251031	5.6	.	.
NFATC2IP	16	28950807	28967097	N	.	N	Y	-0.393703195	24.72072698	0.002327345	61.4	.	.
NFATC4	14	24365673	24379604	N	Viable	N	Y	-0.472915409	21.34051051	0.985383664	10.9	DP	.
NFE2L2	2	177227595	177392697	N	.	N	Y	-0.043626754	46.35063958	0.686008362	25	DFP	.
NFE2L3	7	26152240	26187125	N	.	N	Y	0.486674995	79.95022284	1.10E-07	86	.	.
NFIC	19	3359563	3469217	N	.	N	Y	0.107389526	57.79938647	0.842498931	20.2	.	.
NFIL3	9	91409045	91423862	N	.	N	Y	-0.396420408	24.5991781	0.948599643	14.9	.	.
NFKB2	10	102394110	102402529	N	.	N	Y	-0.619600205	16.18915321	0.999696458	4.6	.	Immunodeficiency, common variable, 10, 615577 (3)
NFKBIB	19	38899700	38908893	N	.	N	Y	-0.286592944	30.25409504	0.249570217	37.1	.	.
NFKBID	19	35887653	35902303	N	.	N	Y	-0.059741353	45.11778665	0.795064374	21.9	.	.
NFKBIE	6	44258166	44265788	N	.	N	Y	.	.	0.548429215	28.7	DP	.
NFKBIL1	6	31546870	31558829	N	.	N	N	-0.086078072	43.11512415	0.81664717	21.1	DFP	{Rheumatoid arthritis, susceptibility to}, 180300 (3)
NFRKB	11	129863636	129895590	N	.	N	N	-1.060803774	7.049835041	0.752744578	23.1	.	.
NFS1	20	35668055	35699359	N	.	N	N	0.028532581	51.68721422	0.832120909	20.6	.	.
NFU1	2	69395750	69437628	N	.	N	N	-0.099170261	42.1543092	0.000687751	66	DM	Multiple mitochondrial dysfunctions syndrome 1, 605711 (3)
NFX1	9	33290511	33371157	N	.	N	N	-0.537577331	18.70695144	0.386441239	33.1	.	.
NFXL1	4	47847233	47914667	N	.	N	Y	-0.065984258	44.68368351	0.00788898	56	.	.
NFYB	12	104117077	104138289	N	.	N	N	0.033014066	52.06922498	0.003273758	60	.	.
NFYC	1	40691570	40771603	N	.	N	N	-0.251145013	32.40145859	0.63195935	26.6	.	.
NGB	14	77265483	77271312	N	.	N	Y	0.08457904	56.06876194	0.0025318	61.1	.	.
NGDN	14	23469688	23509862	N	.	N	N	0.521014761	81.29304856	6.84E-07	83.2	.	.
NGEF	2	232878686	233013272	N	.	N	Y	-1.065025053	7.003530706	0.949825525	14.8	.	.
NGFRAP1	X	103376340	103378077	N	.	N	N	0.227138911	66.07628639	0.254415485	37	.	.
NGLY1	3	25718944	25790039	N	.	N	N	-0.438416515	22.82803727	2.20E-10	92.4	DM	Congenital disorder of deglycosylation, 615273 (3)
NHEJ1	2	219075317	219160865	N	.	N	Y	-0.080336605	43.59553163	0.027184525	50.2	DM	Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3)
NHLH1	1	160367067	160372848	N	.	N	Y	0.177486232	63.00862418	0.640239275	26.3	.	.
NHLH2	1	115836377	115843917	N	Viable	N	Y	-0.006414986	48.96104648	0.537457457	28.9	FP	.
NHLRC1	6	18121419	18122606	N	.	N	Y	0.126071509	59.22903282	0.036006534	48.8	DM	Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3)
NHLRC2	10	113854661	113917194	N	.	N	N	0.430170878	77.43821265	0.000339055	68.3	.	.
NHLRC3	13	39038306	39050109	N	.	N	N	0.647613662	85.55883545	0.003808656	59.3	.	.
NHLRC4	16	566996	569495	N	.	N	N	0.087449076	56.25976732	0.002427507	61.2	.	.
NHS	X	17375420	17735994	N	.	N	N	1.315095237	95.90206633	0.999461889	5.2	DM	Nance-Horan syndrome, 302350 (3); Cataract 40, X-linked, 302200 (3)
NHSL1	6	138422043	138692571	N	.	N	N	.	.	.	.	.	.
NHSL2	X	71910818	72161750	N	.	N	N	.	.	0.812282091	21.2	.	.
NICN1	3	49422946	49429326	N	.	N	N	-0.175157533	37.05504428	0.257245529	36.9	.	.
NID1	1	235975830	236065162	N	.	N	Y	0.829612913	89.78410604	0.000366476	68	DM	.
NID2	14	52004803	52069228	N	.	N	N	2.778940243	99.36331539	6.95E-07	83.1	.	.
NIF3L1	2	200889327	200903930	N	.	N	N	0.545437394	82.24807548	0.005177005	58	.	.
NIFK	2	121726945	121736923	N	.	N	N	-0.049367758	45.85286797	.	.	.	.
NIM1K	5	43192071	43280850	N	.	N	N	.	.	.	.	.	.
NIN	14	50719763	50831121	N	.	N	N	-0.016232699	48.19702495	8.94E-06	78.3	DM	Seckel syndrome 7, 614851 (3)
NINJ1	9	93121489	93134288	N	.	N	Y	0.24597088	67.24547086	0.061293909	45.9	FP	.
NINJ2	12	564296	663779	N	.	N	Y	0.538742637	81.99918967	0.020138862	51.6	.	.
NINL	20	25452705	25585517	N	.	N	N	1.300052518	95.79209353	3.97E-33	99.8	.	.
NIPA1	15	22773063	22829791	N	.	N	N	-0.680738037	14.48168085	0.214097496	38.3	DM	Spastic paraplegia 6, autosomal dominant, 600363 (3)
NIPA2	15	22838641	22868384	N	.	N	N	-0.33543894	27.48162297	0.487193754	30.3	DM	.
NIPAL1	4	47914142	48040173	N	.	N	N	0.33806995	72.74989871	3.21E-09	90.1	.	.
NIPAL2	8	98189833	98294393	N	.	N	N	0.236703709	66.62615037	5.79E-06	79.3	.	.
NIPAL3	1	24415794	24472976	N	.	N	Y	-0.293139081	29.82577994	0.000454712	67.3	.	.
NIPAL4	5	157460019	157474717	N	.	N	N	0.460989431	78.87943509	0.000898829	65.1	DM	Ichthyosis, congenital, autosomal recessive 6, 612281 (3)
NIPSNAP1	22	29554808	29581337	N	.	N	Y	-0.321544247	28.21670429	0.979278957	11.9	DM	.
NIPSNAP3A	9	104747688	104760122	N	Viable	N	Y	0.463710367	79.01834809	1.64E-05	76.8	DM	.
NIPSNAP3B	9	104764157	104777457	N	.	N	N	0.857710008	90.32239393	0.023882968	50.7	.	.
NISCH	3	52455118	52493071	N	.	N	N	-2.074079383	1.504890895	0.817101389	21.1	DM?	.
NIT1	1	161118086	161125445	N	.	N	Y	-0.320432866	28.29194883	0.000861525	65.3	.	.
NIT2	3	100334701	100361635	N	.	N	N	-0.489328961	20.62279331	1.60E-10	92.6	.	.
NKAIN1	1	31179745	31239554	N	.	N	N	0.017051112	50.83058401	0.615737173	27.1	.	.
NKAIN2	6	123804141	124825657	N	.	N	N	-0.183617621	36.51675638	0.007832385	56.1	DM	.
NKAIN3	8	62248591	62999652	N	.	N	N	0.343512144	73.05666493	0.010179443	54.9	.	.
NKAIN4	20	63240784	63272694	N	.	N	N	0.412953559	76.48897378	0.023717185	50.8	.	.
NKAP	X	119920672	119943772	N	.	N	N	-0.115133273	41.12403774	0.995513908	8.2	.	.
NKAPL	6	28259320	28260958	N	.	N	N	1.088556897	93.82994733	0.000165621	70.4	.	.
NKD1	16	50548330	50640739	N	.	N	Y	0.122395494	58.93963072	0.997929799	7	.	.
NKD2	5	1008829	1038943	N	.	N	Y	0.482542375	79.82867396	2.36E-05	75.8	.	.
NKG7	19	51371606	51372715	N	Viable	N	Y	0.29385898	70.12212768	0.004006662	59.1	.	.
NKIRAS1	3	23891660	23946591	N	.	N	N	-0.133010364	39.8622446	0.034887772	49	.	.
NKIRAS2	17	42011382	42025644	N	.	N	Y	-0.343096194	27.10540024	0.063309458	45.7	.	.
NKPD1	19	45149750	45160150	N	.	N	N	.	.	1.89E-09	90.6	.	.
NKRF	X	119588337	119605895	N	.	N	Y	0.206691474	64.80870522	0.955812168	14.3	.	.
NKTR	3	42600614	42648741	N	.	N	N	-0.006462988	48.93210627	0.99187751	9.5	.	.
NKX1-2	10	124445239	124450184	N	.	N	N	.	.	.	.	.	.
NKX2-4	20	21395367	21398028	N	.	N	N	.	.	0.278447692	36.2	.	.
NKX2-6	8	23702451	23706598	N	.	N	Y	.	.	0.003522543	59.7	DM	Persistent truncus arteriosus, 217095 (3); Conotruncal heart malformations, 217095 (3)
NKX2-8	14	36580579	36582607	N	.	N	Y	.	.	0.243402675	37.3	.	.
NKX3-1	8	23678693	23682927	N	.	N	Y	0.112828307	58.21033744	0.000884341	65.2	DFP	.
NKX6-2	10	132783179	132786052	N	.	N	Y	-0.514710293	19.63882619	0.013461307	53.7	.	.
NKX6-3	8	41645178	41650669	N	.	N	Y	0.342555909	72.99878451	0.190054226	39	.	.
NLGN1	3	173396284	174286644	N	.	N	Y	-1.174860514	5.845922324	0.755797512	23	DM?	.
NLGN2	17	7404874	7419860	N	.	N	Y	-1.06804498	6.95722637	0.9926247	9.3	DM	.
NLGN3	X	71144831	71171201	N	.	N	Y	-0.478954353	21.04532037	0.896227168	17.9	DM	{Autism susceptibility, X-linked 1}, 300425 (3); {Asperger syndrome susceptibility, X-linked 1}, 300494 (3)
NLGN4X	X	5840637	6228863	N	.	N	N	-0.942245059	8.826763906	0.932298559	16	DM	.
NLGN4Y	Y	14522638	14845650	N	.	N	N	.	.	0.645547567	26.2	DM	.
NLN	5	65722196	65871725	N	.	N	Y	-0.090406755	42.76784164	3.60E-07	84.3	.	.
NLRC3	16	3539033	3577400	N	.	N	Y	.	.	1.03E-12	95.2	.	.
NLRC4	2	32224453	32265854	N	.	N	Y	-1.33885276	4.40469989	4.35E-08	87.2	.	Autoinflammation with infantile enterocolitis, 616050 (3); ?Familial cold autoinflammatory syndrome 4, 616115 (3)
NLRC5	16	56989485	57083531	N	.	N	Y	-1.069028096	6.916710077	6.72E-05	73	.	.
NLRP1	17	5499427	5619424	N	.	N	Y	1.078197718	93.71997453	2.08E-12	95	DM	{Vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3); ?Corneal intraepithelial dyskeratosis and ectodermal dysplasia, 615225 (3)
NLRP10	11	7959424	7965426	N	.	N	Y	0.321452825	71.85275221	5.10E-12	94.6	.	.
NLRP11	19	55785397	55836800	N	.	N	N	-0.286144353	30.27145917	3.92E-06	80	.	.
NLRP12	19	53793603	53824394	N	.	N	Y	0.100650412	57.25531053	3.14E-27	99.5	DM	Familial cold autoinflammatory syndrome 2, 611762 (3)
NLRP13	19	55891699	55932336	N	.	N	N	0.456979998	78.63054929	5.16E-14	96.3	.	.
NLRP14	11	7020446	7071308	N	.	N	N	1.562123853	97.2796203	9.15E-23	99.1	DM	.
NLRP2	19	54953130	55001142	N	.	N	N	1.80555844	98.19413093	1.88E-20	98.8	DM	.
NLRP4	19	55836578	55881854	N	.	N	N	0.229966261	66.19783527	5.16E-05	73.8	.	.
NLRP5	19	55999726	56061813	N	.	N	Y	0.281849797	69.41598657	1.24E-07	85.9	.	.
NLRP6	11	278365	285359	N	.	N	Y	0.208907564	64.99392256	.	.	.	.
NLRP7	19	54923509	54966312	N	.	N	N	2.505324718	99.18967413	1.10E-12	95.2	DM	.
NLRP8	19	55947832	55988629	N	.	N	N	0.980471547	92.50448573	1.26E-18	98.4	.	.
NLRP9	19	55708432	55738402	N	Viable	N	Y	-0.26731288	31.40591538	5.68E-17	97.8	.	.
NLRX1	11	119166568	119184016	N	.	N	Y	1.426084434	96.51559877	9.84E-22	99	DM?	.
NMB	15	84655129	84658563	N	.	N	N	0.442966544	78.02280489	0.156904105	40.3	DP	.
NMBR	6	142058330	142088799	N	.	N	Y	0.81474924	89.43103548	0.000742389	65.8	.	.
NMD3	3	161104696	161253532	N	.	N	N	-0.845656541	10.65578515	4.42E-05	74.2	.	.
NME1-NME2	17	51165435	51171747	N	.	N	N	0.371759592	74.49209932	0.010430774	54.8	.	.
NME2	17	51153590	51171744	N	Viable	N	Y	-0.049519725	45.82392777	0.010430774	54.8	.	.
NME3	16	1770286	1771730	N	.	N	N	0.587441516	83.76454246	2.37E-06	81	.	.
NME4	16	396725	410367	N	.	N	N	0.492766925	80.17595647	0.134065502	41.4	.	.
NME5	5	138115172	138139443	N	.	N	Y	0.133424212	59.69786421	0.570640716	28.2	.	.
NME7	1	169132531	169367967	N	.	N	Y	0.376541981	74.76413729	0.003528477	59.7	DM?	.
NME8	7	37848597	37900401	N	.	N	N	0.927454043	91.66521966	2.03E-21	99	DM	Ciliary dyskinesia, primary, 6, 610852 (3)
NME9	3	138261437	138329886	N	.	N	N	0.038754674	52.485964	2.63E-05	75.5	.	.
NMI	2	151270465	151290057	N	.	N	N	0.580084093	83.4809284	6.23E-09	89.4	.	.
NMNAT3	3	139560180	139678017	N	.	N	N	-0.225764638	33.98159403	5.34E-08	86.9	.	.
NMRAL1	16	4461680	4495763	N	Viable	N	Y	0.865360015	90.44394281	0.000731171	65.8	.	.
NMRK1	9	75060573	75088217	N	.	N	N	0.422369205	76.96359322	0.001066368	64.5	.	.
NMRK2	19	3933103	3942416	N	Viable	N	Y	0.472169912	79.41193494	1.17E-07	86	.	.
NMS	2	100470482	100483280	N	.	N	N	0.414865996	76.60473462	2.78E-10	92.2	.	.
NMT2	10	15102584	15168693	N	.	N	N	-0.122483898	40.59153788	0.317678321	35.2	DM?	.
NMU	4	55595229	55636698	N	.	N	Y	0.412953559	76.48897378	0.008931842	55.4	DM?	.
NMUR1	2	231523160	231530495	N	Viable	N	Y	0.634669724	85.19418881	1.07E-05	77.9	.	.
NMUR2	5	152391532	152433368	N	.	N	Y	1.039855766	93.26271922	0.421657261	32.2	.	.
NNAT	20	37521215	37523693	N	.	N	Y	0.144604076	60.5660705	0.11256796	42.5	.	.
NNMT	11	114257787	114313285	N	.	N	N	0.23207049	66.37147653	0.004279164	58.8	.	Homocysteine plasma level (2)
NNT	5	43602692	43707405	N	.	N	Y	-1.048919759	7.235052382	0.999550477	5.1	DM	Glucocorticoid deficiency 4, 614736 (3)
NOB1	16	69741867	69754940	N	.	N	N	0.187203344	63.63952075	8.61E-08	86.3	.	.
NOC2L	1	944204	959309	N	.	N	N	0.166111008	62.21566244	1.33E-19	98.6	.	.
NOC4L	12	132144448	132152473	N	.	N	N	1.961453305	98.52404931	.	.	.	.
NOCT	4	139015789	139045939	N	.	N	Y	.	.	.	.	.	.
NOD1	7	30424527	30478784	N	.	N	Y	0.703631509	86.96532963	5.05E-13	95.5	DFP	.
NOD2	16	50693603	50733077	N	.	N	Y	1.621386626	97.58059848	5.52E-19	98.4	DM	{Inflammatory bowel disease 1}, 266600 (3); Blau syndrome, 186580 (3); {Psoriatic arthritis, susceptibility to}, 607507 (3); Sarcoidosis, early-onset, 609464 (3)
NOL10	2	10570766	10689987	N	.	N	N	0.507921503	80.78370087	0.803303948	21.5	.	.
NOL11	17	67717833	67744531	N	.	N	N	0.305489774	70.82248075	0.027829353	50.1	.	.
NOL12	22	37681673	37693478	N	.	N	N	0.302318539	70.64305146	0.090553698	43.7	.	.
NOL3	16	67170154	67175735	N	.	N	Y	0.870805519	90.61179603	0.000536476	66.8	DM	Myoclonus, familial cortical, 614937 (3)
NOL4	18	33851100	34224952	N	.	N	N	-1.103649308	6.505759102	0.998788438	6.1	.	.
NOL4L	20	32443059	32585074	N	.	N	N	.	.	.	.	.	.
NOL6	9	33461441	33473930	N	.	N	N	0.858495013	90.3455461	0.999078032	5.8	.	.
NOL7	6	13615327	13632739	N	.	N	N	0.291946181	70.03530706	0.010960121	54.5	.	.
NOL9	1	6521347	6554535	N	.	N	N	-0.177723518	36.87561498	0.00447024	58.6	.	.
NOLC1	10	102152176	102163871	N	.	N	N	-0.405534288	24.1303467	0.246823454	37.2	.	.
NOM1	7	156949723	156973182	N	.	N	N	0.8262361	89.68570932	0.000163383	70.4	.	.
NOMO1	16	14833681	14896160	N	.	N	N	1.102111553	93.95149621	.	.	.	.
NOMO2	16	18417325	18562211	N	.	N	N	.	.	.	.	.	.
NOMO3	16	16232495	16294814	N	.	N	N	.	.	.	.	.	.
NONO	X	71283192	71301168	N	.	N	N	0.018007904	50.90004052	0.9939465	8.9	.	.
NOP10	15	34341713	34343177	N	.	N	N	0.076119241	55.36840887	0.802013759	21.6	DM	Dyskeratosis congenita, autosomal recessive 1, 224230 (3)
NOP14	4	2937933	2963385	N	.	N	N	-0.233621899	33.45488221	0.017449165	52.3	.	.
NOP16	5	176383938	176388975	N	.	N	N	0.789222232	88.97378017	0.145044757	40.8	.	.
NOP2	12	6556863	6568691	N	.	N	N	0.355293324	73.71650171	0.048927642	47.1	.	.
NOP56	20	2652145	2658393	N	.	N	N	-0.114829257	41.15876599	0.97325682	12.6	DM	Spinocerebellar ataxia 36, 614153 (3)
NOP58	2	202265716	202303666	N	.	N	N	-0.986462395	8.103258668	0.509478886	29.7	.	.
NOP9	14	24299862	24309124	N	.	N	N	0.511901029	80.95734213	6.32E-06	79.1	.	.
NOS1	12	117208142	117452170	N	.	N	Y	-0.998861533	7.877525033	0.998694761	6.3	DFP	.
NOS1AP	1	162069774	162370475	N	Viable	N	Y	-0.455487979	22.06401574	0.119913961	42.1	DM?	.
NOS2	17	27756766	27800499	N	.	N	Y	-0.610700304	16.43803901	7.26E-09	89.3	DM?	.
NOSIP	19	49555711	49590262	N	.	N	N	-0.378697035	25.5252648	0.002301566	61.4	.	.
NOSTRIN	2	168786539	168865514	N	.	N	Y	0.124309052	59.07275569	3.58E-10	92	.	.
NOTCH2NL	1	146146203	146229026	N	.	N	N	2.948686665	99.5022284	0.000100623	71.8	.	.
NOTCH3	19	15159038	15200981	N	Viable	N	Y	0.111180846	58.08878856	0.207712385	38.5	DM	Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, 125310 (3); ?Myofibromatosis, infantile 2, 615293 (3); Lateral meningocele syndrome, 130720 (3)
NOTCH4	6	32194843	32224067	N	Viable	N	Y	0.381479149	74.98408288	1.20E-10	92.8	DP	.
NOTUM	17	81952507	81961840	N	.	N	N	0.173002985	62.75973838	0.0008604	65.3	.	.
NOX1	X	100843324	100874345	N	.	N	Y	0.824973219	89.63940499	0.000386452	67.9	.	.
NOX3	6	155395370	155455903	N	.	N	N	0.170435624	62.53979279	3.58E-09	89.9	.	.
NOX4	11	89324356	89498187	N	.	N	Y	-0.534044514	18.82850032	8.16E-07	82.9	.	.
NOX5	15	68930525	69062743	N	.	N	N	1.029788219	93.15274643	1.72E-13	95.9	.	.
NOXA1	9	137423350	137434406	N	.	N	Y	.	.	4.73E-06	79.6	.	.
NOXO1	16	1978917	1984192	N	.	N	N	1.308085156	95.84418591	3.17E-11	93.7	.	.
NOXRED1	14	77394021	77423517	N	.	N	N	-0.565317646	17.76928865	0.118495408	42.2	.	.
NPAP1	15	24675868	24683393	N	.	N	N	0.832318134	89.84198646	0.273009366	36.4	.	.
NPAS1	19	47019820	47045775	N	.	N	N	0.113935742	58.3145222	0.916472527	16.9	.	.
NPAS2	2	100820152	100996829	N	.	N	Y	0.148883562	60.91914105	0.990888562	9.8	DP	.
NPAS4	11	66421004	66426707	N	.	N	Y	-1.232023433	5.290270302	0.424264241	32.2	DM	.
NPAT	11	108157215	108222642	N	.	N	N	0.057390895	53.86930601	0.142676569	40.9	DM	.
NPB	17	81900745	81902905	N	.	N	Y	.	.	0.428299526	32	.	.
NPBWR1	8	52938431	52941117	N	.	N	Y	0.059501305	54.07188748	0.000132407	71.1	FP	.
NPBWR2	20	64105820	64107171	N	.	N	N	0.547350629	82.34068415	0.002224334	61.5	.	.
NPC1L1	7	44512535	44541315	N	.	N	Y	-0.024038065	47.64137292	1.37E-10	92.7	DM	[Ezetimibe, nonresponse to] (3)
NPC2	14	74476192	74494177	N	Viable	N	Y	0.116504775	58.48816345	0.008700693	55.5	DM	Niemann-pick disease, type C2, 607625 (3)
NPDC1	9	137039470	137046203	N	.	N	Y	0.547202136	82.32910806	0.703401664	24.5	.	.
NPEPL1	20	58689131	58719238	N	.	N	N	0.31092756	71.10609481	1.80E-07	85.3	.	.
NPFF	12	53506690	53507638	N	.	N	N	0.457017001	78.64212537	0.000253702	69.1	.	.
NPFFR1	10	70247329	70283676	N	.	N	Y	.	.	4.69E-09	89.6	.	.
NPFFR2	4	72031804	72148067	N	.	N	N	0.484606379	79.9039185	9.71E-06	78.2	DM?	.
NPHP1	2	110122311	110205066	N	Viable	N	Y	-0.255472839	32.15257278	1.37E-08	88.5	DM	Nephronophthisis 1, juvenile, 256100 (3); Senior-Loken syndrome-1, 266900 (3); Joubert syndrome 4, 609583 (3)
NPHP3-ACAD11	3	132558142	132722459	N	.	N	N	.	.	.	.	.	.
NPHP4	1	5862811	5992473	N	.	N	N	3.884404854	99.73375007	1.29E-17	98	DM	Nephronophthisis 4, 606966 (3); Senior-Loken syndrome 4, 606996 (3)
NPIPA1	16	14750813	14952060	N	.	N	N	.	.	0.495053839	30.1	.	.
NPIPA2	16	14748066	14765413	N	.	N	N	.	.	.	.	.	.
NPIPA3	16	14708944	14952073	N	.	N	N	.	.	.	.	.	.
NPIPA5	16	15363624	15381047	N	.	N	N	.	.	0.544994923	28.8	.	.
NPIPA7	16	16379055	16393954	N	.	N	N	.	.	.	.	.	.
NPIPA8	16	18317942	18336736	N	.	N	N	.	.	.	.	.	.
NPIPB11	16	29381354	29404029	N	.	N	N	.	.	.	.	.	.
NPIPB15	16	74377878	74392080	N	.	N	N	.	.	0.000277932	68.9	.	.
NPIPB3	16	21402237	21448567	N	.	N	N	.	.	0.502865157	29.9	.	.
NPIPB4	16	21834569	21880827	N	.	N	N	.	.	.	.	.	.
NPIPB5	16	22479121	22536521	N	.	N	N	.	.	.	.	.	.
NPIPB6	16	28342555	28363508	N	.	N	N	.	.	0.636136512	26.4	.	.
NPIPB7	16	28456372	28471175	N	.	N	N	.	.	0.151766813	40.5	.	.
NPIPB8	16	28637654	28658682	N	.	N	N	.	.	0.014229505	53.4	.	.
NPIPB9	16	28751787	28772807	N	.	N	N	.	.	.	.	.	.
NPL	1	182789293	182830384	N	.	N	N	-0.087839602	42.97621115	4.51E-07	83.9	DM	.
NPM2	8	22024125	22036897	N	.	N	Y	0.370803213	74.41685478	0.000671457	66.1	.	.
NPM3	10	101781325	101783413	N	Viable	N	Y	0.164393154	62.10568965	0.859176476	19.5	.	.
NPNT	4	105894775	106004027	N	.	N	Y	0.902071833	91.10956763	7.28E-06	78.8	.	.
NPPA	1	11845709	11848345	N	.	N	Y	0.612819541	84.5575042	0.016931635	52.5	DM	Atrial fibrillation, familial, 6, 612201 (3); Atrial standstill 2, 615745 (3)
NPPB	1	11857464	11858931	N	.	N	Y	0.565887443	82.91948834	0.00038006	67.9	DM?	.
NPR1	1	153678637	153693992	N	.	N	Y	-0.241423479	32.93974648	0.000172509	70.3	DFP	.
NPRL2	3	50347330	50351091	N	.	N	N	-0.543765506	18.41754934	0.345174794	34.4	.	.
NPS	10	127549369	127552639	N	.	N	N	0.442010439	77.98228859	0.00010008	71.9	.	.
NPSR1	7	34658239	34878332	N	.	N	Y	1.511804486	97.02494646	8.18E-07	82.9	DFP	{Asthma, susceptibility to, 2}, 608584 (3)
NPTN	15	73560014	73634134	N	Viable	N	Y	-0.416212455	23.64993923	0.988917853	10.2	DFP	.
NPTX1	17	80467148	80477843	N	.	N	Y	-0.040907923	46.57058517	0.426444497	32.1	.	.
NPTX2	7	98617297	98629868	N	.	N	Y	-0.427389804	23.21583608	0.097568454	43.3	.	.
NPTXR	22	38818452	38843982	N	.	N	Y	-0.33080711	27.69578052	.	.	.	.
NPVF	7	25224570	25228486	N	.	N	N	0.680350018	86.42704173	0.002640283	60.9	.	.
NPW	16	2009926	2020755	N	.	N	N	.	.	.	.	.	.
NPY	7	24284163	24291865	N	.	N	Y	0.153063769	61.21433119	0.588186086	27.8	DFP	.
NPY1R	4	163323961	163344832	N	.	N	Y	-0.272697012	31.12808937	0.651605219	26	DFP	.
NPY2R	4	155208629	155217078	N	.	N	Y	-0.17787558	36.8640389	0.188394785	39	DM?	.
NPY4R	10	46461099	46465881	N	.	N	Y	1.323395163	95.94258262	6.12E-09	89.4	.	.
NPY5R	4	163343939	163351934	N	.	N	Y	-0.799833369	11.59923598	0.491800968	30.2	.	.
NQO1	16	69706996	69726951	N	.	N	Y	0.51527665	81.07889101	4.52E-11	93.4	DFP	{Benzene toxicity, susceptibility to} (3); {Leukemia, post-chemotherapy, susceptibility to} (3); {Breast cancer, poor survival after chemotherapy for} (3)
NQO2	6	2987987	3028869	N	.	N	Y	0.782674771	88.85223129	1.27E-05	77.4	DFP	{?Breast cancer susceptibility}, 114480 (1)
NR0B1	X	30304206	30309598	N	.	N	Y	0.061263744	54.22237657	0.791995495	21.9	DM	Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 (3); 46XY sex reversal 2, dosage-sensitive, 300018 (3)
NR0B2	1	26911489	26913966	N	.	N	Y	0.670123656	86.20709614	5.83E-08	86.8	DM	Obesity, mild, early-onset, 601665 (3)
NR1H2	19	50329653	50382982	N	.	N	Y	-0.77908304	12.03912716	0.821872624	20.9	DFP	.
NR1H3	11	47248300	47269032	N	Viable	N	Y	-0.500506623	20.165538	0.856185983	19.7	DM	.
NR1H4	12	100473708	100564413	N	.	N	Y	0.044495337	52.92585518	0.161696751	40.1	DM	.
NR1I2	3	119780484	119818485	N	.	N	Y	-1.032288472	7.437633848	0.000129417	71.1	DM	.
NR1I3	1	161229666	161238302	N	.	N	Y	0.642979476	85.46622678	0.00035522	68.1	DM	.
NR2C1	12	95020229	95073703	N	.	N	Y	-0.392592402	24.83069977	0.982333197	11.4	.	.
NR2C2AP	19	19201416	19203424	N	.	N	N	-0.170525669	37.3618105	0.527167735	29.2	.	.
NR2E1	6	108166058	108188809	N	.	N	Y	-0.531631495	18.90953291	0.990508625	9.8	DM?	.
NR2E3	15	71792638	71818259	N	.	N	Y	.	.	.	.	DM	Enhanced S-cone syndrome, 268100 (3); Retinitis pigmentosa 37, 611131 (3)
NR2F6	19	17231883	17245940	N	.	N	Y	.	.	0.152636356	40.5	.	.
NR4A1	12	52022832	52059507	N	.	N	Y	-0.439373167	22.77015686	0.959497621	14	.	.
NRAP	10	113588716	113664127	N	.	N	N	3.183281612	99.59483707	2.59E-31	99.7	.	.
NRARP	9	137300482	137302251	N	.	N	Y	0.121138064	58.78914163	0.150570049	40.6	.	.
NRBF2	10	63133247	63155031	N	.	N	N	-0.173243497	37.15922903	0.082106241	44.3	.	.
NRBP2	8	143833594	143840974	N	.	N	N	.	.	0.002412945	61.2	.	.
NRCAM	7	108147623	108456717	N	Viable	N	Y	-1.347178917	4.329455345	0.456484598	31.2	.	.
NREP	5	111662621	111997464	N	.	N	Y	0.25810805	67.9284598	0.563643143	28.4	.	.
NRG3	10	81875314	82987179	N	.	N	N	-0.634456013	15.81293049	0.21033799	38.4	DM?	.
NRG4	15	75935969	76059795	N	.	N	N	-0.058936621	45.1930312	0.024387547	50.6	.	.
NRGN	11	124739846	124747210	N	.	N	Y	0.142690981	60.37506512	0.536942023	28.9	DM	.
NRIP1	21	14961235	15065000	N	.	N	Y	0.203626963	64.56560745	0.991172158	9.7	DP	.
NRIP2	12	2825348	2835544	N	.	N	N	0.475995728	79.57978816	9.12E-08	86.2	.	.
NRIP3	11	8980576	9004049	N	.	N	N	0.42987242	77.39769636	2.35E-05	75.8	.	.
NRL	14	24080107	24115014	N	.	N	Y	-0.057022786	45.34352029	0.079735109	44.5	DM	Retinitis pigmentosa 27, 613750 (3); Retinal degeneration, autosomal recessive, clumped pigment type (3)
NRM	6	30688047	30691420	N	.	N	N	0.080902701	55.81408809	0.142577187	40.9	.	.
NRN1	6	5997999	6007605	N	.	N	Y	-0.042016662	46.43167217	0.823897693	20.8	DM?	.
NRN1L	16	67884805	67888855	N	Viable	N	Y	1.183240604	94.88337096	0.000386711	67.9	.	.
NRROS	3	196639686	196662004	N	.	N	N	-0.191621929	36.07107715	0.457686198	31.2	.	.
NRSN1	6	24126122	24154900	N	.	N	N	0.012418429	50.43120912	0.004307251	58.8	.	.
NRSN2	20	346782	359660	N	.	N	N	0.340790619	72.91775192	0.001973312	61.9	.	.
NRTN	19	5823802	5828324	N	.	N	Y	.	.	0.100149119	43.1	DM	.
NRXN1	2	49918505	51032561	N	Viable	N	Y	-1.826448334	2.118423337	0.999948738	3.3	DM	Pitt-Hopkins-like syndrome 2, 614325 (3); {Schizophrenia, susceptibility to, 17}, 614332 (3)
NSA2	5	74766991	74780113	N	.	N	N	-0.100127206	42.09064074	0.686235241	25	.	.
NSFL1C	20	1442162	1473842	N	.	N	N	0.0931893	56.64756613	0.159362129	40.2	.	.
NSL1	1	212726153	212791782	N	.	N	N	0.432741275	77.53082132	0.043155917	47.8	FTV	.
NSMAF	8	58583504	58659844	N	.	N	Y	-1.0161784	7.674943567	3.18E-08	87.5	.	.
NSMCE1	16	27224991	27268794	N	.	N	N	-0.082250388	43.42189037	0.038388415	48.5	.	.
NSMCE2	8	125091679	125367120	N	.	N	N	-0.069158154	44.44637379	0.072450721	44.9	.	.
NSMCE4A	10	121957088	121975217	N	.	N	N	0.39426906	75.53973491	0.085946995	44	.	.
NSMF	9	137447570	137459334	N	.	N	N	-0.495874865	20.37969555	0.046546174	47.4	.	Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3)
NSUN2	5	6599239	6633291	N	.	N	Y	-1.267632058	4.954563871	0.961845836	13.8	DM	Mental retardation, autosomal recessive 5, 611091 (3)
NSUN3	3	94062916	94128545	N	.	N	N	-0.118808507	40.85199977	2.57E-07	84.8	.	.
NSUN4	1	46340177	46365152	N	.	N	N	0.339026533	72.81356717	1.39E-06	82.1	.	.
NSUN5	7	73302517	73308867	N	.	N	N	0.213539768	65.27753661	1.45E-06	82	.	.
NSUN6	10	18545561	18659285	N	.	N	N	-0.259299737	31.92683915	1.73E-14	96.6	.	.
NSUN7	4	40749897	40809985	N	Viable	N	Y	0.531387625	81.71557562	0.048551891	47.2	DM?	.
NT5C	17	75130225	75131795	N	.	N	N	0.352927885	73.57180066	0.01264883	54	.	.
NT5C1A	1	39659121	39672038	N	.	N	N	-0.417972557	23.58048272	8.15E-05	72.5	.	.
NT5C1B	2	18562872	18589572	N	.	N	N	1.02500032	93.10065405	3.45E-05	74.9	DM?	.
NT5C1B-RDH14	2	18555545	18589564	N	.	N	N	0.956510792	92.12826301	5.07E-05	73.8	.	.
NT5C2	10	103088017	103193306	N	.	N	N	-0.442395976	22.60809168	0.052197863	46.8	.	Spastic paraplegia 45, 613162 (3)
NT5C3A	7	33014114	33062797	N	.	N	N	-0.475279987	21.20738554	0.012372194	54.1	.	Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3)
NT5C3B	17	41825181	41836263	N	.	N	N	-0.11785159	40.91566823	7.88E-05	72.6	.	.
NT5DC1	6	116100849	116249497	N	.	N	N	0.127984973	59.3100654	0.326411116	35	.	.
NT5DC2	3	52524385	52535054	N	.	N	N	-0.972259363	8.35214447	0.004608866	58.5	.	.
NT5DC3	12	103770453	103841197	N	.	N	N	-0.448941955	22.34184175	0.000112402	71.5	.	.
NT5DC4	2	112721486	112742879	N	.	N	N	.	.	.	.	.	.
NT5E	6	85449584	85495791	N	.	N	Y	0.489238883	80.06598368	2.34E-06	81	DM	Calcification of joints and arteries, 211800 (3)
NT5M	17	17303335	17347663	N	.	N	N	0.248840271	67.3901719	3.30E-05	75	.	.
NTAN1	16	15037853	15056079	N	.	N	Y	0.016245619	50.75533947	0.015873662	52.9	DM?	.
NTF4	19	49055793	49065076	N	Viable	N	Y	-0.101084162	42.05591248	0.1075829	42.7	DM	.
NTHL1	16	2039815	2047866	N	.	N	Y	0.536021154	81.91815709	1.77E-09	90.7	DM	Familial adenomatous polyposis 3, 616415 (3)
NTM	11	131370478	132336822	N	.	N	N	-0.715382035	13.51507785	0.525365694	29.3	DM?	.
NTMT1	9	129608884	129636131	N	.	N	N	-0.53817717	18.67222319	0.40245054	32.7	.	.
NTN3	16	2471499	2474145	N	.	N	N	0.413251052	76.53527812	5.82E-05	73.5	.	.
NTN4	12	95657807	95791152	N	Viable	N	Y	-0.222741485	34.17259941	0.994426785	8.6	.	.
NTN5	19	48661407	48673081	N	.	N	N	0.913103167	91.31793714	3.27E-06	80.4	.	.
NTNG1	1	107140007	107483458	N	.	N	N	-0.273500756	31.08178503	0.441031128	31.7	DM	.
NTNG2	9	132161676	132244534	N	.	N	Y	-0.576495149	17.46252243	0.82958323	20.6	.	.
NTPCR	1	232950605	232983882	N	.	N	N	0.157846676	61.58476587	1.70E-05	76.7	.	.
NTS	12	85874295	85882992	N	.	N	Y	0.079946001	55.69832726	7.97E-06	78.6	.	.
NTSR1	20	62708837	62762771	N	.	N	Y	0.294159089	70.15106789	9.73E-08	86.1	.	.
NTSR2	2	11658178	11670164	N	.	N	Y	0.585674735	83.69508595	2.53E-05	75.6	.	.
NUB1	7	151341699	151378449	N	.	N	N	-0.092471964	42.67523297	1.15E-05	77.7	DM	.
NUBP2	16	1782901	1789191	N	.	N	N	0.825929637	89.67413324	0.008816822	55.4	.	.
NUCB1	19	48900050	48923372	N	.	N	N	0.479822239	79.75921746	4.17E-05	74.4	.	.
NUCB2	11	17208153	17349974	N	.	N	N	-0.140360582	39.38762517	8.59E-08	86.3	DP	.
NUCKS1	1	205712819	205750276	N	.	N	N	-0.27652577	30.82132315	0.979237658	11.9	.	.
NUDC	1	26900238	26946862	N	.	N	N	-0.03627546	46.84841118	0.822775133	20.9	DM	.
NUDCD1	8	109240919	109334385	N	.	N	N	0.026770398	51.55987729	3.84E-06	80.1	.	.
NUDCD2	5	163446526	163460140	N	.	N	N	-0.094538075	42.4726515	0.000812082	65.5	.	.
NUDCD3	7	44379121	44490880	N	.	N	N	0.330566867	72.36788794	0.706731712	24.4	.	.
NUDT1	7	2242222	2251146	N	.	N	Y	0.228244069	66.13416681	1.29E-09	91	DM?	.
NUDT10	X	51332231	51337525	N	.	N	N	-0.035470476	46.91207964	.	.	.	.
NUDT11	X	51490011	51496596	N	.	N	N	-0.149930626	38.75094056	0.699091255	24.6	.	.
NUDT12	5	103548855	103562793	N	.	N	N	-0.14307911	39.17346762	3.28E-11	93.6	.	.
NUDT13	10	73110375	73131828	N	.	N	N	0.641066664	85.39098223	5.73E-07	83.5	.	.
NUDT14	14	105172938	105181323	N	Viable	N	Y	0.137250784	59.99305435	0.000705233	65.9	.	.
NUDT15	13	48037567	48047222	N	.	N	N	0.275983486	69.05712797	0.09722958	43.4	.	.
NUDT16	3	131381671	131388830	N	.	N	N	0.440244459	77.90125601	0.001460676	63.1	.	.
NUDT16L1	16	4693694	4695859	N	.	N	N	-0.204212609	35.19708283	0.020449384	51.5	.	.
NUDT17	1	145845629	145848953	N	.	N	N	0.523736129	81.40302136	0.005379908	57.8	.	.
NUDT18	8	22106872	22109419	N	.	N	N	.	.	0.000135276	71	.	.
NUDT19	19	32691961	32713796	N	Viable	N	Y	0.764945783	88.45864444	1.09E-05	77.8	DP	.
NUDT2	9	34329506	34343713	N	.	N	N	0.412953559	76.48897378	0.002367748	61.3	.	.
NUDT21	16	56429133	56452199	N	.	N	N	0.039560397	52.53226833	0.947296446	15	.	.
NUDT22	11	64225941	64230686	N	.	N	N	0.760164388	88.30236731	0.000315497	68.5	.	.
NUDT3	6	34279679	34392674	N	.	N	N	-0.057022786	45.34352029	0.876816622	18.8	.	.
NUDT4	12	93377883	93408146	N	.	N	N	0.284443026	69.58383979	0.164174989	40	.	.
NUDT5	10	12165325	12196144	N	.	N	N	-0.145145404	39.04034265	0.009460687	55.2	.	.
NUDT6	4	122888697	122922968	N	.	N	N	0.239573531	66.85188401	0.000761662	65.7	DP	.
NUDT7	16	77722492	77742260	N	.	N	N	0.609140858	84.45331944	0.000107932	71.6	.	.
NUDT8	11	67627938	67629930	N	.	N	N	0.029338097	51.71036638	0.003288168	59.9	.	.
NUDT9	4	87422582	87459454	N	.	N	N	-0.209801572	34.94819702	1.27E-05	77.4	.	.
NUF2	1	163266576	163355764	N	.	N	N	-0.192881585	36.00162065	6.56E-05	73.1	.	.
NUFIP1	13	44939249	44989483	N	.	N	N	0.429214031	77.35718007	3.92E-06	80	.	.
NUFIP2	17	29255836	29294118	N	.	N	N	-0.749875342	12.63529548	0.99208608	9.4	.	.
NUGGC	8	28021964	28083871	N	.	N	N	0.796066823	89.12426926	1.96E-07	85.2	.	.
NUMBL	19	40665905	40690972	N	.	N	Y	.	.	0.751917062	23.1	DP	.
NUP107	12	68686734	68745809	N	.	N	N	-1.023682178	7.547606645	1.20E-06	82.3	.	.
NUP153	6	17615035	17706834	N	.	N	N	-1.307507157	4.64779765	0.999994457	2.3	.	.
NUP160	11	47778087	47848555	N	.	N	N	-1.208156375	5.475487643	0.023979153	50.7	.	.
NUP188	9	128947699	129007096	N	.	N	N	-1.27547487	4.896683452	0.987079307	10.6	.	.
NUP205	7	135557919	135648757	N	.	N	N	-2.472952774	0.989755166	0.999998808	1.8	.	.
NUP210	3	13316235	13420309	N	.	N	N	0.179193053	63.11280894	1.45E-10	92.7	.	.
NUP210L	1	153992685	154155116	N	.	N	N	-1.450106222	3.669618568	0.14464062	40.8	.	.
NUP35	2	183117513	183161680	N	.	N	N	-0.353316263	26.61920472	0.123687365	41.9	.	.
NUP37	12	102073103	102120124	N	.	N	N	-0.006263422	49.00156277	0.000998328	64.7	.	.
NUP43	6	149724315	149749665	N	.	N	N	-0.192881585	36.00162065	3.54E-06	80.2	.	.
NUP54	4	76114659	76148515	N	.	N	N	-0.223850595	34.10314291	0.96017275	13.9	.	.
NUP62CL	X	107123427	107206433	N	.	N	N	0.199995603	64.38039011	0.004394552	58.7	.	.
NUP88	17	5360963	5420160	N	.	N	Y	-0.675650498	14.60901777	4.70E-06	79.7	.	.
NUP93	16	56730105	56850286	N	.	N	N	-0.848230086	10.59790473	0.004868044	58.2	.	.
NUPL1	13	25301524	25349800	N	.	N	N	0.247227331	67.29177519	0.084827555	44.1	.	.
NUPL2	7	23181827	23201011	N	.	N	N	0.226480797	66.06471031	3.67E-05	74.7	.	.
NUPR1	16	28532708	28539174	N	.	N	Y	0.411997394	76.41951728	0.007541089	56.2	.	.
NUPR1L	7	56114681	56116400	N	.	N	N	.	.	.	.	.	.
NUTM1	15	34343315	34357737	N	.	N	N	0.196123774	64.13150431	0.005981126	57.2	.	.
NUTM2A	10	87225448	87236908	N	.	N	N	.	.	0.672316973	25.4	.	.
NUTM2B	10	79703227	79714681	N	Viable	N	Y	.	.	0.841786847	20.2	.	.
NUTM2D	10	87357668	87370695	N	.	N	N	.	.	0.227557524	37.8	.	.
NUTM2E	10	79841358	79850878	N	.	N	N	.	.	.	.	.	.
NUTM2F	9	94318196	94328644	N	.	N	N	0.322257551	71.89905655	.	.	.	.
NUTM2G	9	96928310	96940253	N	.	N	N	2.290916569	98.98130462	.	.	.	.
NVL	1	224227334	224330387	N	.	N	N	0.285851735	69.69960063	7.76E-12	94.4	.	.
NWD1	19	16719976	16817963	N	.	N	N	2.7920174	99.36910343	1.37E-19	98.6	.	.
NWD2	4	37244220	37449465	N	.	N	N	.	.	.	.	.	.
NXF1	11	62792123	62806302	N	.	N	N	-1.27064872	4.937199745	0.998990475	5.9	.	.
NXF2	X	102247161	102326719	N	.	N	Y	.	.	.	.	.	.
NXF2B	X	102360395	102463274	N	.	N	N	.	.	0.760751148	22.8	.	.
NXF3	X	103075810	103093125	N	.	N	N	0.497548723	80.36117381	0.008537813	55.6	DM	.
NXF5	X	101832112	101857577	N	.	N	N	1.162639977	94.65763732	0.004207845	58.9	DM	.
NXNL1	19	17455425	17460954	N	.	N	Y	0.604360167	84.27967818	0.061690604	45.8	DM	.
NXNL2	9	88535101	88584274	N	.	N	N	0.191535973	63.89419459	0.477417234	30.6	.	.
NXPE1	11	114521715	114559895	N	.	N	N	0.274369075	68.95294322	3.49E-10	92.1	.	.
NXPE2	11	114678386	114706933	N	.	N	N	.	.	0.244911849	37.3	.	.
NXPE3	3	101779202	101828229	N	.	N	N	-0.73214908	13.11570296	0.402099827	32.7	.	.
NXPE4	11	114570591	114595762	N	.	N	N	1.164699834	94.68657753	2.75E-08	87.8	.	.
NXPH1	7	8433955	8752963	N	.	N	Y	-0.53817717	18.67222319	0.555861072	28.5	DM?	.
NXPH2	2	138670772	138780348	N	.	N	N	-0.214586899	34.6414308	0.798014407	21.8	.	.
NXPH3	17	49575858	49583827	N	.	N	Y	-0.106673287	41.69126584	0.79327242	21.9	.	.
NXPH4	12	57216795	57226449	N	.	N	Y	-0.060698235	45.04254211	0.462095794	31.1	.	.
NXT1	20	23350736	23354777	N	.	N	N	0.001088113	49.55142675	0.574740218	28.1	.	.
NXT2	X	109535781	109544690	N	.	N	N	0.327549473	72.20003473	0.777280518	22.4	.	.
NYAP1	7	100483927	100494799	N	.	N	N	-0.474019054	21.27684204	0.99093213	9.7	.	.
NYAP2	2	225400648	225654018	N	.	N	N	-0.262975874	31.66058922	0.906196258	17.5	.	.
NYNRIN	14	24398786	24419288	N	.	N	N	-1.675186391	2.535162355	0.000549672	66.8	.	.
NYX	X	41447434	41475710	N	.	N	N	.	.	0.06241315	45.8	DM	Night blindness, congenital stationary (complete), 1A, X-linked, 310500 (3)
OAF	11	120210767	120230332	N	.	N	N	0.735741938	87.75250333	0.006168883	57.1	.	.
OARD1	6	41033627	41097787	N	.	N	N	0.405450329	76.1185391	0.123751371	41.9	DM	.
OAS1	12	112906777	112933222	N	Viable	N	Y	1.420795053	96.48665856	0.001239241	63.8	DFP	{Viral infection, susceptibility to} (3); {Diabetes mellitus, type 1, susceptibility to}, 222100 (3)
OAS2	12	112978395	113011723	N	.	N	N	-0.547138186	18.31336459	1.89E-14	96.6	FTV	.
OAS3	12	112938352	112973249	N	.	N	N	1.264656803	95.54320773	1.82E-23	99.2	DM?	.
OASL	12	121019111	121039242	N	.	N	Y	0.118719679	58.66180471	5.07E-12	94.7	.	.
OAZ1	19	2269509	2273490	N	.	N	N	0.630694555	85.08421601	0.088995157	43.8	DP	.
OAZ2	15	64687573	64703281	N	.	N	N	-0.03642736	46.82525901	0.866153028	19.2	.	.
OAZ3	1	151762969	151771332	N	.	N	Y	0.195362073	64.12571627	9.17E-05	72.1	.	.
OBFC1	10	103882542	103918205	N	.	N	N	0.308057642	70.95560572	1.33E-05	77.3	.	.
OBP2A	9	135546139	135549969	N	.	N	N	1.379305906	96.2840771	0.000133914	71	.	.
OBP2B	9	133205277	133209250	N	Viable	N	Y	1.051851176	93.37269202	0.182972936	39.2	.	.
OBSCN	1	228208130	228378876	N	.	N	Y	11.76477189	99.95948371	5.36E-91	100	DM	.
OBSL1	2	219550729	219571859	N	.	N	N	0.887310887	90.89541008	6.64E-16	97.4	DM	3-M syndrome 2, 612921 (3)
OC90	8	132024220	132059380	N	.	N	Y	0.900157756	91.09220351	8.17E-09	89.2	.	.
OCEL1	19	17226204	17229219	N	.	N	N	1.049125804	93.34953985	0.000144705	70.8	.	.
OCIAD1	4	48805212	48861817	N	.	N	N	-0.160151469	38.02743532	4.72E-06	79.7	.	.
OCIAD2	4	48885019	48906937	N	.	N	N	0.457973076	78.70579383	0.004591571	58.6	.	.
OCLM	1	186400572	186401455	N	.	N	N	0.143647524	60.46767379	0.017329039	52.4	.	.
OCLN	5	69492292	69558104	N	.	N	Y	0.657986057	85.85402558	0.49102545	30.2	DM	Band-like calcification with simplified gyration and polymicrogyria, 251290 (3)
OCM	7	5879827	5886362	N	.	N	N	0.345424702	73.15506164	5.57E-06	79.3	.	.
OCM2	7	97984684	97991169	N	.	N	Y	0.571478862	83.14522197	0.080068737	44.5	.	.
OCRL	X	129539849	129592561	N	.	N	Y	-0.470494176	21.42154309	0.999918298	3.6	DM	Lowe syndrome, 309000 (3); Dent disease 2, 300555 (3)
OCSTAMP	20	46540946	46550574	N	Viable	N	Y	.	.	.	.	.	.
ODAM	4	70196496	70204576	N	.	N	N	0.140120824	60.21878798	1.16E-13	96	.	.
ODF1	8	102551572	102561017	N	.	N	Y	0.607228418	84.37228686	0.417383751	32.3	.	.
ODF2L	1	86346824	86396342	N	.	N	N	0.334544937	72.53574116	3.32E-09	90	.	.
ODF3	11	196738	200261	N	.	N	N	0.454294559	78.50321236	0.586974862	27.8	.	.
ODF3B	22	50529710	50532580	N	.	N	N	0.594944888	83.97870001	0.009167458	55.3	.	.
ODF3L1	15	75723977	75727688	N	.	N	N	0.579127749	83.41725994	5.18E-07	83.7	.	.
ODF3L2	19	463346	474983	N	Viable	N	Y	.	.	0.003142588	60.1	.	.
ODF4	17	8339864	8346046	N	.	N	N	0.51527665	81.07889101	0.000650824	66.2	.	.
OFCC1	6	9596110	10211608	N	.	N	N	.	.	.	.	.	.
OFD1	X	13734745	13769353	N	.	N	Y	0.237962628	66.68981883	0.982887662	11.3	DM	Orofaciodigital syndrome I, 311200 (3); Simpson-Golabi-Behmel syndrome, type 2, 300209 (3); Joubert syndrome 10, 300804 (3); ?Retinitis pigmentosa 23, 300424 (3)
OGDHL	10	49734643	49762379	N	.	N	N	-0.542073019	18.50436997	3.47E-05	74.8	.	.
OGFOD1	16	56451490	56479100	N	.	N	Y	0.338220438	72.790415	1.29E-08	88.6	.	.
OGFOD2	12	122974580	122980043	N	.	N	N	0.494828508	80.28592927	3.81E-07	84.1	.	.
OGFOD3	17	82389223	82418637	N	Viable	N	Y	0.821295921	89.5583724	0.000595569	66.5	.	.
OGFR	20	62804835	62814000	N	.	N	N	.	.	0.01341817	53.7	.	.
OGFRL1	6	71288803	71308950	N	.	N	N	-0.385242872	25.15483012	0.000150359	70.6	.	.
OGG1	3	9749944	9788219	N	.	N	Y	0.258557786	67.96318805	7.80E-08	86.4	DM	Renal cell carcinoma, clear cell, somatic, 144700 (3)
OGN	9	92383967	92404696	N	.	N	Y	-0.462188395	21.78618973	0.00751075	56.3	.	.
OGT	X	71533083	71575897	N	.	N	N	-0.650725068	15.36146322	0.999947207	3.3	.	.
OIP5	15	41309268	41332621	N	.	N	N	-0.11785159	40.91566823	1.54E-08	88.4	.	.
OIT3	10	72893581	72933033	N	.	N	Y	-0.479758918	21.01638016	1.04E-09	91.1	.	.
OLA1	2	174072447	174248698	N	.	N	N	-0.209801572	34.94819702	0.0436207	47.8	.	.
OLAH	10	15032227	15073852	N	Viable	N	Y	-0.006263422	49.00156277	0.001328464	63.6	.	.
OLFM1	9	135075243	135121179	N	.	N	Y	-0.980873791	8.219019506	0.935993731	15.8	.	.
OLFM2	19	9853718	9936552	N	.	N	N	-0.819471332	11.19407305	0.964592021	13.5	DM	.
OLFM3	1	101802574	101997030	N	.	N	N	-0.720970763	13.3703768	6.97E-05	72.9	.	.
OLFM4	13	53028759	53052057	N	.	N	Y	0.110259893	58.00196793	2.41E-06	80.9	FTV	.
OLFML1	11	7485388	7511377	N	.	N	N	0.978869896	92.46975748	0.000497437	67	.	.
OLFML2A	9	124777158	124814885	N	.	N	N	0.986682536	92.61445853	1.74E-05	76.6	.	.
OLFML2B	1	161983192	162023854	N	.	N	N	0.445486114	78.1212016	3.02E-06	80.5	.	.
OLFML3	1	113979391	114035572	N	.	N	Y	-0.297923775	29.57689414	0.000588287	66.5	.	.
OLIG1	21	33070144	33072420	N	.	N	Y	.	.	0.119038216	42.2	.	.
OLR1	12	10158301	10172138	N	.	N	Y	-0.114176312	41.19928228	0.297321524	35.8	DFP	{Myocardial infarction, susceptibility to}, 608446 (3)
OMA1	1	58415384	58546802	N	.	N	Y	0.662769054	86.01030271	3.51E-09	90	.	.
OMD	9	92414245	92424461	N	.	N	Y	0.466579567	79.16883718	0.002350833	61.3	.	.
OMG	17	31272013	31297539	N	.	N	Y	-0.188249534	36.2562945	0.863213192	19.4	DM	.
OMP	11	77102840	77103331	N	.	N	Y	0.712275627	87.20263935	0.045566821	47.5	.	.
ONECUT2	18	57435685	57491297	N	.	N	Y	-0.992051392	7.993285871	0.903998414	17.6	.	.
ONECUT3	19	1752373	1780988	N	.	N	N	.	.	.	.	.	.
OOEP	6	73368555	73395133	N	.	N	Y	-0.018550615	48.01759565	0.230723598	37.7	.	.
OOSP2	11	60040275	60048044	N	.	N	N	-0.011047557	48.60797592	.	.	.	.
OPALIN	10	96343216	96359365	N	.	N	N	0.542421446	82.15546681	0.060642755	45.9	.	.
OPCML	11	132414977	133532519	N	.	N	N	-0.293291902	29.80841581	0.578155981	28	DM	{Ovarian cancer, somatic}, 167000 (3)
OPLAH	8	144051266	144063832	N	.	N	Y	.	.	2.99E-11	93.7	DM	5-oxoprolinase deficiency, 260005 (3)
OPN1LW	X	154144224	154159032	N	.	N	N	0.623191232	84.85269433	0.907796475	17.5	DM	Colorblindness, protan, 303900 (3); Blue cone monochromacy, 303700 (3)
OPN1MW	X	154182596	154196135	N	.	N	Y	.	.	0.502014147	29.9	DM	Colorblindness, deutan, 303800 (3); Blue cone monochromacy, 303700 (3)
OPN1MW2	X	154219756	154233286	N	.	N	N	.	.	0.574117353	28.1	.	.
OPN1MW3	X	154257538	154271805	N	.	N	N	.	.	.	.	.	.
OPN1SW	7	128772491	128775790	N	.	N	N	0.279958701	69.3233779	0.369090989	33.6	DM	Colorblindness, tritan, 190900 (3)
OPN3	1	241590102	241677376	N	.	N	N	0.133574517	59.72680442	0.84628904	20	.	.
OPN4	10	86654557	86666848	N	.	N	Y	-0.19831891	35.60224576	1.10E-06	82.4	DP	.
OPN5	6	47781982	47832780	N	.	N	N	-0.302709198	29.29906813	0.948752683	14.9	.	.
OPRD1	1	28812142	28871267	N	.	N	Y	-0.248273713	32.55773572	0.109062189	42.7	DFP	.
OPRK1	8	53225716	53251697	N	.	N	Y	-0.524930204	19.22208717	0.018815519	52	DFP	.
OPRL1	20	64080173	64100643	N	.	N	Y	-0.151538959	38.60623951	0.602075924	27.4	DM?	.
OPRM1	6	154010496	154246867	N	.	N	Y	1.492162071	96.94391387	4.21E-05	74.3	DFP	.
OPTC	1	203494143	203508864	N	.	N	Y	0.348442859	73.32291486	4.31E-07	83.9	DM	.
OR10A2	11	6869693	6870745	N	.	N	N	0.262082672	68.1773456	0.000920372	65	.	.
OR10A3	11	7938534	7939594	N	.	N	N	0.914059295	91.35266539	4.36E-09	89.7	.	.
OR10A4	11	6876625	6877619	N	.	N	Y	0.861534378	90.39763848	2.78E-05	75.4	.	.
OR10A5	11	6845652	6846705	N	.	N	N	0.787456004	88.92747583	0.008422131	55.7	.	.
OR10A6	11	7927718	7928662	N	.	N	N	0.469449146	79.30196215	8.59E-09	89.1	.	.
OR10A7	12	55221025	55221975	N	.	N	N	1.074505402	93.68524628	0.268100024	36.5	.	.
OR10AD1	12	48202083	48203387	N	.	N	N	0.922519097	91.57839903	0.003516762	59.7	.	.
OR10AG1	11	55967558	55968463	N	.	N	N	0.617600446	84.70220524	0.000135734	71	.	.
OR10C1	6	29440016	29440954	N	.	N	N	1.831645318	98.2462233	0.227592079	37.8	FTV	.
OR10D3	11	124185216	124186245	N	.	N	N	.	.	.	.	.	.
OR10G2	14	21633836	21634940	N	.	N	N	0.810922742	89.35000289	0.046093647	47.5	.	.
OR10G3	14	21569803	21570744	N	.	N	N	1.005059293	92.82282804	0.234560474	37.6	.	.
OR10G4	11	124015575	124016510	N	.	N	N	1.705970276	97.91630491	0.216924072	38.2	.	.
OR10G6	11	123994163	123995161	N	.	N	N	.	.	.	.	.	.
OR10G7	11	124038066	124039010	N	.	N	N	2.398562834	99.07970134	0.007122109	56.5	.	.
OR10G8	11	124029590	124030634	N	.	N	N	1.091425568	93.87046362	0.636591633	26.4	.	.
OR10G9	11	124023013	124023948	N	.	N	N	2.869771899	99.44434798	0.007138452	56.5	.	.
OR10H1	19	15807003	15808126	N	.	N	N	0.780909061	88.81750304	0.637065116	26.4	.	.
OR10H2	19	15728020	15729060	N	.	N	N	0.098929771	57.09324536	0.007636435	56.2	.	.
OR10H3	19	15741393	15742343	N	.	N	N	0.839023849	89.99247555	0.00545456	57.7	.	.
OR10H4	19	15949008	15949958	N	.	N	N	1.506066562	96.97864213	0.000560233	66.7	.	.
OR10H5	19	15793951	15795082	N	.	N	N	1.706926614	97.93945708	0.043953004	47.7	.	.
OR10J1	1	159439722	159440811	N	.	N	N	0.819382688	89.51785611	1.59E-08	88.4	.	.
OR10J3	1	159313670	159314659	N	.	N	N	0.187052315	63.62794467	0.001039428	64.6	.	.
OR10J5	1	159535078	159536007	N	.	N	N	0.367125811	74.23163744	0.723391071	23.9	.	.
OR10K1	1	158465562	158466503	N	.	N	N	0.799593969	89.15320947	0.013099189	53.8	.	.
OR10K2	1	158419928	158420866	N	.	N	N	0.224567453	65.92000926	8.05E-05	72.6	.	.
OR10P1	12	55636860	55637854	N	.	N	N	0.605463152	84.30861839	0.019235079	51.9	.	.
OR10Q1	11	58227882	58228918	N	.	N	N	0.226480797	66.06471031	0.254569448	37	.	.
OR10R2	1	158479878	158480885	N	.	N	N	1.234956206	95.35799039	0.044375651	47.7	.	.
OR10S1	11	123976661	123977781	N	.	N	N	0.294008138	70.13370377	0.001889299	62.1	.	.
OR10T2	1	158398522	158399466	N	.	N	N	0.954446134	92.08195867	0.063110527	45.7	.	.
OR10V1	11	59712823	59713864	N	.	N	N	0.747069906	88.03032934	0.001681465	62.6	DM?	.
OR10W1	11	58266792	58268260	N	.	N	N	0.436566952	77.72182671	0.047326021	47.3	.	.
OR10X1	1	158578919	158579899	N	.	N	N	0.537934204	81.97024946	0.005902742	57.3	FTV	.
OR10Z1	1	158606439	158607380	N	.	N	N	0.407510974	76.22851189	0.00736423	56.4	DP	.
OR11A1	6	29425504	29457071	N	.	N	N	0.077226532	55.46680558	0.043484403	47.8	.	.
OR11G2	14	20197336	20198446	N	.	N	N	0.595090612	83.99027609	0.00022869	69.4	.	.
OR11H1	22	15528158	15529139	N	.	N	N	.	.	0.769596447	22.6	.	.
OR11H12	14	18601045	18602129	N	.	N	N	.	.	0.79839868	21.7	.	.
OR11H2	14	19712936	19713920	N	.	N	N	.	.	.	.	.	.
OR11H4	14	20242739	20243820	N	.	N	N	0.263995952	68.32783469	6.23E-05	73.3	.	.
OR11H6	14	20223632	20224805	N	.	N	N	1.41314539	96.45193031	0.021049156	51.3	.	.
OR11L1	1	247840928	247841896	N	.	N	N	0.968497077	92.30190427	0.019479858	51.8	.	.
OR12D2	6	29396700	29397623	N	.	N	N	1.201115834	95.01649592	0.601033125	27.4	FP	.
OR12D3	6	29373423	29375291	N	.	N	N	-0.142274465	39.26028824	1.34E-05	77.3	.	.
OR13A1	10	45302654	45315608	N	.	N	N	0.359772785	73.92487122	0.000212217	69.7	.	.
OR13C2	9	104604671	104605627	N	.	N	N	0.970409785	92.33084448	0.044347988	47.7	.	.
OR13C3	9	104535749	104536856	N	.	N	N	0.370952088	74.45158303	0.000119524	71.3	.	.
OR13C4	9	104526253	104527209	N	.	N	N	0.550071139	82.43908086	5.66E-08	86.8	.	.
OR13C5	9	104598457	104599413	N	.	N	N	1.683455541	97.85842449	0.624784091	26.8	.	.
OR13C8	9	104569168	104570130	N	.	N	N	0.178592613	63.09544481	0.012318064	54.1	.	.
OR13C9	9	104617248	104618204	N	.	N	N	1.141084038	94.44347977	0.043665235	47.7	.	.
OR13D1	9	104694422	104695462	N	.	N	N	0.952533561	92.05301846	0.010955869	54.5	.	.
OR13F1	9	104504263	104505222	N	.	N	N	0.748026206	88.05926955	0.000231792	69.3	.	.
OR13G1	1	247672118	247673041	N	.	N	N	0.435610474	77.68131041	0.005667958	57.5	DP	.
OR13H1	X	131544074	131545000	N	.	N	N	0.674758577	86.28812873	0.066074216	45.4	DM?	.
OR13J1	9	35869263	35870601	N	.	N	N	-0.138446759	39.5439023	1.01E-05	78	.	.
OR14A16	1	247814800	247815729	N	.	N	N	0.290181792	69.94269839	0.005998375	57.2	.	.
OR14A2	1	247723099	247724043	N	.	N	N	.	.	.	.	.	.
OR14C36	1	248348775	248349713	N	.	N	N	0.412144579	76.45424553	0.010180069	54.8	.	.
OR14I1	1	248681369	248682304	N	.	N	N	1.044490311	93.30902356	3.00E-05	75.2	.	.
OR14J1	6	29306690	29307655	N	.	N	N	0.123201392	58.99751114	8.02E-08	86.4	.	.
OR14K1	1	247738615	247739559	N	.	N	N	.	.	0.002407092	61.2	.	.
OR1A1	17	3215621	3216550	N	.	N	N	0.861534378	90.39763848	0.000357575	68.1	.	.
OR1A2	17	3197519	3198448	N	.	N	N	0.517189167	81.13098339	0.013214652	53.8	.	.
OR1B1	9	122628579	122629535	N	.	N	N	0.853074636	90.25293743	0.000898341	65.1	FTV	.
OR1C1	1	247757462	247758406	N	.	N	N	-0.084968981	43.20194478	0.253342625	37	.	.
OR1D2	17	3092058	3092996	N	.	N	N	0.610097161	84.49383574	0.002382562	61.3	.	.
OR1D5	17	3062669	3063607	N	.	N	N	0.829607924	89.778318	0.712159403	24.3	.	.
OR1E1	17	3397104	3398410	N	.	N	N	0.298641418	70.42310586	0.111199868	42.5	.	.
OR1E2	17	3432870	3433841	N	.	N	N	0.490045546	80.10071193	0.020874072	51.4	.	.
OR1F1	16	3204247	3205188	N	.	N	N	0.75935546	88.29657927	8.88E-05	72.2	.	.
OR1G1	17	3126584	3127581	N	.	N	N	0.140120824	60.21878798	0.008711007	55.5	.	.
OR1I1	19	15086980	15088221	N	.	N	N	1.446986702	96.68924003	0.00172069	62.5	.	.
OR1J1	9	122476958	122477926	N	.	N	N	0.536021154	81.91815709	0.008024653	55.9	DM?	.
OR1J2	9	122510802	122511743	N	.	N	N	0.369038883	74.34161023	0.00168245	62.6	.	.
OR1J4	9	122519141	122520082	N	.	N	N	0.327697272	72.21161081	0.240446421	37.3	.	.
OR1K1	9	122800123	122801073	N	.	N	N	0.848440048	90.17769289	0.000145199	70.7	.	.
OR1L1	9	122661566	122662648	N	.	N	N	1.071637256	93.65051803	0.000185743	70	.	.
OR1L3	9	122675130	122676104	N	.	N	N	0.549114755	82.41014065	0.000337194	68.3	.	.
OR1L4	9	122723990	122724925	N	.	N	N	1.128944711	94.31035481	0.043165056	47.8	.	.
OR1L6	9	122749740	122750783	N	.	N	N	1.020066747	93.01383342	0.010695662	54.7	.	.
OR1L8	9	122567548	122568477	N	.	N	N	0.533151945	81.77345604	0.325912944	35	.	.
OR1M1	19	9093179	9094213	N	.	N	N	0.628929435	85.03212363	0.00018347	70.1	.	.
OR1N1	9	122526358	122527296	N	.	N	N	0.421560678	76.91728888	0.002943785	60.4	.	.
OR1N2	9	122553112	122555173	N	.	N	N	0.375585437	74.723621	0.00140501	63.3	.	.
OR1Q1	9	122614738	122615682	N	.	N	N	0.616644153	84.65011287	0.000120115	71.3	.	.
OR1S1	11	58214745	58215722	N	.	N	N	1.343839326	96.06991955	0.0079009	56	FP	.
OR1S2	11	58203202	58204181	N	.	N	N	1.442351399	96.67766395	0.00106333	64.5	.	.
OR2A1	7	144318125	144319057	N	.	N	N	.	.	0.646778692	26.1	.	.
OR2A12	7	144095048	144096093	N	.	N	N	0.412144579	76.45424553	0.000159693	70.5	.	.
OR2A14	7	144109583	144130069	N	.	N	N	0.37749856	74.80465359	0.002127035	61.6	.	.
OR2A2	7	144109514	144110564	N	.	N	N	0.218021088	65.55536262	0.391377426	33	.	.
OR2A25	7	144074182	144075195	N	.	N	N	0.718012692	87.37049256	0.347763291	34.3	.	.
OR2A4	6	131700469	131701401	N	.	N	N	0.45892919	78.75788621	0.68482796	25	.	.
OR2A42	7	144231911	144232843	N	.	N	N	.	.	0.595675112	27.5	.	.
OR2A5	7	144050368	144051380	N	.	N	N	0.929066508	91.70573595	2.24E-05	75.9	.	.
OR2A7	7	144258607	144259722	N	.	N	N	0.018159209	50.92319268	.	.	.	.
OR2AE1	7	99875987	99877057	N	.	N	N	0.679539596	86.40388956	0.00537432	57.8	.	.
OR2AG1	11	6785038	6785988	N	.	N	N	0.694546274	86.78590033	8.88E-06	78.4	.	.
OR2AG2	11	6767987	6769055	N	.	N	N	1.128944711	94.31035481	0.216721902	38.2	.	.
OR2AJ1	1	247933769	247934755	N	.	N	N	.	.	0.015283314	53	.	.
OR2AK2	1	247965233	247966339	N	.	N	N	0.846527348	90.14296464	0.015957698	52.8	.	.
OR2AP1	12	55574415	55575344	N	.	N	N	.	.	0.002903946	60.5	.	.
OR2AT4	11	75088713	75089754	N	.	N	N	0.451573248	78.41060369	0.046085153	47.5	.	.
OR2B11	1	247451029	247451982	N	.	N	N	1.681543252	97.84106037	0.021516518	51.3	.	.
OR2B2	6	27911185	27912396	N	.	N	N	0.381175578	74.97829484	6.87E-05	72.9	.	.
OR2B3	6	29086307	29087313	N	.	N	N	-0.172286507	37.23447358	0.001336932	63.6	.	.
OR2B6	6	27957241	27958182	N	.	N	N	-0.142274465	39.26028824	0.040730928	48.2	.	.
OR2C1	16	3355889	3357294	N	.	N	N	0.794959429	89.10690513	0.097548172	43.3	.	.
OR2C3	1	247530132	247533839	N	.	N	N	0.635476197	85.21734097	0.114992647	42.4	.	.
OR2D2	11	6891490	6892599	N	.	N	N	0.831520358	89.83041037	5.51E-07	83.6	.	.
OR2D3	11	6920974	6922043	N	.	N	N	0.960037204	92.19771951	0.003089507	60.2	.	.
OR2F2	7	143935166	143936279	N	.	N	N	0.036035566	52.3065347	0.000573456	66.6	.	.
OR2G2	1	247588360	247589313	N	.	N	N	0.225524115	65.99525381	0.057128042	46.3	.	.
OR2G3	1	247605586	247606515	N	.	N	N	0.867125588	90.48445911	0.057092658	46.3	.	.
OR2G6	1	248521647	248522597	N	.	N	N	0.052955103	53.58569196	0.009751701	55	.	.
OR2H1	6	29457181	29464328	N	.	N	N	1.838195076	98.27516351	0.044904061	47.6	.	.
OR2H2	6	29587455	29589038	N	.	N	N	0.905599564	91.18481218	0.089945925	43.8	.	.
OR2J2	6	29173303	29174574	N	.	N	N	0.762076736	88.34867164	0.010726719	54.6	.	.
OR2J3	6	29111891	29112826	N	.	N	N	0.739566505	87.83932396	0.028143501	50	FP	[C3HEX, ability to smell], 615082 (3)
OR2K2	9	111327483	111328520	N	.	N	N	0.058544531	53.99664294	0.001461518	63.1	.	.
OR2L13	1	247937191	248100922	N	.	N	N	0.511598665	80.93418996	0.014419191	53.4	.	.
OR2L2	1	248038268	248039206	N	.	N	N	0.794959429	89.10690513	0.001867748	62.1	.	.
OR2L3	1	248060682	248061620	N	.	N	N	1.378491392	96.27250101	6.39E-05	73.2	.	.
OR2L5	1	248021948	248022886	N	.	N	N	0.196468728	64.17780865	7.11E-05	72.9	.	.
OR2L8	1	247948858	247949796	N	.	N	N	1.227452183	95.27695781	0.17916862	39.4	.	.
OR2M2	1	248179986	248181029	N	.	N	N	0.31747395	71.6154425	0.000216665	69.6	DM?	.
OR2M3	1	248203068	248204006	N	.	N	N	0.97600073	92.40030098	0.067199712	45.3	.	.
OR2M4	1	248238929	248239864	N	.	N	N	0.252666418	67.59275337	0.000224878	69.4	.	.
OR2M5	1	248145148	248146086	N	.	N	N	1.843930945	98.29831568	0.001566155	62.9	.	.
OR2M7	1	248323630	248324568	N	.	N	N	1.188019818	94.94703942	0.01235641	54.1	.	.
OR2S2	9	35957139	35958098	N	.	N	N	1.346562211	96.08149563	0.000575667	66.6	.	.
OR2T1	1	248405995	248407104	N	.	N	N	0.410380843	76.3674249	7.29E-07	83.1	.	.
OR2T10	1	248592830	248593768	N	.	N	N	0.381175578	74.97829484	0.000155749	70.5	.	.
OR2T11	1	248626178	248627128	N	.	N	N	1.574564107	97.35486485	2.01E-05	76.2	.	.
OR2T12	1	248294616	248295578	N	.	N	N	2.194932031	98.85975574	0.017041702	52.5	.	.
OR2T2	1	248452798	248453772	N	.	N	N	1.877779187	98.36198414	0.692627481	24.8	.	.
OR2T27	1	248649931	248650884	N	.	N	N	2.777759553	99.35752735	0.000134198	71	.	.
OR2T29	1	248558544	248559491	N	.	N	N	.	.	0.476864535	30.6	.	.
OR2T3	1	248473351	248474307	N	.	N	N	2.033480821	98.62244603	0.358715347	34	.	.
OR2T33	1	248272852	248273814	N	.	N	N	3.219974176	99.61798923	0.016492203	52.7	.	.
OR2T34	1	248573801	248574757	N	.	N	N	2.548703349	99.22440238	0.746970218	23.2	.	.
OR2T35	1	248638287	248639258	N	.	N	N	.	.	0.536149911	29	.	.
OR2T4	1	248361581	248362627	N	.	N	N	3.034963578	99.54853273	0.337136812	34.7	.	.
OR2T5	1	248488589	248489536	N	.	N	N	.	.	0.620583477	26.9	FTV	.
OR2T6	1	248387609	248388535	N	.	N	N	1.134536169	94.39138739	0.050581547	46.9	.	.
OR2T8	1	247921018	247921956	N	.	N	N	2.688480138	99.30543497	0.717437697	24.1	.	.
OR2V1	5	181124357	181125304	N	.	N	N	0.550071139	82.43908086	1.74E-08	88.3	.	.
OR2V2	5	181154943	181155890	N	.	N	N	0.739566505	87.83932396	0.225731244	37.8	.	.
OR2W1	6	29044213	29045240	N	.	N	N	0.008742604	50.21705157	0.086561891	44	.	.
OR2W3	1	247895587	247896531	N	.	N	N	1.386951884	96.32459339	0.079635091	44.5	.	.
OR2Y1	5	180739042	180740099	N	.	N	N	0.611053519	84.5169879	5.16E-07	83.7	.	.
OR2Z1	19	8730954	8732009	N	.	N	N	0.014483413	50.59906234	1.27E-08	88.6	.	.
OR3A1	17	3291635	3292600	N	.	N	N	1.060454103	93.48266481	0.029568461	49.7	.	.
OR3A2	17	3277899	3278974	N	.	N	N	1.391588024	96.3535336	0.564393311	28.4	.	.
OR3A3	17	3420568	3421533	N	.	N	N	0.415822269	76.63946287	0.416001528	32.4	.	.
OR4A15	11	55367884	55368918	N	.	N	N	0.463054026	78.98940788	.	.	.	.
OR4A16	11	55343201	55344187	N	.	N	N	1.766159786	98.1073103	2.61E-05	75.6	.	.
OR4A47	11	48488717	48489780	N	.	N	N	0.328803814	72.25791515	1.43E-05	77.1	.	.
OR4A5	11	54706885	54707832	N	.	N	N	1.138513186	94.4203276	.	.	.	.
OR4B1	11	48216792	48217762	N	.	N	N	0.530431019	81.67505933	0.010938019	54.5	.	.
OR4C11	11	55603354	55604398	N	.	N	N	1.727529043	97.99154946	1.41E-06	82.1	.	.
OR4C12	11	49981473	49982535	N	.	N	N	0.474082735	79.50454361	0.23821319	37.4	.	.
OR4C13	11	49952391	49953419	N	.	N	N	0.661812332	85.96978642	8.59E-09	89.1	.	.
OR4C15	11	55554307	55555419	N	.	N	N	1.222970359	95.25380564	3.39E-11	93.6	.	.
OR4C16	11	55572128	55573060	N	.	N	N	1.098122688	93.92834404	.	.	.	.
OR4C3	11	48324920	48328471	N	.	N	N	2.044013592	98.63402211	0.008745131	55.5	.	.
OR4C46	11	54603069	54603998	N	.	N	N	1.410571903	96.42877814	8.77E-07	82.8	.	.
OR4C5	11	48365485	48366465	N	.	N	N	.	.	0.016567663	52.6	.	.
OR4C6	11	55665167	55666096	N	.	N	N	0.653352401	85.7324767	1.08E-05	77.8	.	.
OR4D1	17	58155133	58156156	N	.	N	N	0.085686282	56.13821844	0.000295714	68.7	.	.
OR4D10	11	59477373	59478396	N	.	N	N	0.073550514	55.19476761	0.064012392	45.6	.	.
OR4D11	11	59503576	59504511	N	.	N	N	0.527561494	81.54772241	0.000895035	65.1	.	.
OR4D2	17	58169656	58170579	N	.	N	N	0.754573317	88.21554668	0.01384437	53.6	.	.
OR4D5	11	123939543	123940637	N	.	N	N	1.014475406	92.93280083	0.001867571	62.1	.	.
OR4D6	11	59456938	59457991	N	.	N	N	1.938632651	98.44301673	0.015012118	53.2	.	.
OR4D9	11	59514913	59515857	N	.	N	N	0.824016877	89.62204086	4.89E-05	74	.	.
OR4E2	14	21665083	21666024	N	.	N	N	0.899052125	91.06905134	0.000222164	69.5	.	.
OR4F15	15	101805720	101819147	N	.	N	N	0.853074636	90.25293743	0.205470538	38.6	.	.
OR4F16	1	685716	686654	N	.	N	N	.	.	.	.	.	.
OR4F17	19	107461	111696	N	.	N	N	.	.	0.505111518	29.8	.	.
OR4F21	8	166049	167043	N	.	N	N	.	.	.	.	.	.
OR4F29	1	450740	451678	N	.	N	N	.	.	.	.	.	.
OR4F3	5	181367268	181368262	N	.	N	N	.	.	.	.	.	.
OR4F4	15	101922042	101923095	N	.	N	N	.	.	0.545956056	28.7	.	.
OR4F5	1	69091	70008	N	.	N	N	.	.	0.176329298	39.5	FP	.
OR4F6	15	101805699	101806686	N	.	N	N	0.178592613	63.09544481	1.34E-05	77.3	.	.
OR4K1	14	19935608	19936683	N	.	N	N	1.255703836	95.48532731	2.21E-06	81.1	.	.
OR4K13	14	20033844	20034760	N	.	N	N	0.769580165	88.55704115	6.76E-05	73	.	.
OR4K14	14	20014260	20015193	N	.	N	N	0.404641438	76.06644672	0.027453438	50.1	.	.
OR4K15	14	19975444	19976659	N	.	N	N	1.213400536	95.16119697	0.635537855	26.5	.	.
OR4K17	14	20117407	20118438	N	.	N	N	0.068917845	54.82433293	0.047180154	47.3	.	.
OR4K2	14	19876232	19877309	N	.	N	N	0.100843326	57.30161486	8.67E-06	78.4	.	.
OR4K5	14	19920582	19921659	N	.	N	N	1.313822724	95.88470221	0.000430658	67.5	.	.
OR4L1	14	20060045	20060983	N	.	N	N	1.439482295	96.64293569	0.002783407	60.7	.	.
OR4M1	14	19780242	19781357	N	.	N	N	1.147778493	94.50714823	0.005168787	58	.	.
OR4M2	15	22080527	22081659	N	.	N	N	1.881609134	98.37934827	.	.	DM?	.
OR4N2	14	19719015	19828372	N	.	N	N	1.308232128	95.84997395	0.073788912	44.8	.	.
OR4N4	15	22094431	22095556	N	.	N	N	2.545980852	99.21861434	0.018050601	52.2	.	.
OR4N5	14	20143736	20144662	N	.	N	N	0.800550194	89.16478555	0.235716666	37.5	.	.
OR4P4	11	55638358	55639296	N	.	N	N	0.754573317	88.21554668	0.057383801	46.3	.	.
OR4Q3	14	19747428	19748369	N	.	N	N	1.202219246	95.03964809	.	.	.	.
OR4S1	11	48306223	48307152	N	.	N	N	0.659899072	85.911906	0.004617191	58.5	.	.
OR4S2	11	55650904	55651839	N	.	N	N	1.76969231	98.11309834	0.001038603	64.6	.	.
OR4X1	11	48263861	48264778	N	.	N	N	0.447896377	78.26590265	0.000157675	70.5	DP	.
OR4X2	11	48245104	48246015	N	.	N	N	0.17778674	63.04335243	1.11E-08	88.8	.	.
OR51A2	11	4954772	4955713	N	.	N	N	1.587662081	97.41853331	0.645582291	26.2	FP	.
OR51A4	11	4946159	4947100	N	.	N	N	1.401960496	96.38826185	0.239072288	37.4	.	.
OR51A7	11	4907370	4908308	N	.	N	N	0.080096755	55.71569138	1.66E-06	81.7	.	.
OR51B2	11	5323359	5324297	N	.	N	N	-0.002436163	49.25623662	0.007355186	56.4	.	.
OR51B4	11	5301014	5301996	N	.	N	N	0.831520358	89.83041037	0.012339243	54.1	.	.
OR51B5	11	5342586	5343524	N	.	N	N	1.516439417	97.04231059	0.000317629	68.5	.	.
OR51B6	11	5351508	5352446	N	.	N	N	1.940544519	98.45459281	0.000174878	70.2	.	.
OR51D1	11	4639715	4640838	N	.	N	N	0.57545022	83.27834694	0.001709584	62.5	.	.
OR51E1	11	4643420	4655488	N	.	N	N	0.663576603	86.05081901	0.000349921	68.2	.	.
OR51E2	11	4680171	4697854	N	.	N	Y	-0.008025521	48.81634543	0.003691226	59.4	.	.
OR51F1	11	4768979	4769917	N	.	N	N	1.264016275	95.53163165	0.053940335	46.5	FTV	.
OR51F2	11	4821386	4822414	N	.	N	N	0.696459078	86.83220467	0.000112097	71.5	.	.
OR51G1	11	4923374	4924339	N	.	N	N	1.106433189	94.00937663	6.16E-05	73.3	FP	.
OR51G2	11	4914719	4915663	N	.	N	N	0.522927841	81.36829311	0.003100737	60.2	.	.
OR51H1	11	4859656	4860564	N	.	N	N	.	.	.	.	.	.
OR51I1	11	5440570	5441514	N	.	N	N	1.311909714	95.87312612	0.002377027	61.3	FTV	.
OR51I2	11	5453489	5454427	N	.	N	N	0.909424628	91.26584476	0.000888957	65.2	.	.
OR51J1	11	5402597	5403547	N	.	N	N	.	.	.	.	.	.
OR51L1	11	4998983	4999930	N	.	N	N	1.208619869	95.10331655	0.015580366	53	.	.
OR51M1	11	5389399	5390379	N	.	N	N	1.743495203	98.03785379	0.253410704	37	.	.
OR51Q1	11	5422111	5423206	N	.	N	N	1.28189325	95.6763327	0.003685054	59.4	.	.
OR51S1	11	4848237	4849208	N	.	N	N	0.734932275	87.72356312	0.00381804	59.3	.	.
OR51T1	11	4881819	4882883	N	.	N	N	-0.106521065	41.70862997	0.019722347	51.8	.	.
OR51V1	11	5199735	5200700	N	.	N	N	0.378455173	74.86832205	0.003714741	59.4	.	.
OR52A1	11	5151009	5186382	N	.	N	N	0.139164133	60.1377554	0.001070019	64.5	.	.
OR52A5	11	5131692	5132642	N	.	N	N	0.755529606	88.24448689	0.000168134	70.3	.	.
OR52B2	11	6169330	6170408	N	.	N	N	1.492013478	96.93812583	5.18E-05	73.8	.	.
OR52B6	11	5580877	5581884	N	.	N	N	0.922519097	91.57839903	0.073588528	44.8	.	.
OR52D1	11	5488685	5489749	N	.	N	N	0.022943191	51.29941541	0.003674386	59.4	.	.
OR52E2	11	5058650	5059627	N	.	N	N	1.492013478	96.93812583	0.000427749	67.6	.	.
OR52E4	11	5884271	5885300	N	.	N	N	1.028526616	93.14117034	4.45E-07	83.9	.	.
OR52E5	11	5900777	5902090	N	.	N	N	.	.	.	.	.	.
OR52E6	11	5840928	5841952	N	.	N	N	1.523943957	97.07703884	0.068094888	45.2	.	.
OR52E8	11	5856674	5857734	N	.	N	N	0.886914013	90.88962204	0.016692038	52.6	.	.
OR52H1	11	5544561	5545523	N	.	N	N	1.279980629	95.64160445	0.013070599	53.8	FP	.
OR52I1	11	4593750	4595013	N	.	N	N	1.689048175	97.87578862	0.062056089	45.8	.	.
OR52I2	11	4586791	4587905	N	.	N	N	1.144908804	94.47241998	0.074557837	44.8	.	.
OR52J3	11	5046526	5047461	N	.	N	N	1.538953088	97.15807142	0.001012548	64.7	.	.
OR52K1	11	4488879	4489908	N	.	N	N	0.394417992	75.55131099	1.75E-05	76.6	.	.
OR52K2	11	4449295	4450361	N	.	N	N	0.896330612	91.05168721	1.59E-06	81.8	.	.
OR52L1	11	5985892	5986985	N	.	N	N	1.355978592	96.14516409	0.00634036	57	.	.
OR52M1	11	4545191	4546144	N	.	N	N	0.685278874	86.54280257	4.69E-06	79.7	.	.
OR52N1	11	5787854	5788816	N	.	N	N	0.875585258	90.67546449	0.020478535	51.5	.	.
OR52N2	11	5820314	5821348	N	.	N	N	0.763033015	88.39497598	7.31E-05	72.8	.	.
OR52N4	11	5754693	5755729	N	.	N	N	0.679539596	86.40388956	3.29E-05	75	FTV	.
OR52N5	11	5777634	5778667	N	.	N	N	0.473126302	79.46402732	0.049291964	47.1	.	.
OR52R1	11	4803433	4804380	N	.	N	N	0.93657013	91.82149679	6.92E-06	79	.	.
OR52W1	11	6199146	6200259	N	.	N	N	0.218021088	65.55536262	0.000404093	67.7	.	.
OR56A1	11	6026671	6027741	N	.	N	N	0.134531237	59.82520113	0.263101577	36.7	.	.
OR56A3	11	5947340	5948361	N	.	N	N	-0.09438571	42.50159171	7.11E-08	86.6	.	.
OR56A4	11	6001986	6003194	N	.	N	N	0.242443541	67.04288939	0.307699476	35.5	.	.
OR56A5	11	5967177	5968494	N	.	N	N	.	.	.	.	.	.
OR56B1	11	5736517	5737491	N	.	N	N	0.846527348	90.14296464	1.27E-08	88.6	.	.
OR56B4	11	6107684	6108835	N	.	N	N	-0.018398956	48.03495977	1.19E-05	77.6	.	.
OR5A1	11	59443144	59444194	N	.	N	N	0.891548555	90.97644267	2.03E-05	76.2	.	.
OR5A2	11	59421943	59422976	N	.	N	N	0.314604136	71.36076865	0.001403982	63.3	.	.
OR5AC2	3	98087173	98088102	N	.	N	N	0.475995728	79.57978816	5.96E-05	73.4	DM?	.
OR5AK2	11	56988872	56989867	N	.	N	N	0.552940591	82.54905366	2.88E-07	84.6	.	.
OR5AN1	11	59364412	59365448	N	.	N	N	0.21610777	65.42223766	0.001177313	64.1	.	.
OR5AP2	11	56641466	56642471	N	.	N	N	0.140120824	60.21878798	0.069223233	45.1	.	.
OR5AR1	11	56663686	56664618	N	.	N	N	0.104519243	57.57365283	0.000179721	70.1	.	.
OR5AS1	11	56030419	56031393	N	.	N	N	0.930978973	91.7404642	0.255635873	36.9	.	.
OR5AU1	14	21154865	21156063	N	.	N	N	1.593398208	97.45326156	1.42E-06	82	.	.
OR5B12	11	58439120	58440173	N	.	N	N	0.352119595	73.52549632	0.310930146	35.4	.	.
OR5B17	11	58358124	58359069	N	.	N	N	1.021022884	93.04277363	0.077236341	44.6	.	.
OR5B2	11	58422265	58423313	N	.	N	N	0.505051907	80.64478787	0.00563537	57.6	.	.
OR5B21	11	58507175	58508105	N	.	N	N	0.375585437	74.723621	9.45E-05	72.1	.	.
OR5B3	11	58402464	58403409	N	.	N	N	0.724559727	87.51519361	0.001001727	64.7	.	.
OR5C1	9	122788933	122789895	N	.	N	N	0.241486849	66.96764485	0.000111246	71.5	.	.
OR5D13	11	55773438	55774382	N	.	N	N	0.323063788	71.95114893	1.74E-07	85.4	.	.
OR5D14	11	55795556	55796500	N	.	N	N	1.179559776	94.83127858	0.000814345	65.5	.	.
OR5D16	11	55838752	55839738	N	.	N	N	-0.137489868	39.60757076	2.34E-07	84.9	.	.
OR5D18	11	55819630	55820571	N	.	N	N	0.602593883	84.18706951	0.000954998	64.9	.	.
OR5F1	11	55993681	55994625	N	.	N	N	0.340939791	72.94090409	0.006473814	56.9	.	.
OR5H1	3	98132698	98133639	N	.	N	N	1.835469296	98.26358743	0.067414777	45.3	.	.
OR5H14	3	98149326	98150405	N	.	N	N	2.407983454	99.10864155	0.000175214	70.2	.	.
OR5H15	3	98168700	98198138	N	.	N	N	2.383549351	99.05076113	1.78E-06	81.5	.	.
OR5H2	3	98282888	98283832	N	.	N	N	0.905599564	91.18481218	1.56E-05	76.9	.	.
OR5H6	3	98264285	98265262	N	.	N	N	0.479822239	79.75921746	4.75E-05	74	FP	.
OR5I1	11	55935456	55936400	N	.	N	N	0.315560713	71.44180124	0.237661332	37.5	.	.
OR5J2	11	56176618	56177556	N	.	N	N	0.467536051	79.21514152	0.000124682	71.2	.	.
OR5K1	3	98469480	98470576	N	.	N	N	0.763033015	88.39497598	9.41E-05	72.1	.	.
OR5K2	3	98497604	98498663	N	.	N	N	0.157040256	61.54424958	9.19E-05	72.1	.	.
OR5K3	3	98390666	98391631	N	.	N	N	0.57545022	83.27834694	0.001920531	62	.	.
OR5K4	3	98353854	98354819	N	.	N	N	1.529536239	97.08861492	9.27E-07	82.6	.	.
OR5L1	11	55811467	55812402	N	.	N	N	0.856899996	90.31660589	5.94E-07	83.4	.	.
OR5L2	11	55827219	55828154	N	.	N	N	0.682408952	86.50228628	0.000593861	66.5	.	.
OR5M1	11	56612555	56613502	N	.	N	N	0.90192108	91.10377959	0.047382673	47.3	.	.
OR5M10	11	56576774	56577721	N	.	N	N	0.18146271	63.30960236	0.007727632	56.1	.	.
OR5M11	11	56542340	56543257	N	.	N	N	0.757442393	88.26185102	0.00076255	65.7	.	.
OR5M3	11	56469574	56470497	N	.	N	N	1.720024043	97.96260925	1.25E-05	77.5	.	.
OR5M8	11	56490435	56491370	N	.	N	N	1.303449243	95.8152457	0.009733883	55	.	.
OR5M9	11	56462469	56463401	N	.	N	N	0.89346113	91.022747	0.007750943	56.1	.	.
OR5P2	11	7795905	7796973	N	.	N	N	0.605463152	84.30861839	0.010138324	54.9	.	.
OR5P3	11	7825037	7825972	N	.	N	N	0.421560678	76.91728888	0.615021497	27.1	.	.
OR5R1	11	56417258	56418232	N	.	N	N	1.74158316	98.02048967	2.19E-05	76	.	.
OR5T1	11	56275639	56276619	N	.	N	N	0.021986393	51.23574695	0.00013089	71.1	.	.
OR5T2	11	56232106	56233185	N	.	N	N	0.38787158	75.28506106	0.001079075	64.4	.	.
OR5T3	11	56252200	56253222	N	.	N	N	0.149537247	60.98280952	1.28E-05	77.4	.	.
OR5V1	6	29355230	29431967	N	.	N	N	0.27517563	69.0050356	0.003442619	59.8	.	.
OR5W2	11	55913650	55914582	N	.	N	N	0.400007863	75.84071309	0.048812322	47.1	.	.
OR6A2	11	6794627	6795783	N	.	N	N	0.748026206	88.05926955	0.267851555	36.6	.	.
OR6B1	7	144003929	144004983	N	.	N	N	0.29113834	69.98900272	3.07E-05	75.2	.	.
OR6B2	2	240028965	240030456	N	.	N	N	1.157047914	94.57660473	0.695947065	24.7	.	.
OR6B3	2	240045077	240046072	N	.	N	N	1.452579115	96.72396828	0.064610848	45.6	.	.
OR6C1	12	55320561	55321624	N	.	N	N	0.330566867	72.36788794	0.012385871	54.1	.	.
OR6C2	12	55452214	55453152	N	.	N	N	0.497548723	80.36117381	0.65829342	25.8	.	.
OR6C3	12	55331701	55332636	N	.	N	N	0.506008393	80.70845633	0.00012312	71.3	.	.
OR6C4	12	55551199	55552244	N	.	N	N	0.295921468	70.25525265	1.10E-07	86	.	.
OR6C6	12	55294288	55295232	N	.	N	N	1.339057962	96.03519129	0.065837551	45.5	.	.
OR6C65	12	55400430	55401505	N	.	N	N	0.16167322	61.90310818	0.001061487	64.5	.	.
OR6C68	12	55492378	55493316	N	.	N	N	0.922519097	91.57839903	0.000123417	71.3	.	.
OR6C70	12	55469200	55470138	N	.	N	N	0.603550251	84.24494993	1.41E-05	77.2	.	.
OR6C74	12	55247198	55248302	N	.	N	N	0.418691306	76.76679979	0.078008695	44.6	.	.
OR6C75	12	55365111	55366049	N	.	N	N	0.593178019	83.91503154	0.048477564	47.2	.	.
OR6C76	12	55426254	55427192	N	.	N	N	0.155126864	61.40533657	0.001021771	64.6	.	.
OR6F1	1	247711829	247712755	N	.	N	N	0.624147457	84.88742258	0.000152779	70.6	.	.
OR6J1	14	22633768	22634811	N	.	N	N	.	.	0.406852694	32.6	.	.
OR6K2	1	158699678	158700652	N	.	N	N	1.173011897	94.76761012	6.63E-05	73.1	.	.
OR6K3	1	158717168	158718163	N	.	N	N	0.626060077	84.945303	0.006906368	56.7	.	.
OR6K6	1	158754720	158755891	N	.	N	N	0.688955753	86.6296232	0.010483104	54.7	.	.
OR6M1	11	123805335	123806387	N	.	N	N	0.156083554	61.48058112	0.001963648	61.9	.	.
OR6N1	1	158765744	158766682	N	.	N	N	1.067001612	93.59842565	0.00123986	63.8	.	.
OR6N2	1	158776682	158777635	N	.	N	N	0.677627004	86.34600915	0.023439916	50.8	.	.
OR6P1	1	158562651	158563604	N	.	N	N	.	.	.	.	.	.
OR6Q1	11	58030953	58031906	N	.	N	N	1.080097034	93.73733866	0.004863354	58.2	FTV	.
OR6S1	14	20640696	20641691	N	.	N	N	0.58391	83.64878162	0.000222105	69.5	.	.
OR6T1	11	123942785	123943873	N	.	N	N	0.764945783	88.45864444	7.96E-05	72.6	.	.
OR6V1	7	143052320	143053347	N	.	N	N	1.040666104	93.26850726	0.07647453	44.7	.	.
OR6X1	11	123753488	123754545	N	.	N	N	0.979680151	92.48712161	0.000346596	68.2	.	.
OR6Y1	1	158547128	158548105	N	.	N	N	1.567059419	97.30856051	0.017981897	52.2	DP	.
OR7A10	19	14840948	14841877	N	.	N	N	1.119528403	94.17722984	0.007992982	55.9	.	.
OR7A17	19	14880426	14881452	N	.	N	N	0.421560678	76.91728888	0.000117083	71.4	.	.
OR7A5	19	14792490	14835376	N	.	N	N	0.859622035	90.36291023	0.001397169	63.4	.	.
OR7C1	19	14799146	14800211	N	.	N	N	0.730150671	87.57886207	0.22002709	38	.	.
OR7C2	19	14941489	14942448	N	.	N	N	0.322107219	71.89326851	0.042449032	48	.	.
OR7D2	19	9185594	9188817	N	.	N	N	0.383088549	75.0824796	0.092527122	43.6	.	.
OR7D4	19	9213850	9214871	N	.	N	N	0.763033015	88.39497598	8.94E-06	78.3	FP	.
OR7E24	19	9250930	9252479	N	.	N	N	0.580084093	83.4809284	0.298717571	35.8	.	.
OR7G1	19	9114828	9115763	N	.	N	N	0.769580165	88.55704115	0.075716676	44.7	.	.
OR7G2	19	9102269	9103306	N	.	N	N	0.186095639	63.59900446	0.007093766	56.5	.	.
OR7G3	19	9126012	9126950	N	.	N	N	0.906555705	91.21375239	0.4059637	32.6	.	.
OR8A1	11	124569997	124571142	N	.	N	Y	0.284591847	69.63014412	0.058828646	46.1	.	.
OR8B12	11	124542682	124543679	N	.	N	N	0.488132675	80.00231522	0.178075256	39.4	.	.
OR8B2	11	124382395	124383362	N	.	N	N	0.673949128	86.2707646	0.20571284	38.6	.	.
OR8B3	11	124396382	124397368	N	.	N	N	0.823060612	89.60467674	0.618283248	27	.	.
OR8B4	11	124423942	124424871	N	.	N	N	0.153213524	61.2432714	0.707743835	24.4	.	.
OR8B8	11	124440126	124441158	N	.	N	N	0.520058292	81.25832031	0.005555205	57.6	.	.
OR8D1	11	124309812	124310837	N	.	N	N	1.329642021	95.98888696	0.215921299	38.2	.	.
OR8D2	11	124319262	124320197	N	.	N	N	0.449660369	78.35272327	0.616576837	27	.	.
OR8D4	11	123906146	123907476	N	.	N	N	1.202071758	95.03386005	0.050486338	46.9	.	.
OR8G1	11	124249676	124250611	N	.	N	N	.	.	0.285950159	36.1	.	.
OR8G5	11	124264827	124265867	N	.	N	N	.	.	0.652742659	26	.	.
OR8H1	11	56290053	56291090	N	.	N	N	0.79304674	89.03744863	1.47E-05	77.1	DM?	.
OR8H2	11	56105018	56106055	N	.	N	N	1.735034062	98.00312554	0.000858972	65.3	.	.
OR8H3	11	56122373	56123311	N	.	N	N	0.667402358	86.14921572	7.95E-07	83	.	.
OR8I2	11	56093308	56094240	N	.	N	N	0.597959909	84.04815651	0.000129181	71.1	.	.
OR8J1	11	56360215	56361288	N	.	N	N	1.021979115	93.07171384	4.47E-06	79.8	.	.
OR8J3	11	56136771	56137718	N	.	N	N	0.392504758	75.48764253	0.065557023	45.5	.	.
OR8K1	11	56346039	56346998	N	.	N	N	1.300580966	95.80366962	0.002039164	61.8	.	.
OR8K3	11	56318307	56319245	N	.	N	N	0.073550514	55.19476761	4.46E-06	79.8	DM?	.
OR8K5	11	56159394	56160317	N	.	N	N	0.421560678	76.91728888	4.11E-07	84	.	.
OR8S1	12	48507354	48529897	N	.	N	N	0.916928187	91.44527406	3.08E-06	80.5	.	.
OR8U1	11	56375624	56376553	N	.	N	N	4.017306477	99.78584245	0.013454141	53.7	.	.
OR9A2	7	143026158	143027195	N	.	N	N	0.426194468	77.17775077	8.86E-05	72.3	.	.
OR9A4	7	141918817	141919909	N	.	N	N	0.460032897	78.82155467	0.000344415	68.2	.	.
OR9G1	11	56700388	56701305	N	.	N	N	2.638942044	99.25334259	0.000995316	64.7	.	.
OR9G4	11	56742827	56743811	N	.	N	N	0.531387625	81.71557562	0.000306988	68.6	.	.
OR9I1	11	58118500	58119444	N	.	N	N	0.755529606	88.24448689	0.612331301	27.1	.	.
OR9K2	12	55129681	55130802	N	.	N	N	0.802462863	89.1995138	9.75E-05	72	.	.
OR9Q1	11	58023881	58181616	N	.	N	N	0.580084093	83.4809284	0.008594897	55.5	.	.
OR9Q2	11	58190434	58191518	N	.	N	N	0.043538553	52.85061064	1.30E-07	85.8	.	.
ORAI2	7	102433106	102456821	N	.	N	N	-0.250187888	32.45355096	0.336548284	34.7	.	.
ORAI3	16	30949066	30956461	N	.	N	N	-0.391788739	24.87121607	0.01095069	54.5	.	.
ORAOV1	11	69653076	69675416	N	.	N	N	0.003958565	49.8061006	0.032990257	49.2	.	.
ORC2	2	200908973	200963680	N	.	N	N	-0.439524773	22.76436881	0.971869811	12.8	.	.
ORC4	2	147930397	148021604	N	.	N	Y	-0.176918638	36.94507148	2.29E-06	81.1	DM	Meier-Gorlin syndrome 2, 613800 (3)
ORC5	7	104126341	104208047	N	.	N	N	-0.36162327	26.26034612	2.29E-05	75.9	.	.
ORC6	16	46689643	46698394	N	.	N	N	-0.007220243	48.88580193	0.000734226	65.8	DM	Meier-Gorlin syndrome 3, 613803 (3)
ORM1	9	114323056	114326475	N	.	N	N	0.744201416	87.96666088	0.132357511	41.5	.	.
ORM2	9	114329869	114333252	N	.	N	N	1.032206482	93.17589859	0.005043484	58.1	.	.
ORMDL1	2	189770323	189784371	N	.	N	N	-0.141470476	39.31238062	0.0758239	44.7	.	.
ORMDL2	12	55817919	55821879	N	.	N	N	0.239424197	66.81136771	0.150868778	40.6	.	.
ORMDL3	17	39921041	39927601	N	.	N	N	-0.155519548	38.35156567	0.721819207	24	DFP	.
OSBP	11	59574398	59616144	N	.	N	N	-0.947030043	8.757307403	0.999542555	5.1	.	.
OSBP2	22	30693782	30907824	N	.	N	Y	0.265256787	68.39150315	0.036148744	48.8	.	.
OSBPL10	3	31657890	32077580	N	.	N	N	-1.117551885	6.389998264	0.000141846	70.8	.	.
OSBPL11	3	125528858	125595090	N	.	N	N	-0.829692794	10.98570354	0.898599332	17.8	.	.
OSBPL1A	18	24162044	24397880	N	.	N	N	-0.622170946	16.11969671	4.11E-05	74.4	.	.
OSBPL2	20	62231922	62296213	N	.	N	N	-0.240617998	33.02077907	0.504911841	29.8	.	Deafness, autosomal dominant 67, 616340 (3)
OSBPL3	7	24796539	24981634	N	.	N	N	-1.065838318	6.98616658	0.00266193	60.8	.	.
OSBPL5	11	3087116	3166739	N	.	N	N	-0.261869862	31.70689356	0.000848898	65.3	.	.
OSBPL6	2	178194481	178402891	N	.	N	N	-1.441186873	3.721710945	0.999012304	5.9	.	.
OSBPL7	17	47807372	47821834	N	.	N	N	-0.645637133	15.52352839	0.18160538	39.3	.	.
OSBPL8	12	76351797	76559809	N	.	N	N	-0.69830864	13.97233316	0.988348146	10.3	.	.
OSBPL9	1	51577179	51798427	N	.	N	N	-0.488218838	20.65752156	0.998515313	6.5	.	.
OSCAR	19	54094668	54102692	N	.	N	Y	.	.	0.632157857	26.6	.	.
OSCP1	1	36415827	36450451	N	.	N	N	-0.326978896	27.91572611	0.000148147	70.7	.	.
OSER1	20	44196496	44210791	N	.	N	N	-0.112262427	41.3266192	0.008728888	55.5	.	.
OSGEP	14	20446411	20455105	N	.	N	N	0.041624995	52.67118134	1.80E-05	76.5	.	.
OSGEPL1	2	189746660	189763227	N	.	N	N	-0.338310159	27.33692192	0.000202434	69.8	.	.
OSGIN1	16	83948282	83966332	N	.	N	N	0.216410569	65.43960178	0.016050625	52.8	DM?	.
OSGIN2	8	89901859	89927888	N	.	N	N	-0.441438866	22.67176014	0.988642484	10.2	.	.
OSM	22	30262829	30266840	N	Viable	N	Y	0.472169912	79.41193494	0.397920808	32.8	.	.
OSMR	5	38845858	38945596	N	.	N	Y	0.581500882	83.53880882	3.10E-11	93.7	DM	Amyloidosis, primary localized cutaneous, 1, 105250 (3)
OST4	2	27070472	27071773	N	.	N	N	.	.	.	.	.	.
OSTC	4	108650584	108667820	N	.	N	N	0.06302642	54.36707762	0.608151849	27.2	.	.
OSTF1	9	75088543	75147265	N	.	N	N	0.141883914	60.31139665	0.666040393	25.6	.	.
OSTN	3	191199241	191265615	N	.	N	N	0.154976897	61.35903224	0.085856051	44	.	.
OTOA	16	21678514	21760729	N	Viable	N	Y	-0.437311627	22.88012965	4.16E-08	87.2	DM	Deafness, autosomal recessive 22, 607039 (3)
OTOF	2	26457203	26558698	N	.	N	Y	0.488200966	80.00810326	4.33E-25	99.3	DM	Deafness, autosomal recessive 9, 601071 (3); Auditory neuropathy, autosomal recessive, 1, 601071 (3)
OTOG	11	17547373	17647150	N	.	N	Y	.	.	.	.	DM	Deafness, autosomal recessive 18B, 614945 (3)
OTOGL	12	80209453	80379090	N	.	N	N	.	.	3.73E-31	99.7	DM	Deafness, autosomal recessive 84B, 614944 (3)
OTOL1	3	161496808	161503942	N	.	N	N	0.58199694	83.58511316	1.72E-07	85.4	.	.
OTOP1	4	4188803	4226889	N	.	N	Y	0.746415105	88.01296521	7.31E-16	97.4	.	.
OTOP2	17	74924275	74933912	N	.	N	N	-0.246056484	32.69086068	3.08E-09	90.1	.	.
OTOP3	17	74935719	74949992	N	.	N	Y	1.591794299	97.43589744	9.57E-06	78.2	.	.
OTOR	20	16748358	16770062	N	.	N	N	0.24597088	67.24547086	0.014821336	53.2	DP	.
OTOS	2	240139026	240144562	N	.	N	Y	0.351015356	73.42131157	2.79E-07	84.7	.	.
OTUB2	14	94026329	94048930	N	.	N	Y	0.190728755	63.83052613	9.31E-06	78.2	.	.
OTUD1	10	23439458	23442390	N	.	N	N	.	.	.	.	.	.
OTUD3	1	19882513	19912945	N	.	N	N	0.237660296	66.68403079	2.63E-05	75.5	.	.
OTUD4	4	145110838	145180161	N	.	N	N	-0.028318057	47.40406321	0.999916478	3.7	DM	.
OTUD5	X	48922028	48958386	N	.	N	Y	-0.186488904	36.36626729	0.976548569	12.2	.	.
OTUD6A	X	70062491	70064179	N	Viable	N	Y	0.488942276	80.04283151	0.573824004	28.2	.	.
OTUD7A	15	31475398	31870789	N	.	N	N	-0.485348588	20.73855415	0.974595441	12.5	.	.
OTUD7B	1	149937812	150010676	N	.	N	Y	-1.318250346	4.584129189	0.100123441	43.1	.	.
OVCA2	17	2041936	2043430	N	.	N	N	0.006828994	50.02025815	3.95E-05	74.6	.	.
OVCH1	12	29412474	29497686	N	.	N	N	.	.	1.53E-28	99.6	.	.
OVCH2	11	7689438	7706421	N	.	N	N	.	.	7.83E-14	96.2	FTV	.
OVGP1	1	111414314	111427777	N	Viable	N	Y	1.006319643	92.83440412	0.000935884	65	DP	.
OVOL3	19	36111151	36113711	N	.	N	N	.	.	.	.	.	.
OVOS2	12	31111652	31206154	N	.	N	N	.	.	.	.	.	.
OXA1L	14	22766522	22773041	N	.	N	N	0.31953887	71.74856746	5.96E-09	89.4	.	.
OXCT2	1	39769523	39771348	N	.	N	N	.	.	.	.	.	.
OXER1	2	42762481	42764261	N	.	N	N	1.9068434	98.40250043	4.77E-07	83.8	.	.
OXGR1	13	96985719	96994730	N	.	N	Y	-0.048410911	45.9396886	0.000863936	65.3	.	.
OXLD1	17	81665036	81666635	N	.	N	N	0.982405668	92.53342594	0.041423225	48.1	.	.
OXNAD1	3	16265160	16350299	N	.	N	N	1.12703228	94.27562656	2.37E-05	75.8	.	.
OXR1	8	106270178	106752694	N	.	N	Y	-1.020958787	7.611275106	0.48853443	30.3	.	.
OXSM	3	25782917	25794534	N	.	N	N	-0.86449177	10.29113851	0.003306417	59.9	.	.
OXT	20	3071620	3072517	N	.	N	Y	0.039560397	52.53226833	0.62795746	26.7	.	.
OXTR	3	8750408	8769628	N	Viable	N	Y	-0.121527027	40.6494183	5.74E-05	73.5	DFP	.
P2RX1	17	3896592	3916500	N	.	N	Y	-0.190010792	36.18104995	6.47E-08	86.7	DM	Bleeding disorder due to P2RX1 defect, somatic, 609821 (3)
P2RX2	12	132618780	132622386	N	.	N	Y	0.315711326	71.46495341	9.69E-12	94.3	DM	Deafness, autosomal dominant 41, 608224 (3)
P2RX3	11	57338374	57370600	N	.	N	Y	0.134531237	59.82520113	0.011497581	54.3	.	.
P2RX4	12	121209857	121234106	N	Viable	N	Y	-0.121527027	40.6494183	2.37E-09	90.3	DFP	.
P2RX5	17	3672199	3696404	N	.	N	Y	0.338220438	72.790415	1.83E-05	76.5	DM	.
P2RX5-TAX1BP3	17	3663063	3696194	N	.	N	N	.	.	.	.	.	.
P2RX6	22	21009808	21028830	N	Viable	N	Y	0.521971277	81.33356486	1.88E-07	85.2	.	.
P2RX7	12	121132819	121188032	N	Viable	N	Y	1.116001895	94.14250159	3.79E-06	80.1	DFP	.
P2RY1	3	152834693	152841439	N	.	N	Y	-0.284831791	30.36985588	0.581732804	27.9	.	.
P2RY10	X	78945332	78961954	N	.	N	N	-0.183617621	36.51675638	0.690389562	24.9	.	.
P2RY11	19	10111538	10115372	N	.	N	N	1.354369391	96.13358801	9.08E-08	86.2	DP	.
P2RY12	3	151337380	151384812	N	.	N	Y	-0.285788866	30.29461133	0.107032258	42.7	DM	Bleeding disorder, platelet-type, 8, 609821 (3)
P2RY13	3	151326312	151329548	N	.	N	Y	0.055674233	53.76512126	0.327928324	34.9	.	.
P2RY14	3	151212117	151278467	N	.	N	Y	0.300554575	70.56201887	0.000377084	68	.	.
P2RY2	11	73218298	73236352	N	.	N	Y	0.161823975	61.9204723	0.070471984	45	.	.
P2RY6	11	73264505	73298617	N	.	N	Y	-0.144992854	39.06349482	4.64E-07	83.9	.	.
P2RY8	X	1462572	1537107	N	.	N	N	-0.306383832	29.09069862	0.012844117	53.9	.	.
P3H1	1	42746335	42767084	N	.	N	Y	.	.	.	.	.	Osteogenesis imperfecta, type VIII, 610915 (3)
P3H3	12	6828410	6839851	N	Viable	N	Y	.	.	.	.	.	.
P3H4	17	41801947	41812604	N	.	N	N	.	.	.	.	.	.
P4HA2	5	132191838	132295315	N	.	N	N	-0.328740556	27.78838919	6.46E-05	73.2	.	.
P4HA3	11	74235801	74311657	N	.	N	N	0.298791665	70.43468195	1.60E-07	85.5	.	.
P4HTM	3	48989886	49007154	N	.	N	Y	-0.11115351	41.40186375	0.023274936	50.9	.	.
PA2G4	12	56104319	56113907	N	.	N	Y	-0.056065882	45.38982462	0.998000991	6.9	.	.
PAAF1	11	73876699	73931124	N	.	N	N	0.118568504	58.65022863	1.03E-06	82.5	.	.
PABPC1	8	100685816	100722809	N	.	N	N	2.724247112	99.32858714	0.999692443	4.7	FTV	.
PABPC1L	20	44910062	44959035	N	.	N	Y	0.408618533	76.28060427	0.99334975	9.1	.	.
PABPC1L2A	X	73077276	73079512	N	.	N	N	.	.	0.343427414	34.4	.	.
PABPC1L2B	X	73003517	73005713	N	.	N	N	.	.	.	.	.	.
PABPC3	13	25095868	25099254	N	.	N	N	3.703871957	99.7105979	3.37E-11	93.6	.	.
PABPC4	1	39560816	39576790	N	.	N	Y	-1.550220513	3.085026336	0.992493064	9.3	.	.
PABPC4L	4	134196333	134201748	N	.	N	N	.	.	0.220668248	38	DM	.
PABPC5	X	91434595	91438584	N	.	N	N	-0.220175737	34.30572437	0.362703123	33.8	.	.
PABPN1	14	23321289	23326185	N	.	N	N	-0.019507464	47.94813914	0.599824569	27.5	DM	Oculopharyngeal muscular dystrophy, 164300 (3)
PABPN1L	16	88863333	88866660	N	.	N	Y	.	.	2.65E-11	93.7	.	.
PACRG	6	162727132	163315492	N	.	N	N	0.038754674	52.485964	0.000104677	71.7	DM?	.
PACRGL	4	20696282	20752907	N	.	N	N	0.257299872	67.86479134	9.14E-08	86.2	.	.
PACS1	11	66070363	66244747	N	.	N	N	-1.129837298	6.274237425	0.999906352	3.7	DM	Mental retardation, autosomal dominant 17, 615009 (3)
PACS2	14	105300563	105398147	N	.	N	Y	-0.868829287	10.221682	0.999324515	5.5	.	.
PACSIN1	6	34466061	34535231	N	.	N	Y	-0.255776741	32.13520866	0.991339222	9.6	.	.
PACSIN3	11	47177525	47186443	N	.	N	Y	-0.01265806	48.49800313	0.016793048	52.5	.	.
PADI1	1	17205126	17246005	N	.	N	N	0.583258584	83.62562945	5.27E-11	93.3	.	.
PADI3	1	17249098	17284233	N	.	N	N	2.147342454	98.77872316	4.69E-10	91.8	.	.
PADI6	1	17372196	17401699	N	.	N	Y	.	.	.	.	.	.
PAEP	9	135561756	135566955	N	.	N	N	0.472979635	79.42351103	0.031618374	49.4	.	.
PAF1	19	39385852	39391195	N	.	N	N	-0.174047919	37.14186491	0.84547263	20.1	.	.
PAFAH1B2	11	117144267	117176894	N	.	N	Y	-0.193034849	35.95531632	0.962029472	13.8	.	.
PAFAH1B3	19	42297033	42303546	N	.	N	Y	-0.349641992	26.83336227	0.021057918	51.3	DM	.
PAFAH2	1	25959767	25998157	N	.	N	Y	0.478865545	79.695549	2.69E-07	84.7	.	.
PAG1	8	80967810	81112068	N	.	N	Y	-0.508009746	19.8761359	0.010837278	54.6	.	.
PAGE1	X	49687450	49695993	N	.	N	N	0.282530296	69.45650287	0.389289496	33	.	.
PAGE2	X	55089008	55092842	N	.	N	N	0.48703021	79.96758697	0.201620359	38.7	.	.
PAGE2B	X	55075063	55078909	N	.	N	N	0.326593235	72.13057823	0.203304959	38.7	.	.
PAGE3	X	55258412	55264846	N	.	N	N	.	.	0.050523543	46.9	.	.
PAGE4	X	49829260	49833973	N	.	N	N	0.295624092	70.22631244	0.648195518	26.1	.	.
PAGE5	X	55089045	55288785	N	.	N	N	0.440098343	77.88389188	0.071254313	45	.	.
PAH	12	102836885	102958410	N	.	N	N	0.011764461	50.40805695	1.20E-10	92.9	DM	Phenylketonuria, 261600 (3); [Hyperphenylalaninemia, non-PKU mild], 261600 (3)
PAICS	4	56435741	56464579	N	.	N	N	0.68226197	86.49071019	0.068314123	45.2	.	.
PAIP1	5	43526267	43557758	N	.	N	N	-0.315801021	28.52347051	0.994278972	8.7	.	.
PAIP2	5	139341587	139369720	N	.	N	Y	-0.014874933	48.27805753	0.79947261	21.7	.	.
PAIP2B	2	71182739	71227083	N	.	N	N	0.403538004	75.98541413	0.0917531	43.7	.	.
PAK1	11	77321707	77474635	N	Viable	N	Y	-0.695744556	14.07072987	0.670970123	25.5	.	.
PAK3	X	110944285	111227361	N	.	N	Y	-0.199580796	35.52700122	0.987004717	10.6	DM	Mental retardation, X-linked 30/47, 300558 (3)
PAK6	15	40217428	40277486	N	.	N	Y	0.054215218	53.65514846	0.001281791	63.7	.	.
PAK7	20	9537389	9839041	N	.	N	Y	-0.475932167	21.19002142	0.998363567	6.6	DM?	.
PALD1	10	70478821	70568449	N	.	N	N	0.334854126	72.5415292	0.000887741	65.2	.	.
PALM	19	708939	748329	N	.	N	N	0.24898988	67.40753603	0.393531039	32.9	.	.
PALM2	9	109640788	109946703	N	.	N	N	0.173002985	62.75973838	0.003893171	59.2	.	.
PALM2-AKAP2	9	109780309	110172512	N	.	N	N	0.72805897	87.54413382	0.066517954	45.4	.	.
PALM3	19	14053365	14059159	N	.	N	N	.	.	.	.	.	.
PALMD	1	99645943	99694541	N	.	N	N	0.07178822	55.02691439	0.03695201	48.7	.	.
PAMR1	11	35431823	35530300	N	.	N	N	0.212735582	65.23123227	4.63E-21	98.9	.	.
PAN2	12	56316223	56334053	Y	Viable	N	Y	-0.732809632	13.07518666	0.946674807	15.1	.	.
PAN3	13	28138506	28295335	N	.	N	N	-1.155218948	6.031139665	0.999989677	2.6	.	.
PANK1	10	89579497	89645572	N	.	N	Y	-0.319475863	28.315101	0.00212215	61.7	.	.
PANK3	5	168548495	168579600	N	.	N	N	0.036841134	52.32389883	0.000282413	68.8	.	.
PANK4	1	2508533	2526628	N	.	N	N	-1.260127918	5.052960583	0.945333402	15.2	.	.
PANO1	11	797511	799190	N	.	N	N	.	.	.	.	.	.
PANX1	11	94128928	94181972	N	Viable	N	Y	-0.391635495	24.88858019	0.003095496	60.2	.	.
PANX2	22	50170731	50180294	N	Viable	N	Y	-0.64402392	15.57562077	0.014900767	53.2	.	.
PANX3	11	124611490	124620356	N	Viable	N	Y	0.462902626	78.98361984	0.001881242	62.1	.	.
PAOX	10	133379234	133391694	N	.	N	N	0.196620018	64.18938473	0.000435556	67.5	.	.
PAPD4	5	79612120	79686648	N	.	N	Y	-0.069963016	44.41743358	0.00095687	64.9	.	.
PAPD5	16	50152918	50235310	N	.	N	N	-0.287703102	30.21357875	0.998506441	6.5	.	.
PAPD7	5	6713007	6757048	N	.	N	N	-0.854116945	10.49371997	0.998369134	6.6	DP	.
PAPL	19	39083913	39111493	N	.	N	N	0.382281971	75.03617526	5.71E-06	79.3	.	.
PAPLN	14	73237497	73274640	N	.	N	N	3.194567266	99.60641315	5.13E-22	99	.	.
PAPOLA	14	96501433	96567111	N	.	N	N	-0.599961813	16.71007698	0.99997169	3	.	.
PAPOLB	7	4857733	4861994	N	.	N	Y	.	.	0.03717918	48.7	.	.
PAPOLG	2	60756230	60802085	N	.	N	N	-1.231214826	5.296058343	0.989888395	10	.	.
PAPPA	9	116153804	116402322	N	.	N	Y	-0.932276399	8.994617121	0.967751417	13.3	.	.
PAPPA2	1	176463171	176845605	N	.	N	Y	-0.5839644	17.265729	0.001250054	63.8	.	.
PAPSS1	4	107590276	107720452	N	.	N	N	-0.306231452	29.11385078	2.62E-06	80.7	.	.
PAPSS2	10	87659613	87747705	N	.	N	N	-0.688892092	14.23858309	2.50E-07	84.8	DM	Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3)
PAQR3	4	78887127	78939438	N	.	N	Y	-0.808294265	11.39665451	0.020391704	51.6	.	.
PAQR4	16	2969245	2973489	N	.	N	N	-0.129986883	40.1111304	6.76E-05	73	.	.
PAQR5	15	69298947	69407780	N	.	N	N	-0.163826529	37.7901256	0.153782977	40.4	.	.
PAQR6	1	156243321	156248117	N	Viable	N	Y	0.287461744	69.74011692	0.000721604	65.9	.	.
PAQR7	1	25861210	25871253	N	.	N	N	0.218021088	65.55536262	0.009310768	55.2	.	.
PAQR8	6	52361421	52407777	N	.	N	N	-0.640349555	15.66822944	0.177868817	39.4	.	.
PAQR9	3	142949164	142963682	N	.	N	N	-0.801748514	11.52399143	0.800794307	21.6	.	.
PARD3B	2	204545793	205620162	N	Viable	N	Y	0.270355413	68.70405742	8.65E-08	86.3	DP	.
PARD6A	16	67660946	67662778	N	.	N	N	-0.216347583	34.5025178	0.854734701	19.7	DFP	.
PARD6B	20	50731544	50756795	N	.	N	N	-0.179789518	36.75985414	0.807577375	21.3	.	.
PARD6G	18	80157232	80247546	N	.	N	N	-0.31116943	28.88232911	0.11193541	42.5	.	.
PARK2	6	161347420	162727771	N	.	N	Y	0.91612174	91.41633385	0.021808832	51.2	DM	Parkinson disease, juvenile, type 2, 600116 (3); Adenocarcinoma of lung, somatic, 211980 (3); Adenocarcinoma, ovarian, somatic, 167000 (3); {Leprosy, susceptibility to}, 607572 (3)
PARK7	1	7954291	7985505	N	.	N	Y	0.13438084	59.79626092	0.903949397	17.6	DM	Parkinson disease 7, autosomal recessive early-onset, 606324 (3)
PARL	3	183829385	183884933	N	.	N	Y	0.111065501	58.08300052	1.07E-05	77.9	DM	.
PARM1	4	74933095	75050115	N	.	N	N	0.450616788	78.37587544	0.006063363	57.2	.	.
PARN	16	14435701	14632728	N	.	N	N	-0.134619278	39.77542397	0.387183623	33.1	.	Dyskeratosis congenita, autosomal recessive 6, 616353 (3); Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4, 616371 (3)
PARP10	8	143977153	144012772	N	.	N	Y	0.440855794	77.91862013	0.002911316	60.5	.	.
PARP11	12	3791047	3873448	N	Viable	N	Y	-0.847726506	10.60948081	0.000159466	70.5	.	.
PARP12	7	140023744	140063721	N	Viable	N	Y	-0.081946999	43.43346646	7.93E-06	78.6	.	.
PARP14	3	122680618	122730840	N	.	N	N	-1.451169671	3.663830526	0.01296069	53.9	.	.
PARP15	3	122577602	122639047	N	.	N	N	0.654309067	85.76720495	2.71E-07	84.7	.	.
PARP16	15	65234460	65300618	N	Viable	N	Y	0.118568504	58.65022863	1.93E-08	88.2	.	.
PARP2	14	20343582	20357905	N	.	N	Y	0.188160176	63.68003704	2.10E-07	85.1	FP	.
PARP3	3	51942345	51948867	N	.	N	N	1.250113981	95.42744689	1.49E-08	88.5	.	.
PARP4	13	24420926	24512810	N	.	N	Y	3.104974511	99.57747294	2.13E-20	98.8	.	.
PARP6	15	72241181	72272999	N	.	N	N	-0.993965971	7.95855762	0.997418878	7.3	.	.
PARP8	5	50665899	50846522	N	Viable	N	Y	-0.822040307	11.13619263	0.119242934	42.1	.	.
PARP9	3	122527924	122564577	N	.	N	N	0.019418972	51.05052961	5.14E-06	79.5	.	.
PARPBP	12	102120185	102197520	N	.	N	N	0.041776336	52.69433351	9.67E-13	95.3	.	.
PARS2	1	54756898	54764514	N	.	N	N	-0.127116299	40.27319558	0.701898	24.6	.	.
PARVB	22	43999211	44172949	N	.	N	Y	0.374778905	74.66574058	1.17E-12	95.2	.	.
PARVG	22	44172956	44219533	N	.	N	Y	0.642023041	85.42571048	0.01202245	54.2	.	.
PASD1	X	151563622	151676739	N	.	N	N	0.87014387	90.60021995	0.897076709	17.9	.	.
PASK	2	241106099	241150264	N	.	N	Y	-0.146818404	38.94773398	9.06E-20	98.6	DM	.
PATE1	11	125746293	125749867	N	.	N	N	0.139970692	60.17827169	7.59E-08	86.5	.	.
PATE2	11	125776113	125778819	N	Viable	N	Y	0.093995484	56.69387046	3.37E-05	74.9	.	.
PATE3	11	125788111	125791600	N	.	N	N	.	.	.	.	.	.
PATE4	11	125833316	125840069	N	.	N	N	.	.	.	.	.	.
PATL2	15	44665732	44711316	N	.	N	Y	.	.	0.067710089	45.2	.	.
PAXBP1	21	32733899	32771858	N	.	N	N	-1.326854117	4.503096602	0.999970426	3	.	.
PBDC1	X	76172936	76178204	N	.	N	N	0.237511303	66.66087862	0.845464415	20.1	.	.
PBK	8	27809620	27838095	N	.	N	Y	0.055674233	53.76512126	4.09E-05	74.4	.	.
PBLD	10	68282660	68333049	N	.	N	N	-0.163826529	37.7901256	2.82E-05	75.3	.	.
PBOV1	6	138215986	138218491	N	.	N	N	0.768480455	88.5223129	0.007572397	56.2	.	.
PBX2	6	32184741	32190186	N	.	N	Y	0.139164133	60.1377554	0.889707316	18.2	.	.
PBX4	19	19561707	19618916	N	.	N	N	0.354032699	73.67598541	0.006772126	56.7	DM?	.
PBXIP1	1	154944076	154956123	N	.	N	N	0.677928319	86.36337327	5.80E-07	83.5	.	.
PCBD1	10	70882280	70888784	N	.	N	Y	0.115548149	58.40713087	0.001094413	64.4	DM	Hyperphenylalaninemia, BH4-deficient, D, 264070 (3)
PCBD2	5	134904906	135007959	N	.	N	N	-0.052390454	45.59819413	0.003062596	60.3	.	.
PCBP1	2	70087454	70089203	N	.	N	N	-0.719211967	13.43404526	0.727131612	23.8	.	.
PCBP2	12	53452102	53481162	N	.	N	N	-0.510079547	19.80089136	0.98703033	10.6	.	.
PCBP3	21	45643694	45942454	N	.	N	N	-0.346770353	26.9201829	0.980315405	11.7	.	.
PCBP4	3	51957454	51974016	N	.	N	N	-0.569949107	17.64195173	0.233370936	37.6	.	.
PCCB	3	136250306	136337896	N	.	N	N	0.134682454	59.83098918	0.000735839	65.8	DM	Propionicacidemia, 606054 (3)
PCDH1	5	141853111	141879246	N	.	N	N	-1.789026577	2.228396134	0.87319544	18.9	.	.
PCDH11X	X	91779261	92623230	N	.	N	N	-1.01713429	7.669155525	0.925742125	16.3	DM	.
PCDH11Y	Y	5000226	5742224	N	.	N	N	.	.	0.036368643	48.8	.	.
PCDH12	5	141943585	141969741	N	.	N	Y	0.456979998	78.63054929	1.29E-10	92.8	.	.
PCDH15	10	53802771	55627942	N	.	N	N	0.396826589	75.65549575	7.23E-11	93.2	DM	Usher syndrome, type 1F, 602083 (3); Deafness, autosomal recessive 23, 609533 (3); Usher syndrome, type 1D/F digenic, 601067 (3)
PCDH17	13	57631810	57729311	N	.	N	Y	-1.611755813	2.79562424	0.960498313	13.9	.	.
PCDH18	4	137518918	137532494	N	Viable	N	Y	-1.32930757	4.485732477	0.000442525	67.4	DM?	.
PCDH19	X	100291644	100410273	N	.	N	N	-0.838003561	10.8004862	0.977158513	12.2	DM	Epileptic encephalopathy, early infantile, 9, 300088 (3)
PCDH20	13	61409858	61427849	N	.	N	N	-0.72721813	13.21409967	0.881149073	18.6	.	.
PCDH7	4	30720415	31146805	N	.	N	N	-1.537659433	3.16027088	.	.	.	.
PCDH8	13	52842889	52848641	N	.	N	Y	0.077529154	55.49574579	.	.	.	.
PCDH9	13	66302834	67230445	N	.	N	N	-1.265584424	4.995080164	0.973014277	12.7	.	.
PCDHA1	5	140786136	141012347	N	.	N	Y	-0.280407152	30.6071656	0.000559475	66.7	.	.
PCDHA10	5	140855883	141012344	N	.	N	N	1.055508626	93.43636048	4.18E-11	93.5	DM	.
PCDHA11	5	140868183	141012344	N	.	N	N	-0.337566281	27.36586213	3.59E-10	92	.	.
PCDHA12	5	140875302	141012344	N	.	N	N	0.426008805	77.13144643	3.52E-10	92.1	.	.
PCDHA13	5	140882208	141012344	N	.	N	N	-0.402373043	24.23453146	4.29E-11	93.5	DM?	.
PCDHA2	5	140794852	141012344	N	.	N	N	-0.422016068	23.44156972	1.99E-09	90.5	.	.
PCDHA3	5	140801028	141012344	N	.	N	N	-0.938000956	8.896220409	1.46E-13	96	DM?	.
PCDHA4	5	140806929	141012344	N	.	N	N	1.154978029	94.54766453	2.88E-15	97	.	.
PCDHA5	5	140821604	141012344	N	.	N	N	0.325593163	72.06112172	0.003538248	59.6	.	.
PCDHA6	5	140827958	141012344	N	.	N	N	-0.616154782	16.29912601	6.16E-08	86.7	.	.
PCDHA7	5	140834248	141012344	N	.	N	N	-1.054379856	7.159807837	0.000137152	70.9	.	.
PCDHA8	5	140841187	141012344	N	.	N	N	1.006822015	92.84019216	3.70E-10	92	.	.
PCDHA9	5	140847463	141012344	N	.	N	N	1.961035932	98.51826127	7.89E-14	96.2	.	.
PCDHAC1	5	140926369	141012344	N	.	N	Y	0.222307202	65.74057996	4.58E-09	89.7	.	.
PCDHAC2	5	140966235	141012344	N	.	N	Y	-0.791881927	11.72078486	0.916966112	16.9	.	.
PCDHB1	5	141051135	141059344	N	.	N	N	0.186398556	63.6047925	2.81E-08	87.7	.	.
PCDHB10	5	141187319	141195642	N	.	N	N	2.799072067	99.38067952	1.18E-06	82.3	.	.
PCDHB11	5	141199582	141203779	N	.	N	N	0.074158512	55.20055565	3.09E-07	84.5	.	.
PCDHB12	5	141208697	141212571	N	.	N	N	0.569529665	83.02946113	0.000155402	70.6	.	.
PCDHB13	5	141213919	141218979	N	.	N	N	0.270198172	68.69826938	1.69E-09	90.7	.	.
PCDHB14	5	141222932	141227759	N	.	N	N	0.459693288	78.78682642	9.06E-09	89	.	.
PCDHB15	5	141245349	141249365	N	.	N	N	1.494405795	96.95548996	0.006800825	56.7	.	.
PCDHB16	5	141181399	141186399	N	.	N	N	0.245773915	67.20495456	0.001770815	62.4	DM?	.
PCDHB2	5	141094578	141098703	N	.	N	N	0.551488074	82.50274932	.	.	.	.
PCDHB3	5	141100473	141152636	N	.	N	N	-0.084515628	43.23088499	.	.	.	.
PCDHB4	5	141121799	141125623	N	.	N	N	0.491462634	80.13544018	.	.	DM?	.
PCDHB5	5	141135218	141138625	N	.	N	N	-0.00470073	49.08259536	9.45E-07	82.6	.	.
PCDHB6	5	141150022	141153287	N	.	N	N	1.63987067	97.69057128	0.001726641	62.5	.	.
PCDHB7	5	141172619	141176383	N	.	N	N	1.210386576	95.12646872	1.30E-15	97.2	.	.
PCDHB8	5	141177790	141180529	N	.	N	N	1.27522369	95.58951207	4.80E-08	87	.	.
PCDHB9	5	141187127	141191541	N	.	N	N	.	.	.	.	.	.
PCDHGA1	5	141330571	141512981	N	.	N	Y	0.161325015	61.85680384	0.000268174	69	.	.
PCDHGA10	5	141412987	141512979	N	.	N	N	0.323521426	71.96851305	5.44E-06	79.4	FTV	.
PCDHGA11	5	141421047	141512979	N	.	N	N	0.469910793	79.31353823	4.55E-05	74.2	FTV	.
PCDHGA12	5	141430589	141512979	N	.	N	N	-0.271137911	31.19175783	0.000727679	65.8	.	.
PCDHGA2	5	141338760	141512979	N	.	N	N	0.171699713	62.63240146	8.23E-07	82.9	.	.
PCDHGA3	5	141343829	141512979	N	.	N	N	-0.313288815	28.65080743	0.000592397	66.5	.	.
PCDHGA4	5	141355025	141512979	N	.	N	N	.	.	5.96E-07	83.4	.	.
PCDHGA5	5	141364232	141512979	N	.	N	N	-0.602241252	16.64062048	0.000468775	67.2	.	.
PCDHGA6	5	141373914	141512979	N	.	N	N	-0.257897165	32.00787174	8.20E-07	82.9	.	.
PCDHGA7	5	141382739	141512979	N	.	N	N	0.526264404	81.47247786	5.28E-06	79.4	.	.
PCDHGA8	5	141390157	141512979	N	.	N	N	0.404297615	76.02014239	9.45E-09	89	.	.
PCDHGA9	5	141402932	141512979	N	.	N	N	1.014943104	92.93858888	3.68E-05	74.7	.	.
PCDHGB1	5	141350102	141512979	N	.	N	N	-0.063769252	44.84574868	0.168083945	39.8	.	.
PCDHGB2	5	141360042	141512979	N	.	N	N	-0.318069754	28.39034555	3.54E-07	84.3	.	.
PCDHGB3	5	141370264	141512979	N	.	N	N	0.503754723	80.58690745	0.000624135	66.3	.	.
PCDHGB4	5	141387698	141512979	N	.	N	N	0.169631488	62.47033629	0.002561316	61	.	.
PCDHGB5	5	141397987	141512979	N	.	N	N	.	.	.	.	.	.
PCDHGB6	5	141408021	141512979	N	.	N	N	-0.054503261	45.48243329	6.47E-05	73.2	.	.
PCDHGB7	5	141417645	141512979	N	.	N	N	0.565536764	82.89054813	0.016070626	52.8	.	.
PCDHGC3	5	141475947	141512979	N	.	N	N	-0.944821741	8.797823696	0.705736989	24.5	.	.
PCDHGC4	5	141484997	141512979	N	.	N	N	-0.849186025	10.55160039	0.936149575	15.8	.	.
PCDHGC5	5	141489121	141512979	N	.	N	N	-0.998303674	7.889101117	2.85E-05	75.3	.	.
PCED1A	20	2835314	2841190	N	Viable	N	Y	-0.212519778	34.79191989	0.016026707	52.8	.	.
PCED1B	12	47079603	47236662	N	.	N	N	-0.447027861	22.42866238	0.008266127	55.7	.	.
PCF11	11	83156988	83187451	N	.	N	N	-1.193273293	5.6491289	0.999999874	1.2	.	.
PCGF1	2	74505043	74508580	N	.	N	N	0.026467762	51.52514904	0.987060431	10.6	.	.
PCGF3	4	705748	770640	N	.	N	N	-0.047605945	46.02072119	0.943399927	15.4	.	.
PCGF5	10	91163012	91284331	N	.	N	N	0.162480005	61.94941251	0.996021946	8	.	.
PCGF6	10	103302796	103351134	N	.	N	N	0.074356355	55.24107195	0.000251716	69.1	.	.
PCID2	13	113177539	113208715	N	.	N	N	-0.205973698	35.14499045	6.37E-09	89.4	.	.
PCIF1	20	45934628	45948023	N	.	N	N	-0.612902778	16.4090988	0.999961616	3.1	.	.
PCK2	14	24094053	24110598	N	.	N	N	1.357243904	96.15674017	2.19E-17	97.9	.	PEPCK deficiency, mitochondrial, 261650 (1)
PCLO	7	82754013	83162930	N	.	N	Y	-3.071974657	0.590380274	1	0.3	.	?Pontocerebellar hypoplasia, type 3, 608027 (3)
PCM1	8	17922840	18029944	N	.	N	N	0.844401901	90.10244834	.	.	DM	.
PCMT1	6	149749443	149811420	N	.	N	Y	0.481438994	79.79973375	0.446383566	31.5	FP	.
PCMTD1	8	51817575	51899186	N	.	N	N	1.067001612	93.59842565	2.56E-06	80.8	.	.
PCMTD2	20	64255695	64287821	N	.	N	N	-0.211715637	34.80928402	0.012329763	54.1	.	.
PCNP	3	101574095	101594437	N	.	N	N	0.08457904	56.06876194	0.87242341	18.9	.	.
PCNT	21	46324122	46445769	N	.	N	N	2.688926909	99.31122301	4.18E-38	99.9	DM	Microcephalic osteodysplastic primordial dwarfism, type II, 210720 (3)
PCNX	14	70907405	71115382	N	.	N	N	-3.199595814	0.503559646	0.999999565	1.5	.	.
PCNXL2	1	232983435	233295713	N	.	N	N	0.667765803	86.1607918	7.55E-14	96.2	.	.
PCNXL3	11	65615773	65637439	N	.	N	N	-1.678897964	2.512010187	0.488259802	30.3	.	.
PCNXL4	14	60091911	60169133	N	.	N	N	.	.	4.27E-16	97.5	.	.
PCOLCE	7	100602177	100608175	N	.	N	Y	0.311884256	71.19291544	0.500664878	29.9	DM?	.
PCOLCE2	3	142815922	142889203	N	.	N	Y	0.188965718	63.72634138	6.88E-07	83.2	FTV	.
PCP2	19	7631611	7633748	N	.	N	Y	0.404494149	76.04329455	1.28E-05	77.4	.	.
PCP4	21	39867317	39929397	N	.	N	Y	0.045150018	52.96637148	0.075103915	44.8	.	.
PCP4L1	1	161258727	161285450	N	.	N	N	0.098628637	57.02378885	0.22398583	37.9	.	.
PCSK1N	X	48831094	48835633	N	Viable	N	Y	.	.	0.444049067	31.6	.	.
PCSK2	20	17226107	17484578	N	.	N	Y	-0.786586394	11.81918157	0.994186022	8.8	DP	.
PCSK4	19	1481428	1490752	N	Viable	N	Y	0.865668715	90.4555189	6.59E-13	95.4	.	.
PCSK7	11	117204337	117232525	N	.	N	N	-0.314540604	28.57556289	0.191369613	38.9	.	.
PCSK9	1	55039548	55064852	N	.	N	Y	1.723045673	97.97418533	1.03E-10	92.9	DM	Hypercholesterolemia, familial, 3, 603776 (3); {Low density lipoprotein cholesterol level QTL 1}, 603776 (3)
PCTP	17	55750979	55842830	N	.	N	Y	0.680350018	86.42704173	1.63E-05	76.8	.	.
PCYOX1	2	70257386	70281191	N	.	N	Y	0.603699992	84.26231406	6.73E-12	94.4	.	.
PCYOX1L	5	149358007	149369653	N	.	N	N	0.020224237	51.10841002	1.27E-05	77.4	.	.
PCYT1B	X	24558087	24672677	N	.	N	Y	0.119374702	58.69074492	0.944740314	15.2	.	.
PDAP1	7	99392048	99408829	N	.	N	N	-0.018550615	48.01759565	0.005589378	57.6	.	.
PDC	1	186443566	186461122	N	.	N	Y	0.301362114	70.58517104	2.23E-06	81.1	.	Paroxysmal nonkinesigenic dyskinesia, 118800 (3)
PDCD1	2	241849881	241858908	N	.	N	Y	0.023748636	51.34571974	0.017954048	52.2	DM?	{Systemic lupus erythematosus, susceptibility to, 2}, 605218 (3); {Multiple sclerosis, disease progression, modifier of}, 126200 (3)
PDCD11	10	103396648	103446292	N	.	N	N	-1.446203587	3.704346819	0.468448698	30.9	.	.
PDCD1LG2	9	5510570	5571254	N	.	N	Y	0.533151945	81.77345604	0.000429826	67.5	.	.
PDCD2L	19	34404384	34426168	N	.	N	N	-0.147863581	38.90142965	4.99E-05	73.9	.	.
PDCD4	10	110871795	110900006	N	.	N	Y	-0.60555081	16.60010418	0.000577684	66.6	.	.
PDCD5	19	32581068	32587452	N	.	N	N	-0.013918082	48.39381837	0.007120942	56.5	DFP	.
PDCD6	5	271621	353856	N	.	N	Y	0.135337478	59.85414134	0.714212209	24.2	.	.
PDCD6IP	3	33798352	33869707	N	.	N	N	-0.489981901	20.60542918	0.751958922	23.1	.	.
PDCD7	15	65117379	65133836	N	.	N	N	-0.243641967	32.83556173	0.045374794	47.5	.	.
PDCL	9	122798389	122828631	N	.	N	N	-0.106673287	41.69126584	0.31202797	35.4	.	.
PDCL2	4	55556525	55592212	N	.	N	N	0.191535973	63.89419459	0.041360287	48.1	.	.
PDCL3	2	100562690	100576735	N	.	N	N	0.16167322	61.90310818	0.000392971	67.8	.	.
PDDC1	11	767220	777488	N	.	N	N	0.129747743	59.39109799	0.617289948	27	.	.
PDE10A	6	165327287	165986603	N	.	N	Y	-0.656159394	15.18782196	0.998485351	6.6	.	.
PDE11A	2	177623252	178108339	N	.	N	Y	1.169811994	94.75024599	4.17E-31	99.7	DM	Pigmented nodular adrenocortical disease, primary, 2, 610475 (3)
PDE1A	2	182140036	182523192	N	.	N	N	-0.778126027	12.06806737	0.730656355	23.7	DM?	.
PDE1B	12	54549350	54579239	N	Viable	N	Y	-0.402009394	24.309776	0.946737284	15.1	.	.
PDE1C	7	31751179	32299329	N	.	N	Y	0.112325491	58.15824507	0.000270704	69	DM?	.
PDE3A	12	20369245	20684381	N	.	N	Y	-1.054513326	7.154019795	0.106612096	42.8	.	Hypertension and brachydactyly syndrome, 112410 (3)
PDE3B	11	14643723	14872044	N	.	N	Y	-1.0620173	7.038258957	0.00361647	59.5	.	.
PDE4A	19	10416773	10469631	N	.	N	N	-0.607164335	16.54222377	0.976417636	12.2	.	.
PDE4B	1	65792514	66374579	N	.	N	Y	-0.96938953	8.386872721	0.709078617	24.4	DM	.
PDE4C	19	18207961	18255419	N	.	N	N	-0.01250659	48.50379117	4.89E-05	74	DM?	.
PDE5A	4	119494395	119628991	N	.	N	N	0.488434514	80.02546738	0.003390906	59.8	.	.
PDE6A	5	149857955	149944793	N	.	N	N	1.128456987	94.29299068	6.61E-12	94.5	DM	Retinitis pigmentosa 43, 613810 (3)
PDE6B	4	625584	670782	N	.	N	Y	0.877169376	90.69282862	1.63E-13	95.9	DM	Night blindness, congenital stationary, autosomal dominant 2, 163500 (3); Retinitis pigmentosa-40, 613801 (3)
PDE6C	10	93612588	93666010	N	.	N	N	-0.25914937	31.93262719	7.42E-08	86.5	DM	Cone dystrophy 4, 613093 (3)
PDE6D	2	231732425	231786272	N	.	N	N	0.039560397	52.53226833	0.084496093	44.1	.	?Joubert syndrome 22, 615665 (3)
PDE6G	17	81650459	81663112	N	.	N	Y	0.39603475	75.62655554	0.014216424	53.4	DM	Retinitis pigmentosa 57, 613582 (3)
PDE6H	12	14973022	14981865	N	.	N	N	0.145560638	60.65289113	0.006528713	56.9	DM	Retinal cone dystrophy 3, 610024 (3); Achromatopsia 6, 610024 (3)
PDE7A	8	65717510	65842322	N	.	N	N	-0.463948146	21.72830931	0.192057714	38.9	.	.
PDE7B	6	135851696	136195574	N	.	N	N	-0.063416885	44.9036291	0.946452269	15.1	FP	.
PDE8A	15	84980440	85139145	N	Viable	N	Y	-0.300491102	29.42640505	0.713477057	24.2	.	.
PDE8B	5	77210449	77429807	N	.	N	Y	-0.859706529	10.38374718	0.986862336	10.7	DM	Pigmented nodular adrenocortical disease, primary, 3, 614190 (3); Striatal degeneration, autosomal dominant, 609161 (3)
PDE9A	21	42653636	42775509	N	.	N	N	-0.325870286	27.99097065	0.002017364	61.8	.	.
PDF	16	69328621	69330595	N	.	N	N	.	.	0.050315418	47	.	.
PDGFD	11	103907186	104164379	N	.	N	N	0.331523457	72.40840424	0.015948336	52.9	DFP	.
PDGFRL	8	17576433	17644071	N	.	N	N	0.347637183	73.26503444	4.17E-10	91.9	DFP	Hepatocellular cancer, somatic, 114550 (3); Colorectal cancer, somatic, 114500 (3)
PDHA2	4	95840019	95841474	N	.	N	N	0.569860199	83.0526133	4.52E-11	93.4	.	.
PDHB	3	58427630	58433857	N	.	N	N	-0.255776741	32.13520866	0.357305589	34	DM	Pyruvate dehydrogenase E1-beta deficiency, 614111 (3)
PDHX	11	34915829	35020591	N	.	N	N	0.87014387	90.60021995	0.001370288	63.5	DM	.
PDIA2	16	283152	287215	N	.	N	N	3.236295474	99.62956532	2.53E-21	98.9	.	.
PDIA4	7	149003062	149028641	N	Viable	N	Y	0.178895556	63.10123285	0.014774297	53.2	DM?	.
PDIA5	3	123067062	123225227	N	.	N	N	-0.137338205	39.61914684	1.00E-06	82.5	.	.
PDIK1L	1	26111165	26125543	N	.	N	N	-0.336550417	27.43531863	0.381253877	33.3	.	.
PDILT	16	20359170	20404737	N	.	N	Y	1.269909282	95.55478382	9.26E-06	78.3	.	.
PDK1	2	172555373	172608669	N	Viable	N	Y	0.149537247	60.98280952	0.004656689	58.5	.	.
PDK2	17	50094737	50112152	N	.	N	Y	-0.427389804	23.21583608	0.168975525	39.8	.	.
PDK3	X	24465221	24539837	N	.	N	N	0.208455225	64.9591943	0.87927552	18.6	DM	?Charcot-Marie-Tooth disease, X-linked dominant, 6, 300905 (3)
PDK4	7	95583499	95596491	N	Viable	N	Y	0.121438731	58.82965793	4.55E-06	79.7	.	.
PDLIM1	10	95237572	95291024	N	.	N	Y	-0.383328502	25.24743879	1.38E-05	77.2	.	.
PDLIM2	8	22578279	22598025	N	.	N	Y	.	.	0.049749311	47	.	.
PDLIM4	5	132257671	132273454	N	.	N	N	-0.019355782	47.95971523	0.924088702	16.4	.	.
PDLIM5	4	94451857	94668227	N	.	N	Y	-0.150430658	38.69884818	0.012278281	54.1	DFP	.
PDP1	8	93857807	93926066	N	.	N	N	-0.886044899	9.862823407	0.340047358	34.5	DM	Pyruvate dehydrogenase phosphatase deficiency, 608782 (3)
PDP2	16	66878589	66895754	N	.	N	N	-0.323151188	28.07200324	1.86E-05	76.4	.	.
PDPR	16	70113626	70162537	N	.	N	N	1.747043312	98.04364184	4.85E-08	87	.	.
PDRG1	20	31944342	31952092	N	.	N	N	0.366021797	74.14481681	0.001086939	64.4	.	.
PDSS1	10	26697659	26746798	N	.	N	N	-0.119765437	40.78833131	0.26315186	36.7	DM	Coenzyme Q10 deficiency, primary, 2, 614651 (3)
PDXDC1	16	14974591	15139339	N	.	N	N	-0.068552734	44.48689009	2.30E-07	85	.	.
PDXP	22	37658727	37666934	N	.	N	N	0.171896242	62.66134167	0.042715349	47.9	.	.
PDYN	20	1978757	1994285	N	.	N	Y	0.033165214	52.10395323	0.000256778	69.1	DM	Spinocerebellar ataxia 23, 610245 (3)
PDZD11	X	70286595	70290514	N	.	N	N	0.166157019	62.22723853	0.813638005	21.2	.	.
PDZD2	5	31639410	32110931	N	.	N	N	-0.309191388	28.96914974	0.999645171	4.8	.	.
PDZD3	11	119185457	119190223	N	.	N	Y	0.820339266	89.52943219	3.36E-07	84.4	.	.
PDZD4	X	153802166	153830565	N	.	N	N	-0.81755696	11.25195346	0.930873832	16.1	.	.
PDZD7	10	101007683	101031157	N	.	N	Y	0.093340348	56.65335417	0.722769808	24	DM	{Retinal disease in Usher syndrome type IIA, modifier of}, 276901 (3); Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 (3)
PDZD8	10	117277274	117375467	N	.	N	N	-1.050830532	7.206112172	0.997263557	7.4	.	.
PDZD9	16	21983865	22001110	N	.	N	N	0.208455225	64.9591943	0.545260625	28.7	.	.
PDZK1	1	145670852	145708148	N	.	N	Y	0.35770974	73.83805059	0.000134102	71	.	.
PDZK1IP1	1	47183593	47191044	N	.	N	N	0.488942276	80.04283151	0.000484065	67.1	.	.
PDZRN3	3	73382433	73624940	N	.	N	N	-0.738261201	12.95363778	0.908376144	17.4	.	.
PDZRN4	12	41188448	41574590	N	.	N	N	0.063632022	54.41916999	0.070852773	45	.	.
PEA15	1	160205337	160215376	N	.	N	Y	0.030143764	51.8087631	0.698679172	24.6	.	.
PEAK1	15	77100656	77420144	N	.	N	N	-1.657415064	2.633559067	0.760544633	22.8	.	.
PEAR1	1	156893698	156916434	N	.	N	Y	0.528180406	81.55351045	1.19E-14	96.7	DFP	.
PEBP1	12	118135858	118145584	N	.	N	N	-0.057022786	45.34352029	0.148864265	40.6	.	.
PEBP4	8	22713251	23000000	N	.	N	N	1.542633814	97.18701163	0.038898535	48.5	.	.
PECAM1	17	64319415	64413776	N	.	N	Y	.	.	.	.	DFP	.
PECR	2	215996329	216082955	N	.	N	N	0.632607038	85.1247323	0.000786066	65.6	DM	.
PEF1	1	31629862	31644896	N	Viable	N	Y	0.009699407	50.29229612	0.323496549	35	.	.
PELI2	14	56117814	56301526	N	.	N	N	-0.259451686	31.91526307	0.948506495	14.9	.	.
PELI3	11	66466327	66477337	N	.	N	Y	-0.265040808	31.57376859	0.027343382	50.2	.	.
PELP1	17	4669774	4704337	N	.	N	N	-0.305932297	29.12542687	0.999794752	4.3	.	.
PEMT	17	17505563	17591708	N	.	N	Y	0.539698884	82.04549401	0.367752728	33.7	DFP	.
PENK	8	56436674	56446734	N	Viable	N	Y	0.426194468	77.17775077	2.76E-05	75.4	DFP	.
PER1	17	8140472	8156506	N	.	N	Y	0.473108399	79.42929907	0.875748962	18.8	DM?	.
PER2	2	238244038	238290102	N	.	N	Y	0.288235321	69.76326909	0.933004687	15.9	DM	Advanced sleep phase syndrome, familial, 1, 604348 (3)
PER3	1	7784320	7845177	N	.	N	Y	0.225493277	65.97788968	2.19E-10	92.4	DP	.
PERM1	1	975204	982093	N	.	N	N	.	.	.	.	.	.
PET100	19	7629737	7631956	N	.	N	N	.	.	.	.	.	Mitochondrial complex IV deficiency, 220110 (3)
PET117	20	18137873	18143169	N	.	N	N	.	.	.	.	.	.
PEX1	7	92487020	92528531	N	.	N	Y	0.13881566	60.07408694	3.97E-05	74.5	DM	.
PEX11A	15	89677764	89690783	N	.	N	Y	-0.190163599	36.15789778	5.94E-07	83.4	.	.
PEX11G	19	7476875	7497449	N	.	N	N	.	.	0.000252773	69.1	.	.
PEX12	17	35574795	35578863	N	.	N	N	0.139164133	60.1377554	3.70E-12	94.8	DM	Peroxisome biogenesis disorder 3A (Zellweger), 614859 (3); Peroxisome biogenesis disorder 3B, 266510 (3)
PEX16	11	45909669	45918812	N	.	N	Y	0.180505995	63.22856977	0.001746608	62.4	DM	Peroxisome biogenesis disorder 8A, (Zellweger), 614876 (3); Peroxisome biogenesis disorder 8B, 614877 (3)
PEX19	1	160276812	160286348	N	.	N	N	-0.329850009	27.74208485	0.042922172	47.9	DM	Peroxisome biogenesis disorder 12A (Zellweger), 614886 (3)
PEX3	6	143450807	143490010	N	.	N	Y	-0.506249788	19.96874457	0.002761374	60.7	DM	Peroxisome biogenesis disorder 10A (Zellweger), 614882 (3)
PEX5L	3	179794958	180037053	N	.	N	Y	-0.371040176	25.82045494	0.664004906	25.7	.	.
PEX6	6	42963870	42979220	N	.	N	N	0.054215218	53.65514846	0.002849588	60.6	DM	Peroxisome biogenesis disorder 4A (Zellweger), 614862 (3); Peroxisome biogenesis disorder 4B, 614863 (3)
PF4	4	73981077	73982124	N	.	N	Y	-0.082402837	43.40452625	0.033296817	49.2	.	.
PF4V1	4	73853189	73854155	N	.	N	N	0.161523449	61.87995601	0.006892094	56.7	.	.
PFDN1	5	140245039	140303121	N	.	N	N	0.092082157	56.56653354	0.805475103	21.4	.	.
PFDN4	20	54207847	54228052	N	.	N	N	0.220592134	65.68848758	0.100179293	43.1	.	.
PFDN5	12	53295291	53299450	N	.	N	N	-0.124550289	40.46420096	0.043385561	47.8	.	.
PFKFB1	X	54932961	54998534	N	Viable	N	Y	0.207648094	64.90710193	0.00022207	69.5	DM?	.
PFKFB2	1	207034366	207081024	N	Viable	N	Y	0.053911889	53.6319963	0.001088627	64.4	.	.
PFKFB4	3	48517684	48562015	N	Viable	N	Y	-0.969540674	8.381084679	0.000321134	68.4	.	.
PFKP	10	3066333	3137712	N	.	N	N	-0.802929929	11.48347514	7.08E-15	96.8	.	.
PFN2	3	149964904	150050788	N	.	N	Y	-0.149930626	38.75094056	0.638693742	26.4	.	.
PFN3	5	177400107	177400636	N	.	N	N	-0.043930449	46.31591133	0.519957351	29.5	.	.
PFN4	2	24115371	24123477	N	Viable	N	Y	0.299449341	70.47519824	0.001131063	64.2	.	.
PGA3	11	61203307	61213098	N	.	N	N	.	.	0.645340634	26.2	.	.
PGA4	11	61222216	61231927	N	.	N	N	.	.	.	.	.	.
PGA5	11	61241042	61251448	N	.	N	N	.	.	0.00127358	63.7	.	.
PGAM1	10	97426160	97433441	N	.	N	N	0.008742604	50.21705157	0.623538729	26.8	DM	.
PGAM2	7	44062727	44065587	N	.	N	N	0.262082672	68.1773456	0.000842262	65.4	DM	Glycogen storage disease X, 261670 (3)
PGAM4	X	77968874	77969638	N	.	N	N	0.968353566	92.29032818	0.283270085	36.1	DFP	.
PGAM5	12	132710819	132722734	N	Viable	N	Y	0.204778284	64.66400417	0.035216688	48.9	DM	.
PGAP2	11	3797724	3826371	N	.	N	N	0.218021088	65.55536262	0.15222416	40.5	DM	Hyperphosphatasia with mental retardation syndrome 3, 614207 (3)
PGAP3	17	39671122	39696797	N	.	N	Y	0.378306375	74.85095792	0.09098473	43.7	.	Hyperphosphatasia with mental retardation syndrome 4, 615716 (3)
PGBD1	6	28281572	28302549	N	.	N	N	0.76892506	88.53388899	1.47E-05	77.1	DP	.
PGBD2	1	248906196	248919946	N	.	N	N	-0.476888788	21.15529316	3.89E-07	84.1	.	.
PGBD3	10	49515105	49524227	N	.	N	N	-0.154257752	38.43838629	3.02E-06	80.5	.	.
PGBD4	15	34102073	34108684	N	.	N	N	-0.134619278	39.77542397	5.91E-05	73.4	.	.
PGBD5	1	230314482	230425729	N	.	N	N	.	.	0.028063243	50	.	.
PGC	6	41736711	41754109	N	.	N	N	0.136444713	59.97569022	3.30E-06	80.4	FP	.
PGD	1	10398592	10420144	N	.	N	Y	-0.749069701	12.66423569	0.968660462	13.2	FP	.
PGF	14	74941834	74955784	N	.	N	Y	0.074356355	55.24107195	0.898304164	17.8	.	.
PGGT1B	5	115204012	115262872	N	.	N	Y	-0.481825845	20.92377149	0.625204501	26.8	.	.
PGK1	X	78065188	78129296	N	.	N	N	-0.188249534	36.2562945	0.971138952	12.9	DM	Phosphoglycerate kinase 1 deficiency, 300653 (3)
PGK2	6	49785934	49787187	N	.	N	Y	0.615836151	84.63274874	9.51E-06	78.2	.	.
PGLS	19	17511629	17521288	N	.	N	N	0.346381025	73.21294206	0.042057999	48	.	.
PGLYRP1	19	46019153	46023065	N	.	N	Y	0.26384649	68.31047057	0.167200721	39.9	.	.
PGLYRP2	19	15468645	15498956	N	.	N	Y	0.413251052	76.53527812	1.33E-08	88.6	DP	.
PGLYRP3	1	153297862	153310718	N	.	N	Y	0.58199694	83.58511316	9.00E-05	72.2	DP	.
PGLYRP4	1	153330120	153348840	N	.	N	Y	0.577363401	83.35359148	2.63E-08	87.8	DP	.
PGM1	1	63593276	63660245	N	.	N	N	-0.079076712	43.71129247	9.96E-06	78.1	DM	Congenital disorder of glycosylation, type It, 614921 (3)
PGM2	4	37826633	37862937	N	.	N	N	0.356097127	73.757018	1.06E-12	95.2	.	.
PGM2L1	11	74330318	74398473	N	.	N	N	-0.53897936	18.62591885	0.390476073	33	.	.
PGM5	9	68328308	68531061	N	.	N	N	0.252816761	67.59854141	0.961611244	13.8	.	.
PGP	16	2211997	2214807	N	.	N	N	.	.	0.757807855	22.9	.	.
PGPEP1	19	18340587	18369950	N	.	N	N	-0.272697012	31.12808937	0.000353365	68.2	.	.
PGPEP1L	15	98968230	99007795	N	.	N	N	0.411188149	76.40794119	6.98E-06	78.9	.	.
PGR	11	101029624	101130524	N	.	N	Y	-0.331459984	27.66684031	0.884782623	18.4	DM	?Progesterone resistance, 264080 (2)
PGRMC1	X	119236245	119244466	N	.	N	N	0.366978017	74.20848527	0.622396927	26.9	DM	.
PGRMC2	4	128269237	128288829	N	.	N	N	-0.027967398	47.43300341	0.403432082	32.7	.	.
PHACTR1	6	12716805	13290484	N	.	N	N	.	.	0.664117315	25.7	DM?	.
PHACTR2	6	143536845	143831185	N	.	N	N	0.014634888	50.60485038	0.007389423	56.4	.	.
PHACTR3	20	59577509	59847711	N	.	N	N	-0.002284668	49.2678127	0.971713289	12.8	.	.
PHAX	5	126600268	126627252	N	.	N	N	-0.229439648	33.75586039	0.002693196	60.8	.	.
PHC2	1	33323623	33431052	N	.	N	Y	-0.654096722	15.24570238	0.205656048	38.6	.	.
PHC3	3	170086732	170181749	N	.	N	N	-0.984251786	8.155351045	0.999955541	3.2	.	.
PHEX	X	22032441	22251310	N	.	N	Y	-0.674036865	14.64953406	0.999645685	4.8	DM	Hypophosphatemic rickets, X-linked dominant, 307800 (3)
PHF1	6	33410399	33416453	N	.	N	N	0.097973006	57.00063668	0.999558759	5	.	.
PHF10	6	169703905	169725566	N	.	N	N	-0.222893607	34.16102333	0.083884164	44.2	.	.
PHF12	17	28905250	28951771	N	.	N	N	-1.081801619	6.772009029	0.999959675	3.2	.	.
PHF19	9	120855652	120894896	N	.	N	N	-0.273500756	31.08178503	0.995642239	8.1	.	.
PHF20	20	35771974	35950381	N	.	N	Y	-0.812624446	11.33298605	0.975739228	12.3	.	.
PHF20L1	8	132775358	132848807	N	.	N	N	-1.647635509	2.697227528	0.999911984	3.7	.	.
PHF21B	22	44881162	45009999	N	.	N	N	0.176829957	62.97389593	0.914020956	17	.	.
PHF23	17	7235028	7239722	N	.	N	N	-0.525887379	19.15841871	0.991271958	9.7	.	.
PHF24	9	34957608	34982544	N	.	N	N	.	.	.	.	.	.
PHF3	6	63635820	63779336	N	.	N	N	-3.268156561	0.474619436	0.99946942	5.2	DM?	.
PHF7	3	52410561	52423641	N	.	N	N	-0.610336728	16.45540314	0.064913882	45.5	.	.
PHF8	X	53936676	54048958	N	.	N	N	-0.848527708	10.5805406	0.998239853	6.7	DM	Mental retardation syndrome, X-linked, Siderius type, 300263 (3)
PHGR1	15	40351033	40356434	N	.	N	N	.	.	.	.	.	.
PHKA1	X	72578814	72714319	N	.	N	N	-0.738546232	12.94784974	0.881287038	18.6	DM	Muscle glycogenosis, 300559 (3)
PHKA2	X	18892300	18984598	N	.	N	N	0.07863809	55.58256642	0.90808228	17.4	DM	Glycogen storage disease, type IXa1, 306000 (3); Glycogen storage disease, type IXa2, 306000 (3)
PHKB	16	47461123	47701523	N	.	N	N	-0.222293262	34.18417549	3.16E-10	92.1	DM	Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 (3)
PHKG1	7	56080283	56092996	N	.	N	N	0.161823975	61.9204723	3.58E-10	92	.	.
PHKG2	16	30748270	30761176	N	.	N	N	-0.758487286	12.43271401	0.021634494	51.2	DM	Glycogen storage disease IXc, 613027 (3); Cirrhosis due to liver phosphorylase kinase deficiency (3)
PHLDA1	12	76025447	76033932	N	.	N	N	0.037797903	52.3759912	0.166867883	39.9	.	.
PHLDA2	11	2928273	2929455	N	.	N	Y	0.010504826	50.32702437	0.024259662	50.6	DFP	.
PHLDA3	1	201464383	201469237	N	.	N	N	0.23846774	66.7534873	0.527854532	29.2	.	.
PHLDB1	11	118606440	118658038	N	.	N	N	-0.778377187	12.05649129	0.818580152	21	.	.
PHLDB2	3	111732497	111976517	N	.	N	N	-0.376039439	25.62944956	0.011215767	54.4	.	.
PHLDB3	19	43474954	43504935	N	.	N	N	0.821295921	89.5583724	9.97E-17	97.7	.	.
PHLPP1	18	62715450	62980433	N	.	N	Y	-1.239253687	5.197661631	0.918153757	16.8	.	.
PHLPP2	16	71637835	71724701	N	.	N	N	-1.219353451	5.388667014	0.01579732	52.9	FP	.
PHOSPHO1	17	49223362	49230766	N	.	N	N	.	.	0.631109188	26.6	.	.
PHOSPHO2	2	169694454	169701708	N	.	N	N	0.232877563	66.3946287	0.015524683	53	.	.
PHPT1	9	136848724	136851027	N	Viable	N	Y	0.113784984	58.30294611	0.004339632	58.7	.	.
PHRF1	11	576486	612222	N	.	N	N	-1.435684702	3.762227239	0.948919011	14.8	.	.
PHTF1	1	113696831	113759489	N	Viable	N	Y	-0.156020198	38.31683741	5.47E-18	98.1	.	.
PHTF2	7	77798792	77957503	N	.	N	Y	-0.591501503	16.99369103	0.024946427	50.5	.	.
PHYH	10	13277796	13302412	N	Viable	N	Y	0.330566867	72.36788794	1.81E-05	76.5	DM	Refsum disease, 266500 (3)
PHYHD1	9	128920895	128942041	N	.	N	N	0.633563367	85.15367251	5.93E-10	91.6	.	.
PHYHIP	8	22219704	22232341	N	.	N	N	-0.645137007	15.52931643	0.873268768	18.9	.	.
PHYHIPL	10	59176590	59247774	N	.	N	N	-0.726715257	13.21988771	0.402880317	32.7	.	.
PHYKPL	5	178208497	178232791	N	.	N	Y	-0.343746643	27.07067199	1.73E-10	92.6	.	[?Phosphohydroxylysinuria], 615011 (3)
PI15	8	74824537	74855029	N	.	N	N	-0.083207293	43.33506975	0.004309392	58.8	.	.
PI16	6	36948263	36964837	N	.	N	N	0.061414866	54.25131678	4.40E-07	83.9	.	.
PI3	20	45174876	45176544	N	.	N	N	0.617455056	84.68484112	0.005640314	57.5	DP	.
PI4K2A	10	97640686	97676434	N	.	N	N	-0.188249534	36.2562945	0.980219633	11.7	.	.
PI4K2B	4	25233975	25279092	N	.	N	N	-0.119765437	40.78833131	0.04265635	47.9	.	.
PI4KB	1	151291797	151327715	N	.	N	N	-1.367245054	4.167390172	0.998716211	6.3	.	.
PIANP	12	6693792	6700800	N	.	N	N	0.035884366	52.28917057	0.61950924	27	.	.
PIAS2	18	46803224	46920160	N	.	N	Y	-0.634606635	15.80714244	0.997942261	7	.	.
PIAS3	1	145848522	145859836	N	.	N	N	-0.449746467	22.30132546	0.99817498	6.8	.	.
PICK1	22	38056311	38075701	N	.	N	Y	-0.351402069	26.69444927	0.555069205	28.5	DM	.
PID1	2	228850526	229271285	N	.	N	N	-0.098213329	42.19482549	0.403719374	32.7	DM?	.
PIDD1	11	799179	809753	N	.	N	Y	.	.	.	.	.	.
PIEZO1	16	88715343	88785211	N	.	N	N	.	.	0.53596901	29	DM	Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3)
PIEZO2	18	10666483	11148762	N	.	N	N	.	.	0.603955313	27.4	DM	Arthrogryposis, distal, type 5, 108145 (3); Arthrogryposis, distal, type 3, 114300 (3); ?Marden-Walker syndrome, 248700 (3)
PIF1	15	64815632	64825668	N	.	N	Y	1.334572872	96.00625109	7.58E-12	94.4	DM	.
PIGB	15	55318960	55355648	N	.	N	N	0.226480797	66.06471031	0.000232192	69.3	.	.
PIGBOS1	15	55317184	55319161	N	.	N	N	.	.	.	.	.	.
PIGC	1	172370189	172444086	N	.	N	N	-0.074747377	44.06436303	0.000110183	71.5	.	.
PIGG	4	499210	540196	N	.	N	N	1.292753114	95.72842507	8.78E-07	82.7	.	.
PIGK	1	77088990	77219430	N	.	N	N	-0.58686987	17.17890838	0.000544788	66.8	.	.
PIGM	1	160027673	160031991	N	.	N	N	-0.523016006	19.30311975	0.000916858	65.1	DM	Glycosylphosphatidylinositol deficiency, 610293 (3)
PIGN	18	62043567	62187118	N	.	N	N	-0.493808428	20.44915205	9.02E-16	97.3	DM	Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3)
PIGO	9	35088688	35096601	N	.	N	N	-0.818892411	11.20564913	1.13E-06	82.4	DM	Hyperphosphatasia with mental retardation syndrome 2, 614749 (3)
PIGP	21	37059170	37073170	N	.	N	N	0.520867599	81.28726052	0.000394929	67.8	.	.
PIGQ	16	566995	584136	N	.	N	N	1.544057783	97.20437576	3.39E-10	92.1	.	.
PIGR	1	206928518	206946466	N	.	N	Y	-0.114678301	41.16455403	0.650095687	26	DP	.
PIGS	17	28553383	28571872	N	.	N	N	-0.735825246	13.00573016	0.079952448	44.5	.	.
PIGT	20	45416077	45426244	N	.	N	N	-0.096952969	42.29901024	4.66E-12	94.7	DM	?Paroxysmal nocturnal hemoglobinuria 2, 615399 (3); ?Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398 (3)
PIGV	1	26787472	26798398	N	.	N	N	-0.437610849	22.86276553	7.20E-06	78.9	DM	Hyperphosphatasia with mental retardation syndrome 1, 239300 (3)
PIGW	17	36535020	36539310	N	.	N	N	-0.21715214	34.4620015	5.93E-07	83.4	.	?Hyperphosphatasia with mental retardation syndrome 5, 616025 (3)
PIGX	3	196639775	196736007	N	.	N	N	0.498357775	80.40169011	.	.	.	.
PIGY	4	88521573	88521789	N	.	N	N	0.273114451	68.84297042	0.106390613	42.8	.	.
PIGZ	3	196946343	196969060	N	.	N	N	0.010959166	50.34438849	0.000159853	70.5	.	.
PIH1D1	19	49446298	49453497	N	.	N	N	0.026619	51.54251317	0.087951253	43.9	.	.
PIH1D2	11	112064010	112074274	N	.	N	N	0.067810037	54.72014817	0.000130201	71.1	.	.
PIH1D3	X	107206632	107244243	N	.	N	Y	0.124007879	59.04381548	0.814438564	21.1	.	.
PIK3AP1	10	96593312	96720514	N	.	N	Y	0.434955725	77.64658216	0.999656619	4.8	.	.
PIK3C2B	1	204422628	204494724	N	.	N	N	-0.783973133	11.87127395	0.976238395	12.2	.	.
PIK3C2G	12	18247614	18648416	N	.	N	N	1.036837082	93.21062684	9.19E-32	99.7	DP	.
PIK3CD	1	9651732	9729114	N	.	N	Y	-1.248801485	5.128205128	0.999984295	2.7	DM?	Immunodeficiency 14, 615513 (3)
PIK3CG	7	106865278	106907145	N	.	N	Y	-0.77209699	12.13752388	0.563963871	28.4	DM?	.
PIK3IP1	22	31281593	31292534	N	.	N	N	0.23846774	66.7534873	0.059750976	46	.	.
PIK3R2	19	18153118	18170540	N	.	N	Y	-0.98454781	8.132198877	0.939626884	15.6	DM	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3)
PIK3R3	1	46043661	46176488	N	.	N	N	-0.326021923	27.98518261	1.41E-06	82.1	DM?	.
PIK3R5	17	8878911	8965712	N	.	N	Y	-0.168156173	37.49493546	0.817693684	21.1	DM	Ataxia-oculomotor apraxia 3, 615217 (3)
PIK3R6	17	8802723	8867677	N	.	N	N	.	.	1.38E-15	97.2	.	.
PILRA	7	100367530	100400099	N	.	N	Y	-0.192881585	36.00162065	2.14E-08	88.1	.	.
PILRB	7	100352176	100367733	N	.	N	Y	1.070681405	93.63894195	3.37E-06	80.3	.	.
PIM1	6	37170203	37175426	N	.	N	Y	-0.566274989	17.74613648	0.886575783	18.3	.	.
PIM2	X	48913182	48919024	N	.	N	Y	0.12592113	59.20588065	0.894760123	18	.	.
PIM3	22	49960513	49964080	N	.	N	Y	-0.227678773	33.88319731	0.937120654	15.8	.	.
PIN1	19	9835257	9849682	N	.	N	Y	-0.043930449	46.31591133	0.340906809	34.5	DM	.
PIN4	X	72181353	72302926	N	.	N	N	0.184032836	63.46009145	0.646369633	26.1	.	.
PINK1	1	20633455	20651511	N	Viable	N	Y	0.613117004	84.56329224	4.08E-07	84	DM	Parkinson disease 6, early onset, 605909 (3)
PINLYP	19	43576800	43583964	N	.	N	N	.	.	.	.	.	.
PIP	7	143132077	143139746	N	.	N	Y	0.603404191	84.22179777	0.005505596	57.7	.	.
PIP4K2A	10	22534849	22714555	N	.	N	Y	-0.487414582	20.68067373	0.788196367	22	DFP	.
PIP4K2C	12	57591174	57603418	N	.	N	N	-0.58495545	17.22521271	0.013378735	53.7	.	.
PIP5K1B	9	68705414	69009176	N	.	N	Y	-0.29042075	30.03993749	0.007443047	56.3	.	.
PIP5KL1	9	127920879	127930797	N	.	N	N	.	.	4.90E-06	79.6	.	.
PIPOX	17	28950513	29057220	N	Viable	N	Y	0.652395794	85.70353649	9.88E-11	92.9	.	.
PIR	X	15384799	15493564	N	.	N	N	0.652248451	85.69774845	1.16E-05	77.7	DM?	.
PIRT	17	10822475	10838445	N	.	N	Y	0.457973076	78.70579383	0.150384796	40.6	.	.
PITHD1	1	23778405	23788232	N	.	N	N	-0.133967403	39.81015223	0.102416723	43	.	.
PITPNC1	17	67377281	67697261	N	.	N	N	-0.416212455	23.64993923	0.967498711	13.3	.	.
PITPNM1	11	67491768	67506263	N	.	N	Y	-1.354558537	4.265786884	0.722090614	24	.	.
PITPNM2	12	122983480	123150015	N	.	N	Y	-1.384701863	4.04005325	0.999993632	2.3	.	.
PITPNM3	17	6451264	6556494	N	.	N	N	-1.107041422	6.476818892	0.999503783	5.2	DM	Cone-rod dystrophy 5, 600977 (3)
PITX3	10	102230186	102241474	N	Viable	N	Y	-0.206126746	35.13920241	0.768360298	22.6	DM	Anterior segment mesenchymal dysgenesis, 107250 (3); Cataract 11, multiple types, 610623 (3); Cataract 11, syndromic, 610623 (3)
PIWIL1	12	130337887	130372637	N	.	N	Y	-1.156983625	6.019563582	2.13E-07	85.1	.	.
PIWIL2	8	22275297	22357563	N	.	N	Y	-0.884652628	9.880187533	0.002483152	61.1	.	.
PIWIL3	22	24719034	24774720	N	.	N	N	2.237591408	98.91763616	9.87E-26	99.4	DP	.
PIWIL4	11	94543840	94621421	N	.	N	Y	0.081356602	55.81987614	7.41E-06	78.8	DM?	.
PJA1	X	69160851	69165793	N	.	N	N	0.158953701	61.6715865	0.894042635	18	.	.
PJA2	5	109334709	109409994	N	Viable	N	Y	-0.258342977	31.98471957	0.466603862	30.9	.	.
pk	2	173075435	173268010	N	.	N	N	.	.	.	.	.	.
PKD1L3	16	71929538	71999978	N	.	N	N	.	.	.	.	.	.
PKD2L1	10	100288154	100330486	N	.	N	Y	1.089979643	93.8530995	6.57E-17	97.8	.	.
PKD2L2	5	137887968	137942747	N	Viable	N	Y	-0.065178849	44.7647161	3.50E-07	84.3	.	.
PKDREJ	22	46255663	46263355	N	.	N	Y	-0.193466627	35.91480002	4.71E-20	98.7	.	.
PKHD1L1	8	109362477	109530330	N	.	N	N	5.835040674	99.87845112	9.13E-65	100	DM?	.
PKIA	8	78516139	78605267	N	Viable	N	Y	0.045150018	52.96637148	0.254973076	36.9	.	.
PKIB	6	122471917	122726373	N	.	N	Y	0.220592134	65.68848758	0.219496928	38	.	.
PKIG	20	44531785	44624247	N	Viable	N	Y	-0.037384251	46.76159055	0.564580331	28.3	.	.
PKLR	1	155289839	155301434	N	.	N	N	-0.264889266	3.16E+01	1.00E-05	78.1	DM	Pyruvate kinase deficiency, 266200 (3); Adenosine triphosphate, elevated, of erythrocytes, 102900 (3)
PKMYT1	16	2968024	2980539	N	.	N	N	-0.296966779	29.62319847	0.667410731	25.6	.	.
PKN1	19	14433053	14471867	N	Viable	N	Y	-0.153956776	38.47890259	0.85469464	19.7	.	.
PKN2	1	88684222	88836255	N	.	N	N	-0.332416646	27.63211206	0.999995223	2.2	.	.
PKN3	9	128702523	128720918	N	.	N	Y	-0.177422646	36.89297911	1.47E-09	90.8	FTV	.
PKNOX2	11	125164687	125433389	N	.	N	N	-0.666533619	14.84053945	0.917368947	16.8	.	.
PKP1	1	201283452	201332993	N	.	N	N	-0.08834239	42.94727094	0.004802364	58.3	DM	Ectodermal dysplasia/skin fragility syndrome, 604536 (3)
PKP3	11	392614	404908	N	.	N	Y	1.213710021	95.17277305	0.194350415	38.9	.	.
PKP4	2	158456964	158682879	N	Viable	N	Y	-0.549576654	18.21496788	1.60E-05	76.9	.	.
PLA1A	3	119597842	119629811	N	.	N	N	0.140271809	60.22457603	0.001690148	62.5	.	.
PLA2G10	16	14672545	14694669	N	Viable	N	Y	.	.	0.021747733	51.2	FP	.
PLA2G12A	4	109709989	109730077	N	.	N	N	0.353884195	73.67019737	0.001881561	62.1	.	.
PLA2G12B	10	72935170	72954778	N	.	N	N	-0.260562407	31.82844244	0.059869032	46	.	.
PLA2G15	16	68245304	68261062	N	.	N	Y	-0.235985706	33.32175725	0.65843	25.8	.	.
PLA2G16	11	63573195	63616883	N	.	N	N	0.331374701	72.39104011	1.19E-05	77.6	.	.
PLA2G1B	12	120322111	120327789	N	.	N	Y	-0.137642372	39.56705447	3.65E-11	93.6	.	.
PLA2G2A	1	19975431	19980416	N	.	N	N	0.351971606	73.48498003	0.398124558	32.8	DM	{Colorectal cancer}, 114500 (3)
PLA2G2C	1	20161253	20177424	N	.	N	N	.	.	0.000569563	66.6	.	.
PLA2G2D	1	20111939	20119566	N	.	N	Y	0.422369205	76.96359322	0.000177683	70.2	DFP	.
PLA2G2E	1	19920009	19923617	N	Viable	N	Y	0.421412982	76.87677259	0.000343166	68.3	.	.
PLA2G2F	1	20139326	20150386	N	.	N	N	0.294815417	70.1800081	2.10E-06	81.2	.	.
PLA2G4A	1	186828953	186988981	N	.	N	Y	-0.131748807	39.96064132	0.001100018	64.3	DM	Phospholipase A2, group IV A, deficiency of (3)
PLA2G4B	15	41837775	41848147	N	.	N	N	0.823686163	89.61625282	9.16E-25	99.3	.	.
PLA2G4C	19	48047843	48110817	N	.	N	N	1.305514024	95.82682179	4.42E-08	87.1	DP	.
PLA2G4D	15	42067009	42094554	N	.	N	N	1.650080493	97.73108757	6.29E-10	91.5	.	.
PLA2G4E	15	41981582	42051190	N	.	N	N	0.160061943	61.76419517	2.28E-06	81.1	.	.
PLA2G4F	15	42139034	42156636	N	.	N	N	1.170771308	94.75603403	1.40E-09	90.9	.	.
PLA2G5	1	20028179	20091190	N	.	N	Y	-0.291531924	29.91838861	0.000190275	70	DM	[Fleck retina, familial benign], 228980 (3)
PLA2G6	22	38111495	38205690	N	.	N	Y	-0.033101966	47.07414482	2.66E-08	87.8	DM	Infantile neuroaxonal dystrophy 1, 256600 (3); Neurodegeneration with brain iron accumulation 2B, 610217 (3); Parkinson disease 14, autosomal recessive, 612953 (3)
PLA2G7	6	46704201	46735693	N	.	N	N	1.322283531	95.9252185	8.02E-11	93.1	DM	Platelet-activating factor acetylhydrolase deficiency, 614278 (3); {Asthma, susceptibility to}, 600807 (3); {Atopy, susceptibility to}, 147050 (3)
PLA2R1	2	159932006	160062610	N	.	N	Y	1.305240274	95.82103374	5.18E-15	96.8	DP	.
PLAA	9	26904083	26947463	N	.	N	N	-1.235848663	5.249754008	0.648657498	26.1	.	.
PLAC8	4	83090048	83137075	N	.	N	Y	-0.074899744	44.03542282	0.372859442	33.5	.	.
PLAC8L1	5	146084386	146104369	N	.	N	N	0.398903333	75.78283267	0.132377855	41.5	.	.
PLAC9	10	80131682	80145359	N	.	N	N	0.586485615	83.7298142	0.010238569	54.8	.	.
PLAG1	8	56160904	56211324	N	.	N	Y	0.284591847	69.63014412	0.829917236	20.6	.	Adenomas, salivary gland pleomorphic, 181030 (3)
PLAT	8	42175233	42207724	N	Viable	N	Y	0.048474078	53.29050182	0.00019718	69.8	DM?	Thrombophilia, familial, due to decreased release of PLAT, 612348 (1); Hyperfibrinolysis, familial, due to increased release of PLAT, 612348 (1)
PLAU	10	73909177	73917497	N	.	N	Y	0.931935334	91.75782833	0.00055027	66.7	DM	{Alzheimer disease, late-onset, susceptibility to}, 104300 (3); Quebec platelet disorder, 601709 (3)
PLAUR	19	43646095	43670547	N	.	N	Y	0.088556503	56.32922382	0.306584926	35.6	DP	.
PLB1	2	28457145	28643788	N	.	N	N	2.257325672	98.94078833	1.99E-56	100	.	.
PLBD1	12	14503661	14568349	N	.	N	N	0.260319777	68.05579672	9.67E-13	95.3	.	.
PLBD2	12	113358566	113391625	N	.	N	N	0.114892509	58.36661457	7.18E-08	86.5	.	.
PLCB2	15	40278176	40307935	N	Viable	N	Y	0.163239354	61.98992881	3.02E-12	94.9	.	Platelet PLC beta-2 deficiency (1)
PLCD1	3	38007496	38029762	N	.	N	Y	-0.504840743	20.00347283	2.55E-09	90.3	DM	Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 (3)
PLCD3	17	45108967	45133354	N	.	N	N	.	.	0.000143297	70.8	.	.
PLCD4	2	218607765	218637184	N	.	N	Y	-0.345509503	26.97227528	8.12E-09	89.2	DM?	.
PLCE1	10	93993989	94332823	N	.	N	Y	-1.359749467	4.219482549	0.204555596	38.6	DM	Nephrotic syndrome, type 3, 610725 (3)
PLCG2	16	81739097	81962693	N	.	N	Y	-0.782065245	11.93494241	0.999993047	2.4	DM	Familial cold autoinflammatory syndrome 3, 614468 (3); Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 (3)
PLCH1	3	155375580	155745067	N	.	N	N	-2.233713014	1.232852926	0.425540925	32.1	.	.
PLCH2	1	2425980	2505530	N	.	N	Y	0.972008325	92.34242056	1.71E-08	88.3	.	.
PLCL1	2	197804702	198572581	N	.	N	Y	-1.107180261	6.47103085	0.011052371	54.5	.	.
PLCL2	3	16802651	17090594	N	.	N	Y	-1.401896392	3.912716328	0.99911878	5.7	.	.
PLCXD1	X	276322	303356	N	.	N	N	0.060609534	54.16449615	1.57E-12	95.1	.	.
PLCXD2	3	111674676	111846447	N	.	N	N	-0.12631151	40.31371187	5.17E-05	73.8	.	.
PLCXD3	5	41306954	41510628	N	.	N	N	-0.679780532	14.50483301	0.048488739	47.2	.	.
PLCZ1	12	18683169	18738057	N	.	N	N	-0.537870687	18.7011634	6.45E-10	91.5	DM	.
PLD1	3	171600405	171810950	N	.	N	Y	0.650149553	85.62829195	7.21E-16	97.4	.	.
PLD2	17	4807096	4823434	N	.	N	Y	0.39503781	75.56867512	8.13E-14	96.2	DP	.
PLD3	19	40348456	40380439	N	.	N	N	-0.234071877	33.43751809	0.015972164	52.8	.	{Alzheimer disease 19, late onset, susceptibility to}, 615711 (3)
PLD4	14	104924816	104937790	N	.	N	N	0.219934482	65.64797129	1.23E-13	96	.	.
PLD5	1	242082986	242524696	N	Viable	N	Y	-0.486457463	20.70961394	0.124197737	41.9	.	.
PLD6	17	17200995	17206315	N	.	N	Y	.	.	0.075462604	44.7	.	.
PLEK	2	68365173	68397453	N	.	N	Y	0.626060077	84.945303	0.140273937	41.1	.	.
PLEK2	14	67386983	67412200	N	.	N	N	-0.078422859	43.78074897	2.22E-08	88	.	.
PLEKHA2	8	38901235	38973909	N	.	N	N	.	.	0.363909174	33.8	.	.
PLEKHA3	2	178480468	178516462	N	.	N	N	-0.197666633	35.6485501	0.022978699	50.9	.	.
PLEKHA4	19	48837097	48868632	N	.	N	N	1.484022881	96.88603345	4.74E-09	89.6	.	.
PLEKHA5	12	19129752	19376400	N	.	N	N	-1.229017643	5.319210511	0.999999408	1.5	.	.
PLEKHA6	1	204218851	204377665	N	.	N	N	0.153821898	61.27799965	0.98196907	11.4	.	.
PLEKHA7	11	16778295	17014443	N	.	N	N	-1.558147182	3.038722	0.000173041	70.2	.	.
PLEKHA8	7	30027404	30130483	N	Viable	N	Y	0.030446167	51.85506743	2.06E-06	81.3	.	.
PLEKHB1	11	73646178	73662819	N	.	N	Y	0.448703989	78.31799502	0.000703307	65.9	.	.
PLEKHB2	2	131104847	131353709	N	.	N	N	0.122244706	58.89332639	3.54E-06	80.2	.	.
PLEKHD1	14	69484692	69531551	N	.	N	N	.	.	.	.	.	.
PLEKHF1	19	29665056	29675457	N	.	N	N	0.370803213	74.41685478	0.099066997	43.2	.	.
PLEKHF2	8	95133804	95156684	N	.	N	N	-0.322501565	28.10673149	0.749566017	23.2	.	.
PLEKHG1	6	150599863	150843665	N	.	N	Y	-0.46689777	21.5604561	0.000178677	70.2	.	.
PLEKHG2	19	39412585	39428415	N	.	N	N	1.394329452	96.36510968	3.59E-08	87.4	.	.
PLEKHG3	14	64704102	64750247	N	Viable	N	Y	1.566930619	97.30277247	1.16E-08	88.8	.	.
PLEKHG4	16	67277510	67289499	N	.	N	N	0.529138487	81.62875499	1.46E-09	90.8	DM	.
PLEKHG4B	5	140258	189970	N	.	N	N	2.06149693	98.66296232	7.81E-20	98.6	.	.
PLEKHG5	1	6466092	6520061	N	.	N	Y	1.146341385	94.49557215	4.03E-05	74.5	DM	Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3); Charcot-Marie-Tooth disease, recessive intermediate C, 615376 (3)
PLEKHG6	12	6310436	6328506	N	.	N	N	0.072896737	55.12531111	1.17E-10	92.9	.	.
PLEKHG7	12	92721505	92772455	N	.	N	N	0.37749856	74.80465359	3.68E-11	93.6	.	.
PLEKHH1	14	67533301	67589612	N	.	N	N	1.464566628	96.79921283	0.000660285	66.2	FTV	.
PLEKHH2	2	43637273	43767987	N	.	N	N	-0.678786388	14.52798518	1.79E-26	99.5	.	.
PLEKHH3	17	42667914	42676994	N	.	N	N	-0.237747492	33.21178445	0.003760662	59.3	.	.
PLEKHJ1	19	2230084	2237704	N	.	N	N	0.533962119	81.81976038	0.46324813	31.1	.	.
PLEKHM1	17	45435900	45490749	N	Viable	N	Y	-1.056423681	7.125079586	0.84054321	20.3	DM	Osteopetrosis, autosomal recessive 6, 611497 (3)
PLEKHM2	1	15684332	15734769	N	.	N	Y	0.277391673	69.1439486	0.005065575	58	.	.
PLEKHM3	2	207828303	208025560	N	.	N	N	0.075615479	55.33946866	0.766248376	22.7	.	.
PLEKHN1	1	966497	975865	N	.	N	N	1.556985218	97.26225618	2.02E-08	88.1	.	.
PLEKHO1	1	150149183	150164720	N	.	N	Y	-0.007068709	48.91474214	0.949230797	14.8	.	.
PLEKHO2	15	64841883	64868007	N	.	N	N	0.267822797	68.56514441	0.004753842	58.3	.	.
PLEKHS1	10	113751454	113783429	N	.	N	N	0.5098348	80.86473346	1.17E-15	97.3	.	.
PLET1	11	112248479	112260860	N	.	N	N	.	.	.	.	.	.
PLG	6	160702238	160753315	N	.	N	Y	0.160214418	61.76998321	0.002435117	61.2	DM	Dysplasminogenemia, 217090 (3); Plasminogen deficiency, type I, 217090 (3)
PLGLB1	2	87002559	87021852	N	.	N	N	.	.	.	.	.	.
PLGLB2	2	87748087	87758793	N	.	N	N	.	.	.	.	.	.
PLGRKT	9	5357973	5437878	N	.	N	N	0.035884366	52.28917057	8.36E-08	86.3	.	.
PLIN1	15	89664365	89679427	N	.	N	Y	0.552940591	82.54905366	3.56E-07	84.3	DM	Lipodystrophy, familial partial, type 4, 613877 (3)
PLIN2	9	19108375	19149290	N	.	N	Y	-0.195600015	35.79903919	1.20E-05	77.6	.	.
PLIN3	19	4838341	4867768	N	.	N	N	0.000585754	49.48197025	1.24E-08	88.6	.	.
PLIN4	19	4502180	4518465	N	Viable	N	Y	7.788153846	99.9305435	1.66E-12	95.1	DFP	.
PLIN5	19	4522531	4535224	N	.	N	Y	0.296878173	70.31892111	1.32E-07	85.8	.	.
PLK5	19	1524074	1535456	N	.	N	N	.	.	0.07162546	45	.	.
PLLP	16	57248547	57284687	N	.	N	N	0.118418051	58.60971233	0.519581852	29.5	.	.
PLN	6	118548298	118560730	N	.	N	Y	0.105175156	57.60838108	0.111194229	42.5	DM	Cardiomyopathy, dilated, 1P, 609909 (3); Cardiomyopathy, hypertrophic, 18, 613874 (3)
PLOD1	1	11934205	11975538	N	Viable	N	Y	0.33661299	72.65729004	2.70E-07	84.7	DM	Ehlers-Danlos syndrome, type VI, 225400 (3)
PLOD2	3	146069440	146163653	N	.	N	N	-0.127921681	40.20952712	0.00117484	64.1	DM	Bruck syndrome 2, 609220 (3)
PLP2	X	49171926	49175239	N	.	N	N	0.677482548	86.33443306	0.112369205	42.5	DM?	.
PLS1	3	142596387	142713664	N	.	N	Y	-0.534194499	18.82271228	0.000310388	68.5	.	.
PLS3	X	115561174	115650861	N	.	N	Y	-0.400249026	24.39659663	0.987821983	10.4	.	Bone mineral density QTL18, osteoporosis, 300910 (3)
PLSCR1	3	146515180	146544864	N	Viable	N	Y	0.493723196	80.22226081	0.002931645	60.4	.	.
PLSCR2	3	146391421	146495991	N	Viable	N	Y	0.241337169	66.9618568	2.19E-05	76	.	.
PLSCR4	3	146192339	146251179	N	.	N	N	0.307101058	70.88036117	0.001692409	62.5	.	.
PLSCR5	3	146576555	146606216	N	.	N	N	0.116655069	58.50552758	1.17E-09	91	.	.
PLTP	20	45898621	45912155	N	.	N	Y	0.042733143	52.78694218	0.000142042	70.8	DM?	[High density lipoprotein cholesterol level QTL 9] (3)
PLXDC1	17	39063303	39154394	N	.	N	N	0.131812033	59.53579904	0.000149406	70.6	.	.
PLXDC2	10	19816239	20289856	N	.	N	N	-0.187140168	36.325751	0.613047817	27.1	DM?	.
PLXNA1	3	126988594	127037392	N	.	N	Y	-3.886203995	0.254673844	0.999998425	1.9	.	.
PLXNA2	1	208022242	208244320	N	.	N	Y	-1.184356372	5.735949528	0.993981182	8.9	DM?	.
PLXNA3	X	154458281	154477779	N	.	N	Y	-0.73214678	13.121491	0.983112793	11.2	.	.
PLXNA4	7	132123332	132648688	N	.	N	Y	-1.462076201	3.559645772	0.999999702	1.4	DM?	.
PLXNB1	3	48403854	48430051	N	.	N	Y	-0.553818474	18.11078312	0.850195108	19.9	DM?	.
PLXNB3	X	153764196	153779346	N	.	N	N	1.597143396	97.47641373	0.103343014	42.9	.	.
PLXNC1	12	94148723	94307675	N	.	N	Y	-1.462611211	3.55385773	0.99971484	4.6	.	.
PM20D1	1	205828022	205850132	N	.	N	N	0.777232305	88.74225849	1.27E-09	91	.	.
PM20D2	6	89146050	89165565	N	.	N	N	0.463710367	79.01834809	0.001166743	64.1	.	.
PMAIP1	18	59899948	59904306	N	.	N	Y	0.218679327	65.57851479	0.461950506	31.1	FP	.
PMCH	12	102196459	102197845	N	.	N	Y	0.169983117	62.51085258	0.115285756	42.3	.	.
PMEL	12	55954105	55973317	N	.	N	Y	0.01846215	50.93476877	1.12E-07	86	.	.
PMEPA1	20	57648392	57711536	N	.	N	N	0.005872186	49.93922556	0.416594874	32.4	.	.
PMF1	1	156212993	156240042	N	.	N	N	0.7047722	87.01163396	1.71E-05	76.7	.	.
PMF1-BGLAP	1	156212982	156243332	N	.	N	N	0.812688748	89.3789431	1.71E-05	76.7	.	.
PMFBP1	16	72112157	72176878	N	.	N	N	0.133226762	59.65155988	4.06E-25	99.3	.	.
PML	15	73994673	74047812	N	.	N	Y	-0.239065731	33.1075997	0.937511029	15.7	DM?	Leukemia, acute promyelocytic, PML/RARA type (3)
PMM1	22	41576894	41589890	N	.	N	Y	-0.072833607	44.24958037	0.000159925	70.4	.	.
PMP2	8	81440326	81447523	N	.	N	N	0.563975498	82.86739596	0.033981701	49.1	.	.
PMPCA	9	136410570	136423761	N	.	N	N	-0.587523537	17.17312033	0.00018605	70	.	.
PMS1	2	189784085	189877629	N	.	N	N	0.43223852	77.50188111	6.56E-14	96.3	DM	.
PMS2	7	5973239	6009125	N	.	N	Y	1.273907241	95.57214794	1.14E-13	96	DM	Mismatch repair cancer syndrome, 276300 (3); Colorectal cancer, hereditary nonpolyposis, type 4, 614337 (3)
PMVK	1	154924734	154936991	N	.	N	N	0.399859596	75.829137	0.000305455	68.6	.	.
PNCK	X	153669730	153689010	N	Viable	N	Y	-0.141317516	39.35289691	0.00047919	67.1	.	.
PNISR	6	99398051	99425331	N	.	N	N	-0.211411415	34.85558835	0.999085487	5.8	.	.
PNKD	2	218270392	218346793	N	.	N	Y	0.780909061	88.81750304	1.90E-08	88.2	DM	Paroxysmal nonkinesigenic dyskinesia, 118800 (3)
PNKP	19	49861204	49878351	N	.	N	N	0.167564929	62.36036349	2.88E-07	84.6	DM	Microcephaly, seizures, and developmental delay, 613402 (3); Ataxia-oculomotor apraxia 4, 616267 (3)
PNLDC1	6	159800249	159820704	N	.	N	N	-0.11674285	40.99670082	2.54E-08	87.9	.	.
PNLIP	10	116545931	116567855	N	.	N	Y	-0.377586284	25.59472131	0.009354471	55.2	.	Pancreatic lipase deficiency, 614338 (1)
PNLIPRP1	10	116590385	116609175	N	.	N	N	-0.245250499	32.76031718	6.28E-10	91.6	.	.
PNLIPRP3	10	116427867	116477957	N	.	N	N	0.449809762	78.35851132	2.75E-09	90.2	.	.
PNMA1	14	73711783	73714372	N	.	N	N	-0.170372579	37.39075071	0.059310372	46.1	.	.
PNMA2	8	26504686	26514092	N	.	N	N	0.239573531	66.85188401	0.101076995	43	.	.
PNMA3	X	153056409	153060467	N	.	N	N	0.314604136	71.36076865	0.005337808	57.8	.	.
PNMA5	X	152988824	152994127	N	.	N	N	0.36808233	74.28951786	0.006097075	57.1	.	.
PNMA6A	X	153072482	153075018	N	.	N	N	.	.	.	.	.	.
PNMAL1	19	46466491	46471563	N	.	N	N	0.292245427	70.07003531	0.04443696	47.7	.	.
PNMAL2	19	46486906	46496498	N	.	N	N	0.011764461	50.40805695	.	.	.	.
PNMT	17	39667981	39670475	N	Viable	N	Y	0.115698365	58.41870695	0.00075382	65.7	DFP	.
PNOC	8	28316986	28343355	N	.	N	Y	0.155933478	61.44006483	0.151495123	40.5	.	.
PNPLA2	11	818902	825573	N	.	N	Y	0.71146575	87.17948718	0.001141193	64.2	DM	Neutral lipid storage disease with myopathy, 610717 (3)
PNPLA3	22	43923739	43964488	N	.	N	N	0.537128297	81.95288534	0.000103859	71.7	DFP	.
PNPLA4	X	7898247	7927739	N	.	N	N	0.241337169	66.9618568	0.011068508	54.5	.	.
PNPLA5	22	43879678	43892013	N	.	N	N	1.129901083	94.33350697	9.38E-07	82.6	.	.
PNPLA7	9	137459953	137550534	N	.	N	N	2.641866765	99.25913064	6.23E-27	99.5	.	.
PNRC1	6	89080751	89085160	N	.	N	N	-0.076661182	43.91387394	0.83615928	20.4	.	.
PNRC2	1	23959109	23963462	N	.	N	Y	.	.	.	.	.	.
POC1A	3	52075253	52154690	N	.	N	N	0.348442859	73.32291486	1.15E-05	77.7	DM	Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3)
POC1B	12	89419718	89526024	N	Viable	N	Y	-0.052086548	45.6213463	5.89E-05	73.5	.	Cone-rod dystrophy 20, 615973 (3)
POC1B-GALNT4	12	89519408	89526262	N	.	N	N	-0.442243367	22.62545581	0.037596493	48.6	.	.
POC5	5	75674124	75717481	N	.	N	N	0.598916451	84.09446084	0.002138162	61.6	.	.
PODN	1	53062052	53085502	N	Viable	N	Y	0.024051489	51.38044799	5.20E-07	83.7	.	.
PODNL1	19	13931187	13953392	N	.	N	N	.	.	2.51E-14	96.5	.	.
PODXL2	3	127629181	127672809	N	Viable	N	Y	0.501374974	80.48851074	0.977986099	12	.	.
POF1B	X	85277396	85379743	N	.	N	Y	0.718012692	87.37049256	0.000181225	70.1	DP	Premature ovarian failure 2B, 300604 (3)
POGK	1	166839447	166856344	N	.	N	N	0.089513257	56.41025641	0.917279175	16.8	.	.
POGZ	1	151402724	151459465	N	.	N	N	-1.884812304	1.94478208	0.999999128	1.6	DM?	Mental retardation, autosomal dominant 37, 616364 (3)
POLA1	X	24693919	24996986	N	.	N	N	0.021332626	51.17207849	0.999999525	1.5	.	?N syndrome, 310465 (1)
POLA2	11	65261762	65305589	N	.	N	N	-0.068854605	44.475314	0.000215959	69.6	.	.
POLD2	7	44114681	44124358	N	.	N	N	-0.953576407	8.664698732	0.044324393	47.7	.	.
POLD4	11	67350777	67356972	N	.	N	N	0.144604076	60.5660705	0.745036469	23.3	.	.
POLDIP3	22	42583721	42614962	N	.	N	N	-0.749069701	12.66423569	0.832319947	20.6	.	.
POLE2	14	49643555	49688422	N	.	N	N	-0.42451861	23.36632517	0.000153356	70.6	FTV	.
POLE3	9	113407235	113410672	N	.	N	N	0.230008154	66.23835157	0.077745399	44.6	.	.
POLE4	2	74958492	74970128	N	.	N	N	.	.	0.000410965	67.7	.	.
POLH	6	43576150	43615660	N	.	N	Y	0.812987893	89.38473115	0.003590871	59.6	DM	Xeroderma pigmentosum, variant type, 278750 (3)
POLI	18	54269404	54321266	N	.	N	N	1.215466464	95.20171326	4.27E-09	89.7	.	.
POLK	5	75511756	75601144	N	.	N	Y	0.255839634	67.81269896	6.00E-07	83.4	.	.
POLL	10	101578882	101588270	N	.	N	Y	0.135639287	59.89465764	2.25E-11	93.8	FP	.
POLM	7	44072247	44082540	N	.	N	Y	0.496742012	80.34380969	2.43E-08	87.9	.	.
POLN	4	2071918	2242121	N	Viable	N	Y	1.371459735	96.23777276	3.00E-32	99.8	.	.
POLQ	3	121431427	121546641	N	.	N	Y	0.17280811	62.68449384	9.95E-47	100	.	.
POLR1A	2	86020216	86106155	N	.	N	N	-2.624138603	0.862418244	0.999861746	4.1	.	Acrofacial dysostosis, Cincinnati type, 616462 (3)
POLR1C	6	43509702	43529585	N	.	N	N	-0.257537798	32.06575216	0.000291623	68.8	DM	Treacher Collins syndrome 3, 248390 (3); Leukodystrophy, hypomyelinating, 11, 616494 (3)
POLR1D	13	27620742	27667415	N	.	N	N	-0.084164209	43.24824912	0.257868791	36.8	DM	Treacher Collins syndrome 2, 613717 (3)
POLR2B	4	56977722	57031168	N	.	N	N	-1.520202512	3.241303467	0.988161838	10.4	.	.
POLR2C	16	57462387	57472010	N	.	N	N	-0.342138919	27.14591654	0.047007726	47.4	.	.
POLR2D	2	127843551	127858157	N	.	N	N	0.190579485	63.80158592	0.470737785	30.8	.	.
POLR2E	19	1086579	1095380	N	.	N	N	-0.006263422	49.00156277	4.41E-08	87.2	DP	.
POLR2F	22	37952607	38041915	N	.	N	N	-0.148016487	38.85512531	0.652869046	25.9	.	.
POLR2G	11	62761544	62766710	N	.	N	N	-0.209955284	34.90768073	0.006465395	56.9	.	.
POLR2I	19	36113710	36115346	N	.	N	N	-0.027967398	47.43300341	0.054160278	46.5	.	.
POLR2J	7	102473118	102478907	N	.	N	N	.	.	0.444173139	31.6	.	.
POLR2J2	7	102665368	102671629	N	.	N	N	.	.	0.092340906	43.6	.	.
POLR2J3	7	102537918	102572656	N	.	N	N	.	.	.	.	.	.
POLR2K	8	100150584	100154002	N	.	N	N	0.03764689	52.34705099	0.011778252	54.3	.	.
POLR2L	11	837356	842545	N	.	N	N	-0.119918286	40.73045089	0.532880511	29.1	.	.
POLR2M	15	57706629	57782762	N	.	N	N	0.331523457	72.40840424	0.169086389	39.8	DM?	.
POLR3A	10	77969251	78029545	N	.	N	N	-2.052691913	1.533831105	7.39E-14	96.2	DM	Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3)
POLR3B	12	106357658	106510198	N	.	N	N	-1.242252732	5.174509463	2.73E-09	90.2	DM	Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3)
POLR3C	1	145824088	145842505	N	.	N	N	-0.02575038	47.53718817	8.66E-06	78.4	.	.
POLR3D	8	22245104	22254600	N	.	N	N	-0.183464709	36.53990855	5.66E-11	93.3	.	.
POLR3E	16	22297375	22335103	N	.	N	N	-0.806077123	11.41401864	0.019465818	51.8	.	.
POLR3GL	1	145964702	145978848	N	.	N	N	0.044344174	52.90849106	0.002440213	61.2	.	.
POLR3H	22	41525804	41544606	N	.	N	N	-0.119765437	40.78833131	0.002007106	61.9	.	.
POLR3K	16	46407	53628	N	.	N	N	-0.004501323	49.10574753	0.324223635	35	.	.
POLRMT	19	617224	633604	N	.	N	N	0.041732742	52.67696938	2.60E-13	95.8	FTV	.
POM121	7	72879365	72951440	N	.	N	N	1.909268355	98.40828848	.	.	.	.
POM121C	7	75416787	75486271	N	.	N	N	1.105782729	94.00358859	.	.	.	.
POM121L12	7	53035642	53036924	N	.	N	N	1.359804338	96.1741043	8.97E-05	72.2	.	.
POM121L2	6	27285903	27312170	N	.	N	N	.	.	.	.	.	.
POM121L7	22	21125660	21128063	N	.	N	N	.	.	.	.	.	.
POMK	8	43093506	43123434	N	.	N	N	0.149537247	60.98280952	0.000523312	66.9	.	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 (3); ?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094 (3)
POMP	13	28659104	28678925	N	.	N	N	0.002044933	49.63824738	0.861423056	19.5	DM	Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3)
POMZP3	7	76609986	76627261	N	.	N	N	0.538742637	81.99918967	0.879121225	18.7	.	.
PON1	7	95297676	95324707	N	.	N	Y	0.921562896	91.52630665	0.002208844	61.5	DM	{Coronary artery disease, susceptibility to} (3); {Coronary artery spasm 2, susceptibility to (3); {Organophosphate poisoning, sensitivity to} (3); {Microvascular complications of diabetes 5}, 612633 (3)
PON2	7	95404863	95435329	N	.	N	Y	-0.11785159	40.91566823	0.001404248	63.3	DM	{Coronary artery disease, susceptibility to} (3)
POP1	8	98117297	98159834	N	.	N	N	-0.258044198	32.0020837	2.42E-08	87.9	DM	.
POP5	12	120578764	120581398	N	.	N	N	-0.048562831	45.92232448	1.28E-05	77.4	.	.
POP7	7	100706053	100707495	N	.	N	N	0.079946001	55.69832726	0.285660409	36.1	.	.
POPDC2	3	119636457	119665324	N	.	N	Y	0.013526612	50.54118192	0.000116008	71.4	.	.
POPDC3	6	105158280	105179995	N	Viable	N	Y	0.031251654	51.92452393	1.71E-05	76.7	.	.
POSTN	13	37562583	37598844	Y	Viable	N	Y	-0.895163491	9.683394108	5.52E-05	73.7	DFP	.
POTEB	15	21846329	21877703	N	.	N	N	.	.	.	.	.	.
POTEB2	15	20835372	20866314	N	.	N	N	.	.	0.571892791	28.2	.	.
POTEB3	15	21408243	21440451	N	.	N	N	.	.	.	.	.	.
POTEC	18	14507339	14543585	N	.	N	N	1.824285691	98.24043526	0.161704414	40.1	.	.
POTED	21	13609858	13641585	N	.	N	N	.	.	0.736659832	23.6	.	.
POTEE	2	131218067	131265278	N	.	N	N	.	.	.	.	.	.
POTEF	2	130073535	130129222	N	.	N	N	2.409274578	99.12021763	.	.	.	.
POTEG	14	19402486	19434341	N	.	N	N	.	.	.	.	.	.
POTEH	22	15690026	15721631	N	.	N	N	3.094229701	99.5716849	.	.	FTV	.
POTEI	2	130459455	130509666	N	.	N	N	.	.	.	.	.	.
POTEJ	2	130611481	130658091	N	.	N	N	.	.	.	.	.	.
POTEM	14	18967434	18999012	N	.	N	N	.	.	0.784476802	22.2	.	.
POU1F1	3	87259404	87276587	N	.	N	N	-0.240770687	32.9976269	0.618818419	27	DM	Pituitary hormone deficiency, combined, 1, 613038 (3)
POU2AF1	11	111352252	111455630	N	.	N	Y	-0.187292531	36.30259883	0.752817875	23.1	.	.
POU2F3	11	120236640	120319944	N	.	N	Y	0.045452123	53.0242519	0.002888395	60.5	.	.
POU3F4	X	83508250	83512127	N	.	N	Y	0.019921484	51.06789373	0.720490939	24.1	DM	Deafness, X-linked 2, 304400 (3)
POU4F2	4	146638893	146642474	N	.	N	Y	-0.219065877	34.38675696	0.180133326	39.3	.	.
POU4F3	5	146339024	146340520	N	.	N	Y	-0.387960287	25.05064537	0.721115139	24	DM	Deafness, autosomal dominant 15, 602459 (3)
POU5F1B	8	127414290	127420069	N	.	N	N	0.944073763	91.90831742	7.27E-07	83.1	DP	.
POU5F2	5	93734806	93741637	N	.	N	Y	-0.647852776	15.44828385	0.001008753	64.7	.	.
POU6F1	12	51186936	51217693	N	.	N	N	-0.189206557	36.19841408	0.907559367	17.5	.	.
POU6F2	7	38977998	39493095	N	.	N	Y	-0.080033468	43.6186838	0.000369076	68	DM?	{Wilms tumor susceptibility-5}, 601583 (3)
PP2672	1	234757621	234760056	N	.	N	N	.	.	.	.	.	.
PP2D1	3	19979961	20012330	N	.	N	N	.	.	.	.	.	.
PPA1	10	70202830	70233911	N	.	N	N	-0.136685385	39.64229901	0.002556402	61	.	.
PPA2	4	105369077	105474081	N	.	N	N	0.297684879	70.38258957	9.23E-06	78.3	.	.
PPAN	19	10106289	10111634	N	.	N	N	0.236048768	66.56826995	1.17E-08	88.7	.	.
PPAN-P2RY11	19	10106223	10114780	N	.	N	N	1.150355028	94.51872432	1.17E-08	88.7	.	.
PPAP2A	5	55424854	55535050	N	.	N	Y	-0.392745948	24.81333565	0.799472952	21.7	.	.
PPAP2C	19	281040	291504	N	.	N	Y	0.330566867	72.36788794	0.002860745	60.6	.	.
PPAPDC1A	10	120456954	120589855	N	.	N	N	-0.287703102	30.21357875	0.184092341	39.2	.	.
PPAPDC1B	8	38263130	38269243	N	.	N	N	0.179399332	63.14753719	3.07E-07	84.5	.	.
PPAPDC2	9	4662315	4665258	N	.	N	N	-0.225764638	33.98159403	0.810402577	21.3	.	.
PPAPDC3	9	131289694	131309262	N	.	N	N	-0.246359639	32.67349656	0.810567266	21.3	.	.
PPARA	22	46150521	46243756	N	.	N	Y	-0.112110344	41.35555941	0.463829864	31	DM?	{Hyperapobetalipoproteinemia, susceptibility to} (3)
PPAT	4	56393362	56435615	N	.	N	N	-0.49124353	20.54754876	0.994564413	8.6	DP	.
PPBP	4	73987038	73988197	N	Viable	N	Y	0.147473793	60.82653238	0.267236204	36.6	.	.
PPCDC	15	75023555	75117462	N	.	N	N	0.105325255	57.63153325	0.000879601	65.2	.	.
PPCS	1	42456117	42473385	N	.	N	N	0.0931893	56.64756613	0.003536336	59.7	.	.
PPDPF	20	63520724	63522206	N	Viable	N	Y	-0.094538075	42.4726515	0.000225837	69.4	.	.
PPEF1	X	18675909	18827921	N	.	N	Y	0.026619	51.54251317	0.984407236	11	.	.
PPEF2	4	75859864	75902571	N	.	N	Y	0.903185945	91.14429588	7.34E-10	91.3	.	.
PPFIA1	11	70270700	70384403	N	.	N	N	-0.901435329	9.561845228	0.999999874	1.2	.	.
PPFIA2	12	81257975	81759553	N	.	N	N	-1.101588124	6.540487353	0.999975972	2.9	.	.
PPFIA3	19	49119389	49151026	N	.	N	N	-1.353045932	4.28315101	0.999999595	1.4	.	.
PPFIA4	1	203026498	203078740	N	.	N	N	-0.200232492	35.49227296	0.001515533	63	.	.
PPFIBP1	12	27523431	27695564	N	.	N	N	-0.812481477	11.33877409	2.10E-12	95	.	.
PPFIBP2	11	7513298	7657127	N	.	N	N	-0.399649431	24.44290097	1.42E-18	98.3	.	.
PPIAL4A	1	120889746	120890405	N	.	N	N	.	.	0.377823123	33.4	.	.
PPIAL4C	1	149583865	149584464	N	.	N	N	.	.	.	.	.	.
PPIAL4D	1	145241630	145242124	N	.	N	N	.	.	.	.	.	.
PPIAL4E	1	144372875	144373659	N	.	N	N	.	.	.	.	.	.
PPIAL4F	1	144592868	144593527	N	.	N	N	.	.	.	.	.	.
PPIAL4G	1	148479824	148483679	N	.	N	N	0.928110403	91.68837182	0.606751613	27.3	.	.
PPIB	15	64155812	64163205	N	.	N	Y	-0.387157394	25.09116166	0.010651528	54.7	DM	Osteogenesis imperfecta, type IX, 259440 (3)
PPIC	5	123023250	123036741	N	.	N	N	0.885812789	90.84331771	0.000967993	64.9	.	.
PPID	4	158709134	158723396	N	.	N	N	0.071637002	55.02112635	1.71E-06	81.6	.	.
PPIE	1	39692182	39763914	N	.	N	N	0.016245619	50.75533947	0.98080984	11.6	.	.
PPIF	10	79347469	79355337	N	.	N	Y	0.618410947	84.71956937	0.005186213	57.9	.	.
PPIG	2	169584340	169641406	N	.	N	N	-0.943201879	8.820975864	0.984147329	11.1	DP	.
PPIH	1	42658425	42676758	N	.	N	N	-0.087991978	42.95305898	0.004755027	58.3	.	.
PPIL1	6	36854827	36875024	N	.	N	N	-0.063568931	44.88047693	0.013003976	53.8	.	.
PPIL2	22	21652270	21700015	N	.	N	N	-0.253710318	32.23939341	0.027492987	50.1	.	.
PPIL3	2	200870907	200889303	N	.	N	Y	0.184989352	63.48903166	0.549646605	28.6	.	.
PPIL4	6	149504733	149546038	N	.	N	N	-0.298880801	29.53637784	1.68E-05	76.7	.	.
PPIL6	6	109390215	109441171	N	.	N	N	-0.249230788	32.49406726	6.30E-08	86.7	.	.
PPIP5K1	15	43533462	43590253	N	.	N	N	.	.	0.102604913	42.9	.	.
PPIP5K2	5	103120149	103212799	N	.	N	N	-1.773310843	2.268912427	4.05E-10	91.9	.	.
PPL	16	4882507	4960741	N	.	N	Y	2.13470006	98.76135903	1.08E-25	99.4	.	.
PPM1A	14	60245752	60299087	N	Viable	N	Y	-0.494115743	20.42599988	0.985449561	10.9	.	.
PPM1E	17	58755869	58985176	N	.	N	N	-0.559574726	17.94871795	0.973416929	12.6	.	.
PPM1H	12	62643982	62935037	N	.	N	N	-0.184421636	36.49360421	0.855024041	19.7	.	.
PPM1J	1	112709994	112715477	N	Viable	N	Y	1.099885788	93.93413208	2.31E-07	85	.	.
PPM1L	3	160755602	161078907	N	.	N	Y	-0.264236856	31.60849685	0.570549299	28.2	.	.
PPM1M	3	52245793	52250597	N	.	N	N	0.477760474	79.6550327	0.092328926	43.6	.	.
PPM1N	19	45488777	45502510	N	.	N	N	.	.	0.000104897	71.7	.	.
PPOX	1	161166410	161178013	N	.	N	N	0.029489373	51.73930659	0.32833176	34.9	DM	Porphyria variegata, 176200 (3)
PPP1CA	11	67398183	67421183	N	.	N	N	-0.689198868	14.227007	0.941508636	15.5	.	.
PPP1CC	12	110719680	110742939	N	.	N	Y	-0.224004258	34.09156682	0.944905081	15.2	.	.
PPP1R11	6	30066709	30070333	N	.	N	N	-0.03642736	46.82525901	0.78308701	22.2	.	.
PPP1R12B	1	202348699	202592706	N	.	N	N	0.407970442	76.24587602	0.124454642	41.9	.	.
PPP1R12C	19	55090913	55117559	N	.	N	N	0.135639287	59.89465764	0.462120927	31.1	.	.
PPP1R13B	14	103733752	103847590	N	.	N	Y	-1.383747819	4.045841292	0.976929374	12.2	.	.
PPP1R14A	19	38251237	38256591	N	.	N	N	0.517999482	81.17149968	0.287406517	36	.	.
PPP1R14B	11	64244480	64246941	N	.	N	N	0.0545666	53.67251259	0.709204424	24.4	.	.
PPP1R14D	15	40815445	40828709	N	.	N	N	0.064939857	54.54650692	0.030341653	49.6	.	.
PPP1R15A	19	48872392	48876057	N	.	N	Y	1.485773838	96.89760954	3.34E-09	90	.	.
PPP1R16A	8	144477969	144502121	N	.	N	N	0.047365707	53.22683336	0.047670337	47.3	.	.
PPP1R16B	20	38805705	38923024	N	.	N	Y	-0.772536783	12.12015975	0.99853694	6.5	.	.
PPP1R17	7	31686715	31708455	N	.	N	N	0.640921144	85.36783006	0.000392906	67.8	.	.
PPP1R18	6	30676389	30687895	N	.	N	N	0.260319777	68.05579672	0.121201533	42	.	.
PPP1R1A	12	54575387	54588659	N	.	N	Y	-0.033556726	47.03941657	0.008576141	55.5	FP	.
PPP1R1B	17	39626740	39636626	N	.	N	Y	0.073399639	55.17740348	0.082106282	44.3	.	.
PPP1R1C	2	181954241	182131398	N	.	N	N	0.189623012	63.7437055	0.002533589	61.1	.	.
PPP1R2	3	195514425	195543386	N	.	N	N	0.103411903	57.457892	0.042709257	47.9	.	.
PPP1R21	2	48440598	48515391	N	.	N	N	-0.868829287	10.221682	0.0004021	67.7	.	.
PPP1R26	9	135479079	135488893	N	.	N	N	1.109174062	94.04410488	0.985547303	10.8	.	.
PPP1R27	17	81833492	81835050	N	.	N	N	-0.132053341	39.94906523	0.001955162	61.9	.	.
PPP1R32	11	61481120	61490931	N	Viable	N	Y	1.186254599	94.92967529	2.68E-07	84.7	.	.
PPP1R36	14	64549902	64589380	N	.	N	N	1.249008108	95.42165885	2.77E-07	84.7	.	.
PPP1R37	19	45091396	45148077	N	.	N	N	.	.	.	.	.	.
PPP1R3A	7	113876777	114075920	N	.	N	Y	1.200786712	95.01070788	6.59E-07	83.2	DM	Insulin resistance, severe, digenic, 604367 (3)
PPP1R3B	8	9136255	9151574	N	.	N	N	0.269585727	68.68669329	0.022919141	51	.	.
PPP1R3D	20	59936668	59940297	N	.	N	N	-0.180746515	36.69039764	0.067765274	45.2	.	.
PPP1R3E	14	23295643	23302848	N	.	N	N	.	.	.	.	.	.
PPP1R3F	X	49269843	49301461	N	.	N	N	0.318430612	71.66753487	0.004749429	58.3	.	.
PPP1R3G	6	5084581	5089487	N	.	N	N	.	.	.	.	.	.
PPP1R42	8	66964099	67056604	N	.	N	N	0.057436789	53.89824622	0.012746531	54	.	.
PPP1R7	2	241149576	241183652	N	.	N	N	-0.095342599	42.403195	0.840144247	20.3	.	.
PPP1R9A	7	94907202	95296415	N	.	N	Y	-0.209199526	34.97713723	0.051340412	46.9	.	.
PPP1R9B	17	50133735	50150630	N	Viable	N	Y	.	.	0.997286914	7.4	.	.
PPP2CB	8	30774457	30814314	N	.	N	Y	0.003958565	49.8061006	0.622505955	26.9	.	.
PPP2R1B	11	111726908	111766427	N	Viable	N	Y	0.150645248	61.03490189	2.19E-07	85	DM?	Lung cancer, 211980 (3)
PPP2R2A	8	26291491	26372680	N	.	N	N	-0.062612024	44.95572148	0.959642692	14	.	.
PPP2R2B	5	146581146	147084784	N	Viable	N	Y	-0.638435006	15.72032182	0.900682517	17.8	DM	Spinocerebellar ataxia 12, 604326 (3)
PPP2R2C	4	6320578	6563600	N	.	N	N	-0.927391577	9.098801875	0.564450095	28.3	DM	.
PPP2R2D	10	131900644	131959834	N	.	N	N	.	.	.	.	FP	.
PPP2R3A	3	135965673	136147891	N	.	N	N	0.316174739	71.48231753	0.920487875	16.7	.	.
PPP2R3B	X	333963	386955	N	.	N	N	0.553245899	82.56062974	1.71E-09	90.7	.	.
PPP2R3C	14	35085467	35122517	N	.	N	N	-0.299837855	29.4611333	8.06E-07	82.9	.	.
PPP2R5A	1	212285537	212361863	N	.	N	N	-0.59165691	16.97053887	0.899520424	17.8	.	.
PPP2R5B	11	64917553	64934473	N	.	N	N	-0.678823093	14.52219714	0.932458812	15.9	.	.
PPP2R5E	14	63371357	63543374	N	.	N	N	-0.500661427	20.13080975	0.999433464	5.3	.	.
PPP3CA	4	101023409	101348278	N	.	N	Y	-0.559729217	17.94292991	0.998148789	6.8	.	.
PPP3CB	10	73436428	73496024	N	.	N	Y	-0.266151109	31.49273601	0.999703649	4.6	.	.
PPP3CC	8	22440819	22541142	N	.	N	N	-0.167501818	37.55860392	0.016624643	52.6	.	.
PPP3R2	9	101591615	101595001	N	Viable	N	Y	0.444878869	78.09226139	0.047665504	47.3	.	.
PPP4R1	18	9546791	9615240	N	.	N	N	0.071939875	55.03849048	0.998557752	6.5	.	.
PPP4R3A	14	91457611	91510554	N	.	N	N	.	.	.	.	.	.
PPP4R3B	2	55547292	55618880	N	.	N	N	.	.	.	.	.	.
PPP4R4	14	94146128	94279735	N	.	N	N	-0.670059681	14.75371882	0.005674255	57.5	.	.
PPP5D1	19	46480796	46601200	N	.	N	N	.	.	0.039345023	48.4	.	.
PPP6R1	19	55229780	55258995	N	.	N	N	-0.127770995	40.21531516	0.997854506	7	.	.
PPP6R2	22	50343304	50445090	N	.	N	N	-0.007571173	48.82792151	0.718789474	24.1	.	.
PPP6R3	11	68460731	68615334	N	.	N	N	-1.164487547	5.950107079	0.995714714	8.1	.	.
PPT1	1	40072705	40097703	N	.	N	Y	-0.284831791	30.36985588	3.75E-05	74.6	DM	Ceroid lipofuscinosis, neuronal, 1, 256730 (3)
PPT2	6	32153441	32163680	N	Viable	N	Y	0.30327499	70.71250796	0.772683335	22.5	.	.
PPT2-EGFL8	6	32153845	32171978	N	.	N	N	.	.	.	.	.	.
PPTC7	12	110533245	110583320	N	.	N	N	-0.10299811	41.92278752	0.354852283	34	.	.
PPWD1	5	65563236	65587549	N	.	N	N	-0.254667152	32.16993691	0.031785775	49.4	.	.
PPY	17	43940804	43942468	N	.	N	N	0.326593235	72.13057823	0.563418204	28.4	.	.
PQBP1	X	48897912	48903143	N	.	N	N	-0.262476861	31.67216531	0.592844114	27.6	DM	Renpenning syndrome, 309500 (3)
PQLC1	18	79902420	79951664	N	.	N	N	-0.426432699	23.27950454	0.000252469	69.1	.	.
PQLC2	1	19312326	19329300	N	.	N	N	-0.328892939	27.7768131	0.000146809	70.7	.	.
PQLC2L	3	157543246	157677749	N	.	N	N	.	.	.	.	.	.
PQLC3	2	11155198	11178874	N	.	N	N	0.422369205	76.96359322	6.75E-07	83.2	.	.
PRAC1	17	48721719	48722522	N	.	N	N	.	.	0.001779923	62.4	.	.
PRAC2	17	48723168	48724758	N	.	N	N	.	.	.	.	.	.
PRADC1	2	73228006	73233238	N	.	N	Y	0.42987242	77.39769636	3.31E-07	84.4	.	.
PRAF2	X	49071156	49074071	N	.	N	Y	0.365065607	74.12745268	0.651276475	26	.	.
PRAM1	19	8490056	8503112	N	Viable	N	Y	0.693892116	86.76274816	0.007624896	56.2	.	.
PRAME	22	22547701	22559361	N	.	N	N	0.167564929	62.36036349	0.000838035	65.4	.	.
PRAMEF1	1	12791397	12796628	N	.	N	N	5.06355086	99.84951091	0.098105164	43.3	.	.
PRAMEF10	1	12892896	12898270	N	.	N	N	.	.	0.875594719	18.8	.	.
PRAMEF11	1	12824605	12831410	N	.	N	N	3.659584558	99.69323378	0.285437975	36.1	.	.
PRAMEF12	1	12774841	12777906	N	.	N	N	1.942609363	98.4661689	3.90E-06	80	.	.
PRAMEF14	1	13342034	13347134	N	.	N	N	.	.	0.559641613	28.4	.	.
PRAMEF15	1	13303509	13322598	N	.	N	N	.	.	.	.	.	.
PRAMEF17	1	13389632	13392629	N	.	N	N	.	.	0.790929576	22	.	.
PRAMEF18	1	13222695	13226133	N	.	N	N	.	.	.	.	.	.
PRAMEF19	1	13369067	13371693	N	.	N	N	.	.	0.583094142	27.9	.	.
PRAMEF2	1	12857086	12861909	N	.	N	N	5.368222467	99.85529895	0.00056761	66.6	DM?	.
PRAMEF20	1	13410450	13421328	N	Viable	N	Y	.	.	.	.	.	.
PRAMEF25	1	13172455	13179464	N	.	N	N	.	.	.	.	.	.
PRAMEF26	1	13060853	13077884	N	.	N	N	.	.	.	.	.	.
PRAMEF4	1	12879224	12886201	N	.	N	N	3.212624746	99.61220119	0.074609525	44.8	FTV	.
PRAMEF5	1	13254212	13263314	N	.	N	N	.	.	.	.	.	.
PRAMEF6	1	12938472	13056491	N	.	N	N	.	.	0.691325858	24.8	.	.
PRAMEF7	1	12916610	12920482	N	.	N	N	.	.	0.176862963	39.5	.	.
PRAMEF8	1	13281035	13285174	N	.	N	N	.	.	.	.	.	.
PRAP1	10	133309410	133352683	N	.	N	Y	0.201908627	64.49036291	0.000246549	69.2	.	.
PRB1	12	11351823	11395566	N	.	N	N	1.120484578	94.19459397	2.09E-05	76.1	FP	.
PRB2	12	11391540	11501041	N	.	N	N	2.307849016	98.99288071	2.88E-14	96.5	.	.
PRB3	12	11265924	11269805	N	.	N	N	.	.	2.57E-07	84.8	DM	.
PRB4	12	11307083	11310435	N	.	N	N	1.403873224	96.40562598	8.85E-08	86.3	FP	.
PRCC	1	156750610	156800817	N	.	N	N	0.344616494	73.13190948	0.921293122	16.6	.	Renal cell carcinoma, papillary, 605074 (3)
PRCD	17	76527586	76553578	N	.	N	N	0.295624092	70.22631244	0.003105096	60.2	DM	Retinitis pigmentosa 36, 610599 (3)
PRCP	11	82823502	82970584	N	.	N	N	-0.494765173	20.40284772	3.34E-08	87.5	DM?	.
PRDM11	11	45095806	45235124	N	.	N	N	-0.371040176	25.82045494	0.942263571	15.4	.	.
PRDM12	9	130664594	130682981	N	.	N	N	-0.387157394	25.09116166	0.29787033	35.8	.	Neuropathy, hereditary sensory and autonomic, type VIII, 616488 (3)
PRDM13	6	99606730	99615578	N	.	N	N	0.404791194	76.08381085	.	.	.	.
PRDM14	8	70051651	70071693	N	Viable	N	Y	-0.36640817	26.06934074	0.968775953	13.1	.	.
PRDM15	21	41798225	41879482	N	.	N	N	-1.133943071	6.216357006	0.753744615	23	.	.
PRDM2	1	13700198	13825079	N	.	N	Y	-0.366343679	26.07512878	0.995040619	8.4	DM	.
PRDM4	12	107732866	107761272	N	Viable	N	Y	-1.232979569	5.278694218	0.833196848	20.5	.	.
PRDM5	4	120684919	120922870	N	.	N	N	-0.872799944	10.11749725	0.742419321	23.4	DM	Brittle cornea syndrome 2, 614170 (3)
PRDM7	16	90056566	90092072	N	.	N	N	1.672272373	97.81212016	3.14E-10	92.1	.	.
PRDM8	4	80183879	80204329	N	.	N	Y	-0.214433638	34.65879493	.	.	DM	.
PRDM9	5	23507155	23528597	N	.	N	Y	1.63428692	97.65005499	1.95E-22	99.1	DM?	.
PRDX1	1	45511036	45523047	N	.	N	Y	-0.350599275	26.7407536	1.44E-07	85.7	.	.
PRDX2	19	12796820	12801859	N	.	N	Y	0.066853307	54.65069167	0.496065281	30.1	.	.
PRDX3	10	119167703	119178833	N	.	N	N	-0.219218665	34.36360479	0.221688706	37.9	.	.
PRDX4	X	23664262	23686399	N	.	N	Y	-0.019507464	47.94813914	0.281507845	36.2	DM?	.
PRDX5	11	64318088	64321811	N	.	N	N	0.545289715	82.23649939	0.003140381	60.1	.	.
PRDX6	1	173477266	173488807	N	.	N	Y	-0.041059779	46.53585692	0.009989768	54.9	.	.
PREB	2	27130756	27134675	N	.	N	N	0.188965718	63.72634138	0.001898363	62	.	.
PRELID1	5	177303774	177306959	N	.	N	N	0.300405715	70.5388667	0.865363912	19.3	.	.
PRELID2	5	145471799	145835369	N	Viable	N	Y	-0.003544497	49.14626382	1.73E-05	76.7	.	.
PRELP	1	203475828	203491352	N	Viable	N	Y	0.439436623	77.86073971	0.003736486	59.3	.	.
PREPL	2	44316281	44361862	N	.	N	Y	-0.342491895	27.13434045	2.43E-11	93.8	DM	.
PREX1	20	48624252	48827883	N	.	N	Y	-1.163009198	5.967471204	0.999999622	1.4	.	.
PREX2	8	67952118	68237030	N	.	N	Y	-1.256877436	5.087688835	1.01E-10	92.9	.	.
PRF1	10	70597348	70602775	N	.	N	Y	0.133877569	59.74416855	1.40E-07	85.7	DM	Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3); Lymphoma, non-Hodgkin, 605027 (3); Aplastic anemia, 609135 (3)
PRG2	11	57386794	57390657	N	.	N	Y	0.05935026	54.0603114	1.37E-05	77.2	.	.
PRG3	11	57376769	57381150	N	Viable	N	Y	0.842702881	90.05614401	0.000177441	70.2	.	.
PRG4	1	186296279	186314562	N	.	N	Y	0.658948099	85.88875383	0.469279559	30.9	DM	.
PRH1	12	10824960	11171544	N	.	N	N	.	.	0.284195071	36.1	.	.
PRH1-PRR4	12	10845849	11171598	N	.	N	N	.	.	.	.	.	.
PRH2	12	10929236	10932341	N	.	N	N	0.732874214	87.64253053	0.595625943	27.5	.	.
PRICKLE2	3	64093867	64445476	N	.	N	Y	-1.814658294	2.164727673	0.987837186	10.4	DM?	Epilepsy, progressive myoclonic 5, 613832 (3)
PRICKLE3	X	49175264	49186528	N	.	N	N	0.506008393	80.70845633	0.152656461	40.5	.	.
PRICKLE4	6	41780349	41790141	N	.	N	N	0.506008393	80.70845633	7.01E-06	78.9	.	.
PRIM1	12	56731596	56752373	N	.	N	N	0.490854514	80.1238641	0.026897939	50.2	.	.
PRIM2	6	57314805	57646849	N	.	N	N	.	.	5.15E-08	86.9	.	.
PRIMA1	14	93718298	93788481	N	.	N	Y	-0.171482763	37.26341379	0.367086766	33.7	.	.
PRIMPOL	4	184649613	184694963	N	Viable	N	Y	0.354183362	73.68177346	2.79E-13	95.7	.	.
PRKAA1	5	40759379	40798374	N	.	N	Y	-0.677865718	14.55113735	0.035101034	48.9	.	.
PRKAA2	1	56645322	56715335	N	Viable	N	Y	-0.524930204	19.22208717	1.44E-05	77.1	DP	.
PRKAB1	12	119667753	119681630	Y	Viable	N	Y	0.031251654	51.92452393	0.051879133	46.8	.	.
PRKACB	1	84078062	84238498	N	.	N	Y	-0.49315829	20.47809226	0.612478409	27.1	.	.
PRKACG	9	69012505	69014113	N	.	N	N	-0.123440781	40.55680963	0.005058191	58.1	.	?Bleeding disorder, platelet-type, 19, 616176 (3)
PRKAG1	12	49002274	49019197	N	.	N	Y	-0.371193959	25.80887886	0.001637087	62.7	.	.
PRKAG2	7	151556111	151877125	N	.	N	N	0.011764461	50.40805695	0.977557429	12.1	DM	Wolff-Parkinson-White syndrome, 194200 (3); Cardiomyopathy, hypertrophic 6, 600858 (3); Glycogen storage disease of heart, lethal congenital, 261740 (3)
PRKAG3	2	218822383	218832086	N	.	N	Y	-0.114829257	41.15876599	9.67E-05	72	DM	.
PRKAR1B	7	549197	727650	N	.	N	Y	-0.169415642	37.44284309	0.0247578	50.5	.	.
PRKAR2A	3	48744597	48847846	N	.	N	Y	0.403684998	75.99699022	0.983250576	11.2	.	.
PRKAR2B	7	107044649	107161811	N	.	N	Y	-0.457557544	21.97140707	0.995321216	8.3	.	.
PRKCA	17	66302636	66810743	N	.	N	Y	-1.353193626	4.277362968	0.952135908	14.5	.	Pituitary tumor, invasive (3)
PRKCB	16	23836001	24220611	N	.	N	Y	-1.104606377	6.494183018	0.99990807	3.7	FP	.
PRKCD	3	53156009	53192717	N	.	N	Y	-0.58017037	17.3757018	0.997593707	7.2	DM	Autoimmune lymphoproliferative syndrome, type III, 615559 (3)
PRKCDBP	11	6318946	6320647	N	Viable	N	Y	0.636285654	85.24628118	4.93E-05	73.9	.	.
PRKCE	2	45651345	46187990	N	.	N	Y	-0.631735985	15.8418707	0.999891646	3.8	.	.
PRKCG	19	53879190	53907652	N	.	N	Y	-0.749069701	12.66423569	0.99982368	4.2	DM	Spinocerebellar ataxia 14, 605361 (3)
PRKCQ	10	6427143	6580301	N	.	N	Y	-0.227374171	33.90634948	0.967595406	13.3	.	.
PRKCZ	1	2050470	2185395	N	.	N	Y	-0.885087781	9.874399491	0.266923657	36.6	.	.
PRKD2	19	46674275	46717127	N	.	N	N	-0.959016857	8.583666146	0.999696407	4.7	.	.
PRKD3	2	37250502	37324808	N	.	N	N	-0.545225628	18.37703305	0.008075656	55.9	FTV	.
PRKG2	4	81087370	81215117	N	.	N	Y	-0.458206381	21.95404295	0.449903081	31.4	DM?	.
PRKRIP1	7	102363872	102426676	N	.	N	N	-0.061655126	44.98466169	0.0003948	67.8	.	.
PRKRIR	11	76349956	76380971	N	.	N	N	-0.450703279	22.237657	0.968969189	13.1	.	.
PRKX	X	3604370	3713608	N	.	N	N	-0.062612024	44.95572148	0.221428118	38	.	.
PRL	6	22287244	22297501	N	.	N	Y	-0.046649065	46.09017769	0.002641102	60.9	DFP	.
PRLH	2	237566574	237567175	N	.	N	Y	0.130554386	59.44897841	0.04017093	48.3	.	.
PRLHR	10	118589989	118595699	N	.	N	Y	-0.084968981	43.20194478	0.000426454	67.6	DP	.
PRLR	5	35048756	35230589	N	.	N	Y	0.392655504	75.49343057	0.916128016	16.9	DFP	Multiple fibroadenomas of the breast, 615554 (3); ?Hyperprolactinemia, 615555 (3)
PRM1	16	11280836	11281350	N	.	N	Y	0.190579485	63.80158592	0.371061724	33.6	DM?	.
PRM2	16	11275639	11276480	N	.	N	Y	-0.041059779	46.53585692	0.108047166	42.7	DM	.
PRM3	16	11273218	11273641	N	.	N	Y	.	.	.	.	.	.
PRMT2	21	46635167	46665124	N	.	N	Y	-0.345660302	26.9606992	0.751420208	23.1	.	.
PRMT6	1	107056679	107059294	N	.	N	Y	-0.593415811	16.91265845	0.024127621	50.7	.	.
PRMT7	16	68310974	68358563	N	.	N	Y	-1.107180261	6.47103085	8.31E-09	89.2	DM	.
PRMT8	12	3381349	3593973	N	.	N	Y	-0.234224724	33.42015396	0.958752744	14.1	.	.
PRMT9	4	147637785	147684230	N	.	N	N	.	.	.	.	.	.
PRND	20	4721910	4728460	N	.	N	Y	0.582806208	83.59668924	0.067796655	45.2	DM	.
PRNP	20	4686236	4701590	N	.	N	Y	0.046257695	53.10528448	0.029139027	49.8	DM	Creutzfeldt-Jakob disease, 123400 (3); Gerstmann-Straussler disease, 137440 (3); Insomnia, fatal familial, 600072 (3); Prion disease with protracted course, 606688 (3); Huntington disease-like 1, 603218 (3); {Kuru, susceptibility to}, 245300 (3); Cerebral amyloid angiopathy, PRNP-related, 137440 (3)
PRNT	20	4731282	4740668	N	.	N	N	.	.	0.105498859	42.8	.	.
PROB1	5	139390592	139395713	N	.	N	N	.	.	.	.	.	.
PROCA1	17	28703197	28711854	N	.	N	N	0.48445544	79.89234242	0.000876151	65.2	FTV	.
PRODH	22	18912777	18936553	N	Viable	N	Y	1.360761091	96.17989234	4.75E-06	79.6	DM	Hyperprolinemia, type I, 239500 (3); {Schizophrenia, susceptibility to, 4}, 600850 (3)
PRODH2	19	35799988	35813299	N	.	N	N	0.991157255	92.64339874	7.21E-12	94.4	.	Hyperprolinemia, type I, 239500 (3); {Schizophrenia, susceptibility to, 4}, 600850 (3)
PROK1	1	110451200	110457354	N	.	N	N	0.260977174	68.09052498	0.020669166	51.5	DM?	.
PROK2	3	71771656	71785206	N	.	N	Y	0.107088402	57.71835388	0.270454067	36.5	DM	Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3)
PROKR1	2	68643589	68658247	N	Viable	N	Y	-0.560531745	17.9139897	5.42E-10	91.7	DM?	.
PROL1	4	70397882	70410194	N	.	N	N	1.009695126	92.88070846	1.28E-06	82.2	.	.
PROM1	4	15963076	16084378	N	.	N	Y	0.659248124	85.89454188	7.17E-17	97.8	DM	Retinitis pigmentosa 41, 612095 (3); Cone-rod dystrophy 12, 612657 (3); Stargardt disease 4, 603786 (3); Macular dystrophy, retinal, 2, 608051 (3)
PROM2	2	95274453	95291308	N	Viable	N	Y	0.390091918	75.37188169	7.90E-08	86.4	.	.
PRORY	Y	21382954	21386360	N	.	N	N	.	.	.	.	.	.
PROSC	8	37762593	37779767	N	.	N	N	0.044344174	52.90849106	0.297119448	35.8	.	.
PROSER1	13	39009866	39038076	N	.	N	N	-0.501016486	20.10186954	0.736135592	23.6	.	.
PROSER2	10	11823339	11872277	N	.	N	N	.	.	0.005463151	57.7	.	.
PROSER3	19	35758143	35771028	N	.	N	N	.	.	.	.	.	.
PROX2	14	74852871	74871940	N	.	N	Y	0.475995728	79.57978816	7.89E-07	83	DM?	.
PROZ	13	113158654	113172383	N	.	N	Y	0.17491644	62.86392313	3.84E-09	89.9	DM	[Protein Z deficiency], 614024 (3)
PRPF18	10	13586927	13630868	N	.	N	N	-0.303666373	29.26433987	0.099443259	43.2	.	.
PRPF38A	1	52404564	52420839	N	.	N	N	-0.409666664	23.96249349	0.996467619	7.8	.	.
PRPF38B	1	108692323	108701803	N	.	N	N	-0.373911225	25.72784627	0.990908108	9.7	.	.
PRPF39	14	45084099	45116282	N	.	N	N	-0.316758145	28.47137813	0.995121732	8.4	DM?	.
PRPF4	9	113275343	113292905	N	.	N	N	-0.502420818	20.06714129	0.999643089	4.8	.	Retinitis pigmentosa 70, 615922 (3)
PRPF40A	2	152651593	152717997	N	.	N	N	-1.536168599	3.166058922	0.966325783	13.4	.	.
PRPF40B	12	49568218	49644666	N	.	N	N	-1.238431725	5.209237715	0.988653394	10.2	.	.
PRPF4B	6	4021267	4064983	N	.	N	N	-0.802399101	11.50662731	0.999999729	1.3	.	.
PRPF6	20	63981135	64033100	N	.	N	N	-2.037097201	1.562771314	0.280831795	36.2	DM	Retinitis pigmentosa 60, 613983 (3)
PRPF8	17	1650629	1684882	N	.	N	N	-4.745043235	0.104184754	0.999999999	0.6	DM	Retinitis pigmentosa 13, 600059 (3)
PRPH	12	49293252	49298686	N	.	N	Y	-0.621514277	16.14863692	5.05E-10	91.7	DM	{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3)
PRPH2	6	42696600	42722574	N	.	N	Y	0.512555096	80.99207038	0.388059586	33.1	DM	Retinitis pigmentosa 7 and digenic, 608133 (3); Leber congenital amaurosis 18, 608133 (3); Macular dystrophy, patterned, 1, 169150 (3); Retinitis punctata albescens, 136880 (3); Choriodal dystrophy, central areolar 2, 613105 (3); Macular dystrophy, vitelliform, 3, 608161 (3)
PRPS1L1	7	18026774	18027863	N	.	N	N	0.579127749	83.41725994	.	.	.	.
PRPS2	X	12791355	12824222	N	.	N	Y	-0.231507329	33.61694739	0.922707345	16.5	.	.
PRPSAP1	17	76309486	76384521	N	.	N	N	-0.626300493	15.98657174	1.97E-10	92.5	.	.
PRPSAP2	17	18840085	18931287	N	.	N	Y	-0.181703531	36.63251722	0.072045202	44.9	.	.
PRR11	17	59155499	59204705	N	.	N	N	0.640110346	85.33310181	3.72E-06	80.1	.	.
PRR12	19	49591643	49626439	N	.	N	N	-2.287214652	1.146032297	0.999969577	3	.	.
PRR13	12	53441605	53446645	N	.	N	N	0.190579485	63.80158592	0.634332002	26.5	.	.
PRR14	16	30650717	30656440	N	.	N	N	-0.39148464	24.90015628	0.258591291	36.8	.	.
PRR14L	22	31676256	31750140	N	.	N	N	.	.	0.984999167	10.9	.	.
PRR15	7	29563811	29567295	N	.	N	N	-0.03642736	46.82525901	0.446963257	31.5	.	.
PRR15L	17	47951967	47957878	N	Viable	N	Y	0.328505738	72.23476298	0.481246951	30.5	.	.
PRR16	5	120464278	120687332	N	.	N	N	0.485263696	79.90970655	0.526199282	29.3	.	.
PRR18	6	166305300	166308448	N	.	N	N	.	.	0.488137896	30.3	.	.
PRR19	19	42302098	42310821	N	.	N	N	-0.281960735	30.55507322	0.196398788	38.8	.	.
PRR20A	13	57140918	57143939	N	.	N	N	.	.	.	.	.	.
PRR20B	13	57147488	57150509	N	.	N	N	.	.	.	.	.	.
PRR20C	13	57140918	57157082	N	.	N	N	.	.	.	.	.	.
PRR20D	13	57160632	57163653	N	.	N	N	.	.	.	.	.	.
PRR20E	13	57167197	57170218	N	.	N	N	.	.	.	.	.	.
PRR21	2	240041813	240042982	N	.	N	N	.	.	0.003652752	59.5	.	.
PRR22	19	5782960	5784765	N	.	N	N	0.37749856	74.80465359	0.020640559	51.5	.	.
PRR23A	3	139005468	139006268	N	.	N	N	-0.002587674	49.23887249	0.018079935	52.2	.	.
PRR23B	3	139019031	139020926	N	.	N	N	0.637241741	85.28100943	0.00253402	61.1	.	.
PRR23C	3	139042102	139044892	N	.	N	N	0.247883787	67.32650344	0.000636018	66.3	.	.
PRR23D1	8	7539628	7542450	N	.	N	N	.	.	.	.	.	.
PRR23D2	8	7778591	7781413	N	.	N	N	.	.	.	.	.	.
PRR25	16	805443	813861	N	.	N	N	0.923475384	91.58997511	3.13E-06	80.5	.	.
PRR26	10	649948	669581	N	.	N	N	.	.	.	.	.	.
PRR27	4	70133616	70176799	N	.	N	N	.	.	.	.	.	.
PRR29	17	63998351	64004304	N	.	N	N	.	.	.	.	.	.
PRR3	6	30556886	30563723	N	.	N	N	0.406406543	76.17063148	0.114320039	42.4	.	.
PRR30	2	27136848	27139410	N	.	N	N	.	.	.	.	.	.
PRR32	X	126819764	126821786	N	.	N	N	.	.	.	.	.	.
PRR33	11	1889145	1890854	N	.	N	N	.	.	.	.	.	.
PRR34	22	46049478	46054144	N	.	N	N	.	.	.	.	.	.
PRR35	16	560422	565528	N	.	N	N	.	.	.	.	.	.
PRR36	19	7868719	7874379	N	.	N	N	.	.	.	.	.	.
PRR4	12	10845849	11171613	N	.	N	N	0.072442927	55.09058286	1.03E-05	78	.	Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3)
PRR5	22	44668547	44737681	N	.	N	N	0.192792725	64.00416739	0.972989445	12.7	.	.
PRR5-ARHGAP8	22	44702233	44862784	N	.	N	N	3.309663093	99.64692944	.	.	.	.
PRR5L	11	36296288	36465204	N	.	N	N	0.362492381	74.04063205	0.078768861	44.5	.	.
PRR7	5	177446445	177456286	N	.	N	N	.	.	0.724989126	23.9	.	.
PRR9	1	153217584	153219317	N	.	N	N	.	.	.	.	.	.
PRRC1	5	127517609	127555089	N	.	N	N	0.288418427	69.82114951	2.13E-05	76.1	.	.
PRRC2A	6	31620720	31637771	N	.	N	N	0.089293016	56.35816403	1	0.3	DP	.
PRRC2B	9	131394093	131500197	N	.	N	N	-1.763181062	2.297852636	0.999999104	1.7	.	.
PRRC2C	1	171485551	171593511	N	.	N	N	-2.104039105	1.452798518	1	0.3	.	.
PRRG1	X	37349275	37457295	N	.	N	N	0.427960039	77.28193552	0.335254587	34.8	.	.
PRRG2	19	49580646	49591015	N	.	N	N	0.526458794	81.4782659	5.97E-05	73.4	.	.
PRRG3	X	151695124	151705924	N	.	N	N	0.713231642	87.23157956	2.07E-05	76.1	.	.
PRRG4	11	32829943	32858123	N	.	N	N	0.444878869	78.09226139	0.181401743	39.3	.	.
PRRT1	6	32148359	32154373	N	.	N	N	0.069572814	54.86484922	0.40794573	32.6	.	.
PRRT2	16	29811382	29815892	N	.	N	N	0.316517317	71.52862187	0.301735693	35.7	DM	Episodic kinesigenic dyskinesia 1, 128200 (3); Seizures, benign familial infantile, 2, 605751 (3); Convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3)
PRRT3	3	9945542	9952394	N	.	N	N	-0.538827354	18.63170689	0.658018522	25.8	.	.
PRRT4	7	128350325	128361685	N	.	N	N	.	.	.	.	.	.
PRRX2	9	129665641	129722674	N	.	N	Y	0.073399639	55.17740348	0.305924077	35.6	.	.
PRSS1	7	142749468	142763997	N	Viable	N	Y	2.70172362	99.31701106	0.001220295	63.9	DM	Pancreatitis, hereditary, 167800 (3); Trypsinogen deficiency, 614044 (1)
PRSS12	4	118280038	118353003	N	.	N	Y	-0.278789029	30.69398622	4.55E-18	98.2	DM	Mental retardation, autosomal recessive 1, 249500 (3)
PRSS16	6	27247701	27256624	N	.	N	Y	-0.348531035	26.86230248	2.24E-06	81.1	.	.
PRSS2	7	142748662	142774564	N	.	N	N	.	.	.	.	DFP	{Pancreatitis, chronic, protection against}, 167800 (3)
PRSS21	16	2817180	2826304	N	.	N	Y	0.025662211	51.48463275	3.27E-07	84.4	.	.
PRSS22	16	2852727	2858170	N	.	N	N	-0.17883254	36.80037043	0.015476364	53	.	.
PRSS23	11	86791059	86952910	N	.	N	N	-0.015528497	48.24911732	1.27E-06	82.3	.	.
PRSS27	16	2712418	2720551	N	.	N	Y	0.751704862	88.11136193	8.69E-07	82.8	.	.
PRSS3	9	33750466	33799231	N	.	N	N	2.402244626	99.09127742	4.80E-10	91.8	.	.
PRSS33	16	2783953	2787948	N	.	N	N	.	.	0.000160244	70.4	.	.
PRSS35	6	83512538	83525704	N	.	N	N	-0.256580891	32.10626845	1.34E-06	82.2	.	.
PRSS36	16	31138925	31150094	N	.	N	N	-0.090406755	42.76784164	4.42E-13	95.6	.	.
PRSS37	7	141836286	141841487	N	.	N	Y	0.401772227	75.92174567	0.001727085	62.5	.	.
PRSS38	1	227815693	227846470	N	.	N	N	1.115849909	94.13671355	0.030266614	49.6	.	.
PRSS42	3	46829542	46834095	N	.	N	N	0.156890071	61.50952133	4.68E-05	74.1	.	.
PRSS45	3	46742092	46812558	N	.	N	N	1.061266122	93.50581698	8.78E-05	72.3	.	.
PRSS46	3	46719583	46736429	N	.	N	N	.	.	.	.	.	.
PRSS48	4	151277171	151291453	N	.	N	N	0.549114755	82.41014065	0.000223314	69.4	.	.
PRSS50	3	46712116	46812574	N	.	N	Y	1.082965441	93.77785495	2.62E-05	75.5	.	.
PRSS53	16	31083425	31089628	N	.	N	N	0.777232305	88.74225849	7.27E-11	93.2	DP	.
PRSS54	16	58279997	58295047	N	.	N	N	0.340939791	72.94090409	4.50E-05	74.2	.	.
PRSS55	8	10525546	10554166	N	.	N	N	1.350538501	96.11043584	1.23E-08	88.6	.	.
PRSS56	2	232520463	232525716	N	.	N	Y	.	.	.	.	DM	Microphthalmia, isolated 6, 613517 (3)
PRSS57	19	685546	695498	N	.	N	N	0.448703989	78.31799502	1.73E-07	85.4	.	.
PRSS58	7	142252143	142258058	N	.	N	N	0.153213524	61.2432714	6.16E-05	73.3	.	.
PRTFDC1	10	24848607	24952604	N	.	N	N	0.227287513	66.09365052	5.28E-09	89.5	.	.
PRTG	15	55611546	55743090	N	.	N	N	-0.351761449	26.6712971	0.019529107	51.8	.	.
PRTN3	19	840960	848175	N	.	N	N	0.762888245	88.37182381	0.000831489	65.4	.	.
PRUNE	1	151008420	151035713	N	.	N	Y	0.082010267	55.87196851	0.010761766	54.6	.	.
PRUNE2	9	76611376	76906087	N	.	N	N	1.678710086	97.83527233	3.68E-12	94.8	.	.
PRX	19	40393768	40413366	N	.	N	Y	0.476943095	79.62030445	3.70E-11	93.6	DM	Dejerine-Sottas disease, 145900 (3); Charcot-Marie-Tooth disease, type 4F, 614895 (3)
PRY	Y	22490397	22514637	N	.	N	N	.	.	.	.	.	.
PRY2	Y	22071756	22096007	N	.	N	N	.	.	.	.	.	.
PSAPL1	4	7432258	7434945	N	.	N	N	1.602970324	97.51114198	3.34E-11	93.6	.	.
PSCA	8	142670308	142682724	N	.	N	Y	0.198082641	64.25305319	0.008948427	55.4	DFP	.
PSD	10	102402617	102421539	N	.	N	N	-0.295560131	29.69265497	0.987334022	10.5	.	.
PSD2	5	139795821	139844466	N	.	N	N	0.071135056	54.95166985	0.180222827	39.3	.	.
PSD3	8	18527301	19084730	N	.	N	N	-0.049569127	45.77762343	0.851705649	19.8	.	.
PSD4	2	113157325	113209396	N	.	N	N	-0.112614802	41.26295074	0.80549607	21.4	.	.
PSEN2	1	226870184	226896105	N	.	N	Y	-0.049216095	45.88759623	0.027014182	50.2	DM	Alzheimer disease-4, 606889 (3); Cardiomyopathy, dilated, 1V, 613697 (3)
PSG1	19	42866464	42879822	N	.	N	N	2.796946662	99.37489147	3.44E-12	94.8	.	.
PSG11	19	43007656	43026512	N	.	N	N	1.196629346	94.98176767	7.20E-09	89.3	.	.
PSG2	19	43064211	43083045	N	.	N	N	0.918993216	91.48579036	6.19E-07	83.4	FTV	.
PSG3	19	42721638	42740569	N	.	N	N	2.048808898	98.64559819	2.31E-12	95	.	.
PSG4	19	43192702	43207299	N	.	N	N	2.031879096	98.61665798	7.90E-10	91.3	.	.
PSG5	19	43166256	43186536	N	.	N	N	2.290751624	98.97551658	1.21E-10	92.8	.	.
PSG6	19	42902079	42919563	N	.	N	N	3.787464235	99.72217399	2.97E-09	90.1	.	.
PSG7	19	42906822	43082671	N	.	N	N	.	.	.	.	.	.
PSG8	19	42752686	42855691	N	.	N	N	2.117319343	98.74978295	1.93E-10	92.5	.	.
PSG9	19	43211791	43269530	N	.	N	N	2.446633676	99.14915784	2.75E-14	96.5	.	.
PSKH1	16	67893272	67929678	N	.	N	Y	-0.265997742	31.51588818	0.017874205	52.2	.	.
PSKH2	8	86048373	86088621	N	.	N	N	1.02293544	93.08328992	1.74E-07	85.4	.	.
PSMA1	11	14504874	14643635	N	.	N	N	-0.198623704	35.57909359	0.947988405	15	.	.
PSMA2	7	42916857	42932223	N	.	N	N	-0.284986118	30.32933958	0.937474829	15.8	.	.
PSMA3	14	58244831	58272012	N	.	N	N	-0.177071645	36.92770736	0.990281922	9.9	.	.
PSMA4	15	78540405	78552419	N	.	N	N	-0.299035003	29.50743763	0.62042359	26.9	.	.
PSMA5	1	109399031	109426427	N	.	N	N	-0.043930449	46.31591133	0.974255885	12.5	.	.
PSMA6	14	35278633	35317493	N	.	N	N	-0.224004258	34.09156682	0.94398764	15.3	DFP	{Myocardial infarcation, susceptibility to}, 608446 (3)
PSMA7	20	62136735	62143440	N	.	N	N	-0.275568538	30.94287203	0.965751461	13.4	DM?	.
PSMA8	18	26133852	26193355	N	.	N	N	0.067810037	54.72014817	0.003979648	59.1	.	.
PSMB1	6	170535117	170553341	N	.	N	N	-0.190163599	36.15789778	0.718811352	24.1	.	.
PSMB10	16	67934502	67937087	N	.	N	Y	-0.134771456	39.75805985	2.34E-05	75.8	.	.
PSMB11	14	23042167	23044276	N	.	N	Y	0.73397582	87.68304683	0.017139131	52.4	.	.
PSMB2	1	35599544	35641844	N	.	N	N	0.003958565	49.8061006	0.972351383	12.8	.	.
PSMB3	17	38752736	38764231	N	.	N	N	-0.101084162	42.05591248	0.697590277	24.7	.	.
PSMB4	1	151399534	151401944	N	.	N	N	-0.462188395	21.78618973	0.398813285	32.8	.	.
PSMB5	14	23016543	23035230	N	.	N	N	-0.115133273	41.12403774	0.758964107	22.9	.	.
PSMB6	17	4796144	4798503	N	.	N	N	0.172852824	62.72501013	0.14318639	40.9	.	.
PSMB7	9	124353466	124415444	N	.	N	N	-0.114176312	41.19928228	0.941261763	15.5	.	.
PSMB8	6	32840717	32844703	N	.	N	Y	0.009699407	50.29229612	0.012003172	54.2	DM	Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 (3)
PSMB9	6	32844136	32859585	N	.	N	Y	0.48335126	79.84025004	0.225647028	37.8	DFP	.
PSMC2	7	103344254	103369395	N	.	N	N	-0.387157394	25.09116166	0.999210833	5.7	.	.
PSMC3IP	17	42572315	42577831	N	.	N	Y	0.158803293	61.65422238	0.000192545	69.9	DM	Ovarian dysgenesis 3, 614324 (3)
PSMC5	17	63827152	63832026	N	.	N	N	-0.395617806	24.63390635	0.969571425	13	.	.
PSMC6	14	52707172	52728587	N	.	N	N	-0.388114712	25.02170516	0.995511977	8.2	.	.
PSMD1	2	231056864	231172827	N	.	N	N	-0.821232546	11.15355675	0.999999203	1.6	.	.
PSMD10	X	108084207	108091618	N	.	N	N	0.207498734	64.86658563	0.403603163	32.7	.	.
PSMD11	17	32444261	32483318	N	.	N	N	-0.840223104	10.7599699	0.999745809	4.5	.	.
PSMD12	17	67337916	67366627	N	.	N	N	-0.45372795	22.13347225	0.997267742	7.4	.	.
PSMD13	11	236546	252984	N	.	N	N	-0.054957051	45.47085721	0.993513212	9	.	.
PSMD2	3	184298709	184309054	N	.	N	N	-0.521907714	19.37257626	0.999997116	2	.	.
PSMD3	17	39980797	39997960	N	.	N	N	-0.772536783	12.12015975	0.999288335	5.5	.	.
PSMD5	9	120815496	120842984	N	.	N	N	-0.027663999	47.45615558	1.27E-05	77.5	.	.
PSMD6	3	64010549	64024010	N	.	N	N	-0.080336605	43.59553163	0.962085715	13.7	.	.
PSMD8	19	38374536	38383824	N	.	N	N	.	.	0.176154541	39.5	.	.
PSMD9	12	121888731	121918297	N	.	N	N	0.712275627	87.20263935	3.78E-05	74.6	.	.
PSME1	14	24136158	24138967	N	.	N	Y	-0.053195214	45.56346588	0.050880833	46.9	.	.
PSME2	14	24143362	24147570	N	.	N	Y	0.224417956	65.88528101	0.108796042	42.7	.	.
PSME3	17	42824385	42843758	N	.	N	Y	-0.260562407	31.82844244	0.988103823	10.4	.	.
PSME4	2	53864067	53970840	N	.	N	Y	-2.835414016	0.688776987	0.999999997	0.7	.	.
PSMG2	18	12658043	12725740	N	.	N	N	0.219784433	65.64218325	0.00355676	59.6	.	.
PSMG3	7	1567330	1571005	N	.	N	N	0.1249645	59.10748394	0.194253225	38.9	.	.
PSMG4	6	3231403	3303373	N	.	N	N	.	.	.	.	.	.
PSORS1C1	6	31114750	31140092	N	.	N	N	0.8210057	89.54100828	0.000855356	65.3	DP	.
PSORS1C2	6	31137536	31139350	N	.	N	N	0.92796837	91.67679574	0.104502853	42.9	FTV	.
PSPC1	13	19674752	19783019	N	.	N	N	-0.688086328	14.26173525	0.99260702	9.3	.	.
PSPN	19	6375148	6379058	N	.	N	Y	.	.	0.007741412	56.1	DM	.
PSRC1	1	109279556	109283186	N	.	N	N	0.514468098	81.0499508	1.75E-06	81.6	.	.
PSTK	10	122954381	122997513	N	.	N	N	0.019116005	51.00422527	0.004110024	59	.	.
PSTPIP1	15	76993359	77037332	N	.	N	Y	1.673082421	97.8179082	0.00072615	65.8	DM	Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3)
PSTPIP2	18	45983536	46072272	N	.	N	N	-0.181703531	36.63251722	0.107611557	42.7	.	.
PTAFR	1	28147166	28193936	N	.	N	Y	0.094146026	56.71123459	0.118775353	42.2	DP	.
PTAR1	9	69709522	69759959	N	.	N	N	0.077226532	55.46680558	0.731558291	23.7	.	.
PTBP3	9	112217716	112333667	N	.	N	N	-0.446070878	22.45181455	0.978776733	12	.	.
PTCD1	7	99416739	99466163	N	.	N	N	0.801012073	89.17636164	1.78E-09	90.6	DM	.
PTCD2	5	72320367	72368395	N	.	N	N	0.112022239	58.14666898	3.49E-08	87.4	.	.
PTCD3	2	86106182	86142157	N	.	N	N	-0.427087162	23.23320021	1.03E-06	82.5	.	.
PTCH2	1	44819844	44843063	N	.	N	Y	-0.411645595	23.80621636	6.11E-10	91.6	DM	Medulloblastoma, 155255 (3); Basal cell carcinoma, somatic, 605462 (3); Basal cell nevus syndrome, 109400 (3)
PTCHD1	X	23334015	23404372	N	Viable	N	Y	-0.733106044	13.06361058	0.947053079	15	DM	{Autism, susceptibility to, X-linked 4}, 300830 (3)
PTCHD2	1	11479166	11537584	N	.	N	N	-0.302630439	29.30485617	4.17E-05	74.4	.	.
PTCHD3	10	27398187	27414368	N	.	N	N	1.083434648	93.78364299	6.38E-11	93.2	DM?	.
PTCHD4	6	47878028	48068689	N	.	N	N	-1.838949534	2.101059212	0.002760598	60.7	.	.
PTCRA	6	42915989	42925835	N	.	N	Y	0.331374701	72.39104011	0.011395153	54.4	.	.
PTDSS1	8	96261715	96336995	N	Viable	N	Y	-0.17787558	36.8640389	0.857749192	19.6	.	Lenz-Majewski hyperostotic dwarfism, 151050 (3)
PTDSS2	11	448268	491399	N	.	N	N	-0.590544433	17.03999537	0.000109483	71.6	.	.
PTER	10	16436943	16513745	N	.	N	N	0.173002985	62.75973838	2.39E-10	92.3	.	.
PTGDR	14	52267713	52276724	N	.	N	Y	0.37190874	74.50946345	4.02E-05	74.5	DFP	{Asthma, susceptibility to, 1}, 607277 (3)
PTGDR2	11	60850940	60855971	N	.	N	Y	.	.	0.184110369	39.2	.	.
PTGDS	9	136977505	136985435	N	.	N	Y	-0.046649065	46.09017769	0.008870389	55.4	DP	.
PTGER1	19	14472466	14475362	N	.	N	Y	.	.	0.255749329	36.9	.	.
PTGER2	14	52314305	52328606	N	.	N	Y	-0.358905118	26.34137871	0.105022888	42.8	DFP	{Asthma, aspirin-induced, susceptibility to}, 208550 (3)
PTGER3	1	70852353	71047808	N	.	N	Y	0.226480797	66.06471031	0.787642829	22	.	.
PTGES	9	129738331	129753047	N	.	N	Y	.	.	0.624659347	26.8	.	.
PTGES2	9	128120693	128128462	N	.	N	Y	-0.15536658	38.37471783	2.07E-05	76.1	DP	.
PTGES3L	17	42968088	42980433	N	.	N	N	-0.0579797	45.26827574	0.024744074	50.5	.	.
PTGES3L-AARSD1	17	42950526	42980528	N	.	N	N	0.402072395	75.92753372	2.57E-08	87.9	.	.
PTGFR	1	78303884	78539749	N	.	N	Y	0.064133998	54.51756671	0.760040675	22.8	.	.
PTGFRN	1	116910057	116990358	N	.	N	N	0.016700113	50.79585576	0.638859233	26.4	.	.
PTGIS	20	49503874	49568146	N	.	N	Y	0.885150795	90.83174162	2.42E-05	75.7	DM	Hypertension, essential, 145500 (3)
PTGR1	9	111549722	111599855	N	Viable	N	Y	0.025662211	51.48463275	0.044277116	47.7	.	.
PTGR2	14	73851844	73886827	N	.	N	N	0.168219607	62.41824391	7.20E-07	83.1	.	.
PTH	11	13492055	13496181	N	.	N	Y	-0.066439705	44.63737917	0.270149119	36.5	DM	Hypoparathyroidism, autosomal dominant, 146200 (3); Hypoparathyroidism, autosomal recessive, 146200 (3)
PTH2	19	49422414	49423441	N	.	N	Y	0.539553608	82.02812988	0.522952192	29.4	.	.
PTH2R	2	208359714	208854503	N	.	N	N	0.312035841	71.21027956	1.32E-15	97.2	DM?	.
PTK2B	8	27311482	27459391	N	.	N	Y	-1.717782873	2.390461307	0.984520871	11	.	.
PTK6	20	63528001	63537370	N	.	N	Y	0.777232305	88.74225849	1.18E-07	85.9	.	.
PTN	7	137227341	137343865	N	.	N	Y	-0.081445868	43.46240667	0.289147235	36	.	.
PTOV1	19	49850735	49860744	N	.	N	N	-0.511685065	19.76037507	0.358456527	34	.	.
PTP4A1	6	63521761	63583587	N	.	N	N	-0.194949121	35.83376744	0.889900786	18.2	.	.
PTP4A2	1	31906421	31944856	N	.	N	Y	-0.013918082	48.39381837	0.760772901	22.8	.	.
PTPDC1	9	94030794	94109856	N	Viable	N	Y	0.735238353	87.74671529	0.002095722	61.7	.	.
PTPN1	20	50510321	50585241	N	.	N	Y	-0.248273713	32.55773572	0.697644969	24.7	DP	{Insulin resistance, susceptibility to}, 125853 (3)
PTPN13	4	86594315	86815171	N	.	N	Y	1.103211085	93.97464838	5.06E-10	91.7	DP	.
PTPN18	2	130356007	130375409	N	.	N	N	0.250903275	67.50593274	6.52E-07	83.3	.	.
PTPN20	10	46911396	47002488	N	.	N	N	.	.	.	.	.	.
PTPN21	14	88465778	88554733	N	.	N	N	-1.336689741	4.4336401	2.36E-07	84.9	DP	.
PTPN22	1	113813811	113871759	N	.	N	Y	0.435912819	77.6928865	3.08E-16	97.5	DM	{Diabetes, type 1, susceptibility to}, 222100 (3); {Rheumatoid arthritis, susceptibility to}, 180300 (3); {Systemic lupus erythematosus susceptibility to}, 152700 (3)
PTPN3	9	109375466	109498313	N	.	N	Y	-0.576050113	17.47988655	0.000188228	70	.	.
PTPN4	2	119759631	119983818	N	.	N	Y	-0.447832968	22.39393413	0.999997516	2	.	.
PTPN5	11	18727928	18792721	N	.	N	N	0.180657188	63.23435782	0.000777688	65.6	.	.
PTPN7	1	202147013	202161588	N	.	N	Y	0.144904459	6.06E+01	2.57E-07	84.8	.	.
PTPRA	20	2864184	3039076	N	.	N	Y	-1.204876245	5.52758002	0.999976744	2.9	.	.
PTPRCAP	11	67435510	67438067	N	.	N	Y	0.565887443	82.91948834	0.770195972	22.6	FP	.
PTPRD	9	8314246	10612723	N	.	N	Y	-3.681409638	0.353070556	0.999999982	0.9	DM	.
PTPRE	10	127907061	128085855	N	.	N	Y	-0.686979096	14.30225155	0.010010042	54.9	.	.
PTPRF	1	43525187	43623666	N	.	N	Y	-3.47851728	0.399374891	0.999998379	1.9	DM	?Breasts and/or nipples, aplasia or hypoplasia of, 2, 616001 (3)
PTPRG	3	61561569	62297613	N	.	N	Y	-1.439854822	3.733287029	0.004176573	58.9	.	.
PTPRH	19	55181248	55209506	N	.	N	N	1.421651412	96.49823465	5.10E-29	99.6	.	.
PTPRK	6	127968779	128520674	N	.	N	N	-1.562911438	2.986629623	0.980388546	11.7	DM?	.
PTPRM	18	7566782	8406861	N	.	N	Y	-2.004799084	1.632227817	0.999958214	3.2	FTV	.
PTPRN	2	219289623	219309648	N	.	N	Y	-0.607975376	16.5190716	0.021748201	51.2	.	.
PTPRN2	7	157539056	158587788	N	.	N	Y	0.907183475	91.22532847	0.016557153	52.6	.	.
PTPRO	12	15322397	15597399	N	.	N	Y	-1.550761648	3.079238294	0.30462609	35.6	DM	Nephrotic syndrome, type 6, 614196 (3)
PTPRQ	12	80402178	80680234	N	.	N	Y	.	.	.	.	DM	Deafness, autosomal recessive 84A, 613391 (3)
PTPRR	12	70638073	70920843	N	.	N	Y	0.221999681	65.72900388	0.000430476	67.5	.	.
PTPRT	20	42072752	43189970	N	.	N	Y	-1.364803992	4.196330381	0.999998893	1.7	DM?	.
PTPRU	1	29236516	29326813	N	.	N	N	-1.496090285	3.386004515	0.990698956	9.8	.	.
PTPRZ1	7	121873089	122062036	N	.	N	Y	-1.219033498	5.394455056	0.994707963	8.5	.	{H. pylori infection, susceptibility to}, 600263 (1)
PTRH1	9	127692978	127724873	N	.	N	N	0.150343606	61.02332581	0.001586335	62.9	.	.
PTRHD1	2	24789734	24793382	N	.	N	N	-0.320586962	28.25722058	9.18E-06	78.3	.	.
PTTG1	5	160421822	160428744	N	.	N	Y	-0.275568538	30.94287203	0.169726364	39.7	.	.
PTTG1IP	21	44849585	44873903	N	.	N	N	0.170939673	62.57452104	0.266254067	36.6	DP	.
PTTG2	4	37960435	37961125	N	.	N	N	0.438331876	77.80285929	0.001731611	62.4	.	.
PTX3	3	157436789	157443628	N	.	N	Y	0.341747043	72.9698443	0.0129819	53.9	.	.
PTX4	16	1485886	1488981	N	.	N	N	3.349721474	99.65271749	1.78E-12	95	.	.
PUF60	8	143816344	143829859	N	.	N	N	-0.768862541	12.2243445	0.849324855	19.9	.	Verheij syndrome, 615583 (3)
PUM1	1	30931506	31065991	N	.	N	Y	-1.477754114	3.472825143	0.999998855	1.8	.	.
PUM2	2	20248691	20352234	N	.	N	Y	-1.888756662	1.927417955	0.999922864	3.6	.	.
PURB	7	44876293	44885361	N	.	N	N	-0.395617806	24.63390635	0.605935033	27.3	.	.
PURG	8	30995802	31033715	N	.	N	N	-0.454685281	22.09295595	0.934741137	15.9	.	.
PUS1	12	131929200	131945896	N	.	N	N	-0.299685249	29.47849742	0.019988423	51.7	DM	Mitochondrial myopathy and sideroblastic anemia 1, 600462 (3)
PUS10	2	60940222	61018259	N	.	N	N	-1.026698372	7.518666435	5.27E-10	91.7	.	.
PUS3	11	125893485	125903221	N	.	N	N	0.342853172	73.02193668	1.09E-05	77.8	.	.
PUS7	7	105439661	105522267	N	.	N	N	-1.130793918	6.245297216	2.17E-05	76	.	.
PUS7L	12	43718993	43758817	N	.	N	Y	1.784042864	98.14782659	1.57E-06	81.8	.	.
PUSL1	1	1308567	1311677	N	.	N	N	0.321150679	71.84696417	6.59E-12	94.5	.	.
PVALB	22	36800684	36819479	N	.	N	Y	0.070529515	54.92272964	0.067870192	45.2	.	.
PVR	19	44643798	44663583	N	.	N	Y	0.824973219	89.63940499	5.51E-07	83.6	DP	.
PVRIG	7	100218241	100221490	N	.	N	N	0.518145495	81.19465185	0.001001892	64.7	.	.
PVRL1	11	119623408	119729084	N	.	N	Y	-0.085622968	43.1498524	0.503155896	29.9	DM	Cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3); Orofacial cleft 7, 225060 (3)
PVRL2	19	44846175	44889228	N	.	N	Y	0.662769054	86.01030271	0.531937435	29.1	.	.
PVRL3	3	111070071	111275563	N	.	N	Y	-0.326978896	27.91572611	0.73366099	23.6	DM	.
PVRL4	1	161070995	161089599	N	.	N	N	-0.057675878	45.29142791	0.439337893	31.7	DM	Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3)
PWP1	12	107685732	107713167	N	.	N	N	-0.264083901	31.62007293	1.85E-05	76.5	.	.
PWP2	21	44107290	44131181	N	.	N	N	1.097652248	93.91676796	0.875422848	18.8	.	.
PWWP2A	5	160061801	160119423	N	.	N	N	-0.615925383	16.32227817	0.920215651	16.7	DM?	.
PWWP2B	10	132397168	132417863	N	.	N	N	0.351464982	73.46761591	0.716153887	24.2	.	.
PXDC1	6	3722614	3752026	N	Viable	N	Y	0.020878273	51.13735023	0.550017217	28.6	.	.
PXDN	2	1631887	1744852	N	.	N	N	-1.375053224	4.115297795	2.04E-05	76.2	DM	Corneal opacification and other ocular anomalies, 269400 (3)
PXDNL	8	51319578	51809445	N	.	N	N	1.375663319	96.26092493	1.94E-27	99.5	.	.
PXK	3	58332880	58426126	N	.	N	N	-0.164631207	37.74960931	0.932144256	16	.	.
PXMP2	12	132687606	132704991	N	.	N	Y	0.415822269	76.63946287	0.028894308	49.9	.	.
PXMP4	20	33702754	33720319	N	.	N	N	0.385809542	75.19824044	0.604956427	27.3	.	.
PXT1	6	36390551	36442889	N	.	N	N	0.017051112	50.83058401	1.32E-05	77.3	.	.
PXYLP1	3	141228726	141294906	N	.	N	N	.	.	.	.	.	.
PYCARD	16	31201485	31203450	N	.	N	Y	-0.078575026	43.76338485	0.016503554	52.7	.	.
PYCR1	17	81932384	81942412	N	Viable	N	Y	-0.387003268	25.10852579	0.000359029	68.1	DM	Cutis laxa, autosomal recessive, type IIB, 612940 (3); Cutis laxa, autosomal recessive, type IIIB, 614438 (3)
PYCR2	1	225919877	225924340	N	.	N	N	-0.686326345	14.33119176	0.005062942	58.1	.	Leukodystrophy, hypomyelinating, 10, 616420 (3)
PYCRL	8	143603913	143609773	N	.	N	N	0.957169041	92.14562713	0.017128414	52.4	DP	.
PYDC1	16	31215962	31217359	N	.	N	N	0.047063497	53.15737686	0.465269918	31	.	.
PYDC2	3	191461163	191461456	N	.	N	N	.	.	0.022170522	51.1	.	.
PYGB	20	25248069	25298014	N	.	N	N	-0.949322941	8.734155235	4.76E-07	83.8	.	.
PYGL	14	50857891	50944736	N	.	N	N	-0.87537728	10.07698096	1.31E-09	90.9	DM	Glycogen storage disease VI, 232700 (3)
PYGM	11	64746389	64760297	N	.	N	N	-0.113571418	41.22822249	2.62E-08	87.8	DM	McArdle disease, 232600 (3)
PYGO1	15	55538890	55588947	N	.	N	N	0.105475995	57.64310934	0.956651522	14.2	.	.
PYHIN1	1	158930796	158977054	N	.	N	N	0.615836151	8.46E+01	0.000917068	65.1	.	.
PYROXD2	10	98383565	98415184	N	.	N	N	1.020369156	93.0254095	8.99E-08	86.2	FTV	.
PYURF	4	88520985	88523813	N	.	N	N	.	.	.	.	.	.
PYY	17	43952738	44004469	N	.	N	Y	0.124007879	59.04381548	0.054416635	46.5	DFP	.
PZP	12	9148840	9208370	N	.	N	Y	0.318409619	71.64438271	1.35E-21	99	DM?	.
QARS	3	49095932	49105101	N	.	N	N	-0.985207551	8.120622793	8.79E-08	86.3	.	Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 (3)
QPCT	2	37344574	37373322	N	.	N	N	0.137401468	60.01041848	1.87E-08	88.2	.	.
QPCTL	19	45692483	45703989	N	.	N	N	0.272455663	68.8256063	0.00026154	69	.	.
QPRT	16	29679008	29698699	N	.	N	N	0.547202136	82.32910806	0.593365506	27.6	.	.
QRFP	9	130892702	130896812	N	.	N	N	1.113793511	94.09619726	0.007623349	56.2	.	.
QRFPR	4	121329312	121381059	N	.	N	Y	1.7219365	97.96839729	1.87E-12	95	.	.
QRICH1	3	49029707	49094363	N	.	N	N	-0.920691275	9.214562713	0.996069748	7.9	.	.
QRICH2	17	76274049	76307680	N	.	N	N	0.450932536	78.38745153	1.22E-18	98.4	.	.
QRSL1	6	106629578	106668417	N	.	N	N	-0.120570168	40.6899346	8.78E-05	72.3	.	.
QSER1	11	32893178	32993316	N	.	N	N	-0.679870475	14.49904497	0.999935659	3.4	.	.
QSOX1	1	180154834	180204030	N	.	N	N	0.172349506	62.67870579	6.78E-05	73	.	.
QSOX2	9	136206333	136245841	N	.	N	N	-0.715079795	13.53244197	0.007830613	56.1	.	.
QTRT1	19	10701430	10713437	N	.	N	N	-0.780040126	12.00439891	0.00022325	69.4	.	.
QTRTD1	3	114005833	114088422	N	.	N	N	-0.213476698	34.71088731	2.19E-05	76	.	.
R3HCC1	8	23270120	23296279	N	.	N	N	.	.	.	.	.	.
R3HCC1L	10	98134624	98244897	N	.	N	N	1.60967978	97.54008219	2.88E-05	75.3	.	.
R3HDM1	2	135531455	135725270	N	.	N	N	-0.927903167	9.08143775	0.00602514	57.2	.	.
R3HDM2	12	57253762	57431005	N	.	N	N	-0.43856779	22.82224923	0.995928589	8	.	.
R3HDM4	19	896503	913245	N	.	N	N	-0.065330609	44.75314001	0.019345311	51.9	.	.
R3HDML	20	44336986	44351235	N	.	N	N	0.693589967	86.75117208	0.002996175	60.3	.	.
RAB10	2	26034107	26137454	N	.	N	N	-0.082402837	43.40452625	0.944404791	15.2	DM	.
RAB11A	15	65726054	65891991	N	.	N	N	-0.142427542	39.22555999	0.983220857	11.2	.	.
RAB11B	19	8389981	8404434	N	.	N	N	-0.321544247	28.21670429	0.664363643	25.7	.	.
RAB11FIP1	8	37858618	37899467	N	.	N	N	0.952376215	92.04144238	2.11E-05	76.1	.	.
RAB11FIP2	10	118004916	118046603	N	.	N	N	-0.356991058	26.48029172	0.910707841	17.3	.	.
RAB11FIP3	16	425619	523011	N	.	N	N	-0.306231452	29.11385078	0.996242513	7.9	.	.
RAB11FIP4	17	31391624	31538217	N	.	N	N	-0.652484268	15.30937084	0.993663613	9	.	.
RAB11FIP5	2	73073382	73156721	N	.	N	Y	-0.067897817	44.53898246	0.002675916	60.8	DM	.
RAB12	18	8609445	8639381	N	.	N	N	-0.086078072	43.11512415	0.718356947	24.1	.	.
RAB13	1	153981617	153986358	N	.	N	N	0.178442775	63.08386873	0.570125705	28.2	.	.
RAB14	9	121178137	121223014	N	.	N	N	0.053609874	53.60305609	0.973482565	12.6	.	.
RAB15	14	64945814	64972776	N	.	N	Y	0.346381025	73.21294206	5.21E-06	79.5	.	.
RAB17	2	237574322	237601614	N	.	N	N	0.326740798	72.14794235	0.00739028	56.4	.	.
RAB19	7	140404043	140426250	N	Viable	N	Y	0.645701223	85.52410719	4.08E-05	74.5	.	.
RAB1A	2	65070701	65130106	N	.	N	N	0.023597424	51.32256758	0.602945641	27.4	.	.
RAB1B	11	66268533	66277492	N	.	N	N	0.04897698	53.33680616	0.751684325	23.1	.	.
RAB20	13	110523066	110561733	N	Viable	N	Y	-0.205169667	35.16235458	0.697708788	24.7	.	.
RAB21	12	71754874	71800285	N	.	N	N	0.314455675	71.33761648	0.882341696	18.5	.	.
RAB22A	20	58309696	58367507	N	.	N	N	0.366978017	74.20848527	0.685129848	25	.	.
RAB24	5	177301198	177303744	N	Viable	N	Y	-0.306538083	29.06754645	0.725032093	23.9	.	.
RAB25	1	156061160	156070514	N	.	N	Y	0.402728595	75.95647392	9.31E-06	78.2	.	.
RAB26	16	2140803	2154165	N	.	N	N	0.379262743	74.89726226	3.56E-06	80.2	.	.
RAB27A	15	55202966	55319113	N	.	N	N	-0.000674037	49.38936158	8.23E-05	72.5	DM	Griscelli syndrome, type 2, 607624 (3)
RAB27B	18	54717860	54895516	N	Viable	N	Y	0.211324798	65.16756381	0.6873001	24.9	.	.
RAB28	4	13361354	13484365	N	.	N	N	-0.114176312	41.19928228	0.000997907	64.7	DM	Cone-rod dystrophy 18, 615374 (3)
RAB29	1	205767986	205775460	N	.	N	Y	.	.	.	.	.	.
RAB2A	8	60516857	60623627	N	.	N	N	0.159610371	61.7121028	0.970735513	12.9	DM?	.
RAB2B	14	21459020	21476973	N	.	N	N	-0.374065873	25.71627019	0.000147822	70.7	.	.
RAB30	11	82973133	83071923	N	.	N	N	-0.0579797	45.26827574	0.95912396	14	.	.
RAB31	18	9708165	9862551	N	.	N	N	0.062069705	54.29762111	0.054033484	46.5	.	.
RAB33A	X	130171649	130184870	N	.	N	N	-0.027967398	47.43300341	0.713538247	24.2	.	.
RAB33B	4	139453232	139476609	N	.	N	N	0.104368575	57.54471262	0.902062769	17.7	DM	Smith-McCort dysplasia 2, 615222 (3)
RAB36	22	23145326	23164350	N	Viable	N	Y	0.521971277	81.33356486	1.44E-05	77.1	.	.
RAB37	17	74670578	74747335	N	.	N	N	0.406554426	76.19378364	8.23E-05	72.5	.	.
RAB38	11	88113242	88175467	N	.	N	N	0.804229247	89.21687793	0.004717618	58.4	.	.
RAB39A	11	107928503	107963482	N	Viable	N	Y	-0.366562778	26.04618857	0.00185649	62.1	.	.
RAB39B	X	155258241	155264589	N	.	N	N	-0.059893552	45.10042253	0.715196297	24.2	DM	Mental retardation, X-linked 72, 300271 (3); ?Waisman syndrome, 311510 (3)
RAB3A	19	18196784	18204074	N	.	N	Y	-0.411581382	23.84673265	0.870967555	19	.	.
RAB3B	1	51907956	51990764	N	.	N	Y	-0.160151469	38.02743532	0.15644302	40.3	.	.
RAB3C	5	58582221	58859394	N	.	N	Y	-0.228635876	33.80216473	0.015496264	53	.	.
RAB3D	19	11322046	11346270	N	.	N	Y	0.387722289	75.27927302	0.001426284	63.2	.	.
RAB3GAP1	2	135052265	135176394	N	.	N	Y	-0.953281124	8.6878509	3.66E-05	74.7	DM	Warburg micro syndrome 1, 600118 (3)
RAB3GAP2	1	220148293	220272454	N	.	N	N	-0.827351086	11.00306766	0.998736483	6.2	DM	Martsolf syndrome, 212720 (3); Warburg micro syndrome 2, 614225 (3)
RAB3IL1	11	61897301	61920269	N	.	N	N	0.057587761	53.92139839	0.000894541	65.2	.	.
RAB3IP	12	69738681	69823204	N	Viable	N	Y	-0.64402392	15.57562077	0.016752943	52.6	.	.
RAB40A	X	103499750	103519489	N	.	N	N	0.44679135	78.19644614	0.06660882	45.4	.	.
RAB40AL	X	102937250	102938962	N	.	N	N	0.767667839	88.51073682	0.306490452	35.6	DM	.
RAB40B	17	82654973	82698728	N	.	N	N	-0.260408668	31.84580656	0.00383601	59.2	.	.
RAB41	X	70282093	70285002	N	.	N	N	0.080902701	55.81408809	0.012182153	54.1	.	.
RAB42	1	28592200	28595443	N	.	N	N	0.160566904	61.79892342	0.002554984	61	.	.
RAB43	3	129087569	129122801	N	Viable	N	Y	0.071486219	54.9863981	0.341400603	34.5	.	.
RAB44	6	36697851	36733183	N	.	N	N	.	.	.	.	.	.
RAB4A	1	229271062	229305894	N	.	N	N	0.133424212	59.69786421	0.081107904	44.4	.	.
RAB4B	19	40778216	40796944	N	.	N	N	-0.190163599	36.15789778	0.940202326	15.6	.	.
RAB4B-EGLN2	19	40778242	40808198	N	.	N	N	.	.	.	.	.	.
RAB5A	3	19947079	19985175	N	Viable	N	Y	-0.260562407	31.82844244	0.774403049	22.5	.	.
RAB5B	12	55973913	55996683	N	.	N	N	0.140927298	60.26509232	0.215698854	38.2	.	.
RAB6A	11	73675638	73761137	N	.	N	N	-0.224004258	34.09156682	0.87776086	18.7	.	.
RAB6B	3	133824239	133895836	N	.	N	N	-0.321544247	28.21670429	0.893311149	18	.	.
RAB6C	2	129979664	129982738	N	.	N	N	1.594211366	97.4590496	0.377324685	33.4	.	.
RAB7A	3	128726122	128814796	N	.	N	Y	-0.224961447	34.00474619	0.922269116	16.6	DM	.
RAB7B	1	205976740	206003461	N	.	N	N	.	.	.	.	.	.
RAB8A	19	16111629	16134234	N	.	N	Y	-0.155519548	38.35156567	0.962128955	13.7	.	.
RAB8B	15	63189469	63267782	N	.	N	Y	-0.065482771	44.7241998	0.049515248	47.1	.	.
RAB9A	X	13689121	13710506	N	.	N	N	0.001088113	49.55142675	0.779010977	22.3	.	.
RAB9B	X	103822322	103832228	N	.	N	N	0.024554204	51.41517625	0.618182541	27	.	.
RABAC1	19	41956681	41959390	N	.	N	N	-0.215544031	34.54882213	0.07654707	44.7	.	.
RABEP1	17	5282265	5385812	N	.	N	N	-1.228344669	5.330786595	0.982815073	11.3	.	.
RABEP2	16	28904421	28936526	N	.	N	N	-0.2423802	32.90501823	0.002736644	60.7	.	.
RABEPK	9	125200542	125234158	N	.	N	N	0.68991226	86.66435145	4.19E-06	79.9	.	.
RABGAP1	9	122940833	123104866	N	.	N	N	-0.875521131	10.07119292	0.9999998	1.3	.	.
RABGAP1L	1	174159410	174995308	N	.	N	N	-1.065025053	7.003530706	0.089172714	43.8	.	.
RABGGTB	1	75786197	75795079	N	.	N	N	-0.455642657	22.04665162	0.449469062	31.4	.	.
RABIF	1	202878957	202889135	N	.	N	N	0.276939876	69.10922035	0.025290257	50.5	.	.
RABL2A	2	113627229	113643396	N	Viable	N	Y	0.57434681	83.2320426	0.940339178	15.5	.	.
RABL2B	22	50767501	50783663	N	.	N	N	0.491810698	80.14701626	0.765589454	22.7	.	.
RABL3	3	120686681	120742993	N	.	N	N	-0.379654309	25.47317243	0.136652215	41.3	.	.
RABL6	9	136807922	136957733	N	Viable	N	Y	0.895525526	91.03432309	0.970513088	13	.	.
RAC2	22	37225261	37244448	N	.	N	Y	-0.202452202	35.31863171	0.87309232	18.9	DM	Neutrophil immunodeficiency syndrome, 608203 (3)
RAC3	17	82031624	82034204	N	.	N	Y	-0.410624002	23.91618915	0.035442249	48.9	.	.
RAD1	5	34905264	34918989	N	.	N	N	-0.234224724	33.42015396	0.000186646	70	.	.
RAD18	3	8775402	8963773	N	.	N	Y	-0.080184792	43.61289576	5.20E-05	73.7	.	.
RAD21L1	20	1226056	1296421	N	Viable	N	Y	.	.	.	.	DM?	.
RAD23A	19	12945855	12953642	N	.	N	Y	-0.047454069	46.03229727	0.039256536	48.4	.	.
RAD51AP1	12	4538798	4560048	N	.	N	N	0.207648094	64.90710193	0.022353284	51.1	.	.
RAD51AP2	2	17510584	17518439	N	.	N	N	0.320805326	71.80065984	1.70E-18	98.3	.	.
RAD51L3-RFFL	17	35011349	35121493	N	.	N	N	.	.	2.24E-05	75.9	.	.
RAD52	12	912077	990053	N	.	N	N	0.047365707	53.22683336	2.38E-07	84.9	DFP	.
RAD54B	8	94371960	94475109	N	.	N	Y	0.452833322	78.45111999	8.51E-10	91.2	DM	Lymphoma, non-Hodgkin, somatic, 605027 (3); Colon cancer, somatic, 114500 (3)
RAD54L	1	46247688	46278473	N	.	N	Y	-0.12968435	40.12849453	2.74E-13	95.7	DM	{Breast cancer, invasive ductal}, 114480 (3); Lymphoma, non-Hodgkin, somatic, 605027 (3); Adenocarcinoma, colonic, somatic (3)
RADIL	7	4797055	4883719	N	.	N	N	0.97567468	92.38872489	1.31E-12	95.2	.	.
RAET1E	6	149883375	149898102	N	.	N	N	1.070681405	93.63894195	1.86E-05	76.4	.	.
RAET1G	6	149916878	149923121	N	.	N	N	1.558598886	97.26804422	0.001470729	63.1	.	.
RAET1L	6	150018334	150025532	N	.	N	N	1.706785413	97.927881	0.00020021	69.8	DP	.
RAG1	11	36510709	36593156	N	.	N	Y	-0.700884049	13.89130057	0.001898001	62.1	DM	Severe combined immunodeficiency, B cell-negative, 601457 (3); Omenn syndrome, 603554 (3); Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3); Combined cellular and humoral immune defects with granulomas, 233650 (3)
RAG2	11	36575574	36598279	N	.	N	Y	0.319387303	71.73699138	0.010519312	54.7	DM	Severe combined immunodeficiency, B cell-negative, 601457 (3); Omenn syndrome, 603554 (3); Combined cellular and humoral immune defects with granulomas, 233650 (3)
RAI14	5	34656237	34832627	N	.	N	N	-0.439224242	22.7759449	0.487656416	30.3	.	.
RAI2	X	17800049	17861337	N	.	N	N	0.324977012	72.03796955	0.298853667	35.8	.	.
RALB	2	120240064	120294713	N	.	N	Y	-0.178028729	36.84667477	0.193989191	38.9	.	.
RALBP1	18	9475009	9538116	N	.	N	N	-0.771579694	12.14909996	0.670181325	25.5	.	.
RALGAPA1	14	35538352	35809304	N	.	N	N	-1.248419974	5.13399317	0.999999978	0.9	DM	.
RALGAPA2	20	20389552	20712488	N	.	N	Y	0.254709338	67.73745442	8.49E-06	78.5	.	.
RALGDS	9	133097720	133149334	N	.	N	Y	-1.044282205	7.281356717	0.296706348	35.8	DM	.
RALGPS1	9	126914774	127223166	N	.	N	N	-0.161912646	37.86537015	0.999856881	4.1	.	.
RALGPS2	1	178725147	178921841	N	.	N	Y	-0.432978714	23.05377091	0.922194824	16.6	.	.
RALY	20	33993646	34108308	N	.	N	N	0.428107326	77.30508769	0.55457384	28.5	.	.
RALYL	8	84182787	84921844	N	.	N	N	0.143797178	60.51397812	0.029690036	49.7	.	.
RAMP1	2	237858893	237912114	N	Viable	N	Y	0.028381319	51.66985009	0.057792824	46.2	.	.
RAMP3	7	45157791	45186302	N	.	N	Y	0.519911514	81.24674423	0.009528751	55.1	.	.
RAN	12	130871879	130877678	N	.	N	N	-0.202452202	35.31863171	0.955937968	14.3	.	.
RANBP1	22	20115938	20127357	N	.	N	Y	-0.20053791	35.44596863	0.336215104	34.7	.	.
RANBP10	16	67723066	67806652	N	.	N	Y	-0.537065264	18.73010361	0.951824229	14.6	.	.
RANBP17	5	170861870	171300015	N	.	N	N	0.060109127	54.08925161	8.61E-36	99.8	.	.
RANBP3	19	5916139	5978142	N	.	N	N	-1.085771193	6.708340568	0.999905044	3.7	.	.
RANBP3L	5	36248434	36302114	N	.	N	N	0.188965718	63.72634138	1.13E-10	92.9	.	.
RANBP6	9	6011043	6015625	N	.	N	N	-0.817118947	11.26352955	0.04174251	48.1	DM?	.
RANGRF	17	8288497	8290092	N	.	N	N	-0.099170261	42.1543092	0.02076333	51.4	DM	.
RAP1GAP	1	21596215	21669363	N	.	N	N	-0.629822514	15.88817503	0.974156915	12.5	.	.
RAP1GAP2	17	2777056	3037739	N	.	N	N	-0.714271963	13.55559414	0.955938553	14.3	.	.
RAP1GDS1	4	98261384	98443861	N	.	N	N	-0.42451861	23.36632517	0.824878145	20.8	.	Lymphocytic leukemia, acute T-cell (3)
RAP2A	13	97434222	97469128	N	.	N	N	-0.141470476	39.31238062	0.717339657	24.1	.	.
RAP2B	3	153162270	153167173	N	.	N	N	-0.194949121	35.83376744	0.275476508	36.3	.	.
RAP2C	X	132203024	132219480	N	.	N	N	0.016094318	50.71482318	0.212765647	38.4	.	.
RAPGEF3	12	47734367	47771040	N	.	N	Y	0.138662337	60.06829889	2.10E-15	97.1	.	.
RAPGEF4	2	172735274	173052893	N	.	N	Y	-0.863237248	10.32586676	0.95722585	14.2	DM?	.
RAPGEF5	7	22118238	22357144	N	.	N	N	0.222804723	65.81003646	0.997815953	7.1	.	.
RAPGEF6	5	131423921	131635236	N	.	N	Y	-1.903412197	1.85217341	0.998026273	6.9	.	.
RAPGEFL1	17	40177010	40195656	N	.	N	Y	-0.137489868	39.60757076	0.874145904	18.9	.	.
RAPH1	2	203394345	203535410	N	.	N	Y	-0.591871326	16.96475082	0.957851233	14.1	.	.
RARB	3	25174332	25597932	N	.	N	Y	-0.800790903	11.55871969	0.999317519	5.5	.	Microphthalmia, syndromic 12, 615524 (3)
RARG	12	53210567	53232980	N	.	N	Y	-0.45181342	22.19714071	0.970063074	13	.	.
RARRES1	3	158696892	158732696	N	.	N	N	0.110914976	58.05984835	8.41E-07	82.8	.	.
RARRES2	7	150338317	150341674	N	.	N	Y	0.282530296	69.45650287	0.002954453	60.4	.	.
RARRES3	11	63536809	63546462	N	.	N	N	-0.131096333	39.98379348	0.000504117	67	.	.
RASA2	3	141487047	141615342	N	.	N	N	-1.287420596	4.786710656	5.32E-17	97.8	.	.
RASA4	7	102573807	102616757	N	.	N	Y	.	.	0.661336762	25.7	.	.
RASA4B	7	102482445	102517781	N	.	N	N	.	.	0.575646327	28.1	.	.
RASAL1	12	113098819	113136239	N	.	N	N	0.423778171	77.06198993	4.86E-08	87	.	.
RASAL2	1	178094141	178484147	N	.	N	Y	-0.935269758	8.942524744	0.226449659	37.8	.	.
RASAL3	19	15451624	15464571	N	.	N	N	0.135639287	59.89465764	8.35E-07	82.8	.	.
RASD1	17	17494437	17496395	N	Viable	N	Y	-0.258648061	31.95577936	0.06071602	45.9	.	.
RASD2	22	35540868	35554001	N	.	N	Y	-0.113219363	41.24558662	0.716620457	24.2	.	.
RASEF	9	82979585	83063177	N	.	N	N	-0.083860557	43.30034149	3.27E-05	75	.	.
RASGEF1A	10	43194535	43266919	N	.	N	N	-0.246359639	32.67349656	0.910096302	17.3	.	.
RASGEF1B	4	81426393	82044244	N	.	N	N	-0.705964203	13.78132778	0.488529662	30.3	DM?	.
RASGEF1C	5	180100791	180209153	N	.	N	N	-0.638435006	15.72032182	0.0033181	59.9	.	.
RASGRF1	15	78959947	79090773	N	.	N	Y	-2.274304906	1.186548591	0.999614037	4.9	.	.
RASGRF2	5	80960672	81230156	N	.	N	Y	-1.2365219	5.243965966	0.998743354	6.2	.	.
RASGRP1	15	38488103	38565575	N	.	N	Y	-0.541697655	18.51594606	0.18967697	39	.	.
RASGRP2	11	64726911	64745456	N	.	N	Y	-0.200232492	35.49227296	0.995280465	8.3	DM?	?Bleeding disorder, platelet-type, 18, 615888 (3)
RASGRP3	2	33436324	33564750	N	.	N	Y	-0.30431789	29.24697575	0.110282852	42.6	DP	.
RASGRP4	19	38409051	38426305	N	.	N	Y	1.120633958	94.20617005	0.050117752	47	.	.
RASL10A	22	29312933	29319679	N	.	N	N	.	.	0.678377624	25.2	.	.
RASL10B	17	35731649	35743521	N	.	N	Y	-0.018550615	48.01759565	0.036792615	48.7	.	.
RASL11A	13	27270327	27273690	N	.	N	N	0.036841134	52.32389883	0.007689742	56.1	.	.
RASL11B	4	52862290	52866835	N	.	N	N	-0.347727532	26.88545465	0.290784778	36	.	.
RASL12	15	65053337	65076690	N	.	N	N	0.053760719	53.61463217	0.006968222	56.6	.	.
RASSF1	3	50329782	50340980	N	.	N	Y	0.180505995	63.22856977	4.86E-08	87	DFP	Lung cancer, 211980 (2)
RASSF10	11	13009577	13012106	N	.	N	N	.	.	.	.	.	.
RASSF2	20	4780023	4823645	N	.	N	Y	-0.034361771	46.9757481	0.000156232	70.5	.	.
RASSF3	12	64610513	64697567	N	.	N	N	0.167262974	62.32563524	0.001597862	62.8	.	.
RASSF4	10	44959407	44995891	N	.	N	N	2.176093563	98.81923945	2.05E-11	93.9	.	.
RASSF5	1	206507530	206589283	N	.	N	Y	0.250753302	67.48856862	0.248711066	37.1	.	.
RASSF6	4	73571550	73620631	N	.	N	N	0.697415576	86.86114487	1.00E-17	98.1	.	.
RASSF7	11	560404	564021	N	.	N	N	0.976957029	92.43502923	3.45E-06	80.3	.	.
RAVER1	19	10316212	10333640	N	.	N	Y	-0.039799513	46.63425363	0.982340267	11.4	.	.
RAVER2	1	64745095	64833232	N	.	N	N	-0.934741508	8.954100828	1.86E-06	81.4	.	.
RAX2	19	3769089	3772221	N	.	N	N	.	.	0.510132429	29.7	DM	?Macular degeneration, age-related, 6, 613757 (3); Cone-rod dystrophy 11, 610381 (3); ?Spinal muscular atrophy, distal, autosomal recessive, 2, 605726 (3)
RBAK	7	5045821	5069488	N	.	N	N	-0.549050942	18.24390809	0.009676899	55.1	.	.
RBAK-RBAKDN	7	4983718	5073221	N	.	N	N	0.350059136	73.36343115	0.724663171	23.9	.	.
RBBP4	1	32651142	32686211	N	.	N	N	-0.321544247	28.21670429	0.989804589	10	.	.
RBBP5	1	205086142	205122015	N	.	N	N	-0.666689105	14.82317532	0.995054147	8.4	.	.
RBBP7	X	16839283	16870414	N	.	N	Y	-0.163022609	37.81906581	0.983294258	11.2	.	.
RBBP8NL	20	62410237	62427533	N	.	N	N	1.107389593	94.01516467	0.007488465	56.3	.	.
RBBP9	20	18486540	18497243	N	.	N	N	0.452382104	78.42796782	0.103910134	42.9	.	.
RBCK1	20	407498	430966	N	.	N	Y	-0.53897936	18.62591885	0.212094448	38.4	DM	Polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3)
RBFA	18	80034358	80046397	N	.	N	N	0.544480852	82.23071135	0.000358068	68.1	.	.
RBFOX1	16	6019094	7713338	N	.	N	N	-1.236805257	5.232389883	0.935961018	15.8	DM	.
RBFOX2	22	35738736	36028425	N	.	N	N	-0.283874745	30.4277363	0.993206875	9.1	.	.
RBFOX3	17	79089345	79516148	N	.	N	Y	.	.	.	.	.	.
RBKS	2	27781364	27891098	N	.	N	N	0.504095467	80.61584766	1.93E-05	76.3	.	.
RBM10	X	47144869	47186813	N	.	N	N	-0.571863524	17.58407131	0.999912181	3.7	DM	TARP syndrome, 311900 (3)
RBM11	21	14216130	14228372	N	.	N	N	0.135337478	59.85414134	2.91E-05	75.3	.	.
RBM12	20	35648925	35664956	N	.	N	N	-1.50872789	3.304971928	0.474673921	30.7	.	.
RBM12B	8	93729356	93741017	N	.	N	N	-1.02354245	7.553394687	0.120424619	42.1	.	.
RBM14	11	66616582	66627347	N	.	N	N	-1.104456529	6.49997106	0.98790765	10.4	.	.
RBM14-RBM4	11	66616626	66646469	N	.	N	N	-0.980873791	8.219019506	0.918848169	16.8	.	.
RBM15B	3	51391268	51397908	N	.	N	N	-1.97609561	1.713260404	0.998677124	6.3	.	.
RBM17	10	6088987	6117457	N	.	N	N	-0.652640244	15.29200671	0.998602405	6.4	.	.
RBM18	9	122237624	122264839	N	.	N	N	-0.216501186	34.48515367	0.038009873	48.6	.	.
RBM20	10	110644397	110839469	N	.	N	N	.	.	.	.	DM	Cardiomyopathy, dilated, 1DD, 613172 (3)
RBM22	5	150690794	150701107	N	.	N	N	-0.167654501	37.52966371	0.995946456	8	.	.
RBM23	14	22893206	22919184	N	.	N	N	0.451723315	78.41639173	4.63E-08	87.1	.	.
RBM24	6	17281346	17293875	N	.	N	N	0.110914976	58.05984835	0.196222354	38.8	.	.
RBM25	14	73058436	73123898	N	.	N	N	-1.24909392	5.122417086	0.999999967	0.9	.	.
RBM26	13	79311824	79406477	N	.	N	N	-1.149479717	6.077444001	0.999996998	2.1	.	.
RBM27	5	146203600	146289132	N	.	N	N	-1.181264419	5.788041905	0.999999942	1	.	.
RBM28	7	128297685	128343908	N	.	N	N	0.156386559	61.4921572	2.05E-09	90.5	DM	?Alopecia, neurologic defects, and endocrinopathy syndrome, 612079 (3)
RBM3	X	48574449	48579066	N	.	N	Y	0.076119241	55.36840887	0.700968681	24.6	.	.
RBM33	7	155644451	155781485	N	.	N	N	-0.853822044	10.49950802	0.999967325	3.1	.	.
RBM34	1	235131183	235161457	N	.	N	N	0.494828508	80.28592927	7.95E-09	89.2	.	.
RBM38	20	57391407	57409333	N	.	N	Y	0.203821715	64.60033571	0.859282996	19.5	.	.
RBM4	11	66638617	66666682	N	.	N	Y	-0.928349113	9.075649708	0.943908957	15.3	.	.
RBM41	X	107064420	107118823	N	.	N	N	-0.203255573	35.26075129	0.229027555	37.7	.	.
RBM42	19	35629030	35637686	N	.	N	N	-0.519341466	19.49991318	0.759889531	22.9	.	.
RBM43	2	151247940	151261879	N	.	N	N	0.691677544	86.71065579	0.05186677	46.8	DM?	.
RBM44	2	237798389	237842808	N	.	N	Y	-0.034058751	46.98732419	0.01414988	53.5	.	.
RBM45	2	178112424	178139011	N	.	N	N	-0.36640817	26.06934074	0.000125349	71.2	.	.
RBM46	4	154781213	154828813	N	.	N	N	-0.488371748	20.65173352	0.020362858	51.6	.	.
RBM47	4	40423267	40630875	N	.	N	N	-0.645785708	15.51195231	0.958532355	14.1	.	.
RBM48	7	92528773	92538005	N	.	N	N	0.125114793	59.14221219	5.12E-05	73.8	.	.
RBM4B	11	66664998	66677921	N	.	N	Y	-0.456445049	22.02349945	0.442246702	31.6	.	.
RBM5	3	50088908	50119021	N	.	N	N	-1.255640729	5.105052961	0.99999947	1.5	.	.
RBM6	3	49940007	50100045	N	.	N	N	-0.852866351	10.5110841	0.999999964	0.9	.	.
RBM7	11	114400030	114414203	N	.	N	N	-0.333678613	27.54529143	0.769935289	22.6	.	.
RBM8A	1	145917714	145927678	N	.	N	N	-0.149930626	38.75094056	0.962186023	13.7	DM	Thrombocytopenia-absent radius syndrome, 274000 (3)
RBMS2	12	56521929	56596196	N	.	N	N	-0.979916263	8.242171673	0.002914798	60.5	.	.
RBMS3	3	29280982	30010391	N	.	N	N	-0.495874865	20.37969555	0.741403241	23.4	.	.
RBMX	X	136848004	136880764	N	Viable	N	Y	1.966744026	98.54141344	0.948299697	14.9	.	.
RBMX2	X	130401969	130413343	N	.	N	N	0.29385898	70.12212768	0.772803906	22.5	.	.
RBMXL1	1	88979456	88992960	N	.	N	N	1.017344696	92.97331713	0.119596956	42.1	.	.
RBMXL2	11	7089027	7090900	N	.	N	N	0.111065501	58.08300052	0.677816821	25.2	DM?	.
RBMXL3	X	115189427	115192868	N	.	N	N	.	.	.	.	.	.
RBMY1A1	Y	21511372	21549326	N	.	N	N	.	.	.	.	.	.
RBMY1B	Y	21511338	21549094	N	.	N	N	.	.	.	.	.	.
RBMY1D	Y	21880076	21894526	N	.	N	N	.	.	.	.	.	.
RBMY1E	Y	21880076	21918067	N	.	N	N	.	.	.	.	.	.
RBMY1F	Y	22168542	22182982	N	.	N	N	.	.	.	.	.	.
RBMY1J	Y	22308823	22417881	N	.	N	N	.	.	.	.	.	.
RBP1	3	139517434	139539829	N	.	N	Y	0.117461409	58.54604387	0.000490535	67.1	.	.
RBP2	3	139452884	139480747	N	.	N	Y	0.207498734	64.86658563	0.433554514	31.9	.	.
RBP3	10	47348371	47357875	N	.	N	Y	0.235870235	66.55669387	0.016654151	52.6	DM	?Retinitis pigmentosa 66, 615233 (3)
RBP4	10	93591687	93601744	N	Viable	N	Y	-0.092624171	42.6520808	0.578618956	28	DM	Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 (3); Microphthalmia, isolated, with coloboma 10, 616428 (3)
RBP5	12	7123684	7128942	N	.	N	N	0.397947105	75.72495225	0.00181921	62.3	.	.
RBP7	1	9997206	10016020	N	.	N	Y	0.358518573	73.84962667	0.408810206	32.5	.	.
RBPJL	20	45306851	45317824	N	Viable	N	Y	0.566184045	82.9426405	1.89E-11	94	.	.
RBPMS	8	30384479	30572261	N	.	N	N	-0.108587205	41.55814088	0.783171944	22.2	.	.
RBPMS2	15	64739892	64775587	N	.	N	N	-0.002587674	49.23887249	0.323534851	35	.	.
RCAN1	21	34513142	34615142	N	.	N	Y	0.12592113	59.20588065	0.557669158	28.5	.	.
RCAN2	6	46220736	46491972	N	.	N	Y	-0.26151962	31.75319789	0.430936968	31.9	.	.
RCAN3	1	24502351	24541040	N	.	N	N	0.379262743	74.89726226	0.003206422	60	.	.
RCBTB1	13	49531946	49585583	N	.	N	N	-0.921648201	9.191410546	0.000217674	69.6	.	[Beta-glycopyranoside tasting] (3); {Alcohol dependence, susceptibility to}, 103780 (3)
RCBTB2	13	48488959	48533256	N	.	N	N	-0.259299737	31.92683915	7.22E-09	89.3	.	.
RCC1	1	28505943	28539300	N	.	N	N	-0.750983967	12.57162702	0.193943931	38.9	.	.
RCC2	1	17406760	17439724	N	Viable	N	Y	-0.837350249	10.81785032	0.787633127	22.1	.	.
RCCD1	15	90954870	90963125	N	.	N	N	0.090319161	56.46813683	1.63E-05	76.8	.	.
RCHY1	4	75479037	75514764	N	.	N	Y	-0.290574674	29.99363315	0.823377801	20.8	.	.
RCL1	9	4792869	4885917	N	.	N	N	0.068917845	54.82433293	0.948080583	15	.	.
RCN1	11	31812391	32105755	N	.	N	N	0.667255193	86.13763964	0.016338564	52.7	.	.
RCN2	15	76931619	76954392	N	.	N	N	0.202865163	64.54245529	0.449457627	31.4	.	.
RCN3	19	49527618	49546962	N	.	N	N	0.570668188	83.09312959	1.78E-09	90.6	.	.
RCOR2	11	63911221	63916844	N	.	N	Y	-0.73230344	13.09255079	0.115753697	42.3	.	.
RCOR3	1	211258377	211316385	N	.	N	N	-0.316758145	28.47137813	0.672007746	25.5	.	.
RCSD1	1	167630093	167706249	N	.	N	N	0.014483413	50.59906234	0.10822184	42.7	.	.
RCVRN	17	9896320	9905621	N	.	N	Y	0.136294125	59.95253806	2.96E-07	84.6	.	.
RD3	1	211476522	211492917	N	.	N	N	0.568755737	83.01209701	0.097516227	43.3	DM	Leber congenital amaurosis 12, 610612 (3)
RD3L	14	103940426	103942308	N	.	N	N	.	.	.	.	.	.
RDH11	14	67676801	67695814	N	.	N	Y	-0.277328762	30.80974706	0.009665331	55.1	.	?Retinal dystrophy, juvenile cataracts, and short stature syndrome, 616108 (3)
RDH12	14	67701886	67734452	N	.	N	Y	0.163586571	62.05938531	4.71E-06	79.7	DM	Leber congenital amaurosis 13, 612712 (3)
RDH13	19	55039108	55071291	N	.	N	Y	0.569860199	83.0526133	5.35E-12	94.6	.	.
RDH14	2	18554723	18560680	N	.	N	N	0.088405766	56.3118597	0.232943493	37.6	.	.
RDH16	12	56951431	56959374	N	.	N	Y	0.445026606	78.09804943	8.60E-05	72.3	.	.
RDH5	12	55720367	55724705	N	.	N	Y	0.02757579	51.6293338	3.11E-06	80.5	DM	Fundus albipunctatus, 136880 (3)
RDH8	19	10013249	10022279	N	.	N	Y	-0.014571683	48.31278578	3.73E-05	74.7	.	.
RDM1	17	35918066	35930773	N	.	N	N	0.539698884	82.04549401	0.005030965	58.1	.	.
REC114	15	73443158	73560014	N	.	N	N	.	.	.	.	.	.
RECQL	12	21468911	21501669	N	.	N	Y	0.100038089	57.21479424	7.14E-13	95.4	.	.
RECQL5	17	75626845	75667189	N	.	N	Y	0.536641759	81.92973317	3.01E-07	84.5	.	.
REEP1	2	86213993	86338083	N	.	N	Y	0.140927298	60.26509232	0.938706616	15.7	DM	Spastic paraplegia 31, autosomal dominant, 610250 (3); ?Neuronopathy, distal hereditary motor, type VB, 614751 (3)
REEP2	5	138439017	138446969	N	.	N	N	-0.448139541	22.37657001	0.876388829	18.8	.	?Spastic paraplegia 72, autosomal recessive, 615625 (3); ?Spastic paraplegia 72, autosomal dominant, 615625 (3)
REEP3	10	63521363	63625123	N	.	N	N	-0.057022786	45.34352029	0.012981299	53.9	.	.
REEP4	8	22138020	22141951	N	.	N	N	0.465623125	79.12832089	0.175027611	39.5	.	.
REEP5	5	112876379	112922539	N	.	N	N	-0.002587674	49.23887249	0.062887596	45.7	.	.
REEP6	19	1490747	1497927	N	.	N	N	0.878309149	90.71019274	0.000463082	67.3	.	.
REG1A	2	79120362	79123419	N	.	N	Y	-0.268065472	31.35961104	0.008527628	55.6	.	.
REG1B	2	79085030	79088019	N	Viable	N	Y	0.339834225	72.85987151	0.001954167	62	.	.
REG3A	2	79157003	79159753	N	.	N	Y	0.211324798	65.16756381	0.001428607	63.2	.	.
REG3G	2	79025686	79028505	N	.	N	Y	0.841746956	90.04456792	2.18E-05	76	.	.
REG4	1	119794018	119811660	N	.	N	N	0.581850138	83.55617295	5.62E-05	73.6	.	.
REL	2	60881521	60931610	N	Viable	N	Y	-0.378543229	25.54262893	0.969516333	13	.	.
RELL1	4	37590800	37686376	N	.	N	N	0.168219607	62.41824391	0.883550395	18.4	.	.
RELL2	5	141636950	141641077	N	.	N	N	0.21515114	65.34120507	0.800132421	21.7	.	.
RELT	11	73376264	73397474	N	.	N	N	0.422667795	76.98674538	1.51E-05	77	.	.
REM1	20	31475293	31484905	N	.	N	N	0.791134341	89.00272038	1.68E-05	76.8	.	.
REM2	14	22883165	22887686	N	.	N	N	0.332331078	72.43734445	0.000502406	67	.	.
RENBP	X	153935263	153944691	N	.	N	Y	0.746113675	88.00138913	0.962622292	13.7	.	.
REP15	12	27696519	27697596	N	.	N	N	0.028381319	51.66985009	0.001398952	63.3	.	.
REPIN1	7	150368189	150374044	N	.	N	N	0.137401468	60.01041848	0.961996441	13.8	.	.
REPS1	6	138903493	138988261	N	.	N	N	-0.576343288	17.46831047	0.99936361	5.4	.	.
REPS2	X	16946691	17153280	N	.	N	N	-0.381414283	25.35741159	0.968427758	13.2	DM	.
RER1	1	2391775	2405444	N	.	N	N	-0.284028847	30.40458413	0.969239733	13.1	.	.
RERG	12	15107783	15348675	N	.	N	N	-0.047605945	46.02072119	0.001164957	64.1	.	.
RERGL	12	18080869	18320107	N	.	N	N	1.091281695	93.86467558	5.32E-09	89.5	.	.
RESP18	2	219327409	219333177	Y	Viable	N	Y	.	.	.	.	.	.
RETN	19	7669044	7670454	N	.	N	Y	-0.013918082	48.39381837	0.07400279	44.8	DM?	{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3); {Hypertension, insulin resistance-related, susceptibility to}, 125853 (3)
RETNLB	3	108743424	108757384	N	.	N	Y	0.412953559	76.48897378	0.009947457	54.9	.	.
RETSAT	2	85342088	85354620	N	.	N	N	1.324353091	95.94837067	2.05E-10	92.4	.	.
REXO1	19	1815246	1848463	N	.	N	N	0.565860143	82.89633617	0.567927564	28.3	.	.
REXO4	9	133406059	133418096	N	.	N	N	0.547350629	82.34068415	9.99E-06	78.1	.	.
RFC2	7	74231499	74254458	N	.	N	N	-0.489328961	20.62279331	4.04E-05	74.5	DM	.
RFC3	13	33818049	33966558	N	.	N	N	-0.381414283	25.35741159	0.00098446	64.8	.	.
RFC4	3	186789880	186807058	N	.	N	N	-0.008982334	48.74110089	9.67E-05	72	.	.
RFC5	12	118013588	118033130	N	.	N	N	-0.658228302	15.08363721	0.01471033	53.3	.	.
RFESD	5	95646754	95684773	N	.	N	N	0.04897698	53.33680616	0.000253688	69.1	.	.
RFFL	17	35005990	35089319	N	.	N	Y	0.397138302	75.69601204	0.379222205	33.3	.	.
RFPL1	22	29438583	29442455	N	.	N	N	1.051994066	93.37848006	0.00732601	56.4	.	.
RFPL2	22	32190435	32203477	N	.	N	N	1.706926614	97.93945708	7.38E-05	72.8	.	.
RFPL3	22	32354885	32361161	N	.	N	N	1.009841029	92.8864965	0.000158443	70.5	.	.
RFPL3S	22	32359906	32382052	N	.	N	N	.	.	0.415441822	32.4	.	.
RFPL4A	19	55759014	55763175	N	.	N	N	.	.	0.345800478	34.3	.	.
RFPL4AL1	19	55769141	55773179	N	.	N	N	.	.	0.348004808	34.3	.	.
RFPL4B	6	112347330	112351296	N	.	N	N	0.198231811	64.27620536	0.000430794	67.5	.	.
RFT1	3	53088483	53130462	N	.	N	N	0.17778674	63.04335243	3.17E-06	80.4	DM	Congenital disorder of glycosylation, type In, 612015 (3)
RFTN1	3	16313574	16514026	N	.	N	Y	-0.089449983	42.83729814	5.14E-12	94.6	.	.
RFTN2	2	197568224	197676045	N	.	N	N	-0.021117842	47.85553047	0.002076962	61.7	.	.
RFWD3	16	74621394	74666881	N	.	N	N	-0.952325474	8.693638942	0.525273499	29.3	.	.
RFX2	19	5993164	6199572	N	.	N	N	-0.28085205	30.59558951	0.989509333	10	DM?	.
RFX5	1	151340640	151347357	N	.	N	Y	-0.653288963	15.26885455	0.000136786	70.9	DM	Bare lymphocyte syndrome, type II, complementation group C, 209920 (3); Bare lymphocyte syndrome, type II, complementation group E, 209920 (3)
RFX8	2	101397361	101474703	N	.	N	N	.	.	0.379276472	33.3	DM?	.
RFXANK	19	19192229	19201869	N	.	N	N	-0.125354587	40.43526075	0.000671164	66.1	DM	MHC class II deficiency, complementation group B, 209920 (3)
RFXAP	13	36819224	36829104	N	.	N	N	.	.	0.439791637	31.7	DM	Bare lymphocyte syndrome, type II, complementation group D, 209920 (3)
RGAG1	X	110358816	110456334	N	.	N	N	0.948369538	91.98935	0.912655333	17.1	.	.
RGAG4	X	72127110	72131901	N	.	N	N	0.83998017	90.00405163	0.01519778	53.1	.	.
RGCC	13	41457559	41470882	N	Viable	N	Y	0.319090009	71.70805117	0.07039691	45	.	.
RGL1	1	183636085	183928531	N	.	N	N	-1.030375296	7.4723621	0.987846909	10.4	.	.
RGL2	6	33291654	33299324	N	.	N	N	-0.499398226	20.21184233	0.0747683	44.8	.	.
RGL3	19	11384341	11419342	N	.	N	N	1.069222261	93.61578978	4.36E-21	98.9	.	.
RGL4	22	23688136	23699176	N	.	N	N	2.016706273	98.59929386	2.33E-10	92.3	.	.
RGN	X	47078355	47093314	N	.	N	Y	0.438331876	77.80285929	0.041645338	48.1	.	.
RGPD1	2	86907953	87013981	N	.	N	N	.	.	.	.	.	.
RGPD2	2	87755955	87825952	N	.	N	N	.	.	.	.	.	.
RGPD3	2	106391290	106468376	N	.	N	N	2.910942336	99.46750014	.	.	.	.
RGPD4	2	107826937	107890841	N	.	N	N	.	.	.	.	.	.
RGPD5	2	109792758	109857695	N	.	N	N	.	.	.	.	.	.
RGPD6	2	110513812	110577185	N	.	N	N	.	.	0.401313701	32.7	.	.
RGR	10	84245053	84259960	N	.	N	Y	-0.024945118	47.60085663	1.56E-06	81.8	DM	.
RGS1	1	192575727	192580031	N	.	N	Y	-0.086078072	43.11512415	0.635710552	26.5	.	.
RGS11	16	268301	275980	N	.	N	Y	2.01000732	98.58192973	1.26E-09	91	.	.
RGS12	4	3293028	3439913	N	.	N	Y	-0.900110217	9.573421312	0.000560374	66.7	.	.
RGS13	1	192636138	192660306	N	.	N	Y	0.353884195	73.67019737	9.34E-05	72.1	.	.
RGS16	1	182598623	182604408	N	.	N	Y	0.44583509	78.14435377	0.009002649	55.3	.	.
RGS17	6	153004459	153131249	N	.	N	N	-0.034513598	46.96996006	0.38068417	33.3	.	.
RGS18	1	192158457	192185815	N	.	N	N	0.104368575	57.54471262	0.090828367	43.7	.	.
RGS19	20	64073181	64079988	N	.	N	N	-0.334635847	27.50477513	0.879309173	18.6	.	.
RGS2	1	192809039	192812283	N	.	N	Y	0.658795771	85.87717775	0.002945119	60.4	DM	Rieger syndrome, type 2 (2)
RGS20	8	53851808	53959303	N	.	N	N	0.078183267	55.57099033	0.016215258	52.7	.	.
RGS21	1	192316992	192367285	N	.	N	N	0.178442775	63.08386873	0.007405454	56.3	.	.
RGS22	8	99960936	100131268	N	.	N	N	0.216718658	65.44538982	1.19E-20	98.8	.	.
RGS3	9	113444731	113597743	N	.	N	N	0.772463095	88.61492157	9.68E-05	72	.	.
RGS5	1	163111121	163321791	N	Viable	N	Y	0.337921524	72.70938242	0.040499886	48.2	.	[Blood pressure regulation QTL], 145500 (2)
RGS6	14	71932439	72566529	N	.	N	Y	-0.236942655	33.25230075	0.801361183	21.6	FP	.
RGS7	1	240775514	241357230	N	.	N	Y	-0.989334973	8.028014123	0.781745873	22.2	DM	.
RGS7BP	5	64506257	64612312	N	.	N	Y	-0.252102165	32.32621404	0.978832468	12	.	.
RGS8	1	182641816	182684576	N	.	N	N	-0.132053341	39.94906523	0.520349598	29.4	.	.
RGS9	17	65137431	65227703	N	.	N	Y	0.786804029	88.91589975	2.04E-10	92.5	DM	Bradyopsia, 608415 (3)
RGS9BP	19	32675407	32678300	N	.	N	Y	.	.	0.037702874	48.6	DM	Bradyopsia, 608415 (3)
RGSL1	1	182450121	182560599	N	.	N	N	.	.	.	.	.	.
RHAG	6	49605158	49636839	N	.	N	Y	-0.055913898	45.41297679	0.340299251	34.5	DM	Anemia, hemolytic, Rh-null, regulator type, 268150 (3); Rh-mod syndrome (3)
RHBDD1	2	226835581	226999215	N	.	N	N	0.914059295	91.35266539	4.74E-09	89.6	.	.
RHBDD2	7	75842602	75888926	N	.	N	N	-0.465862421	21.6299126	0.646226807	26.1	.	.
RHBDD3	22	29259852	29268209	N	.	N	Y	0.896183914	91.04589917	2.04E-05	76.2	.	.
RHBDF2	17	76470891	76501790	N	Viable	N	Y	-0.045237653	46.19436245	0.000966721	64.9	DM	Tylosis with esophageal cancer, 148500 (3)
RHBDL2	1	38885807	38941799	N	Viable	N	Y	0.160716564	61.81628755	2.70E-06	80.7	.	.
RHBG	1	156369212	156385219	N	.	N	Y	.	.	3.73E-10	92	.	.
RHCE	1	25362249	25430192	N	.	N	N	1.874908574	98.35040806	0.861454126	19.5	DM	[Blood group, Rhesus], 111690 (3); Rh-null disease, amorph type (3)
RHCG	15	89471398	89496613	N	.	N	Y	-0.140208598	39.40498929	4.91E-06	79.6	.	.
RHD	1	25272393	25330445	N	.	N	Y	2.333874528	99.02182092	0.0060601	57.2	FP	[Rh-negative blood type] (3)
RHEBL1	12	49064685	49070025	N	.	N	Y	-0.118004239	40.88093998	3.29E-06	80.4	.	.
RHNO1	12	2876258	2889523	N	.	N	N	0.288268772	69.80378538	0.000558185	66.7	.	.
RHO	3	129528640	129535169	N	.	N	Y	-0.402009394	24.309776	0.000556528	66.7	DM	Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 (3); Night blindness, congenital stationary, autosomal dominant 1, 610445 (3); Retinitis punctata albescens, 136880 (3)
RHOA	3	49359145	49412998	N	.	N	N	-0.029881147	47.28251433	0.804697934	21.5	.	.
RHOB	2	20447074	20449445	N	.	N	Y	-0.193034849	35.95531632	0.245030977	37.2	DFP	.
RHOBTB1	10	60869438	61001440	N	.	N	N	-0.612902778	16.4090988	0.001838227	62.2	.	.
RHOBTB2	8	22987417	23020199	N	.	N	N	-0.938418657	8.884644325	0.508425068	29.7	.	.
RHOBTB3	5	95713522	95824383	N	.	N	Y	-0.231201301	33.65746368	0.000533732	66.9	.	.
RHOC	1	112701106	112707434	N	.	N	Y	0.291946181	70.03530706	0.586036085	27.8	.	.
RHOD	11	67056818	67072013	N	.	N	N	0.345424702	73.15506164	0.20323506	38.7	.	.
RHOF	12	121777754	121803403	N	.	N	Y	0.505861042	80.68530416	0.00520736	57.9	.	.
RHOG	11	3826978	3840983	N	.	N	Y	-0.20053791	35.44596863	0.600682842	27.4	DM	.
RHOH	4	40191053	40246967	N	.	N	Y	-0.185531789	36.42414771	0.123279463	41.9	DM	.
RHOJ	14	63204114	63293219	N	.	N	Y	-0.258648061	31.95577936	0.229657761	37.7	.	.
RHOQ	2	46541806	46583121	N	.	N	N	-0.199580796	35.52700122	0.304654917	35.6	.	.
RHOT2	16	668086	674174	N	.	N	Y	-0.33116381	27.67841639	9.27E-12	94.3	.	.
RHOU	1	228735077	228746669	N	.	N	N	-0.115133273	41.12403774	0.531957244	29.1	.	.
RHOV	15	40872214	40874289	N	.	N	N	-0.042016662	46.43167217	0.590311999	27.7	.	.
RHOXF1	X	120109053	120115937	N	.	N	N	0.285399426	69.6822365	0.826599974	20.7	.	.
RHOXF2	X	120158561	120164039	N	.	N	N	.	.	0.592958782	27.6	.	.
RHOXF2B	X	120072264	120077705	N	.	N	N	.	.	0.576875871	28.1	.	.
RHPN1	8	143368855	143384220	N	Viable	N	Y	0.683365529	86.5196504	1.30E-06	82.2	.	.
RHPN2	19	32978593	33064888	N	.	N	Y	1.537346078	97.15228338	0.000336631	68.3	DP	.
RIBC1	X	53422690	53431120	N	.	N	N	0.105325255	57.63153325	0.966259507	13.4	.	.
RIBC2	22	45413691	45432496	N	.	N	N	.	.	3.91E-07	84.1	.	.
RIC1	9	5629025	5776557	N	.	N	Y	.	.	.	.	.	.
RIC3	11	8106093	8169055	N	.	N	N	0.446939746	78.20223418	0.012261351	54.1	.	.
RIIAD1	1	151710433	151729805	N	.	N	N	.	.	.	.	.	.
RILP	17	1646145	1650077	N	Viable	N	Y	.	.	0.00067086	66.1	.	.
RILPL1	12	123470054	123533718	N	Viable	N	Y	-0.000674037	49.38936158	0.066019566	45.4	.	.
RILPL2	12	123410683	123436717	N	Viable	N	Y	-0.057022786	45.34352029	0.060872187	45.9	.	.
RIMBP2	12	130396137	130716281	N	.	N	N	0.038556443	52.41071945	0.292582176	35.9	.	.
RIMBP3	22	18605815	18611919	N	.	N	N	.	.	.	.	.	.
RIMBP3B	22	21383374	21389478	N	.	N	N	.	.	.	.	.	.
RIMBP3C	22	21545357	21551461	N	.	N	Y	.	.	.	.	.	.
RIMKLA	1	42380795	42422578	N	.	N	N	-0.067244365	44.5852868	0.087395327	44	.	.
RIMKLB	12	8681600	8783095	N	Viable	N	Y	-0.294249011	29.74474735	0.911252634	17.2	.	.
RIMS2	8	103500748	104256094	N	.	N	Y	-0.14137419	39.31816866	0.999998399	1.9	.	.
RIMS3	1	40620679	40665657	N	Viable	N	Y	-0.095342599	42.403195	0.007251108	56.4	DM	.
RIMS4	20	44751808	44810338	N	.	N	N	-0.314041164	28.6045031	0.952765435	14.5	.	.
RIN1	11	66330242	66336840	N	.	N	Y	0.583104234	83.61984141	0.000202047	69.8	.	.
RIN2	20	19886521	20002457	N	.	N	N	1.320682022	95.91364241	0.008295585	55.7	DM	Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3)
RIN3	14	92513774	92688994	N	.	N	N	0.10976023	57.96145164	0.00027683	68.9	.	.
RING1	6	33208495	33212722	N	.	N	Y	-0.105716346	41.73178214	0.915792422	17	.	.
RINL	19	38867834	38878279	N	.	N	N	-0.049367758	45.85286797	0.030110536	49.6	.	.
RIOK1	6	7389496	7418037	N	.	N	N	0.122395494	58.93963072	8.14E-07	82.9	.	.
RIOK2	5	97160867	97183260	N	.	N	N	0.617749602	84.70799329	0.001140112	64.2	.	.
RIOK3	18	23452823	23486603	N	.	N	N	-0.425475634	23.3142328	0.000146775	70.7	.	.
RIPK2	8	89757747	89791063	N	.	N	Y	-0.124397678	40.48156509	0.554263286	28.6	DM?	.
RIPK3	14	24336021	24340045	N	Viable	N	Y	-0.22178469	34.23626787	2.24E-06	81.1	FTV	.
RIPPLY1	X	106900063	106903335	N	.	N	Y	0.426047805	77.14302252	0.007805819	56.1	.	.
RIT1	1	155897808	155911404	N	.	N	Y	-0.284028847	30.40458413	0.666809792	25.6	DM	Noonan syndrome 8, 615355 (3)
RIT2	18	42743227	43115691	N	.	N	N	-0.245556279	32.71401285	0.060048528	46	.	.
RITA1	12	113185526	113192368	N	.	N	N	0.328653775	72.25212711	.	.	.	.
RLBP1	15	89209869	89221751	N	Viable	N	Y	0.034121997	52.16762169	5.41E-05	73.7	DM	Fundus albipunctatus, 136880 (3); Retinitis punctata albescens, 136880 (3); Newfoundland rod-cone dystrophy, 607476 (3); Bothnia retinal dystrophy, 607475 (3)
RLN1	9	5334969	5339873	Y	Viable	N	Y	0.60627228	84.34334665	0.000528757	66.9	.	.
RLN2	9	5299868	5304969	N	.	N	N	0.781718739	88.82907912	5.04E-05	73.9	.	.
RLN3	19	14028148	14031042	N	Viable	N	Y	0.42987242	77.39769636	9.78E-05	72	.	.
RLTPR	16	67644919	67657569	N	.	N	Y	-0.657493547	15.1241535	0.022353307	51.1	.	.
RMDN1	8	86468257	86514357	N	.	N	N	0.312691067	71.2565839	8.91E-07	82.7	.	.
RMDN2	2	37923187	38067142	N	.	N	N	0.445330226	78.11541356	5.21E-16	97.4	FTV	.
RMDN3	15	40735884	40755851	N	.	N	Y	0.192792725	64.00416739	0.023779598	50.7	.	.
RMI2	16	11249619	11351762	N	.	N	N	.	.	0.024604188	50.6	.	.
RMND1	6	151404763	151452181	N	.	N	N	0.460989431	78.87943509	7.66E-07	83	DM	Combined oxidative phosphorylation deficiency 11, 614922 (3)
RMND5A	2	86720173	86778041	N	.	N	N	-0.251145013	32.40145859	0.964712069	13.5	.	.
RMND5B	5	178130996	178150565	N	.	N	N	-0.256580891	32.10626845	6.92E-08	86.6	.	.
RNASE1	14	20801228	20803278	N	.	N	N	0.45892919	78.75788621	0.161588977	40.1	.	.
RNASE10	14	20505537	20511169	N	.	N	Y	0.546245901	82.28280373	0.013059519	53.8	.	.
RNASE11	14	20583559	20609884	N	.	N	N	0.597812859	84.04236847	0.000992587	64.7	.	.
RNASE12	14	20590193	20590823	N	.	N	N	0.330418352	72.31579557	0.006838299	56.7	.	.
RNASE13	14	21032820	21034785	N	.	N	N	0.565887443	82.91948834	0.001156915	64.2	.	.
RNASE2	14	20955452	20956436	N	.	N	N	0.375437469	74.69468079	0.038022749	48.6	.	.
RNASE3	14	20891399	20892348	N	.	N	N	0.453338311	78.48584824	0.000178636	70.2	DFP	.
RNASE4	14	20684100	20701215	N	.	N	N	0.360431074	73.9364473	0.007017134	56.6	.	.
RNASE6	14	20781051	20782467	N	.	N	N	0.436419446	77.71025062	5.43E-08	86.9	.	.
RNASE7	14	21042226	21044234	N	.	N	N	0.807909588	89.28633443	0.280449166	36.2	.	.
RNASE8	14	21057822	21058455	N	.	N	N	0.465476352	79.10516872	0.005169102	58	.	.
RNASE9	14	20556093	20560931	N	.	N	N	0.970264824	92.31926839	1.67E-05	76.8	.	.
RNASEH2A	19	12806580	12813638	N	.	N	N	0.26862913	68.62881287	0.050079134	47	DM	Aicardi-Goutieres syndrome 4, 610333 (3)
RNASEK	17	7012417	7014532	N	.	N	N	0.381028261	74.95514268	0.339227906	34.6	.	.
RNASEK-C17orf49	17	7012635	7017520	N	.	N	N	.	.	.	.	.	.
RNASEL	1	182573634	182589256	N	.	N	Y	0.127331492	59.26376107	8.98E-09	89	DM	Prostate cancer 1, 601518 (3)
RNASET2	6	166929504	166957191	N	Viable	N	Y	0.38485322	75.1519361	0.009480406	55.2	DM	Leukoencephalopathy, cystic, without megalencephaly, 612951 (3)
RND1	12	48857145	48865898	N	.	N	N	0.13438084	59.79626092	0.965631678	13.4	.	.
RND2	17	43025241	43032036	N	.	N	N	-0.01759377	48.06389998	0.000138854	70.9	.	.
RND3	2	150468195	150539011	Y	Viable	N	Y	-0.266151109	31.49273601	0.940812851	15.5	.	.
RNF10	12	120533480	120577594	N	Viable	N	Y	-1.327665697	4.497308561	0.502963048	29.9	.	.
RNF103	2	86603393	86623866	N	.	N	Y	-0.432826756	23.07113504	0.832672501	20.5	.	.
RNF103-CHMP3	2	86505668	86721122	N	.	N	N	-0.312126643	28.79550848	0.036245866	48.8	.	.
RNF11	1	51236271	51273455	N	.	N	N	-0.073942787	44.13960757	0.420327239	32.3	.	.
RNF112	17	19411125	19417276	N	.	N	N	-0.085774145	43.14406436	0.00365674	59.4	.	.
RNF113A	X	119870475	119871827	N	.	N	N	0.118418051	58.60971233	0.822115117	20.9	FTV	?Trichothiodystrophy 5, nonphotosensitive, 300953 (3)
RNF113B	13	98175785	98177265	N	.	N	N	0.247076574	67.28019911	0.135168377	41.3	.	.
RNF114	20	49936336	49953892	N	.	N	N	0.110914976	58.05984835	0.0170046	52.5	DM	.
RNF115	1	145738868	145824077	N	.	N	N	-0.114176312	41.19928228	0.080634744	44.4	.	.
RNF121	11	71928701	71997597	N	.	N	N	-0.387157394	25.09116166	0.972894709	12.7	.	.
RNF122	8	33547755	33567125	N	.	N	N	-0.08703502	43.03409157	0.076386253	44.7	.	.
RNF123	3	49689499	49721529	N	.	N	N	-0.617109799	16.26439775	0.969714694	13	.	.
RNF125	18	32018372	32073213	N	.	N	N	0.51527665	81.07889101	0.080624845	44.4	.	Tenorio syndrome, 616260 (3)
RNF126	19	647526	663277	N	.	N	N	.	.	0.774554603	22.5	.	.
RNF128	X	106693794	106796993	N	.	N	Y	0.535064702	81.88342884	0.768185327	22.7	DM?	.
RNF13	3	149812708	149962139	N	Viable	N	Y	-0.247316664	32.6098281	0.001985489	61.9	.	.
RNF130	5	179911651	180072118	N	.	N	N	-0.2707828	31.23227412	0.864935169	19.3	.	.
RNF133	7	122697712	122699156	N	.	N	N	0.31747395	71.6154425	0.015150794	53.1	.	.
RNF135	17	30968785	30999911	N	.	N	N	0.061263744	54.22237657	0.003075166	60.3	DM	Macrocephaly, macrosomia, facial dysmorphism syndrome, 614192 (3)
RNF138	18	32091855	32131561	N	.	N	N	0.116504775	58.48816345	0.738927914	23.5	.	.
RNF139	8	124474738	124487914	N	.	N	N	-0.959165893	8.572090062	0.060873833	45.9	DM	Renal cell carcinoma, 144700 (3)
RNF14	5	141958328	141990291	N	.	N	N	-0.2153906	34.56618626	0.00753477	56.3	.	.
RNF141	11	10511678	10541230	N	.	N	N	0.248840271	67.3901719	0.000702153	66	.	.
RNF144A	2	6917392	7068286	N	.	N	N	-0.195752553	35.7874631	0.988258457	10.3	.	.
RNF144B	6	18387350	18468874	N	Viable	N	Y	-0.233267662	33.50118655	0.027637716	50.1	.	.
RNF145	5	159157409	159210053	N	.	N	N	-0.074595468	44.09909128	0.663621979	25.7	.	.
RNF146	6	127266610	127288567	N	.	N	N	0.031251654	51.92452393	0.445213313	31.6	.	.
RNF148	7	122701664	122702967	N	.	N	N	-0.159998829	38.04479944	0.000117584	71.4	.	.
RNF149	2	101271219	101308701	N	.	N	N	0.277088785	69.12079643	0.000502224	67	.	.
RNF150	4	140859807	141212877	N	.	N	N	-0.13094377	40.00115761	0.013689752	53.6	.	.
RNF151	16	1966823	1968975	N	.	N	N	0.709407966	87.09845459	3.80E-07	84.2	.	.
RNF152	18	61808063	61894247	N	.	N	N	-0.220175737	34.30572437	0.007053846	56.6	.	.
RNF157	17	76142453	76240373	N	Viable	N	Y	0.147926643	60.87862476	0.000108023	71.6	.	.
RNF165	18	46326809	46463140	N	.	N	N	-0.324261194	28.05463912	0.971099075	12.9	.	.
RNF166	16	88696495	88706421	N	.	N	N	0.420456796	76.83046825	0.551620567	28.6	.	.
RNF167	17	4940008	4945222	N	.	N	N	-0.212519778	34.79191989	0.129414192	41.6	.	.
RNF168	3	196468783	196503768	N	.	N	N	0.251054778	67.51172078	1.37E-10	92.7	DM	RIDDLE syndrome, 611943 (3)
RNF169	11	74748868	74842413	N	.	N	Y	-0.520145081	19.48254905	0.084139282	44.2	.	.
RNF17	13	24764152	24879921	N	.	N	Y	-0.041109088	46.47218846	0.999999987	0.8	.	.
RNF170	8	42849637	42897290	N	.	N	N	-0.002587674	49.23887249	0.648136151	26.1	DM	Ataxia, sensory, 1, autosomal dominant, 608984 (3)
RNF175	4	153710125	153760235	N	.	N	N	0.7751713	88.66701395	6.79E-10	91.4	.	.
RNF180	5	64165844	64372869	N	.	N	N	-0.357948071	26.40504717	5.17E-05	73.8	.	.
RNF181	2	85595725	85597613	N	.	N	N	0.519911514	81.24674423	3.14E-09	90.1	.	.
RNF182	6	13924446	13980302	N	.	N	N	-0.226721694	33.94107773	0.012068777	54.2	.	.
RNF183	9	113297093	113303376	N	Viable	N	Y	0.954301666	92.07617063	0.037593501	48.6	.	.
RNF185	22	31160183	31207019	N	.	N	N	-0.108587205	41.55814088	0.679395061	25.2	.	.
RNF186	1	19814029	19815278	N	.	N	N	0.958125007	92.15141518	0.015478324	53	.	.
RNF187	1	228487061	228495766	N	.	N	N	.	.	.	.	.	.
RNF19A	8	100257059	100410015	N	.	N	N	-1.378427172	4.074781501	0.027076096	50.2	.	.
RNF19B	1	32936445	32964685	N	.	N	Y	-0.743480655	12.77999653	0.625353365	26.8	.	.
RNF207	1	6205475	6221299	N	.	N	N	0.968646498	92.30769231	5.19E-06	79.5	.	.
RNF208	9	137220247	137221581	N	.	N	N	0.281722177	69.41019853	0.603529096	27.4	.	.
RNF212	4	1056250	1113562	N	.	N	Y	0.8136448	89.39051919	0.125225584	41.8	.	Recombination rate QTL 1, 612042 (3)
RNF212B	14	23185316	23273477	N	.	N	N	.	.	.	.	.	.
RNF213	17	80260866	80398786	N	.	N	Y	-1.387567376	4.028477166	1.68E-29	99.7	DM?	{Moyamoya disease 2, susceptibility to}, 607151 (3)
RNF214	11	117232625	117286445	N	.	N	N	-1.138297747	6.164264629	0.830018245	20.6	.	.
RNF215	22	30368811	30421771	N	.	N	N	0.213237933	65.26017248	0.000386646	67.9	.	.
RNF216	7	5620047	5781739	N	Viable	N	Y	-1.465346464	3.542281646	0.409334345	32.5	DM	Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3)
RNF217	6	124962545	125092633	N	.	N	N	0.151300234	61.07541819	0.029983663	49.6	.	.
RNF219	13	78614291	78659179	N	.	N	N	-0.618493002	16.2296695	2.49E-05	75.7	.	.
RNF220	1	44405194	44651724	N	.	N	N	-0.81755696	11.25195346	0.999277879	5.6	.	.
RNF222	17	8390704	8397826	N	.	N	N	.	.	.	.	.	.
RNF223	1	1070966	1074307	N	.	N	N	.	.	.	.	.	.
RNF224	9	137227271	137229638	N	.	N	N	.	.	.	.	.	.
RNF225	19	58396090	58397079	N	.	N	N	.	.	.	.	.	.
RNF24	20	3927309	4015582	N	.	N	N	0.024554204	51.41517625	0.898356865	17.8	.	.
RNF25	2	218663864	218672411	N	Viable	N	Y	0.661812332	85.96978642	0.829695266	20.6	.	.
RNF26	11	119334527	119337313	N	.	N	N	0.082010267	55.87196851	0.677950757	25.2	.	.
RNF32	7	156640281	156677130	N	.	N	N	0.423473783	77.05041384	1.60E-08	88.4	DM?	.
RNF34	12	121400041	121430623	N	.	N	N	-0.505292472	19.99768478	0.190893162	39	.	.
RNF39	6	30070266	30075887	N	.	N	N	.	.	0.006661207	56.8	.	.
RNF40	16	30761745	30776307	N	.	N	N	-1.521826789	3.235515425	0.999994909	2.2	.	.
RNF41	12	56202175	56221933	N	.	N	N	-0.17611458	36.99137582	0.856083577	19.7	.	.
RNF43	17	58352500	58417595	N	.	N	N	0.615031039	84.59802049	0.324237752	35	.	.
RNF44	5	176526697	176538025	N	.	N	N	0.186095639	63.59900446	0.567929658	28.3	.	.
RNF5	6	32178354	32180793	N	.	N	Y	-0.139556392	39.44550559	0.002990424	60.3	.	.
RNF6	13	26132115	26222493	N	.	N	N	0.119676499	58.71968513	0.170343293	39.7	.	Esophageal carcinoma, somatic, 133239 (3)
RNF8	6	37353972	37394738	N	.	N	N	-0.354273411	26.59605256	0.995892885	8	.	.
RNFT1	17	59952240	59964761	N	.	N	N	0.422517211	76.9751693	0.011205655	54.4	.	.
RNFT2	12	116738178	116853631	N	.	N	N	0.325784353	72.08427389	0.79070997	22	.	.
RNGTT	6	88610272	88963721	N	.	N	N	-0.857945637	10.40689935	0.763456431	22.8	.	.
RNH1	11	494512	507300	N	.	N	N	-0.228330922	33.84268102	0.000213432	69.6	.	.
RNLS	10	88273864	88584530	N	.	N	Y	0.149537247	60.98280952	1.04E-06	82.5	DM	.
RNMT	18	13726660	13764558	N	.	N	N	0.263995952	68.32783469	0.080932806	44.4	.	.
RNPC3	1	103525691	103555239	N	.	N	N	.	.	0.525297994	29.3	.	.
RNPEP	1	201982372	202006147	N	.	N	N	0.155277776	61.41112462	4.81E-11	93.4	.	.
RNPEPL1	2	240565804	240581372	N	.	N	N	.	.	0.027901617	50.1	.	.
RNPS1	16	2253116	2268412	N	.	N	N	-0.590699388	17.02263124	0.948502987	14.9	.	.
ROGDI	16	4796968	4802950	N	.	N	N	0.3596227	73.91329513	3.13E-12	94.8	DM	Kohlschutter-Tonz syndrome, 226750 (3)
ROM1	11	62611722	62615120	N	.	N	Y	0.356902595	73.80332234	0.00326883	60	DM	Retinitis pigmentosa 7, digenic, 608133 (3)
ROMO1	20	35699272	35700984	N	.	N	N	0.159610371	61.7121028	0.726806954	23.8	.	.
ROPN1	3	123968521	123992178	N	.	N	N	0.26384649	68.31047057	0.008185352	55.8	.	.
ROPN1B	3	125969144	125983454	N	.	N	N	0.414865996	76.60473462	5.67E-05	73.6	.	.
ROPN1L	5	10441524	10472029	N	Viable	N	Y	0.311734573	71.17555131	0.001635436	62.7	DP	.
RORB	9	74497365	74693177	N	.	N	Y	-0.529716584	19.0195057	0.998551701	6.5	.	.
RORC	1	151806071	151831872	N	.	N	Y	-0.014571683	48.31278578	0.997845135	7.1	.	.
ROS1	6	117288300	117425855	N	.	N	Y	-0.198778306	35.54436534	1.78E-44	100	DM?	.
RP1	8	54616067	54630834	N	.	N	Y	0.112450993	58.16403311	3.68E-10	92	DM	.
RP11-1012A1.4	14	67659820	67690367	N	.	N	N	.	.	.	.	.	.
RP11-101E3.5	9	128941478	128957021	N	.	N	N	.	.	.	.	.	.
RP11-1021N1.1	16	15395754	15515348	N	.	N	N	.	.	.	.	.	.
RP11-1035H13.3	16	18788063	18801519	N	.	N	N	.	.	.	.	.	.
RP11-106M3.2	15	72284727	72375981	N	.	N	N	.	.	.	.	.	.
RP11-106M3.5	15	72266746	72319946	N	.	N	N	.	.	.	.	.	.
RP11-108K14.8	10	133390834	133420495	N	.	N	N	.	.	0.029365312	49.8	.	.
RP11-108O10.8	11	111786286	111879425	N	.	N	N	.	.	.	.	.	.
RP11-1099M24.7	17	7925931	7930622	N	.	N	N	.	.	.	.	.	.
RP11-111H13.1	2	99141485	99322741	N	.	N	N	.	.	.	.	.	.
RP11-111M22.2	11	76381313	76414619	N	.	N	N	.	.	.	.	.	.
RP11-11N7.5	1	244845167	244855497	N	.	N	N	.	.	.	.	.	.
RP11-1212A22.4	16	18358086	18379331	N	.	N	N	.	.	.	.	.	.
RP11-123K3.4	12	57249609	57296484	N	.	N	N	.	.	.	.	.	.
RP11-125O5.2	12	21047179	21176895	N	.	N	N	.	.	.	.	.	.
RP11-1277H1.5	16	33303739	33306935	N	.	N	N	.	.	.	.	.	.
RP11-12J10.3	10	124617080	124791727	N	.	N	N	.	.	.	.	.	.
RP11-136C24.3	3	42809446	43055871	N	.	N	N	.	.	.	.	.	.
RP11-140L24.4	11	14493783	14520344	N	.	N	N	.	.	.	.	.	.
RP11-145E5.5	9	21802636	22032986	N	.	N	N	.	.	.	.	.	.
RP11-146B14.1	9	6720863	7077263	N	.	N	N	.	.	.	.	.	.
RP11-152F13.10	15	82540032	82555932	N	.	N	N	.	.	.	.	.	.
RP11-156P1.2	17	46923133	47047154	N	.	N	N	.	.	.	.	.	.
RP11-159D12.5	17	57989038	58005253	N	.	N	N	.	.	.	.	.	.
RP11-15K19.2	7	55887277	55955239	N	.	N	N	.	.	.	.	.	.
RP11-162P23.2	12	111753890	111791418	N	.	N	N	.	.	.	.	.	.
RP11-166B2.1	16	11927373	11976643	N	.	N	N	.	.	1.60E-08	88.4	.	.
RP11-166N6.3	3	150882997	150941743	N	.	N	N	.	.	.	.	.	.
RP11-176H8.1	14	31334312	31457441	N	.	N	N	.	.	0.172135497	39.7	.	.
RP11-178C3.1	17	59940908	59973101	N	.	N	N	.	.	.	.	.	.
RP11-178L8.4	16	87302876	87334273	N	.	N	N	.	.	.	.	.	.
RP11-190A12.7	1	159857900	159873053	N	.	N	N	.	.	.	.	.	.
RP11-192H23.4	17	28455752	28614197	N	.	N	N	.	.	.	.	.	.
RP11-195F19.29	9	34646645	34657113	N	.	N	N	.	.	.	.	.	.
RP11-195F19.5	9	34664163	34666112	N	.	N	N	.	.	.	.	.	.
RP11-196G11.1	16	31083439	31094956	N	.	N	N	.	.	.	.	.	.
RP11-201K10.3	1	155169409	155187272	N	.	N	N	.	.	.	.	.	.
RP11-20I23.1	16	2496032	2520218	N	.	N	N	.	.	1.15E-07	86	.	.
RP11-20I23.3	16	2513965	2527955	N	.	N	N	.	.	.	.	.	.
RP11-212D19.4	11	114400682	114443932	N	.	N	N	.	.	.	.	.	.
RP11-214K3.25	12	123973944	124088594	N	.	N	N	.	.	.	.	.	.
RP11-215A19.2	4	186426546	186555328	N	.	N	N	.	.	.	.	.	.
RP11-216L13.16	9	136738167	136748453	N	.	N	N	.	.	.	.	.	.
RP11-216L13.17	9	136791379	136800595	N	.	N	N	.	.	.	.	.	.
RP11-219A15.1	17	16690261	16804453	N	.	N	N	.	.	.	.	.	.
RP11-229P13.27	9	137031241	137040436	N	.	N	N	.	.	.	.	.	.
RP11-231C14.4	16	29483642	29505999	N	.	N	N	.	.	.	.	.	.
RP11-234B24.6	12	4657634	4744581	N	.	N	N	.	.	.	.	.	.
RP11-23E10.6	16	33459045	33462249	N	.	N	N	.	.	.	.	.	.
RP11-240B13.2	8	132024238	132085655	N	.	N	N	.	.	.	.	.	.
RP11-244H3.4	1	34981533	35031741	N	.	N	N	.	.	.	.	.	.
RP11-248J23.7	10	95860548	95924844	N	.	N	N	.	.	.	.	.	.
RP11-249C24.12	16	56676132	56677763	N	.	N	N	.	.	.	.	.	.
RP11-257K9.8	6	73209746	73263196	N	.	N	N	.	.	.	.	.	.
RP11-26J3.4	8	79918860	80080831	N	.	N	N	.	.	.	.	.	.
RP11-277P12.6	12	10412312	10436001	N	.	N	N	.	.	.	.	.	.
RP11-286N22.8	11	61429220	61485822	N	.	N	N	.	.	.	.	.	.
RP11-287D1.3	2	74211604	74363377	N	.	N	N	.	.	.	.	.	.
RP11-290H9.2	17	47253897	47344292	N	.	N	N	.	.	.	.	.	.
RP11-293I14.2	12	71674204	71698968	N	.	N	N	.	.	.	.	.	.
RP11-294C11.3	15	21651844	21653039	N	.	N	N	.	.	.	.	.	.
RP11-295K3.1	11	1747806	1759051	N	.	N	N	.	.	.	.	.	.
RP11-296A16.1	15	43772617	43799133	N	.	N	N	.	.	.	.	.	.
RP11-298I3.5	14	22946270	22982258	N	.	N	N	.	.	.	.	.	.
RP11-302B13.5	12	48903503	48957365	N	.	N	N	.	.	0.630270461	26.6	.	.
RP11-302M6.4	1	89633140	89933250	N	.	N	N	.	.	.	.	.	.
RP11-307N16.6	13	23979700	24321031	N	.	N	N	.	.	.	.	.	.
RP1-130H16.18	22	30285238	30299482	N	.	N	N	.	.	.	.	.	.
RP11-310N16.1	2	48632291	48755724	N	.	N	N	.	.	.	.	.	.
RP11-314N13.10	20	1317571	1393096	N	.	N	N	.	.	.	.	.	.
RP11-315D16.2	15	68193801	68229718	N	.	N	N	.	.	0.060362916	46	.	.
RP11-318A15.7	17	76732978	76738522	N	.	N	N	.	.	.	.	.	.
RP11-321N4.5	6	85557978	85615234	N	.	N	N	.	.	.	.	.	.
RP11-322E11.6	18	35443871	35497940	N	.	N	N	.	.	0.01381961	53.6	.	.
RP11-322N21.2	1	46175486	46176478	N	.	N	N	.	.	.	.	.	.
RP11-330H6.5	3	52221081	52231190	N	.	N	N	.	.	.	.	.	.
RP11-343C2.11	16	69299682	69322700	N	.	N	N	.	.	.	.	.	.
RP11-343C2.12	16	69328644	69334871	N	.	N	N	.	.	.	.	.	.
RP11-343C2.7	16	69335276	69351730	N	.	N	N	.	.	.	.	.	.
RP11-343C2.9	16	69335091	69356306	N	.	N	N	.	.	.	.	.	.
RP11-345J4.3	16	29464967	29467833	N	.	N	N	.	.	.	.	.	.
RP11-345J4.5	16	29443056	29454651	N	.	N	N	.	.	.	.	.	.
RP11-347C12.1	16	30222937	30254510	N	.	N	N	.	.	.	.	.	.
RP11-347C12.3	16	30204316	30209071	N	.	N	N	.	.	.	.	.	.
RP11-350O14.18	9	137168854	137171984	N	.	N	N	.	.	.	.	.	.
RP11-35N6.1	9	101028709	101325135	N	.	N	N	.	.	.	.	.	.
RP11-371E8.4	14	93184973	93218586	N	.	N	N	.	.	.	.	.	.
RP11-385D13.1	17	15571491	15651653	N	.	N	N	.	.	.	.	.	.
RP11-385J1.3	3	178419123	178843300	N	.	N	N	.	.	.	.	.	.
RP1-138B7.6	20	43540171	43569498	N	.	N	N	.	.	.	.	.	.
RP11-38C17.1	2	99154998	99195298	N	.	N	N	.	.	.	.	.	.
RP11-392E22.9	9	38540569	38577207	N	.	N	N	.	.	.	.	.	.
RP1-139D8.6	6	42155426	42163439	N	.	N	N	.	.	.	.	.	.
RP11-400G3.5	10	94688154	94853073	N	.	N	N	.	.	.	.	.	.
RP11-403P17.5	16	66469812	66517312	N	.	N	N	.	.	.	.	.	.
RP11-404P21.8	14	96204844	96263929	N	.	N	N	.	.	0.02260712	51	.	.
RP11-407N17.3	14	39233902	39350423	N	.	N	N	.	.	0.00613602	57.1	.	.
RP11-407P15.2	2	94588522	94604573	N	.	N	N	.	.	.	.	.	.
RP11-411B6.6	10	100505628	100529881	N	.	N	N	.	.	.	.	.	.
RP11-426L16.10	1	112702614	112711433	N	.	N	N	.	.	.	.	.	.
RP11-432B6.3	3	160227454	160449829	N	.	N	N	.	.	.	.	.	.
RP11-434D12.1	3	14135217	14148252	N	.	N	N	.	.	.	.	.	.
RP11-437B10.1	15	92883413	92949230	N	.	N	N	.	.	.	.	.	.
RP11-438J1.1	3	10249372	10285796	N	.	N	N	.	.	.	.	.	.
RP11-444E17.6	6	44273194	44378957	N	.	N	N	.	.	.	.	.	.
RP11-446E24.4	1	54141224	54200073	N	.	N	N	.	.	.	.	.	.
RP11-447L10.1	3	196248230	196318222	N	.	N	N	.	.	.	.	.	.
RP11-449H3.3	5	146203550	146339251	N	.	N	N	.	.	.	.	.	.
RP11-457D20.2	16	60358455	60359480	N	.	N	N	.	.	.	.	.	.
RP11-458D21.5	1	146113652	146229000	N	.	N	N	.	.	.	.	.	.
RP11-45M22.4	17	17202649	17237185	N	.	N	N	.	.	.	.	.	.
RP11-463C8.4	14	77098311	77225462	N	.	N	N	.	.	.	.	.	.
RP11-463D19.2	8	73688691	73878854	N	.	N	N	.	.	.	.	.	.
RP11-468E2.1	14	24189157	24213473	N	.	N	N	.	.	.	.	.	.
RP11-468E2.2	14	24180395	24190416	N	.	N	N	.	.	.	.	.	.
RP11-468E2.4	14	24151218	24167402	N	.	N	N	.	.	.	.	.	.
RP11-468E2.6	14	24120956	24131829	N	.	N	N	.	.	.	.	.	.
RP11-475E11.9	1	108837660	108963484	N	.	N	N	.	.	.	.	.	.
RP11-47I22.4	14	61529128	61657964	N	.	N	N	.	.	.	.	.	.
RP11-484M3.5	3	119147375	119187807	N	.	N	N	.	.	.	.	.	.
RP11-49K24.6	18	47134656	47176281	N	.	N	N	.	.	.	.	.	.
RP11-49K24.9	18	47022287	47023927	N	.	N	N	.	.	.	.	.	.
RP11-500M8.7	12	4604944	4662643	N	.	N	N	.	.	.	.	.	.
RP11-505K9.4	16	83908132	83951445	N	.	N	N	.	.	.	.	.	.
RP11-507M3.1	2	24124366	24190436	N	.	N	N	.	.	.	.	.	.
RP11-512M8.5	12	122207779	122266423	N	.	N	N	.	.	.	.	.	.
RP11-514O12.4	6	166858094	166956124	N	.	N	N	.	.	.	.	.	.
RP11-514P8.6	7	102582523	102642869	N	.	N	N	.	.	.	.	.	.
RP11-514P8.7	7	102541501	102592444	N	.	N	N	.	.	.	.	.	.
RP11-51F16.8	17	63702845	63752097	N	.	N	N	.	.	.	.	.	.
RP11-51L5.7	17	62272487	62282915	N	.	N	N	.	.	.	.	.	.
RP11-520P18.5	8	143080457	143083001	N	.	N	N	.	.	.	.	.	.
RP11-529K1.3	16	70299194	70366260	N	.	N	N	.	.	.	.	.	.
RP11-540D14.8	1	155063748	155086807	N	.	N	N	.	.	.	.	.	.
RP11-542C16.2	17	7312661	7319174	N	.	N	N	.	.	.	.	.	.
RP11-544M22.13	1	160997957	161038962	N	.	N	N	.	.	.	.	.	.
RP11-545J16.1	12	20815674	21090245	N	.	N	N	.	.	.	.	.	.
RP11-546B8.6	5	171305981	171308755	N	.	N	N	.	.	.	.	.	.
RP11-548K23.11	10	97584374	97673910	N	.	N	N	.	.	.	.	.	.
RP11-54C4.3	5	151769793	151771508	N	.	N	N	.	.	.	.	.	.
RP11-552F3.12	17	75898645	75930129	N	.	N	N	.	.	.	.	.	.
RP11-561B11.2	14	35122549	35317474	N	.	N	N	.	.	.	.	.	.
RP11-565P22.6	1	162365407	162383531	N	.	N	N	.	.	.	.	.	.
RP11-569G13.3	9	96106661	96116411	N	.	N	N	.	.	.	.	.	.
RP11-571M6.15	12	57773028	57787046	N	.	N	N	.	.	.	.	.	.
RP11-574F21.3	1	160217464	160285130	N	.	N	N	.	.	.	.	.	.
RP11-574K11.31	10	73796514	73811651	N	.	N	N	.	.	.	.	.	.
RP11-58C22.1	16	76553417	76819624	N	.	N	N	.	.	.	.	.	.
RP11-598P20.5	8	43018424	43077334	N	.	N	N	.	.	.	.	.	.
RP11-599B13.6	17	8150816	8162975	N	.	N	N	.	.	.	.	.	.
RP11-5A19.5	16	67163385	67165815	N	.	N	N	.	.	.	.	.	.
RP11-603J24.9	12	56101331	56109289	N	.	N	N	.	.	.	.	.	.
RP11-613M10.8	9	37512547	37592469	N	.	N	N	.	.	.	.	.	.
RP11-613M10.9	9	37588413	38068687	N	.	N	N	.	.	.	.	.	.
RP11-618P17.4	19	34396315	34409364	N	.	N	N	.	.	.	.	.	.
RP11-637O19.3	6	10747794	10930423	N	.	N	N	.	.	.	.	.	.
RP11-644F5.10	12	55716036	55724703	N	.	N	N	.	.	0.038610316	48.5	.	.
RP11-691N7.6	11	57742163	57793243	N	.	N	N	.	.	.	.	.	.
RP11-697E2.12	15	90266317	90314499	N	.	N	N	.	.	.	.	.	.
RP11-697E2.6	15	90249556	90272208	N	.	N	N	.	.	.	.	.	.
RP11-722G7.1	X	104063871	104076212	N	.	N	N	.	.	.	.	.	.
RP11-723O4.6	3	128909874	128971330	N	.	N	N	.	.	.	.	.	.
RP11-724O16.1	2	169479480	169525922	N	.	N	N	.	.	0.004395974	58.7	.	.
RP11-729L2.2	18	50968019	51058144	N	.	N	N	.	.	.	.	.	.
RP11-73M18.2	14	103562962	103685924	N	.	N	N	.	.	0.007052546	56.6	.	.
RP11-745O10.4	12	66123917	66169985	N	.	N	N	.	.	.	.	.	.
RP11-761B3.1	2	47065941	47176511	N	.	N	N	.	.	.	.	.	.
RP11-762I7.5	12	55757275	55827546	N	.	N	N	.	.	.	.	.	.
RP11-766F14.2	4	99636529	99654648	N	.	N	N	.	.	.	.	.	.
RP11-77K12.1	16	75412684	75464706	N	.	N	N	.	.	.	.	.	.
RP11-77K12.7	16	75528532	75545428	N	.	N	N	.	.	.	.	.	.
RP11-793H13.10	12	53506688	53625979	N	.	N	N	.	.	0.48088645	30.6	.	.
RP11-795F19.5	18	80034346	80097088	N	.	N	N	.	.	.	.	.	.
RP11-812E19.9	16	33844784	33845229	N	.	N	N	.	.	.	.	.	.
RP11-831H9.11	11	62649694	62665178	N	.	N	N	.	.	0.079166678	44.5	.	.
RP11-834C11.12	12	53985845	54034888	N	.	N	N	.	.	.	.	.	.
RP11-849F2.7	17	8368638	8383187	N	.	N	N	.	.	.	.	.	.
RP11-849H4.2	11	71865509	71928654	N	.	N	N	.	.	.	.	.	.
RP11-864I4.1	11	62559603	62591531	N	.	N	N	.	.	.	.	.	.
RP11-872D17.8	11	57387365	57424059	N	.	N	N	.	.	.	.	.	.
RP11-87C12.2	12	121888809	121921470	N	.	N	N	.	.	.	.	.	.
RP11-886H22.1	18	49795793	49837623	N	.	N	N	.	.	.	.	.	.
RP11-894J14.5	3	52969119	53099453	N	.	N	N	.	.	.	.	.	.
RP11-903H12.5	14	20684587	20700576	N	.	N	N	.	.	.	.	.	.
RP11-934B9.3	14	24332310	24337382	N	.	N	N	.	.	0.005965155	57.2	.	.
RP11-96O20.4	15	45587351	45676314	N	.	N	N	.	.	.	.	.	.
RP11-977G19.10	12	56285916	56316059	N	.	N	N	.	.	.	.	.	.
RP1-27O5.3	1	32465057	32600792	N	.	N	N	.	.	.	.	.	.
RP1-309K20.6	20	35632340	35674544	N	.	N	N	.	.	.	.	.	.
RP13-1032I1.10	17	81703371	81720539	N	.	N	N	.	.	.	.	.	.
RP1-317E23.6	1	25811470	25823744	N	.	N	N	.	.	.	.	.	.
RP1-321E8.5	X	120877496	120878924	N	.	N	N	.	.	.	.	.	.
RP13-279N23.2	1	18849273	18921121	N	.	N	N	.	.	.	.	.	.
RP13-512J5.1	2	3531984	3547957	N	.	N	N	.	.	.	.	.	.
RP13-582O9.6	8	143247110	143276403	N	.	N	N	.	.	.	.	.	.
RP13-672B3.2	12	132688049	132714912	N	.	N	N	.	.	.	.	.	.
RP1-37E16.12	22	37686414	37726503	N	.	N	N	.	.	.	.	.	.
RP1-4G17.5	17	7246829	7262089	N	.	N	N	.	.	.	.	.	.
RP1-66C13.4	17	27798806	27893365	N	.	N	N	.	.	0.052336302	46.7	.	.
RP1L1	8	10606349	10712187	N	.	N	Y	5.942589846	99.8900272	.	.	DM	Occult macular dystrophy, 613587 (3)
RP2	X	46836940	46882358	N	.	N	Y	0.33887786	72.80777913	0.851505577	19.8	DM	Retinitis pigmentosa 2, 312600 (3)
RP3-461F17.3	12	6970921	6997428	N	.	N	N	.	.	.	.	.	.
RP3-468K18.5	6	143807092	143844617	N	.	N	N	.	.	.	.	.	.
RP3-468K18.7	6	143857318	143938471	N	.	N	N	.	.	.	.	.	.
RP3-509I19.11	6	138725211	138773652	N	.	N	N	.	.	.	.	.	.
RP4-539M6.19	22	30409255	30428990	N	.	N	N	.	.	.	.	.	.
RP4-559A3.7	1	225886696	225924278	N	.	N	N	.	.	0.016354595	52.7	.	.
RP4-576H24.4	20	1540144	1620009	N	.	N	N	.	.	.	.	.	.
RP4-583P15.14	20	63738270	63740398	N	.	N	N	.	.	.	.	.	.
RP4-583P15.15	20	63708864	63739103	N	.	N	N	.	.	.	.	.	.
RP4-608O15.3	1	196819745	196959210	N	.	N	N	.	.	.	.	.	.
RP4-734P14.4	20	2467212	2508907	N	.	N	N	.	.	.	.	.	.
RP5-1021I20.4	14	73851971	73932278	N	.	N	N	.	.	.	.	.	.
RP5-1042K10.14	22	40364958	40404362	N	.	N	N	.	.	.	.	.	.
RP5-1052I5.2	1	86993009	87169204	N	.	N	N	.	.	0.088823164	43.8	.	.
RP5-850E9.3	20	646626	675800	N	.	N	N	.	.	0.031957746	49.4	.	.
RP5-860F19.8	20	2814968	2818066	N	.	N	N	.	.	.	.	.	.
RP5-864K19.6	1	38864501	38881617	N	.	N	N	.	.	.	.	.	.
RP5-874C20.8	6	28267121	28281580	N	.	N	N	.	.	.	.	.	.
RP5-877J2.1	7	30852273	30923812	N	.	N	N	.	.	.	.	.	.
RP5-966M1.6	3	52813282	52835729	N	.	N	N	.	.	.	.	.	.
RP5-972B16.2	X	37349330	38687674	N	.	N	N	.	.	.	.	.	.
RP6-24A23.6	X	108722070	108732687	N	.	N	N	.	.	.	.	.	.
RP9	7	33094797	33109401	N	.	N	N	0.147473793	60.82653238	0.174162978	39.6	DM	?Retinitis pigmentosa 9, 180104 (3)
RPA2	1	27891524	27914746	N	.	N	N	-0.167654501	37.52966371	0.888461679	18.3	DP	.
RPA3	7	7636518	7718607	N	.	N	N	-0.314998473	28.52925855	7.56E-05	72.7	.	.
RPA4	X	96883908	96885467	N	.	N	N	0.005872186	49.93922556	0.273955521	36.4	FP	.
RPAIN	17	5419641	5432876	N	.	N	N	0.11474167	58.35503849	6.36E-06	79.1	.	.
RPAP1	15	41517176	41544269	N	.	N	N	2.074788206	98.69190253	5.02E-15	96.8	.	.
RPAP3	12	47661249	47706061	N	.	N	N	-0.449746467	22.30132546	0.14030954	41.1	.	.
RPE	2	210002565	210022259	N	.	N	N	-0.334635847	27.50477513	0.316665037	35.3	.	.
RPE65	1	68428822	68449959	N	.	N	Y	-0.479758918	21.01638016	1.46E-07	85.7	DM	Leber congenital amaurosis 2, 204100 (3); Retinitis pigmentosa 20, 613794 (3)
RPEL1	10	103245887	103248016	N	.	N	N	.	.	.	.	.	.
RPF1	1	84479259	84497790	N	.	N	N	0.544480852	82.23071135	9.48E-07	82.6	.	.
RPF2	6	110982015	111028263	N	.	N	N	0.889636308	90.92435029	0.393258892	32.9	.	.
RPGR	X	38269163	38327564	N	.	N	Y	1.498709367	96.96706604	0.997857546	7	DM	Retinitis pigmentosa 3, 300029 (3); Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 (3); Macular degeneration, X-linked atrophic, 300834 (3); Cone-rod dystrophy, X-linked, 1, 304020 (3)
RPGRIP1	14	21287939	21351301	N	.	N	Y	0.098582196	57.00642473	2.57E-21	98.9	DM	Leber congenital amaurosis 6, 613826 (3); Cone-rod dystrophy 13, 608194 (3)
RPH3A	12	112570380	112898881	N	Viable	N	Y	0.253925617	67.70272617	0.738603478	23.5	.	.
RPH3AL	17	212389	386254	N	.	N	Y	0.733019432	87.65410662	5.11E-10	91.7	DFP	.
RPL10	X	154389955	154409168	N	.	N	N	0.433551085	77.55397349	0.901193298	17.7	DM	{Autism, susceptibility to, X-linked 5}, 300847 (3)
RPL10A	6	35468408	35470785	N	.	N	N	-0.389072069	24.99276495	0.302378831	35.7	.	.
RPL10L	14	46651010	46651821	N	.	N	N	0.295771879	70.24367656	0.02605492	50.3	.	.
RPL11	1	23691779	23696425	N	.	N	N	-0.186488904	36.36626729	0.725843321	23.9	DM	Diamond-Blackfan anemia 7, 612562 (3)
RPL12	9	127447674	127451405	N	.	N	N	0.010504826	50.32702437	0.164356185	40	.	.
RPL13	16	89560657	89566828	N	.	N	N	-0.31116943	28.88232911	0.914867445	17	.	.
RPL13A	19	49487554	49492308	N	.	N	N	-0.025096816	47.5834925	0.633828369	26.5	.	.
RPL14	3	40457292	40468587	N	.	N	N	0.899864455	91.08641547	0.936435428	15.8	.	.
RPL15	3	23916545	23923692	N	.	N	N	0.041473905	52.65960526	0.956294174	14.2	.	?Diamond-Blackfan anemia 12, 615550 (3)
RPL17	18	49488453	49492565	N	.	N	N	-0.239010401	33.13075187	0.494059426	30.1	.	.
RPL17-C18orf32	18	49481681	49491586	N	.	N	N	-0.092624171	42.6520808	0.605942172	27.3	.	.
RPL18	19	48615328	48619536	N	.	N	N	-0.312126643	28.79550848	0.554781181	28.5	.	.
RPL18A	19	17859876	17864153	N	.	N	N	-0.108587205	41.55814088	0.963491173	13.6	.	.
RPL19	17	39200283	39204727	N	.	N	N	0.322915185	71.92799676	0.974448375	12.5	.	.
RPL21	13	27251309	27256691	N	.	N	N	-0.043930449	46.31591133	0.920443069	16.7	DM	Hypotrichosis 12, 615885 (3)
RPL22	1	6181269	6209389	N	.	N	N	0.016094318	50.71482318	0.348492156	34.2	.	.
RPL22L1	3	170864875	170870483	N	.	N	N	0.191535973	63.89419459	0.093959393	43.5	.	.
RPL23	17	38847865	38853843	N	.	N	N	-0.013918082	48.39381837	0.93162443	16	.	.
RPL23A	17	28719393	28724359	N	.	N	N	0.298492991	70.40574174	0.876904382	18.8	.	.
RPL26	17	8377520	8383213	N	.	N	N	0.123051266	58.96278289	0.915888681	17	DM	?Diamond-Blackfan anemia 11, 614900 (3)
RPL26L1	5	172958729	172969771	N	.	N	N	0.527414817	81.53035828	0.49226027	30.2	.	.
RPL27	17	42998273	43002959	N	.	N	N	-0.110501175	41.41343983	0.822384681	20.9	.	.
RPL28	19	55385345	55403250	N	.	N	N	0.340790619	72.91775192	0.671038473	25.5	.	.
RPL3	22	39312882	39320389	N	.	N	N	-0.700375489	13.90287666	0.994251971	8.8	.	.
RPL30	8	98024851	98046469	N	.	N	N	0.030143764	51.8087631	0.774790168	22.4	.	.
RPL31	2	101001715	101024032	N	.	N	N	-0.11145818	41.38449962	0.843001843	20.1	.	.
RPL32	3	12834485	12841588	N	.	N	N	0.154020328	61.30693986	0.755582038	23	.	.
RPL34	4	108620566	108630412	N	.	N	N	0.107088402	57.71835388	0.891623097	18.1	.	.
RPL35	9	124857880	124861981	N	.	N	N	0.033014066	52.06922498	0.527875069	29.2	.	.
RPL35A	3	197949987	197956610	N	.	N	N	0.099585278	57.16270186	0.914385546	17	DM	Diamond-Blackfan anemia 5, 612528 (3)
RPL36	19	5674947	5691876	N	.	N	N	0.121138064	58.78914163	0.623121945	26.8	DM?	.
RPL36A	X	101390824	101396154	N	.	N	N	0.205585801	64.70452046	0.793206864	21.9	.	.
RPL36A-HNRNPH2	X	101391011	101412297	N	.	N	N	.	.	.	.	.	.
RPL36AL	14	49618519	49620685	N	.	N	N	-0.022378042	47.78028593	0.041833199	48	.	.
RPL37	5	40825262	40835335	N	.	N	N	-0.088948948	42.87202639	0.577671288	28	.	.
RPL37A	2	216498189	216579180	N	.	N	N	0.002044933	49.63824738	0.004770765	58.3	.	.
RPL39	X	119786504	119791643	N	.	N	N	0.21021973	65.0691671	0.620183578	26.9	.	.
RPL39L	3	187120948	187180908	N	.	N	N	0.552648777	82.53168953	0.175781235	39.5	.	.
RPL3L	16	1943974	1957606	N	.	N	N	1.965125549	98.5356254	2.14E-08	88.1	.	.
RPL4	15	66498015	66524532	N	.	N	N	-0.48550039	20.72697806	0.999281604	5.6	.	.
RPL41	12	56116586	56117943	N	.	N	N	.	.	0.041529599	48.1	.	.
RPL5	1	92832025	92841924	N	.	N	N	-0.099170261	42.1543092	0.994762229	8.5	DM	Diamond-Blackfan anemia 6, 612561 (3)
RPL6	12	112405190	112418838	N	.	N	N	-0.068201255	44.52161834	0.988288271	10.3	.	.
RPL7	8	73290267	73295789	N	.	N	N	-0.425630209	23.29686867	0.991153032	9.7	.	.
RPL7A	9	133348214	133351426	N	.	N	N	-0.45372795	22.13347225	0.979405409	11.9	.	.
RPL7L1	6	42879618	42889925	N	.	N	N	0.274219089	68.94136714	0.201503933	38.7	.	.
RPL8	8	144789765	144792587	N	.	N	N	-0.386200114	25.12588991	0.932693413	15.9	.	.
RPL9	4	39454124	39458948	N	.	N	N	0.072442927	55.09058286	0.918456438	16.8	.	.
RPLP0	12	120196686	120201235	N	.	N	N	-0.437764465	22.83961336	0.978691783	12	.	.
RPLP1	15	69452784	69456194	N	.	N	N	0.175573187	62.89865139	0.680907047	25.1	.	.
RPLP2	11	809647	812880	N	.	N	N	0.216914842	65.45696591	0.708517553	24.4	.	.
RPN1	3	128619970	128681075	N	.	N	N	-0.392592402	24.83069977	0.664450734	25.7	.	.
RPP14	3	58306262	58318574	N	.	N	N	0.624002642	84.88163454	0.147340973	40.7	.	.
RPP21	6	30345131	30346884	N	.	N	N	0.518955475	81.21780402	0.082453977	44.3	.	.
RPP25	15	74954416	74957464	N	.	N	N	-0.095495045	42.38583087	0.006957577	56.6	.	.
RPP25L	9	34610486	34612104	N	.	N	N	-0.306538083	29.06754645	0.834923219	20.5	.	.
RPP30	10	90871716	90908553	N	.	N	N	-0.313886865	28.62186722	2.35E-05	75.8	.	.
RPP38	10	15097180	15139818	N	.	N	N	0.207648094	64.90710193	1.68E-05	76.7	.	.
RPP40	6	4994732	5004063	N	.	N	N	0.687042931	86.57753082	0.002577208	61	.	.
RPRD1A	18	35984387	36067576	N	.	N	N	-0.440636427	22.72385252	0.251149109	37.1	.	.
RPRD1B	20	38033546	38127780	N	.	N	Y	-0.440636427	22.72385252	0.595211393	27.6	FTV	.
RPRD2	1	150363091	150476566	N	.	N	N	-1.27582182	4.89089541	0.999977311	2.9	.	.
RPRM	2	153477338	153478808	N	.	N	N	-0.066439705	44.63737917	0.532566515	29.1	.	.
RPRML	17	46978156	46979248	N	.	N	N	0.000131289	49.44145396	0.421294823	32.2	.	.
RPS10	6	34417454	34426125	N	.	N	N	-0.224004258	34.09156682	0.946462998	15.1	DM	Diamond-Blackfan anemia 9, 613308 (3)
RPS10-NUDT3	6	34288770	34426048	N	.	N	N	.	.	.	.	.	.
RPS11	19	49496365	49499689	N	.	N	N	-0.049519725	45.82392777	0.913344861	17.1	.	.
RPS12	6	132814441	132817564	N	.	N	N	-0.0579797	45.26827574	0.827435142	20.7	.	.
RPS13	11	17074389	17077787	N	.	N	N	-0.15743371	38.19528853	0.960207217	13.9	.	.
RPS14	5	150443190	150449756	N	.	N	N	0.001088113	49.55142675	0.864815342	19.3	.	Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3)
RPS15	19	1438358	1440494	N	.	N	N	0.099585278	57.16270186	0.697325165	24.7	DM?	.
RPS15A	16	18781295	18790383	N	.	N	N	0.022640642	51.24732303	0.833355705	20.5	.	.
RPS16	19	39433207	39435948	N	.	N	N	-0.239010401	33.13075187	0.281859103	36.2	.	.
RPS17	15	82536753	82540564	N	.	N	N	.	.	.	.	DM	Diamond-Blackfan anemia 4, 612527 (3)
RPS18	6	33272010	33276510	N	.	N	N	0.08362237	55.98772935	0.962013321	13.8	.	.
RPS2	16	1962052	1964860	N	.	N	N	-0.452770663	22.14504833	0.23687207	37.5	.	.
RPS21	20	62387116	62388520	N	.	N	N	0.108045035	57.83990276	0.465534819	31	.	.
RPS23	5	82273358	82278577	N	.	N	N	0.046106757	53.06476819	0.878578938	18.7	.	.
RPS24	10	78033760	78056812	N	.	N	N	.	.	0.852844135	19.8	DM	Diamond-blackfan anemia 3, 610629 (3)
RPS25	11	119015712	119018691	N	.	N	N	-0.029881147	47.28251433	0.809686936	21.3	.	.
RPS26	12	56041853	56044675	N	.	N	N	-0.119918286	40.73045089	0.753342825	23.1	DM	Diamond-Blackfan anemia 10, 613309 (3)
RPS27	1	153990759	153992150	N	.	N	N	0.000131289	49.44145396	0.697777961	24.7	.	.
RPS27A	2	55231903	55235853	N	.	N	N	-0.239010401	33.13075187	0.525112782	29.3	DM?	.
RPS27L	15	63125872	63158021	N	.	N	N	0.08362237	55.98772935	0.335851902	34.7	.	.
RPS28	19	8321158	8323340	N	.	N	N	0.211176126	65.14441165	0.688845092	24.9	.	Diamond Blackfan anemia 15 with mandibulofacial dysostosis, 606164 (3)
RPS29	14	49570984	49599164	N	.	N	N	0.015137522	50.6627308	0.34940701	34.2	.	Diamond-Blackfan anemia 13, 615909 (3)
RPS3	11	75399486	75422280	N	.	N	N	0.018964694	50.97528506	0.957385986	14.1	FP	.
RPS3A	4	151099573	151104652	N	.	N	N	-0.162065544	37.85379406	0.744269731	23.3	.	.
RPS4X	X	72255679	72277300	N	.	N	N	0.008591214	50.15917115	0.886149634	18.4	.	.
RPS4Y1	Y	2841486	2932000	N	.	N	N	.	.	0.50239633	29.9	.	.
RPS5	19	58386400	58394806	N	.	N	N	-0.26151962	31.75319789	0.903178121	17.6	.	.
RPS6	9	19375715	19380254	N	.	N	N	-0.371193959	25.80887886	0.789114983	22	.	.
RPS6KA1	1	26529761	26575030	N	.	N	N	-0.735825246	13.00573016	0.725875553	23.9	.	.
RPS6KA2	6	166409364	166906451	N	.	N	Y	-1.459062976	3.582797939	0.084700886	44.1	.	.
RPS6KA3	X	20149911	20267100	N	.	N	Y	0.034927599	52.21971407	0.999905699	3.7	DM	Coffin-Lowry syndrome, 303600 (3); Mental retardation, X-linked 19, 300844 (3)
RPS6KA4	11	64359148	64372215	N	.	N	N	-0.354120223	26.60762864	0.99947454	5.2	.	.
RPS6KA5	14	90847862	91060636	N	.	N	Y	0.061566363	54.27446895	0.999801807	4.3	.	.
RPS6KA6	X	84058346	84187907	N	.	N	N	-0.299837855	29.4611333	0.744166834	23.3	.	.
RPS6KB1	17	59893046	59950564	N	.	N	Y	-0.620712187	16.16600104	0.99822324	6.7	FTV	.
RPS6KB2	11	67428460	67435408	N	.	N	Y	-0.150430658	38.69884818	3.21E-11	93.7	DP	.
RPS6KC1	1	213051233	213274773	N	.	N	N	-0.752452811	12.54268681	0.020440097	51.5	.	.
RPS6KL1	14	74903954	74923396	N	.	N	N	1.118720025	94.16565376	0.000674281	66.1	FTV	.
RPS8	1	44775251	44778779	N	.	N	N	-0.269979946	31.27279042	0.965122842	13.5	.	.
RPS9	19	54200742	54249003	N	.	N	N	-0.239967611	33.04971928	0.787131549	22.1	.	.
RPTN	1	152153595	152159228	N	.	N	N	1.191198476	94.95282746	3.18E-18	98.2	.	.
RPUSD1	16	784974	788397	N	.	N	N	-0.112110344	41.35555941	3.06E-08	87.6	.	.
RPUSD2	15	40569300	40574943	N	.	N	N	0.368232636	74.30688198	0.000105171	71.7	.	.
RPUSD3	3	9837849	9844602	N	.	N	N	0.98541706	92.5970944	0.000322774	68.4	.	.
RPUSD4	11	126202094	126211692	N	.	N	N	0.077377607	55.48416971	0.006729138	56.8	.	.
RRAD	16	66921679	66925644	N	Viable	N	Y	-0.174200506	37.13028882	0.310768743	35.4	.	.
RRAGB	X	55717739	55758774	N	.	N	N	-0.192077745	36.04213695	0.893169859	18.1	.	.
RRAGC	1	38838198	38859823	N	.	N	N	-0.230550154	33.7153441	0.600078052	27.5	.	.
RRAGD	6	89364636	89412270	N	.	N	N	-0.146102415	38.98246223	0.812902091	21.2	.	.
RRAS	19	49635292	49640201	N	.	N	N	-0.03818917	46.70949818	0.287257429	36	.	.
RRAS2	11	14277926	14364506	N	.	N	Y	-0.095495045	42.38583087	0.674254314	25.4	.	Ovarian carcinoma (3)
RRBP1	20	17613678	17682295	N	.	N	N	0.843487934	90.06772009	0.000136332	71	.	.
RREB1	6	7107597	7251980	N	.	N	N	0.014893049	50.61642646	0.999967928	3	DM?	.
RRH	4	109827994	109844604	N	.	N	N	0.157040256	61.54424958	5.11E-06	79.5	DM?	.
RRM1	11	4094707	4138876	N	.	N	N	-0.802550202	11.49505122	0.999994804	2.3	FP	.
RRM2B	8	102204502	102239118	N	.	N	Y	-0.402163571	24.28662384	0.157235868	40.3	DM	Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 (3); Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5, 613077 (3); Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 (3)
RRNAD1	1	156728442	156736960	N	.	N	N	-0.23966114	33.10181166	2.12E-08	88.1	.	.
RRP1	21	43789513	43805293	N	.	N	N	0.765902273	88.46443248	0.001850411	62.2	.	.
RRP12	10	97356358	97426076	N	.	N	N	-0.634846878	15.79556636	4.36E-06	79.8	.	.
RRP15	1	218285287	218337983	N	.	N	N	0.44120081	77.9417723	0.00163197	62.7	.	.
RRP1B	21	43659548	43696079	N	.	N	N	0.151602096	61.11014644	0.036818435	48.7	DP	.
RRP36	6	43021645	43034156	N	.	N	N	0.273262571	68.86033455	9.22E-11	93	.	.
RRP7A	22	42509968	42519802	N	.	N	N	2.104715464	98.73241882	0.002372959	61.3	.	.
RRP9	3	51933430	51941941	N	.	N	N	-0.121527027	40.6494183	0.342043484	34.5	.	.
RRS1	8	66429028	66430733	N	.	N	N	0.570668188	83.09312959	0.551023834	28.6	.	.
RS1	X	18639910	18672109	N	.	N	Y	0.132467594	59.58789142	0.89291234	18.1	DM	Retinoschisis, 312700 (3)
RSAD1	17	50478800	50485975	N	Viable	N	Y	-0.238704305	33.15390403	5.75E-06	79.3	.	.
RSAD2	2	6865806	6898239	N	.	N	Y	0.255536257	67.80112288	4.59E-12	94.7	.	.
RSBN1L	7	77696443	77783022	N	.	N	N	-0.557510609	18.00081033	0.500030091	30	.	.
RSC1A1	1	15659869	15661722	N	.	N	Y	1.107540809	94.02095271	1.46E-08	88.5	.	.
RSG1	1	16231700	16237162	N	.	N	N	0.418691306	76.76679979	1.08E-06	82.4	.	.
RSL1D1	16	11833850	11851585	N	.	N	N	0.372060158	74.51525149	0.000364294	68	.	.
RSL24D1	15	55180806	55197067	N	.	N	N	0.170939673	62.57452104	0.946909507	15	.	.
RSPH1	21	42472486	42496354	N	.	N	Y	1.06795787	93.60421369	0.00021057	69.7	.	Ciliary dyskinesia, primary, 24, 615481 (3)
RSPH10B	7	5925550	5970683	N	.	N	N	.	.	.	.	.	.
RSPH10B2	7	6754109	6799365	N	.	N	N	.	.	.	.	.	.
RSPH14	22	23059415	23145021	N	.	N	N	.	.	.	.	.	.
RSPH3	6	158972871	159000187	N	.	N	N	1.455597553	96.74133241	0.001396232	63.4	.	Ciliary dyskinesia, primary, 32, 616481 (3)
RSPH4A	6	116616479	116632985	N	.	N	N	-0.226417441	33.95265382	1.84E-07	85.3	DM	Ciliary dyskinesia, primary, 11, 612649 (3)
RSPH6A	19	45795710	45815319	N	.	N	N	0.361994282	74.01169184	2.55E-08	87.9	.	.
RSPO1	1	37611350	37634923	N	Viable	N	Y	-0.209801572	34.94819702	0.002910514	60.5	DM	Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3); Palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3)
RSPO4	20	958452	1002264	N	.	N	N	0.690721426	86.69329166	0.000413043	67.6	DM	Anonychia congenita, 206800 (3)
RSPRY1	16	57186137	57240475	N	.	N	N	-0.761359217	12.36904555	0.999778005	4.4	.	.
RSRC1	3	158105855	158545730	N	.	N	N	0.026619	51.54251317	3.41E-05	74.9	FTV	.
RSRC2	12	122503458	122527000	N	.	N	N	-0.815797634	11.28668172	0.992877361	9.2	.	.
RSRP1	1	25242237	25338213	N	.	N	N	.	.	.	.	.	.
RSU1	10	16590611	16817528	N	.	N	N	-0.127268446	40.25583145	0.047765679	47.3	.	.
RTBDN	19	12825478	12835428	N	.	N	Y	0.380219143	74.93777855	3.28E-07	84.4	.	.
RTCA	1	100266207	100292769	N	.	N	N	0.271498993	68.77351392	0.002920978	60.4	.	.
RTCB	22	32387582	32412255	N	.	N	N	-0.931065821	9.035133414	0.058729233	46.1	.	.
RTEL1-TNFRSF6B	20	63659300	63698698	N	.	N	N	.	.	.	.	.	.
RTFDC1	20	56468585	56519449	N	.	N	N	0.068766772	54.77802859	0.003932276	59.1	.	.
RTKN	2	74425836	74442422	N	.	N	N	-0.60635615	16.57695202	0.000149538	70.6	.	.
RTKN2	10	62183035	62268707	N	.	N	N	-0.222741485	34.17259941	1.31E-14	96.6	DP	.
RTN1	14	59595976	59870966	N	Viable	N	Y	0.356097127	73.757018	0.959599486	14	.	.
RTN2	19	45485289	45497061	N	.	N	Y	-0.343746643	27.07067199	0.636179982	26.4	DM	Spastic paraplegia 12, autosomal dominant, 604805 (3)
RTN3	11	63681446	63759891	N	.	N	N	-1.265584424	4.995080164	0.040022823	48.3	DP	.
RTN4IP1	6	106571971	106629487	N	.	N	N	0.279002038	69.25970944	3.75E-06	80.1	.	.
RTN4R	22	20241415	20283246	N	.	N	Y	0.145861223	60.69919546	0.526443418	29.2	DM?	{Schizophrenia, susceptibility to}, 181500 (3)
RTN4RL1	17	1934677	2025345	N	.	N	N	-0.158085076	38.15477224	0.787530525	22.1	DM?	.
RTN4RL2	11	57460549	57477534	N	.	N	Y	-0.195752553	35.7874631	0.975814588	12.3	.	.
RTP1	3	187197486	187201465	N	.	N	Y	0.148580539	60.91335301	0.563829726	28.4	.	.
RTP2	3	187698259	187702557	N	.	N	Y	-0.283874745	30.4277363	0.003381055	59.9	.	.
RTP3	3	46497491	46500949	N	.	N	N	-0.191120662	36.08265324	0.181516461	39.3	.	.
RTP4	3	187368332	187372076	N	.	N	N	0.7047722	87.01163396	0.010845646	54.6	.	.
RTP5	2	241869600	241873823	N	.	N	N	.	.	.	.	.	.
RUFY1	5	179550558	179610026	N	.	N	N	-0.925324561	9.139318169	0.064670215	45.5	.	.
RUFY2	10	68341107	68407294	N	.	N	Y	-0.437610849	22.86276553	0.416574096	32.4	.	.
RUFY4	2	218034960	218090581	N	.	N	N	.	.	4.88E-09	89.6	.	.
RUNDC3A	17	44308413	44318671	N	.	N	N	.	.	0.960334019	13.9	.	.
RUNDC3B	7	87627548	87832296	N	.	N	N	-0.473365526	21.30578225	0.001491894	63	.	.
RUSC1	1	155320896	155331114	N	.	N	N	-0.835134974	10.87573074	0.949429118	14.8	.	.
RUSC2	9	35490127	35561898	N	.	N	N	-1.874240404	1.979510332	0.99997732	2.9	.	.
RUVBL1	3	128064778	128153914	N	.	N	Y	-0.506249788	19.96874457	0.99889769	6	DM?	.
RWDD1	6	116571367	116597675	N	Viable	N	Y	-0.033556726	47.03941657	0.372943967	33.5	.	.
RWDD2A	6	83193379	83198932	N	.	N	N	-0.289617454	30.09202987	0.000931282	65	.	.
RWDD2B	21	29004384	29019378	N	.	N	N	0.523736129	81.40302136	0.000174917	70.2	.	.
RWDD4	4	183639635	183659225	N	.	N	N	-0.178028729	36.84667477	0.482983522	30.5	.	.
RXFP1	4	158315311	158653372	N	.	N	Y	-0.583846494	17.27151705	3.07E-07	84.5	.	.
RXFP2	13	31739542	31803388	N	Viable	N	Y	-0.346466122	26.93175899	2.94E-08	87.7	DM?	.
RXFP3	5	33936386	33938237	N	.	N	Y	-0.094233924	42.51895584	2.31E-11	93.8	.	.
RXFP4	1	155941710	155942949	N	.	N	Y	0.319387303	71.73699138	0.005495818	57.7	.	.
RXRG	1	165400917	165445355	N	.	N	Y	-0.949902102	8.71679111	0.937024402	15.8	DP	.
RYR3	15	33310962	33866102	N	.	N	Y	-4.490345347	0.138913006	0.999999945	1	DM?	.
S100A1	1	153627926	153632039	N	.	N	Y	0.176529703	62.94495572	0.004656021	58.5	.	.
S100A10	1	151982915	151994390	N	.	N	Y	0.099585278	57.16270186	0.173245481	39.6	.	.
S100A11	1	152032506	152047907	N	.	N	Y	0.624002642	84.88163454	0.050106159	47	.	.
S100A12	1	153373706	153375649	N	.	N	N	0.100541925	57.24952249	0.033529746	49.2	.	.
S100A13	1	153618787	153634092	N	.	N	N	0.077075925	55.43207733	0.035153142	48.9	.	.
S100A16	1	153606886	153613145	N	.	N	N	0.139014096	60.0972391	0.005638452	57.5	.	.
S100A2	1	153561108	153567890	N	.	N	N	0.047063497	53.15737686	0.000135122	71	.	.
S100A3	1	153547329	153549372	N	.	N	N	0.283486649	69.50859524	0.000978354	64.8	.	.
S100A5	1	153537147	153541765	N	.	N	Y	0.21500187	65.32384094	4.81E-05	74	.	.
S100A7	1	153457744	153460701	N	.	N	N	0.253474025	67.62169358	0.547478872	28.7	.	.
S100A7A	1	153416524	153423225	N	.	N	N	1.020880255	93.03698559	0.031599277	49.4	.	.
S100A7L2	1	153437058	153439949	N	.	N	N	.	.	0.558124074	28.5	.	.
S100A9	1	153357854	153361027	N	.	N	Y	0.093038818	56.61283788	0.667440118	25.6	.	.
S100B	21	46598962	46605208	N	.	N	Y	0.046106757	53.06476819	0.181611099	39.3	DFP	.
S100G	X	16650158	16654670	N	.	N	Y	0.242145304	67.0023731	0.141285757	41	.	.
S100P	4	6693069	6697170	N	.	N	N	0.510496156	80.89367367	0.048649365	47.2	.	.
S100PBP	1	32816767	32858879	N	.	N	N	-0.402966415	24.21137929	0.947039389	15	.	.
S100Z	5	76850001	76921650	N	.	N	N	0.108045035	57.83990276	0.009594703	55.1	.	.
S1PR3	9	88991447	89005010	N	.	N	Y	-0.122483898	40.59153788	0.07933389	44.5	DM	.
S1PR5	19	10512742	10517931	N	.	N	Y	0.707640477	87.06951438	0.057413295	46.3	.	.
SAA1	11	18266174	18269977	N	.	N	Y	0.821961205	89.56994849	0.181814611	39.2	DFP	.
SAA2-SAA4	11	18231423	18248635	N	.	N	N	.	.	.	.	.	.
SAA4	11	18112617	18236893	N	.	N	N	0.436419446	77.71025062	0.014635941	53.3	.	.
SAAL1	11	18069935	18106091	N	.	N	N	0.266866049	68.4667477	0.000128877	71.1	.	.
SAC3D1	11	65040901	65044828	N	.	N	Y	.	.	4.62E-05	74.1	.	.
SACS	13	23328823	23433728	N	.	N	N	-3.947991709	0.219945592	6.15E-12	94.5	DM	Spastic ataxia, Charlevoix-Saguenay type, 270550 (3)
SAE1	19	47113274	47210636	N	.	N	N	0.473126302	79.46402732	0.988952422	10.2	DM?	.
SAFB2	19	5586999	5624046	N	.	N	N	-0.870740845	10.16958963	0.999582501	5	.	.
SAG	2	233307816	233347055	N	.	N	Y	0.970409785	92.33084448	1.57E-08	88.4	DM	.
SAGE1	X	135889205	135913061	N	.	N	N	1.124622721	94.23511026	1.64E-09	90.7	FTV	.
SAMD1	19	14087840	14091036	N	.	N	N	.	.	0.204726949	38.6	.	.
SAMD10	20	63974113	63980008	N	.	N	N	-0.138599374	39.52075013	0.006051139	57.2	.	.
SAMD11	1	924880	944581	N	.	N	N	1.798257609	98.18255484	1.35E-10	92.7	.	.
SAMD12	8	118189459	118621995	N	.	N	N	0.158803293	61.65422238	0.001317243	63.7	.	.
SAMD13	1	84298366	84389957	N	.	N	N	0.001088113	49.55142675	0.128562761	41.6	.	.
SAMD14	17	50110040	50129882	N	.	N	N	-0.328892939	27.7768131	0.02026443	51.6	.	.
SAMD15	14	77376689	77391497	N	.	N	N	0.386109337	75.21560456	2.34E-06	81	.	.
SAMD3	6	130144315	130365425	N	.	N	N	0.399201715	75.79440875	1.10E-06	82.4	.	.
SAMD4A	14	54567097	54793315	N	.	N	N	-0.158890404	38.10846791	0.999267732	5.6	FTV	.
SAMD4B	19	39342396	39385710	N	.	N	N	-1.344732532	4.358395555	0.998551353	6.5	.	.
SAMD5	6	147508927	147737547	N	.	N	N	0.654972172	85.79035712	0.000898004	65.1	.	.
SAMD7	3	169911572	169939175	N	.	N	N	0.098929771	57.09324536	6.78E-06	79	.	.
SAMD8	10	75099586	75182123	N	.	N	N	-0.333678613	27.54529143	0.004351697	58.7	.	.
SAMD9	7	93099513	93118023	N	.	N	N	-0.138652752	39.48023384	1.29E-23	99.2	DM	Tumoral calcinosis, familial, normophosphatemic, 610455 (3)
SAMD9L	7	93130055	93148369	N	Viable	N	Y	-1.331090998	4.474156393	3.80E-10	92	.	.
SAMHD1	20	36890229	36951843	N	.	N	Y	-0.800636123	11.57608381	1.50E-05	77	DM	Aicardi-Goutieres syndrome 5, 612952 (3); Chilblain lupus 2, 614415 (3)
SAMM50	22	43955421	44010531	N	.	N	N	-0.64961309	15.39619147	0.000727115	65.8	.	.
SAMSN1	21	14485228	14583402	N	.	N	Y	0.041624995	52.67118134	0.075602358	44.7	.	.
SAP18	13	21140514	21149084	N	.	N	N	-0.034513598	46.96996006	0.045756241	47.5	.	.
SAP25	7	100572228	100573820	N	.	N	N	.	.	.	.	.	.
SAP30	4	173369969	173377532	N	.	N	N	-0.170525669	37.3618105	0.228585001	37.7	.	.
SAP30BP	17	75667116	75708062	N	.	N	N	-0.393703195	24.72072698	1.57E-05	76.9	.	.
SAP30L	5	154445957	154461054	N	.	N	N	-0.035470476	46.91207964	0.857185856	19.6	.	.
SAPCD1	6	31762799	31764851	N	.	N	N	0.550880798	82.46802107	2.32E-07	85	.	.
SAPCD2	9	137062124	137070588	N	.	N	Y	.	.	0.004799009	58.3	.	.
SAR1A	10	70147289	70170523	N	.	N	N	0.048020238	53.25577357	0.630165514	26.6	.	.
SARAF	8	30063012	30083208	N	.	N	N	.	.	.	.	.	.
SARDH	9	133663560	133739955	N	.	N	N	0.607842099	84.38386294	8.20E-10	91.2	DM	[Sarcosinemia], 268900 (3)
SARM1	17	28364356	28404049	N	.	N	Y	.	.	9.19E-09	89	.	.
SARNP	12	55752463	55817756	N	.	N	N	-0.216501186	34.48515367	0.989074046	10.1	.	.
SARS	1	109213918	109238169	N	.	N	N	-0.352359149	26.65972102	0.999150651	5.7	.	.
SARS2	19	38915266	38930896	N	.	N	N	-0.471299039	21.3810268	5.31E-05	73.7	DM	Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3)
SART1	11	65961689	65979828	N	.	N	N	-1.059433781	7.07877525	0.99255633	9.3	DP	.
SART3	12	108522580	108561400	N	.	N	N	-1.237476756	5.226601841	0.991709385	9.5	DM	.
SASH1	6	148272304	148552050	N	.	N	N	-0.618884371	16.20651734	0.003254445	60	.	.
SASH3	X	129779979	129795201	N	.	N	Y	0.113784984	58.30294611	0.891377605	18.1	.	.
SASS6	1	100083563	100132955	N	.	N	N	-0.526691349	19.14105458	5.00E-05	73.9	.	?Microcephaly 14, primary, autosomal recessive, 616402 (3)
SAT1	X	23783173	23786226	N	.	N	Y	0.092082157	56.56653354	0.811595279	21.3	DM	.
SAT2	17	7626234	7627876	N	.	N	N	0.133424212	59.69786421	0.017616305	52.3	.	.
SATL1	X	85092287	85109048	N	.	N	N	2.124507458	98.75557099	6.50E-12	94.5	DM?	.
SAXO1	9	18927658	19049354	N	.	N	N	.	.	.	.	.	.
SAXO2	15	82262810	82284930	N	.	N	N	.	.	.	.	.	.
SAYSD1	6	39104064	39115189	N	.	N	N	-0.030686146	47.24199803	0.000747904	65.7	.	.
SBF2	11	9778667	10294207	N	.	N	N	-2.841913245	0.682988945	0.38005409	33.3	DM	Charcot-Marie-Tooth disease, type 4B2, 604563 (3)
SBK1	16	28292519	28323849	N	.	N	N	-0.168611538	37.4717833	0.437577104	31.8	.	.
SBK2	19	55529733	55537089	N	.	N	N	0.496592274	80.33223361	0.001474848	63.1	.	.
SBK3	19	55540656	55545543	N	.	N	N	.	.	.	.	.	.
SBNO1	12	123289109	123364843	N	.	N	N	-1.895178153	1.881113619	0.999999984	0.9	DP	.
SBSN	19	35523367	35528351	N	.	N	N	0.506964925	80.73739654	0.035145281	48.9	.	.
SBSPON	8	73064540	73124088	N	.	N	N	0.442157199	77.99386468	5.95E-05	73.4	.	.
SCAF1	19	49642125	49658642	N	.	N	N	-0.293795251	29.7794756	0.998787539	6.1	.	.
SCAF11	12	45919131	45992120	N	.	N	N	-0.532658834	18.86322857	0.999681331	4.7	.	.
SCAF4	21	31671033	31732075	N	.	N	N	-0.955052351	8.641546565	0.999999693	1.4	.	.
SCAF8	6	154733325	154834244	N	.	N	N	-2.018967888	1.591711524	0.999999979	0.9	.	.
SCAI	9	124942608	125143506	N	.	N	N	-0.705964203	13.78132778	0.999445289	5.3	.	.
SCAMP1	5	78360583	78479071	N	.	N	Y	.	.	0.84227628	20.2	.	.
SCAMP2	15	74843730	74873365	N	.	N	N	0.107238638	57.76465822	0.383700654	33.2	.	.
SCAMP3	1	155255979	155262430	N	.	N	N	-0.132857585	39.9027609	0.01289441	53.9	.	.
SCAMP4	19	1905214	1926013	N	.	N	N	0.280765669	69.35810615	0.020951714	51.4	.	.
SCAMP5	15	74957219	75021496	N	.	N	N	0.051847216	53.50465937	0.345427473	34.4	.	.
SCAND1	20	35953617	35959472	N	.	N	N	.	.	0.158311342	40.2	.	.
SCAP	3	47413694	47477126	N	.	N	N	-2.189825079	1.296521387	0.02255475	51	FP	.
SCAPER	15	76347904	76905444	N	.	N	N	-1.00948976	7.744400069	0.039282898	48.4	.	.
SCARA3	8	27633868	27676776	N	.	N	N	0.161018822	61.84522776	1.62E-07	85.5	.	.
SCARA5	8	27869882	27992727	N	.	N	Y	-0.175004808	37.08977253	0.066991777	45.3	.	.
SCARB1	12	124776856	124882668	Y	Viable	N	Y	-0.53515137	18.78219598	0.077224403	44.6	DM	[High density lipoprotein cholesterol level QTL6], 610762 (3)
SCARB2	4	76158737	76213893	N	.	N	Y	0.506964925	80.73739654	0.072442869	44.9	DM	Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3)
SCARF1	17	1633858	1645747	N	.	N	Y	1.437873325	96.62557157	0.000660074	66.2	.	.
SCARF2	22	20424585	20437859	N	Viable	N	Y	.	.	.	.	DM	Van den Ende-Gupta syndrome, 600920 (3)
SCCPDH	1	246724047	246768137	N	.	N	N	0.253623009	67.679574	0.011900703	54.2	.	.
SCD5	4	82629539	82798857	N	.	N	N	-0.341984971	27.1690687	0.005017086	58.1	.	.
SCEL	13	77535674	77645263	N	.	N	Y	0.494980525	80.29171731	5.00E-12	94.7	.	.
SCFD1	14	30622112	30735812	N	.	N	N	-0.401052411	24.3502923	0.991579194	9.6	.	.
SCFD2	4	52872982	53366075	N	.	N	N	-0.338006426	27.36007409	1.87E-06	81.4	.	.
SCG2	2	223596940	223602503	N	.	N	N	-0.312777691	28.73184002	0.898323134	17.8	DFP	.
SCG3	15	51681353	51721031	N	.	N	N	-0.266954701	31.4637958	0.267523893	36.6	DFP	.
SCGB1A1	11	62405103	62423195	N	.	N	Y	0.093038818	56.61283788	0.007661332	56.2	DFP	.
SCGB1C1	11	193080	194573	N	.	N	N	0.938338578	91.83886091	3.34E-05	75	.	.
SCGB1C2	17	137526	139067	N	.	N	N	.	.	.	.	.	.
SCGB1D1	11	62190216	62193539	N	.	N	N	0.389487678	75.3313654	1.19E-05	77.6	.	.
SCGB1D2	11	62242210	62244808	N	.	N	N	0.237511303	66.66087862	0.096113681	43.4	FP	.
SCGB1D4	11	62296277	62299064	N	.	N	N	0.145560638	60.65289113	0.002902192	60.5	.	.
SCGB2A1	11	62208668	62213939	N	.	N	N	0.381028261	74.95514268	0.056401295	46.3	.	.
SCGB2A2	11	62270155	62273156	N	.	N	N	0.30503986	70.79354055	0.008924277	55.4	.	.
SCGB2B2	19	34593329	34675699	N	.	N	N	0.448557666	78.28905481	0.000675653	66.1	.	.
SCGB3A1	5	180590103	180591540	N	.	N	N	.	.	0.452637902	31.3	.	.
SCGB3A2	5	147870682	147882191	N	.	N	N	0.008591214	50.15917115	0.042427477	48	DFP	{Asthma, susceptibility to}, 600807 (3)
SCGN	6	25652201	25701783	N	.	N	N	0.457163544	78.66527754	0.035946002	48.8	.	.
SCIMP	17	5208961	5234860	N	.	N	Y	0.199995603	64.38039011	0.012575344	54	.	.
SCIN	7	12570577	12660179	N	.	N	N	1.252833539	95.4563871	4.08E-16	97.5	.	.
SCLT1	4	128864921	129093607	N	.	N	N	0.327041902	72.1826706	5.17E-12	94.6	.	.
SCLY	2	238060889	238099413	N	.	N	Y	0.309165138	71.01927418	1.52E-06	81.9	.	.
SCMH1	1	41027200	41242154	N	.	N	Y	-0.167350159	37.57018001	0.524101684	29.3	.	.
SCML1	X	17737449	17754988	N	.	N	N	0.321958851	71.87011634	0.948610392	14.9	.	.
SCML2	X	18239314	18354727	N	.	N	N	-0.490286222	20.58227702	0.998434048	6.6	.	.
SCML4	6	107704104	107824317	N	.	N	N	-0.125354587	40.43526075	0.268213055	36.5	.	.
SCN10A	3	38696802	38794010	N	.	N	Y	0.37719157	74.77571338	6.14E-26	99.4	DM	Episodic pain syndrome, familial, 2, 615551 (3)
SCN11A	3	38845769	38950561	N	.	N	Y	-2.104108841	1.447010476	2.52E-19	98.5	.	Neuropathy, hereditary sensory and autonomic, type VII, 615548 (3); Episodic pain syndrome, familial, 3, 615552 (3)
SCN2B	11	118161951	118176673	N	.	N	Y	-0.075704275	43.9775424	0.133477243	41.4	DM	Atrial fibrillation, familial, 14, 615378 (3)
SCN3B	11	123629187	123655244	N	.	N	Y	-0.024139966	47.63558488	0.347297034	34.3	DM	Brugada syndrome 7, 613120 (3); Atrial fibrillation, familial, 16, 613120 (3)
SCN4B	11	118133377	118152888	N	.	N	N	0.182269088	63.36169474	0.001535227	62.9	DM	Long QT syndrome-10, 611819 (3); Atrial fibrillation, familial, 17, 611819 (3)
SCN7A	2	166403573	166494247	N	.	N	Y	1.01607083	92.96174104	1.72E-15	97.2	.	.
SCNM1	1	151156664	151170297	N	.	N	Y	0.082816117	55.93563697	4.73E-05	74	.	.
SCNN1D	1	1280436	1292029	N	.	N	N	3.425005039	99.65850553	2.82E-15	97	.	.
SCOC	4	140257286	140385726	N	.	N	N	0.068616116	54.74908838	0.280616506	36.2	.	.
SCP2	1	52927229	53051703	N	.	N	Y	-0.71346748	13.57295827	0.00013976	70.9	DM	.
SCP2D1	20	18813726	18814392	N	.	N	N	0.200952107	64.44405857	0.031553448	49.4	.	.
SCPEP1	17	56978105	57006768	N	.	N	Y	-0.454530953	22.09874399	6.99E-08	86.6	.	.
SCRG1	4	173384701	173406380	N	.	N	N	0.130554386	59.44897841	0.034529027	49	.	.
SCRN1	7	29920103	29990289	N	.	N	N	-0.296009812	29.68107889	0.065188552	45.5	.	.
SCRN2	17	47837692	47841333	N	.	N	N	0.503288375	80.58111941	6.56E-07	83.2	.	.
SCRN3	2	174395730	174429575	N	.	N	N	0.529474463	81.64611912	1.32E-06	82.2	.	.
SCRT1	8	144330565	144336281	N	.	N	N	-0.0579797	45.26827574	0.294251147	35.9	.	.
SCRT2	20	661596	676179	N	.	N	N	.	.	0.364922305	33.8	.	.
SCT	11	626431	627143	N	.	N	Y	.	.	0.406650722	32.6	FP	.
SCTR	2	119439843	119525301	N	.	N	Y	0.760312099	88.31973143	1.96E-09	90.5	.	.
SCUBE2	11	9020391	9138114	N	.	N	N	-0.652995945	15.28621867	1.49E-13	96	DM?	.
SCUBE3	6	35214419	35253079	N	.	N	Y	-0.879200336	9.955432077	0.999983707	2.7	.	.
SCX	8	144266560	144268481	N	.	N	Y	.	.	.	.	.	.
SCYL1	11	65525077	65538704	N	.	N	Y	-0.146603776	38.95931007	0.007784407	56.1	.	.
SCYL2	12	100267140	100341724	N	.	N	N	-1.140063572	6.146900504	0.931828671	16	.	.
SCYL3	1	169849631	169894267	N	.	N	N	0.031554464	51.95346414	0.547053808	28.7	.	.
SDAD1	4	75940950	75990962	N	.	N	N	0.185441616	63.55270012	3.78E-09	89.9	.	.
SDC1	2	20200797	20225433	N	.	N	Y	0.147623843	60.84968455	0.290469547	36	.	.
SDC2	8	96493351	96611780	N	Viable	N	Y	0.269436731	68.66354112	0.579949601	28	.	.
SDC3	1	30869467	30908761	N	.	N	Y	0.603699992	84.26231406	0.527916181	29.2	DP	{Obesity, association with}, 601665 (3)
SDC4	20	45325288	45348424	N	.	N	Y	-0.077618099	43.83284135	0.011803491	54.2	.	.
SDCBP	8	58552924	58582860	N	.	N	N	-0.097256408	42.28164612	0.000811572	65.5	.	.
SDCBP2	20	1309909	1329239	N	.	N	N	1.125120265	94.25826243	0.410340822	32.5	.	.
SDCCAG3	9	136401922	136410609	N	.	N	N	0.364557107	74.1158766	1.38E-07	85.7	.	.
SDE2	1	225982702	225999331	N	.	N	N	-0.066135668	44.67789547	5.17E-07	83.7	.	.
SDF2	17	28648356	28662189	N	.	N	N	-0.146102415	38.98246223	0.68281004	25.1	.	.
SDF2L1	22	21642261	21644298	N	.	N	N	.	.	0.05429609	46.5	.	.
SDF4	1	1216908	1232031	N	.	N	N	0.391698646	75.46449036	0.001309827	63.7	.	.
SDHAF1	19	35995199	35996315	N	.	N	N	.	.	0.106593834	42.8	DM	Mitochondrial complex II deficiency, 252011 (3)
SDHAF2	11	61430042	61447529	N	.	N	N	0.058393523	53.97927881	6.98E-05	72.9	DM	Paragangliomas 2, 601650 (3)
SDHAF3	7	97116590	97181763	N	.	N	N	.	.	.	.	.	.
SDHAF4	6	70566917	70589569	N	.	N	N	.	.	.	.	.	.
SDK1	7	3301448	4269000	N	.	N	N	-0.44980254	22.28974938	0.005015997	58.1	.	.
SDK2	17	73334384	73644089	N	.	N	N	1.159195208	94.62869711	0.029034431	49.9	.	.
SDPR	2	191834302	191847255	N	.	N	Y	0.236853976	66.63772646	0.000704633	65.9	.	.
SDR16C5	8	56300010	56320776	N	.	N	N	-0.506249788	19.96874457	0.00291744	60.4	.	.
SDR39U1	14	24439766	24442905	N	.	N	N	1.476048459	96.84551716	7.41E-08	86.5	.	.
SDR42E1	16	81988855	82011488	N	.	N	N	1.997865954	98.57035365	3.53E-07	84.3	.	.
SDR42E2	16	22165583	22191754	N	.	N	N	.	.	.	.	.	.
SDR9C7	12	56923154	56934405	N	.	N	N	-0.154409651	38.42681021	0.013528777	53.7	.	.
SDS	12	113392445	113426301	N	.	N	N	-0.350445024	26.76390577	0.005484262	57.7	.	.
SDSL	12	113422237	113438276	N	Viable	N	Y	0.324977012	72.03796955	2.99E-09	90.1	.	.
SEBOX	17	28364268	28365244	N	.	N	N	1.142854062	94.45505585	.	.	.	.
SEC11A	15	84669538	84716716	N	.	N	N	-0.20053791	35.44596863	0.173327555	39.6	.	.
SEC11C	18	59139477	59158836	N	.	N	N	0.14651721	60.7454998	0.694287699	24.8	.	.
SEC13	3	10293131	10321178	N	.	N	N	-0.623428585	16.06181629	0.584365053	27.8	.	.
SEC14L1	17	77086716	77217101	N	.	N	N	-0.954382307	8.647334607	0.179640443	39.3	.	.
SEC14L2	22	30396857	30425317	N	.	N	Y	-0.055913898	45.41297679	4.31E-05	74.3	.	.
SEC14L3	22	30447959	30472049	N	.	N	N	0.722795389	87.49204144	4.21E-18	98.2	.	.
SEC14L4	22	30488913	30505711	N	.	N	N	0.737802049	87.79301962	5.60E-05	73.6	.	.
SEC14L5	16	4958317	5019158	N	.	N	N	-1.288233337	4.775134572	6.57E-10	91.5	.	.
SEC14L6	22	30522799	30546682	N	.	N	N	.	.	0.045916184	47.5	.	.
SEC16A	9	136440096	136483759	N	.	N	N	0.338092805	72.75568675	0.687007221	25	.	.
SEC16B	1	177923956	177984303	N	.	N	Y	2.583853502	99.23019043	4.44E-13	95.6	.	.
SEC22A	3	123201927	123274130	N	.	N	N	-0.051281473	45.6908028	0.638909265	26.3	.	.
SEC22C	3	42547969	42601080	N	.	N	N	0.078183267	55.57099033	1.72E-06	81.6	.	.
SEC23IP	10	119892711	119944658	N	.	N	Y	-1.078935525	6.818313365	0.373415108	33.5	.	.
SEC24A	5	134648789	134727823	N	.	N	Y	-1.112635851	6.430514557	1.31E-05	77.3	.	.
SEC24C	10	73744384	73772161	N	.	N	N	-0.795563292	11.66290444	0.99999234	2.4	.	.
SEC31A	4	82818661	82901166	N	.	N	N	-1.125734969	6.337905886	0.003699346	59.4	.	.
SEC31B	10	100486642	100519864	N	.	N	N	1.064932107	93.55790936	1.30E-24	99.3	.	.
SEC61A1	3	128051641	128071683	N	.	N	N	-0.764231802	12.32274122	0.995608072	8.1	.	.
SEC61A2	10	12129637	12169961	N	.	N	N	-0.513752923	19.67355444	0.950042172	14.7	.	.
SEC61B	9	99222064	99230615	N	.	N	N	0.031100532	51.89558372	0.742840233	23.4	.	.
SEC61G	7	54752250	54759974	N	.	N	N	0.18116337	63.25172194	0.611529457	27.1	.	.
SEC62	3	169966635	169998373	N	.	N	N	-0.280200056	30.62452972	0.967257863	13.3	.	.
SECISBP2L	15	48988476	49046563	N	.	N	N	-0.87265272	10.12907333	0.101713052	43	.	.
SECTM1	17	82321024	82334074	N	.	N	N	0.419647726	76.80731608	0.172404203	39.6	.	.
SEL1L2	20	13849247	13996443	N	.	N	N	0.581190406	83.53302078	2.69E-11	93.7	.	.
SEL1L3	4	25747427	25863760	N	.	N	N	-0.374417221	25.7046941	0.628820332	26.7	.	.
SELE	1	169722641	169764705	N	.	N	Y	0.090621427	56.49707704	1.66E-08	88.4	DP	[Blood pressure regulation QTL], 145500 (2)
SELENBP1	1	151364302	151372733	N	Viable	N	Y	0.262233352	68.20049777	1.22E-06	82.3	.	.
SELK	3	53884410	53891988	N	Viable	N	Y	.	.	0.003228653	60	.	.
SELL	1	169690667	169711698	N	.	N	Y	0.105325255	57.63153325	0.001734631	62.4	DP	.
SELM	22	31104772	31120069	N	.	N	Y	0.078989305	55.61150663	6.37E-07	83.3	.	.
SELO	22	50200979	50217616	N	.	N	N	0.405098119	76.10117497	5.81E-15	96.8	.	.
SELP	1	169588849	169630193	N	.	N	Y	1.052461262	93.39005614	4.62E-20	98.7	DFP	{Atopy, susceptibility to}, 147050 (3)
SELPLG	12	108622277	108633959	N	.	N	Y	1.078330989	93.72576257	0.004954425	58.1	DFP	.
SELT	3	150602875	150630445	N	.	N	N	-0.118961255	40.82305956	0.14377878	40.9	.	.
SELV	19	39515113	39520686	N	.	N	N	.	.	0.000392719	67.8	.	.
SEMA3B	3	50267558	50277546	N	.	N	Y	.	.	.	.	.	.
SEMA3D	7	84995553	85186855	N	.	N	Y	-0.329546751	27.75944898	3.53E-05	74.8	DM?	.
SEMA3E	7	83363906	83649010	N	.	N	Y	-0.707576422	13.71187127	0.030447872	49.5	DM	CHARGE syndrome, 214800 (3)
SEMA3G	3	52433053	52445085	N	.	N	Y	-0.92135498	9.197198588	6.08E-10	91.6	.	.
SEMA4A	1	156147366	156177752	N	.	N	Y	-0.260105961	31.87474677	0.615371621	27.1	DM	Retinitis pigmentosa 35, 610282 (3); Cone-rod dystrophy 10, 610283 (3)
SEMA4B	15	90160604	90229679	N	.	N	Y	-0.078119962	43.7981131	0.001608001	62.8	.	.
SEMA4D	9	89360787	89498130	N	Viable	N	Y	-0.535665729	18.75325577	0.995825192	8.1	DM?	.
SEMA4F	2	74654228	74683853	N	.	N	N	-0.612755288	16.41488684	6.74E-10	91.4	.	.
SEMA4G	10	100969518	100985871	N	.	N	Y	0.222152762	65.73479192	0.000802235	65.5	DM?	.
SEMA5B	3	122909193	123028605	N	.	N	Y	0.201712346	64.47299878	0.0003315	68.4	.	.
SEMA6A	5	116443616	116574934	N	.	N	Y	-1.168029185	5.921166869	0.999546537	5.1	.	.
SEMA6B	19	4542593	4559808	N	.	N	Y	-0.74891881	12.67581177	0.742578967	23.4	.	.
SEMA6C	1	151131685	151146664	N	.	N	Y	0.085032132	56.10349019	5.65E-05	73.6	.	.
SEMA6D	15	47184101	47774223	N	.	N	N	-1.699081957	2.454129768	0.999469976	5.2	DM?	.
SEMA7A	15	74409289	74434467	N	.	N	Y	-0.098866514	42.17167332	0.025393401	50.4	DM	[Blood group, John-Milton-Hagen system], 614745 (3)
SEMG1	20	45206997	45209772	N	.	N	Y	0.70411288	86.98269375	1.94E-14	96.5	DP	.
SEMG2	20	45221300	45224458	N	.	N	N	0.318581939	71.67332291	6.77E-15	96.8	.	.
SENP3	17	7561875	7571969	N	.	N	N	.	.	0.99599542	8	.	.
SENP3-EIF4A1	17	7563287	7578715	N	.	N	N	.	.	.	.	.	.
SENP5	3	196867856	196934714	N	.	N	N	-0.306231452	29.11385078	0.996261183	7.9	.	.
SENP7	3	101324205	101513241	N	.	N	N	-0.516168934	19.58094577	0.987260725	10.5	.	.
SENP8	15	72114258	72143688	N	.	N	N	-0.215544031	34.54882213	0.257288613	36.8	.	.
SEP15	1	86862445	86914424	N	.	N	Y	.	.	0.428149535	32.1	.	.
SEPHS1	10	13317424	13348298	N	.	N	N	-0.461231059	21.83249407	0.979964055	11.7	.	.
SEPHS2	16	30443631	30446181	N	.	N	N	0.0077858	50.10707878	0.001786053	62.3	.	.
SEPN1	1	25800176	25818224	N	.	N	Y	0.315711326	71.46495341	1.08E-07	86	DM	Muscular dystrophy, rigid spine, 1, 602771 (3); Myopathy, congenital, with fiber-type disproportion, 255310 (3)
SEPSECS	4	25120014	25160442	N	.	N	N	-0.402009394	24.309776	2.65E-06	80.7	DM	Pontocerebellar hypoplasia type 2D, 613811 (3)
SEPT1	16	30378133	30395991	N	.	N	N	0.109152052	57.94408752	0.002937466	60.4	.	.
SEPT10	2	109542982	109614206	N	.	N	Y	0.169326965	62.4587602	0.002883286	60.5	.	.
SEPT11	4	76949703	77040384	N	.	N	N	-0.301752054	29.35694854	0.681901564	25.1	.	.
SEPT12	16	4777669	4788521	N	.	N	Y	-0.146754769	38.95352202	4.59E-10	91.8	DM	Spermatogenic failure 10, 614822 (3)
SEPT14	7	55793544	55862789	N	.	N	N	0.869994186	90.58285582	4.97E-05	73.9	.	.
SEPT2	2	241315100	241354027	N	.	N	N	-0.522213436	19.34942409	0.866554503	19.2	.	.
SEPT3	22	41976272	41998221	N	.	N	Y	-0.067244365	44.5852868	0.069248203	45.1	.	.
SEPT4	17	58520250	58540818	N	.	N	Y	-0.075552304	44.00069457	0.01183686	54.2	.	.
SEPT5	22	19714464	19724772	N	.	N	Y	-0.817712941	11.2288013	0.914631983	17	.	.
SEPT6	X	119615724	119693370	N	.	N	Y	0.158803293	61.65422238	0.948998032	14.8	.	.
SEPT8	5	132750817	132807241	N	.	N	Y	-0.81755696	11.25195346	0.954285718	14.4	.	.
SEPW1	19	47778572	47784686	N	.	N	N	0.206542259	64.76240088	0.000743621	65.7	.	.
SERAC1	6	158109515	158168270	N	.	N	N	-0.313734483	28.63923135	0.002400981	61.3	DM	3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 (3)
SERBP1	1	67407810	67430415	N	.	N	N	-0.595330347	16.85477803	0.999863114	4	.	.
SERF1A	5	70900665	70918530	N	.	N	Y	.	.	.	.	.	.
SERF1B	5	70025247	70043113	N	.	N	N	.	.	.	.	.	.
SERF2	15	43777087	43802589	N	.	N	N	0.04897698	53.33680616	0.138975962	41.1	.	.
SERGEF	11	17788048	18013162	N	.	N	N	0.316517317	71.52862187	2.22E-10	92.4	.	.
SERHL2	22	42553617	42574382	N	.	N	N	0.807097444	89.28054639	1.17E-11	94.2	.	.
SERINC1	6	122443354	122471822	N	.	N	N	-0.341984971	27.1690687	0.074621456	44.8	.	.
SERINC2	1	31409565	31434680	N	.	N	N	0.743543456	87.94929675	1.03E-06	82.5	.	.
SERINC3	20	44496221	44522109	N	.	N	Y	-0.499549597	20.20605429	0.590252232	27.7	.	.
SERINC4	15	43794162	43800221	N	.	N	N	0.466579567	79.16883718	0.010759429	54.6	.	.
SERINC5	5	80111651	80256079	N	.	N	N	-0.298880801	29.53637784	0.000839904	65.4	.	.
SERP2	13	44373665	44397714	N	.	N	N	0.015137522	50.6627308	0.229121363	37.7	.	.
SERPINA10	14	94280455	94293271	N	.	N	Y	1.177793967	94.81970249	1.21E-05	77.6	DM	.
SERPINA11	14	94442464	94452790	N	.	N	N	-0.483586384	20.81958673	1.41E-07	85.7	.	.
SERPINA12	14	94487274	94517844	N	.	N	Y	0.686235642	86.56595474	7.47E-06	78.8	.	.
SERPINA3	14	94592058	94624646	N	.	N	Y	0.537128297	81.95288534	5.34E-12	94.6	DM	Alpha-1-antichymotrypsin deficiency (3); Cerebrovascular disease, occlusive (3)
SERPINA4	14	94561091	94569913	N	.	N	N	-0.139251787	39.47444579	1.58E-07	85.5	.	.
SERPINA5	14	94561442	94593120	N	.	N	Y	0.528668245	81.61139087	0.052638583	46.7	.	.
SERPINA6	14	94304248	94323394	N	.	N	Y	-0.014571683	48.31278578	5.27E-07	83.6	DM	Corticosteroid-binding globulin deficiency, 611489 (3)
SERPINA7	X	106032442	106038738	N	.	N	N	0.222654188	65.80424842	0.13249872	41.4	DM	.
SERPINA9	14	94462717	94479689	N	.	N	N	1.507170908	96.98443017	1.79E-09	90.6	.	.
SERPINB1	6	2832332	2842006	N	.	N	Y	-0.479911471	20.98743995	0.020343016	51.6	.	.
SERPINB10	18	63897174	63936111	N	.	N	N	0.948855468	91.99513804	6.27E-05	73.3	.	.
SERPINB11	18	63647579	63726432	N	.	N	N	.	.	5.09E-07	83.7	FP	.
SERPINB12	18	63556160	63567011	N	.	N	N	0.493871825	80.23962493	7.76E-17	97.7	.	.
SERPINB13	18	63586989	63604639	N	.	N	N	0.425387042	77.11408231	0.000102299	71.8	.	.
SERPINB2	18	63871692	63903890	N	.	N	Y	0.480778977	79.78236962	5.76E-05	73.5	DM?	.
SERPINB3	18	63637719	63661963	N	.	N	N	1.156239112	94.56502865	8.69E-14	96.1	DP	.
SERPINB4	18	63637259	63644298	N	.	N	Y	0.359772785	73.92487122	1.28E-11	94.1	DM?	.
SERPINB5	18	63476761	63505085	Y	Viable	N	Y	0.194555337	64.09677606	0.450309367	31.4	FP	.
SERPINB6	6	2948159	2972165	N	.	N	Y	-0.007068709	48.91474214	0.035668799	48.9	DM	?Deafness, autosomal recessive 91, 613453 (3)
SERPINB7	18	63752935	63805376	N	.	N	N	-0.045540401	46.17121028	7.67E-05	72.7	.	Palmoplantar keratoderma, Nagashima type, 615598 (3)
SERPINB8	18	63969925	64005667	N	.	N	N	0.107389526	57.79938647	6.74E-07	83.2	.	.
SERPINB9	6	2887266	2903280	N	.	N	Y	-0.409512462	23.96828153	0.004898534	58.2	.	.
SERPINE1	7	101127089	101139266	N	.	N	Y	0.046408913	53.12264861	0.219519977	38	DM	Plasminogen activator inhibitor-1 deficiency, 613329 (3); {Transcription of plasminogen activator inhibitor, modulator of} (3)
SERPINE2	2	223975112	224039319	N	.	N	Y	-0.479911471	20.98743995	0.643023919	26.2	.	.
SERPINE3	13	51335773	51364735	N	.	N	N	0.004110017	49.83504081	0.00116718	64.1	.	.
SERPINF1	17	1761959	1777574	N	.	N	Y	0.693738925	86.75696012	8.29E-05	72.4	DM	Osteogenesis imperfecta, type VI, 613982 (3)
SERPINF2	17	1742836	1755268	N	.	N	Y	-0.081141613	43.508711	0.423433542	32.2	DM	Alpha-2-plasmin inhibitor deficiency, 262850 (3)
SERPING1	11	57597387	57614853	N	.	N	N	-0.55398566	18.10499508	0.972837399	12.7	DM	Angioedema, hereditary, types I and II, 106100 (3); Complement component 4, partial deficiency of, 120790 (3)
SERPINI1	3	167735243	167825568	N	.	N	Y	0.405597914	76.13011518	0.930874238	16.1	DM	Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3)
SERPINI2	3	167441789	167479004	N	.	N	N	0.192642013	63.98680326	2.00E-10	92.5	DP	.
SERTAD1	19	40421592	40426025	N	.	N	Y	0.164393154	62.10568965	0.04218449	48	FP	.
SERTAD2	2	64631621	64751005	N	.	N	Y	-0.441438866	22.67176014	0.736975237	23.5	.	.
SERTAD3	19	40440844	40444705	N	.	N	N	-0.328090038	27.8173294	0.06539173	45.5	.	.
SERTAD4	1	210232799	210246631	N	.	N	N	-0.064373744	44.83996064	0.641278925	26.3	.	.
SERTM1	13	36673912	36697839	N	.	N	N	0.038603643	52.45123575	0.467667126	30.9	.	.
SESN1	6	108986437	109094819	N	.	N	N	-0.992051392	7.993285871	0.000638248	66.3	.	.
SESN2	1	28259527	28282491	N	.	N	Y	0.12989848	59.41425016	0.000763709	65.6	DM?	.
SESN3	11	95165540	95232541	N	.	N	Y	-0.467776875	21.53730393	0.994296083	8.7	.	.
SET	9	128683424	128696400	N	.	N	N	0.108045035	57.83990276	0.96336428	13.6	.	.
SETD2	3	47016429	47163967	Y	Viable	N	Y	-2.311555306	1.117092088	0.999992944	2.4	DM?	.
SETD3	14	99397746	99480889	N	.	N	N	-0.813729137	11.31562193	0.371891003	33.6	.	.
SETD4	21	36034541	36079389	N	.	N	Y	0.143947707	60.52555421	2.55E-12	94.9	.	.
SETD6	16	58515479	58521181	N	Viable	N	Y	-0.249077884	32.50564334	1.02E-09	91.1	.	.
SETD9	5	56909260	56925532	N	.	N	N	-0.149777475	38.76251664	0.000533498	66.9	.	.
SETDB2	13	49444374	49495003	N	.	N	N	-0.139251787	39.47444579	0.043730109	47.7	DM?	.
SETMAR	3	4303304	4317567	N	.	N	N	0.378455173	74.86832205	0.002131279	61.6	.	.
SETSIP	1	92074533	92075441	N	.	N	N	.	.	.	.	.	.
SETX	9	132261356	132354985	N	Viable	N	Y	-1.28540006	4.79828674	0.200249584	38.7	DM	Amyotrophic lateral sclerosis 4, juvenile, 602433 (3); Spinocerebellar ataxia, autosomal recessive 1, 606002 (3)
SEZ6	17	28954901	29006440	N	.	N	Y	0.498809229	80.40747815	1.39E-05	77.2	DM?	.
SEZ6L	22	26169474	26383597	N	Viable	N	Y	0.23635616	66.574058	0.928831047	16.2	.	.
SEZ6L2	16	29871159	29899547	N	Viable	N	Y	-1.040460587	7.373965388	0.13015316	41.6	DP	.
SF3A2	19	2236504	2248679	N	.	N	N	.	.	0.774375362	22.5	.	.
SF3A3	1	37956975	37990921	N	.	N	N	-0.317715301	28.40770967	0.999895352	3.8	.	.
SF3B2	11	66050729	66069308	N	.	N	N	-1.27241241	4.931411703	0.999459845	5.2	.	.
SF3B3	16	70523788	70577670	N	.	N	N	-1.305152971	4.665161776	0.999962978	3.1	.	.
SF3B4	1	149923317	149928344	N	.	N	N	-0.243641967	32.83556173	0.918007232	16.8	DM	Acrofacial dysostosis 1, Nager type, 154400 (3)
SF3B5	6	144094881	144095573	N	.	N	N	0.220592134	65.68848758	0.600475507	27.4	.	.
SF3B6	2	24067584	24076443	N	.	N	N	.	.	.	.	.	.
SFI1	22	31488688	31618586	N	.	N	N	1.17670974	94.80812641	5.99E-25	99.3	.	.
SFMBT1	3	52903572	53046750	N	.	N	N	-0.550963897	18.18023962	0.995894208	8	.	.
SFMBT2	10	7158624	7411486	N	.	N	N	-0.550816557	18.18602767	0.99640777	7.8	.	.
SFR1	10	104122058	104126385	N	.	N	N	0.371759592	74.49209932	0.000222755	69.5	.	.
SFRP1	8	41261958	41309497	N	.	N	Y	-0.507207153	19.92244024	0.465845742	31	.	.
SFRP2	4	153780592	153789120	N	.	N	Y	-0.104759418	41.81281472	0.053884519	46.6	.	.
SFRP4	7	37905932	38025695	N	.	N	N	-0.304469805	29.22961162	4.46E-05	74.2	.	.
SFRP5	10	97766751	97771952	N	.	N	Y	0.313647588	71.30867627	1.17E-05	77.6	.	.
SFSWAP	12	131711081	131799737	N	.	N	N	-1.003896493	7.80806853	0.999425434	5.3	.	.
SFT2D1	6	166319728	166342591	N	.	N	N	0.442966544	78.02280489	0.350193452	34.2	.	.
SFT2D2	1	168225938	168253025	N	.	N	N	0.116504775	58.48816345	0.003949651	59.1	.	.
SFT2D3	2	127701508	127705242	N	.	N	N	.	.	.	.	.	.
SFTA2	6	30931353	30932175	N	.	N	N	0.031100532	51.89558372	0.594981142	27.6	.	.
SFTA3	14	36473288	36513829	N	.	N	N	0.296580367	70.28419286	0.294636982	35.8	.	.
SFTPA2	10	79555852	79560397	N	.	N	N	0.702049624	86.94217746	0.014599505	53.3	DM	Pulmonary fibrosis, idiopathic, 178500 (3)
SFTPC	8	22156913	22164479	N	.	N	Y	0.203821715	64.60033571	0.068448802	45.2	DM	Surfactant metabolism dysfunction, pulmonary, 2, 610913 (3)
SFTPD	10	79937740	79982614	N	.	N	Y	0.284591847	69.63014412	0.240356031	37.4	DM?	.
SFXN1	5	175477062	175529742	N	.	N	N	0.116655069	58.50552758	0.58517755	27.8	.	.
SFXN2	10	102714538	102743492	N	.	N	N	0.043538553	52.85061064	0.001084574	64.4	.	.
SFXN3	10	101031234	101041244	N	Viable	N	Y	-0.041864765	46.45482433	1.27E-11	94.1	.	.
SFXN4	10	119140767	119165667	N	.	N	N	-0.739806738	12.88996932	0.00014832	70.7	.	Combined oxidative phosphorylation deficiency 18, 615578 (3)
SFXN5	2	72942036	73075619	N	.	N	N	0.41501409	76.61052266	0.014030451	53.5	.	.
SGCA	17	50164214	50175931	N	.	N	Y	0.556617993	82.67639058	0.194446674	38.9	DM	Muscular dystrophy, limb-girdle, type 2D, 608099 (3)
SGCB	4	52020706	52038482	N	.	N	Y	-0.337353053	27.42374255	0.003600152	59.5	DM	Muscular dystrophy, limb-girdle, type 2E, 604286 (3)
SGCD	5	155870344	156767788	N	.	N	Y	0.432741275	77.53082132	0.0023391	61.3	DM	Muscular dystrophy, limb-girdle, type 2F, 601287 (3); Cardiomyopathy, dilated, 1L, 606685 (3)
SGCE	7	94585230	94656209	N	.	N	Y	-0.668447919	14.80002315	0.001386322	63.4	DM	Dystonia-11, myoclonic, 159900 (3)
SGCG	13	23180952	23325165	N	.	N	Y	0.313647588	71.30867627	0.006370384	57	DM	Muscular dystrophy, limb-girdle, type 2C, 253700 (3)
SGCZ	8	14089864	15238339	N	.	N	N	-0.411426546	23.88724894	0.001985816	61.9	DM?	.
SGIP1	1	66533383	66748299	N	Viable	N	Y	-0.955192685	8.635758523	0.999651093	4.8	.	.
SGK1	6	134169246	134318112	N	.	N	Y	-0.055762257	45.41876483	0.986448163	10.7	FP	.
SGK2	20	43558968	43588237	N	.	N	N	-0.21156288	34.83822423	2.93E-07	84.6	.	.
SGK223	8	8317736	8386498	N	.	N	N	0.988917542	92.6376107	5.12E-20	98.7	.	.
SGK3	8	66712418	66862022	N	.	N	Y	-0.527801879	19.0889622	0.13683256	41.2	.	.
SGK494	17	28607964	28614200	N	Viable	N	Y	.	.	2.61E-05	75.6	.	.
SGMS1	10	50305586	50625163	N	.	N	Y	-0.377739799	25.58314522	0.890866798	18.2	.	.
SGMS2	4	107824563	107915047	N	.	N	Y	-0.33080711	27.69578052	0.037128404	48.7	.	.
SGOL2	2	200510008	200583782	N	.	N	Y	1.313345943	95.87891416	6.61E-05	73.1	.	.
SGPP2	2	222424517	222560948	N	.	N	N	-0.261365676	31.77635006	0.012273761	54.1	.	.
SGSH	17	80206716	80220923	N	.	N	N	1.085986995	93.8125832	0.00010579	71.7	DM	Mucopolysaccharidisis type IIIA (Sanfilippo A), 252900 (3)
SGSM1	22	24806169	24927578	N	Viable	N	Y	-0.654766065	15.21676217	0.977248923	12.2	.	.
SGSM2	17	2337498	2381058	N	.	N	N	0.179358178	63.12438502	5.56E-08	86.8	DP	.
SGSM3	22	40370591	40410289	N	.	N	N	-1.388519298	4.005324999	1.01E-06	82.5	DM?	.
SGTA	19	2754714	2783371	N	Viable	N	Y	-0.45181342	22.19714071	0.470281213	30.8	.	.
SGTB	5	65665928	65723035	N	.	N	N	-0.10204113	42.00382011	0.991633523	9.6	.	.
SH2B2	7	102285091	102321711	N	.	N	Y	.	.	0.011359941	54.4	.	.
SH2B3	12	111405948	111451623	N	.	N	Y	-0.059589522	45.15830295	0.00592219	57.3	DM?	Myelofibrosis, somatic, 254450 (3); Thrombocythemia, somatic, 187950 (3); Erythrocytosis, somatic, 133100 (3)
SH2D1A	X	124346344	124373155	N	.	N	Y	0.15865385	61.61949413	0.082608811	44.2	DM	Lymphoproliferative syndrome, X-linked, 1, 308240 (3)
SH2D1B	1	162395266	162412138	N	.	N	Y	0.359474808	73.90171905	0.059883365	46	.	.
SH2D2A	1	156806243	156816862	N	.	N	Y	0.322107219	71.89326851	8.43E-05	72.4	.	.
SH2D3A	19	6752160	6767588	N	.	N	N	1.57934546	97.38380506	4.11E-06	79.9	.	.
SH2D4A	8	19313617	19396218	N	.	N	Y	-0.324913589	28.02569891	1.53E-18	98.3	.	.
SH2D4B	10	80537902	80646560	N	.	N	N	0.770536433	88.57440528	3.12E-07	84.5	.	.
SH2D5	1	20719732	20732837	N	.	N	Y	0.145861223	60.69919546	0.002653616	60.9	.	.
SH2D6	2	85418721	85437029	N	.	N	N	0.746925466	88.0245413	0.003696498	59.4	.	.
SH2D7	15	78077808	78104909	N	.	N	N	1.212444178	95.14962088	0.001420981	63.3	.	.
SH3BGR	21	39445855	39515506	N	.	N	N	0.758252316	88.2734271	0.000352353	68.2	.	.
SH3BGRL	X	81201943	81298547	N	.	N	N	0.08362237	55.98772935	0.281416437	36.2	.	.
SH3BGRL2	6	79631283	79703659	N	.	N	N	0.04051715	52.61908896	7.17E-06	78.9	.	.
SH3BGRL3	1	26279176	26281522	N	.	N	N	0.319090009	71.70805117	0.795103829	21.8	.	.
SH3BP1	22	37634654	37666932	N	.	N	N	-0.209649144	34.96556115	0.152682968	40.5	.	.
SH3BP2	4	2793023	2841098	N	Viable	N	Y	-0.045388889	46.17699832	0.0031019	60.2	DM	Cherubism, 118400 (3)
SH3BP4	2	234951973	235055714	N	.	N	N	-0.034713313	46.94680789	0.080964436	44.4	.	.
SH3BP5	3	15254853	15341368	N	Viable	N	Y	-0.734063077	13.04045841	0.00902325	55.3	.	.
SH3BP5L	1	248810446	248826633	N	.	N	N	-0.312929834	28.70868785	0.140999406	41	.	.
SH3D19	4	151102751	151325632	N	.	N	N	0.199490684	64.35723795	0.375087386	33.5	.	.
SH3D21	1	36306387	36324886	N	.	N	N	.	.	0.000722998	65.9	.	.
SH3GL1	19	4360370	4400547	N	.	N	Y	-0.368169446	25.94779186	0.058636754	46.1	DM	Leukemia, acute myeloid, 601626 (1)
SH3GL2	9	17579082	17797129	N	Viable	N	Y	-0.384285668	25.21271054	0.916295307	16.9	.	.
SH3GL3	15	83447228	83618743	N	.	N	Y	-0.438721742	22.81646119	0.00035935	68.1	.	.
SH3GLB1	1	86704570	86748184	N	.	N	Y	-0.515667713	19.60409793	0.730421397	23.7	.	.
SH3GLB2	9	129007036	129028303	N	.	N	N	-0.088796495	42.91254269	0.370053036	33.6	.	.
SH3KBP1	X	19533975	19887601	N	.	N	Y	-0.113067189	41.2571627	0.998643128	6.3	.	.
SH3PXD2A	10	103594027	103855543	N	.	N	N	0.505670648	80.66794004	0.232738023	37.6	.	.
SH3RF1	4	169094256	169271105	N	.	N	N	-0.721626953	13.35880072	0.046395528	47.4	.	.
SH3RF2	5	145936579	146081791	N	.	N	N	0.300054882	70.50413845	1.79E-11	94	.	.
SH3RF3	2	109129348	109504632	N	.	N	N	.	.	0.981100872	11.6	.	.
SH3TC1	4	8182072	8241803	N	.	N	N	3.754077834	99.71638595	1.08E-27	99.5	.	.
SH3TC2	5	148923639	149063163	N	Viable	N	Y	0.87559512	90.68125253	1.73E-12	95.1	DM	Charcot-Marie-Tooth disease, type 4C, 601596 (3); Mononeuropathy of the median nerve, mild, 613353 (3)
SH3YL1	2	217730	266398	N	.	N	N	0.68226197	86.49071019	1.00E-05	78	.	.
SHANK1	19	50661827	50719450	N	.	N	Y	.	.	0.999999761	1.3	DM	.
SHARPIN	8	144098633	144108124	N	.	N	N	0.635476197	85.21734097	0.019887336	51.7	.	.
SHBG	17	7613946	7633383	N	.	N	N	-0.08305528	43.36400996	0.000188842	70	DM	.
SHC2	19	416583	460996	N	.	N	Y	0.760312099	88.31973143	1.22E-05	77.5	.	.
SHC3	9	89005771	89178767	N	.	N	N	-0.60555081	16.60010418	0.457668719	31.2	.	.
SHC4	15	48823735	48963444	N	.	N	N	-0.384938162	25.17219425	1.17E-05	77.7	.	.
SHCBP1	16	46580554	46621626	N	.	N	Y	0.163737564	62.07096139	5.53E-06	79.3	.	.
SHCBP1L	1	182899865	182953525	N	.	N	N	0.715292071	87.27788389	7.09E-10	91.4	.	.
SHD	19	4278601	4290724	N	.	N	N	0.121438731	58.82965793	5.18E-06	79.5	.	.
SHE	1	154469772	154502113	N	.	N	N	-0.669405164	14.77687098	0.721620119	24	.	.
SHF	15	45167214	45201175	N	.	N	N	0.203015042	64.55981941	0.028083266	50	.	.
SHFM1	7	96481626	96709891	N	.	N	N	0.128641213	59.32164149	0.418592332	32.3	DM	Split hand/foot malformation 1 (4)
SHISA3	4	42397839	42402487	N	.	N	Y	0.097822207	56.98327256	0.000449562	67.3	.	.
SHISA4	1	201888680	201892306	N	.	N	Y	0.383896931	75.09984372	0.001071482	64.4	.	.
SHISA5	3	48467798	48504826	N	.	N	Y	0.381175578	74.97829484	9.94E-08	86.1	.	.
SHISA6	17	11241263	11564063	N	.	N	N	.	.	.	.	.	.
SHISA7	19	55428740	55442863	N	.	N	N	.	.	.	.	.	.
SHISA8	22	41909554	41914667	N	.	N	N	.	.	.	.	.	.
SHISA9	16	12901620	13240413	N	.	N	N	.	.	.	.	.	.
SHKBP1	19	40576851	40591399	N	.	N	N	-0.231050406	33.66903976	0.000346951	68.2	.	.
SHMT1	17	18327860	18363563	N	Viable	N	Y	-0.17868034	36.80615848	1.86E-07	85.3	DM?	.
SHMT2	12	57229327	57234935	N	.	N	N	-0.301598985	29.37431267	0.007487535	56.3	.	.
SHOX	X	624344	659411	N	.	N	N	-0.114176312	41.19928228	0.73845761	23.5	DM	Short stature, idiopathic familial, 300582 (3); Leri-Weill dyschondrosteosis, 127300 (3); Langer mesomelic dysplasia, 249700 (3)
SHPK	17	3608262	3636322	N	.	N	N	-0.039799513	46.63425363	3.97E-06	80	.	.
SHPRH	6	145864245	145964423	N	.	N	N	-2.008502522	1.614863692	0.491308216	30.2	.	.
SHQ1	3	72749277	72861914	N	.	N	N	0.325128069	72.04954564	1.17E-10	92.9	.	.
SHROOM1	5	132822141	132830898	N	.	N	N	-0.565970317	17.75771257	0.009595549	55.1	.	.
SHROOM2	X	9786456	9949443	N	.	N	N	1.647557899	97.70214736	0.006945002	56.6	.	.
SHROOM4	X	50591647	50814302	N	.	N	N	2.969633284	99.51959252	0.997425925	7.3	DM	?Stocco dos Santos X-linked mental retardation syndrome, 300434 (3)
SHTN1	10	116881482	117126586	N	.	N	N	.	.	.	.	.	.
SI	3	164978898	165078495	N	.	N	N	-2.553621154	0.943450831	7.97E-26	99.4	DM	Sucrase-isomaltase deficiency, congenital, 222900 (3)
SIAE	11	124633113	124695707	N	.	N	Y	0.719119456	87.41100886	2.59E-09	90.3	DM	{Autoimmune disease, susceptibility to, 6}, 613551 (3)
SIAH1	16	48356364	48448402	N	.	N	Y	0.088405766	56.3118597	0.949054585	14.8	.	.
SIAH2	3	150741127	150763477	N	.	N	Y	-0.290574674	29.99363315	0.360182186	33.9	.	.
SIAH3	13	45777243	45851736	N	.	N	N	-0.754813354	12.47901835	0.001832081	62.2	.	.
SIDT1	3	113532296	113629578	N	Viable	N	Y	0.588046365	83.77611854	5.03E-13	95.5	.	.
SIDT2	11	117178733	117197445	N	.	N	Y	-0.216851217	34.46778955	0.002572401	61	.	.
SIGIRR	11	405716	417455	N	.	N	Y	0.824973219	89.63940499	0.005308889	57.8	.	.
SIGLEC1	20	3686970	3707128	N	.	N	Y	-0.403595511	24.19980321	1.62E-28	99.6	.	.
SIGLEC10	19	51410021	51417803	N	.	N	Y	1.396681517	96.37089773	4.06E-06	79.9	.	.
SIGLEC11	19	49948985	49961172	N	.	N	N	1.80384466	98.18834288	2.64E-08	87.8	.	.
SIGLEC12	19	51491357	51501789	N	.	N	N	1.850792733	98.30989176	1.54E-10	92.6	FTV	.
SIGLEC14	19	51642553	51646801	N	.	N	N	0.272306077	68.81981826	0.035662741	48.9	FP	.
SIGLEC15	18	45825512	45844080	N	.	N	Y	.	.	1.08E-11	94.2	.	.
SIGLEC5	19	51611503	51645545	N	.	N	Y	0.640259297	85.3446779	7.61E-05	72.7	.	.
SIGLEC6	19	51519525	51531856	N	.	N	N	0.776275536	88.68437807	0.024724479	50.5	.	.
SIGLEC7	19	51142299	51153526	N	.	N	N	0.282828845	69.49123112	8.93E-06	78.3	.	.
SIGLEC8	19	51450847	51458456	N	.	N	Y	1.089661909	93.84731145	0.000488762	67.1	.	.
SIGLEC9	19	51124908	51136651	N	.	N	N	0.632756059	85.13052034	0.000328335	68.4	.	.
SIGLECL1	19	51246348	51269330	N	.	N	N	0.581850138	83.55617295	0.000332347	68.4	.	.
SIGMAR1	9	34634722	34637809	N	.	N	Y	-0.118004239	40.88093998	0.125068129	41.8	DM	Amyotrophic lateral sclerosis 16, juvenile, 614373 (3)
SIK1	21	43414515	43427128	N	Viable	N	Y	0.070983022	54.94588181	0.993830465	8.9	.	Epileptic encephalopathy, early infantile, 30, 616341 (3)
SIK2	11	111602391	111730853	N	.	N	Y	-0.870886764	10.16380159	0.999836809	4.2	.	.
SIKE1	1	114769479	114780685	N	.	N	N	-0.237096056	33.23493662	0.072982309	44.8	.	.
SIMC1	5	176238367	176345991	N	.	N	N	0.415970669	76.65103895	0.000207487	69.7	.	.
SIPA1	11	65585395	65650930	N	.	N	Y	0.248184157	67.3612317	0.027905143	50.1	DP	.
SIPA1L1	14	71320449	71741229	N	.	N	N	-2.500210182	0.966602998	0.999999774	1.3	.	.
SIPA1L2	1	232397965	232561558	N	.	N	N	-2.158487147	1.36597789	0.999219706	5.6	.	.
SIPA1L3	19	37907228	38208372	N	.	N	N	0.238108363	66.69560688	0.999676986	4.7	.	.
SIRPA	20	1894167	1940592	N	Viable	N	Y	1.182578782	94.86600683	0.13772081	41.2	.	.
SIRPB1	20	1563521	1620061	N	.	N	N	1.583173193	97.39538114	2.22E-09	90.4	.	.
SIRPB2	20	1470741	1491587	N	.	N	N	0.785543295	88.88695954	0.014588095	53.3	.	.
SIRPD	20	1534251	1558843	N	.	N	N	0.674758577	86.28812873	7.78E-05	72.6	.	.
SIRPG	20	1629152	1657779	N	.	N	N	0.828799349	89.74937779	5.21E-08	86.9	.	.
SIRT2	19	38878555	38899862	N	.	N	Y	0.642979476	85.46622678	1.08E-05	77.8	.	.
SIRT3	11	215458	236931	N	Viable	N	Y	0.21706442	65.48590612	2.70E-05	75.5	DFP	.
SIRT4	12	120302316	120313249	N	Viable	N	Y	-0.09438571	42.50159171	1.81E-07	85.3	.	.
SIRT5	6	13574529	13615158	N	.	N	Y	0.468492577	79.26144585	1.88E-05	76.4	DP	.
SIRT7	17	81911939	81921323	N	.	N	Y	-0.25099172	32.42461075	0.567108372	28.3	.	.
SIT1	9	35649295	35650950	N	.	N	Y	0.344468409	73.11454535	0.035413132	48.9	.	.
SIVA1	14	104753100	104768494	N	Viable	N	Y	0.111871637	58.12930486	0.313588965	35.3	.	.
SIX4	14	60709528	60724348	N	.	N	Y	-0.188902396	36.22735429	0.685504308	25	.	.
SIX5	19	45764785	45769226	N	.	N	Y	.	.	0.310828643	35.4	DM	Branchiootorenal syndrome 2, 610896 (3)
SIX6	14	60508951	60512850	N	.	N	Y	0.135337478	59.85414134	0.757754035	22.9	DM	Optic disc anomalies with retinal and/or macular dystrophy, 212550 (3)
SKA1	18	50374995	50394173	N	.	N	N	0.082816117	55.93563697	1.32E-06	82.2	.	.
SKA3	13	21153595	21176602	N	.	N	N	1.03139556	93.17011055	3.00E-07	84.5	.	.
SKAP1	17	48133440	48430275	N	.	N	N	0.358666204	73.88435492	0.00030184	68.6	.	.
SKAP2	7	26667062	26995239	N	.	N	Y	0.281722177	69.41019853	0.909797278	17.3	.	.
SKIV2L2	5	55307760	55425581	N	.	N	N	-1.094084265	6.644672107	0.725400925	23.9	.	.
SKOR1	15	67819704	67834561	N	.	N	N	-0.413340789	23.74833594	.	.	.	.
SKP1	5	134148935	134177038	N	.	N	N	-0.044887353	46.22330266	0.224830619	37.8	.	.
SKP2	5	36151989	36184319	N	.	N	Y	-0.570906288	17.61301152	0.994258761	8.7	.	.
SLA	8	133036724	133103054	N	.	N	Y	-0.158237463	38.14319616	0.72295317	24	.	.
SLA2	20	36612318	36646216	N	.	N	N	-0.043778467	46.32748741	0.384130951	33.2	.	.
SLAIN1	13	77697854	77764242	N	.	N	N	0.009699407	50.29229612	0.959443822	14	.	.
SLAIN2	4	48341322	48426212	N	.	N	N	-0.729431296	13.17937142	0.88343847	18.4	.	.
SLAMF1	1	160608100	160647295	N	.	N	Y	-0.147863581	38.90142965	0.135406432	41.3	.	.
SLAMF6	1	160485030	160523262	N	.	N	Y	-0.537219736	18.72431556	0.356879515	34	.	.
SLAMF7	1	160739057	160754821	N	.	N	Y	0.360579228	73.94802338	0.006544626	56.9	.	.
SLAMF8	1	159826750	159837249	N	.	N	Y	0.951577407	92.0298663	1.71E-06	81.6	.	.
SLAMF9	1	159951492	159954254	N	.	N	N	0.207648094	64.90710193	0.007857832	56	.	.
SLBP	4	1692800	1712555	N	.	N	N	-0.24459911	32.77768131	0.515659458	29.5	DM	.
SLC10A1	14	69775417	69797289	N	.	N	N	0.050236113	53.42362679	8.44E-16	97.3	FP	.
SLC10A2	13	103043998	103066846	N	.	N	Y	0.55963777	82.75742316	1.61E-13	95.9	DM	Bile acid malabsorption, primary, 613291 (3)
SLC10A3	X	154487306	154490690	N	.	N	N	-0.488371748	20.65173352	0.629239799	26.7	.	.
SLC10A4	4	48483343	48489196	N	.	N	Y	-0.166697481	37.63384847	0.167299362	39.8	.	.
SLC10A5	8	81693607	81696174	N	.	N	N	0.342853172	73.02193668	0.000395027	67.8	.	.
SLC10A6	4	86823468	86849263	N	.	N	N	0.324020385	71.98008914	1.84E-06	81.5	.	.
SLC10A7	4	146253975	146521964	N	.	N	N	-0.134771456	39.75805985	0.028807428	49.9	.	.
SLC11A1	2	218382029	218396894	N	.	N	Y	0.39089437	75.42397407	6.59E-12	94.5	DFP	{Mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3); {Buruli ulcer, susceptibility to}, 610446 (3)
SLC12A3	16	56865207	56915850	N	.	N	Y	-0.686553489	14.31382763	5.54E-18	98.1	DM	Gitelman syndrome, 263800 (3)
SLC12A4	16	67943474	67969601	N	.	N	N	-1.42305542	3.791167448	1.83E-07	85.3	.	.
SLC12A6	15	34229996	34338060	N	.	N	Y	-1.838949534	2.101059212	0.978179973	12	DM	Agenesis of the corpus callosum with peripheral neuropathy, 218000 (3)
SLC12A7	5	1050376	1112035	N	.	N	Y	-1.558988629	3.032933958	8.45E-11	93	.	.
SLC12A8	3	125082636	125212864	N	.	N	N	0.07017815	54.90536551	7.93E-13	95.3	.	.
SLC12A9	7	100826820	100867009	N	.	N	N	-0.770327084	12.18961625	2.37E-06	81	.	.
SLC13A1	7	123113531	123199986	N	.	N	Y	0.181614038	63.32696649	1.84E-09	90.6	.	.
SLC13A2	17	28473293	28497781	N	.	N	Y	-0.261062576	31.78792614	8.29E-07	82.8	FP	.
SLC13A3	20	46557823	46684467	N	Viable	N	Y	-0.312777691	28.73184002	0.053286803	46.6	.	.
SLC13A4	7	135681237	135729258	N	.	N	N	-0.543611442	18.44070151	0.915550851	17	.	.
SLC13A5	17	6684713	6713567	N	.	N	Y	-0.971302662	8.369508595	0.353400874	34.1	.	Epileptic encephalopathy, early infantile, 25, 615905 (3)
SLC14A1	18	45724127	45752520	N	.	N	Y	0.833433098	89.87092667	1.90E-09	90.5	DM	[Blood group, Kidd], 111000 (3)
SLC14A2	18	45212995	45683686	N	.	N	Y	0.239228122	66.79979163	8.43E-14	96.2	DP	.
SLC15A1	13	98683801	98752654	N	.	N	Y	-0.037734634	46.73265034	8.69E-08	86.3	DFP	.
SLC15A2	3	121894089	121944102	N	.	N	Y	-0.481522215	20.9527117	1.50E-10	92.7	.	.
SLC15A3	11	60937083	60952530	N	Viable	N	Y	0.586779993	83.75296637	3.66E-07	84.2	.	.
SLC15A4	12	128793191	128823983	N	.	N	N	-0.092471964	42.67523297	2.99E-09	90.1	DP	.
SLC15A5	12	16188485	16277685	N	.	N	N	.	.	.	.	.	.
SLC16A10	6	111087503	111231194	N	.	N	N	-0.274457717	31.01811657	0.067607006	45.3	.	.
SLC16A11	17	7041630	7043923	N	.	N	N	0.630694555	85.08421601	0.045918307	47.5	.	.
SLC16A12	10	89430299	89556641	N	.	N	N	-0.841981514	10.74839382	0.002018906	61.8	DM	Cataract, juvenile, with microcornea and glucosuria, 612018 (3)
SLC16A13	17	7036075	7040121	N	.	N	N	0.061414866	54.25131678	7.51E-07	83	.	.
SLC16A14	2	230034974	230068999	N	.	N	N	0.291288637	69.99479076	0.215983364	38.2	.	.
SLC16A2	X	74421461	74533917	N	.	N	Y	0.225374457	65.97210164	0.934351643	15.9	DM	Allan-Herndon-Dudley syndrome, 300523 (3)
SLC16A3	17	82228397	82261129	N	Viable	N	Y	-0.471299039	21.3810268	0.325132712	35	DM	.
SLC16A4	1	110362848	110391082	N	.	N	N	-0.166544931	37.66857672	0.005835233	57.4	.	.
SLC16A5	17	75087727	75106162	N	.	N	N	0.242594876	67.05446547	3.71E-05	74.7	.	.
SLC16A6	17	68267026	68291267	N	.	N	N	0.098929771	57.09324536	0.205129421	38.6	.	.
SLC16A7	12	59596067	59789855	N	.	N	N	-0.028620813	47.39827516	0.001785766	62.3	DM?	.
SLC16A8	22	38078134	38084093	N	.	N	Y	.	.	0.110164819	42.6	.	.
SLC16A9	10	59650761	59736002	N	.	N	N	-0.369126321	25.91885165	0.642448765	26.3	.	.
SLC17A1	6	25782897	25832059	N	.	N	N	0.24435699	67.14707414	2.59E-10	92.2	DP	.
SLC17A2	6	25912754	25930726	N	.	N	N	0.005066824	49.89292122	0.004669854	58.5	.	.
SLC17A3	6	25833066	25882286	N	Viable	N	Y	0.337263633	72.67465416	9.88E-14	96.1	DM	[Uric acid concentration, serum, QTL4], 612671 (3); {Gout susceptibility 4}, 612671 (3)
SLC17A4	6	25754699	25781191	N	.	N	N	0.435760317	7.77E+01	6.33E-06	79.1	FTV	.
SLC17A8	12	100357079	100422059	N	.	N	Y	-0.814685978	11.2982578	0.04492625	47.6	DM	Deafness, autosomal dominant 25, 605583 (3)
SLC17A9	20	62952647	62969585	N	Viable	N	Y	0.41788394	76.71470741	5.27E-08	86.9	DM?	Porokeratosis 8, disseminated superficial actinic type, 616063 (3)
SLC18A1	8	20144855	20183206	N	.	N	Y	0.885305739	90.83752966	1.89E-14	96.6	DFP	.
SLC18B1	6	132769370	132798553	N	.	N	N	-0.210606002	34.88452856	3.95E-10	91.9	.	.
SLC19A2	1	169463909	169486003	N	.	N	Y	0.044495337	52.92585518	0.004285879	58.8	DM	Thiamine-responsive megaloblastic anemia syndrome, 249270 (3)
SLC19A3	2	227685210	227718012	N	.	N	Y	0.534257737	81.84291254	0.001631087	62.7	DM	Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3)
SLC1A1	9	4490444	4587469	N	Viable	N	Y	-0.831456436	10.95097529	0.001271167	63.8	DM	{?Schizophrenia susceptibility 18}, 615232 (3); Dicarboxylic aminoaciduria, 222730 (3)
SLC1A4	2	64988477	65023865	N	.	N	N	-0.227525777	33.90056144	0.242897704	37.3	.	.
SLC1A5	19	46774883	46788594	N	.	N	N	0.657986057	85.85402558	0.051811209	46.8	.	.
SLC1A6	19	14950034	15022990	N	.	N	Y	-0.104607368	41.83596689	0.928911024	16.2	.	.
SLC1A7	1	53087179	53142632	N	.	N	Y	0.375888247	74.73519708	1.87E-05	76.4	.	.
SLC22A1	6	160121789	160158718	N	.	N	Y	1.225843544	95.27116976	1.24E-13	96	FP	.
SLC22A10	11	63137867	63369718	N	.	N	N	1.595465754	97.47062569	1.54E-14	96.6	.	.
SLC22A11	11	64555626	64572875	N	.	N	N	-0.226417441	33.95265382	5.80E-05	73.5	DFP	.
SLC22A12	11	64590641	64602353	N	.	N	Y	-0.090406755	42.76784164	4.90E-06	79.6	DM	Hypouricemia, renal, 220150 (3)
SLC22A13	3	38265812	38278315	N	.	N	N	0.222956617	65.82161255	2.16E-15	97.1	.	.
SLC22A14	3	38282294	38318575	N	.	N	N	1.579498756	97.3895931	9.57E-09	88.9	DFP	.
SLC22A15	1	115976498	116070054	N	.	N	N	0.085837372	56.15558257	8.66E-06	78.4	.	.
SLC22A16	6	110424687	110476641	N	.	N	N	1.005361963	92.82861608	2.09E-22	99.1	.	.
SLC22A17	14	23346306	23352912	N	.	N	N	-0.342941981	27.12276437	0.772286751	22.5	.	.
SLC22A18	11	2899721	2925246	N	.	N	N	0.819382688	89.51785611	0.001923068	62	.	.
SLC22A18AS	11	2887780	2903740	N	.	N	N	.	.	.	.	.	.
SLC22A2	6	160171061	160277638	N	.	N	Y	-0.595983239	16.82004978	1.42E-09	90.9	DFP	.
SLC22A23	6	3268962	3457022	N	.	N	N	-0.657116328	15.15309371	0.366550903	33.7	.	.
SLC22A24	11	63079940	63144221	N	.	N	N	.	.	0.000186761	70	.	.
SLC22A25	11	63163776	63229652	N	.	N	N	0.062523198	54.31498524	4.63E-13	95.6	DM?	.
SLC22A3	6	160348268	160452581	N	.	N	Y	-0.483586384	20.81958673	3.32E-05	75	DM	.
SLC22A31	16	89195761	89201664	N	.	N	N	.	.	.	.	.	.
SLC22A4	5	132294443	132344206	N	.	N	Y	0.283785611	69.53174741	4.64E-06	79.7	DM	{Rheumatoid arthritis, susceptibility to}, 180300 (3)
SLC22A5	5	132369752	132395614	N	.	N	N	0.650633105	85.64565607	4.90E-09	89.6	DM	Carnitine deficiency, systemic primary, 212140 (3)
SLC22A6	11	62936385	62984983	N	.	N	Y	-0.139251787	39.47444579	2.19E-05	76	FP	.
SLC22A7	6	43295694	43305538	N	.	N	N	-0.357795969	26.4224113	3.72E-06	80.1	.	.
SLC22A8	11	62989154	63015839	N	Viable	N	Y	-0.003241475	49.17520403	1.50E-10	92.6	.	.
SLC22A9	11	63369789	63410294	N	.	N	N	0.464011037	79.02992418	3.62E-14	96.4	DM?	.
SLC23A3	2	219161465	219170095	N	.	N	N	-0.378543229	25.54262893	0.002312618	61.4	.	.
SLC24A1	15	65611366	65660995	N	.	N	N	0.264299709	68.3567749	0.000127201	71.2	DM	Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 (3)
SLC24A2	9	19507452	19786928	N	.	N	Y	-0.650419078	15.37882734	0.035059826	48.9	DM	.
SLC24A3	20	19212646	19722937	N	.	N	N	0.338220438	72.790415	0.959518181	14	.	.
SLC24A5	15	48120972	48142672	N	Viable	N	Y	-0.156171384	38.30526133	3.20E-05	75	DM	[Skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3); Albinism, oculocutaneous, type VI, 113750 (3)
SLC25A1	22	19175575	19178830	N	.	N	N	-0.257690928	32.05996411	0.633538573	26.5	DM	Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 (3)
SLC25A10	17	81712236	81721016	N	.	N	N	0.102605765	57.4173757	0.002439368	61.2	.	.
SLC25A11	17	4937130	4940251	N	.	N	N	-0.544722892	18.39439718	0.666467127	25.6	.	.
SLC25A13	7	96120220	96322147	N	.	N	Y	-1.187955601	5.695433235	1.94E-15	97.1	DM	Citrullinemia, adult-onset type II, 603471 (3); Citrullinemia, type II, neonatal-onset, 605814 (3)
SLC25A14	X	130339888	130373361	N	.	N	N	-0.232464529	33.55327893	0.979191684	11.9	.	.
SLC25A15	13	40789412	40810111	N	.	N	N	0.465623125	79.12832089	0.00124732	63.8	DM	Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3)
SLC25A16	10	68477999	68527474	N	.	N	N	-0.604748305	16.61168027	0.000247608	69.2	.	.
SLC25A17	22	40769630	40819399	N	.	N	N	0.040668219	52.64224113	0.024184844	50.6	.	.
SLC25A18	22	17563439	17590994	N	.	N	N	0.155126864	61.40533657	0.011064687	54.5	.	.
SLC25A2	5	141302629	141304045	N	.	N	N	0.609140858	84.45331944	0.036597354	48.7	.	.
SLC25A21	14	36677921	37172866	N	Viable	N	Y	0.281722177	69.41019853	6.47E-07	83.3	.	.
SLC25A22	11	790475	798333	N	.	N	N	-0.170372579	37.39075071	0.568405565	28.3	DM	Epileptic encephalopathy, early infantile, 3, 609304 (3)
SLC25A23	19	6436079	6465203	N	.	N	Y	-0.889720408	9.799154946	0.076041695	44.7	.	.
SLC25A24	1	108134036	108200849	N	.	N	N	0.160867203	61.83943972	4.90E-09	89.6	.	.
SLC25A25	9	128068201	128109245	N	.	N	Y	-1.493861919	3.414944724	0.973302049	12.6	.	.
SLC25A27	6	46652915	46678193	N	.	N	N	0.228244069	66.13416681	0.160724478	40.1	.	.
SLC25A28	10	99610522	99620609	N	Viable	N	Y	-0.343096194	27.10540024	0.765079078	22.8	.	.
SLC25A29	14	100291111	100306547	N	.	N	N	0.385809542	75.19824044	0.006060973	57.2	.	.
SLC25A30	13	45393316	45418455	N	.	N	Y	-0.03627546	46.84841118	8.39E-06	78.5	.	.
SLC25A31	4	127730378	127774299	N	.	N	Y	0.298641418	70.42310586	3.02E-06	80.5	.	.
SLC25A32	8	103398635	103415189	N	.	N	N	-0.171329534	37.29814204	7.69E-07	83	.	.
SLC25A33	1	9539482	9585179	N	.	N	N	-0.02031261	47.87868264	0.451158319	31.4	.	.
SLC25A34	1	15736405	15741396	N	.	N	N	0.33806995	72.74989871	0.000948153	64.9	.	.
SLC25A35	17	8287763	8295343	N	Viable	N	Y	-0.079379727	43.6881403	3.54E-09	89.9	.	.
SLC25A36	3	140941830	140979933	N	.	N	N	0.150343606	61.02332581	0.883013619	18.4	.	.
SLC25A38	3	39383348	39397351	N	.	N	Y	0.427150878	77.22984314	0.068217829	45.2	DM	Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3)
SLC25A39	17	44319625	44324870	N	.	N	N	-0.316605038	28.47716617	0.000102385	71.8	DM?	.
SLC25A4	4	185143241	185150382	N	.	N	Y	-0.335593115	27.47004688	0.483364233	30.4	DM	Progressive external ophthalmoplegia with mitochondrial DNA deletions 2, 609283 (3); Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type), 615418 (3)
SLC25A40	7	87833568	87876357	N	.	N	N	0.098778904	57.07588123	2.15E-07	85.1	.	.
SLC25A41	19	6426037	6433779	N	.	N	N	1.048316062	93.34375181	5.98E-05	73.4	.	.
SLC25A42	19	19063999	19112888	N	.	N	N	0.288268772	69.80378538	0.20830845	38.5	.	.
SLC25A43	X	119399060	119454478	N	.	N	N	0.299449341	70.47519824	0.052955024	46.7	DM?	.
SLC25A44	1	156193932	156212796	N	.	N	N	-0.250187888	32.45355096	0.247810862	37.2	.	.
SLC25A45	11	65375192	65383701	N	.	N	N	0.687999311	86.60068299	7.20E-07	83.1	.	.
SLC25A46	5	110738136	110765161	N	.	N	N	-0.284831791	30.36985588	0.001176117	64.1	DM?	Neuropathy, hereditary motor and sensory, type VIB, 616505 (3)
SLC25A47	14	100323337	100330378	N	.	N	N	0.275325819	69.02818776	3.18E-12	94.8	.	.
SLC25A48	5	135834649	135888637	N	.	N	N	0.255386906	67.77218267	0.391014478	33	.	.
SLC25A5	X	119468400	119471319	N	.	N	N	1.507838333	96.99021821	0.857861937	19.6	.	.
SLC25A51	9	37879400	37904353	N	.	N	N	-0.17611458	36.99137582	0.049200369	47.1	.	.
SLC25A52	18	31759562	31760880	N	.	N	N	0.843658882	90.07929617	0.005855927	57.3	.	.
SLC25A53	X	104099214	104157027	N	.	N	N	0.23383407	66.45250912	0.10191671	43	.	.
SLC25A6	X	1386152	1392724	N	.	N	N	-0.962994377	8.508421601	0.066919698	45.3	.	.
SLC26A1	4	979073	993440	N	.	N	Y	1.911630167	98.41986456	4.01E-06	80	DM	.
SLC26A10	12	57619527	57626151	N	.	N	N	1.212594302	95.15540893	1.17E-09	91	FTV	.
SLC26A11	17	80219699	80253500	N	.	N	N	1.568322274	97.31434856	4.11E-10	91.9	FTV	.
SLC26A2	5	149960737	149993455	N	.	N	N	-0.300491102	29.42640505	2.17E-05	76	DM	Diastrophic dysplasia, 222600 (3); Atelosteogenesis II, 256050 (3); Achondrogenesis Ib, 600972 (3); Epiphyseal dysplasia, multiple, 4, 226900 (3); Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3); De la Chapelle dysplasia, 256050 (3)
SLC26A4	7	107660635	107717809	N	.	N	Y	0.997060569	92.72443132	6.37E-13	95.4	DM	Pendred syndrome, 274600 (3); Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 (3)
SLC26A5	7	103352730	103446177	N	.	N	Y	-0.64946257	15.40197951	0.001375555	63.5	DM	?Deafness, autosomal recessive 61, 613865 (3)
SLC26A6	3	48625723	48635493	N	.	N	Y	0.168674455	62.42403195	3.31E-05	75	FP	.
SLC26A7	8	91209494	91398152	N	.	N	Y	0.123503895	59.02066331	3.32E-08	87.5	.	.
SLC26A8	6	35943514	36024868	N	.	N	Y	0.360079542	73.93065926	7.65E-08	86.4	DM	Spermatogenic failure 3, 606766 (3)
SLC26A9	1	205913048	205943460	N	.	N	Y	-0.052589802	45.56925392	0.002985459	60.3	FP	.
SLC27A1	19	17468769	17506168	N	.	N	Y	-1.247031557	5.139781212	0.000340154	68.3	.	.
SLC27A2	15	50182196	50236395	N	.	N	Y	-0.847419813	10.61526885	2.58E-05	75.6	.	.
SLC27A3	1	153774354	153780157	N	.	N	N	2.324782382	99.01024483	7.80E-11	93.1	.	.
SLC27A5	19	58479512	58512413	N	.	N	Y	0.267017721	68.47253574	7.71E-08	86.4	DM	.
SLC27A6	5	128538013	129033642	N	.	N	N	0.51653284	81.12519535	2.86E-09	90.2	.	.
SLC28A1	15	84884654	84945796	N	.	N	N	0.228698707	66.1457429	6.35E-07	83.3	DM	.
SLC28A2	15	45252230	45277845	N	.	N	N	0.02692196	51.57724142	9.71E-12	94.3	FP	.
SLC28A3	9	84275457	84340683	N	.	N	N	0.275477688	69.03397581	1.96E-17	98	FP	.
SLC29A1	6	44219505	44234151	N	Viable	N	Y	-0.432978714	23.05377091	0.964281535	13.5	DFP	.
SLC29A2	11	66362521	66372214	N	.	N	N	-0.189053899	36.22156624	1.32E-08	88.6	DM	.
SLC29A3	10	71319258	71363385	N	.	N	Y	0.843001461	90.06193205	2.99E-08	87.6	DM	Histiocytosis-lymphadenopathy plus syndrome, 602782 (3)
SLC29A4	7	5274369	5306870	N	.	N	Y	-0.047956921	45.97441685	0.001147488	64.2	DM?	.
SLC2A10	20	46709487	46736347	N	.	N	N	0.183527791	63.44272733	0.008201737	55.8	DM	Arterial tortuosity syndrome, 208050 (3)
SLC2A11	22	23856703	23886309	N	.	N	N	0.718162509	87.3762806	5.46E-12	94.6	.	.
SLC2A12	6	133988697	134052636	N	.	N	N	-0.903770636	9.503964809	0.019408411	51.8	.	.
SLC2A13	12	39755021	40106089	N	.	N	N	-0.25099172	32.42461075	0.956100909	14.3	.	.
SLC2A14	12	7812512	7891148	N	.	N	N	-0.103650534	41.89963535	0.989967414	9.9	.	.
SLC2A4	17	7281667	7288257	N	.	N	Y	-0.881260137	9.93227991	0.135386793	41.3	DM	.
SLC2A4RG	20	63739861	63743505	N	.	N	N	0.251709849	67.54644904	0.007944387	56	.	.
SLC2A5	1	9035107	9088478	N	Viable	N	Y	0.457312874	78.67106558	5.68E-05	73.5	.	.
SLC2A6	9	133471095	133479137	N	.	N	N	0.300705268	70.56780691	0.000366664	68	.	.
SLC2A7	1	9003300	9026345	N	.	N	N	1.131009411	94.33929502	2.99E-17	97.9	.	.
SLC30A10	1	219685427	219958647	N	.	N	N	-0.180746515	36.69039764	0.921869998	16.6	DM	Hypermanganesemia with dystonia, polycythemia, and cirrhosis, 613280 (3)
SLC30A2	1	26037252	26046133	N	.	N	N	0.246119954	67.25704694	0.708283236	24.4	DM	Zinc deficiency, transient neonatal, 608118 (3)
SLC30A3	2	27253684	27275817	N	.	N	Y	1.036986567	93.22220293	0.646083872	26.2	DM?	.
SLC30A5	5	69093646	69131069	N	.	N	Y	-0.085774145	43.14406436	0.230512232	37.7	DM?	.
SLC30A6	2	32165841	32224379	N	.	N	N	0.047365707	53.22683336	0.012659612	54	.	.
SLC30A7	1	100896076	100981753	N	.	N	N	-0.2153906	34.56618626	0.028992047	49.9	.	.
SLC30A8	8	116950273	117176714	N	.	N	Y	0.48445544	79.89234242	1.80E-09	90.6	DP	{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3)
SLC30A9	4	41990472	42090457	N	.	N	N	-0.498592618	20.25235863	0.001423485	63.3	.	.
SLC31A2	9	113150942	113164137	N	.	N	N	0.495489526	80.30908144	2.78E-05	75.4	.	.
SLC33A1	3	155821024	155854429	N	.	N	Y	-0.381414283	25.35741159	0.100521118	43.1	DM	Spastic paraplegia 42, autosomal dominant, 612539 (3); Congenital cataracts, hearing loss, and neurodegeneration, 614482 (3)
SLC34A3	9	137230757	137236554	N	.	N	Y	0.601137479	84.13497714	2.03E-11	93.9	DM	Hypophosphatemic rickets with hypercalciuria, 241530 (3)
SLC35A2	X	48903182	48911958	N	.	N	N	0.05935026	54.0603114	0.780526259	22.3	DM	Congenital disorder of glycosylation, type IIm, 300896 (3)
SLC35A3	1	99969789	100026979	N	.	N	N	-0.267108277	31.41749146	0.069315375	45.1	.	?Arthrogryposis, mental retardation, and seizures, 615553 (3)
SLC35A4	5	140564456	140569103	N	.	N	N	0.006980435	50.03762227	0.000744269	65.7	.	.
SLC35A5	3	112561709	112585577	N	.	N	N	0.082010267	55.87196851	0.001412251	63.3	.	.
SLC35B1	17	49700943	49709014	N	.	N	N	0.125114793	59.14221219	0.013286269	53.7	.	.
SLC35B2	6	44254096	44257890	N	.	N	N	-0.248121003	32.57509984	0.70003825	24.6	.	.
SLC35B3	6	8413068	8435483	N	.	N	N	0.132617807	59.62261967	0.000566464	66.7	.	.
SLC35B4	7	134289332	134317051	N	.	N	N	-0.118808507	40.85199977	4.54E-06	79.7	.	.
SLC35C2	20	46345980	46364458	N	.	N	N	-0.356034079	26.53238409	0.04714901	47.3	.	.
SLC35D2	9	96320706	96383710	N	.	N	N	-0.121679336	40.63205418	9.13E-05	72.2	.	.
SLC35D3	6	136922264	136925639	N	.	N	N	-0.063416885	44.9036291	0.149614411	40.6	.	.
SLC35E1	19	16549831	16572382	N	.	N	N	-0.392745948	24.81333565	0.09684283	43.4	.	.
SLC35E2	1	1724838	1745992	N	.	N	N	1.158817501	94.62290907	0.374305908	33.5	.	.
SLC35E2B	1	1659529	1692728	N	.	N	N	.	.	0.621002459	26.9	.	.
SLC35E3	12	68746106	68793964	N	.	N	N	-0.339267298	27.29640563	0.000406779	67.7	.	.
SLC35E4	22	30635652	30669016	N	.	N	N	0.004110017	49.83504081	0.032252529	49.3	.	.
SLC35F1	6	117907526	118317676	N	.	N	N	0.017202414	50.84794814	0.38850627	33.1	.	.
SLC35F2	11	107790991	107928293	N	.	N	N	0.503139072	80.5521792	0.009521677	55.2	.	.
SLC35F3	1	233904933	234324516	N	.	N	N	-0.583998323	17.25415292	0.894523108	18	.	.
SLC35F4	14	57563922	57982194	N	.	N	N	.	.	0.009692574	55.1	.	.
SLC35F5	2	113705011	113756823	N	.	N	N	0.046408913	53.12264861	0.001215718	64	.	.
SLC35F6	2	26764284	26781231	N	.	N	Y	-0.481825845	20.92377149	0.016130758	52.8	.	.
SLC35G1	10	93893973	93956062	N	.	N	N	-0.294249011	29.74474735	0.917135938	16.9	.	.
SLC35G2	3	136818647	136855892	N	.	N	N	-0.041864765	46.45482433	0.066395336	45.4	.	.
SLC35G3	17	35192520	35194523	N	.	N	N	0.203971741	64.62927592	0.029034747	49.9	.	.
SLC35G5	8	11330888	11332208	N	.	N	N	2.153725392	98.7845112	0.027484635	50.1	.	.
SLC35G6	17	7481332	7483496	N	.	N	N	1.402916795	96.39983793	0.000990015	64.7	FTV	.
SLC36A1	5	151437046	151492381	N	.	N	N	-0.39913856	24.4892053	0.023472432	50.8	.	.
SLC36A2	5	151314978	151347590	N	.	N	N	0.671229099	86.21288418	1.41E-06	82.1	DM	Iminoglycinuria, digenic, 242600 (3); Hyperglycinuria, 138500 (3)
SLC36A3	5	151276762	151303766	N	.	N	N	0.391698646	75.46449036	1.19E-06	82.3	.	.
SLC36A4	11	93144171	93197964	N	.	N	N	0.456356165	78.6189732	2.70E-09	90.2	.	.
SLC37A1	21	42496008	42581440	N	.	N	N	0.104670547	57.58522892	0.028612842	49.9	.	.
SLC37A2	11	125063067	125090312	N	.	N	N	0.151602096	61.11014644	5.01E-10	91.8	.	.
SLC37A3	7	140293693	140404433	N	.	N	N	-0.085774145	43.14406436	7.16E-08	86.5	DM?	.
SLC38A1	12	46183063	46270017	N	.	N	N	-0.495874865	20.37969555	0.975432123	12.4	.	.
SLC38A10	17	81245000	81295547	N	.	N	Y	0.267800601	68.54199224	4.09E-08	87.3	.	.
SLC38A11	2	164896186	164955525	N	.	N	N	-0.29042075	30.03993749	1.93E-06	81.4	.	.
SLC38A2	12	46358189	46372867	N	.	N	N	-0.234071877	33.43751809	0.969357	13.1	.	.
SLC38A3	3	50205246	50221486	N	.	N	N	.	.	.	.	.	.
SLC38A4	12	46764761	46832408	N	.	N	N	0.243400254	67.11234589	0.942982186	15.4	.	.
SLC38A5	X	48458537	48470256	N	.	N	N	0.270393157	68.7156335	0.976708482	12.2	.	.
SLC38A6	14	60981114	61083733	N	.	N	N	0.34380991	73.08560514	6.11E-16	97.4	.	.
SLC38A7	16	58665109	58685104	N	.	N	N	-0.159041945	38.09689182	0.031405693	49.5	.	.
SLC38A8	16	84009667	84042636	N	.	N	N	0.862955727	90.42079065	.	.	.	Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 (3)
SLC38A9	5	55625845	55773194	N	.	N	N	0.076420824	55.39156103	0.755167399	23	.	.
SLC39A1	1	153959099	153968184	N	.	N	Y	0.00123959	49.58036696	0.16707683	39.9	.	.
SLC39A10	2	195575977	195737702	N	.	N	N	-1.128880783	6.291601551	0.99785064	7	.	.
SLC39A11	17	72645949	73092712	N	.	N	N	0.18146271	63.30960236	7.78E-05	72.6	.	.
SLC39A12	10	17951839	18043292	N	.	N	N	1.012865555	92.91543671	0.000292986	68.7	.	.
SLC39A13	11	47407132	47416501	N	.	N	Y	-0.220022777	34.31151242	0.011852031	54.2	DM	Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 (3)
SLC39A14	8	22367249	22434129	N	.	N	Y	-0.129986883	40.1111304	0.314629296	35.3	.	.
SLC39A2	14	20999255	21001871	N	.	N	Y	0.891548555	90.97644267	0.000671706	66.1	.	.
SLC39A3	19	2732204	2740152	N	.	N	Y	-0.58863046	17.126816	0.060846454	45.9	.	.
SLC39A5	12	56230049	56237846	N	Viable	N	Y	0.502483645	80.53481507	1.21E-07	85.9	DM?	Myopia 24, autosomal dominant, 615946 (3)
SLC39A6	18	36108532	36129385	N	.	N	N	-1.022871602	7.56497077	0.00076185	65.7	DFP	.
SLC39A9	14	69398015	69462388	N	.	N	N	-0.069158154	44.44637379	0.529198523	29.2	.	.
SLC3A1	2	44275458	44321494	N	.	N	Y	-0.046043433	46.13069399	7.55E-16	97.3	DM	Cystinuria, 220100 (3)
SLC41A1	1	205789093	205813748	N	.	N	N	-1.029569457	7.489726226	0.705784065	24.5	DM?	.
SLC41A2	12	104802553	104958744	N	.	N	N	-0.587827164	17.15575621	0.913051821	17.1	.	.
SLC41A3	3	126006355	126101561	N	.	N	Y	-0.402814388	24.22295537	0.00013967	70.9	.	.
SLC43A1	11	57484534	57515786	N	.	N	N	-0.297771627	29.58268218	7.85E-05	72.6	.	.
SLC43A2	17	1569267	1628886	N	.	N	N	-0.165588061	37.68594085	0.061842704	45.8	.	.
SLC43A3	11	57406954	57427580	N	.	N	N	0.01926743	51.03895352	0.000317449	68.5	.	.
SLC44A1	9	105244622	105439171	N	Viable	N	Y	-0.376629375	25.62366152	0.999253571	5.6	.	.
SLC44A2	19	10602457	10644559	N	.	N	N	-0.678519363	14.54534931	0.041464588	48.1	DFP	.
SLC44A3	1	94820342	94895246	N	.	N	N	1.00712149	92.85755629	1.82E-24	99.3	.	.
SLC44A4	6	31863192	31879046	N	.	N	N	0.056933905	53.86351797	8.28E-08	86.4	.	.
SLC44A5	1	75202131	75611116	N	.	N	Y	-0.682345388	14.45274064	0.03422869	49	.	.
SLC45A1	1	8317826	8344167	N	.	N	N	-0.686833039	14.30803959	0.045189256	47.6	.	.
SLC45A2	5	33944616	33984730	N	.	N	N	0.258557786	67.96318805	7.86E-05	72.6	DM	Albinism, oculocutaneous, type IV, 606574 (3); [Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3); [Skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3); [Skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3)
SLC45A3	1	205657851	205680459	N	Viable	N	Y	-0.161760738	37.87694623	0.036849535	48.7	.	.
SLC45A4	8	141207166	141308305	N	.	N	N	-0.040302983	46.59373734	0.00458961	58.6	.	.
SLC46A1	17	28394756	28407197	N	.	N	Y	.	.	0.104422521	42.9	DM	Folate malabsorption, hereditary, 229050 (3)
SLC46A2	9	112878920	112890913	N	.	N	Y	0.497698833	80.36696186	0.000292934	68.7	.	.
SLC46A3	13	28700064	28718970	N	Viable	N	Y	0.173959705	62.80604272	1.30E-07	85.8	.	.
SLC47A1	17	19495385	19579034	N	Viable	N	Y	-0.12983522	40.11691845	1.22E-09	91	FP	.
SLC47A2	17	19678288	19718979	N	Viable	N	Y	0.34300494	73.03351276	9.02E-14	96.1	FP	.
SLC48A1	12	47753916	47782753	N	.	N	N	.	.	0.437511991	31.8	.	.
SLC4A10	2	161424332	161985282	N	.	N	Y	-1.096952708	6.615731898	0.002635544	60.9	DM	.
SLC4A11	20	3227417	3239190	N	.	N	Y	-0.63034459	15.86502286	1.37E-08	88.5	DM	Corneal endothelial dystrophy 2, autosomal recessive, 217700 (3); Corneal endothelial dystrophy and perceptive deafness, 217400 (3); Corneal dystrophy, Fuchs endothelial, 4, 613268 (3)
SLC4A1AP	2	27663471	27694976	N	.	N	N	-0.867061369	10.25641026	7.74E-07	83	.	.
SLC4A3	2	219627327	219641980	N	.	N	Y	-0.413556885	23.7425479	0.21842022	38.1	DM	.
SLC4A5	2	74216242	74343414	N	.	N	Y	-1.403400722	3.906928286	1.37E-07	85.7	.	.
SLC4A8	12	51391317	51515763	N	.	N	Y	-1.740562451	2.315216762	0.999867374	4	.	.
SLC4A9	5	140360202	140375143	N	.	N	Y	0.220238608	65.65375933	5.69E-18	98.1	.	.
SLC50A1	1	155135344	155138857	N	.	N	N	0.103411903	57.457892	0.130229792	41.6	.	.
SLC51A	3	196211487	196243178	N	.	N	Y	-0.09438571	42.50159171	0.057568812	46.2	.	.
SLC51B	15	65045370	65053396	N	.	N	N	0.129597795	59.37952191	0.222197462	37.9	.	.
SLC52A1	17	5032600	5052009	N	.	N	N	0.534257737	81.84291254	2.74E-05	75.4	.	Riboflavin deficiency, 615026 (3)
SLC5A10	17	18950345	19022595	N	.	N	Y	-0.507709403	19.89928807	3.66E-12	94.8	.	.
SLC5A11	16	24845841	24911628	N	.	N	N	0.234287607	66.48144933	1.50E-06	81.9	FP	.
SLC5A12	11	26667019	26723427	N	.	N	N	0.657179433	85.82508537	2.15E-05	76	.	.
SLC5A2	16	31483002	31490860	N	.	N	Y	-1.534926473	3.171846964	8.35E-11	93.1	DM	Renal glucosuria, 233100 (3)
SLC5A4	22	32218476	32255341	N	.	N	N	1.217381812	95.21328934	2.60E-13	95.8	.	.
SLC5A5	19	17871973	17895174	N	.	N	N	-0.88780693	9.845459281	0.740011195	23.5	DM	Thyroid dyshormonogenesis 1, 274400 (3)
SLC5A8	12	101155493	101210407	N	.	N	Y	0.34300494	73.03351276	2.86E-11	93.7	.	.
SLC5A9	1	48222685	48248644	N	.	N	N	1.531758561	97.10597905	6.42E-13	95.4	.	.
SLC6A1	3	10992724	11039247	N	.	N	Y	-0.887002101	9.857035365	0.999301879	5.5	DM?	Myoclonic-atonic epilepsy, 616421 (3)
SLC6A12	12	190077	214570	N	.	N	N	0.587736767	83.7703305	7.90E-07	83	DP	.
SLC6A13	12	220621	262873	N	.	N	Y	-0.08466623	43.21930891	1.86E-08	88.2	DM?	.
SLC6A14	X	116436622	116461458	N	.	N	Y	-0.389874437	24.9580367	0.986093843	10.8	DP	{Obesity, susceptibility to, BMIQ11}, 300306 (3)
SLC6A15	12	84859488	84913615	N	.	N	Y	-0.385894816	25.137466	0.002262596	61.5	.	.
SLC6A16	19	49289638	49325225	N	.	N	N	-0.550963897	18.18023962	4.48E-11	93.4	.	.
SLC6A17	1	110150486	110202202	N	.	N	N	-1.263952019	5.01244429	0.962734836	13.7	.	Mental retardation, autosomal recessive 48, 616269 (3)
SLC6A18	5	1225355	1246189	N	.	N	Y	1.336648666	96.02940325	1.67E-22	99.1	FP	.
SLC6A19	5	1201595	1225117	N	.	N	Y	-0.543313266	18.46964172	8.52E-18	98.1	DM	Hartnup disorder, 234500 (3); Iminoglycinuria, digenic, 242600 (3); Hyperglycinuria, 138500 (3)
SLC6A2	16	55655604	55706192	N	.	N	Y	-0.279895326	30.63610581	0.2771183	36.3	DM	Orthostatic intolerance, 604715 (3)
SLC6A20	3	45755450	45796535	N	.	N	N	-0.240466779	33.02656711	6.45E-10	91.5	FP	Hyperglycinuria, 138500 (3); Iminoglycinuria, digenic, 242600 (3)
SLC6A3	5	1392790	1445430	N	Viable	N	Y	-0.903770636	9.503964809	0.997036902	7.5	DM	{Nicotine dependence, protection against}, 188890 (3); Parkinsonism-dystonia, infantile, 613135 (3)
SLC6A6	3	14402576	14489349	N	.	N	Y	-0.552071566	18.15129942	0.98227565	11.4	.	.
SLC6A7	5	150189957	150222788	N	.	N	N	-0.307037536	29.0328182	7.15E-06	78.9	.	.
SLC6A8	X	153688099	153696593	N	.	N	N	0.099735608	57.19164207	0.991889603	9.5	DM	Cerebral creatine deficiency syndrome 1, 300352 (3)
SLC7A11	4	138164097	138242349	N	Viable	N	Y	0.107389526	57.79938647	0.000970109	64.8	.	.
SLC7A13	8	86214052	86321146	N	Viable	N	Y	0.982696723	92.55079007	4.71E-15	96.9	.	.
SLC7A14	3	170459584	170586074	N	.	N	N	-0.32476418	28.03727499	0.332594382	34.8	.	Retinitis pigmentosa 68, 615725 (3)
SLC7A2	8	17497088	17570573	N	.	N	Y	-0.743038067	12.79157261	1.17E-08	88.7	DM	.
SLC7A3	X	70925582	70931125	N	.	N	N	0.253623009	67.679574	0.967794266	13.2	.	.
SLC7A4	22	21028718	21032840	N	.	N	N	0.229655803	66.19204723	0.000100466	71.9	.	.
SLC7A6	16	68264516	68301823	N	.	N	N	-0.203103007	35.27811541	0.0224285	51.1	.	.
SLC7A6OS	16	68284503	68310951	N	.	N	N	0.593178019	83.91503154	0.807327025	21.4	.	.
SLC7A8	14	23125295	23183674	N	.	N	Y	-0.251796722	32.34936621	0.00016618	70.4	.	.
SLC7A9	19	32830509	32869766	N	.	N	Y	-0.169263725	37.45441917	0.246082408	37.2	DM	Cystinuria, 220100 (3)
SLC8A2	19	47428017	47472168	N	.	N	N	-1.295075174	4.723042195	.	.	.	.
SLC8A3	14	70044217	70189070	N	Viable	N	Y	-1.078935525	6.818313365	0.621079527	26.9	.	.
SLC8B1	12	113298759	113359493	N	.	N	N	-0.021923169	47.79765005	5.48E-10	91.6	DM?	.
SLC9A2	2	102619707	102711318	N	.	N	Y	-1.141975821	6.123748336	0.481161337	30.5	.	.
SLC9A3	5	473310	524332	N	Viable	N	Y	-0.017139182	48.09284019	0.988153998	10.4	.	.
SLC9A3R2	16	2025356	2039026	N	.	N	N	.	.	0.022703762	51	.	.
SLC9A4	2	102473303	102533972	N	Viable	N	Y	-0.427895937	23.19268392	1.58E-06	81.8	.	.
SLC9A5	16	67237683	67272190	N	.	N	N	-0.648506122	15.42513168	0.036251926	48.8	.	.
SLC9A6	X	135985424	136047269	N	.	N	Y	-0.71825438	13.44562135	0.975667934	12.3	DM	Mental retardation, X-linked syndromic, Christianson type, 300243 (3)
SLC9A7	X	46599252	46759172	N	.	N	N	-0.123440781	40.55680963	0.953699987	14.4	.	.
SLC9A8	20	49812713	49892242	N	.	N	Y	-1.237761967	5.215025757	2.82E-05	75.3	.	.
SLC9A9	3	143265222	143848531	N	.	N	N	-0.716036094	13.50928981	2.48E-08	87.9	DM	?{Autism susceptibility 16}, 613410 (3)
SLC9B1	4	102885048	103019739	N	.	N	N	0.594283197	83.96133588	8.49E-05	72.4	.	.
SLC9B2	4	103019868	103085829	N	Viable	N	Y	0.6112032	84.52277594	0.067056662	45.3	.	.
SLC9C1	3	112140887	112294258	N	.	N	Y	0.110717303	58.01354402	7.82E-11	93.1	DM?	.
SLC9C2	1	173500464	173603094	N	.	N	N	0.494178127	80.25120102	1.19E-06	82.3	.	.
SLCO1A2	12	21264600	21419594	N	.	N	Y	-0.157933655	38.16056028	5.58E-15	96.8	FP	.
SLCO1B1	12	21131202	21239246	N	.	N	N	0.468796761	79.26723389	3.45E-16	97.5	DM	Hyperbilirubinemia, Rotor type, digenic, 237450 (3)
SLCO1B3	12	20810702	20916911	N	.	N	Y	0.130202332	59.4200382	9.24E-17	97.7	DM	Hyperbilirubinemia, Rotor type, digenic, 237450 (3)
SLCO1B7	12	21015696	21092745	N	.	N	N	1.480983252	96.87445737	4.92E-17	97.8	.	.
SLCO1C1	12	20695355	20753386	N	.	N	Y	-0.337049831	2.74E+01	7.62E-06	78.7	DM?	.
SLCO2B1	11	75100563	75206549	N	.	N	Y	-0.001176377	49.32569312	0.003353563	59.9	FP	.
SLCO3A1	15	91853695	92172435	N	.	N	N	-0.856836351	10.44741564	0.732171683	23.7	.	.
SLCO4A1	20	62642445	62685785	N	.	N	N	0.830067567	89.78989408	5.34E-07	83.6	.	.
SLCO4C1	5	102233986	102296549	N	.	N	N	-0.784523017	11.86548591	1.37E-06	82.1	.	.
SLCO5A1	8	69667047	69835064	N	.	N	N	-0.954236861	8.658910691	1.52E-05	77	.	.
SLCO6A1	5	102371782	102499016	N	.	N	N	0.740826586	87.86247612	2.71E-06	80.7	.	.
SLF1	5	94618347	94739436	N	.	N	Y	.	.	.	.	.	.
SLF2	10	100912569	100965136	N	.	N	N	.	.	.	.	.	.
SLFN11	17	35350305	35373701	N	.	N	N	2.080750738	98.70926666	7.42E-16	97.3	.	.
SLFN12	17	35411060	35433283	N	.	N	N	0.21721532	65.4974822	5.04E-10	91.7	.	.
SLFN12L	17	35464249	35537861	N	Viable	N	Y	0.257449595	67.87057938	2.35E-05	75.8	.	.
SLFN13	17	35435096	35448837	N	.	N	N	1.840580356	98.2867396	8.75E-15	96.7	.	.
SLFN14	17	35548125	35558098	N	.	N	N	.	.	.	.	.	.
SLFN5	17	35243036	35273655	N	.	N	N	0.776585991	88.69595416	1.22E-09	91	DM?	.
SLFNL1	1	41015597	41023237	N	.	N	N	0.581190406	83.53302078	0.000108969	71.6	.	.
SLIT1	10	96998038	97185920	N	Viable	N	Y	-0.985760041	8.114834751	0.999930815	3.5	.	.
SLIT3	5	168661733	169301129	N	.	N	Y	-0.673190249	14.66111015	0.991788384	9.5	DM	.
SLITRK1	13	83877205	83882393	Y	Viable	N	Y	-0.910317479	9.399780054	0.988430446	10.3	DM	Tourette syndrome, 137580 (3); ?Trichotillomania, 613229 (3)
SLITRK2	X	145817832	145825842	N	.	N	N	-0.960122879	8.548937894	0.240674716	37.3	.	.
SLITRK3	3	165186720	165197109	N	.	N	N	-1.352906494	4.288939052	0.603043296	27.4	.	.
SLITRK4	X	143622790	143635777	N	.	N	N	-0.484543364	20.78485848	0.613671416	27.1	.	.
SLITRK5	13	87672615	87696272	N	.	N	Y	-1.379105753	4.06899346	0.812088308	21.2	.	.
SLITRK6	13	85792790	85799488	N	.	N	Y	-0.9692443	8.392660763	8.61E-06	78.5	DM	Deafness and myopia, 221200 (3)
SLK	10	103967201	104029233	N	.	N	N	-1.058334419	7.101927418	0.428398338	32	DM?	.
SLMAP	3	57755450	57929168	N	.	N	N	-0.931871552	9.011981247	0.999325965	5.5	DM	.
SLMO1	18	12407896	12432238	N	.	N	N	-0.057022786	45.34352029	1.95E-07	85.2	.	.
SLMO2	20	59033145	59042909	N	.	N	N	0.527414817	81.53035828	0.241368679	37.3	.	.
SLN	11	107707378	107719693	N	.	N	Y	0.302171081	70.59674712	0.393191121	32.9	.	.
SLPI	20	45252239	45254564	N	.	N	Y	-0.057022786	45.34352029	0.00034794	68.2	.	.
SLTM	15	58879045	58933653	N	.	N	N	-1.600695349	2.836140534	0.999996387	2.1	.	.
SLU7	5	160401641	160421711	N	.	N	N	-0.441438866	22.67176014	0.000115176	71.4	.	.
SLURP1	8	142740944	142742411	N	.	N	Y	0.434507168	77.58870174	0.328314103	34.9	DM	Meleda disease, 248300 (3)
SLX1A	16	30193887	30197561	N	.	N	N	.	.	0.625453893	26.8	.	.
SLX1A-SULT1A3	16	30193892	30204310	N	.	N	N	.	.	.	.	.	.
SLX1B	16	29454501	29458219	N	.	N	Y	.	.	0.516792296	29.5	.	.
SLX4IP	20	10435303	10636829	N	.	N	N	0.120481978	58.76598947	2.34E-05	75.8	.	.
SMAD3	15	67063763	67195195	N	.	N	Y	-0.513752923	19.67355444	0.868268313	19.1	DM	Loeys-Dietz syndrome 3, 613795 (3)
SMAD9	13	36844831	36920765	N	.	N	Y	-0.370083231	25.87254732	0.00069136	66	DM	Pulmonary hypertension, primary, 2, 615342 (3)
SMAGP	12	51244558	51270890	N	.	N	N	0.600536585	84.12340105	0.045174611	47.6	.	.
SMAP1	6	70667776	70862015	N	.	N	N	-0.600918996	16.66956069	0.983689233	11.1	.	.
SMAP2	1	40344850	40423326	N	.	N	N	-0.497789345	20.304451	0.014285645	53.4	.	Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3)
SMARCA1	X	129446501	129523500	N	.	N	N	-0.421647781	23.47050993	0.999946646	3.3	.	.
SMARCA2	9	2015219	2193624	N	.	N	Y	-2.307077787	1.128668172	0.999998264	1.9	DM	Nicolaides-Baraitser syndrome, 601358 (3)
SMARCAL1	2	216412414	216483053	N	.	N	Y	-0.17837921	36.81773456	0.000314359	68.5	DM	Schimke immunoosseous dysplasia, 242900 (3)
SMARCD1	12	50084972	50100712	N	.	N	N	-0.568189839	17.69983215	0.9995273	5.1	.	.
SMARCD3	7	151238764	151277896	N	.	N	N	-0.428346952	23.18689587	0.231918432	37.6	.	.
SMC1A	X	53374149	53422728	N	.	N	N	-1.087839851	6.685188401	0.999988494	2.6	DM	.
SMC1B	22	45344063	45413619	N	.	N	Y	-0.207435076	35.0697459	0.986578246	10.7	DP	.
SMC2	9	104094260	104141417	N	.	N	N	-0.182056178	36.58621288	0.998014292	6.9	.	Smith-McCort dysplasia 2, 615222 (3)
SMC4	3	160399274	160434962	N	.	N	N	-1.526339485	3.218151299	0.105530996	42.8	FP	.
SMC6	2	17663812	17800242	N	.	N	N	-1.070616778	6.910922035	0.45541979	31.2	.	.
SMCO1	3	196506877	196515366	N	.	N	N	.	.	4.63E-05	74.1	.	.
SMCO2	12	27466810	27502185	N	Viable	N	Y	.	.	.	.	.	.
SMCO3	12	14804650	14814182	N	.	N	N	0.294815417	70.1800081	0.205394525	38.6	.	.
SMCO4	11	93478472	93543508	N	.	N	N	0.11459153	58.34925045	0.00205705	61.8	.	.
SMCP	1	152878317	152885047	N	.	N	Y	0.442010439	77.98228859	0.04299324	47.8	.	.
SMCR8	17	18315310	18328055	N	.	N	N	0.103214148	57.43473983	0.319420058	35.2	.	.
SMG5	1	156249224	156282825	N	.	N	N	-1.456060832	3.600162065	0.998179753	6.8	.	.
SMG7	1	183472216	183598246	N	.	N	N	-0.498293669	20.26972275	0.999981493	2.8	.	.
SMG8	17	59209400	59215247	N	.	N	N	-0.370739403	25.83781907	0.021939147	51.2	.	.
SMG9	19	43727992	43754990	N	.	N	N	-0.492046478	20.51282051	4.85E-11	93.4	.	.
SMIM1	1	3772788	3775982	N	.	N	N	.	.	.	.	FP	[Blood group, Vel system], 615264 (3)
SMIM10	X	134990938	134992473	N	.	N	N	.	.	.	.	.	.
SMIM10L1	12	11171222	11176016	N	.	N	N	.	.	.	.	.	.
SMIM10L2A	X	135421943	135428074	N	.	N	N	.	.	.	.	.	.
SMIM10L2B	X	135095028	135098634	N	.	N	N	.	.	.	.	.	.
SMIM11	21	7744962	7777853	N	.	N	N	0.295624092	70.22631244	0.556682788	28.5	.	.
SMIM12	1	34712737	34859816	N	.	N	N	.	.	0.396299543	32.9	.	.
SMIM13	6	11094033	11138733	N	.	N	N	.	.	.	.	.	.
SMIM14	4	39546330	39639090	N	.	N	N	0.030143764	51.8087631	0.742727363	23.4	.	.
SMIM15	5	61157709	61162474	N	.	N	N	0.37161271	74.48052324	0.228320204	37.7	.	.
SMIM17	19	56643145	56655766	N	.	N	N	.	.	.	.	.	.
SMIM18	8	30638600	30646064	N	.	N	N	.	.	.	.	.	.
SMIM19	8	42541155	42555193	N	.	N	N	0.024554204	51.41517625	0.323327861	35.1	.	.
SMIM2	13	44143543	44161257	N	.	N	N	.	.	.	.	.	.
SMIM20	4	25861830	25929874	N	.	N	N	.	.	.	.	.	.
SMIM21	18	75409476	75427703	N	.	N	N	0.275027119	68.98767147	0.000512614	67	.	.
SMIM22	16	4788397	4796491	N	.	N	N	.	.	.	.	.	.
SMIM23	5	171785872	171794598	N	.	N	N	.	.	.	.	.	.
SMIM24	19	3473986	3480542	N	.	N	N	.	.	.	.	.	.
SMIM3	5	150777946	150796734	N	.	N	N	0.38757536	75.25033281	0.001492065	63	.	.
SMIM4	3	52534013	52579237	N	.	N	N	.	.	.	.	.	.
SMIM5	17	75633434	75641404	N	.	N	N	.	.	.	.	.	.
SMIM6	17	75646243	75647977	N	.	N	N	.	.	.	.	.	.
SMIM7	19	16630751	16660442	N	.	N	N	0.077075925	55.43207733	0.417815347	32.3	.	.
SMIM8	6	87322583	87399749	N	.	N	N	0.85102036	90.21820918	0.035853617	48.8	.	.
SMIM9	X	154823348	154834662	N	.	N	N	.	.	.	.	.	.
SMKR1	7	129502479	129512932	N	.	N	N	.	.	.	.	.	.
SMLR1	6	130827406	130837135	N	.	N	N	.	.	.	.	.	.
SMN2	5	70049612	70078522	N	.	N	N	.	.	0.095255983	43.5	DM	{Spinal muscular atrophy, type III, modifier of}, 253400 (3)
SMNDC1	10	110290730	110304951	N	.	N	N	-0.066439705	44.63737917	0.275797515	36.3	.	.
SMOC2	6	168441151	168673445	N	Viable	N	Y	-0.48167256	20.94692366	0.012969779	53.9	DM	Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3)
SMOX	20	4120980	4187747	N	.	N	N	-0.875670325	10.06540487	0.837563766	20.3	.	.
SMPD1	11	6390431	6394998	N	.	N	Y	0.566337528	82.94842855	4.20E-07	84	DM	Niemann-Pick disease, type A, 257200 (3); Niemann-Pick disease, type B, 607616 (3)
SMPD2	6	109440763	109443919	N	.	N	Y	-0.740609356	12.8726052	8.12E-11	93.1	.	.
SMPDL3A	6	122789049	122809720	N	.	N	N	0.210518064	65.10968339	1.67E-13	95.9	.	.
SMPDL3B	1	27934993	27959157	N	.	N	Y	0.35322653	73.60074087	1.39E-07	85.7	.	.
SMPX	X	21705972	21758163	N	.	N	Y	0.061112993	54.1992244	0.593774442	27.6	DM	Deafness, X-linked 4, 300066 (3)
SMR3A	4	70360761	70367158	N	.	N	N	0.298492991	70.40574174	0.039054647	48.4	.	.
SMR3B	4	70370093	70390244	N	.	N	N	0.191535973	63.89419459	0.536532375	29	.	.
SMS	X	21940573	21994835	N	.	N	Y	-0.275568538	30.94287203	0.921460277	16.6	DM	Mental retardation, X-linked, Snyder-Robinson type, 309583 (3)
SMTNL1	11	57542641	57550274	N	.	N	Y	.	.	6.40E-06	79.1	.	.
SMTNL2	17	4583999	4608319	N	.	N	N	0.680495985	86.43861782	0.001237124	63.9	.	.
SMU1	9	33041764	33076659	N	.	N	N	-0.365605444	26.09828095	0.998978044	5.9	.	.
SMUG1	12	54164745	54188994	N	.	N	Y	0.0077858	50.10707878	0.001230088	63.9	DP	.
SMURF1	7	99027438	99144100	N	Viable	N	Y	-1.674930149	2.540950396	0.996803391	7.6	.	.
SMYD2	1	214281102	214337131	N	.	N	Y	0.012569811	50.44857325	0.005368937	57.8	.	.
SMYD3	1	245749342	246507312	N	.	N	N	-0.441438866	22.67176014	7.80E-06	78.7	DFP	.
SMYD4	17	1779485	1830634	N	.	N	N	0.471668741	79.36563061	2.01E-11	93.9	.	.
SMYD5	2	73214222	73227237	N	.	N	N	-0.114980914	41.14140186	0.103327058	42.9	.	.
SNAI3	16	88677682	88686493	N	.	N	Y	1.532404866	97.11755513	0.008305659	55.7	.	.
SNAP47	1	227728539	227781231	N	.	N	Y	0.580233574	83.49250449	0.000304823	68.6	.	.
SNAP91	6	83552880	83709691	N	.	N	N	-0.840067157	10.76575794	0.974350744	12.5	.	.
SNAPC1	14	61762357	61796428	N	.	N	N	-0.275414705	30.96023615	3.82E-07	84.1	.	.
SNAPC2	19	7920316	7923250	N	.	N	N	0.229350964	66.18625919	0.10316814	42.9	.	.
SNAPC3	9	15422704	15465953	N	.	N	N	-0.008025521	48.81634543	5.54E-05	73.6	.	.
SNAPC5	15	66490135	66497813	N	.	N	N	0.21500187	65.32384094	1.40E-05	77.2	DM?	.
SNCA	4	89724099	89838315	N	.	N	Y	0.199039114	64.30514557	0.841962359	20.2	DM	Parkinson disease 4, 605543 (3); Dementia, Lewy body, 127750 (3); Parkinson disease 1, 168601 (3)
SNCAIP	5	122311354	122464219	N	.	N	N	-0.232813931	33.54170284	0.000362968	68.1	DM?	.
SNCB	5	176620084	176630556	N	.	N	Y	-0.103955104	41.8649071	0.198196528	38.8	DM	Dementia, Lewy body, 127750 (3)
SNCG	10	86958618	86963260	N	.	N	Y	0.791946787	89.01429646	0.382299481	33.2	.	.
SND1	7	127652180	128092609	N	.	N	N	-1.050973715	7.194536088	0.999917089	3.6	.	.
SNED1	2	240998838	241095568	N	.	N	N	-0.987797536	8.068530416	0.98376281	11.1	.	.
SNN	16	11668414	11679159	N	.	N	N	-0.043930449	46.31591133	0.020249059	51.6	.	.
SNRK	3	43286512	43424764	N	.	N	N	-0.957252191	8.624182439	0.994142268	8.8	DM?	.
SNRNP25	16	53010	57669	N	.	N	N	0.367934269	74.27215373	0.007478041	56.3	.	.
SNRNP35	12	123457641	123473154	N	.	N	N	-0.28674597	30.23094287	2.28E-07	85	.	.
SNRNP40	1	31259568	31296782	N	.	N	N	-0.560686665	17.89662557	0.825363236	20.8	.	.
SNRNP48	6	7590199	7611967	N	.	N	N	0.243250221	67.10655785	7.93E-05	72.6	.	.
SNRNP70	19	49085419	49108605	N	.	N	N	-0.312126643	28.79550848	0.993095086	9.1	.	.
SNRPA	19	40750637	40765389	N	.	N	N	-0.75577088	12.46744226	0.060279449	46	.	.
SNRPA1	15	101281510	101295282	N	.	N	N	0.072442927	55.09058286	0.969077644	13.1	.	.
SNRPB	20	2461634	2470853	N	.	N	N	-0.343096194	27.10540024	0.691451245	24.8	.	Cerebrocostomandibular syndrome, 117650 (3)
SNRPB2	20	16729961	16742563	N	.	N	N	-0.208998116	34.98292528	0.320265019	35.1	.	.
SNRPC	6	34757406	34773794	N	.	N	N	-0.066439705	44.63737917	0.727261778	23.8	.	.
SNRPD1	18	21612267	21633524	N	.	N	N	0.105175156	57.60838108	0.847045313	20	.	.
SNRPD2	19	45687454	45692569	N	.	N	N	-0.067396649	44.56792267	0.747515256	23.2	.	.
SNRPD3	22	24555503	24609980	N	.	N	N	0.000131289	49.44145396	0.877845312	18.7	.	.
SNRPE	1	203861603	203870550	N	.	N	N	0.000131289	49.44145396	0.891456792	18.1	DM	Hypotrichosis 11, 615059 (3)
SNRPF	12	95858928	95903828	N	.	N	N	0.112678313	58.18139723	0.734661648	23.6	.	.
SNRPG	2	70281362	70293771	N	.	N	N	0.075162561	55.29316432	0.866844386	19.2	.	.
SNTA1	20	33407955	33443892	N	.	N	Y	0.151450703	61.09857035	0.428235398	32	DM	Long QT syndrome 12, 612955 (3)
SNTB1	8	120535745	120813273	N	.	N	N	-0.504181931	20.02083695	0.618933425	27	.	.
SNTB2	16	69187129	69309052	N	.	N	Y	-0.520298739	19.46518493	0.036218318	48.8	.	.
SNTG1	8	49909789	50794118	N	.	N	N	-0.926281221	9.127742085	0.037927565	48.6	DM?	.
SNTG2	2	950868	1367613	N	.	N	N	1.542779302	97.19279968	9.18E-07	82.7	DM	.
SNTN	3	63652668	63679020	N	.	N	N	0.193448992	64.03889564	0.002737944	60.7	.	.
SNU13	22	41673930	41690504	N	.	N	N	.	.	.	.	.	.
SNUPN	15	75598083	75626469	N	.	N	N	0.156083554	61.48058112	2.18E-10	92.4	.	.
SNURF	15	24955034	25000276	N	.	N	N	-0.052390454	45.59819413	0.780882316	22.3	DM?	.
SNW1	14	77717599	77761207	N	.	N	N	-0.519341466	19.49991318	0.999633196	4.9	.	.
SNX1	15	64094123	64146090	N	.	N	Y	-0.666533619	14.84053945	0.939839945	15.6	.	.
SNX10	7	26291895	26374329	N	.	N	N	-0.306538083	29.06754645	0.005857505	57.3	DM	Osteopetrosis, autosomal recessive 8, 615085 (3)
SNX11	17	48103357	48123074	N	.	N	N	-0.241727755	32.9281704	3.86E-05	74.6	.	.
SNX12	X	71056332	71073426	N	.	N	N	0.091125502	56.52022921	0.695492432	24.8	.	.
SNX14	6	85505496	85594156	N	.	N	N	-0.762012753	12.35746947	6.80E-10	91.4	.	Spinocerebellar ataxia, autosomal recessive 20, 616354 (3)
SNX15	11	65027408	65040572	N	Viable	N	Y	0.641066664	85.39098223	0.000705751	65.9	.	.
SNX16	8	81799581	81842866	N	.	N	N	-0.143231429	39.15031545	4.22E-08	87.2	.	.
SNX17	2	27370496	27377533	N	.	N	Y	-0.672122822	14.71320252	0.686180301	25	.	.
SNX18	5	54517759	54546585	N	.	N	N	-0.982633595	8.195867338	0.146597452	40.7	.	.
SNX19	11	130875436	130916509	N	.	N	N	1.428787046	96.54453898	9.83E-07	82.6	DM?	.
SNX2	5	122774996	122830108	N	.	N	Y	-0.563403124	17.82716907	0.997941242	7	.	.
SNX20	16	50666300	50681353	N	.	N	N	0.662620317	85.99872663	4.13E-05	74.4	.	.
SNX21	20	45833810	45843275	N	.	N	N	0.734932275	87.72356312	0.020814016	51.4	.	.
SNX24	5	122843439	123029354	N	.	N	N	-0.291531924	29.91838861	0.001392807	63.4	.	.
SNX25	4	185204237	185370185	N	.	N	N	-0.58656713	17.18469642	5.35E-05	73.7	.	.
SNX29	16	11976737	12574289	N	Viable	N	Y	-0.76541089	12.29958905	1.78E-06	81.5	.	.
SNX3	6	108211222	108261260	N	.	N	N	-0.217458365	34.43884934	0.466342862	30.9	DM?	.
SNX30	9	112750838	112881671	N	.	N	N	-0.192881585	36.00162065	0.970626803	12.9	.	.
SNX31	8	100572882	100663415	N	.	N	N	0.577363401	83.35359148	1.96E-10	92.5	.	.
SNX32	11	65833641	65856896	N	.	N	N	-0.357795969	26.4224113	2.73E-13	95.8	.	.
SNX33	15	75647906	75662301	N	.	N	N	-0.859706529	10.38374718	0.006757144	56.8	.	.
SNX4	3	125446644	125520197	N	.	N	N	-0.701332867	13.86236036	0.011061879	54.5	.	.
SNX6	14	34561094	34630183	N	.	N	N	-0.484697758	20.7732824	0.965428129	13.5	.	.
SNX7	1	98661701	98760500	N	.	N	N	-0.237899627	33.20599641	0.028838862	49.9	.	.
SNX8	7	2251770	2354318	N	.	N	N	-1.005144403	7.784916363	0.165170969	39.9	DM?	.
SNX9	6	157700387	157945077	N	.	N	N	-0.028620813	47.39827516	0.578575161	28	.	.
SOAT1	1	179293714	179358680	N	.	N	Y	-0.283722377	30.43931238	1.67E-05	76.8	.	.
SOAT2	12	53103518	53124538	N	.	N	Y	0.021181046	51.1605024	9.10E-18	98.1	.	.
SOBP	6	107489958	107660167	N	.	N	N	-0.600766325	16.68113677	.	.	DM	Mental retardation, anterior maxillary protrusion, and strabismus, 613671 (3)
SOCS2	12	93569814	93583487	N	.	N	Y	-0.066439705	44.63737917	0.098530408	43.2	.	.
SOCS4	14	55027230	55049488	N	.	N	N	-0.371997156	25.78572669	1.86E-06	81.4	.	.
SOCS5	2	46698952	46763129	N	.	N	Y	-1.141168217	6.141112462	0.410273257	32.5	.	.
SOCS6	18	70288901	70330200	N	.	N	Y	-0.716185569	13.49771372	0.879897418	18.6	.	.
SOD1	21	31659622	31668931	N	.	N	Y	-0.081445868	43.46240667	0.442188724	31.7	DM	Amyotrophic lateral sclerosis 1, 105400 (3)
SOD3	4	24789912	24800842	N	.	N	Y	.	.	0.223646616	37.9	DFP	[Superoxide dismutase, elevated extracellular] (3)
SOGA1	20	36777442	36863686	N	.	N	N	.	.	0.997564312	7.2	.	.
SOGA3	6	127438406	127519355	N	.	N	N	-1.180451652	5.799617989	.	.	.	.
SOHLH1	9	135693407	135699528	N	.	N	Y	1.222817554	95.2480176	0.010418987	54.8	DM	.
SOHLH2	13	36168208	36214615	N	.	N	Y	0.188009008	63.674249	0.429898601	32	.	.
SON	21	33542618	33577481	N	.	N	N	-3.370578928	0.439891185	0.99999991	1.1	.	.
SORBS1	10	95311771	95561414	N	.	N	Y	-0.182716909	36.55148463	2.14E-08	88.1	DP	.
SORBS2	4	185585444	185956652	N	Viable	N	Y	-0.704425926	13.80447994	0.088806284	43.8	.	.
SORBS3	8	22544986	22575788	N	.	N	Y	1.176190834	94.80233837	2.31E-06	81	.	.
SORCS1	10	106573663	107164534	N	.	N	N	-0.684780454	14.39486022	0.969565842	13	DM?	.
SORCS2	4	7192538	7742836	N	.	N	Y	-0.508519814	19.85298374	0.002646288	60.9	.	.
SORCS3	10	104641101	105265235	N	.	N	Y	-1.872661033	1.991086415	0.325134264	35	.	.
SORD	15	45023104	45077185	N	.	N	N	0.550071139	82.43908086	0.004347946	58.7	.	?Cataract, congenital (2)
SORL1	11	121452203	121633693	N	.	N	Y	-0.659717537	15.04890895	0.017414123	52.3	DM?	{Alzheimer disease, pathogenesis, association with}, 104300 (3)
SOS2	14	50117120	50231558	N	.	N	Y	-0.706476008	13.7292354	0.999427841	5.3	.	Noonan syndrome 9, 616559 (3)
SOST	17	43753731	43758788	N	.	N	Y	-0.070115062	44.4058575	0.379603155	33.3	DM	Sclerosteosis 1, 269500 (3); Van Buchem disease, 239100 (3); Craniodiaphyseal dysplasia, autosomal dominant, 122860 (3)
SOWAHA	5	132813587	132816797	N	.	N	N	.	.	.	.	.	.
SOWAHB	4	76894928	76898147	N	.	N	N	-0.0163338	48.1912369	0.004102368	59	.	.
SOWAHC	2	109614334	109618990	N	.	N	N	.	.	.	.	.	.
SOWAHD	X	119758613	119760164	N	.	N	N	.	.	0.477013933	30.6	.	.
SOX1	13	112067647	112070488	N	.	N	Y	.	.	.	.	.	.
SOX12	20	325401	330224	N	.	N	Y	.	.	.	.	.	.
SOX13	1	204073115	204127743	N	.	N	Y	-0.098061234	42.21218962	0.96409953	13.6	.	.
SOX14	3	137764284	137766338	N	.	N	N	-0.033556726	47.03941657	0.720669572	24	.	.
SOX15	17	7588178	7590170	N	.	N	Y	0.245014457	67.16443827	0.361605911	33.9	.	.
SOX18	20	64047582	64049641	Y	Viable	N	Y	.	.	.	.	DM	Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3); Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome, 137940 (3)
SOX21	13	94709622	94712399	N	.	N	Y	.	.	.	.	.	.
SOX30	5	157625679	157671480	N	Viable	N	Y	0.800699266	89.17057359	0.998986334	5.9	.	.
SOX8	16	981808	986979	N	.	N	Y	0.383088549	75.0824796	0.87370846	18.9	DM	.
SP100	2	230415942	230544090	N	.	N	N	-0.243037859	32.84713781	8.71E-07	82.8	FP	.
SP140	2	230203110	230313215	N	.	N	N	0.955710407	92.10511084	2.00E-08	88.2	.	.
SP140L	2	230327184	230403732	N	.	N	N	0.91612174	91.41633385	6.07E-05	73.4	.	.
SP5	2	170715351	170718078	N	.	N	Y	-0.271739892	31.18018174	0.432721441	31.9	.	.
SP6	17	47844908	47855874	N	.	N	Y	0.242293684	67.01973722	0.022947566	51	.	.
SP9	2	174334946	174338492	N	.	N	N	.	.	0.498147938	30	.	.
SPA17	11	124673798	124697518	N	.	N	N	0.04243066	52.74063784	0.006263474	57	.	.
SPACA1	6	88047789	88066832	N	.	N	Y	-0.31116943	28.88232911	0.38222174	33.2	.	.
SPACA3	17	32970376	32997877	N	.	N	N	0.668211287	86.16657985	0.053962912	46.5	.	.
SPACA4	19	48606743	48607714	N	.	N	N	0.282530296	69.45650287	0.577152663	28.1	.	.
SPACA5	X	48004336	48009729	N	.	N	N	.	.	.	.	.	.
SPACA5B	X	48130657	48132613	N	.	N	N	.	.	.	.	.	.
SPACA7	13	112376319	112434689	N	.	N	N	0.302318539	70.64305146	2.10E-06	81.2	.	.
SPAG1	8	100157906	100259278	N	.	N	N	0.132920659	59.63419575	2.33E-07	85	.	Ciliary dyskinesia, primary, 28, 615505 (3)
SPAG11A	8	7847876	7868867	N	.	N	N	.	.	0.039012166	48.4	.	.
SPAG11B	8	7442684	7463674	N	.	N	N	1.419694207	96.48087052	0.04723769	47.3	.	.
SPAG16	2	213284379	214410501	N	.	N	Y	-0.45805624	21.96561903	3.66E-20	98.7	FP	.
SPAG17	1	117953861	118185223	N	.	N	N	0.704510222	86.99426984	9.35E-16	97.3	DM?	.
SPAG4	20	35615892	35621049	N	.	N	N	0.064133998	54.51756671	0.110567923	42.6	.	.
SPAG5	17	28577565	28599279	N	.	N	Y	0.586290354	83.71245008	7.26E-06	78.8	.	.
SPAG6	10	22345445	22454224	N	.	N	Y	-0.393549347	24.76703131	7.41E-06	78.8	.	.
SPAG7	17	4959226	4967872	N	.	N	N	-0.287703102	30.21357875	0.001147197	64.2	.	.
SPAG8	9	35808045	35812272	N	.	N	N	0.234135	66.47566128	2.75E-07	84.7	.	.
SPAG9	17	50962174	51120865	N	.	N	Y	-0.926947722	9.110377959	0.999998938	1.7	.	.
SPAM1	7	123925237	123971414	N	.	N	Y	0.00793724	50.1244429	1.24E-06	82.3	.	.
SPANXA1	X	141583674	141698444	N	.	N	N	.	.	.	.	.	.
SPANXA2	X	141589435	141590772	N	.	N	N	.	.	.	.	.	.
SPANXB1	X	141002591	141003706	N	.	N	N	.	.	.	.	.	.
SPANXC	X	141241463	141242496	N	.	N	N	1.968521216	98.54720148	0.00058968	66.5	.	.
SPANXD	X	141697411	141698739	N	.	N	N	1.415873107	96.4635064	0.177812636	39.4	.	.
SPANXN1	X	145246828	145256112	N	.	N	N	0.198082641	64.25305319	0.51040517	29.7	.	.
SPANXN2	X	143711955	143721423	N	.	N	N	0.035884366	52.28917057	2.60E-05	75.6	.	.
SPANXN3	X	143508735	143517475	N	.	N	N	0.389487678	75.3313654	0.599707835	27.5	.	.
SPANXN4	X	143025918	143034702	N	.	N	N	.	.	0.107493144	42.7	.	.
SPANXN5	X	52796144	52798101	N	.	N	N	0.097672002	56.94854431	0.50096616	29.9	DM	.
SPARC	5	151661096	151687165	N	.	N	Y	0.206691474	64.80870522	0.886494106	18.4	.	Osteogenesis imperfecta, type XVII, 616507 (3)
SPARCL1	4	87473335	87531061	N	.	N	Y	0.484606379	79.9039185	1.07E-06	82.4	.	.
SPAST	2	32063611	32157637	N	.	N	Y	-0.242531784	32.88186606	0.997074713	7.5	DM	Spastic paraplegia 4, autosomal dominant, 182601 (3)
SPATA12	3	57060441	57075432	N	.	N	N	0.201908627	64.49036291	0.007174635	56.5	.	.
SPATA13	13	23979805	24307074	N	.	N	N	-0.260105961	31.87474677	0.528844213	29.2	DM?	.
SPATA16	3	172889358	173141268	N	.	N	N	0.314754515	71.37813278	1.65E-06	81.7	DM	?Spermatogenic failure 6, 102530 (3)
SPATA17	1	217631324	217871696	N	.	N	N	0.234940518	66.52775366	0.004739108	58.4	.	.
SPATA18	4	52051331	52097292	N	.	N	N	0.789520593	88.97956821	1.03E-11	94.3	.	.
SPATA19	11	133840631	133845538	N	.	N	N	0.210368257	65.09231927	5.98E-05	73.4	.	.
SPATA2	20	49903391	49915508	N	Viable	N	Y	-0.303361152	29.28749204	0.848756563	19.9	.	.
SPATA20	17	50543058	50555852	N	.	N	N	0.307557959	70.8977253	1.11E-05	77.8	.	.
SPATA21	1	16387117	16437424	N	.	N	N	1.96033828	98.51247323	3.58E-06	80.2	DM?	.
SPATA22	17	3440019	3513852	N	Viable	N	Y	0.323063788	71.95114893	0.000465618	67.2	.	.
SPATA24	5	139396563	139404088	N	.	N	N	.	.	.	.	.	.
SPATA25	20	45886489	45887635	N	.	N	N	0.083772833	56.01666956	0.000413851	67.6	.	.
SPATA2L	16	89696343	89701705	N	.	N	N	-0.186183329	36.3952075	0.046921864	47.4	.	.
SPATA3	2	230996121	231025055	N	.	N	N	.	.	.	.	.	.
SPATA31A1	9	39355669	39361959	N	.	N	N	.	.	.	.	.	.
SPATA31A3	9	66986304	66992583	N	.	N	N	.	.	.	.	.	.
SPATA31A5	9	60914374	60920650	N	.	N	N	.	.	.	.	.	.
SPATA31A6	9	42183659	42189882	N	.	N	N	.	.	.	.	.	.
SPATA31A7	9	61190003	61196280	N	.	N	N	.	.	0.481345575	30.5	.	.
SPATA31D1	9	81988772	81995256	N	.	N	N	1.647654209	97.70793541	2.73E-09	90.2	.	.
SPATA31D3	9	81943500	81995251	N	.	N	N	.	.	.	.	.	.
SPATA31D4	9	81928514	81934948	N	.	N	N	.	.	.	.	.	.
SPATA31E1	9	87882826	87888899	N	.	N	N	2.188800024	98.84239162	6.08E-21	98.9	.	.
SPATA32	17	45254393	45262112	N	.	N	N	0.339983147	72.87144759	2.95E-05	75.2	DM?	.
SPATA33	16	89657802	89671272	N	.	N	N	0.810776864	89.34421485	2.73E-06	80.7	.	.
SPATA4	4	176184638	176195671	N	.	N	N	0.367125811	74.23163744	0.000481542	67.1	.	.
SPATA45	1	212830141	212847649	N	.	N	N	.	.	.	.	.	.
SPATA5L1	15	45402331	45421419	N	.	N	N	-0.28835508	30.17885049	4.80E-11	93.4	.	.
SPATA6	1	48295372	48472208	N	Viable	N	Y	-0.194643158	35.86849569	2.03E-11	93.9	.	.
SPATA6L	9	4553386	4666674	N	.	N	N	0.963862661	92.23244776	1.92E-11	94	.	.
SPATA7	14	88384924	88470350	N	.	N	Y	0.550220861	82.45065694	3.14E-09	90.1	DM	Leber congenital amaurosis 3, 604232 (3); Retinitis pigmentosa, juvenile, autosomal recessive, 604232 (3)
SPATA8	15	96783389	96785615	N	.	N	N	0.745969788	87.98981305	0.158580482	40.2	FTV	.
SPATA9	5	95652181	95698711	N	.	N	N	-0.130139339	40.0821902	0.002189742	61.5	.	.
SPATC1	8	144012414	144047085	N	.	N	N	1.405940542	96.41720206	3.59E-08	87.4	.	.
SPATC1L	21	46161148	46184476	N	.	N	N	0.715143866	87.26630781	3.78E-06	80.1	.	.
SPATS1	6	44342660	44377167	N	.	N	N	0.214194527	65.30647682	0.00019125	70	.	.
SPATS2	12	49366584	49527424	N	.	N	N	0.593326484	83.93239567	0.98965126	10	.	.
SPATS2L	2	200305881	200482263	N	.	N	N	-0.168458721	37.48335938	0.970345372	13	.	.
SPC24	19	11131520	11155808	N	.	N	N	.	.	0.006275544	57	.	.
SPC25	2	168834132	168913371	N	.	N	N	-0.041059779	46.53585692	0.05942945	46.1	.	.
SPCS1	3	52704955	52711146	N	.	N	N	0.159610371	61.7121028	0.118910838	42.2	.	.
SPCS2	11	74949247	74979031	N	.	N	N	0.032057299	51.99976848	0.725113281	23.9	.	.
SPCS3	4	176319964	176332245	N	.	N	N	0.0545666	53.67251259	0.697040879	24.7	.	.
SPDL1	5	169583634	169604778	N	.	N	N	1.01845409	92.99068125	8.72E-10	91.2	.	.
SPDYA	2	28782517	28850611	N	.	N	N	-0.01663693	48.16808474	0.166884224	39.9	.	.
SPDYC	11	65170154	65173244	N	.	N	N	-0.421801054	23.46472188	0.001855149	62.2	.	.
SPDYE1	7	44000889	44010122	N	.	N	N	0.852118493	90.23557331	0.206335953	38.6	.	.
SPDYE16	7	76531319	76541459	N	.	N	N	.	.	.	.	.	.
SPDYE2	7	102551232	102562308	N	.	N	N	.	.	.	.	.	.
SPDYE2B	7	102650325	102661398	N	.	N	N	.	.	.	.	.	.
SPDYE3	7	100307702	100322196	N	.	N	N	.	.	0.825434138	20.8	.	.
SPDYE4	17	8753106	8758559	N	.	N	N	0.240380673	66.89818834	0.001221667	63.9	.	.
SPDYE5	7	75493625	75504304	N	.	N	N	.	.	.	.	.	.
SPDYE6	7	102347206	102356444	N	.	N	N	.	.	.	.	.	.
SPECC1	17	20009344	20319026	N	.	N	N	-1.128468197	6.308965677	0.10945964	42.6	.	.
SPECC1L	22	24270817	24417740	N	.	N	N	-0.76841557	12.24749667	0.993395147	9	DM	?Facial clefting, oblique, 1, 600251 (3); Opitz GBBB syndrome, type II, 145410 (3)
SPECC1L-ADORA2A	22	24270898	24442356	N	.	N	N	.	.	.	.	.	.
SPEM1	17	7420360	7421632	N	.	N	Y	0.664532951	86.07397118	0.023453063	50.8	.	.
SPERT	13	45702311	45714559	N	.	N	N	0.089513257	56.41025641	0.000527781	66.9	DM?	.
SPESP1	15	68818221	68946811	N	.	N	Y	-0.192881585	36.00162065	1.98E-05	76.3	.	.
SPG11	15	44562696	44663678	N	.	N	N	-2.008173172	1.620651734	2.91E-22	99.1	DM	Spastic paraplegia 11, autosomal recessive, 604360 (3); Amyotrophic lateral sclerosis 5, juvenile, 602099 (3)
SPG20	13	36301638	36370180	N	Viable	N	Y	-0.128878445	40.18058691	0.000159489	70.5	DM	Troyer syndrome, 275900 (3)
SPG21	15	64963021	64990310	N	.	N	N	-0.53817717	18.67222319	9.88E-05	71.9	DM	Mast syndrome, 248900 (3)
SPG7	16	89490917	89557768	N	.	N	Y	-0.578775191	17.39306593	1.38E-18	98.3	DM	Spastic paraplegia 7, autosomal recessive, 607259 (3)
SPHAR	1	229304857	229305504	N	.	N	N	0.242145304	67.0023731	0.014463117	53.4	.	.
SPHK1	17	76376584	76387860	N	.	N	Y	-0.430107764	23.15216762	1.29E-05	77.4	.	.
SPHK2	19	48619291	48630717	N	.	N	Y	-0.16719952	37.58175609	8.66E-06	78.4	.	.
SPHKAP	2	227979950	228181645	N	.	N	N	-0.58205613	17.32360942	0.233358015	37.6	.	.
SPIB	19	50418938	50431313	N	.	N	Y	0.763844026	88.41234011	0.89985367	17.8	.	.
SPICE1	3	113442718	113515187	N	.	N	N	-0.232813931	33.54170284	5.14E-08	86.9	.	.
SPIDR	8	47260575	47736306	N	.	N	N	-0.316304619	28.50610638	1.07E-14	96.7	.	.
SPIN2A	X	57134530	57137625	N	.	N	N	0.22250501	65.75794409	0.22066142	38	.	.
SPIN2B	X	57118551	57121547	N	.	N	N	0.15865385	61.61949413	0.620083821	26.9	.	.
SPIN3	X	56976370	56995537	N	.	N	N	-0.012004394	48.53851942	0.674771548	25.3	.	.
SPIN4	X	63347228	63351344	N	.	N	N	0.14651721	60.7454998	0.725861947	23.9	.	.
SPINK13	5	148268180	148286254	N	.	N	N	0.08457904	56.06876194	0.024356953	50.6	.	.
SPINK14	5	148169733	148175398	N	.	N	N	0.326593235	72.13057823	0.016352158	52.7	.	.
SPINK2	4	56809860	56821742	N	Viable	N	Y	0.143647524	60.46767379	0.717781973	24.1	.	.
SPINK4	9	33218365	33248567	N	.	N	N	0.327549473	72.20003473	0.713655356	24.2	.	.
SPINK6	5	148202794	148215137	N	.	N	N	0.357562369	73.8264745	2.42E-05	75.7	.	.
SPINK7	5	148312419	148315922	N	.	N	N	0.41008517	76.32112056	0.076116714	44.7	DFP	.
SPINK8	3	48306842	48328341	N	.	N	N	0.356606194	73.78595821	0.001121286	64.3	.	.
SPINK9	5	148321203	148339849	N	.	N	N	0.493577577	80.20489668	0.326828103	35	.	.
SPINT3	20	45512461	45515624	N	.	N	N	.	.	.	.	.	.
SPINT4	20	45722351	45725830	N	.	N	N	0.411041265	76.39636511	0.093389522	43.6	.	.
SPIRE1	18	12446512	12658134	N	.	N	N	-1.338185338	4.416275974	0.330091752	34.9	.	.
SPIRE2	16	89818179	89871319	N	.	N	N	0.004412995	49.84082885	1.13E-10	92.9	.	.
SPN	16	29662979	29670876	N	.	N	Y	0.430020338	77.42084853	0.091271392	43.7	.	.
SPNS2	17	4498838	4539035	N	Viable	N	Y	-0.703898724	13.81605603	0.00382444	59.2	.	.
SPNS3	17	4433688	4488208	N	.	N	N	0.70139538	86.92481334	2.77E-10	92.2	.	.
SPO11	20	57329759	57343994	N	Viable	N	Y	0.134531237	59.82520113	0.0003563	68.1	.	.
SPOCD1	1	31790422	31816051	N	.	N	N	-0.322704383	28.08936737	8.80E-06	78.4	.	.
SPOCK1	5	136975298	137598379	N	.	N	Y	-0.25099172	32.42461075	0.320886445	35.1	.	.
SPOCK2	10	72059035	72089032	N	.	N	N	0.23207049	66.37147653	0.881279639	18.6	.	.
SPOCK3	4	166733384	167234796	N	.	N	Y	0.151450703	61.09857035	0.495144484	30.1	.	.
SPON1	11	13962689	14267884	N	.	N	Y	.	.	.	.	.	.
SPON2	4	1166932	1208962	N	.	N	Y	-0.190967704	36.11159345	1.09E-06	82.4	.	.
SPOPL	2	138501801	138573547	N	.	N	Y	-0.147863581	38.90142965	0.045446953	47.5	.	.
SPP1	4	87975650	87983426	N	.	N	Y	0.929066508	91.70573595	1.51E-06	81.9	DFP	.
SPP2	2	234050679	234077134	N	.	N	N	0.190728755	63.83052613	1.27E-06	82.2	DM?	.
SPPL2A	15	50702266	50765808	N	.	N	Y	0.309970893	71.06557851	0.047077934	47.4	.	.
SPPL2B	19	2328615	2354806	N	.	N	N	.	.	.	.	.	.
SPPL2C	17	45844835	45847072	N	.	N	N	2.664510789	99.2822828	2.30E-05	75.9	DP	.
SPPL3	12	120762510	120904371	N	.	N	N	-0.137642372	39.56705447	0.907785634	17.5	.	.
SPRED1	15	38252326	38357249	N	.	N	Y	0.071637002	55.02112635	0.868668326	19.1	DM	Legius syndrome, 611431 (3)
SPRED2	2	65310851	65432637	N	.	N	Y	-0.627103417	15.95184349	0.000973023	64.8	DM?	.
SPRED3	19	38388421	38399587	N	.	N	N	.	.	0.422884638	32.2	.	.
SPRN	10	133420666	133424572	N	.	N	Y	.	.	0.386597169	33.1	DM?	.
SPRR1A	1	152985231	152985500	N	.	N	N	0.032057299	51.99976848	0.175108854	39.5	.	.
SPRR1B	1	153031202	153032900	N	.	N	N	0.14651721	60.7454998	0.172609046	39.6	.	.
SPRR2A	1	153056113	153057537	N	.	N	N	0.30503986	70.79354055	0.160255855	40.2	.	.
SPRR2B	1	153070224	153070840	N	.	N	N	0.115548149	58.40713087	0.157442686	40.3	.	.
SPRR2D	1	153039725	153041931	N	.	N	N	0.449513717	78.32957111	0.003680974	59.4	.	.
SPRR2E	1	153093135	153106184	N	.	N	N	0.479526897	79.73027725	0.154587337	40.4	.	.
SPRR2F	1	153112114	153113515	N	.	N	N	0.320046263	71.77750767	0.003622031	59.5	.	.
SPRR2G	1	153149582	153150869	N	.	N	N	0.380072103	74.92620247	0.026608019	50.3	.	.
SPRR3	1	153001747	153003856	N	.	N	N	0.318281227	71.63859466	0.006042967	57.2	DP	.
SPRR4	1	152970666	152972574	N	.	N	N	0.175573187	62.89865139	0.582181679	27.9	.	.
SPRTN	1	231337104	231355023	N	.	N	N	-0.157128223	38.22422874	0.981335747	11.5	.	Ruijs-Aalfs syndrome, 616200 (3)
SPRY3	X	155767812	155782459	N	.	N	N	0.27517563	69.0050356	0.005844747	57.4	FP	.
SPRYD3	12	53064316	53079420	N	.	N	N	-0.445267562	22.48075476	0.946942478	15	.	.
SPRYD4	12	56468567	56479707	N	.	N	N	0.044344174	52.90849106	0.000589212	66.5	.	.
SPRYD7	13	49912706	49936490	N	.	N	N	-0.171482763	37.26341379	0.091157166	43.7	.	.
SPSB1	1	9292880	9369532	N	.	N	N	-0.61320898	16.38015859	0.709596082	24.4	.	.
SPSB2	12	6870935	6889358	N	.	N	Y	-0.133814513	39.83909244	0.125059417	41.8	.	.
SPSB3	16	1776712	1793700	N	.	N	N	-0.572667189	17.57828327	0.514185342	29.6	.	.
SPSB4	3	141051402	141148611	N	.	N	N	.	.	0.005228639	57.9	.	.
SPTBN2	11	66685248	66729226	N	Viable	N	Y	-3.116076027	0.555652023	0.999977957	2.9	DM	Spinocerebellar ataxia 5, 600224 (3); Spinocerebellar ataxia, autosomal recessive 14, 615386 (3)
SPTBN4	19	40466241	40576464	N	.	N	Y	-0.573727624	17.53776697	.	.	.	.
SPTBN5	15	41848144	41894077	N	.	N	N	3.922664997	99.7511142	1.09E-70	100	DM?	.
SPTLC3	20	13008979	13169103	N	.	N	N	-0.996683833	7.906465243	0.00275524	60.7	.	.
SPTSSB	3	161344792	161372880	N	Viable	N	Y	0.107088402	57.71835388	0.005899591	57.3	.	.
SPTY2D1	11	18606401	18634791	N	.	N	N	0.068112506	54.73172426	0.997915214	7	.	.
SPX	12	21526307	21537377	N	.	N	N	.	.	.	.	.	.
SPZ1	5	80319625	80321842	N	.	N	N	1.127988443	94.28720264	0.001510593	63	FTV	.
SQRDL	15	45631148	45691294	N	.	N	N	-0.036123783	46.87156335	1.10E-05	77.8	.	.
SQSTM1	5	179806398	179838078	N	.	N	Y	0.371103225	74.46315911	0.003538991	59.6	DM	Paget disease of bone 3, 167250 (3); Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3)
SRA1	5	140537340	140558310	N	Viable	N	Y	0.509685942	80.85894542	5.00E-06	79.5	FTV	Campomelic dysplasia with autosomal sex reversal, 114290 (3); Acampomelic campomelic dysplasia, 114290 (3); Campomelic dysplasia, 114290 (3)
SRBD1	2	45388680	45612165	N	.	N	N	0.378115691	74.82201771	1.67E-14	96.6	.	.
SRCAP	16	30698209	30741409	N	.	N	N	-3.820104245	0.283614053	0.999999997	0.7	DM	Floating-Harbor syndrome, 136140 (3)
SRCIN1	17	38530016	38605930	N	.	N	N	-0.079076712	43.71129247	0.99550429	8.2	.	.
SRD5A1	5	6633343	6674386	N	.	N	Y	-0.500661427	20.13080975	1.82E-06	81.5	.	.
SRD5A2	2	31522480	31581067	N	.	N	Y	.	.	.	.	DM	Pseudovaginal perineoscrotal hypospadias, 264600 (3)
SREK1	5	66139971	66183615	N	.	N	N	-0.629974609	15.88238699	0.988373472	10.3	FP	.
SREK1IP1	5	64718144	64768685	N	.	N	N	0.290033479	69.90218209	0.656016357	25.9	.	.
SRFBP1	5	121961961	122075570	N	.	N	N	0.730298715	87.58465011	8.19E-05	72.5	.	.
SRGAP1	12	63844293	64162221	N	.	N	N	-0.739357251	12.90154541	0.987851405	10.4	DM	{Thyroid cancer, nonmedullary, 2}, 188470 (3)
SRGAP2B	1	144887265	145095528	N	.	N	N	.	.	.	.	.	.
SRGAP2C	1	121184810	121392822	N	.	N	N	.	.	.	.	.	.
SRGAP3	3	8980591	9363053	N	.	N	Y	-1.759124352	2.303640678	0.99999775	2	DM	.
SRGN	10	69088106	69104811	N	.	N	Y	0.12592113	59.20588065	0.140766947	41.1	.	.
SRI	7	88205118	88226993	N	.	N	N	0.111871637	58.12930486	9.98E-05	71.9	DM	.
SRL	16	4189374	4242080	N	.	N	Y	-1.004187452	7.802280489	0.001233427	63.9	.	.
SRM	1	11054584	11060024	N	.	N	N	-0.054152096	45.51716154	0.869848472	19.1	.	.
SRMS	20	63540810	63547504	N	.	N	Y	1.858135781	98.32146785	5.13E-12	94.6	.	.
SRP14	15	40035739	40039188	N	.	N	N	-0.050476626	45.73710714	0.835395731	20.4	.	.
SRP19	5	112861188	112869788	N	.	N	N	-0.056065882	45.38982462	0.085267996	44.1	.	.
SRP54	14	34981957	35029567	N	.	N	N	-0.402163571	24.28662384	0.996689717	7.7	.	.
SRP68	17	76038775	76072653	N	.	N	N	-0.284679206	30.37564392	0.365044973	33.8	.	.
SRP72	4	56466915	56503680	N	.	N	N	-0.358752744	26.36453088	0.014188139	53.4	DM	Bone marrow failure syndrome 1, 614675 (3)
SRPK1	6	35832966	35921342	N	.	N	N	-0.128073148	40.20373908	0.000394807	67.8	.	.
SRPK2	7	105110704	105399308	N	.	N	N	-0.77908304	12.03912716	0.997504054	7.3	.	.
SRPK3	X	153776412	153785732	N	.	N	Y	0.239724325	66.86346009	0.179643538	39.3	.	.
SRPR	11	126262919	126269144	N	.	N	N	-1.008820814	7.755976153	0.992611254	9.3	.	.
SRPRB	3	133784033	133825772	N	.	N	N	0.00123959	49.58036696	0.010790626	54.6	.	.
SRPX	X	38149336	38220924	N	.	N	Y	1.43102179	96.56769115	0.008482621	55.6	DM	.
SRPX2	X	100644218	100671299	N	.	N	N	1.225539855	95.26538172	0.962529393	13.7	DM	?Rolandic epilepsy, mental retardation, and speech dyspraxia, 300643 (3)
SRR	17	2303383	2325260	N	.	N	Y	-0.378697035	25.5252648	0.179017047	39.4	DFP	.
SRRD	22	26483877	26494658	N	.	N	N	0.077226532	55.46680558	1.59E-06	81.8	.	.
SRRM1	1	24631716	24673267	N	.	N	N	-0.529262888	19.04265787	0.999999022	1.7	.	.
SRRM2	16	2752329	2772538	N	.	N	N	-2.166296495	1.342825722	.	.	.	.
SRRM3	7	76201900	76287288	N	.	N	N	.	.	0.911827253	17.2	.	.
SRRM4	12	118981495	119163051	N	.	N	Y	-0.048259287	45.95126469	0.411747626	32.5	.	.
SRRM5	19	43596617	43614497	N	.	N	N	.	.	7.19E-06	78.9	.	.
SRSF11	1	70205682	70253052	N	.	N	N	-0.595330347	16.85477803	0.999787767	4.3	.	.
SRSF12	6	89095959	89118081	N	.	N	N	0.074356355	55.24107195	0.01623122	52.7	.	.
SRSF4	1	29147743	29181987	N	.	N	Y	-0.302555896	29.33379638	0.934762697	15.9	.	.
SRSF5	14	69726900	69772005	N	.	N	N	-0.371193959	25.80887886	0.339129155	34.6	.	.
SRSF6	20	43457928	43464247	N	.	N	N	-0.542808172	18.4812178	0.992976413	9.2	.	.
SRSF8	11	95067197	95071224	N	.	N	N	.	.	.	.	.	.
SRSF9	12	120461668	120469793	N	.	N	N	-0.056065882	45.38982462	0.819638672	21	.	.
SRXN1	20	646615	653370	N	.	N	Y	.	.	0.008657879	55.5	.	.
SRY	Y	2786855	2787699	N	.	N	Y	.	.	0.416019592	32.4	DM	46XY sex reversal 1, 400044 (3); 46XX sex reversal 1, 400045 (3)
SS18L1	20	62143795	62182484	N	.	N	Y	-0.742523485	12.81472478	0.812233116	21.2	DM	.
SS18L2	3	42581840	42595114	N	.	N	N	-0.082402837	43.40452625	0.060207196	46	.	.
SSBP2	5	81413021	81751797	Y	Viable	N	Y	-0.137642372	39.56705447	0.976772519	12.2	.	.
SSBP4	19	18418864	18434562	N	.	N	N	-0.127268446	40.25583145	0.961658882	13.8	.	.
SSC4D	7	76389334	76409695	N	.	N	N	.	.	.	.	.	.
SSC5D	19	55488404	55519098	N	.	N	N	.	.	0.346968714	34.3	.	.
SSFA2	2	181891833	181930738	N	.	N	Y	-0.392957955	24.7786074	7.68E-05	72.7	.	.
SSH1	12	108778192	108857590	N	.	N	N	-0.345214226	26.97806332	0.987158741	10.6	DM	.
SSH2	17	29625938	29930276	N	.	N	N	-0.115335039	41.09509753	0.999753485	4.5	.	.
SSH3	11	67303448	67312607	N	.	N	Y	0.057890757	53.94455056	1.32E-07	85.8	.	.
SSMEM1	7	130207860	130216843	N	.	N	N	0.575302895	83.26677085	6.43E-13	95.4	.	.
SSNA1	9	137188647	137190370	N	.	N	N	-0.012961236	48.47485096	0.008002609	55.9	.	.
SSPN	12	26121991	26299290	N	.	N	Y	0.686897579	86.57174278	0.753322775	23.1	.	.
SSPO	7	149776042	149833979	N	.	N	N	.	.	.	.	.	.
SSR2	1	156009048	156020959	N	.	N	N	0.1249645	59.10748394	0.822108921	20.9	.	.
SSR4	X	153793516	153798505	N	.	N	N	-0.254973777	32.16414887	0.806792212	21.4	.	?Congenital disorder of glycosylation, type Iy, 300934 (3)
SSSCA1	11	65570430	65573942	N	.	N	N	-0.03259986	47.11466111	0.00200151	61.9	.	.
SST	3	187668906	187670399	N	Viable	N	Y	0.326593235	72.13057823	0.665498024	25.7	DP	.
SSTR1	14	38207999	38213067	N	.	N	Y	-0.320432866	28.29194883	0.829919497	20.6	.	.
SSTR2	17	73165012	73176633	N	.	N	Y	-0.497789345	20.304451	0.235751811	37.5	DP	.
SSTR3	22	37204238	37212322	N	.	N	N	0.302618984	70.67777971	0.037224359	48.6	.	.
SSTR4	20	23035386	23036812	N	.	N	Y	0.06987463	54.88800139	8.69E-05	72.3	.	.
SSTR5	16	1078781	1080142	N	.	N	Y	0.74067244	87.85668808	0.062334466	45.8	DM	Somatostatin analog, resistance to (3)
SSU72	1	1541673	1574869	N	.	N	N	-0.187446039	36.28523471	0.606848849	27.3	.	.
SSUH2	3	8619400	8745040	N	.	N	N	0.289375137	69.87324188	2.49E-08	87.9	.	.
SSX1	X	48255317	48267444	N	.	N	N	0.868081708	90.53076344	6.95E-28	99.6	DM?	?Sarcoma, synovial, 300813 (3)
SSX2	X	52644567	52707189	N	.	N	N	.	.	.	.	.	?Sarcoma, synovial, 300813 (3)
SSX2B	X	52751132	52790305	N	.	N	N	.	.	.	.	.	.
SSX2IP	1	84643707	84690803	N	.	N	N	-0.192729499	36.01898478	0.000829859	65.4	.	.
SSX3	X	48346428	48356707	N	.	N	N	0.226330975	66.02998206	0.146323758	40.8	.	.
SSX4	X	48383516	48393347	N	.	N	N	.	.	0.443294514	31.6	.	.
SSX4B	X	48402078	48411910	N	.	N	N	.	.	0.474319599	30.7	.	.
SSX5	X	48186220	48277578	N	.	N	N	1.282705342	95.68212074	2.33E-07	84.9	.	.
SSX7	X	52644090	52654900	N	.	N	N	0.910235282	91.27742085	7.68E-05	72.7	DM	.
ST13	22	40824535	40857022	N	.	N	N	-0.277328762	30.80974706	0.659423624	25.8	.	.
ST18	8	52110839	52460959	N	.	N	Y	-0.355585906	26.54974822	0.999009548	5.9	.	.
ST20	15	79898840	79923702	N	.	N	N	0.281573966	69.3928344	0.113592064	42.4	.	.
ST20-MTHFS	15	79845195	79923754	N	.	N	N	0.481438994	79.79973375	0.036371283	48.8	.	.
ST3GAL1	8	133454848	133571940	N	.	N	Y	0.399051307	75.78862071	0.593559246	27.6	.	.
ST3GAL2	16	70375978	70439237	N	.	N	Y	-0.782911829	11.91179024	0.947101299	15	.	.
ST3GAL3	1	43705824	43931165	N	.	N	N	-0.403923475	24.17665104	0.573989459	28.1	DM	Mental retardation, autosomal recessive 12, 611090 (3); Epileptic encephalopathy, early infantile, 15, 615006 (3)
ST3GAL4	11	126355640	126440344	N	.	N	Y	0.175722654	62.91601551	0.439048571	31.7	.	.
ST3GAL5	2	85839144	85889014	N	.	N	Y	0.018159209	50.92319268	0.02785491	50.1	DM	.
ST3GAL6	3	98732236	98821201	N	.	N	Y	-0.005306604	49.07680732	0.001061672	64.5	DM?	.
ST5	11	8693351	8910951	N	.	N	N	-0.080688941	43.52028709	0.999989779	2.5	DM	.
ST6GAL1	3	186930485	187078553	N	.	N	Y	-0.086882719	43.06881982	0.814435678	21.1	.	.
ST6GAL2	2	106801600	106887108	N	.	N	N	0.601786408	84.15234126	0.014936438	53.2	.	.
ST6GALNAC1	17	76624761	76643838	N	.	N	N	0.192944613	64.01574347	2.24E-11	93.8	.	.
ST6GALNAC2	17	76563710	76586956	N	.	N	Y	0.082010267	5.59E+01	4.43E-08	87.1	.	.
ST6GALNAC3	1	76074719	76634601	N	.	N	N	0.002196401	49.64982346	0.178471681	39.4	.	.
ST6GALNAC4	9	127907886	127917038	N	.	N	N	-0.175961714	36.99716386	0.005077205	58	.	.
ST6GALNAC5	1	76867441	77065711	N	.	N	N	-0.314843927	28.5639868	0.852521023	19.8	.	.
ST6GALNAC6	9	127885321	127905408	N	.	N	N	0.179549296	63.17068936	0.00205356	61.8	.	.
ST7	7	116953238	117230103	N	.	N	N	-0.327935902	27.84048157	0.998051872	6.9	.	.
ST7L	1	112523518	112620825	N	.	N	N	0.778189146	88.75962262	1.94E-06	81.4	.	.
ST8SIA1	12	22063773	22437041	N	.	N	Y	-0.156323524	38.27632112	0.211574644	38.4	.	.
ST8SIA2	15	92393828	92468728	N	.	N	Y	0.01161301	50.38490479	0.512756894	29.6	DM?	.
ST8SIA3	18	57350813	57371731	N	.	N	N	-0.203255573	35.26075129	0.963677659	13.6	.	.
ST8SIA4	5	100806935	100903266	N	.	N	Y	-0.227678773	33.88319731	0.675929296	25.3	.	.
ST8SIA5	18	46667821	46759257	N	.	N	N	-0.411426546	23.88724894	0.01839285	52.1	.	.
ST8SIA6	10	17318383	17454330	N	.	N	N	-0.084012126	43.26561324	2.71E-08	87.8	.	.
STAB1	3	52495338	52524495	N	.	N	Y	-0.824439798	11.06673612	2.80E-25	99.4	.	.
STAB2	12	103587273	103766727	N	.	N	Y	1.457123521	96.74712045	4.18E-28	99.6	.	.
STAC	3	36380344	36548007	N	.	N	N	0.112978986	58.22191353	0.010710269	54.7	.	.
STAC2	17	39210536	39225872	N	.	N	N	-0.492046478	20.51282051	1.66E-05	76.8	.	.
STAG2	X	123960212	124422664	N	.	N	N	-1.053037628	7.177171963	0.999999813	1.2	.	.
STAG3	7	100177563	100221488	N	Viable	N	Y	-1.205419848	5.510215894	1.10E-06	82.4	.	?Premature ovarian failure 8, 615723 (3)
STAG3L5P-PVRIG2P-PILRB	7	100336104	100367831	N	.	N	N	.	.	.	.	.	.
STAM	10	17644125	17715914	N	.	N	Y	-0.784672448	11.84812178	0.902578081	17.7	.	.
STAM2	2	152116801	152175992	N	.	N	Y	-0.468580168	21.49678764	0.034504986	49	.	.
STAMBPL1	10	88879734	88975153	N	.	N	N	-0.007068709	48.91474214	1.93E-05	76.3	.	.
STAP1	4	67558728	67607337	N	.	N	N	-0.421801054	23.46472188	0.00012955	71.1	.	.
STAP2	19	4324043	4342786	N	.	N	Y	0.256492914	67.83006309	1.63E-13	95.9	.	.
STARD10	11	72754729	72794168	N	Viable	N	Y	0.085686282	56.13821844	0.051037146	46.9	.	.
STARD13	13	33103135	33350630	N	.	N	Y	-0.364712924	26.1330092	1.85E-07	85.3	.	.
STARD3	17	39637065	39663484	N	.	N	Y	-0.109239873	41.51762459	0.149477765	40.6	.	.
STARD3NL	7	38178222	38230671	N	.	N	N	-0.434090717	23.00746657	0.005545828	57.7	.	.
STARD4	5	111496033	111512590	N	.	N	Y	-0.138599374	39.52075013	2.96E-07	84.6	.	.
STARD5	15	81309053	81324183	N	.	N	Y	0.409275399	76.30375644	0.061597118	45.8	.	.
STARD6	18	54324358	54357964	N	.	N	N	0.529327004	81.64033108	0.026335162	50.3	DM?	.
STARD7	2	96184859	96208825	N	.	N	N	-0.142274465	39.26028824	0.927709616	16.2	.	.
STARD8	X	68647666	68725842	N	Viable	N	Y	2.487045997	99.18388609	0.035830869	48.9	.	.
STARD9	15	42575659	42720981	N	.	N	N	.	.	.	.	.	.
STAT2	12	56341597	56360155	N	.	N	Y	-0.983440383	8.166927129	0.041094737	48.2	DM	.
STAT4	2	191029576	191151596	N	.	N	Y	-0.006111899	49.02471494	0.988867843	10.2	DP	.
STAT5A	17	42287547	42311943	N	.	N	Y	-0.76775206	12.25907276	0.999866029	4	.	.
STAT5B	17	42199168	42276707	N	Viable	N	Y	-0.976087079	8.300052092	0.99995316	3.2	DM	Leukemia, acute promyelocytic, somatic, 102578 (3); Growth hormone insensitivity with immunodeficiency, 245590 (3)
STAT6	12	57095408	57132139	N	.	N	Y	-0.437459904	22.87434161	0.100774662	43.1	DFP	.
STATH	4	69995930	70002570	N	.	N	N	0.395078624	75.58603924	0.002082806	61.7	.	.
STAU1	20	49113339	49188367	N	.	N	N	-0.992051392	7.993285871	0.996415825	7.8	.	.
STAU2	8	73420369	73747708	N	.	N	N	-0.866406436	10.2621983	0.95043919	14.7	.	.
STC1	8	23841915	23854807	N	.	N	Y	0.004915377	49.86976906	0.47349905	30.7	.	.
STC2	5	173314713	173329503	N	.	N	Y	0.047214459	53.18052903	0.453518118	31.3	.	.
STEAP1	7	90154375	90164829	N	.	N	N	0.397138302	75.69601204	0.434511094	31.8	.	.
STEAP1B	7	22419444	22632925	N	.	N	N	1.27520115	95.58372403	4.60E-05	74.1	.	.
STEAP2	7	90167590	90238137	N	.	N	N	0.082967032	55.94721306	0.002449747	61.2	.	.
STEAP3	2	119223831	119265652	N	.	N	Y	1.2323896	95.32326214	3.94E-07	84.1	DM?	?Anemia, hypochromic microcytic, with iron overload 2, 615234 (3)
STEAP4	7	88270892	88306891	N	.	N	Y	-0.228482701	33.83110494	1.50E-05	77	DP	.
STH	17	45999250	45999694	N	.	N	N	0.586485615	83.7298142	0.004444666	58.6	DP	.
STIM2	4	26857678	27025381	N	.	N	Y	-1.418818063	3.820107658	.	.	.	.
STK10	5	172042073	172188386	N	.	N	Y	-0.499104621	20.21763038	1.50E-07	85.6	DP	.
STK11IP	2	219597860	219616451	N	.	N	N	0.192294693	63.94628697	.	.	.	.
STK16	2	219245455	219250337	N	Viable	N	Y	0.099735608	57.19164207	0.000478667	67.1	.	.
STK17A	7	43582758	43626786	N	.	N	N	0.056630995	53.83457776	0.176185205	39.5	.	.
STK17B	2	196133566	196176503	N	.	N	Y	-0.219218665	34.36360479	0.089825746	43.8	.	.
STK19	6	31971091	31982821	N	.	N	N	-0.326978896	27.91572611	0.004617081	58.5	FTV	.
STK24	13	98445185	98577940	N	.	N	N	-0.662859235	14.96208833	0.797998297	21.8	.	.
STK25	2	241492674	241509730	N	.	N	Y	-0.796003991	11.6571164	0.04526709	47.5	.	.
STK26	X	132023265	132075943	N	.	N	N	.	.	.	.	.	.
STK3	8	98401403	98942827	N	.	N	Y	-0.449899067	22.28396134	5.74E-09	89.5	.	.
STK31	7	23710167	23832513	N	Viable	N	Y	1.180983492	94.8486427	0.233315307	37.6	.	.
STK32A	5	147234963	147387852	N	.	N	Y	0.00602363	49.96237773	5.72E-05	73.5	FTV	.
STK32B	4	5051442	5500998	N	.	N	N	-0.873756656	10.10592117	0.00432349	58.8	.	.
STK32C	10	132207492	132331847	N	.	N	N	-0.069963016	44.41743358	0.309709769	35.5	.	.
STK33	11	8391868	8594289	N	.	N	N	-0.067092495	44.59686288	0.000137426	70.9	FTV	.
STK35	20	2101611	2177038	N	.	N	N	-0.38061162	25.41529201	0.918199526	16.8	.	.
STK38	6	36493892	36547470	N	.	N	N	-0.163826529	37.7901256	0.853295086	19.8	.	.
STK38L	12	27243968	27325959	N	.	N	Y	-0.418127104	23.56890664	0.965893632	13.4	.	.
STK39	2	167954020	168248141	N	.	N	Y	-0.444310324	22.50969497	0.999462431	5.2	DFP	.
STK4	20	44966474	45079959	N	.	N	Y	-0.129986883	40.1111304	0.118311922	42.2	DM	T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3)
STKLD1	9	133376367	133406096	N	.	N	N	.	.	.	.	.	.
STMN1	1	25884181	25906991	N	.	N	Y	-0.022378042	47.78028593	0.648591504	26.1	DP	.
STMN2	8	79610814	79666175	N	.	N	N	-0.187446039	36.28523471	0.932287578	16	.	.
STMN3	20	63639705	63657682	N	.	N	N	-0.170525669	37.3618105	0.489817097	30.3	.	.
STMN4	8	27235323	27258420	N	.	N	N	-0.252102165	32.32621404	0.146519525	40.8	.	.
STMND1	6	17102258	17131372	N	.	N	N	.	.	.	.	.	.
STOM	9	121338988	121370304	N	.	N	N	0.014332026	50.57012213	0.000669923	66.1	.	.
STOML1	15	73978923	73994622	N	.	N	N	-0.245402639	32.7487411	5.53E-05	73.6	.	.
STOML2	9	35099776	35103195	N	.	N	N	-0.141317516	39.35289691	0.529200678	29.2	.	.
STOML3	13	38965925	38991066	N	.	N	Y	0.186095639	63.59900446	1.97E-08	88.2	.	.
STON1	2	48529383	48598513	N	.	N	N	0.45857736	78.74631012	4.45E-08	87.1	.	.
STON1-GTF2A1L	2	48529925	48776517	N	.	N	N	-0.17138833	37.26920183	1.65E-14	96.6	.	.
STON2	14	81260656	81436465	N	.	N	Y	0.133073302	59.63998379	0.568326468	28.3	DP	.
STOX1	10	68827541	68895432	N	.	N	N	0.16771744	62.36615153	2.34E-07	84.9	DM	Preeclampsia/eclampsia 4, 609404 (3)
STOX2	4	183853431	184023526	N	.	N	N	-0.124094735	40.49314117	0.963216442	13.7	.	.
STPG1	1	24356999	24416934	N	.	N	N	0.79304674	89.03744863	0.000106434	71.7	.	.
STPG2	4	97184093	98143240	N	.	N	N	0.746262113	88.00717717	1.01E-12	95.2	.	.
STRA13	17	82018702	82024107	N	.	N	N	.	.	0.591966927	27.7	.	.
STRA8	7	135231979	135258492	N	.	N	Y	0.104368575	57.54471262	0.002684914	60.8	.	.
STRADA	17	63702832	63741970	N	.	N	N	0.044495337	52.92585518	0.002015391	61.9	DM	Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3)
STRADB	2	201387858	201480846	N	.	N	N	-0.021269443	47.84974243	0.669632058	25.5	.	.
STRC	15	43599398	43618800	N	.	N	Y	.	.	0.005321845	57.8	DM	Deafness, autosomal recessive 16, 603720 (3)
STRIP1	1	110031577	110074641	N	.	N	N	-1.18332098	5.759101696	0.130901316	41.5	.	.
STRIP2	7	129434433	129488399	N	.	N	N	-1.200095311	5.585460439	7.35E-10	91.3	.	.
STRN	2	36843640	36966472	N	.	N	N	-1.096952708	6.615731898	0.969336393	13.1	DM?	.
STRN4	19	46719507	46746994	N	.	N	N	-0.953425857	8.682062858	0.999575132	5	.	.
STS	X	7219456	7354810	N	.	N	N	0.916928187	91.44527406	0.981414316	11.5	DM	Ichthyosis, X-linked, 308100 (3)
STT3A	11	125591712	125625215	N	.	N	N	-0.696546643	14.05336575	0.978952343	12	.	?Congenital disorder of glycosylation, type Iw, 615596 (3)
STT3B	3	31532638	31637622	N	.	N	N	-0.664619572	14.89263182	0.980028091	11.7	.	?Congenital disorder of glycosylation, type Ix, 615597 (3)
STX10	19	13144058	13150383	N	.	N	N	0.139164133	60.1377554	3.57E-10	92	.	.
STX11	6	144150526	144188370	N	.	N	Y	0.104519243	57.57365283	0.020026056	51.7	DM	Hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3)
STX12	1	27773183	27824452	N	.	N	N	-0.056065882	45.38982462	0.896720266	17.9	.	.
STX16	20	58651253	58679526	N	Viable	N	Y	-0.132857585	39.9027609	0.235503145	37.5	DM?	Pseudohypoparathyroidism, type IB, 603233 (3)
STX16-NPEPL1	20	58651434	58715410	N	.	N	N	.	.	.	.	.	.
STX17	9	99906633	99970341	N	.	N	N	0.304231467	70.75881229	0.08496798	44.1	.	.
STX18	4	4415742	4542346	N	.	N	N	0.262082672	68.1773456	1.17E-06	82.3	.	.
STX19	3	94014369	94028610	N	Viable	N	Y	-0.013766433	48.44591075	1.15E-05	77.7	.	.
STX2	12	130789600	130839266	N	.	N	Y	0.677627004	86.34600915	0.000386516	67.9	.	.
STX5	11	62806897	62832088	N	.	N	N	0.251709849	67.54644904	0.362948406	33.8	.	.
STX6	1	180972712	181023121	N	.	N	N	0.107238638	57.76465822	0.019849117	51.8	.	.
STX7	6	132445867	132513198	N	.	N	N	-0.32617555	27.96781849	0.004263116	58.8	.	.
STX8	17	9250471	9576591	N	.	N	N	0.30327499	70.71250796	0.000144083	70.8	.	.
STXBP4	17	54968727	55173632	N	.	N	N	-0.120570168	40.6899346	1.42E-14	96.6	FTV	.
STXBP5L	3	120908072	121424761	N	Viable	N	Y	-1.538613517	3.154482838	0.999948371	3.3	DM?	.
STXBP6	14	24809656	25050297	N	.	N	N	-0.359059685	26.33559067	0.097897674	43.3	.	.
STYK1	12	10618939	10674318	N	.	N	N	0.318430612	71.66753487	1.54E-05	77	.	.
STYX	14	52730180	52774998	N	.	N	Y	0.04897698	53.33680616	0.972068618	12.8	.	.
STYXL1	7	75996338	76048004	N	.	N	N	0.070680254	54.93430572	0.009746543	55	.	.
SUB1	5	32531633	32604079	N	.	N	N	-0.059893552	45.10042253	0.800760314	21.6	.	.
SUCLG1	2	84423523	84460045	N	.	N	N	0.146667159	60.78022805	0.059768646	46	DM	Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3)
SUCLG2	3	67360460	67654614	N	.	N	N	0.37190874	74.50946345	3.28E-05	75	.	.
SUCNR1	3	151873643	151884619	N	.	N	Y	0.253623009	67.679574	6.25E-08	86.7	.	.
SUGCT	7	40134977	40860763	N	.	N	N	0.431933505	77.49030503	.	.	.	.
SUGP1	19	19276018	19320844	N	.	N	N	-0.772385473	12.13173583	0.99963556	4.9	.	.
SUGP2	19	18990888	19034023	N	.	N	N	-0.306741671	29.03860624	0.999366871	5.4	.	.
SUGT1	13	52652709	52700909	N	.	N	N	-0.013766433	48.44591075	0.977752129	12.1	.	.
SULF1	8	69466624	69660915	N	.	N	Y	-0.493659292	20.46072814	0.879274683	18.7	DM	.
SULT1A1	16	28605196	28623625	N	.	N	Y	1.104669401	93.9920125	2.24E-09	90.4	DFP	.
SULT1A2	16	28591943	28597109	N	.	N	N	1.046402992	93.32059964	1.84E-08	88.3	.	.
SULT1A3	16	30199228	30204310	N	.	N	N	.	.	0.372332179	33.6	FP	.
SULT1A4	16	29459889	29464976	N	.	N	N	.	.	0.392852564	32.9	.	.
SULT1B1	4	69721162	69787961	N	.	N	N	0.253623009	67.679574	6.24E-05	73.3	.	.
SULT1C2	2	108288639	108309915	N	.	N	N	0.413101046	76.51212595	1.42E-05	77.2	FP	.
SULT1C3	2	108247195	108265351	N	Viable	N	Y	1.132624181	94.35665914	3.00E-11	93.7	DM?	.
SULT1C4	2	108377911	108388057	N	.	N	N	0.35770974	73.83805059	0.000445387	67.4	.	.
SULT1E1	4	69810780	69860152	N	.	N	Y	0.068766772	54.77802859	7.40E-05	72.8	DP	.
SULT2A1	19	47870466	47886397	N	.	N	N	-0.051281473	45.6908028	1.39E-07	85.7	FP	.
SULT2B1	19	48552075	48599425	N	.	N	Y	0.512555096	80.99207038	0.827919002	20.7	FP	.
SULT4A1	22	43824509	43862503	N	.	N	N	-0.352513948	26.63078081	0.968128305	13.2	FP	.
SULT6B1	2	37167820	37196598	N	.	N	N	0.670123656	86.20709614	3.48E-11	93.6	.	.
SUMF2	7	56064002	56080670	N	.	N	N	1.485465127	96.8918215	5.53E-05	73.6	.	.
SUMO2	17	75165586	75182983	N	.	N	N	0.18116337	63.25172194	0.850515884	19.9	.	.
SUMO3	21	44805617	44818779	N	.	N	N	0.167113525	62.29669503	0.312496155	35.4	.	.
SUMO4	6	149400227	149401292	N	.	N	N	0.57802637	83.37095561	0.217538235	38.1	DP	{Diabetes mellitus, insulin-dependent, 5}, 600320 (3)
SUN1	7	816615	896435	N	.	N	Y	0.538397203	81.97603751	0.835840781	20.4	.	.
SUN2	22	38734725	38794143	N	.	N	Y	0.000737247	49.49354633	2.41E-07	84.9	DP	.
SUN3	7	47987148	48029119	N	.	N	N	1.073549255	93.67945824	3.80E-05	74.6	.	.
SUN5	20	32983773	33004433	N	.	N	N	0.460032897	78.82155467	6.53E-11	93.2	.	.
SUOX	12	55997180	56006641	N	.	N	N	0.042733143	52.78694218	0.002084769	61.7	DM	Sulfite oxidase deficiency, 272300 (3)
SUPT16H	14	21351472	21384266	N	.	N	N	-1.179644424	5.816982115	0.999999606	1.4	DM?	.
SUPT5H	19	39436156	39476670	N	.	N	N	-2.571023176	0.908722579	0.999999735	1.3	DM	.
SUPT6H	17	28662091	28702684	N	.	N	N	-2.279799704	1.174972507	1	0.4	.	.
SURF2	9	133356552	133361169	N	.	N	N	0.508729649	80.80685304	3.07E-07	84.5	.	.
SURF4	9	133361449	133376166	N	.	N	N	-0.282114394	30.53770909	0.686424183	25	.	.
SURF6	9	133328774	133336398	N	.	N	N	0.018310624	50.92898073	8.12E-05	72.5	.	.
SUSD1	9	112040785	112175408	N	.	N	N	-0.154106795	38.46153846	8.56E-09	89.1	.	.
SUSD2	22	24181259	24189110	N	.	N	N	0.844279189	90.0966603	1.33E-10	92.7	.	.
SUSD3	9	93058688	93085138	N	.	N	N	0.902731639	91.12693176	0.003195143	60.1	.	.
SUSD4	1	223220819	223364202	N	.	N	N	-0.124245827	40.48735313	0.004571754	58.6	.	.
SUSD5	3	33150042	33219215	N	.	N	N	0.215453614	65.36435724	4.31E-09	89.7	.	.
SUSD6	14	69611596	69715142	N	.	N	Y	.	.	.	.	.	.
SUV39H1	X	48695554	48709012	N	.	N	Y	0.201908627	64.49036291	0.936945044	15.8	.	.
SUV39H2	10	14878820	14904315	N	.	N	Y	-0.289617454	30.09202987	0.910307361	17.3	.	.
SUV420H2	19	55339853	55348120	N	.	N	Y	-0.134771456	39.75805985	0.690731173	24.9	.	.
SV2B	15	91099950	91301309	N	.	N	Y	-0.091363535	42.7215373	0.534784655	29	DM?	.
SV2C	5	76083172	76353939	N	.	N	Y	-0.14469041	39.08085895	6.36E-05	73.2	.	.
SVBP	1	42807052	42817252	N	.	N	N	.	.	.	.	.	.
SVIL	10	29457338	29736781	N	.	N	N	-0.480301003	20.96428778	0.999399704	5.4	DM?	.
SVIP	11	22813799	22830299	N	.	N	N	0.122094661	58.87017422	0.011431624	54.3	.	.
SVOP	12	108907741	109021240	N	.	N	Y	.	.	.	.	.	.
SVOPL	7	138594285	138701352	N	.	N	N	1.565292974	97.29119639	0.001133272	64.2	.	.
SWAP70	11	9664077	9752991	N	.	N	Y	-0.691914915	14.19227875	0.348844347	34.2	.	.
SWI5	9	128275379	128288990	N	.	N	N	.	.	0.026359331	50.3	.	.
SWSAP1	19	11374685	11376951	N	.	N	N	-0.068201255	44.52161834	0.00013467	71	.	.
SWT1	1	185157080	185291765	N	.	N	N	0.283937688	69.53753545	0.117421725	42.3	.	.
SYAP1	X	16719632	16765336	N	.	N	N	0.1249645	59.10748394	0.502110068	29.9	.	.
SYBU	8	109573978	109691791	N	.	N	N	-0.293944711	29.77368756	0.005953429	57.3	.	.
SYCE1	10	133553901	133569835	N	.	N	Y	1.05567373	93.44214852	0.000763635	65.6	.	.
SYCE1L	16	77199397	77213215	N	.	N	N	.	.	0.072137507	44.9	.	.
SYCE2	19	12898786	12919276	N	.	N	N	0.26384649	68.31047057	0.41925559	32.3	.	.
SYCE3	22	50551112	50562905	N	.	N	Y	.	.	.	.	.	.
SYCN	19	39202831	39204266	N	.	N	Y	0.382940675	75.05932743	0.005726526	57.5	.	.
SYCP1	1	114854803	114995370	N	.	N	Y	-0.839916338	10.77154599	0.949997702	14.8	.	.
SYCP2	20	59863563	59933655	N	.	N	Y	1.096867557	93.91097992	0.999993567	2.3	.	.
SYCP2L	6	10886831	10979320	N	.	N	N	-0.001176377	49.32569312	4.34E-11	93.5	.	.
SYCP3	12	101728648	101739472	N	Viable	N	Y	-0.275568538	30.94287203	5.53E-05	73.7	DM	Spermatogenic failure 4, 270960 (3); {Pregnancy loss, susceptibility to} (3)
SYDE1	19	15107403	15114988	N	.	N	Y	.	.	0.946542807	15.1	.	.
SYDE2	1	85156873	85201046	N	.	N	N	0.436067983	77.69867454	3.20E-12	94.8	.	.
SYN1	X	47571898	47619853	N	.	N	Y	.	.	0.879529753	18.6	DM	Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 (3)
SYN2	3	12004402	12191400	N	.	N	Y	.	.	.	.	.	{Schizophrenia, susceptibility to}, 181500 (3)
SYN3	22	32512552	33058372	N	Viable	N	Y	0.035230174	52.24286624	0.577812324	28	DP	.
SYNC	1	32680360	32703596	N	.	N	Y	.	.	0.041685306	48.1	.	.
SYNCRIP	6	85607785	85643792	N	.	N	N	-0.964909164	8.462117266	0.999378591	5.4	DM?	.
SYNDIG1	20	24469199	24666616	N	.	N	N	0.191685376	63.90577068	0.433641203	31.9	.	.
SYNDIG1L	14	74405893	74426102	N	Viable	N	Y	0.379262743	74.89726226	0.003664182	59.4	.	.
SYNE2	14	63852983	64226433	N	.	N	Y	1.546377523	97.22173989	1.85E-11	94	DM	Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 (3)
SYNE3	14	95407266	95475836	N	Viable	N	Y	0.864080292	90.42657869	2.95E-15	97	.	.
SYNE4	19	36003307	36008793	N	.	N	Y	1.605538946	97.52271806	5.96E-11	93.2	DM	Deafness, autosomal recessive 76, 615540 (3)
SYNGR1	22	39349925	39385588	N	.	N	Y	-0.359862201	26.32401459	0.581490268	27.9	DM	.
SYNGR2	17	78168558	78173527	N	.	N	N	0.083772833	56.01666956	0.000588832	66.5	.	.
SYNGR3	16	1989660	1994275	N	.	N	N	.	.	0.292054619	35.9	.	.
SYNGR4	19	48364395	48376376	N	.	N	N	0.434654036	77.61764195	0.001215749	64	.	.
SYNJ2	6	157981887	158099176	N	.	N	Y	-1.165752222	5.944319037	3.52E-05	74.8	.	.
SYNJ2BP	14	70366496	70417061	N	.	N	N	0.23846774	66.7534873	0.503944509	29.8	.	.
SYNJ2BP-COX16	14	70326064	70417074	N	.	N	N	.	.	.	.	.	.
SYNM	15	99098217	99135593	N	Viable	N	Y	.	.	2.33E-12	94.9	DM	.
SYNPO	5	150601080	150659220	N	.	N	Y	0.044798475	52.94900735	0.980249085	11.7	DM	.
SYNPO2L	10	73644881	73663803	N	.	N	N	-0.624083495	16.03866412	0.026739766	50.2	.	.
SYNPR	3	63228315	63616921	N	.	N	N	-0.219218665	34.36360479	0.171706356	39.7	.	.
SYNRG	17	37514797	37609496	N	.	N	N	-0.533754312	18.84586444	0.972748212	12.7	.	.
SYP	X	49187804	49200259	N	.	N	Y	0.080902701	55.81408809	0.611984997	27.1	DM?	Mental retardation, X-linked 96, 300802 (3)
SYPL1	7	106090503	106112576	N	Viable	N	Y	0.172852824	62.72501013	0.28913231	36	.	.
SYPL2	1	109466628	109482137	N	.	N	Y	0.168219607	62.41824391	0.016771099	52.6	.	.
SYS1	20	45361937	45376798	N	.	N	N	-0.148973548	38.82039706	0.474140969	30.7	.	.
SYS1-DBNDD2	20	45363200	45410610	N	.	N	N	.	.	.	.	.	.
SYT10	12	33374238	33439819	N	.	N	N	0.109303094	57.94987556	0.123246845	41.9	.	.
SYT11	1	155859509	155885199	N	.	N	N	-0.268868697	31.33645888	0.801740135	21.6	FP	.
SYT12	11	67006778	67050863	N	.	N	N	0.452680154	78.44533194	1.03E-05	78	.	.
SYT13	11	45240301	45286319	N	.	N	N	-0.52956212	19.03686983	0.220165779	38	.	.
SYT14	1	209938174	210171315	N	.	N	N	-0.001479352	49.31411703	0.966548707	13.4	DM	Spinocerebellar ataxia, autosomal recessive 11, 614229 (3)
SYT15	10	46578217	46594173	N	.	N	N	2.391379481	99.06812525	3.40E-18	98.2	.	.
SYT16	14	61995823	62112550	N	.	N	N	-0.035015539	46.93523181	0.001246518	63.8	.	.
SYT17	16	19167971	19268334	N	Viable	N	Y	-0.618643257	16.21809342	0.02363635	50.8	.	.
SYT3	19	50621307	50668394	N	.	N	N	-0.967626441	8.421600972	0.225605579	37.8	.	.
SYT4	18	43267878	43277650	N	.	N	Y	-0.176918638	36.94507148	0.127604754	41.7	.	.
SYT6	1	114089291	114153919	N	.	N	N	0.032359762	52.04607281	0.032845524	49.3	.	.
SYT7	11	61515313	61581148	N	.	N	Y	-0.662859235	14.96208833	0.904578639	17.6	.	.
SYT8	11	1828307	1837521	N	.	N	N	1.347666669	96.08728367	7.59E-13	95.4	.	.
SYT9	11	7238778	7469042	N	.	N	N	-0.273500756	31.08178503	0.331363732	34.8	.	.
SYTL1	1	27342020	27353937	N	.	N	Y	0.636432699	85.26364531	1.08E-07	86	.	.
SYTL2	11	85694224	85811159	N	.	N	Y	0.458436484	78.74052208	2.12E-19	98.5	.	.
SYTL3	6	158650014	158764876	N	.	N	N	0.601938918	84.16391735	2.14E-17	98	FTV	.
SYTL4	X	100674491	100732123	N	.	N	Y	0.370952088	74.45158303	0.024606552	50.6	FTV	.
SYTL5	X	38006582	38128819	N	.	N	N	0.533300984	81.79660821	0.064488655	45.6	FTV	.
SZRD1	1	16352575	16398145	N	.	N	N	0.100541925	57.24952249	0.719865991	24.1	.	.
TAAR1	6	132644984	132646003	N	.	N	Y	0.618556794	84.73114545	0.000283698	68.8	.	.
TAAR2	6	132617022	132624275	N	Viable	N	Y	0.628929435	85.03212363	3.41E-06	80.3	DM?	.
TAAR5	6	132588673	132589686	N	.	N	Y	0.515424669	81.09625514	3.46E-07	84.3	.	.
TAAR6	6	132570322	132571359	N	Viable	N	Y	0.577363401	83.35359148	0.153131232	40.4	.	.
TAAR8	6	132552693	132553721	N	.	N	N	0.33806995	72.74989871	0.000303108	68.6	.	.
TAAR9	6	132538290	132539336	N	.	N	N	.	.	.	.	FP	.
TAB3	X	30827442	30975084	N	.	N	Y	-0.145949748	39.0056144	0.921511504	16.6	.	.
TAC1	7	97731908	97740472	N	.	N	Y	-0.112415198	41.29189095	0.877314615	18.7	.	.
TAC3	12	57010000	57028883	N	.	N	Y	0.214045409	65.29490074	0.040450005	48.3	DM	Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3)
TAC4	17	49838309	49848017	N	.	N	Y	0.207498734	64.86658563	0.041958906	48	.	.
TACC1	8	38728186	38853028	N	.	N	N	-0.388615014	25.01012907	0.015120874	53.1	.	.
TACC2	10	121989174	122254545	N	.	N	Y	1.57125228	97.32592464	3.52E-19	98.5	.	.
TACO1	17	63600872	63608365	N	.	N	N	-0.121679336	40.63205418	0.357585528	34	DM	Mitochondrial complex IV deficiency, 220110 (3)
TACR1	2	75046463	75199700	N	.	N	Y	-0.463948146	21.72830931	0.000227889	69.4	.	.
TACR2	10	69403903	69416867	N	.	N	N	0.713378778	87.2373676	9.88E-07	82.5	.	.
TACR3	4	103586031	103719816	N	.	N	Y	-0.14307911	39.17346762	1.90E-06	81.4	DM	Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3)
TACSTD2	1	58575423	58577773	N	.	N	N	0.047214459	53.18052903	0.205248032	38.6	DM	Corneal dystrophy, gelatinous drop-like, 204870 (3)
TADA1	1	166856510	166876327	N	.	N	N	-0.233267662	33.50118655	0.358858663	33.9	.	.
TADA2A	17	37406874	37479730	N	.	N	N	-0.530519144	18.97898941	9.66E-05	72	.	.
TADA2B	4	7041899	7057952	N	.	N	N	-0.633803705	15.81871853	0.345059566	34.4	.	.
TAF1	X	71366239	71532374	N	.	N	N	-1.001170879	7.848584824	0.999999756	1.3	DP	Dystonia-Parkinsonism, X-linked, 314250 (3)
TAF11	6	34877778	34888089	N	.	N	N	0.148430386	60.90756497	0.875431937	18.8	.	.
TAF12	1	28589323	28643085	N	.	N	N	0.275027119	68.98767147	0.892665248	18.1	.	.
TAF13	1	109062486	109076002	N	.	N	N	-0.028924269	47.36354691	0.019850195	51.7	.	.
TAF15	17	35713791	35864615	N	.	N	N	-0.120418693	40.70151068	0.354285878	34.1	DM	Chondrosarcoma, extraskeletal myxoid, 612237 (1)
TAF1A	1	222557902	222589933	N	.	N	N	0.551027573	82.47959715	6.60E-07	83.2	.	.
TAF1B	2	9843354	9934416	N	.	N	N	0.314754515	71.37813278	4.29E-06	79.8	.	.
TAF1C	16	84177847	84187070	N	.	N	N	1.572511977	97.33171268	3.23E-11	93.6	DP	.
TAF1D	11	93729948	93784391	N	.	N	N	0.288268772	69.80378538	0.005911467	57.3	.	.
TAF1L	9	32629454	32635669	N	.	N	N	0.394569211	75.55709903	0.119270692	42.1	FTV	.
TAF2	8	119730775	119832863	N	.	N	N	-1.020815111	7.617063148	0.56608706	28.3	DM	Mental retardation, autosomal recessive 40, 615599 (3)
TAF3	10	7818504	8016627	N	.	N	N	-0.950557033	8.699426984	0.99512518	8.4	.	.
TAF4B	18	26225936	26391685	N	.	N	Y	-0.151236787	38.62360363	0.879312142	18.6	.	?Spermatogenic failure 13, 615841 (3)
TAF5	10	103367967	103389065	N	.	N	N	-0.547439633	18.30757655	0.999555181	5	.	.
TAF5L	1	229593111	229626047	N	.	N	N	-0.875670325	10.06540487	0.985849777	10.8	.	.
TAF6L	11	62771303	62787342	N	.	N	N	-0.571710334	17.59564739	0.819819294	21	.	.
TAF7L	X	101268253	101293057	N	.	N	Y	0.27517563	69.0050356	0.843722649	20.1	DP	.
TAF9	5	69364743	69370013	N	.	N	N	-0.280200056	30.62452972	5.74E-05	73.5	.	.
TAF9B	X	78129748	78139706	N	.	N	Y	0.111871637	58.12930486	0.000410983	67.7	.	.
TAGAP	6	159034468	159045152	N	.	N	N	-0.177572541	36.88719106	0.927102798	16.3	DP	.
TAGLN	11	117199321	117204782	N	.	N	Y	0.423325465	77.03304972	0.24153768	37.3	.	.
TAGLN2	1	159918107	159925732	N	.	N	N	0.074356355	55.24107195	0.003290733	59.9	.	.
TAGLN3	3	111998664	112013887	N	.	N	N	-0.337507753	27.3890143	0.685406598	25	.	.
TALDO1	11	747329	765024	N	.	N	Y	-0.135576128	39.70596747	0.000175588	70.2	DM	Transaldolase deficiency, 606003 (3)
TAMM41	3	11790442	11846919	N	.	N	N	-0.299837855	29.4611333	0.0001846	70.1	.	.
TANC1	2	158968634	159232659	N	.	N	N	-1.375800679	4.097933669	0.140685896	41.1	.	.
TANGO2	22	20017014	20065926	N	.	N	N	0.269585727	68.68669329	4.22E-06	79.9	.	.
TANK	2	161136908	161236221	N	.	N	Y	0.823060612	89.60467674	0.943798418	15.3	.	.
TAOK1	17	29390464	29551904	N	.	N	N	-1.375706164	4.103721711	0.999999739	1.3	.	.
TAOK2	16	29973641	29992261	N	.	N	N	-1.886498038	1.938994038	0.998764492	6.2	.	.
TAOK3	12	118149801	118372945	N	.	N	N	-0.530367513	18.99635353	0.999977598	2.9	.	.
TAP1	6	32845209	32853978	N	.	N	Y	1.629158242	97.6384789	0.286650163	36	DM	Bare lymphocyte syndrome, type I, 604571 (3)
TAP2	6	32821833	32838780	N	.	N	N	0.712573182	87.22000347	0.001713418	62.5	DM	.
TAPBP	6	33299694	33314387	N	.	N	Y	0.479822239	79.75921746	0.000393582	67.8	DM	Bare lymphocyte syndrome, type I, 604571 (3)
TAPBPL	12	6451690	6466517	N	.	N	N	0.918841204	91.48000232	3.29E-07	84.4	.	.
TARBP1	1	234391313	234479103	N	.	N	N	-0.084215956	43.23667303	5.70E-16	97.4	.	.
TARM1	19	54069895	54081365	N	.	N	N	.	.	.	.	.	.
TARS	5	33440696	33469539	N	.	N	N	0.890894084	90.95907854	1.19E-09	91	.	.
TARS2	1	150487364	150507609	N	.	N	N	-1.240483611	5.180297505	1.87E-08	88.2	.	?Combined oxidative phosphorylation deficiency 21, 615918 (3)
TARSL2	15	101653598	101724604	N	.	N	N	-0.777975942	12.07385541	2.86E-09	90.2	.	.
TAS1R1	1	6555181	6579757	N	.	N	Y	1.180983492	94.8486427	7.91E-09	89.2	DFP	.
TAS1R2	1	18839599	18859682	N	.	N	Y	0.831189625	89.81883429	6.18E-13	95.4	DP	.
TAS1R3	1	1331314	1335306	N	.	N	Y	2.22780173	98.894484	.	.	DFP	.
TAS2R1	5	9628997	9712378	N	.	N	N	-0.390831569	24.90594432	0.24158113	37.3	.	.
TAS2R10	12	10825317	10826358	N	.	N	N	0.421560678	76.91728888	0.428565951	32	.	.
TAS2R13	12	10907926	10909562	N	.	N	N	0.048171225	53.26734966	0.579968727	28	.	.
TAS2R14	12	10937406	11171573	N	.	N	N	0.155126864	61.40533657	0.001055428	64.5	.	.
TAS2R16	7	122994704	122995700	N	.	N	N	0.336156875	72.63992591	0.01499653	53.2	DP	{Alcohol dependence}, 103780 (3)
TAS2R19	12	11021619	11022620	N	.	N	N	1.498562012	96.961278	0.004146198	58.9	DP	.
TAS2R20	12	10996495	10997875	N	.	N	N	0.960037204	92.19771951	0.004476015	58.6	.	.
TAS2R3	7	141764097	141765197	N	.	N	N	0.155126864	61.40533657	0.000144124	70.8	DM?	.
TAS2R30	12	11077313	11134644	N	.	N	N	1.843930945	98.29831568	0.001703148	62.5	.	.
TAS2R31	12	11030387	11031407	N	.	N	N	4.040805295	99.79163049	2.54E-05	75.6	DP	.
TAS2R38	7	141972631	141973773	N	.	N	N	1.450667644	96.7123922	0.065390402	45.5	DP	[Phenylthiocarbamide tasting], 171200 (3)
TAS2R39	7	143183419	143184435	N	.	N	N	0.034121997	52.16762169	5.30E-08	86.9	.	.
TAS2R4	7	141778442	141780819	N	.	N	N	0.690721426	86.69329166	0.04973845	47	.	.
TAS2R40	7	143222037	143223079	N	.	N	N	0.297684879	70.38258957	0.002499832	61.1	.	.
TAS2R41	7	143477873	143478796	N	.	N	N	0.261126067	68.10210106	4.93E-09	89.6	.	.
TAS2R42	12	11185993	11186937	N	.	N	N	0.7751713	88.66701395	0.002580997	61	.	.
TAS2R43	12	11091287	11134244	N	.	N	N	4.081101534	99.80320658	0.002104274	61.7	DP	.
TAS2R46	12	11061365	11062294	N	.	N	N	1.668445809	97.80633212	3.10E-08	87.6	FTV	.
TAS2R5	7	141790217	141791367	N	.	N	N	0.578171457	83.38831973	0.000103903	71.7	.	.
TAS2R50	12	10985913	10986912	N	.	N	N	0.025662211	51.48463275	1.89E-07	85.2	DP	.
TAS2R60	7	143443453	143444409	N	.	N	N	0.358666204	73.88435492	6.30E-06	79.1	.	.
TAS2R7	12	10801532	10802627	N	.	N	N	0.589500178	83.82242287	0.023077451	50.9	.	.
TAS2R8	12	10806051	10807293	N	.	N	N	0.262082672	68.1773456	0.012468263	54	.	.
TAS2R9	12	10809137	10810168	N	.	N	N	0.580084093	83.4809284	0.000278743	68.9	DFP	.
TAT	16	71565660	71577130	N	.	N	N	-0.462991075	21.75724952	0.021438444	51.3	DM	Tyrosinemia, type II, 276600 (3)
TATDN1	8	124488485	124539458	N	.	N	N	-0.072833607	44.24958037	1.73E-08	88.3	.	.
TATDN2	3	10248023	10281218	N	.	N	N	0.282177121	69.42177461	0.000742651	65.8	.	.
TATDN3	1	212791828	212816626	N	Viable	N	Y	0.993731808	92.69549112	4.62E-05	74.1	.	.
TAX1BP3	17	3662896	3668682	N	.	N	N	-0.141470476	39.31238062	0.002348033	61.3	.	.
TAZ	X	154411518	154421726	N	.	N	N	0.04051715	52.61908896	0.966526482	13.4	DM	Barth syndrome, 302060 (3)
TBATA	10	70771239	70785401	N	.	N	Y	0.734932275	87.72356312	1.69E-07	85.4	.	.
TBC1D1	4	37891087	38139175	N	.	N	N	-0.180951479	36.67303351	3.94E-08	87.3	DP	.
TBC1D10A	22	30291990	30327046	N	.	N	Y	-0.040756318	46.57637321	0.975495335	12.4	.	.
TBC1D10B	16	30357102	30370264	N	.	N	N	.	.	0.981784128	11.5	.	.
TBC1D10C	11	67403915	67410089	N	.	N	Y	-0.268868697	31.33645888	0.001609098	62.8	.	.
TBC1D12	10	94402504	94535930	N	.	N	N	-0.419886724	23.51681426	0.00264365	60.9	.	.
TBC1D13	9	128787204	128810432	N	.	N	N	-0.581281335	17.35833767	0.611736247	27.1	.	.
TBC1D15	12	71839707	71927248	N	.	N	N	-1.266821325	4.966139955	0.148718809	40.6	.	.
TBC1D16	17	79932343	80035848	N	.	N	N	-0.209348123	34.97134919	0.006198257	57.1	.	.
TBC1D17	19	49877425	49888749	N	.	N	N	-0.419584024	23.52839035	1.12E-12	95.2	.	.
TBC1D19	4	26576437	26755351	N	.	N	N	-0.564360358	17.79244082	0.016101241	52.8	.	.
TBC1D2	9	98198999	98255721	N	.	N	N	0.356406043	73.76859408	2.31E-08	88	.	.
TBC1D20	20	435480	462553	N	.	N	N	-0.277328762	30.80974706	0.912642498	17.1	.	Warburg micro syndrome 4, 615663 (3)
TBC1D21	15	73873608	73889214	N	.	N	N	0.162629888	61.97256468	0.022326759	51.1	.	.
TBC1D22A	22	46762617	47175699	N	Viable	N	Y	-0.215238485	34.57776234	0.957287978	14.2	.	.
TBC1D22B	6	37257772	37332970	N	.	N	N	-0.766947849	12.27064884	0.006370626	57	.	.
TBC1D23	3	100261000	100325251	N	.	N	N	-0.83623939	10.85836661	0.000111512	71.5	DM?	.
TBC1D24	16	2475118	2505734	N	.	N	N	-0.483435313	20.83695086	5.84E-07	83.5	DM	Myoclonic epilepsy, infantile, familial, 605021 (3); Epileptic encephalopathy, early infantile, 16, 615338 (3); DOOR syndrome, 220500 (3); Deafness , autosomal recessive 86, 614617 (3); Deafness, autosomal dominant 65, 616044 (3)
TBC1D25	X	48539457	48562609	N	.	N	N	-0.252905653	32.27412166	0.71197335	24.3	.	.
TBC1D26	17	15732247	15749192	N	.	N	N	0.865213587	90.43815477	0.861486844	19.5	.	.
TBC1D28	17	18635006	18661950	N	.	N	N	0.538742637	81.99918967	1.44E-05	77.1	.	.
TBC1D29	17	30557112	30563493	N	.	N	N	0.512408218	80.9804943	8.25E-05	72.4	.	.
TBC1D2B	15	77984036	78077724	N	.	N	Y	-0.283571741	30.44510042	6.51E-05	73.1	.	.
TBC1D3	17	38181659	38192541	N	.	N	N	.	.	0.455180215	31.2	.	.
TBC1D30	12	64781193	64881032	N	.	N	N	.	.	.	.	DM?	.
TBC1D31	8	123041968	123152153	N	.	N	N	-0.28901326	30.1383342	1.34E-09	90.9	.	.
TBC1D32	6	121079494	121334745	N	.	N	N	0.06856934	54.7375123	1.35E-12	95.1	.	.
TBC1D3B	17	36165624	36264527	N	.	N	N	.	.	0.636923623	26.4	.	.
TBC1D3C	17	37978470	38068592	N	.	N	N	.	.	0.425665089	32.1	.	.
TBC1D3D	17	37924458	38139051	N	.	N	N	.	.	.	.	.	.
TBC1D3E	17	38005561	38138862	N	.	N	N	.	.	.	.	.	.
TBC1D3F	17	36377846	36439566	N	.	N	N	.	.	0.620380557	26.9	.	.
TBC1D3G	17	36323884	36334759	N	.	N	N	.	.	0.490002147	30.2	.	.
TBC1D3H	17	36377348	36439566	N	.	N	N	.	.	.	.	.	.
TBC1D3I	17	36253456	36439559	N	.	N	N	.	.	.	.	.	.
TBC1D3K	17	37924415	37935365	N	.	N	N	.	.	.	.	.	.
TBC1D3L	17	37977972	38068651	N	.	N	N	.	.	.	.	.	.
TBC1D4	13	75284665	75482114	Y	Viable	N	Y	-0.38545452	25.14325404	3.64E-13	95.7	DM	{Diabetes mellitus, noninsulin-dependent, 5}, 616087 (3)
TBC1D5	3	17157162	18444817	N	.	N	N	-0.686022693	14.34276784	6.52E-10	91.5	.	.
TBC1D7	6	13266542	13328583	N	.	N	N	0.276132196	69.08028014	8.30E-06	78.5	.	Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000 (3)
TBC1D8	2	101007617	101252866	N	.	N	N	-0.516836104	19.56936968	5.26E-07	83.6	.	.
TBC1D8B	X	106802680	106876145	N	.	N	N	0.460336422	78.83891879	1.87E-05	76.4	.	.
TBC1D9	4	140620765	140756120	N	.	N	N	-1.721597704	2.367309139	0.876941195	18.8	.	.
TBC1D9B	5	179862066	179907859	N	.	N	N	-1.023281722	7.559182728	1.49E-07	85.6	.	.
TBCA	5	77691166	77868780	N	.	N	N	0.031100532	51.89558372	0.716435529	24.2	.	.
TBCB	19	36114289	36125947	N	.	N	N	-0.313083888	28.69711177	0.405521803	32.6	.	.
TBCC	6	42744481	42746096	N	.	N	N	0.877497714	90.69861666	0.011002826	54.5	.	.
TBCCD1	3	186546073	186570543	N	Viable	N	Y	-0.278133044	30.72292643	0.012110984	54.2	.	.
TBCD	17	82752064	82945922	N	.	N	N	-1.053425601	7.171383921	6.98E-05	72.9	.	.
TBCE	1	235367360	235448968	N	.	N	Y	0.519251431	81.23516814	6.29E-07	83.3	DM	Kenny-Caffey syndrome-1, 244460 (3); Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3)
TBCEL	11	121024072	121090775	N	.	N	N	-0.083207293	43.33506975	0.971498209	12.8	.	.
TBCK	4	106041599	106321495	N	.	N	N	-0.645637133	15.52352839	3.22E-06	80.4	.	.
TBKBP1	17	47694081	47712050	N	Viable	N	Y	0.315560713	71.44180124	0.038377766	48.5	.	.
TBL1X	X	9463295	9719743	N	.	N	N	-0.703247825	13.82763211	0.998500303	6.5	DM	.
TBL1XR1	3	177019355	177197396	N	.	N	N	-0.411581382	23.84673265	0.998821952	6.1	DM?	.
TBL1Y	Y	6910686	7091683	N	.	N	N	.	.	.	.	DM?	.
TBL2	7	73568932	73578791	N	.	N	N	-0.375672502	25.64681368	0.004376507	58.7	.	.
TBL3	16	1972037	1982933	N	.	N	N	0.4981674	80.38432598	1.54E-06	81.9	.	.
TBPL1	6	133952170	133990432	N	.	N	Y	0.107088402	57.71835388	0.879617094	18.6	.	.
TBPL2	14	55413541	55456726	N	.	N	Y	0.165499977	62.20408636	4.93E-08	87	.	.
TBRG1	11	124622836	124635398	N	.	N	N	.	.	8.03E-05	72.6	.	.
TBRG4	7	45100100	45112047	N	.	N	N	-0.582889864	17.31203334	0.780939583	22.2	.	.
TBX10	11	67631303	67639560	Y	Viable	N	Y	-0.500506623	20.165538	2.15E-07	85.1	DM?	.
TBX19	1	168281040	168314426	N	.	N	Y	-0.104607368	41.83596689	2.80E-05	75.4	DM	Adrenocorticotropic hormone deficiency, 201400 (3)
TBX21	17	47733244	47746119	N	.	N	Y	-0.200384589	35.4691208	0.963242651	13.7	DFP	{Asthma, aspirin-induced, susceptibility to}, 208550 (3); Asthma and nasal polyps, 208550 (3)
TBXA2R	19	3594506	3606840	N	.	N	Y	0.398094787	75.74231637	0.113768131	42.4	DM	{Bleeding disorder, platelet-type, 13, susceptibility to}, 614009 (3)
TBXAS1	7	139777051	140020325	N	.	N	Y	0.822405902	89.59310065	1.37E-08	88.5	DM	Ghosal hematodiaphyseal syndrome, 231095 (3); ?Thromboxane synthase deficiency, 614158 (1)
TC2N	14	91779751	91867536	N	.	N	N	-0.218108998	34.42727325	0.012189329	54.1	.	.
TCAF1	7	143851375	143902198	N	.	N	N	.	.	.	.	.	.
TCAF2	7	143620950	143730409	N	.	N	N	.	.	.	.	.	.
TCAIM	3	44338119	44409451	N	Viable	N	Y	0.029489373	51.73930659	4.46E-05	74.2	.	.
TCAP	17	39664187	39666555	N	.	N	Y	0.391400129	75.43555015	0.075771008	44.7	DM	Muscular dystrophy, limb-girdle, type 2G, 601954 (3); Cardiomyopathy, hypertrophic, 25, 607487 (3)
TCEA2	20	64049836	64072347	N	.	N	N	-0.340224471	27.22116108	0.007817971	56.1	.	.
TCEA3	1	23381061	23424740	N	.	N	N	-0.284831791	30.36985588	0.000965886	64.9	.	.
TCEAL1	X	103628704	103630953	N	.	N	N	0.355650049	73.72807779	0.488641004	30.3	.	.
TCEAL2	X	102125688	102127711	N	.	N	N	0.209411733	65.03443885	0.679466606	25.2	.	.
TCEAL3	X	103607451	103629690	N	.	N	N	0.057436789	53.89824622	0.60333907	27.4	.	.
TCEAL4	X	103576231	103587736	N	.	N	N	0.191535973	63.89419459	0.683649622	25.1	.	.
TCEAL5	X	103273691	103276872	N	Viable	N	Y	0.421412982	76.87677259	0.666797567	25.6	.	.
TCEAL6	X	102140476	102142970	N	.	N	N	0.512408218	80.9804943	0.65079697	26	.	.
TCEAL7	X	103330196	103332326	N	.	N	N	0.249648508	67.42490016	0.450194394	31.4	.	.
TCEAL8	X	103252995	103255203	N	.	N	N	0.113634918	58.26821786	0.483466806	30.4	.	.
TCEANC	X	13653189	13681964	N	.	N	N	0.184989352	63.48903166	0.096354455	43.4	.	.
TCEANC2	1	54053587	54112519	N	.	N	N	-0.054152096	45.51716154	2.81E-05	75.4	.	.
TCEB1	8	73939169	73972287	N	.	N	N	0.060156283	54.10082769	0.643993932	26.2	.	.
TCEB2	16	2771414	2777297	N	.	N	N	0.664387272	86.06818313	0.020784292	51.4	.	.
TCEB3B	18	47032572	47035621	N	.	N	N	1.25907294	95.50269144	1.80E-08	88.3	.	.
TCEB3C	18	47028202	47030078	N	.	N	N	.	.	.	.	.	.
TCEB3CL	18	46968695	47029842	N	.	N	N	.	.	.	.	.	.
TCEB3CL2	18	46962768	46964408	N	.	N	N	.	.	.	.	.	.
TCERG1	5	146447311	146511961	N	.	N	N	-1.888756662	1.927417955	0.999962712	3.1	.	.
TCERG1L	10	131092391	131311721	N	.	N	N	0.718969098	87.40522081	0.000228294	69.4	.	.
TCF19	6	31158542	31167159	N	Viable	N	Y	0.0931893	56.64756613	0.000232744	69.3	.	.
TCF20	22	42160013	42343616	N	.	N	N	-3.737760591	0.312554263	0.999977934	2.9	.	.
TCF23	2	27149004	27156974	N	.	N	N	0.246927324	67.26862302	0.000503312	67	.	.
TCF24	8	66946501	66962590	N	.	N	N	.	.	.	.	.	.
TCF25	16	89873586	89911384	N	.	N	N	-0.505796918	19.9861087	0.051778277	46.8	.	.
TCF7	5	134114711	134151865	N	.	N	Y	-0.031491274	47.21884586	0.36155457	33.9	DP	.
TCFL5	20	62841115	62861763	N	.	N	N	0.21515114	65.34120507	0.958069155	14.1	.	.
TCHH	1	152106317	152115454	N	.	N	N	0.61598383	84.63853678	3.87E-23	99.1	.	.
TCHHL1	1	152084144	152089064	N	.	N	N	0.16212845	61.93204839	2.23E-08	88	.	.
TCHP	12	109900264	109983841	N	.	N	Y	0.67218594	86.23603635	7.00E-12	94.4	.	.
TCL1A	14	95709967	95714196	N	.	N	Y	-0.063568931	44.88047693	0.001223305	63.9	.	Leukemia/lymphoma, T-cell (2)
TCL1B	14	95686417	95692643	N	.	N	N	0.194405525	64.08519998	0.004686731	58.4	.	Leukemia/lymphoma, T-cell (2)
TCN1	11	59852800	59866575	N	.	N	N	0.844762943	90.11402443	3.86E-16	97.5	DM	.
TCN2	22	30606838	30627278	N	.	N	N	1.175074932	94.79076229	0.022289553	51.1	DM	Transcobalamin II deficiency, 275350 (3)
TCP1	6	159778498	159789749	N	.	N	N	-0.668447919	14.80002315	0.989085752	10.1	DP	.
TCP10	6	167357031	167384510	N	.	N	N	2.453837799	99.16073392	0.264645829	36.7	.	.
TCP10L	21	32574841	32587373	N	.	N	N	0.113784984	58.30294611	0.001913614	62	.	.
TCP10L2	6	167146414	167196913	N	.	N	N	1.698465346	97.89315275	0.694467188	24.8	.	.
TCP11	6	35118071	35148610	N	.	N	N	0.245313747	67.19337848	4.01E-05	74.5	.	.
TCP11L1	11	33039417	33105943	N	.	N	N	-0.265040808	31.57376859	0.088046987	43.9	.	.
TCP11L2	12	106301929	106347015	N	.	N	N	0.169326965	62.4587602	7.49E-07	83.1	.	.
TCP11X2	X	102374628	102471812	N	.	N	N	.	.	.	.	.	.
TCTA	3	49412206	49416475	N	.	N	N	0.465476352	79.10516872	0.013264848	53.8	.	.
TCTE1	6	44278743	44297688	N	.	N	Y	0.528668245	81.61139087	3.26E-07	84.4	FTV	.
TCTE3	6	169740114	169751587	N	.	N	N	0.733830056	87.67725878	0.003218733	60	DM?	.
TCTEX1D1	1	66752459	66778787	N	.	N	N	0.149386991	60.95386931	0.006424682	56.9	.	.
TCTEX1D2	3	196291219	196318299	N	.	N	Y	0.427003903	77.20669098	0.000234712	69.3	.	.
TCTEX1D4	1	44805913	44806675	N	.	N	N	.	.	0.208823534	38.5	.	.
TCTN2	12	123671113	123708403	N	.	N	Y	-0.784523017	11.86548591	1.97E-05	76.3	DM	?Meckel syndrome 8, 613885 (3)
TCTN3	10	95663396	95694143	N	.	N	N	-0.501463696	20.08450541	6.44E-08	86.7	DM	Orofaciodigital syndrome IV, 258860 (3); Joubert syndrome 18, 614815 (3)
TDO2	4	155854738	155920406	N	.	N	Y	-0.659987499	15.04312091	1.52E-08	88.4	DP	.
TDP1	14	89954939	90044768	N	.	N	N	0.144099113	60.53713029	1.11E-11	94.2	DM	Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 (3)
TDP2	6	24649977	24667033	N	.	N	Y	-0.221936642	34.22469179	0.000137008	70.9	.	.
TDRD1	10	114179270	114232304	N	.	N	Y	-0.810570593	11.36192626	0.999760762	4.4	.	.
TDRD10	1	154502219	154548147	N	.	N	N	0.186095639	63.59900446	2.45E-06	80.9	.	.
TDRD12	19	32719753	32829580	N	.	N	Y	.	.	.	.	.	.
TDRD15	2	21123917	21143272	N	.	N	N	.	.	.	.	.	.
TDRD3	13	60396457	60573878	N	.	N	N	-0.260256521	31.86317069	0.000211829	69.7	.	.
TDRD5	1	179591613	179691272	N	.	N	Y	-0.664322798	14.91578399	0.975818615	12.3	.	.
TDRD6	6	46687875	46704319	N	.	N	Y	1.470425911	96.83394108	6.46E-23	99.1	.	.
TDRD7	9	97411950	97496125	N	.	N	Y	-1.160525039	5.98483533	4.57E-05	74.2	DM	Cataract 36, 613887 (3)
TDRD9	14	103928462	104052667	N	.	N	Y	-0.698160609	13.98390924	3.82E-07	84.1	.	.
TDRKH	1	151770107	151791416	N	Viable	N	Y	0.144904459	60.59501071	0.006962423	56.6	.	.
TDRP	8	489792	545781	N	Viable	N	Y	0.158803293	61.65422238	0.001321928	63.6	.	.
TEAD3	6	35473597	35497076	N	.	N	N	0.252666418	67.59275337	.	.	.	.
TEC	4	48135783	48269864	N	.	N	Y	-0.900094726	9.579209353	0.002573311	61	.	Transient erythroblastopenia of childhood (2)
TECPR1	7	98214624	98252251	N	.	N	Y	0.316018337	71.47652949	2.43E-07	84.9	.	.
TECPR2	14	102362963	102502481	N	.	N	N	-1.127391372	6.326329803	0.94851586	14.9	DM	Spastic paraplegia 49, autosomal recessive, 615031 (3)
TECR	19	14517085	14565980	N	.	N	N	-0.074747377	44.06436303	0.75750139	22.9	DM	Mental retardation, autosomal recessive 14, 614020 (3)
TECRL	4	64275257	64409468	N	.	N	N	-0.06150319	44.99623777	6.40E-10	91.5	.	.
TECTA	11	121101173	121191493	N	.	N	Y	-1.451646107	3.652254442	1.06E-12	95.2	DM	Deafness, autosomal dominant 8/12, 601543 (3); Deafness, autosomal recessive 21, 603629 (3)
TECTB	10	112283735	112305035	N	.	N	Y	0.158953701	61.6715865	5.95E-09	89.4	.	.
TEDDM1	1	182398117	182400616	N	.	N	N	-0.082250388	43.42189037	0.084146706	44.2	.	.
TEF	22	41367333	41399326	N	.	N	Y	-0.314041164	28.6045031	0.421035621	32.2	.	.
TEFM	17	30897336	30906820	N	.	N	N	-0.118808507	40.85199977	0.043302606	47.8	.	.
TEKT1	17	6789133	6831761	N	.	N	N	1.109302711	94.06146901	0.000108975	71.6	.	.
TEKT2	1	36084075	36088275	N	.	N	N	1.110259425	94.06725705	4.73E-09	89.6	DM?	.
TEKT3	17	15303811	15341641	N	.	N	Y	0.605613802	84.32598252	3.20E-14	96.4	.	.
TEKT4	2	94871433	94876829	N	.	N	Y	2.135999532	98.76714707	2.56E-11	93.7	.	.
TEKT5	16	10627501	10694945	N	.	N	N	2.072285293	98.68032645	1.10E-14	96.7	.	.
TEN1	17	75979220	76000586	N	.	N	N	.	.	.	.	.	.
TEN1-CDK3	17	75979231	76005999	N	.	N	N	.	.	.	.	.	.
TENM1	X	124375903	124963817	N	.	N	N	-0.294170957	29.75053539	0.999995817	2.2	.	.
TENM2	5	167284799	168264157	N	.	N	Y	.	.	0.99995109	3.2	.	.
TENM3	4	182143987	182803024	N	.	N	Y	-2.177143055	1.325461596	0.999937944	3.4	DM	?Microphthalmia, isolated, with coloboma 9, 615145 (3)
TEP1	14	20365667	20413429	N	Viable	N	Y	2.968833249	99.51380448	4.51E-24	99.2	DP	.
TEPP	16	57976435	57988116	N	.	N	N	-0.132857585	39.9027609	6.80E-05	73	.	.
TERT	5	1253147	1295069	N	.	N	Y	-0.591349706	17.00526712	0.866151189	19.2	DM	{Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1}, 614742 (3); {Dyskeratosis congenita, autosomal recessive 4}, 613989 (3); {Dyskeratosis congenita, autosomal dominant 2}, 613989 (3); {Leukemia, acute myeloid}, 601626 (3); {Melanoma, cutaneous malignant, 9}, 615134 (3)
TES	7	116210493	116258783	N	.	N	Y	-0.054000211	45.52294959	4.84E-11	93.4	.	.
TESC	12	117038923	117099479	N	.	N	N	-0.133967403	39.81015223	0.692139731	24.8	.	.
TESK1	9	35605305	35610041	N	.	N	N	-0.442243367	22.62545581	0.999003535	5.9	.	.
TESK2	1	45343883	45491166	N	.	N	N	0.340134142	72.88302367	8.65E-06	78.4	.	.
TESPA1	12	54948018	54984746	N	.	N	Y	1.039855766	93.26271922	1.92E-05	76.3	.	.
TET3	2	73986404	74108176	N	.	N	N	-1.225905481	5.348150721	0.999942651	3.4	.	.
TEX10	9	100302077	100352939	N	.	N	N	-0.953425857	8.682062858	0.999988107	2.6	.	.
TEX101	19	43401496	43418597	N	.	N	Y	0.098778904	57.07588123	0.000898939	65.1	.	.
TEX11	X	70528940	70908731	N	.	N	Y	0.198382189	64.28778144	0.999964221	3.1	.	Spermatogenic failure, X-linked, 2, 309120 (3)
TEX12	11	112167372	112172559	N	.	N	Y	0.078032613	55.54205012	0.133134682	41.4	.	.
TEX13A	X	105218929	105220674	N	.	N	N	.	.	0.007481489	56.3	.	.
TEX13B	X	107980864	107982370	N	.	N	N	1.00682807	92.85176825	0.025228035	50.5	DM?	.
TEX14	17	58556678	58692055	N	.	N	Y	0.030400882	51.8377033	6.67E-23	99.1	FTV	.
TEX15	8	30831544	30890606	N	.	N	Y	0.622527032	84.82954217	3.89E-17	97.9	.	.
TEX2	17	64147227	64263301	N	.	N	N	-0.615478783	16.32806622	0.44097988	31.7	.	.
TEX22	14	105398579	105450106	N	.	N	N	.	.	.	.	.	.
TEX26	13	30932703	30975502	N	.	N	N	0.717056351	87.32997627	8.72E-09	89.1	.	.
TEX261	2	70985938	70994945	N	.	N	N	0.004915377	49.86976906	0.000195342	69.9	.	.
TEX264	3	51662693	51704323	N	.	N	N	-0.208844572	35.00607744	0.910814339	17.2	.	.
TEX28	X	154271265	154295853	N	.	N	N	.	.	.	.	.	.
TEX29	13	111316184	111344249	N	.	N	N	0.527414817	81.53035828	0.001451668	63.2	.	.
TEX30	13	102765990	102773811	N	.	N	N	0.315412023	71.43022515	0.006295441	57	.	.
TEX33	22	36991120	37007841	N	.	N	N	0.841746956	90.04456792	0.000322691	68.4	.	.
TEX35	1	178513077	178548602	N	.	N	N	0.7047722	87.01163396	0.001664771	62.6	.	.
TEX36	10	125576522	125683144	N	.	N	N	.	.	.	.	.	.
TEX37	2	88524651	88529584	N	Viable	N	Y	0.773259281	88.62070961	3.71E-06	80.1	.	.
TEX38	1	46668855	46673594	N	.	N	N	.	.	.	.	.	.
TEX40	11	64300446	64304770	N	.	N	N	.	.	0.477043302	30.6	.	.
TEX43	5	126631722	126636287	N	.	N	N	.	.	.	.	.	.
TEX9	15	56244009	56445997	N	.	N	N	-0.074595468	44.09909128	2.59E-17	97.9	.	.
TFAP2D	6	50713828	50772988	N	.	N	Y	-0.629974609	15.88238699	0.981586998	11.5	.	.
TFAP2E	1	35573370	35595328	N	.	N	N	0.283635266	69.52017133	0.000972259	64.8	.	.
TFB2M	1	246540560	246566324	N	.	N	N	-0.166544931	37.66857672	9.62E-05	72	.	.
TFCP2	12	51093663	51173134	N	.	N	Y	-0.467776875	21.53730393	0.000102419	71.8	DP	.
TFDP2	3	141944428	142149544	N	.	N	N	-0.201341563	35.40545234	0.975087598	12.4	.	.
TFDP3	X	133216669	133218348	N	.	N	N	0.169176254	62.44718412	2.30E-06	81	.	.
TFE3	X	49028726	49043486	N	.	N	Y	0.236703709	66.62615037	0.97374221	12.6	.	Renal cell carcinoma, papillary, 1, 300854 (3)
TFEC	7	115935148	116159896	N	Viable	N	Y	-0.169415642	37.44284309	4.73E-05	74	.	.
TFF1	21	42362282	42366594	N	.	N	Y	0.321002544	71.81802396	0.00630356	57	DP	.
TFF2	21	42346357	42351128	N	.	N	Y	0.875442305	90.66388841	0.000144474	70.8	.	.
TFF3	21	42311667	42315651	N	.	N	Y	0.39603475	75.62655554	0.08568702	44.1	.	.
TFG	3	100709331	100748966	N	.	N	N	0.019116005	51.00422527	0.757056423	22.9	DM	Hereditary motor and sensory neuropathy, Okinawa type, 604484 (3); ?Spastic paraplegia 57, autosomal recessive, 615658 (3)
TFIP11	22	26491225	26512505	N	.	N	N	-0.977703817	8.271111883	1.97E-06	81.3	.	.
TFPI2	7	93885397	93890991	N	.	N	N	0.577215218	83.32465127	0.237365842	37.5	.	.
TFPT	19	54107013	54115675	N	.	N	N	0.313647588	71.30867627	0.00019137	69.9	.	.
TFR2	7	100620416	100642779	N	.	N	Y	0.646958153	85.54725936	0.000139031	70.9	DM	Hemochromatosis, type 3, 604250 (3)
TG	8	132866958	133134903	N	.	N	Y	2.673752433	99.28807085	2.63E-29	99.6	DM	Thyroid dyshormonogenesis 3, 274700 (3); {Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3)
TGDS	13	94574051	94596257	N	.	N	N	-0.232310623	33.58800718	8.78E-06	78.4	.	Catel-Manzke syndrome, 616145 (3)
TGFA	2	70447280	70554193	N	.	N	Y	0.760976889	88.32551948	0.574368122	28.1	.	.
TGFB1I1	16	31471585	31477960	N	.	N	N	0.006980435	50.03762227	0.074916919	44.8	.	.
TGFBI	5	136028895	136063818	N	.	N	Y	0.254882613	67.75481854	0.00372244	59.3	DM	Corneal dystrophy, Groenouw type I, 121900 (3); Corneal dystrophy, lattice type I, 122200 (3); Corneal dystrophy, Reis-Bucklers type, 608470 (3); Corneal dystrophy, Avellino type, 607541 (3); Corneal dystrophy, lattice type IIIA, 608471 (3); Corneal dystrophy, Thiel-Behnke type, 602082 (3); Corneal dystrophy, epithelial basement membrane, 121820 (3)
TGFBR3L	19	7916145	7919097	N	.	N	N	.	.	.	.	.	.
TGFBRAP1	2	105264391	105330034	N	.	N	N	-1.453329976	3.629102275	0.129423466	41.6	DP	.
TGIF2-C20orf24	20	36574553	36612384	N	.	N	N	-0.239967611	33.04971928	0.932314275	16	.	.
TGIF2LX	X	89921882	89922883	N	.	N	N	0.110914976	58.05984835	0.592887022	27.6	.	.
TGIF2LY	Y	3579041	3580041	N	.	N	N	.	.	0.076870762	44.6	.	.
TGM2	20	38127387	38166578	N	.	N	Y	0.356250497	73.76280604	4.86E-14	96.3	DM	.
TGM3	20	2296001	2341078	N	.	N	Y	0.646156788	85.53568328	9.87E-06	78.1	.	.
TGM4	3	44874608	44914990	N	.	N	Y	1.441706702	96.66608786	1.14E-11	94.2	DM?	.
TGM5	15	43232595	43266857	N	.	N	N	0.741784085	87.90878046	5.37E-16	97.4	DM	Peeling skin syndrome 2, 609796 (3)
TGM6	20	2380908	2432753	N	.	N	N	3.077640723	99.56589686	2.76E-18	98.2	DM	Spinocerebellar ataxia 35, 613908 (3)
TGM7	15	43276280	43302255	N	.	N	N	1.129251893	94.32193089	6.34E-10	91.5	.	.
TGOLN2	2	85318020	85328425	N	.	N	N	0.598916451	84.09446084	0.000179691	70.1	.	.
THADA	2	43230836	43596046	N	Viable	N	Y	0.20441999	64.64664004	1.24E-28	99.6	DP	.
THAP1	8	42836674	42843325	N	.	N	N	0.063983137	54.4886265	0.899169328	17.8	DM	Dystonia 6, torsion, 602629 (3)
THAP10	15	70881342	70892785	N	.	N	N	-0.053195214	45.56346588	0.001194344	64	.	.
THAP2	12	71663009	71680639	N	.	N	N	0.05935026	54.0603114	5.17E-05	73.8	.	.
THAP3	1	6624866	6635586	N	.	N	N	0.554705396	82.60114603	0.001484225	63.1	.	.
THAP4	2	241584405	241637449	N	.	N	N	-0.327783769	27.85784569	0.116840641	42.3	.	.
THAP5	7	108554543	108569750	N	.	N	N	-0.161108498	37.92903861	0.002792035	60.6	.	.
THAP6	4	75513946	75550473	N	.	N	N	0.825783966	89.65098107	0.001440423	63.2	.	.
THAP7	22	20999104	21002196	N	.	N	N	-0.197666633	35.6485501	0.029327855	49.8	.	.
THAP8	19	36034985	36054762	N	.	N	N	0.309821667	71.05979047	0.000639752	66.3	.	.
THAP9	4	82900684	82919969	N	.	N	N	-0.44496303	22.49233084	7.48E-10	91.3	.	.
THBS1	15	39581079	39599466	Y	Viable	N	Y	-0.47563866	21.2015975	0.999073127	5.8	DM	.
THBS2	6	169215780	169254044	N	.	N	Y	-0.550531951	18.19181571	0.245000803	37.3	DP	{Lumbar disc herniation, susceptibility to}, 603932 (3)
THBS3	1	155195588	155209051	N	.	N	Y	-1.634399379	2.731955779	1.21E-08	88.7	.	.
THBS4	5	79991311	80083287	N	.	N	Y	-0.471003248	21.38681484	1.74E-08	88.3	DP	.
THEG	19	361747	376670	N	.	N	N	1.734225362	97.9973375	4.93E-07	83.8	.	.
THEGL	4	56530609	56603507	N	Viable	N	Y	.	.	.	.	.	.
THEM4	1	151873584	151909808	N	.	N	Y	0.044344174	52.90849106	0.000241348	69.2	.	.
THEM5	1	151847263	151853697	N	.	N	Y	0.493723196	80.22226081	5.98E-07	83.4	.	.
THEM6	8	142727203	142736927	N	.	N	N	.	.	0.02427983	50.6	.	.
THEMIS	6	127708072	127918631	N	.	N	Y	0.320495832	71.79487179	0.14251698	40.9	.	.
THEMIS2	1	27872543	27886685	N	.	N	Y	0.210669154	65.1386236	0.064721712	45.5	.	.
THG1L	5	157731197	157741448	N	.	N	N	0.087599756	56.28870753	3.48E-05	74.8	.	.
THNSL1	10	25016658	25026664	N	.	N	N	-0.131597747	39.96642936	5.62E-12	94.6	.	.
THNSL2	2	88170295	88186636	N	.	N	N	0.830712876	89.8072582	3.94E-06	80	.	.
THOC2	X	123600561	123733056	N	.	N	N	-1.277195716	4.873531284	0.999999919	1.1	DM	Mental retardation, X-linked 12/35, 300957 (3)
THOC3	5	175917873	176034680	N	.	N	N	0.308865253	70.99612201	.	.	.	.
THOC6	16	3024027	3027755	N	.	N	N	-0.705007026	13.7986919	0.002193448	61.5	DM	Beaulieu-Boycott-Innes syndrome, 613680 (3)
THOC7	3	63833870	63863903	N	.	N	N	-0.238053216	33.17126816	0.978320489	12	.	.
THOP1	19	2785460	2815807	N	.	N	N	-0.734721565	13.02888233	0.023492093	50.8	.	.
THPO	3	184371935	184378144	N	Viable	N	Y	-0.033404934	47.05678069	0.005140229	58	DM	Thrombocythemia 1, 187950 (3)
THRAP3	1	36224416	36305357	N	.	N	N	-0.941141259	8.83833999	0.999996899	2.1	.	.
THRB	3	24117160	24495282	N	.	N	Y	-0.238856623	33.14811599	0.994541861	8.6	DM	Thyroid hormone resistance, 188570 (3); Thyroid hormone resistance, autosomal recessive, 274300 (3); Thyroid hormone resistance, selective pituitary, 145650 (3)
THRSP	11	78063861	78068351	N	.	N	Y	0.140927298	60.26509232	0.00560131	57.6	.	.
THSD1	13	52377167	52406494	N	Viable	N	Y	-0.818215884	11.22301325	2.45E-05	75.7	.	.
THSD4	15	71096952	71783383	N	.	N	N	0.284247047	69.54332349	0.001818272	62.3	.	.
THSD7A	7	11370357	11832198	N	.	N	N	-1.289534625	4.751982404	0.999280749	5.6	DM?	.
THSD7B	2	136765545	137677717	N	.	N	N	.	.	5.65E-06	79.3	DM?	.
THTPA	14	23555988	23560271	N	.	N	N	-0.377739799	25.58314522	0.000116051	71.4	.	.
THUMPD1	16	20733664	20742084	N	.	N	N	0.370803213	74.41685478	0.001035463	64.6	.	.
THUMPD2	2	39736060	39779267	N	.	N	N	-0.407598535	24.04931412	1.94E-08	88.2	.	.
THUMPD3	3	9362842	9386791	N	.	N	N	0.533300984	81.79660821	4.00E-11	93.5	.	.
THY1	11	119417378	119424985	N	.	N	Y	0.056480057	53.81721364	0.164135342	40	.	.
THYN1	11	134248279	134253370	N	.	N	N	-0.129182361	40.14585866	1.40E-09	90.9	.	.
TIAF1	17	29073521	29078857	N	.	N	N	0.351015356	73.42131157	0.026393545	50.3	.	.
TIAM1	21	31118416	31559977	N	.	N	Y	-0.69474891	14.11124617	0.999932006	3.5	.	.
TIAM2	6	154832697	155257723	N	.	N	N	0.457477225	78.68264166	0.124829516	41.8	.	.
TICAM1	19	4815932	4831704	N	.	N	Y	0.962256069	92.22665972	0.852477311	19.8	DM	{Herpes simplex encephalitic, susceptibility to, 6}, 614850 (3)
TICAM2	5	115578650	115602479	N	.	N	Y	0.333287484	72.48364878	0.004709637	58.4	.	.
TICRR	15	89575482	89631056	N	.	N	N	1.339715191	96.04676738	9.15E-12	94.3	.	.
TIFA	4	112274542	112285903	N	.	N	N	0.527414817	81.53035828	0.118201141	42.2	.	.
TIFAB	5	135444218	135452399	N	.	N	N	0.354840535	73.70492562	1.15E-06	82.4	.	.
TIGAR	12	4321205	4354593	N	.	N	Y	.	.	.	.	.	.
TIGD1	2	232547968	232550592	N	.	N	N	.	.	.	.	.	.
TIGD2	4	89111500	89114899	N	.	N	N	-0.748112675	12.68738786	7.02E-06	78.9	.	.
TIGD3	11	65354767	65357613	N	.	N	N	-0.643066859	15.59298489	7.78E-11	93.1	.	.
TIGD4	4	152769354	152779764	N	.	N	N	0.31284098	71.27973607	0.001924505	62	.	.
TIGD5	8	143597835	143603224	N	.	N	N	.	.	0.000172429	70.3	.	.
TIGD6	5	149993118	150001167	N	.	N	N	0.914207853	91.36424148	4.86E-06	79.6	.	.
TIGD7	16	3298832	3305729	N	.	N	N	0.46481599	79.08201655	1.87E-07	85.3	.	.
TIGIT	3	114276913	114310288	N	.	N	Y	0.060307001	54.1297679	0.0451499	47.6	.	.
TIMD4	5	156919282	156963255	N	.	N	Y	0.676818883	86.32864502	4.34E-08	87.2	.	.
TIMM10	11	57528463	57530803	N	.	N	N	-0.006414986	48.96104648	0.009494762	55.2	.	.
TIMM10B	11	6481447	6484679	N	.	N	N	0.473935719	79.48717949	0.00115871	64.1	.	.
TIMM13	19	2425624	2427894	N	.	N	N	0.010504826	50.32702437	0.309091874	35.5	.	.
TIMM17A	1	201955491	201970661	N	.	N	N	0.086492393	56.17873473	0.243777584	37.3	.	.
TIMM17B	X	48893447	48898143	N	.	N	N	0.168070043	62.3893037	0.826908629	20.7	.	.
TIMM21	18	74148511	74160530	N	.	N	N	0.153213524	61.2432714	0.005320931	57.8	.	.
TIMM23B	10	49942033	49974850	N	.	N	N	.	.	.	.	.	.
TIMM44	19	7926718	7943920	N	.	N	N	-0.088644586	42.93569485	0.818201942	21	DM	.
TIMM8A	X	101345661	101349196	N	.	N	N	0.090168851	56.43919662	0.605876721	27.3	DM	Deafness, X-linked 1, progressive (3); Mohr-Tranebjaerg syndrome, 304700 (3); Jensen syndrome, 311150 (3)
TIMM8B	11	112084800	112086798	N	.	N	N	0.078989305	55.61150663	0.226807933	37.8	.	.
TIMM9	14	58408494	58427614	N	.	N	N	0.107088402	57.71835388	0.437845525	31.7	.	.
TIMP1	X	47582313	47586789	N	.	N	Y	1.208480766	95.09752851	0.766877188	22.7	DP	.
TIMP2	17	78852977	78925387	N	.	N	Y	0.087449076	56.25976732	0.526868279	29.2	DP	.
TIMP3	22	32801701	32863043	N	Viable	N	Y	-0.201495045	35.359148	0.112088669	42.5	DM	Sorsby fundus dystrophy, 136900 (3)
TIMP4	3	12153051	12159351	N	.	N	Y	-0.331764245	27.65526422	0.003554031	59.6	.	.
TINAG	6	54307859	54390152	N	.	N	N	0.539042257	82.01076576	4.11E-18	98.2	DM	.
TINAGL1	1	31576485	31587686	N	.	N	N	-0.463948146	21.72830931	0.245105548	37.2	.	.
TIPIN	15	66336206	66386746	N	.	N	N	0.44120081	77.9417723	0.009832085	55	.	.
TIPRL	1	168178933	168202114	N	.	N	N	-0.177071645	36.92770736	0.86724967	19.2	.	.
TIRAP	11	126283065	126298845	N	.	N	Y	0.662620317	85.99872663	0.002669231	60.8	DM	{Pneumococcal disease, invasive, protection against}, 610799 (3); {Bacteremia, protection against}, 614382 (3); {Malaria, protection against}, 611162 (3); {Tuberculosis, protection against}, 607948 (3)
TISP43	2	130570829	130584161	N	.	N	N	.	.	.	.	.	.
TJAP1	6	43477523	43506556	N	.	N	N	0.400158571	75.84650113	0.001059393	64.5	.	.
TJP1	15	29699367	29968865	N	.	N	Y	-1.728770415	2.349945014	0.999999982	0.9	.	.
TJP3	19	3708109	3750813	N	.	N	Y	2.453742141	99.15494588	2.20E-21	98.9	.	.
TKFC	11	61333210	61353295	N	.	N	N	.	.	.	.	.	.
TKTL1	X	154295671	154330350	N	.	N	Y	-0.478802164	21.05110841	0.997026231	7.5	.	.
TKTL2	4	163471093	163473746	N	.	N	N	0.555005615	82.6242982	8.54E-05	72.4	.	.
TLCD1	17	28724348	28727935	N	.	N	N	-0.195752553	35.7874631	0.011149875	54.5	.	.
TLCD2	17	1702790	1710438	N	.	N	N	.	.	.	.	.	.
TLDC1	16	84476421	84554033	N	.	N	N	1.509245404	97.00179429	2.29E-12	95	.	.
TLDC2	20	36876121	36894235	N	.	N	N	1.230176303	95.30589801	0.113178686	42.5	.	.
TLE1	9	81583683	81689305	N	.	N	N	-1.020958787	7.611275106	0.957285091	14.2	.	.
TLE2	19	2997638	3047635	N	.	N	N	-1.040601561	7.368177346	0.000766445	65.6	.	.
TLE4	9	79571773	79726882	N	.	N	N	-1.099822064	6.581003646	0.99992164	3.6	.	.
TLE6	19	2977446	2995184	N	.	N	N	0.061566363	54.27446895	0.001011458	64.7	.	.
TLK1	2	170990823	171231314	N	.	N	N	-0.826974718	11.0088557	0.999994768	2.3	FTV	.
TLK2	17	62458658	62615481	N	.	N	N	-0.979916263	8.242171673	0.999999806	1.2	.	.
TLL2	10	96364606	96513918	N	.	N	Y	-0.741944641	12.8320889	2.18E-19	98.5	.	.
TLN2	15	62390526	62844631	N	.	N	Y	-3.508806826	0.382010766	0.999853231	4.1	.	.
TLR1	4	38790677	38856817	N	.	N	Y	1.592752951	97.44747352	2.02E-14	96.5	DFP	{Leprosy, protection against}, 613223 (3); {Leprosy, susceptibility to, 5}, 613223 (3)
TLR10	4	38772239	38782990	N	.	N	N	1.634904946	97.65584303	8.43E-08	86.3	DP	.
TLR2	4	153701500	153705699	N	.	N	Y	0.451876138	78.42217978	9.23E-05	72.1	DFP	{Leprosy, susceptibility to}, 246300 (3); {Colorectal cancer, susceptibility to}, 114500 (3); {Mycobacterium tuberculosis, susceptibility to}, 607948 (3)
TLR3	4	186069152	186088069	N	.	N	Y	-0.16719952	37.58175609	0.001211245	64	DM	{Herpes simplex encephalitis, susceptibility to, 2} 613002 (3); {HIV1 infection, resistance to}, 609423 (3)
TLR4	9	117704332	117716871	N	.	N	Y	0.709856007	87.1273948	4.18E-06	79.9	DM?	Endotoxin hyporesponsiveness (3); {Macular degeneration, age-related, 10}, 611488 (3); {Colorectal cancer, susceptibility to}, 114500 (3)
TLR5	1	223109406	223143282	N	.	N	Y	0.637695968	85.29837356	5.69E-09	89.5	DM?	{Legionaire disease, susceptibility to}, 608556 (3); {Systemic lupus erythematosus, resistance to}, 601744 (3); {Systemic lupus erythematosus, susceptibility to, 1}, 601744 (2); {Melioidosis, susceptibility to}, 615557 (3)
TLR6	4	38823715	38856817	N	.	N	Y	0.488434514	80.02546738	0.007304908	56.4	DFP	.
TLR7	X	12867083	12890380	N	.	N	Y	-0.574581061	17.50882676	0.872917549	18.9	DFP	.
TLR8	X	12906620	12923169	N	.	N	Y	-0.27063003	31.24385021	0.931026133	16.1	DFP	.
TLR9	3	52221080	52226163	N	.	N	Y	-1.500135096	3.368640389	0.000525226	66.9	DM	.
TLX1	10	101130505	101137789	N	.	N	Y	0.058393523	53.97927881	0.463723105	31.1	.	.
TM2D1	1	61681046	61725423	N	.	N	N	.	.	0.042061483	48	.	.
TM2D2	8	38988808	38996824	N	.	N	N	-0.05223834	45.61555826	0.071028872	45	.	.
TM2D3	15	101621444	101652391	N	.	N	N	0.344616494	73.13190948	0.000338995	68.3	.	.
TM4SF1	3	149369022	149377865	N	.	N	N	-0.318672489	28.34982925	0.00085911	65.3	.	.
TM4SF18	3	149318498	149334414	N	.	N	N	0.066853307	54.65069167	2.10E-07	85.1	.	.
TM4SF19	3	196319342	196338503	N	.	N	N	0.354840535	73.70492562	0.013930843	53.6	DM?	.
TM4SF19-TCTEX1D2	3	196316082	196338373	N	.	N	N	.	.	.	.	.	.
TM4SF20	2	227362156	227381995	N	.	N	N	0.577215218	83.32465127	2.19E-06	81.1	DM	{Specific language impairment 5}, 615432 (3)
TM4SF4	3	149473974	149503281	N	Viable	N	Y	0.380219143	74.93777855	0.002511015	61.1	.	.
TM4SF5	17	4771884	4783213	N	.	N	N	0.257299872	67.86479134	1.24E-05	77.5	.	.
TM6SF1	15	83107407	83144854	N	.	N	N	-0.27637172	30.86762748	6.47E-05	73.2	.	.
TM6SF2	19	19264364	19273391	N	.	N	N	0.339983147	72.87144759	1.94E-05	76.3	.	.
TM7SF2	11	65111845	65116384	N	.	N	Y	0.263039301	68.2178619	0.000447934	67.4	.	.
TM7SF3	12	26973195	27014434	N	.	N	N	-0.179637179	36.77143023	0.089899598	43.8	.	.
TM9SF1	14	24189143	24195687	N	.	N	N	-0.608269539	16.50749551	0.000166484	70.3	.	.
TM9SF2	13	99501417	99564006	N	.	N	N	-0.932023003	9.000405163	0.99992836	3.5	.	.
TM9SF3	10	96518109	96587452	N	.	N	N	-0.680738037	14.48168085	0.999654187	4.8	.	.
TM9SF4	20	32109506	32167258	N	.	N	Y	-0.414144703	23.73097181	0.999970772	3	.	.
TMA16	4	163494442	163520539	N	.	N	N	0.549924771	82.42171673	0.029470024	49.7	.	.
TMA7	3	48440257	48444208	N	.	N	N	-0.013918082	48.39381837	0.010007308	54.9	.	.
TMBIM1	2	218274192	218292586	N	.	N	Y	-0.147863581	38.90142965	7.40E-05	72.8	.	.
TMBIM4	12	66135846	66170072	N	.	N	N	0.04243066	52.74063784	0.002079962	61.7	.	.
TMBIM6	12	49707725	49764934	N	.	N	N	-0.089753398	42.80835793	0.016169744	52.8	.	.
TMC1	9	72521801	72836351	N	.	N	Y	-0.755465733	12.47323031	3.81E-07	84.1	DM	Deafness, autosomal recessive 7, 600974 (3); Deafness, autosomal dominant 36, 606705 (3)
TMC2	20	2536607	2641784	N	.	N	Y	0.512056899	80.96313017	7.89E-16	97.3	.	.
TMC3	15	81331217	81374213	N	Viable	N	Y	0.708259536	87.07530243	9.78E-16	97.3	DM?	.
TMC4	19	54160108	54173250	N	.	N	N	-0.356839227	26.4918678	9.29E-09	89	.	.
TMC5	16	19410496	19499113	N	.	N	N	0.784251737	88.86959542	0.000196303	69.8	.	.
TMC6	17	78110458	78132407	N	.	N	Y	0.528821762	81.62296695	5.08E-08	86.9	DM	Epidermodysplasia verruciformis, 226400 (3)
TMC7	16	18983934	19063942	N	.	N	N	-0.049064732	45.89917231	4.32E-06	79.8	.	.
TMC8	17	78130770	78142968	N	.	N	Y	-0.042518524	46.39694391	5.57E-12	94.6	DM	Epidermodysplasia verruciformis, 226400 (3)
TMCC1	3	129647792	129893576	N	.	N	N	-0.986462395	8.103258668	0.209385317	38.5	.	.
TMCC2	1	205228176	205273343	N	.	N	N	-0.495572089	20.39127163	0.288835547	36	.	.
TMCC3	12	94567124	94650562	N	.	N	N	-0.074595468	44.09909128	0.000392184	67.8	.	.
TMCO1	1	165724293	165827755	N	.	N	N	-0.162065544	37.85379406	9.55E-07	82.6	DM	Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 213980 (3)
TMCO2	1	40245947	40251691	N	.	N	N	0.018964694	50.97528506	0.039711313	48.4	.	.
TMCO3	13	113490995	113554590	N	.	N	N	0.628277759	84.99739538	6.68E-10	91.4	.	.
TMCO4	1	19682213	19799945	N	.	N	N	1.752269113	98.066794	9.98E-13	95.3	.	.
TMCO5A	15	37921939	37967724	N	.	N	N	0.244206777	67.1412861	0.000421007	67.6	.	.
TMCO6	5	140639427	140645408	N	.	N	N	-0.255624009	32.14678474	8.15E-06	78.6	.	.
TMED1	19	10832438	10836318	N	.	N	N	0.26384649	68.31047057	0.000162417	70.4	.	.
TMED3	15	79311062	79427432	N	.	N	N	0.486219979	79.93864676	0.002656742	60.9	.	.
TMED4	7	44577894	44582287	N	.	N	N	-0.132053341	39.94906523	0.292927703	35.9	.	.
TMED5	1	93149742	93180728	N	.	N	N	0.104368575	57.54471262	0.002437131	61.2	.	.
TMED6	16	69343248	69351809	N	.	N	N	0.94216169	91.88516525	0.000563599	66.7	.	.
TMED7	5	115613508	115632992	N	.	N	N	-0.140513426	39.38183712	0.363701355	33.8	.	.
TMED7-TICAM2	5	115578642	115626161	N	.	N	N	0.019116005	51.00422527	0.004709637	58.4	.	.
TMED8	14	77335021	77377109	N	.	N	N	-0.119765437	40.78833131	0.084324998	44.1	.	.
TMED9	5	177592158	177596124	N	.	N	N	-0.167654501	37.52966371	0.159567867	40.2	.	.
TMEFF1	9	100473113	100577636	N	.	N	N	-0.099170261	42.1543092	0.551607066	28.6	.	.
TMEM101	17	44011188	44023946	N	.	N	N	-0.213629789	34.6819471	0.161635624	40.1	.	.
TMEM102	17	7435443	7437679	N	.	N	N	0.255536257	67.80112288	.	.	.	.
TMEM104	17	74776483	74839779	N	.	N	N	0.753918416	88.17503039	2.89E-05	75.3	.	.
TMEM105	17	81311270	81330674	N	.	N	N	0.679394134	86.39231348	0.011619609	54.3	.	.
TMEM106A	17	43211835	43220041	N	.	N	N	0.469300995	79.2961741	0.000328022	68.4	.	.
TMEM106B	7	12211241	12243367	N	Viable	N	Y	-0.272697012	31.12808937	0.515078464	29.6	DFP	.
TMEM106C	12	47963569	47968878	N	.	N	N	0.311734573	71.17555131	3.96E-06	80	.	.
TMEM108	3	133038391	133397792	N	Viable	N	Y	-0.175809925	37.02031603	0.98371876	11.1	.	.
TMEM109	11	60913874	60923443	N	.	N	Y	-0.090710311	42.74468947	0.051890547	46.8	.	.
TMEM11	17	21197280	21214624	N	.	N	N	-0.42004192	23.49945014	0.784308456	22.2	.	.
TMEM110	3	52836219	52897596	N	.	N	N	-0.251145013	32.40145859	0.901349033	17.7	.	.
TMEM110-MUSTN1	3	52833121	52897562	N	.	N	N	0.176679292	62.95653181	0.684628072	25	.	.
TMEM114	16	8537605	8590193	N	.	N	N	.	.	.	.	DM	.
TMEM115	3	50354749	50359610	N	.	N	N	-0.194795544	35.85113156	0.876895269	18.8	.	.
TMEM116	12	111931282	112013185	N	.	N	N	0.243250221	67.10655785	1.15E-09	91	.	.
TMEM117	12	43835967	44389762	N	.	N	N	-0.144992854	39.06349482	3.57E-05	74.8	.	.
TMEM119	12	108589846	108598320	N	Viable	N	Y	0.118568504	58.65022863	0.009567375	55.1	.	.
TMEM120A	7	75986837	75994659	N	.	N	N	0.21021973	65.0691671	.	.	.	.
TMEM120B	12	121712752	121783001	N	.	N	N	0.732063112	87.61937836	0.264378756	36.7	.	.
TMEM121	14	105526603	105530202	N	.	N	N	.	.	0.178807336	39.4	.	.
TMEM123	11	102396332	102470384	N	.	N	Y	0.279809186	69.29443769	0.605287081	27.3	.	.
TMEM125	1	43269994	43274002	N	.	N	N	0.833287532	89.86513862	0.000428556	67.5	.	.
TMEM126A	11	85647967	85656547	N	.	N	Y	0.42987242	77.39769636	0.004874178	58.2	DM	Optic atrophy 7, 612989 (3)
TMEM126B	11	85628573	85636539	N	.	N	N	0.438331876	77.80285929	0.000531076	66.9	.	.
TMEM127	2	96248516	96265994	N	.	N	Y	0.021835061	51.22417086	0.101457374	43	DM	{Pheochromocytoma, susceptibility to}, 171300 (3)
TMEM128	4	4235542	4248212	N	.	N	N	0.192492475	63.9636511	0.110058363	42.6	.	.
TMEM129	4	1715952	1721358	N	.	N	N	.	.	1.57E-06	81.8	.	.
TMEM130	7	98846488	98870771	N	.	N	N	-0.148668402	38.83776119	1.29E-08	88.6	.	.
TMEM131	2	97756333	97995891	N	.	N	N	-1.134896002	6.187416797	0.999999482	1.5	.	.
TMEM132B	12	125186836	125662377	N	.	N	N	-0.621070679	16.15442496	0.455834501	31.2	.	.
TMEM132C	12	128267403	128707915	N	.	N	N	.	.	0.66707188	25.6	.	.
TMEM132D	12	129071725	129903666	N	.	N	N	-1.364923403	4.19054234	0.999010387	5.9	DM?	.
TMEM132E	17	34580749	34639318	N	.	N	N	-0.471959308	21.35208659	2.40E-05	75.8	.	.
TMEM133	11	100991989	100993941	N	.	N	N	0.306952505	70.86878509	0.025317131	50.4	.	.
TMEM134	11	67461710	67469272	N	.	N	N	.	.	3.03E-08	87.6	.	.
TMEM135	11	87037844	87323758	N	.	N	N	0.072593755	55.0963709	0.879933359	18.6	DM	.
TMEM136	11	120325129	120333682	N	Viable	N	Y	0.423325465	77.03304972	0.034871924	49	.	.
TMEM138	11	61362001	61369509	N	.	N	N	0.163436574	62.02465706	0.531121157	29.1	DM	Joubert syndrome 16, 614465 (3)
TMEM139	7	143279957	143288048	N	.	N	N	0.530283168	81.66927129	0.018754136	52	.	.
TMEM140	7	135148072	135166215	N	.	N	N	0.529327004	81.64033108	0.039728243	48.3	.	.
TMEM141	9	136791355	136793257	N	.	N	N	0.189623012	63.7437055	0.099111972	43.2	.	.
TMEM143	19	48332356	48364237	N	.	N	N	0.474232641	79.51033165	3.71E-08	87.4	.	.
TMEM144	4	158201604	158255411	N	.	N	N	-0.009939149	48.69479655	7.82E-08	86.4	.	.
TMEM145	19	42313325	42325062	N	.	N	N	-0.447027861	22.42866238	8.14E-05	72.5	.	.
TMEM147	19	35545595	35547526	N	.	N	N	-0.358102358	26.39347109	0.137954529	41.2	.	.
TMEM14A	6	52671109	52686588	N	.	N	N	0.509540192	80.83000521	0.121253231	42	.	.
TMEM14B	6	10747759	10852753	N	.	N	N	0.534918128	81.86027667	6.48E-07	83.3	.	.
TMEM14E	3	152340527	152340904	N	.	N	N	0.502992837	80.54639116	0.185564714	39.1	.	.
TMEM150A	2	85598548	85603196	N	.	N	N	-0.197666633	35.6485501	0.145714084	40.8	.	.
TMEM150B	19	55312801	55334048	N	.	N	N	0.250753302	67.48856862	4.55E-06	79.7	.	.
TMEM150C	4	82483170	82562357	N	.	N	N	0.080902701	55.81408809	0.011339251	54.4	.	.
TMEM151A	11	66291870	66296664	N	.	N	N	.	.	0.788175023	22	.	.
TMEM151B	6	44270466	44307506	N	Viable	N	Y	.	.	.	.	.	.
TMEM154	4	152618632	152680165	N	.	N	N	0.08936246	56.39289228	0.000320383	68.4	.	.
TMEM155	4	121758933	121765427	N	.	N	N	0.828509349	89.72622562	0.00120021	64	.	.
TMEM156	4	38966744	39032922	N	.	N	N	0.654160748	85.75562887	5.76E-09	89.5	.	.
TMEM158	3	45224466	45226278	N	.	N	N	.	.	0.382809463	33.2	.	.
TMEM159	16	21158377	21180616	N	.	N	N	0.215958347	65.40487353	0.003174027	60.1	.	.
TMEM160	19	47045907	47048630	N	.	N	N	.	.	0.654855933	25.9	.	.
TMEM161A	19	19119169	19138513	N	.	N	N	-0.183464709	36.53990855	2.05E-06	81.3	.	.
TMEM163	2	134455759	134719000	N	.	N	N	-0.130139339	40.0821902	0.067262465	45.3	.	.
TMEM164	X	110002631	110182734	N	.	N	N	0.063983137	54.4886265	0.877400449	18.7	.	.
TMEM165	4	55395957	55453397	N	.	N	N	-0.275568538	30.94287203	0.943796614	15.3	DM	Congenital disorder of glycosylation, type IIk, 614727 (3)
TMEM167A	5	83052846	83077863	N	.	N	Y	0.167113525	62.29669503	0.388457895	33.1	.	.
TMEM167B	1	109089803	109096934	N	.	N	N	0.015137522	50.6627308	0.632476719	26.6	.	.
TMEM168	7	112762382	112790592	N	.	N	N	-0.635412537	15.78399028	0.013413085	53.7	.	.
TMEM169	2	216081866	216102783	N	.	N	N	-0.315801021	28.52347051	0.011784537	54.3	.	.
TMEM17	2	62500221	62511894	N	.	N	N	0.165349748	62.17514615	0.004023962	59	.	.
TMEM170A	16	75443054	75465497	N	.	N	N	0.550880798	82.46802107	0.000303172	68.6	.	.
TMEM170B	6	11538278	11583524	N	.	N	N	0.007634404	50.08971465	0.674229052	25.4	.	.
TMEM171	5	73120292	73131817	N	.	N	N	0.786499614	88.89853563	0.000165604	70.4	.	.
TMEM173	5	139475534	139482935	N	.	N	Y	0.603550251	84.24494993	0.032330621	49.3	FP	STING-associated vasculopathy, infantile-onset, 615934 (3)
TMEM174	5	73173195	73175143	N	.	N	N	0.662620317	85.99872663	0.015255886	53.1	.	.
TMEM175	4	932387	958656	N	.	N	N	2.11444115	98.74399491	0.00043963	67.4	.	.
TMEM176A	7	150800403	150805120	N	.	N	N	0.59126564	83.85715113	0.399810437	32.8	.	.
TMEM176B	7	150791285	150801360	N	.	N	Y	1.247096088	95.40429473	3.00E-09	90.1	.	.
TMEM177	2	119679167	119686507	N	.	N	N	0.421560678	76.91728888	0.428469416	32	.	.
TMEM178A	2	39664982	39717963	N	.	N	N	-0.343096194	27.10540024	0.951747716	14.6	.	.
TMEM178B	7	141074232	141480380	N	.	N	N	.	.	.	.	.	.
TMEM179	14	104474678	104605647	N	.	N	N	-0.012004394	48.53851942	0.278562205	36.2	.	.
TMEM179B	11	62787415	62790405	N	.	N	N	-0.364648146	26.14458529	0.010781151	54.6	.	.
TMEM18	2	667335	677439	N	.	N	N	0.155933478	61.44006483	0.053635149	46.6	.	.
TMEM180	10	102461395	102477045	N	.	N	N	-0.857792997	10.41847543	0.000178664	70.2	.	.
TMEM181	6	158536436	158635428	N	.	N	N	-0.078271172	43.79232506	0.468986734	30.9	.	.
TMEM182	2	102736908	102843893	N	.	N	N	0.198231811	64.27620536	0.015987695	52.8	.	.
TMEM183A	1	203007386	203024848	N	.	N	N	-0.051281473	45.6908028	0.948747425	14.9	.	.
TMEM184A	7	1542235	1560821	N	.	N	N	1.706120607	97.92209296	8.89E-05	72.2	.	.
TMEM184C	4	147617383	147672044	N	.	N	N	-0.636676166	15.75505007	0.017595035	52.3	.	.
TMEM185A	X	149596556	149631912	N	.	N	Y	.	.	0.040063074	48.3	.	.
TMEM185B	2	120221278	120223408	N	.	N	N	.	.	0.493451137	30.1	.	.
TMEM186	16	8780384	8797648	N	.	N	N	0.843658882	90.07929617	0.001409854	63.3	.	.
TMEM187	X	153972327	153983195	N	.	N	N	-0.028772452	47.38091104	0.218658492	38.1	DM?	.
TMEM189	20	50118254	50153734	N	.	N	Y	-0.053195214	45.56346588	0.005185006	57.9	.	.
TMEM189-UBE2V1	20	50081124	50153637	N	.	N	N	-0.248273713	32.55773572	0.005185006	57.9	.	.
TMEM19	12	71686087	71705046	N	.	N	N	0.292094913	70.04688314	0.001380694	63.5	.	.
TMEM190	19	55376836	55378244	N	.	N	Y	0.164393154	62.10568965	0.060986378	45.9	.	.
TMEM191B	22	18527802	18530573	N	.	N	N	.	.	.	.	.	.
TMEM192	4	165070608	165208549	N	.	N	N	-0.233267662	33.50118655	0.004698135	58.4	.	.
TMEM196	7	19719310	19773598	N	.	N	N	0.116504775	58.48816345	1.50E-05	77	.	.
TMEM198	2	219543663	219550595	N	.	N	N	-0.658073323	15.10678937	0.061248393	45.9	.	.
TMEM199	17	28357581	28363683	N	.	N	N	0.153213524	61.2432714	0.000653685	66.2	.	.
TMEM2	9	71683366	71816690	N	.	N	N	-1.260688934	5.047172542	1.28E-09	91	DP	.
TMEM200A	6	130365734	130443063	N	.	N	N	-0.157128223	38.22422874	0.835246152	20.5	.	.
TMEM200B	1	29119428	29123935	N	.	N	N	.	.	0.155282701	40.4	.	.
TMEM200C	18	5882072	5895955	N	.	N	N	.	.	.	.	.	.
TMEM201	1	9588922	9614873	N	.	N	N	-0.21156288	34.83822423	0.841903867	20.2	.	.
TMEM202	15	72398273	72408029	N	.	N	N	0.311734573	71.17555131	6.16E-07	83.4	.	.
TMEM203	9	137204082	137205638	N	.	N	N	0.11459153	58.34925045	0.500301666	29.9	.	.
TMEM204	16	1528688	1555580	N	.	N	Y	0.009699407	50.29229612	0.902171045	17.7	.	.
TMEM205	19	11342776	11346518	N	.	N	N	0.12592113	59.20588065	0.394574027	32.9	.	.
TMEM206	1	212363931	212414901	N	.	N	N	-0.495874865	20.37969555	8.01E-06	78.6	.	.
TMEM207	3	190428655	190449876	N	.	N	N	0.914871845	91.3816056	0.000192959	69.9	.	.
TMEM208	16	67227103	67229278	N	.	N	N	-0.305580815	29.14857904	0.424874173	32.2	.	.
TMEM209	7	130164715	130207770	N	.	N	N	-0.080184792	43.61289576	0.005204565	57.9	.	.
TMEM210	9	137170858	137172409	N	.	N	N	.	.	0.313442755	35.3	.	.
TMEM211	22	24935110	24946695	N	.	N	N	0.435463288	77.66394629	0.216382272	38.2	.	.
TMEM212	3	171843349	171938715	N	.	N	N	.	.	.	.	.	.
TMEM213	7	138797952	138838101	N	.	N	N	0.320046263	71.77750767	0.045260468	47.5	.	.
TMEM214	2	27032910	27041695	N	.	N	N	0.002499372	49.67297563	0.001167355	64.1	.	.
TMEM215	9	32783499	32787399	N	.	N	N	0.166306355	62.25039069	0.008215827	55.8	.	.
TMEM216	11	61391687	61398863	N	.	N	N	0.570522981	83.06997743	0.002019295	61.8	DM	Joubert syndrome 2, 608091 (3); Meckel syndrome 2, 603194 (3)
TMEM217	6	37212180	37258155	N	.	N	N	0.082816117	55.93563697	0.005006027	58.1	.	.
TMEM218	11	125096545	125111763	N	.	N	N	0.116504775	58.48816345	0.00149019	63	.	.
TMEM219	16	29940885	29973052	N	.	N	N	0.166306355	62.25039069	0.001035357	64.6	.	.
TMEM220	17	10699015	10730316	N	.	N	N	0.04897698	53.33680616	2.02E-06	81.3	.	.
TMEM221	19	17435509	17448567	N	.	N	N	.	.	.	.	.	.
TMEM222	1	27322145	27336400	N	.	N	N	0.202865163	64.54245529	0.071986075	44.9	.	.
TMEM223	11	62771629	62792021	N	.	N	N	0.472023591	79.37720669	0.012435531	54	.	.
TMEM225	11	123882926	123885642	N	.	N	N	0.613775611	84.56908028	0.541094557	28.9	.	.
TMEM229A	7	124030916	124033023	N	.	N	N	.	.	.	.	.	.
TMEM229B	14	67447084	67533739	N	.	N	N	-0.15647662	38.26474504	0.21424997	38.3	.	.
TMEM230	20	5068232	5113103	N	.	N	N	0.275983486	69.05712797	0.013819609	53.6	.	.
TMEM232	5	110289233	110738956	N	.	N	N	.	.	.	.	.	.
TMEM233	12	119593459	119643066	N	.	N	N	.	.	.	.	.	.
TMEM234	1	32214472	32222359	N	.	N	N	0.04243066	52.74063784	0.000523998	66.9	.	.
TMEM235	17	78231310	78240987	N	.	N	N	.	.	.	.	.	.
TMEM236	10	17752252	17800868	N	.	N	N	.	.	.	.	.	.
TMEM237	2	201620184	201643570	N	.	N	N	0.198231811	64.27620536	9.40E-10	91.2	DM	Joubert syndrome 14, 614424 (3)
TMEM238	19	55379245	55384598	N	.	N	N	.	.	.	.	.	.
TMEM239	20	2816302	2820284	N	.	N	N	.	.	.	.	.	.
TMEM240	1	1535174	1540453	N	.	N	N	.	.	.	.	.	Spinocerebellar ataxia 21, 607454 (3)
TMEM241	18	23197144	23437961	N	.	N	N	0.433697636	77.55976153	7.76E-05	72.7	.	.
TMEM242	6	157289386	157323601	N	.	N	N	0.694401032	86.77432425	0.000194208	69.9	.	.
TMEM243	7	87196160	87220587	N	.	N	N	0.063983137	54.4886265	1.29E-05	77.4	.	.
TMEM244	6	129831244	129861547	N	.	N	N	0.579938151	83.45198819	0.037087536	48.7	.	.
TMEM245	9	109015152	109119945	N	.	N	N	-0.668295493	14.80581119	0.000362237	68.1	.	.
TMEM246	9	101473171	101533537	N	.	N	N	-0.002436163	49.25623662	0.278461424	36.2	.	.
TMEM247	2	46429190	46484425	N	.	N	N	.	.	.	.	.	.
TMEM248	7	66921225	66958551	N	Viable	N	Y	-0.73230344	13.09255079	0.42273152	32.2	.	.
TMEM249	8	144352219	144354914	N	.	N	N	.	.	0.341068399	34.5	.	.
TMEM25	11	118531041	118547280	N	.	N	N	0.499461757	80.4422064	0.000421369	67.6	.	.
TMEM251	14	93184951	93187089	N	.	N	N	0.525502816	81.44353765	0.077112	44.6	.	.
TMEM252	9	68536580	68540867	N	.	N	N	0.149386991	60.95386931	0.003645147	59.5	.	.
TMEM253	14	21098937	21103724	N	.	N	N	.	.	.	.	.	.
TMEM254	10	80078646	80092557	N	.	N	N	0.451425935	78.40481565	0.00506595	58	.	.
TMEM255A	X	120258650	120311556	N	.	N	N	0.143797178	60.51397812	0.469576566	30.9	.	.
TMEM255B	13	113759240	113816995	N	.	N	Y	1.109302711	94.06146901	3.85E-10	91.9	.	.
TMEM256	17	7402975	7404137	N	Viable	N	Y	0.069572814	54.86484922	2.95E-05	75.2	.	.
TMEM256-PLSCR3	17	7389727	7394843	N	.	N	N	.	.	0.245307294	37.2	.	.
TMEM257	X	145827410	145829850	N	.	N	N	0.440098343	77.88389188	0.114594791	42.4	.	.
TMEM258	11	61768501	61792802	N	.	N	N	0.107088402	57.71835388	0.000864646	65.3	.	.
TMEM259	19	1009648	1021179	N	.	N	N	.	.	0.899319773	17.8	.	.
TMEM26	10	61406643	61453450	N	.	N	N	-0.53897936	18.62591885	1.73E-07	85.4	.	.
TMEM260	14	56488354	56650606	N	.	N	N	0.058847615	54.0197951	5.88E-12	94.5	.	.
TMEM261	9	7796490	7888380	N	.	N	N	-0.010090723	48.66585634	0.00077764	65.6	.	.
TMEM262	11	65084979	65089375	N	.	N	N	.	.	.	.	.	.
TMEM263	12	106955719	106978778	N	.	N	N	.	.	.	.	.	.
TMEM27	X	15627318	15665031	N	.	N	Y	-0.094538075	42.4726515	0.003108045	60.2	.	.
TMEM30B	14	61277370	61281840	N	.	N	N	.	.	0.02118173	51.3	.	.
TMEM30C	3	100185824	100194191	N	.	N	N	.	.	.	.	.	.
TMEM31	X	103710909	103714028	N	.	N	N	0.297536667	70.34207328	0.000256766	69.1	FTV	.
TMEM33	4	41935120	41960572	N	.	N	N	-0.175157533	37.05504428	0.229168918	37.7	.	.
TMEM35	X	101078720	101096364	N	.	N	N	0.099585278	57.16270186	0.648723791	26.1	.	.
TMEM37	2	119429901	119438520	N	.	N	N	0.393312715	75.5107947	0.041816145	48	.	.
TMEM38A	19	16661127	16690029	N	.	N	N	-0.147863581	38.90142965	0.030760166	49.5	.	.
TMEM39A	3	119429500	119468830	N	.	N	N	-0.615925383	16.32227817	0.979617998	11.8	DP	.
TMEM39B	1	32072031	32102866	N	.	N	N	-0.031491274	47.21884586	0.021450432	51.3	.	.
TMEM40	3	12733525	12769457	N	.	N	N	0.008742604	50.21705157	0.000135844	71	.	.
TMEM41A	3	185476496	185499057	N	.	N	N	0.18977215	63.74949355	0.002246609	61.5	.	.
TMEM41B	11	9280654	9314780	N	.	N	N	0.172852824	62.72501013	0.020189931	51.6	.	.
TMEM42	3	44861869	44865670	N	.	N	N	0.373525026	74.60207212	0.306977503	35.6	.	.
TMEM43	3	14124940	14143679	N	Viable	N	Y	1.263207838	95.52005557	9.85E-08	86.1	DM	Arrhythmogenic right ventricular dysplasia 5, 604400 (3); Emery-Dreifuss muscular dystrophy 7, AD, 614302 (3)
TMEM44	3	194587673	194633689	N	.	N	N	0.367125811	74.23163744	1.19E-06	82.3	.	.
TMEM45A	3	100492619	100577444	N	.	N	N	-0.160151469	38.02743532	0.010183625	54.8	.	.
TMEM45B	11	129815819	129860003	N	.	N	N	0.260169485	68.0384326	8.87E-07	82.7	.	.
TMEM47	X	34627064	34657288	N	.	N	N	-0.007371823	48.85686172	0.641023924	26.3	.	.
TMEM5	12	63779803	63809558	N	.	N	N	-0.017442134	48.06968802	1.85E-06	81.4	DM	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 (3)
TMEM50A	1	25337917	25362361	N	.	N	N	0.396990911	75.66707183	0.333486481	34.8	.	.
TMEM50B	21	33432485	33480011	N	.	N	N	0.192492475	63.9636511	0.298982341	35.8	.	.
TMEM51	1	15152532	15220480	N	.	N	N	0.366169324	74.15639289	0.870759443	19	.	.
TMEM52	1	1917590	1919273	N	.	N	N	0.217871355	65.53221045	0.328693114	34.9	.	.
TMEM52B	12	10170542	10191801	N	.	N	N	0.672846598	86.25918852	0.040180498	48.3	.	.
TMEM53	1	44635238	44674555	N	.	N	N	0.35116309	73.45025178	0.038975168	48.5	.	.
TMEM54	1	32894594	32901438	N	.	N	N	0.353884195	73.67019737	0.164454121	40	.	.
TMEM55A	8	90993796	91041064	N	.	N	N	-0.258648061	31.95577936	0.021990365	51.2	.	.
TMEM55B	14	20457719	20461612	N	.	N	N	0.043387416	52.82745847	0.80039951	21.7	.	.
TMEM56	1	95117338	95197607	N	.	N	N	-0.304623579	29.21803554	0.338393703	34.6	.	.
TMEM56-RWDD3	1	95117923	95247225	N	.	N	N	-0.049519725	45.82392777	.	.	.	.
TMEM57	1	25430858	25500209	N	.	N	N	-0.932980272	8.971464953	0.992504411	9.3	.	.
TMEM59	1	54026681	54053504	N	.	N	N	-0.081293491	43.49713492	2.23E-07	85	.	.
TMEM59L	19	18607430	18621039	N	.	N	N	0.267672556	68.5362042	0.015100786	53.1	.	.
TMEM60	7	77793728	77798580	N	.	N	N	0.267523946	68.51884008	0.661431576	25.7	.	.
TMEM61	1	54980792	54992293	N	.	N	N	0.311734573	71.17555131	0.004375773	58.7	.	.
TMEM62	15	43123279	43185146	N	.	N	N	-0.035166968	46.92944377	5.99E-08	86.7	.	.
TMEM63A	1	225845536	225882369	N	.	N	N	0.007283443	50.04919836	6.11E-05	73.4	.	.
TMEM63C	14	77116568	77259495	N	.	N	N	-0.104455956	41.84175493	0.988496792	10.3	.	.
TMEM64	8	90621995	90791632	N	.	N	N	.	.	0.157412876	40.3	.	.
TMEM65	8	124306189	124372692	N	.	N	N	0.062069705	54.29762111	0.594652549	27.6	.	.
TMEM68	8	55696424	55773407	N	.	N	Y	-0.040102903	46.61110146	0.01693697	52.5	.	.
TMEM69	1	45687214	45694443	N	.	N	N	0.058393523	53.97927881	0.000261683	69	.	.
TMEM70	8	73972437	73982783	N	.	N	N	0.569711937	83.03524918	0.003240983	60	DM	Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 (3)
TMEM71	8	132685007	132760712	N	.	N	N	0.868081708	90.53076344	4.17E-10	91.9	.	.
TMEM72	10	44911200	44937002	N	.	N	N	0.373672448	74.62522429	0.49453097	30.1	.	.
TMEM74	8	108606850	108787615	N	.	N	N	-0.163826529	37.7901256	0.000331226	68.4	.	.
TMEM74B	20	1180561	1185415	N	.	N	N	0.239573531	66.85188401	0.001473822	63.1	.	.
TMEM78	1	229249636	229251810	N	.	N	N	.	.	.	.	.	.
TMEM79	1	156282935	156293185	N	.	N	Y	1.528727202	97.08282688	3.50E-07	84.3	.	.
TMEM80	11	695428	705028	N	.	N	N	.	.	4.91E-05	73.9	.	.
TMEM81	1	205083129	205084460	N	.	N	N	0.501226419	80.48272269	0.000222029	69.5	.	.
TMEM82	1	15742422	15747982	N	.	N	N	0.748026206	88.05926955	1.23E-05	77.5	.	.
TMEM86A	11	18693122	18704785	N	.	N	N	-0.068201255	44.52161834	0.032960138	49.2	.	.
TMEM86B	19	55226639	55229264	N	.	N	N	1.061266122	93.50581698	2.76E-05	75.4	.	.
TMEM87A	15	42210452	42273663	N	.	N	N	-0.657116328	15.15309371	0.785702662	22.1	.	.
TMEM87B	2	112055223	112119318	N	.	N	N	-0.497635687	20.31602709	7.98E-08	86.4	.	.
TMEM88	17	7855065	7856099	N	.	N	N	0.536830287	81.94130926	0.353473968	34.1	.	.
TMEM88B	1	1426128	1427787	N	.	N	N	.	.	.	.	.	.
TMEM89	3	48620759	48621855	N	.	N	N	0.871761308	90.62337211	0.711075965	24.3	.	.
TMEM8A	16	370773	387113	N	.	N	N	0.700756193	86.91323725	0.000118507	71.4	DM?	.
TMEM8B	9	35814451	35854847	N	.	N	N	-0.414144703	23.73097181	0.001307689	63.7	.	.
TMEM9	1	201134772	201171574	N	.	N	N	-0.041059779	46.53585692	0.298539882	35.8	DP	.
TMEM91	19	41350911	41384083	N	.	N	N	0.23383407	66.45250912	0.422100728	32.2	.	.
TMEM92	17	50271406	50281485	N	.	N	N	-0.033556726	47.03941657	0.129143042	41.6	.	.
TMEM95	17	7355123	7357219	N	.	N	N	0.44583509	78.14435377	0.00145965	63.1	.	.
TMEM97	17	28319095	28328685	N	Viable	N	Y	0.164393154	62.10568965	0.028406015	50	.	.
TMEM99	17	40819106	40836274	N	.	N	N	0.008742604	50.21705157	3.15E-05	75.1	.	.
TMEM9B	11	8947294	8965011	N	.	N	N	-0.11145818	41.38449962	0.911174543	17.2	.	.
TMF1	3	69019827	69052303	N	.	N	Y	-0.652995945	15.28621867	2.84E-06	80.6	.	.
TMIE	3	46701333	46710886	N	.	N	N	0.344468409	73.11454535	0.000366606	68	DM	Deafness, autosomal recessive 6, 600971 (3)
TMIGD1	17	30316333	30334059	N	.	N	N	0.008742604	50.21705157	0.104144558	42.9	.	.
TMIGD2	19	4292232	4302431	N	.	N	N	1.309041113	95.855762	0.01525187	53.1	.	.
TMIGD3	1	111483348	111563962	N	.	N	N	.	.	.	.	.	.
TMLHE	X	155490115	155669944	N	.	N	N	0.067810037	54.72014817	0.00276292	60.7	DM	Epsilon-trimethyllysine hydroxylase deficiency, 300872 (3)
TMOD2	15	51751561	51816368	N	.	N	Y	-0.587827164	17.15575621	0.138407691	41.2	.	.
TMOD4	1	151169986	151176284	N	.	N	N	0.641066664	85.39098223	1.33E-07	85.8	.	.
TMPO	12	98515512	98550379	N	.	N	Y	0.353533797	73.61231695	0.000659536	66.2	DM	?Cardiomyopathy, dilated, 1T, 613740 (3)
TMPPE	3	33090421	33096801	N	.	N	N	-0.218108998	34.42727325	4.86E-05	74	.	.
TMPRSS11A	4	67909385	67964140	N	.	N	Y	0.568903575	83.02367309	9.57E-11	93	DP	.
TMPRSS11B	4	68226653	68245720	N	.	N	N	0.318430612	71.66753487	1.68E-11	94	.	.
TMPRSS11D	4	67820876	67884032	N	.	N	N	-0.425475634	23.3142328	0.06251897	45.7	.	.
TMPRSS11E	4	68447449	68497604	N	.	N	N	-0.387960287	25.05064537	3.75E-05	74.6	.	.
TMPRSS11F	4	68053198	68129880	N	.	N	N	0.515424669	81.09625514	4.98E-07	83.8	.	.
TMPRSS12	12	50842920	50887884	N	.	N	N	0.977768569	92.44660531	0.003116275	60.2	FTV	.
TMPRSS13	11	117900643	117929459	N	.	N	Y	0.891697353	90.98801875	6.09E-05	73.4	.	.
TMPRSS15	21	18269116	18485879	N	.	N	Y	0.753279702	88.15766626	1.29E-18	98.4	DM	.
TMPRSS2	21	41464551	41531116	N	.	N	Y	-0.324913589	28.02569891	0.062064328	45.8	.	.
TMPRSS3	21	42371890	42396846	N	.	N	Y	0.635626645	85.2347051	4.03E-05	74.5	DM	Deafness, autosomal recessive 8/10, 601072 (3)
TMPRSS4	11	118077012	118121890	N	.	N	N	0.108346305	57.8862071	1.20E-08	88.7	DM	.
TMPRSS5	11	113687550	113706373	N	.	N	N	.	.	2.58E-08	87.9	DM	.
TMPRSS7	3	112034843	112081269	N	.	N	N	1.549480736	97.23910401	6.09E-15	96.8	.	.
TMPRSS9	19	2389771	2426239	N	.	N	N	1.806316354	98.19991897	1.77E-18	98.3	.	.
TMSB10	2	84905625	84906675	N	.	N	N	0.120181475	58.72547317	0.124315434	41.9	.	.
TMSB15A	X	102513676	102516784	N	.	N	N	0.112678313	58.18139723	0.482094888	30.5	.	.
TMSB15B	X	103918896	103966712	N	.	N	N	0.135187809	59.83677722	0.48187122	30.5	.	.
TMSB4Y	Y	13703567	13706024	N	.	N	N	.	.	0.334409877	34.8	.	.
TMTC1	12	29500840	29784759	N	.	N	N	0.096362593	56.8501476	3.06E-07	84.5	.	.
TMTC2	12	82686880	83134870	N	.	N	N	-0.455186963	22.07559183	0.863100806	19.4	.	.
TMTC4	13	100603927	100675093	N	.	N	N	-0.846318438	10.64999711	3.91E-06	80	.	.
TMUB1	7	151081080	151083546	N	.	N	Y	0.051847216	53.50465937	0.314893201	35.3	.	.
TMUB2	17	44186970	44191731	N	.	N	N	-0.350445024	26.76390577	0.001301139	63.7	.	.
TMX1	14	51240162	51257546	N	.	N	N	-0.656313373	15.18203392	0.00332854	59.9	.	.
TMX2	11	57712600	57740973	N	.	N	N	0.139164133	60.1377554	0.429913785	32	.	.
TMX2-CTNND1	11	57712605	57791586	N	.	N	N	.	.	.	.	.	.
TMX3	18	68673688	68715298	N	.	N	N	0.09510276	56.80384326	0.191322508	38.9	.	.
TMX4	20	7977348	8019829	N	.	N	N	0.099735608	57.19164207	0.010662181	54.7	.	.
TNC	9	115019578	115118257	N	.	N	Y	0.97893651	92.47554552	1.45E-05	77.1	DM	Deafness, autosomal dominant 56, 615629 (3)
TNF	6	31575567	31578336	N	.	N	Y	-0.047605945	46.02072119	0.27282919	36.4	DFP	{Malaria, cerebral, susceptibility to}, 611162 (3); {Septic shock, susceptibility to} (3); {Asthma, susceptibility to}, 600807 (3); {Dementia, vascular, susceptibility to} (3); {Migraine without aura, susceptibility to}, 157300 (3)
TNFAIP1	17	28335602	28347009	N	.	N	Y	-0.050324612	45.75447126	0.007361605	56.4	.	.
TNFAIP2	14	103123442	103137439	N	.	N	N	-0.245402639	32.7487411	0.002678208	60.8	FP	.
TNFAIP6	2	151357592	151380048	N	.	N	Y	0.530283168	81.66927129	4.02E-06	80	.	.
TNFAIP8	5	119268692	119399688	N	.	N	N	-0.042016662	46.43167217	0.239737017	37.4	DFP	.
TNFAIP8L1	19	4639518	4655568	N	.	N	N	.	.	0.463548117	31.1	.	.
TNFAIP8L2	1	151156629	151159749	N	.	N	Y	-0.047605945	46.02072119	0.504728365	29.8	.	.
TNFAIP8L3	15	51056598	51105276	N	.	N	N	0.592221803	83.88030329	2.33E-06	81	.	.
TNFRSF10A	8	23190452	23225126	N	.	N	N	0.458269625	78.73473404	3.93E-13	95.6	DFP	.
TNFRSF10B	8	23020133	23069179	N	.	N	Y	0.55676724	82.68796666	9.80E-07	82.6	DM	Squamous cell carcinoma, head and neck, 275355 (3)
TNFRSF10C	8	23084355	23117437	N	.	N	N	0.329610306	72.28106731	1.32E-07	85.8	.	.
TNFRSF10D	8	23135588	23164030	N	.	N	N	2.178962948	98.83660358	3.28E-05	75	.	.
TNFRSF11A	18	62325287	62391292	N	.	N	Y	-0.036123783	46.87156335	0.879917354	18.6	DM	Osteolysis, familial expansile, 174810 (3); {Paget disease of bone 2, early-onset}, 602080 (3); Osteopetrosis, autosomal recessive 7, 612301 (3)
TNFRSF12A	16	3018445	3022383	N	.	N	Y	0.306952505	70.86878509	0.036421307	48.8	.	.
TNFRSF13B	17	16929816	16972118	N	.	N	Y	0.902877564	91.13850784	6.72E-13	95.4	DM	Immunoglobulin A deficiency 2, 609529 (3); Immunodeficiency, common variable, 2, 240500 (3)
TNFRSF13C	22	41922023	41926818	N	.	N	Y	0.145560638	60.65289113	0.641054688	26.3	DM	Immunodeficiency, common variable, 4, 613494 (3)
TNFRSF14	1	2555639	2565382	N	.	N	Y	-0.033404934	47.05678069	0.819999054	21	DP	.
TNFRSF17	16	11965107	11968068	N	.	N	Y	0.364256447	74.10430052	0.003104419	60.2	.	.
TNFRSF18	1	1203508	1206691	N	Viable	N	Y	1.08568913	93.79521908	8.37E-07	82.8	.	.
TNFRSF19	13	23570370	23676104	N	.	N	Y	-0.186183329	36.3952075	0.019882513	51.7	.	.
TNFRSF1A	12	6328757	6342114	N	.	N	Y	0.00315321	49.71927997	0.985476047	10.9	DM	Periodic fever, familial, 142680 (3); {Multiple sclerosis, susceptibility to, 5}, 614810 (3)
TNFRSF1B	1	12167003	12209228	N	.	N	Y	0.249946566	67.45384037	0.778880984	22.3	DFP	.
TNFRSF21	6	47231532	47309905	N	.	N	Y	-0.760248704	12.39219772	0.656653056	25.9	.	.
TNFRSF25	1	6461151	6466195	N	.	N	Y	-0.11785159	40.91566823	0.448738853	31.4	DP	.
TNFRSF4	1	1211326	1214138	N	.	N	Y	0.65129239	85.65144412	0.00720933	56.5	DP	?Immunodeficiency 16, 615593 (3)
TNFRSF6B	20	63696668	63698684	N	.	N	N	0.766858833	88.48179661	4.83E-05	74	DM	.
TNFRSF8	1	12063377	12144207	N	.	N	Y	0.000585754	49.48197025	0.845965387	20.1	.	.
TNFSF10	3	172505508	172523507	N	.	N	Y	0.213237933	65.26017248	0.405364744	32.6	DFP	.
TNFSF11	13	42562736	42608013	N	.	N	Y	-0.007220243	48.88580193	0.130191547	41.6	DM	Osteopetrosis, autosomal recessive 2, 259710 (3)
TNFSF12	17	7548891	7557890	N	.	N	Y	-0.283071606	30.49140476	0.997954015	7	DM	.
TNFSF12-TNFSF13	17	7549099	7561601	N	.	N	N	-0.053195214	45.56346588	0.997954015	7	.	.
TNFSF13	17	7558292	7561608	N	.	N	Y	0.278852726	69.23076923	0.877768013	18.7	DP	.
TNFSF13B	13	108251240	108308484	N	.	N	Y	-0.245556279	32.71401285	0.954794121	14.3	DFP	.
TNFSF14	19	6661253	6670588	N	.	N	Y	0.296728366	70.30734503	0.813514843	21.2	DFP	.
TNFSF15	9	114784635	114806126	N	.	N	Y	-0.000674037	49.38936158	0.364139466	33.8	DFP	.
TNFSF18	1	173039960	173050963	N	.	N	N	0.23383407	66.45250912	0.000468356	67.2	DM?	.
TNFSF4	1	173183734	173207313	N	.	N	Y	-0.034513598	46.96996006	0.125230007	41.8	DFP	{Myocardial infarction, susceptibility to}, 608446 (3)
TNFSF8	9	114893343	114930595	N	.	N	Y	0.044344174	52.90849106	0.852776651	19.8	DM	.
TNFSF9	19	6530999	6535928	N	.	N	Y	0.385809542	75.19824044	0.096826856	43.4	.	.
TNIK	3	171061339	171460408	N	.	N	Y	-1.563171534	2.980841581	0.997185846	7.4	.	.
TNIP2	4	2741648	2756376	N	.	N	Y	0.273412356	68.86612259	2.97E-06	80.6	.	.
TNIP3	4	121131408	121227466	N	.	N	N	0.200145052	64.3919662	0.324695186	35	.	.
TNK1	17	7380534	7389774	N	.	N	Y	0.685278874	86.54280257	8.55E-05	72.3	.	.
TNK2	3	195863364	195911945	N	.	N	N	0.553729211	82.56641778	1.21E-10	92.8	.	.
TNKS	8	9555914	9782346	N	.	N	Y	-3.252272376	0.480407478	0.777115954	22.4	DM?	.
TNKS1BP1	11	57299638	57324952	N	.	N	N	0.733381531	87.6656827	0.02971088	49.7	.	.
TNMD	X	100584802	100599885	N	.	N	Y	0.058393523	53.97927881	0.816440949	21.1	.	.
TNN	1	175067858	175148066	N	.	N	N	1.052025286	93.3842681	5.19E-15	96.8	.	.
TNNC1	3	52451102	52454070	N	.	N	N	-0.232464529	33.55327893	0.510486368	29.7	DM	Cardiomyopathy, dilated, 1Z, 611879 (3); Cardiomyopathy, hypertrophic, 13, 613243 (3)
TNNC2	20	45823214	45833745	N	.	N	N	-0.148973548	38.82039706	0.547150267	28.7	.	.
TNNI1	1	201403768	201429866	N	.	N	N	0.224417956	65.88528101	0.120125045	42.1	.	.
TNNI2	11	1838989	1841680	N	.	N	N	-0.357145068	26.46871563	0.086152741	44	DM	Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3)
TNNI3K	1	74235401	74544428	N	.	N	N	-0.228987981	33.77901256	1.80E-38	99.9	FTV	?Cardiac conduction disease with or without dilated cardiomyopathy, 616117 (3)
TNNT1	19	55132794	55149354	N	.	N	N	0.031251654	51.92452393	3.23E-06	80.4	DM	Nemaline myopathy 5, Amish type, 605355 (3)
TNP1	2	216859458	216860064	N	.	N	Y	0.129597795	59.37952191	0.222164609	37.9	DM?	.
TNP2	16	11267748	11269533	N	.	N	Y	1.279839116	95.6358164	0.04397134	47.7	.	.
TNPO1	5	72816312	72916733	N	.	N	N	-1.022065824	7.588122938	0.999998701	1.8	.	.
TNPO2	19	12699194	12724011	N	.	N	N	-0.921648201	9.191410546	0.999885944	3.9	DM?	.
TNR	1	175315194	175743770	N	.	N	Y	-0.225825483	33.9642299	0.987762732	10.5	DM	.
TNRC18	7	5306790	5425414	N	.	N	N	.	.	0.999973966	3	.	.
TNRC6B	22	40044817	40335808	N	.	N	N	-1.586263975	2.888232911	0.999999803	1.2	.	.
TNRC6C	17	78004168	78108835	N	.	N	N	-1.497152949	3.374428431	0.999997824	2	.	.
TNS1	2	217799789	218002995	N	.	N	Y	1.30026116	95.79788158	0.924939889	16.4	.	.
TNS2	12	53046969	53064372	N	.	N	Y	.	.	.	.	.	.
TNS4	17	40475828	40501597	N	.	N	N	-0.071573715	44.31324883	0.000130733	71.1	.	.
TNXB	6	32041154	32115334	N	.	N	Y	.	.	0.774153752	22.5	DM	Ehlers-Danlos syndrome due to tenascin X deficiency, 606408 (3); Vesicoureteral reflux 8, 615963 (3)
TOB1	17	50862223	50867978	N	.	N	Y	-0.081293491	43.49713492	0.798204384	21.7	.	.
TOB2	22	41433492	41447023	N	.	N	Y	0.177635945	63.02598831	0.703190337	24.5	.	.
TOE1	1	45339670	45343975	N	.	N	N	0.55676724	82.68796666	6.59E-09	89.3	.	.
TOLLIP	11	1274371	1309654	N	.	N	Y	0.707640477	87.06951438	0.522906268	29.4	.	.
TOM1	22	35299275	35347994	N	.	N	N	0.056782277	53.85194189	6.78E-06	79	.	.
TOM1L1	17	54899387	54961956	N	.	N	N	-0.592458629	16.93581062	0.002934147	60.4	.	.
TOM1L2	17	17843511	17972422	N	.	N	N	-0.555747173	18.05869074	0.414475508	32.4	.	.
TOMM20	1	235109336	235128936	N	.	N	N	-0.089905929	42.77941772	0.577780758	28	.	.
TOMM20L	14	58395916	58408701	N	Viable	N	Y	0.169983117	62.51085258	0.000787655	65.6	.	.
TOMM22	22	38681948	38685421	N	.	N	N	-0.020464318	47.86710656	0.78583296	22.1	.	.
TOMM34	20	44942130	44960486	N	.	N	Y	-0.290574674	29.99363315	0.721089133	24	.	.
TOMM40	19	44890569	44903689	N	.	N	N	-0.159194457	38.09110378	0.963682324	13.6	DP	.
TOMM40L	1	161225939	161230744	N	.	N	N	0.023748636	51.34571974	0.744035828	23.3	.	.
TOMM6	6	41787662	41789898	N	.	N	N	.	.	.	.	.	.
TOMM7	7	22812628	22822852	N	.	N	N	0.25810805	67.9284598	0.054735298	46.5	.	.
TOMM70A	3	100363431	100401398	N	.	N	N	-0.510881113	19.77773919	0.998235566	6.7	.	.
TONSL	8	144428775	144444444	N	.	N	N	1.060308675	93.47687677	6.06E-05	73.4	.	.
TOP1MT	8	143304384	143359979	N	.	N	Y	1.206206162	95.06280025	1.63E-19	98.5	DP	.
TOP2A	17	40388516	40417950	N	.	N	N	-0.862281415	10.34323088	0.996224029	7.9	.	DNA topoisomerase II, resistance to inhibition of, by amsacrine (3)
TOP3B	22	21957025	21982816	N	.	N	Y	-0.790114004	11.74972507	0.114528013	42.4	DM?	.
TOPAZ1	3	44241886	44332098	N	.	N	N	.	.	.	.	.	.
TOPORS	9	32540544	32552553	N	.	N	N	-1.058334419	7.101927418	0.975842587	12.3	DM	Retinitis pigmentosa 31, 609923 (3)
TOR1AIP2	1	179839967	179877803	N	.	N	N	-0.114024046	41.20507032	4.04E-05	74.5	.	.
TOR1B	9	129803153	129811281	N	.	N	N	-0.397377504	24.54708572	0.743694124	23.3	.	.
TOR2A	9	127731524	127735317	N	.	N	N	0.019116005	51.00422527	0.056747579	46.3	.	.
TOR3A	1	179081377	179098023	N	.	N	N	0.48445544	79.89234242	2.47E-08	87.9	.	.
TOR4A	9	137277749	137282641	N	.	N	N	.	.	0.215534136	38.3	.	.
TOX	8	58805418	59119208	N	.	N	Y	0.607376276	84.3780749	0.892971025	18.1	DP	.
TOX2	20	43914864	44069616	N	.	N	N	0.006175108	49.97395381	0.674075157	25.4	.	.
TOX4	14	21476597	21499175	N	.	N	N	0.000434265	49.47039417	0.81196579	21.2	.	.
TP53AIP1	11	128934731	128943399	N	.	N	N	0.654972172	85.79035712	9.47E-07	82.6	DP	.
TP53BP1	15	43403061	43510728	N	.	N	Y	-0.696656943	14.04178966	0.999855964	4.1	DP	.
TP53I11	11	44885903	44951306	N	.	N	N	-0.246513473	32.65613243	0.067174271	45.3	.	.
TP53I13	17	29566052	29573157	N	.	N	N	0.960037204	92.19771951	0.062734293	45.7	.	.
TP53I3	2	24077433	24085861	N	.	N	N	0.184182333	63.46587949	3.76E-07	84.2	DFP	.
TP53INP1	8	94925972	94949411	N	.	N	Y	-0.076661182	43.91387394	6.86E-05	73	.	.
TP53INP2	20	34704290	34713439	N	.	N	N	0.38485322	75.1519361	0.34145439	34.5	.	.
TP53RK	20	46684365	46689779	N	.	N	N	0.465476352	79.10516872	0.349270746	34.2	FTV	.
TP53TG3	16	32673528	32676732	N	.	N	N	.	.	.	.	.	.
TP53TG3B	16	33360274	33363478	N	.	N	N	.	.	.	.	.	.
TP53TG3C	16	33193659	33306938	N	.	N	N	.	.	.	.	.	.
TP53TG3D	16	32252719	32255922	N	.	N	N	.	.	0.641056796	26.3	.	.
TP53TG5	20	45372563	45407889	N	.	N	N	0.860578167	90.38027435	3.30E-06	80.4	.	.
TPBG	6	82363206	82370828	N	.	N	Y	-0.159998829	38.04479944	0.12323426	42	.	.
TPBGL	11	75240905	75243697	N	.	N	N	.	.	.	.	.	.
TPCN1	12	113221050	113298585	N	.	N	Y	-1.438320869	3.739075071	0.003858916	59.2	.	.
TPCN2	11	69048897	69090604	N	Viable	N	Y	0.585173525	83.68929791	2.06E-06	81.3	DP	[Skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3)
TPD52	8	80034745	80231232	N	.	N	N	0.112828307	58.21033744	0.005112083	58	.	.
TPD52L1	6	125119049	125264407	N	.	N	N	0.110914976	58.05984835	0.008420056	55.7	.	.
TPD52L2	20	63865228	63891545	N	.	N	Y	-0.039146033	46.66319384	0.595604698	27.5	.	.
TPD52L3	9	6328375	6331900	N	.	N	N	0.339834225	72.85987151	0.163388307	40	.	.
TPGS1	19	507497	519654	N	.	N	N	.	.	0.003467495	59.8	.	.
TPGS2	18	36777647	36829216	N	Viable	N	Y	-0.26232271	31.69531747	0.000133032	71.1	.	.
TPH1	11	18017564	18042426	N	.	N	Y	-0.138446759	39.5439023	2.67E-05	75.5	DM	.
TPK1	7	144451941	144836395	N	.	N	N	-0.334635847	27.50477513	0.028254579	50	DM	Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3)
TPM2	9	35681992	35691020	N	.	N	N	-0.546637823	18.31915263	4.59E-05	74.1	DM	Arthrogryposis multiplex congenita, distal, type 1, 108120 (3); Arthrogryposis, distal, type 2B, 601680 (3); Nemaline myopathy 4, autosomal dominant, 609285 (3); CAP myopathy 2, 609285 (3)
TPM4	19	16067021	16103005	N	.	N	N	-0.122636306	40.5799618	0.109402017	42.6	.	.
TPMT	6	18128311	18155074	N	.	N	Y	0.439288148	77.85495167	7.57E-05	72.7	DM	6-mercaptopurine sensitivity, 610460 (3)
TPO	2	1374223	1543711	N	.	N	N	-0.096651892	42.30479829	1.36E-07	85.7	DM	Thrombocythemia 1, 187950 (3)
TPP1	11	6612763	6619461	N	.	N	Y	0.634669724	85.19418881	0.025756063	50.4	DM	Ceroid lipofuscinosis, neuronal, 2, 204500 (3); Spinocerebellar ataxia, autosomal recessive 7, 609270 (3)
TPP2	13	102597003	102679958	N	.	N	Y	-1.226289002	5.342362679	0.999863189	4	FP	.
TPPP	5	659862	693395	N	Viable	N	Y	-0.066287483	44.66631938	0.447860539	31.4	DM?	.
TPPP2	14	21024109	21036276	N	.	N	N	0.854842552	90.28766568	0.017186617	52.4	.	.
TPPP3	16	67389809	67393535	N	.	N	N	0.073399639	55.17740348	0.311517277	35.4	.	.
TPR	1	186311652	186375693	N	.	N	N	-2.68415692	0.810325867	1	0.3	.	.
TPRA1	3	127573069	127598251	N	.	N	N	0.559487267	82.75163512	0.05835802	46.2	.	.
TPRG1	3	188947214	189325304	N	.	N	N	-0.065330609	44.75314001	4.88E-05	74	.	.
TPRG1L	1	3625002	3630127	N	.	N	N	-0.075704275	43.9775424	0.002845285	60.6	.	.
TPRKB	2	73729104	73737400	N	.	N	N	0.072442927	55.09058286	0.020618027	51.5	.	.
TPRN	9	137191617	137204193	N	Viable	N	Y	.	.	.	.	DM	Deafness, autosomal recessive 79, 613307 (3)
TPRX1	19	47801243	47819051	N	.	N	N	0.652248451	85.69774845	0.000613268	66.4	.	.
TPRXL	3	13937256	14082811	N	.	N	N	.	.	.	.	.	.
TPSAB1	16	1240696	1242554	N	.	N	N	1.39909238	96.37668577	4.56E-05	74.2	.	.
TPSB2	16	1227272	1230184	N	.	N	Y	.	.	2.35E-08	88	FP	.
TPSD1	16	1256059	1258998	N	.	N	N	2.057911328	98.65138624	8.52E-09	89.1	.	.
TPSG1	16	1221651	1225257	N	.	N	N	1.155282343	94.55924061	4.09E-06	79.9	.	.
TPST1	7	66205199	66420543	N	.	N	Y	-0.672277284	14.70741448	0.011481102	54.3	.	.
TPST2	22	26521983	26596717	N	.	N	Y	-0.515512873	19.61567402	0.599488923	27.5	.	.
TPTE	21	10521553	10606140	N	.	N	N	4.476720666	99.8205707	5.11E-31	99.7	FTV	.
TPTE2	13	19422877	19536762	N	.	N	N	1.341119693	96.05834346	3.69E-08	87.4	.	.
TRA2A	7	23504780	23532041	N	.	N	N	-0.349641992	26.83336227	0.212371727	38.4	DM?	.
TRABD	22	50185915	50199598	N	.	N	N	-0.499549597	20.20605429	0.931187269	16.1	.	.
TRABD2A	2	84821650	84907008	N	.	N	N	0.697415576	86.86114487	7.94E-10	91.3	.	.
TRABD2B	1	47760528	47996895	N	.	N	N	.	.	0.370916244	33.6	.	.
TRADD	16	67154180	67160298	N	.	N	Y	-0.094538075	42.4726515	0.680264799	25.2	DM?	.
TRAF1	9	120902393	120929173	N	.	N	Y	0.400964456	75.88701742	0.056744289	46.3	.	.
TRAF3IP2	6	111556454	111606278	N	.	N	Y	0.570816875	83.10470568	7.11E-05	72.9	DFP	{Psoriasis susceptibility 13}, 614070 (3); ?Candidiasis, familial, 8, 615527 (3)
TRAF3IP3	1	209756032	209782320	N	.	N	Y	0.123352267	59.00329918	1.38E-06	82.1	.	.
TRAF5	1	211326615	211374946	N	.	N	Y	0.519251431	81.23516814	8.83E-06	78.4	.	.
TRAF7	16	2155698	2178129	N	.	N	N	-1.198328825	5.602824564	0.460647228	31.1	DM?	.
TRAFD1	12	112125501	112153609	N	.	N	Y	-0.215238485	34.57776234	1.83E-05	76.5	.	.
TRAK1	3	42013802	42225889	N	.	N	N	-0.465126155	21.65885281	9.71E-05	72	.	.
TRAK2	2	201377207	201451611	N	.	N	N	-0.301298369	29.38010071	6.92E-10	91.4	DP	.
TRAM1	8	70573442	70608387	N	.	N	N	-0.40679489	24.07246628	0.676696974	25.3	.	.
TRAM1L1	4	117083554	117085576	N	.	N	N	-0.511838334	19.74301094	0.030231447	49.6	.	.
TRANK1	3	36826820	36945057	N	.	N	N	-3.438164245	0.405162933	2.79E-10	92.2	.	.
TRAP1	16	3651639	3717597	N	.	N	N	1.021655727	93.06013776	1.62E-17	98	.	.
TRAPPC1	17	7930345	7932123	N	.	N	N	-0.08048891	43.56080338	0.227722385	37.8	.	.
TRAPPC10	21	44012319	44106552	N	Viable	N	Y	-0.849862609	10.54581235	0.999998954	1.7	.	.
TRAPPC11	4	183659267	183713594	N	.	N	N	-1.318115242	4.589917231	0.000208772	69.7	DM	Muscular dystrophy, limb-girdle, type 2S, 615356 (3)
TRAPPC12	2	3379675	3485094	N	.	N	N	-0.46269015	21.76303756	1.34E-09	90.9	.	.
TRAPPC13	5	65624716	65666233	N	.	N	N	-0.084164209	43.24824912	0.765500289	22.7	.	.
TRAPPC2	X	13712244	13734635	N	.	N	N	.	.	0.624929856	26.8	DM	Spondyloepiphyseal dysplasia tarda, 313400 (3)
TRAPPC2B	19	57363511	57365353	N	.	N	N	.	.	.	.	.	.
TRAPPC2L	16	88856220	88862686	N	.	N	N	0.187858986	63.66846096	3.55E-05	74.8	.	.
TRAPPC3	1	36136570	36156053	N	.	N	N	0.055523327	53.73618105	0.81053922	21.3	.	.
TRAPPC3L	6	116494989	116545610	N	.	N	N	.	.	.	.	.	.
TRAPPC4	11	119018432	119025454	N	.	N	N	-0.31116943	28.88232911	0.001323696	63.6	.	.
TRAPPC5	19	7680843	7687703	N	.	N	N	0.297536667	70.34207328	0.577704359	28	.	.
TRAPPC6A	19	45162928	45178237	N	.	N	N	0.695356886	86.79168837	0.000705278	65.9	.	.
TRAPPC6B	14	39147811	39170532	N	.	N	N	-0.230550154	33.7153441	0.021980278	51.2	.	.
TRAPPC8	18	31829173	31953136	N	.	N	N	-1.284156203	4.815650865	0.999999744	1.3	.	.
TRAPPC9	8	139730343	140458579	N	.	N	N	-0.469903978	21.43311918	5.76E-06	79.3	DM	Mental retardation, autosomal recessive 13, 613192 (3)
TRAT1	3	108822698	108855005	N	.	N	Y	0.620322894	84.75429762	0.486401717	30.4	.	.
TRDMT1	10	17142254	17202054	N	.	N	Y	-0.023988294	47.67610117	1.67E-06	81.7	.	.
TRDN	6	123216339	123637093	N	.	N	Y	.	.	1.82E-10	92.6	DM	Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 (3)
TREH	11	118657316	118679690	N	.	N	Y	.	.	1.40E-14	96.6	FP	Trehalase deficiency, 612119 (1)
TREM1	6	41267926	41286719	N	.	N	Y	0.228244069	66.13416681	0.000343966	68.2	.	.
TREM2	6	41158506	41163186	N	.	N	Y	0.965628686	92.24402385	2.35E-08	88	DM	Nasu-Hakola disease, 221770 (3)
TREML1	6	41149342	41154337	N	Viable	N	Y	0.420604183	76.84204434	1.00E-05	78	.	.
TREML2	6	41190277	41201194	N	.	N	N	1.391588024	96.3535336	1.29E-07	85.8	.	.
TREML4	6	41228324	41238882	N	.	N	N	0.455250847	78.5495167	2.78E-05	75.4	.	.
TRERF1	6	42224931	42452051	N	.	N	N	-0.090912154	42.73311339	0.999595777	4.9	DP	.
TREX1	3	48465046	48467645	N	.	N	Y	-0.552071566	18.15129942	0.093340719	43.6	DM	Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 (3); Chilblain lupus, 610448 (3); Vasculopathy, retinal, with cerebral leukodystrophy, 192315 (3); {Systemic lupus erythematosus, susceptibility to}, 152700 (3)
TREX2	X	153444720	153470587	N	.	N	Y	.	.	0.126734816	41.7	DM?	.
TRH	3	129974305	129977938	N	.	N	Y	0.34365998	73.06824101	0.010806915	54.6	.	Thyrotropin-releasing hormone deficiency, 275120 (1)
TRHDE	12	72087266	72670757	N	.	N	N	-1.483488443	3.449672976	0.080996509	44.4	.	.
TRHR	8	109086621	109119584	N	.	N	Y	-0.2707828	31.23227412	0.265021781	36.6	DM	Thyrotropin-releasing hormone resistance, generalized (3)
TRIAP1	12	120443961	120446412	N	.	N	N	0.167113525	62.29669503	0.590216384	27.7	.	.
TRIB1	8	125430321	125438405	N	.	N	Y	-0.23518181	33.35069746	0.606587657	27.3	DP	.
TRIB2	2	12716889	12742734	N	.	N	Y	-0.316758145	28.47137813	0.926787339	16.3	.	.
TRIB3	20	362835	397559	N	.	N	Y	0.882280274	90.76807316	2.12E-10	92.4	DFP	.
TRIL	7	28953358	28958292	N	.	N	N	.	.	.	.	FTV	.
TRIM10	6	30151945	30160934	N	.	N	N	0.605613802	84.32598252	9.95E-06	78.1	.	.
TRIM11	1	228393673	228406840	N	.	N	N	-0.312929834	28.70868785	0.547146513	28.7	.	.
TRIM13	13	49995888	50020481	N	.	N	N	-0.267911686	31.37118713	0.505141848	29.8	.	.
TRIM14	9	98069275	98119212	N	.	N	N	-0.064373744	44.83996064	0.010213118	54.8	.	.
TRIM15	6	30163206	30172696	N	.	N	N	0.528517954	81.59981478	2.18E-11	93.8	.	.
TRIM16	17	15627960	15684311	N	.	N	N	0.733169122	87.65989466	0.000114779	71.4	.	.
TRIM16L	17	18697998	18736118	N	.	N	N	0.991964346	92.67233895	0.016879392	52.5	.	.
TRIM17	1	228407940	228416861	N	.	N	N	-0.204865148	35.18550674	2.40E-05	75.8	DM?	.
TRIM2	4	153152342	153339320	N	.	N	N	-1.503279718	3.351276263	0.894263856	18	DM	Charcot-Marie-Tooth disease, type 2R, 615490 (3)
TRIM21	11	4384897	4393696	N	.	N	Y	0.01735382	50.85373618	0.093051815	43.6	DP	.
TRIM22	11	5689689	5737089	N	.	N	N	1.164699834	94.68657753	3.16E-12	94.8	DP	.
TRIM23	5	65589680	65625975	N	.	N	N	-1.076505966	6.841465532	0.066967184	45.3	.	.
TRIM24	7	138460334	138589993	N	.	N	Y	-0.574430068	17.52040285	0.999995048	2.2	.	.
TRIM25	17	56887909	56914038	N	.	N	Y	-0.049216095	45.88759623	0.135290442	41.3	.	.
TRIM26	6	30184455	30213427	N	.	N	N	-0.031491274	47.21884586	0.829653548	20.6	.	.
TRIM27	6	28903002	28923989	N	.	N	Y	-0.460273767	21.90195057	0.878751858	18.7	.	.
TRIM29	11	120111275	120185529	N	Viable	N	Y	0.305489774	70.82248075	9.17E-05	72.1	.	.
TRIM3	11	6448613	6474459	N	.	N	Y	-1.100778721	6.563639521	0.952560875	14.5	.	.
TRIM31	6	30102897	30113106	N	.	N	N	1.082965441	93.77785495	0.016388134	52.7	.	.
TRIM32	9	116687302	116701300	N	.	N	Y	-0.863383269	10.30850263	0.097317644	43.3	DM	Muscular dystrophy, limb-girdle, type 2H, 254110 (3); ?Bardet-Biedl syndrome 11, 615988 (3)
TRIM34	11	5619764	5644398	N	.	N	N	0.35035623	73.38079528	0.00020889	69.7	.	.
TRIM35	8	27284887	27311319	N	.	N	N	0.264147024	68.34519882	0.000940308	65	.	.
TRIM36	5	115124762	115180546	N	.	N	N	-0.258192801	31.99050761	0.00067573	66.1	.	.
TRIM37	17	58982638	59106921	N	.	N	N	-1.32016144	4.560977021	0.172389368	39.6	DM	Mulibrey nanism, 253250 (3)
TRIM38	6	25962802	25991226	N	.	N	N	0.347486221	73.24188227	4.75E-06	79.6	.	.
TRIM39	6	30326479	30343729	N	.	N	N	-0.209801572	34.94819702	0.999421098	5.3	.	.
TRIM39-RPP21	6	30328907	30346858	N	.	N	N	.	.	.	.	.	.
TRIM4	7	99876958	99919600	N	.	N	N	-0.032448102	47.13781328	1.68E-06	81.6	.	.
TRIM40	6	30136108	30148735	N	.	N	N	0.508729649	80.80685304	1.53E-07	85.6	.	.
TRIM41	5	181222499	181235809	N	.	N	N	0.020375797	51.11419807	0.965388636	13.5	.	.
TRIM42	3	140678039	140701150	N	.	N	N	0.689261116	86.63541124	5.58E-15	96.8	.	.
TRIM43	2	95592018	95599778	N	.	N	N	.	.	0.484034993	30.4	.	.
TRIM44	11	35662805	35818007	N	.	N	N	-0.318672489	28.34982925	0.163653747	40	.	.
TRIM46	1	155173787	155184971	N	.	N	N	-0.369931993	25.87833536	0.998652125	6.3	.	.
TRIM47	17	75874161	75878575	N	.	N	N	-0.088644586	42.93569485	0.321925208	35.1	.	.
TRIM48	11	55262182	55271119	N	.	N	N	1.453535053	96.72975632	1.77E-14	96.6	.	.
TRIM49	11	89797655	89808575	N	.	N	N	0.890592391	90.9532905	0.645523396	26.2	.	.
TRIM49B	11	49027501	49038451	N	.	N	N	0.383238758	75.08826764	7.56E-05	72.7	.	.
TRIM49C	11	90031106	90042025	N	.	N	N	.	.	0.161108014	40.1	.	.
TRIM49D1	11	89911111	89921767	N	.	N	N	.	.	.	.	.	.
TRIM49D2	11	89924064	89933063	N	.	N	N	.	.	.	.	.	.
TRIM5	11	5663557	5938619	N	.	N	N	0.492109495	80.16438039	4.37E-08	87.2	DFP	.
TRIM50	7	73312539	73328082	N	.	N	Y	0.531387625	81.71557562	2.73E-06	80.7	.	.
TRIM51	11	55883297	55891810	N	.	N	N	.	.	1.05E-05	77.9	.	.
TRIM52	5	181254417	181261139	N	.	N	N	-0.097256408	42.28164612	8.08E-06	78.6	.	.
TRIM54	2	27282392	27307439	N	.	N	Y	0.013526612	50.54118192	8.25E-07	82.9	.	.
TRIM55	8	66126896	66175487	N	.	N	Y	-0.340876394	27.19222087	0.000207996	69.7	.	.
TRIM56	7	101085439	101097967	N	.	N	N	-0.896119509	9.66024194	0.080157922	44.5	.	.
TRIM58	1	247857199	247878205	N	.	N	N	-0.029577629	47.32881866	2.08E-07	85.1	DP	.
TRIM59	3	160432445	160485773	N	.	N	N	0.642023041	85.42571048	0.032110957	49.3	.	.
TRIM6	11	5596109	5612958	N	.	N	N	-0.039799513	46.63425363	3.79E-10	92	.	.
TRIM60	4	165031953	165041744	N	.	N	N	-0.120570168	40.6899346	2.87E-07	84.6	.	.
TRIM61	4	164954446	164977668	N	.	N	N	0.351015356	73.42131157	0.672137879	25.5	.	.
TRIM62	1	33145402	33182059	N	.	N	Y	-0.098061234	42.21218962	0.001611418	62.8	.	.
TRIM63	1	26051304	26068436	N	.	N	Y	0.196468728	64.17780865	4.72E-12	94.7	DM	.
TRIM64	11	89968502	89975228	N	.	N	N	.	.	.	.	.	.
TRIM64B	11	89869282	89876017	N	.	N	N	.	.	.	.	.	.
TRIM64C	11	49053714	49059112	N	.	N	N	.	.	0.012116567	54.2	.	.
TRIM65	17	75880335	75897003	N	Viable	N	Y	.	.	2.48E-09	90.3	.	.
TRIM66	11	8612037	8671866	N	.	N	Y	.	.	.	.	.	.
TRIM67	1	231162112	231221556	N	.	N	N	-0.272543821	31.13387741	0.672039658	25.5	.	.
TRIM68	11	4598672	4608259	N	.	N	N	-0.094233924	42.51895584	2.15E-11	93.9	.	.
TRIM69	15	44728988	44767829	N	.	N	N	-0.142122259	39.27186433	1.96E-10	92.5	.	.
TRIM6-TRIM34	11	5596725	5644398	N	.	N	N	-0.104305182	41.84754298	2.31E-11	93.8	.	.
TRIM7	5	181193924	181205293	N	.	N	N	0.143947707	60.52555421	0.065940078	45.4	.	.
TRIM72	16	31214021	31231537	N	.	N	Y	.	.	0.000530648	66.9	.	.
TRIM73	7	75395063	75410996	N	.	N	N	.	.	.	.	.	.
TRIM74	7	72959485	72969466	N	.	N	N	.	.	0.78033382	22.3	.	.
TRIM77	11	89710299	89717872	N	.	N	N	.	.	.	.	.	.
TRIM8	10	102644496	102658407	N	.	N	N	-0.568991981	17.68825606	0.992012341	9.4	.	.
TRIM9	14	50975262	51096061	N	.	N	Y	-1.261230767	5.035596458	0.987914428	10.4	.	.
TRIML1	4	188139419	188147743	N	.	N	N	0.044646769	52.94321931	9.17E-11	93	.	.
TRIML2	4	188091273	188109603	N	.	N	N	1.02389186	93.08907796	8.26E-10	91.2	.	.
TRIP10	19	6737925	6751526	N	.	N	Y	-0.484391928	20.79064652	0.354472308	34	.	.
TRIP13	5	892643	919357	Y	Viable	N	Y	-0.564360358	17.79244082	0.968635141	13.2	.	.
TRIP4	15	64387748	64455303	N	.	N	N	-0.247164145	32.62140418	3.04E-07	84.5	.	.
TRIP6	7	100867138	100873454	N	.	N	N	0.133725635	59.73838051	0.659398351	25.8	.	.
TRIQK	8	92883530	93017673	N	.	N	N	.	.	.	.	.	.
TRIT1	1	39841022	39883511	N	.	N	N	0.227437499	66.09943856	9.43E-10	91.2	.	.
TRMT10A	4	99546709	99564032	N	.	N	Y	0.054717474	53.7014528	2.84E-05	75.3	.	Microcephaly, short stature, and impaired glucose metabolism, 616033 (3)
TRMT10B	9	37753803	37778972	N	.	N	N	-0.104759418	41.81281472	8.98E-05	72.2	.	.
TRMT10C	3	101561862	101566446	N	.	N	N	-0.132857585	39.9027609	1.06E-05	77.9	.	.
TRMT11	6	125986430	126039276	N	.	N	N	0.279958701	69.3233779	8.24E-06	78.6	.	.
TRMT112	11	64316460	64318084	N	.	N	N	-0.10299811	41.92278752	0.141017363	41	.	.
TRMT12	8	124450820	124462150	N	.	N	N	-0.084968981	43.20194478	0.942425529	15.4	.	.
TRMT13	1	100133150	100150497	N	.	N	N	-0.599004688	16.73901719	2.93E-05	75.3	.	.
TRMT1L	1	185118098	185157072	N	.	N	N	-0.382218725	25.31689529	0.939618901	15.6	.	.
TRMT2A	22	20111866	20117392	N	Viable	N	Y	0.103061106	57.42895179	1.31E-05	77.3	.	.
TRMT2B	X	101009346	101052116	N	.	N	N	-0.277328762	30.80974706	0.000100905	71.8	.	.
TRMT44	4	8436140	8493531	N	.	N	N	1.164699834	94.68657753	1.48E-13	96	DM?	.
TRMT5	14	60971451	60981358	N	.	N	N	0.75935546	88.29657927	0.96526793	13.5	.	Combined oxidative phosphorylation deficiency 26, 616539 (3)
TRMT6	20	5937235	5950558	N	.	N	N	-0.871037997	10.15801354	0.000492532	67.1	.	.
TRMT61A	14	103529184	103537073	N	.	N	N	-0.142274465	39.26028824	0.005702065	57.5	.	.
TRMT61B	2	28849821	28870301	N	.	N	N	0.041776336	52.69433351	4.01E-06	80	.	.
TRMU	22	46330875	46357340	N	.	N	N	0.047365707	53.22683336	5.76E-09	89.5	DM	{Deafness, mitochondrial, modifier of}, 580000 (3); Liver failure, transient infantile, 613070 (3)
TRNAU1AP	1	28553085	28578545	N	.	N	N	-0.500661427	20.13080975	0.882819952	18.5	.	.
TRNP1	1	26993707	27000898	N	.	N	N	.	.	.	.	.	.
TRNT1	3	3126916	3150879	N	.	N	N	-0.240617998	33.02077907	2.46E-06	80.9	.	Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3)
TROAP	12	49323236	49331731	N	.	N	N	0.40222616	75.9391098	3.02E-07	84.5	DM?	.
TROVE2	1	193059422	193091777	N	.	N	Y	-0.483586384	20.81958673	0.0190449	51.9	DM?	.
TRPA1	8	72019917	72075617	N	.	N	Y	-0.653810709	15.25149042	9.97E-23	99.1	DM	Episodic pain syndrome, familial, 615040 (3)
TRPC1	3	142724074	142807888	N	.	N	Y	-0.860663415	10.36638305	0.784921837	22.1	.	.
TRPC4	13	37636636	37870425	N	.	N	Y	-1.027506248	7.512878393	0.967651076	13.3	DFP	.
TRPC5	X	111774315	112082776	N	Viable	N	Y	-0.589587419	17.08051166	0.993636098	9	DM	.
TRPC6	11	101451564	101872562	N	Viable	N	Y	-1.369966643	4.144238004	0.004564105	58.6	DM	Glomerulosclerosis, focal segmental, 2, 603965 (3)
TRPC7	5	136213320	136365537	N	.	N	Y	-1.398071789	3.935868496	0.002986152	60.3	.	.
TRPM1	15	31001061	31161273	N	Viable	N	Y	0.418998606	76.78995196	1.17E-31	99.7	DM	Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 (3)
TRPM2	21	44350163	44443081	N	.	N	Y	1.54524893	97.21595184	3.37E-25	99.3	DM	.
TRPM3	9	70529063	71446904	N	.	N	Y	-1.705301859	2.4309776	7.74E-06	78.7	DM	.
TRPM4	19	49157741	49211836	N	.	N	Y	-0.563628752	17.80980494	6.36E-19	98.4	DM	Progressive familial heart block, type IB, 604559 (3)
TRPM5	11	2404515	2423045	N	.	N	Y	0.505670648	80.66794004	7.64E-17	97.7	.	.
TRPM8	2	233917398	234019522	N	.	N	Y	-1.234483994	5.261330092	4.74E-15	96.9	.	.
TRPT1	11	64223799	64226254	N	.	N	N	0.317324799	71.58071424	0.008675849	55.5	.	.
TRPV1	17	3565444	3597098	N	.	N	Y	0.980137036	92.49869769	5.64E-14	96.3	DFP	.
TRPV2	17	16415542	16437003	N	.	N	Y	-1.025594024	7.530242519	0.005629157	57.6	.	.
TRPV3	17	3510502	3557995	N	.	N	Y	-0.509475797	19.81825548	8.74E-14	96.1	DM	Olmsted syndrome, 614594 (3); ?Palmoplantar keratoderma, nonepidermolytic, focal 2, 616400 (3)
TRPV4	12	109783085	109833401	N	.	N	Y	-0.937318019	8.907796492	7.32E-06	78.8	DM	Brachyolmia type 3, 113500 (3); Spondylometaphyseal dysplasia, Kozlowski type, 184252 (3); Metatropic dysplasia, 156530 (3); Hereditary motor and sensory neuropathy, type IIc, 606071 (3); Scapuloperoneal spinal muscular atrophy, 181405 (3); [Sodium serum level QTL 1], 613508 (3); Parastremmatic dwarfism, 168400 (3); SED, Maroteaux type, 184095 (3); Spinal muscular atrophy, distal, congenital nonprogressive, 600175 (3); Digital arthropathy-brachydactyly, familial, 606835 (3)
TRPV5	7	142908101	142933808	N	.	N	Y	-0.521759631	19.3783643	4.66E-10	91.8	FP	.
TRPV6	7	142871203	142885762	N	.	N	Y	-0.501162499	20.0960815	0.001413484	63.3	.	.
TRUB1	10	114938193	114977676	N	.	N	N	-0.011852785	48.56745963	0.000523645	66.9	.	.
TSACC	1	156337314	156346995	N	.	N	N	0.389487678	75.3313654	0.069791726	45.1	.	.
TSC22D1	13	44432143	44577147	N	.	N	Y	-1.486907762	3.43230885	0.941151546	15.5	.	.
TSC22D2	3	150408335	150466431	N	.	N	N	0.605613802	84.32598252	0.831881107	20.6	.	.
TSC22D3	X	107713221	107777342	N	.	N	Y	-0.178028729	36.84667477	0.771725905	22.6	.	.
TSC22D4	7	100463359	100479279	N	.	N	N	0.208604733	64.97655843	0.894817347	18	.	.
TSEN15	1	184051677	184074212	N	.	N	N	0.099585278	57.16270186	0.504749058	29.8	.	.
TSEN2	3	12484432	12539623	N	.	N	N	-0.009787637	48.71216068	0.000104861	71.7	DM	Pontocerebellar hypoplasia type 2B, 612389 (3)
TSEN34	19	54189938	54194536	N	.	N	N	-0.26232271	31.69531747	0.396480812	32.8	DM	Pontocerebellar hypoplasia type 2C, 612390 (3)
TSEN54	17	75516060	75524739	N	.	N	N	1.689048175	97.87578862	1.76E-05	76.6	DM	Pontocerebellar hypoplasia type 2A, 277470 (3); Pontocerebellar hypoplasia type 4, 225753 (3); ?Pontocerebellar hypoplasia type 5, 610204 (3)
TSGA10	2	98997261	99154964	N	.	N	N	0.476146347	79.59715228	0.894352624	18	.	.
TSGA10IP	11	65945445	65959963	N	.	N	N	.	.	.	.	.	.
TSGA13	7	130668648	130687432	N	.	N	N	0.032208434	52.02870869	6.10E-09	89.4	FTV	.
TSHB	1	115029824	115034309	N	.	N	Y	0.237511303	66.66087862	0.005758085	57.4	DM	Hypothryoidism, congenital, nongoitrous 4, 275100 (3)
TSKS	19	49739753	49763330	N	.	N	N	0.05597706	53.77669734	0.980813772	11.6	.	.
TSKU	11	76782251	76798154	N	.	N	Y	0.658942534	85.88296579	0.729712731	23.8	.	.
TSLP	5	111070062	111078024	N	Viable	N	Y	-0.442551286	22.56757539	0.044788174	47.6	DFP	.
TSN	2	121737103	121767853	N	.	N	N	-0.277483031	30.77501881	0.945966338	15.2	.	.
TSNARE1	8	142212080	142403240	N	.	N	N	0.828951935	89.75516583	3.60E-07	84.2	.	.
TSNAX	1	231528653	231566524	N	.	N	N	-0.448139541	22.37657001	0.972037851	12.8	.	.
TSNAX-DISC1	1	231528653	231819244	N	.	N	N	.	.	.	.	.	.
TSNAXIP1	16	67806765	67832148	N	.	N	N	0.634823568	85.19997685	9.27E-18	98.1	.	.
TSPAN1	1	46175073	46185958	N	.	N	N	0.265759477	68.41465532	0.000714382	65.9	.	.
TSPAN10	17	81637171	81648749	N	.	N	N	.	.	7.87E-07	83	.	.
TSPAN11	12	30926428	30996599	N	.	N	N	0.405597914	76.13011518	2.96E-05	75.2	.	.
TSPAN12	7	120787320	120858402	N	.	N	Y	0.046257695	53.10528448	0.554920626	28.5	DM	Exudative vitreoretinopathy 5, 613310 (3)
TSPAN13	7	16753535	16784536	N	.	N	N	-0.366562778	26.04618857	0.609851374	27.2	.	.
TSPAN14	10	80454166	80533123	N	.	N	N	-0.335593115	27.47004688	0.863069548	19.4	.	.
TSPAN15	10	69451473	69507669	N	.	N	N	0.774215256	88.62649766	0.001855808	62.2	.	.
TSPAN16	19	11296139	11326996	N	.	N	N	0.509685942	80.85894542	0.000252238	69.1	.	.
TSPAN17	5	176647387	176659054	N	.	N	N	-0.261365676	31.77635006	1.32E-05	77.3	DM?	.
TSPAN18	11	44726465	44932421	N	Viable	N	Y	0.017202414	50.84794814	0.161860431	40.1	.	.
TSPAN19	12	85014311	85036277	N	.	N	N	0.442010439	77.98228859	2.64E-09	90.3	.	.
TSPAN2	1	115048011	115089500	N	.	N	Y	0.08936246	56.39289228	0.000100587	71.8	.	.
TSPAN3	15	77041404	77083984	N	.	N	N	-0.012004394	48.53851942	0.284424065	36.1	.	.
TSPAN31	12	57738013	57750211	N	.	N	N	-0.223047092	34.13208312	0.32725853	34.9	.	.
TSPAN32	11	2301997	2318200	N	.	N	N	1.078185261	93.71418649	0.000537261	66.8	.	.
TSPAN33	7	129144892	129169697	N	.	N	Y	-0.144188409	39.10979915	0.000103178	71.8	.	.
TSPAN4	11	842808	867116	N	.	N	N	0.173002985	62.75973838	2.52E-06	80.8	.	.
TSPAN5	4	98470367	98658629	N	.	N	N	-0.465060678	21.67042889	0.927948897	16.2	.	.
TSPAN6	X	100627109	100639991	N	.	N	N	0.366978017	74.20848527	0.028202183	50	.	.
TSPAN7	X	38561370	38688920	N	.	N	N	0.0545666	53.67251259	0.869950131	19.1	DM	Mental retardation, X-linked 58, 300210 (3)
TSPAN8	12	71125085	71441898	N	.	N	N	0.652248451	85.69774845	0.008694721	55.5	.	.
TSPAN9	12	3077355	3286564	N	.	N	N	-0.207083847	35.09289807	0.779777701	22.3	.	.
TSPEAR	21	44497892	44711580	N	.	N	N	1.029950341	93.15853447	1.87E-10	92.5	DM	Deafness, autosomal recessive 98, 614861 (3)
TSPO	22	43151514	43163242	N	Viable	N	Y	.	.	0.021753057	51.2	DP	.
TSPO2	6	41042554	41044337	N	.	N	N	0.12592113	59.20588065	4.29E-07	84	.	.
TSPY1	Y	9466955	9490081	N	.	N	N	.	.	.	.	DP	.
TSPY10	Y	9527880	9530682	N	.	N	N	.	.	.	.	.	.
TSPY2	Y	6246223	6249019	N	.	N	N	.	.	.	.	.	.
TSPY3	Y	9398421	9401223	N	.	N	N	.	.	.	.	.	.
TSPY4	Y	9337464	9340284	N	.	N	N	.	.	.	.	.	.
TSPY6P	Y	9487286	9490081	N	.	N	N	.	.	.	.	.	.
TSPY8	Y	9357797	9380870	N	.	N	N	.	.	.	.	.	.
TSPYL1	6	116276578	116279903	N	.	N	N	0.562357003	82.81530358	0.007991587	55.9	DM	Sudden infant death with dysgenesis of the testes syndrome, 608800 (3)
TSPYL2	X	53082367	53088540	N	Viable	N	Y	-0.043626754	46.35063958	0.874635828	18.9	.	.
TSPYL4	6	116249961	116254140	N	.	N	N	0.789222232	88.97378017	0.002618666	60.9	.	.
TSPYL5	8	97273474	97277964	N	.	N	N	-0.411426546	23.88724894	0.852598058	19.8	FP	.
TSPYL6	2	54253184	54256272	N	.	N	N	0.711616165	87.19106326	0.581660026	27.9	.	.
TSR1	17	2322503	2337507	N	.	N	N	-0.231857415	33.61115934	8.33E-20	98.6	.	.
TSR2	X	54440401	54445487	N	.	N	N	0.046106757	53.06476819	0.760610429	22.8	.	?Diamond-Blackfan anemia 14 with mandibulofacial dysostosis, 300946 (3)
TSR3	16	1349240	1351911	N	.	N	N	-0.207887594	35.06395786	0.002407582	61.2	.	.
TSSC1	2	3188925	3377882	N	.	N	N	-0.45181342	22.19714071	0.121031637	42	.	.
TSSC4	11	2400488	2403878	N	.	N	N	0.83247669	89.8477745	0.013278189	53.7	DP	.
TSSK1B	5	113432554	113435031	N	.	N	N	0.290331873	69.95427447	0.000465468	67.2	.	.
TSSK2	22	19130808	19132623	N	.	N	N	0.333436727	72.48943682	0.004156529	58.9	DP	.
TSSK3	1	32351521	32364312	N	.	N	N	0.108195341	57.87463101	0.763235263	22.8	FTV	.
TSSK4	14	24205697	24208362	N	.	N	N	0.124158088	59.0611796	2.51E-11	93.8	DP	.
TSSK6	19	19512418	19515685	N	.	N	Y	0.00123959	49.58036696	0.587550747	27.8	.	.
TST	22	37010859	37020183	N	Viable	N	Y	0.979680151	92.48712161	0.000731843	65.8	FP	.
TSTD1	1	161037631	161038990	N	.	N	N	.	.	.	.	.	.
TSTD2	9	97600080	97633575	N	.	N	N	0.315711326	71.46495341	1.63E-06	81.7	.	.
TTBK1	6	43243680	43288259	N	.	N	N	-0.695292411	14.09388204	0.997306963	7.3	.	.
TTC1	5	160009113	160065543	N	.	N	N	0.091275867	56.54338137	0.001851677	62.2	.	.
TTC12	11	113314529	113383544	N	.	N	N	0.232373568	66.38305261	1.45E-07	85.7	.	.
TTC13	1	230906243	230978875	N	.	N	N	-1.18332098	5.759101696	0.673224182	25.4	.	.
TTC14	3	180602130	180617828	N	.	N	N	-0.405534288	24.1303467	4.42E-06	79.8	.	.
TTC16	9	127716066	127731600	N	.	N	N	2.166194439	98.80766337	5.08E-12	94.6	.	.
TTC17	11	43358932	43494933	N	.	N	N	-1.355637738	4.2542108	0.999727594	4.5	.	.
TTC19	17	15999380	16045015	N	.	N	N	0.033165214	52.10395323	1.05E-10	92.9	DM	Mitochondrial complex III deficiency, nuclear type 2, 615157 (3)
TTC21A	3	39107704	39138903	N	.	N	N	0.552770537	82.53747757	2.12E-16	97.6	.	.
TTC21B	2	165857475	165953843	N	.	N	Y	0.237627036	66.66666667	3.39E-22	99	DM	Nephronophthisis 12, 613820 (3); Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3)
TTC22	1	54779712	54801267	N	.	N	N	.	.	0.000878027	65.2	.	.
TTC23	15	99136323	99251223	N	.	N	N	0.191835947	63.9231348	4.35E-16	97.5	.	.
TTC23L	5	34838833	34899456	N	.	N	N	0.702049624	86.94217746	2.22E-09	90.4	.	.
TTC24	1	156579727	156586770	N	.	N	N	.	.	6.58E-05	73.1	.	.
TTC25	17	41930635	41965651	N	.	N	N	.	.	.	.	.	.
TTC27	2	32628032	32821051	N	.	N	N	0.094601099	56.72859872	6.54E-09	89.3	.	.
TTC28	22	27978014	28679865	N	Viable	N	Y	.	.	.	.	.	.
TTC29	4	146706638	146945882	N	.	N	N	0.794959429	89.10690513	1.57E-06	81.8	.	.
TTC3	21	37073226	37203112	N	.	N	N	-1.87874564	1.967934248	5.39E-20	98.7	.	.
TTC30A	2	177612992	177618966	N	.	N	N	0.169478709	62.46454824	1.36E-05	77.2	.	.
TTC30B	2	177548998	177553014	N	.	N	N	0.737954513	87.79880766	0.001861851	62.1	.	.
TTC31	2	74483073	74494886	N	.	N	N	0.732212252	87.62516641	2.62E-15	97	.	.
TTC32	2	19896643	19901986	N	.	N	N	0.06589658	54.61017538	0.089897896	43.8	.	.
TTC33	5	40714475	40755975	N	.	N	N	-0.039146033	46.66319384	0.022618545	51	.	.
TTC34	1	2635976	2801721	N	.	N	N	.	.	.	.	.	.
TTC36	11	118527472	118531197	N	.	N	N	0.335052688	72.57046941	0.507038898	29.8	.	.
TTC37	5	95463895	95555007	N	.	N	N	0.518129295	81.17728772	7.99E-20	98.6	DM	Trichohepatoenteric syndrome 1, 222470 (3)
TTC38	22	46267961	46294008	N	.	N	N	0.278196204	69.21340511	5.70E-10	91.6	.	.
TTC39A	1	51287258	51345116	N	.	N	N	-0.069006169	44.45216183	0.098310255	43.3	.	.
TTC39B	9	15163622	15307360	N	.	N	Y	-0.329546751	27.75944898	1.07E-11	94.2	.	.
TTC39C	18	23992773	24135610	N	.	N	N	-0.517427071	19.54042947	0.014646861	53.3	.	.
TTC4	1	54715822	54742657	N	.	N	N	0.096059501	56.83857151	0.043967592	47.7	.	.
TTC5	14	20256558	20305994	N	.	N	N	-0.106521065	41.70862997	0.002493625	61.1	.	.
TTC6	14	37595847	38041442	N	.	N	N	.	.	8.74E-09	89.1	DM?	.
TTC7B	14	90524564	90816479	N	.	N	N	-0.652184261	15.32673497	0.999902561	3.7	.	.
TTC9	14	70641787	70675360	N	.	N	N	0.039560397	52.53226833	0.058556658	46.1	.	.
TTC9B	19	40216058	40218399	N	.	N	N	-0.299992293	29.44376917	0.027179794	50.2	.	.
TTC9C	11	62728069	62740293	N	.	N	N	0.112828307	58.21033744	0.000139735	70.9	.	.
TTF1	9	132375548	132406851	N	.	N	N	1.79459056	98.17097876	1.47E-06	82	.	{Thyroid cancer, monmedullary, 1}, 188550 (3); Chorea, hereditary benign, 118700 (3); Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3)
TTF2	1	117060303	117107453	N	.	N	N	0.242100324	66.98500897	7.35E-16	97.4	DM?	Bamforth-Lazarus syndrome, 241850 (3); {Thyroid cancer, nonmedullary, 4}, 616534 (3)
TTI1	20	37983007	38033468	N	.	N	N	-0.309610286	28.95178561	0.000238871	69.2	.	.
TTI2	8	33473386	33513601	N	.	N	N	0.231264514	66.30780807	0.001886337	62.1	DM	Mental retardation, autosomal recessive 39, 615541 (3)
TTK	6	80003887	80042527	N	.	N	N	-0.147560478	38.90721769	0.005357769	57.8	.	.
TTLL1	22	43039644	43089428	N	.	N	Y	-0.263127019	31.65480118	0.005632995	57.6	.	.
TTLL10	1	1173884	1197935	N	.	N	N	.	.	1.95E-05	76.3	.	.
TTLL11	9	121821928	122093606	N	.	N	N	.	.	0.018231837	52.1	DM?	.
TTLL12	22	43166622	43187133	N	.	N	N	-0.262826333	31.66637726	1.99E-15	97.1	.	.
TTLL2	6	167325086	167359503	N	.	N	N	1.531598864	97.10019101	4.94E-06	79.6	.	.
TTLL3	3	9808086	9855138	N	.	N	Y	0.983011769	92.56815419	3.84E-14	96.4	.	.
TTLL4	2	218710845	218755416	N	.	N	Y	0.699004041	86.87272096	2.83E-06	80.6	.	.
TTLL5	14	75633625	75955078	N	.	N	N	-0.21273075	34.72246339	1.98E-09	90.5	.	Cone-rod dystrophy 19, 615860 (3)
TTLL6	17	48762235	48817214	N	Viable	N	Y	0.325128069	72.04954564	7.49E-08	86.5	.	.
TTLL7	1	83865028	83999150	N	.	N	N	-0.749875342	12.63529548	0.268072469	36.6	.	.
TTLL8	22	50015123	50056935	N	.	N	N	.	.	.	.	.	.
TTLL9	20	31870702	31944963	N	.	N	N	1.011754378	92.90386062	4.49E-10	91.8	.	.
TTPA	8	63048553	63086053	N	.	N	Y	0.332331078	72.43734445	0.009884316	55	DM	Ataxia with isolated vitamin E deficiency, 277460 (3)
TTPAL	20	44475886	44494603	N	.	N	N	-0.217304588	34.45621346	0.640756733	26.3	.	.
TTR	18	31591726	31599021	N	.	N	Y	0.314455675	71.33761648	0.130835841	41.5	DM	Amyloidosis, hereditary, transthyretin-related, 105210 (3); [Dystransthyretinemic hyperthyroxinemia], 145680 (3); Carpal tunnel syndrome, familial, 115430 (3)
TTYH2	17	74213514	74262020	N	.	N	N	0.663879122	86.06239509	0.347961542	34.3	.	.
TTYH3	7	2631951	2664802	N	.	N	N	-0.310058921	28.94020953	0.979598759	11.8	.	.
TUB	11	8019244	8106112	N	.	N	Y	-0.65792236	15.11836546	0.471428314	30.8	.	?Retinal dystrophy and obesity, 616188 (3)
TUBA1A	12	49184796	49189324	N	.	N	N	0.489898374	80.08913585	0.836535571	20.4	DM	Lissencephaly 3, 611603 (3)
TUBA1B	12	49127782	49131397	N	.	N	N	-0.275568538	30.94287203	0.828418235	20.7	.	.
TUBA1C	12	49188736	49274603	N	.	N	N	-0.949902102	8.71679111	0.84015077	20.3	.	.
TUBA3C	13	19173770	19181852	N	.	N	N	-0.587673557	17.16733229	0.006817594	56.7	.	.
TUBA3D	2	131476093	131482934	N	.	N	N	0.377649382	74.81044163	3.71E-08	87.4	.	.
TUBA3E	2	130191743	130198461	N	Viable	N	Y	0.517489897	81.14255947	0.001205278	64	.	.
TUBA4A	2	219249711	219278170	N	.	N	N	-0.823301011	11.09567633	0.029637936	49.7	.	Amyotrophic lateral sclerosis 22 with or without frontotemoral dementia, 616208 (3)
TUBA4B	2	219253243	219272188	N	.	N	N	.	.	.	.	.	.
TUBA8	22	18110331	18146554	N	.	N	N	0.146818001	60.78601609	0.003227497	60	DM	Polymicrogyria with optic nerve hypoplasia, 613180 (3)
TUBAL3	10	5393098	5404830	N	.	N	N	0.846676602	90.15454072	0.000170843	70.3	FTV	.
TUBB	6	30720201	30725426	N	.	N	N	-0.291531924	29.91838861	0.875276521	18.9	DM	Cortical dysplasia, complex, with other brain malformations 6, 615771 (3)
TUBB1	20	59019254	59026654	N	.	N	Y	0.429214031	77.35718007	7.17E-06	78.9	DM	Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 (3)
TUBB2A	6	3153669	3157526	N	.	N	N	0.118418051	58.60971233	.	.	DFP	Cortical dysplasia, complex, with other brain malformations 5, 615763 (3)
TUBB4A	19	6494319	6502848	N	.	N	N	-0.662859235	14.96208833	0.003055663	60.3	DM	Dystonia 4, torsion, autosomal dominant, 128101 (3); Leukodystrophy, hypomyelinating, 6, 612438 (3)
TUBB4B	9	137241213	137243707	N	.	N	N	-0.924519496	9.145106211	0.929541174	16.2	.	.
TUBB6	18	12307669	12344320	N	.	N	N	-0.698460933	13.95496903	0.000511267	67	.	.
TUBB8	10	46892	74163	N	.	N	N	2.189340232	98.84817966	0.266953543	36.6	.	.
TUBB8P12	18	47221	73545	N	.	N	N	.	.	.	.	.	.
TUBD1	17	59859482	59892945	N	.	N	N	-0.129986883	40.1111304	0.000375248	68	.	.
TUBE1	6	112070777	112087529	N	.	N	N	-0.190010792	36.18104995	1.25E-05	77.5	.	.
TUBG2	17	42659305	42667006	N	.	N	Y	-1.038987633	7.397117555	0.004310019	58.8	.	.
TUBGCP2	10	133278630	133312337	N	.	N	N	-0.530073956	19.00214158	5.05E-05	73.9	.	.
TUBGCP3	13	112485005	112588167	N	.	N	N	-1.52851566	3.200787174	0.952526134	14.5	.	.
TUBGCP4	15	43369221	43409771	N	.	N	N	-0.542654523	18.49279389	0.005283482	57.9	DM?	Microcephaly and chorioretinopathy, autosomal recessive, 3, 616335 (3)
TUBGCP5	15	22983192	23039673	N	.	N	N	-1.045237847	7.269780633	0.000126197	71.2	DM?	.
TUBGCP6	22	50217689	50244992	N	.	N	N	-0.163163167	37.79591364	5.09E-19	98.4	DM?	Microcephaly and chorioretinopathy, autosomal recessive, 1, 251270 (3)
TUFM	16	28842411	28846408	N	.	N	N	-0.311015862	28.89390519	0.651456012	26	DM	Combined oxidative phosphorylation deficiency 4, 610678 (3)
TUFT1	1	151540305	151583583	N	.	N	N	0.3596227	73.91329513	0.018080099	52.2	.	.
TULP1	6	35497874	35512938	N	.	N	Y	0.145861223	60.69919546	0.80790432	21.3	DM	Retinitis pigmentosa 14, 600132 (3); Leber congenital amaurosis 15, 613843 (3)
TULP2	19	48880965	48898733	N	.	N	N	1.13755586	94.41453956	1.83E-07	85.3	.	.
TULP4	6	158232236	158511828	N	.	N	N	-1.022093918	7.576546854	0.999936803	3.4	.	.
TUSC1	9	25676389	25678440	N	.	N	N	.	.	0.324671553	35	.	.
TUSC2	3	50320027	50328251	N	.	N	Y	.	.	0.703033004	24.5	.	.
TUSC3	8	15417215	15766649	N	.	N	N	-1.033398927	7.426057765	0.001898764	62	DM	Mental retardation, autosomal recessive 7, 611093 (3)
TUSC5	17	1279663	1300987	N	.	N	N	0.532195638	81.73293975	0.101235964	43	.	.
TUT1	11	62575045	62592177	N	.	N	N	-0.3499951	26.79284598	9.99E-06	78.1	.	.
TVP23A	16	10760919	10818794	N	.	N	N	0.292902568	70.08739943	2.04E-06	81.3	.	.
TVP23B	17	18780995	18806714	N	.	N	N	-0.214586899	34.6414308	0.429732873	32	.	.
TVP23C	17	15502264	15563595	N	.	N	N	0.269585727	68.68669329	0.000136737	71	.	.
TVP23C-CDRT4	17	15436021	15563561	N	.	N	N	0.088405766	56.3118597	0.002362297	61.3	.	.
TWF1	12	43793723	43806375	N	.	N	Y	-0.119765437	40.78833131	0.007963693	55.9	.	.
TWF2	3	52228610	52239260	N	.	N	N	-0.487414582	20.68067373	0.857810164	19.6	.	.
TWISTNB	7	19695462	19709087	N	.	N	N	0.207648094	64.90710193	0.309424388	35.5	.	.
TXK	4	48066393	48134256	N	.	N	Y	0.01926743	51.03895352	1.25E-07	85.9	.	.
TXLNA	1	32179686	32198285	N	.	N	N	-0.137489868	39.60757076	0.995925358	8	.	.
TXLNB	6	139240061	139292139	N	.	N	N	0.756790706	88.25606297	1.65E-16	97.6	DM?	.
TXLNG	X	16786427	16844519	N	.	N	Y	0.109152052	57.94408752	0.992209566	9.4	.	.
TXNDC11	16	11679080	11742878	N	.	N	N	0.017808679	50.85952422	0.003178008	60.1	.	.
TXNDC12	1	52020131	52056171	N	.	N	N	0.094952155	56.76911501	0.344869173	34.4	.	.
TXNDC15	5	134873803	134901525	N	.	N	N	0.0200728	51.09683394	0.109182713	42.6	.	.
TXNDC16	14	52430590	52552522	N	.	N	N	0.046712199	53.12843665	1.69E-07	85.4	.	.
TXNDC17	17	6640758	6644541	N	.	N	N	0.139970692	60.17827169	0.035515895	48.9	.	.
TXNDC2	18	9885726	9889275	N	.	N	Y	0.469600161	79.30775019	2.94E-07	84.6	.	.
TXNDC5	6	7881517	7910814	N	Viable	N	Y	0.264952627	68.37992707	1.79E-06	81.5	.	.
TXNDC8	9	110303521	110337884	N	.	N	N	0.412953559	76.48897378	0.835982582	20.4	.	.
TXNDC9	2	99318982	99340702	N	.	N	N	-0.011047557	48.60797592	0.223930351	37.9	.	.
TXNIP	1	145992435	145996600	N	Viable	N	Y	-0.482629449	20.86589107	0.252140354	37	.	.
TXNL1	18	56597208	56651600	N	.	N	N	-0.198623704	35.57909359	0.956025974	14.3	.	.
TXNL4A	18	79970811	80033949	N	.	N	N	-0.059893552	45.10042253	0.001546737	62.9	.	Burn-McKeown syndrome, 608572 (3)
TXNL4B	16	72044289	72094431	N	.	N	N	0.117461409	58.54604387	0.017306522	52.4	.	.
TXNRD3	3	126571779	126655155	N	.	N	N	.	.	.	.	.	.
TXNRD3NB	3	126571789	126572636	N	.	N	N	-0.065482771	44.7241998	0.001774175	62.4	.	.
TYK2	19	10350529	10380676	N	.	N	Y	-0.058985812	45.16987903	0.004314482	58.8	DM	Immunodeficiency 35, 611521 (3)
TYMP	22	50525752	50530085	N	.	N	Y	-0.132857585	39.9027609	0.000465859	67.2	DM	Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 (3)
TYMS	18	657604	673578	N	.	N	N	-0.170525669	37.3618105	0.924544533	16.4	DFP	.
TYRO3	15	41557675	41583586	N	.	N	Y	-0.664322798	14.91578399	0.761822543	22.8	.	.
TYROBP	19	35904401	35908295	N	.	N	Y	0.678438311	86.37494935	0.485203147	30.4	DM	Nasu-Hakola disease, 221770 (3)
TYSND1	10	70137981	70146676	N	.	N	N	.	.	0.0666401	45.4	.	.
TYW1	7	66995173	67239519	N	.	N	N	0.006326625	49.97974185	0.000457249	67.3	.	.
TYW1B	7	72558744	72828198	N	.	N	N	.	.	8.12E-09	89.2	.	.
TYW3	1	74733152	74766678	N	.	N	N	0.091275867	56.54338137	0.43187196	31.9	.	.
TYW5	2	199929975	199955736	N	.	N	N	-0.066287483	44.66631938	2.20E-07	85	.	.
U2AF1	21	43092956	43107587	N	.	N	N	-0.148973548	38.82039706	0.98659563	10.7	.	.
U2AF1L4	19	35742464	35745445	N	.	N	Y	-0.074747377	44.06436303	5.80E-07	83.5	.	.
U2AF1L5	21	6484623	6499261	N	.	N	N	.	.	.	.	.	.
U2AF2	19	55654146	55674715	N	.	N	N	-0.641306922	15.65086531	0.997188847	7.4	.	.
U2SURP	3	142964497	143060546	N	.	N	N	-1.314716032	4.624645482	0.999999613	1.4	.	.
U51561.1	22	46915328	46915908	N	.	N	N	.	.	.	.	.	.
U82695.5	X	153395640	153401420	N	.	N	N	.	.	.	.	.	.
UACA	15	70654554	70763593	N	.	N	Y	0.738438948	87.80459571	2.35E-17	97.9	.	.
UAP1	1	162561506	162599842	N	.	N	N	-0.137489868	39.60757076	0.90807501	17.4	.	.
UAP1L1	9	137077501	137084539	N	.	N	N	-0.213476698	34.71088731	0.00112977	64.2	.	.
UBA1	X	47190861	47215128	N	.	N	N	-0.912230915	9.347687677	0.999990742	2.5	DM	Spinal muscular atrophy, X-linked 2, infantile, 301830 (3)
UBA52	19	18571730	18577550	N	.	N	N	-0.037384251	46.76159055	0.44680007	31.5	.	.
UBA7	3	49805207	49813946	N	.	N	N	-0.160503316	37.97534294	2.68E-14	96.5	DM?	.
UBAC1	9	135932969	135961380	N	.	N	N	0.100843326	57.30161486	0.865452587	19.2	.	.
UBAC2	13	99200774	99386434	N	.	N	N	0.063177242	54.40180587	0.111492354	42.5	DFP	.
UBALD1	16	4608883	4615027	N	.	N	N	0.422369205	76.96359322	0.700158646	24.6	.	.
UBALD2	17	76265202	76271299	N	.	N	N	.	.	0.262586852	36.7	.	.
UBAP1L	15	65092770	65115197	N	.	N	N	.	.	.	.	.	.
UBAP2	9	33921693	34048949	N	.	N	N	0.122048968	58.85281009	0.98950935	10	DM?	.
UBAP2L	1	154220179	154271510	N	.	N	Y	-1.562216068	3.009781791	0.999999873	1.2	.	.
UBASH3A	21	42403899	42447681	N	Viable	N	Y	0.194858521	64.1025641	3.97E-07	84	.	.
UBASH3B	11	122655675	122814473	N	.	N	N	-0.290268599	30.04572553	0.988510645	10.3	.	.
UBB	17	16380798	16382745	N	.	N	Y	-0.532589029	18.86901661	0.620802082	26.9	.	Cleft palate, isolated, 119540 (2)
UBD	6	29555515	29559925	N	.	N	Y	0.853886889	90.27030156	0.079895751	44.5	DP	.
UBE2D1	10	58334975	58370753	N	.	N	N	0.357562369	73.8264745	0.90888495	17.4	.	.
UBE2D2	5	139526431	139628433	N	.	N	Y	0.090168851	56.43919662	0.94531266	15.2	.	.
UBE2D3	4	102794383	102868896	N	.	N	N	0.251561226	67.52329687	0.74820302	23.2	.	.
UBE2D4	7	43926438	43956136	N	.	N	N	-0.019507464	47.94813914	0.002318608	61.4	FTV	.
UBE2E1	3	23805903	23891316	N	.	N	N	-0.088948948	42.87202639	0.872957997	18.9	.	.
UBE2E2	3	23203020	23591793	N	Viable	N	Y	-0.202452202	35.31863171	0.924393312	16.4	.	.
UBE2E3	2	180967248	181076585	N	.	N	N	0.092082157	56.56653354	0.653907526	25.9	.	.
UBE2F	2	237966827	238042782	N	.	N	N	-0.186488904	36.36626729	0.950479185	14.7	.	.
UBE2F-SCLY	2	237967014	238099412	N	.	N	N	.	.	.	.	.	.
UBE2G1	17	4269259	4366628	N	Viable	N	Y	0.046106757	53.06476819	0.745694457	23.3	.	.
UBE2G2	21	44768580	44802019	N	.	N	N	-0.15647662	38.26474504	0.247416499	37.2	.	.
UBE2J1	6	89326625	89352848	N	Viable	N	Y	0.282678709	69.47965503	0.857925444	19.6	.	.
UBE2J2	1	1253909	1273885	N	.	N	N	-0.349641992	26.83336227	0.415938847	32.4	.	.
UBE2K	4	39698044	39782792	N	.	N	N	0.08362237	55.98772935	0.962613421	13.7	.	.
UBE2L6	11	57551656	57568284	N	.	N	N	0.300405715	70.5388667	0.01401033	53.5	.	.
UBE2Q2	15	75843285	75901078	N	.	N	N	0.109152052	57.94408752	0.00105604	64.5	.	.
UBE2Q2L	15	84172490	84182234	N	.	N	N	.	.	.	.	.	.
UBE2QL1	5	6448623	6494909	N	.	N	N	.	.	.	.	.	.
UBE2R2	9	33817567	33920404	N	.	N	N	-0.277483031	30.77501881	0.908519449	17.4	.	.
UBE2S	19	55399745	55407777	N	.	N	N	0.123201392	58.99751114	0.801671664	21.6	.	.
UBE2T	1	202331657	202341980	N	.	N	N	0.087449076	56.25976732	0.000369195	68	DM?	Fanconi anemia, complementation group T, 616435 (3)
UBE2U	1	64203627	64267368	N	Viable	N	Y	0.195362073	64.12571627	7.81E-08	86.4	.	.
UBE2V1	20	50081124	50115959	N	.	N	N	-0.15647662	38.26474504	0.001954526	62	.	.
UBE2V2	8	48008400	48064708	N	.	N	N	0.032057299	51.99976848	0.108879326	42.7	.	.
UBE2W	8	73780097	73878910	N	.	N	N	.	.	0.954557961	14.3	.	.
UBE2Z	17	48908369	48929056	N	.	N	N	-0.224961447	34.00474619	0.92755873	16.2	.	.
UBE3C	7	157138913	157269372	N	Viable	N	Y	-1.415807333	3.837471783	0.999999273	1.6	DM?	.
UBE3D	6	82892398	83065841	N	.	N	N	0.369038883	74.34161023	9.58E-08	86.2	.	.
UBE4A	11	118359585	118399211	N	.	N	N	-0.46460294	21.68200498	0.937619432	15.7	.	.
UBFD1	16	23557362	23574389	N	.	N	N	0.028381319	51.66985009	0.839698364	20.3	.	.
UBIAD1	1	11273206	11296049	N	.	N	N	-0.42930414	23.16374371	0.568905634	28.3	DM	Corneal dystrophy, Schnyder type, 121800 (3)
UBL3	13	29764371	29850684	N	.	N	N	0.205585801	64.70452046	0.71809918	24.1	.	.
UBL4A	X	154483717	154486670	N	.	N	Y	0.032057299	51.99976848	0.275271317	36.3	.	.
UBL4B	1	110112468	110113945	N	.	N	N	0.793858151	89.06638884	0.000847798	65.4	.	.
UBL5	19	9827892	9830115	N	.	N	N	0.113634918	58.26821786	0.08015833	44.5	.	.
UBL7	15	74445977	74461182	N	.	N	N	-0.042821613	46.39115587	0.02775544	50.1	.	.
UBN1	16	4846665	4882360	N	.	N	N	-1.624743314	2.749319905	0.997776757	7.1	.	.
UBN2	7	139230356	139308236	N	.	N	N	-0.059942498	45.07727036	0.998642623	6.4	DM?	.
UBOX5	20	3107573	3160196	N	Viable	N	Y	0.003304686	49.75979626	0.001786825	62.3	.	.
UBQLN1	9	83659963	83708203	N	.	N	N	-0.691914915	14.19227875	0.998753262	6.2	DM?	.
UBQLN2	X	56563639	56567868	N	.	N	N	-0.325218356	28.00833478	0.804317268	21.5	DM	Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3)
UBQLN3	11	5507300	5509985	N	.	N	N	1.219297621	95.22486543	0.003828068	59.2	.	.
UBQLN4	1	156035301	156053794	N	.	N	N	-0.076509147	43.9370261	0.99752242	7.2	.	.
UBQLNL	11	5514393	5516705	N	.	N	N	1.224731043	95.25959368	3.53E-09	90	.	.
UBR1	15	42942897	43106113	N	.	N	Y	-1.120839855	6.366846096	0.319889981	35.2	DM	Johanson-Blizzard syndrome, 243800 (3)
UBR7	14	93207056	93229215	N	.	N	N	-0.060698235	45.04254211	0.426811632	32.1	DM	.
UBTD1	10	97498868	97571209	N	.	N	N	-0.03818917	46.70949818	0.777525004	22.4	.	.
UBTD2	5	172209640	172284071	N	.	N	N	-0.109544183	41.48289634	0.748758502	23.2	.	.
UBTF	17	44205033	44221626	N	.	N	N	-0.983590656	8.161139087	0.999998048	1.9	.	.
UBTFL1	11	90085950	90087131	N	.	N	N	.	.	.	.	.	.
UBXN1	11	62676498	62679117	N	.	N	N	0.222654188	65.80424842	0.76841751	22.6	.	.
UBXN10	1	20186085	20196048	N	.	N	N	0.335200382	72.59362158	0.000293935	68.7	.	.
UBXN11	1	26281328	26318363	N	.	N	N	1.336487831	96.02361521	1.20E-10	92.8	.	.
UBXN2A	2	23927285	24004909	N	.	N	N	0.090319161	56.46813683	0.000588703	66.5	.	.
UBXN2B	8	58411264	58451501	N	.	N	N	-0.356187814	26.51501997	0.487567803	30.3	.	.
UBXN4	2	135741619	135785055	N	.	N	N	-0.387960287	25.05064537	0.974205695	12.5	.	.
UBXN6	19	4444999	4457822	N	.	N	N	1.439631624	96.64872374	0.047326898	47.3	DP	.
UBXN7	3	196347662	196432474	N	.	N	N	-0.30079494	29.40904092	0.99065719	9.8	.	.
UBXN8	8	30732247	30767006	N	.	N	N	.	.	.	.	.	.
UCHL1	4	41256413	41268455	N	.	N	Y	-0.057022786	45.34352029	0.972670211	12.7	DM	?{Parkinson disease 5, susceptibility to}, 613643 (3); ?Neurodegeneration with optic atrophy, childhood onset, 615491 (3)
UCHL3	13	75549480	75606020	N	.	N	Y	-0.25960522	31.89789894	1.95E-05	76.3	.	.
UCK1	9	131523801	131531268	N	.	N	N	-0.309255099	28.96336169	0.002126631	61.6	.	.
UCK2	1	165827531	165911618	N	.	N	N	-0.048562831	45.92232448	0.962082764	13.7	.	.
UCKL1	20	63939829	63956415	N	.	N	N	-0.600766325	16.68113677	1.43E-08	88.5	.	.
UCMA	10	13221767	13234334	N	.	N	N	0.741333534	87.88562829	1.85E-07	85.3	FP	.
UCN	2	27307400	27308445	N	.	N	Y	.	.	0.517240163	29.5	.	.
UCN2	3	48561727	48563773	N	.	N	Y	0.30503986	70.79354055	0.157235729	40.3	.	.
UCN3	10	5365009	5374692	N	Viable	N	Y	0.665343186	86.07975922	0.50814391	29.7	.	.
UCP1	4	140559434	140568805	N	Viable	N	Y	0.390591665	75.41239799	4.52E-08	87.1	DM?	{Obesity, susceptibility to}, 601665 (3)
UCP2	11	73974667	73983307	N	.	N	Y	0.279002038	69.25970944	1.92E-08	88.2	DM	{Obesity, susceptibility to, BMIQ4}, 607447 (3)
UCP3	11	74000281	74009435	N	.	N	Y	0.403834454	76.00277826	1.07E-05	77.9	DM	{Obesity, severe, and type II diabetes}, 601665 (3)
UEVLD	11	18529609	18588747	N	.	N	N	-0.356034079	26.53238409	1.09E-07	86	.	.
UFC1	1	161152776	161158856	N	.	N	N	0.027424541	51.61775771	0.089954188	43.8	.	.
UFD1L	22	19449910	19479215	N	.	N	Y	-0.419084491	23.53417839	0.997407163	7.3	DM	.
UFM1	13	38349849	38363619	N	.	N	N	-0.044887353	46.22330266	0.464066114	31	.	.
UFSP1	7	100888723	100889718	N	.	N	N	-0.083207293	43.33506975	0.005599269	57.6	.	.
UFSP2	4	185399540	185425985	N	.	N	N	-0.393549347	24.76703131	6.11E-06	79.2	.	?Hip dysplasia, Beukes type, 142669 (3)
UGGT1	2	128091200	128195677	N	.	N	N	-1.653813582	2.656711235	0.002897263	60.5	.	.
UGGT2	13	95801580	96053482	N	.	N	N	0.322080701	71.87590438	1.02E-21	99	.	.
UGP2	2	63840940	63891562	N	.	N	N	-0.774451181	12.10279562	0.001020131	64.6	.	.
UGT1A1	2	233760248	233773299	N	.	N	N	-0.19831891	35.60224576	2.94E-09	90.2	DM	Crigler-Najjar syndrome, type I, 218800 (3); [Gilbert syndrome], 143500 (3); Crigler-Najjar syndrome, type II, 606785 (3); Hyperbilirubinemia, familial transient neonatal, 237900 (3); [Bilirubin, serum level of, QTL1], 601816 (3)
UGT1A10	2	233636454	233773305	N	.	N	N	0.375888247	74.73519708	1.09E-11	94.2	DFP	.
UGT1A3	2	233729108	233773299	N	.	N	N	0.907816111	91.2426926	2.94E-09	90.2	FP	.
UGT1A4	2	233718778	233773299	N	.	N	N	1.326269323	95.97152283	2.34E-06	81	DM	.
UGT1A5	2	233712992	233773299	N	.	N	N	1.632988763	97.64426694	0.000100215	71.9	FP	.
UGT1A6	2	233691607	233773300	N	.	N	N	0.225675149	66.00104185	0.00021788	69.6	DFP	.
UGT1A7	2	233681938	233773299	N	.	N	N	0.547502461	82.35226023	1.80E-12	95	DFP	.
UGT1A8	2	233617645	233773310	N	.	N	N	-0.156020198	38.31683741	6.96E-05	72.9	FP	.
UGT1A9	2	233671853	233773300	N	.	N	N	0.883390635	90.80280141	1.32E-08	88.6	DM?	.
UGT2A1	4	69589194	69653249	N	.	N	N	1.088062547	93.82415929	2.73E-11	93.7	DM?	.
UGT2A2	4	69589309	69639642	N	.	N	N	0.97997876	92.49290965	2.33E-07	84.9	.	.
UGT2A3	4	68928463	68951791	N	.	N	N	0.09253511	56.58389767	5.00E-06	79.5	FP	.
UGT2B10	4	68815993	68831196	N	.	N	N	.	.	5.51E-15	96.8	DM?	.
UGT2B11	4	69004618	69214731	N	.	N	N	1.328186059	95.97731088	3.15E-13	95.7	.	.
UGT2B15	4	68537413	68670628	N	.	N	N	0.7745139	88.64386178	1.92E-10	92.5	DFP	.
UGT2B17	4	68537184	68568527	N	.	N	N	1.123353728	94.22932222	0.010255606	54.8	DFP	{Bone mineral density QTL 12, osteoporosis}, 612560 (3)
UGT2B28	4	69280487	69423402	N	.	N	N	1.208920201	95.10910459	6.44E-08	86.7	FP	.
UGT2B4	4	69480165	69526014	N	.	N	N	0.029640828	51.75088268	8.45E-11	93.1	.	.
UGT2B7	4	69051363	69112987	N	.	N	N	-0.220827915	34.28836025	3.50E-08	87.4	DFP	.
UGT3A1	5	35951010	36001028	N	.	N	N	0.6271665	84.98003126	5.21E-10	91.7	.	.
UGT3A2	5	36035017	36071358	N	.	N	N	-0.123289027	40.56838572	2.94E-10	92.2	.	.
UGT8	4	114598455	114678224	N	.	N	Y	-0.067092495	44.59686288	0.226816186	37.8	DP	.
UHMK1	1	162497251	162529629	N	.	N	Y	-0.456445049	22.02349945	0.729319452	23.8	.	.
UHRF1BP1	6	34792015	34883138	N	.	N	N	0.239384584	66.80557967	2.47E-07	84.8	DP	.
UHRF1BP1L	12	100028455	100142848	N	.	N	N	0.001997106	49.60930717	0.989377601	10.1	.	.
UIMC1	5	176905005	177022633	N	.	N	Y	-0.142927664	39.19083174	0.032645863	49.3	FP	.
ULBP1	6	149964007	149973710	N	.	N	N	0.511598665	80.93418996	0.000172612	70.3	.	.
ULBP2	6	149942000	149949235	N	.	N	N	0.889636308	90.92435029	0.001101388	64.3	.	.
ULBP3	6	150063150	150069095	N	.	N	N	0.456207175	78.59582103	1.85E-08	88.3	.	.
ULK1	12	131894651	131923167	N	.	N	Y	-0.857234758	10.43005151	0.964459663	13.5	.	.
ULK2	17	19770829	19867936	N	.	N	Y	-0.844407097	10.67893732	1.30E-05	77.3	.	.
ULK3	15	74836116	74843346	N	.	N	N	.	.	0.016927159	52.5	.	.
ULK4	3	41246599	41962430	N	.	N	Y	1.094166216	93.88782775	1.69E-23	99.2	.	.
UMOD	16	20333052	20356301	N	.	N	Y	-0.707725431	13.70608323	3.18E-08	87.5	DM	Hyperuricemic nephropathy, familial juvenile 1, 162000 (3); Medullary cystic kidney disease 2, 603860 (3); Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 (3)
UMODL1	21	42062959	42143453	N	.	N	N	3.522883218	99.67008161	2.27E-24	99.3	.	.
UMPS	3	124730366	124749273	N	.	N	N	0.151450703	61.09857035	0.000109217	71.6	DM	Orotic aciduria, 258900 (3)
UNC119	17	28546707	28552668	N	Viable	N	Y	0.218827885	65.61903108	0.009717421	55	DM	?Cone-rod dystrophy (3); ?Immunodeficiency 13, 615518 (3)
UNC119B	12	120710435	120723640	N	Viable	N	Y	-0.215544031	34.54882213	0.677325341	25.3	.	.
UNC13C	15	54012904	54633414	N	.	N	Y	-0.763118679	12.34010534	3.69E-07	84.2	.	.
UNC13D	17	75827225	75844717	N	.	N	N	0.134183897	59.75574463	2.52E-12	94.9	DM	Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3)
UNC50	2	98608579	98618515	N	.	N	N	-0.198623704	35.57909359	0.011618307	54.3	.	.
UNC5A	5	176810477	176880895	N	.	N	Y	-0.715079795	13.53244197	0.996259997	7.9	.	.
UNC5CL	6	41026911	41039217	N	.	N	N	0.622534242	84.83533021	1.67E-07	85.5	FTV	.
UNC5D	8	35235457	35796550	N	.	N	Y	-1.290144562	4.746194362	0.849201861	19.9	.	.
UNC80	2	209771993	209999300	N	.	N	N	.	.	0.139839111	41.1	DM?	.
UNC93A	6	167271169	167316019	N	.	N	N	0.888022062	90.90698617	1.38E-06	82.1	DM?	.
UNC93B1	11	67991104	68004982	N	.	N	Y	.	.	0.513837376	29.6	DM	{Herpes simplex encephalitis, susceptibility to, 1}, 610551 (3)
UNG	12	109097574	109110992	N	.	N	Y	0.012569811	50.44857325	0.046581153	47.4	DM	Immunodeficiency with hyper IgM, type 5, 608106 (3)
UNK	17	75784771	75825799	N	.	N	N	-0.261213329	31.7821381	0.994321108	8.7	.	.
UNKL	16	1363205	1414751	N	.	N	N	.	.	0.098857019	43.2	FP	.
UPB1	22	24494107	24528390	N	.	N	N	0.792239054	89.02587255	1.85E-07	85.3	DM	Beta-ureidopropionase deficiency, 613161 (3)
UPF3A	13	114281584	114305817	N	.	N	N	-0.023031474	47.74555768	0.000813153	65.5	.	.
UPF3B	X	119834022	119852998	N	.	N	N	-0.128225396	40.19216299	0.933766901	15.9	DM	Mental retardation, X-linked, syndromic 14, 300676 (3)
UPK1A	19	35666516	35678483	N	.	N	N	1.157047914	94.57660473	3.36E-05	74.9	.	.
UPK1B	3	119173517	119205153	N	.	N	Y	0.220740999	65.70006367	4.50E-05	74.2	.	.
UPK3A	22	45284982	45295874	N	.	N	Y	0.716100076	87.30103606	1.41E-07	85.7	DM	.
UPK3B	7	76510428	76516521	N	.	N	N	1.125120265	94.25826243	0.000192328	69.9	.	.
UPK3BL	7	102637025	102642791	N	.	N	N	.	.	.	.	.	.
UPP1	7	48088628	48108733	N	.	N	Y	-0.220979699	34.27678416	9.01E-05	72.2	.	.
UPP2	2	157876702	158136154	N	.	N	N	0.170132915	62.53400475	0.002024923	61.8	.	.
UPRT	X	75274085	75304600	N	.	N	N	-0.140513426	39.38183712	0.814813817	21.1	.	.
UQCC1	20	35302566	35412141	N	.	N	N	0.487176305	79.97337501	0.004854425	58.2	.	.
UQCC2	6	33694293	33711727	N	.	N	N	0.184989352	63.48903166	0.059547733	46.1	.	?Mitochondrial complex III deficiency, nuclear type 7, 615824 (3)
UQCC3	11	62670273	62673687	N	.	N	N	.	.	.	.	.	?Mitochondrial complex III deficiency, nuclear type 9, 616111 (3)
UQCR10	22	29767369	29770413	N	.	N	N	0.654016419	85.73826475	0.149717439	40.6	.	.
UQCR11	19	1597172	1605490	N	.	N	N	0.183076334	63.39063495	0.030503461	49.5	.	.
UQCRC1	3	48599002	48610976	N	.	N	N	-0.413187838	23.76570006	0.132467103	41.4	.	.
UQCRC2	16	21952660	21983660	N	.	N	N	0.021029596	51.14892632	0.007235543	56.5	DM	Mitochondrial complex III deficiency, nuclear type 5, 615160 (3)
UQCRH	1	46303631	46316776	N	.	N	N	0.214045409	65.29490074	0.218440721	38.1	.	.
UQCRHL	1	15807169	15809348	N	.	N	N	.	.	.	.	.	.
UQCRQ	5	132866560	132868031	N	.	N	N	0.009548021	50.25756786	0.091912978	43.6	DM	Mitochondrial complex III deficiency, nuclear type 4, 615159 (3)
URAD	13	27977714	27988654	N	.	N	N	.	.	0.003783636	59.3	.	.
URB1	21	32311018	32393026	N	.	N	N	.	.	.	.	.	.
URB2	1	229626234	229660199	N	.	N	N	-0.406729257	24.07825433	3.34E-11	93.6	.	.
URGCP	7	43875894	43926411	N	.	N	N	-0.249733173	32.46512705	0.207220454	38.5	.	.
URGCP-MRPS24	7	43866558	43906589	N	.	N	N	0.31158679	71.14082306	0.011551688	54.3	.	.
URI1	19	29923644	30016608	N	.	N	Y	-1.239675733	5.191873589	0.211667123	38.4	.	.
URM1	9	128371319	128392016	N	.	N	N	-0.245556279	32.71401285	0.498052547	30	.	.
UROC1	3	126481281	126517773	N	.	N	N	0.383546197	75.09405568	3.36E-10	92.1	DM	?Urocanase deficiency, 276880 (3)
USB1	16	57999546	58021618	N	.	N	N	0.199188423	64.32250969	0.122774716	42	.	.
USF1	1	161039251	161045977	N	.	N	Y	-0.355230595	26.57290039	0.381283032	33.3	DFP	{Hyperlipidemia, familial combined, susceptibility to}, 602491 (3)
USH1C	11	17493895	17544416	N	.	N	Y	-0.107831816	41.59286913	2.72E-12	94.9	DM	Usher syndrome, type 1C, 276904 (3); Deafness, autosomal recessive 18A, 602092 (3)
USH1G	17	74916084	74923256	N	.	N	Y	0.144904459	60.59501071	0.001086219	64.4	DM	Usher syndrome, type 1G, 606943 (3)
USH2A	1	215622894	216423396	N	.	N	Y	3.89262621	99.74532616	3.68E-43	100	DM	Usher syndrome, type 2A, 276901 (3); Retinitis pigmentosa 39, 613809 (3)
USHBP1	19	17249176	17282786	N	.	N	Y	0.766209253	88.47022052	3.28E-13	95.7	.	.
USMG5	10	103389041	103396466	N	Viable	N	Y	0.167113525	62.29669503	0.2433522	37.3	.	.
USP11	X	47232690	47248328	N	.	N	Y	-1.071720503	6.887769867	0.998323457	6.7	.	.
USP12	13	27066142	27171896	N	Viable	N	Y	-0.494115743	20.42599988	0.794991969	21.9	.	.
USP13	3	179652755	179789401	N	.	N	N	-0.845507056	10.66157319	2.17E-08	88	.	.
USP15	12	62260338	62417431	N	.	N	N	-0.749069701	12.66423569	0.990365016	9.9	DM?	.
USP17L1	8	7332387	7333979	N	.	N	N	.	.	.	.	.	.
USP17L10	4	9210657	9212608	N	.	N	N	.	.	.	.	.	.
USP17L11	4	9215405	9217356	N	.	N	N	.	.	.	.	.	.
USP17L12	4	9220152	9221744	N	.	N	N	.	.	.	.	.	.
USP17L13	4	9224896	9226847	N	.	N	N	.	.	.	.	.	.
USP17L15	4	9234385	9365080	N	.	N	N	.	.	.	.	.	.
USP17L17	4	9243879	9245830	N	.	N	N	.	.	.	.	.	.
USP17L18	4	9248630	9250581	N	.	N	N	.	.	.	.	.	.
USP17L19	4	9253378	9255329	N	.	N	N	.	.	.	.	.	.
USP17L2	8	12137168	12139077	N	.	N	N	3.945224421	99.75690224	0.013858726	53.6	.	.
USP17L20	4	9258124	9260075	N	.	N	N	.	.	.	.	.	.
USP17L21	4	9262872	9264823	N	.	N	N	.	.	.	.	.	.
USP17L22	4	9267619	9269570	N	.	N	N	.	.	.	.	.	.
USP17L23	4	9272364	9272914	N	.	N	N	.	.	.	.	.	.
USP17L24	4	9325165	9327116	N	.	N	N	.	.	.	.	.	.
USP17L25	4	9329911	9331862	N	.	N	N	.	.	.	.	.	.
USP17L26	4	9334658	9336609	N	.	N	N	.	.	.	.	.	.
USP17L27	4	9344148	9345740	N	.	N	N	.	.	.	.	.	.
USP17L28	4	9348893	9350485	N	.	N	N	.	.	.	.	.	.
USP17L29	4	9353638	9355230	N	.	N	N	.	.	.	.	.	.
USP17L3	8	7976393	7977985	N	.	N	N	.	.	.	.	.	.
USP17L30	4	9363129	9364721	N	.	N	N	.	.	.	.	.	.
USP17L4	8	7337115	7338707	N	.	N	N	.	.	.	.	.	.
USP17L5	4	9339403	9340995	N	.	N	N	.	.	.	.	.	.
USP17L7	8	12132417	12134444	N	.	N	N	.	.	.	.	.	.
USP17L8	8	7971661	7977985	N	.	N	N	.	.	.	.	.	.
USP18	22	18149899	18177397	N	.	N	Y	0.321150679	71.84696417	0.392598705	33	.	.
USP19	3	49108046	49120938	N	.	N	N	-0.999942291	7.860160908	0.999991981	2.4	.	.
USP2	11	119355215	119381726	N	Viable	N	Y	-0.2423802	32.90501823	0.185180862	39.1	.	.
USP20	9	129834698	129881838	N	.	N	N	-0.059136203	45.16409099	0.00188749	62.1	.	.
USP21	1	161159450	161165723	N	.	N	Y	-0.231201301	33.65746368	0.074651654	44.8	.	.
USP24	1	55066359	55215113	N	.	N	Y	-2.372646624	1.064999711	0.999999998	0.6	DFP	.
USP25	21	15730025	15880069	N	.	N	Y	-0.991755546	8.004861955	0.990130458	9.9	.	.
USP26	X	133024631	133097109	N	.	N	N	0.614073992	84.58644441	0.01049438	54.7	DM	.
USP27X	X	49879948	49882565	N	.	N	N	.	.	0.592784999	27.6	.	.
USP28	11	113797874	113875570	N	.	N	N	-1.525512459	3.229727383	0.031657505	49.4	.	.
USP29	19	57119138	57131926	N	.	N	N	0.239073126	66.79400359	9.29E-15	96.7	.	.
USP30	12	109023089	109088026	N	.	N	N	-0.370083231	25.87254732	0.309014179	35.5	DM?	.
USP31	16	23061406	23149270	N	.	N	N	-0.803884764	11.46032297	0.008751105	55.4	.	.
USP32	17	60179094	60422470	N	.	N	N	-1.842519424	2.054754876	0.999999997	0.7	.	.
USP33	1	77695987	77759852	N	.	N	Y	-0.757378711	12.45007814	0.996116691	7.9	.	.
USP34	2	61187463	61470769	N	.	N	N	-5.864561425	0.057880419	1	0.1	DM	.
USP35	11	78188812	78214711	N	.	N	N	0.93719768	91.82728483	0.043478464	47.8	.	.
USP38	4	143184917	143223830	N	Viable	N	Y	-1.634399379	2.731955779	5.91E-05	73.4	.	.
USP4	3	49277831	49340712	N	.	N	Y	-0.699928248	13.92024078	6.20E-07	83.3	.	.
USP40	2	233475520	233566782	N	.	N	N	0.548774111	82.38120044	1.74E-14	96.6	.	.
USP41	22	20350578	20390758	N	.	N	N	.	.	.	.	.	.
USP42	7	6104884	6161564	N	.	N	Y	0.029139383	51.69300226	0.998681653	6.3	.	.
USP43	17	9644698	9729691	N	.	N	N	-0.280702041	30.60137755	0.009534304	55.1	.	.
USP44	12	95516560	95551490	N	.	N	Y	-0.173896395	37.15344099	1.46E-09	90.8	DM	.
USP45	6	99432379	99521728	N	.	N	N	1.119832309	94.18301789	8.70E-14	96.1	FTV	.
USP46	4	52590972	52659335	N	.	N	N	-0.215544031	34.54882213	0.911054239	17.2	DM?	.
USP47	11	11841423	11959323	N	Viable	N	Y	-1.936522447	1.8232332	0.999999875	1.2	.	.
USP48	1	21678298	21783606	N	.	N	N	-1.040748883	7.362389304	0.999997429	2	.	.
USP49	6	41789896	41895361	N	.	N	N	-0.479758918	21.01638016	0.943537459	15.4	.	.
USP51	X	55484616	55489202	N	.	N	N	0.391548194	75.45291428	0.912300847	17.2	.	.
USP53	4	119212587	119295517	N	.	N	N	0.224067009	65.86791688	0.001053353	64.5	DM?	.
USP54	10	73497538	73625953	N	Viable	N	Y	-0.378764424	25.50211264	3.94E-05	74.6	DM?	.
USP6	17	5116438	5175034	N	.	N	N	2.178157638	98.83081554	1.76E-18	98.3	.	.
USP6NL	10	11453946	11611754	N	.	N	N	-0.493659292	20.46072814	0.102392915	43	DM?	.
USP9X	X	41085635	41236579	N	.	N	N	-2.406690156	1.047635585	1	0.3	FTV	Mental retardation, X-linked 99, 300919 (3)
USP9Y	Y	12701231	12860839	N	.	N	N	.	.	0.140701438	41.1	DM	Spermatogenic failure, Y-linked, 2, 415000 (3)
USPL1	13	30617693	30660770	N	.	N	N	-0.075099153	44.00648261	0.49129698	30.2	.	.
UST	6	148747328	149076990	N	.	N	N	0.222654188	65.80424842	0.984203295	11.1	.	.
UTP11L	1	38009258	38024824	N	.	N	N	-0.113219363	41.24558662	1.27E-06	82.2	.	.
UTP14A	X	129906121	129929761	N	.	N	N	0.58391	83.64878162	0.999629563	4.9	.	.
UTP14C	13	52024691	52033600	N	.	N	N	0.488434514	80.02546738	0.001178362	64.1	.	.
UTP15	5	73565443	73583377	N	.	N	N	0.727428919	87.53255774	0.985835503	10.8	.	.
UTP18	17	51260528	51297936	N	.	N	N	-0.613054008	16.39173468	0.415444933	32.4	.	.
UTP20	12	101280109	101386616	N	.	N	N	0.625220845	84.91057475	0.170231063	39.7	.	.
UTP23	8	116766503	116849463	N	.	N	N	0.26384649	68.31047057	0.033108947	49.2	.	.
UTP3	4	70688479	70690551	N	.	N	N	-0.084968981	43.20194478	0.002776963	60.7	.	.
UTP6	17	31860899	31901765	N	.	N	N	0.247227331	67.29177519	4.83E-06	79.6	.	.
UTRN	6	144285701	144853034	N	.	N	Y	-1.890771553	1.904265787	2.97E-09	90.2	DM?	.
UTS2	1	7843083	7853512	N	.	N	Y	0.74788121	88.03611738	0.151041459	40.5	DP	.
UTS2B	3	191267168	191330536	N	Viable	N	Y	0.593989004	83.93818371	0.011039991	54.5	.	.
UTS2R	17	82374230	82375586	N	.	N	Y	.	.	1.80E-05	76.5	.	.
UTY	Y	13248379	13480673	N	.	N	Y	.	.	0.632058104	26.6	.	.
UVRAG	11	75815167	76143195	N	.	N	N	-0.548244002	18.2728483	0.8586025	19.6	.	.
UVSSA	4	1347266	1388049	N	.	N	N	2.024734091	98.6050819	8.89E-14	96.1	DM	UV-sensitive syndrome 3, 614640 (3)
UXT	X	47651798	47659161	N	.	N	N	0.008591214	50.15917115	0.836315941	20.4	.	.
VAMP3	1	7771269	7781432	N	.	N	Y	-0.118961255	40.82305956	0.054263067	46.5	.	.
VAMP4	1	171700160	171742247	N	.	N	N	0.002044933	49.63824738	0.919995934	16.7	.	.
VAMP5	2	85584408	85593412	N	.	N	N	0.147473793	60.82653238	0.051619746	46.8	.	.
VAMP7	X	155881293	155943769	N	.	N	Y	0.484307457	79.86340221	0.004631963	58.5	DP	.
VANGL1	1	115641953	115698224	N	.	N	Y	-0.431870058	23.10007524	0.533615186	29	DM	Caudal regression syndrome, 600145 (3); {Neural tube defects, susceptibility to}, 182940 (3)
VAPA	18	9914002	9960021	N	.	N	N	-0.265193969	31.55061643	0.123795283	41.9	.	.
VAPB	20	58389122	58451101	N	.	N	Y	-0.078575026	43.76338485	0.73972383	23.5	DM	Amyotrophic lateral sclerosis 8, 608627 (3); Spinal muscular atrophy, late-onset, Finkel type, 182980 (3)
VARS	6	31777518	31795953	N	.	N	N	-0.311376616	28.82444869	0.679794135	25.2	.	.
VARS2	6	30908242	30926459	N	.	N	N	0.741943324	87.9145685	4.22E-14	96.4	.	Combined oxidative phosphorylation deficiency 20, 615917 (3)
VASH1	14	76762189	76783015	N	.	N	Y	-0.327132777	27.8867859	0.730608114	23.7	.	.
VASH2	1	212950520	212992037	N	.	N	Y	-0.119765437	40.78833131	0.819582565	21	.	.
VASN	16	4371848	4383528	N	.	N	Y	0.644086851	85.4835909	0.053807166	46.6	.	.
VASP	19	45506579	45526983	N	.	N	Y	-0.081293491	43.49713492	0.583670616	27.9	.	.
VAT1	17	43014605	43025123	N	.	N	N	0.063177242	54.40180587	0.019956013	51.7	.	.
VAT1L	16	77788530	77980107	N	.	N	Y	-0.265997742	31.51588818	1.90E-05	76.4	.	.
VAV2	9	133761894	133992604	N	.	N	Y	-0.810570593	11.36192626	0.00251877	61.1	.	.
VAV3	1	107571160	107965144	N	.	N	Y	-0.273198957	31.08757307	0.020059323	51.7	DM?	.
VAX2	2	70900590	70933446	N	.	N	Y	0.821148306	89.54679632	0.315038571	35.3	.	.
VBP1	X	155197007	155239817	N	.	N	N	0.038603643	52.45123575	0.822547587	20.9	.	.
VCPIP1	8	66628487	66667217	N	.	N	N	-1.719819552	2.373097181	0.999341018	5.5	.	.
VCPKMT	14	50108632	50116600	N	Viable	N	Y	0.108195341	57.87463101	2.62E-08	87.8	.	.
VCX	X	7842262	7844143	N	.	N	N	.	.	0.577712383	28	.	.
VCX2	X	8169944	8171267	N	.	N	N	.	.	0.103436662	42.9	.	.
VCX3A	X	6533618	6535118	N	.	N	N	.	.	0.506384678	29.8	DM	.
VCX3B	X	8464830	8466510	N	.	N	N	.	.	0.2213496	38	.	.
VCY	Y	13985772	13986513	N	.	N	N	.	.	.	.	.	.
VCY1B	Y	14056217	14056958	N	.	N	N	.	.	.	.	.	.
VDAC2	10	75210154	75231448	N	.	N	N	-0.10763024	41.63338543	0.819301261	21	.	.
VDAC3	8	42391624	42405897	N	.	N	Y	-0.334635847	27.50477513	0.970696229	12.9	.	.
VDR	12	47841537	47943048	N	.	N	Y	-0.008025521	48.81634543	0.392125212	33	DM	Rickets, vitamin D-resistant, type IIA, 277440 (3); ?Osteoporosis, involutional, 166710 (1)
VEGFB	11	64234538	64238793	N	Viable	N	Y	0.858665982	90.35133414	1.52E-06	81.9	.	.
VENTX	10	133237404	133241929	N	.	N	N	0.837111437	89.94617121	3.99E-09	89.8	.	.
VEPH1	3	157259742	157533619	N	.	N	Y	0.890094983	90.93013833	9.33E-12	94.3	.	.
VGLL1	X	136532152	136556807	N	.	N	N	0.528370887	81.58245066	0.449924752	31.4	.	.
VGLL2	6	117265558	117273565	N	.	N	N	0.451425935	78.40481565	0.860675375	19.5	.	.
VGLL3	3	86937969	86991119	N	.	N	N	-0.15536658	38.37471783	0.336018872	34.7	.	.
VGLL4	3	11556070	11771350	N	.	N	N	0.238616903	66.76506338	0.469478553	30.9	.	.
VHLL	1	156298624	156299299	N	.	N	N	.	.	0.002900573	60.5	.	.
VIL1	2	218419092	218453295	N	.	N	Y	0.027073687	51.58302946	1.21E-05	77.6	.	Cholestasis, progressive canalicular (1)
VILL	3	37988059	38007188	N	.	N	N	-0.410020958	23.9509174	3.01E-12	94.9	.	.
VIM	10	17228259	17237593	N	.	N	Y	-0.455487979	22.06401574	0.959386089	14	DM	Cataract 30, pulverulent, 116300 (3)
VIMP	15	101270817	101277500	N	.	N	N	0.573390777	83.20310239	5.00E-11	93.4	DFP	.
VIP	6	152750798	152759765	N	.	N	Y	-0.018550615	48.01759565	0.005828944	57.4	DM?	.
VIPAS39	14	77426675	77457952	N	.	N	N	-0.590544433	17.03999537	0.000534939	66.8	.	Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3)
VIPR2	7	159028175	159144957	N	.	N	Y	0.644892524	85.51253111	9.34E-07	82.6	DM?	.
VIT	2	36696690	36814792	N	.	N	N	-0.046043433	46.13069399	4.91E-22	99	.	.
VKORC1L1	7	65873267	65959563	N	.	N	N	-0.019507464	47.94813914	0.851484219	19.9	.	.
VLDLR	9	2621834	2660053	N	.	N	Y	-0.503884612	20.03241303	0.000865741	65.2	DM	Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 (3)
VMA21	X	151396515	151409364	N	.	N	N	0.303127316	70.68356775	0.651805242	26	DM	Myopathy, X-linked, with excessive autophagy, 310440 (3)
VMAC	19	5904858	5910853	N	.	N	N	.	.	0.023464709	50.8	.	.
VMO1	17	4785285	4786433	N	.	N	N	-0.174200506	37.13028882	0.000437154	67.4	.	.
VMP1	17	59707192	59842255	N	.	N	N	-0.49315829	20.47809226	0.930655518	16.1	.	.
VN1R1	19	57454790	57457142	N	.	N	N	0.882132724	90.75070904	0.310171245	35.5	.	.
VN1R2	19	53258292	53261837	N	.	N	N	0.60163757	84.14655322	0.000121566	71.3	.	.
VN1R4	19	53266676	53267723	N	.	N	N	0.829607924	89.778318	0.261583303	36.7	.	.
VNN1	6	132681590	132714049	N	.	N	Y	0.741629376	87.90299242	2.35E-07	84.9	DP	[High density lipoprotein cholesterol level QTL 8] (3)
VNN2	6	132743870	132763459	N	.	N	N	-0.053848657	45.52873763	1.02E-08	88.9	.	.
VNN3	6	132722787	132734765	N	.	N	N	.	.	0.034731445	49	.	.
VOPP1	7	55436056	55572988	N	.	N	N	0.337921524	72.70938242	0.125315641	41.8	.	.
VPREB1	22	22244675	22245515	N	.	N	Y	0.649380445	85.58198761	0.00134359	63.6	DFP	.
VPREB3	22	23752743	23754468	N	.	N	N	0.512408218	80.9804943	0.016148567	52.8	.	.
VPS11	11	119067692	119081978	N	.	N	N	.	.	0.223659482	37.9	.	.
VPS13A	9	77177353	77421541	N	Viable	N	Y	-2.891648909	0.642472652	0.004238311	58.9	DM	Choreoacanthocytosis, 200150 (3)
VPS13B	8	99013266	99877580	N	.	N	N	-3.337525389	0.445679227	9.81E-27	99.5	DM	Cohen syndrome, 216550 (3)
VPS13C	15	61852389	62060473	N	Viable	N	Y	-3.156315741	0.532499855	1.86E-37	99.9	.	.
VPS16	20	2840703	2866732	N	.	N	N	-0.132404112	39.91433698	2.29E-05	75.9	.	.
VPS26B	11	134224645	134247792	N	.	N	N	-0.695744556	14.07072987	0.970719438	12.9	.	.
VPS28	8	144423601	144428563	N	.	N	N	-0.166697481	37.63384847	0.115974874	42.3	.	.
VPS29	12	110491097	110502117	N	.	N	N	-0.073942787	44.13960757	0.934744448	15.9	.	.
VPS33A	12	122229564	122266521	N	.	N	N	-0.98071975	8.23059559	0.687968695	24.9	.	.
VPS36	13	52412602	52450628	N	.	N	N	-0.650725068	15.36146322	0.100608361	43.1	.	.
VPS37A	8	17246571	17302427	N	.	N	N	0.043538553	52.85061064	0.53495834	29	DM	Spastic paraplegia 53, autosomal recessive, 614898 (3)
VPS37B	12	122865328	122896444	N	.	N	N	0.253623009	67.679574	0.676809637	25.3	.	.
VPS37C	11	61130256	61161617	N	.	N	N	0.805185239	89.25160618	0.197171488	38.8	.	.
VPS39	15	42158701	42208316	N	.	N	N	-0.754509349	12.48480639	0.000738265	65.8	DM?	.
VPS45	1	150067293	150145327	N	.	N	N	-0.029577629	47.32881866	0.00030557	68.6	DM	Neutropenia, severe congenital, 5, autosomal recessive, 615285 (3)
VPS4B	18	63389190	63422483	N	.	N	N	0.116655069	58.50552758	0.213873857	38.3	.	.
VPS50	7	93232340	93361121	N	.	N	N	.	.	.	.	.	.
VPS8	3	184812143	185052614	N	.	N	N	0.071287528	54.95745789	3.62E-06	80.2	.	.
VPS9D1	16	89707134	89720986	N	.	N	N	-0.128878445	40.18058691	0.001766484	62.4	.	.
VRK1	14	96797304	96931722	N	.	N	N	-0.338310159	27.33692192	0.042898405	47.9	DM	Pontocerebellar hypoplasia type 1A, 607596 (3)
VRK2	2	57907651	58159920	N	.	N	N	0.511748286	80.94576605	1.22E-08	88.7	.	.
VRK3	19	49976467	50025946	N	.	N	N	0.405747972	76.13590322	1.57E-06	81.8	.	.
VRTN	14	74303069	74360008	N	.	N	N	-0.246056484	32.69086068	0.858358429	19.6	.	.
VSIG1	X	108044970	108079184	N	.	N	Y	-0.03627546	46.84841118	0.00569225	57.5	DM?	.
VSIG10	12	118063593	118136026	N	.	N	N	0.110259893	58.00196793	5.55E-07	83.6	FTV	.
VSIG10L	19	51331536	51342124	N	.	N	N	.	.	.	.	.	.
VSIG2	11	124747472	124752238	N	.	N	N	0.142990968	60.43294553	0.000163566	70.4	.	.
VSIG4	X	66021738	66040125	N	.	N	Y	0.680495985	86.43861782	0.000110511	71.5	DM?	.
VSIG8	1	159854316	159862657	N	Viable	N	Y	-0.30079494	29.40904092	0.003159998	60.1	.	.
VSNL1	2	17539126	17657018	N	.	N	N	-0.112415198	41.29189095	0.744967825	23.3	.	.
VSTM1	19	54040825	54063953	N	.	N	N	0.062220491	54.30340916	4.39E-09	89.7	.	.
VSTM2A	7	54542325	54571080	N	.	N	N	0.113784984	58.30294611	0.107352766	42.7	.	.
VSTM2B	19	29526499	29564479	N	.	N	N	.	.	.	.	.	.
VSTM2L	20	37903104	37945350	N	.	N	N	0.513364317	81.01522255	0.362003649	33.9	.	.
VSTM4	10	49014245	49115509	N	.	N	N	0.70396241	86.97690571	0.155399626	40.4	.	.
VSTM5	11	93818232	93850531	N	.	N	N	.	.	.	.	.	.
VSX1	20	25070885	25082365	N	.	N	Y	.	.	0.006599733	56.8	DM	Keratoconus 1, 148300 (3); Corneal dystrophy, posterior polymorphous, 1, 122000 (3); Craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3)
VTA1	6	142147162	142224689	N	.	N	N	0.109152052	57.94408752	0.082406141	44.3	.	.
VTCN1	1	117143587	117210960	N	.	N	Y	0.274219089	68.94136714	7.29E-09	89.3	.	.
VTI1A	10	112446998	112818744	N	Viable	N	Y	-0.046649065	46.09017769	0.413424038	32.4	.	.
VTI1B	14	67647075	67674831	N	.	N	Y	0.400815894	75.88122938	0.209578769	38.5	.	.
VTN	17	28367276	28373091	N	.	N	Y	-0.033253349	47.06256873	1.14E-09	91.1	DP	.
VWA1	1	1434861	1442882	N	.	N	Y	0.224567453	65.92000926	0.03319976	49.2	.	.
VWA2	10	114239330	114291513	N	.	N	N	1.413607369	96.45771835	2.58E-13	95.8	.	.
VWA3A	16	22092538	22156966	N	Viable	N	Y	1.251395399	95.43902298	1.84E-20	98.8	.	.
VWA3B	2	98087116	98313299	N	.	N	N	1.600797228	97.4995659	3.27E-18	98.2	DM?	.
VWA5A	11	124115362	124147721	N	.	N	N	0.637695968	85.29837356	1.89E-15	97.2	.	.
VWA5B1	1	20290919	20354894	N	.	N	N	.	.	.	.	.	.
VWA5B2	3	184230429	184242329	N	.	N	N	.	.	0.354623648	34	.	.
VWA7	6	31765590	31777294	N	.	N	N	1.371293822	96.22619668	4.29E-07	84	.	.
VWA8	13	41566837	41961120	N	Viable	N	Y	-0.460900613	21.86722232	2.93E-40	99.9	FTV	.
VWA9	15	65578753	65611289	N	.	N	N	-0.405837712	24.10719454	0.003093813	60.2	.	.
VWC2	7	49773661	49921950	N	.	N	N	.	.	0.79516087	21.8	.	.
VWC2L	2	214411065	214578959	N	.	N	N	0.200952107	64.44405857	0.612117521	27.1	.	.
VWCE	11	61258286	61295424	N	.	N	N	-0.472915409	21.34051051	5.90E-13	95.5	.	.
VWDE	7	12330885	12403941	N	.	N	N	.	.	.	.	.	.
VWF	12	5948874	6124770	N	.	N	Y	1.570969151	97.3201366	1.52E-11	94.1	DM	von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 (3); von Willebrand disease, type 1, 193400 (3); von Willibrand disease, type 3, 277480 (3)
WAC	10	28532493	28623112	N	.	N	N	-0.400095467	24.4197488	0.999891943	3.8	DM?	.
WAS	X	48676596	48691427	N	.	N	Y	0.179399332	63.14753719	0.991202084	9.7	DM	Wiskott-Aldrich syndrome, 301000 (3); Thrombocytopenia, X-linked, 313900 (3); Neutropenia, severe congenital, X-linked, 300299 (3); Thrombocytopenia, X-linked, intermittent, 313900 (3)
WASF3	13	26557703	26688948	N	.	N	N	0.011764461	50.40805695	0.960588202	13.9	DM?	.
WASH1	9	14521	29739	N	.	N	N	.	.	.	.	.	.
WBP1	2	74458329	74460891	N	.	N	N	0.594134289	83.9497598	0.000303097	68.6	.	.
WBP11	12	14784579	14803540	N	.	N	N	-0.682497233	14.4469526	0.999928146	3.5	.	.
WBP1L	10	102743970	102816267	N	.	N	N	0.261126067	68.10210106	0.909387314	17.3	.	.
WBP2	17	75845699	75856507	N	.	N	N	-0.144188409	39.10979915	0.089618233	43.8	.	.
WBP2NL	22	41998725	42058456	N	.	N	N	0.838067604	89.96932338	2.07E-09	90.5	.	.
WBP4	13	41061274	41084006	N	.	N	N	-0.055913898	45.41297679	0.000482126	67.1	.	.
WBP5	X	103356445	103358469	N	.	N	Y	0.08362237	55.98772935	0.152692408	40.5	.	.
WBSCR16	7	75027122	75074228	N	.	N	N	.	.	0.000647048	66.2	.	.
WBSCR17	7	71132169	71713600	N	Viable	N	Y	-1.009777476	7.738612028	0.095617428	43.4	.	.
WBSCR22	7	73683025	73705161	N	.	N	N	-0.528759206	19.07738612	0.52115194	29.4	.	.
WBSCR27	7	73834590	73842535	N	.	N	N	1.185151962	94.91231117	0.067911663	45.2	.	.
WBSCR28	7	73861159	73865893	N	.	N	N	0.883088819	90.78543729	1.59E-06	81.8	.	.
WDFY1	2	223855716	223945387	N	.	N	N	-0.319475863	28.315101	1.69E-05	76.7	.	.
WDFY2	13	51584455	51767707	N	.	N	N	-0.115937794	41.07194536	0.003595002	59.6	.	.
WDFY3	4	84669610	84966391	N	.	N	N	-4.683342707	0.12154888	1	0.1	DM?	.
WDFY4	10	48684876	48982956	N	.	N	N	.	.	.	.	DFP	.
WDHD1	14	54938950	55027105	N	.	N	N	-0.062812562	44.91520519	1.82E-11	94	.	.
WDR11	10	120851175	120909524	N	.	N	N	-1.219603939	5.382878972	0.070328055	45	DM	Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3)
WDR13	X	48590042	48608867	N	.	N	N	0.045300934	53.00688777	0.940346119	15.5	DM	.
WDR17	4	176065834	176182818	N	.	N	N	0.07144044	54.96324593	7.02E-16	97.4	.	.
WDR18	19	984271	998438	N	.	N	N	-0.003392975	49.1578399	0.90160756	17.7	.	.
WDR20	14	102139503	102224847	N	.	N	N	-0.626146471	15.99814783	0.939272873	15.6	.	.
WDR24	16	684622	690444	N	.	N	N	-1.098720632	6.59257973	0.004702416	58.4	.	.
WDR25	14	100376418	100530303	N	.	N	N	-0.128878445	40.18058691	0.04222611	48	.	.
WDR26	1	224385143	224437033	N	.	N	N	-0.492200886	20.50124443	0.999677391	4.7	.	.
WDR27	6	169457212	169702048	N	.	N	N	2.863556128	99.43855994	2.40E-15	97.1	.	.
WDR31	9	113313222	113340298	N	.	N	N	-0.169415642	37.44284309	5.54E-06	79.3	DM?	.
WDR33	2	127701022	127811187	N	.	N	N	-2.091288093	1.475950686	0.999997733	2	.	.
WDR34	9	128633661	128656787	N	.	N	N	-0.296814857	29.62898651	3.70E-05	74.7	.	Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3)
WDR37	10	1049538	1132297	N	.	N	Y	-1.075548672	6.858829658	0.996766803	7.7	.	.
WDR38	9	124853417	124857890	N	.	N	N	0.930022697	91.72888812	0.000345295	68.2	.	.
WDR4	21	42843094	42879568	N	.	N	N	0.200295721	64.41511837	5.34E-06	79.4	DM?	.
WDR41	5	77425970	77620611	N	.	N	N	0.548307322	82.3754124	2.52E-06	80.8	.	.
WDR43	2	28894643	28948222	N	.	N	N	0.410380843	76.3674249	0.99894244	6	.	.
WDR44	X	118346073	118449961	N	.	N	N	0.279958701	69.3233779	0.999844186	4.2	.	.
WDR45	X	49074433	49101170	N	.	N	N	0.028381319	51.66985009	0.965710816	13.4	DM	Neurodegeneration with brain iron accululation 5, 300894 (3)
WDR45B	17	82614562	82648553	N	.	N	N	-0.467776875	21.53730393	0.637042299	26.4	.	.
WDR46	6	33279108	33289527	N	.	N	N	-0.517274597	19.5577936	8.42E-06	78.5	.	.
WDR47	1	108970214	109042113	N	.	N	Y	-0.946878712	8.763095445	0.905661618	17.6	.	.
WDR49	3	167478684	167653983	N	.	N	N	0.71544464	87.28367193	2.30E-12	95	.	.
WDR5	9	134135365	134159968	N	.	N	N	-0.456600078	21.99455924	0.99870216	6.3	DM	.
WDR53	3	196554177	196568674	N	.	N	N	0.185138978	63.52375991	0.000341189	68.3	.	.
WDR54	2	74421678	74425755	N	.	N	N	0.210518064	65.10968339	2.40E-06	80.9	.	.
WDR5B	3	122412332	122416051	N	.	N	N	-0.125354587	40.43526075	5.47E-05	73.7	.	.
WDR6	3	49007062	49015953	N	.	N	N	-0.407009098	24.0608902	9.20E-07	82.6	.	.
WDR60	7	158856578	158956747	N	.	N	N	0.543984882	82.20177114	2.01E-07	85.2	.	Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3)
WDR61	15	78277835	78299794	N	.	N	N	-0.312126643	28.79550848	0.089774579	43.8	.	.
WDR62	19	36054881	36105106	N	.	N	N	-0.348608857	26.85651444	3.70E-13	95.7	DM	Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 (3)
WDR63	1	84999147	85133138	N	.	N	N	-0.782610543	11.92915437	0.000118222	71.4	.	.
WDR64	1	241652278	241802133	N	.	N	N	.	.	4.90E-15	96.9	.	.
WDR66	12	121917862	122003927	N	.	N	N	0.467196511	79.18041327	1.25E-10	92.8	DM?	.
WDR7	18	56651343	57036606	N	.	N	N	-1.454028282	3.623314233	0.999999984	0.9	.	.
WDR70	5	37379212	37753435	N	.	N	N	-1.157132886	6.01377554	0.802235273	21.6	.	.
WDR72	15	53513741	53762878	N	.	N	Y	-0.197870785	35.6080338	1.62E-16	97.6	DM	Amelogenesis imperfecta, type IIA3, 613211 (3)
WDR73	15	84639281	84654343	N	.	N	N	0.164543267	62.12884181	7.90E-06	78.7	.	Galloway-Mowat syndrome, 251300 (3)
WDR74	11	62832342	62841809	N	.	N	N	0.049127994	53.35995833	2.46E-08	87.9	.	.
WDR75	2	189441433	189475565	N	.	N	N	0.116957788	58.52289171	0.566494634	28.3	.	.
WDR76	15	43826963	43868419	N	.	N	N	-0.143884421	39.12716328	0.002305191	61.4	.	.
WDR78	1	66812885	66924887	N	.	N	N	0.016700113	50.79585576	7.88E-11	93.1	.	.
WDR81	17	1716523	1738599	N	.	N	N	.	.	1.26E-05	77.5	DM	Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 (3)
WDR82	3	52254421	52288020	N	.	N	N	-0.277483031	30.77501881	0.923062144	16.5	.	.
WDR83OS	19	12668071	12671356	N	.	N	N	0.14651721	60.7454998	0.001766861	62.4	.	.
WDR86	7	151375909	151410727	N	.	N	N	0.466579567	79.16883718	3.31E-11	93.6	.	.
WDR87	19	37884823	37906677	N	.	N	N	.	.	.	.	.	.
WDR88	19	33132090	33175795	N	.	N	N	0.063328449	54.40759391	3.30E-08	87.5	.	.
WDR89	14	63597039	63641861	N	.	N	N	-0.171329534	37.29814204	0.000198089	69.8	.	.
WDR90	16	649311	667833	N	.	N	N	1.007578036	92.86334433	4.02E-46	100	.	.
WDR91	7	135183839	135211534	N	.	N	N	-1.207599338	5.492851768	0.00140854	63.3	.	.
WDR92	2	68122936	68157560	N	.	N	N	0.185138978	63.52375991	0.805659459	21.4	.	.
WDR93	15	89690797	89743638	N	.	N	N	0.185441616	63.55270012	6.27E-15	96.8	.	.
WDYHV1	8	123416725	123467230	N	.	N	N	0.217871355	65.53221045	0.000384005	67.9	.	.
WEE2	7	141708353	141731271	N	.	N	N	-0.162717545	37.82485385	0.000967997	64.8	.	.
WFDC1	16	84294646	84329851	N	Viable	N	Y	0.972176436	92.35399664	2.97E-06	80.6	.	.
WFDC10A	20	45629526	45631196	N	.	N	N	0.411041265	76.39636511	0.274663286	36.4	.	.
WFDC10B	20	45684653	45705019	N	.	N	N	0.161523449	61.87995601	0.014843387	53.2	.	.
WFDC11	20	45648563	45670270	N	.	N	N	0.320046263	71.77750767	0.003350138	59.9	.	.
WFDC12	20	45123425	45124465	N	.	N	N	0.510496156	80.89367367	0.05685317	46.3	.	.
WFDC13	20	45702016	45708817	N	.	N	N	0.160566904	61.79892342	0.252946357	37	.	.
WFDC2	20	45469706	45481532	N	.	N	N	-0.050476626	45.73710714	0.634143545	26.5	.	.
WFDC3	20	45747944	45791932	N	.	N	N	0.416778578	76.67419112	0.019237532	51.9	.	.
WFDC5	20	45109452	45115172	N	.	N	N	0.041473905	52.65960526	5.60E-05	73.6	.	.
WFDC6	20	45534196	45539495	N	.	N	N	0.335052688	72.57046941	0.054913983	46.4	.	.
WFDC8	20	45551153	45579326	N	.	N	N	0.167262974	62.32563524	4.97E-06	79.6	.	.
WFDC9	20	45607939	45631268	N	.	N	N	0.335052688	72.57046941	0.010811346	54.6	.	.
WFIKKN1	16	629239	634116	N	.	N	Y	0.76318244	88.40655206	4.90E-08	87	.	.
WFIKKN2	17	50834650	50842348	N	.	N	Y	-0.592157754	16.95896278	0.025878488	50.4	.	.
WHAMM	15	82809628	82836108	N	.	N	N	1.458316765	96.75290849	1.04E-05	78	.	.
WI2-2610K16.2	9	136280942	136306901	N	.	N	N	.	.	.	.	.	.
WI2-3308P17.2	1	13049476	13155947	N	.	N	N	.	.	.	.	.	.
WIBG	12	55901413	55932618	N	.	N	N	0.033970832	52.15025757	0.862135667	19.4	.	.
WIF1	12	65050626	65121566	N	.	N	Y	-0.125354587	40.43526075	2.42E-05	75.7	.	.
WIPF1	2	174559572	174682916	N	.	N	Y	-0.452617031	22.15662441	0.944313925	15.3	DM	?Wiskott-Aldrich syndrome 2, 614493 (3)
WIPF2	17	40219304	40284136	N	.	N	N	-0.119613321	40.80569543	0.366730469	33.7	.	.
WIPF3	7	29806486	29917066	N	.	N	Y	.	.	0.000296999	68.7	.	.
WIPI1	17	68420948	68457513	N	.	N	N	-0.063416885	44.9036291	0.523500461	29.3	.	.
WIPI2	7	5190188	5233826	N	.	N	N	-0.210606002	34.88452856	0.093680612	43.5	.	.
WISP1	8	133191039	133230344	N	.	N	Y	0.563313685	82.85003183	0.00332828	59.9	.	.
WISP2	20	44714844	44728509	N	Viable	N	Y	0.211324798	65.16756381	0.001690793	62.5	.	.
WISP3	6	112054072	112070969	N	.	N	Y	0.353076131	73.59495283	0.008090856	55.8	DM	Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3); Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3)
WIZ	19	15419980	15449951	N	.	N	N	-0.647549733	15.45985993	0.998940437	6	.	.
WNK2	9	93184916	93320572	N	.	N	N	.	.	0.79276208	21.9	.	.
WNK3	X	54192823	54358642	N	.	N	Y	-0.300341933	29.43798113	0.999998367	1.9	DM?	.
WNK4	17	42780678	42796936	N	.	N	Y	0.609921902	84.47068357	1.83E-13	95.9	DM	Pseudohypoaldosteronism, type IIB, 614491 (3)
WNT10A	2	218880363	218899581	N	Viable	N	Y	0.794959429	89.10690513	0.010169289	54.9	DM	Odontoonychodermal dysplasia, 257980 (3); Schopf-Schulz-Passarge syndrome, 224750 (3); Tooth agenesis, selective, 4, 150400 (3)
WNT10B	12	48965340	48971763	N	Viable	N	Y	-0.193838554	35.89164786	0.003998126	59.1	DM	Split-hand/foot malformation 6, 225300 (3)
WNT11	11	76186325	76210736	Y	Viable	N	Y	-0.203255573	35.26075129	0.118580135	42.2	.	.
WNT16	7	121325367	121341104	N	Viable	N	Y	-0.447984887	22.38235805	0.000185159	70.1	DP	.
WNT2B	1	112466541	112530165	N	Viable	N	Y	-0.652484268	15.30937084	0.285537291	36.1	.	.
WNT5B	12	1529891	1647243	N	Viable	N	Y	-0.230396616	33.72113214	0.835340309	20.4	DP	.
WNT8A	5	138083892	138092365	N	.	N	Y	0.314604136	71.36076865	0.875728926	18.8	DM	.
WNT8B	10	100463041	100483744	N	.	N	N	-0.204212609	35.19708283	0.485778277	30.4	.	.
WRAP73	1	3630767	3652761	N	.	N	N	-0.114829257	41.15876599	0.02692199	50.2	.	.
WRB	21	39380244	39428528	N	.	N	N	0.103411903	57.457892	0.059159107	46.1	.	.
WRNIP1	6	2765414	2786952	N	.	N	N	0.077529154	55.49574579	0.637334638	26.4	.	.
WSB1	17	27294076	27315926	N	.	N	N	-0.42451861	23.36632517	0.92319404	16.5	.	.
WSB2	12	118032694	118062430	N	Viable	N	Y	-0.222893607	34.16102333	0.503215469	29.9	.	.
WSCD1	17	5772234	6124427	N	.	N	N	0.049430919	53.36574637	2.91E-06	80.6	.	.
WSCD2	12	108129471	108250537	N	.	N	N	-0.251796722	32.34936621	0.494025684	30.1	.	.
WWC1	5	168291651	168472303	N	.	N	Y	-1.141697857	6.129536378	0.018384506	52.1	DFP	[Memory, enhanced, QTL], 615602 (3)
WWC2	4	183099293	183320777	N	.	N	N	-0.105111665	41.76651039	2.48E-05	75.7	DM?	.
WWC3	X	10015562	10144478	N	.	N	N	0.82910958	89.76095387	0.999632961	4.9	DM?	.
WWP1	8	86342738	86478420	N	.	N	Y	-0.915907936	9.289807258	0.956844284	14.2	.	.
WWP2	16	69762306	69941741	N	.	N	N	-0.351907655	26.66550906	0.977902374	12.1	.	.
XAF1	17	6755447	6775647	N	.	N	N	1.368119208	96.20883255	2.07E-08	88.1	.	.
XAGE1A	X	52495676	52500812	N	.	N	N	.	.	.	.	.	.
XAGE1B	X	52512077	52520803	N	.	N	N	.	.	.	.	.	.
XAGE2	X	52369030	52375680	N	.	N	N	.	.	.	.	.	.
XAGE3	X	52862525	52868068	N	.	N	N	0.206542259	64.76240088	0.088580304	43.9	.	.
XAGE5	X	52812204	52818301	N	.	N	N	0.191535973	63.89419459	0.000119391	71.3	.	.
XCL1	1	168576473	168582077	N	.	N	Y	0.397947105	75.72495225	0.088160228	43.9	.	.
XCL2	1	168540765	168543997	N	.	N	N	0.268480327	68.6056607	0.087432539	44	.	.
XCR1	3	46017024	46027742	N	.	N	Y	0.132617807	59.62261967	0.09785415	43.3	.	.
XG	X	2752050	2815927	N	.	N	N	0.027424541	51.61775771	0.013679982	53.6	.	.
XIRP1	3	39183210	39192596	N	.	N	Y	2.262436038	98.95815246	2.18E-17	97.9	.	.
XK	X	37685759	37732130	N	.	N	Y	0.04243066	52.74063784	0.869601996	19.1	DM	McLeod syndrome with or without chronic granulomatous disease, 300842 (3)
XKR3	22	16783412	16821699	N	.	N	N	0.453338311	78.48584824	0.00085456	65.3	.	.
XKR4	8	55102389	55542054	N	.	N	N	-1.299707865	4.705678069	0.97759169	12.1	DM	.
XKR5	8	6808517	6835644	N	.	N	N	.	.	.	.	.	.
XKR6	8	10896045	11201366	N	.	N	N	-0.838153116	10.79469815	0.956776701	14.2	.	.
XKR7	20	31968002	32003387	N	.	N	N	-0.470494176	21.42154309	0.923951243	16.4	.	.
XKR8	1	27959462	27968096	N	.	N	N	-0.15536658	38.37471783	1.43E-05	77.2	.	.
XKR9	8	70669365	70790371	N	.	N	N	0.303424512	70.72408404	3.61E-08	87.4	.	.
XKRX	X	100913445	100929433	N	Viable	N	Y	0.473126302	79.46402732	0.000300218	68.7	.	.
XPC	3	14145147	14178783	N	.	N	Y	0.978383776	92.45239336	1.32E-10	92.8	DM	Xeroderma pigmentosum, group C, 278720 (3)
XPNPEP2	X	129738974	129769538	N	.	N	N	-0.156171384	38.30526133	1.69E-06	81.6	FP	{Angioedema induced by ACE inhibitors, susceptibility to}, 300909 (3)
XPNPEP3	22	40857077	40932815	N	.	N	N	-0.968583512	8.404236847	8.88E-06	78.4	DM	Nephronophthisis-like nephropathy 1, 613159 (3)
XPO1	2	61477849	61538626	N	.	N	N	-1.265059143	5.000868206	0.999999567	1.4	DM?	.
XPO4	13	20777329	20903048	N	.	N	N	-1.469435731	3.507553395	0.999999613	1.4	.	.
XPO5	6	43522330	43576075	N	.	N	N	-0.984251786	8.155351045	0.999999369	1.6	DM?	.
XPO6	16	28097979	28211920	N	.	N	N	-1.135284787	6.181628755	0.999999448	1.5	.	.
XPO7	8	21919671	22006585	N	.	N	N	-1.55389815	3.050298084	0.999999311	1.6	.	.
XPR1	1	180632004	180890251	N	.	N	N	-1.129989454	6.2568733	0.998119588	6.8	.	Basal ganglia calcification, idiopathic, 6, 616413 (3)
XRCC6	22	41621119	41664048	N	.	N	Y	-1.033398927	7.426057765	0.996855853	7.6	DFP	.
XRCC6BP1	12	57941541	57957269	N	.	N	N	0.309821667	71.05979047	0.00463367	58.5	.	.
XRN1	3	142306607	142448062	N	.	N	N	-1.071168769	6.893557909	0.995837599	8.1	.	.
XRN2	20	21303304	21389827	N	.	N	N	-1.187955601	5.695433235	0.813170186	21.2	.	.
XRRA1	11	74807739	74949200	N	.	N	N	0.985724572	92.60867049	4.25E-05	74.3	.	.
XXbac-B562F10.12	22	20429241	20446620	N	.	N	N	.	.	.	.	.	.
XXbac-BPG116M5.17	6	31927698	31952048	N	.	N	N	.	.	.	.	.	.
XXbac-BPG181M17.5	6	32937364	32953122	N	.	N	N	.	.	.	.	.	.
XXbac-BPG246D15.9	6	32813767	32838822	N	.	N	N	.	.	.	.	.	.
XXbac-BPG32J3.19	6	31706904	31717918	N	.	N	N	.	.	.	.	.	.
XXbac-BPG32J3.20	6	31686962	31714072	N	.	N	N	.	.	.	.	.	.
XXcos-LUCA11.5	3	50350892	50367923	N	.	N	N	.	.	0.206890279	38.5	.	.
XXYLT1	3	195068279	195271167	N	.	N	Y	0.389635172	75.36030561	0.051603507	46.8	.	.
XYLB	3	38346760	38421348	N	.	N	Y	0.507115742	80.74897262	2.63E-13	95.8	.	.
XYLT2	17	50346092	50363138	N	.	N	Y	-0.478652896	21.05689645	0.337133945	34.7	DP	{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3); Spondyloocular syndrome, 605822 (3)
YAF2	12	42157104	42238349	N	.	N	N	-0.052390454	45.59819413	0.842513636	20.2	.	.
YARS2	12	32727490	32755902	N	.	N	N	-0.416058551	23.66730335	6.88E-06	79	DM	Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3)
YBEY	21	46286337	46297751	N	.	N	N	-0.057022786	45.34352029	0.000726358	65.8	.	.
YBX2	17	7288252	7294615	N	.	N	Y	0.160716564	61.81628755	0.968725623	13.1	DM?	.
YBX3	12	10699089	10723312	N	.	N	Y	0.825929637	89.67413324	0.006628067	56.8	.	.
YDJC	22	21628089	21630064	N	.	N	Y	.	.	0.002150464	61.6	DP	.
YEATS2	3	183697818	183812625	N	.	N	N	-0.393771649	24.69178677	0.999977829	2.9	.	.
YEATS4	12	69359703	69390796	N	.	N	N	-0.072985841	44.23221624	0.098738789	43.2	.	.
YES1	18	721588	812546	N	.	N	Y	-0.023031474	47.74555768	0.046391622	47.4	.	.
YIF1A	11	66284580	66289170	N	.	N	N	0.58199694	83.58511316	2.08E-09	90.5	.	.
YIF1B	19	38305104	38317273	N	.	N	N	-0.482783102	20.8427389	0.037524214	48.6	.	.
YIPF1	1	53851719	53889834	N	.	N	Y	0.283635266	69.52017133	0.017379324	52.3	.	.
YIPF2	19	10922185	10928681	N	.	N	N	1.682499319	97.84684841	0.001099175	64.3	.	.
YIPF3	6	43511827	43516990	N	.	N	N	-0.532433342	18.88638074	0.812100974	21.2	.	.
YIPF4	2	32277910	32316594	N	.	N	N	0.180355903	63.21120565	0.019788591	51.8	.	.
YIPF6	X	68498323	68537285	N	.	N	N	0.335052688	72.57046941	0.571047385	28.2	.	.
YIPF7	4	44622065	44678556	N	.	N	N	0.469300995	79.2961741	2.38E-05	75.8	.	.
YJEFN3	19	19528861	19537581	N	.	N	N	0.388678713	75.30821323	2.64E-06	80.7	.	.
YKT6	7	44200968	44214294	N	.	N	N	0.110914976	58.05984835	0.852902233	19.8	.	.
YLPM1	14	74763366	74859435	N	.	N	N	-2.178173208	1.319673554	0.999933059	3.4	FTV	.
YME1L1	10	27110112	27155266	N	.	N	N	-0.837196214	10.83521445	0.994242145	8.8	.	.
YOD1	1	207043849	207052980	N	.	N	N	-0.521256062	19.41309255	0.543401294	28.8	.	.
YPEL1	22	21697544	21735834	N	.	N	N	-0.052390454	45.59819413	0.224430518	37.9	.	.
YPEL2	17	59331689	59401729	N	.	N	N	0.015137522	50.6627308	0.928981264	16.2	.	.
YPEL3	16	30092314	30096915	N	Viable	N	Y	-0.035470476	46.91207964	0.122709139	42	.	.
YPEL4	11	57645087	57649944	N	.	N	N	0.061112993	54.1992244	0.805554819	21.4	.	.
YPEL5	2	30146941	30160533	N	.	N	N	-0.022378042	47.78028593	0.799401084	21.7	.	.
YRDC	1	37802944	37808185	N	.	N	N	-0.011047557	48.60797592	0.133395608	41.4	.	.
YTHDC1	4	68310387	68350089	N	.	N	N	-0.520145081	19.48254905	0.999999899	1.1	.	.
YTHDC2	5	113513683	113595285	N	.	N	N	-1.18373607	5.74173757	0.999999572	1.4	.	.
YTHDF1	20	63195429	63216234	N	.	N	N	-0.402814388	24.22295537	0.983709939	11.1	.	.
YTHDF2	1	28736621	28769775	N	.	N	N	-0.833520891	10.91045899	0.991165728	9.7	FP	.
YTHDF3	8	63168553	63212786	N	.	N	N	.	.	0.975545265	12.4	.	.
YWHAB	20	44885676	44908532	N	.	N	N	-0.094538075	42.4726515	0.938360894	15.7	.	.
YWHAG	7	76326794	76359031	N	.	N	Y	-0.404078275	24.15349887	0.937613569	15.7	.	.
YWHAH	22	31944461	31957603	N	.	N	N	-0.171482763	37.26341379	0.555591182	28.5	.	.
YWHAZ	8	100916525	100953388	N	.	N	N	-0.194949121	35.83376744	0.817170005	21.1	.	.
YY1AP1	1	155659443	155689000	N	.	N	N	-0.616434641	16.28754992	0.000145221	70.7	.	.
YY2	X	21855987	21858727	N	.	N	N	-0.498746657	20.24078254	0.383414003	33.2	.	.
ZACN	17	76071961	76083666	N	.	N	N	0.748175766	88.07084563	1.96E-15	97.1	FTV	.
ZADH2	18	75195108	75209348	N	.	N	N	-0.144992854	39.06349482	0.000446821	67.4	.	.
ZAN	7	100733626	100797797	N	.	N	Y	.	.	1.56E-43	100	DM?	.
ZAP70	2	97713560	97739862	N	.	N	Y	-0.823146294	11.10725242	0.272667248	36.4	DM	Selective T-cell defect, 269840 (3)
ZAR1	4	48490252	48494389	N	.	N	Y	.	.	0.016684021	52.6	.	.
ZAR1L	13	32303700	32315344	N	.	N	N	.	.	.	.	.	.
ZBBX	3	167240287	167381346	N	.	N	N	0.743699297	87.95508479	4.33E-11	93.5	.	.
ZBED1	X	2486414	2500967	N	.	N	N	-1.096809474	6.633096024	0.001833093	62.2	.	.
ZBED2	3	111592900	111595443	N	.	N	N	0.159759922	61.72946692	0.00205866	61.8	.	.
ZBED3	5	77072072	77087323	N	.	N	N	.	.	0.078436436	44.5	.	.
ZBED5	11	10812074	10858796	N	Viable	N	Y	.	.	.	.	.	.
ZBED6	1	203796309	203800558	N	.	N	N	.	.	.	.	.	.
ZBED6CL	7	150329789	150332721	N	.	N	N	0.434654036	77.61764195	0.002922262	60.4	.	.
ZBED8	5	160393148	160400097	N	.	N	N	.	.	.	.	.	.
ZBED9	6	28571630	28616212	N	.	N	N	.	.	.	.	.	.
ZBP1	20	57603846	57620576	N	.	N	N	1.702291703	97.91051687	1.30E-10	92.8	.	.
ZBTB1	14	64503712	64533690	N	.	N	Y	-0.562445944	17.85610928	0.973423964	12.6	.	.
ZBTB10	8	80485619	80526265	N	.	N	N	-0.29042075	30.03993749	0.881586183	18.5	.	.
ZBTB11	3	101648889	101677495	N	.	N	N	-1.201865964	5.550732187	0.269451352	36.5	.	.
ZBTB12	6	31899607	31901992	N	.	N	N	-0.460273767	21.90195057	0.807401019	21.4	.	.
ZBTB14	18	5289019	5297053	N	.	N	N	-0.846768806	10.63263298	0.628505782	26.7	.	.
ZBTB16	11	114059593	114250676	N	.	N	Y	-0.935698335	8.93094866	0.980087306	11.7	DM	Leukemia, acute promyelocytic, PL2F/RARA type (3); Skeletal defects, genital hypoplasia, and mental retardation, 612447 (3)
ZBTB2	6	151364117	151391548	N	.	N	N	-0.872952495	10.11170921	0.979834594	11.8	.	.
ZBTB21	21	41986831	42010387	N	.	N	N	-1.393160648	3.970596747	0.986130663	10.8	.	.
ZBTB22	6	33314406	33317942	N	.	N	N	-0.130792007	40.01852173	0.235099437	37.5	.	.
ZBTB25	14	64449106	64505213	N	.	N	N	-0.137489868	39.60757076	3.31E-05	75	.	.
ZBTB26	9	122915566	122931500	N	.	N	N	-0.658228302	15.08363721	0.015475125	53	.	.
ZBTB3	11	62748319	62754188	N	.	N	N	-0.528605147	19.08317416	0.243280561	37.3	.	.
ZBTB32	19	35704527	35717038	N	Viable	N	Y	-0.089601417	42.81993402	0.016210167	52.7	.	.
ZBTB33	X	120250752	120258398	N	.	N	Y	0.142990968	60.43294553	0.893444537	18	.	.
ZBTB34	9	126860665	126885878	N	.	N	N	-0.986462395	8.103258668	0.829622812	20.6	.	.
ZBTB37	1	173868082	173903549	N	.	N	N	-0.218261615	34.41569717	0.734036618	23.6	.	.
ZBTB38	3	141324213	141449792	N	.	N	N	-0.798429835	11.62817619	0.979491449	11.8	.	.
ZBTB39	12	56998834	57006446	N	.	N	N	0.528821762	81.62296695	0.00973093	55	.	.
ZBTB4	17	7459366	7484263	N	Viable	N	Y	-0.713023874	13.57874631	0.998490203	6.6	.	.
ZBTB40	1	22451851	22531157	N	.	N	N	-1.201731911	5.556520229	1.21E-05	77.6	DM	.
ZBTB41	1	197153680	197200542	N	.	N	N	-0.833369386	10.92203508	0.769627403	22.6	DM?	.
ZBTB42	14	104800596	104804712	N	.	N	N	.	.	.	.	.	?Lethal congenital contracture syndrome 6, 616248 (3)
ZBTB43	9	126805006	126838210	N	.	N	N	-0.268868697	31.33645888	0.877041935	18.8	.	.
ZBTB44	11	130226677	130314686	N	.	N	N	-0.367365256	26.00567228	0.992064124	9.4	.	.
ZBTB45	19	58513530	58538911	N	.	N	N	-0.490938465	20.55912485	0.02663698	50.3	.	.
ZBTB47	3	42653684	42665854	N	.	N	N	.	.	0.974750217	12.4	.	.
ZBTB48	1	6580001	6589280	N	.	N	N	-1.581048175	2.911385078	0.680198376	25.2	.	.
ZBTB49	4	4290251	4321786	N	.	N	N	-0.264739339	31.59113272	0.009164155	55.3	.	.
ZBTB5	9	37438114	37465399	N	.	N	N	-0.69735199	14.02442554	0.798455361	21.7	.	.
ZBTB6	9	122908056	122913330	N	.	N	N	0.037797903	52.3759912	0.357932618	34	.	.
ZBTB7B	1	155002630	155018522	N	.	N	Y	0.130855251	59.47791862	0.837393371	20.4	.	.
ZBTB7C	18	48026673	48410752	N	.	N	Y	0.317625038	71.63280662	0.90722146	17.5	.	.
ZBTB8A	1	32539427	32605939	N	.	N	N	0.278045399	69.20761706	0.106372648	42.8	.	.
ZBTB8B	1	32465069	32496686	N	.	N	N	.	.	0.360954125	33.9	.	.
ZBTB8OS	1	32600172	32650903	N	.	N	N	0.094952155	56.76911501	0.955749358	14.3	.	.
ZBTB9	6	33453970	33457548	N	.	N	N	0.234940518	66.52775366	0.012159363	54.1	.	.
ZC2HC1A	8	78666047	78719765	N	.	N	N	-0.521256062	19.41309255	0.811433032	21.3	.	.
ZC2HC1B	6	143864436	143938356	N	.	N	N	.	.	.	.	.	.
ZC2HC1C	14	75064170	75079987	N	.	N	N	0.2133882	65.27174857	1.62E-06	81.7	FTV	.
ZC3H10	12	56118159	56127514	N	.	N	N	-0.345813209	26.95491115	0.792020464	21.9	.	.
ZC3H11A	1	203795654	203854124	N	.	N	N	-0.906491622	9.469236557	0.997151605	7.4	.	.
ZC3H12A	1	37474552	37484379	N	.	N	Y	0.044646769	52.94321931	0.911632715	17.2	.	.
ZC3H12B	X	65366638	65507887	N	.	N	N	-0.175004808	37.08977253	0.972148733	12.8	DM?	.
ZC3H12C	11	110093361	110171841	N	.	N	N	-0.695438882	14.08230596	0.998726025	6.3	.	.
ZC3H12D	6	149446795	149485061	N	.	N	Y	.	.	0.727798126	23.8	.	.
ZC3H13	13	45954465	46052759	N	.	N	N	-1.669776621	2.569890606	1	0.2	.	.
ZC3H14	14	88562909	88627596	N	.	N	N	-1.063112955	7.015106789	0.999785297	4.4	DM	.
ZC3H15	2	186486156	186509363	N	.	N	N	0.243250221	67.10655785	0.947515648	15	.	.
ZC3H18	16	88570381	88631966	N	.	N	N	-0.983157836	8.178503212	0.999519576	5.2	.	.
ZC3H3	8	143437655	143541453	N	.	N	N	1.328530106	95.98309892	0.964538765	13.5	DP	.
ZC3H4	19	47064187	47113752	N	.	N	N	-1.148952448	6.089020085	0.999999772	1.3	.	.
ZC3H6	2	112275594	112340063	N	.	N	N	-1.075253288	6.8646177	0.938245509	15.7	.	.
ZC3H7A	16	11750586	11797267	N	.	N	N	-0.72721813	13.21409967	0.999987025	2.7	.	.
ZC3H7B	22	41301522	41360147	N	.	N	N	-1.232837822	5.28448226	0.990761551	9.8	.	.
ZC3H8	2	112211525	112255136	N	.	N	N	0.171896242	62.66134167	0.464854053	31	.	.
ZC3HAV1	7	139043520	139109719	N	.	N	N	0.522275928	81.3393529	0.021872618	51.2	DP	.
ZC3HAV1L	7	139025706	139036029	N	.	N	N	0.459885344	78.80419054	0.04176161	48.1	.	.
ZC4H2	X	64915802	65034713	N	.	N	N	0.101498578	57.33634312	0.825852221	20.8	DM	Wieacker-Wolff syndrome, 314580 (3)
ZCCHC10	5	132996985	133026604	N	.	N	N	-0.254016546	32.19887712	0.160801911	40.1	.	.
ZCCHC12	X	118823790	118826968	N	.	N	N	0.076269801	55.37998495	0.119948129	42.1	DM	.
ZCCHC13	X	74304190	74305031	N	.	N	N	0.381984452	75.00723505	0.000210272	69.7	DM?	.
ZCCHC14	16	87406246	87492045	N	.	N	Y	-1.055334205	7.136655669	0.948835727	14.9	.	.
ZCCHC16	X	112454500	112457112	N	.	N	N	0.607228418	84.37228686	0.000561725	66.7	DM?	.
ZCCHC17	1	31296982	31364953	N	.	N	N	-0.197666633	35.6485501	0.21514759	38.3	.	.
ZCCHC18	X	104112131	104115846	N	.	N	N	0.717867255	87.34734039	0.259266478	36.8	.	.
ZCCHC2	18	62523007	62587709	N	.	N	N	-0.759144048	12.42113793	0.305659357	35.6	.	.
ZCCHC24	10	79382325	79445627	N	.	N	N	1.133439538	94.36244718	0.473546851	30.7	.	.
ZCCHC3	20	296968	300321	N	.	N	N	-0.531631495	18.90953291	.	.	.	.
ZCCHC4	4	25312785	25370383	N	.	N	N	1.102755647	93.96886033	3.22E-05	75	.	.
ZCCHC5	X	78656069	78659328	N	.	N	N	0.651439248	85.66880824	7.23E-09	89.3	.	.
ZCCHC6	9	86287733	86354454	N	.	N	N	-0.747675382	12.6931759	0.999999563	1.5	.	.
ZCCHC7	9	37120539	37358149	N	.	N	N	1.080244383	93.7431267	3.37E-09	90	.	.
ZCCHC8	12	122471600	122501073	N	.	N	N	.	.	0.777819067	22.4	DM	.
ZCCHC9	5	81301590	81313297	N	.	N	N	0.720735065	87.46310123	0.007473948	56.3	.	.
ZCRB1	12	42312078	42326118	N	.	N	N	0.080902701	55.81408809	0.000953936	64.9	.	.
ZCWPW1	7	100400826	100428992	N	.	N	N	0.621577198	84.79481391	1.15E-12	95.2	.	.
ZCWPW2	3	28349146	28538122	N	.	N	N	0.23207049	66.37147653	6.76E-05	73	.	.
ZDBF2	2	206274663	206314428	N	.	N	N	0.650057059	85.62250391	1.38E-07	85.7	.	.
ZDHHC1	16	67394419	67416833	N	.	N	N	-0.797918528	11.63396423	5.11E-06	79.5	.	.
ZDHHC11	5	795606	850986	N	Viable	N	Y	2.934627626	99.49065231	5.60E-11	93.3	.	.
ZDHHC11B	5	710360	766952	N	.	N	N	.	.	0.043228373	47.8	.	.
ZDHHC12	9	128720869	128724127	N	.	N	N	0.316368397	71.5054697	0.011766228	54.3	.	.
ZDHHC13	11	19117099	19176422	N	.	N	Y	-0.233114996	33.52433872	2.55E-14	96.5	.	.
ZDHHC14	6	157381133	157678146	N	.	N	N	-0.078422859	43.78074897	0.982366558	11.4	.	.
ZDHHC15	X	75368427	75523502	N	.	N	N	0.073399639	55.17740348	0.896641058	17.9	.	?Mental retardation, X-linked 91, 300577 (3)
ZDHHC16	10	97446131	97457370	N	.	N	N	-0.563403124	17.82716907	0.018065827	52.2	.	.
ZDHHC17	12	76763588	76853696	N	.	N	N	-0.396420408	24.5991781	0.998394624	6.6	.	.
ZDHHC18	1	26826710	26857602	N	.	N	N	-0.037232312	46.79053076	0.00119785	64	.	.
ZDHHC19	3	196197449	196211437	N	.	N	N	0.494679511	80.27435319	0.052427427	46.7	.	.
ZDHHC2	8	17156029	17224799	N	Viable	N	Y	0.09223258	56.57232158	0.007033007	56.6	.	.
ZDHHC20	13	21372573	21459370	N	.	N	N	0.171896242	62.66134167	0.002330071	61.4	.	.
ZDHHC21	9	14611071	14693471	N	.	N	N	-0.400249026	24.39659663	0.051230379	46.9	.	.
ZDHHC22	14	77131270	77142734	N	.	N	N	0.170939673	62.57452104	0.318481045	35.2	.	.
ZDHHC23	3	113947901	113965401	N	Viable	N	Y	-0.456445049	22.02349945	3.89E-06	80	.	.
ZDHHC24	11	66520637	66546238	N	Viable	N	Y	0.121288029	58.8122938	0.006140308	57.1	.	.
ZDHHC3	3	44915257	44976185	N	.	N	N	-0.007220243	48.88580193	0.144015391	40.9	.	.
ZDHHC4	7	6577434	6589374	N	.	N	N	0.188965718	63.72634138	5.32E-10	91.7	.	.
ZDHHC5	11	57667747	57701187	N	.	N	N	-0.641959288	15.6219251	0.999924209	3.6	.	.
ZDHHC6	10	112424428	112446917	N	.	N	N	-0.360819318	26.28349829	0.00067586	66.1	.	.
ZDHHC7	16	84974181	85011535	N	.	N	N	-0.176918638	36.94507148	0.005074125	58	.	.
ZDHHC8	22	20129456	20148007	N	.	N	Y	-0.399795672	24.43132488	0.988991096	10.1	DP	.
ZDHHC9	X	129803288	129843909	N	.	N	N	-0.268065472	31.35961104	0.885437564	18.4	DM	Mental retardation, X-linked syndromic, Raymond type, 300799 (3)
ZER1	9	128729786	128772414	N	.	N	N	-0.889720408	9.799154946	0.998769063	6.2	.	.
ZFAND1	8	81701334	81732903	N	.	N	N	0.045300934	53.00688777	0.000588041	66.5	.	.
ZFAND2A	7	1152071	1160759	N	.	N	N	-0.024139966	47.63558488	0.000389857	67.8	.	.
ZFAND2B	2	219195237	219209651	N	.	N	N	-0.195752553	35.7874631	0.004951515	58.1	.	.
ZFAND3	6	37819499	38154624	N	.	N	N	-0.041059779	46.53585692	0.961977905	13.8	.	.
ZFAND4	10	45615501	45672780	N	.	N	N	0.784889091	88.87538346	0.009251565	55.3	.	.
ZFAND6	15	80059568	80138393	N	.	N	N	0.003001751	49.6961278	0.218468573	38.1	.	.
ZFC3H1	12	71609472	71667725	N	.	N	N	-2.46550913	1.00133125	1	0.5	.	.
ZFHX2	14	23520855	23556192	N	.	N	N	.	.	.	.	.	.
ZFHX4	8	76681219	76867285	N	.	N	N	-3.195174326	0.51513573	0.999999642	1.4	DM	?Ptosis, congenital, 178300 (2)
ZFP1	16	75148492	75172236	N	.	N	N	-0.415101607	23.69045552	0.009251623	55.3	.	.
ZFP14	19	36334453	36379199	N	.	N	N	-0.253862657	32.21624125	0.000162248	70.4	DM?	.
ZFP2	5	178895894	178933212	N	.	N	N	0.410380843	76.3674249	5.62E-12	94.6	.	.
ZFP28	19	56538948	56556810	N	.	N	N	-0.474019054	21.27684204	2.49E-06	80.8	.	.
ZFP3	17	5078248	5096374	N	.	N	N	-0.070919872	44.37691729	0.00058403	66.5	.	.
ZFP30	19	37613749	37692337	N	.	N	N	0.046408913	53.12264861	9.06E-08	86.2	.	.
ZFP37	9	113038380	113056759	N	.	N	N	-0.037885915	46.7268623	4.11E-09	89.8	.	.
ZFP41	8	143246821	143262705	N	.	N	N	0.290181792	69.94269839	0.000671958	66.1	.	.
ZFP42	4	187995771	188005050	Y	Viable	N	Y	-0.11785159	40.91566823	0.004753298	58.3	.	.
ZFP62	5	180847611	180861285	N	.	N	N	.	.	0.115212077	42.3	.	.
ZFP64	20	52051663	52204308	N	.	N	N	-0.21111235	34.8613764	0.005189853	57.9	.	.
ZFP69	1	40477215	40496343	N	.	N	N	0.577363401	83.35359148	8.56E-08	86.3	.	.
ZFP69B	1	40450102	40463718	N	.	N	N	0.719925571	87.43416102	2.52E-09	90.3	.	.
ZFP82	19	36383120	36418656	N	.	N	N	-0.435850038	22.9148579	0.0523308	46.7	.	.
ZFP90	16	68530090	68576072	N	.	N	N	-0.585759916	17.21363663	0.008861928	55.4	DM?	.
ZFP91	11	58579111	58621042	N	.	N	N	-0.046497232	46.10754182	0.983773003	11.1	.	.
ZFP91-CNTF	11	58579172	58624639	N	.	N	N	.	.	.	.	.	.
ZFP92	X	153418322	153426481	N	.	N	N	.	.	0.529624187	29.1	.	.
ZFPL1	11	65084223	65088400	N	Viable	N	Y	0.528517954	81.59981478	0.654739309	25.9	DM?	.
ZFR2	19	3804024	3869032	N	.	N	N	.	.	5.37E-09	89.5	.	.
ZFY	Y	2935281	2982506	N	.	N	N	.	.	0.255459999	36.9	.	.
ZFYVE1	14	72969451	73027212	N	.	N	N	-0.997491413	7.900677201	0.953726203	14.4	.	.
ZFYVE16	5	80408013	80479350	N	.	N	N	0.107196603	57.72414192	1.30E-08	88.6	.	.
ZFYVE19	15	40807086	40815084	N	.	N	N	0.233178149	66.41778086	7.41E-09	89.3	.	.
ZFYVE21	14	103715730	103733668	N	.	N	N	-0.372151226	25.76836256	0.713442898	24.2	.	.
ZFYVE26	14	67727374	67816590	N	.	N	N	-1.436562546	3.756439197	1.04E-11	94.2	DM	Spastic paraplegia 15, autosomal recessive, 270700 (3)
ZFYVE27	10	97737121	97760907	N	.	N	N	0.553897176	82.57799386	0.003703953	59.4	DM?	Spastic paraplegia 33, autosomal dominant, 610244 (3)
ZFYVE28	4	2269582	2418663	N	Viable	N	Y	0.616466694	84.64432482	0.88846015	18.3	.	.
ZFYVE9	1	52142094	52346686	N	.	N	N	0.225179156	65.94316143	0.943796744	15.3	.	.
ZG16	16	29778240	29782973	N	.	N	N	.	.	.	.	.	.
ZG16B	16	2830169	2839585	N	.	N	N	0.159759922	61.72946692	0.004094707	59	.	.
ZGLP1	19	10304803	10309880	N	.	N	Y	0.081859407	55.83724026	0.437504524	31.8	.	.
ZGPAT	20	63707465	63736142	N	Viable	N	Y	-0.666382202	14.85211553	2.80E-05	75.4	.	.
ZGRF1	4	112539333	112636995	N	.	N	N	.	.	.	.	.	.
ZHX1	8	123248451	123275541	N	.	N	N	-0.612902778	16.4090988	0.821482967	20.9	.	.
ZHX1-C8orf76	8	123226189	123274487	N	.	N	N	.	.	.	.	.	.
ZHX2	8	122781394	122974512	N	.	N	Y	0.29446638	70.16264398	0.408482949	32.5	.	.
ZIK1	19	57578456	57593777	N	.	N	N	0.18146271	63.30960236	4.79E-08	87	.	.
ZIM2	19	56774552	56840729	N	.	N	N	0.650633105	85.64565607	0.472093394	30.8	.	.
ZIM3	19	57134096	57145202	N	.	N	N	1.147778493	94.50714823	4.32E-11	93.5	FTV	.
ZKSCAN1	7	100015572	100041689	N	.	N	N	-0.165588061	37.68594085	0.607275237	27.3	.	.
ZKSCAN2	16	25236001	25257931	N	.	N	N	1.167893706	94.71551774	0.002937675	60.4	.	.
ZKSCAN3	6	28349914	28369177	N	.	N	N	-0.530519144	18.97898941	0.000122608	71.3	.	.
ZKSCAN4	6	28244623	28252224	N	.	N	N	0.335350119	72.61677375	6.74E-05	73	.	.
ZKSCAN5	7	99504651	99534700	N	.	N	N	-0.548094539	18.29021242	0.000618303	66.4	DM?	.
ZKSCAN7	3	44555193	44594173	N	.	N	N	0.056933905	53.86351797	1.18E-05	77.6	.	.
ZKSCAN8	6	28141910	28159472	N	.	N	N	0.06987463	54.88800139	0.000231595	69.4	.	.
ZMAT1	X	101882288	101932031	N	.	N	N	0.09510276	56.80384326	0.063950515	45.6	.	.
ZMAT2	5	140698680	140706676	N	.	N	N	-0.127421372	40.23267928	0.97143376	12.8	.	.
ZMAT3	3	179017223	179072279	N	.	N	N	-0.265193969	31.55061643	0.056703158	46.3	.	.
ZMAT4	8	40530590	40897833	N	.	N	N	-0.284028847	30.40458413	0.019326863	51.9	.	.
ZMAT5	22	29730956	29767011	N	.	N	N	-0.154562494	38.40365804	0.000193623	69.9	.	.
ZMYM1	1	35059786	35115859	N	.	N	N	-0.468280741	21.50836372	0.001729001	62.5	.	.
ZMYM3	X	71239624	71255146	N	.	N	N	-0.122332238	40.60890201	0.999966816	3.1	DM?	.
ZMYM4	1	35268967	35422058	N	.	N	N	-1.212099669	5.458123517	0.999999929	1.1	.	.
ZMYM5	13	19823482	19863636	N	.	N	N	0.566034018	82.93685246	0.200378135	38.7	DM?	.
ZMYM6	1	34986165	35031968	N	.	N	N	-0.291074804	29.95311686	1.40E-08	88.5	DM?	.
ZMYM6NB	1	34981535	34985353	N	.	N	N	.	.	.	.	.	.
ZMYND10	3	50341110	50346852	N	.	N	N	0.424430393	77.07356601	3.60E-07	84.2	DM	Ciliary dyskinesia, primary, 22, 615444 (3)
ZMYND11	10	134465	254637	N	.	N	N	-0.722885318	13.32986051	0.999963586	3.1	DM?	Mental retardation, autosomal dominant 30, 616083 (3)
ZMYND12	1	42430329	42456267	N	.	N	N	0.162629888	61.97256468	0.001059947	64.5	.	.
ZMYND15	17	4740015	4746119	N	.	N	N	-0.544417257	18.40597326	1.44E-05	77.1	.	?Spermatogenic failure 14, 615842 (3)
ZMYND19	9	137582079	137590490	N	.	N	N	-0.290574674	29.99363315	0.879391539	18.6	.	.
ZMYND8	20	47209214	47356889	N	.	N	N	-2.107253894	1.441222434	0.999997106	2	.	.
ZNF10	12	133130575	133159465	N	.	N	N	-0.621514277	16.14863692	0.000431501	67.5	.	.
ZNF100	19	21722766	21767628	N	.	N	N	0.562508773	82.82109162	7.10E-13	95.4	.	.
ZNF101	19	19668796	19683509	N	.	N	N	0.475995728	79.57978816	5.77E-07	83.5	.	.
ZNF106	15	42412823	42491123	N	.	N	Y	-1.487533221	3.426520808	0.219458519	38	.	.
ZNF107	7	64666083	64711582	N	.	N	N	0.022289459	51.24153499	7.59E-17	97.7	.	.
ZNF112	19	44326555	44367217	N	.	N	N	0.204275526	64.640852	0.154211258	40.4	.	.
ZNF114	19	48172318	48287608	N	.	N	N	-0.038994253	46.68055797	1.07E-06	82.4	.	.
ZNF117	7	64971776	65006684	N	.	N	N	0.465772737	79.13410893	0.000213601	69.6	.	.
ZNF12	7	6688433	6706923	N	.	N	N	-0.918777683	9.237714881	0.551264006	28.6	.	.
ZNF121	19	9560353	9584533	N	.	N	N	-0.498746657	20.24078254	0.724859401	23.9	.	.
ZNF124	1	247121975	247172016	N	.	N	N	0.191685376	63.90577068	1.30E-07	85.8	.	.
ZNF131	5	43065176	43192021	N	.	N	N	-0.244445663	32.81240956	0.999460222	5.2	.	.
ZNF132	19	58432814	58440222	N	.	N	N	-0.367062197	26.02882445	8.15E-13	95.3	.	.
ZNF133	20	18288283	18316996	N	.	N	N	-0.448789697	22.35341784	0.949610073	14.8	.	.
ZNF134	19	57614233	57624723	N	.	N	N	0.696459078	86.83220467	0.001145501	64.2	.	.
ZNF135	19	58059239	58086310	N	.	N	N	0.939745514	91.86201308	3.87E-09	89.8	.	.
ZNF136	19	12163064	12189881	N	.	N	N	-0.546482508	18.33072871	1.49E-08	88.5	.	.
ZNF138	7	64794388	64833681	N	.	N	N	0.731106858	87.60780228	2.22E-07	85	.	.
ZNF14	19	19710471	19733097	N	.	N	N	0.205079881	64.68136829	5.72E-16	97.4	.	.
ZNF140	12	133079838	133107544	N	.	N	N	0.598768956	84.07709672	0.002065051	61.8	.	.
ZNF141	4	337814	384864	N	.	N	N	0.493871825	80.23962493	0.161888983	40.1	DM	?Polydactyly, postaxial, type A6, 615226 (3)
ZNF142	2	218637916	218659655	N	.	N	N	0.667586519	86.15500376	1.88E-15	97.2	.	.
ZNF143	11	9460319	9528524	N	.	N	N	-1.277195716	4.873531284	0.021966996	51.2	.	.
ZNF146	19	36214602	36238774	N	.	N	N	0.033970832	52.15025757	0.811745909	21.3	.	.
ZNF154	19	57697367	57709194	N	.	N	N	0.447896377	78.26590265	5.19E-05	73.8	.	.
ZNF155	19	43967862	43998325	N	.	N	N	0.642172954	85.43149852	1.34E-09	90.9	.	.
ZNF157	X	47370583	47414305	N	.	N	N	0.59604699	83.99606413	8.04E-07	82.9	DM?	.
ZNF16	8	144930358	144950888	N	.	N	N	0.225827559	66.00682989	4.59E-12	94.7	.	.
ZNF160	19	53066606	53103436	N	.	N	N	0.207950613	64.91867801	0.001927209	62	.	.
ZNF165	6	28080975	28089563	N	.	N	N	0.088556503	56.32922382	0.000563292	66.7	.	.
ZNF169	9	94259311	94301454	N	.	N	N	-0.316453863	28.4945303	1.75E-09	90.7	.	.
ZNF17	19	57411163	57421939	N	.	N	N	-0.577299978	17.43937026	0.000331513	68.4	.	.
ZNF174	16	3401235	3409370	N	.	N	N	0.006980435	50.03762227	0.053032859	46.7	.	.
ZNF175	19	51571298	51592508	N	.	N	Y	0.591564412	83.86293917	0.000451569	67.3	.	.
ZNF177	19	9363020	9382617	N	.	N	N	0.31747395	71.6154425	5.54E-06	79.3	.	.
ZNF18	17	11977439	11997510	N	.	N	N	-0.233114996	33.52433872	0.000238202	69.2	.	.
ZNF180	19	44474428	44500524	N	.	N	N	0.40494342	76.08959889	7.36E-06	78.8	.	.
ZNF181	19	34734155	34745378	N	.	N	N	0.822252653	89.58731261	3.18E-08	87.5	.	.
ZNF182	X	47974851	48003978	N	Viable	N	Y	0.063177242	54.40180587	0.856542477	19.7	.	.
ZNF184	6	27450743	27473118	N	.	N	N	-1.04361964	7.310296927	0.133748636	41.4	.	.
ZNF185	X	152914442	152973480	N	.	N	N	0.763989364	88.43549227	5.21E-10	91.7	.	.
ZNF189	9	101398873	101410660	N	.	N	N	-0.380305159	25.44423222	0.004617885	58.5	.	.
ZNF19	16	71464555	71565089	N	.	N	N	-0.302555896	29.33379638	1.78E-05	76.6	.	.
ZNF195	11	3339261	3379222	N	.	N	N	-0.265040808	31.57376859	0.731668925	23.7	.	.
ZNF197	3	44584888	44648471	N	.	N	N	-0.867873626	10.24483417	5.95E-14	96.3	.	.
ZNF2	2	95165432	95184317	N	.	N	N	-0.151538959	38.60623951	0.298104857	35.8	.	.
ZNF20	19	12092843	12140407	N	.	N	N	-0.144035975	39.12137524	0.023572367	50.8	.	.
ZNF200	16	3222325	3236221	N	.	N	N	0.305337941	70.81090467	2.25E-06	81.1	.	.
ZNF202	11	123724177	123741675	N	.	N	Y	-0.775255425	12.09700758	0.138743298	41.2	DFP	.
ZNF205	16	3112560	3120517	N	.	N	Y	-0.405534288	24.1303467	0.141235328	41	.	.
ZNF208	19	21932958	22010949	N	.	N	N	0.727617805	87.53834578	5.00E-20	98.7	.	.
ZNF211	19	57630395	57642779	N	.	N	N	0.020224237	51.10841002	3.03E-08	87.6	.	.
ZNF212	7	149239651	149255609	N	.	N	N	0.338220438	72.790415	1.89E-06	81.4	.	.
ZNF213	16	3129777	3142805	N	.	N	N	-0.435697089	22.93222203	0.000112	71.5	DM?	.
ZNF214	11	6999318	7020368	N	.	N	N	0.743543456	87.94929675	2.50E-14	96.5	.	.
ZNF215	11	6926404	6984632	N	.	N	N	0.757593025	88.26763906	4.25E-13	95.6	.	.
ZNF217	20	53567065	53609907	N	.	N	N	-1.684901696	2.488858019	0.995447744	8.2	.	.
ZNF219	14	21090046	21104722	N	.	N	N	.	.	0.988717808	10.2	.	.
ZNF22	10	45000475	45005326	N	.	N	N	0.210368257	65.09231927	0.126684327	41.7	.	.
ZNF221	19	43951223	43967709	N	.	N	N	1.820610156	98.22307114	2.58E-09	90.3	.	.
ZNF222	19	44025342	44033112	N	.	N	N	1.517395794	97.04809863	9.21E-11	93	.	.
ZNF223	19	44051367	44067991	N	.	N	N	0.045452123	53.0242519	5.14E-09	89.6	.	.
ZNF224	19	44094339	44109886	N	.	N	N	0.191987689	63.94049893	2.07E-09	90.5	DP	.
ZNF225	19	44112181	44134816	N	.	N	N	1.063475933	93.54633328	3.37E-08	87.5	.	.
ZNF226	19	44165073	44178381	N	Viable	N	Y	0.154625412	61.34166811	5.27E-15	96.8	.	.
ZNF227	19	44207547	44237268	N	.	N	N	-0.592157754	16.95896278	1.69E-05	76.7	.	.
ZNF229	19	44417519	44448578	N	.	N	N	0.543984882	82.20177114	6.31E-09	89.4	.	.
ZNF23	16	71447597	71463095	N	.	N	N	-0.192729499	36.01898478	8.37E-07	82.8	.	.
ZNF230	19	44002948	44013926	N	.	N	N	0.681452437	86.46755803	0.008341085	55.7	.	.
ZNF232	17	5105541	5123116	N	.	N	N	-0.64402392	15.57562077	0.000435398	67.5	.	.
ZNF233	19	44259880	44275317	N	.	N	N	0.946135829	91.93146958	3.27E-17	97.9	DP	.
ZNF234	19	44141557	44160309	N	.	N	N	0.788563462	88.950628	1.08E-13	96.1	.	.
ZNF235	19	44228729	44305046	N	.	N	N	-0.179485936	36.77721827	1.86E-10	92.5	.	.
ZNF236	18	76822607	76970727	N	.	N	N	-2.297487337	1.134456213	0.999998364	1.9	.	.
ZNF239	10	43556344	43574618	N	Viable	N	Y	0.031402963	51.9476761	0.000867929	65.2	.	.
ZNF248	10	37776526	37858106	N	.	N	N	-0.680583067	14.48746889	0.685698353	25	.	.
ZNF25	10	37949572	37976633	N	.	N	N	0.00602363	49.96237773	0.000386916	67.9	.	.
ZNF250	8	144876497	144902168	N	.	N	N	-0.393549347	24.76703131	0.067619888	45.3	.	.
ZNF251	8	144720907	144756417	N	.	N	N	-0.910317479	9.399780054	3.06E-06	80.5	.	.
ZNF253	19	19865886	19894674	N	.	N	N	-0.074595468	44.09909128	1.33E-06	82.2	.	.
ZNF254	19	24033405	24129961	N	.	N	N	1.004564152	92.81125195	9.15E-27	99.5	.	.
ZNF256	19	57940833	57947675	N	.	N	N	-0.084817347	4.32E+01	1.77E-05	76.6	.	.
ZNF257	19	22052452	22091480	N	.	N	N	0.840130127	90.01562771	1.12E-09	91.1	.	.
ZNF26	12	132986365	133032952	N	.	N	N	.	.	.	.	.	.
ZNF260	19	36510695	36528660	N	Viable	N	Y	-0.435850038	22.9148579	3.07E-06	80.5	.	.
ZNF263	16	3263800	3301401	N	.	N	N	-0.375521858	25.65838977	0.008180516	55.8	.	.
ZNF264	19	57191500	57222846	N	.	N	N	-0.285485	30.31197546	7.10E-06	78.9	.	.
ZNF267	16	31873758	31917357	N	.	N	N	-0.665425649	14.88105574	1.49E-06	81.9	.	.
ZNF268	12	133181409	133214831	N	.	N	N	.	.	1.62E-09	90.7	.	.
ZNF273	7	64870172	64930966	N	.	N	N	-0.253710318	32.23939341	8.55E-06	78.5	.	.
ZNF275	X	153334155	153360110	N	.	N	N	.	.	0.056608997	46.3	.	.
ZNF276	16	89720400	89740903	N	.	N	N	-0.021771814	47.80922614	0.000257275	69.1	.	.
ZNF277	7	112206588	112343096	N	.	N	Y	-0.249077884	32.50564334	4.87E-14	96.3	.	.
ZNF28	19	52797409	52857600	N	.	N	N	1.072096799	93.66788216	1.98E-16	97.6	.	.
ZNF280A	22	22513736	22520270	N	.	N	N	0.827037465	89.71464953	1.34E-08	88.6	.	.
ZNF280B	22	22484421	22509154	N	.	N	N	0.54080415	82.10337443	0.28301568	36.2	.	.
ZNF280C	X	130202711	130268899	N	.	N	N	0.021029596	51.14892632	0.992273042	9.4	.	.
ZNF280D	15	56630181	56918571	N	.	N	N	-1.044282205	7.281356717	0.820128047	21	.	.
ZNF282	7	149195485	149226248	N	.	N	N	-0.788500635	11.77866528	0.277662873	36.3	.	.
ZNF283	19	43827292	43852017	N	.	N	N	0.428257224	77.31666377	4.46E-08	87.1	.	.
ZNF284	19	44072144	44089613	N	.	N	N	0.385152441	75.17508827	7.90E-09	89.2	.	.
ZNF285	19	44382298	44401608	N	.	N	N	2.308639327	98.99866875	0.002403055	61.2	.	.
ZNF286A	17	15699692	15744783	N	.	N	N	0.203971741	64.62927592	0.012910605	53.9	.	.
ZNF286B	17	18658429	18682262	N	.	N	N	0.790325614	88.9911443	0.003746029	59.3	.	.
ZNF287	17	16551387	16569206	N	Viable	N	Y	-0.73214908	13.11570296	0.608657331	27.2	.	.
ZNF292	6	87152833	87264196	N	.	N	N	-1.070721565	6.905133993	0.999976984	2.9	DM?	.
ZNF296	19	45071500	45076588	N	.	N	N	-0.101736898	42.02697228	0.973288664	12.6	.	.
ZNF3	7	100064033	100082548	N	.	N	N	-0.417015534	23.62099902	0.008961057	55.4	.	.
ZNF30	19	34926903	34945170	N	.	N	N	0.736040148	87.76986745	8.06E-09	89.2	.	.
ZNF300	5	150894392	150904983	N	.	N	N	0.33630686	72.651502	0.000952651	64.9	.	.
ZNF302	19	34677639	34686397	N	.	N	N	0.577363401	83.35359148	0.007071956	56.5	.	.
ZNF304	19	57351307	57359898	N	.	N	N	-0.071725006	44.30746079	0.85265032	19.8	.	.
ZNF311	6	28994785	29005316	N	.	N	N	0.284742403	69.63593216	0.000129446	71.1	DM?	.
ZNF316	7	6637322	6656432	N	.	N	N	.	.	.	.	.	.
ZNF317	19	9140380	9163424	N	.	N	N	-0.381261924	25.37477571	0.01570657	52.9	.	.
ZNF318	6	43307134	43369478	N	.	N	Y	-3.131980419	0.544075939	0.053782967	46.6	.	.
ZNF319	16	57994668	58000453	N	.	N	N	-0.512641945	19.71985877	0.959545481	14	.	.
ZNF32	10	43643859	43648856	N	.	N	N	-0.344053504	27.04173178	0.276205823	36.3	.	.
ZNF320	19	52863790	52897693	N	.	N	N	0.245313747	67.19337848	0.018449658	52.1	.	.
ZNF321P	19	52928475	52962823	N	.	N	N	.	.	0.184601492	39.1	.	.
ZNF322	6	26634383	26659752	N	.	N	N	0.476804223	79.61451641	.	.	.	.
ZNF324	19	58467045	58475436	N	.	N	N	-0.329546751	27.75944898	0.473925409	30.7	.	.
ZNF324B	19	58451604	58457833	N	.	N	N	-0.210454696	34.89610465	0.005747898	57.5	.	.
ZNF326	1	89995112	90035531	N	.	N	N	-0.742523485	12.81472478	0.977917717	12.1	.	.
ZNF329	19	58126252	58155110	N	.	N	N	-0.701178982	13.88551253	2.31E-05	75.9	.	.
ZNF330	4	141220887	141234697	N	.	N	N	0.220740999	65.70006367	0.838316379	20.3	.	.
ZNF331	19	53520981	53580269	N	.	N	N	-0.662859235	14.96208833	0.680597794	25.1	.	.
ZNF333	19	14689801	14733746	N	.	N	N	1.678016915	97.82948429	3.60E-09	89.9	.	.
ZNF334	20	46499630	46513559	N	.	N	N	0.260471658	68.06158477	4.09E-08	87.3	.	.
ZNF337	20	25674215	25696841	N	.	N	N	-0.479609292	21.02795624	2.29E-09	90.4	.	.
ZNF33A	10	38010650	38065088	N	.	N	N	0.63673844	85.26943335	0.00046648	67.2	.	.
ZNF33B	10	42574185	42638568	N	.	N	N	0.461293654	78.88522313	2.25E-06	81.1	.	.
ZNF34	8	144773114	144787345	N	.	N	N	-0.333524957	27.5684436	0.246110578	37.2	.	.
ZNF341	20	33731657	33792269	N	.	N	N	-0.130490874	40.02430978	0.124189157	41.9	.	.
ZNF343	20	2481817	2524702	N	.	N	N	0.539999313	82.06285814	1.21E-14	96.6	.	.
ZNF345	19	36850361	36913029	N	.	N	N	-0.470494176	21.42154309	2.33E-11	93.8	.	.
ZNF347	19	53124072	53159075	N	.	N	N	-0.692424777	14.16333854	1.26E-17	98	DM?	.
ZNF35	3	44648727	44660791	N	.	N	N	0.19742545	64.22990102	0.079290627	44.5	.	.
ZNF350	19	51964343	51986856	N	.	N	N	1.024848375	93.09486601	0.000264162	69	DP	.
ZNF354A	5	178711592	178730702	N	.	N	N	0.25473034	67.7490305	0.000195111	69.9	.	.
ZNF354B	5	178859953	178888122	N	.	N	N	0.263190175	68.22943798	1.96E-05	76.3	.	.
ZNF354C	5	179060415	179083537	N	.	N	N	-0.020161029	47.89604677	0.000135489	71	.	.
ZNF358	19	7515292	7521026	N	.	N	N	0.088556503	56.32922382	0.86702533	19.2	.	.
ZNF362	1	33256545	33300719	N	.	N	N	-0.332721412	27.59738381	0.928285965	16.2	.	.
ZNF365	10	62374192	62672011	N	.	N	Y	0.299900751	70.49835041	3.62E-05	74.7	DP	{Nephrolithiasis, uric acid, susceptibility to}, 605990 (3)
ZNF366	5	72442652	72507727	N	.	N	N	-0.291882381	29.8894484	0.504819504	29.8	.	.
ZNF367	9	96385941	96418329	N	.	N	Y	-0.20804097	35.04659374	0.802012369	21.6	.	.
ZNF37A	10	38094336	38125544	N	.	N	N	-0.482629449	20.86589107	0.001924415	62	.	.
ZNF382	19	36604817	36634113	N	.	N	N	-0.228482701	33.83110494	0.853323188	19.7	.	.
ZNF383	19	37217926	37248738	N	.	N	N	-0.274457717	31.01811657	6.28E-08	86.7	.	.
ZNF384	12	6666477	6689572	N	.	N	Y	-1.302579215	4.699890027	0.94199644	15.5	.	.
ZNF385B	2	179441982	179861505	N	.	N	N	-0.500506623	20.165538	0.001065303	64.5	DM	.
ZNF385C	17	42025576	42065365	N	.	N	N	.	.	.	.	.	.
ZNF385D	3	21415071	22373321	N	.	N	N	-0.318518891	28.37876946	0.724321867	23.9	.	.
ZNF391	6	27374615	27403904	N	.	N	N	0.29113834	69.98900272	9.26E-07	82.6	.	.
ZNF395	8	28345585	28402701	N	.	N	N	-0.943201879	8.820975864	0.819057406	21	.	.
ZNF396	18	35366697	35377337	N	.	N	N	0.290181792	69.94269839	4.72E-07	83.8	.	.
ZNF397	18	35241030	35267133	N	.	N	N	.	.	0.001048463	64.6	.	.
ZNF398	7	149126416	149182802	N	.	N	N	-0.418777308	23.55733056	0.959343722	14	.	.
ZNF404	19	43872363	43901385	N	.	N	N	0.753765456	88.16924235	1.49E-05	77.1	.	.
ZNF407	18	74597870	75065671	N	.	N	N	-1.478905261	3.467037101	0.999995919	2.2	DM	.
ZNF408	11	46700818	46705912	N	Viable	N	Y	-0.863237248	10.32586676	7.89E-06	78.7	DM	?Exudative vitreoretinopathy 6, 616468 (3); Retinitis pigmentosa 72, 616469 (3)
ZNF41	X	47445879	47482946	N	.	N	N	1.463908086	96.78763674	0.001389682	63.4	DM	.
ZNF410	14	73886617	73932511	N	.	N	N	-0.367365256	26.00567228	0.661705781	25.7	.	.
ZNF414	19	8509678	8514164	N	.	N	N	.	.	0.002749206	60.7	.	.
ZNF415	19	53107879	53133077	N	.	N	N	0.48173576	79.81130983	0.005828488	57.4	.	.
ZNF416	19	57571566	57578927	N	.	N	N	-0.209649144	34.96556115	0.000574204	66.6	.	.
ZNF417	19	57900296	57916610	N	.	N	N	1.751149884	98.05521792	1.13E-06	82.4	.	.
ZNF418	19	57921884	57935393	N	.	N	N	0.422820958	76.99253343	4.09E-21	98.9	.	.
ZNF419	19	57487711	57496097	N	.	N	N	0.555005615	82.6242982	2.08E-06	81.2	FP	.
ZNF420	19	37007857	37130314	N	.	N	N	-0.027663999	47.45615558	3.29E-08	87.5	DM?	.
ZNF425	7	149102784	149126346	N	.	N	N	-0.125857678	40.34265208	3.19E-14	96.4	.	.
ZNF426	19	9523224	9538627	N	.	N	N	-0.797765568	11.63975227	5.95E-13	95.5	.	.
ZNF428	19	43607219	43619874	N	.	N	N	0.207498734	64.86658563	0.720275479	24.1	.	.
ZNF429	19	21496682	21556270	N	.	N	N	0.616945307	84.66168895	9.71E-14	96.1	.	.
ZNF43	19	21804949	21852125	N	.	N	N	-0.684110075	14.41222434	2.15E-08	88.1	.	.
ZNF430	19	21020620	21060050	N	.	N	N	0.326890353	72.17109452	0.000180791	70.1	.	.
ZNF431	19	21142024	21196053	N	.	N	N	0.002347879	49.66139955	0.000233579	69.3	.	.
ZNF432	19	52031379	52095738	N	.	N	N	-0.096952969	42.29901024	6.81E-11	93.2	.	.
ZNF433	19	12014732	12035741	N	.	N	N	-0.399944349	24.42553684	1.95E-12	95	.	.
ZNF436	1	23359448	23369442	N	.	N	N	-0.296009812	29.68107889	0.304488387	35.6	.	.
ZNF438	10	30820207	31031937	N	.	N	N	-0.045237653	46.19436245	3.46E-05	74.9	.	.
ZNF439	19	11848726	11883750	N	.	N	N	0.161823975	61.9204723	3.21E-08	87.5	.	.
ZNF44	19	12224686	12294887	N	.	N	N	-0.009787637	48.71216068	8.94E-07	82.7	DM?	.
ZNF440	19	11814284	11835201	N	.	N	N	1.822525979	98.23464722	5.59E-13	95.5	.	.
ZNF441	19	11767000	11784078	N	.	N	N	-0.24620731	32.6792846	0.027667096	50.1	.	.
ZNF442	19	12345949	12365905	N	.	N	N	1.426537863	96.52138681	1.47E-07	85.7	.	.
ZNF443	19	12429707	12441112	N	.	N	N	1.169645334	94.74445795	1.83E-05	76.5	.	.
ZNF444	19	56132599	56160893	N	.	N	N	.	.	0.691714109	24.8	.	.
ZNF445	3	44439770	44477670	N	.	N	N	-0.383832994	25.21849858	0.996478491	7.8	.	.
ZNF446	19	58474017	58481230	N	.	N	N	0.754722242	88.22133472	3.39E-06	80.3	.	.
ZNF449	X	135344796	135363152	N	.	N	N	0.044344174	52.90849106	0.871457179	19	.	.
ZNF45	19	43912629	43935278	N	.	N	N	0.257600888	67.89373155	0.000102512	71.8	DM?	.
ZNF451	6	57086844	57170307	N	.	N	N	-0.863237248	10.32586676	1.98E-06	81.3	DM?	.
ZNF454	5	178941191	178966433	N	.	N	N	-0.10747793	41.66232564	4.44E-05	74.2	.	.
ZNF460	19	57280051	57293569	N	.	N	N	-0.196556891	35.70643051	0.647011502	26.1	.	.
ZNF461	19	36637192	36666853	N	.	N	N	0.44039326	77.90704405	3.16E-06	80.5	.	.
ZNF462	9	106863097	107013634	N	.	N	N	-2.818356265	0.700353071	0.999999998	0.6	.	.
ZNF467	7	149764182	149773479	N	.	N	N	-0.275414705	30.96023615	1.71E-07	85.4	.	.
ZNF468	19	52838008	52857649	N	.	N	N	1.450008274	96.70660416	4.58E-12	94.7	.	.
ZNF469	16	88427471	88440757	N	.	N	N	.	.	.	.	DM	Brittle cornea syndrome 1, 229200 (3)
ZNF470	19	56567511	56588911	N	.	N	N	-0.215087684	34.58355038	2.39E-07	84.9	.	.
ZNF471	19	56507843	56530221	N	.	N	N	0.534257737	81.84291254	3.61E-10	92	.	.
ZNF473	19	50025714	50053414	N	.	N	N	0.917235036	91.45106211	0.77456836	22.5	.	.
ZNF474	5	122129513	122179617	N	.	N	N	1.662853966	97.77739191	5.66E-07	83.6	.	.
ZNF479	7	57119614	57139864	N	.	N	N	2.006328558	98.57614169	0.008101317	55.8	.	.
ZNF480	19	52297177	52325922	N	.	N	N	-0.088644586	42.93569485	2.36E-07	84.9	FTV	.
ZNF483	9	111525159	111577844	N	.	N	N	-0.891634218	9.764426694	0.413497359	32.4	.	.
ZNF484	9	92845031	92878038	N	.	N	N	0.312035841	71.21027956	4.88E-09	89.6	.	.
ZNF485	10	43606407	43617903	N	.	N	N	-0.151538959	38.60623951	3.53E-05	74.8	.	.
ZNF486	19	20167228	20200490	N	.	N	N	1.182578782	94.86600683	1.88E-08	88.2	.	.
ZNF487	10	43436841	43483179	N	.	N	N	.	.	0.381487324	33.3	.	.
ZNF488	10	47365496	47384273	N	.	N	N	1.114893411	94.12513747	0.000246117	69.2	.	.
ZNF490	19	12577961	12640098	N	.	N	N	-0.120570168	40.6899346	0.072046336	44.9	.	.
ZNF491	19	11797667	11809622	N	.	N	N	1.402916795	96.39983793	5.13E-07	83.7	.	.
ZNF492	19	22634324	22667670	N	.	N	N	1.448899278	96.70081611	0.017430622	52.3	.	.
ZNF493	19	21397119	21427573	N	.	N	N	0.054215218	53.65514846	3.19E-08	87.5	.	.
ZNF497	19	58354357	58362848	N	.	N	N	0.29496479	70.19737223	5.39E-08	86.9	.	.
ZNF500	16	4748239	4767624	N	.	N	N	0.176981701	62.98547201	0.000679411	66.1	.	.
ZNF501	3	44729596	44737083	N	.	N	N	0.646657413	85.54147132	0.005498058	57.7	.	.
ZNF502	3	44712643	44723831	N	.	N	N	0.068917845	54.82433293	1.41E-05	77.2	.	.
ZNF503	10	75397830	75401906	N	.	N	N	-0.739652395	12.89575737	0.887882313	18.3	.	.
ZNF506	19	19785839	19821751	N	.	N	N	-0.213476698	34.71088731	2.00E-08	88.2	.	.
ZNF507	19	32345594	32387667	N	.	N	N	-1.691576748	2.477281936	0.885285924	18.4	.	.
ZNF510	9	96755865	96778129	N	.	N	N	0.431127766	77.4729409	2.36E-09	90.4	.	.
ZNF511	10	133308475	133313162	N	.	N	N	0.158803293	61.65422238	0.014444704	53.4	.	.
ZNF512	2	27582969	27623215	N	.	N	N	-0.91046979	9.382415929	0.949146986	14.8	.	.
ZNF512B	20	63956702	64048758	N	.	N	N	-1.186857728	5.712797361	0.999557046	5	DFP	.
ZNF513	2	27377231	27380790	N	.	N	N	-0.470342325	21.42733113	0.940738428	15.5	DM	Retinitis pigmentosa 58, 613617 (3)
ZNF514	2	95147330	95165413	N	.	N	N	-0.084968981	43.20194478	7.05E-09	89.3	.	.
ZNF516	18	76358190	76495190	N	.	N	N	.	.	0.268830209	36.5	.	.
ZNF517	8	144798876	144811169	N	.	N	N	0.454442874	78.52057649	2.01E-05	76.2	DM?	.
ZNF518A	10	96129715	96205288	N	.	N	N	.	.	.	.	.	.
ZNF518B	4	10439874	10457410	N	.	N	N	0.016046741	50.68588297	0.591536151	27.7	.	.
ZNF519	18	14057457	14132490	N	.	N	N	0.982696723	92.55079007	8.85E-07	82.7	.	.
ZNF521	18	25061926	25352190	N	.	N	Y	-2.702239493	0.798749783	0.999979351	2.8	.	.
ZNF524	19	55600022	55603138	N	.	N	N	0.535874184	81.906581	0.006803764	56.7	.	.
ZNF525	19	53365693	53392217	N	.	N	N	.	.	0.001291108	63.7	.	.
ZNF526	19	42220271	42228201	N	.	N	N	-0.344552916	27.02436766	0.068124994	45.2	DM	.
ZNF527	19	37371061	37393066	N	.	N	N	0.033316563	52.10974127	4.12E-05	74.4	.	.
ZNF528	19	52397849	52418412	N	.	N	N	0.171392556	62.61503733	1.01E-13	96.1	.	.
ZNF529	19	36534774	36605276	N	.	N	N	-0.229439648	33.75586039	0.001067137	64.5	.	.
ZNF530	19	57599885	57612722	N	.	N	N	0.87014387	90.60021995	1.74E-10	92.6	.	.
ZNF532	18	58862600	58986480	N	.	N	N	-2.079018627	1.493314812	0.90513824	17.6	.	.
ZNF534	19	52429187	52452315	N	.	N	N	1.89742457	98.39671239	4.41E-14	96.4	FTV	.
ZNF540	19	37551406	37614097	N	.	N	N	-0.654245712	15.2341263	0.00697653	56.6	.	.
ZNF541	19	47520685	47555856	N	.	N	N	.	.	.	.	.	.
ZNF543	19	57320509	57330776	N	.	N	N	0.117914677	58.563408	9.06E-12	94.3	FTV	.
ZNF544	19	58228594	58277495	N	.	N	N	0.749287392	88.08820976	3.81E-13	95.6	FTV	.
ZNF546	19	39984134	40021041	N	.	N	N	0.546700161	82.30016785	2.54E-10	92.2	.	.
ZNF547	19	57363477	57379565	N	.	N	N	-0.123440781	40.55680963	2.12E-11	93.9	.	.
ZNF548	19	57389850	57402992	N	.	N	N	0.084880585	56.09770215	0.099573543	43.1	.	.
ZNF549	19	57527325	57557542	N	.	N	N	0.157191398	61.55582566	5.83E-05	73.5	.	.
ZNF550	19	57535257	57559863	N	.	N	N	1.087748126	93.81837125	1.52E-10	92.6	.	.
ZNF551	19	57681969	57717301	N	.	N	N	0.009045538	50.2344157	6.09E-07	83.4	.	.
ZNF552	19	57803841	57814913	N	.	N	N	-0.284831791	30.36985588	0.011944108	54.2	.	.
ZNF554	19	2819874	2835773	N	.	N	N	1.126223818	94.26405047	4.61E-06	79.7	.	.
ZNF555	19	2841435	2860484	N	.	N	N	-0.878390268	9.978584245	1.74E-09	90.7	.	.
ZNF556	19	2867335	2883445	N	.	N	N	0.886107801	90.86068183	1.58E-05	76.9	.	.
ZNF557	19	7069444	7087968	N	.	N	N	-0.180594035	36.70776176	1.51E-06	81.9	.	.
ZNF558	19	8806170	8832328	N	.	N	N	-0.585912632	17.20206054	0.000767127	65.6	.	.
ZNF559	19	9323772	9351162	N	.	N	N	1.493119335	96.94970192	7.72E-09	89.2	.	.
ZNF559-ZNF177	19	9324174	9382617	N	.	N	N	0.571478862	83.14522197	.	.	.	.
ZNF560	19	9466507	9498607	N	.	N	N	-0.35764605	26.43398738	7.36E-10	91.3	.	.
ZNF561	19	9604680	9621399	N	.	N	N	-0.112110344	41.35555941	0.009762547	55	.	.
ZNF562	19	9641808	9675086	N	.	N	N	0.36808233	74.28951786	0.139679896	41.1	.	.
ZNF563	19	12317477	12333720	N	.	N	N	0.094297141	56.72281067	8.58E-07	82.8	.	.
ZNF564	19	12525370	12551542	N	.	N	N	-0.77908304	12.03912716	8.59E-05	72.3	.	.
ZNF565	19	36182060	36246257	N	Viable	N	Y	-0.456445049	22.02349945	0.001766689	62.4	.	.
ZNF566	19	36445119	36489902	N	.	N	N	-0.329850009	27.74208485	0.637363545	26.4	.	.
ZNF567	19	36687612	36727701	N	.	N	N	-0.690000491	14.21543092	1.87E-06	81.4	.	.
ZNF568	19	36916329	36998700	N	.	N	N	0.447090868	78.20802223	4.91E-09	89.6	.	.
ZNF569	19	37411155	37469275	N	.	N	N	-0.701178982	13.88551253	3.33E-05	75	.	.
ZNF57	19	2900898	2918476	N	.	N	N	0.547502461	82.35226023	1.00E-06	82.5	.	.
ZNF570	19	37467585	37488652	N	.	N	N	0.036992354	52.33547491	0.001232864	63.9	.	.
ZNF571	19	37554782	37594790	N	.	N	N	0.788563462	88.950628	2.83E-09	90.2	.	.
ZNF572	8	124973298	124979389	N	.	N	N	0.068917845	54.82433293	0.000651451	66.2	.	.
ZNF573	19	37735833	37817300	N	.	N	N	0.202209328	64.51351508	9.43E-09	89	.	.
ZNF574	19	42068477	42081565	N	.	N	N	-0.540445085	18.55067431	0.908434997	17.4	.	.
ZNF575	19	43525497	43536130	N	.	N	N	0.353884195	73.67019737	0.456203449	31.2	.	.
ZNF576	19	43596392	43601157	N	.	N	N	0.300405715	70.5388667	0.007545748	56.2	.	.
ZNF577	19	51855802	51890950	N	.	N	N	1.777341293	98.13625051	0.012941322	53.9	DP	.
ZNF578	19	52453576	52512154	N	.	N	N	0.585975389	83.70666204	8.81E-14	96.1	.	.
ZNF579	19	55576770	55580845	N	.	N	N	.	.	.	.	.	.
ZNF580	19	55635016	55643469	N	.	N	N	.	.	0.508634075	29.7	.	.
ZNF581	19	55635459	55645622	N	.	N	N	-0.077618099	43.83284135	0.064555003	45.6	.	.
ZNF582	19	56375846	56393545	N	.	N	N	-0.810053577	11.3677143	0.000410371	67.7	.	.
ZNF583	19	56397966	56436035	N	.	N	N	-0.746352589	12.73369219	0.376960746	33.4	.	.
ZNF584	19	58401504	58418327	N	.	N	N	0.302467839	70.66620362	1.31E-05	77.3	.	.
ZNF585A	19	37106734	37172741	N	.	N	N	-0.150430658	38.69884818	0.711326552	24.3	.	.
ZNF585B	19	37181579	37218153	N	.	N	N	-0.463646524	21.74567344	0.005691666	57.5	.	.
ZNF586	19	57769655	57819939	N	.	N	N	-0.077465999	43.85599352	0.005012176	58.1	.	.
ZNF587	19	57849857	57865112	N	.	N	N	0.988439728	92.62603461	0.00025345	69.1	.	.
ZNF587B	19	57819741	57846238	N	.	N	N	1.054717946	93.4247844	0.008092643	55.8	.	.
ZNF589	3	48241100	48299253	N	.	N	N	0.511598665	80.93418996	6.50E-07	83.3	.	.
ZNF592	15	84748635	84806432	N	.	N	N	-1.588168431	2.876656827	0.949422558	14.8	DM	.
ZNF593	1	26169871	26172060	N	.	N	N	0.098628637	57.02378885	0.156440974	40.3	.	.
ZNF594	17	5179536	5191883	N	.	N	N	0.552445819	82.52590149	1.14E-10	92.9	.	.
ZNF595	4	53285	88211	N	.	N	N	.	.	1.78E-05	76.6	.	.
ZNF596	8	232137	247342	N	.	N	N	-0.186988947	36.33732708	2.90E-14	96.4	.	.
ZNF597	16	3432422	3443542	N	.	N	N	0.873820107	90.65231232	0.134235997	41.4	.	.
ZNF598	16	1997654	2009823	N	.	N	N	.	.	0.20167323	38.7	.	.
ZNF599	19	34758076	34773229	N	.	N	N	0.635626645	85.2347051	4.70E-07	83.8	.	.
ZNF600	19	52764195	52818004	N	.	N	N	1.101153262	93.93992013	1.48E-13	96	DP	.
ZNF605	12	132918308	132956306	N	.	N	N	.	.	0.960905075	13.9	.	.
ZNF606	19	57977053	58003349	N	.	N	N	-0.665425649	14.88105574	0.32038965	35.1	.	.
ZNF607	19	37696363	37719790	N	.	N	N	-0.141014188	39.35868496	8.48E-08	86.3	.	.
ZNF608	5	124636913	124748807	N	.	N	N	-1.840509824	2.072119002	0.999968158	3	.	.
ZNF609	15	64460742	64686068	N	.	N	N	-1.989786228	1.666956069	0.999945907	3.3	.	.
ZNF610	19	52336245	52367778	N	.	N	N	0.669315604	86.18973201	1.22E-10	92.8	.	.
ZNF611	19	52702813	52735073	N	.	N	N	1.121748153	94.21195809	1.16E-17	98.1	.	.
ZNF613	19	51879872	51948759	N	.	N	N	0.263190175	68.22943798	0.000362474	68.1	.	.
ZNF614	19	52012765	52030240	N	.	N	N	-0.327783769	27.85784569	0.002120628	61.7	.	.
ZNF615	19	51991332	52008230	N	.	N	N	-0.533088092	18.85744053	6.53E-12	94.5	.	.
ZNF616	19	52113091	52139922	N	.	N	N	0.142337495	60.36348903	1.07E-08	88.8	.	.
ZNF618	9	113876282	114056591	N	.	N	N	-1.42235672	3.808531574	0.994715997	8.5	.	.
ZNF619	3	40477113	40490236	N	.	N	N	0.08870778	56.34079991	2.36E-05	75.8	.	.
ZNF620	3	40505992	40518736	N	.	N	N	0.270542348	68.72142154	6.83E-06	79	.	.
ZNF621	3	40524878	40574685	N	.	N	N	0.133574517	59.72680442	4.18E-05	74.3	.	.
ZNF622	5	16451519	16465792	N	.	N	N	-0.650570088	15.3730393	0.088803853	43.9	.	.
ZNF623	8	143636013	143656418	N	.	N	N	-0.232158138	33.59958326	0.094197002	43.5	.	.
ZNF624	17	16620737	16653856	N	.	N	N	-0.477845454	21.10320079	0.000305863	68.6	DP	.
ZNF625	19	12142090	12156729	N	.	N	N	-0.355230595	26.57290039	0.000825562	65.4	.	.
ZNF625-ZNF20	19	12132117	12156731	N	.	N	N	.	.	.	.	.	.
ZNF626	19	20544571	20863281	N	.	N	N	0.580233574	83.49250449	2.34E-07	84.9	FTV	.
ZNF627	19	11559374	11619135	N	.	N	N	0.142990968	60.43294553	0.005644146	57.5	DP	.
ZNF628	19	55476332	55484487	N	.	N	N	-0.494765173	20.40284772	0.986868379	10.6	.	.
ZNF629	16	30778449	30787202	N	.	N	N	-0.677712298	14.56850148	0.992317752	9.3	.	.
ZNF630	X	47983356	48071658	N	.	N	N	0.802462863	89.1995138	0.002230235	61.5	.	.
ZNF638	2	71276561	71435069	N	.	N	N	-1.533428828	3.18921109	0.99995995	3.2	DM?	.
ZNF639	3	179322991	179338583	N	.	N	N	-0.791372557	11.73236094	0.122945965	42	.	.
ZNF641	12	48337180	48351414	N	.	N	N	-0.169415642	37.44284309	0.228415943	37.7	.	.
ZNF644	1	90915298	91022272	N	.	N	N	-0.574138594	17.52619089	0.99732858	7.3	DM?	Myopia 21, autosomal dominant, 614167 (3)
ZNF645	X	22272943	22274457	N	.	N	N	0.465623125	79.12832089	0.01646562	52.7	.	.
ZNF646	16	31074422	31084196	N	.	N	N	0.991605692	92.65497482	0.00556536	57.6	.	.
ZNF648	1	182054570	182061712	N	.	N	N	0.944221988	91.91410546	8.27E-06	78.5	.	.
ZNF649	19	51889224	51905040	N	.	N	N	0.000434265	49.47039417	0.711121458	24.3	.	.
ZNF652	17	49289206	49362473	N	.	N	N	-0.407598535	24.04931412	0.970739626	12.9	.	.
ZNF653	19	11483427	11505923	N	.	N	N	-0.365299028	26.12143312	0.142112313	41	.	.
ZNF654	3	88139104	88144665	N	.	N	N	0.165499977	62.20408636	0.947346015	15	.	.
ZNF655	7	99558406	99576453	N	.	N	N	0.234135	66.47566128	0.03789182	48.6	.	.
ZNF658	9	66856426	66932141	N	Viable	N	Y	1.143301431	94.4608439	.	.	.	.
ZNF66	19	20776304	20807322	N	.	N	N	.	.	5.45E-17	97.8	.	.
ZNF660	3	44578223	44599694	N	.	N	N	0.040668219	52.64224113	0.054805105	46.4	.	.
ZNF662	3	42905731	42917641	N	.	N	N	0.356902595	73.80332234	3.72E-10	92	.	.
ZNF664	12	123971845	124015439	N	.	N	N	-0.139556392	39.44550559	0.001626794	62.7	.	.
ZNF665	19	53159213	53193386	N	.	N	N	1.437873325	96.62557157	7.68E-08	86.4	.	.
ZNF667	19	56439325	56478065	N	.	N	N	0.294159089	70.15106789	0.000142443	70.8	.	.
ZNF668	16	31060843	31074320	N	.	N	N	-0.940331683	8.844128031	0.268892373	36.5	DM?	.
ZNF669	1	247099962	247104372	N	.	N	N	1.436760474	96.60820744	0.060499399	45.9	.	.
ZNF670	1	247036784	247078755	N	.	N	N	-0.397377504	24.54708572	0.451260083	31.3	.	.
ZNF671	19	57719751	57727624	N	.	N	N	-0.829692794	10.98570354	4.22E-13	95.6	.	.
ZNF672	1	248838210	248849517	N	.	N	N	.	.	0.000127541	71.2	.	.
ZNF674	X	46497727	46545457	N	.	N	N	1.025658526	93.10644209	0.004274941	58.8	DM	.
ZNF675	19	23525631	23687220	N	.	N	N	-0.206778689	35.1102622	3.88E-06	80.1	.	.
ZNF676	19	22179091	22196951	N	.	N	N	1.004404379	92.80546391	1.69E-06	81.6	.	.
ZNF677	19	53235381	53254898	N	.	N	N	-0.175809925	37.02031603	6.09E-07	83.4	.	.
ZNF678	1	227563543	227677443	N	.	N	N	.	.	4.67E-07	83.9	.	.
ZNF679	7	64228474	64266931	N	.	N	N	0.804375828	89.22266597	1.43E-09	90.8	.	.
ZNF680	7	64519884	64563106	N	.	N	N	-0.089601417	42.81993402	4.59E-06	79.7	.	.
ZNF681	19	23739195	23758891	N	.	N	N	0.994028604	92.70127916	2.16E-08	88.1	.	.
ZNF682	19	19997058	20039506	N	.	N	N	-0.028620813	47.39827516	3.67E-09	89.9	.	.
ZNF683	1	26361634	26374522	N	.	N	Y	1.021171743	93.04856167	0.001560697	62.9	DM?	.
ZNF684	1	40531561	40548169	N	.	N	N	0.276132196	69.08028014	0.002217419	61.5	.	.
ZNF687	1	151281618	151292180	N	.	N	N	-0.562812639	17.83874515	0.975942573	12.3	.	.
ZNF688	16	30569346	30572734	N	.	N	N	-0.172286507	37.23447358	7.09E-05	72.9	.	.
ZNF69	19	11887784	11914329	N	.	N	N	0.231921074	66.33674828	7.35E-05	72.8	.	.
ZNF691	1	42846573	42852477	N	.	N	N	-0.392745948	24.81333565	0.41775865	32.3	.	.
ZNF692	1	248850006	248859144	N	.	N	N	-0.201189312	35.41124038	3.97E-07	84	.	.
ZNF695	1	246945547	247008093	N	.	N	N	0.53234428	81.73872779	1.30E-10	92.8	.	.
ZNF696	8	143289676	143298061	N	.	N	N	0.321150679	71.84696417	0.005979722	57.2	.	.
ZNF697	1	119619422	119647773	N	.	N	N	.	.	0.191081027	39	.	.
ZNF699	19	9294275	9309838	N	.	N	N	-0.753702167	12.50217052	1.57E-07	85.6	.	.
ZNF7	8	144827464	144847509	N	.	N	N	-1.330533207	4.479944435	0.000238234	69.2	.	.
ZNF70	22	23738678	23751092	N	.	N	N	-0.701178982	13.88551253	0.168320382	39.8	.	.
ZNF700	19	11925068	11950773	N	.	N	N	-0.460777525	21.87301036	4.39E-11	93.5	.	.
ZNF701	19	52555822	52587174	N	.	N	N	0.438630851	77.81443538	2.35E-07	84.9	.	.
ZNF703	8	37695751	37700021	N	.	N	N	.	.	.	.	.	.
ZNF704	8	80628451	80874781	N	.	N	Y	-0.27637172	30.86762748	0.972642497	12.7	.	.
ZNF705A	12	8138137	8188537	N	.	N	N	1.10915659	94.03831684	0.05247837	46.7	.	.
ZNF705B	8	7926337	7952413	N	.	N	N	.	.	0.652541804	26	.	.
ZNF705D	8	12104389	12115516	N	.	N	N	.	.	.	.	.	.
ZNF705G	8	7355517	7385558	N	.	N	N	.	.	4.25E-09	89.7	.	.
ZNF706	8	101177878	101206193	N	.	N	N	0.507628396	80.75476066	0.216281952	38.2	.	.
ZNF707	8	143684452	143713898	N	.	N	N	-0.014571683	48.31278578	0.012770085	53.9	.	.
ZNF708	19	21221500	21329425	N	.	N	N	0.869186937	90.55970365	4.18E-09	89.8	.	.
ZNF709	19	12461559	12551474	N	.	N	N	-0.711553195	13.60189848	5.65E-06	79.3	.	.
ZNF71	19	56595264	56626481	N	.	N	N	-0.582889864	17.31203334	8.09E-06	78.6	.	.
ZNF710	15	90001392	90082206	N	.	N	N	-0.041561741	46.46640042	0.943123585	15.4	.	.
ZNF711	X	85244032	85273362	N	.	N	N	-0.070919872	44.37691729	0.989393564	10.1	DM?	Mental retardation, X-linked 97, 300803 (3)
ZNF713	7	55887475	55942225	N	.	N	N	-0.298880801	29.53637784	0.001115198	64.3	.	.
ZNF714	19	21082159	21125270	N	.	N	N	0.866316624	90.47867107	7.34E-06	78.8	.	.
ZNF716	7	57450177	57473546	N	.	N	N	-0.171177353	37.31550616	2.56E-08	87.9	.	.
ZNF717	3	75709643	75785583	N	.	N	N	.	.	0.332205459	34.8	FTV	.
ZNF718	4	124480	163989	N	.	N	N	.	.	.	.	.	.
ZNF720	16	31713229	31794869	N	.	N	N	0.273114451	68.84297042	0.055960456	46.4	.	.
ZNF721	4	425815	499156	N	.	N	N	0.588206552	83.78769462	5.97E-11	93.2	.	.
ZNF724P	19	23221599	23250390	N	.	N	N	.	.	0.006696031	56.8	.	.
ZNF726	19	23914876	23945159	N	.	N	N	0.396483307	75.63813162	.	.	.	.
ZNF727	7	64045443	64078549	N	.	N	N	.	.	1.56E-07	85.6	.	.
ZNF728	19	22975468	23003176	N	.	N	N	0.606570793	84.34913469	1.36E-07	85.7	.	.
ZNF729	19	22286408	22317176	N	.	N	N	1.516136329	97.03652254	3.73E-10	92	.	.
ZNF730	19	23075210	23147219	N	.	N	N	1.051037882	93.36690398	1.86E-10	92.5	.	.
ZNF732	4	270675	305321	N	.	N	N	1.597225258	97.48220177	1.31E-09	90.9	.	.
ZNF735	7	64207090	64470627	N	.	N	N	.	.	.	.	.	.
ZNF736	7	64307459	64354860	N	.	N	N	.	.	0.143727833	40.9	.	.
ZNF737	19	20535825	20565809	N	.	N	N	2.323652051	99.00445679	1.11E-07	86	.	.
ZNF738	19	21358930	21379302	N	.	N	N	.	.	0.106373219	42.8	.	.
ZNF74	22	20394115	20408461	N	.	N	N	0.64136944	85.40255831	0.000355878	68.1	.	.
ZNF740	12	53180700	53195141	N	.	N	N	0.275983486	69.05712797	0.653748288	25.9	.	.
ZNF746	7	149472794	149497817	N	.	N	N	-0.537870687	18.7011634	0.051738567	46.8	.	.
ZNF747	16	30530367	30535347	N	.	N	N	0.905457131	91.16744805	2.75E-05	75.4	.	.
ZNF749	19	57435329	57445485	N	.	N	N	0.007283443	50.04919836	1.63E-06	81.7	.	.
ZNF750	17	82829435	82840578	N	.	N	N	0.227741635	66.1052266	0.865734364	19.2	DM	Seborrhea-like dermatitis with psoriasiform elements, 610227 (3)
ZNF75A	16	3305406	3318852	N	.	N	N	-0.446224844	22.44602651	0.000203485	69.7	.	.
ZNF75D	X	135248920	135344087	N	.	N	N	0.276132196	69.08028014	0.000185372	70	DM?	.
ZNF76	6	35258909	35295985	N	.	N	N	0.079442861	55.64623488	5.07E-16	97.5	.	.
ZNF761	19	53431993	53458261	N	.	N	N	.	.	.	.	.	.
ZNF763	19	11965037	11980381	N	.	N	N	1.236868967	95.36377843	0.000236873	69.3	.	.
ZNF764	16	30553764	30558498	N	.	N	N	0.418840633	76.77837588	3.07E-08	87.6	DM?	.
ZNF765	19	53389793	53430413	N	.	N	N	-0.023836771	47.69925334	9.05E-10	91.2	.	.
ZNF766	19	52269571	52296046	N	.	N	N	0.136444713	59.97569022	7.45E-08	86.5	.	.
ZNF768	16	30524001	30526821	N	.	N	N	-0.678669157	14.53956127	0.57930558	28	.	.
ZNF77	19	2933218	2944971	N	.	N	N	0.799895792	89.15899751	4.31E-13	95.6	DM?	.
ZNF770	15	34978341	34988287	N	.	N	N	-0.957252191	8.624182439	0.827513247	20.7	.	.
ZNF771	16	30407297	30431108	N	.	N	N	.	.	0.295812869	35.8	.	.
ZNF772	19	57466663	57477570	N	.	N	N	0.392504758	75.48764253	0.007956155	56	.	.
ZNF773	19	57499915	57518404	N	.	N	N	0.458269625	78.73473404	5.50E-09	89.5	.	.
ZNF774	15	90352245	90369146	N	.	N	N	0.419797365	76.81889217	1.10E-10	92.9	.	.
ZNF775	7	150368790	150412470	N	.	N	N	-0.172286507	37.23447358	0.012229259	54.1	.	.
ZNF776	19	57746796	57758159	N	.	N	N	-0.560531745	17.9139897	7.87E-06	78.7	.	.
ZNF777	7	149431363	149461123	N	.	N	N	-0.608120603	16.51328356	0.99761441	7.2	.	.
ZNF778	16	89217703	89237071	N	.	N	N	1.475732941	96.83972912	1.63E-15	97.2	DM	.
ZNF780A	19	40069152	40090938	N	.	N	N	0.144099113	60.53713029	1.73E-06	81.6	.	.
ZNF780B	19	40028260	40056209	N	.	N	N	-0.080839341	43.51449904	3.90E-13	95.6	DM?	.
ZNF781	19	37667751	37692322	N	.	N	N	-0.043778467	46.32748741	7.22E-06	78.9	.	.
ZNF782	9	96816472	96875623	N	.	N	N	0.841087159	90.03299184	4.93E-05	73.9	.	.
ZNF783	7	149262171	149297302	N	.	N	N	0.269736366	68.69248133	0.000963929	64.9	.	.
ZNF784	19	55620742	55624601	N	.	N	N	0.469300995	79.2961741	0.352694144	34.1	.	.
ZNF785	16	30573740	30585771	N	.	N	N	0.279002038	69.25970944	3.84E-14	96.4	.	.
ZNF786	7	149069643	149090782	N	.	N	N	-1.168029185	5.921166869	1.40E-08	88.5	.	.
ZNF787	19	56087366	56121280	N	.	N	N	.	.	0.741821108	23.4	.	.
ZNF788	19	12092263	12137235	N	.	N	N	.	.	0.05299439	46.7	.	.
ZNF789	7	99472841	99503650	N	.	N	N	0.104519243	57.57365283	7.06E-08	86.6	.	.
ZNF79	9	127424374	127445372	N	.	N	N	-0.100780094	42.06170053	0.017129421	52.4	DM?	.
ZNF790	19	36817428	36850787	N	.	N	N	0.901114752	91.09799155	3.28E-12	94.8	.	.
ZNF791	19	12610918	12633840	N	.	N	N	-0.697503755	14.01863749	0.008271905	55.7	.	.
ZNF792	19	34956354	34964049	N	.	N	N	0.691977605	86.71644383	3.90E-07	84.1	.	.
ZNF793	19	37506939	37548762	N	.	N	N	0.157996972	61.60213	5.31E-06	79.4	.	.
ZNF799	19	12390016	12401271	N	.	N	N	1.080398324	93.75470278	6.79E-05	73	FTV	.
ZNF8	19	58278951	58302805	N	.	N	N	0.209712323	65.05759102	.	.	.	.
ZNF80	3	114234631	114237578	N	.	N	N	0.768623967	88.52810094	5.32E-08	86.9	FTV	.
ZNF800	7	127346790	127431924	N	.	N	N	-0.017290605	48.08126411	0.99703262	7.5	.	.
ZNF804A	2	184598366	184939492	N	.	N	N	0.293665186	70.09897552	0.827436291	20.7	DFP	.
ZNF804B	7	88759368	89337057	N	.	N	N	1.74338772	98.03206575	4.78E-14	96.3	.	.
ZNF805	19	57240685	57255135	N	.	N	N	-0.447027861	22.42866238	0.794368612	21.9	.	.
ZNF808	19	52527652	52564464	N	.	N	N	0.418346298	76.7262835	1.80E-05	76.5	.	.
ZNF81	X	47836902	48002561	N	.	N	N	0.778039859	88.75383458	0.303589182	35.6	DM	Mental retardation, X-linked 45, 300498 (3)
ZNF812	19	9689924	9700817	N	.	N	N	0.993071394	92.68970307	6.00E-07	83.4	.	.
ZNF813	19	53467735	53496255	N	.	N	N	0.358968028	73.89014296	8.50E-10	91.2	DM?	.
ZNF814	19	57848731	57889074	N	.	N	N	-0.10908872	41.52341263	6.75E-10	91.4	.	.
ZNF816	19	52949379	52962911	N	.	N	N	1.655502764	97.75423974	5.10E-09	89.6	.	.
ZNF821	16	71859680	71895336	N	.	N	N	-0.050324612	45.75447126	0.158430833	40.2	.	.
ZNF823	19	11721265	11739009	N	.	N	N	-0.301598985	29.37431267	2.09E-06	81.2	.	.
ZNF827	4	145757627	145938635	N	.	N	N	-1.380060197	4.057417376	0.999865838	4	.	.
ZNF829	19	36888124	36916291	N	.	N	N	-0.389874437	24.9580367	1.85E-08	88.3	.	.
ZNF83	19	52594060	52690496	N	.	N	N	0.012721269	50.46593737	3.82E-06	80.1	.	.
ZNF831	20	59191020	59259113	N	.	N	N	0.754752321	88.22712276	7.65E-09	89.2	.	.
ZNF835	19	56661981	56671783	N	.	N	N	0.49593763	80.31486948	9.62E-13	95.3	.	.
ZNF836	19	52153864	52171643	N	.	N	N	0.623647111	84.86427042	3.02E-09	90.1	.	.
ZNF837	19	58367618	58381060	N	.	N	N	.	.	0.258440636	36.8	.	.
ZNF839	14	102317377	102342702	N	.	N	N	1.404185681	96.41141402	9.19E-05	72.1	.	.
ZNF84	12	133037292	133063304	N	.	N	N	.	.	.	.	.	.
ZNF841	19	52064466	52095765	N	.	N	N	-0.595983239	16.82004978	4.05E-08	87.3	.	.
ZNF843	16	31432593	31443160	N	.	N	N	.	.	.	.	.	.
ZNF844	19	12064699	12081565	N	.	N	N	0.996747108	92.71864328	1.01E-05	78	.	.
ZNF845	19	53333749	53354869	N	.	N	N	1.357410864	96.16252822	6.26E-08	86.7	.	.
ZNF846	19	9751993	9793180	N	.	N	N	0.552134607	82.5143254	3.75E-16	97.5	.	.
ZNF85	19	20923222	20950697	N	.	N	N	1.365546768	96.20304451	2.28E-10	92.3	.	.
ZNF850	19	36714383	36772825	N	.	N	N	.	.	0.188901355	39	.	.
ZNF852	3	44498970	44510640	N	.	N	N	.	.	6.54E-09	89.4	.	.
ZNF853	7	6615617	6624290	N	.	N	N	.	.	0.000958951	64.9	.	.
ZNF860	3	31981771	31991628	N	.	N	N	0.854180038	90.28187764	7.86E-11	93.1	.	.
ZNF862	7	149838367	149867479	N	.	N	N	0.441015358	77.92440817	3.69E-09	89.9	.	.
ZNF865	19	55605405	55617269	N	.	N	N	.	.	.	.	.	.
ZNF878	19	12043805	12052939	N	.	N	N	1.037942871	93.23377901	1.49E-07	85.6	.	.
ZNF879	5	179023752	179035064	N	.	N	N	.	.	0.000705396	65.9	.	.
ZNF880	19	52369917	52385795	N	.	N	N	2.147025477	98.77293512	3.88E-09	89.8	.	.
ZNF891	12	133106817	133130473	N	.	N	N	.	.	0.636347899	26.4	.	.
ZNF90	19	20077994	20127076	N	.	N	N	0.311078911	71.11188285	1.22E-07	85.9	.	.
ZNF91	19	23304991	23395560	N	.	N	N	-0.068402422	44.49846617	9.92E-05	71.9	.	.
ZNF92	7	65373799	65401135	N	.	N	N	-0.597090606	16.7679574	9.99E-08	86.1	.	.
ZNF93	19	19900913	19935575	N	.	N	N	0.585018282	83.68350987	0.001691822	62.5	.	.
ZNF98	19	22391019	22532485	N	.	N	N	1.112024538	94.07883313	1.80E-06	81.5	.	.
ZNF99	19	22752183	22784107	N	.	N	N	2.075165357	98.69769057	3.04E-09	90.1	FTV	.
ZNFX1	20	49237946	49278426	N	.	N	N	-0.308223014	28.99808995	0.999981099	2.8	.	.
ZNHIT1	7	101217668	101224190	N	.	N	N	-0.01663693	48.16808474	0.000428046	67.5	.	.
ZNHIT2	11	65116403	65117708	N	.	N	N	0.323063788	71.95114893	0.200832999	38.7	.	.
ZNHIT3	17	36486629	36499310	N	.	N	N	-0.282114394	30.53770909	1.21E-05	77.6	.	.
ZNHIT6	1	85649423	85708433	N	.	N	N	0.120481978	58.76598947	0.000536151	66.8	.	.
ZNRD1	6	30058899	30064909	N	.	N	N	0.199039114	64.30514557	0.14486273	40.8	.	.
ZNRF1	16	74999030	75110994	N	.	N	N	.	.	0.754396423	23	DM	.
ZNRF2	7	30284307	30367692	N	.	N	N	.	.	0.590835928	27.7	.	.
ZNRF4	19	5455431	5456856	N	.	N	N	1.335530289	96.01782717	0.26322427	36.7	.	.
ZP1	11	60867562	60875693	N	.	N	Y	-0.328590179	27.79417723	4.96E-10	91.8	.	Oocyte maturation defect, 615774 (3)
ZP2	16	21197450	21214510	N	.	N	Y	-0.63158679	15.84765874	1.04E-05	77.9	.	.
ZP3	7	76397518	76442071	N	.	N	Y	1.055819777	93.44793656	0.001596815	62.8	.	.
ZP4	1	237877864	237890922	N	.	N	N	0.844916081	90.11981247	3.79E-10	92	.	.
ZPBP	7	49850421	50121329	N	.	N	Y	-0.088796495	42.91254269	0.159636079	40.2	DM	.
ZPBP2	17	39868164	39877896	N	.	N	Y	0.01161301	50.38490479	0.000986594	64.8	DFP	.
ZPLD1	3	102099244	102479841	N	.	N	N	0.048322504	53.28471378	0.000311007	68.5	DM	.
ZRANB3	2	135136916	135531236	N	.	N	N	0.975508207	92.38293685	7.43E-15	96.8	.	.
ZRSR1	5	112891422	112893094	N	.	N	N	.	.	1.31E-05	77.3	.	.
ZRSR2	X	15790472	15823260	N	.	N	N	0.426194468	77.17775077	0.998381925	6.6	.	.
ZSCAN1	19	58034032	58054631	N	.	N	N	0.003304686	49.75979626	6.40E-07	83.3	.	.
ZSCAN12	6	28378955	28399734	N	.	N	N	.	.	1.44E-05	77.1	.	.
ZSCAN16	6	28124560	28130082	N	.	N	N	0.639154087	85.32152573	2.67E-06	80.7	.	.
ZSCAN18	19	58083838	58118427	N	.	N	N	0.08870778	56.34079991	0.748253934	23.2	.	.
ZSCAN2	15	84600986	84627796	N	.	N	N	-1.420584927	3.814319616	0.018203704	52.2	.	.
ZSCAN20	1	33472645	33496507	N	.	N	N	-0.880969926	9.938067952	0.071955283	44.9	.	.
ZSCAN21	7	100049774	100065038	N	.	N	Y	-0.195600015	35.79903919	1.71E-11	94	.	.
ZSCAN22	19	58327019	58342332	N	.	N	N	0.295115961	70.20316027	1.29E-05	77.4	.	.
ZSCAN23	6	28431930	28443502	N	.	N	N	.	.	0.002702951	60.8	.	.
ZSCAN25	7	99616946	99632407	N	.	N	N	-0.305274657	29.1717312	0.214589397	38.3	.	.
ZSCAN26	6	28267010	28278224	N	.	N	N	.	.	.	.	.	.
ZSCAN29	15	43358172	43371025	N	.	N	N	0.555160805	82.63008624	2.29E-06	81	DM?	.
ZSCAN30	18	35251058	35290245	N	.	N	N	0.275325819	69.02818776	9.22E-09	89	.	.
ZSCAN31	6	28324693	28356271	N	.	N	N	-0.327935902	27.84048157	3.77E-09	89.9	.	.
ZSCAN32	16	3382081	3401065	N	.	N	N	0.423624684	77.05620189	1.16E-05	77.7	.	.
ZSCAN4	19	57668935	57679152	N	.	N	N	0.051041541	53.45835504	0.004598953	58.5	.	.
ZSCAN5A	19	56219670	56368383	N	.	N	N	1.281087169	95.66475661	0.081218246	44.4	.	.
ZSCAN5B	19	56189570	56197920	N	.	N	N	2.340582543	99.033397	1.77E-15	97.2	.	.
ZSCAN5CP	19	56202301	56209452	N	.	N	N	.	.	.	.	.	.
ZSCAN9	6	28224886	28233482	N	.	N	N	0.202058361	64.50772704	4.10E-08	87.3	.	.
ZSWIM1	20	45881227	45885266	N	.	N	N	0.053911889	53.6319963	8.44E-05	72.4	.	.
ZSWIM2	2	186827835	186849208	N	.	N	N	0.624448509	84.89899867	5.14E-10	91.7	.	.
ZSWIM3	20	45857617	45879122	N	.	N	N	0.183527791	63.44272733	0.001413288	63.3	.	.
ZSWIM4	19	13795460	13832230	N	.	N	N	-1.01140034	7.709671818	0.165803304	39.9	.	.
ZSWIM6	5	61332273	61546170	N	.	N	N	.	.	0.330184634	34.8	.	Acromelic frontonasal dysostosis, 603671 (3)
ZSWIM7	17	15976560	15999717	N	.	N	N	0.282530296	69.45650287	0.087925501	43.9	.	.
ZSWIM8	10	73785582	73801797	N	.	N	N	-3.002603824	0.601956358	0.999999921	1.1	.	.
ZUFSP	6	116635618	116668794	N	.	N	N	-0.193686319	35.8974359	2.28E-06	81.1	.	.
ZW10	11	113733187	113773811	N	.	N	N	-0.633499547	15.82450657	0.047262892	47.3	.	.
ZWILCH	15	66504959	66550128	N	.	N	N	-0.068854605	44.475314	8.31E-06	78.5	.	.
ZWINT	10	56357228	56361275	N	.	N	N	0.548158421	82.36962436	1.33E-08	88.6	.	.
ZXDA	X	57906708	57910820	N	.	N	N	0.763989364	88.43549227	0.005210895	57.9	.	.
ZXDB	X	57591652	57597545	N	.	N	N	0.327697272	72.21161081	0.842955569	20.1	.	.
ZXDC	3	126437601	126475919	N	.	N	N	0.493066458	80.1933206	0.000818652	65.5	.	.
ZYG11A	1	52842511	52894998	N	.	N	N	.	.	.	.	.	.
ZYG11B	1	52726467	52827342	N	.	N	N	-0.698460933	13.95496903	0.999923789	3.6	.	.
ZYX	7	143381080	143391111	N	.	N	Y	0.448047836	78.27747873	7.74E-06	78.7	.	.
ZZEF1	17	4004445	4143020	N	Viable	N	Y	-2.90393688	0.630896568	0.999923091	3.6	.	.